<SEC-DOCUMENT>0000899923-21-000090.txt : 20211104
<SEC-HEADER>0000899923-21-000090.hdr.sgml : 20211104
<ACCEPTANCE-DATETIME>20211104160455
ACCESSION NUMBER:		0000899923-21-000090
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		88
CONFORMED PERIOD OF REPORT:	20210930
FILED AS OF DATE:		20211104
DATE AS OF CHANGE:		20211104

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MYRIAD GENETICS INC
		CENTRAL INDEX KEY:			0000899923
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				870494517
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-26642
		FILM NUMBER:		211379864

	BUSINESS ADDRESS:	
		STREET 1:		320 WAKARA WAY
		CITY:			SALT LAKE CITY
		STATE:			UT
		ZIP:			84108
		BUSINESS PHONE:		801-584-3600

	MAIL ADDRESS:	
		STREET 1:		320 WAKARA WAY
		CITY:			SALT LAKE CITY
		STATE:			UT
		ZIP:			84108
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>mygn-20210930.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:902b74c1-bcf1-4420-82df-87d4ebd2f6e9,g:dcd0bc70-dec4-4a37-a022-ac912887efc6,d:5814a71962934792901cb2330361bb17--><html xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:mygn="http://www.myriad.com/20210930" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns="http://www.w3.org/1999/xhtml" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>mygn-20210930</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180L2ZyYWc6Y2FkZjRhNjFjOTVhNDJjZWEyM2JlMWRlMmExNTU0ZWMvdGFibGU6ODdjYTk4Mjg5MmRmNDM3N2EwNWQyMzc3ZWYxYzgyZjkvdGFibGVyYW5nZTo4N2NhOTgyODkyZGY0Mzc3YTA1ZDIzNzdlZjFjODJmOV8xLTEtMS0xLTE4MTY0_96278c5c-fda7-4208-b1e1-694116496589">false</ix:nonNumeric><ix:nonNumeric contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180L2ZyYWc6Y2FkZjRhNjFjOTVhNDJjZWEyM2JlMWRlMmExNTU0ZWMvdGFibGU6ODdjYTk4Mjg5MmRmNDM3N2EwNWQyMzc3ZWYxYzgyZjkvdGFibGVyYW5nZTo4N2NhOTgyODkyZGY0Mzc3YTA1ZDIzNzdlZjFjODJmOV8yLTEtMS0xLTE4MTY0_5e3f64d3-85c2-48a1-bc9e-1f84c72a57c0">0000899923</ix:nonNumeric><ix:nonNumeric contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" format="ixt:date-month-day" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180L2ZyYWc6Y2FkZjRhNjFjOTVhNDJjZWEyM2JlMWRlMmExNTU0ZWMvdGFibGU6ODdjYTk4Mjg5MmRmNDM3N2EwNWQyMzc3ZWYxYzgyZjkvdGFibGVyYW5nZTo4N2NhOTgyODkyZGY0Mzc3YTA1ZDIzNzdlZjFjODJmOV8zLTEtMS0xLTE4MTY0_c6838d1b-cdce-4ebf-84ea-ab9c3499873c">12/31</ix:nonNumeric><ix:nonNumeric contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180L2ZyYWc6Y2FkZjRhNjFjOTVhNDJjZWEyM2JlMWRlMmExNTU0ZWMvdGFibGU6ODdjYTk4Mjg5MmRmNDM3N2EwNWQyMzc3ZWYxYzgyZjkvdGFibGVyYW5nZTo4N2NhOTgyODkyZGY0Mzc3YTA1ZDIzNzdlZjFjODJmOV80LTEtMS0xLTE4MTY0_7e19b56c-c569-4da6-98ff-4cf142fc6939">2021</ix:nonNumeric><ix:nonNumeric contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180L2ZyYWc6Y2FkZjRhNjFjOTVhNDJjZWEyM2JlMWRlMmExNTU0ZWMvdGFibGU6ODdjYTk4Mjg5MmRmNDM3N2EwNWQyMzc3ZWYxYzgyZjkvdGFibGVyYW5nZTo4N2NhOTgyODkyZGY0Mzc3YTA1ZDIzNzdlZjFjODJmOV81LTEtMS0xLTE4MTY0_b3d8c391-fccf-45c8-9059-79908618a32b">Q3</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="mygn-20210930.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i526dd58342b2430ab657188009969982_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i686dc3f8181f43699bf8c3b5a9751e8c_I20211027"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-10-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i7bca861d20d64642b8c0cb91a290112d_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i21cc3685be5d4e2e8f00283addc53a8f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifbc28960af99464087c70e2155273621_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticTestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc0e2c6320b64071a6e19bf0ded7e102_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticTestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8a469542115473daa7666e3dceae657_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticTestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie51b08f1c1f44da4bb023303aa0fb7d9_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticTestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79cd3eef56ae4f639da562ce851a382e_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:PharmaceuticalAndClinicalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie94a660aba69415a910d7f90711081eb_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:PharmaceuticalAndClinicalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i695f1ac67bde49628842e3563e17c85e_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:PharmaceuticalAndClinicalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib855c77efb97481b968697136ef35610_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:PharmaceuticalAndClinicalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic2c3e03438af4889ac973627c642f5ec_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="ic932914e17ea4777879ab952bc47a286_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if653f84940094fdc88956b69c3739df5_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9fd2bfc03de94eb4a23ff40a2dfd6fe7_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6735c278f56c4d2286aba604c5af25f6_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8fe9a482f344283b898248f34c5db4d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic698543044ba4469ba8751bae898951c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c851333c120429494592618fb0e4572_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic26cca04ca2b4dd694bd9641fa5123c4_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie993214cd1d8450aa22158093bdba0b6_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8808683eb1f94ae4a2c56f558c2c44d0_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic487f8b588f74b249c58ff8b2e14f2f2_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i749ef50c3e724e34a1c233ae09ec290a_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i838807b0749e445cb7c40c97e6854df5_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia60976ab8abc463ebc9edd0688cead34_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1c450cd54f5427891132bfd983e0317_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie2b71276d33f4f37af748f45b0cac148_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i71bfb9a9cbab40e4b2ee82f3c9d4e30b_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib2ef1fdcdaaa463faa4cb4a9e259428b_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61643ef3fddf427bab68f34f288ffdbe_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i273996af01934354b9835c65bd479b9e_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief2d705cf1e84ddebcf24754f7a3b890_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd849afda7b942948aa9c83f57ffaeac_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5fc7e59c62b42ad92216ba6836b6eb8_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1bce2263b540455893f4d80b0de511c9_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8acfa22e3dc144acaa3254b56b5c801f_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc4b5cd85a7a4e8291ff3e4c80dc8756_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic976e79981cb4e17a90b071ed83778dd_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia9f2038ca2c74e13bf97f356d8a0ef8e_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i809ae31b44854c4eab5bc730c4471cb7_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7055540d7cfb415fafe2dac25f373950_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic19852c9069943c28e1fa3345a711650_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i691c4f02f3464e09bb1a483b5726a5c3_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i26e03ce4366849f4ad19d964861a49f7_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib871f90b68b641f89b0eabe7f24ebcf9_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5237cb26929043d6b2c706d0a5a289d6_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9be196750c9340469be5f26a4d4e5835_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c6bac27ede64afeb4dbc13729f58578_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd82562daef9481db9764cfedc560e47_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i602bb4299a7f49a78984421bea48e2d2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f1113acaf4c4991a6389007d99fd17f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic00338bab29748f28e289324358531f0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc25381d7b004bd686b31d1d7f06dc8a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0fd66a47efdc463d8b56854a06ea9eb0_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie59a85cd0de74256a4070826a06ab2ee_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03600303e63e4b17b220e55c943b073d_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f2d8d71b25549ff846e9b42b31323ef_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i740bb39577154e0a943a066cee5730d4_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i14c8904c520e416b9c51933b8b024cd1_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9fa028178e4d40088533a95f689bc888_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9644cd21559142acbc76c26cfab92eb6_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie6b465bbce9349f88227b2188438b68d_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i24dac68960214b9f993eaa8df10274b2_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8032c809a65c47bda9a36a0b5229bfef_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9af20bf23942493aad5860b2c2e56978_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2a868eedf484113abf4a011ceff8fd4_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib07b6c87c8e242108fbc9023fce23cc9_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia74c427781b6435fa165763f7d2b6818_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03c0a03785d94bfa95d4de1d0a89a121_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4438d624363b4476a68d74da26614067_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a1959e9612e44579e775f75a541e4a8_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b38d81b9f4e4aa8b1b021b9bb1b0958_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0450de8f0b54d7591325d511dad90ca_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i171029b6cf5d41df9d00d9688277e104_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70b7a4c941544cd7894d1e4defd87c79_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53e5c42e5a894d47b34f9f9504d85a50_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id7bead8553aa40e19e389e9e36a5a52f_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic89788fb0cac4113ab3e5d22b824bee3_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5489fa2beb84874846c50045cb4a8fe_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i12b5bd71050148fe920686b278365e75_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1926bf39b52c48a4957fc9a924a82cf7_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icffee6692ce64627b1016dc94b08f0f0_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida000af1413e4fddbdffb1f6b6d73047_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticHereditaryCancerTestingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia65390d217d44664a03c7762eb80226c_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticHereditaryCancerTestingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb939ee30c9346759fabe2cbfd1ebf71_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticHereditaryCancerTestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib782ea6f17aa43faaa46806bd14f5af2_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticHereditaryCancerTestingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7942c920d42c4be98d7627dea2b75aab_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticHereditaryCancerTestingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d4b33a6e9cf4ff695a151252fa5202d_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticHereditaryCancerTestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9987b934bd0a407b89b3de550f71f1eb_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticTumorProfilingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i120342914ab84d57803cdba7e390e6e0_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticTumorProfilingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifacd49fb220e4e6688cac0490136867d_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticTumorProfilingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc7756538c044225a9ce5c1d9d342449_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticTumorProfilingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3bbf9b3b2d1b4c0c904cdd117771580a_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticTumorProfilingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc9ac75befb64b00b1cbd10949fa3e69_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticTumorProfilingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f8b38682e3a4c6586f56116a4e54db9_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticPrenatalTestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b8709823fb647138c0501d0018d62cc_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticPrenatalTestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac13adff54494e56be97dcfc0308c7f5_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticPrenatalTestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie36dcf4cd4e14f4890cf021f262a8b82_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticPrenatalTestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia94b623d77a449e49aa7fce28c810d9c_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticPrenatalTestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4acdbc594a6a4b88a090b04e5ef69aec_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticPrenatalTestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5e3a39bcef84311a38d3c37cbbee981_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticPharmacogenomicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e84513d519942359ce079c27c934ab7_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticPharmacogenomicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f4d0d8a569142149d4db9527cbf6122_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticPharmacogenomicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i632d974bc19746629c875de8d85005de_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticPharmacogenomicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8ffaf88f5554b8a8bfb8d0f7aaef001_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticPharmacogenomicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e91c91b1c9a4945acdfe9e7245038ed_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticPharmacogenomicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7376ab53741d440ba61c388e5c932c1b_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticAutoimmuneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c33023861bc44e592a2a61939a657a6_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticAutoimmuneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ce0af94533d4d0cb17bfae079adab31_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticAutoimmuneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1e715fa83dc47248899710d4f312340_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticAutoimmuneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d9d935b97a14723b2ce8cd0fdd3685b_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticAutoimmuneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5880f6561e344b698bf53ef48281f5f_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticAutoimmuneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8511c5f276ed4618bd7d3abcdfd81278_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticOtherTestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7cd8b28b3de341ab88d9b759b56cb960_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticOtherTestingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2269a2a3c55f4f48b394d629ae9ece31_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticOtherTestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic301e05aafb54177bf154d4e00dca137_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticOtherTestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie0c4bdb320014fe28dabebe98a245d34_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticOtherTestingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5428af14384f4775a235df5d1a72c351_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticOtherTestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i978447da133848e09d69b6941e3c3e12_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticTestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e833f5a117c4014b693ba5dbcd17f05_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticTestingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f6b592da0d94089824ddd9eeaec60ca_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticTestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i628878e014504ba3927b3541bbfee9d6_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticTestingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2777203c45e44986ad24f2e01bb5cd2c_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:PharmaceuticalAndClinicalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4bb010a87eb34230a4d879b7f8b5d7f3_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:PharmaceuticalAndClinicalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4850f75cb284b14b1e3b920fd17fee3_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:PharmaceuticalAndClinicalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if98b526cb9c84315b8808c1225488499_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:PharmaceuticalAndClinicalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34864de2cd5e41bd98ef24a86d7f39a1_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e6310ec543143dc8a87a1867afc2439_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b754f9a3006470cb13ba2789a352d5e_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7eb57d5345554df7a7ffeb66aa7ef9d6_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48501743237742c6975110396e917242_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticHereditaryCancerTestingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7824951a746645c39acedbdd215f57f5_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticHereditaryCancerTestingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifcc2e81b5a204336b461cdc53955b3cd_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticHereditaryCancerTestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7c83e62f13142e3bf47bdf15510f328_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticHereditaryCancerTestingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i18e0522d4e264244b4b7ff08c869a121_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticHereditaryCancerTestingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee003a09d07f4dbf86ab56c0275a5909_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticHereditaryCancerTestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e5e62422b964677bbf81111118a8530_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticTumorProfilingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2dd22965d073433da620ee6bb158d276_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticTumorProfilingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7fe0144d6efa41859c2eba711e85303a_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticTumorProfilingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i55af35cd863d4959bf0125bc9cb46d23_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticTumorProfilingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c2131fe4d3c47358dd98a5d078c009b_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticTumorProfilingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic91ecdd5628742b5828be3bf25416996_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticTumorProfilingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifae9cf930088446e9ad24962231957ba_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticPrenatalTestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ee8c5ff36994621b42226a17e561d2e_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticPrenatalTestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c200a9b3e0d4ac49242d25105281dcd_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticPrenatalTestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8fb168011b74d318bab8b56b11dbda3_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticPrenatalTestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic992acb15b7b4eb7a73e11782d653862_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticPrenatalTestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4efd4f48f7f647819d1ee5f36d044d08_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticPrenatalTestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1fc1f94f6c144040a6a027fe642d8327_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticPharmacogenomicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e578e3ded2b44bfb1c2e543c14336fe_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticPharmacogenomicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf03794b4694454c96339d25e089fd86_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticPharmacogenomicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4790f46fe81f43b7a34b7d4e7be6b08d_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticPharmacogenomicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d82cbad6d4f4ad4b4867f492374ddbc_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticPharmacogenomicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i227a5837ccdc40d09a3935542fa8f306_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticPharmacogenomicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1643deb3ad9f45619ca4221f05389dc7_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticAutoimmuneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0485078c2524525b58fcac4538292d8_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticAutoimmuneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1413cd2d66404ae0b0033e4828c87987_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticAutoimmuneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ad30cfcd30642859241e76dc224b27e_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticAutoimmuneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia022822da300492793546d0fe4c7b26b_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticAutoimmuneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b38c623286c42b898b7e8154ca4672e_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticAutoimmuneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c5bea7f5b774599827c2380d64fab41_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticOtherTestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic2e771554aba45edaeb4d3458b0c1d77_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticOtherTestingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c5c05f89d074455a96647a1c66e3797_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticOtherTestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie293ea67e0dc4e379586937a664f26a6_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticOtherTestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96fe192a524c4c7780b693b19a1ee594_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticOtherTestingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85e565a842f34303958c7c5dbc22906f_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticOtherTestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2150fb2a47cc41a8a8afed1f431f9875_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticTestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieeda1d918cdc4e4c8c9a40ede0b9980e_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticTestingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i54646e3f899541a2892e6c43188dd3ca_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticTestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4765fcb411c541578d82bf58e0edcd57_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticTestingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9ffcf60567a49298db6b5581ef8dbec_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:PharmaceuticalAndClinicalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67ed4f8f16804e2d91b367cc0ad882e6_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:PharmaceuticalAndClinicalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i822cef9d3a1148dfa0df42a55879158a_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:PharmaceuticalAndClinicalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id2561e4e6a72407fa6fcb4dda8635c44_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:PharmaceuticalAndClinicalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb886d225660433bb8c479ba4c1cf8ce_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaab7b12e36bb4e709ac9d2fd74a39b5e_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7eb822f2ce54831a5e78a74b2e44672_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2bc09983c7244893bff666d06f800fa8_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7d2894297e4420e8cad6a4c76510fc1_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic929fbb9734546f8ba6190d002b58254_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">mygn:PerformanceObligationEstimatedTransactionPriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i437a8c83f80c43f5bb7969a1427d84af_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">mygn:PerformanceObligationEstimatedTransactionPriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="ib2b1d515b0df442caf3a61b77cd756eb_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mygn:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c9ecd2a8793414a828047a9bf1593e4_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mygn:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide0992200fac419ab9eb95a8229f286b_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mygn:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9463c7d008224ba994869b57828ab6a2_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mygn:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie18df879613d4bb19a671fecd56a73ef_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i55b41215c9044cb8bdb7a95355f2cee3_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i20c433933c2b4c689e241c3fd658ffa4_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i474e395867254271927d4271ff603665_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f849fd49ae643249e914d79d76dcb81_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i50d5d52f5abe44ae90e97be189c0c2c0_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89beb1b281b84d588eff0b2c4a0c5dfb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i784e7cc69b2447578da174c05c94a660_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide2c0b04a05e4f40b02f2431e83b3536_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e3de8ef1a9243968a201ad829b59152_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id5e0328e3e08484f88ad3cfbf16c738f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i47594399039d468c97b0901e9244c85e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="security"><xbrli:measure>mygn:security</xbrli:measure></xbrli:unit><xbrli:context id="i1f71ce0e78ae4d43bdf7b1af72891a7e_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib44dd41f27d8480d8f588e0a3bf99cba_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d975988e4a74a9dbe6e71a5b5546389_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4996139414984f65bb79f0d63ac3f655_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id012a77974384595bcd158dfde0ea68e_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22cef9e6ab314518ab6c3a7c7d612f84_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4d9dbc5ea804408a5936ee65bfc03fe_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0dd65111dedb44d595f99ccb1991e8fe_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib78f55a38b1d452e8216debd6bd284c8_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1e3572a358f489bacc6b0b33b2e63d5_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b6dea85317046bc87a3e54a0f0f3ffc_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ec450647a3c4906981f1552178b524d_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i69d2dc8810554913bdaf6702c8068256_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i83b400ca04df4b53901e5ccced571202_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba04c9e73cfd46ad82a9eea96b7282e2_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i20eb373912734049b280784af93920ce_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibdc5dad50ef14763bc23b7f645b991d5_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i53fc983dd40d4345b5662806620d7a69_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mygn:ContingentConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i92c674fcb51e4f128ed0956b57defa1a_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mygn:ContingentConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i36f381783c3a43ca93842d8b7723cb09_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mygn:ContingentConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i476783a7d7a846aca1e3115c994a7824_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mygn:ContingentConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb3432fef1734dcf938bc72ecde8321c_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ba8c79bbcbe4cfdae12d33bf2783cb3_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if8c6a3bacee84320baf1e19f8abf5951_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic9870ea197d5485389a0710db39dac7e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idac1b2ac3b4c4ea287843c55138d31fe_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iefe8366531d2402295ef25ebb060e068_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if070826acb484e4b88cfbb934f2510a0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e8d32c49f294155b6e1ca65383d3960_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c5647e0218944d0aa8af898642f148e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf68d852a72c4154b30db158bdb79561_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0330620427f647ed9cc3899d676e3b70_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1213355c05b74525b0feb4f71cee0825_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a792264bad64b069150fc3385ef30ea_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i02209a0a76af4ebdbef9df556c34a6d8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia5d2a4f35b5e4114a4bdedc325290a90_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i591bb847d18a4e38a3b89e766c088008_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb2b2109f1474e9d98f51788f0de8c5e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc1c646e04584219aac582f20b8676ad_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i707c13e32e584ee3a2051a60c642c899_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81a717b368544963b5d0268a420c7e31_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mygn:ContingentConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if110d6f8bc9445f19d915e3c19311eb2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mygn:ContingentConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i353263ed75ed4422b659d68ccbb565d7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mygn:ContingentConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f239555bbeb4f1085317b6f3100affb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mygn:ContingentConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i41e4b0464a314ee7a5506f2010385fab_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2460434fcbba45b1b2398bd2547de226_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f3a1bdca0f24500a339d8a108a0211f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i94b157c71c86440fa7ba1b5891dd3e43_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc0bbee828074f62b3cdac04425562c8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i80977ee86e3c41ebb192c62d6bfce59a_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ebba697932d49ea8da9c7220efb9033_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i38ac573972c0484c9db1cb89e06de15a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mygn:DiagnosticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibde16baaa28343bd960624b1aaf1ae77_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i90324a4d56084a4391c5819f5c839f86_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mygn:DiagnosticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee82af509aa24703b7bb72450fba9e9f_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6edc95151d8a4e0d834e3ba92ab2a90b_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mygn:DiagnosticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i579d27c0f10940d8a1ceface7d29c915_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b032b60a10145f682547141173ac516_I20210701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">mygn:PurchasedLicensesAndTechnologiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mygn:MyriadRBMIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id4c41467e09242c3a31f5150b7bc13fe_I20210701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">mygn:InProcessResearchAndDevelopmentWithIndefiniteLivesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mygn:MyriadRBMIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e1dbd573f0047b298ea8f3eb9afc6cf_I20210701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mygn:MyriadRBMIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5951f47f63a2499780fd5e72af21ade5_I20210701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mygn:MyriadRBMIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a2255bae3b5469a85c3193359dabe47_I20210701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mygn:MyriadRBMIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie644acbcb7a046da9f6a9073e27ef84f_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">mygn:PurchasedLicensesAndTechnologiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia5b94635b0ee49179e69f248a30a5218_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">mygn:PurchasedLicensesAndTechnologiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b16ee9a891f452fbef45868672b00d6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0cc0c3bdd23f47d483982f371199a356_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id685e06a6fe54277a65c4a43bf1ca98b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">mygn:InProcessResearchAndDevelopmentWithIndefiniteLivesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia36cf797382046e0a337c61433dfd1b6_D20180731-20180731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mygn:AmendmentToCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-31</xbrli:startDate><xbrli:endDate>2018-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20dcb26940bd445f93184c60d07dab71_I20161223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-12-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if69f7cf080614d7fa0f9398ec3a0d790_I20180731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mygn:AmendmentToCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d7436f51ca44c63b220baabb793f869_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mygn:AmendmentToCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic14444ddb59c4b859b297e3eb63f800d_I20210221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mygn:AmendmentToCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i12f34ee4c63b4e07a09ead597eb2afb8_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mygn:AmendmentToCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id22d71fd31db4689a2b97ef092347fe3_D20200401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mygn:AmendmentToCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1cd2ac076ee74bdaaad3ecd73d94eee1_D20200401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mygn:AmendmentToCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4847f17e28e147c0a68edabf5abcea78_D20220701-20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mygn:AmendmentToCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7adf104e7dc740cbb75258256d3d3de0_D20220701-20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mygn:AmendmentToCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b9e6a1375a94b0e869e4e993a658963_D20220701-20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mygn:AmendmentToCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i417e2a66751b4095bd0c48dc41dd4530_D20220701-20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mygn:AmendmentToCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib42c463d1fe74078a52b79074501653e_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i408d12bd10e24b0daf055d6dce17ee34_D20210731-20210731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mygn:AmendmentToCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-31</xbrli:startDate><xbrli:endDate>2021-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb96586e8d014be6a63ed5c14054d982_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mygn:AmendmentToCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3269c20860fd42e5b0cecdb3249f343d_I20160630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">mygn:EighthShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i52adcde188a640e99ba9a44e311c8d73_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mygn:TwoThousandSeventeenEmployeeDirectorAndConsultantEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief9e8a3ae25b43aeb183d65978160f05_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69bf2abe7da64ff79bc46cba39640e19_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mygn:OptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">mygn:NonEmployeeDirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92c8275b0ba847e78c2cd5b91dd57e8c_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i965028ac5b28491f8ce013eceafc3791_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">mygn:OptionsGrantedAfterDecemberFiveTwentyTwelveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d8d18090245443bb8fcbbabba18bd99_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">mygn:OptionsGrantedPriorToDecemberFiveTwentyTwelveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4801dc9ebc814bf4a4e7c0b3d186670f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i82ee8762af6f49b6830a17198018205b_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8bcfc26140eb424887a7993eb83c6035_I20121231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mygn:EmployeeStockPurchasePlanTwentyTwelveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2012-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib0ff30ba23574507a2d7f464c815dfac_D20210923-20210923"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mygn:EmployeeStockPurchasePlanTwentyTwelveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-23</xbrli:startDate><xbrli:endDate>2021-09-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c1a3b837ee04e2c812eb8cbc112adaf_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mygn:EmployeeStockPurchasePlanTwentyTwelveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie53d91b4b6c74e609ea917eadc9521fb_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">mygn:CostOfMolecularDiagnosticTestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0b0e187d88d4a79a51af53f0c258395_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">mygn:CostOfMolecularDiagnosticTestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15b426ffab40406b9ce00055e4e71cc7_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">mygn:CostOfMolecularDiagnosticTestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i10453dc072584904908a86492c478db1_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">mygn:CostOfMolecularDiagnosticTestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8134e30745e401f875787e150c90a29_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">mygn:CostOfPharmaceuticalAndClinicalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a4213b0025742348a551e459281952a_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">mygn:CostOfPharmaceuticalAndClinicalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96d4380fb0a44bda931ad908ae56cd15_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">mygn:CostOfPharmaceuticalAndClinicalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if45947be73124386a5d96c5f812ce163_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">mygn:CostOfPharmaceuticalAndClinicalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b57125252b04e19a0ab135ecb14306e_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74a661b5521240d6b08faf29ed4cca5f_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1e22d907e804cb3a166674ed56d1159_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa209599dfc04850bdd9bb0c340449ec_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4fba22e0d9a14b43ae418e9b7737a767_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8738e02b8c234e90be4290e058314e09_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b061eccb63f4b98914dd480e34a8f10_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib580291452e04f9790478ef2b24b14d7_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if31d376449604749a8d84a4ea233ed1b_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:EarliestTaxYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CaliforniaFranchiseTaxBoardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b90c2422e9e4d78837a3d9edef5f3aa_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:LatestTaxYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CaliforniaFranchiseTaxBoardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c84552a53104c5d863802c21e95e8d4_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:EarliestTaxYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:NewJerseyDivisionOfTaxationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idab04f47fe4d4dfa8e8043a6d25016fd_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:NewJerseyDivisionOfTaxationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:LatestTaxYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d977692ef0d4d53a4a9b42cabf5e593_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:EarliestTaxYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:FederalMinistryOfFinanceGermanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf68da87f99f4445b6e3aaf98ff69a2a_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:LatestTaxYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:FederalMinistryOfFinanceGermanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib988f9d7160144ba85f9202205918ecc_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:EarliestTaxYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:SwissFederalTaxAdministrationFTAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84120dcedb01422a848d3618dbae3f74_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:LatestTaxYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:SwissFederalTaxAdministrationFTAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>mygn:segment</xbrli:measure></xbrli:unit><xbrli:context id="ife30149d9d1d4b99ac1339407e85293d_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mygn:DiagnosticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iacd3d37549084b26b52a7a2565dbb4ab_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i19766b831a824fe78592ac40be72d491_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mygn:DiagnosticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i91eb354042484b21815c154fc961e6c4_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9a30e30fb7d46af9ad9962658bc3126_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mygn:DiagnosticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7eb09159cfc64597873d8167aa298bfe_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b97fc75f0ec45e0bd58df1dad474b32_D20210528-20210528"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mygn:MyriadMyPathLLCLaboratoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-28</xbrli:startDate><xbrli:endDate>2021-05-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5db1cb383af4d9091b44997a3e2b23f_D20210701-20210701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mygn:MyriadRBMIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b8313a324f94c6caad8b75523488f35_D20210913-20210913"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mygn:MyriadAutoimmuneAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-13</xbrli:startDate><xbrli:endDate>2021-09-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8b44ab869f44ebd9da9cf10c35e35c4_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mygn:MyriadRBMIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae9bd564d0e24269a0860f286b76a8c8_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mygn:MyriadRBMIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7ad8f15a58548759fdb4e238c847c6b_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mygn:MyriadMyPathLLCLaboratoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b39e1079fcf498da2478fc0bfa35a9c_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mygn:MyriadMyPathLLCLaboratoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id8db12274a5e41019919e2f3e84a1cfd_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6f9bab1ac3d4f769be2cf49d2c11dc1_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if410392a6c864eb4bcc542e0317057f6_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mygn:MyriadAutoimmuneAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7f3ca65537e48c2a6d04c65e5799212_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mygn:MyriadAutoimmuneAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i5814a71962934792901cb2330361bb17_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">_________________________________________</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xL2ZyYWc6M2JjM2JkYzFkYmFiNDdiN2E1YTZlN2IxODA1MmRmNGUvdGV4dHJlZ2lvbjozYmMzYmRjMWRiYWI0N2I3YTVhNmU3YjE4MDUyZGY0ZV8yMzc4_df59c0de-d8e5-489c-a81e-ca23d0a6274b">10-Q</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">_________________________________________</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Mark One)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:2.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.977%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" format="ixt:fixed-true" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xL2ZyYWc6M2JjM2JkYzFkYmFiNDdiN2E1YTZlN2IxODA1MmRmNGUvdGFibGU6MTQ5OTA1MzI4MDU5NDA0ODg2NzFkZjhlZmVmZmJjYmEvdGFibGVyYW5nZToxNDk5MDUzMjgwNTk0MDQ4ODY3MWRmOGVmZWZmYmNiYV8wLTAtMS0xLTE4MTY0_3cce996b-2566-44b6-8ecb-b0337b926e41">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xL2ZyYWc6M2JjM2JkYzFkYmFiNDdiN2E1YTZlN2IxODA1MmRmNGUvdGV4dHJlZ2lvbjozYmMzYmRjMWRiYWI0N2I3YTVhNmU3YjE4MDUyZGY0ZV8yMTc_d13b264b-5231-4b45-9a55-a3041259b707">September 30, 2021</ix:nonNumeric></span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OR</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:2.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.977%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" format="ixt:fixed-false" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xL2ZyYWc6M2JjM2JkYzFkYmFiNDdiN2E1YTZlN2IxODA1MmRmNGUvdGFibGU6ZTVjY2UyZTU0YmQ3NGRhYmJlM2FlNDc3YzlhZjYwMGQvdGFibGVyYW5nZTplNWNjZTJlNTRiZDc0ZGFiYmUzYWU0NzdjOWFmNjAwZF8wLTAtMS0xLTE4MTY0_92709980-3639-43b5-8654-43ec6f871755">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission file number:&#160;&#160;<ix:nonNumeric contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xL2ZyYWc6M2JjM2JkYzFkYmFiNDdiN2E1YTZlN2IxODA1MmRmNGUvdGV4dHJlZ2lvbjozYmMzYmRjMWRiYWI0N2I3YTVhNmU3YjE4MDUyZGY0ZV8yMzc0_be0df4d4-f1dd-43df-af86-d50a83f98524">0-26642</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">_________________________________________</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xL2ZyYWc6M2JjM2JkYzFkYmFiNDdiN2E1YTZlN2IxODA1MmRmNGUvdGV4dHJlZ2lvbjozYmMzYmRjMWRiYWI0N2I3YTVhNmU3YjE4MDUyZGY0ZV8yMzcx_378f5bdd-ee5e-4d85-931e-c206debf5382">MYRIAD GENETICS, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">_________________________________________</span></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><ix:nonNumeric contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xL2ZyYWc6M2JjM2JkYzFkYmFiNDdiN2E1YTZlN2IxODA1MmRmNGUvdGV4dHJlZ2lvbjozYmMzYmRjMWRiYWI0N2I3YTVhNmU3YjE4MDUyZGY0ZV8yMzc5_939d683c-5f49-4c0c-a8f2-7946cc552209">Delaware</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(State or other jurisdiction</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">of incorporation or organization)</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><ix:nonNumeric contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xL2ZyYWc6M2JjM2JkYzFkYmFiNDdiN2E1YTZlN2IxODA1MmRmNGUvdGV4dHJlZ2lvbjozYmMzYmRjMWRiYWI0N2I3YTVhNmU3YjE4MDUyZGY0ZV8yMzgw_bdfb9bf4-92f4-4da5-8d73-1dfd98a36e34">320 Wakara Way</ix:nonNumeric>, <ix:nonNumeric contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xL2ZyYWc6M2JjM2JkYzFkYmFiNDdiN2E1YTZlN2IxODA1MmRmNGUvdGV4dHJlZ2lvbjozYmMzYmRjMWRiYWI0N2I3YTVhNmU3YjE4MDUyZGY0ZV8yMzc1_f1b8ea0a-7921-415e-b413-2bdd9d53615e">Salt Lake City</ix:nonNumeric>, <ix:nonNumeric contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xL2ZyYWc6M2JjM2JkYzFkYmFiNDdiN2E1YTZlN2IxODA1MmRmNGUvdGV4dHJlZ2lvbjozYmMzYmRjMWRiYWI0N2I3YTVhNmU3YjE4MDUyZGY0ZV8yMzc3_c6484499-5fdd-482d-a1e2-c2dfdef032d3">UT</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Address of principal executive offices)</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><ix:nonNumeric contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xL2ZyYWc6M2JjM2JkYzFkYmFiNDdiN2E1YTZlN2IxODA1MmRmNGUvdGV4dHJlZ2lvbjozYmMzYmRjMWRiYWI0N2I3YTVhNmU3YjE4MDUyZGY0ZV8yMzgx_379496e6-c769-4113-8441-de9bd0b6315b">87-0494517</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(I.R.S. Employer Identification No.)</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><ix:nonNumeric contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xL2ZyYWc6M2JjM2JkYzFkYmFiNDdiN2E1YTZlN2IxODA1MmRmNGUvdGV4dHJlZ2lvbjozYmMzYmRjMWRiYWI0N2I3YTVhNmU3YjE4MDUyZGY0ZV8yMzcy_e8e64dad-78d2-407b-9cc6-67977ae88486">84108</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Zip Code)</span></div></div></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Registrant's telephone number, including area code: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">(<ix:nonNumeric contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xL2ZyYWc6M2JjM2JkYzFkYmFiNDdiN2E1YTZlN2IxODA1MmRmNGUvdGV4dHJlZ2lvbjozYmMzYmRjMWRiYWI0N2I3YTVhNmU3YjE4MDUyZGY0ZV8yMzcz_204381ca-142f-467a-8c52-fdd24d7f0433">801</ix:nonNumeric>) <ix:nonNumeric contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xL2ZyYWc6M2JjM2JkYzFkYmFiNDdiN2E1YTZlN2IxODA1MmRmNGUvdGV4dHJlZ2lvbjozYmMzYmRjMWRiYWI0N2I3YTVhNmU3YjE4MDUyZGY0ZV8yMzgy_36a3ebc0-4610-446c-81d3-8c68bc4dac43">584-3600</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">_________________________________________</span></div><div style="margin-top:4pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&#160;12(b) of the Act:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.359%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.520%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.363%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Trading<br/>Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xL2ZyYWc6M2JjM2JkYzFkYmFiNDdiN2E1YTZlN2IxODA1MmRmNGUvdGFibGU6MjhhMDlkNmU4NTEyNGEyYTkwMWYzZWJjYWJjZGJhOGUvdGFibGVyYW5nZToyOGEwOWQ2ZTg1MTI0YTJhOTAxZjNlYmNhYmNkYmE4ZV8xLTAtMS0xLTE4MTY0_eae810e8-4d00-4f7c-8e4b-e91ab8fd6829">Common Stock, $0.01 par value</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xL2ZyYWc6M2JjM2JkYzFkYmFiNDdiN2E1YTZlN2IxODA1MmRmNGUvdGFibGU6MjhhMDlkNmU4NTEyNGEyYTkwMWYzZWJjYWJjZGJhOGUvdGFibGVyYW5nZToyOGEwOWQ2ZTg1MTI0YTJhOTAxZjNlYmNhYmNkYmE4ZV8xLTItMS0xLTE4MTY0_71e8e639-3c30-4a35-a28d-8685140b994f">MYGN</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xL2ZyYWc6M2JjM2JkYzFkYmFiNDdiN2E1YTZlN2IxODA1MmRmNGUvdGFibGU6MjhhMDlkNmU4NTEyNGEyYTkwMWYzZWJjYWJjZGJhOGUvdGFibGVyYW5nZToyOGEwOWQ2ZTg1MTI0YTJhOTAxZjNlYmNhYmNkYmE4ZV8xLTQtMS0xLTE4MTY0_a79a4891-85eb-479c-bb6c-7e741b673226">Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160; <ix:nonNumeric contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xL2ZyYWc6M2JjM2JkYzFkYmFiNDdiN2E1YTZlN2IxODA1MmRmNGUvdGV4dHJlZ2lvbjozYmMzYmRjMWRiYWI0N2I3YTVhNmU3YjE4MDUyZGY0ZV8yMzgz_288171b3-d88c-4bdf-a03b-c18a11d47303">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#168;</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160; <ix:nonNumeric contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xL2ZyYWc6M2JjM2JkYzFkYmFiNDdiN2E1YTZlN2IxODA1MmRmNGUvdGV4dHJlZ2lvbjozYmMzYmRjMWRiYWI0N2I3YTVhNmU3YjE4MDUyZGY0ZV8yMzg0_00f6a8df-1029-4377-913e-76243ffbc09b">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#168;</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.192%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.847%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.192%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.849%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xL2ZyYWc6M2JjM2JkYzFkYmFiNDdiN2E1YTZlN2IxODA1MmRmNGUvdGFibGU6NDNjM2I3MmRmNGZmNGViOWEwZWRiNWY1MWM0MjY5MTQvdGFibGVyYW5nZTo0M2MzYjcyZGY0ZmY0ZWI5YTBlZGI1ZjUxYzQyNjkxNF8wLTAtMS0xLTE4MTY0_5327c66a-2611-4ab4-9771-dd301c42ea91">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" format="ixt:fixed-false" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xL2ZyYWc6M2JjM2JkYzFkYmFiNDdiN2E1YTZlN2IxODA1MmRmNGUvdGFibGU6NDNjM2I3MmRmNGZmNGViOWEwZWRiNWY1MWM0MjY5MTQvdGFibGVyYW5nZTo0M2MzYjcyZGY0ZmY0ZWI5YTBlZGI1ZjUxYzQyNjkxNF8xLTQtMS0xLTE4MTY0_31e16f29-7d97-483d-a7ef-b4fd97d6b160">&#9744;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" format="ixt:fixed-false" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xL2ZyYWc6M2JjM2JkYzFkYmFiNDdiN2E1YTZlN2IxODA1MmRmNGUvdGFibGU6NDNjM2I3MmRmNGZmNGViOWEwZWRiNWY1MWM0MjY5MTQvdGFibGVyYW5nZTo0M2MzYjcyZGY0ZmY0ZWI5YTBlZGI1ZjUxYzQyNjkxNF8yLTQtMS0xLTE4MTY0_dd979d46-acae-4182-8346-e1e68cb5603f">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#168;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;<ix:nonNumeric contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" format="ixt:fixed-false" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xL2ZyYWc6M2JjM2JkYzFkYmFiNDdiN2E1YTZlN2IxODA1MmRmNGUvdGV4dHJlZ2lvbjozYmMzYmRjMWRiYWI0N2I3YTVhNmU3YjE4MDUyZGY0ZV8yNzQ4Nzc5MDcxODMw_03eac384-5cd5-49ba-b5e2-13fd8ea5fb49">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of October&#160;27, 2021, the registrant had <ix:nonFraction unitRef="shares" contextRef="i686dc3f8181f43699bf8c3b5a9751e8c_I20211027" decimals="INF" format="ixt:num-dot-decimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xL2ZyYWc6M2JjM2JkYzFkYmFiNDdiN2E1YTZlN2IxODA1MmRmNGUvdGV4dHJlZ2lvbjozYmMzYmRjMWRiYWI0N2I3YTVhNmU3YjE4MDUyZGY0ZV8yMzE4_0df2f291-940e-4d16-a32e-0beeb968c6f0">79,854,649</ix:nonFraction> shares of $0.01 par value common stock outstanding.</span></div><div style="margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="i5814a71962934792901cb2330361bb17_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MYRIAD GENETICS, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INDEX TO FORM 10-Q</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"></td><td style="width:8.032%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.679%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.989%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Page</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i5814a71962934792901cb2330361bb17_10">PART I - Financial Information</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i5814a71962934792901cb2330361bb17_13">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i5814a71962934792901cb2330361bb17_13">Financial Statements</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5814a71962934792901cb2330361bb17_16">Condensed Consolidated Balance Sheets as of September 30, 2021 (unaudited) and December 31, 2020</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i5814a71962934792901cb2330361bb17_16">4</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5814a71962934792901cb2330361bb17_19">Condensed Consolidated Statements of Operations for the three and </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5814a71962934792901cb2330361bb17_19">nine</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5814a71962934792901cb2330361bb17_19"> months ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5814a71962934792901cb2330361bb17_19">Sept</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5814a71962934792901cb2330361bb17_19">ember</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5814a71962934792901cb2330361bb17_19"> 30, 2021 and 2020 (unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i5814a71962934792901cb2330361bb17_19">5</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5814a71962934792901cb2330361bb17_22">Condensed Consolidated Statements of Comprehensive Income (Loss) for the three and nine months ended September 30, 2021 and 2020 (unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i5814a71962934792901cb2330361bb17_22">6</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5814a71962934792901cb2330361bb17_25">Condensed Consolidated Statements of Stockholders&#8217; Equity for the three and </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5814a71962934792901cb2330361bb17_25">n</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5814a71962934792901cb2330361bb17_25">ine</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5814a71962934792901cb2330361bb17_25"> months ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5814a71962934792901cb2330361bb17_25">September</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5814a71962934792901cb2330361bb17_25"> 30, 2021 and 2020 (unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i5814a71962934792901cb2330361bb17_25">7</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5814a71962934792901cb2330361bb17_28">Condensed Consolidated Statements of Cash Flows for the </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5814a71962934792901cb2330361bb17_28">nine</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5814a71962934792901cb2330361bb17_28"> months ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5814a71962934792901cb2330361bb17_28">September</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5814a71962934792901cb2330361bb17_28"> 30, 2021 and 2020 (unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i5814a71962934792901cb2330361bb17_28">8</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5814a71962934792901cb2330361bb17_31">Notes to Condensed Consolidated Financial Statements (unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i5814a71962934792901cb2330361bb17_31">9</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i5814a71962934792901cb2330361bb17_85">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5814a71962934792901cb2330361bb17_85">Management's Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i5814a71962934792901cb2330361bb17_85">24</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i5814a71962934792901cb2330361bb17_106">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5814a71962934792901cb2330361bb17_106">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i5814a71962934792901cb2330361bb17_106">33</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i5814a71962934792901cb2330361bb17_109">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5814a71962934792901cb2330361bb17_109">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i5814a71962934792901cb2330361bb17_109">34</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i5814a71962934792901cb2330361bb17_112">PART II - Other Information</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i5814a71962934792901cb2330361bb17_115">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5814a71962934792901cb2330361bb17_115">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i5814a71962934792901cb2330361bb17_115">36</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i5814a71962934792901cb2330361bb17_118">Item 1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5814a71962934792901cb2330361bb17_118">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i5814a71962934792901cb2330361bb17_118">38</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i5814a71962934792901cb2330361bb17_121">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5814a71962934792901cb2330361bb17_121">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i5814a71962934792901cb2330361bb17_121">40</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i5814a71962934792901cb2330361bb17_124">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5814a71962934792901cb2330361bb17_124">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i5814a71962934792901cb2330361bb17_124">40</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i5814a71962934792901cb2330361bb17_127">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5814a71962934792901cb2330361bb17_127">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i5814a71962934792901cb2330361bb17_127">40</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i5814a71962934792901cb2330361bb17_130">Item 5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5814a71962934792901cb2330361bb17_130">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i5814a71962934792901cb2330361bb17_130">40</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i5814a71962934792901cb2330361bb17_133">Item 6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5814a71962934792901cb2330361bb17_133">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i5814a71962934792901cb2330361bb17_133">41</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5814a71962934792901cb2330361bb17_136">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i5814a71962934792901cb2330361bb17_136">42</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i5814a71962934792901cb2330361bb17_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5814a71962934792901cb2330361bb17_7">Table of Contents</a></span></div></div><div><span><br/></span></div><div id="i5814a71962934792901cb2330361bb17_13"></div><div><span><br/></span></div><div id="i5814a71962934792901cb2330361bb17_16"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MYRIAD GENETICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Condensed Consolidated Balance Sheets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in millions)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:74.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfNC0xLTEtMS0xODE2NA_d3d7f6e9-d736-42ef-8048-7e38d3f69e94">295.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfNC0zLTEtMS0xODE2NA_21573806-7b6c-44e9-ac7e-56f72e96ff19">117.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable investment securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930" decimals="-5" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfNS0xLTEtMS0xODE2NA_5b3a3db6-b61f-4623-b7c2-c22be3f55253">70.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231" decimals="-5" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfNS0zLTEtMS0xODE2NA_4f043a99-f955-47a7-b22b-3863244c5654">33.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfNi0xLTEtMS0xODE2NA_4a7b0e15-0993-48bb-ac81-8e9e8ba33a6f">93.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfNi0zLTEtMS0xODE2NA_c24fcc0a-1bf7-45e2-95b2-009c6323a063">89.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930" decimals="-5" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfNy0xLTEtMS0xODE2NA_41d21a86-b4a8-48b7-8308-231ae38db79c">18.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231" decimals="-5" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfNy0zLTEtMS0xODE2NA_7448e780-4de2-4c52-a4b8-a192717adc92">27.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930" decimals="-5" name="us-gaap:PrepaidTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfOS0xLTEtMS0xODE2NA_8c763535-a362-49bb-b195-e3abcf893861">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231" decimals="-5" name="us-gaap:PrepaidTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfOS0zLTEtMS0xODE2NA_72c0e6b4-4866-4104-8774-1baa09a32a7a">108.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930" decimals="-5" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfMTAtMS0xLTEtMTgxNjQ_92347ac0-ff42-4505-810e-724a9895b08f">20.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231" decimals="-5" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfMTAtMy0xLTEtMTgxNjQ_587d7ea3-afcb-4bf2-a197-6dc336fa731e">13.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930" decimals="-5" name="us-gaap:AssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfMTEtMS0xLTEtMTgxNjQ_cd77b91b-cb50-484a-8539-97e107039695">498.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231" decimals="-5" name="us-gaap:AssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfMTEtMy0xLTEtMTgxNjQ_3785fe2e-c71a-4363-ab5f-a08934c20493">389.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfMTItMS0xLTEtMTgxNjQ_c65816e1-524e-464e-be56-18b0f2e7b89d">83.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfMTItMy0xLTEtMTgxNjQ_c86ff5ac-e4be-47d3-bb2d-bca4fb5bc62f">59.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term marketable investment securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930" decimals="-5" name="us-gaap:MarketableSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfMTMtMS0xLTEtMTgxNjQ_d0652cc8-ff0a-4db5-b4ed-17431dda5252">47.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231" decimals="-5" name="us-gaap:MarketableSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfMTMtMy0xLTEtMTgxNjQ_ef6c4831-2da6-4b41-aac8-855039e6cad5">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant, and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfMTQtMS0xLTEtMTgxNjQ_cf38ef2f-dbf5-48ee-8514-4dba41d6b7f9">43.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfMTQtMy0xLTEtMTgxNjQ_00f16b00-4065-4fc7-9db5-3e5a41100649">40.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangibles, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfMTUtMS0xLTEtMTgxNjQ_bae631dc-8661-4478-9de6-f4598fe07a2d">414.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfMTUtMy0xLTEtMTgxNjQ_aa55c803-e276-42ee-be10-eb014c31616e">576.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930" decimals="-5" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfMTYtMS0xLTEtMTgxNjQ_ec36e420-f857-40bd-9451-fab3a7adf079">239.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231" decimals="-5" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfMTYtMy0xLTEtMTgxNjQ_b5f99a3f-0889-4f2f-a252-e33252c8759c">329.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930" decimals="-5" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfMTctMS0xLTEtMTgxNjQ_1dbe64bd-70bb-4b25-a83d-c6052c39050f">8.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231" decimals="-5" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfMTctMy0xLTEtMTgxNjQ_37663049-b2b3-4c93-9800-a4946aa9a0f8">2.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfMTgtMS0xLTEtMTgxNjQ_0de1e99f-d3a7-45c7-91e2-e785cebcd278">1,335.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfMTgtMy0xLTEtMTgxNjQ_b5e140c9-b49d-4ca1-9c92-2ddc97bf1e96">1,418.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LIABILITIES AND STOCKHOLDERS' EQUITY</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930" decimals="-5" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfMjEtMS0xLTEtMTgxNjQ_da2aadaf-5a9a-4f05-98f0-0c2ef69e4cb8">15.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231" decimals="-5" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfMjEtMy0xLTEtMTgxNjQ_72b93a4c-d644-4435-96b2-33d758997067">20.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930" decimals="-5" name="us-gaap:AccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfMjItMS0xLTEtMTgxNjQ_9144c901-e75e-47b6-9b7f-6ff3db3036a4">163.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231" decimals="-5" name="us-gaap:AccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfMjItMy0xLTEtMTgxNjQ_6f8b5cfd-04a4-4013-8009-b2fbfb6cf3e4">79.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current maturities of operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930" decimals="-5" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfMjMtMS0xLTEtMTgxNjQ_6a5b4c7a-ee82-47d6-b5c2-84183ba442f0">12.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231" decimals="-5" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfMjMtMy0xLTEtMTgxNjQ_cccf1ccf-c040-4156-9425-53cb71d91390">13.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfMjQtMS0xLTEtMTgxNjQ_ba53f249-0912-4a4e-a141-3116579a75a7">11.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfMjQtMy0xLTEtMTgxNjQ_a0b7f4e3-7bb0-4b5a-9755-db1854326f92">32.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930" decimals="-5" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfMjctMS0xLTEtMTgxNjQ_d18c0e13-681e-4801-b005-de785e9eb686">203.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231" decimals="-5" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfMjctMy0xLTEtMTgxNjQ_14364af2-b40d-44c5-9d9f-49062f51918e">145.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrecognized tax benefits</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfMjgtMS0xLTEtMTgxNjQ_7ea33e76-dd34-4831-b708-408835168d35">32.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfMjgtMy0xLTEtMTgxNjQ_95dd40fb-76cc-4730-b862-5189c9c0e44f">30.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term deferred taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930" decimals="-5" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfMjktMS0xLTEtMTgxNjQ_5efbc52d-4c39-4f01-997b-7bd2d41a7eca">40.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231" decimals="-5" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfMjktMy0xLTEtMTgxNjQ_930e1ded-4b1f-4699-83d4-8fa66914c923">71.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Noncurrent operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfMzAtMS0xLTEtMTgxNjQ_4504c41c-b88a-4cd3-8566-3fe26d12eb66">80.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfMzAtMy0xLTEtMTgxNjQ_e2fb8299-49e8-4266-b697-0b07fc55720d">50.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfMzEtMS0xLTEtMTgxNjQ_5e3815d0-9e5e-4fe9-8060-73db2d8bade6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231" decimals="-5" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfMzEtMy0xLTEtMTgxNjQ_da3e3f4a-10a4-4a0b-b717-a68c154b3652">224.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfMzItMS0xLTEtMTgxNjQ_5b5c868c-685f-4360-8db0-3944859114e9">10.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfMzItMy0xLTEtMTgxNjQ_a1e9ba7b-7d7c-4ec0-bb49-2cf366658b8e">14.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930" decimals="-5" name="us-gaap:Liabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfMzMtMS0xLTEtMTgxNjQ_36c677aa-02f4-4112-ab44-cfa729fd69e5">367.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231" decimals="-5" name="us-gaap:Liabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfMzMtMy0xLTEtMTgxNjQ_984aac74-7e6a-4ba0-ba9f-3d6581b5a272">537.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commitments and contingencies</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfMzQtMS0xLTEtMTgxNjQ_17e0d001-89f8-4a3c-94c2-0aa26dc1e688"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfMzQtMy0xLTEtMTgxNjQ_a2cf8ff8-1c82-4db1-b386-3823e111ff6d"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stock, <ix:nonFraction unitRef="shares" contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfMzYtMC0xLTEtMTgxNjQvdGV4dHJlZ2lvbjpjYjIyMDIzYWUzY2Q0MDIxYTQ2MGNjNzI2NTU1Mzc4NV8xOA_0e86a9f9-11b7-4000-82c5-e04f1b9ad688">79.7</ix:nonFraction> million and <ix:nonFraction unitRef="shares" contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfMzYtMC0xLTEtMTgxNjQvdGV4dHJlZ2lvbjpjYjIyMDIzYWUzY2Q0MDIxYTQ2MGNjNzI2NTU1Mzc4NV8yNQ_de819335-b25f-4e23-97f6-9414b8c7633b">75.4</ix:nonFraction> million shares outstanding at September&#160;30, 2021 and December 31, 2020, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930" decimals="-5" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfMzYtMS0xLTEtMTgxNjQ_360751c8-8f1c-4da7-a264-f11fa8fa619b">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231" decimals="-5" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfMzYtMy0xLTEtMTgxNjQ_0a41cede-4b1e-4c0a-8a64-b11a319323dc">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfMzctMS0xLTEtMTgxNjQ_3ccd035c-d9a9-4dfd-8acf-3d181e8dc9fc">1,218.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfMzctMy0xLTEtMTgxNjQ_fab12ea7-02bd-408b-a3d4-b79375e2ddee">1,109.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfMzgtMS0xLTEtMTgxNjQ_79826020-cd6f-4c1c-b288-796c14ed0457">4.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfMzgtMy0xLTEtMTgxNjQ_42e4f0db-371a-4c0a-943e-bd4514a18c12">2.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfMzktMS0xLTEtMTgxNjQ_eeef7933-91b8-41a9-87d6-cf68de73b0fa">246.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfMzktMy0xLTEtMTgxNjQ_98f7af64-5015-4ee2-9950-fb68ea49b127">227.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Myriad Genetics, Inc. stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfNDAtMS0xLTEtMTgxNjQ_517291a5-4271-49a3-a12a-b09db42f6ba1">968.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfNDAtMy0xLTEtMTgxNjQ_432997ca-c7e9-48a6-b457-1b718527dda0">881.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-controlling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930" decimals="-5" sign="-" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfNDEtMS0xLTEtMTgxNjQ_46480876-9514-4054-b383-0c542bfab0b4">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfNDEtMy0xLTEtMTgxNjQ_a84e6d85-fed6-4742-8891-70e76e619625">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stockholders' equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfNDItMS0xLTEtMTgxNjQ_f985232f-e58b-4d80-948a-9eba40a3022c">968.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfNDItMy0xLTEtMTgxNjQ_e7c851b7-96f7-4bdc-85b0-1ff1fedf12a5">881.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfNDMtMS0xLTEtMTgxNjQ_dd4bbd0f-839a-4e34-9a99-f0d1baaeb21b">1,335.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfNDMtMy0xLTEtMTgxNjQ_c41958ef-d01c-47d7-a11d-9272cd7c4ea8">1,418.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to Condensed Consolidated Financial Statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i5814a71962934792901cb2330361bb17_19"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5814a71962934792901cb2330361bb17_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MYRIAD GENETICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Condensed Consolidated Statements of Operations (unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in millions, except per share amounts)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.309%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.577%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine months ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molecular diagnostic testing</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ifbc28960af99464087c70e2155273621_D20210701-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMy0xLTEtMS0xODE2NA_4795704e-aa44-4b57-a8c9-3127cb849d4f">167.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="icc0e2c6320b64071a6e19bf0ded7e102_D20200701-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMy0zLTEtMS0xODE2NA_c298afdb-2442-4fb7-91e5-fa879f4bb31f">135.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie8a469542115473daa7666e3dceae657_D20210101-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMy01LTEtMS0xODE2NA_dbe912c3-93ed-4d1a-a3df-ce54061ee4c8">505.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie51b08f1c1f44da4bb023303aa0fb7d9_D20200101-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMy03LTEtMS0xODE2NA_2acf78a7-1ca4-4578-9ecc-c89d283daa10">369.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical and clinical services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i79cd3eef56ae4f639da562ce851a382e_D20210701-20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfNC0xLTEtMS0xODE2NA_47219182-7810-483b-a86e-a8728299174c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie94a660aba69415a910d7f90711081eb_D20200701-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfNC0zLTEtMS0xODE2NA_f5cdbf58-edf8-46e1-b3f8-e3efb13e3ab0">9.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i695f1ac67bde49628842e3563e17c85e_D20210101-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfNC01LTEtMS0xODE2NA_7ce9a299-53da-457e-bb39-0d4aa074bd9b">24.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib855c77efb97481b968697136ef35610_D20200101-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfNC03LTEtMS0xODE2NA_55a8e536-acc5-42ab-899e-d9d0e8d0d07a">32.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfNS0xLTEtMS0xODE2NA_160cbe9c-fa52-4bcc-9baa-56e1c24c254e">167.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic2c3e03438af4889ac973627c642f5ec_D20200701-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfNS0zLTEtMS0xODE2NA_d5b35215-d8eb-44d3-8c65-8a9d96fe3763">145.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfNS01LTEtMS0xODE2NA_c941c349-327d-4dca-bd1a-5099bb33fbab">529.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfNS03LTEtMS0xODE2NA_536a7551-dee3-48dd-a3aa-bdae86640650">402.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs and expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of molecular diagnostic testing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ifbc28960af99464087c70e2155273621_D20210701-20210930" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfNy0xLTEtMS0xODE2NA_1b7e1c4a-50f2-4196-ad1e-6b13df3054d4">47.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="icc0e2c6320b64071a6e19bf0ded7e102_D20200701-20200930" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfNy0zLTEtMS0xODE2NA_14ecc94d-b222-416f-97d1-238710f3586a">39.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie8a469542115473daa7666e3dceae657_D20210101-20210930" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfNy01LTEtMS0xODE2NA_8bd3b69a-b612-4b10-bff5-8ed727ccb1b9">139.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie51b08f1c1f44da4bb023303aa0fb7d9_D20200101-20200930" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfNy03LTEtMS0xODE2NA_c0c48be0-5537-48a2-bd06-c9f2ba0c47bc">115.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of pharmaceutical and clinical services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i79cd3eef56ae4f639da562ce851a382e_D20210701-20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfOC0xLTEtMS0xODE2NA_a3b19587-163a-4b97-a9f3-98b03de70d9a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie94a660aba69415a910d7f90711081eb_D20200701-20200930" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfOC0zLTEtMS0xODE2NA_0a143a34-33d5-4ad3-a15f-3a38d52ead9f">4.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i695f1ac67bde49628842e3563e17c85e_D20210101-20210930" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfOC01LTEtMS0xODE2NA_3b5380f6-00a4-47f7-be85-9f8e30c6f202">11.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib855c77efb97481b968697136ef35610_D20200101-20200930" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfOC03LTEtMS0xODE2NA_32e8f46b-7fd4-40b6-8b0e-155306913532">15.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfOS0xLTEtMS0xODE2NA_da070723-cbe2-4cb2-9def-e258e62fd1dc">18.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic2c3e03438af4889ac973627c642f5ec_D20200701-20200930" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfOS0zLTEtMS0xODE2NA_40c9e451-130a-4183-877c-b506aeb5a10a">17.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfOS01LTEtMS0xODE2NA_524833f4-70a5-4517-ace6-f2f04c05e4cd">61.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfOS03LTEtMS0xODE2NA_3523e7f5-4a35-46f3-9171-48c3e52a0a3f">54.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general, and administrative expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMTAtMS0xLTEtMTgxNjQ_4fe9c70b-3596-4548-975c-5f141aa97d93">180.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic2c3e03438af4889ac973627c642f5ec_D20200701-20200930" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMTAtMy0xLTEtMTgxNjQ_dd8ad2ee-7b56-4a8e-b7d3-ec124f15e57b">124.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMTAtNS0xLTEtMTgxNjQ_cbb8ad65-61b1-40d7-a1d0-bb64d9fa15aa">460.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMTAtNy0xLTEtMTgxNjQ_c8d65ca6-a4e3-425c-b2ba-6310def39bb1">364.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in the fair value of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMTEtMS0xLTEtMTgxNjQ_17e71853-7b89-4f4b-b1ce-ff5e180050d1">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ic2c3e03438af4889ac973627c642f5ec_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMTEtMy0xLTEtMTgxNjQ_80765321-c202-4448-a619-54fa253abdee">1.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMTEtNS0xLTEtMTgxNjQ_8f1fb03f-0c47-4a43-9dd6-1fa4809dd95c">1.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMTEtNy0xLTEtMTgxNjQ_915455f1-df41-4afd-be1c-7c7c16980dbc">4.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill and long-lived asset impairment charges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:GoodwillAndIntangibleAssetImpairment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMTItMS0xLTEtMTgxNjQ_94348c9e-4a87-41d8-9726-177e07b5dcc3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic2c3e03438af4889ac973627c642f5ec_D20200701-20200930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:GoodwillAndIntangibleAssetImpairment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMTItMy0xLTEtMTgxNjQ_0158d351-7423-40a0-a90c-5a808da2c819">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" decimals="-5" name="us-gaap:GoodwillAndIntangibleAssetImpairment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMTItNS0xLTEtMTgxNjQ_2f8e4b93-dd9d-486f-8d51-355b9440e02e">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930" decimals="-5" name="us-gaap:GoodwillAndIntangibleAssetImpairment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMTItNy0xLTEtMTgxNjQ_1620edd7-03ad-4fea-a5ab-c51cb677a283">98.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total costs and expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMTMtMS0xLTEtMTgxNjQ_d9555c38-528c-40b6-a91f-b69aa544786f">247.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic2c3e03438af4889ac973627c642f5ec_D20200701-20200930" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMTMtMy0xLTEtMTgxNjQ_64f53080-e1ab-4b58-8b6b-e5412e747b19">184.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMTMtNS0xLTEtMTgxNjQ_13c9673b-ffc6-439d-bcba-56d26405f64d">677.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMTMtNy0xLTEtMTgxNjQ_48e10758-5b79-4241-b3e6-95f98a8a2063">644.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMTQtMS0xLTEtMTgxNjQ_34c83d2b-c054-4e14-8fdc-72dfd0273dfd">79.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ic2c3e03438af4889ac973627c642f5ec_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMTQtMy0xLTEtMTgxNjQ_169f8039-7d00-44bc-9126-cf445d772fbe">39.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMTQtNS0xLTEtMTgxNjQ_cf3cc77c-c831-4783-8c6b-4b1a5eac8959">147.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMTQtNy0xLTEtMTgxNjQ_ad483248-f1d4-405b-aca9-0b8854786b96">241.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930" decimals="-5" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMTYtMS0xLTEtMTgxNjQ_d66f1dde-c963-4da9-8c86-b80bf3bd299b">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic2c3e03438af4889ac973627c642f5ec_D20200701-20200930" decimals="-5" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMTYtMy0xLTEtMTgxNjQ_89c9b2cc-e3a5-4b28-ad22-828ddccf9c75">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" decimals="-5" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMTYtNS0xLTEtMTgxNjQ_8f941836-837b-4454-a1f9-ae4d004cee65">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930" decimals="-5" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMTYtNy0xLTEtMTgxNjQ_a3522544-7534-435a-807d-f2de3a743ec7">1.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMTctMS0xLTEtMTgxNjQ_5fbdb68b-1deb-4a8e-ae3c-d95fe508db09">1.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ic2c3e03438af4889ac973627c642f5ec_D20200701-20200930" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMTctMy0xLTEtMTgxNjQ_161ce08f-5759-4f0d-95ed-10fa639e5236">2.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMTctNS0xLTEtMTgxNjQ_19bae33b-07fa-4683-86f5-3cc3094c13c3">6.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMTctNy0xLTEtMTgxNjQ_d685b969-5c5d-43da-936d-60c600f67a95">8.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMTgtMS0xLTEtMTgxNjQ_fc26f893-7078-4eaf-96d2-9e44a4a64c22">120.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ic2c3e03438af4889ac973627c642f5ec_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMTgtMy0xLTEtMTgxNjQ_999cc151-d702-401f-b4c3-9ea063679592">1.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMTgtNS0xLTEtMTgxNjQ_6de3ee92-9c71-480c-87c5-0aef02c4ceaf">139.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMTgtNy0xLTEtMTgxNjQ_a05cccad-30fa-40c3-9060-21ba30226d3a">14.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930" decimals="-5" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMTktMS0xLTEtMTgxNjQ_2f96b92a-c4cd-424d-a978-1b65ee321b5e">119.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ic2c3e03438af4889ac973627c642f5ec_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMTktMy0xLTEtMTgxNjQ_09b1e35e-ab75-43dc-ae99-356d1ae3a13d">4.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" decimals="-5" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMTktNS0xLTEtMTgxNjQ_b53e916b-f654-4428-9adf-97c886011938">133.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930" decimals="-5" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMTktNy0xLTEtMTgxNjQ_c0d8bf87-647a-403b-ac0d-2f826a087f79">8.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income (loss) before income tax</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMjAtMS0xLTEtMTgxNjQ_cc3f2039-cf30-4010-9c5d-ad0374b595eb">39.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ic2c3e03438af4889ac973627c642f5ec_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMjAtMy0xLTEtMTgxNjQ_d48d2b2a-0716-4764-91ea-3d0ed7221ecb">43.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMjAtNS0xLTEtMTgxNjQ_92c052c5-5c3c-4745-8844-313193b606f7">13.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMjAtNy0xLTEtMTgxNjQ_39db9493-0e1b-452c-9577-f2ee5fd6c763">233.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax expense (benefit)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMjEtMS0xLTEtMTgxNjQ_56ad8eb3-6175-40af-ad1c-52446cce1d79">15.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ic2c3e03438af4889ac973627c642f5ec_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMjEtMy0xLTEtMTgxNjQ_9e148a86-9a9c-40e8-b8f4-15259ca011eb">28.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMjEtNS0xLTEtMTgxNjQ_fb2144d5-b28f-4212-8d7b-6a375f875dc5">6.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMjEtNy0xLTEtMTgxNjQ_229c7a36-1986-4293-8cf9-37c6bd88793b">47.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMjItMS0xLTEtMTgxNjQ_d69d3624-96b0-4720-ae62-9d826fd145b1">24.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ic2c3e03438af4889ac973627c642f5ec_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMjItMy0xLTEtMTgxNjQ_eff902e2-0c51-434c-8fc9-75e1f87f3173">15.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMjItNS0xLTEtMTgxNjQ_60308322-614c-426b-a4e3-c45615614b76">19.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMjItNy0xLTEtMTgxNjQ_939280dd-772c-495c-a2be-a2f00bf7edcc">185.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss attributable to non-controlling interest</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMjMtMS0xLTEtMTgxNjQ_d352147b-0aa3-4ef4-8bca-0d27a208f385">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic2c3e03438af4889ac973627c642f5ec_D20200701-20200930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMjMtMy0xLTEtMTgxNjQ_6a55236f-2490-4c2a-bf15-1dd3da01f542">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMjMtNS0xLTEtMTgxNjQ_8fb83360-4745-403f-a162-c89c8bd4e8c9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMjMtNy0xLTEtMTgxNjQ_e976ca03-feda-4586-879c-9238935dd349">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income (loss) attributable to Myriad Genetics, Inc. stockholders</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMjQtMS0xLTEtMTgxNjQ_df2b0bb6-822a-4101-9045-fe01978adbcb">24.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ic2c3e03438af4889ac973627c642f5ec_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMjQtMy0xLTEtMTgxNjQ_b153b368-ca44-454d-8ee3-53f824969636">15.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMjQtNS0xLTEtMTgxNjQ_b03736f6-45b4-48bd-a863-d700108d10ce">19.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMjQtNy0xLTEtMTgxNjQ_01f21dd6-48ce-4000-b6d9-c8ea236bdeab">185.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income (loss) per share:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMjYtMS0xLTEtMTgxNjQ_50a9a26e-9573-42cd-a861-8799f789bc41">0.31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ic2c3e03438af4889ac973627c642f5ec_D20200701-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMjYtMy0xLTEtMTgxNjQ_c634d5ca-92d8-4eda-9616-e7935d0ed38c">0.20</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMjYtNS0xLTEtMTgxNjQ_2910ba48-1533-45a2-9c9d-b02783f28144">0.25</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMjYtNy0xLTEtMTgxNjQ_e1a7c20a-1917-4c63-9a45-8cb593c99f4b">2.49</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMjctMS0xLTEtMjE4ODA_209f2c76-07a7-4efa-b96d-dc76081f1610">0.30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ic2c3e03438af4889ac973627c642f5ec_D20200701-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMjctMy0xLTEtMjE4ODA_d5924d25-beb3-47b2-92ce-bdcda9414935">0.20</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMjctNS0xLTEtMjE4ODA_bdcf2018-b6e8-4fb0-9aec-00e2aa0daa46">0.25</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMjctNy0xLTEtMjE4ODA_a61aed65-e4bc-4b8f-9674-b71cba3b331d">2.49</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average shares outstanding:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMjgtMS0xLTEtMTgxNjQ_a839bcee-936f-4da2-90a7-4ef06eb92f24">78.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ic2c3e03438af4889ac973627c642f5ec_D20200701-20200930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMjgtMy0xLTEtMTgxNjQ_ca57c2b0-7659-4968-a30e-f079b005c5ed">74.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMjgtNS0xLTEtMTgxNjQ_c25a4093-f22d-4252-980e-2f5091b35d75">77.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMjgtNy0xLTEtMTgxNjQ_df558b05-2795-4af0-918c-1747adf389c1">74.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diluted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMzAtMS0xLTEtMjE4ODI_0c8e7e01-606d-4602-9b86-76f5f588ed17">81.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ic2c3e03438af4889ac973627c642f5ec_D20200701-20200930" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMzAtMy0xLTEtMjE4ODI_313ea036-ce0e-4367-a1ff-4eeb11b01890">74.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMzAtNS0xLTEtMjE4ODI_a5575434-e859-44fb-b629-dbcc493119bf">77.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMzAtNy0xLTEtMjE4ODI_ef1438e0-341d-43a0-9af5-96b63527f652">74.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to Condensed Consolidated Financial Statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i5814a71962934792901cb2330361bb17_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5814a71962934792901cb2330361bb17_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MYRIAD GENETICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Condensed Consolidated Statements of Comprehensive Income (Loss) (unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in millions)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.309%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.577%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine months ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income (loss) attributable to Myriad Genetics, Inc. stockholders</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yMi9mcmFnOjc1NDM0MThjZWZjZDRmYjZiYjMzZmRlY2UzMDdmMzIxL3RhYmxlOmU4ZTFhMzg1YzI4NTQyNmRiMGMyNjM1ZjYyMTM2M2ZiL3RhYmxlcmFuZ2U6ZThlMWEzODVjMjg1NDI2ZGIwYzI2MzVmNjIxMzYzZmJfMi0xLTEtMS0xODE2NA_ddeca0ea-ec8b-4f5f-906b-086244fc866a">24.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ic2c3e03438af4889ac973627c642f5ec_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yMi9mcmFnOjc1NDM0MThjZWZjZDRmYjZiYjMzZmRlY2UzMDdmMzIxL3RhYmxlOmU4ZTFhMzg1YzI4NTQyNmRiMGMyNjM1ZjYyMTM2M2ZiL3RhYmxlcmFuZ2U6ZThlMWEzODVjMjg1NDI2ZGIwYzI2MzVmNjIxMzYzZmJfMi0zLTEtMS0xODE2NA_ec9b41dc-21b2-4499-a77f-5f0f05d8bf03">15.2</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yMi9mcmFnOjc1NDM0MThjZWZjZDRmYjZiYjMzZmRlY2UzMDdmMzIxL3RhYmxlOmU4ZTFhMzg1YzI4NTQyNmRiMGMyNjM1ZjYyMTM2M2ZiL3RhYmxlcmFuZ2U6ZThlMWEzODVjMjg1NDI2ZGIwYzI2MzVmNjIxMzYzZmJfMi01LTEtMS0xODE2NA_4b2380f7-faf6-4817-9f6c-2fd25cfa391d">19.6</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yMi9mcmFnOjc1NDM0MThjZWZjZDRmYjZiYjMzZmRlY2UzMDdmMzIxL3RhYmxlOmU4ZTFhMzg1YzI4NTQyNmRiMGMyNjM1ZjYyMTM2M2ZiL3RhYmxlcmFuZ2U6ZThlMWEzODVjMjg1NDI2ZGIwYzI2MzVmNjIxMzYzZmJfMi03LTEtMS0xODE2NA_b3e0d203-6254-4233-ae82-9debeea383fb">185.8</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized gain (loss) on available-for-sale debt securities, net of tax</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yMi9mcmFnOjc1NDM0MThjZWZjZDRmYjZiYjMzZmRlY2UzMDdmMzIxL3RhYmxlOmU4ZTFhMzg1YzI4NTQyNmRiMGMyNjM1ZjYyMTM2M2ZiL3RhYmxlcmFuZ2U6ZThlMWEzODVjMjg1NDI2ZGIwYzI2MzVmNjIxMzYzZmJfMy0xLTEtMS0xODE2NA_95f87e5e-8f7b-4120-b3f0-56715e5dfd24">0.2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ic2c3e03438af4889ac973627c642f5ec_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yMi9mcmFnOjc1NDM0MThjZWZjZDRmYjZiYjMzZmRlY2UzMDdmMzIxL3RhYmxlOmU4ZTFhMzg1YzI4NTQyNmRiMGMyNjM1ZjYyMTM2M2ZiL3RhYmxlcmFuZ2U6ZThlMWEzODVjMjg1NDI2ZGIwYzI2MzVmNjIxMzYzZmJfMy0zLTEtMS0xODE2NA_8b0acd45-7f84-45c9-bab6-abd1e048327a">0.2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yMi9mcmFnOjc1NDM0MThjZWZjZDRmYjZiYjMzZmRlY2UzMDdmMzIxL3RhYmxlOmU4ZTFhMzg1YzI4NTQyNmRiMGMyNjM1ZjYyMTM2M2ZiL3RhYmxlcmFuZ2U6ZThlMWEzODVjMjg1NDI2ZGIwYzI2MzVmNjIxMzYzZmJfMy01LTEtMS0xODE2NA_d782a635-ace3-4540-a8a0-35918993e29f">0.5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yMi9mcmFnOjc1NDM0MThjZWZjZDRmYjZiYjMzZmRlY2UzMDdmMzIxL3RhYmxlOmU4ZTFhMzg1YzI4NTQyNmRiMGMyNjM1ZjYyMTM2M2ZiL3RhYmxlcmFuZ2U6ZThlMWEzODVjMjg1NDI2ZGIwYzI2MzVmNjIxMzYzZmJfMy03LTEtMS0xODE2NA_00330840-9a10-4914-9891-6267f9ef9e33">0.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in foreign currency translation adjustment, net of tax</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yMi9mcmFnOjc1NDM0MThjZWZjZDRmYjZiYjMzZmRlY2UzMDdmMzIxL3RhYmxlOmU4ZTFhMzg1YzI4NTQyNmRiMGMyNjM1ZjYyMTM2M2ZiL3RhYmxlcmFuZ2U6ZThlMWEzODVjMjg1NDI2ZGIwYzI2MzVmNjIxMzYzZmJfNC0xLTEtMS0xODE2NA_586d838c-87bc-4138-a9da-0a2efff6f00a">0.2</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic2c3e03438af4889ac973627c642f5ec_D20200701-20200930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yMi9mcmFnOjc1NDM0MThjZWZjZDRmYjZiYjMzZmRlY2UzMDdmMzIxL3RhYmxlOmU4ZTFhMzg1YzI4NTQyNmRiMGMyNjM1ZjYyMTM2M2ZiL3RhYmxlcmFuZ2U6ZThlMWEzODVjMjg1NDI2ZGIwYzI2MzVmNjIxMzYzZmJfNC0zLTEtMS0xODE2NA_f816f39d-2c2d-41e4-8448-e575c8e7a930">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yMi9mcmFnOjc1NDM0MThjZWZjZDRmYjZiYjMzZmRlY2UzMDdmMzIxL3RhYmxlOmU4ZTFhMzg1YzI4NTQyNmRiMGMyNjM1ZjYyMTM2M2ZiL3RhYmxlcmFuZ2U6ZThlMWEzODVjMjg1NDI2ZGIwYzI2MzVmNjIxMzYzZmJfNC01LTEtMS0xODE2NA_bbcc27fa-9367-4a33-9803-b68a20ea3bb5">1.6</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yMi9mcmFnOjc1NDM0MThjZWZjZDRmYjZiYjMzZmRlY2UzMDdmMzIxL3RhYmxlOmU4ZTFhMzg1YzI4NTQyNmRiMGMyNjM1ZjYyMTM2M2ZiL3RhYmxlcmFuZ2U6ZThlMWEzODVjMjg1NDI2ZGIwYzI2MzVmNjIxMzYzZmJfNC03LTEtMS0xODE2NA_c7bba50a-949f-4b2b-8438-47da93e1e05e">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive income (loss)</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yMi9mcmFnOjc1NDM0MThjZWZjZDRmYjZiYjMzZmRlY2UzMDdmMzIxL3RhYmxlOmU4ZTFhMzg1YzI4NTQyNmRiMGMyNjM1ZjYyMTM2M2ZiL3RhYmxlcmFuZ2U6ZThlMWEzODVjMjg1NDI2ZGIwYzI2MzVmNjIxMzYzZmJfNS0xLTEtMS0xODE2NA_bbcc669b-92f8-45e9-ba40-21d23b367416">24.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ic2c3e03438af4889ac973627c642f5ec_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yMi9mcmFnOjc1NDM0MThjZWZjZDRmYjZiYjMzZmRlY2UzMDdmMzIxL3RhYmxlOmU4ZTFhMzg1YzI4NTQyNmRiMGMyNjM1ZjYyMTM2M2ZiL3RhYmxlcmFuZ2U6ZThlMWEzODVjMjg1NDI2ZGIwYzI2MzVmNjIxMzYzZmJfNS0zLTEtMS0xODE2NA_2e515e9c-ba30-4239-b991-a9694ef8afce">13.6</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yMi9mcmFnOjc1NDM0MThjZWZjZDRmYjZiYjMzZmRlY2UzMDdmMzIxL3RhYmxlOmU4ZTFhMzg1YzI4NTQyNmRiMGMyNjM1ZjYyMTM2M2ZiL3RhYmxlcmFuZ2U6ZThlMWEzODVjMjg1NDI2ZGIwYzI2MzVmNjIxMzYzZmJfNS01LTEtMS0xODE2NA_13895aa2-9870-42fe-84e7-22b9e2519628">21.7</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yMi9mcmFnOjc1NDM0MThjZWZjZDRmYjZiYjMzZmRlY2UzMDdmMzIxL3RhYmxlOmU4ZTFhMzg1YzI4NTQyNmRiMGMyNjM1ZjYyMTM2M2ZiL3RhYmxlcmFuZ2U6ZThlMWEzODVjMjg1NDI2ZGIwYzI2MzVmNjIxMzYzZmJfNS03LTEtMS0xODE2NA_a791aeb8-100a-4463-a37d-fe70c31b7b22">184.2</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive income (loss) attributable to Myriad Genetics, Inc. stockholders</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yMi9mcmFnOjc1NDM0MThjZWZjZDRmYjZiYjMzZmRlY2UzMDdmMzIxL3RhYmxlOmU4ZTFhMzg1YzI4NTQyNmRiMGMyNjM1ZjYyMTM2M2ZiL3RhYmxlcmFuZ2U6ZThlMWEzODVjMjg1NDI2ZGIwYzI2MzVmNjIxMzYzZmJfNy0xLTEtMS0xODE2NA_c2330e81-e7c9-4bc8-8d33-24132b04f14c">24.2</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ic2c3e03438af4889ac973627c642f5ec_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yMi9mcmFnOjc1NDM0MThjZWZjZDRmYjZiYjMzZmRlY2UzMDdmMzIxL3RhYmxlOmU4ZTFhMzg1YzI4NTQyNmRiMGMyNjM1ZjYyMTM2M2ZiL3RhYmxlcmFuZ2U6ZThlMWEzODVjMjg1NDI2ZGIwYzI2MzVmNjIxMzYzZmJfNy0zLTEtMS0xODE2NA_8e747f41-71b1-40a3-b4e0-2558f032dbb1">13.6</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yMi9mcmFnOjc1NDM0MThjZWZjZDRmYjZiYjMzZmRlY2UzMDdmMzIxL3RhYmxlOmU4ZTFhMzg1YzI4NTQyNmRiMGMyNjM1ZjYyMTM2M2ZiL3RhYmxlcmFuZ2U6ZThlMWEzODVjMjg1NDI2ZGIwYzI2MzVmNjIxMzYzZmJfNy01LTEtMS0xODE2NA_aa41579b-df68-4fd8-b019-f87df1e2f5ad">21.7</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yMi9mcmFnOjc1NDM0MThjZWZjZDRmYjZiYjMzZmRlY2UzMDdmMzIxL3RhYmxlOmU4ZTFhMzg1YzI4NTQyNmRiMGMyNjM1ZjYyMTM2M2ZiL3RhYmxlcmFuZ2U6ZThlMWEzODVjMjg1NDI2ZGIwYzI2MzVmNjIxMzYzZmJfNy03LTEtMS0xODE2NA_2c8b779b-ef11-4d92-b5da-0cb32b181786">184.2</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to Condensed Consolidated Financial Statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="i5814a71962934792901cb2330361bb17_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5814a71962934792901cb2330361bb17_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MYRIAD GENETICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Condensed Consolidated Statements of Stockholders&#8217; Equity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in millions)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:30.811%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:9.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Common<br/>stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Additional<br/>paid-in<br/>capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Accumulated<br/>other<br/>comprehensive<br/>loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Accumulated<br/>deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Non-controlling interest</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Total<br/>stockholders&#8217;<br/>equity</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">BALANCES AT DECEMBER 31, 2019</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic932914e17ea4777879ab952bc47a286_I20191231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMS0xLTEtMS0xODE2NA_46bce2d1-6ff1-4f83-b4e6-8a9c4f30b8c1">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if653f84940094fdc88956b69c3739df5_I20191231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMS0zLTEtMS0xODE2NA_e33df6f4-04bf-4600-923c-f9eb641fedbf">1,085.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i9fd2bfc03de94eb4a23ff40a2dfd6fe7_I20191231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMS01LTEtMS0xODE2NA_eeba45dd-9d86-4835-ac5b-90dd64ddb27f">5.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i6735c278f56c4d2286aba604c5af25f6_I20191231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMS03LTEtMS0xODE2NA_54c22fc4-1f32-4e07-b132-20031751ff5e">3.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id8fe9a482f344283b898248f34c5db4d_I20191231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMS05LTEtMS0xODE2NA_1dec9e82-9ed3-4815-ad56-15f94f68881c">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic698543044ba4469ba8751bae898951c_I20191231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMS0xMy0xLTEtMTgxNjQ_f608570b-b1c5-4b40-b50b-58aa15614900">1,077.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Issuance of common stock under stock-based compensation plans, net of shares exchanged for withholding tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3c851333c120429494592618fb0e4572_D20200101-20200331" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMi0zLTEtMS0xODE2NA_77ea950f-8b63-4e08-995c-51ddd6dd7c06">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic26cca04ca2b4dd694bd9641fa5123c4_D20200101-20200331" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMi0xMy0xLTEtMTgxNjQ_331622e9-d6f2-433c-9af2-51f3b3eca853">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Stock-based payment expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c851333c120429494592618fb0e4572_D20200101-20200331" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMy0zLTEtMS0xODE2NA_63ec7a72-9d88-4899-afc9-2de183e298e7">7.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic26cca04ca2b4dd694bd9641fa5123c4_D20200101-20200331" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMy0xMy0xLTEtMTgxNjQ_0ced49a2-c54d-4d92-9f64-085575a248e7">7.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-controlling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ie993214cd1d8450aa22158093bdba0b6_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:MinorityInterestPeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfNC05LTEtMS0xODE2NA_266c7464-56ba-4399-b052-7f3fca357c3e">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ic26cca04ca2b4dd694bd9641fa5123c4_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:MinorityInterestPeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfNC0xMy0xLTEtMTgxNjQ_db3e0194-f86d-4daf-9743-e22e092397ba">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i8808683eb1f94ae4a2c56f558c2c44d0_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfNS03LTEtMS0xODE2NA_26a8f081-b84f-47d8-8b37-63336b582edb">115.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ic26cca04ca2b4dd694bd9641fa5123c4_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfNS0xMy0xLTEtMTgxNjQ_3f613c8f-50a7-4105-9ba6-d0b2c8c468ec">115.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Reclassification out of accumulated other comprehensive loss upon the deconsolidation of a subsidiary</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic487f8b588f74b249c58ff8b2e14f2f2_D20200101-20200331" decimals="-5" name="mygn:ReclassificationFromAccumulatedOtherComprehensiveLossDeconsolidationOfSubsidiary" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfNi01LTEtMS0xODE2NA_7b21a6eb-6c6a-457f-9cc5-591428551fdd">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic26cca04ca2b4dd694bd9641fa5123c4_D20200101-20200331" decimals="-5" name="mygn:ReclassificationFromAccumulatedOtherComprehensiveLossDeconsolidationOfSubsidiary" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfNi0xMy0xLTEtMTgxNjQ_dbeafcbb-3b7a-46fe-b66a-36dfa02d6d64">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other comprehensive loss, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ic487f8b588f74b249c58ff8b2e14f2f2_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfNy01LTEtMS0xODE2NA_0fcf254b-f47a-4d3d-9d6d-01be34dc50a9">2.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ic26cca04ca2b4dd694bd9641fa5123c4_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfNy0xMy0xLTEtMTgxNjQ_dc0ce079-cb92-4b11-8a0e-e3c6bb61d5a4">2.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">BALANCES AT MARCH 31, 2020</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i749ef50c3e724e34a1c233ae09ec290a_I20200331" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfOC0xLTEtMS0xODE2NA_0c329c17-bc0c-4600-a430-2af096033748">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i838807b0749e445cb7c40c97e6854df5_I20200331" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfOC0zLTEtMS0xODE2NA_66bfcf7b-0010-4e86-96fc-14d2e1ffc708">1,092.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ia60976ab8abc463ebc9edd0688cead34_I20200331" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfOC01LTEtMS0xODE2NA_1577a740-0878-41b5-b595-6f97022f74fe">7.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ia1c450cd54f5427891132bfd983e0317_I20200331" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfOC03LTEtMS0xODE2NA_1451116c-3a46-4046-95fc-eb3cc62765ca">118.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie2b71276d33f4f37af748f45b0cac148_I20200331" decimals="-5" format="ixt:fixed-zero" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfOC05LTEtMS0xODE2NA_bb230958-dbe1-4ff4-834d-eee2e3096b6f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i71bfb9a9cbab40e4b2ee82f3c9d4e30b_I20200331" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfOC0xMy0xLTEtMTgxNjQ_cc30e54a-b16b-4250-9834-5b69a507cdb5">967.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Issuance of common stock under stock-based compensation plans, net of shares exchanged for withholding tax</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib2ef1fdcdaaa463faa4cb4a9e259428b_D20200401-20200630" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfOS0zLTEtMS0xODE2NA_152a3160-6cad-4d27-a8b1-bdf75611324a">1.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i61643ef3fddf427bab68f34f288ffdbe_D20200401-20200630" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfOS0xMy0xLTEtMTgxNjQ_2c0417f6-bc83-4d84-98c0-c0cd89d97f74">1.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Stock-based payment expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2ef1fdcdaaa463faa4cb4a9e259428b_D20200401-20200630" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMTAtMy0xLTEtMTgxNjQ_cdc34687-4139-4d23-8700-f9224710f116">1.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61643ef3fddf427bab68f34f288ffdbe_D20200401-20200630" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMTAtMTMtMS0xLTE4MTY0_c55ce39f-8620-4559-8877-9dcc9aa353f6">1.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i273996af01934354b9835c65bd479b9e_D20200401-20200630" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMTEtNy0xLTEtMTgxNjQ_455d51a8-707d-4f01-b1bb-d7ada527a5a1">55.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i61643ef3fddf427bab68f34f288ffdbe_D20200401-20200630" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMTEtMTMtMS0xLTE4MTY0_2f16eead-dc25-4244-ab06-8e397e554fb8">55.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other comprehensive income, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ief2d705cf1e84ddebcf24754f7a3b890_D20200401-20200630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMTItNS0xLTEtMTgxNjQ_97dcd716-7acc-4e67-9f2c-658322903a6b">2.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i61643ef3fddf427bab68f34f288ffdbe_D20200401-20200630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMTItMTMtMS0xLTE4MTY0_b741316e-c49a-4a34-b937-50e62cfc5d60">2.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">BALANCES AT JUNE 30, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="idd849afda7b942948aa9c83f57ffaeac_I20200630" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMTMtMS0xLTEtMTgxNjQ_978c36cb-6c8b-4ab1-9d5c-d5d2105ecd55">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if5fc7e59c62b42ad92216ba6836b6eb8_I20200630" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMTMtMy0xLTEtMTgxNjQ_fb15d273-6d52-4775-913d-7e574d09e258">1,096.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i1bce2263b540455893f4d80b0de511c9_I20200630" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMTMtNS0xLTEtMTgxNjQ_f493e15b-4e21-46e9-8052-d018cbe60a45">5.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i8acfa22e3dc144acaa3254b56b5c801f_I20200630" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMTMtNy0xLTEtMTgxNjQ_ecf0ae08-c80c-4e4a-9984-2599741988e3">173.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibc4b5cd85a7a4e8291ff3e4c80dc8756_I20200630" decimals="-5" format="ixt:fixed-zero" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMTMtOS0xLTEtMTgxNjQ_3a85b9bf-b66c-4fca-bad1-3e6c190a9fb8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic976e79981cb4e17a90b071ed83778dd_I20200630" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMTMtMTMtMS0xLTE4MTY0_6e7bca12-eba9-4a25-9060-65105c8f3b4a">918.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Issuance of common stock under stock-based compensation plans, net of shares exchanged for withholding tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia9f2038ca2c74e13bf97f356d8a0ef8e_D20200701-20200930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMTQtMS0xLTEtMTk0MDY_f8fd0988-7cb8-421c-8409-e3255d7f4d75">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i809ae31b44854c4eab5bc730c4471cb7_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMTQtMy0xLTEtMTk0MDY_f1c4a37e-9bdb-4e25-a42d-5301a5826406">3.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ic2c3e03438af4889ac973627c642f5ec_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMTQtMTMtMS0xLTE5NDg5_4edb8c31-b4fb-4755-83f5-a7472d0c83a4">3.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Stock-based payment expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i809ae31b44854c4eab5bc730c4471cb7_D20200701-20200930" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMTUtMy0xLTEtMTk0MDY_6a9c7a60-5265-44c8-9b53-c3a676647f6d">8.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2c3e03438af4889ac973627c642f5ec_D20200701-20200930" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMTUtMTMtMS0xLTE5NDg5_eb6c18e1-9bf3-4b45-962b-e935eee48d91">8.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i7055540d7cfb415fafe2dac25f373950_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMTYtNy0xLTEtMTk0MDY_282f3cdb-b661-453a-a6c4-b39139b14911">15.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ic2c3e03438af4889ac973627c642f5ec_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMTYtMTMtMS0xLTE5NDg5_3ce8d88e-99c4-4062-8f21-e0a7dcb0c84b">15.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other comprehensive income, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic19852c9069943c28e1fa3345a711650_D20200701-20200930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMTctNS0xLTEtMTk0MDY_83bee0a2-0204-4aef-80bf-19476c68ed45">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic2c3e03438af4889ac973627c642f5ec_D20200701-20200930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMTctMTMtMS0xLTE5NDg5_13b3ff4f-2180-49ee-bc45-a68ffe56a11b">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">BALANCES AT SEPTEMBER 30, 2020</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i691c4f02f3464e09bb1a483b5726a5c3_I20200930" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMTgtMS0xLTEtMTk0MjI_b500e02a-4850-49dd-803d-c69eb37b462c">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i26e03ce4366849f4ad19d964861a49f7_I20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMTgtMy0xLTEtMTk0MjI_61b3083b-828b-49d4-ab9c-3ce3040407e9">1,101.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ib871f90b68b641f89b0eabe7f24ebcf9_I20200930" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMTgtNS0xLTEtMTk0MjI_c1dbcd4b-8121-44cf-bb6c-a57110f86aa2">3.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i5237cb26929043d6b2c706d0a5a289d6_I20200930" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMTgtNy0xLTEtMTk0MjI_0338fabc-25b4-4af8-a31f-6849cf298cf3">189.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9be196750c9340469be5f26a4d4e5835_I20200930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMTgtOS0xLTEtMTk0NjE_ddcde6ef-c8c1-4341-9e5f-fc54534a1e9f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0c6bac27ede64afeb4dbc13729f58578_I20200930" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMTgtMTMtMS0xLTE5NDg5_61a496d1-134e-4bc9-911c-a7516d19c5ba">909.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">BALANCES AT DECEMBER 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ifd82562daef9481db9764cfedc560e47_I20201231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMTUtMS0xLTEtMTgxNjQ_bcabf902-7b4a-4ec3-b8ce-9e04d280d351">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i602bb4299a7f49a78984421bea48e2d2_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMTUtMy0xLTEtMTgxNjQ_d82b8765-75dc-4bbf-9d45-39056cb50cf6">1,109.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i6f1113acaf4c4991a6389007d99fd17f_I20201231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMTUtNS0xLTEtMTgxNjQ_fa79e8f1-1a6d-45e0-9d3c-300a7915a603">2.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ic00338bab29748f28e289324358531f0_I20201231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMTUtNy0xLTEtMTgxNjQ_13802261-2cca-4b7d-ab31-564a7cceeda0">227.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="icc25381d7b004bd686b31d1d7f06dc8a_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMTUtOS0xLTEtMTgxNjQ_8fc54182-419c-4822-9418-a09d9942c9f4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMTUtMTMtMS0xLTE4MTY0_cc36c861-7a56-4815-b7c2-6fe3913595cd">881.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Issuance of common stock under stock-based compensation plans, net of shares exchanged for withholding tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0fd66a47efdc463d8b56854a06ea9eb0_D20210101-20210331" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMTYtMy0xLTEtMTgxNjQ_6300dd0e-474f-4247-a12c-987098ce1bb4">26.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie59a85cd0de74256a4070826a06ab2ee_D20210101-20210331" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMTYtMTMtMS0xLTE4MTY0_0e0451bf-32b9-45e4-8a63-d13d81e508c3">26.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Stock-based payment expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0fd66a47efdc463d8b56854a06ea9eb0_D20210101-20210331" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMTctMy0xLTEtMTgxNjQ_b0685d9c-516b-45fb-b500-aef3c0468f33">9.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie59a85cd0de74256a4070826a06ab2ee_D20210101-20210331" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMTctMTMtMS0xLTE4MTY0_81b6daa4-21ed-4984-bc8f-b4a59b896ea3">9.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i03600303e63e4b17b220e55c943b073d_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMTgtNy0xLTEtMTgxNjQ_958a8d04-2936-4abc-8fd0-cb2780e6cfb0">39.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ie59a85cd0de74256a4070826a06ab2ee_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMTgtMTMtMS0xLTE4MTY0_8acfddc6-b2ca-4c1e-8eeb-3b967466612c">39.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other comprehensive loss, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i1f2d8d71b25549ff846e9b42b31323ef_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMTktNS0xLTEtMTgxNjQ_7c27bb94-2997-44dc-a47e-6901006486b2">1.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ie59a85cd0de74256a4070826a06ab2ee_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMTktMTMtMS0xLTE4MTY0_d6f50997-5663-4b60-9c04-6a6120b968ec">1.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">BALANCES AT MARCH 31, 2021</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i740bb39577154e0a943a066cee5730d4_I20210331" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMjAtMS0xLTEtMTgxNjQ_8ede0b15-88a7-402e-bf1e-b265a34f107f">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i14c8904c520e416b9c51933b8b024cd1_I20210331" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMjAtMy0xLTEtMTgxNjQ_2bfb5c6a-29d8-45de-ad23-c2f846e37c20">1,144.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i9fa028178e4d40088533a95f689bc888_I20210331" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMjAtNS0xLTEtMTgxNjQ_9e9ae347-4e03-44ad-975d-0e5599e8c651">3.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i9644cd21559142acbc76c26cfab92eb6_I20210331" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMjAtNy0xLTEtMTgxNjQ_6398c026-6da9-4ada-ab44-db23eee78e63">266.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie6b465bbce9349f88227b2188438b68d_I20210331" decimals="-5" format="ixt:fixed-zero" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMjAtOS0xLTEtMTgxNjQ_f3178ec4-9a18-4be8-acd2-80f3aed20de1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i24dac68960214b9f993eaa8df10274b2_I20210331" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMjAtMTMtMS0xLTE4MTY0_60c4696c-b50e-4f5c-9cc2-ba859ac5f96a">875.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Issuance of common stock under stock-based compensation plans, net of shares exchanged for withholding tax</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8032c809a65c47bda9a36a0b5229bfef_D20210401-20210630" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMjEtMy0xLTEtMTgxNjQ_6c224715-c397-49a7-a2d7-972e9a3d6229">23.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9af20bf23942493aad5860b2c2e56978_D20210401-20210630" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMjEtMTMtMS0xLTE4MTY0_3cb5d6c6-3441-4da5-a286-4a4d4739a36b">23.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Stock-based payment expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8032c809a65c47bda9a36a0b5229bfef_D20210401-20210630" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMjItMy0xLTEtMTgxNjQ_dbcfb3ea-4ad9-4d1a-95f9-119c57e037c8">8.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9af20bf23942493aad5860b2c2e56978_D20210401-20210630" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMjItMTMtMS0xLTE4MTY0_0c03fe92-48b0-4ff8-8c44-d86be62f147e">8.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-controlling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ie2a868eedf484113abf4a011ceff8fd4_D20210401-20210630" decimals="-5" sign="-" name="us-gaap:MinorityInterestPeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMjMtOS0xLTEtMTgxNjQ_0a445784-3abf-432a-a328-2bf396fce6a0">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i9af20bf23942493aad5860b2c2e56978_D20210401-20210630" decimals="-5" sign="-" name="us-gaap:MinorityInterestPeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMjMtMTMtMS0xLTE4MTY0_52e4afea-1887-4b67-944b-027de297b8ef">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ib07b6c87c8e242108fbc9023fce23cc9_D20210401-20210630" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMjQtNy0xLTEtMTgxNjQ_d40c672d-26c1-470e-9a97-95f1f7afa4fc">4.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i9af20bf23942493aad5860b2c2e56978_D20210401-20210630" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMjQtMTMtMS0xLTE4MTY0_865378fe-9dd7-4555-9ef9-20edeef7df0c">4.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other comprehensive loss, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ia74c427781b6435fa165763f7d2b6818_D20210401-20210630" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMjUtNS0xLTEtMTgxNjQ_064114da-6daa-4c5c-8917-2c518dd4b836">0.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i9af20bf23942493aad5860b2c2e56978_D20210401-20210630" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMjUtMTMtMS0xLTE4MTY0_3cc8e4ef-3d55-413f-81ef-cf0320c294c7">0.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">BALANCES AT JUNE 30, 2021</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i03c0a03785d94bfa95d4de1d0a89a121_I20210630" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMjYtMS0xLTEtMTgxNjQ_71bfd4aa-cbe5-4590-b514-82c95b29fe39">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4438d624363b4476a68d74da26614067_I20210630" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMjYtMy0xLTEtMTgxNjQ_3985a827-0d58-4ad8-a1d5-b50c5aae593e">1,176.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i3a1959e9612e44579e775f75a541e4a8_I20210630" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMjYtNS0xLTEtMTgxNjQ_3c804431-0bd5-4384-8d04-9bd593de110c">4.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i4b38d81b9f4e4aa8b1b021b9bb1b0958_I20210630" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMjYtNy0xLTEtMTgxNjQ_44ead5fe-d83e-4208-a650-2c2404b620a1">271.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ie0450de8f0b54d7591325d511dad90ca_I20210630" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMjYtOS0xLTEtMTgxNjQ_166dd98c-fe57-424f-a920-b0c56c3efcd2">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i171029b6cf5d41df9d00d9688277e104_I20210630" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMjYtMTMtMS0xLTE4MTY0_4b414959-14bc-4087-8a62-72fb2b0b0ab4">902.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Issuance of common stock under stock-based compensation plans, net of shares exchanged for withholding tax</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i70b7a4c941544cd7894d1e4defd87c79_D20210701-20210930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMzItMy0xLTEtMTk1MzY_50de8eeb-aa10-402c-b7ac-40bbbfaacc1d">31.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMzItMTMtMS0xLTE5NTg4_9c6d4308-4f52-430f-a1f8-52ccd36ca74b">31.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Stock-based payment expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i70b7a4c941544cd7894d1e4defd87c79_D20210701-20210930" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMzMtMy0xLTEtMTk1MzY_07861e56-3d91-4138-ba1e-ba6074f563f6">10.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMzMtMTMtMS0xLTE5NTg4_42fef40c-d9ef-4fae-8f45-02ce63fb2c3a">10.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i53e5c42e5a894d47b34f9f9504d85a50_D20210701-20210930" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMzQtNy0xLTEtMTk1NjI_9d42e0a5-a4cf-40cc-b2b4-a7ff8fa44010">24.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMzQtMTMtMS0xLTE5NTg4_0e2635ae-808c-4ec3-a124-21dd41a945c9">24.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other comprehensive loss, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="id7bead8553aa40e19e389e9e36a5a52f_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMzUtNS0xLTEtMTk1MzY_6dc815dc-42ef-4233-8427-14d5a587f690">0.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMzUtMTMtMS0xLTE5NTg4_c5a13f8a-56c1-4aa1-8577-0efc596bdf9a">0.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">BALANCES AT SEPTEMBER 30, 2021</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic89788fb0cac4113ab3e5d22b824bee3_I20210930" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMzYtMS0xLTEtMTk1MDc_cac39b42-29fa-4236-906e-45eab4b4b689">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if5489fa2beb84874846c50045cb4a8fe_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMzYtMy0xLTEtMTk1MDc_ba34b5bc-c234-4fb1-9cd4-095da6534ed9">1,218.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i12b5bd71050148fe920686b278365e75_I20210930" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMzYtNS0xLTEtMTk1MDc_08ad2ff1-4b5d-45ce-95a5-08b19c63fde1">4.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i1926bf39b52c48a4957fc9a924a82cf7_I20210930" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMzYtNy0xLTEtMTk1MDc_695bbce1-b112-480b-91d6-a1bd3671ca43">246.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="icffee6692ce64627b1016dc94b08f0f0_I20210930" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMzYtOS0xLTEtMTk1MDc_7753349a-85a5-41fe-b3a3-e3900941698b">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMzYtMTMtMS0xLTE5NTg4_5337fe91-0746-40af-8376-5ef10fef85a2">968.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to Condensed Consolidated Financial Statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="i5814a71962934792901cb2330361bb17_28"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5814a71962934792901cb2330361bb17_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MYRIAD GENETICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Condensed Consolidated Statements of Cash Flows (unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in millions)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:74.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine months ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">CASH FLOWS FROM OPERATING ACTIVITIES:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net loss attributable to Myriad Genetics, Inc. stockholders</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfMy0xLTEtMS0xODE2NA_0e7ee652-2c61-4b36-99d3-89bb5755ddd8">19.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfMy0zLTEtMS0xODE2NA_1d22cd64-a4e9-49eb-ae70-663b9a7ae0a6">185.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfNS0xLTEtMS0xODE2NA_4b84a5ea-7764-48e8-80d8-6046e4e8b031">49.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfNS0zLTEtMS0xODE2NA_378ee569-4f35-447e-9b1e-c30d3974b575">53.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Non-cash interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" decimals="-5" name="mygn:NonCashInterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfNi0xLTEtMS0xODE2NA_479f543e-685d-4bf3-b6fe-c3b11969b0c7">1.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930" decimals="-5" name="mygn:NonCashInterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfNi0zLTEtMS0xODE2NA_df80881d-fe2a-49a7-9f1b-583b848120ad">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Non-cash lease expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfNy0xLTEtMS0xODE2NA_51f9e695-eafb-4a7c-9abd-8e78e25cfd6a">9.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfNy0zLTEtMS0xODE2NA_5f2b9ec7-693f-4760-97a0-f59dd509e4ea">9.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfOC0xLTEtMS0xODE2NA_5cea998f-f9e3-4f06-abd8-adf39ce8830b">27.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfOC0zLTEtMS0xODE2NA_15bf3bc2-0d02-46a5-8c3a-c2f2a72bd25e">17.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Deferred income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" decimals="-5" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfOS0xLTEtMS0xODE2NA_62640085-90b4-437f-861a-9acf00468364">27.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930" decimals="-5" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfOS0zLTEtMS0xODE2NA_bbc90e7e-8805-4383-9feb-fe2b94e5ffcb">0.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Unrecognized tax benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" decimals="-5" name="mygn:IncreaseDecreaseInUnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfMTAtMS0xLTEtMTgxNjQ_24285b8c-6078-477e-b945-556dd0f2c372">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930" decimals="-5" name="mygn:IncreaseDecreaseInUnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfMTAtMy0xLTEtMTgxNjQ_c8d7bc1d-26d5-47ab-b46e-b4ee97d213fa">14.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Change in fair value of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" decimals="-5" name="mygn:ChangeInFairValueOfContingentConsideration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfMTEtMS0xLTEtMTgxNjQ_8407add2-6003-4c60-acd4-c7d61a071cc9">1.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930" decimals="-5" sign="-" name="mygn:ChangeInFairValueOfContingentConsideration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfMTEtMy0xLTEtMTgxNjQ_cd57fcbc-09bc-4155-b314-47c9f35c51ce">4.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Loss on inventory</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" decimals="-5" name="us-gaap:InventoryWriteDown" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfMTItMS0xLTEtMTgxNjQ_b5dd97c1-d174-4618-af0f-5c4e479844a2">6.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:InventoryWriteDown" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfMTItMy0xLTEtMTgxNjQ_385fa59f-fe08-4a0e-a1f6-091f60aef673">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Impairment of goodwill and long-lived assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" decimals="-5" name="mygn:ImpairmentOfGoodwillAndLongLivedAssetsHeldForUse" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfMTMtMS0xLTEtMTgxNjQ_d326da25-7ea1-4378-9d42-bc105196a294">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930" decimals="-5" name="mygn:ImpairmentOfGoodwillAndLongLivedAssetsHeldForUse" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfMTMtMy0xLTEtMTgxNjQ_fbf9f217-e2c9-4765-b252-94b0da093025">98.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Gain on sale of businesses and assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" decimals="-5" name="us-gaap:GainLossOnDispositionOfAssets1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfMTQtMS0xLTEtMTgxNjQ_ee994d75-610d-4807-9c74-f0553dbba739">162.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930" decimals="-5" name="us-gaap:GainLossOnDispositionOfAssets1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfMTQtMy0xLTEtMTgxNjQ_09366d74-2eee-4999-afb7-186a4fbd0d77">1.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Changes in assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" decimals="-5" name="us-gaap:IncreaseDecreaseInPrepaidExpensesOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfMTctMS0xLTEtMTgxNjQ_bf62ae9d-91e8-4a79-99ca-1ee2fa62ebb9">6.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidExpensesOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfMTctMy0xLTEtMTgxNjQ_1c6546d4-63db-4442-8a36-0d55b52e88b3">5.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Trade accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfMTgtMS0xLTEtMTgxNjQ_b388b8a9-5996-41d1-9b02-317d8e2d4563">11.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfMTgtMy0xLTEtMTgxNjQ_a10ac906-f900-4d83-9446-95686fbbbab5">33.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Inventory</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" decimals="-5" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfMjAtMS0xLTEtMTgxNjQ_72168cff-f264-4d33-8ec3-ca7aa4b24c17">1.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfMjAtMy0xLTEtMTgxNjQ_c58a0d14-6b01-4e4e-827a-14629122e452">1.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Prepaid taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfMjEtMS0xLTEtMTgxNjQ_c2d49c34-039b-48a6-827b-b24c747d7f17">108.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930" decimals="-5" name="us-gaap:IncreaseDecreaseInPrepaidTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfMjEtMy0xLTEtMTgxNjQ_df56b492-ee05-43cd-85f3-dcb9fde4ec0a">83.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" decimals="-5" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfMjItMS0xLTEtMTgxNjQ_758b6259-97b0-4c7b-bb8b-a48744d0014c">3.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930" decimals="-5" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfMjItMy0xLTEtMTgxNjQ_a14dfbee-8f78-4b80-ba30-9372d6688081">1.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfMjMtMS0xLTEtMTgxNjQ_6d70744e-a966-4c94-8e28-7b612f2c9b48">4.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfMjMtMy0xLTEtMTgxNjQ_523ea073-fa80-42cf-a05a-f1cd568cc304">2.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" decimals="-5" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfMjQtMS0xLTEtMTgxNjQ_631f51fe-14cd-435a-b1fd-eb0894224da4">78.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930" decimals="-5" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfMjQtMy0xLTEtMTgxNjQ_4378e2d5-6bd8-48db-bb3f-0f4d5e521e69">3.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Deferred revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfMjUtMS0xLTEtMTgxNjQ_8015b350-3a69-463b-98e9-a3aaa82668e1">20.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930" decimals="-5" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfMjUtMy0xLTEtMTgxNjQ_c6fff754-4b75-4352-9c24-27bf107388f9">28.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net cash provided by (used in) operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" decimals="-5" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfMjYtMS0xLTEtMTgxNjQ_e8d62e3e-f7b7-4002-b1be-81c220816aeb">28.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfMjYtMy0xLTEtMTgxNjQ_de43012c-399b-47be-9ad3-8cdddefb52ab">12.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">CASH FLOWS FROM INVESTING ACTIVITIES:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Capital expenditures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" decimals="-5" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfMjgtMS0xLTEtMTgxNjQ_f5979e48-3d89-4934-8be8-fc1449181070">14.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930" decimals="-5" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfMjgtMy0xLTEtMTgxNjQ_30d97ae4-6ceb-4589-bbdc-e8afbd35b411">6.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Proceeds from sale of businesses and assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" decimals="-5" name="us-gaap:ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfMjktMS0xLTEtMTgxNjQ_976369dd-c22d-41ec-a01c-5e7a450a4f08">379.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930" decimals="-5" name="us-gaap:ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfMjktMy0xLTEtMTgxNjQ_8e614be5-3d38-43b4-bfce-9dd8008cfba6">21.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Purchases of marketable investment securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" decimals="-5" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfMzEtMS0xLTEtMTgxNjQ_9d8dda34-a791-4def-8cb4-df0e3d34c237">101.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930" decimals="-5" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfMzEtMy0xLTEtMTgxNjQ_dc93aa47-4440-4b22-8a88-fb2a5a71c736">15.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Proceeds from maturities and sales of marketable investment securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" decimals="-5" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfMzItMS0xLTEtMTgxNjQ_d027cc56-5f1b-497c-9a2a-d20d04d5480d">36.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930" decimals="-5" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfMzItMy0xLTEtMTgxNjQ_61889fd3-fad5-4377-88a4-cd417e725732">51.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net cash provided by investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" decimals="-5" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfMzMtMS0xLTEtMTgxNjQ_e06127db-7389-41d2-84fd-a2e12fd9fc14">300.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930" decimals="-5" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfMzMtMy0xLTEtMTgxNjQ_bea699e2-cb86-4162-9a7f-6e3666bf5286">50.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">CASH FLOWS FROM FINANCING ACTIVITIES:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Proceeds from common stock issued under stock-based compensation plans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfMzUtMS0xLTEtMTgxNjQ_895c3d53-521e-48c5-9439-a6912f1500a1">90.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfMzUtMy0xLTEtMTgxNjQ_a287ca7a-1314-45d7-b684-f88aad795c61">2.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Payment of tax withheld for common stock issued under stock-based compensation plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" decimals="-5" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfMzYtMS0xLTEtMTgxNjQ_a5980f0d-c760-4e64-b5f5-c5eb7d8c382c">8.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930" decimals="-5" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfMzYtMy0xLTEtMTgxNjQ_db450f0b-ad9e-4197-8dea-f77ef1ac3456">3.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Payment of contingent consideration recognized at acquisition</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" decimals="-5" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfMzctMS0xLTEtMTgxNjQ_c85e82ec-482f-458d-a917-a6bd118bc4f5">3.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930" decimals="-5" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfMzctMy0xLTEtMTgxNjQ_119da050-e31b-458c-a621-6efce96f1c23">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Fees associated with refinancing of revolving credit facility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" decimals="-5" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfMzgtMS0xLTEtMTgxNjQ_02e81b17-1799-49da-85ce-28124b7f0a78">1.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930" decimals="-5" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfMzgtMy0xLTEtMTgxNjQ_d68f0b48-66d6-43df-a07f-99457400db68">1.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Repayment of revolving credit facility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" decimals="-5" name="us-gaap:RepaymentsOfLinesOfCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfMzktMS0xLTEtMTgxNjQ_18c633d1-635e-4a58-97a4-1aca11e2c3ce">226.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:RepaymentsOfLinesOfCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfMzktMy0xLTEtMTgxNjQ_2b00f2f2-bb6f-403b-9dda-7835f093b1f9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net cash used in financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfNDAtMS0xLTEtMTgxNjQ_a2c54904-7be0-4250-a7ae-41a9fb03a82a">149.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfNDAtMy0xLTEtMTgxNjQ_810ca2d6-9b1e-457f-a93c-cd1621bcd3ae">2.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Effect of foreign exchange rates on cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfNDEtMS0xLTEtMTgxNjQ_5a713626-126f-4b78-869f-d9099e8bc825">0.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930" decimals="-5" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfNDEtMy0xLTEtMTgxNjQ_b4613069-3f5d-41ae-8892-7de4e789387e">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Change in cash and cash equivalents classified as held for sale</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" decimals="-5" format="ixt:fixed-zero" name="mygn:NetChangeInCashAndCashEquivalentsClassifiedAsHeldForSale" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfNDItMS0xLTEtMTgxNjQ_35f1c52d-5283-47c7-8831-65bb5125fd69">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930" decimals="-5" name="mygn:NetChangeInCashAndCashEquivalentsClassifiedAsHeldForSale" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfNDItMy0xLTEtMTgxNjQ_394535c9-2483-49bf-8ba1-a7060faece8e">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net increase in cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfNDMtMS0xLTEtMTgxNjQ_d75e6426-fbf1-40e4-8652-285f78bdb166">178.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfNDMtMy0xLTEtMTgxNjQ_84cd9319-f827-4f44-a411-e1bdb3ce5c2f">37.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cash and cash equivalents at beginning of the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfNDQtMS0xLTEtMTgxNjQ_06a4bb4f-196e-43e0-812c-69fc8ed560be">117.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic698543044ba4469ba8751bae898951c_I20191231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfNDQtMy0xLTEtMTgxNjQ_6c571cee-c2b9-4cb6-9e1e-9890f3511c86">81.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cash and cash equivalents at end of the period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfNDUtMS0xLTEtMTgxNjQ_e92d3411-fc60-4502-955f-215ada627b89">295.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0c6bac27ede64afeb4dbc13729f58578_I20200930" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfNDUtMy0xLTEtMTgxNjQ_5a7b8861-47fb-461f-bbee-571544c78ccd">118.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to Condensed Consolidated Financial Statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="i5814a71962934792901cb2330361bb17_31"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5814a71962934792901cb2330361bb17_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)</span></div><div id="i5814a71962934792901cb2330361bb17_34"></div><div style="margin-top:18pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNC9mcmFnOmIyNjgwNTlkNzdlZDQ4YjZhOWZlMGRmYzJlM2Q1N2ZkL3RleHRyZWdpb246YjI2ODA1OWQ3N2VkNDhiNmE5ZmUwZGZjMmUzZDU3ZmRfNTAzNA_30ed1fa6-26a9-4f4a-8af6-b8998a4d0529" continuedAt="i151d614a209c4426ad77a090901953e0" escape="true">BASIS OF PRESENTATION</ix:nonNumeric></span></div><ix:continuation id="i151d614a209c4426ad77a090901953e0"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Myriad Genetics, Inc. and its subsidiaries (collectively, the &#8220;Company&#8221; or &#8220;Myriad&#8221;) discover and commercialize genetic tests that determine the risk of developing disease, assess the risk of disease progression, and guide treatment decisions across medical specialties where critical genetic insights can significantly improve patient care and lower healthcare costs. The Company's mission and purpose is to advance health and well-being for all, empower individuals with vital genetic insights and enable healthcare providers to better detect, treat and prevent disease. The Company generates revenue by performing molecular diagnostic tests and, prior to the sale of Myriad RBM, Inc. on July 1, 2021 as described in Note 16, by providing pharmaceutical services to the pharmaceutical and biotechnology industries and medical research institutions utilizing its multiplexed immunoassay technology. The Company&#8217;s corporate headquarters are located in Salt Lake City, Utah.</span></div><ix:nonNumeric contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNC9mcmFnOmIyNjgwNTlkNzdlZDQ4YjZhOWZlMGRmYzJlM2Q1N2ZkL3RleHRyZWdpb246YjI2ODA1OWQ3N2VkNDhiNmE5ZmUwZGZjMmUzZDU3ZmRfNTAzOA_6c845d23-3c3e-449d-88c6-b37abb20d937" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying Condensed Consolidated Financial Statements for the Company have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) for interim financial information and pursuant to the applicable rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;).&#160;All intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, the accompanying financial statements contain all adjustments (consisting of normal and recurring accruals) necessary to present fairly all financial statements in accordance with GAAP. The Condensed Consolidated Financial Statements herein should be read in conjunction with the Company&#8217;s audited Consolidated Financial Statements and notes thereto included in the Company&#8217;s Transition Report on Form 10-K for the transition period ended December&#160;31, 2020 (the &#8220;Transition Report on Form 10-K&#8221;). </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenue and expenses during the reporting period. Operating results for the three and nine months ended September&#160;30, 2021 may not necessarily be indicative of results to be expected for any other interim period or for the full year.</span></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has historically experienced seasonality in its testing business. The volume of testing is negatively impacted by the summer season, which is generally reflected in the quarter ending June 30 and the quarter ending September 30. The quarter ending December 31 is generally strong as the Company sees an increase in volumes from patients who have met their annual insurance deductible. Conversely, the quarter ending March 31 is typically negatively impacted by the annual reset of patient deductibles.  </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the COVID-19 global pandemic, including variants of COVID-19 (&#8220;COVID-19&#8221;), seasonality may not follow the same pattern as in prior years. Volumes and results of operations were impacted negatively in calendar year 2020 by COVID-19. As such, the Company&#8217;s year over year results may not be comparable. Management continues to monitor the impact of COVID-19 on the Company&#8217;s financial condition, liquidity, operations, suppliers, industry, and workforce. Given the variants of COVID-19 that have surfaced around the world, the Company is not able to fully estimate the effects of COVID-19 on results of operations, financial condition, or liquidity for future periods.</span></div><ix:nonNumeric contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNC9mcmFnOmIyNjgwNTlkNzdlZDQ4YjZhOWZlMGRmYzJlM2Q1N2ZkL3RleHRyZWdpb246YjI2ODA1OWQ3N2VkNDhiNmE5ZmUwZGZjMmUzZDU3ZmRfNTAzNg_46da4dd2-8ff1-49df-a567-38547708e07d" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reclassifications</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior period amounts have been reclassified to conform with the current period presentation. The reclassifications have no impact on the total assets, total liabilities, stockholders&#8217; equity, cash flows from operations, or net income (loss) for the period.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNC9mcmFnOmIyNjgwNTlkNzdlZDQ4YjZhOWZlMGRmYzJlM2Q1N2ZkL3RleHRyZWdpb246YjI2ODA1OWQ3N2VkNDhiNmE5ZmUwZGZjMmUzZDU3ZmRfNTA0MA_b7db37b0-b428-449a-a09b-58ddc6219806" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Adopted Standards</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (&#8220;ASU 2019-12&#8221;). ASU 2019-12 is a new accounting standard to simplify accounting for income taxes and remove, modify, and add to the disclosure requirements of income taxes. The standard is effective for fiscal years beginning after December 15, 2020, with early adoption permitted. This guidance was adopted</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> with no material impact to t</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he Company's Condensed Consolidated Financial Statements.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5814a71962934792901cb2330361bb17_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div id="i5814a71962934792901cb2330361bb17_37"></div><div style="padding-left:18pt;padding-right:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RleHRyZWdpb246NTI5NjY0NzZiODk1NGMzMTkwYzQ4Y2FkYWZkMzM5NTlfNzQ0OQ_46fe1876-63ff-4203-ba71-1d4cadb75b84" continuedAt="i563684fabec742a5818d2ccdc58af466" escape="true">REVENUE</ix:nonNumeric></span></div><ix:continuation id="i563684fabec742a5818d2ccdc58af466" continuedAt="ia62be5f4313c45ae9f85421d2022bbab"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Myriad generates revenue by performing molecular diagnostic testing, and prior to the sale of Myriad RBM, Inc. on July 1, 2021, pharmaceutical services. Molecular diagnostic revenues consists of the following categories (products): Hereditary Cancer (myRisk, BRACAnalysis, BRACAnalysis CDx), Tumor Profiling (myChoice CDx, Prolaris, and EndoPredict), Prenatal (Foresight and Prequel), Pharmacogenomics (GeneSight), Autoimmune (Vectra), and Other. The Company previously provided pharmaceutical services and clinical services prior to the sale of Myriad RBM, Inc. and Privatklinik Dr. Robert Schindlbeck GmbH &amp; Co. KG (the &#8220;Clinic&#8221;), respectively. Prior to the sale of the Myriad myPath, LLC laboratory in May 2021 and select assets of the Myriad Autoimmune (Vectra) business unit in September 2021, the associated revenue was included within Molecular diagnostic revenues. See Note 16 for a discussion of these divestitures. Revenue is recorded at the estimated amount of consideration to be received. The Company has determined that the communication of test results or the completion of pharmaceutical and clinical services indicates transfer of control for revenue recognition purposes.</span></div><ix:nonNumeric contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RleHRyZWdpb246NTI5NjY0NzZiODk1NGMzMTkwYzQ4Y2FkYWZkMzM5NTlfNzQ0OA_729d5c30-ac55-4a89-bec9-b2fee1f907ed" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents detail regarding the composition of the Company&#8217;s total revenue by category and by U.S. versus rest of world (&#8220;RoW&#8221;):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.200%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.624%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.624%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.624%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.624%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.624%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.630%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="36" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">RoW</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">RoW</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molecular diagnostic revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hereditary Cancer</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ida000af1413e4fddbdffb1f6b6d73047_D20210701-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfNC0xLTEtMS0xODE2NA_9f14b430-6e53-4125-a14b-5f4efa1c020d">68.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia65390d217d44664a03c7762eb80226c_D20210701-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfNC0zLTEtMS0xODE2NA_e0c0c251-8980-40bd-9d74-2a322b2fc645">11.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="idb939ee30c9346759fabe2cbfd1ebf71_D20210701-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfNC01LTEtMS0xODE2NA_9bcc4e01-c18d-4bbf-8e27-5119ffbd1255">79.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib782ea6f17aa43faaa46806bd14f5af2_D20200701-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfNC03LTEtMS0xODE2NA_84e32431-b87f-4e9c-b851-adf93b28ef29">72.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7942c920d42c4be98d7627dea2b75aab_D20200701-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfNC05LTEtMS0xODE2NA_4d819305-c390-443f-abb8-01b8ad2251f8">8.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7d4b33a6e9cf4ff695a151252fa5202d_D20200701-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfNC0xMS0xLTEtMTgxNjQ_54c3d5f3-3928-4bf5-bbca-7baae9e89429">80.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tumor Profiling</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9987b934bd0a407b89b3de550f71f1eb_D20210701-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfNS0xLTEtMS0xODE2NA_35cab7af-42a4-42f7-8690-6096d01fa97f">21.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i120342914ab84d57803cdba7e390e6e0_D20210701-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfNS0zLTEtMS0xODE2NA_3ad695af-1b84-4e9d-88d8-aeaca8c8b743">11.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ifacd49fb220e4e6688cac0490136867d_D20210701-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfNS01LTEtMS0xODE2NA_45ad5cc2-41d8-494f-886b-d66a2cc83c43">32.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="idc7756538c044225a9ce5c1d9d342449_D20200701-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfNS03LTEtMS0xODE2NA_ab0c5339-60a3-4b87-b556-14002303f6f9">14.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bbf9b3b2d1b4c0c904cdd117771580a_D20200701-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfNS05LTEtMS0xODE2NA_1566cc2d-7757-4eed-b6d7-ce443b7513b5">2.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="icc9ac75befb64b00b1cbd10949fa3e69_D20200701-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfNS0xMS0xLTEtMTgxNjQ_d771c5d0-a533-4922-9e2e-64c932e5f243">17.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prenatal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5f8b38682e3a4c6586f56116a4e54db9_D20210701-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfNi0xLTEtMS0xODE2NA_bf9b2383-fd93-4eb0-b282-9a5c2307c058">23.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b8709823fb647138c0501d0018d62cc_D20210701-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfNi0zLTEtMS0xODE2NA_5bf0109d-f057-4444-aa41-110e5e8557cf">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iac13adff54494e56be97dcfc0308c7f5_D20210701-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfNi01LTEtMS0xODE2NA_57cce671-77dd-4695-9ad9-7b8ef291aacc">23.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie36dcf4cd4e14f4890cf021f262a8b82_D20200701-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfNi03LTEtMS0xODE2NA_13b2f713-8a1f-4b14-9766-4d8ae4d6a2d6">16.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia94b623d77a449e49aa7fce28c810d9c_D20200701-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfNi05LTEtMS0xODE2NA_853f94ad-5bd8-493f-a065-cebb426a67b9">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4acdbc594a6a4b88a090b04e5ef69aec_D20200701-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfNi0xMS0xLTEtMTgxNjQ_8aab277c-1d9f-4e69-bd50-6588fd5b62da">16.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmacogenomics</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia5e3a39bcef84311a38d3c37cbbee981_D20210701-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfNy0xLTEtMS0xODE2NA_7c83914e-96aa-488a-8eb8-866993d7d2d0">24.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e84513d519942359ce079c27c934ab7_D20210701-20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfNy0zLTEtMS0xODE2NA_f301e87f-98c2-4dbc-8d4b-66cda388fdd4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7f4d0d8a569142149d4db9527cbf6122_D20210701-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfNy01LTEtMS0xODE2NA_7403457a-4ef2-43b2-883b-4bfefd0d7269">24.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i632d974bc19746629c875de8d85005de_D20200701-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfNy03LTEtMS0xODE2NA_9ace4159-a844-4ba2-b9a1-4a38d8f7df1d">11.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8ffaf88f5554b8a8bfb8d0f7aaef001_D20200701-20200930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfNy05LTEtMS0xODE2NA_6d53b2b3-c2b5-4b93-8a18-56fe453a92dd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7e91c91b1c9a4945acdfe9e7245038ed_D20200701-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfNy0xMS0xLTEtMTgxNjQ_5e5562d5-6d25-4fb1-b71a-a6fb3b13cffc">11.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Autoimmune</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7376ab53741d440ba61c388e5c932c1b_D20210701-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfOC0xLTEtMS0xODE2NA_5ae21dd6-0506-45ba-a0c6-8c1f9fccb4a4">7.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c33023861bc44e592a2a61939a657a6_D20210701-20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfOC0zLTEtMS0xODE2NA_d9a3f513-e290-472a-92a0-78531a4f0fd8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1ce0af94533d4d0cb17bfae079adab31_D20210701-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfOC01LTEtMS0xODE2NA_5a36a74d-baf1-48c3-9b5d-11bc1010b015">7.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic1e715fa83dc47248899710d4f312340_D20200701-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfOC03LTEtMS0xODE2NA_0b17728f-7375-49f9-a2b4-3506f33f63b5">9.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d9d935b97a14723b2ce8cd0fdd3685b_D20200701-20200930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfOC05LTEtMS0xODE2NA_3945ea1a-9595-419c-a9cf-511093bc49fd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia5880f6561e344b698bf53ef48281f5f_D20200701-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfOC0xMS0xLTEtMTgxNjQ_be318eb6-f8e7-453d-a2e8-ca3603acffa4">9.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8511c5f276ed4618bd7d3abcdfd81278_D20210701-20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfOS0xLTEtMS0xODE2NA_aafad47b-8035-4fff-b40a-5ef909c96919">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7cd8b28b3de341ab88d9b759b56cb960_D20210701-20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfOS0zLTEtMS0xODE2NA_e5534fa8-3d39-4f58-bc35-83b5f3316bbb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2269a2a3c55f4f48b394d629ae9ece31_D20210701-20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfOS01LTEtMS0xODE2NA_b91c8c0a-c606-4093-b089-fbce6a584f9a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic301e05aafb54177bf154d4e00dca137_D20200701-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfOS03LTEtMS0xODE2NA_61b5e572-0b44-4f13-a9fa-944bbb5940f9">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie0c4bdb320014fe28dabebe98a245d34_D20200701-20200930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfOS05LTEtMS0xODE2NA_9080e700-0b7f-44c6-a702-729246c3bac5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5428af14384f4775a235df5d1a72c351_D20200701-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfOS0xMS0xLTEtMTgxNjQ_a8a6fe70-9e50-4d23-9170-e2955a7adb6b">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total molecular diagnostic revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i978447da133848e09d69b6941e3c3e12_D20210701-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMTAtMS0xLTEtMTgxNjQ_a92ef01c-02ff-464f-92d0-a0e502c9e9da">144.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9e833f5a117c4014b693ba5dbcd17f05_D20210701-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMTAtMy0xLTEtMTgxNjQ_e2f57387-13c2-44c7-b4ca-9b215b98396d">22.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ifbc28960af99464087c70e2155273621_D20210701-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMTAtNS0xLTEtMTgxNjQ_6375e7b5-82b7-42ca-83b0-dedab871ef16">167.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9f6b592da0d94089824ddd9eeaec60ca_D20200701-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMTAtNy0xLTEtMTgxNjQ_7b146de5-5f65-4967-9335-b2963653a6f7">124.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i628878e014504ba3927b3541bbfee9d6_D20200701-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMTAtOS0xLTEtMTgxNjQ_15274a78-cee9-4cff-956c-a57c25219e8b">11.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="icc0e2c6320b64071a6e19bf0ded7e102_D20200701-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMTAtMTEtMS0xLTE4MTY0_a60fd831-7628-4420-897c-45dc5107401a">135.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical and clinical services revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2777203c45e44986ad24f2e01bb5cd2c_D20210701-20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMTEtMS0xLTEtMTgxNjQ_daff5cbd-bdfd-492f-a11d-fa42817d8178">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4bb010a87eb34230a4d879b7f8b5d7f3_D20210701-20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMTEtMy0xLTEtMTgxNjQ_65b9a2f1-0b90-405e-a66e-cc63b9d774cc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i79cd3eef56ae4f639da562ce851a382e_D20210701-20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMTEtNS0xLTEtMTgxNjQ_b28ca841-d00c-4a67-aca1-c6e85b4b5c2c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if4850f75cb284b14b1e3b920fd17fee3_D20200701-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMTEtNy0xLTEtMTgxNjQ_de8cd57f-44a5-4bea-ae7a-f565b5295578">9.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if98b526cb9c84315b8808c1225488499_D20200701-20200930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMTEtOS0xLTEtMTgxNjQ_d82d922b-17cb-4577-b63f-1365c3a6be89">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie94a660aba69415a910d7f90711081eb_D20200701-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMTEtMTEtMS0xLTE4MTY0_175d15dd-4e52-42f5-99ae-23bd7896e494">9.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i34864de2cd5e41bd98ef24a86d7f39a1_D20210701-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMTItMS0xLTEtMTgxNjQ_8a499631-b134-4256-8d33-dc52afb9ad5c">144.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5e6310ec543143dc8a87a1867afc2439_D20210701-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMTItMy0xLTEtMTgxNjQ_fb94d02d-8522-4289-9154-2a58ddaf0133">22.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMTItNS0xLTEtMTgxNjQ_ede47b7e-7e13-4686-b525-47916f3e1205">167.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3b754f9a3006470cb13ba2789a352d5e_D20200701-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMTItNy0xLTEtMTgxNjQ_d78d2728-2df2-4d04-8486-36bdce2c0498">134.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7eb57d5345554df7a7ffeb66aa7ef9d6_D20200701-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMTItOS0xLTEtMTgxNjQ_bf2f70e8-871e-4f39-959e-f6a218dc4cf5">11.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic2c3e03438af4889ac973627c642f5ec_D20200701-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMTItMTEtMS0xLTE4MTY0_e39c6ed6-4402-4294-ba6a-6dc473922676">145.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="36" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">RoW</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">RoW</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molecular diagnostic revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hereditary Cancer</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i48501743237742c6975110396e917242_D20210101-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMTgtMS0xLTEtMTgxNjQ_b3067a9b-5fc5-436d-8761-d08d163571e4">207.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7824951a746645c39acedbdd215f57f5_D20210101-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMTgtMy0xLTEtMTgxNjQ_8544fa12-c2d6-434b-a75f-e1d58f2d1ee8">34.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ifcc2e81b5a204336b461cdc53955b3cd_D20210101-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMTgtNS0xLTEtMTgxNjQ_19918e53-80db-42a0-a5b9-e6bb20ec31b6">241.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic7c83e62f13142e3bf47bdf15510f328_D20200101-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMTgtNy0xLTEtMTgxNjQ_a3c8d36f-f039-42d2-a877-3d1a12f73e3d">188.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i18e0522d4e264244b4b7ff08c869a121_D20200101-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMTgtOS0xLTEtMTgxNjQ_ba915b16-66ae-4609-8f20-89279dae774e">17.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iee003a09d07f4dbf86ab56c0275a5909_D20200101-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMTgtMTEtMS0xLTE4MTY0_f195ddb2-523a-46ae-a819-f85359e0dc79">205.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tumor Profiling</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9e5e62422b964677bbf81111118a8530_D20210101-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMTktMS0xLTEtMTgxNjQ_fff77a54-d2af-4264-961f-8c925859f19c">63.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dd22965d073433da620ee6bb158d276_D20210101-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMTktMy0xLTEtMTgxNjQ_0b5c6f38-ef7e-4dd8-8c01-70998a93c759">30.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7fe0144d6efa41859c2eba711e85303a_D20210101-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMTktNS0xLTEtMTgxNjQ_429d2c2a-2f54-450f-a620-dafa68df35e1">94.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i55af35cd863d4959bf0125bc9cb46d23_D20200101-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMTktNy0xLTEtMTgxNjQ_58b8f320-6901-4d92-bf18-22fc23e4295a">33.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c2131fe4d3c47358dd98a5d078c009b_D20200101-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMTktOS0xLTEtMTgxNjQ_6f20a80e-be5e-4d0e-8481-92aa56c5ec4d">7.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic91ecdd5628742b5828be3bf25416996_D20200101-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMTktMTEtMS0xLTE4MTY0_55cac39a-ca2f-4b36-b68c-6231c842d15a">41.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prenatal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ifae9cf930088446e9ad24962231957ba_D20210101-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMjAtMS0xLTEtMTgxNjQ_35749316-95ea-44b7-a04a-da29c9af8339">76.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ee8c5ff36994621b42226a17e561d2e_D20210101-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMjAtMy0xLTEtMTgxNjQ_df35cb93-fdd4-46c6-a842-ee7f27cd520e">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8c200a9b3e0d4ac49242d25105281dcd_D20210101-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMjAtNS0xLTEtMTgxNjQ_1e4323f3-ae2c-4b43-8d4b-f0d8aeedf68a">76.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib8fb168011b74d318bab8b56b11dbda3_D20200101-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMjAtNy0xLTEtMTgxNjQ_185e88d1-2285-4759-8806-f1087517ae4e">53.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic992acb15b7b4eb7a73e11782d653862_D20200101-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMjAtOS0xLTEtMTgxNjQ_24682cb3-0454-4f0d-8ff7-b4225b0c9c4e">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4efd4f48f7f647819d1ee5f36d044d08_D20200101-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMjAtMTEtMS0xLTE4MTY0_54fb717a-ab22-4573-bdcd-2954b3eb396a">53.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmacogenomics</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1fc1f94f6c144040a6a027fe642d8327_D20210101-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMjEtMS0xLTEtMTgxNjQ_4b24c094-1621-4dad-a61f-8b67fcc95248">64.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e578e3ded2b44bfb1c2e543c14336fe_D20210101-20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMjEtMy0xLTEtMTgxNjQ_2b1ce6aa-82db-470d-94e1-3383cb01b6a4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibf03794b4694454c96339d25e089fd86_D20210101-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMjEtNS0xLTEtMTgxNjQ_85ac93bb-5eec-40f4-ab80-8136cfb1a451">64.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4790f46fe81f43b7a34b7d4e7be6b08d_D20200101-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMjEtNy0xLTEtMTgxNjQ_af59036d-1bec-4f99-8265-acb4aead0ddd">40.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d82cbad6d4f4ad4b4867f492374ddbc_D20200101-20200930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMjEtOS0xLTEtMTgxNjQ_dfbcfe02-2fdf-4d88-8b51-e37a6a204569">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i227a5837ccdc40d09a3935542fa8f306_D20200101-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMjEtMTEtMS0xLTE4MTY0_07f180f3-d57b-48ec-b503-194f7aed3f53">40.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Autoimmune</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1643deb3ad9f45619ca4221f05389dc7_D20210101-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMjItMS0xLTEtMTgxNjQ_d88b49e0-1670-449e-b392-6f2eb3b1aad1">28.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0485078c2524525b58fcac4538292d8_D20210101-20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMjItMy0xLTEtMTgxNjQ_7e02eae0-fdc3-4ca0-a1a5-78bd3d36ec6f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1413cd2d66404ae0b0033e4828c87987_D20210101-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMjItNS0xLTEtMTgxNjQ_2b56c375-c577-4957-a252-a1ebd80c6b07">28.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0ad30cfcd30642859241e76dc224b27e_D20200101-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMjItNy0xLTEtMTgxNjQ_d4fd8e12-4a18-4587-93c7-5913695c2532">26.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia022822da300492793546d0fe4c7b26b_D20200101-20200930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMjItOS0xLTEtMTgxNjQ_1d276388-9e81-4dc0-a1f0-19ad134b38ab">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2b38c623286c42b898b7e8154ca4672e_D20200101-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMjItMTEtMS0xLTE4MTY0_e5d32232-9a45-4640-9a9d-591f012483f3">26.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c5bea7f5b774599827c2380d64fab41_D20210101-20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMjMtMS0xLTEtMTgxNjQ_68f133c6-a315-4cb5-a237-2a1b0108e972">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic2e771554aba45edaeb4d3458b0c1d77_D20210101-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMjMtMy0xLTEtMTgxNjQ_2fa7202e-5194-42e9-a8a5-889bb8222abb">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8c5c05f89d074455a96647a1c66e3797_D20210101-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMjMtNS0xLTEtMTgxNjQ_b20e2ab1-0416-40a4-92d7-82c7bd8e7881">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie293ea67e0dc4e379586937a664f26a6_D20200101-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMjMtNy0xLTEtMTgxNjQ_eb6987ff-7315-403d-a60d-13a2ec78d4f4">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i96fe192a524c4c7780b693b19a1ee594_D20200101-20200930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMjMtOS0xLTEtMTgxNjQ_d530a1e4-394d-4fdc-95c3-a95888222e73">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i85e565a842f34303958c7c5dbc22906f_D20200101-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMjMtMTEtMS0xLTE4MTY0_612b34e5-db3e-4fd4-88ca-338d127f927d">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total molecular diagnostic revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2150fb2a47cc41a8a8afed1f431f9875_D20210101-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMjQtMS0xLTEtMTgxNjQ_88d29cc3-fa49-4789-9c3a-7bb464b674c9">439.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ieeda1d918cdc4e4c8c9a40ede0b9980e_D20210101-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMjQtMy0xLTEtMTgxNjQ_c50f7c7e-4c65-493d-9743-cc896845ea5c">65.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie8a469542115473daa7666e3dceae657_D20210101-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMjQtNS0xLTEtMTgxNjQ_8c3509aa-c805-4bfe-b7a6-6bdc79897284">505.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i54646e3f899541a2892e6c43188dd3ca_D20200101-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMjQtNy0xLTEtMTgxNjQ_5221f789-d71c-4872-9f97-7e1155197071">344.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4765fcb411c541578d82bf58e0edcd57_D20200101-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMjQtOS0xLTEtMTgxNjQ_5275a55c-fb08-4fbc-a49a-c2de762f2574">25.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie51b08f1c1f44da4bb023303aa0fb7d9_D20200101-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMjQtMTEtMS0xLTE4MTY0_d32af0ab-1af7-4778-a981-ae4683061531">369.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical and clinical services revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie9ffcf60567a49298db6b5581ef8dbec_D20210101-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMjUtMS0xLTEtMTgxNjQ_ebae0cd6-b764-44d6-87d3-4710e1944316">24.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i67ed4f8f16804e2d91b367cc0ad882e6_D20210101-20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMjUtMy0xLTEtMTgxNjQ_fb86dd16-1c86-4383-ba81-43566478963c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i695f1ac67bde49628842e3563e17c85e_D20210101-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMjUtNS0xLTEtMTgxNjQ_c5dc7632-5eb4-47d6-ae1c-82ad0c81aa8b">24.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i822cef9d3a1148dfa0df42a55879158a_D20200101-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMjUtNy0xLTEtMTgxNjQ_3cf83f4f-4071-4088-ba4f-91ebe6ae7ef7">29.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id2561e4e6a72407fa6fcb4dda8635c44_D20200101-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMjUtOS0xLTEtMTgxNjQ_52df8475-7703-47f1-b7d3-474caab93d9e">3.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib855c77efb97481b968697136ef35610_D20200101-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMjUtMTEtMS0xLTE4MTY0_aa22029b-f75f-4611-a9fa-e3fdf8ab5681">32.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ifb886d225660433bb8c479ba4c1cf8ce_D20210101-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMjYtMS0xLTEtMTgxNjQ_de240585-4eaf-4bf7-8fee-758dc435ad30">464.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iaab7b12e36bb4e709ac9d2fd74a39b5e_D20210101-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMjYtMy0xLTEtMTgxNjQ_4c2cbe67-59d8-486e-8119-792aabc1ee1b">65.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMjYtNS0xLTEtMTgxNjQ_b7dd923b-14ad-4d13-bb2c-b3373ea9be77">529.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia7eb822f2ce54831a5e78a74b2e44672_D20200101-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMjYtNy0xLTEtMTgxNjQ_a2721c52-a4d7-49f9-a580-6fe0c4db898e">373.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2bc09983c7244893bff666d06f800fa8_D20200101-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMjYtOS0xLTEtMTgxNjQ_de045c6b-0aee-46c8-816c-4e4c7d6ba511">29.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMjYtMTEtMS0xLTE4MTY0_3d63dd4b-f3c1-4b2b-b6aa-b9d1de6870d3">402.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5814a71962934792901cb2330361bb17_7">Table of Contents</a></span></div></div><ix:continuation id="ia62be5f4313c45ae9f85421d2022bbab" continuedAt="id3f74da50ac44b13bcc9b5cfc755c421"><div style="margin-bottom:3pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The Company performs its obligation under a contract with a customer by processing diagnostic tests and communicating the test results to customers, in exchange for consideration from the customer. The Company has the right to bill its customers upon the completion of performance obligations and thus does not record contract assets. Occasionally, customers make payments prior to the Company&#8217;s performance of its contractual obligations. When this occurs, the Company records a contract liability as deferred revenue. Included within the Company's deferred revenues are advance Medicare payments. During the fiscal year ended June 30, 2020, the Company received approximately $<ix:nonFraction unitRef="usd" contextRef="ia7d2894297e4420e8cad6a4c76510fc1_D20190701-20200630" decimals="-5" format="ixt:num-dot-decimal" name="mygn:CARESActOf2020MedicarePaymentAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RleHRyZWdpb246NTI5NjY0NzZiODk1NGMzMTkwYzQ4Y2FkYWZkMzM5NTlfMTg3Mw_121a244a-b74f-4c2b-acf8-260b66add9e4">29.7</ix:nonFraction> million in advance Medicare payments to provide relief from the economic impacts of COVID-19 on the Company. The advanced Medicare payments began being applied against services performed in April 2021 and will continue until the funds previously received are fully earned. <ix:nonNumeric contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RleHRyZWdpb246NTI5NjY0NzZiODk1NGMzMTkwYzQ4Y2FkYWZkMzM5NTlfNzQ1Mg_99ed8b56-ea05-4c79-a4f5-7f82a83f7ae0" continuedAt="i0acdc99326df4c06b9b9cbc25461011b" escape="true">A reconciliation of the beginning and ending balances of deferred revenues is shown in the table below:</ix:nonNumeric></span></div><div><ix:continuation id="i0acdc99326df4c06b9b9cbc25461011b"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.000%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.624%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.626%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine months ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenues - beginning balance</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjZiODFjNGQ2OTBkODQ4NTdhZmQ2MjE4YTRlZGNkMTNjL3RhYmxlcmFuZ2U6NmI4MWM0ZDY5MGQ4NDg1N2FmZDYyMThhNGVkY2QxM2NfMi0xLTEtMS0xODE2NA_b78cd921-af7c-4445-9211-ce58c14a6069">32.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic698543044ba4469ba8751bae898951c_I20191231" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjZiODFjNGQ2OTBkODQ4NTdhZmQ2MjE4YTRlZGNkMTNjL3RhYmxlcmFuZ2U6NmI4MWM0ZDY5MGQ4NDg1N2FmZDYyMThhNGVkY2QxM2NfMi0zLTEtMS0xODE2NA_082beb86-703c-4162-9b96-431c40e07145">3.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue recognized</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" decimals="-5" name="mygn:ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjZiODFjNGQ2OTBkODQ4NTdhZmQ2MjE4YTRlZGNkMTNjL3RhYmxlcmFuZ2U6NmI4MWM0ZDY5MGQ4NDg1N2FmZDYyMThhNGVkY2QxM2NfMy0xLTEtMS0xODE2NA_33f36152-02ad-474a-a20b-85cc52e3a8c6">30.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930" decimals="-5" name="mygn:ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjZiODFjNGQ2OTBkODQ4NTdhZmQ2MjE4YTRlZGNkMTNjL3RhYmxlcmFuZ2U6NmI4MWM0ZDY5MGQ4NDg1N2FmZDYyMThhNGVkY2QxM2NfMy0zLTEtMS0xODE2NA_b706ce54-5e57-4a12-b02d-8b7f97ea8fe8">8.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepayments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" decimals="-5" name="mygn:ContractWithCustomerLiabilityPrepayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjZiODFjNGQ2OTBkODQ4NTdhZmQ2MjE4YTRlZGNkMTNjL3RhYmxlcmFuZ2U6NmI4MWM0ZDY5MGQ4NDg1N2FmZDYyMThhNGVkY2QxM2NfNC0xLTEtMS0xODE2NA_4a3f08c1-99b9-4a4f-bfa9-8d828e42f381">10.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930" decimals="-5" name="mygn:ContractWithCustomerLiabilityPrepayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjZiODFjNGQ2OTBkODQ4NTdhZmQ2MjE4YTRlZGNkMTNjL3RhYmxlcmFuZ2U6NmI4MWM0ZDY5MGQ4NDg1N2FmZDYyMThhNGVkY2QxM2NfNC0zLTEtMS0xODE2NA_fca94103-d6da-46ab-9e1e-a45bc15e9dcc">37.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Divestitures</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" decimals="-5" name="mygn:ContractWithCustomerLiabilityDivestitures" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjZiODFjNGQ2OTBkODQ4NTdhZmQ2MjE4YTRlZGNkMTNjL3RhYmxlcmFuZ2U6NmI4MWM0ZDY5MGQ4NDg1N2FmZDYyMThhNGVkY2QxM2NfNS0xLTEtMS0yODc4Mw_17b8982e-67b8-4445-822f-d09ddcb5ec97">1.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930" decimals="-5" format="ixt:fixed-zero" name="mygn:ContractWithCustomerLiabilityDivestitures" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjZiODFjNGQ2OTBkODQ4NTdhZmQ2MjE4YTRlZGNkMTNjL3RhYmxlcmFuZ2U6NmI4MWM0ZDY5MGQ4NDg1N2FmZDYyMThhNGVkY2QxM2NfNS00LTEtMS0yODc4OA_10638e9e-cfef-4368-901f-d7dfb177fffc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenues - ending balance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjZiODFjNGQ2OTBkODQ4NTdhZmQ2MjE4YTRlZGNkMTNjL3RhYmxlcmFuZ2U6NmI4MWM0ZDY5MGQ4NDg1N2FmZDYyMThhNGVkY2QxM2NfNi0xLTEtMS0xODE2NA_a0a365b0-7acb-4e74-a46f-7a71971aa6b5">11.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0c6bac27ede64afeb4dbc13729f58578_I20200930" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjZiODFjNGQ2OTBkODQ4NTdhZmQ2MjE4YTRlZGNkMTNjL3RhYmxlcmFuZ2U6NmI4MWM0ZDY5MGQ4NDg1N2FmZDYyMThhNGVkY2QxM2NfNi0zLTEtMS0xODE2NA_eb68f228-7387-4c4d-81e3-55a7df85f126">32.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with ASC Topic 606, Revenue from Contracts with Customers, the Company has elected not to disclose the aggregate amount of the transaction price allocated to remaining performance obligations for its contracts that are one year or less, as the revenue is expected to be recognized within the next year. Furthermore, the Company has elected not to disclose the aggregate amount of the transaction price allocated to remaining performance obligations for its agreements wherein the Company&#8217;s right to payment is in an amount that directly corresponds with the value of the Company&#8217;s performance to date. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In determining the transaction price, the Company includes an estimate of the expected amount of consideration as revenue. The Company applies this method consistently for similar contracts when estimating the effect of any uncertainty on an amount of variable consideration to which it will be entitled. An estimate of transaction price does not include any estimated amount of variable consideration that is constrained. In addition, the Company considers all the information (historical, current, and forecast) that is reasonably available to identify possible consideration amounts. The Company considers the probability of the variable consideration for each possible scenario. The Company also has significant experience with historical discount patterns and uses this experience to estimate transaction prices. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The estimate of revenue is affected by assumptions in payor behavior such as changes in payor mix, payor collections, current customer contractual requirements, and experience with collections from third-party payors. When assessing the total consideration for insurance carriers and patients, revenues are further constrained for estimated refunds. The Company reserves certain amounts in Accrued liabilities in the Company&#8217;s Condensed Consolidated Balance Sheets in anticipation of requests for refunds of payments made previously by insurance carriers, which are accounted for as reductions in revenues in the Condensed Consolidated Statements of Operations and Comprehensive Income (Loss).</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cash collections for certain diagnostic tests delivered may differ from rates originally estimated, primarily driven by changes in the estimated transaction price due to contractual adjustments, obtaining updated information from payors and patients that was unknown at the time the performance obligation was met, and settlements with third party payors. During the three and nine months ended September 30, 2021, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RleHRyZWdpb246NTI5NjY0NzZiODk1NGMzMTkwYzQ4Y2FkYWZkMzM5NTlfNTE0MQ_8ff564d8-6007-4b40-8658-cb478aede2a6">7.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RleHRyZWdpb246NTI5NjY0NzZiODk1NGMzMTkwYzQ4Y2FkYWZkMzM5NTlfNTE0OA_8898541d-aebc-44c7-9790-4813b9f8adb2">16.6</ix:nonFraction> million in revenue, respectively, which resulted in a $<ix:nonFraction unitRef="usdPerShare" contextRef="ic929fbb9734546f8ba6190d002b58254_D20210701-20210930" decimals="2" name="mygn:IncreaseDecreaseInEarningsLossPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RleHRyZWdpb246NTI5NjY0NzZiODk1NGMzMTkwYzQ4Y2FkYWZkMzM5NTlfNTE5Nw_81e612dd-22af-4c03-8cf8-7a2b25557bb8">0.07</ix:nonFraction> impact and $<ix:nonFraction unitRef="usdPerShare" contextRef="i437a8c83f80c43f5bb7969a1427d84af_D20210101-20210930" decimals="2" name="mygn:IncreaseDecreaseInEarningsLossPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RleHRyZWdpb246NTI5NjY0NzZiODk1NGMzMTkwYzQ4Y2FkYWZkMzM5NTlfMTA5OTUxMTYzNjk3Ng_9e2f43f3-a56f-4b76-9084-2db6b6ba845b">0.16</ix:nonFraction> impact to earnings per share, respectively, for tests in which the performance obligation of delivering the tests results was met in prior periods. The changes were primarily driven by changes in the estimated transaction price. Additionally, during the three months ended March 31, 2021, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="ie59a85cd0de74256a4070826a06ab2ee_D20210101-20210331" decimals="-5" format="ixt:num-dot-decimal" name="mygn:ContractWithCustomerAssetAdjustmentToRevenueForExpandedCoveragePreviouslyConstrained" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RleHRyZWdpb246NTI5NjY0NzZiODk1NGMzMTkwYzQ4Y2FkYWZkMzM5NTlfNTUxMg_bd8c42e9-6bec-48c2-85b6-fc7fa92cc7e1">6.8</ix:nonFraction> million of revenue due to expanded coverage for Prolaris, for which revenue was fully constrained in a prior period. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies the practical expedient related to costs to obtain or fulfill a contract since the amortization period for such costs will be one year or less. Accordingly, <ix:nonFraction unitRef="usd" contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:CapitalizedContractCostGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RleHRyZWdpb246NTI5NjY0NzZiODk1NGMzMTkwYzQ4Y2FkYWZkMzM5NTlfNTgwMg_7ebbab95-0a43-46ec-8dc4-c0de60b065e0">no</ix:nonFraction> costs incurred to obtain or fulfill a contract have been capitalized. The Company also applies the practical expedient for not adjusting revenue recognized for the effects of the time value of money. This practical expedient has been elected because the Company collects very little cash from customers under payment terms and the vast majority of payment terms have a payback period of less than one year. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5814a71962934792901cb2330361bb17_7">Table of Contents</a></span></div></div><ix:continuation id="id3f74da50ac44b13bcc9b5cfc755c421"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable. Substantially all of the Company&#8217;s accounts receivable are with companies in the healthcare industry, U.S. and state governmental agencies that make payments on the customer's behalf, and individuals. The Company does not believe that receivables due from U.S. and state governmental agencies, such as Medicare, represent a credit risk since the related healthcare programs are funded by the U.S. and state governments. The Company only has one payor, Medicare, that represents greater than 10% of its revenues. Revenues received from Medicare represented approximately <ix:nonFraction unitRef="number" contextRef="ib2b1d515b0df442caf3a61b77cd756eb_D20210701-20210930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RleHRyZWdpb246NTI5NjY0NzZiODk1NGMzMTkwYzQ4Y2FkYWZkMzM5NTlfNjk3Ng_7c7f98e7-b85f-49f1-83ae-f9b21da1276f"><ix:nonFraction unitRef="number" contextRef="i4c9ecd2a8793414a828047a9bf1593e4_D20210101-20210930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RleHRyZWdpb246NTI5NjY0NzZiODk1NGMzMTkwYzQ4Y2FkYWZkMzM5NTlfNjk3Ng_d3d7424a-fb12-4890-9c21-d804bc8f9c1d">17</ix:nonFraction></ix:nonFraction>% of total revenue for each of the three and nine months ended September&#160;30, 2021, and <ix:nonFraction unitRef="number" contextRef="ide0992200fac419ab9eb95a8229f286b_D20200701-20200930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RleHRyZWdpb246NTI5NjY0NzZiODk1NGMzMTkwYzQ4Y2FkYWZkMzM5NTlfNzA0OQ_700b09d5-05ec-4524-80c4-365cf3395e12">16</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i9463c7d008224ba994869b57828ab6a2_D20200101-20200930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RleHRyZWdpb246NTI5NjY0NzZiODk1NGMzMTkwYzQ4Y2FkYWZkMzM5NTlfNzA1Ng_c595ef2b-c449-4d1c-b08b-e492216aa292">15</ix:nonFraction>% of total revenue for the three and nine months ended September&#160;30, 2020, respectively. Concentrations of credit risk are mitigated due to the number of the Company&#8217;s customers as well as their dispersion across many geographic regions. No payor accounted for more than 10% of accounts receivable at September&#160;30, 2021 or December&#160;31, 2020. The Company does not require collateral from its customers.</span></div></ix:continuation><div id="i5814a71962934792901cb2330361bb17_40"></div><div style="margin-top:12pt"><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RleHRyZWdpb246MzAwZWUxYzI4MGM4NGY0Y2IzNGRiZTNmY2YxODkyYmJfNjE5_fbbb98e8-149b-40e8-ade0-a084edf7e0d4" continuedAt="i7522f98eb22247e6bccfea2ffbd146c9" escape="true">MARKETABLE INVESTMENT SECURITIES</ix:nonNumeric></span></div><ix:continuation id="i7522f98eb22247e6bccfea2ffbd146c9" continuedAt="if24b257cfb2341c989aec4e205014d92"><ix:nonNumeric contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RleHRyZWdpb246MzAwZWUxYzI4MGM4NGY0Y2IzNGRiZTNmY2YxODkyYmJfNjIw_95c730fe-5407-41cb-bb64-0d6d6f701452" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortized cost, gross unrealized holding gains, gross unrealized holding losses, and fair value for available-for-sale securities by major security type and class of security at September&#160;30, 2021 and December&#160;31, 2020 were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized<br/>cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>unrealized<br/>holding<br/>gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>unrealized<br/>holding<br/>losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated<br/>fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie18df879613d4bb19a671fecd56a73ef_I20210930" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOmE0OTgwYTMzNmQzMDQ0NmY5NTAwMGY2YjJmNzhjMDNmL3RhYmxlcmFuZ2U6YTQ5ODBhMzM2ZDMwNDQ2Zjk1MDAwZjZiMmY3OGMwM2ZfMy0xLTEtMS0xODE2NA_3f7f9de5-1099-4b3d-a7be-7cffb070a4e4">208.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie18df879613d4bb19a671fecd56a73ef_I20210930" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOmE0OTgwYTMzNmQzMDQ0NmY5NTAwMGY2YjJmNzhjMDNmL3RhYmxlcmFuZ2U6YTQ5ODBhMzM2ZDMwNDQ2Zjk1MDAwZjZiMmY3OGMwM2ZfMy03LTEtMS0xODE2NA_0a708567-2168-4b73-aaad-2b13616e5e7a">208.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i55b41215c9044cb8bdb7a95355f2cee3_I20210930" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOmE0OTgwYTMzNmQzMDQ0NmY5NTAwMGY2YjJmNzhjMDNmL3RhYmxlcmFuZ2U6YTQ5ODBhMzM2ZDMwNDQ2Zjk1MDAwZjZiMmY3OGMwM2ZfNC0xLTEtMS0xODE2NA_66b3d514-b77d-4557-9e3d-8837caaf7316">86.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i55b41215c9044cb8bdb7a95355f2cee3_I20210930" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOmE0OTgwYTMzNmQzMDQ0NmY5NTAwMGY2YjJmNzhjMDNmL3RhYmxlcmFuZ2U6YTQ5ODBhMzM2ZDMwNDQ2Zjk1MDAwZjZiMmY3OGMwM2ZfNC03LTEtMS0xODE2NA_583cd608-70cb-4b02-ac31-f6736fd6a545">86.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOmE0OTgwYTMzNmQzMDQ0NmY5NTAwMGY2YjJmNzhjMDNmL3RhYmxlcmFuZ2U6YTQ5ODBhMzM2ZDMwNDQ2Zjk1MDAwZjZiMmY3OGMwM2ZfNS0xLTEtMS0xODE2NA_cbc39476-46bd-43f7-ac77-eb8992d3c7c9">295.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOmE0OTgwYTMzNmQzMDQ0NmY5NTAwMGY2YjJmNzhjMDNmL3RhYmxlcmFuZ2U6YTQ5ODBhMzM2ZDMwNDQ2Zjk1MDAwZjZiMmY3OGMwM2ZfNS03LTEtMS0xODE2NA_d8bb1e62-1f1b-4393-bd76-048e22d54a2c">295.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-sale:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate bonds and notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i20c433933c2b4c689e241c3fd658ffa4_I20210930" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOmE0OTgwYTMzNmQzMDQ0NmY5NTAwMGY2YjJmNzhjMDNmL3RhYmxlcmFuZ2U6YTQ5ODBhMzM2ZDMwNDQ2Zjk1MDAwZjZiMmY3OGMwM2ZfNy0xLTEtMS0xODE2NA_2b5d8a62-3c07-41b0-b3dd-f89f4f102bd6">90.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i20c433933c2b4c689e241c3fd658ffa4_I20210930" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOmE0OTgwYTMzNmQzMDQ0NmY5NTAwMGY2YjJmNzhjMDNmL3RhYmxlcmFuZ2U6YTQ5ODBhMzM2ZDMwNDQ2Zjk1MDAwZjZiMmY3OGMwM2ZfNy0zLTEtMS0xODE2NA_3f72e529-512c-4156-a2a5-85faa98c7d6c">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i20c433933c2b4c689e241c3fd658ffa4_I20210930" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOmE0OTgwYTMzNmQzMDQ0NmY5NTAwMGY2YjJmNzhjMDNmL3RhYmxlcmFuZ2U6YTQ5ODBhMzM2ZDMwNDQ2Zjk1MDAwZjZiMmY3OGMwM2ZfNy01LTEtMS0xODE2NA_c622c4dc-195c-457b-95e0-16bee1243c3d">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i20c433933c2b4c689e241c3fd658ffa4_I20210930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOmE0OTgwYTMzNmQzMDQ0NmY5NTAwMGY2YjJmNzhjMDNmL3RhYmxlcmFuZ2U6YTQ5ODBhMzM2ZDMwNDQ2Zjk1MDAwZjZiMmY3OGMwM2ZfNy03LTEtMS0xODE2NA_aa3bcafc-6427-4f68-9f32-52cef32b92c3">90.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Municipal bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i474e395867254271927d4271ff603665_I20210930" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOmE0OTgwYTMzNmQzMDQ0NmY5NTAwMGY2YjJmNzhjMDNmL3RhYmxlcmFuZ2U6YTQ5ODBhMzM2ZDMwNDQ2Zjk1MDAwZjZiMmY3OGMwM2ZfOC0xLTEtMS0xODE2NA_a5b89fa9-a5cb-4776-a72e-da33fe6d3016">19.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i474e395867254271927d4271ff603665_I20210930" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOmE0OTgwYTMzNmQzMDQ0NmY5NTAwMGY2YjJmNzhjMDNmL3RhYmxlcmFuZ2U6YTQ5ODBhMzM2ZDMwNDQ2Zjk1MDAwZjZiMmY3OGMwM2ZfOC0zLTEtMS0xODE2NA_e0d7968d-aded-4105-9c08-2aa7706c23b3">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i474e395867254271927d4271ff603665_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOmE0OTgwYTMzNmQzMDQ0NmY5NTAwMGY2YjJmNzhjMDNmL3RhYmxlcmFuZ2U6YTQ5ODBhMzM2ZDMwNDQ2Zjk1MDAwZjZiMmY3OGMwM2ZfOC01LTEtMS0xODE2NA_c84fa9b0-1c47-468c-9c56-f0bbab6a115f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i474e395867254271927d4271ff603665_I20210930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOmE0OTgwYTMzNmQzMDQ0NmY5NTAwMGY2YjJmNzhjMDNmL3RhYmxlcmFuZ2U6YTQ5ODBhMzM2ZDMwNDQ2Zjk1MDAwZjZiMmY3OGMwM2ZfOC03LTEtMS0xODE2NA_f8848f68-4bda-405e-87d1-e70d5ac05f72">19.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal agency issues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0f849fd49ae643249e914d79d76dcb81_I20210930" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOmE0OTgwYTMzNmQzMDQ0NmY5NTAwMGY2YjJmNzhjMDNmL3RhYmxlcmFuZ2U6YTQ5ODBhMzM2ZDMwNDQ2Zjk1MDAwZjZiMmY3OGMwM2ZfOS0xLTEtMS0xODE2NA_c5a472e4-a6d3-4087-9b3e-5164b6b11bbd">2.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0f849fd49ae643249e914d79d76dcb81_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOmE0OTgwYTMzNmQzMDQ0NmY5NTAwMGY2YjJmNzhjMDNmL3RhYmxlcmFuZ2U6YTQ5ODBhMzM2ZDMwNDQ2Zjk1MDAwZjZiMmY3OGMwM2ZfOS0zLTEtMS0xODE2NA_67da37bc-804c-4b3d-b6c9-31c3da88bdbc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0f849fd49ae643249e914d79d76dcb81_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOmE0OTgwYTMzNmQzMDQ0NmY5NTAwMGY2YjJmNzhjMDNmL3RhYmxlcmFuZ2U6YTQ5ODBhMzM2ZDMwNDQ2Zjk1MDAwZjZiMmY3OGMwM2ZfOS01LTEtMS0xODE2NA_1ed792d1-2b81-4d03-87a5-d3a9c445be2d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0f849fd49ae643249e914d79d76dcb81_I20210930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOmE0OTgwYTMzNmQzMDQ0NmY5NTAwMGY2YjJmNzhjMDNmL3RhYmxlcmFuZ2U6YTQ5ODBhMzM2ZDMwNDQ2Zjk1MDAwZjZiMmY3OGMwM2ZfOS03LTEtMS0xODE2NA_ffd36d3e-ca15-4808-bcae-1cfd7ec15f47">2.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">US government securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i50d5d52f5abe44ae90e97be189c0c2c0_I20210930" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOmE0OTgwYTMzNmQzMDQ0NmY5NTAwMGY2YjJmNzhjMDNmL3RhYmxlcmFuZ2U6YTQ5ODBhMzM2ZDMwNDQ2Zjk1MDAwZjZiMmY3OGMwM2ZfMTAtMS0xLTEtMTgxNjQ_daf9e16c-fe1d-420f-901c-34e4b701ccaa">5.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i50d5d52f5abe44ae90e97be189c0c2c0_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOmE0OTgwYTMzNmQzMDQ0NmY5NTAwMGY2YjJmNzhjMDNmL3RhYmxlcmFuZ2U6YTQ5ODBhMzM2ZDMwNDQ2Zjk1MDAwZjZiMmY3OGMwM2ZfMTAtMy0xLTEtMTgxNjQ_bc8b6256-cbb1-4df3-bae1-731015e5cee2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i50d5d52f5abe44ae90e97be189c0c2c0_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOmE0OTgwYTMzNmQzMDQ0NmY5NTAwMGY2YjJmNzhjMDNmL3RhYmxlcmFuZ2U6YTQ5ODBhMzM2ZDMwNDQ2Zjk1MDAwZjZiMmY3OGMwM2ZfMTAtNS0xLTEtMTgxNjQ_72e5140d-2860-49d6-a122-fb85143ef4d4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i50d5d52f5abe44ae90e97be189c0c2c0_I20210930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOmE0OTgwYTMzNmQzMDQ0NmY5NTAwMGY2YjJmNzhjMDNmL3RhYmxlcmFuZ2U6YTQ5ODBhMzM2ZDMwNDQ2Zjk1MDAwZjZiMmY3OGMwM2ZfMTAtNy0xLTEtMTgxNjQ_a0fd4575-3362-4539-9576-2add2b4b4dd1">5.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930" decimals="-5" name="mygn:InvestmentsAndCashAmortizedCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOmE0OTgwYTMzNmQzMDQ0NmY5NTAwMGY2YjJmNzhjMDNmL3RhYmxlcmFuZ2U6YTQ5ODBhMzM2ZDMwNDQ2Zjk1MDAwZjZiMmY3OGMwM2ZfMTEtMS0xLTEtMTgxNjQ_bb582ca8-437f-4aee-a243-e83700e5df5e">413.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930" decimals="-5" name="mygn:InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOmE0OTgwYTMzNmQzMDQ0NmY5NTAwMGY2YjJmNzhjMDNmL3RhYmxlcmFuZ2U6YTQ5ODBhMzM2ZDMwNDQ2Zjk1MDAwZjZiMmY3OGMwM2ZfMTEtMy0xLTEtMTgxNjQ_a95ac3c4-5ebb-483d-8801-e312f7522d05">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930" decimals="-5" name="mygn:InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOmE0OTgwYTMzNmQzMDQ0NmY5NTAwMGY2YjJmNzhjMDNmL3RhYmxlcmFuZ2U6YTQ5ODBhMzM2ZDMwNDQ2Zjk1MDAwZjZiMmY3OGMwM2ZfMTEtNS0xLTEtMTgxNjQ_42e3614c-8a51-4286-b921-c7dc18ca007b">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930" decimals="-5" name="us-gaap:InvestmentsAndCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOmE0OTgwYTMzNmQzMDQ0NmY5NTAwMGY2YjJmNzhjMDNmL3RhYmxlcmFuZ2U6YTQ5ODBhMzM2ZDMwNDQ2Zjk1MDAwZjZiMmY3OGMwM2ZfMTEtNy0xLTEtMTgxNjQ_8dedef1d-ef9f-456b-979c-ea05fce50b21">413.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized<br/>cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>unrealized<br/>holding<br/>gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>unrealized<br/>holding<br/>losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated<br/>fair value</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2020:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i89beb1b281b84d588eff0b2c4a0c5dfb_I20201231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOjI2MzAxNzUxOThhNzRhODNiMGIzNmM0NWVmZGU0ZWQ3L3RhYmxlcmFuZ2U6MjYzMDE3NTE5OGE3NGE4M2IwYjM2YzQ1ZWZkZTRlZDdfMy0xLTEtMS0xODE2NA_99d0b38a-f8cb-45b9-9617-3d8f8bf34774">47.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i89beb1b281b84d588eff0b2c4a0c5dfb_I20201231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOjI2MzAxNzUxOThhNzRhODNiMGIzNmM0NWVmZGU0ZWQ3L3RhYmxlcmFuZ2U6MjYzMDE3NTE5OGE3NGE4M2IwYjM2YzQ1ZWZkZTRlZDdfMy03LTEtMS0xODE2NA_308f0890-8ce9-489b-85e9-bd5c9b07a78b">47.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i784e7cc69b2447578da174c05c94a660_I20201231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOjI2MzAxNzUxOThhNzRhODNiMGIzNmM0NWVmZGU0ZWQ3L3RhYmxlcmFuZ2U6MjYzMDE3NTE5OGE3NGE4M2IwYjM2YzQ1ZWZkZTRlZDdfNC0xLTEtMS0xODE2NA_5fbc2477-27dc-41b8-ab4d-d1030ac624ee">69.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i784e7cc69b2447578da174c05c94a660_I20201231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOjI2MzAxNzUxOThhNzRhODNiMGIzNmM0NWVmZGU0ZWQ3L3RhYmxlcmFuZ2U6MjYzMDE3NTE5OGE3NGE4M2IwYjM2YzQ1ZWZkZTRlZDdfNC03LTEtMS0xODE2NA_509cc2ec-5690-408f-a55e-f42e2d1c79de">69.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total cash and cash equivalents</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOjI2MzAxNzUxOThhNzRhODNiMGIzNmM0NWVmZGU0ZWQ3L3RhYmxlcmFuZ2U6MjYzMDE3NTE5OGE3NGE4M2IwYjM2YzQ1ZWZkZTRlZDdfNS0xLTEtMS0xODE2NA_eb49b5bf-e955-4d57-90e4-88cc1761eca2">117.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOjI2MzAxNzUxOThhNzRhODNiMGIzNmM0NWVmZGU0ZWQ3L3RhYmxlcmFuZ2U6MjYzMDE3NTE5OGE3NGE4M2IwYjM2YzQ1ZWZkZTRlZDdfNS03LTEtMS0xODE2NA_ce837d40-aec4-4298-a734-f4247bb19c1e">117.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-sale:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate bonds and notes</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ide2c0b04a05e4f40b02f2431e83b3536_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOjI2MzAxNzUxOThhNzRhODNiMGIzNmM0NWVmZGU0ZWQ3L3RhYmxlcmFuZ2U6MjYzMDE3NTE5OGE3NGE4M2IwYjM2YzQ1ZWZkZTRlZDdfNy0xLTEtMS0xODE2NA_ccc6a795-9c67-4ab6-ab2a-106ed50b92d7">28.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ide2c0b04a05e4f40b02f2431e83b3536_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOjI2MzAxNzUxOThhNzRhODNiMGIzNmM0NWVmZGU0ZWQ3L3RhYmxlcmFuZ2U6MjYzMDE3NTE5OGE3NGE4M2IwYjM2YzQ1ZWZkZTRlZDdfNy0zLTEtMS0xODE2NA_e0796bf1-991d-4909-8638-b4eb1ff6dd78">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ide2c0b04a05e4f40b02f2431e83b3536_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOjI2MzAxNzUxOThhNzRhODNiMGIzNmM0NWVmZGU0ZWQ3L3RhYmxlcmFuZ2U6MjYzMDE3NTE5OGE3NGE4M2IwYjM2YzQ1ZWZkZTRlZDdfNy01LTEtMS0xODE2NA_275c2a49-78d8-4f4e-8992-367b38ecf57f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ide2c0b04a05e4f40b02f2431e83b3536_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOjI2MzAxNzUxOThhNzRhODNiMGIzNmM0NWVmZGU0ZWQ3L3RhYmxlcmFuZ2U6MjYzMDE3NTE5OGE3NGE4M2IwYjM2YzQ1ZWZkZTRlZDdfNy03LTEtMS0xODE2NA_073e4053-7715-4b5e-9dae-137146d3ea1a">29.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Municipal bonds</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1e3de8ef1a9243968a201ad829b59152_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOjI2MzAxNzUxOThhNzRhODNiMGIzNmM0NWVmZGU0ZWQ3L3RhYmxlcmFuZ2U6MjYzMDE3NTE5OGE3NGE4M2IwYjM2YzQ1ZWZkZTRlZDdfOC0xLTEtMS0xODE2NA_d51ede9e-7596-44e3-8c4c-a6c98adbd6ca">9.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1e3de8ef1a9243968a201ad829b59152_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOjI2MzAxNzUxOThhNzRhODNiMGIzNmM0NWVmZGU0ZWQ3L3RhYmxlcmFuZ2U6MjYzMDE3NTE5OGE3NGE4M2IwYjM2YzQ1ZWZkZTRlZDdfOC0zLTEtMS0xODE2NA_1a76eaa8-72a4-49d6-81df-0c203a861703">0.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1e3de8ef1a9243968a201ad829b59152_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOjI2MzAxNzUxOThhNzRhODNiMGIzNmM0NWVmZGU0ZWQ3L3RhYmxlcmFuZ2U6MjYzMDE3NTE5OGE3NGE4M2IwYjM2YzQ1ZWZkZTRlZDdfOC01LTEtMS0xODE2NA_c24b2294-a797-4371-8fee-65a11fb39d87">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1e3de8ef1a9243968a201ad829b59152_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOjI2MzAxNzUxOThhNzRhODNiMGIzNmM0NWVmZGU0ZWQ3L3RhYmxlcmFuZ2U6MjYzMDE3NTE5OGE3NGE4M2IwYjM2YzQ1ZWZkZTRlZDdfOC03LTEtMS0xODE2NA_e7168083-477c-4827-b16e-2cc9955f00f1">9.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal agency issues</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id5e0328e3e08484f88ad3cfbf16c738f_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOjI2MzAxNzUxOThhNzRhODNiMGIzNmM0NWVmZGU0ZWQ3L3RhYmxlcmFuZ2U6MjYzMDE3NTE5OGE3NGE4M2IwYjM2YzQ1ZWZkZTRlZDdfOS0xLTEtMS0xODE2NA_3ee606ee-17d9-4441-898f-466fc1212855">4.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id5e0328e3e08484f88ad3cfbf16c738f_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOjI2MzAxNzUxOThhNzRhODNiMGIzNmM0NWVmZGU0ZWQ3L3RhYmxlcmFuZ2U6MjYzMDE3NTE5OGE3NGE4M2IwYjM2YzQ1ZWZkZTRlZDdfOS0zLTEtMS0xODE2NA_e594c28c-b49f-4f2d-af62-559a65624d93">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id5e0328e3e08484f88ad3cfbf16c738f_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOjI2MzAxNzUxOThhNzRhODNiMGIzNmM0NWVmZGU0ZWQ3L3RhYmxlcmFuZ2U6MjYzMDE3NTE5OGE3NGE4M2IwYjM2YzQ1ZWZkZTRlZDdfOS01LTEtMS0xODE2NA_c15b76a6-cc4f-4437-ba90-cb6fa4208a59">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id5e0328e3e08484f88ad3cfbf16c738f_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOjI2MzAxNzUxOThhNzRhODNiMGIzNmM0NWVmZGU0ZWQ3L3RhYmxlcmFuZ2U6MjYzMDE3NTE5OGE3NGE4M2IwYjM2YzQ1ZWZkZTRlZDdfOS03LTEtMS0xODE2NA_795c33ab-17b8-44a6-bdb0-3fdb99b153ef">4.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">US government securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i47594399039d468c97b0901e9244c85e_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOjI2MzAxNzUxOThhNzRhODNiMGIzNmM0NWVmZGU0ZWQ3L3RhYmxlcmFuZ2U6MjYzMDE3NTE5OGE3NGE4M2IwYjM2YzQ1ZWZkZTRlZDdfMTAtMS0xLTEtMTgxNjQ_25da06eb-8195-4c26-8e28-b0e5ff178099">11.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i47594399039d468c97b0901e9244c85e_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOjI2MzAxNzUxOThhNzRhODNiMGIzNmM0NWVmZGU0ZWQ3L3RhYmxlcmFuZ2U6MjYzMDE3NTE5OGE3NGE4M2IwYjM2YzQ1ZWZkZTRlZDdfMTAtMy0xLTEtMTgxNjQ_a89a2f8e-b6bb-4d17-8c0a-101427d926a8">0.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i47594399039d468c97b0901e9244c85e_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOjI2MzAxNzUxOThhNzRhODNiMGIzNmM0NWVmZGU0ZWQ3L3RhYmxlcmFuZ2U6MjYzMDE3NTE5OGE3NGE4M2IwYjM2YzQ1ZWZkZTRlZDdfMTAtNS0xLTEtMTgxNjQ_430e5d15-3cb8-4148-8734-f236c9e9674a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i47594399039d468c97b0901e9244c85e_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOjI2MzAxNzUxOThhNzRhODNiMGIzNmM0NWVmZGU0ZWQ3L3RhYmxlcmFuZ2U6MjYzMDE3NTE5OGE3NGE4M2IwYjM2YzQ1ZWZkZTRlZDdfMTAtNy0xLTEtMTgxNjQ_d89fc6b3-46c9-4582-8b3f-f551f87be2e7">11.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231" decimals="-5" name="mygn:InvestmentsAndCashAmortizedCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOjI2MzAxNzUxOThhNzRhODNiMGIzNmM0NWVmZGU0ZWQ3L3RhYmxlcmFuZ2U6MjYzMDE3NTE5OGE3NGE4M2IwYjM2YzQ1ZWZkZTRlZDdfMTEtMS0xLTEtMTgxNjQ_51cae036-6b65-4f13-8fbf-fd4bf3f9ea76">170.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231" decimals="-5" name="mygn:InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOjI2MzAxNzUxOThhNzRhODNiMGIzNmM0NWVmZGU0ZWQ3L3RhYmxlcmFuZ2U6MjYzMDE3NTE5OGE3NGE4M2IwYjM2YzQ1ZWZkZTRlZDdfMTEtMy0xLTEtMTgxNjQ_c0d9f5a4-9333-4ad6-bea6-e128e13e9f20">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231" decimals="-5" format="ixt:fixed-zero" name="mygn:InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOjI2MzAxNzUxOThhNzRhODNiMGIzNmM0NWVmZGU0ZWQ3L3RhYmxlcmFuZ2U6MjYzMDE3NTE5OGE3NGE4M2IwYjM2YzQ1ZWZkZTRlZDdfMTEtNS0xLTEtMTgxNjQ_8d82a80b-9618-43d0-987b-6a9e8c258ccf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231" decimals="-5" name="us-gaap:InvestmentsAndCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOjI2MzAxNzUxOThhNzRhODNiMGIzNmM0NWVmZGU0ZWQ3L3RhYmxlcmFuZ2U6MjYzMDE3NTE5OGE3NGE4M2IwYjM2YzQ1ZWZkZTRlZDdfMTEtNy0xLTEtMTgxNjQ_2c2a6f89-8a4e-4419-a5b7-610fd53aa2fc">171.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5814a71962934792901cb2330361bb17_7">Table of Contents</a></span></div></div><ix:continuation id="if24b257cfb2341c989aec4e205014d92"><ix:nonNumeric contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RleHRyZWdpb246MzAwZWUxYzI4MGM4NGY0Y2IzNGRiZTNmY2YxODkyYmJfNjE4_4b09e02a-347a-4174-b5ee-37ad7e53061b" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents, and maturities of debt securities classified as available-for-sale securities were as follows at September&#160;30, 2021:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized<br/>cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated<br/>fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie18df879613d4bb19a671fecd56a73ef_I20210930" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOjVhMTA0NzA3ZWViYzQxNDFhOGQ0NjAxMzU2N2YyNTYzL3RhYmxlcmFuZ2U6NWExMDQ3MDdlZWJjNDE0MWE4ZDQ2MDEzNTY3ZjI1NjNfMS0xLTEtMS0xODE2NA_2f3bd2ad-3005-4ba3-9042-ecc1ffa67937">208.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie18df879613d4bb19a671fecd56a73ef_I20210930" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOjVhMTA0NzA3ZWViYzQxNDFhOGQ0NjAxMzU2N2YyNTYzL3RhYmxlcmFuZ2U6NWExMDQ3MDdlZWJjNDE0MWE4ZDQ2MDEzNTY3ZjI1NjNfMS0zLTEtMS0xODE2NA_a21777a6-c3f0-4c4b-8e3e-382e11223910">208.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55b41215c9044cb8bdb7a95355f2cee3_I20210930" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOjVhMTA0NzA3ZWViYzQxNDFhOGQ0NjAxMzU2N2YyNTYzL3RhYmxlcmFuZ2U6NWExMDQ3MDdlZWJjNDE0MWE4ZDQ2MDEzNTY3ZjI1NjNfMi0xLTEtMS0xODE2NA_90bfdae0-2840-4674-8f36-32c193c7fa28">86.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55b41215c9044cb8bdb7a95355f2cee3_I20210930" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOjVhMTA0NzA3ZWViYzQxNDFhOGQ0NjAxMzU2N2YyNTYzL3RhYmxlcmFuZ2U6NWExMDQ3MDdlZWJjNDE0MWE4ZDQ2MDEzNTY3ZjI1NjNfMi0zLTEtMS0xODE2NA_afd637b0-1a8a-4f9a-a116-c059f4336af2">86.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due within one year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOjVhMTA0NzA3ZWViYzQxNDFhOGQ0NjAxMzU2N2YyNTYzL3RhYmxlcmFuZ2U6NWExMDQ3MDdlZWJjNDE0MWE4ZDQ2MDEzNTY3ZjI1NjNfNC0xLTEtMS0xODE2NA_8759220a-123c-444d-9e61-4ad00eb793c4">70.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOjVhMTA0NzA3ZWViYzQxNDFhOGQ0NjAxMzU2N2YyNTYzL3RhYmxlcmFuZ2U6NWExMDQ3MDdlZWJjNDE0MWE4ZDQ2MDEzNTY3ZjI1NjNfNC0zLTEtMS0xODE2NA_a4271e95-a81d-4a01-91c1-336dac5ddde0">70.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due after one year through five years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOjVhMTA0NzA3ZWViYzQxNDFhOGQ0NjAxMzU2N2YyNTYzL3RhYmxlcmFuZ2U6NWExMDQ3MDdlZWJjNDE0MWE4ZDQ2MDEzNTY3ZjI1NjNfNS0xLTEtMS0xODE2NA_096563b1-45c0-49fa-8296-216b0dd3853d">47.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOjVhMTA0NzA3ZWViYzQxNDFhOGQ0NjAxMzU2N2YyNTYzL3RhYmxlcmFuZ2U6NWExMDQ3MDdlZWJjNDE0MWE4ZDQ2MDEzNTY3ZjI1NjNfNS0zLTEtMS0xODE2NA_661cd566-65e9-4999-af21-809b4bce6cc9">47.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due after five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOjVhMTA0NzA3ZWViYzQxNDFhOGQ0NjAxMzU2N2YyNTYzL3RhYmxlcmFuZ2U6NWExMDQ3MDdlZWJjNDE0MWE4ZDQ2MDEzNTY3ZjI1NjNfNi0xLTEtMS0xODE2NA_a0502219-05c5-4691-ba31-76ad1d3c3c6e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOjVhMTA0NzA3ZWViYzQxNDFhOGQ0NjAxMzU2N2YyNTYzL3RhYmxlcmFuZ2U6NWExMDQ3MDdlZWJjNDE0MWE4ZDQ2MDEzNTY3ZjI1NjNfNi0zLTEtMS0xODE2NA_963468ba-a6d4-4738-ab2b-6de8eb2bc9e0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930" decimals="-5" name="mygn:InvestmentsAndCashAmortizedCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOjVhMTA0NzA3ZWViYzQxNDFhOGQ0NjAxMzU2N2YyNTYzL3RhYmxlcmFuZ2U6NWExMDQ3MDdlZWJjNDE0MWE4ZDQ2MDEzNTY3ZjI1NjNfNy0xLTEtMS0xODE2NA_cad9bc20-102c-492a-b881-ea5e14b35da6">413.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930" decimals="-5" name="us-gaap:InvestmentsAndCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOjVhMTA0NzA3ZWViYzQxNDFhOGQ0NjAxMzU2N2YyNTYzL3RhYmxlcmFuZ2U6NWExMDQ3MDdlZWJjNDE0MWE4ZDQ2MDEzNTY3ZjI1NjNfNy0zLTEtMS0xODE2NA_764b9c06-5b56-42e5-b7dc-9da047681ded">413.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were <ix:nonFraction unitRef="security" contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RleHRyZWdpb246MzAwZWUxYzI4MGM4NGY0Y2IzNGRiZTNmY2YxODkyYmJfMzky_532f1975-53fb-47fe-b310-e7a0d5d795a5"><ix:nonFraction unitRef="security" contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231" decimals="INF" format="ixt:fixed-zero" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RleHRyZWdpb246MzAwZWUxYzI4MGM4NGY0Y2IzNGRiZTNmY2YxODkyYmJfMzky_cf3f16a1-53ee-4872-81b4-155a37e94fc5">no</ix:nonFraction></ix:nonFraction> debt securities classified as available-for-sale in a gross unrealized loss position as of September&#160;30, 2021 or December 31, 2020.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional information relating to fair value of marketable investment securities can be found in Note 4.</span></div></ix:continuation><div id="i5814a71962934792901cb2330361bb17_43"></div><div style="margin-top:18pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RleHRyZWdpb246MzQ4MWIzZWU0NWZjNDRiYTk0OThkMGEzNzJhMGYwM2NfNDczOA_8c8e62b8-d29b-4608-b972-f1160981df73" continuedAt="i901e36af6c934ec6b42e0abe9a7b6151" escape="true">FAIR VALUE MEASUREMENTS</ix:nonNumeric></span></div><ix:continuation id="i901e36af6c934ec6b42e0abe9a7b6151" continuedAt="i4df3fe310a5c47fca7b29d4c73332682"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Company&#8217;s financial instruments reflects the amounts that the Company estimates it will receive in connection with the sale of an asset or pay in connection with the transfer of a liability in an orderly transaction between market participants at the measurement date (exit price). The fair value hierarchy prioritizes the use of inputs used in valuation techniques into the following three levels:</span></div><div style="margin-top:9pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1&#8212;quoted prices in active markets for identical assets and liabilities.</span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2&#8212;observable inputs other than quoted prices in active markets for identical assets and liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&#160;&#160;Some of the Company&#8217;s marketable securities primarily utilize broker quotes in a non-active market for valuation of these securities.</span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3&#8212;unobservable inputs.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the Company&#8217;s financial instruments are valued using quoted prices in active markets or based on other observable inputs.&#160;&#160;For Level 2 securities, the Company uses a third party pricing service which provides documentation on an ongoing basis that includes, among other things, pricing information with respect to reference data, methodology, inputs summarized by asset class, pricing application and corroborative information. For Level 3 contingent consideration, the Company reassesses the fair value of expected contingent consideration and the corresponding liability each reporting period using the Monte Carlo Method, which is consistent with the initial measurement of the expected earn out liability.&#160;This fair value measurement is considered a Level 3 measurement because the Company estimates projections during the expected measurement period of approximately <ix:nonNumeric contextRef="i1f71ce0e78ae4d43bdf7b1af72891a7e_D20210101-20210930" format="ixt-sec:duryear" name="mygn:BusinessCombinationContingentConsiderationLiabilityMeasurementInputTerm" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RleHRyZWdpb246MzQ4MWIzZWU0NWZjNDRiYTk0OThkMGEzNzJhMGYwM2NfMTg3MQ_31701f1b-7273-47be-92ff-b5bf5536c102">13.8</ix:nonNumeric> years, utilizing various potential pay-out scenarios.&#160;&#160;Probabilities were applied to each potential scenario and the resulting values were discounted using a rate that considers weighted average cost of capital as well as a specific risk premium associated with the riskiness of the earn-out itself, the related projections, and the overall business.&#160;The contingent earn-out liabilities are classified as components of Accrued liabilities and Other long-term liabilities in the Company&#8217;s Condensed Consolidated Balance Sheets.&#160;&#160;Changes to contingent consideration liabilities are reflected in Change in the fair value of contingent consideration in the Company&#8217;s Condensed Consolidated Statements of Operations. Changes to the unobservable inputs could have a material impact on the Company&#8217;s financial statements.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5814a71962934792901cb2330361bb17_7">Table of Contents</a></span></div></div><ix:continuation id="i4df3fe310a5c47fca7b29d4c73332682"><ix:nonNumeric contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RleHRyZWdpb246MzQ4MWIzZWU0NWZjNDRiYTk0OThkMGEzNzJhMGYwM2NfNDczNw_94a0ae38-4c72-47d2-8414-48c3fb11599f" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the fair value of the financial assets and liabilities that the Company re-measures on a regular basis:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September 30, 2021</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds (a)</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib44dd41f27d8480d8f588e0a3bf99cba_I20210930" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RhYmxlOjhjN2UwODE2YWQxYjQ5MjVhNzRmYWI1YzIzZjA5Mzc5L3RhYmxlcmFuZ2U6OGM3ZTA4MTZhZDFiNDkyNWE3NGZhYjVjMjNmMDkzNzlfMi0xLTEtMS0xODE2NA_d6c6429a-2a5e-49d1-ac6d-ec2a1524d008">86.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3d975988e4a74a9dbe6e71a5b5546389_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RhYmxlOjhjN2UwODE2YWQxYjQ5MjVhNzRmYWI1YzIzZjA5Mzc5L3RhYmxlcmFuZ2U6OGM3ZTA4MTZhZDFiNDkyNWE3NGZhYjVjMjNmMDkzNzlfMi0zLTEtMS0xODE2NA_5902e50a-964a-472c-af24-bf4be423c8cf">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4996139414984f65bb79f0d63ac3f655_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RhYmxlOjhjN2UwODE2YWQxYjQ5MjVhNzRmYWI1YzIzZjA5Mzc5L3RhYmxlcmFuZ2U6OGM3ZTA4MTZhZDFiNDkyNWE3NGZhYjVjMjNmMDkzNzlfMi01LTEtMS0xODE2NA_cda3921d-8a97-4390-8ae3-fc4528dd4428">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id012a77974384595bcd158dfde0ea68e_I20210930" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RhYmxlOjhjN2UwODE2YWQxYjQ5MjVhNzRmYWI1YzIzZjA5Mzc5L3RhYmxlcmFuZ2U6OGM3ZTA4MTZhZDFiNDkyNWE3NGZhYjVjMjNmMDkzNzlfMi03LTEtMS0xODE2NA_4d25fc4f-083f-4514-ac70-e6401884241f">86.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate bonds and notes</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i22cef9e6ab314518ab6c3a7c7d612f84_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RhYmxlOjhjN2UwODE2YWQxYjQ5MjVhNzRmYWI1YzIzZjA5Mzc5L3RhYmxlcmFuZ2U6OGM3ZTA4MTZhZDFiNDkyNWE3NGZhYjVjMjNmMDkzNzlfMy0xLTEtMS0xODE2NA_ced838b1-d6d3-460e-bbf7-dd369e5194c2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia4d9dbc5ea804408a5936ee65bfc03fe_I20210930" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RhYmxlOjhjN2UwODE2YWQxYjQ5MjVhNzRmYWI1YzIzZjA5Mzc5L3RhYmxlcmFuZ2U6OGM3ZTA4MTZhZDFiNDkyNWE3NGZhYjVjMjNmMDkzNzlfMy0zLTEtMS0xODE2NA_b6f37167-761b-4c63-a340-cfd4eb98f2b8">90.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0dd65111dedb44d595f99ccb1991e8fe_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RhYmxlOjhjN2UwODE2YWQxYjQ5MjVhNzRmYWI1YzIzZjA5Mzc5L3RhYmxlcmFuZ2U6OGM3ZTA4MTZhZDFiNDkyNWE3NGZhYjVjMjNmMDkzNzlfMy01LTEtMS0xODE2NA_c30cce71-5614-4831-806d-5b5372fd42dd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i20c433933c2b4c689e241c3fd658ffa4_I20210930" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RhYmxlOjhjN2UwODE2YWQxYjQ5MjVhNzRmYWI1YzIzZjA5Mzc5L3RhYmxlcmFuZ2U6OGM3ZTA4MTZhZDFiNDkyNWE3NGZhYjVjMjNmMDkzNzlfMy03LTEtMS0xODE2NA_b9c4a480-5b4b-4164-9698-364f18bd367d">90.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Municipal bonds</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib78f55a38b1d452e8216debd6bd284c8_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RhYmxlOjhjN2UwODE2YWQxYjQ5MjVhNzRmYWI1YzIzZjA5Mzc5L3RhYmxlcmFuZ2U6OGM3ZTA4MTZhZDFiNDkyNWE3NGZhYjVjMjNmMDkzNzlfNC0xLTEtMS0xODE2NA_79d8439e-79a3-47bd-b2f4-5bf535c7716a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia1e3572a358f489bacc6b0b33b2e63d5_I20210930" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RhYmxlOjhjN2UwODE2YWQxYjQ5MjVhNzRmYWI1YzIzZjA5Mzc5L3RhYmxlcmFuZ2U6OGM3ZTA4MTZhZDFiNDkyNWE3NGZhYjVjMjNmMDkzNzlfNC0zLTEtMS0xODE2NA_41333d78-7e60-4d49-9b1f-a846d8966557">19.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4b6dea85317046bc87a3e54a0f0f3ffc_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RhYmxlOjhjN2UwODE2YWQxYjQ5MjVhNzRmYWI1YzIzZjA5Mzc5L3RhYmxlcmFuZ2U6OGM3ZTA4MTZhZDFiNDkyNWE3NGZhYjVjMjNmMDkzNzlfNC01LTEtMS0xODE2NA_0521ad94-a985-489b-ade8-f09fed4783bb">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i474e395867254271927d4271ff603665_I20210930" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RhYmxlOjhjN2UwODE2YWQxYjQ5MjVhNzRmYWI1YzIzZjA5Mzc5L3RhYmxlcmFuZ2U6OGM3ZTA4MTZhZDFiNDkyNWE3NGZhYjVjMjNmMDkzNzlfNC03LTEtMS0xODE2NA_62c57c16-3f1c-4d1e-8456-181bb964bf3f">19.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal agency issues</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7ec450647a3c4906981f1552178b524d_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RhYmxlOjhjN2UwODE2YWQxYjQ5MjVhNzRmYWI1YzIzZjA5Mzc5L3RhYmxlcmFuZ2U6OGM3ZTA4MTZhZDFiNDkyNWE3NGZhYjVjMjNmMDkzNzlfNS0xLTEtMS0xODE2NA_9de9cf32-f42f-45e9-a26e-9d044c4c489b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i69d2dc8810554913bdaf6702c8068256_I20210930" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RhYmxlOjhjN2UwODE2YWQxYjQ5MjVhNzRmYWI1YzIzZjA5Mzc5L3RhYmxlcmFuZ2U6OGM3ZTA4MTZhZDFiNDkyNWE3NGZhYjVjMjNmMDkzNzlfNS0zLTEtMS0xODE2NA_5b9ee4f5-7a17-47d9-8a57-60bf111ae4b7">2.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i83b400ca04df4b53901e5ccced571202_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RhYmxlOjhjN2UwODE2YWQxYjQ5MjVhNzRmYWI1YzIzZjA5Mzc5L3RhYmxlcmFuZ2U6OGM3ZTA4MTZhZDFiNDkyNWE3NGZhYjVjMjNmMDkzNzlfNS01LTEtMS0xODE2NA_bc7ece10-fe4a-4657-a242-a65d6e94d704">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0f849fd49ae643249e914d79d76dcb81_I20210930" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RhYmxlOjhjN2UwODE2YWQxYjQ5MjVhNzRmYWI1YzIzZjA5Mzc5L3RhYmxlcmFuZ2U6OGM3ZTA4MTZhZDFiNDkyNWE3NGZhYjVjMjNmMDkzNzlfNS03LTEtMS0xODE2NA_04136bdb-6a17-4d6d-a464-6f70b1987843">2.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">US government securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iba04c9e73cfd46ad82a9eea96b7282e2_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RhYmxlOjhjN2UwODE2YWQxYjQ5MjVhNzRmYWI1YzIzZjA5Mzc5L3RhYmxlcmFuZ2U6OGM3ZTA4MTZhZDFiNDkyNWE3NGZhYjVjMjNmMDkzNzlfNi0xLTEtMS0xODE2NA_1c22e8ac-3848-4446-b71e-9477173aa74c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i20eb373912734049b280784af93920ce_I20210930" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RhYmxlOjhjN2UwODE2YWQxYjQ5MjVhNzRmYWI1YzIzZjA5Mzc5L3RhYmxlcmFuZ2U6OGM3ZTA4MTZhZDFiNDkyNWE3NGZhYjVjMjNmMDkzNzlfNi0zLTEtMS0xODE2NA_9780c0dc-f1bc-4121-9535-b1e1b43a02f4">5.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibdc5dad50ef14763bc23b7f645b991d5_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RhYmxlOjhjN2UwODE2YWQxYjQ5MjVhNzRmYWI1YzIzZjA5Mzc5L3RhYmxlcmFuZ2U6OGM3ZTA4MTZhZDFiNDkyNWE3NGZhYjVjMjNmMDkzNzlfNi01LTEtMS0xODE2NA_3e0b9718-1536-4896-ba97-ee29a06d3b74">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i50d5d52f5abe44ae90e97be189c0c2c0_I20210930" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RhYmxlOjhjN2UwODE2YWQxYjQ5MjVhNzRmYWI1YzIzZjA5Mzc5L3RhYmxlcmFuZ2U6OGM3ZTA4MTZhZDFiNDkyNWE3NGZhYjVjMjNmMDkzNzlfNi03LTEtMS0xODE2NA_70d55362-7e98-4875-9484-d72a0cb76091">5.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i53fc983dd40d4345b5662806620d7a69_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RhYmxlOjhjN2UwODE2YWQxYjQ5MjVhNzRmYWI1YzIzZjA5Mzc5L3RhYmxlcmFuZ2U6OGM3ZTA4MTZhZDFiNDkyNWE3NGZhYjVjMjNmMDkzNzlfNy0xLTEtMS0xODE2NA_d4cacec6-866c-4d14-9f82-d717d237bea2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i92c674fcb51e4f128ed0956b57defa1a_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RhYmxlOjhjN2UwODE2YWQxYjQ5MjVhNzRmYWI1YzIzZjA5Mzc5L3RhYmxlcmFuZ2U6OGM3ZTA4MTZhZDFiNDkyNWE3NGZhYjVjMjNmMDkzNzlfNy0zLTEtMS0xODE2NA_99b96c22-4498-4e86-8165-d18ab8e06557">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i36f381783c3a43ca93842d8b7723cb09_I20210930" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RhYmxlOjhjN2UwODE2YWQxYjQ5MjVhNzRmYWI1YzIzZjA5Mzc5L3RhYmxlcmFuZ2U6OGM3ZTA4MTZhZDFiNDkyNWE3NGZhYjVjMjNmMDkzNzlfNy01LTEtMS0xODE2NA_6cdf2d4c-9d99-4b80-959d-05f79824417a">8.8</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i476783a7d7a846aca1e3115c994a7824_I20210930" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RhYmxlOjhjN2UwODE2YWQxYjQ5MjVhNzRmYWI1YzIzZjA5Mzc5L3RhYmxlcmFuZ2U6OGM3ZTA4MTZhZDFiNDkyNWE3NGZhYjVjMjNmMDkzNzlfNy03LTEtMS0xODE2NA_5bdfecf6-1cec-43ca-959b-285d34e49226">8.8</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ifb3432fef1734dcf938bc72ecde8321c_I20210930" decimals="-5" name="us-gaap:FairValueNetAssetLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RhYmxlOjhjN2UwODE2YWQxYjQ5MjVhNzRmYWI1YzIzZjA5Mzc5L3RhYmxlcmFuZ2U6OGM3ZTA4MTZhZDFiNDkyNWE3NGZhYjVjMjNmMDkzNzlfOC0xLTEtMS0xODE2NA_f540a6af-a090-47d8-95ec-64c9394a884e">86.4</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0ba8c79bbcbe4cfdae12d33bf2783cb3_I20210930" decimals="-5" name="us-gaap:FairValueNetAssetLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RhYmxlOjhjN2UwODE2YWQxYjQ5MjVhNzRmYWI1YzIzZjA5Mzc5L3RhYmxlcmFuZ2U6OGM3ZTA4MTZhZDFiNDkyNWE3NGZhYjVjMjNmMDkzNzlfOC0zLTEtMS0xODE2NA_d13eb491-fa15-4a2d-b1d7-759b837cfe91">118.4</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="if8c6a3bacee84320baf1e19f8abf5951_I20210930" decimals="-5" sign="-" name="us-gaap:FairValueNetAssetLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RhYmxlOjhjN2UwODE2YWQxYjQ5MjVhNzRmYWI1YzIzZjA5Mzc5L3RhYmxlcmFuZ2U6OGM3ZTA4MTZhZDFiNDkyNWE3NGZhYjVjMjNmMDkzNzlfOC01LTEtMS0xODE2NA_edd2ce24-ad62-4d8e-8709-ae0a67307a31">8.8</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930" decimals="-5" name="us-gaap:FairValueNetAssetLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RhYmxlOjhjN2UwODE2YWQxYjQ5MjVhNzRmYWI1YzIzZjA5Mzc5L3RhYmxlcmFuZ2U6OGM3ZTA4MTZhZDFiNDkyNWE3NGZhYjVjMjNmMDkzNzlfOC03LTEtMS0xODE2NA_c8a7919e-af10-415a-a3ac-2ec354a7e4d4">196.0</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:27.13pt">Money market funds are primarily comprised of exchange traded funds and accrued interest.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2020</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds (a)</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic9870ea197d5485389a0710db39dac7e_I20201231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RhYmxlOjc3OWViZTkxOGQwMTQ5YmJiY2FkOTZiNDc1OTMwYjI3L3RhYmxlcmFuZ2U6Nzc5ZWJlOTE4ZDAxNDliYmJjYWQ5NmI0NzU5MzBiMjdfMi0xLTEtMS0xODE2NA_dbb0e8f2-ba6b-4190-b7c0-6a37ebb6ee7b">69.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="idac1b2ac3b4c4ea287843c55138d31fe_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RhYmxlOjc3OWViZTkxOGQwMTQ5YmJiY2FkOTZiNDc1OTMwYjI3L3RhYmxlcmFuZ2U6Nzc5ZWJlOTE4ZDAxNDliYmJjYWQ5NmI0NzU5MzBiMjdfMi0zLTEtMS0xODE2NA_46a41442-bceb-42ff-8d56-89c4ec50935e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iefe8366531d2402295ef25ebb060e068_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RhYmxlOjc3OWViZTkxOGQwMTQ5YmJiY2FkOTZiNDc1OTMwYjI3L3RhYmxlcmFuZ2U6Nzc5ZWJlOTE4ZDAxNDliYmJjYWQ5NmI0NzU5MzBiMjdfMi01LTEtMS0xODE2NA_da01dee5-06f3-4edd-aa0e-b4d0363e3e3f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if070826acb484e4b88cfbb934f2510a0_I20201231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RhYmxlOjc3OWViZTkxOGQwMTQ5YmJiY2FkOTZiNDc1OTMwYjI3L3RhYmxlcmFuZ2U6Nzc5ZWJlOTE4ZDAxNDliYmJjYWQ5NmI0NzU5MzBiMjdfMi03LTEtMS0xODE2NA_b24a5764-9677-459e-b280-777eca9f603c">69.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate bonds and notes</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i6e8d32c49f294155b6e1ca65383d3960_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RhYmxlOjc3OWViZTkxOGQwMTQ5YmJiY2FkOTZiNDc1OTMwYjI3L3RhYmxlcmFuZ2U6Nzc5ZWJlOTE4ZDAxNDliYmJjYWQ5NmI0NzU5MzBiMjdfMy0xLTEtMS0xODE2NA_a40030bc-389c-4450-af54-a57f1cb4efe4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9c5647e0218944d0aa8af898642f148e_I20201231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RhYmxlOjc3OWViZTkxOGQwMTQ5YmJiY2FkOTZiNDc1OTMwYjI3L3RhYmxlcmFuZ2U6Nzc5ZWJlOTE4ZDAxNDliYmJjYWQ5NmI0NzU5MzBiMjdfMy0zLTEtMS0xODE2NA_9e21d5cb-ebe6-43ea-a24a-0ec2025f4900">29.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibf68d852a72c4154b30db158bdb79561_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RhYmxlOjc3OWViZTkxOGQwMTQ5YmJiY2FkOTZiNDc1OTMwYjI3L3RhYmxlcmFuZ2U6Nzc5ZWJlOTE4ZDAxNDliYmJjYWQ5NmI0NzU5MzBiMjdfMy01LTEtMS0xODE2NA_bb26450b-ffe4-4010-af3b-e6fb58ba5332">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ide2c0b04a05e4f40b02f2431e83b3536_I20201231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RhYmxlOjc3OWViZTkxOGQwMTQ5YmJiY2FkOTZiNDc1OTMwYjI3L3RhYmxlcmFuZ2U6Nzc5ZWJlOTE4ZDAxNDliYmJjYWQ5NmI0NzU5MzBiMjdfMy03LTEtMS0xODE2NA_a8089b00-c7fc-4bdb-b3f2-f8b4c708617d">29.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Municipal bonds</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0330620427f647ed9cc3899d676e3b70_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RhYmxlOjc3OWViZTkxOGQwMTQ5YmJiY2FkOTZiNDc1OTMwYjI3L3RhYmxlcmFuZ2U6Nzc5ZWJlOTE4ZDAxNDliYmJjYWQ5NmI0NzU5MzBiMjdfNC0xLTEtMS0xODE2NA_1520e52d-db3c-4b25-b72f-abc95c7dcf83">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1213355c05b74525b0feb4f71cee0825_I20201231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RhYmxlOjc3OWViZTkxOGQwMTQ5YmJiY2FkOTZiNDc1OTMwYjI3L3RhYmxlcmFuZ2U6Nzc5ZWJlOTE4ZDAxNDliYmJjYWQ5NmI0NzU5MzBiMjdfNC0zLTEtMS0xODE2NA_f6019149-326b-4d50-8b4c-35f5aa3109f5">9.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8a792264bad64b069150fc3385ef30ea_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RhYmxlOjc3OWViZTkxOGQwMTQ5YmJiY2FkOTZiNDc1OTMwYjI3L3RhYmxlcmFuZ2U6Nzc5ZWJlOTE4ZDAxNDliYmJjYWQ5NmI0NzU5MzBiMjdfNC01LTEtMS0xODE2NA_726b132e-63f5-47d8-8481-acf748f250b8">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1e3de8ef1a9243968a201ad829b59152_I20201231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RhYmxlOjc3OWViZTkxOGQwMTQ5YmJiY2FkOTZiNDc1OTMwYjI3L3RhYmxlcmFuZ2U6Nzc5ZWJlOTE4ZDAxNDliYmJjYWQ5NmI0NzU5MzBiMjdfNC03LTEtMS0xODE2NA_4966d761-66a9-4fc5-b074-e79ce656ecca">9.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal agency issues</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i02209a0a76af4ebdbef9df556c34a6d8_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RhYmxlOjc3OWViZTkxOGQwMTQ5YmJiY2FkOTZiNDc1OTMwYjI3L3RhYmxlcmFuZ2U6Nzc5ZWJlOTE4ZDAxNDliYmJjYWQ5NmI0NzU5MzBiMjdfNS0xLTEtMS0xODE2NA_a63b1f2f-6351-4676-b426-1ca36c86f14f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia5d2a4f35b5e4114a4bdedc325290a90_I20201231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RhYmxlOjc3OWViZTkxOGQwMTQ5YmJiY2FkOTZiNDc1OTMwYjI3L3RhYmxlcmFuZ2U6Nzc5ZWJlOTE4ZDAxNDliYmJjYWQ5NmI0NzU5MzBiMjdfNS0zLTEtMS0xODE2NA_9a760cf9-efbb-4cdb-964b-32c83ece4171">4.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i591bb847d18a4e38a3b89e766c088008_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RhYmxlOjc3OWViZTkxOGQwMTQ5YmJiY2FkOTZiNDc1OTMwYjI3L3RhYmxlcmFuZ2U6Nzc5ZWJlOTE4ZDAxNDliYmJjYWQ5NmI0NzU5MzBiMjdfNS01LTEtMS0xODE2NA_45fc67d7-e4b1-44ce-832a-461033a57bd3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id5e0328e3e08484f88ad3cfbf16c738f_I20201231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RhYmxlOjc3OWViZTkxOGQwMTQ5YmJiY2FkOTZiNDc1OTMwYjI3L3RhYmxlcmFuZ2U6Nzc5ZWJlOTE4ZDAxNDliYmJjYWQ5NmI0NzU5MzBiMjdfNS03LTEtMS0xODE2NA_6db52d82-35d1-4960-90a6-cb6b534319c5">4.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">US government securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ieb2b2109f1474e9d98f51788f0de8c5e_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RhYmxlOjc3OWViZTkxOGQwMTQ5YmJiY2FkOTZiNDc1OTMwYjI3L3RhYmxlcmFuZ2U6Nzc5ZWJlOTE4ZDAxNDliYmJjYWQ5NmI0NzU5MzBiMjdfNi0xLTEtMS0xODE2NA_6ef4edbb-26e6-4288-9edc-ac00a44e2587">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="idc1c646e04584219aac582f20b8676ad_I20201231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RhYmxlOjc3OWViZTkxOGQwMTQ5YmJiY2FkOTZiNDc1OTMwYjI3L3RhYmxlcmFuZ2U6Nzc5ZWJlOTE4ZDAxNDliYmJjYWQ5NmI0NzU5MzBiMjdfNi0zLTEtMS0xODE2NA_90e6bde0-8456-4d81-aaf6-d66528ba95cd">11.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i707c13e32e584ee3a2051a60c642c899_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RhYmxlOjc3OWViZTkxOGQwMTQ5YmJiY2FkOTZiNDc1OTMwYjI3L3RhYmxlcmFuZ2U6Nzc5ZWJlOTE4ZDAxNDliYmJjYWQ5NmI0NzU5MzBiMjdfNi01LTEtMS0xODE2NA_4f5e1811-92c7-44ca-8c2f-74d83f3b2b52">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i47594399039d468c97b0901e9244c85e_I20201231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RhYmxlOjc3OWViZTkxOGQwMTQ5YmJiY2FkOTZiNDc1OTMwYjI3L3RhYmxlcmFuZ2U6Nzc5ZWJlOTE4ZDAxNDliYmJjYWQ5NmI0NzU5MzBiMjdfNi03LTEtMS0xODE2NA_05b0bccd-6668-47af-96dc-6656ddf3f464">11.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i81a717b368544963b5d0268a420c7e31_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RhYmxlOjc3OWViZTkxOGQwMTQ5YmJiY2FkOTZiNDc1OTMwYjI3L3RhYmxlcmFuZ2U6Nzc5ZWJlOTE4ZDAxNDliYmJjYWQ5NmI0NzU5MzBiMjdfNy0xLTEtMS0xODE2NA_4491f5dc-cd68-4e29-81d1-63529206a74f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if110d6f8bc9445f19d915e3c19311eb2_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RhYmxlOjc3OWViZTkxOGQwMTQ5YmJiY2FkOTZiNDc1OTMwYjI3L3RhYmxlcmFuZ2U6Nzc5ZWJlOTE4ZDAxNDliYmJjYWQ5NmI0NzU5MzBiMjdfNy0zLTEtMS0xODE2NA_37cdf108-45aa-47c9-8000-fb3398ee6ab6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i353263ed75ed4422b659d68ccbb565d7_I20201231" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RhYmxlOjc3OWViZTkxOGQwMTQ5YmJiY2FkOTZiNDc1OTMwYjI3L3RhYmxlcmFuZ2U6Nzc5ZWJlOTE4ZDAxNDliYmJjYWQ5NmI0NzU5MzBiMjdfNy01LTEtMS0xODE2NA_e66108f6-3abe-4f65-af14-03c3b14eb4e9">10.9</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i6f239555bbeb4f1085317b6f3100affb_I20201231" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RhYmxlOjc3OWViZTkxOGQwMTQ5YmJiY2FkOTZiNDc1OTMwYjI3L3RhYmxlcmFuZ2U6Nzc5ZWJlOTE4ZDAxNDliYmJjYWQ5NmI0NzU5MzBiMjdfNy03LTEtMS0xODE2NA_74fb1e12-a975-4660-95f8-56edf9da2c00">10.9</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i41e4b0464a314ee7a5506f2010385fab_I20201231" decimals="-5" name="us-gaap:FairValueNetAssetLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RhYmxlOjc3OWViZTkxOGQwMTQ5YmJiY2FkOTZiNDc1OTMwYjI3L3RhYmxlcmFuZ2U6Nzc5ZWJlOTE4ZDAxNDliYmJjYWQ5NmI0NzU5MzBiMjdfOC0xLTEtMS0xODE2NA_3ecbe33f-22de-4097-855a-3066dd848017">69.1</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2460434fcbba45b1b2398bd2547de226_I20201231" decimals="-5" name="us-gaap:FairValueNetAssetLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RhYmxlOjc3OWViZTkxOGQwMTQ5YmJiY2FkOTZiNDc1OTMwYjI3L3RhYmxlcmFuZ2U6Nzc5ZWJlOTE4ZDAxNDliYmJjYWQ5NmI0NzU5MzBiMjdfOC0zLTEtMS0xODE2NA_843a4b69-fa0b-4000-9634-8a812c824c37">54.7</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i3f3a1bdca0f24500a339d8a108a0211f_I20201231" decimals="-5" sign="-" name="us-gaap:FairValueNetAssetLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RhYmxlOjc3OWViZTkxOGQwMTQ5YmJiY2FkOTZiNDc1OTMwYjI3L3RhYmxlcmFuZ2U6Nzc5ZWJlOTE4ZDAxNDliYmJjYWQ5NmI0NzU5MzBiMjdfOC01LTEtMS0xODE2NA_ee82d577-1939-4fab-8aad-a1f792498389">10.9</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231" decimals="-5" name="us-gaap:FairValueNetAssetLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RhYmxlOjc3OWViZTkxOGQwMTQ5YmJiY2FkOTZiNDc1OTMwYjI3L3RhYmxlcmFuZ2U6Nzc5ZWJlOTE4ZDAxNDliYmJjYWQ5NmI0NzU5MzBiMjdfOC03LTEtMS0xODE2NA_745e53bf-4431-4f24-921d-ea1e5df174e0">112.9</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:27.13pt">Money market funds are primarily comprised of exchange traded funds and accrued interest.</span></div></ix:nonNumeric><div style="padding-left:36pt"><span><br/></span></div><ix:nonNumeric contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RleHRyZWdpb246MzQ4MWIzZWU0NWZjNDRiYTk0OThkMGEzNzJhMGYwM2NfNDczNg_2a7c9cf9-f56b-4044-9144-4849fb647afb" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following table reconciles the change in the fair value of the contingent consideration during the periods presented:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.596%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance December 31, 2020</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RhYmxlOmMxZjQzNjIzYjFkNjQwNWZhYzA3NGVlZmVmYjliMmQxL3RhYmxlcmFuZ2U6YzFmNDM2MjNiMWQ2NDA1ZmFjMDc0ZWVmZWZiOWIyZDFfMS0xLTEtMS0xODE2NA_54813767-8878-4119-8274-f56470ad34f6">10.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payment of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RhYmxlOmMxZjQzNjIzYjFkNjQwNWZhYzA3NGVlZmVmYjliMmQxL3RhYmxlcmFuZ2U6YzFmNDM2MjNiMWQ2NDA1ZmFjMDc0ZWVmZWZiOWIyZDFfMi0xLTEtMS0xODE2NA_04a3205a-4c39-482f-8a19-c3bb51582113">3.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in fair value recognized in the income statement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RhYmxlOmMxZjQzNjIzYjFkNjQwNWZhYzA3NGVlZmVmYjliMmQxL3RhYmxlcmFuZ2U6YzFmNDM2MjNiMWQ2NDA1ZmFjMDc0ZWVmZWZiOWIyZDFfMy0xLTEtMS0xODE2NA_076a0166-ef93-49e7-bf15-ee7eae492838">1.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Translation adjustments recognized in other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RhYmxlOmMxZjQzNjIzYjFkNjQwNWZhYzA3NGVlZmVmYjliMmQxL3RhYmxlcmFuZ2U6YzFmNDM2MjNiMWQ2NDA1ZmFjMDc0ZWVmZWZiOWIyZDFfNC0xLTEtMS0xODE2NA_a74937c0-8007-47b4-af81-4669ab214f87">0.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ending balance September 30, 2021</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RhYmxlOmMxZjQzNjIzYjFkNjQwNWZhYzA3NGVlZmVmYjliMmQxL3RhYmxlcmFuZ2U6YzFmNDM2MjNiMWQ2NDA1ZmFjMDc0ZWVmZWZiOWIyZDFfNS0xLTEtMS0xODE2NA_9884ec9f-3236-4efe-9094-a9c85d18aac2">8.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i5814a71962934792901cb2330361bb17_46"></div><div style="margin-top:18pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180Ni9mcmFnOmVjMGQzZWIyYTkwZjQzYzlhZjIxZTE5MzRhZjgwNzRlL3RleHRyZWdpb246ZWMwZDNlYjJhOTBmNDNjOWFmMjFlMTkzNGFmODA3NGVfNDU_e33c6453-7016-4a33-89ef-ea44e0339c6c" continuedAt="i0b199b678e0c4dd694d1f980698abccf" escape="true">PROPERTY, PLANT AND EQUIPMENT, NET</ix:nonNumeric></span></div><ix:continuation id="i0b199b678e0c4dd694d1f980698abccf"><ix:nonNumeric contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180Ni9mcmFnOmVjMGQzZWIyYTkwZjQzYzlhZjIxZTE5MzRhZjgwNzRlL3RleHRyZWdpb246ZWMwZDNlYjJhOTBmNDNjOWFmMjFlMTkzNGFmODA3NGVfNDY_1a3847c8-7aff-4936-99d6-026bd25b3f0a" escape="true"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.511%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.513%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold improvements</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i94b157c71c86440fa7ba1b5891dd3e43_I20210930" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180Ni9mcmFnOmVjMGQzZWIyYTkwZjQzYzlhZjIxZTE5MzRhZjgwNzRlL3RhYmxlOmJjYzFkYzM5NDU3NjQ3ZTVhM2EyYzAxMjUwZTEwOTYzL3RhYmxlcmFuZ2U6YmNjMWRjMzk0NTc2NDdlNWEzYTJjMDEyNTBlMTA5NjNfMS0xLTEtMS0xODE2NA_4f17e341-411b-4d96-9c01-0559749ab01c">38.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ifc0bbee828074f62b3cdac04425562c8_I20201231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180Ni9mcmFnOmVjMGQzZWIyYTkwZjQzYzlhZjIxZTE5MzRhZjgwNzRlL3RhYmxlOmJjYzFkYzM5NDU3NjQ3ZTVhM2EyYzAxMjUwZTEwOTYzL3RhYmxlcmFuZ2U6YmNjMWRjMzk0NTc2NDdlNWEzYTJjMDEyNTBlMTA5NjNfMS0zLTEtMS0xODE2NA_a7019201-bbda-4781-9a2b-9d3d38da7993">35.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equipment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i80977ee86e3c41ebb192c62d6bfce59a_I20210930" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180Ni9mcmFnOmVjMGQzZWIyYTkwZjQzYzlhZjIxZTE5MzRhZjgwNzRlL3RhYmxlOmJjYzFkYzM5NDU3NjQ3ZTVhM2EyYzAxMjUwZTEwOTYzL3RhYmxlcmFuZ2U6YmNjMWRjMzk0NTc2NDdlNWEzYTJjMDEyNTBlMTA5NjNfMi0xLTEtMS0xODE2NA_e79be712-9976-4fbb-8dd3-e62d0da413d7">110.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9ebba697932d49ea8da9c7220efb9033_I20201231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180Ni9mcmFnOmVjMGQzZWIyYTkwZjQzYzlhZjIxZTE5MzRhZjgwNzRlL3RhYmxlOmJjYzFkYzM5NDU3NjQ3ZTVhM2EyYzAxMjUwZTEwOTYzL3RhYmxlcmFuZ2U6YmNjMWRjMzk0NTc2NDdlNWEzYTJjMDEyNTBlMTA5NjNfMi0zLTEtMS0xODE2NA_e09d1acf-4ad8-48bb-93bb-5371c272e8aa">117.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment, gross</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180Ni9mcmFnOmVjMGQzZWIyYTkwZjQzYzlhZjIxZTE5MzRhZjgwNzRlL3RhYmxlOmJjYzFkYzM5NDU3NjQ3ZTVhM2EyYzAxMjUwZTEwOTYzL3RhYmxlcmFuZ2U6YmNjMWRjMzk0NTc2NDdlNWEzYTJjMDEyNTBlMTA5NjNfMy0xLTEtMS0xODE2NA_de42e315-9c59-46c9-a89a-16dce3da2bf2">148.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180Ni9mcmFnOmVjMGQzZWIyYTkwZjQzYzlhZjIxZTE5MzRhZjgwNzRlL3RhYmxlOmJjYzFkYzM5NDU3NjQ3ZTVhM2EyYzAxMjUwZTEwOTYzL3RhYmxlcmFuZ2U6YmNjMWRjMzk0NTc2NDdlNWEzYTJjMDEyNTBlMTA5NjNfMy0zLTEtMS0xODE2NA_d64d8bbd-315f-41d9-b7d3-d4d45379290f">153.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less accumulated depreciation</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930" decimals="-5" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180Ni9mcmFnOmVjMGQzZWIyYTkwZjQzYzlhZjIxZTE5MzRhZjgwNzRlL3RhYmxlOmJjYzFkYzM5NDU3NjQ3ZTVhM2EyYzAxMjUwZTEwOTYzL3RhYmxlcmFuZ2U6YmNjMWRjMzk0NTc2NDdlNWEzYTJjMDEyNTBlMTA5NjNfNC0xLTEtMS0xODE2NA_d19361de-ab9d-4f00-9859-d9a04465fea7">105.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231" decimals="-5" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180Ni9mcmFnOmVjMGQzZWIyYTkwZjQzYzlhZjIxZTE5MzRhZjgwNzRlL3RhYmxlOmJjYzFkYzM5NDU3NjQ3ZTVhM2EyYzAxMjUwZTEwOTYzL3RhYmxlcmFuZ2U6YmNjMWRjMzk0NTc2NDdlNWEzYTJjMDEyNTBlMTA5NjNfNC0zLTEtMS0xODE2NA_31ccc27a-4650-48c0-b8b4-68cc5ff7b8e9">112.9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment, net</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180Ni9mcmFnOmVjMGQzZWIyYTkwZjQzYzlhZjIxZTE5MzRhZjgwNzRlL3RhYmxlOmJjYzFkYzM5NDU3NjQ3ZTVhM2EyYzAxMjUwZTEwOTYzL3RhYmxlcmFuZ2U6YmNjMWRjMzk0NTc2NDdlNWEzYTJjMDEyNTBlMTA5NjNfNS0xLTEtMS0xODE2NA_3c1c6290-b280-47e5-b163-38cfa87f029e">43.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180Ni9mcmFnOmVjMGQzZWIyYTkwZjQzYzlhZjIxZTE5MzRhZjgwNzRlL3RhYmxlOmJjYzFkYzM5NDU3NjQ3ZTVhM2EyYzAxMjUwZTEwOTYzL3RhYmxlcmFuZ2U6YmNjMWRjMzk0NTc2NDdlNWEzYTJjMDEyNTBlMTA5NjNfNS0zLTEtMS0xODE2NA_30d8a46e-5bc1-4c0d-af21-53366601947a">40.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in equipment from December 31, 2020 to September 30, 2021 was primarily due to the sales of Myriad RBM, Inc. and select assets of the Myriad Autoimmune business. See Note 16 for additional information on these divestitures.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.215%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine months ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930" decimals="-5" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180Ni9mcmFnOmVjMGQzZWIyYTkwZjQzYzlhZjIxZTE5MzRhZjgwNzRlL3RhYmxlOmExNmNmNzJhZGIzNTQ2YjQ5MGFjZDM4YTVhMzZlNzA1L3RhYmxlcmFuZ2U6YTE2Y2Y3MmFkYjM1NDZiNDkwYWNkMzhhNWEzNmU3MDVfMi0xLTEtMS0xODE2NA_e9e2a9ea-31b6-44c5-9cd4-b51564574d64">2.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic2c3e03438af4889ac973627c642f5ec_D20200701-20200930" decimals="-5" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180Ni9mcmFnOmVjMGQzZWIyYTkwZjQzYzlhZjIxZTE5MzRhZjgwNzRlL3RhYmxlOmExNmNmNzJhZGIzNTQ2YjQ5MGFjZDM4YTVhMzZlNzA1L3RhYmxlcmFuZ2U6YTE2Y2Y3MmFkYjM1NDZiNDkwYWNkMzhhNWEzNmU3MDVfMi0zLTEtMS0xODE2NA_6fc5808c-42b0-45ad-8aa2-6e825f36876e">2.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" decimals="-5" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180Ni9mcmFnOmVjMGQzZWIyYTkwZjQzYzlhZjIxZTE5MzRhZjgwNzRlL3RhYmxlOmExNmNmNzJhZGIzNTQ2YjQ5MGFjZDM4YTVhMzZlNzA1L3RhYmxlcmFuZ2U6YTE2Y2Y3MmFkYjM1NDZiNDkwYWNkMzhhNWEzNmU3MDVfMi01LTEtMS0xODE2NA_307668c4-9b33-47aa-9dba-00068346f9ae">8.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930" decimals="-5" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180Ni9mcmFnOmVjMGQzZWIyYTkwZjQzYzlhZjIxZTE5MzRhZjgwNzRlL3RhYmxlOmExNmNmNzJhZGIzNTQ2YjQ5MGFjZDM4YTVhMzZlNzA1L3RhYmxlcmFuZ2U6YTE2Y2Y3MmFkYjM1NDZiNDkwYWNkMzhhNWEzNmU3MDVfMi03LTEtMS0xODE2NA_aabb2e33-fdfd-47ee-9b2d-06d563c147b0">7.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><div id="i5814a71962934792901cb2330361bb17_49"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5814a71962934792901cb2330361bb17_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180OS9mcmFnOjhjMzIzNjRiN2RmMDQyNTNiMTQzYmE5ZmQ4MzJhYTFhL3RleHRyZWdpb246OGMzMjM2NGI3ZGYwNDI1M2IxNDNiYTlmZDgzMmFhMWFfOTIy_0e4a21db-8617-480c-b729-7dc8b91bca0d" continuedAt="i13d87c3637754e4991a033e39ea665aa" escape="true">GOODWILL AND INTANGIBLE ASSETS</ix:nonNumeric></span></div><ix:continuation id="i13d87c3637754e4991a033e39ea665aa"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><ix:nonNumeric contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" name="us-gaap:ScheduleOfGoodwillTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180OS9mcmFnOjhjMzIzNjRiN2RmMDQyNTNiMTQzYmE5ZmQ4MzJhYTFhL3RleHRyZWdpb246OGMzMjM2NGI3ZGYwNDI1M2IxNDNiYTlmZDgzMmFhMWFfOTIz_f7c7623e-beb4-4b63-8cb9-1fdbbc429454" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the carrying amount of goodwill for the nine months ended September&#160;30, 2021:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.321%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.759%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.636%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.716%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Diagnostic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ac573972c0484c9db1cb89e06de15a_I20201231" decimals="-5" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180OS9mcmFnOjhjMzIzNjRiN2RmMDQyNTNiMTQzYmE5ZmQ4MzJhYTFhL3RhYmxlOjYzZTdhYmJlOGEzMTQ3Mjc5NTk3NDg3MmMxY2MzYTAyL3RhYmxlcmFuZ2U6NjNlN2FiYmU4YTMxNDcyNzk1OTc0ODcyYzFjYzNhMDJfMS0xLTEtMS0xODE2NA_2ea5bdfd-8bea-4e05-85a8-e8537022c706">272.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibde16baaa28343bd960624b1aaf1ae77_I20201231" decimals="-5" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180OS9mcmFnOjhjMzIzNjRiN2RmMDQyNTNiMTQzYmE5ZmQ4MzJhYTFhL3RhYmxlOjYzZTdhYmJlOGEzMTQ3Mjc5NTk3NDg3MmMxY2MzYTAyL3RhYmxlcmFuZ2U6NjNlN2FiYmU4YTMxNDcyNzk1OTc0ODcyYzFjYzNhMDJfMS0zLTEtMS0xODE2NA_52b022a4-be6b-497b-a6a8-de5718fec801">56.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231" decimals="-5" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180OS9mcmFnOjhjMzIzNjRiN2RmMDQyNTNiMTQzYmE5ZmQ4MzJhYTFhL3RhYmxlOjYzZTdhYmJlOGEzMTQ3Mjc5NTk3NDg3MmMxY2MzYTAyL3RhYmxlcmFuZ2U6NjNlN2FiYmU4YTMxNDcyNzk1OTc0ODcyYzFjYzNhMDJfMS01LTEtMS0xODE2NA_e54fffbf-a7ea-4557-ab7e-293e58b4dc89">329.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Divestitures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i90324a4d56084a4391c5819f5c839f86_D20210101-20210930" decimals="-5" name="us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180OS9mcmFnOjhjMzIzNjRiN2RmMDQyNTNiMTQzYmE5ZmQ4MzJhYTFhL3RhYmxlOjYzZTdhYmJlOGEzMTQ3Mjc5NTk3NDg3MmMxY2MzYTAyL3RhYmxlcmFuZ2U6NjNlN2FiYmU4YTMxNDcyNzk1OTc0ODcyYzFjYzNhMDJfMi0xLTEtMS0xODE2NA_41b78cc1-8ac7-4130-9735-141fc5a231ad">31.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iee82af509aa24703b7bb72450fba9e9f_D20210101-20210930" decimals="-5" name="us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180OS9mcmFnOjhjMzIzNjRiN2RmMDQyNTNiMTQzYmE5ZmQ4MzJhYTFhL3RhYmxlOjYzZTdhYmJlOGEzMTQ3Mjc5NTk3NDg3MmMxY2MzYTAyL3RhYmxlcmFuZ2U6NjNlN2FiYmU4YTMxNDcyNzk1OTc0ODcyYzFjYzNhMDJfMi0zLTEtMS0xODE2NA_152b89f6-7b79-407e-9a5f-450f5674937a">56.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" decimals="-5" name="us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180OS9mcmFnOjhjMzIzNjRiN2RmMDQyNTNiMTQzYmE5ZmQ4MzJhYTFhL3RhYmxlOjYzZTdhYmJlOGEzMTQ3Mjc5NTk3NDg3MmMxY2MzYTAyL3RhYmxlcmFuZ2U6NjNlN2FiYmU4YTMxNDcyNzk1OTc0ODcyYzFjYzNhMDJfMi01LTEtMS0xODE2NA_d4b15feb-59d3-46b0-b990-c225a8c33f53">88.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Translation adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i90324a4d56084a4391c5819f5c839f86_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180OS9mcmFnOjhjMzIzNjRiN2RmMDQyNTNiMTQzYmE5ZmQ4MzJhYTFhL3RhYmxlOjYzZTdhYmJlOGEzMTQ3Mjc5NTk3NDg3MmMxY2MzYTAyL3RhYmxlcmFuZ2U6NjNlN2FiYmU4YTMxNDcyNzk1OTc0ODcyYzFjYzNhMDJfMy0xLTEtMS0xODE2NA_0f049354-526a-4a75-8924-868c579ea697">1.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee82af509aa24703b7bb72450fba9e9f_D20210101-20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180OS9mcmFnOjhjMzIzNjRiN2RmMDQyNTNiMTQzYmE5ZmQ4MzJhYTFhL3RhYmxlOjYzZTdhYmJlOGEzMTQ3Mjc5NTk3NDg3MmMxY2MzYTAyL3RhYmxlcmFuZ2U6NjNlN2FiYmU4YTMxNDcyNzk1OTc0ODcyYzFjYzNhMDJfMy0zLTEtMS0xODE2NA_6630deba-191a-4809-8cfe-7111155a5077">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180OS9mcmFnOjhjMzIzNjRiN2RmMDQyNTNiMTQzYmE5ZmQ4MzJhYTFhL3RhYmxlOjYzZTdhYmJlOGEzMTQ3Mjc5NTk3NDg3MmMxY2MzYTAyL3RhYmxlcmFuZ2U6NjNlN2FiYmU4YTMxNDcyNzk1OTc0ODcyYzFjYzNhMDJfMy01LTEtMS0xODE2NA_e9a62ca3-b59b-429c-822a-1f30f3704af6">1.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6edc95151d8a4e0d834e3ba92ab2a90b_I20210930" decimals="-5" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180OS9mcmFnOjhjMzIzNjRiN2RmMDQyNTNiMTQzYmE5ZmQ4MzJhYTFhL3RhYmxlOjYzZTdhYmJlOGEzMTQ3Mjc5NTk3NDg3MmMxY2MzYTAyL3RhYmxlcmFuZ2U6NjNlN2FiYmU4YTMxNDcyNzk1OTc0ODcyYzFjYzNhMDJfNC0xLTEtMS0xODE2NA_79e66cc5-0377-40fb-898d-a7da913fc921">239.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i579d27c0f10940d8a1ceface7d29c915_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180OS9mcmFnOjhjMzIzNjRiN2RmMDQyNTNiMTQzYmE5ZmQ4MzJhYTFhL3RhYmxlOjYzZTdhYmJlOGEzMTQ3Mjc5NTk3NDg3MmMxY2MzYTAyL3RhYmxlcmFuZ2U6NjNlN2FiYmU4YTMxNDcyNzk1OTc0ODcyYzFjYzNhMDJfNC0zLTEtMS0xODE2NA_557eb7f0-0249-4c19-98a3-e1c6bc6c2f8b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930" decimals="-5" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180OS9mcmFnOjhjMzIzNjRiN2RmMDQyNTNiMTQzYmE5ZmQ4MzJhYTFhL3RhYmxlOjYzZTdhYmJlOGEzMTQ3Mjc5NTk3NDg3MmMxY2MzYTAyL3RhYmxlcmFuZ2U6NjNlN2FiYmU4YTMxNDcyNzk1OTc0ODcyYzFjYzNhMDJfNC01LTEtMS0xODE2NA_2421b65b-45ca-4a82-ac8e-a8926b36f647">239.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the quarter ended September 30, 2021, the Company completed the sale of Myriad RBM, Inc. and select operating assets and intellectual property, including the Vectra&#174; test, from the Myriad Autoimmune business unit. See Note 16 for additional information on these divestitures.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets have primarily consisted of amortizable assets of purchased licenses and technologies, customer relationships, and trade names as well as non-amortizable intangible assets of in-process technologies and research and development.&#160;As of September 30, 2021, the Company's intangible assets consist of only purchased licenses and technologies due to the completion of the sales of Myriad RBM, Inc. and select operating assets and intellectual property, including the Vectra&#174; test, from the Myriad Autoimmune business unit. In connection with these sales, the Company sold $<ix:nonFraction unitRef="usd" contextRef="i7b032b60a10145f682547141173ac516_I20210701" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180OS9mcmFnOjhjMzIzNjRiN2RmMDQyNTNiMTQzYmE5ZmQ4MzJhYTFhL3RleHRyZWdpb246OGMzMjM2NGI3ZGYwNDI1M2IxNDNiYTlmZDgzMmFhMWFfMTA5OTUxMTYzMDc0MQ_ae5f046f-113d-48ea-8e73-4d79dc2ad99b">199.1</ix:nonFraction> million in purchased licenses and technologies, $<ix:nonFraction unitRef="usd" contextRef="id4c41467e09242c3a31f5150b7bc13fe_I20210701" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180OS9mcmFnOjhjMzIzNjRiN2RmMDQyNTNiMTQzYmE5ZmQ4MzJhYTFhL3RleHRyZWdpb246OGMzMjM2NGI3ZGYwNDI1M2IxNDNiYTlmZDgzMmFhMWFfMTA5OTUxMTYzMDY5NA_71f4b702-79f5-451e-a893-86d1e80e38a9">4.8</ix:nonFraction> million in-process research and development intangible assets, $<ix:nonFraction unitRef="usd" contextRef="i2e1dbd573f0047b298ea8f3eb9afc6cf_I20210701" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180OS9mcmFnOjhjMzIzNjRiN2RmMDQyNTNiMTQzYmE5ZmQ4MzJhYTFhL3RleHRyZWdpb246OGMzMjM2NGI3ZGYwNDI1M2IxNDNiYTlmZDgzMmFhMWFfMTA5OTUxMTYzMDcyNA_2f2a7fd6-17d7-4c4d-b76b-7fb82434948e">4.7</ix:nonFraction> million in customer relationships, and $<ix:nonFraction unitRef="usd" contextRef="i5951f47f63a2499780fd5e72af21ade5_I20210701" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180OS9mcmFnOjhjMzIzNjRiN2RmMDQyNTNiMTQzYmE5ZmQ4MzJhYTFhL3RleHRyZWdpb246OGMzMjM2NGI3ZGYwNDI1M2IxNDNiYTlmZDgzMmFhMWFfMTA5OTUxMTYzMDcwOQ_ce6cc8cb-41b7-41c7-a4fd-8c6286259b51">3.0</ix:nonFraction> million in trademarks, resulting in an aggregate decrease of intangible assets of $<ix:nonFraction unitRef="usd" contextRef="i5a2255bae3b5469a85c3193359dabe47_I20210701" decimals="-5" format="ixt:num-dot-decimal" name="mygn:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNetNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180OS9mcmFnOjhjMzIzNjRiN2RmMDQyNTNiMTQzYmE5ZmQ4MzJhYTFhL3RleHRyZWdpb246OGMzMjM2NGI3ZGYwNDI1M2IxNDNiYTlmZDgzMmFhMWFfMTA5OTUxMTYzMDY3OQ_857b5bbc-0111-49a7-9ccb-b5f3e92ebf1e">120.0</ix:nonFraction> million, net of $<ix:nonFraction unitRef="usd" contextRef="i5a2255bae3b5469a85c3193359dabe47_I20210701" decimals="-5" format="ixt:num-dot-decimal" name="mygn:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsAccumulatedAmortizationNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180OS9mcmFnOjhjMzIzNjRiN2RmMDQyNTNiMTQzYmE5ZmQ4MzJhYTFhL3RleHRyZWdpb246OGMzMjM2NGI3ZGYwNDI1M2IxNDNiYTlmZDgzMmFhMWFfMTA5OTUxMTYzMDY2Nw_3880ea18-baee-486f-8228-706c03687fac">91.6</ix:nonFraction> million in accumulated amortization. See Note 16 for additional information on these divestitures.  <ix:nonNumeric contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" name="us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180OS9mcmFnOjhjMzIzNjRiN2RmMDQyNTNiMTQzYmE5ZmQ4MzJhYTFhL3RleHRyZWdpb246OGMzMjM2NGI3ZGYwNDI1M2IxNDNiYTlmZDgzMmFhMWFfOTI0_9235072f-e002-43be-8d4a-17836dadcd4b" continuedAt="i83c1bf4d6f354605a03b55a474e87a3e" escape="true"><ix:nonNumeric contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180OS9mcmFnOjhjMzIzNjRiN2RmMDQyNTNiMTQzYmE5ZmQ4MzJhYTFhL3RleHRyZWdpb246OGMzMjM2NGI3ZGYwNDI1M2IxNDNiYTlmZDgzMmFhMWFfOTI0_b9169103-876c-4c60-9ec9-547f481e1cf7" continuedAt="iea6137d8c2c748f5919f4460aaa35616" escape="true">The following summarizes the amounts reported as intangible assets:</ix:nonNumeric></ix:nonNumeric></span></div><ix:continuation id="i83c1bf4d6f354605a03b55a474e87a3e"><ix:continuation id="iea6137d8c2c748f5919f4460aaa35616"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.350%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September 30, 2021:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchased licenses and technologies</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie644acbcb7a046da9f6a9073e27ef84f_I20210930" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180OS9mcmFnOjhjMzIzNjRiN2RmMDQyNTNiMTQzYmE5ZmQ4MzJhYTFhL3RhYmxlOmMxNjg1ZDJiNmFjNjQ2MWRhYjIzMDgwYjAzNmYxY2E5L3RhYmxlcmFuZ2U6YzE2ODVkMmI2YWM2NDYxZGFiMjMwODBiMDM2ZjFjYTlfMi0xLTEtMS0xODE2NA_130e7fdb-e054-4961-b10a-5c1beed12b6d">617.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ie644acbcb7a046da9f6a9073e27ef84f_I20210930" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180OS9mcmFnOjhjMzIzNjRiN2RmMDQyNTNiMTQzYmE5ZmQ4MzJhYTFhL3RhYmxlOmMxNjg1ZDJiNmFjNjQ2MWRhYjIzMDgwYjAzNmYxY2E5L3RhYmxlcmFuZ2U6YzE2ODVkMmI2YWM2NDYxZGFiMjMwODBiMDM2ZjFjYTlfMi0zLTEtMS0xODE2NA_5603dde6-82ca-47db-a828-a24739007ac7">202.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie644acbcb7a046da9f6a9073e27ef84f_I20210930" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180OS9mcmFnOjhjMzIzNjRiN2RmMDQyNTNiMTQzYmE5ZmQ4MzJhYTFhL3RhYmxlOmMxNjg1ZDJiNmFjNjQ2MWRhYjIzMDgwYjAzNmYxY2E5L3RhYmxlcmFuZ2U6YzE2ODVkMmI2YWM2NDYxZGFiMjMwODBiMDM2ZjFjYTlfMi01LTEtMS0xODE2NA_6dcee605-fe22-4c5d-b367-4076c6bc439a">414.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total amortized intangible assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180OS9mcmFnOjhjMzIzNjRiN2RmMDQyNTNiMTQzYmE5ZmQ4MzJhYTFhL3RhYmxlOmMxNjg1ZDJiNmFjNjQ2MWRhYjIzMDgwYjAzNmYxY2E5L3RhYmxlcmFuZ2U6YzE2ODVkMmI2YWM2NDYxZGFiMjMwODBiMDM2ZjFjYTlfNS0xLTEtMS0xODE2NA_04bc6b3e-3e29-449b-9a73-313cdd93929f">617.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180OS9mcmFnOjhjMzIzNjRiN2RmMDQyNTNiMTQzYmE5ZmQ4MzJhYTFhL3RhYmxlOmMxNjg1ZDJiNmFjNjQ2MWRhYjIzMDgwYjAzNmYxY2E5L3RhYmxlcmFuZ2U6YzE2ODVkMmI2YWM2NDYxZGFiMjMwODBiMDM2ZjFjYTlfNS0zLTEtMS0xODE2NA_269974da-5082-4369-ae51-eca86f8fce62">202.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180OS9mcmFnOjhjMzIzNjRiN2RmMDQyNTNiMTQzYmE5ZmQ4MzJhYTFhL3RhYmxlOmMxNjg1ZDJiNmFjNjQ2MWRhYjIzMDgwYjAzNmYxY2E5L3RhYmxlcmFuZ2U6YzE2ODVkMmI2YWM2NDYxZGFiMjMwODBiMDM2ZjFjYTlfNS01LTEtMS0xODE2NA_9802d9c6-2407-45a4-b86e-a66ee04846df">414.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total intangible assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930" decimals="-5" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180OS9mcmFnOjhjMzIzNjRiN2RmMDQyNTNiMTQzYmE5ZmQ4MzJhYTFhL3RhYmxlOmMxNjg1ZDJiNmFjNjQ2MWRhYjIzMDgwYjAzNmYxY2E5L3RhYmxlcmFuZ2U6YzE2ODVkMmI2YWM2NDYxZGFiMjMwODBiMDM2ZjFjYTlfOS0xLTEtMS0xODE2NA_7f3edea7-f9ca-4c71-a99d-1b81188db931">617.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180OS9mcmFnOjhjMzIzNjRiN2RmMDQyNTNiMTQzYmE5ZmQ4MzJhYTFhL3RhYmxlOmMxNjg1ZDJiNmFjNjQ2MWRhYjIzMDgwYjAzNmYxY2E5L3RhYmxlcmFuZ2U6YzE2ODVkMmI2YWM2NDYxZGFiMjMwODBiMDM2ZjFjYTlfOS0zLTEtMS0xODE2NA_93477223-ac5e-4484-b7d8-bcf8561429c6">202.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180OS9mcmFnOjhjMzIzNjRiN2RmMDQyNTNiMTQzYmE5ZmQ4MzJhYTFhL3RhYmxlOmMxNjg1ZDJiNmFjNjQ2MWRhYjIzMDgwYjAzNmYxY2E5L3RhYmxlcmFuZ2U6YzE2ODVkMmI2YWM2NDYxZGFiMjMwODBiMDM2ZjFjYTlfOS01LTEtMS0xODE2NA_a6585ddd-e3eb-4211-b462-af893ee75ee7">414.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.350%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2020:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchased licenses and technologies</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia5b94635b0ee49179e69f248a30a5218_I20201231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180OS9mcmFnOjhjMzIzNjRiN2RmMDQyNTNiMTQzYmE5ZmQ4MzJhYTFhL3RhYmxlOmMzMzg4YWQ3YmRmNTRkNjE5ODg4ZGU3YzE1Zjk1Nzg4L3RhYmxlcmFuZ2U6YzMzODhhZDdiZGY1NGQ2MTk4ODhkZTdjMTVmOTU3ODhfMi0xLTEtMS0xODE2NA_41cb013f-819a-4d21-9ae9-b6bd843f6b18">818.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ia5b94635b0ee49179e69f248a30a5218_I20201231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180OS9mcmFnOjhjMzIzNjRiN2RmMDQyNTNiMTQzYmE5ZmQ4MzJhYTFhL3RhYmxlOmMzMzg4YWQ3YmRmNTRkNjE5ODg4ZGU3YzE1Zjk1Nzg4L3RhYmxlcmFuZ2U6YzMzODhhZDdiZGY1NGQ2MTk4ODhkZTdjMTVmOTU3ODhfMi0zLTEtMS0xODE2NA_832c63f5-d4ef-4547-9e46-043dd0aa2d56">248.2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia5b94635b0ee49179e69f248a30a5218_I20201231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180OS9mcmFnOjhjMzIzNjRiN2RmMDQyNTNiMTQzYmE5ZmQ4MzJhYTFhL3RhYmxlOmMzMzg4YWQ3YmRmNTRkNjE5ODg4ZGU3YzE1Zjk1Nzg4L3RhYmxlcmFuZ2U6YzMzODhhZDdiZGY1NGQ2MTk4ODhkZTdjMTVmOTU3ODhfMi01LTEtMS0xODE2NA_fdbf1655-b859-472e-a7fd-a81d7a6f3ebd">570.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customer relationships</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2b16ee9a891f452fbef45868672b00d6_I20201231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180OS9mcmFnOjhjMzIzNjRiN2RmMDQyNTNiMTQzYmE5ZmQ4MzJhYTFhL3RhYmxlOmMzMzg4YWQ3YmRmNTRkNjE5ODg4ZGU3YzE1Zjk1Nzg4L3RhYmxlcmFuZ2U6YzMzODhhZDdiZGY1NGQ2MTk4ODhkZTdjMTVmOTU3ODhfMy0xLTEtMS0xODE2NA_07634651-cdc5-49a1-a715-a3a9435fd93a">4.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i2b16ee9a891f452fbef45868672b00d6_I20201231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180OS9mcmFnOjhjMzIzNjRiN2RmMDQyNTNiMTQzYmE5ZmQ4MzJhYTFhL3RhYmxlOmMzMzg4YWQ3YmRmNTRkNjE5ODg4ZGU3YzE1Zjk1Nzg4L3RhYmxlcmFuZ2U6YzMzODhhZDdiZGY1NGQ2MTk4ODhkZTdjMTVmOTU3ODhfMy0zLTEtMS0xODE2NA_723e6e80-ba5d-49eb-abb8-370561d09ea6">4.5</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2b16ee9a891f452fbef45868672b00d6_I20201231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180OS9mcmFnOjhjMzIzNjRiN2RmMDQyNTNiMTQzYmE5ZmQ4MzJhYTFhL3RhYmxlOmMzMzg4YWQ3YmRmNTRkNjE5ODg4ZGU3YzE1Zjk1Nzg4L3RhYmxlcmFuZ2U6YzMzODhhZDdiZGY1NGQ2MTk4ODhkZTdjMTVmOTU3ODhfMy01LTEtMS0xODE2NA_89af134b-171c-4843-8897-f8b6a7299c24">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trademarks</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0cc0c3bdd23f47d483982f371199a356_I20201231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180OS9mcmFnOjhjMzIzNjRiN2RmMDQyNTNiMTQzYmE5ZmQ4MzJhYTFhL3RhYmxlOmMzMzg4YWQ3YmRmNTRkNjE5ODg4ZGU3YzE1Zjk1Nzg4L3RhYmxlcmFuZ2U6YzMzODhhZDdiZGY1NGQ2MTk4ODhkZTdjMTVmOTU3ODhfNC0xLTEtMS0xODE2NA_c1bfe3ee-fbcb-41f5-b223-f870fa3535da">3.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i0cc0c3bdd23f47d483982f371199a356_I20201231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180OS9mcmFnOjhjMzIzNjRiN2RmMDQyNTNiMTQzYmE5ZmQ4MzJhYTFhL3RhYmxlOmMzMzg4YWQ3YmRmNTRkNjE5ODg4ZGU3YzE1Zjk1Nzg4L3RhYmxlcmFuZ2U6YzMzODhhZDdiZGY1NGQ2MTk4ODhkZTdjMTVmOTU3ODhfNC0zLTEtMS0xODE2NA_42a28c22-9c61-454d-a7b1-8f4aec0c54b8">1.5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0cc0c3bdd23f47d483982f371199a356_I20201231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180OS9mcmFnOjhjMzIzNjRiN2RmMDQyNTNiMTQzYmE5ZmQ4MzJhYTFhL3RhYmxlOmMzMzg4YWQ3YmRmNTRkNjE5ODg4ZGU3YzE1Zjk1Nzg4L3RhYmxlcmFuZ2U6YzMzODhhZDdiZGY1NGQ2MTk4ODhkZTdjMTVmOTU3ODhfNC01LTEtMS0xODE2NA_fdac76ca-1fc9-45f0-b1c4-312cbb1cd00f">1.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total amortized intangible assets</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180OS9mcmFnOjhjMzIzNjRiN2RmMDQyNTNiMTQzYmE5ZmQ4MzJhYTFhL3RhYmxlOmMzMzg4YWQ3YmRmNTRkNjE5ODg4ZGU3YzE1Zjk1Nzg4L3RhYmxlcmFuZ2U6YzMzODhhZDdiZGY1NGQ2MTk4ODhkZTdjMTVmOTU3ODhfNS0xLTEtMS0xODE2NA_fa8cbb6c-c99a-436d-9a82-0cb7df3534f9">825.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180OS9mcmFnOjhjMzIzNjRiN2RmMDQyNTNiMTQzYmE5ZmQ4MzJhYTFhL3RhYmxlOmMzMzg4YWQ3YmRmNTRkNjE5ODg4ZGU3YzE1Zjk1Nzg4L3RhYmxlcmFuZ2U6YzMzODhhZDdiZGY1NGQ2MTk4ODhkZTdjMTVmOTU3ODhfNS0zLTEtMS0xODE2NA_fb4aa941-6fc4-40d5-945c-b1d85a3e777e">254.2</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180OS9mcmFnOjhjMzIzNjRiN2RmMDQyNTNiMTQzYmE5ZmQ4MzJhYTFhL3RhYmxlOmMzMzg4YWQ3YmRmNTRkNjE5ODg4ZGU3YzE1Zjk1Nzg4L3RhYmxlcmFuZ2U6YzMzODhhZDdiZGY1NGQ2MTk4ODhkZTdjMTVmOTU3ODhfNS01LTEtMS0xODE2NA_1f9fabee-bb4f-4507-b8fc-82789bf76bdf">571.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In-process research and development</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id685e06a6fe54277a65c4a43bf1ca98b_I20201231" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180OS9mcmFnOjhjMzIzNjRiN2RmMDQyNTNiMTQzYmE5ZmQ4MzJhYTFhL3RhYmxlOmMzMzg4YWQ3YmRmNTRkNjE5ODg4ZGU3YzE1Zjk1Nzg4L3RhYmxlcmFuZ2U6YzMzODhhZDdiZGY1NGQ2MTk4ODhkZTdjMTVmOTU3ODhfNi0xLTEtMS0xODE2NA_0fb8f3a0-1069-4462-8b31-652e2c2d817b">4.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id685e06a6fe54277a65c4a43bf1ca98b_I20201231" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180OS9mcmFnOjhjMzIzNjRiN2RmMDQyNTNiMTQzYmE5ZmQ4MzJhYTFhL3RhYmxlOmMzMzg4YWQ3YmRmNTRkNjE5ODg4ZGU3YzE1Zjk1Nzg4L3RhYmxlcmFuZ2U6YzMzODhhZDdiZGY1NGQ2MTk4ODhkZTdjMTVmOTU3ODhfNi01LTEtMS0xODE2NA_b613a390-b7f5-47e5-95a3-5d791d8833d0">4.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total unamortized intangible assets</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180OS9mcmFnOjhjMzIzNjRiN2RmMDQyNTNiMTQzYmE5ZmQ4MzJhYTFhL3RhYmxlOmMzMzg4YWQ3YmRmNTRkNjE5ODg4ZGU3YzE1Zjk1Nzg4L3RhYmxlcmFuZ2U6YzMzODhhZDdiZGY1NGQ2MTk4ODhkZTdjMTVmOTU3ODhfNy0xLTEtMS0xODE2NA_644bdd70-f085-4990-9552-719a4e963402">4.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180OS9mcmFnOjhjMzIzNjRiN2RmMDQyNTNiMTQzYmE5ZmQ4MzJhYTFhL3RhYmxlOmMzMzg4YWQ3YmRmNTRkNjE5ODg4ZGU3YzE1Zjk1Nzg4L3RhYmxlcmFuZ2U6YzMzODhhZDdiZGY1NGQ2MTk4ODhkZTdjMTVmOTU3ODhfNy01LTEtMS0xODE2NA_0366a48f-890b-4809-bbdf-6343e2d7207b">4.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total intangible assets</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231" decimals="-5" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180OS9mcmFnOjhjMzIzNjRiN2RmMDQyNTNiMTQzYmE5ZmQ4MzJhYTFhL3RhYmxlOmMzMzg4YWQ3YmRmNTRkNjE5ODg4ZGU3YzE1Zjk1Nzg4L3RhYmxlcmFuZ2U6YzMzODhhZDdiZGY1NGQ2MTk4ODhkZTdjMTVmOTU3ODhfOC0xLTEtMS0xODE2NA_beb79bb2-7463-4936-a8c5-1ae6d66dcc87">830.7</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180OS9mcmFnOjhjMzIzNjRiN2RmMDQyNTNiMTQzYmE5ZmQ4MzJhYTFhL3RhYmxlOmMzMzg4YWQ3YmRmNTRkNjE5ODg4ZGU3YzE1Zjk1Nzg4L3RhYmxlcmFuZ2U6YzMzODhhZDdiZGY1NGQ2MTk4ODhkZTdjMTVmOTU3ODhfOC0zLTEtMS0xODE2NA_672b98f8-d19b-4e75-a6a0-bc8b1f83bdcd">254.2</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180OS9mcmFnOjhjMzIzNjRiN2RmMDQyNTNiMTQzYmE5ZmQ4MzJhYTFhL3RhYmxlOmMzMzg4YWQ3YmRmNTRkNjE5ODg4ZGU3YzE1Zjk1Nzg4L3RhYmxlcmFuZ2U6YzMzODhhZDdiZGY1NGQ2MTk4ODhkZTdjMTVmOTU3ODhfOC01LTEtMS0xODE2NA_da155d0d-a32a-4ba4-b495-9f71e41a388a">576.5</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation></ix:continuation><ix:nonNumeric contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180OS9mcmFnOjhjMzIzNjRiN2RmMDQyNTNiMTQzYmE5ZmQ4MzJhYTFhL3RleHRyZWdpb246OGMzMjM2NGI3ZGYwNDI1M2IxNDNiYTlmZDgzMmFhMWFfOTIx_a02e6c4b-a772-4586-a9e6-124d078824b2" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded amortization expense during the respective periods for these intangible assets as follows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.603%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine months ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of intangible assets</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180OS9mcmFnOjhjMzIzNjRiN2RmMDQyNTNiMTQzYmE5ZmQ4MzJhYTFhL3RhYmxlOjVlMWU3MzJmMmZiMzQ1M2M5YmY5OWNkZWUyMjdiODBiL3RhYmxlcmFuZ2U6NWUxZTczMmYyZmIzNDUzYzliZjk5Y2RlZTIyN2I4MGJfMi0xLTEtMS0xODE2NA_dda9224b-9761-49f0-9b19-342da92c2f14">11.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic2c3e03438af4889ac973627c642f5ec_D20200701-20200930" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180OS9mcmFnOjhjMzIzNjRiN2RmMDQyNTNiMTQzYmE5ZmQ4MzJhYTFhL3RhYmxlOjVlMWU3MzJmMmZiMzQ1M2M5YmY5OWNkZWUyMjdiODBiL3RhYmxlcmFuZ2U6NWUxZTczMmYyZmIzNDUzYzliZjk5Y2RlZTIyN2I4MGJfMi0zLTEtMS0xODE2NA_2e26baf8-77c0-49fa-8ea3-3c5ccefab803">15.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180OS9mcmFnOjhjMzIzNjRiN2RmMDQyNTNiMTQzYmE5ZmQ4MzJhYTFhL3RhYmxlOjVlMWU3MzJmMmZiMzQ1M2M5YmY5OWNkZWUyMjdiODBiL3RhYmxlcmFuZ2U6NWUxZTczMmYyZmIzNDUzYzliZjk5Y2RlZTIyN2I4MGJfMi01LTEtMS0xODE2NA_69716194-b561-498b-ac71-502ffe7c7417">40.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180OS9mcmFnOjhjMzIzNjRiN2RmMDQyNTNiMTQzYmE5ZmQ4MzJhYTFhL3RhYmxlOjVlMWU3MzJmMmZiMzQ1M2M5YmY5OWNkZWUyMjdiODBiL3RhYmxlcmFuZ2U6NWUxZTczMmYyZmIzNDUzYzliZjk5Y2RlZTIyN2I4MGJfMi03LTEtMS0xODE2NA_7c0a8317-66e6-49a2-85fe-5852d6bdcf37">45.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><div id="i5814a71962934792901cb2330361bb17_52"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5814a71962934792901cb2330361bb17_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN181Mi9mcmFnOmMzZDM1ZjAyNGY3ZDRiZjFiMDEwMDJhZTkxYjAyZTc2L3RleHRyZWdpb246YzNkMzVmMDI0ZjdkNGJmMWIwMTAwMmFlOTFiMDJlNzZfMjY_75264d21-e240-43b1-9057-eb7646b23574" continuedAt="i6892384949b2421bb17d9ff1139bf379" escape="true">ACCRUED LIABILITIES</ix:nonNumeric></span></div><ix:continuation id="i6892384949b2421bb17d9ff1139bf379"><div style="margin-top:5pt"><ix:nonNumeric contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN181Mi9mcmFnOmMzZDM1ZjAyNGY3ZDRiZjFiMDEwMDJhZTkxYjAyZTc2L3RleHRyZWdpb246YzNkMzVmMDI0ZjdkNGJmMWIwMTAwMmFlOTFiMDJlNzZfMjc_343b996f-ba51-465f-a2ac-fe4440ad1a6b" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.511%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.513%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee compensation and benefits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930" decimals="-5" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN181Mi9mcmFnOmMzZDM1ZjAyNGY3ZDRiZjFiMDEwMDJhZTkxYjAyZTc2L3RhYmxlOmQ4YmFjODI0OTJiMDRmYzhhZjJjMGIzMGQ0NGEyMTZkL3RhYmxlcmFuZ2U6ZDhiYWM4MjQ5MmIwNGZjOGFmMmMwYjMwZDQ0YTIxNmRfMS0xLTEtMS0xODE2NA_0b470fb1-10d0-4354-85cf-8c965eebc9c8">54.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231" decimals="-5" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN181Mi9mcmFnOmMzZDM1ZjAyNGY3ZDRiZjFiMDEwMDJhZTkxYjAyZTc2L3RhYmxlOmQ4YmFjODI0OTJiMDRmYzhhZjJjMGIzMGQ0NGEyMTZkL3RhYmxlcmFuZ2U6ZDhiYWM4MjQ5MmIwNGZjOGFmMmMwYjMwZDQ0YTIxNmRfMS0zLTEtMS0xODE2NA_ee862c87-513b-4833-b3af-8011c8c4af7e">48.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legal accrual</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930" decimals="-5" name="us-gaap:LitigationReserveCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN181Mi9mcmFnOmMzZDM1ZjAyNGY3ZDRiZjFiMDEwMDJhZTkxYjAyZTc2L3RhYmxlOmQ4YmFjODI0OTJiMDRmYzhhZjJjMGIzMGQ0NGEyMTZkL3RhYmxlcmFuZ2U6ZDhiYWM4MjQ5MmIwNGZjOGFmMmMwYjMwZDQ0YTIxNmRfMi0xLTEtMS0yNTU1MA_3ccd6ba4-9093-4c60-86d7-894431d64c19">48.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:LitigationReserveCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN181Mi9mcmFnOmMzZDM1ZjAyNGY3ZDRiZjFiMDEwMDJhZTkxYjAyZTc2L3RhYmxlOmQ4YmFjODI0OTJiMDRmYzhhZjJjMGIzMGQ0NGEyMTZkL3RhYmxlcmFuZ2U6ZDhiYWM4MjQ5MmIwNGZjOGFmMmMwYjMwZDQ0YTIxNmRfMi0zLTEtMS0yNTU1MA_01ba34f9-f081-4e67-831b-c97f78c25c9a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued taxes payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930" decimals="-5" name="us-gaap:TaxesPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN181Mi9mcmFnOmMzZDM1ZjAyNGY3ZDRiZjFiMDEwMDJhZTkxYjAyZTc2L3RhYmxlOmQ4YmFjODI0OTJiMDRmYzhhZjJjMGIzMGQ0NGEyMTZkL3RhYmxlcmFuZ2U6ZDhiYWM4MjQ5MmIwNGZjOGFmMmMwYjMwZDQ0YTIxNmRfMi0xLTEtMS0xODE2NA_6e023031-6313-4115-9b38-c042d93ca6ef">17.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231" decimals="-5" name="us-gaap:TaxesPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN181Mi9mcmFnOmMzZDM1ZjAyNGY3ZDRiZjFiMDEwMDJhZTkxYjAyZTc2L3RhYmxlOmQ4YmFjODI0OTJiMDRmYzhhZjJjMGIzMGQ0NGEyMTZkL3RhYmxlcmFuZ2U6ZDhiYWM4MjQ5MmIwNGZjOGFmMmMwYjMwZDQ0YTIxNmRfMi0zLTEtMS0xODE2NA_dc31326d-6ae6-4dbf-ae0e-2290644e110c">4.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refunds payable and reserves</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930" decimals="-5" name="mygn:RefundsPayableAndReserveCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN181Mi9mcmFnOmMzZDM1ZjAyNGY3ZDRiZjFiMDEwMDJhZTkxYjAyZTc2L3RhYmxlOmQ4YmFjODI0OTJiMDRmYzhhZjJjMGIzMGQ0NGEyMTZkL3RhYmxlcmFuZ2U6ZDhiYWM4MjQ5MmIwNGZjOGFmMmMwYjMwZDQ0YTIxNmRfMy0xLTEtMS0xODE2NA_bc20e1ad-4860-4f9d-a9c5-d83383b88344">8.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231" decimals="-5" name="mygn:RefundsPayableAndReserveCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN181Mi9mcmFnOmMzZDM1ZjAyNGY3ZDRiZjFiMDEwMDJhZTkxYjAyZTc2L3RhYmxlOmQ4YmFjODI0OTJiMDRmYzhhZjJjMGIzMGQ0NGEyMTZkL3RhYmxlcmFuZ2U6ZDhiYWM4MjQ5MmIwNGZjOGFmMmMwYjMwZDQ0YTIxNmRfMy0zLTEtMS0xODE2NA_e611b426-4d59-4286-a453-48bdf10c8624">9.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN181Mi9mcmFnOmMzZDM1ZjAyNGY3ZDRiZjFiMDEwMDJhZTkxYjAyZTc2L3RhYmxlOmQ4YmFjODI0OTJiMDRmYzhhZjJjMGIzMGQ0NGEyMTZkL3RhYmxlcmFuZ2U6ZDhiYWM4MjQ5MmIwNGZjOGFmMmMwYjMwZDQ0YTIxNmRfNC0xLTEtMS0xODE2NA_b6061cac-8d39-4d36-8361-fa08a81c7987">3.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN181Mi9mcmFnOmMzZDM1ZjAyNGY3ZDRiZjFiMDEwMDJhZTkxYjAyZTc2L3RhYmxlOmQ4YmFjODI0OTJiMDRmYzhhZjJjMGIzMGQ0NGEyMTZkL3RhYmxlcmFuZ2U6ZDhiYWM4MjQ5MmIwNGZjOGFmMmMwYjMwZDQ0YTIxNmRfNC0zLTEtMS0xODE2NA_f7a68627-0434-4b24-badf-44205c694780">3.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued royalties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930" decimals="-5" name="us-gaap:AccruedRoyaltiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN181Mi9mcmFnOmMzZDM1ZjAyNGY3ZDRiZjFiMDEwMDJhZTkxYjAyZTc2L3RhYmxlOmQ4YmFjODI0OTJiMDRmYzhhZjJjMGIzMGQ0NGEyMTZkL3RhYmxlcmFuZ2U6ZDhiYWM4MjQ5MmIwNGZjOGFmMmMwYjMwZDQ0YTIxNmRfNS0xLTEtMS0xODE2NA_22c2e5c3-7e51-4069-8b75-4549f1af09cd">5.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231" decimals="-5" name="us-gaap:AccruedRoyaltiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN181Mi9mcmFnOmMzZDM1ZjAyNGY3ZDRiZjFiMDEwMDJhZTkxYjAyZTc2L3RhYmxlOmQ4YmFjODI0OTJiMDRmYzhhZjJjMGIzMGQ0NGEyMTZkL3RhYmxlcmFuZ2U6ZDhiYWM4MjQ5MmIwNGZjOGFmMmMwYjMwZDQ0YTIxNmRfNS0zLTEtMS0xODE2NA_18a189b4-10a3-468d-880d-70b293827d59">3.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchase commitment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930" decimals="-5" name="us-gaap:RecordedUnconditionalPurchaseObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN181Mi9mcmFnOmMzZDM1ZjAyNGY3ZDRiZjFiMDEwMDJhZTkxYjAyZTc2L3RhYmxlOmQ4YmFjODI0OTJiMDRmYzhhZjJjMGIzMGQ0NGEyMTZkL3RhYmxlcmFuZ2U6ZDhiYWM4MjQ5MmIwNGZjOGFmMmMwYjMwZDQ0YTIxNmRfNi0xLTEtMS0xODE2NA_70dd4c2c-f5a5-44db-b0c5-fb63bbbb4d5f">5.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:RecordedUnconditionalPurchaseObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN181Mi9mcmFnOmMzZDM1ZjAyNGY3ZDRiZjFiMDEwMDJhZTkxYjAyZTc2L3RhYmxlOmQ4YmFjODI0OTJiMDRmYzhhZjJjMGIzMGQ0NGEyMTZkL3RhYmxlcmFuZ2U6ZDhiYWM4MjQ5MmIwNGZjOGFmMmMwYjMwZDQ0YTIxNmRfNi0zLTEtMS0xODE2NA_8d1d0ce5-d8cb-459f-9e6d-ec497ef90edf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930" decimals="-5" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN181Mi9mcmFnOmMzZDM1ZjAyNGY3ZDRiZjFiMDEwMDJhZTkxYjAyZTc2L3RhYmxlOmQ4YmFjODI0OTJiMDRmYzhhZjJjMGIzMGQ0NGEyMTZkL3RhYmxlcmFuZ2U6ZDhiYWM4MjQ5MmIwNGZjOGFmMmMwYjMwZDQ0YTIxNmRfNy0xLTEtMS0xODE2NA_b294ab41-0626-487f-b2ab-0590ecf7129e">21.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231" decimals="-5" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN181Mi9mcmFnOmMzZDM1ZjAyNGY3ZDRiZjFiMDEwMDJhZTkxYjAyZTc2L3RhYmxlOmQ4YmFjODI0OTJiMDRmYzhhZjJjMGIzMGQ0NGEyMTZkL3RhYmxlcmFuZ2U6ZDhiYWM4MjQ5MmIwNGZjOGFmMmMwYjMwZDQ0YTIxNmRfNy0zLTEtMS0xODE2NA_88363572-6ba3-4fc0-9a60-f1f9981c785e">9.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total accrued liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930" decimals="-5" name="us-gaap:AccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN181Mi9mcmFnOmMzZDM1ZjAyNGY3ZDRiZjFiMDEwMDJhZTkxYjAyZTc2L3RhYmxlOmQ4YmFjODI0OTJiMDRmYzhhZjJjMGIzMGQ0NGEyMTZkL3RhYmxlcmFuZ2U6ZDhiYWM4MjQ5MmIwNGZjOGFmMmMwYjMwZDQ0YTIxNmRfOC0xLTEtMS0xODE2NA_6f34a809-82df-47d7-aeea-a5e8877fe92c">163.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231" decimals="-5" name="us-gaap:AccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN181Mi9mcmFnOmMzZDM1ZjAyNGY3ZDRiZjFiMDEwMDJhZTkxYjAyZTc2L3RhYmxlOmQ4YmFjODI0OTJiMDRmYzhhZjJjMGIzMGQ0NGEyMTZkL3RhYmxlcmFuZ2U6ZDhiYWM4MjQ5MmIwNGZjOGFmMmMwYjMwZDQ0YTIxNmRfOC0zLTEtMS0xODE2NA_3fedf5ee-41db-41a2-8c40-cb5fbe5feb91">79.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the quarter ended September 30, 2021, the Company accrued $<ix:nonFraction unitRef="usd" contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LitigationReserveCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN181Mi9mcmFnOmMzZDM1ZjAyNGY3ZDRiZjFiMDEwMDJhZTkxYjAyZTc2L3RleHRyZWdpb246YzNkMzVmMDI0ZjdkNGJmMWIwMTAwMmFlOTFiMDJlNzZfMjc0ODc3OTA3MTQ5Ng_9146fb18-cae6-4e44-9621-9d50683e77fb">48.0</ix:nonFraction>&#160;million for a potential settlement of the qui tam lawsuit against Crescendo Bioscience, Inc. and the Company. Refer to Note 13</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional information</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div></ix:continuation><div id="i5814a71962934792901cb2330361bb17_55"></div><div style="margin-top:18pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN181NS9mcmFnOmZhM2YyZmVmNzZjNjQ3MjRhNGMyNjVjYTE0MDU4MmFiL3RleHRyZWdpb246ZmEzZjJmZWY3NmM2NDcyNGE0YzI2NWNhMTQwNTgyYWJfNTMxNQ_456321e1-64f5-4e52-b357-216a3baa5a65" continuedAt="i5001522e130d483f8df9a8ac3b970607" escape="true">LONG-TERM DEBT</ix:nonNumeric></span></div><ix:continuation id="i5001522e130d483f8df9a8ac3b970607" continuedAt="i209b7dcfda5744be814f5d54952afcca"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 23, 2016, the Company entered into a senior secured revolving credit facility (the &#8220;Facility&#8221;) by and among Myriad, as borrower, and the lenders from time to time party thereto. On July 31, 2018, the Company entered into Amendment No. 1 which effected an &#8220;amend and extend&#8221; transaction with respect to the Facility by which the maturity date thereof was extended to <ix:nonNumeric contextRef="ia36cf797382046e0a337c61433dfd1b6_D20180731-20180731" format="ixt:date-monthname-day-year-en" name="us-gaap:DebtInstrumentMaturityDate" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN181NS9mcmFnOmZhM2YyZmVmNzZjNjQ3MjRhNGMyNjVjYTE0MDU4MmFiL3RleHRyZWdpb246ZmEzZjJmZWY3NmM2NDcyNGE0YzI2NWNhMTQwNTgyYWJfMzk4_29eac453-5c1c-4933-819d-55c6bc592586">July 31, 2023</ix:nonNumeric> and the maximum aggregate principal commitment was increased from $<ix:nonFraction unitRef="usd" contextRef="i20dcb26940bd445f93184c60d07dab71_I20161223" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN181NS9mcmFnOmZhM2YyZmVmNzZjNjQ3MjRhNGMyNjVjYTE0MDU4MmFiL3RleHRyZWdpb246ZmEzZjJmZWY3NmM2NDcyNGE0YzI2NWNhMTQwNTgyYWJfNDY3_24998b78-78eb-4fa5-82cc-760d5b26b266">300.0</ix:nonFraction> million to $<ix:nonFraction unitRef="usd" contextRef="if69f7cf080614d7fa0f9398ec3a0d790_I20180731" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN181NS9mcmFnOmZhM2YyZmVmNzZjNjQ3MjRhNGMyNjVjYTE0MDU4MmFiL3RleHRyZWdpb246ZmEzZjJmZWY3NmM2NDcyNGE0YzI2NWNhMTQwNTgyYWJfNDcz_ae31ac02-5c9b-4384-a039-d5d6ef06c4bb">350.0</ix:nonFraction> million.&#160;On May 1, 2020, the Company entered into Amendment No. 2, which waived the Company&#8217;s compliance with certain financial covenants, amended compliance with certain operating covenants, and modified the interest rate and other terms during a modification period from March 31, 2020 through June 30, 2021 (the &#8220;Modification Period&#8221;). On February 22, 2021, the Company entered into Amendment No. 3 (the &#8220;Amended Facility&#8221;), which, among other things, decreased the maximum aggregate principal commitment from $<ix:nonFraction unitRef="usd" contextRef="i2d7436f51ca44c63b220baabb793f869_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN181NS9mcmFnOmZhM2YyZmVmNzZjNjQ3MjRhNGMyNjVjYTE0MDU4MmFiL3RleHRyZWdpb246ZmEzZjJmZWY3NmM2NDcyNGE0YzI2NWNhMTQwNTgyYWJfOTgx_7b5ead9f-7351-45ce-b1f5-364a62a0602e">350.0</ix:nonFraction>&#160;million to $<ix:nonFraction unitRef="usd" contextRef="ic14444ddb59c4b859b297e3eb63f800d_I20210221" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN181NS9mcmFnOmZhM2YyZmVmNzZjNjQ3MjRhNGMyNjVjYTE0MDU4MmFiL3RleHRyZWdpb246ZmEzZjJmZWY3NmM2NDcyNGE0YzI2NWNhMTQwNTgyYWJfOTg3_763d71f5-2925-47fe-8fcd-a116ca7b6aed">300.0</ix:nonFraction>&#160;million, with a further reduction in the maximum aggregate principal commitment from $<ix:nonFraction unitRef="usd" contextRef="ic14444ddb59c4b859b297e3eb63f800d_I20210221" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN181NS9mcmFnOmZhM2YyZmVmNzZjNjQ3MjRhNGMyNjVjYTE0MDU4MmFiL3RleHRyZWdpb246ZmEzZjJmZWY3NmM2NDcyNGE0YzI2NWNhMTQwNTgyYWJfMTA2Nw_53ff763a-5438-4c22-856b-3116423c8e7f">300.0</ix:nonFraction>&#160;million to $<ix:nonFraction unitRef="usd" contextRef="i12f34ee4c63b4e07a09ead597eb2afb8_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN181NS9mcmFnOmZhM2YyZmVmNzZjNjQ3MjRhNGMyNjVjYTE0MDU4MmFiL3RleHRyZWdpb246ZmEzZjJmZWY3NmM2NDcyNGE0YzI2NWNhMTQwNTgyYWJfMTA3Mw_550a4f16-d976-42a0-abdd-0845c7a7b5bb">250.0</ix:nonFraction>&#160;million by September 30, 2021 (if not previously reduced to such amount in connection with certain specified asset sales), waived the Company&#8217;s compliance with certain financial covenants through the quarter ending March 31, 2022, extended the Modification Period for an additional year, through June 30, 2022, and revised certain negative covenants in connection with the extension. The amendments were accounted for as modifications pursuant to guidance in ASC 470-50, Debt.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended Facility contains customary loan terms, interest rates, representations and warranties, affirmative and negative covenants, in each case, subject to customary limitations, exceptions and exclusions. The Amended Facility also contains certain customary events of default. Amendment No. 2 modified the Facility to increase the interest rate to be fixed at a spread of LIBOR plus <ix:nonFraction unitRef="number" contextRef="id22d71fd31db4689a2b97ef092347fe3_D20200401-20220630" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-4" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN181NS9mcmFnOmZhM2YyZmVmNzZjNjQ3MjRhNGMyNjVjYTE0MDU4MmFiL3RleHRyZWdpb246ZmEzZjJmZWY3NmM2NDcyNGE0YzI2NWNhMTQwNTgyYWJfMjAxNw_d32fc680-836d-4302-804a-ba8b0ba39a96">350</ix:nonFraction> basis points on drawn balance and the undrawn fee was increased to <ix:nonFraction unitRef="number" contextRef="i1cd2ac076ee74bdaaad3ecd73d94eee1_D20200401-20220630" decimals="INF" name="us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" scale="-4" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN181NS9mcmFnOmZhM2YyZmVmNzZjNjQ3MjRhNGMyNjVjYTE0MDU4MmFiL3RleHRyZWdpb246ZmEzZjJmZWY3NmM2NDcyNGE0YzI2NWNhMTQwNTgyYWJfMjA4Nw_28d7a2b1-396f-4cc7-9345-40319fbac525">50</ix:nonFraction> basis points during the Modification Period. At the end of the Modification Period, interest rates return to the previous pricing based on a spread of LIBOR plus <ix:nonFraction unitRef="number" contextRef="i4847f17e28e147c0a68edabf5abcea78_D20220701-20220701" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-4" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN181NS9mcmFnOmZhM2YyZmVmNzZjNjQ3MjRhNGMyNjVjYTE0MDU4MmFiL3RleHRyZWdpb246ZmEzZjJmZWY3NmM2NDcyNGE0YzI2NWNhMTQwNTgyYWJfMjI1Mg_671bba5a-381a-48d8-b448-6e85867864bc">150</ix:nonFraction>-<ix:nonFraction unitRef="number" contextRef="i7adf104e7dc740cbb75258256d3d3de0_D20220701-20220701" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-4" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN181NS9mcmFnOmZhM2YyZmVmNzZjNjQ3MjRhNGMyNjVjYTE0MDU4MmFiL3RleHRyZWdpb246ZmEzZjJmZWY3NmM2NDcyNGE0YzI2NWNhMTQwNTgyYWJfMjI1NQ_669836a4-747b-46db-ac55-954b8429dcd2">250</ix:nonFraction> basis points on drawn balances and an undrawn fee ranging from <ix:nonFraction unitRef="number" contextRef="i7b9e6a1375a94b0e869e4e993a658963_D20220701-20220701" decimals="INF" name="us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" scale="-4" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN181NS9mcmFnOmZhM2YyZmVmNzZjNjQ3MjRhNGMyNjVjYTE0MDU4MmFiL3RleHRyZWdpb246ZmEzZjJmZWY3NmM2NDcyNGE0YzI2NWNhMTQwNTgyYWJfMjMyMQ_a84df2e2-8047-4470-a263-059320c3fc52">25</ix:nonFraction> to <ix:nonFraction unitRef="number" contextRef="i417e2a66751b4095bd0c48dc41dd4530_D20220701-20220701" decimals="INF" name="us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" scale="-4" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN181NS9mcmFnOmZhM2YyZmVmNzZjNjQ3MjRhNGMyNjVjYTE0MDU4MmFiL3RleHRyZWdpb246ZmEzZjJmZWY3NmM2NDcyNGE0YzI2NWNhMTQwNTgyYWJfMjMyNw_89489045-6d0e-4c55-8685-cebfcaab8d8b">45</ix:nonFraction> basis points, in each case, based on the Company's leverage ratio. The LIBOR floor was also increased to <ix:nonFraction unitRef="number" contextRef="i1cd2ac076ee74bdaaad3ecd73d94eee1_D20200401-20220630" decimals="INF" name="mygn:DebtInstrumentLIBORFloorPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN181NS9mcmFnOmZhM2YyZmVmNzZjNjQ3MjRhNGMyNjVjYTE0MDU4MmFiL3RleHRyZWdpb246ZmEzZjJmZWY3NmM2NDcyNGE0YzI2NWNhMTQwNTgyYWJfMjQzNQ_82e6fb2a-f3d8-4346-b119-135f76cdd0c2">1.0</ix:nonFraction>% during the Modification Period. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Covenants in the Amended Facility impose operating and financial restrictions on the Company. These restrictions may prohibit or place limitations on, among other things, the Company&#8217;s ability to incur additional indebtedness, create certain types of liens, and complete mergers, consolidations, or change in control transactions. The Amended Facility may also prohibit or place limitations on the Company&#8217;s ability to sell assets, pay dividends or provide other distributions to stockholders. Beginning with the quarter ended June 30, 2022, the Company must maintain specified leverage and interest ratios measured as of the end of each quarter as a financial covenant in the Amended Facility. Amendment No. 2 modified the Amended Facility's compliance with the leverage covenant and the interest coverage ratio covenant, which were waived through March 31, 2021.  Amendment No. 2 also revised certain negative covenants of the Amended Facility during the Modification Period. Amendment No. 3 waived compliance with the leverage ratio and the interest coverage ratio covenants through the quarter ending March 31, 2022 and also lowered the minimum liquidity covenant, which was added by Amendment No. 2, to $<ix:nonFraction unitRef="usd" contextRef="ic14444ddb59c4b859b297e3eb63f800d_I20210221" decimals="-5" format="ixt:num-dot-decimal" name="mygn:DebtCovenantLiquidityCovenantMinimum" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN181NS9mcmFnOmZhM2YyZmVmNzZjNjQ3MjRhNGMyNjVjYTE0MDU4MmFiL3RleHRyZWdpb246ZmEzZjJmZWY3NmM2NDcyNGE0YzI2NWNhMTQwNTgyYWJfMjc0ODc3OTA3OTIyOA_16411760-4680-4424-af77-25d87865b99e">150.0</ix:nonFraction>&#160;million, and made it applicable through such quarter. Amendment No. 3 restricted the Company from borrowing under the Amended Facility if unrestricted cash and cash equivalents exceed $<ix:nonFraction unitRef="usd" contextRef="ic14444ddb59c4b859b297e3eb63f800d_I20210221" decimals="-5" format="ixt:num-dot-decimal" name="mygn:DebtCovenantUnrestrictedCashAndCashEquivalentsThresholdForBorrowingRestrictionMinimum" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN181NS9mcmFnOmZhM2YyZmVmNzZjNjQ3MjRhNGMyNjVjYTE0MDU4MmFiL3RleHRyZWdpb246ZmEzZjJmZWY3NmM2NDcyNGE0YzI2NWNhMTQwNTgyYWJfNDA3OQ_1556a8c9-256f-4d5a-9c6e-5f6355ff6e9a">150.0</ix:nonFraction>&#160;million, unless such borrowings are in connection with acquisitions. The Company was in compliance with all applicable financial covenants at September&#160;30, 2021. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5814a71962934792901cb2330361bb17_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i209b7dcfda5744be814f5d54952afcca" continuedAt="ib699f6eff0c44feaa1671079f2ceab23">During the nine months ended September 30, 2021, the Company made principal repayments totaling $<ix:nonFraction unitRef="usd" contextRef="ib42c463d1fe74078a52b79074501653e_D20210101-20210630" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfLinesOfCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN181NS9mcmFnOmZhM2YyZmVmNzZjNjQ3MjRhNGMyNjVjYTE0MDU4MmFiL3RleHRyZWdpb246ZmEzZjJmZWY3NmM2NDcyNGE0YzI2NWNhMTQwNTgyYWJfMTY0OTI2NzQ0OTcwNw_3b017803-da7c-4c43-a85e-c5cd09389861">226.4</ix:nonFraction>&#160;million on the Amended Facility, including a voluntary principal payment on July 30, 2021 of $<ix:nonFraction unitRef="usd" contextRef="i408d12bd10e24b0daf055d6dce17ee34_D20210731-20210731" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfLinesOfCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN181NS9mcmFnOmZhM2YyZmVmNzZjNjQ3MjRhNGMyNjVjYTE0MDU4MmFiL3RleHRyZWdpb246ZmEzZjJmZWY3NmM2NDcyNGE0YzI2NWNhMTQwNTgyYWJfMTA5OTUxMTYzNTY5NQ_18a631ef-b708-4a4e-a2ee-ba9d0ce60b70">106.4</ix:nonFraction>&#160;million to pay off the remaining outstanding balances on the Amended Facility. As a result, the Company had <ix:nonFraction unitRef="usd" contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:LongTermDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN181NS9mcmFnOmZhM2YyZmVmNzZjNjQ3MjRhNGMyNjVjYTE0MDU4MmFiL3RleHRyZWdpb246ZmEzZjJmZWY3NmM2NDcyNGE0YzI2NWNhMTQwNTgyYWJfMjc0ODc3OTA3NzM4OQ_9f91928a-8970-4d3a-8e70-2a424b20780d">no</ix:nonFraction> outstanding balances under the Amended Facility as of September 30, 2021. During the transition period ended December 31, 2020, the Company did <ix:nonFraction unitRef="usd" contextRef="idb96586e8d014be6a63ed5c14054d982_D20200701-20201231" decimals="INF" format="ixt:fixed-zero" name="us-gaap:RepaymentsOfLinesOfCredit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN181NS9mcmFnOmZhM2YyZmVmNzZjNjQ3MjRhNGMyNjVjYTE0MDU4MmFiL3RleHRyZWdpb246ZmEzZjJmZWY3NmM2NDcyNGE0YzI2NWNhMTQwNTgyYWJfNDQwOQ_4a949f13-e656-413a-8c4e-a8e5a8bc57c4">no</ix:nonFraction>t make any principal repayments. The $<ix:nonFraction unitRef="usd" contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="mygn:OtherAssetsDebtDiscount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN181NS9mcmFnOmZhM2YyZmVmNzZjNjQ3MjRhNGMyNjVjYTE0MDU4MmFiL3RleHRyZWdpb246ZmEzZjJmZWY3NmM2NDcyNGE0YzI2NWNhMTQwNTgyYWJfMTY0OTI2NzQ0OTYwNg_66f953cf-3048-4c8e-bae6-6c4645254fd0">1.8</ix:nonFraction>&#160;million long-term debt discount associated with the Amended Facility is recorded to Other assets in the Condensed Consolidated Balance Sheet. The Company's maximum aggregate principal commitment on its Amended Facility is $<ix:nonFraction unitRef="usd" contextRef="i12f34ee4c63b4e07a09ead597eb2afb8_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN181NS9mcmFnOmZhM2YyZmVmNzZjNjQ3MjRhNGMyNjVjYTE0MDU4MmFiL3RleHRyZWdpb246ZmEzZjJmZWY3NmM2NDcyNGE0YzI2NWNhMTQwNTgyYWJfMTY0OTI2NzQ0OTIwMQ_550a4f16-d976-42a0-abdd-0845c7a7b5bb">250.0</ix:nonFraction>&#160;million as of September 30, 2021.</ix:continuation></span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ib699f6eff0c44feaa1671079f2ceab23">As of December 31, 2020, the Company had a long-term debt balance of $<ix:nonFraction unitRef="usd" contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN181NS9mcmFnOmZhM2YyZmVmNzZjNjQ3MjRhNGMyNjVjYTE0MDU4MmFiL3RleHRyZWdpb246ZmEzZjJmZWY3NmM2NDcyNGE0YzI2NWNhMTQwNTgyYWJfMTY0OTI2NzQ1MDA1OA_9372d04d-4ea1-48f7-b6ca-94f33fb3e788">224.8</ix:nonFraction>&#160;million, net of a $<ix:nonFraction unitRef="usd" contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentUnamortizedDiscountNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN181NS9mcmFnOmZhM2YyZmVmNzZjNjQ3MjRhNGMyNjVjYTE0MDU4MmFiL3RleHRyZWdpb246ZmEzZjJmZWY3NmM2NDcyNGE0YzI2NWNhMTQwNTgyYWJfMTY0OTI2NzQ1MDA3Ng_f51da8bc-687d-4451-a2ca-c76f0c98fb98">1.9</ix:nonFraction>&#160;million long-term debt discount.</ix:continuation> </span></div><div id="i5814a71962934792901cb2330361bb17_58"></div><div style="margin-top:9pt"><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" name="us-gaap:OtherLiabilitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN181OC9mcmFnOjU4N2EyMGJiYjM5OTRjMzk4OGNlNjA0ZGFkYjc1ZTA1L3RleHRyZWdpb246NTg3YTIwYmJiMzk5NGMzOTg4Y2U2MDRkYWRiNzVlMDVfMzE2_a9a46ba4-ffd7-406d-820a-d24884b4e5a1" continuedAt="ic62c9f213daf4ca08663b97d7ec3435e" escape="true">OTHER LONG-TERM LIABILITIES</ix:nonNumeric></span></div><div style="margin-top:5pt"><ix:continuation id="ic62c9f213daf4ca08663b97d7ec3435e" continuedAt="ib8ad2cf58de44d8698602712a4ec5a32"><ix:nonNumeric contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" name="us-gaap:OtherNoncurrentLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN181OC9mcmFnOjU4N2EyMGJiYjM5OTRjMzk4OGNlNjA0ZGFkYjc1ZTA1L3RleHRyZWdpb246NTg3YTIwYmJiMzk5NGMzOTg4Y2U2MDRkYWRiNzVlMDVfMzE3_aaf69452-cb82-4f54-b49b-bcbc45f7fb8c" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.046%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.037%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN181OC9mcmFnOjU4N2EyMGJiYjM5OTRjMzk4OGNlNjA0ZGFkYjc1ZTA1L3RhYmxlOjkzZGI3NDY1NWM1ODRjNzRiMWEzZDQzODRjNzNhNDlkL3RhYmxlcmFuZ2U6OTNkYjc0NjU1YzU4NGM3NGIxYTNkNDM4NGM3M2E0OWRfMS0xLTEtMS0xODE2NA_7c886de2-f5d5-4312-b154-07edbeb55905">5.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN181OC9mcmFnOjU4N2EyMGJiYjM5OTRjMzk4OGNlNjA0ZGFkYjc1ZTA1L3RhYmxlOjkzZGI3NDY1NWM1ODRjNzRiMWEzZDQzODRjNzNhNDlkL3RhYmxlcmFuZ2U6OTNkYjc0NjU1YzU4NGM3NGIxYTNkNDM4NGM3M2E0OWRfMS0zLTEtMS0xODE2NA_056287bf-f737-408e-af23-9743b1a7faad">7.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930" decimals="-5" name="us-gaap:OtherSundryLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN181OC9mcmFnOjU4N2EyMGJiYjM5OTRjMzk4OGNlNjA0ZGFkYjc1ZTA1L3RhYmxlOjkzZGI3NDY1NWM1ODRjNzRiMWEzZDQzODRjNzNhNDlkL3RhYmxlcmFuZ2U6OTNkYjc0NjU1YzU4NGM3NGIxYTNkNDM4NGM3M2E0OWRfMi0xLTEtMS0xODE2NA_1a37d5c9-5c91-49ae-bc7d-38147eb74783">5.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231" decimals="-5" name="us-gaap:OtherSundryLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN181OC9mcmFnOjU4N2EyMGJiYjM5OTRjMzk4OGNlNjA0ZGFkYjc1ZTA1L3RhYmxlOjkzZGI3NDY1NWM1ODRjNzRiMWEzZDQzODRjNzNhNDlkL3RhYmxlcmFuZ2U6OTNkYjc0NjU1YzU4NGM3NGIxYTNkNDM4NGM3M2E0OWRfMi0zLTEtMS0xODE2NA_05b2564c-ec0c-47f2-a2fa-e390e7300c60">7.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other long-term liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN181OC9mcmFnOjU4N2EyMGJiYjM5OTRjMzk4OGNlNjA0ZGFkYjc1ZTA1L3RhYmxlOjkzZGI3NDY1NWM1ODRjNzRiMWEzZDQzODRjNzNhNDlkL3RhYmxlcmFuZ2U6OTNkYjc0NjU1YzU4NGM3NGIxYTNkNDM4NGM3M2E0OWRfMy0xLTEtMS0xODE2NA_657f013e-caaa-4cd2-a984-ddf9f530dc86">10.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN181OC9mcmFnOjU4N2EyMGJiYjM5OTRjMzk4OGNlNjA0ZGFkYjc1ZTA1L3RhYmxlOjkzZGI3NDY1NWM1ODRjNzRiMWEzZDQzODRjNzNhNDlkL3RhYmxlcmFuZ2U6OTNkYjc0NjU1YzU4NGM3NGIxYTNkNDM4NGM3M2E0OWRfMy0zLTEtMS0xODE2NA_981faddd-40d6-47d0-a469-e41260e60bdb">14.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></ix:continuation></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ib8ad2cf58de44d8698602712a4ec5a32">The Company's balance of other long-term liabilities as of September&#160;30, 2021 and December&#160;31, 2020 primarily consists of the Company&#8217;s portion of social security taxes that have been deferred under the Coronavirus Aid, Relief, and Economic Security Act (&#8220;CARES Act&#8221;) that do not have to be remitted until December 2022.</ix:continuation> </span></div><div id="i5814a71962934792901cb2330361bb17_61"></div><div style="margin-top:18pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182MS9mcmFnOjdhYzhiYmE4ZTc4YzRiMzZhNGQ2YjUwOTAyZmU2Y2UwL3RleHRyZWdpb246N2FjOGJiYThlNzhjNGIzNmE0ZDZiNTA5MDJmZTZjZTBfMTkwMQ_41588e59-598a-4bc5-946c-43af42fb2570" continuedAt="i11c0657461ae4e05b27cc77997a2c74b" escape="true">PREFERRED AND COMMON STOCKHOLDERS' EQUITY</ix:nonNumeric></span></div><ix:continuation id="i11c0657461ae4e05b27cc77997a2c74b" continuedAt="i3238694ce8e6476ca3bd9d546f8b849b"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is authorized to issue up to <ix:nonFraction unitRef="shares" contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182MS9mcmFnOjdhYzhiYmE4ZTc4YzRiMzZhNGQ2YjUwOTAyZmU2Y2UwL3RleHRyZWdpb246N2FjOGJiYThlNzhjNGIzNmE0ZDZiNTA5MDJmZTZjZTBfODg_7994c361-8f29-4c13-b887-c2bbbaf43747">5.0</ix:nonFraction> million shares of preferred stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182MS9mcmFnOjdhYzhiYmE4ZTc4YzRiMzZhNGQ2YjUwOTAyZmU2Y2UwL3RleHRyZWdpb246N2FjOGJiYThlNzhjNGIzNmE0ZDZiNTA5MDJmZTZjZTBfMTI4_defd723a-955f-4e51-a22b-cefca95ad39c">0.01</ix:nonFraction> per share. There were <ix:nonFraction unitRef="shares" contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:PreferredStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182MS9mcmFnOjdhYzhiYmE4ZTc4YzRiMzZhNGQ2YjUwOTAyZmU2Y2UwL3RleHRyZWdpb246N2FjOGJiYThlNzhjNGIzNmE0ZDZiNTA5MDJmZTZjZTBfMTUz_34805646-3622-4628-bcec-b4ef91cfa94d">no</ix:nonFraction> preferred shares outstanding at September&#160;30, 2021.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is authorized to issue up to <ix:nonFraction unitRef="shares" contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182MS9mcmFnOjdhYzhiYmE4ZTc4YzRiMzZhNGQ2YjUwOTAyZmU2Y2UwL3RleHRyZWdpb246N2FjOGJiYThlNzhjNGIzNmE0ZDZiNTA5MDJmZTZjZTBfMjMz_fccc63de-d574-4d20-ad85-f1b2cd0d71d8">150.0</ix:nonFraction> million shares of common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182MS9mcmFnOjdhYzhiYmE4ZTc4YzRiMzZhNGQ2YjUwOTAyZmU2Y2UwL3RleHRyZWdpb246N2FjOGJiYThlNzhjNGIzNmE0ZDZiNTA5MDJmZTZjZTBfMjcw_8bce615f-7c41-437f-b5d1-f97495890e75">0.01</ix:nonFraction> per share. There were <ix:nonFraction unitRef="shares" contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182MS9mcmFnOjdhYzhiYmE4ZTc4YzRiMzZhNGQ2YjUwOTAyZmU2Y2UwL3RleHRyZWdpb246N2FjOGJiYThlNzhjNGIzNmE0ZDZiNTA5MDJmZTZjZTBfMjk1_d65d0031-9a43-4de6-9550-e2ced5204802"><ix:nonFraction unitRef="shares" contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182MS9mcmFnOjdhYzhiYmE4ZTc4YzRiMzZhNGQ2YjUwOTAyZmU2Y2UwL3RleHRyZWdpb246N2FjOGJiYThlNzhjNGIzNmE0ZDZiNTA5MDJmZTZjZTBfMjk1_eb288948-8c6a-403e-bbeb-7f42a85a6661">79.7</ix:nonFraction></ix:nonFraction> million shares issued and outstanding at September&#160;30, 2021.</span></div><ix:nonNumeric contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" name="us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182MS9mcmFnOjdhYzhiYmE4ZTc4YzRiMzZhNGQ2YjUwOTAyZmU2Y2UwL3RleHRyZWdpb246N2FjOGJiYThlNzhjNGIzNmE0ZDZiNTA5MDJmZTZjZTBfMTkwMg_9b6b63c3-9a0c-4425-82a7-57e9bca6a22f" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Common shares issued and outstanding</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.046%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.599%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning common stock issued and outstanding</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182MS9mcmFnOjdhYzhiYmE4ZTc4YzRiMzZhNGQ2YjUwOTAyZmU2Y2UwL3RhYmxlOmI1ZGExZDFkMGI1MDRjMzQ4MjIzZTQwNDIwOWFiZjg5L3RhYmxlcmFuZ2U6YjVkYTFkMWQwYjUwNGMzNDgyMjNlNDA0MjA5YWJmODlfMi0xLTEtMS0xODE2NA_6a664d13-7669-4b13-82be-7d2a99a29e3c"><ix:nonFraction unitRef="shares" contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182MS9mcmFnOjdhYzhiYmE4ZTc4YzRiMzZhNGQ2YjUwOTAyZmU2Y2UwL3RhYmxlOmI1ZGExZDFkMGI1MDRjMzQ4MjIzZTQwNDIwOWFiZjg5L3RhYmxlcmFuZ2U6YjVkYTFkMWQwYjUwNGMzNDgyMjNlNDA0MjA5YWJmODlfMi0xLTEtMS0xODE2NA_cb306fa2-cb7f-4dca-aad9-816040064b45">75.4</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ic698543044ba4469ba8751bae898951c_I20191231" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182MS9mcmFnOjdhYzhiYmE4ZTc4YzRiMzZhNGQ2YjUwOTAyZmU2Y2UwL3RhYmxlOmI1ZGExZDFkMGI1MDRjMzQ4MjIzZTQwNDIwOWFiZjg5L3RhYmxlcmFuZ2U6YjVkYTFkMWQwYjUwNGMzNDgyMjNlNDA0MjA5YWJmODlfMi0zLTEtMS0xODE2NA_580b3118-a445-4ce7-8f67-b55f1339ff98"><ix:nonFraction unitRef="shares" contextRef="ic698543044ba4469ba8751bae898951c_I20191231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182MS9mcmFnOjdhYzhiYmE4ZTc4YzRiMzZhNGQ2YjUwOTAyZmU2Y2UwL3RhYmxlOmI1ZGExZDFkMGI1MDRjMzQ4MjIzZTQwNDIwOWFiZjg5L3RhYmxlcmFuZ2U6YjVkYTFkMWQwYjUwNGMzNDgyMjNlNDA0MjA5YWJmODlfMi0zLTEtMS0xODE2NA_c2b840e2-7f97-4512-88bd-cb23a4104016">74.5</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stock issued upon exercise of options, vesting of restricted stock units, and purchases under employee stock purchase plan</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" decimals="-5" name="mygn:StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182MS9mcmFnOjdhYzhiYmE4ZTc4YzRiMzZhNGQ2YjUwOTAyZmU2Y2UwL3RhYmxlOmI1ZGExZDFkMGI1MDRjMzQ4MjIzZTQwNDIwOWFiZjg5L3RhYmxlcmFuZ2U6YjVkYTFkMWQwYjUwNGMzNDgyMjNlNDA0MjA5YWJmODlfMy0xLTEtMS0xODE2NA_305f3ddb-cf87-4585-8dcf-d030b15b4695">4.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930" decimals="-5" name="mygn:StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182MS9mcmFnOjdhYzhiYmE4ZTc4YzRiMzZhNGQ2YjUwOTAyZmU2Y2UwL3RhYmxlOmI1ZGExZDFkMGI1MDRjMzQ4MjIzZTQwNDIwOWFiZjg5L3RhYmxlcmFuZ2U6YjVkYTFkMWQwYjUwNGMzNDgyMjNlNDA0MjA5YWJmODlfMy0zLTEtMS0xODE2NA_75e4b2e7-e6f3-4246-aee8-3f28fb6fa361">0.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stock issued and outstanding at end of period</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182MS9mcmFnOjdhYzhiYmE4ZTc4YzRiMzZhNGQ2YjUwOTAyZmU2Y2UwL3RhYmxlOmI1ZGExZDFkMGI1MDRjMzQ4MjIzZTQwNDIwOWFiZjg5L3RhYmxlcmFuZ2U6YjVkYTFkMWQwYjUwNGMzNDgyMjNlNDA0MjA5YWJmODlfNS0xLTEtMS0xODE2NA_030a0066-d22e-4edc-9bfb-008b08551623"><ix:nonFraction unitRef="shares" contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182MS9mcmFnOjdhYzhiYmE4ZTc4YzRiMzZhNGQ2YjUwOTAyZmU2Y2UwL3RhYmxlOmI1ZGExZDFkMGI1MDRjMzQ4MjIzZTQwNDIwOWFiZjg5L3RhYmxlcmFuZ2U6YjVkYTFkMWQwYjUwNGMzNDgyMjNlNDA0MjA5YWJmODlfNS0xLTEtMS0xODE2NA_fc9e32d1-3fb4-4e3d-97e0-719d278656a5">79.7</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i0c6bac27ede64afeb4dbc13729f58578_I20200930" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182MS9mcmFnOjdhYzhiYmE4ZTc4YzRiMzZhNGQ2YjUwOTAyZmU2Y2UwL3RhYmxlOmI1ZGExZDFkMGI1MDRjMzQ4MjIzZTQwNDIwOWFiZjg5L3RhYmxlcmFuZ2U6YjVkYTFkMWQwYjUwNGMzNDgyMjNlNDA0MjA5YWJmODlfNS0zLTEtMS0xODE2NA_07065ded-7d72-4e63-87f2-534629aa2bbd"><ix:nonFraction unitRef="shares" contextRef="i0c6bac27ede64afeb4dbc13729f58578_I20200930" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182MS9mcmFnOjdhYzhiYmE4ZTc4YzRiMzZhNGQ2YjUwOTAyZmU2Y2UwL3RhYmxlOmI1ZGExZDFkMGI1MDRjMzQ4MjIzZTQwNDIwOWFiZjg5L3RhYmxlcmFuZ2U6YjVkYTFkMWQwYjUwNGMzNDgyMjNlNDA0MjA5YWJmODlfNS0zLTEtMS0xODE2NA_5c35dc36-47da-4e4c-aea5-084fd4d29730">75.2</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings per share is computed based on the weighted-average number of shares of common stock outstanding.&#160;&#160;Diluted earnings per share is computed based on the weighted-average number of shares of common stock, including the dilutive effect of common stock equivalents, outstanding.&#160;&#160;In periods when the Company has a net loss, stock awards are excluded from the calculation of diluted net loss per share as their inclusion would have an antidilutive effect.</span></div><ix:nonNumeric contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" name="us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182MS9mcmFnOjdhYzhiYmE4ZTc4YzRiMzZhNGQ2YjUwOTAyZmU2Y2UwL3RleHRyZWdpb246N2FjOGJiYThlNzhjNGIzNmE0ZDZiNTA5MDJmZTZjZTBfMTkwMw_c2a549ce-62d0-4ebb-af53-6387fe6a0243" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a reconciliation of the denominators of the basic and diluted earnings per share (&#8220;EPS&#8221;) computations:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.603%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine months ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Denominator:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average shares outstanding used to compute basic EPS</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182MS9mcmFnOjdhYzhiYmE4ZTc4YzRiMzZhNGQ2YjUwOTAyZmU2Y2UwL3RhYmxlOmI3NTEzZWUxMzNhYjQ1OGM5YzcwMjQ1M2MzZWM2OTI3L3RhYmxlcmFuZ2U6Yjc1MTNlZTEzM2FiNDU4YzljNzAyNDUzYzNlYzY5MjdfMy0xLTEtMS0xODE2NA_ea1464cd-d62a-46c8-952b-e96e110220c3">78.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ic2c3e03438af4889ac973627c642f5ec_D20200701-20200930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182MS9mcmFnOjdhYzhiYmE4ZTc4YzRiMzZhNGQ2YjUwOTAyZmU2Y2UwL3RhYmxlOmI3NTEzZWUxMzNhYjQ1OGM5YzcwMjQ1M2MzZWM2OTI3L3RhYmxlcmFuZ2U6Yjc1MTNlZTEzM2FiNDU4YzljNzAyNDUzYzNlYzY5MjdfMy0zLTEtMS0xODE2NA_07199ddf-e1f9-49ae-92a0-9303efb1d253">74.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182MS9mcmFnOjdhYzhiYmE4ZTc4YzRiMzZhNGQ2YjUwOTAyZmU2Y2UwL3RhYmxlOmI3NTEzZWUxMzNhYjQ1OGM5YzcwMjQ1M2MzZWM2OTI3L3RhYmxlcmFuZ2U6Yjc1MTNlZTEzM2FiNDU4YzljNzAyNDUzYzNlYzY5MjdfMy01LTEtMS0xODE2NA_149de4d1-5f07-4333-9d03-3cfff95d74d4">77.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182MS9mcmFnOjdhYzhiYmE4ZTc4YzRiMzZhNGQ2YjUwOTAyZmU2Y2UwL3RhYmxlOmI3NTEzZWUxMzNhYjQ1OGM5YzcwMjQ1M2MzZWM2OTI3L3RhYmxlcmFuZ2U6Yjc1MTNlZTEzM2FiNDU4YzljNzAyNDUzYzNlYzY5MjdfMy03LTEtMS0xODE2NA_799335a3-31ce-43f7-93a6-d87df558a3d7">74.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effect of dilutive shares</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930" decimals="-5" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182MS9mcmFnOjdhYzhiYmE4ZTc4YzRiMzZhNGQ2YjUwOTAyZmU2Y2UwL3RhYmxlOmI3NTEzZWUxMzNhYjQ1OGM5YzcwMjQ1M2MzZWM2OTI3L3RhYmxlcmFuZ2U6Yjc1MTNlZTEzM2FiNDU4YzljNzAyNDUzYzNlYzY5MjdfNC0xLTEtMS0xODE2NA_68108580-6c0f-4ef3-8612-36d8030aad0c">2.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ic2c3e03438af4889ac973627c642f5ec_D20200701-20200930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182MS9mcmFnOjdhYzhiYmE4ZTc4YzRiMzZhNGQ2YjUwOTAyZmU2Y2UwL3RhYmxlOmI3NTEzZWUxMzNhYjQ1OGM5YzcwMjQ1M2MzZWM2OTI3L3RhYmxlcmFuZ2U6Yjc1MTNlZTEzM2FiNDU4YzljNzAyNDUzYzNlYzY5MjdfNC0zLTEtMS0xODE2NA_79e85d6c-9021-42a7-b1bc-6579e3e4ab8b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182MS9mcmFnOjdhYzhiYmE4ZTc4YzRiMzZhNGQ2YjUwOTAyZmU2Y2UwL3RhYmxlOmI3NTEzZWUxMzNhYjQ1OGM5YzcwMjQ1M2MzZWM2OTI3L3RhYmxlcmFuZ2U6Yjc1MTNlZTEzM2FiNDU4YzljNzAyNDUzYzNlYzY5MjdfNC01LTEtMS0xODE2NA_04130df7-5980-4140-8bad-6009b528cfe2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182MS9mcmFnOjdhYzhiYmE4ZTc4YzRiMzZhNGQ2YjUwOTAyZmU2Y2UwL3RhYmxlOmI3NTEzZWUxMzNhYjQ1OGM5YzcwMjQ1M2MzZWM2OTI3L3RhYmxlcmFuZ2U6Yjc1MTNlZTEzM2FiNDU4YzljNzAyNDUzYzNlYzY5MjdfNC03LTEtMS0xODE2NA_512adfde-29ab-4b99-9023-f8584c01d036">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average shares outstanding and dilutive securities used to compute diluted EPS</span></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182MS9mcmFnOjdhYzhiYmE4ZTc4YzRiMzZhNGQ2YjUwOTAyZmU2Y2UwL3RhYmxlOmI3NTEzZWUxMzNhYjQ1OGM5YzcwMjQ1M2MzZWM2OTI3L3RhYmxlcmFuZ2U6Yjc1MTNlZTEzM2FiNDU4YzljNzAyNDUzYzNlYzY5MjdfNS0xLTEtMS0xODE2NA_157165af-0604-4a03-9099-8f6312d3711a">81.5</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ic2c3e03438af4889ac973627c642f5ec_D20200701-20200930" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182MS9mcmFnOjdhYzhiYmE4ZTc4YzRiMzZhNGQ2YjUwOTAyZmU2Y2UwL3RhYmxlOmI3NTEzZWUxMzNhYjQ1OGM5YzcwMjQ1M2MzZWM2OTI3L3RhYmxlcmFuZ2U6Yjc1MTNlZTEzM2FiNDU4YzljNzAyNDUzYzNlYzY5MjdfNS0zLTEtMS0xODE2NA_794a6de6-5d33-4aab-aba1-e3e74edd1d9e">74.7</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182MS9mcmFnOjdhYzhiYmE4ZTc4YzRiMzZhNGQ2YjUwOTAyZmU2Y2UwL3RhYmxlOmI3NTEzZWUxMzNhYjQ1OGM5YzcwMjQ1M2MzZWM2OTI3L3RhYmxlcmFuZ2U6Yjc1MTNlZTEzM2FiNDU4YzljNzAyNDUzYzNlYzY5MjdfNS01LTEtMS0xODE2NA_5b095305-04b4-4a6e-8f8a-5bec095273a4">77.3</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182MS9mcmFnOjdhYzhiYmE4ZTc4YzRiMzZhNGQ2YjUwOTAyZmU2Y2UwL3RhYmxlOmI3NTEzZWUxMzNhYjQ1OGM5YzcwMjQ1M2MzZWM2OTI3L3RhYmxlcmFuZ2U6Yjc1MTNlZTEzM2FiNDU4YzljNzAyNDUzYzNlYzY5MjdfNS03LTEtMS0xODE2NA_f21a4694-c69c-4ecb-9bb2-fe4b39a672ce">74.6</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5814a71962934792901cb2330361bb17_7">Table of Contents</a></span></div></div><ix:continuation id="i3238694ce8e6476ca3bd9d546f8b849b"><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain outstanding options and restricted stock units (&#8220;RSUs&#8221;) were excluded from the computation of diluted earnings per share because the effect would have been anti-dilutive. <ix:nonNumeric contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182MS9mcmFnOjdhYzhiYmE4ZTc4YzRiMzZhNGQ2YjUwOTAyZmU2Y2UwL3RleHRyZWdpb246N2FjOGJiYThlNzhjNGIzNmE0ZDZiNTA5MDJmZTZjZTBfMTkwNA_4a92bb59-a1e7-44a7-afb0-5ca2e42446bf" continuedAt="ideae7f02ea5c4da38058e49b9bd31d26" escape="true">These potential dilutive common shares, which may be dilutive to future diluted earnings per share, are as follows:</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:center"><ix:continuation id="ideae7f02ea5c4da38058e49b9bd31d26"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.444%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.377%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.377%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.444%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.377%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.444%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.521%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.521%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.446%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended <br/>September 30, </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine months ended<br/>&#160;September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Anti-dilutive options and RSUs excluded from EPS computation</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182MS9mcmFnOjdhYzhiYmE4ZTc4YzRiMzZhNGQ2YjUwOTAyZmU2Y2UwL3RhYmxlOjhmZjdmM2ZkOWY0YzQyMzhhODc0NTg0MTY5OTFmMzVlL3RhYmxlcmFuZ2U6OGZmN2YzZmQ5ZjRjNDIzOGE4NzQ1ODQxNjk5MWYzNWVfMi0xLTEtMS0yNjk2Mg_36abfcdb-705c-4e45-beba-16def1652e11">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ic2c3e03438af4889ac973627c642f5ec_D20200701-20200930" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182MS9mcmFnOjdhYzhiYmE4ZTc4YzRiMzZhNGQ2YjUwOTAyZmU2Y2UwL3RhYmxlOjhmZjdmM2ZkOWY0YzQyMzhhODc0NTg0MTY5OTFmMzVlL3RhYmxlcmFuZ2U6OGZmN2YzZmQ5ZjRjNDIzOGE4NzQ1ODQxNjk5MWYzNWVfMi0zLTEtMS0yNjkxOA_e25323ca-f4e1-4d6e-923e-be72d3cacbc4">7.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182MS9mcmFnOjdhYzhiYmE4ZTc4YzRiMzZhNGQ2YjUwOTAyZmU2Y2UwL3RhYmxlOjhmZjdmM2ZkOWY0YzQyMzhhODc0NTg0MTY5OTFmMzVlL3RhYmxlcmFuZ2U6OGZmN2YzZmQ5ZjRjNDIzOGE4NzQ1ODQxNjk5MWYzNWVfMi0xLTEtMS0xODE2NA_5d2fdcd9-e1a2-46f3-b956-4b28adda2fe9">4.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182MS9mcmFnOjdhYzhiYmE4ZTc4YzRiMzZhNGQ2YjUwOTAyZmU2Y2UwL3RhYmxlOjhmZjdmM2ZkOWY0YzQyMzhhODc0NTg0MTY5OTFmMzVlL3RhYmxlcmFuZ2U6OGZmN2YzZmQ5ZjRjNDIzOGE4NzQ1ODQxNjk5MWYzNWVfMi0zLTEtMS0xODE2NA_60d960fc-50b4-4fbf-8280-f4294d1766ff">7.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Repurchase Program</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Company&#8217;s Board of Directors authorized a share repurchase program of $<ix:nonFraction unitRef="usd" contextRef="i3269c20860fd42e5b0cecdb3249f343d_I20160630" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182MS9mcmFnOjdhYzhiYmE4ZTc4YzRiMzZhNGQ2YjUwOTAyZmU2Y2UwL3RleHRyZWdpb246N2FjOGJiYThlNzhjNGIzNmE0ZDZiNTA5MDJmZTZjZTBfMTM3MQ_de38bc08-f1e5-4216-b44b-7d2c1476ef17">200.0</ix:nonFraction> million of the Company&#8217;s outstanding common stock from time to time or on an accelerated basis through open market transactions or privately negotiated transactions as determined by the Company's management. The amount and timing of stock repurchases under the program will depend on business and market conditions, stock price, trading restrictions, acquisition activity and other factors.&#160;&#160;As of September&#160;30, 2021, the Company is authorized to repurchase up to $<ix:nonFraction unitRef="usd" contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182MS9mcmFnOjdhYzhiYmE4ZTc4YzRiMzZhNGQ2YjUwOTAyZmU2Y2UwL3RleHRyZWdpb246N2FjOGJiYThlNzhjNGIzNmE0ZDZiNTA5MDJmZTZjZTBfMTgxNA_35684bc5-6451-42e8-a626-b21d94427d89">110.7</ix:nonFraction> million of shares under this authorization. <ix:nonFraction unitRef="shares" contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182MS9mcmFnOjdhYzhiYmE4ZTc4YzRiMzZhNGQ2YjUwOTAyZmU2Y2UwL3RleHRyZWdpb246N2FjOGJiYThlNzhjNGIzNmE0ZDZiNTA5MDJmZTZjZTBfMTg1Mw_9e4e719e-c176-43f6-b0e4-00ec38c62b1f"><ix:nonFraction unitRef="shares" contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182MS9mcmFnOjdhYzhiYmE4ZTc4YzRiMzZhNGQ2YjUwOTAyZmU2Y2UwL3RleHRyZWdpb246N2FjOGJiYThlNzhjNGIzNmE0ZDZiNTA5MDJmZTZjZTBfMTg1Mw_c446205e-d2e3-49ab-888f-209c42608bcc">No</ix:nonFraction></ix:nonFraction> shares were repurchased during the nine months ended September 30, 2021 or 2020.</span></div></ix:continuation><div id="i5814a71962934792901cb2330361bb17_64"></div><div style="margin-top:18pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182NC9mcmFnOjA2NTZiZmUyZmE0ZDQwN2JiYjYwOTZhMDdiNGZmMjQyL3RleHRyZWdpb246MDY1NmJmZTJmYTRkNDA3YmJiNjA5NmEwN2I0ZmYyNDJfMzE4NQ_03f6cb3d-1c7c-491c-a7e5-695f23dbf6c0" continuedAt="idcd11dead1334d4d9b99d3227c698d4e" escape="true">STOCK-BASED COMPENSATION</ix:nonNumeric></span></div><ix:continuation id="idcd11dead1334d4d9b99d3227c698d4e" continuedAt="ib1d68f39607d43d8bdac77b49784bddf"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 30, 2017, the Company&#8217;s stockholders approved the adoption of the 2017 Employee, Director and Consultant Equity Incentive Plan (as amended, the &#8220;2017 Plan&#8221;). The 2017 Plan allows the Company, under the direction of the Compensation and Human Capital Committee of the Board of Directors, to make grants of restricted and unrestricted stock awards to employees, consultants, and directors. Stockholders have approved amendments to the 2017 Plan increasing the shares available to grant.  As of September&#160;30, 2021, the Company has <ix:nonFraction unitRef="shares" contextRef="i52adcde188a640e99ba9a44e311c8d73_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182NC9mcmFnOjA2NTZiZmUyZmE0ZDQwN2JiYjYwOTZhMDdiNGZmMjQyL3RleHRyZWdpb246MDY1NmJmZTJmYTRkNDA3YmJiNjA5NmEwN2I0ZmYyNDJfNTM2_b6c076b8-5649-41b1-ad14-7424fe1dda1d">3.6</ix:nonFraction>&#160;million shares of common stock available for grant under the 2017 Plan.  If an RSU awarded under the 2017 Plan is cancelled or forfeited without the issuance of shares of common stock, the unissued or reacquired shares that were subject to the RSU will again be available for issuance pursuant to the 2017 Plan. To the extent that awards outstanding under the Company's prior equity plans expire or are cancelled without delivery of shares of common stock, they also will be available for issuance pursuant to the 2017 Plan. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of shares, terms, and vesting periods are generally determined by the Company&#8217;s Board of Directors or a committee thereof on an award-by-award basis. RSUs granted to employees generally vest ratably over <ix:nonNumeric contextRef="ief9e8a3ae25b43aeb183d65978160f05_D20210101-20210930" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182NC9mcmFnOjA2NTZiZmUyZmE0ZDQwN2JiYjYwOTZhMDdiNGZmMjQyL3RleHRyZWdpb246MDY1NmJmZTJmYTRkNDA3YmJiNjA5NmEwN2I0ZmYyNDJfMTI3Mg_8217558d-cfe5-4ed0-97d9-29170073ac10">four years</ix:nonNumeric> either on the anniversary of the date on which the RSUs were granted or during the month in which such anniversary dates occur. The number of RSUs awarded to certain employees may be increased or reduced based on certain additional performance metrics. Options and RSUs granted to non-employee directors vest in full upon completion of <ix:nonNumeric contextRef="i69bf2abe7da64ff79bc46cba39640e19_D20210101-20210930" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182NC9mcmFnOjA2NTZiZmUyZmE0ZDQwN2JiYjYwOTZhMDdiNGZmMjQyL3RleHRyZWdpb246MDY1NmJmZTJmYTRkNDA3YmJiNjA5NmEwN2I0ZmYyNDJfMTYxMQ_9cb7ec49-fda8-4a52-bdf7-308fd9eb49b8">one year</ix:nonNumeric> of service on the anniversary following the date of the grant. Options generally vest ratably over service periods of <ix:nonNumeric contextRef="i92c8275b0ba847e78c2cd5b91dd57e8c_D20210101-20210930" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182NC9mcmFnOjA2NTZiZmUyZmE0ZDQwN2JiYjYwOTZhMDdiNGZmMjQyL3RleHRyZWdpb246MDY1NmJmZTJmYTRkNDA3YmJiNjA5NmEwN2I0ZmYyNDJfMTczMg_0cc61b3e-0bfa-46c6-93fc-0f2b67e9a211">four years</ix:nonNumeric>.&#160;Options granted after December 5, 2012 expire <ix:nonNumeric contextRef="i965028ac5b28491f8ce013eceafc3791_D20210101-20210930" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182NC9mcmFnOjA2NTZiZmUyZmE0ZDQwN2JiYjYwOTZhMDdiNGZmMjQyL3RleHRyZWdpb246MDY1NmJmZTJmYTRkNDA3YmJiNjA5NmEwN2I0ZmYyNDJfMTc4Mg_d5fa16cb-1d68-4c31-9568-b6b0f84cfc9c">eight years</ix:nonNumeric> from the date of grant, and options granted prior to that date generally expire <ix:nonNumeric contextRef="i8d8d18090245443bb8fcbbabba18bd99_D20210101-20210930" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182NC9mcmFnOjA2NTZiZmUyZmE0ZDQwN2JiYjYwOTZhMDdiNGZmMjQyL3RleHRyZWdpb246MDY1NmJmZTJmYTRkNDA3YmJiNjA5NmEwN2I0ZmYyNDJfMTg2NQ_ecd14376-ef91-4d3b-abb3-b33bf7286d4b">ten years</ix:nonNumeric> from the date of grant. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options</span></div><ix:nonNumeric contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182NC9mcmFnOjA2NTZiZmUyZmE0ZDQwN2JiYjYwOTZhMDdiNGZmMjQyL3RleHRyZWdpb246MDY1NmJmZTJmYTRkNDA3YmJiNjA5NmEwN2I0ZmYyNDJfMzE4Mw_93a84a01-d64d-44cb-854e-3f4de4bc2927" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the stock option activity under the Company&#8217;s equity plans and inducement awards, for the nine months ended September&#160;30, 2021 is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(number of shares in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number<br/>of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>Average<br/>Exercise<br/>Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182NC9mcmFnOjA2NTZiZmUyZmE0ZDQwN2JiYjYwOTZhMDdiNGZmMjQyL3RhYmxlOjQyOGMzZjlmMzI0YzQ2N2NhMjhlNzk2MmNmMGViNjVkL3RhYmxlcmFuZ2U6NDI4YzNmOWYzMjRjNDY3Y2EyOGU3OTYyY2YwZWI2NWRfMS0xLTEtMS0xODE2NA_dd4e4997-0885-4d6b-896a-5e09d500774d">5.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182NC9mcmFnOjA2NTZiZmUyZmE0ZDQwN2JiYjYwOTZhMDdiNGZmMjQyL3RhYmxlOjQyOGMzZjlmMzI0YzQ2N2NhMjhlNzk2MmNmMGViNjVkL3RhYmxlcmFuZ2U6NDI4YzNmOWYzMjRjNDY3Y2EyOGU3OTYyY2YwZWI2NWRfMS0zLTEtMS0xODE2NA_cda0044a-c972-4f8b-951d-07d7a1f4d4b8">23.24</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182NC9mcmFnOjA2NTZiZmUyZmE0ZDQwN2JiYjYwOTZhMDdiNGZmMjQyL3RhYmxlOjQyOGMzZjlmMzI0YzQ2N2NhMjhlNzk2MmNmMGViNjVkL3RhYmxlcmFuZ2U6NDI4YzNmOWYzMjRjNDY3Y2EyOGU3OTYyY2YwZWI2NWRfMi0xLTEtMS0xODE2NA_12e57be3-c35b-4409-9fcf-97372181cd7c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" decimals="2" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182NC9mcmFnOjA2NTZiZmUyZmE0ZDQwN2JiYjYwOTZhMDdiNGZmMjQyL3RhYmxlOjQyOGMzZjlmMzI0YzQ2N2NhMjhlNzk2MmNmMGViNjVkL3RhYmxlcmFuZ2U6NDI4YzNmOWYzMjRjNDY3Y2EyOGU3OTYyY2YwZWI2NWRfMi0zLTEtMS0xODE2NA_fb53e611-afe6-43bb-b3d5-0a4ff2602134">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options exercised</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182NC9mcmFnOjA2NTZiZmUyZmE0ZDQwN2JiYjYwOTZhMDdiNGZmMjQyL3RhYmxlOjQyOGMzZjlmMzI0YzQ2N2NhMjhlNzk2MmNmMGViNjVkL3RhYmxlcmFuZ2U6NDI4YzNmOWYzMjRjNDY3Y2EyOGU3OTYyY2YwZWI2NWRfNC0xLTEtMS0xODE2NA_9895cbdd-1e37-4ea8-8a1e-264ac31ea18c">3.6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182NC9mcmFnOjA2NTZiZmUyZmE0ZDQwN2JiYjYwOTZhMDdiNGZmMjQyL3RhYmxlOjQyOGMzZjlmMzI0YzQ2N2NhMjhlNzk2MmNmMGViNjVkL3RhYmxlcmFuZ2U6NDI4YzNmOWYzMjRjNDY3Y2EyOGU3OTYyY2YwZWI2NWRfNC0zLTEtMS0xODE2NA_6c0301e1-5b49-46a1-9cc6-26c8c6dd1456">24.26</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options canceled or expired</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182NC9mcmFnOjA2NTZiZmUyZmE0ZDQwN2JiYjYwOTZhMDdiNGZmMjQyL3RhYmxlOjQyOGMzZjlmMzI0YzQ2N2NhMjhlNzk2MmNmMGViNjVkL3RhYmxlcmFuZ2U6NDI4YzNmOWYzMjRjNDY3Y2EyOGU3OTYyY2YwZWI2NWRfNS0xLTEtMS0xODE2NA_dd42736a-17a4-42ab-83a2-12e61d1adfe0">0.1</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182NC9mcmFnOjA2NTZiZmUyZmE0ZDQwN2JiYjYwOTZhMDdiNGZmMjQyL3RhYmxlOjQyOGMzZjlmMzI0YzQ2N2NhMjhlNzk2MmNmMGViNjVkL3RhYmxlcmFuZ2U6NDI4YzNmOWYzMjRjNDY3Y2EyOGU3OTYyY2YwZWI2NWRfNS0zLTEtMS0xODE2NA_a78ac584-2938-4b40-90c6-f697e879aa96">25.03</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options outstanding at September 30, 2021</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182NC9mcmFnOjA2NTZiZmUyZmE0ZDQwN2JiYjYwOTZhMDdiNGZmMjQyL3RhYmxlOjQyOGMzZjlmMzI0YzQ2N2NhMjhlNzk2MmNmMGViNjVkL3RhYmxlcmFuZ2U6NDI4YzNmOWYzMjRjNDY3Y2EyOGU3OTYyY2YwZWI2NWRfNi0xLTEtMS0xODE2NA_bbd346c2-7f6c-46be-ac63-7805d200afa6">1.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182NC9mcmFnOjA2NTZiZmUyZmE0ZDQwN2JiYjYwOTZhMDdiNGZmMjQyL3RhYmxlOjQyOGMzZjlmMzI0YzQ2N2NhMjhlNzk2MmNmMGViNjVkL3RhYmxlcmFuZ2U6NDI4YzNmOWYzMjRjNDY3Y2EyOGU3OTYyY2YwZWI2NWRfNi0zLTEtMS0xODE2NA_baaf66e5-9b4c-4ebc-9bd2-13f9af4710e7">20.57</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options exercisable at September 30, 2021</span></td><td colspan="2" style="background-color:#cff0fc;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182NC9mcmFnOjA2NTZiZmUyZmE0ZDQwN2JiYjYwOTZhMDdiNGZmMjQyL3RhYmxlOjQyOGMzZjlmMzI0YzQ2N2NhMjhlNzk2MmNmMGViNjVkL3RhYmxlcmFuZ2U6NDI4YzNmOWYzMjRjNDY3Y2EyOGU3OTYyY2YwZWI2NWRfNy0xLTEtMS0xODE2NA_028ce7e8-e3ef-4eb0-a261-ecbc9c715e0f">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182NC9mcmFnOjA2NTZiZmUyZmE0ZDQwN2JiYjYwOTZhMDdiNGZmMjQyL3RhYmxlOjQyOGMzZjlmMzI0YzQ2N2NhMjhlNzk2MmNmMGViNjVkL3RhYmxlcmFuZ2U6NDI4YzNmOWYzMjRjNDY3Y2EyOGU3OTYyY2YwZWI2NWRfNy0zLTEtMS0xODE2NA_8c4d525e-f295-4390-b0cb-df661288f9c8">23.20</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5814a71962934792901cb2330361bb17_7">Table of Contents</a></span></div></div><ix:continuation id="ib1d68f39607d43d8bdac77b49784bddf"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021, there was $<ix:nonFraction unitRef="usd" contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182NC9mcmFnOjA2NTZiZmUyZmE0ZDQwN2JiYjYwOTZhMDdiNGZmMjQyL3RleHRyZWdpb246MDY1NmJmZTJmYTRkNDA3YmJiNjA5NmEwN2I0ZmYyNDJfMjA2OA_a838efeb-ba0d-430b-8e1f-a7b257528495">2.6</ix:nonFraction> million of total unrecognized stock-based compensation expense related to stock options that will be recognized over a weighted-average period of <ix:nonNumeric contextRef="i92c8275b0ba847e78c2cd5b91dd57e8c_D20210101-20210930" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182NC9mcmFnOjA2NTZiZmUyZmE0ZDQwN2JiYjYwOTZhMDdiNGZmMjQyL3RleHRyZWdpb246MDY1NmJmZTJmYTRkNDA3YmJiNjA5NmEwN2I0ZmYyNDJfMjIwOQ_c1d8d2eb-b594-483f-beb8-262b0ba01307">2.3</ix:nonNumeric> years. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Units</span></div><ix:nonNumeric contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182NC9mcmFnOjA2NTZiZmUyZmE0ZDQwN2JiYjYwOTZhMDdiNGZmMjQyL3RleHRyZWdpb246MDY1NmJmZTJmYTRkNDA3YmJiNjA5NmEwN2I0ZmYyNDJfMzE4Mg_853fa1db-57b5-4ff9-b5c4-a77fb83d1f40" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the RSU activity under the Company&#8217;s equity plans and inducement awards, including RSU awards with performance metrics, for the nine months ended September&#160;30, 2021 is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(number of shares in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number<br/>of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>Average<br/>Grant Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i4801dc9ebc814bf4a4e7c0b3d186670f_I20201231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182NC9mcmFnOjA2NTZiZmUyZmE0ZDQwN2JiYjYwOTZhMDdiNGZmMjQyL3RhYmxlOmE1Y2Q3N2Q2ODdmNTRlNDlhOTA3MmVhY2Q0NTY4ZmRkL3RhYmxlcmFuZ2U6YTVjZDc3ZDY4N2Y1NGU0OWE5MDcyZWFjZDQ1NjhmZGRfMS0xLTEtMS0xODE2NA_1e9993e5-147c-4ba2-847b-1a2748e95689">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4801dc9ebc814bf4a4e7c0b3d186670f_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182NC9mcmFnOjA2NTZiZmUyZmE0ZDQwN2JiYjYwOTZhMDdiNGZmMjQyL3RhYmxlOmE1Y2Q3N2Q2ODdmNTRlNDlhOTA3MmVhY2Q0NTY4ZmRkL3RhYmxlcmFuZ2U6YTVjZDc3ZDY4N2Y1NGU0OWE5MDcyZWFjZDQ1NjhmZGRfMS0zLTEtMS0xODE2NA_42026c93-1e3a-4993-9681-6bf36a0ee07f">20.56</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ief9e8a3ae25b43aeb183d65978160f05_D20210101-20210930" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182NC9mcmFnOjA2NTZiZmUyZmE0ZDQwN2JiYjYwOTZhMDdiNGZmMjQyL3RhYmxlOmE1Y2Q3N2Q2ODdmNTRlNDlhOTA3MmVhY2Q0NTY4ZmRkL3RhYmxlcmFuZ2U6YTVjZDc3ZDY4N2Y1NGU0OWE5MDcyZWFjZDQ1NjhmZGRfMi0xLTEtMS0xODE2NA_8d60ff2f-a541-4bb3-a32b-3db626d70728">1.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="ief9e8a3ae25b43aeb183d65978160f05_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182NC9mcmFnOjA2NTZiZmUyZmE0ZDQwN2JiYjYwOTZhMDdiNGZmMjQyL3RhYmxlOmE1Y2Q3N2Q2ODdmNTRlNDlhOTA3MmVhY2Q0NTY4ZmRkL3RhYmxlcmFuZ2U6YTVjZDc3ZDY4N2Y1NGU0OWE5MDcyZWFjZDQ1NjhmZGRfMi0zLTEtMS0xODE2NA_370f522a-480b-4123-aa74-3ec836739cff">29.95</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs vested</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="ief9e8a3ae25b43aeb183d65978160f05_D20210101-20210930" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182NC9mcmFnOjA2NTZiZmUyZmE0ZDQwN2JiYjYwOTZhMDdiNGZmMjQyL3RhYmxlOmE1Y2Q3N2Q2ODdmNTRlNDlhOTA3MmVhY2Q0NTY4ZmRkL3RhYmxlcmFuZ2U6YTVjZDc3ZDY4N2Y1NGU0OWE5MDcyZWFjZDQ1NjhmZGRfNC0xLTEtMS0xODE2NA_6d674fb9-ae2f-4a3d-9bb4-df6b2e915208">0.8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="ief9e8a3ae25b43aeb183d65978160f05_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182NC9mcmFnOjA2NTZiZmUyZmE0ZDQwN2JiYjYwOTZhMDdiNGZmMjQyL3RhYmxlOmE1Y2Q3N2Q2ODdmNTRlNDlhOTA3MmVhY2Q0NTY4ZmRkL3RhYmxlcmFuZ2U6YTVjZDc3ZDY4N2Y1NGU0OWE5MDcyZWFjZDQ1NjhmZGRfNC0zLTEtMS0xODE2NA_6832e15d-0e70-48a2-b842-ae979bc71ebe">24.00</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs canceled</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="ief9e8a3ae25b43aeb183d65978160f05_D20210101-20210930" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182NC9mcmFnOjA2NTZiZmUyZmE0ZDQwN2JiYjYwOTZhMDdiNGZmMjQyL3RhYmxlOmE1Y2Q3N2Q2ODdmNTRlNDlhOTA3MmVhY2Q0NTY4ZmRkL3RhYmxlcmFuZ2U6YTVjZDc3ZDY4N2Y1NGU0OWE5MDcyZWFjZDQ1NjhmZGRfNS0xLTEtMS0xODE2NA_1d3d765f-2480-40c2-95b1-96f110458d22">0.7</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="ief9e8a3ae25b43aeb183d65978160f05_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182NC9mcmFnOjA2NTZiZmUyZmE0ZDQwN2JiYjYwOTZhMDdiNGZmMjQyL3RhYmxlOmE1Y2Q3N2Q2ODdmNTRlNDlhOTA3MmVhY2Q0NTY4ZmRkL3RhYmxlcmFuZ2U6YTVjZDc3ZDY4N2Y1NGU0OWE5MDcyZWFjZDQ1NjhmZGRfNS0zLTEtMS0xODE2NA_4c035a61-8c9c-4aac-86e0-646f3f1051b0">24.63</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs outstanding at September 30, 2021</span></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i82ee8762af6f49b6830a17198018205b_I20210930" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182NC9mcmFnOjA2NTZiZmUyZmE0ZDQwN2JiYjYwOTZhMDdiNGZmMjQyL3RhYmxlOmE1Y2Q3N2Q2ODdmNTRlNDlhOTA3MmVhY2Q0NTY4ZmRkL3RhYmxlcmFuZ2U6YTVjZDc3ZDY4N2Y1NGU0OWE5MDcyZWFjZDQ1NjhmZGRfNi0xLTEtMS0xODE2NA_ea2522f5-9ee5-4e31-bb99-3e29d73f9c35">3.4</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i82ee8762af6f49b6830a17198018205b_I20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182NC9mcmFnOjA2NTZiZmUyZmE0ZDQwN2JiYjYwOTZhMDdiNGZmMjQyL3RhYmxlOmE1Y2Q3N2Q2ODdmNTRlNDlhOTA3MmVhY2Q0NTY4ZmRkL3RhYmxlcmFuZ2U6YTVjZDc3ZDY4N2Y1NGU0OWE5MDcyZWFjZDQ1NjhmZGRfNi0zLTEtMS0xODE2NA_d0071ffe-85e7-4be4-9918-a4fb8f43afc0">23.91</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021, there was $<ix:nonFraction unitRef="usd" contextRef="i82ee8762af6f49b6830a17198018205b_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182NC9mcmFnOjA2NTZiZmUyZmE0ZDQwN2JiYjYwOTZhMDdiNGZmMjQyL3RleHRyZWdpb246MDY1NmJmZTJmYTRkNDA3YmJiNjA5NmEwN2I0ZmYyNDJfMjQzNA_089e8fd8-3607-4562-85a4-e149fd914f41">68.2</ix:nonFraction> million of total unrecognized stock-based compensation expense related to RSUs that will be recognized over a </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">weighted-average period of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="ief9e8a3ae25b43aeb183d65978160f05_D20210101-20210930" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182NC9mcmFnOjA2NTZiZmUyZmE0ZDQwN2JiYjYwOTZhMDdiNGZmMjQyL3RleHRyZWdpb246MDY1NmJmZTJmYTRkNDA3YmJiNjA5NmEwN2I0ZmYyNDJfMjU2Ng_353a5e18-6c51-4227-948b-3bafdf4361da">2.6</ix:nonNumeric> years.&#160;</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also has an Employee Stock Purchase Plan that was approved by stockholders in 2012 (the &#8220;2012 Purchase Plan&#8221;), under which <ix:nonFraction unitRef="shares" contextRef="i8bcfc26140eb424887a7993eb83c6035_I20121231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182NC9mcmFnOjA2NTZiZmUyZmE0ZDQwN2JiYjYwOTZhMDdiNGZmMjQyL3RleHRyZWdpb246MDY1NmJmZTJmYTRkNDA3YmJiNjA5NmEwN2I0ZmYyNDJfMjczNQ_4418e70a-ada6-4617-bec8-9b79f966a5f0">2.0</ix:nonFraction> million shares of common stock have been authorized.&#160;&#160;On September 23, 2021, the Board of Directors of the Company approved an amended and restated 2012 Employee Stock Purchase Plan, which authorizes an additional <ix:nonFraction unitRef="shares" contextRef="ib0ff30ba23574507a2d7f464c815dfac_D20210923-20210923" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182NC9mcmFnOjA2NTZiZmUyZmE0ZDQwN2JiYjYwOTZhMDdiNGZmMjQyL3RleHRyZWdpb246MDY1NmJmZTJmYTRkNDA3YmJiNjA5NmEwN2I0ZmYyNDJfMjc0ODc3OTA3NDgzNQ_e38f8624-ca08-4ecc-82b6-0d1e1da0a9a9">2.0</ix:nonFraction>&#160;million shares of common stock and extends the term of the 2012 Purchase Plan to November 30, 2032, subject in each case to obtaining stockholder approval. The amended and restated 2012 Employee Stock Purchase Plan also amended certain provisions of the 2012 Purchase Plan effective upon approval by the Board of Directors, including expanding the definition of "offering period" to provide that the Board of Directors may determine the period in accordance with the terms of the plan, and capping the number of shares that may be purchased by any participant during an offering period at <ix:nonFraction unitRef="shares" contextRef="ib0ff30ba23574507a2d7f464c815dfac_D20210923-20210923" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182NC9mcmFnOjA2NTZiZmUyZmE0ZDQwN2JiYjYwOTZhMDdiNGZmMjQyL3RleHRyZWdpb246MDY1NmJmZTJmYTRkNDA3YmJiNjA5NmEwN2I0ZmYyNDJfMjc0ODc3OTA3NDgyOA_32687a6d-8b3e-40c0-8782-b3985b15d0e8">5,000</ix:nonFraction> shares. Shares are issued under the 2012 Purchase Plan twice yearly at the end of each offering period.&#160;&#160;As of September&#160;30, 2021, approximately <ix:nonFraction unitRef="shares" contextRef="i2c1a3b837ee04e2c812eb8cbc112adaf_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182NC9mcmFnOjA2NTZiZmUyZmE0ZDQwN2JiYjYwOTZhMDdiNGZmMjQyL3RleHRyZWdpb246MDY1NmJmZTJmYTRkNDA3YmJiNjA5NmEwN2I0ZmYyNDJfMjkwNQ_773e8728-dc30-490a-9f91-e0463090f8d7">0.1</ix:nonFraction> million shares of common stock are available for issuance under the 2012 Purchase Plan.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-Based Compensation Expense</span></div><ix:nonNumeric contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182NC9mcmFnOjA2NTZiZmUyZmE0ZDQwN2JiYjYwOTZhMDdiNGZmMjQyL3RleHRyZWdpb246MDY1NmJmZTJmYTRkNDA3YmJiNjA5NmEwN2I0ZmYyNDJfMzE4NA_9236fd89-510d-4d39-be5d-bd880f5a00b3" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense recognized and included in the Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) was allocated as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.603%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine months ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of molecular diagnostic testing</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie53d91b4b6c74e609ea917eadc9521fb_D20210701-20210930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182NC9mcmFnOjA2NTZiZmUyZmE0ZDQwN2JiYjYwOTZhMDdiNGZmMjQyL3RhYmxlOmRmODRkMTkwMTYyMzRmNWU5MGUwYWJlNmE0MTQ0YzI2L3RhYmxlcmFuZ2U6ZGY4NGQxOTAxNjIzNGY1ZTkwZTBhYmU2YTQxNDRjMjZfMi0xLTEtMS0xODE2NA_978a674e-3307-4573-ba20-61f039d6b8b4">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib0b0e187d88d4a79a51af53f0c258395_D20200701-20200930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182NC9mcmFnOjA2NTZiZmUyZmE0ZDQwN2JiYjYwOTZhMDdiNGZmMjQyL3RhYmxlOmRmODRkMTkwMTYyMzRmNWU5MGUwYWJlNmE0MTQ0YzI2L3RhYmxlcmFuZ2U6ZGY4NGQxOTAxNjIzNGY1ZTkwZTBhYmU2YTQxNDRjMjZfMi0zLTEtMS0xODE2NA_868b15fd-3f8b-4429-abe2-dfd18b1ef92b">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i15b426ffab40406b9ce00055e4e71cc7_D20210101-20210930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182NC9mcmFnOjA2NTZiZmUyZmE0ZDQwN2JiYjYwOTZhMDdiNGZmMjQyL3RhYmxlOmRmODRkMTkwMTYyMzRmNWU5MGUwYWJlNmE0MTQ0YzI2L3RhYmxlcmFuZ2U6ZGY4NGQxOTAxNjIzNGY1ZTkwZTBhYmU2YTQxNDRjMjZfMi01LTEtMS0xODE2NA_87cfd5cd-8324-45ce-94ad-d23c77a91dec">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i10453dc072584904908a86492c478db1_D20200101-20200930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182NC9mcmFnOjA2NTZiZmUyZmE0ZDQwN2JiYjYwOTZhMDdiNGZmMjQyL3RhYmxlOmRmODRkMTkwMTYyMzRmNWU5MGUwYWJlNmE0MTQ0YzI2L3RhYmxlcmFuZ2U6ZGY4NGQxOTAxNjIzNGY1ZTkwZTBhYmU2YTQxNDRjMjZfMi03LTEtMS0xODE2NA_9b3219b4-b62f-4572-abbd-769e9b1d22eb">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of pharmaceutical and clinical services</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib8134e30745e401f875787e150c90a29_D20210701-20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182NC9mcmFnOjA2NTZiZmUyZmE0ZDQwN2JiYjYwOTZhMDdiNGZmMjQyL3RhYmxlOmRmODRkMTkwMTYyMzRmNWU5MGUwYWJlNmE0MTQ0YzI2L3RhYmxlcmFuZ2U6ZGY4NGQxOTAxNjIzNGY1ZTkwZTBhYmU2YTQxNDRjMjZfMy0xLTEtMS0xODE2NA_cad2593a-86c3-487e-b98b-c97068504fa6">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0a4213b0025742348a551e459281952a_D20200701-20200930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182NC9mcmFnOjA2NTZiZmUyZmE0ZDQwN2JiYjYwOTZhMDdiNGZmMjQyL3RhYmxlOmRmODRkMTkwMTYyMzRmNWU5MGUwYWJlNmE0MTQ0YzI2L3RhYmxlcmFuZ2U6ZGY4NGQxOTAxNjIzNGY1ZTkwZTBhYmU2YTQxNDRjMjZfMy0zLTEtMS0xODE2NA_3bf95fcd-cd19-4d9f-bb7d-599e4b7322f2">0.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i96d4380fb0a44bda931ad908ae56cd15_D20210101-20210930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182NC9mcmFnOjA2NTZiZmUyZmE0ZDQwN2JiYjYwOTZhMDdiNGZmMjQyL3RhYmxlOmRmODRkMTkwMTYyMzRmNWU5MGUwYWJlNmE0MTQ0YzI2L3RhYmxlcmFuZ2U6ZGY4NGQxOTAxNjIzNGY1ZTkwZTBhYmU2YTQxNDRjMjZfMy01LTEtMS0xODE2NA_9e61a76b-6847-437a-80d3-4c1ba30dd1c2">0.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if45947be73124386a5d96c5f812ce163_D20200101-20200930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182NC9mcmFnOjA2NTZiZmUyZmE0ZDQwN2JiYjYwOTZhMDdiNGZmMjQyL3RhYmxlOmRmODRkMTkwMTYyMzRmNWU5MGUwYWJlNmE0MTQ0YzI2L3RhYmxlcmFuZ2U6ZGY4NGQxOTAxNjIzNGY1ZTkwZTBhYmU2YTQxNDRjMjZfMy03LTEtMS0xODE2NA_a0fedae0-eb79-45aa-adc7-61e04d849a8e">0.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7b57125252b04e19a0ab135ecb14306e_D20210701-20210930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182NC9mcmFnOjA2NTZiZmUyZmE0ZDQwN2JiYjYwOTZhMDdiNGZmMjQyL3RhYmxlOmRmODRkMTkwMTYyMzRmNWU5MGUwYWJlNmE0MTQ0YzI2L3RhYmxlcmFuZ2U6ZGY4NGQxOTAxNjIzNGY1ZTkwZTBhYmU2YTQxNDRjMjZfNC0xLTEtMS0xODE2NA_2e6287c2-38a2-4be7-860b-8762bf9fbdf3">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i74a661b5521240d6b08faf29ed4cca5f_D20200701-20200930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182NC9mcmFnOjA2NTZiZmUyZmE0ZDQwN2JiYjYwOTZhMDdiNGZmMjQyL3RhYmxlOmRmODRkMTkwMTYyMzRmNWU5MGUwYWJlNmE0MTQ0YzI2L3RhYmxlcmFuZ2U6ZGY4NGQxOTAxNjIzNGY1ZTkwZTBhYmU2YTQxNDRjMjZfNC0zLTEtMS0xODE2NA_aae8fb1b-5fa6-4804-b328-407386885d20">1.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic1e22d907e804cb3a166674ed56d1159_D20210101-20210930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182NC9mcmFnOjA2NTZiZmUyZmE0ZDQwN2JiYjYwOTZhMDdiNGZmMjQyL3RhYmxlOmRmODRkMTkwMTYyMzRmNWU5MGUwYWJlNmE0MTQ0YzI2L3RhYmxlcmFuZ2U6ZGY4NGQxOTAxNjIzNGY1ZTkwZTBhYmU2YTQxNDRjMjZfNC01LTEtMS0xODE2NA_33749454-d032-4ca6-895e-7e186855d05a">3.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iaa209599dfc04850bdd9bb0c340449ec_D20200101-20200930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182NC9mcmFnOjA2NTZiZmUyZmE0ZDQwN2JiYjYwOTZhMDdiNGZmMjQyL3RhYmxlOmRmODRkMTkwMTYyMzRmNWU5MGUwYWJlNmE0MTQ0YzI2L3RhYmxlcmFuZ2U6ZGY4NGQxOTAxNjIzNGY1ZTkwZTBhYmU2YTQxNDRjMjZfNC03LTEtMS0xODE2NA_a9ac4fe5-6b3b-4a54-b350-7a3f94eee300">3.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general, and administrative expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4fba22e0d9a14b43ae418e9b7737a767_D20210701-20210930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182NC9mcmFnOjA2NTZiZmUyZmE0ZDQwN2JiYjYwOTZhMDdiNGZmMjQyL3RhYmxlOmRmODRkMTkwMTYyMzRmNWU5MGUwYWJlNmE0MTQ0YzI2L3RhYmxlcmFuZ2U6ZGY4NGQxOTAxNjIzNGY1ZTkwZTBhYmU2YTQxNDRjMjZfNS0xLTEtMS0xODE2NA_f6aa6b7c-82e7-4d4d-be99-e5357ff88816">8.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8738e02b8c234e90be4290e058314e09_D20200701-20200930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182NC9mcmFnOjA2NTZiZmUyZmE0ZDQwN2JiYjYwOTZhMDdiNGZmMjQyL3RhYmxlOmRmODRkMTkwMTYyMzRmNWU5MGUwYWJlNmE0MTQ0YzI2L3RhYmxlcmFuZ2U6ZGY4NGQxOTAxNjIzNGY1ZTkwZTBhYmU2YTQxNDRjMjZfNS0zLTEtMS0xODE2NA_c3a18af6-a658-49e7-944d-80e27d079b2e">6.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4b061eccb63f4b98914dd480e34a8f10_D20210101-20210930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182NC9mcmFnOjA2NTZiZmUyZmE0ZDQwN2JiYjYwOTZhMDdiNGZmMjQyL3RhYmxlOmRmODRkMTkwMTYyMzRmNWU5MGUwYWJlNmE0MTQ0YzI2L3RhYmxlcmFuZ2U6ZGY4NGQxOTAxNjIzNGY1ZTkwZTBhYmU2YTQxNDRjMjZfNS01LTEtMS0xODE2NA_b462d707-5a9d-4fda-a3ab-e732b6557f88">23.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib580291452e04f9790478ef2b24b14d7_D20200101-20200930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182NC9mcmFnOjA2NTZiZmUyZmE0ZDQwN2JiYjYwOTZhMDdiNGZmMjQyL3RhYmxlOmRmODRkMTkwMTYyMzRmNWU5MGUwYWJlNmE0MTQ0YzI2L3RhYmxlcmFuZ2U6ZGY4NGQxOTAxNjIzNGY1ZTkwZTBhYmU2YTQxNDRjMjZfNS03LTEtMS0xODE2NA_1f153604-b44a-4b6f-8b9d-8bfb62f9f27d">12.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total stock-based compensation expense</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182NC9mcmFnOjA2NTZiZmUyZmE0ZDQwN2JiYjYwOTZhMDdiNGZmMjQyL3RhYmxlOmRmODRkMTkwMTYyMzRmNWU5MGUwYWJlNmE0MTQ0YzI2L3RhYmxlcmFuZ2U6ZGY4NGQxOTAxNjIzNGY1ZTkwZTBhYmU2YTQxNDRjMjZfNi0xLTEtMS0xODE2NA_bd603638-1a51-476e-8fed-72f771fa6a13">10.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic2c3e03438af4889ac973627c642f5ec_D20200701-20200930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182NC9mcmFnOjA2NTZiZmUyZmE0ZDQwN2JiYjYwOTZhMDdiNGZmMjQyL3RhYmxlOmRmODRkMTkwMTYyMzRmNWU5MGUwYWJlNmE0MTQ0YzI2L3RhYmxlcmFuZ2U6ZGY4NGQxOTAxNjIzNGY1ZTkwZTBhYmU2YTQxNDRjMjZfNi0zLTEtMS0xODE2NA_23ab6d21-74f2-47a8-923d-a8d5cd995701">8.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182NC9mcmFnOjA2NTZiZmUyZmE0ZDQwN2JiYjYwOTZhMDdiNGZmMjQyL3RhYmxlOmRmODRkMTkwMTYyMzRmNWU5MGUwYWJlNmE0MTQ0YzI2L3RhYmxlcmFuZ2U6ZGY4NGQxOTAxNjIzNGY1ZTkwZTBhYmU2YTQxNDRjMjZfNi01LTEtMS0xODE2NA_4f068073-d89f-4f6a-a968-a7f21395f22d">27.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182NC9mcmFnOjA2NTZiZmUyZmE0ZDQwN2JiYjYwOTZhMDdiNGZmMjQyL3RhYmxlOmRmODRkMTkwMTYyMzRmNWU5MGUwYWJlNmE0MTQ0YzI2L3RhYmxlcmFuZ2U6ZGY4NGQxOTAxNjIzNGY1ZTkwZTBhYmU2YTQxNDRjMjZfNi03LTEtMS0xODE2NA_07e54dca-1479-4084-b954-8a5521cdfa57">17.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i5814a71962934792901cb2330361bb17_67"></div><div style="margin-top:18pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182Ny9mcmFnOjUyY2IyYmViNTUwYTQzODU4NDk3M2U2MmY4NTAwN2Q3L3RleHRyZWdpb246NTJjYjJiZWI1NTBhNDM4NTg0OTczZTYyZjg1MDA3ZDdfMTkyMg_cb49989f-28a5-4597-b319-650d069369f0" continuedAt="i3f2c3b4b36f243a4ad04f54bf95e5a66" escape="true">INCOME TAXES </ix:nonNumeric></span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i3f2c3b4b36f243a4ad04f54bf95e5a66" continuedAt="if3bc8a3ca66546599bddf3467381d068">In order to determine the Company&#8217;s quarterly provision for income taxes, the Company used an estimated annual effective tax rate that is based on expected annual income and statutory tax rates in the various jurisdictions in which the Company operates.&#160;Certain significant or unusual items are separately recognized in the quarter during which they occur and can be a source of variability in the effective tax rate from quarter to quarter.</ix:continuation></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5814a71962934792901cb2330361bb17_7">Table of Contents</a></span></div></div><ix:continuation id="if3bc8a3ca66546599bddf3467381d068"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax expense for the three months ended September&#160;30, 2021 was $<ix:nonFraction unitRef="usd" contextRef="ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182Ny9mcmFnOjUyY2IyYmViNTUwYTQzODU4NDk3M2U2MmY4NTAwN2Q3L3RleHRyZWdpb246NTJjYjJiZWI1NTBhNDM4NTg0OTczZTYyZjg1MDA3ZDdfNTEz_e836bcd3-807d-4b54-a509-624c0b229238">15.2</ix:nonFraction> million, or approximately <ix:nonFraction unitRef="number" contextRef="ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182Ny9mcmFnOjUyY2IyYmViNTUwYTQzODU4NDk3M2U2MmY4NTAwN2Q3L3RleHRyZWdpb246NTJjYjJiZWI1NTBhNDM4NTg0OTczZTYyZjg1MDA3ZDdfNTM0_d9a3997c-a09e-414d-b4c0-23c3647becd5">38.2</ix:nonFraction>% of pre-tax income compared to an income tax benefit of $<ix:nonFraction unitRef="usd" contextRef="ic2c3e03438af4889ac973627c642f5ec_D20200701-20200930" decimals="-5" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182Ny9mcmFnOjUyY2IyYmViNTUwYTQzODU4NDk3M2U2MmY4NTAwN2Q3L3RleHRyZWdpb246NTJjYjJiZWI1NTBhNDM4NTg0OTczZTYyZjg1MDA3ZDdfNTkw_d339a33a-6267-401c-b98f-9d7dd7f3528b">28.5</ix:nonFraction> million, or approximately <ix:nonFraction unitRef="number" contextRef="ic2c3e03438af4889ac973627c642f5ec_D20200701-20200930" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182Ny9mcmFnOjUyY2IyYmViNTUwYTQzODU4NDk3M2U2MmY4NTAwN2Q3L3RleHRyZWdpb246NTJjYjJiZWI1NTBhNDM4NTg0OTczZTYyZjg1MDA3ZDdfNjEx_adfb89a3-0059-44c9-9f01-66ab5a789c44">65.2</ix:nonFraction>% of pre-tax loss, for the three months ended September&#160;30, 2020.&#160;Income tax expense for the nine months ended September&#160;30, 2021 was $<ix:nonFraction unitRef="usd" contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182Ny9mcmFnOjUyY2IyYmViNTUwYTQzODU4NDk3M2U2MmY4NTAwN2Q3L3RleHRyZWdpb246NTJjYjJiZWI1NTBhNDM4NTg0OTczZTYyZjg1MDA3ZDdfMTA5OTUxMTYyOTk2Ng_edaed20a-2b00-47b9-a6c2-87d4869987bb">6.0</ix:nonFraction> million, or approximately (<ix:nonFraction unitRef="number" contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182Ny9mcmFnOjUyY2IyYmViNTUwYTQzODU4NDk3M2U2MmY4NTAwN2Q3L3RleHRyZWdpb246NTJjYjJiZWI1NTBhNDM4NTg0OTczZTYyZjg1MDA3ZDdfMTA5OTUxMTYyOTk3MA_077490a5-bed8-492b-91d1-e80fe0e843f4">44.1</ix:nonFraction>)% of pre-tax loss compared to an income tax benefit of $<ix:nonFraction unitRef="usd" contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930" decimals="-5" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182Ny9mcmFnOjUyY2IyYmViNTUwYTQzODU4NDk3M2U2MmY4NTAwN2Q3L3RleHRyZWdpb246NTJjYjJiZWI1NTBhNDM4NTg0OTczZTYyZjg1MDA3ZDdfMTA5OTUxMTYyOTk3NA_92145c67-c164-4d8f-870d-3088dfcc32a2">47.4</ix:nonFraction> million, or approximately <ix:nonFraction unitRef="number" contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182Ny9mcmFnOjUyY2IyYmViNTUwYTQzODU4NDk3M2U2MmY4NTAwN2Q3L3RleHRyZWdpb246NTJjYjJiZWI1NTBhNDM4NTg0OTczZTYyZjg1MDA3ZDdfMTA5OTUxMTYyOTk3OA_76ef24f9-3b02-4b8a-8a7b-37f78ea46945">20.3</ix:nonFraction>% of pre-tax loss, for the nine months ended September&#160;30, 2020.&#160;&#160;&#160;Income tax expense for the three and nine months ended September&#160;30, 2021 is based on the Company&#8217;s estimated annualized effective tax rate for the fiscal year ending December 31, 2021, adjusted for discrete items recognized during the respective periods.&#160;&#160;For the three and nine months ended September&#160;30, 2021, the Company&#8217;s recognized effective tax rate differs from the U.S. federal statutory rate primarily due to disallowed executive compensation expenses, disallowed meals and entertainment expenses, stock compensation expenses, benefit recorded as a result of the CARES Act, asset impairment expenses, release of a valuation allowance, and differences between the book and tax basis of assets divested.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company files U.S., foreign and state income tax returns in jurisdictions with various statutes of limitations.&#160;&#160;The Company is currently under audit by the State of California for the fiscal years ended June 30, <ix:nonNumeric contextRef="if31d376449604749a8d84a4ea233ed1b_D20210101-20210930" name="us-gaap:IncomeTaxExaminationYearUnderExamination" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182Ny9mcmFnOjUyY2IyYmViNTUwYTQzODU4NDk3M2U2MmY4NTAwN2Q3L3RleHRyZWdpb246NTJjYjJiZWI1NTBhNDM4NTg0OTczZTYyZjg1MDA3ZDdfMTQzMg_1aaaeb24-9bc9-477b-8ba0-01f25a93efd5">2017</ix:nonNumeric>-<ix:nonNumeric contextRef="i4b90c2422e9e4d78837a3d9edef5f3aa_D20210101-20210930" name="us-gaap:IncomeTaxExaminationYearUnderExamination" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182Ny9mcmFnOjUyY2IyYmViNTUwYTQzODU4NDk3M2U2MmY4NTAwN2Q3L3RleHRyZWdpb246NTJjYjJiZWI1NTBhNDM4NTg0OTczZTYyZjg1MDA3ZDdfMTQzNQ_9275bf03-bb3f-42e3-abad-e5fc472c9c6e">2018</ix:nonNumeric>, the State of New Jersey for the fiscal years ended June 30, <ix:nonNumeric contextRef="i7c84552a53104c5d863802c21e95e8d4_D20210101-20210930" name="us-gaap:IncomeTaxExaminationYearUnderExamination" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182Ny9mcmFnOjUyY2IyYmViNTUwYTQzODU4NDk3M2U2MmY4NTAwN2Q3L3RleHRyZWdpb246NTJjYjJiZWI1NTBhNDM4NTg0OTczZTYyZjg1MDA3ZDdfMTQ5Mw_bbc8f1f5-2973-4568-ab67-20623480113f">2013</ix:nonNumeric>-<ix:nonNumeric contextRef="idab04f47fe4d4dfa8e8043a6d25016fd_D20210101-20210930" name="us-gaap:IncomeTaxExaminationYearUnderExamination" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182Ny9mcmFnOjUyY2IyYmViNTUwYTQzODU4NDk3M2U2MmY4NTAwN2Q3L3RleHRyZWdpb246NTJjYjJiZWI1NTBhNDM4NTg0OTczZTYyZjg1MDA3ZDdfMTQ5Ng_41688401-8eb6-4f7e-a5f9-ed6029f5dd19">2017</ix:nonNumeric>; Germany for the fiscal years ended June 30, <ix:nonNumeric contextRef="i1d977692ef0d4d53a4a9b42cabf5e593_D20210101-20210930" name="us-gaap:IncomeTaxExaminationYearUnderExamination" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182Ny9mcmFnOjUyY2IyYmViNTUwYTQzODU4NDk3M2U2MmY4NTAwN2Q3L3RleHRyZWdpb246NTJjYjJiZWI1NTBhNDM4NTg0OTczZTYyZjg1MDA3ZDdfMTkyMA_d0f33cc3-9be5-4053-aea1-9e7ce4177a29">2013</ix:nonNumeric>-<ix:nonNumeric contextRef="iaf68da87f99f4445b6e3aaf98ff69a2a_D20210101-20210930" name="us-gaap:IncomeTaxExaminationYearUnderExamination" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182Ny9mcmFnOjUyY2IyYmViNTUwYTQzODU4NDk3M2U2MmY4NTAwN2Q3L3RleHRyZWdpb246NTJjYjJiZWI1NTBhNDM4NTg0OTczZTYyZjg1MDA3ZDdfMTkyMQ_d6126fb0-d0d0-4818-b3f2-2969671c51a2">2015</ix:nonNumeric>; and Switzerland for the fiscal years ended June 30, <ix:nonNumeric contextRef="ib988f9d7160144ba85f9202205918ecc_D20210101-20210930" name="us-gaap:IncomeTaxExaminationYearUnderExamination" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182Ny9mcmFnOjUyY2IyYmViNTUwYTQzODU4NDk3M2U2MmY4NTAwN2Q3L3RleHRyZWdpb246NTJjYjJiZWI1NTBhNDM4NTg0OTczZTYyZjg1MDA3ZDdfMTY1NA_278b81fb-6222-4a58-ac6a-3fe1310944f3">2015</ix:nonNumeric>-<ix:nonNumeric contextRef="i84120dcedb01422a848d3618dbae3f74_D20210101-20210930" name="us-gaap:IncomeTaxExaminationYearUnderExamination" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182Ny9mcmFnOjUyY2IyYmViNTUwYTQzODU4NDk3M2U2MmY4NTAwN2Q3L3RleHRyZWdpb246NTJjYjJiZWI1NTBhNDM4NTg0OTczZTYyZjg1MDA3ZDdfMTY1Nw_5837c4b0-5e7c-4729-82d2-dfdc9d9937d0">2016</ix:nonNumeric>. Annual and interim tax provisions include amounts considered necessary to pay assessments that may result from examination of prior year tax returns; however, the amount ultimately paid upon resolution of issues may differ materially from the amount accrued.</span></div></ix:continuation><div id="i5814a71962934792901cb2330361bb17_70"></div><div style="margin-top:18pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183MC9mcmFnOjU2MWU4NTAyZDVmMjQ0MTc5YWVkYmRlY2YwNzBmMWI2L3RleHRyZWdpb246NTYxZTg1MDJkNWYyNDQxNzlhZWRiZGVjZjA3MGYxYjZfNjgw_84534649-13d8-4c35-8b32-0e6a2b551590" continuedAt="i18711bbe333343058275e431d3edba3f" escape="true">COMMITMENTS AND CONTINGENCIES</ix:nonNumeric></span></div><ix:continuation id="i18711bbe333343058275e431d3edba3f" continuedAt="i7416e3874af9473393e3decc0cbe6b70"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to various claims and legal proceedings covering matters that arise in the ordinary course of its business activities, including the matters described below. Estimates for resolution of legal and other contingencies are accrued when losses are probable and reasonably estimable in accordance with ASC 450, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Qui Tam Lawsuit</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Company's wholly owned subsidiary, Crescendo Bioscience, Inc. (&#8220;CBI&#8221;), received a subpoena from the Office of Inspector General of the Department of Health and Human Services requesting that CBI produce documents relating to entities that received payment from CBI for the collection and processing of blood specimens for testing, including a named unrelated company, healthcare providers and other third party entities. The Office of Inspector General subsequently requested additional documentation in December 2017. CBI provided to the Office of Inspector General the documents requested. On January 30, 2020, the United States District Court for the Northern District of California unsealed a qui tam complaint, filed on April 16, 2016 against CBI and the Company, alleging violations of the Federal and California False Claims Acts and the California Insurance Fraud Prevention Act.  On January 22, 2020, after a multi-year investigation into CBI&#8217;s and the Company&#8217;s alleged conduct, the United States declined to intervene. On January 27, 2020, the State of California likewise filed its notice of declination. The Company was not aware of the complaint until after it was unsealed. On May 23, 2020, the court denied CBI and the Company&#8217;s motion to dismiss. The Company has accrued $<ix:nonFraction unitRef="usd" contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LitigationReserveCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183MC9mcmFnOjU2MWU4NTAyZDVmMjQ0MTc5YWVkYmRlY2YwNzBmMWI2L3RleHRyZWdpb246NTYxZTg1MDJkNWYyNDQxNzlhZWRiZGVjZjA3MGYxYjZfMTA0NDUzNjA0NzI2Nzc_45952624-4a94-4ef0-91a1-1d38bbc6ae1b">48.0</ix:nonFraction> million for a potential settlement of this qui tam lawsuit against CBI and the Company, which is included in accrued liabilities in the Company's Condensed Consolidated Balance Sheet. If no settlement is reached, the Company intends to continue to vigorously defend this case, but it cannot predict with any degree of certainty the ultimate resolution of this matter or determine whether, or to what extent, any loss with respect to this matter may exceed the amount that it has accrued.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Purported Securities Class Action</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 27, 2019, a purported class action complaint was filed in the United States District Court for the District of Utah, against the Company, its former President and Chief Executive Officer, Mark C. Capone, and its Chief Financial Officer, R. Bryan Riggsbee (&#8220;Defendants&#8221;). On February 21, 2020, the plaintiff filed an amended class action complaint, which added the Company&#8217;s former Executive Vice President of Clinical Development, Bryan M. Dechairo, as an additional Defendant. This action, captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Myriad Genetics, Inc. Securities Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (No. 2:19-cv-00707-DBB), is premised upon allegations that the Defendants made false and misleading statements regarding the Company's business, operations, and acquisitions.  The lead plaintiff seeks the payment of damages allegedly sustained by it and the purported class by reason of the allegations set forth in the amended complaint, plus interest, and legal and other costs and fees.  On March 16, 2021, the United States District Court for the District of Utah denied the Company&#8217;s motion to dismiss. The Company intends to vigorously defend against this action. Due to the nature of this matter and inherent uncertainties, it is not possible to provide an evaluation of the likelihood of an unfavorable outcome or an estimate of the amount or range of potential loss, if any.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5814a71962934792901cb2330361bb17_7">Table of Contents</a></span></div></div><ix:continuation id="i7416e3874af9473393e3decc0cbe6b70" continuedAt="ia2acec1f283a4fa1aba7cf379139a178"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stockholder Derivative Actions</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 9, 2021, a stockholder derivative complaint was filed in the Delaware Court of Chancery against the Company's former President and Chief Executive Officer, Mark C. Capone, its Chief Financial Officer, R. Bryan Riggsbee, its former Executive Vice President of Clinical Development, Bryan M. Dechairo, and certain of its current and former directors, Lawrence C. Best, Walter Gilbert, John T. Henderson, Heiner Dreismann, Dennis Langer, Lee N. Newcomer, S. Louise Phanstiel, and Colleen F. Reitan (collectively, the "Individual Defendants"), and the Company, as nominal defendant. The complaint is premised upon similar allegations as set forth in the securities class action, including that the Individual Defendants made false and misleading statements regarding the Company's business and operations. The plaintiff, Donna Hickock, asserts breach of fiduciary duty and unjust enrichment claims against the Individual Defendants and seeks, on behalf of the Company, damages allegedly sustained by the Company as a result of the alleged breaches, or disgorgement or restitution, from each of the Individual Defendants, plus interest. Plaintiff Hickock also seeks legal and other costs and fees relating to this action. The Company intends to vigorously defend against this action. Due to the nature of this matter and inherent uncertainties, it is not possible to provide an evaluation of the likelihood of an unfavorable outcome or an estimate of the amount or range of potential loss, if any.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 17, 2021, a second stockholder derivative complaint was filed in the United States District Court for the District of Delaware against the Individual Defendants, and the Company, as nominal defendant. The action is premised upon similar allegations as set forth in the securities class action and Hickock stockholder derivative action. The plaintiff, Karen Marcey, asserts that the Individual Defendants violated U.S. securities laws and breached their fiduciary duties, and also asserts unjust enrichment, waste of corporate assets and insider trading claims against all or some of the Individual Defendants. Plaintiff Marcey seeks, on behalf of the Company, damages allegedly sustained by the Company as a result of the alleged violations and restitution from the Individual Defendants, plus interest and, on behalf of herself, legal and other costs and fees relating to this action. The Company intends to vigorously defend against this action. Due to the nature of this matter and inherent uncertainties, it is not possible to provide an evaluation of the likelihood of an unfavorable outcome or an estimate of the amount or range of potential loss, if any.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Matters</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On July 27, 2020, a lawsuit was filed against the Company in the Superior Court of Suffolk County, Massachusetts, by Heide Abelli and Victor Pricolo. The plaintiffs claim negligence, breach of contract and associated torts in connection with an alleged error in testing performed by the Company in 2004.  The plaintiffs seek damages allegedly sustained by them by reason of the allegations set forth in their complaint, together with interest and costs. The Company intends to vigorously defend against this action. Due to the nature of this matter and inherent uncertainties, it is not possible to provide an evaluation of the likelihood of an unfavorable outcome or an estimate of the amount or range of potential loss, if any.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of September&#160;30, 2021, the management of the Company believes any reasonably possible liability that may result from the resolution of any other matters will not have a material adverse effect on the Company&#8217;s consolidated financial position, operating results, or cash flows. However, it is possible that the ultimate resolution of other matters, if unfavorable, may be material to the results of operations or financial condition for a particular period.</span></div></ix:continuation><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ia2acec1f283a4fa1aba7cf379139a178">From time to time, the Company receives recoupment requests from third-party payors for alleged overpayments. The Company disagrees with the contentions of the pending requests or has recorded an estimated reserve for the alleged overpayments.</ix:continuation> </span></div><div id="i5814a71962934792901cb2330361bb17_73"></div><div style="margin-top:18pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" name="us-gaap:SegmentReportingDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RleHRyZWdpb246NjU2MTNmZDlhOGFkNGVkNDhiMzM4ZGZiYTBiZDMwMGRfMTAwNg_f7b92bdb-624b-4fb2-8719-95062e86c9f3" continuedAt="i700f06970d2440bcaec30d1c741971da" escape="true">SEGMENT AND RELATED INFORMATION</ix:nonNumeric></span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i700f06970d2440bcaec30d1c741971da" continuedAt="id5d9909871954efdbdb87c51d289e13a">The Company&#8217;s business is aligned with how the chief operating decision maker reviews performance and makes decisions in managing the Company.&#160;The business units have been aggregated into <ix:nonFraction unitRef="segment" contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfReportableSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RleHRyZWdpb246NjU2MTNmZDlhOGFkNGVkNDhiMzM4ZGZiYTBiZDMwMGRfMjI1_d08c929c-0c1b-4eb8-b6a1-240c6ca0b6fd">two</ix:nonFraction> reportable segments: (i)&#160;diagnostics and (ii) other. The diagnostics segment provides testing and collaborative development of testing that is designed to determine the risk of developing disease, assess the risk of disease progression, and guide treatment decisions across medical specialties where critical genetic insights can significantly improve patient care and lower healthcare costs. The other segment provides testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients, and includes corporate services such as finance, human resources, legal and information technology.</ix:continuation></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5814a71962934792901cb2330361bb17_7">Table of Contents</a></span></div></div><ix:continuation id="id5d9909871954efdbdb87c51d289e13a"><ix:nonNumeric contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RleHRyZWdpb246NjU2MTNmZDlhOGFkNGVkNDhiMzM4ZGZiYTBiZDMwMGRfMTAwNw_fe846d08-8889-4ab5-8c2c-d0626c21e056" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Segment revenue and operating income (loss) were as follows during the periods presented:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.350%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Diagnostics</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Three months ended September 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife30149d9d1d4b99ac1339407e85293d_D20210701-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOmE1ZDg5N2ZkYTQwMDRhODk4OGVhNmVlYjVkODIyYTNhL3RhYmxlcmFuZ2U6YTVkODk3ZmRhNDAwNGE4OTg4ZWE2ZWViNWQ4MjJhM2FfMi0xLTEtMS0xODE2NA_41a34b1e-e887-4b27-92ab-b1882332f352">161.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iacd3d37549084b26b52a7a2565dbb4ab_D20210701-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOmE1ZDg5N2ZkYTQwMDRhODk4OGVhNmVlYjVkODIyYTNhL3RhYmxlcmFuZ2U6YTVkODk3ZmRhNDAwNGE4OTg4ZWE2ZWViNWQ4MjJhM2FfMi0zLTEtMS0xODE2NA_c2b0007b-75d8-4d02-8cd5-a2f43f0f78f5">5.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOmE1ZDg5N2ZkYTQwMDRhODk4OGVhNmVlYjVkODIyYTNhL3RhYmxlcmFuZ2U6YTVkODk3ZmRhNDAwNGE4OTg4ZWE2ZWViNWQ4MjJhM2FfMi01LTEtMS0xODE2NA_e7110459-1cbc-405d-b097-5b4dcb36b528">167.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife30149d9d1d4b99ac1339407e85293d_D20210701-20210930" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOmE1ZDg5N2ZkYTQwMDRhODk4OGVhNmVlYjVkODIyYTNhL3RhYmxlcmFuZ2U6YTVkODk3ZmRhNDAwNGE4OTg4ZWE2ZWViNWQ4MjJhM2FfMy0xLTEtMS0xODE2NA_e798a030-6c3e-48bf-8baa-5f01f6941c61">13.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iacd3d37549084b26b52a7a2565dbb4ab_D20210701-20210930" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOmE1ZDg5N2ZkYTQwMDRhODk4OGVhNmVlYjVkODIyYTNhL3RhYmxlcmFuZ2U6YTVkODk3ZmRhNDAwNGE4OTg4ZWE2ZWViNWQ4MjJhM2FfMy0zLTEtMS0xODE2NA_ed2f0173-ae89-495a-b217-8539f63c1da9">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOmE1ZDg5N2ZkYTQwMDRhODk4OGVhNmVlYjVkODIyYTNhL3RhYmxlcmFuZ2U6YTVkODk3ZmRhNDAwNGE4OTg4ZWE2ZWViNWQ4MjJhM2FfMy01LTEtMS0xODE2NA_79acb9c2-393e-4e7e-af00-c575a96ecb2a">14.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Segment operating loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ife30149d9d1d4b99ac1339407e85293d_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOmE1ZDg5N2ZkYTQwMDRhODk4OGVhNmVlYjVkODIyYTNhL3RhYmxlcmFuZ2U6YTVkODk3ZmRhNDAwNGE4OTg4ZWE2ZWViNWQ4MjJhM2FfNC0xLTEtMS0xODE2NA_03f28a1f-a010-4d90-a342-6a693d8b9544">21.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="iacd3d37549084b26b52a7a2565dbb4ab_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOmE1ZDg5N2ZkYTQwMDRhODk4OGVhNmVlYjVkODIyYTNhL3RhYmxlcmFuZ2U6YTVkODk3ZmRhNDAwNGE4OTg4ZWE2ZWViNWQ4MjJhM2FfNC0zLTEtMS0xODE2NA_350d3d0e-bb14-4013-9df4-b7b4bc0aa8cb">58.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOmE1ZDg5N2ZkYTQwMDRhODk4OGVhNmVlYjVkODIyYTNhL3RhYmxlcmFuZ2U6YTVkODk3ZmRhNDAwNGE4OTg4ZWE2ZWViNWQ4MjJhM2FfNC01LTEtMS0xODE2NA_da298951-ec7d-4cb6-92e3-5fe0f1ee7aa5">79.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Three months ended September 30, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i19766b831a824fe78592ac40be72d491_D20200701-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOmE1ZDg5N2ZkYTQwMDRhODk4OGVhNmVlYjVkODIyYTNhL3RhYmxlcmFuZ2U6YTVkODk3ZmRhNDAwNGE4OTg4ZWE2ZWViNWQ4MjJhM2FfNy0xLTEtMS0xODE2NA_a16dbb58-cf47-477d-8b7d-77d4de21899f">130.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i91eb354042484b21815c154fc961e6c4_D20200701-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOmE1ZDg5N2ZkYTQwMDRhODk4OGVhNmVlYjVkODIyYTNhL3RhYmxlcmFuZ2U6YTVkODk3ZmRhNDAwNGE4OTg4ZWE2ZWViNWQ4MjJhM2FfNy0zLTEtMS0xODE2NA_149d6297-f999-4400-acfa-06e258581827">14.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic2c3e03438af4889ac973627c642f5ec_D20200701-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOmE1ZDg5N2ZkYTQwMDRhODk4OGVhNmVlYjVkODIyYTNhL3RhYmxlcmFuZ2U6YTVkODk3ZmRhNDAwNGE4OTg4ZWE2ZWViNWQ4MjJhM2FfNy01LTEtMS0xODE2NA_c557a8eb-edc0-4731-b205-e0ccdb1cd11a">145.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i19766b831a824fe78592ac40be72d491_D20200701-20200930" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOmE1ZDg5N2ZkYTQwMDRhODk4OGVhNmVlYjVkODIyYTNhL3RhYmxlcmFuZ2U6YTVkODk3ZmRhNDAwNGE4OTg4ZWE2ZWViNWQ4MjJhM2FfOC0xLTEtMS0xODE2NA_8aa3e1cb-483f-4c68-8874-0c6f1addc0d4">16.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i91eb354042484b21815c154fc961e6c4_D20200701-20200930" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOmE1ZDg5N2ZkYTQwMDRhODk4OGVhNmVlYjVkODIyYTNhL3RhYmxlcmFuZ2U6YTVkODk3ZmRhNDAwNGE4OTg4ZWE2ZWViNWQ4MjJhM2FfOC0zLTEtMS0xODE2NA_f5199307-41d0-42f9-8dfc-0042473702ad">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic2c3e03438af4889ac973627c642f5ec_D20200701-20200930" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOmE1ZDg5N2ZkYTQwMDRhODk4OGVhNmVlYjVkODIyYTNhL3RhYmxlcmFuZ2U6YTVkODk3ZmRhNDAwNGE4OTg4ZWE2ZWViNWQ4MjJhM2FfOC01LTEtMS0xODE2NA_152659c6-ced0-474b-8620-fd7ad8eb56e2">17.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Segment operating loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i19766b831a824fe78592ac40be72d491_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOmE1ZDg5N2ZkYTQwMDRhODk4OGVhNmVlYjVkODIyYTNhL3RhYmxlcmFuZ2U6YTVkODk3ZmRhNDAwNGE4OTg4ZWE2ZWViNWQ4MjJhM2FfOS0xLTEtMS0xODE2NA_33b81287-944b-4f50-adab-bbbd8c1aaf82">0.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i91eb354042484b21815c154fc961e6c4_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOmE1ZDg5N2ZkYTQwMDRhODk4OGVhNmVlYjVkODIyYTNhL3RhYmxlcmFuZ2U6YTVkODk3ZmRhNDAwNGE4OTg4ZWE2ZWViNWQ4MjJhM2FfOS0zLTEtMS0xODE2NA_dc206077-3527-4a59-8381-6933467a3f14">39.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ic2c3e03438af4889ac973627c642f5ec_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOmE1ZDg5N2ZkYTQwMDRhODk4OGVhNmVlYjVkODIyYTNhL3RhYmxlcmFuZ2U6YTVkODk3ZmRhNDAwNGE4OTg4ZWE2ZWViNWQ4MjJhM2FfOS01LTEtMS0xODE2NA_f74f661e-546e-4f6d-a16a-c723cd7919e9">39.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nine months ended September 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90324a4d56084a4391c5819f5c839f86_D20210101-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOmE1ZDg5N2ZkYTQwMDRhODk4OGVhNmVlYjVkODIyYTNhL3RhYmxlcmFuZ2U6YTVkODk3ZmRhNDAwNGE4OTg4ZWE2ZWViNWQ4MjJhM2FfMTItMS0xLTEtMTgxNjQ_47d6a13c-61b0-40aa-a3e8-3ccdc6a1093a">496.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee82af509aa24703b7bb72450fba9e9f_D20210101-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOmE1ZDg5N2ZkYTQwMDRhODk4OGVhNmVlYjVkODIyYTNhL3RhYmxlcmFuZ2U6YTVkODk3ZmRhNDAwNGE4OTg4ZWE2ZWViNWQ4MjJhM2FfMTItMy0xLTEtMTgxNjQ_f9fe54d2-33b2-4190-93ff-99ebed74d846">33.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOmE1ZDg5N2ZkYTQwMDRhODk4OGVhNmVlYjVkODIyYTNhL3RhYmxlcmFuZ2U6YTVkODk3ZmRhNDAwNGE4OTg4ZWE2ZWViNWQ4MjJhM2FfMTItNS0xLTEtMTgxNjQ_98126f6f-6449-4b55-99b8-12480836dbc2">529.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90324a4d56084a4391c5819f5c839f86_D20210101-20210930" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOmE1ZDg5N2ZkYTQwMDRhODk4OGVhNmVlYjVkODIyYTNhL3RhYmxlcmFuZ2U6YTVkODk3ZmRhNDAwNGE4OTg4ZWE2ZWViNWQ4MjJhM2FfMTMtMS0xLTEtMTgxNjQ_6f080d66-8a69-4840-aa81-7439192d4d71">45.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iee82af509aa24703b7bb72450fba9e9f_D20210101-20210930" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOmE1ZDg5N2ZkYTQwMDRhODk4OGVhNmVlYjVkODIyYTNhL3RhYmxlcmFuZ2U6YTVkODk3ZmRhNDAwNGE4OTg4ZWE2ZWViNWQ4MjJhM2FfMTMtMy0xLTEtMTgxNjQ_793bf913-43fc-4a34-97d9-d26fe4c4dd4f">3.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOmE1ZDg5N2ZkYTQwMDRhODk4OGVhNmVlYjVkODIyYTNhL3RhYmxlcmFuZ2U6YTVkODk3ZmRhNDAwNGE4OTg4ZWE2ZWViNWQ4MjJhM2FfMTMtNS0xLTEtMTgxNjQ_9068a788-82a7-443a-8b99-e8624a10ce20">49.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Segment operating income (loss)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i90324a4d56084a4391c5819f5c839f86_D20210101-20210930" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOmE1ZDg5N2ZkYTQwMDRhODk4OGVhNmVlYjVkODIyYTNhL3RhYmxlcmFuZ2U6YTVkODk3ZmRhNDAwNGE4OTg4ZWE2ZWViNWQ4MjJhM2FfMTQtMS0xLTEtMTgxNjQ_498cf74d-f1e6-43c4-b70b-ebc71d25d38c">26.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="iee82af509aa24703b7bb72450fba9e9f_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOmE1ZDg5N2ZkYTQwMDRhODk4OGVhNmVlYjVkODIyYTNhL3RhYmxlcmFuZ2U6YTVkODk3ZmRhNDAwNGE4OTg4ZWE2ZWViNWQ4MjJhM2FfMTQtMy0xLTEtMTgxNjQ_6cf7aedb-b72f-48a4-ada2-402fba5a9e3b">173.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOmE1ZDg5N2ZkYTQwMDRhODk4OGVhNmVlYjVkODIyYTNhL3RhYmxlcmFuZ2U6YTVkODk3ZmRhNDAwNGE4OTg4ZWE2ZWViNWQ4MjJhM2FfMTQtNS0xLTEtMTgxNjQ_5f47702c-bcb7-4875-8d80-95e416fc2e36">147.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nine months ended September 30, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id9a30e30fb7d46af9ad9962658bc3126_D20200101-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOmE1ZDg5N2ZkYTQwMDRhODk4OGVhNmVlYjVkODIyYTNhL3RhYmxlcmFuZ2U6YTVkODk3ZmRhNDAwNGE4OTg4ZWE2ZWViNWQ4MjJhM2FfMTctMS0xLTEtMTgxNjQ_008ddab9-c727-4ef1-a1eb-1e9c7bc79c94">362.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7eb09159cfc64597873d8167aa298bfe_D20200101-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOmE1ZDg5N2ZkYTQwMDRhODk4OGVhNmVlYjVkODIyYTNhL3RhYmxlcmFuZ2U6YTVkODk3ZmRhNDAwNGE4OTg4ZWE2ZWViNWQ4MjJhM2FfMTctMy0xLTEtMTgxNjQ_5c30e5cb-de8d-4a8e-a344-d0e24ad96f2f">40.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOmE1ZDg5N2ZkYTQwMDRhODk4OGVhNmVlYjVkODIyYTNhL3RhYmxlcmFuZ2U6YTVkODk3ZmRhNDAwNGE4OTg4ZWE2ZWViNWQ4MjJhM2FfMTctNS0xLTEtMTgxNjQ_d7134769-6e21-46a4-ad92-2dec5fe930af">402.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id9a30e30fb7d46af9ad9962658bc3126_D20200101-20200930" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOmE1ZDg5N2ZkYTQwMDRhODk4OGVhNmVlYjVkODIyYTNhL3RhYmxlcmFuZ2U6YTVkODk3ZmRhNDAwNGE4OTg4ZWE2ZWViNWQ4MjJhM2FfMTgtMS0xLTEtMTgxNjQ_4f0077da-c124-404f-a4f6-30403bab1762">50.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7eb09159cfc64597873d8167aa298bfe_D20200101-20200930" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOmE1ZDg5N2ZkYTQwMDRhODk4OGVhNmVlYjVkODIyYTNhL3RhYmxlcmFuZ2U6YTVkODk3ZmRhNDAwNGE4OTg4ZWE2ZWViNWQ4MjJhM2FfMTgtMy0xLTEtMTgxNjQ_1f185ad8-c43e-44a4-b817-0de38ad709dd">3.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOmE1ZDg5N2ZkYTQwMDRhODk4OGVhNmVlYjVkODIyYTNhL3RhYmxlcmFuZ2U6YTVkODk3ZmRhNDAwNGE4OTg4ZWE2ZWViNWQ4MjJhM2FfMTgtNS0xLTEtMTgxNjQ_c70b946a-1665-4a19-ae7b-18b888bf2a2e">53.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Segment operating loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="id9a30e30fb7d46af9ad9962658bc3126_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOmE1ZDg5N2ZkYTQwMDRhODk4OGVhNmVlYjVkODIyYTNhL3RhYmxlcmFuZ2U6YTVkODk3ZmRhNDAwNGE4OTg4ZWE2ZWViNWQ4MjJhM2FfMTktMS0xLTEtMTgxNjQ_c6be4b75-8e0c-4681-a1bc-c7498dbfa8ee">127.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i7eb09159cfc64597873d8167aa298bfe_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOmE1ZDg5N2ZkYTQwMDRhODk4OGVhNmVlYjVkODIyYTNhL3RhYmxlcmFuZ2U6YTVkODk3ZmRhNDAwNGE4OTg4ZWE2ZWViNWQ4MjJhM2FfMTktMy0xLTEtMTgxNjQ_574ade42-72bd-4e9e-9d0d-7c9b17d609b8">113.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOmE1ZDg5N2ZkYTQwMDRhODk4OGVhNmVlYjVkODIyYTNhL3RhYmxlcmFuZ2U6YTVkODk3ZmRhNDAwNGE4OTg4ZWE2ZWViNWQ4MjJhM2FfMTktNS0xLTEtMTgxNjQ_c292d038-a582-4588-9c3b-6c01a608e1dd">241.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;padding-left:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.603%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine months ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total operating loss for reportable segments</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOjkxMmU2Yjk5ODk2ZTRiMmNiMjBjMzU2ODY5ODVjODQ1L3RhYmxlcmFuZ2U6OTEyZTZiOTk4OTZlNGIyY2IyMGMzNTY4Njk4NWM4NDVfMi0xLTEtMS0xODE2NA_f677ec4b-a3a0-48b4-aab1-78ea55a4f82f">79.9</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ic2c3e03438af4889ac973627c642f5ec_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOjkxMmU2Yjk5ODk2ZTRiMmNiMjBjMzU2ODY5ODVjODQ1L3RhYmxlcmFuZ2U6OTEyZTZiOTk4OTZlNGIyY2IyMGMzNTY4Njk4NWM4NDVfMi0zLTEtMS0xODE2NA_62a9dd87-0b4f-48f4-aca6-c62c24d4efc2">39.6</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOjkxMmU2Yjk5ODk2ZTRiMmNiMjBjMzU2ODY5ODVjODQ1L3RhYmxlcmFuZ2U6OTEyZTZiOTk4OTZlNGIyY2IyMGMzNTY4Njk4NWM4NDVfMi01LTEtMS0xODE2NA_e674346e-9a75-4003-a4e8-78c25635e925">147.4</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOjkxMmU2Yjk5ODk2ZTRiMmNiMjBjMzU2ODY5ODVjODQ1L3RhYmxlcmFuZ2U6OTEyZTZiOTk4OTZlNGIyY2IyMGMzNTY4Njk4NWM4NDVfMi03LTEtMS0xODE2NA_8677b484-6fcf-4b2d-9d44-55c428e89821">241.6</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unallocated amounts:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930" decimals="-5" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOjkxMmU2Yjk5ODk2ZTRiMmNiMjBjMzU2ODY5ODVjODQ1L3RhYmxlcmFuZ2U6OTEyZTZiOTk4OTZlNGIyY2IyMGMzNTY4Njk4NWM4NDVfNC0xLTEtMS0xODE2NA_01c1212b-59d7-40c7-ae36-47558eaf9d44">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic2c3e03438af4889ac973627c642f5ec_D20200701-20200930" decimals="-5" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOjkxMmU2Yjk5ODk2ZTRiMmNiMjBjMzU2ODY5ODVjODQ1L3RhYmxlcmFuZ2U6OTEyZTZiOTk4OTZlNGIyY2IyMGMzNTY4Njk4NWM4NDVfNC0zLTEtMS0xODE2NA_03cc7f4d-0f45-40fd-905a-8f874496ab48">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" decimals="-5" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOjkxMmU2Yjk5ODk2ZTRiMmNiMjBjMzU2ODY5ODVjODQ1L3RhYmxlcmFuZ2U6OTEyZTZiOTk4OTZlNGIyY2IyMGMzNTY4Njk4NWM4NDVfNC01LTEtMS0xODE2NA_8fa376f5-0759-4e07-b678-63a3fa2d8db5">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930" decimals="-5" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOjkxMmU2Yjk5ODk2ZTRiMmNiMjBjMzU2ODY5ODVjODQ1L3RhYmxlcmFuZ2U6OTEyZTZiOTk4OTZlNGIyY2IyMGMzNTY4Njk4NWM4NDVfNC03LTEtMS0xODE2NA_66613e7d-ff25-4f81-a1b5-3a3ac667505c">1.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOjkxMmU2Yjk5ODk2ZTRiMmNiMjBjMzU2ODY5ODVjODQ1L3RhYmxlcmFuZ2U6OTEyZTZiOTk4OTZlNGIyY2IyMGMzNTY4Njk4NWM4NDVfNS0xLTEtMS0xODE2NA_28906cf1-f9b1-460e-8a74-4ffb96153933">1.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ic2c3e03438af4889ac973627c642f5ec_D20200701-20200930" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOjkxMmU2Yjk5ODk2ZTRiMmNiMjBjMzU2ODY5ODVjODQ1L3RhYmxlcmFuZ2U6OTEyZTZiOTk4OTZlNGIyY2IyMGMzNTY4Njk4NWM4NDVfNS0zLTEtMS0xODE2NA_33bddd4b-4303-41f1-8a99-f09b7283d91d">2.9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOjkxMmU2Yjk5ODk2ZTRiMmNiMjBjMzU2ODY5ODVjODQ1L3RhYmxlcmFuZ2U6OTEyZTZiOTk4OTZlNGIyY2IyMGMzNTY4Njk4NWM4NDVfNS01LTEtMS0xODE2NA_113385a1-dec4-4edd-a4e3-8ddbb599e097">6.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOjkxMmU2Yjk5ODk2ZTRiMmNiMjBjMzU2ODY5ODVjODQ1L3RhYmxlcmFuZ2U6OTEyZTZiOTk4OTZlNGIyY2IyMGMzNTY4Njk4NWM4NDVfNS03LTEtMS0xODE2NA_17cd26ef-1617-41ee-b4d8-f4f9857a1482">8.3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOjkxMmU2Yjk5ODk2ZTRiMmNiMjBjMzU2ODY5ODVjODQ1L3RhYmxlcmFuZ2U6OTEyZTZiOTk4OTZlNGIyY2IyMGMzNTY4Njk4NWM4NDVfNi0xLTEtMS0xODE2NA_73033eba-09e9-4ef2-8948-dfa9328685a6">120.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ic2c3e03438af4889ac973627c642f5ec_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOjkxMmU2Yjk5ODk2ZTRiMmNiMjBjMzU2ODY5ODVjODQ1L3RhYmxlcmFuZ2U6OTEyZTZiOTk4OTZlNGIyY2IyMGMzNTY4Njk4NWM4NDVfNi0zLTEtMS0xODE2NA_afc57210-d6b4-44e9-8b52-21c5c4c27ef8">1.6</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOjkxMmU2Yjk5ODk2ZTRiMmNiMjBjMzU2ODY5ODVjODQ1L3RhYmxlcmFuZ2U6OTEyZTZiOTk4OTZlNGIyY2IyMGMzNTY4Njk4NWM4NDVfNi01LTEtMS0xODE2NA_46783b4d-8384-452b-93bb-9ed672ba7387">139.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOjkxMmU2Yjk5ODk2ZTRiMmNiMjBjMzU2ODY5ODVjODQ1L3RhYmxlcmFuZ2U6OTEyZTZiOTk4OTZlNGIyY2IyMGMzNTY4Njk4NWM4NDVfNi03LTEtMS0xODE2NA_e5704da7-2ad9-4dea-817b-c5e73f304b10">14.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income (loss) from operations before income taxes</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOjkxMmU2Yjk5ODk2ZTRiMmNiMjBjMzU2ODY5ODVjODQ1L3RhYmxlcmFuZ2U6OTEyZTZiOTk4OTZlNGIyY2IyMGMzNTY4Njk4NWM4NDVfNy0xLTEtMS0xODE2NA_30dad95f-a5cd-4c7e-be84-73ba2ad27aeb">39.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ic2c3e03438af4889ac973627c642f5ec_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOjkxMmU2Yjk5ODk2ZTRiMmNiMjBjMzU2ODY5ODVjODQ1L3RhYmxlcmFuZ2U6OTEyZTZiOTk4OTZlNGIyY2IyMGMzNTY4Njk4NWM4NDVfNy0zLTEtMS0xODE2NA_b01637de-26c5-4ddf-89fa-a426e2550b00">43.7</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOjkxMmU2Yjk5ODk2ZTRiMmNiMjBjMzU2ODY5ODVjODQ1L3RhYmxlcmFuZ2U6OTEyZTZiOTk4OTZlNGIyY2IyMGMzNTY4Njk4NWM4NDVfNy01LTEtMS0xODE2NA_ce31874b-928d-44bc-91b5-dc5146c583a6">13.6</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOjkxMmU2Yjk5ODk2ZTRiMmNiMjBjMzU2ODY5ODVjODQ1L3RhYmxlcmFuZ2U6OTEyZTZiOTk4OTZlNGIyY2IyMGMzNTY4Njk4NWM4NDVfNy03LTEtMS0xODE2NA_cd790509-eb23-4028-a31e-bf4970267baf">233.3</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax expense (benefit)</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOjkxMmU2Yjk5ODk2ZTRiMmNiMjBjMzU2ODY5ODVjODQ1L3RhYmxlcmFuZ2U6OTEyZTZiOTk4OTZlNGIyY2IyMGMzNTY4Njk4NWM4NDVfOC0xLTEtMS0xODE2NA_c527eac9-9483-44df-a8f0-b3e1843f2874">15.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ic2c3e03438af4889ac973627c642f5ec_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOjkxMmU2Yjk5ODk2ZTRiMmNiMjBjMzU2ODY5ODVjODQ1L3RhYmxlcmFuZ2U6OTEyZTZiOTk4OTZlNGIyY2IyMGMzNTY4Njk4NWM4NDVfOC0zLTEtMS0xODE2NA_9bcf4b77-8baf-43dd-a6d9-2c80f47db642">28.5</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOjkxMmU2Yjk5ODk2ZTRiMmNiMjBjMzU2ODY5ODVjODQ1L3RhYmxlcmFuZ2U6OTEyZTZiOTk4OTZlNGIyY2IyMGMzNTY4Njk4NWM4NDVfOC01LTEtMS0xODE2NA_0a0c1b67-9ba4-4f65-aa1e-73ce96e86b2c">6.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOjkxMmU2Yjk5ODk2ZTRiMmNiMjBjMzU2ODY5ODVjODQ1L3RhYmxlcmFuZ2U6OTEyZTZiOTk4OTZlNGIyY2IyMGMzNTY4Njk4NWM4NDVfOC03LTEtMS0xODE2NA_cf16bb03-8a7d-4712-80d6-2a12ef3f0f68">47.4</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income (loss)</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOjkxMmU2Yjk5ODk2ZTRiMmNiMjBjMzU2ODY5ODVjODQ1L3RhYmxlcmFuZ2U6OTEyZTZiOTk4OTZlNGIyY2IyMGMzNTY4Njk4NWM4NDVfOS0xLTEtMS0xODE2NA_f65f489c-d69c-42c2-8ca7-3bede2cb2276">24.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ic2c3e03438af4889ac973627c642f5ec_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOjkxMmU2Yjk5ODk2ZTRiMmNiMjBjMzU2ODY5ODVjODQ1L3RhYmxlcmFuZ2U6OTEyZTZiOTk4OTZlNGIyY2IyMGMzNTY4Njk4NWM4NDVfOS0zLTEtMS0xODE2NA_a4074eaa-a36a-4948-9e4b-13bf1f1fe36d">15.2</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOjkxMmU2Yjk5ODk2ZTRiMmNiMjBjMzU2ODY5ODVjODQ1L3RhYmxlcmFuZ2U6OTEyZTZiOTk4OTZlNGIyY2IyMGMzNTY4Njk4NWM4NDVfOS01LTEtMS0xODE2NA_3382ebf6-9cd0-403f-9327-36c5a3248b84">19.6</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOjkxMmU2Yjk5ODk2ZTRiMmNiMjBjMzU2ODY5ODVjODQ1L3RhYmxlcmFuZ2U6OTEyZTZiOTk4OTZlNGIyY2IyMGMzNTY4Njk4NWM4NDVfOS03LTEtMS0xODE2NA_8e31fe3e-28ca-430b-9259-0bed23e87f5b">185.9</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss attributable to non-controlling interest</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOjkxMmU2Yjk5ODk2ZTRiMmNiMjBjMzU2ODY5ODVjODQ1L3RhYmxlcmFuZ2U6OTEyZTZiOTk4OTZlNGIyY2IyMGMzNTY4Njk4NWM4NDVfMTAtMS0xLTEtMTgxNjQ_e9ab0712-2096-4643-bfd9-7a2be8f2d0cd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic2c3e03438af4889ac973627c642f5ec_D20200701-20200930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOjkxMmU2Yjk5ODk2ZTRiMmNiMjBjMzU2ODY5ODVjODQ1L3RhYmxlcmFuZ2U6OTEyZTZiOTk4OTZlNGIyY2IyMGMzNTY4Njk4NWM4NDVfMTAtMy0xLTEtMTgxNjQ_d65bd003-64c8-4187-9513-33422a0ba014">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOjkxMmU2Yjk5ODk2ZTRiMmNiMjBjMzU2ODY5ODVjODQ1L3RhYmxlcmFuZ2U6OTEyZTZiOTk4OTZlNGIyY2IyMGMzNTY4Njk4NWM4NDVfMTAtNS0xLTEtMTgxNjQ_ccc07d2f-729d-48ee-9f4b-4f233debfbaa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOjkxMmU2Yjk5ODk2ZTRiMmNiMjBjMzU2ODY5ODVjODQ1L3RhYmxlcmFuZ2U6OTEyZTZiOTk4OTZlNGIyY2IyMGMzNTY4Njk4NWM4NDVfMTAtNy0xLTEtMTgxNjQ_cec41c9a-d422-46df-bb0c-11132f299934">0.1</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income (loss) attributable to Myriad Genetics, Inc. stockholders</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOjkxMmU2Yjk5ODk2ZTRiMmNiMjBjMzU2ODY5ODVjODQ1L3RhYmxlcmFuZ2U6OTEyZTZiOTk4OTZlNGIyY2IyMGMzNTY4Njk4NWM4NDVfMTEtMS0xLTEtMTgxNjQ_350a6d28-298a-44f1-9158-5a6123e1b468">24.6</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ic2c3e03438af4889ac973627c642f5ec_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOjkxMmU2Yjk5ODk2ZTRiMmNiMjBjMzU2ODY5ODVjODQ1L3RhYmxlcmFuZ2U6OTEyZTZiOTk4OTZlNGIyY2IyMGMzNTY4Njk4NWM4NDVfMTEtMy0xLTEtMTgxNjQ_cd9597f5-1969-4da2-a71d-ac65cf1567cc">15.2</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOjkxMmU2Yjk5ODk2ZTRiMmNiMjBjMzU2ODY5ODVjODQ1L3RhYmxlcmFuZ2U6OTEyZTZiOTk4OTZlNGIyY2IyMGMzNTY4Njk4NWM4NDVfMTEtNS0xLTEtMTgxNjQ_21d78e16-ee98-4cbd-8d0e-85f93334f89e">19.6</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOjkxMmU2Yjk5ODk2ZTRiMmNiMjBjMzU2ODY5ODVjODQ1L3RhYmxlcmFuZ2U6OTEyZTZiOTk4OTZlNGIyY2IyMGMzNTY4Njk4NWM4NDVfMTEtNy0xLTEtMTgxNjQ_ea6c4dbc-e823-4675-8498-9aaa6a5739a6">185.8</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i5814a71962934792901cb2330361bb17_76"></div><div style="margin-top:18pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" name="us-gaap:CashFlowSupplementalDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183Ni9mcmFnOjI0N2ExOTlmOTk2OTQ4ODhiMDI4ZGUwM2MwZTY1MTJhL3RleHRyZWdpb246MjQ3YTE5OWY5OTY5NDg4OGIwMjhkZTAzYzBlNjUxMmFfNDI_053280f5-f29c-4514-b85a-027e5bd02496" continuedAt="i302b1407ef3440a2860d7c92ef7e4f72" escape="true">SUPPLEMENTAL CASH FLOW INFORMATION</ix:nonNumeric></span></div><div style="margin-top:5pt"><ix:continuation id="i302b1407ef3440a2860d7c92ef7e4f72"><ix:nonNumeric contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" name="us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183Ni9mcmFnOjI0N2ExOTlmOTk2OTQ4ODhiMDI4ZGUwM2MwZTY1MTJhL3RleHRyZWdpb246MjQ3YTE5OWY5OTY5NDg4OGIwMjhkZTAzYzBlNjUxMmFfNDE_bfad6fc6-e84a-45e0-a346-b90fffc84aae" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.046%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.599%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine months ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid during the period for income taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" decimals="-5" name="us-gaap:IncomeTaxesPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183Ni9mcmFnOjI0N2ExOTlmOTk2OTQ4ODhiMDI4ZGUwM2MwZTY1MTJhL3RhYmxlOjljNDc2YTMxODNhNTRjNjBhMjUzYzZlZDM1ZDA2NzY3L3RhYmxlcmFuZ2U6OWM0NzZhMzE4M2E1NGM2MGEyNTNjNmVkMzVkMDY3NjdfMi0xLTEtMS0xODE2NA_6abee198-ff36-4185-b341-a60edab772e4">2.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930" decimals="-5" name="us-gaap:IncomeTaxesPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183Ni9mcmFnOjI0N2ExOTlmOTk2OTQ4ODhiMDI4ZGUwM2MwZTY1MTJhL3RhYmxlOjljNDc2YTMxODNhNTRjNjBhMjUzYzZlZDM1ZDA2NzY3L3RhYmxlcmFuZ2U6OWM0NzZhMzE4M2E1NGM2MGEyNTNjNmVkMzVkMDY3NjdfMi0zLTEtMS0xODE2NA_d40c12db-a6f8-47ee-a7da-57dd8dd2aef0">2.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" decimals="-5" name="us-gaap:InterestPaidNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183Ni9mcmFnOjI0N2ExOTlmOTk2OTQ4ODhiMDI4ZGUwM2MwZTY1MTJhL3RhYmxlOjljNDc2YTMxODNhNTRjNjBhMjUzYzZlZDM1ZDA2NzY3L3RhYmxlcmFuZ2U6OWM0NzZhMzE4M2E1NGM2MGEyNTNjNmVkMzVkMDY3NjdfMy0xLTEtMS0xODE2NA_0936ea89-3670-4979-b37c-0d94a4783ea6">2.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930" decimals="-5" name="us-gaap:InterestPaidNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183Ni9mcmFnOjI0N2ExOTlmOTk2OTQ4ODhiMDI4ZGUwM2MwZTY1MTJhL3RhYmxlOjljNDc2YTMxODNhNTRjNjBhMjUzYzZlZDM1ZDA2NzY3L3RhYmxlcmFuZ2U6OWM0NzZhMzE4M2E1NGM2MGEyNTNjNmVkMzVkMDY3NjdfMy0zLTEtMS0xODE2NA_24a68675-6429-40d0-9a4b-5072ad6dd07f">6.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash received for income tax receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" decimals="-5" name="us-gaap:ProceedsFromIncomeTaxRefunds" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183Ni9mcmFnOjI0N2ExOTlmOTk2OTQ4ODhiMDI4ZGUwM2MwZTY1MTJhL3RhYmxlOjljNDc2YTMxODNhNTRjNjBhMjUzYzZlZDM1ZDA2NzY3L3RhYmxlcmFuZ2U6OWM0NzZhMzE4M2E1NGM2MGEyNTNjNmVkMzVkMDY3NjdfNC0xLTEtMS0xODE2NA_7d717181-888a-44e4-b4ee-97c94243dce6">89.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:ProceedsFromIncomeTaxRefunds" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183Ni9mcmFnOjI0N2ExOTlmOTk2OTQ4ODhiMDI4ZGUwM2MwZTY1MTJhL3RhYmxlOjljNDc2YTMxODNhNTRjNjBhMjUzYzZlZDM1ZDA2NzY3L3RhYmxlcmFuZ2U6OWM0NzZhMzE4M2E1NGM2MGEyNTNjNmVkMzVkMDY3NjdfNC0zLTEtMS0xODE2NA_958110da-b5ce-4935-aa56-fb3849c566fe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Establishment of operating lease right-of-use assets and lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease right-of-use assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" decimals="-5" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183Ni9mcmFnOjI0N2ExOTlmOTk2OTQ4ODhiMDI4ZGUwM2MwZTY1MTJhL3RhYmxlOjljNDc2YTMxODNhNTRjNjBhMjUzYzZlZDM1ZDA2NzY3L3RhYmxlcmFuZ2U6OWM0NzZhMzE4M2E1NGM2MGEyNTNjNmVkMzVkMDY3NjdfNy0xLTEtMS0xODE2NA_e193d7e4-364f-4862-a0d5-0305e689e08a">40.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183Ni9mcmFnOjI0N2ExOTlmOTk2OTQ4ODhiMDI4ZGUwM2MwZTY1MTJhL3RhYmxlOjljNDc2YTMxODNhNTRjNjBhMjUzYzZlZDM1ZDA2NzY3L3RhYmxlcmFuZ2U6OWM0NzZhMzE4M2E1NGM2MGEyNTNjNmVkMzVkMDY3NjdfNy0zLTEtMS0xODE2NA_c4bde549-5efa-4053-add6-643711ad3f6d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" decimals="-5" name="mygn:OperatingLeaseLiabilityEstablished" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183Ni9mcmFnOjI0N2ExOTlmOTk2OTQ4ODhiMDI4ZGUwM2MwZTY1MTJhL3RhYmxlOjljNDc2YTMxODNhNTRjNjBhMjUzYzZlZDM1ZDA2NzY3L3RhYmxlcmFuZ2U6OWM0NzZhMzE4M2E1NGM2MGEyNTNjNmVkMzVkMDY3NjdfOC0xLTEtMS0xODE2NA_35845e97-70f2-4a8c-9f9b-88ee6775cf7c">46.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930" decimals="-5" format="ixt:fixed-zero" name="mygn:OperatingLeaseLiabilityEstablished" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183Ni9mcmFnOjI0N2ExOTlmOTk2OTQ4ODhiMDI4ZGUwM2MwZTY1MTJhL3RhYmxlOjljNDc2YTMxODNhNTRjNjBhMjUzYzZlZDM1ZDA2NzY3L3RhYmxlcmFuZ2U6OWM0NzZhMzE4M2E1NGM2MGEyNTNjNmVkMzVkMDY3NjdfOC0zLTEtMS0xODE2NA_75f81e3c-aa4d-474f-b1da-5d9462738d29">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></ix:continuation></div><div><span><br/></span></div><div style="padding-left:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><div id="i5814a71962934792901cb2330361bb17_79"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5814a71962934792901cb2330361bb17_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">16.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" name="us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183OS9mcmFnOmNjZjdkY2MyMTZlOTRmNGRiMGI2NmRkYjBjNjIzMGFlL3RleHRyZWdpb246Y2NmN2RjYzIxNmU5NGY0ZGIwYjY2ZGRiMGM2MjMwYWVfMjUwNA_90a2b169-c1ac-47eb-8ccb-c900704ed7f2" continuedAt="i61f65da88fac4954ba652a7e1ea4abea" escape="true">DIVESTITURES</ix:nonNumeric></span></div><ix:continuation id="i61f65da88fac4954ba652a7e1ea4abea"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 28, 2021, the Company completed its sale of the Myriad myPath, LLC laboratory to Castle Biosciences, Inc. for cash consideration of $<ix:nonFraction unitRef="usd" contextRef="i5b97fc75f0ec45e0bd58df1dad474b32_D20210528-20210528" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromSaleOfProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183OS9mcmFnOmNjZjdkY2MyMTZlOTRmNGRiMGI2NmRkYjBjNjIzMGFlL3RleHRyZWdpb246Y2NmN2RjYzIxNmU5NGY0ZGIwYjY2ZGRiMGM2MjMwYWVfMzYw_e4dc6c95-922b-4c7e-b0af-a93a78328e7a">32.5</ix:nonFraction> million. The transaction was accounted for as a sale of assets and the Company recognized a gain of $<ix:nonFraction unitRef="usd" contextRef="i5b97fc75f0ec45e0bd58df1dad474b32_D20210528-20210528" decimals="-5" format="ixt:num-dot-decimal" name="mygn:GainLossOnDispositionOfAssetsNetOfTransactionFees" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183OS9mcmFnOmNjZjdkY2MyMTZlOTRmNGRiMGI2NmRkYjBjNjIzMGFlL3RleHRyZWdpb246Y2NmN2RjYzIxNmU5NGY0ZGIwYjY2ZGRiMGM2MjMwYWVfNDU5_4d5d051f-e948-48a1-864c-dcf00fdb699b">31.2</ix:nonFraction> million, net of transaction costs of $<ix:nonFraction unitRef="usd" contextRef="i5b97fc75f0ec45e0bd58df1dad474b32_D20210528-20210528" decimals="-5" format="ixt:num-dot-decimal" name="mygn:DisposalGroupNotDiscontinuedOperationTransactionCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183OS9mcmFnOmNjZjdkY2MyMTZlOTRmNGRiMGI2NmRkYjBjNjIzMGFlL3RleHRyZWdpb246Y2NmN2RjYzIxNmU5NGY0ZGIwYjY2ZGRiMGM2MjMwYWVfMTA5OTUxMTYzNTc5Nw_296ef2e3-1bea-49b9-9425-3f4120254cac">1.3</ix:nonFraction> million, in Other income (expense) on the Company&#8217;s Condensed Consolidated Statements of Operations related to the sale. Prior to the sale, Myriad myPath operations were included in the Company&#8217;s diagnostics reporting segment.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 1, 2021, the Company completed its sale of Myriad RBM, Inc., a wholly owned subsidiary of the Company, to IQVIA RDS, Inc. for cash consideration of $<ix:nonFraction unitRef="usd" contextRef="ie5db1cb383af4d9091b44997a3e2b23f_D20210701-20210701" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183OS9mcmFnOmNjZjdkY2MyMTZlOTRmNGRiMGI2NmRkYjBjNjIzMGFlL3RleHRyZWdpb246Y2NmN2RjYzIxNmU5NGY0ZGIwYjY2ZGRiMGM2MjMwYWVfMTA5OTUxMTYzNDQ3NA_bc9d43a5-1180-4991-a435-4c8c6f272f0f">197.0</ix:nonFraction> million. The transaction was accounted for as a sale of a business and the Company recognized a gain of $<ix:nonFraction unitRef="usd" contextRef="ie5db1cb383af4d9091b44997a3e2b23f_D20210701-20210701" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183OS9mcmFnOmNjZjdkY2MyMTZlOTRmNGRiMGI2NmRkYjBjNjIzMGFlL3RleHRyZWdpb246Y2NmN2RjYzIxNmU5NGY0ZGIwYjY2ZGRiMGM2MjMwYWVfMTY0OTI2NzQ0ODI1MQ_5dac1006-b708-44f6-8de0-43bb8d2f73be">121.0</ix:nonFraction> million, net of transaction costs of $<ix:nonFraction unitRef="usd" contextRef="ie5db1cb383af4d9091b44997a3e2b23f_D20210701-20210701" decimals="-5" format="ixt:num-dot-decimal" name="mygn:DisposalGroupNotDiscontinuedOperationTransactionCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183OS9mcmFnOmNjZjdkY2MyMTZlOTRmNGRiMGI2NmRkYjBjNjIzMGFlL3RleHRyZWdpb246Y2NmN2RjYzIxNmU5NGY0ZGIwYjY2ZGRiMGM2MjMwYWVfMTA5OTUxMTYzNDUxNA_88908281-7204-4d0c-8a62-6a63c88c0199">4.8</ix:nonFraction> million, in Other income (expense) on the Company's Condensed Consolidated Statements of Operations. Prior to the sale, Myriad RBM, Inc. operations were included in the Company&#8217;s other reporting segment.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 13, 2021, the Company completed its sale of select operating assets and intellectual property, including the Vectra&#174; test, from the Myriad Autoimmune business unit to Laboratory Corporation of America Holdings for cash consideration of $<ix:nonFraction unitRef="usd" contextRef="i6b8313a324f94c6caad8b75523488f35_D20210913-20210913" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183OS9mcmFnOmNjZjdkY2MyMTZlOTRmNGRiMGI2NmRkYjBjNjIzMGFlL3RleHRyZWdpb246Y2NmN2RjYzIxNmU5NGY0ZGIwYjY2ZGRiMGM2MjMwYWVfMTY0OTI2NzQ0NTE5OA_99e90258-77de-40a3-93f4-35ff9b549fd0">150.0</ix:nonFraction> million. The transaction was accounted for as a sale of a business and the Company recognized a loss of $<ix:nonFraction unitRef="usd" contextRef="i6b8313a324f94c6caad8b75523488f35_D20210913-20210913" decimals="-5" sign="-" format="ixt:num-dot-decimal" name="us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183OS9mcmFnOmNjZjdkY2MyMTZlOTRmNGRiMGI2NmRkYjBjNjIzMGFlL3RleHRyZWdpb246Y2NmN2RjYzIxNmU5NGY0ZGIwYjY2ZGRiMGM2MjMwYWVfMTY0OTI2NzQ0ODMyMw_69f8cf6f-2a53-46ea-b402-70e7c072febe">0.6</ix:nonFraction> million, net of transaction costs of $<ix:nonFraction unitRef="usd" contextRef="i6b8313a324f94c6caad8b75523488f35_D20210913-20210913" decimals="-5" format="ixt:num-dot-decimal" name="mygn:DisposalGroupNotDiscontinuedOperationTransactionCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183OS9mcmFnOmNjZjdkY2MyMTZlOTRmNGRiMGI2NmRkYjBjNjIzMGFlL3RleHRyZWdpb246Y2NmN2RjYzIxNmU5NGY0ZGIwYjY2ZGRiMGM2MjMwYWVfMTA5OTUxMTYzNDU1NQ_a34ee1a6-2c18-4b79-a332-0650dae50b87">4.4</ix:nonFraction> million, in Other income (expense) on the Company's Condensed Consolidated Statements of Operations. Prior to the sale, the Myriad Autoimmune business operations were included in the Company&#8217;s diagnostics reporting segment.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The operating results of these businesses do not qualify for reporting as discontinued operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inventory</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the divestiture transactions, the Company recognized losses of $<ix:nonFraction unitRef="usd" contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:InventoryFirmPurchaseCommitmentLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183OS9mcmFnOmNjZjdkY2MyMTZlOTRmNGRiMGI2NmRkYjBjNjIzMGFlL3RleHRyZWdpb246Y2NmN2RjYzIxNmU5NGY0ZGIwYjY2ZGRiMGM2MjMwYWVfMTY0OTI2NzQ0ODE3MQ_506b289b-5869-41fe-b96a-6340508c677b">5.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:InventoryWriteDown" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183OS9mcmFnOmNjZjdkY2MyMTZlOTRmNGRiMGI2NmRkYjBjNjIzMGFlL3RleHRyZWdpb246Y2NmN2RjYzIxNmU5NGY0ZGIwYjY2ZGRiMGM2MjMwYWVfMTY0OTI2NzQ0ODE3OQ_7be5c0c0-881f-42f4-a195-314249073ed7">6.5</ix:nonFraction> million for a non-cancelable inventory purchase commitment and inventory, respectively, during the nine months ended September 30, 2021, as the Company will no longer have use for the goods. Both of these losses are included in Other income (expense) in the Company's Condensed Consolidated Statements of Operations for the nine months ended September 30, 2021.</span></div><ix:nonNumeric contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" name="us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183OS9mcmFnOmNjZjdkY2MyMTZlOTRmNGRiMGI2NmRkYjBjNjIzMGFlL3RleHRyZWdpb246Y2NmN2RjYzIxNmU5NGY0ZGIwYjY2ZGRiMGM2MjMwYWVfMjc0ODc3OTA3ODEzMQ_a0325e83-cef5-487d-b91c-64aeb693fdea" escape="true"><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table details the amounts recognized in Other income for the three and nine months ended September 30, 2021:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.502%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.514%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.516%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine months ended<br/>&#160;September 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain on sale of Myriad RBM, Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib8b44ab869f44ebd9da9cf10c35e35c4_D20210701-20210930" decimals="-5" name="us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183OS9mcmFnOmNjZjdkY2MyMTZlOTRmNGRiMGI2NmRkYjBjNjIzMGFlL3RhYmxlOjBkMTg0NmYwYmNlNjQ4YTI4NjgxYzlmYWU3YmVmZmY4L3RhYmxlcmFuZ2U6MGQxODQ2ZjBiY2U2NDhhMjg2ODFjOWZhZTdiZWZmZjhfMS0xLTEtMS0yODYxNw_31149cbc-6d4d-4d93-b12e-ee1d5ea734a7">121.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iae9bd564d0e24269a0860f286b76a8c8_D20210101-20210930" decimals="-5" name="us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183OS9mcmFnOmNjZjdkY2MyMTZlOTRmNGRiMGI2NmRkYjBjNjIzMGFlL3RhYmxlOjBkMTg0NmYwYmNlNjQ4YTI4NjgxYzlmYWU3YmVmZmY4L3RhYmxlcmFuZ2U6MGQxODQ2ZjBiY2U2NDhhMjg2ODFjOWZhZTdiZWZmZjhfMS0zLTEtMS0yODYxNw_860fa99a-7e01-4f72-b720-48810585e0c2">121.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain on sale of Myriad myPath, LLC laboratory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic7ad8f15a58548759fdb4e238c847c6b_D20210701-20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183OS9mcmFnOmNjZjdkY2MyMTZlOTRmNGRiMGI2NmRkYjBjNjIzMGFlL3RhYmxlOjBkMTg0NmYwYmNlNjQ4YTI4NjgxYzlmYWU3YmVmZmY4L3RhYmxlcmFuZ2U6MGQxODQ2ZjBiY2U2NDhhMjg2ODFjOWZhZTdiZWZmZjhfMi0xLTEtMS0yODYxNw_7cde60bc-2224-4cb8-9c16-261dea7e9c04">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1b39e1079fcf498da2478fc0bfa35a9c_D20210101-20210930" decimals="-5" name="us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183OS9mcmFnOmNjZjdkY2MyMTZlOTRmNGRiMGI2NmRkYjBjNjIzMGFlL3RhYmxlOjBkMTg0NmYwYmNlNjQ4YTI4NjgxYzlmYWU3YmVmZmY4L3RhYmxlcmFuZ2U6MGQxODQ2ZjBiY2U2NDhhMjg2ODFjOWZhZTdiZWZmZjhfMi0zLTEtMS0yODYxNw_3c64ac9c-845c-4f61-b5b7-6c78e8ac2f6a">31.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain (loss) on inventory</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id8db12274a5e41019919e2f3e84a1cfd_D20210701-20210930" decimals="-5" name="mygn:DisposalGroupNotDiscontinuedOperationGainLossOnInventory" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183OS9mcmFnOmNjZjdkY2MyMTZlOTRmNGRiMGI2NmRkYjBjNjIzMGFlL3RhYmxlOjBkMTg0NmYwYmNlNjQ4YTI4NjgxYzlmYWU3YmVmZmY4L3RhYmxlcmFuZ2U6MGQxODQ2ZjBiY2U2NDhhMjg2ODFjOWZhZTdiZWZmZjhfMy0xLTEtMS0yODYyNg_aee6f48e-5127-4551-8f42-b8e24f935367">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="id6f9bab1ac3d4f769be2cf49d2c11dc1_D20210101-20210930" decimals="-5" sign="-" name="mygn:DisposalGroupNotDiscontinuedOperationGainLossOnInventory" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183OS9mcmFnOmNjZjdkY2MyMTZlOTRmNGRiMGI2NmRkYjBjNjIzMGFlL3RhYmxlOjBkMTg0NmYwYmNlNjQ4YTI4NjgxYzlmYWU3YmVmZmY4L3RhYmxlcmFuZ2U6MGQxODQ2ZjBiY2U2NDhhMjg2ODFjOWZhZTdiZWZmZjhfMy0zLTEtMS0yODYzMw_bad9d53d-7ee7-41af-9169-45b59b7af314">11.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss on sale of Myriad Autoimmune assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="if410392a6c864eb4bcc542e0317057f6_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183OS9mcmFnOmNjZjdkY2MyMTZlOTRmNGRiMGI2NmRkYjBjNjIzMGFlL3RhYmxlOjBkMTg0NmYwYmNlNjQ4YTI4NjgxYzlmYWU3YmVmZmY4L3RhYmxlcmFuZ2U6MGQxODQ2ZjBiY2U2NDhhMjg2ODFjOWZhZTdiZWZmZjhfNC0xLTEtMS0yODY0MQ_d1ba30cd-16c1-406c-8a43-3f06e79f5737">0.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ia7f3ca65537e48c2a6d04c65e5799212_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183OS9mcmFnOmNjZjdkY2MyMTZlOTRmNGRiMGI2NmRkYjBjNjIzMGFlL3RhYmxlOjBkMTg0NmYwYmNlNjQ4YTI4NjgxYzlmYWU3YmVmZmY4L3RhYmxlcmFuZ2U6MGQxODQ2ZjBiY2U2NDhhMjg2ODFjOWZhZTdiZWZmZjhfNC0zLTEtMS0yODY0MQ_1fbf6de4-355e-4520-b103-05042e876e67">0.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="id8db12274a5e41019919e2f3e84a1cfd_D20210701-20210930" decimals="-5" sign="-" name="mygn:DisposalGroupNotDiscontinuedOperationGainLossOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183OS9mcmFnOmNjZjdkY2MyMTZlOTRmNGRiMGI2NmRkYjBjNjIzMGFlL3RhYmxlOjBkMTg0NmYwYmNlNjQ4YTI4NjgxYzlmYWU3YmVmZmY4L3RhYmxlcmFuZ2U6MGQxODQ2ZjBiY2U2NDhhMjg2ODFjOWZhZTdiZWZmZjhfNS0xLTEtMS0yODY0MQ_633c861f-392f-4e10-b52a-b4ec887d250f">0.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="id6f9bab1ac3d4f769be2cf49d2c11dc1_D20210101-20210930" decimals="-5" sign="-" name="mygn:DisposalGroupNotDiscontinuedOperationGainLossOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183OS9mcmFnOmNjZjdkY2MyMTZlOTRmNGRiMGI2NmRkYjBjNjIzMGFlL3RhYmxlOjBkMTg0NmYwYmNlNjQ4YTI4NjgxYzlmYWU3YmVmZmY4L3RhYmxlcmFuZ2U6MGQxODQ2ZjBiY2U2NDhhMjg2ODFjOWZhZTdiZWZmZjhfNS0zLTEtMS0yODY0MQ_24379092-f7cf-416f-95d7-db7bc77207a4">0.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Other Income</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183OS9mcmFnOmNjZjdkY2MyMTZlOTRmNGRiMGI2NmRkYjBjNjIzMGFlL3RhYmxlOjBkMTg0NmYwYmNlNjQ4YTI4NjgxYzlmYWU3YmVmZmY4L3RhYmxlcmFuZ2U6MGQxODQ2ZjBiY2U2NDhhMjg2ODFjOWZhZTdiZWZmZjhfNi0xLTEtMS0zNDQwOA_d7df76c3-9adb-4877-aed7-5c2dee24c6af">120.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183OS9mcmFnOmNjZjdkY2MyMTZlOTRmNGRiMGI2NmRkYjBjNjIzMGFlL3RhYmxlOjBkMTg0NmYwYmNlNjQ4YTI4NjgxYzlmYWU3YmVmZmY4L3RhYmxlcmFuZ2U6MGQxODQ2ZjBiY2U2NDhhMjg2ODFjOWZhZTdiZWZmZjhfNi00LTEtMS0zMDQyNg_78652503-b480-410d-962d-470d5d231a9c">139.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i5814a71962934792901cb2330361bb17_82"></div><div style="margin-top:18pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">17.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN184Mi9mcmFnOmMwN2Q2YmYxOGIzMDRhOWY4YTVjNGYyODM2OTc4NGUxL3RleHRyZWdpb246YzA3ZDZiZjE4YjMwNGE5ZjhhNWM0ZjI4MzY5Nzg0ZTFfODM2_db5684d2-5a2f-4775-822e-2464ac7cede5" continuedAt="i30ea19fc3cc94d4fb3bbf0ee7e4b87a8" escape="true">SUBSEQUENT EVENTS</ix:nonNumeric></span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i30ea19fc3cc94d4fb3bbf0ee7e4b87a8">The Company evaluated subsequent events from the balance sheet date through the date the financial statements were issued. Based upon this review, the Company did not identify any subsequent events that would have required adjustment or disclosure in the financial statements.</ix:continuation></span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><div id="i5814a71962934792901cb2330361bb17_85"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5814a71962934792901cb2330361bb17_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;padding-left:18pt;padding-right:18pt;text-align:center;text-indent:-36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.&#160;&#160;&#160;&#160;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Dollars and shares in millions, except per share data)</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with the unaudited Condensed Consolidated Financial Statements and the related notes thereto included in this Quarterly Report on Form 10-Q and the audited Consolidated Financial Statements and notes thereto and Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations for the transition period ended December 31, 2020 included in our Transition Report on Form 10-K filed with the SEC on March 16, 2021. &#8220;We,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;Myriad&#8221; and the &#8220;Company&#8221; as used in this Quarterly Report on Form 10&#8209;Q refer to Myriad Genetics, Inc., a Delaware corporation, and its subsidiaries.</span></div><div id="i5814a71962934792901cb2330361bb17_88"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cautionary Statement Regarding Forward-Looking Statements</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The SEC encourages companies to disclose forward-looking information so that investors can better understand a company&#8217;s future prospects and make informed investment decisions. This Quarterly Report on Form 10&#8209;Q contains such &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Words such as &#8220;may,&#8221; &#8220;anticipate,&#8221; &#8220;estimate,&#8221; &#8220;expects,&#8221; &#8220;projects,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;believes,&#8221; &#8220;seek,&#8221; &#8220;could,&#8221; &#8220;continue,&#8221; &#8220;likely,&#8221; &#8220;will,&#8221; &#8220;strategy&#8221; and &#8220;goal&#8221; and words and terms of similar substance used in connection with any discussion of future operating or financial performance identify forward-looking statements. All forward-looking statements are management&#8217;s present expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those described in the forward-looking statements. These risks include, but are not limited to: </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">uncertainties associated with COVID-19, including its possible effects on our operations and the demand for our products and services; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">risks related to our ability to efficiently and flexibly manage our business amid uncertainties associated with COVID-19; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the risk that sales and profit margins of our existing molecular diagnostic tests may decline or that we may not be able to operate our business on a profitable basis; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">risks related to our ability to generate sufficient revenue from our existing product portfolio or in launching and commercializing new tests; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">risks related to changes in governmental or private insurers&#8217; coverage and reimbursement levels for our tests or our ability to obtain reimbursement for our new tests at comparable levels to our existing tests; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">risks related to increased competition and the development of new competing tests and services; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests in a timely manner, or at all; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the risk that we may not successfully develop new markets for our molecular diagnostic tests, including our ability to successfully generate revenue outside the United States; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the risk that licenses to the technology underlying our molecular diagnostic tests and any future tests are terminated or cannot be maintained on satisfactory terms; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">risks related to delays or other problems with operating our laboratory testing facilities;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">risks related to public concern over genetic testing in general or our tests in particular;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">risks related to our ability to obtain new corporate collaborations or licenses and acquire new technologies or businesses on satisfactory terms, if at all; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license or acquire; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">risks related to our projections about the potential market opportunity for our products; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying our tests; </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5814a71962934792901cb2330361bb17_7">Table of Contents</a></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the risk of patent-infringement claims or challenges to the validity of our patents; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">risks related to changes in intellectual property laws covering our molecular diagnostic tests, or patents or enforcement, in the United States and foreign countries; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">risks related to security breaches, loss of data and other disruptions, including from cyberattacks;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks of new, changing and competitive technologies and regulations in the United States and internationally; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the risk that we may be unable to comply with financial operating covenants under our credit or lending agreements; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks related to the material weakness related to our quarterly income tax provision process, including the impact thereof and our remediation plan.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In light of these assumptions, risks and uncertainties, the results and events discussed in the forward-looking statements contained in this Quarterly Report, or in any document incorporated by reference might not occur. Stockholders are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this Quarterly Report. We are not under any obligation, and we expressly disclaim any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise. All forward-looking statements in this Quarterly Report attributable to us or to any person acting on our behalf are expressly qualified in their entirety by the cautionary statements contained or referred to in this section.</span></div><div id="i5814a71962934792901cb2330361bb17_91"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We discover and commercialize genetic tests that determine the risk of developing disease, assess the risk of disease progression, and guide treatment decisions across medical specialties where critical genetic insights can significantly improve patient care and lower healthcare costs. Since our founding in 1992, we have performed tests for approximately five million patients. Our mission and purpose is to advance health and well-being for all, empower individuals with vital genetic insights and enable healthcare providers to better detect, treat and prevent disease.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently developing and executing upon a strategic transformation plan that is focused on the following strategic priorities: (1) put patients and customers first; (2) build new tech-enabled commercial capabilities; (3) elevate core products to their full potential; and (4) create new avenues for growth. In connection with these strategic priorities, we are focusing our efforts on our Hereditary Cancer, Tumor Profiling, Prenatal and Pharmacogenomics products and, as described below, have divested certain non-core assets and businesses. We intend to execute on our transformation plan by prioritizing product innovation, research and technology initiatives, strategic collaborations and investments, and defining and deploying a customer-centric technology-enabled commercial model. We believe that by focusing on these strategic priorities, we will be able to reduce complexity and cost, improve our financial performance, build a more effective and cost-efficient sales model, and enhance our reimbursement and revenue cycle capabilities. In addition, we believe we can accelerate growth as we invest in innovation, research and partnerships, develop capabilities to support our sales team with new digital tools and add more direct-to-consumer engagement, and build commercial capabilities to support new products and acquisitions.</span></div><div id="i5814a71962934792901cb2330361bb17_94"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business Updates</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the quarter ended September 30, 2021, we continued to see improvement in business fundamentals for our diagnostic products which have been affected by the COVID-19 pandemic. We have also made the following recent announcements:</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">On September 13, 2021, we completed the sale of select operating assets and intellectual property, including the Vectra&#174; test, from the Myriad Autoimmune business unit (the "Autoimmune Business Transaction") to Laboratory Corporation of America Holdings for cash consideration of $150.0&#160;million.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">On July 1, 2021, we completed the sale of Myriad RBM, Inc., a wholly owned subsidiary of the Company, to IQVIA RDS, Inc. for cash consideration of $197.0&#160;million.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">On August 2, 2021, we launched a new version of the myRisk Hereditary Cancer Test which allows women of all ancestries to receive a personalized polygenic breast cancer risk assessment for the first time.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">On October 18, 2021, we announced the appointment of Pamela Wong as Chief Legal Officer of the Company. </span></div><div id="i5814a71962934792901cb2330361bb17_97"></div><div style="margin-top:18pt"><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5814a71962934792901cb2330361bb17_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations for the Three Months Ended September 30, 2021 and 2020</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The results of operations for the three months ended September 30, 2021 and 2020 are discussed below.  See Note 14 &#8220;Segment and Related Information&#8221; in the notes to our Condensed Consolidated Financial Statements for information regarding our operating segments.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.165%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">% of total revenue</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molecular diagnostic revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hereditary Cancer</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tumor Profiling</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prenatal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmacogenomics</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Autoimmune</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total molecular diagnostic revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">167.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">135.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical and clinical services revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9.5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">167.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">145.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100%</span></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molecular diagnostic revenues increased $31.6&#160;million for the three months ended September 30, 2021 compared to the same period in the prior year. Tumor profiling revenues increased $15.9&#160;million compared to the same period in the prior year due to  an $8.3 million increase in revenue from myChoice CDx internationally, including a $4.0 million one-time milestone payment, and a $6.4 million increase in revenue for Prolaris due to expanded coverage.  Prenatal revenues increased $7.0&#160;million compared to the same period in the prior year due primarily to a change in estimate for prior period revenues, a 13% increase in average reimbursement per test, and a 7% increase in volumes. Revenues from Pharmacogenomics increased $12.2&#160;million compared to the same period in the prior year due primarily to a 71% increase in volume. Hereditary Cancer revenues decreased $1.1&#160;million compared to the same period in the prior year due to a slight decrease in reimbursement per test as the market for hereditary cancer products continues to become commoditized, which decrease was partially offset by a slight increase in volume.  Autoimmune revenues decreased $1.8 million primarily due to the completion of the Autoimmune Business Transaction on September 13, 2021.  </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical and clinical services revenues decreased for the three months ended September 30, 2021 compared to the same period in the prior year due to the sale of Myriad RBM, Inc. on July 1, 2021. As a result of the sale, there were no Pharmaceutical and clinical services revenues during the current period. Myriad RBM, Inc. generated $9.3&#160;million in revenues during the prior period.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of Sales</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.039%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of molecular diagnostic testing</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47.8&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39.9&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.9</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of molecular diagnostic testing as a % of revenue</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of pharmaceutical and clinical services</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4.3)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of pharmaceutical and clinical services as a % of revenue</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Cost of molecular diagnostic testing as a percentage of revenue decreased from 29.4% to 28.6% during the three months ended September&#160;30, 2021 compared to the same period in the prior year.&#160;</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Cost of pharmaceutical and clinical services as a percentage of revenue was 45.3% for the three months ended September 30, 2020. The sale of Myriad RBM, Inc. was completed on July 1, 2021, and as a result there were no corresponding costs during the current period.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5814a71962934792901cb2330361bb17_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expense</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.527%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.963%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.963%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.969%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D expense</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18.8&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17.6&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.2</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D expense as a % of total revenue</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expense for the three months ended September&#160;30, 2021 increased compared to the same period in the prior year primarily due to an increase in general information technology-related costs, increases in costs incurred in the current period as part of the Company&#8217;s strategic transformation initiatives, and an increase in bonus expense due to improved performance of the Company, partially offset by a decrease in compensation related costs due to a lower headcount.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, General and Administrative Expense</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.039%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expense</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">180.2&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">124.1&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56.1</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expense as a % of total revenue</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">107.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expense increased for the three months ended September&#160;30, 2021 compared to the same period in the prior year primarily due to a $48.0 million legal accrual related to the Crescendo Bioscience, Inc. qui tam lawsuit, as well as a $2.9 million increase in costs incurred in the current period as part of the Company's strategic transformation initiatives, a $2.2 million increase in stock-based compensation, a $2.1 million increase in marketing costs, a $2.1 million increase in legal expenses, and a $1.9 million increase in consulting fees, partially offset by a $3.7 million decrease in amortization expense and a $1.7 million decrease in commission expense due to a decrease in headcount from the prior period.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Change in the Fair Value of Contingent Consideration</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.039%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in the fair value of contingent consideration</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.4&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1.1)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.5</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in the fair value of contingent consideration as a % of total revenue</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of contingent consideration for the three months ended September&#160;30, 2021 increased compared to the same period in the prior year due to changes in timing of expected cash payments associated with the contingent consideration related to the Sividon Diagnostics GmbH acquisition in fiscal year 2016.&#160;&#160;</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Income (Expense), Net</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.039%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense), net</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">119.7&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4.1)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">123.8</span></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense), net increased for the three months ended September&#160;30, 2021 compared to the same period in the prior year due primarily to the $121.0 million net gain recognized on the sale of Myriad RBM, Inc. in the current period, partially offset by expenses in the current period, including a $0.6 million loss recognized on the sale of the Myriad Autoimmune business unit. The prior year expense primarily relates to foreign exchange losses partially offset by interest income in the prior period. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Tax Expense (Benefit)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.039%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax expense (benefit)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15.2&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(28.5)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43.7</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective tax rate</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our tax rate is the product of a blended U.S. federal effective rate of 21.0% and a blended state income tax rate of approximately 3.4%. Certain significant or unusual items are separately recognized during the period in which they occur and can be a source of variability in the effective tax rates from period to period.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5814a71962934792901cb2330361bb17_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Income tax expense (benefit) for the three months ended September&#160;30, 2021 was $15.2 million, and our effective tax rate was 38.2%.&#160;&#160;The change in the effective tax rate for the three months ended September&#160;30, 2021 as compared to the same period in the prior year is primarily due to the tax benefit recorded in the prior year related to the CARES Act, tax expenses recorded in the current year related to the differences between the book and tax basis of assets divested, disallowed executive compensation expenses, and stock compensation expenses.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations for the Nine Months Ended September 30, 2021 and 2020</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The results of operations for the nine months ended September 30, 2021 and 2020 are discussed below.  See Note 14 &#8220;Segment and Related Information&#8221; in the notes to our Condensed Consolidated Financial Statements for information regarding our operating segments.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.605%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">% of total revenue</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molecular diagnostic revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hereditary Cancer</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">241.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">205.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tumor Profiling</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prenatal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt;padding-left:11.25pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmacogenomics</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Autoimmune</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total molecular diagnostic revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">505.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">369.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">136.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical and clinical services revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8.7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">529.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">402.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">127.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100%</span></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molecular diagnostic revenues for the nine months ended September 30, 2021 increased $136.1 million compared to the same period in the prior year. Revenue for the nine months ended September&#160;30, 2020 was negatively impacted by the pandemic as patients faced significant obstacles to accessing health care professionals. Tumor Profiling revenues increased $53.2 million compared to the same period in the prior year due to a $27.4 million increase in revenue for Prolaris due to expanded coverage and the submission of claims for previously performed tests that were pending clarification of the coverage policy and a $21.1 million increase in revenues from myChoice CDx due to expansion in Japan and other areas. Hereditary Cancer revenues increased $35.9 million compared to the same period in the prior year due primarily to a 21% increase in volume. Revenues from Pharmacogenomics increased $23.5 million compared to the same period in the prior year due primarily to a 56% increase in volume. Prenatal revenues increased $23.2 million compared to the same period in the prior year due primarily to an increase of 15% in volume and an over 10% increase in the average reimbursement per test, as well as a change in estimate related to revenues from prior periods. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical and clinical services revenues decreased for the nine months ended September 30, 2021 compared to the same period in the prior year due to decreased revenue attributable to the sale of Myriad RBM, Inc. on July 1, 2021, which generated $28.9 million in revenue during the prior period and the sale of the Clinic, an internal medicine emergency hospital, which was sold in February 2020 and generated $3.9 million in revenue during the prior period. The decrease was partially offset by $2.9 million generated from processing COVID-19 tests in the current period. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of Sales</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.782%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.544%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.527%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.527%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.544%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.527%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.549%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of molecular diagnostic testing</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">139.9&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">115.2&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24.7</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of molecular diagnostic testing as a % of revenue</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of pharmaceutical and clinical services</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3.9)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of pharmaceutical and clinical services as a % of revenue</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5814a71962934792901cb2330361bb17_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Cost of molecular diagnostic testing as a percentage of revenue decreased from 31.2% to 27.7% during the nine months ended September&#160;30, 2021 compared to the same period in the prior year.&#160;The decrease was primarily driven by the increase in revenue from higher test volumes during the period as the same period from the prior year was impacted by COVID-19; thus, costs decreased as a percentage of revenue as revenue from increases in test volumes outpaced personnel and materials costs to perform the tests.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cost of pharmaceutical and clinical services decreased compared to the same period in the prior year due to the sale of Myriad RBM, Inc. that was completed on July 1, 2021. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expense</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.601%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D expense</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61.4&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54.7&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.7</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D expense as a % of total revenue</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expense for the nine months ended September&#160;30, 2021 increased compared to the same period in the prior year primarily due to increases in costs incurred in the current period as part of the Company&#8217;s strategic transformation initiatives, increases in lab expenses, and increases in compensation costs as a result of employee bonus reductions in the prior period stemming from the significant impact of COVID-19 on the Company's financial results.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, General and Administrative Expense</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.601%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expense</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">460.5&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">364.4&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96.1</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expense as a % of total revenue</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expense increased for the nine months ended September&#160;30, 2021 compared to the same period in the prior year primarily due to a $48.0 million legal accrual related to the Crescendo Bioscience, Inc. qui tam lawsuit, a $14.4 million increase in costs incurred in the current period as part of the Company's strategic transformation initiative, and a $10.5 million increase in stock-based compensation due to lower stock-based compensation in the prior period as a result of adjustments to stock-based compensation related to the departure of our former Chief Executive Officer, as well as an $8.5 million increase in bonus expense as a result of employee bonus reductions in the prior year stemming from the significant impact of COVID-19 on the Company's financial results, a $5.6 million increase in legal expenses, a $3.4 million increase in commissions due to increases in sales, and a $2.9 million increase in consulting fees. Increases were partially offset by a $5.1 million decrease in amortization expense and a decrease in sales and marketing expenses of $2.6 million due primarily to fewer in-person sales and marketing events and travel-related expenses.</span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Change in the Fair Value of Contingent Consideration</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.601%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in the fair value of contingent consideration</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.7&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4.5)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.2</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in the fair value of contingent consideration as a % of total revenue</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of contingent consideration for the nine months ended September&#160;30, 2021 increased compared to the same period in the prior year due to changes in timing of expected cash payments associated with the contingent consideration related to the Sividon Diagnostics GmbH acquisition in fiscal year 2016.&#160;&#160;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5814a71962934792901cb2330361bb17_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill and long-lived asset impairment charges</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.601%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill and long-lived asset impairment charges</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.8&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">98.4&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(96.6)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill and long-lived asset impairment charges as a % of total revenue</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill and long-lived asset impairment charges decreased for the nine months ended September&#160;30, 2021 compared to the same period in the prior year primarily due to the Company recognizing goodwill impairment charges in the prior period related to the Myriad Autoimmune reporting unit, as well as additional charges related to the abandonment of an in-process research and development intangible asset during the prior period.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Income (Expense), Net</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.601%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense), net</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">133.8&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.3&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">125.5</span></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense), net increased for the nine months ended September&#160;30, 2021 compared to the same period in the prior year due primarily to the combined $152.2 million net gain recognized on the sales of Myriad RBM, Inc. and the Myriad myPath, LLC laboratory in the current period, partially offset by expenses or losses in the current period, including the $0.6 million net loss recognized on the sale of the Myriad Autoimmune business unit and losses of $5.2 million and $6.5 million for a non-cancelable purchase commitment and inventory, respectively, recognized in connection with the divestiture transactions. Increases were also partially offset by the receipt of $14.6 million in stimulus funds from the CARES Act in the prior period.  </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Tax Expense (Benefit) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.601%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax benefit</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.0&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(47.4)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53.4</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective tax rate</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(44.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our tax rate is the product of a blended U.S. federal effective rate of 21.0% and a blended state income tax rate of approximately 3.4%. Certain significant or unusual items are separately recognized during the period in which they occur and can be a source of variability in the effective tax rates from period to period.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Income tax expense for the nine months ended September&#160;30, 2021 was $6.0 million, and our effective tax rate was (44.1)%.&#160;&#160;The change in the effective tax rate for the nine months ended September&#160;30, 2021 as compared to the same period in the prior year is primarily due to the tax benefit recorded in the prior year related to the CARES Act, tax expense recorded in the prior year related to asset impairments, tax expense recorded in the current year related to the differences between the book and tax basis of assets divested, disallowed executive compensation expenses, the release of a valuation allowance, and stock compensation expense.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5814a71962934792901cb2330361bb17_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span><br/></span></div><div id="i5814a71962934792901cb2330361bb17_100"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary sources of liquidity are our cash, cash equivalents and marketable investment securities, our cash flows from operations, our cash flows from investing activities, and, in certain circumstances as discussed below, amounts available for borrowing under our Amended Facility. Our capital deployment strategy focuses on use of resources in the key areas of research and development and acquisitions. We believe that investing organically through research and development and acquisitively to support business strategy provides the best return on invested capital. During the three months ended September 30, 2021, our liquidity increased $346.6 million from the combined proceeds from the sales of Myriad RBM, Inc. and the Myriad Autoimmune business. The cash generated from these divestitures provides us with additional liquidity as we seek out strategic opportunities for capital deployment. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our existing capital resources will be sufficient to meet our current and projected operating requirements for the foreseeable future. In addition, our capital resources and cash on hand may be used for acquisitions or other strategic investments.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All remaining borrowings under our Amended Facility, which matures on July 31, 2023, were repaid on July 30, 2021 using cash generated from our recent divestitures. Our available capital resources, however, may be consumed more rapidly than currently expected, and we may need or want to raise additional financing. We may not be able to secure such financing in a timely manner or on favorable terms, if at all.&#160;In addition, we are subject to financial covenants as part of our Amended Facility that could limit our ability to incur additional indebtedness. Without additional funds, we may be forced to delay, scale back or eliminate some of our sales and marketing efforts, research and development activities, or other operations, and potentially delay development of our diagnostic tests in an effort to provide sufficient funds to continue our operations. If any of these events occurs, our ability to achieve our development and commercialization goals could be adversely affected.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended Facility restricts our ability to make future borrowings if unrestricted cash, cash equivalents and marketable securities exceed $150.0 million, unless such borrowings are used in connection with certain permitted acquisitions. Unrestricted cash, cash equivalents and marketable securities totaled $413.6&#160;million as of September 30, 2021. Our revolving commitment amount is $250.0 million as of September 30, 2021. As the Company's total unrestricted cash, cash equivalents, and marketable securities exceeded $150.0 million as of September 30, 2021, we will be unable to make future borrowings unless related to a permitted acquisition. In addition, following the expiration of the waiver of the leverage ratio and interest coverage ratio covenants, which waiver is effective until March 31, 2022, our ability to borrow under the Amended Facility will be limited if we are unable to comply with those financial covenants.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we enter into purchase commitments or other agreements that may materially impact our liquidity position in future periods. In April 2021, a non-cancelable operating lease for our new corporate headquarters in Salt Lake City, Utah, commenced with a lease term of 15 years and total future lease payments of approximately $67.0&#160;million as of September 30, 2021. In addition, we have</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> accrued $48.0 million for a potential settlement of the qui tam lawsuit against Crescendo Bioscience, Inc. and the Company, which is included in accrued liabilities in our Condensed Consolidated Balance Sheet. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5814a71962934792901cb2330361bb17_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the continuing evolving global situation from the COVID-19 pandemic, including the emergence of the more highly transmissible Delta coronavirus variant and its impact on the ongoing recovery from the COVID-19 pandemic, it is not possible to predict whether unanticipated consequences of the pandemic are reasonably likely to materially affect our liquidity and capital resources in the future. Because of the specialized scientific nature of our business, we are highly dependent upon our ability to attract and retain qualified management, scientific, and technical personnel. Competition and compensation for such personnel and other qualified personnel rose as employment vacancies surged during the nine months ended September 30, 2021, and job applicants are often seeking a more flexible work arrangement over the long term as a condition of employment. President Biden's administration is in the process of implementing a mandate requiring companies with 100 or more employees to require full COVID-19 vaccination or regular testing for COVID-19 as a condition of employment. The mandate could  increase already elevated employment vacancies.  In addition, any future federal or state regulations that could require us to mandate full COVID-19 vaccinations for our employees, or any future decision on our part to voluntarily require our employees to receive a COVID-19 vaccine, could impact our ability to hire and retain employees. Loss of the services of or failure to recruit additional key management, scientific and technical personnel and other qualified personnel who are necessary to operate our business would adversely affect our research and development programs and molecular diagnostic business. Additionally, disruptions to our supply chain as a result of COVID-19 could cause shortages of critical materials required to conduct our business, which may have a material adverse effect on our business as a whole. In addition, inflation, led by supply constraints, federal stimulus funding, increases to household savings, and the sudden macroeconomic shift in activity levels arising from the loosening or removal of many government restrictions and the broader availability of COVID-19 vaccines, has had, and may continue to have, an impact on the labor costs we incur to attract and retain qualified personnel, costs to generate sales and produce diagnostic testing results, and costs of lab supplies.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents the balances of cash, cash equivalents and marketable investment securities:&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.601%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30, <br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">295.2&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">117.0&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">178.2&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable investment securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term marketable investment securities</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47.5&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21.0&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26.5&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents and marketable investment securities</span></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">413.6&#160;</span></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">171.7&#160;</span></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">241.9&#160;</span></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in cash, cash equivalents, and marketable investment securities was primarily driven by $379.1 million in total cash consideration from the sale of Myriad RBM, Inc., select assets of the Myriad Autoimmune business unit, and the Myriad myPath, LLC laboratory, the receipt of an $89.6 million U.S. federal tax refund in the quarter ended March 31, 2021, and proceeds of $90.0 million from the exercise of stock options, partially offset by $226.4 million in repayments of the Company's revolving credit facility during the nine months ended September 30, 2021 and $10.5 million in transaction expenses related to the foregoing divestitures, as well as by cash used in operating activities as part of our normal course of business.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents the Condensed Consolidated Cash Flow Statement:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.039%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from operating activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from investing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from financing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(149.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(146.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of foreign exchange rates on cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in cash and cash equivalents classified as held for sale</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase in cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at the beginning of the period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at the end of the period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash Flows from Operating Activities</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in cash flows from operating activities for the nine months ended September 30, 2021, compared to the same period in the prior year, was primarily due to the change in the balance of prepaid taxes due to the receipt of an $89.6&#160;million U.S. federal tax refund, partially offset by a decrease in cash flows from operating activities primarily driven by a $44.9&#160;million change in trade accounts receivable in the current period compared to the prior period due to the change in sales volumes and cash collections as a result of the significant impact of COVID-19 on the Company's financial results during the prior period.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5814a71962934792901cb2330361bb17_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash Flows from Investing Activities</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in cash flows from investing activities for the nine months ended September 30, 2021, compared to the same period in the prior year, was primarily due to incremental cash proceeds of $357.8&#160;million from divestitures in the current period as compared to the prior period. This increase is partially offset by an increase of $85.2&#160;million in purchases of marketable investments securities in the current period as compared to the prior period, a decrease of $15.1&#160;million in proceeds from marketable investment securities during the current period, and an increase of $7.8&#160;million in capital expenditures in the current period.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash Flows from Financing Activities</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in cash flows from financing activities for the nine months ended September 30, 2021, compared to the same period in the prior year, was primarily due to the use of $226.4&#160;million in cash for repayments of the Amended Facility during the nine months ended September 30, 2021. The decrease was partially offset by an increase of $83.1&#160;million in proceeds from the exercise of stock options, net of shares exchanged for payroll withholding tax, for the nine months ended September 30, 2021 compared to the same period in the prior year.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Effects of Inflation</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not believe that inflation has had a material impact on our business, sales, or operating results during the periods presented. However, inflation, led by supply constraints, federal stimulus funding, increases to household savings, and the sudden macroeconomic shift in activity levels arising from the loosening or removal of many government restrictions and the broader availability of COVID-19 vaccines, has had, and may continue to have, an impact on the labor costs we incur to attract and retain qualified personnel, costs to generate sales and produce diagnostic testing results, and costs of lab supplies. Inflationary costs may impact our profitability and could adversely affect our business, financial condition and results of operations.  </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share Repurchase Program</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Board of Directors has previously authorized us to repurchase up to $200.0 million of our outstanding common stock. We may repurchase our common stock from time to time or on an accelerated basis through open market transactions or privately negotiated transactions as determined by our management. The amount and timing of stock repurchases under the program will depend on business and market conditions, stock price, trading restrictions, acquisition activity and other factors.&#160;&#160;As of September&#160;30, 2021, we are authorized to repurchase up to $110.7&#160;million under our current share repurchase authorization.&#160;&#160;See &#8220;Part II, Item 2. Unregistered Sales of Equity Securities and Use of Proceeds &#8211; Issuer Purchases of Equity Securities&#8221; below.</span></div><div id="i5814a71962934792901cb2330361bb17_103"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Critical accounting policies are those policies which are both important to the presentation of a company&#8217;s financial condition and results and require management&#8217;s most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. For a further discussion of our critical accounting policies, see our Transition Report on Form&#160;10-K. No significant changes to our accounting policies took place during the nine months ended September 30, 2021.</span></div><div id="i5814a71962934792901cb2330361bb17_106"></div><div style="margin-top:18pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3.&#160;&#160;&#160;&#160;Quantitative and Qualitative Disclosures About Market Risk</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes in our market risk during the nine months ended September 30, 2021 compared to the disclosures in </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/899923/000089992321000021/mygn-20201231.htm#ic01b255bce00439ba9380fc219eb70e1_67">Part II, Item&#160;7A of our Transition Report on Form 10-K</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which are incorporated by reference herein.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><div id="i5814a71962934792901cb2330361bb17_109"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5814a71962934792901cb2330361bb17_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4.&#160;&#160;&#160;&#160;Controls and Procedures</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain disclosure controls and procedures (&#8220;Disclosure Controls&#8221;) within the meaning of Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended, or the Exchange Act. Our Disclosure Controls are designed to ensure that information required to be disclosed by us in the reports we file or submit under the Exchange Act, such as this Quarterly Report on Form 10-Q, is recorded, processed, summarized, and reported within the time periods specified in the SEC&#8217;s rules and forms. Our Disclosure Controls are also designed to ensure that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating our Disclosure Controls, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management necessarily applied its judgment in evaluating and implementing possible controls and procedures.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the end of the period covered by this Quarterly Report on Form 10-Q, we evaluated the effectiveness of the design and operation of our Disclosure Controls, which was done under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer. Based on the evaluation of our Disclosure Controls, our Chief Executive Officer and Chief Financial Officer have concluded that, as of September 30, 2021, our Disclosure Controls are not effective.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management has concluded that a material weakness in internal control over financial reporting exists related to our quarterly income tax provision process.  Specifically, we did not provide adequate review and control with respect to the completeness and accuracy of inputs used in the gain/loss calculation related to a divestiture within the interim consolidated income tax provision and related accrual. While the control deficiency did not result in a misstatement of our previously issued consolidated financial statements, the control deficiency could have resulted in a misstatement of the income tax related accounts or disclosures that would have resulted in a material misstatement of our annual or interim consolidated financial statements that would not have been prevented or detected on a timely basis.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Plan to Remediate Material Weakness</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management is committed to the remediation of the material weakness described above, as well as the continued improvement of our internal control over financial reporting. Management has been implementing, and will continue to implement, measures designed to ensure that our controls are designed, implemented, and operating effectively.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the material weakness described above, management will take steps that address the underlying causes, including enhancing review of the information underlying discrete transactions in the interim income tax provision. We intend to remediate this material weakness as soon as possible. We will continue to monitor the effectiveness of our controls and will make any further changes that management determines are appropriate.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Remediation of Previously Reported Material Weakness</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The prior period material weakness identified in our internal control over financial reporting in connection with the preparation of our Consolidated Financial Statements as of and for the transition period ended December 31, 2020 has been remediated. The material weakness identified related to the accounting for intercompany transactions, foreign currency exchanges and foreign currency translation related to our international subsidiaries. Specifically, as part of our financial statement close process, certain of our control activities were not sufficiently designed or operating effectively to ensure all of our policies were in compliance with generally accepted accounting principles, consistent in their application, retained in appropriate documentation and communicated to relevant parties. As a result of the material weakness, we recorded certain immaterial corrections to intercompany accounts, as well as foreign currency exchange and translation gains and losses, in our Consolidated Financial Statements for the transition period ended December 31, 2020. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5814a71962934792901cb2330361bb17_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We implemented control measures to improve our internal control over financial reporting and remediated the prior period material weakness. We took the following actions to remediate the prior period material weakness:</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:12.53pt">We designed additional control and review procedures needed to provide more robust and comprehensive internal controls over financial reporting that address the risks of material misstatement related to the accounting for intercompany transactions, foreign currency exchanges and foreign currency translation within our business processes.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We implemented additional application controls in our financial systems, implemented formal review procedures, and formally documented our newly designed processes for the identified areas.  </span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We subjected the additional controls implemented to testing and concluded that the controls are operating effectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in Internal Controls&#160;&#160;</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has completed a multi-year transformation project to achieve better analytics and process efficiencies through the use of Oracle Fusion Cloud Services System ("Oracle Cloud"). As of October 1, 2021, Oracle Cloud is now our primary accounting system.  Emphasis will continue to be placed on the maintenance of effective internal controls and assessment of the design and operating effectiveness of key control activities in the new system.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than as described above, there were no changes in our internal control over financial reporting that occurred during the three months ended September 30, 2021 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><div id="i5814a71962934792901cb2330361bb17_112"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5814a71962934792901cb2330361bb17_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II - Other Information</span></div><div id="i5814a71962934792901cb2330361bb17_115"></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1.&#160;&#160;&#160;&#160;Legal Proceedings.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Qui Tam Lawsuit</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, our wholly owned subsidiary, Crescendo Bioscience, Inc. (&#8220;CBI&#8221;), received a subpoena from the Office of Inspector General of the Department of Health and Human Services requesting that CBI produce documents relating to entities that received payment from CBI for the collection and processing of blood specimens for testing, including a named unrelated company, healthcare providers and other third party entities. The Office of Inspector General subsequently requested additional documentation in December 2017. CBI provided to the Office of Inspector General the documents requested. On January 30, 2020, the United States District Court for the Northern District of California unsealed a qui tam complaint, filed on April 16, 2016 against CBI and the Company, alleging violations of the Federal and California False Claims Acts and the California Insurance Fraud Prevention Act.  On January 22, 2020, after a multi-year investigation into CBI&#8217;s and the Company&#8217;s alleged conduct, the United States declined to intervene. On January 27, 2020, the State of California likewise filed its notice of declination. The Company was not aware of the complaint until after it was unsealed. On May 23, 2020, the court denied CBI and the Company&#8217;s motion to dismiss. We have accrued $48.0 million for a potential settlement of this qui tam lawsuit against CBI and the Company, which is included in accrued liabilities in our Condensed Consolidated Balance Sheet. If no settlement is reached, we intend to continue to vigorously defend this case, but we cannot predict with any degree of certainty the ultimate resolution of this matter or determine whether, or to what extent, any loss with respect to this matter may exceed the amount that we have accrued.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Purported Securities Class Action</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 27, 2019, a purported class action complaint was filed in the United States District Court for the District of Utah, against the Company, its former President and Chief Executive Officer, Mark C. Capone, and its Chief Financial Officer, R. Bryan Riggsbee (&#8220;Defendants&#8221;). On February 21, 2020, the plaintiff filed an amended class action complaint, which added the Company&#8217;s former Executive Vice President of Clinical Development, Bryan M. Dechairo, as an additional Defendant. This action, captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Myriad Genetics, Inc. Securities Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (No. 2:19-cv-00707-DBB), is premised upon allegations that the Defendants made false and misleading statements regarding our business, operations, and acquisitions.  The lead plaintiff seeks the payment of damages allegedly sustained by it and the purported class by reason of the allegations set forth in the amended complaint, plus interest, and legal and other costs and fees.  On March 16, 2021, the United States District Court for the District of Utah denied the Company&#8217;s motion to dismiss. We intend to vigorously defend against this action. Due to the nature of this matter and inherent uncertainties, it is not possible to provide an evaluation of the likelihood of an unfavorable outcome or an estimate of the amount or range of potential loss, if any.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stockholder Derivative Actions</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 9, 2021, a stockholder derivative complaint was filed in the Delaware Court of Chancery against the Company's former President and Chief Executive Officer, Mark C. Capone, its Chief Financial Officer, R. Bryan Riggsbee, its former Executive Vice President of Clinical Development, Bryan M. Dechairo, and certain of its current and former directors, Lawrence C. Best, Walter Gilbert, John T. Henderson, Heiner Dreismann, Dennis Langer, Lee N. Newcomer, S. Louise Phanstiel, and Colleen F. Reitan (collectively, the "Individual Defendants"), and the Company, as nominal defendant. The complaint is premised upon similar allegations as set forth in the securities class action, including that the Individual Defendants made false and misleading statements regarding our business and operations. The plaintiff, Donna Hickock, asserts breach of fiduciary duty and unjust enrichment claims against the Individual Defendants and seeks, on behalf of the Company, damages allegedly sustained by the Company as a result of the alleged breaches, or disgorgement or restitution, from each of the Individual Defendants, plus interest. Plaintiff Hickock also seeks legal and other costs and fees relating to this action. We intend to vigorously defend against this action. Due to the nature of this matter and inherent uncertainties, it is not possible to provide an evaluation of the likelihood of an unfavorable outcome or an estimate of the amount or range of potential loss, if any.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5814a71962934792901cb2330361bb17_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 17, 2021, a second stockholder derivative complaint was filed in the United States District Court for the District of Delaware against the Individual Defendants, and the Company, as nominal defendant. The action is premised upon similar allegations as set forth in the securities class action and Hickock stockholder derivative action. The plaintiff, Karen Marcey, asserts that the Individual Defendants violated U.S. securities laws and breached their fiduciary duties, and also asserts unjust enrichment, waste of corporate assets and insider trading claims against all or some of the Individual Defendants. Plaintiff Marcey seeks, on behalf of the Company, damages allegedly sustained by the Company as a result of the alleged violations and restitution from the Individual Defendants, plus interest and, on behalf of herself, legal and other costs and fees relating to this action. We intend to vigorously defend against this action. Due to the nature of this matter and inherent uncertainties, it is not possible to provide an evaluation of the likelihood of an unfavorable outcome or an estimate of the amount or range of potential loss, if any.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Legal Proceedings</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 27, 2020, a lawsuit was filed against the Company in the Superior Court of Suffolk County, Massachusetts, by Heide Abelli and Victor Pricolo. The plaintiffs claim negligence, breach of contract and associated torts in connection with an alleged error in testing performed by the Company in 2004.  The plaintiffs seek damages allegedly sustained by them by reason of the allegations set forth in their complaint, together with interest and costs. We intend to vigorously defend against this action. Due to the nature of this matter and inherent uncertainties, it is not possible to provide an evaluation of the likelihood of an unfavorable outcome or an estimate of the amount or range of potential loss, if any.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 24, 2018, our wholly owned subsidiary, Assurex Health, Inc. (&#8220;Assurex&#8221;), was served with an Amended Complaint which had been filed in the Circuit Court of Cook County, Illinois, County Department, Law Division, Civil Action No. 2018 L 004972, by Pipe Trades Services MN Welfare Plan (&#8220;Pipe Trades&#8221;), as a qui tam relator, on behalf of the State of Illinois, Pipe Trades, and all others similarly situated, purportedly arising from Assurex&#8217;s alleged violations of the Illinois Insurance Claims Fraud Prevention Act and other causes of action. Pipe Trades seeks certification of a putative class, certification as the purported class representative, and the payment of treble damages allegedly sustained by Pipe Trades and the purported class by reason of the allegations set forth in the amended complaint, plus statutory damages and penalties, plus interest, and legal and other costs and fees. The State of Illinois and Cook County, Illinois, have declined to intervene in the matter. On February 19, 2021, the court granted Assurex&#8217;s motion to dismiss the complaint, without prejudice and with leave for Pipe Trades to file an amended complaint, for failure to state a claim on which relief can be granted. On March 19, 2021, Pipe Trades filed an amended complaint. Assurex and Pipe Trades subsequently agreed to settle the case for $170,000, which settlement was approved by the State of Illinois and Cook County, Illinois on September 9, 2021. Accordingly, the court dismissed the case with prejudice on September 9, 2021.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than as set forth above, we are not a party to any legal proceedings that we believe will have a material impact on our business, financial position or results of operations.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><div id="i5814a71962934792901cb2330361bb17_118"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5814a71962934792901cb2330361bb17_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A.&#160;&#160;&#160;&#160;Risk Factors.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the other information set forth in this Quarterly Report, you should carefully consider the risk factors and other cautionary statements described under the heading &#8220;Item 1A. Risk Factors&#8221; included in the Transition Report on Form 10-K, which could materially affect our business, financial condition or future results. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially and adversely affect our business, financial condition or future results. There have been no material changes in our risk factors from those described in the Transition Report on Form 10-K other than the updates to the risk factors set forth below. We may disclose changes to risk factors or additional risk factors from time to time in our future filings with the SEC.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We have identified a material weakness in our internal control over accounting related to our quarterly income tax provision process and such weakness led to a conclusion that our internal control over financial reporting and disclosure controls and procedures were not effective as of September 30, 2021. Our inability to remediate the material weakness, our discovery of any additional weaknesses, or our inability to achieve and maintain effective disclosure controls and procedures and internal control over financial reporting could adversely affect our results of operations, our stock price and investor confidence in our company.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Section 404 of the Sarbanes-Oxley Act of 2002 requires that companies evaluate and report on the effectiveness of their internal control over financial reporting. In addition, we regularly engage our independent registered public accounting firm to report on its evaluation of those controls. As disclosed in more detail under Part I,Item 4, &#8220;Controls and Procedures&#8221; above, we have identified a material weakness as of September 30, 2021 in our internal control over accounting related to our quarterly income tax provision process. Specifically, we did not provide adequate review and control with respect to the completeness and accuracy of inputs used in the gain/loss calculation related to a divestiture within the interim consolidated income tax provision and related accrual. Due to the material weakness in our internal control over financial reporting, we have also concluded that our disclosure controls and procedures were not effective as of September 30, 2021.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Failure to have effective internal control over financial reporting and disclosure controls and procedures could impair our ability to produce accurate financial statements on a timely basis and could lead to a restatement of our financial statements. If, as a result of the ineffectiveness of our internal control over financial reporting and disclosure controls and procedures, we cannot provide reliable financial statements, our business decision processes may be adversely affected, our business and results of operations could be harmed, investors could lose confidence in our reported financial information and our ability to obtain additional financing, or additional financing on favorable terms, could be adversely affected. In addition, failure to maintain effective internal control over financial reporting could result in investigations or sanctions by regulatory authorities.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our management will take steps to remediate the material weakness, including enhancing review of the information underlying discrete transactions in the interim income tax provision. We intend to remediate this material weakness as soon as possible, but we cannot be certain as to when remediation will be completed. Additional details regarding the remediation efforts are disclosed under Part I, Item 4, &#8220;Controls and Procedures&#8221; above. In addition, we may in the future identify additional internal control deficiencies that could rise to the level of a material weakness or uncover other errors in financial reporting. During the course of our evaluation of this material weakness, we may identify areas requiring improvement and may be required to design additional enhanced processes and controls to address issues identified through this review. In addition, there can be no assurance that such remediation efforts will be successful, that our internal control over financial reporting will be effective as a result of these efforts or that any such future deficiencies identified may not be material weaknesses that would be required to be reported in future periods. In addition, we cannot assure you that our independent registered public accounting firm will be able to attest that such internal controls are effective when they are required to do so.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If we fail to remediate the material weakness and maintain effective disclosure controls and procedures or internal control over financial reporting, we may not be able to rely on the integrity of our financial results, which could result in inaccurate or late reporting of our financial results, as well as delays or the inability to meet our reporting obligations or to comply with SEC rules and regulations. Any of these could result in delisting actions by the Nasdaq Stock Market, investigation and sanctions by regulatory authorities, stockholder investigations and lawsuits, and could adversely affect our business and the trading price of our common stock.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5814a71962934792901cb2330361bb17_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Our financial condition and results of operations could be further adversely affected by the ongoing coronavirus pandemic.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any outbreaks of COVID-19 (including its variant strains, such as the highly transmissible Delta variant) or any other outbreak of contagious disease or adverse public health development, could have a further material and adverse effect on our business operations. For example, government public health officials may place additional restrictions to curb the spread of COVID-19, limiting patients' access to our services, and patients may elect to defer certain testing, each of which would impede our progress in returning to profitability and recovering from the earlier effects of the COVID-19 pandemic. Such adverse effects could also include diversion or prioritization of healthcare resources away from the conduct of genetic testing, disruptions or restrictions on the ability of laboratories to process our tests, and delays or difficulties in patients accessing our tests. In addition, failure to comply with current or future federal or state regulations requiring us to mandate full COVID-19 vaccination for our employees, with or without a regular testing alternative, could result in our losing access to government funding and being fined per violation.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As COVID-19 continues to affect individuals and businesses around the globe, we will likely experience further disruptions from time to time that could severely impact our business, including:</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decreased volume of testing as a result of disruptions to healthcare providers and limitations on the ability of providers to administer tests;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disruptions or restrictions on the ability of our, our collaborators&#8217;, or our suppliers&#8217; personnel to travel, and temporary closures of our facilities or the facilities of our collaborators or suppliers;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limitations on employee resources that would otherwise be focused on the development of our products, processing our diagnostic tests, and the conduct of our clinical trials, including because of sickness of employees or their families or requirements imposed on employees to avoid contact with large groups of people; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in necessary interactions with local regulators, ethics committees and other important agencies and contractors due to limitations in employee resources or access.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the continued spread of COVID-19 globally could further adversely affect our manufacturing and supply chain. Parts of our direct and indirect supply chain are located overseas and both international and domestic components may continue to be subject to disruption as a result of COVID-19 and ongoing responses to it. If the supplies and components necessary to manufacture our products become unavailable or are disrupted as a result of COVID-19 and ongoing responses to it, then we may not be able to successfully perform our research or operate our business on a timely basis or at all. Additionally, our results of operations could be adversely affected to the extent that the continued spread of COVID-19 or any other public health emergency harms our business or the economy in general either domestically or in any other region in which we do business. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent to which COVID-19 continues to affect our operations and impede our recovery from the earlier effects of the COVID-19 pandemic will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration, spread and severity of COVID-19 outbreaks, the rate of vaccination and efficacy of approved vaccines against COVID-19 and its variant strains, actions taken to contain COVID-19 or treat its impact, new information that may emerge concerning the health effects of COVID-19, and how quickly and to what extent normal economic and operating conditions would resume if the pandemic subsided, any of which could have a further adverse effect on our business and financial condition.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5814a71962934792901cb2330361bb17_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to retain our key personnel and hire, train and retain qualified employees and consultants, we may not be able to successfully continue our business.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the specialized scientific nature of our business, we are highly dependent upon our ability to attract and retain qualified management, scientific and technical personnel. Competition and compensation for such personnel and other qualified personnel rose as employment vacancies surged during 2021, and job applicants are often seeking a more flexible work arrangement over the long term as a condition of employment. President Biden's administration is in the process of implementing a mandate requiring companies with 100 or more employees to require full COVID-19 vaccination or regular testing for COVID-19 as a condition of employment.  The mandate could increase already elevated employment vacancies.  In addition, any future federal or state regulations that could require us to mandate full COVID-19 vaccinations for our employees, or any future decision on our part to voluntarily require our employees to receive a COVID-19 vaccine, could impact our ability to hire and retain employees. Loss of the services of or failure to recruit additional key management, scientific and technical personnel and other qualified personnel who are necessary to operate our business would adversely affect our research and development programs and molecular diagnostic business and may have a material adverse effect on our business as a whole. In addition, inflation arising from the recovery from the COVID-19 pandemic, led by supply constraints, federal stimulus funding, increases to household savings, and the sudden macroeconomic shift in activity levels arising from the loosening or removal of many government restrictions and the broader availability of COVID-19 vaccines in the United States, has had, and may continue to have, an impact on the costs that we incur to attract and retain qualified personnel and may make it more difficult for us to attract and retain such personnel.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our agreements with our employees generally provide for employment that can be terminated by either party without cause at any time, subject to specified notice requirements. Further, the non-competition provision that certain key employees are subject to may not be enforceable under certain state or federal laws.</span></div><div id="i5814a71962934792901cb2330361bb17_121"></div><div style="margin-top:18pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.&#160;&#160;&#160;&#160;Unregistered Sales of Equity Securities and Use of Proceeds.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Issuer Purchases of Equity Securities</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Board of Directors has previously authorized us to repurchase up to $200.0 million of our outstanding common stock, of which $110.7 million is still available to repurchase as of September&#160;30, 2021. We are authorized to complete the repurchase through open market transactions or through an accelerated share repurchase program, in each case to be executed at management&#8217;s discretion based on business and market conditions, stock price, trading restrictions, acquisition activity and other factors.&#160;The repurchase program may be suspended or discontinued at any time without prior notice.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No stock repurchases were made under our stock repurchase program during the three months ended September 30, 2021.</span></div><div id="i5814a71962934792901cb2330361bb17_124"></div><div style="margin-top:18pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3.&#160;&#160;&#160;&#160;Defaults Upon Senior Securities.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i5814a71962934792901cb2330361bb17_127"></div><div style="margin-top:18pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4.&#160;&#160;&#160;&#160;Mine Safety Disclosures.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i5814a71962934792901cb2330361bb17_130"></div><div style="margin-top:18pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5.&#160;&#160;&#160;&#160;Other Information.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><div id="i5814a71962934792901cb2330361bb17_133"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5814a71962934792901cb2330361bb17_7">Table of Contents</a></span></div></div><div style="-sec-extract:summary;margin-top:18pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6.&#160;&#160;&#160;&#160;Exhibits.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.187%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit101-amendedandresta.htm">Amended and Restated 2012 Employee Stock Purchase Plan+</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit311-certificationof.htm">Certification of Chief Executive Officer pursuant to Section 302(a) of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit312-certificationof.htm">Certification of Chief Financial Officer pursuant to Section 302(a) of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit321-certificationpu.htm">Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Furnished).</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The cover page from the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2021 has been formatted in Inline XBRL.</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(+) Management contract or compensatory plan arrangement.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><div id="i5814a71962934792901cb2330361bb17_136"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5814a71962934792901cb2330361bb17_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:53.951%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.750%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MYRIAD GENETICS, INC.</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date: November 4, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Paul J. Diaz</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Paul J. Diaz</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">President and Chief Executive Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Principal executive officer)</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date: November 4, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ R. Bryan Riggsbee</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R. Bryan Riggsbee</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Principal financial and accounting officer)</span></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>exhibit101-amendedandresta.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="if2fcd4bc3b334126b0f80c29c92ec129_33"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Exhibit 10.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">MYRIAD GENETICS, INC.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">AMENDED AND RESTATED 2012 EMPLOYEE STOCK PURCHASE PLAN</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">            </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The following constitute the provisions of the Amended and Restated 2012 Employee Stock Purchase Plan (the &#8220;Plan&#8221;) of Myriad Genetics, Inc. (the &#8220;Company&#8221;).</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">            </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Purpose</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The purpose of the Plan is to provide Employees of the Company and its Designated Subsidiaries with an opportunity to purchase Common Stock of the Company.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">It is the intention of the Company to have the Plan qualify as an &#8220;Employee Stock Purchase Plan&#8221; under Section 423 of the Code.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The provisions of the Plan shall, accordingly, be construed so as to extend and limit participation in a manner consistent with the requirements of that section of the Code.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">            </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">            </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8221; shall mean the Board of Directors of the Company, or a committee of the Board of Directors named by the Board to administer the Plan.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">            </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8221; shall mean the Internal Revenue Code of 1986, as amended, including any successor statute, regulation and guidance thereto.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">            </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Common Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8221; shall mean the common stock, $.01 par value per share, of the Company.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">            </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8221; shall mean Myriad Genetics, Inc, a Delaware</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">co</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">rporation.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">            </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8221; shall mean the regular rate of salary or wages received by the Employee from the Company or a Designated Subsidiary that is taxable income for federal income tax purposes or applicable tax law, including payments for overtime and shift premium, but excluding bonuses, commissions, incentive compensation, incentive payments, relocation, expense reimbursements, tuition, or other reimbursements and any other compensation received from the Company or a Designated Subsidiary.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">            </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Continuous Status as an Employee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8221; shall mean the absence of any interruption or termination of service as an Employee.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Continuous Status as an Employee shall not be considered interrupted in the case of a leave of absence agreed to in writing by the Company, provided that such leave is for a period of not more than 90 days or reemployment upon the expiration of such leave is guaranteed by contract or statute.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">            </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Contributions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8221; shall mean all amounts credited to the account of a participant pursuant to the Plan.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">            </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Designated Subsidiaries</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8221; shall mean the Subsidiaries which have been designated by the Board from time to time in its sole discretion as eligible to participate in the Plan.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">            </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Employee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8221; shall mean any person who is employed by the Company or one of its Designated Subsidiaries for tax purposes and who is customarily employed for at least 20</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">hours per week and more than five months in a calendar year by the Company or one of its Designated Subsidiaries.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">            </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Exercise Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8221; shall mean the last business day of each Offering Period of the Plan.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">            </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Exercise Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8221; shall mean with respect to an Offering Period, an amount equal to 85% of the fair market value (as defined in paragraph 7(b)) of a share of Common Stock on the Offering Date or on the Exercise Date, whichever is lower.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">            </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">(l)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Offering Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8221; shall mean the first business day of each Offering Period of the Plan. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">            </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">(m)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Offering Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8221; shall mean a period of six months as set forth in paragraph 4 of the Plan (or such other period as determined by the Board in accordance with this Plan).</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">            </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">(n)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8221; shall mean this Myriad Genetics, Inc. Amended and Restated 2012 Employee Stock Purchase Plan.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">            </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">(o)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Subsidiary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8221; shall mean a corporation, domestic or foreign, of which not less than 50% of the voting shares are held by the Company or a Subsidiary, whether or not such corporation now exists or is hereafter organized or acquired by the Company or a Subsidiary.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">            </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Eligibility</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">            </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Any person who has been continuously employed as an Employee for three months as of the Offering Date of a given Offering Period shall be eligible to participate in such Offering Period under the Plan and further, subject to the requirements of paragraph 5(a) and the limitations imposed by Section 423(b) of the Code. All Employees granted options under the Plan with respect to any Offering Period will have the same rights and privileges except for any differences that may be permitted pursuant to Section 423.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">            </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Any provisions of the Plan to the contrary notwithstanding, no Employee shall be granted an option under the Plan (i) if, immediately after the grant, such Employee (or any other person whose stock would be attributed to such Employee pursuant to Section 424(d) of the Code) would own stock and&#47;or hold outstanding options to purchase stock possessing five percent (5%) or more of the total combined voting power or value of all classes of stock of the Company or of any Subsidiary of the Company, or (ii) which permits his or her rights to purchase stock under all employee stock purchase plans (described in Section 423 of the Code) of the Company and its Subsidiaries to accrue at a rate which exceeds $25,000 of fair market value of such stock as defined in paragraph 7(b) (determined at the time such option is granted) for each calendar year in which such option is outstanding at any time.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">This limitation shall be applied in accordance with Section 423(b)(8) of the Code.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">In addition, the maximum number of shares of Common Stock that may be purchased by any participant during an Offering Period shall be 5,000 shares of Common Stock.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Any option granted under the Plan shall be deemed to be modified to the extent necessary to satisfy this paragraph 3(b).</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">            </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Offering Periods</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Plan shall be implemented by a series of Offering Periods, with a new Offering Period commencing on December 1 and June 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">of each year or the first business day thereafter (or at such other time or times as may be determined by the Board).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The dates and provisions of separate Offering Periods under the Plan need not be identical, provided that the terms of participation are the same within any particular Offering Period except for any differences that may be permitted pursuant to Section 423 of the Code.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">            </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Participation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">            </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">An</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">eligible Employee may become a participant in the Plan by completing an Enrollment Form provided by the Company and filing it with the Company or its designee prior to the applicable Offering Date, unless a later time for filing the Enrollment Form is set by the Board for all eligible Employees with respect to a given Offering Period.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Enrollment Form and its submission may be electronic as directed by the Company.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Enrollment Form shall set forth the percentage of the participant&#8217;s Compensation (which shall be not less than 1% and not more than 10%) to be paid as Contributions pursuant to the Plan.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">            </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Payroll deductions shall commence with the first payroll following the Offering Date, unless a later time is set by the Board with respect to a given Offering Period, and shall end on the last payroll paid on or prior to the Exercise Date of the Offering Period to which the Enrollment Form is applicable, unless sooner terminated as provided in paragraph 10.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">            </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Method of Payment of Contributions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">            </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Each participant shall elect to have payroll deductions made on each payroll during the Offering Period in an amount not less than 1% and not more than 10% of such participant&#8217;s Compensation on each such payroll (in whole percentage amounts)&#59; provided that the aggregate of such payroll deductions during the Offering Period shall not exceed 10% of the participant&#8217;s aggregate Compensation during said Offering Period (or such other percentage as the Board may establish from time to time before an Offering Date).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">All payroll deductions made by a participant shall be credited to his or her account under the Plan.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">A participant may not make any additional payments into such account.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">            </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">A participant may discontinue his or her participation in the Plan as provided in paragraph 10, or, on one occasion only during the Offering Period, may decrease, but may not increase, the rate of his or her Contributions during the Offering Period by completing and filing with the Company a new Enrollment Form authorizing a change in the deduction rate.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The change in rate shall be effective as of the beginning of the next payroll period following the date of filing of the new Enrollment Form, if the Enrollment Form is completed at least ten business days prior to such date, and, if not, as of the beginning of the next succeeding payroll period.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">            </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Notwithstanding the foregoing, to the extent necessary to comply with Section 423(b)(8) of the Code and paragraph 3(b), a participant&#8217;s payroll deductions may be decreased to 0% at such time during any Offering Period which is scheduled to end during the current calendar year that the aggregate of all payroll deductions accumulated with respect to such Offering Period and any other Offering Period ending within the same calendar year equals $21,250. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Payroll deductions shall recommence at the rate provided in such participant&#8217;s Enrollment Form at the beginning of the first Offering Period which is scheduled to end in the following calendar year, unless terminated by the participant as provided in paragraph 10.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">            </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Grant of Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">            </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">On the Offering Date of each Offering Period, each eligible Employee participating in such Offering Period shall be granted an option to purchase on the Exercise Date of such Offering Period a number of shares of the Common Stock determined by dividing such Employee&#8217;s Contributions accumulated prior to such Exercise Date and retained in the participant&#8217;s account as of the Exercise Date by the applicable Exercise Price&#59; provided however, that such purchase shall be subject to the limitations set forth in paragraphs 3(b) and 12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The fair market value of a share of the Common Stock shall be determined as provided in paragraph 7(b).</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">            </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The fair market value of the Common Stock on a given date shall be (i) if the Common Stock is listed on a national securities exchange or traded in the over-the-counter market and sales prices are regularly reported for the Common Stock, the closing or last sale price of the Common Stock for such date (or, in the event that the Common Stock is not traded on such date, on the immediately preceding trading date), on the composite tape or other comparable reporting system&#59; or (ii) if the Common Stock is not listed on a national securities exchange and such price is not regularly reported, the mean between the bid and asked prices per share of the Common Stock at the close of trading in the over-the-counter market.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">            </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Exercise of Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Unless a participant withdraws from the Plan as provided in paragraph 10, his or her option for the purchase of shares will be exercised automatically on the Exercise Date of the Offering Period, and the maximum number of full shares subject to the option will be purchased for him or her at the applicable Exercise Price with the accumulated Contributions in his or her account.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">If a fractional number of shares results, then such number shall be rounded down to the next whole number and any unapplied cash shall be carried forward to the next Exercise Date, unless the participant requests a cash payment.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The shares purchased upon exercise of an option hereunder shall be deemed to be transferred to the participant on the Exercise Date.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">During a participant&#8217;s lifetime, a participant&#8217;s option to purchase shares hereunder is exercisable only by him or her.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">            </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Delivery</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Upon the written request of a participant, certificates representing the shares purchased upon exercise of an option will be issued as promptly as practicable after the Exercise Date of each Offering Period to participants who wish to hold their shares in certificate form, except that the Board may determine that such shares shall be held for each participant&#8217;s benefit by a broker designated by the Board.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Any payroll deductions accumulated in a participant&#8217;s account which are not sufficient to purchase a full Share shall be retained in the participant&#8217;s account for the subsequent Offering Period, subject to earlier withdrawal by the participant as provided in paragraph 10 below.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Any other amounts left over in a participant&#8217;s account after an Exercise Date shall be returned to the participant.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">            </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Withdrawal&#59; Termination of Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">            </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">A participant may withdraw all but not less than all the Contributions credited to his or her account under the Plan at any time prior to the Exercise Date of the Offering Period by giving written notice to the Company or its designee.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">All of the participant&#8217;s Contributions credited to his or her account will be paid to him or her as soon as practicable after receipt of his or her notice of withdrawal and his or her option for the current period will be automatically terminated, and no further Contributions for the purchase of shares will be made during the Offering Period.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">            </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Upon termination of the participant&#8217;s Continuous Status as an Employee prior to the Exercise Date of the Offering Period for any reason, including retirement or death, the Contributions credited to his or her account will be returned to him or her or, in the case of his or her death, to the person or persons entitled thereto under paragraph 14, and his or her option will be automatically terminated.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">            </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">In the event an Employee fails to remain in Continuous Status as an Employee for at least 20 hours per week during the Offering Period in which the Employee is a participant, he or she will be deemed to have elected to withdraw from the Plan and the Contributions credited to his or her account will be returned to him or her and his or her option terminated.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">            </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">A participant&#8217;s withdrawal from an Offering Period will not have any effect upon his or her eligibility to participate in a succeeding offering or in any similar plan which may hereafter be adopted by the Company.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">            </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Interest</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">No interest shall accrue on the Contributions of a participant in the Plan.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">            </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">            </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The maximum number of shares of Common Stock which shall be made available for sale under the Plan as amended and restated shall be 2,000,000</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:112%;position:relative;top:-3.85pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> shares, subject to adjustment upon changes in capitalization of the Company as provided in paragraph 18.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">If the total number of shares which would otherwise be subject to options granted pursuant to paragraph 7(a) on the Offering Date of an Offering Period exceeds the number of shares then available under the Plan (after deduction of all shares for which options have been exercised), the Company shall make a pro rata allocation of the shares remaining available for option grants in as uniform a manner as shall be practicable and as it shall determine to be equitable.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Any amounts remaining in an Employee&#8217;s account not applied to the purchase of shares pursuant to this paragraph 12 shall be refunded on or promptly after the Exercise Date.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">In such event, the Company shall give written notice of such reduction of the number of shares subject to the option to each Employee affected thereby and shall similarly reduce the rate of Contributions, if necessary.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">            </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The participant will have no interest or voting right in shares covered by his or her option until such option has been exercised.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">            </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Administration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Board shall supervise and administer the Plan and shall have full power to adopt, amend and rescind any rules deemed desirable and appropriate for the administration of the Plan and not inconsistent with the Plan, to construe and interpret the Plan, to correct any defect or</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">supply any omission or reconcile any inconsistency or ambiguity in the Plan and to make all other determinations necessary or advisable for the administration of the Plan, including without limitation, adopting subplans applicable to particular Designated Subsidiaries or locations, which subplans may be designed to be outside the scope of Section 423 of the Code.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> If shares of Common Stock remain available for sale under the Plan on December 1, 2021, that number of shares shall be added to the 2.0 million shares approved by this amendment. The amendment to authorize an additional 2.0 million shares of Common Stock will not be effective until stockholder approval is obtained.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">            </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Designation of Beneficiary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">            </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">A participant may designate a beneficiary who is to receive any shares and cash, if any, from the participant&#8217;s account under the Plan in the event of such participant&#8217;s death subsequent to the end of the Offering Period but prior to delivery to him or her of such shares and cash.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">In addition, a participant may designate a beneficiary who is to receive any cash from the participant&#8217;s account under the Plan in the event of such participant&#8217;s death prior to the Exercise Date of the Offering Period.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">If a participant is married and the designated beneficiary is not the spouse, spousal consent shall be required for such designation to be effective.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Beneficiary designations shall be made either in writing or by electronic delivery as directed by the Company.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">            </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Such designation of beneficiary may be changed by the participant (and his or her spouse, if any) at any time by submission of the required notice, which may be electronic.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">In the event of the death of a participant and in the absence of a beneficiary validly designated under the Plan who is living at the time of such participant&#8217;s death, the Company shall deliver such shares and&#47;or cash to the executor or administrator of the estate of the participant, or if no such executor or administrator has been appointed (to the knowledge of the Company), the Company, in its discretion, may deliver such shares and&#47;or cash to the spouse or to any one or more dependents or relatives of the participant, or if no spouse, dependent or relative is known to the Company, then to such other person as the Company may designate.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">            </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Transferability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Neither Contributions credited to a participant&#8217;s account nor any rights with regard to the exercise of an option or to receive shares under the Plan may be assigned, transferred, pledged or otherwise disposed of in any way (other than by will, the laws of descent and distribution or as provided in paragraph 14) by the participant.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Any such attempt at assignment, transfer, pledge or other disposition shall be without effect, except that the Company may treat such act as an election to withdraw funds in accordance with paragraph 10.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">            </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">16.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Use of Funds</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">All Contributions received or held by the Company under the Plan may be used by the Company for any corporate purpose, and the Company shall not be obligated to segregate such Contributions.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">            </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">17.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Reports</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Individual accounts will be maintained for each participant in the Plan.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Statements of account will be given to participating Employees promptly following the Exercise Date, which statements will set forth the amounts of Contributions, the per share purchase price, the number of shares purchased and the remaining cash balance, if any.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">            </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">18.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Adjustments Upon Changes in Capitalization</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Subject to any required action by the stockholders of the Company, the number of shares of Common Stock covered by unexercised options under the Plan and the number of shares of Common Stock which have been authorized for issuance under the Plan but are not yet subject to options under paragraph 12(a), the number of shares of Common Stock set forth in paragraph 12(a)(i), (collectively, the &#8220;Reserves&#8221;), the maximum number of shares of Common Stock that may be purchased by a participant in an Offering Period set forth in paragraph 3(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> as well as the price per share of Common Stock covered by each unexercised option under the Plan, shall be proportionately adjusted for any increase or decrease in the number of issued shares of Common Stock resulting from a stock split, reverse stock split, stock dividend, combination or reclassification of the Common Stock. Such adjustment shall be made by the Board, whose determination in that respect shall be final, binding and conclusive.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">                        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">In the event of the proposed dissolution or liquidation of the Company, an Offering Period then in progress will terminate immediately prior to the consummation of such proposed action, unless otherwise provided by the Board.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">In the event of a proposed sale of all or substantially all of the assets of the Company, or the merger, consolidation or other capital reorganization of the Company with or into another corporation, each option outstanding under the Plan shall be assumed or an equivalent option shall be substituted by such successor corporation or a parent or subsidiary of such successor corporation, unless the Board determines, in the exercise of its sole discretion and in lieu of such assumption or substitution, to shorten the Offering Period then in progress by setting a new Exercise Date (the &#8220;New Exercise Date&#8221;).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">If the Board shortens the Offering Period then in progress in lieu of assumption or substitution in the event of a merger or sale of assets, the Board shall notify each participant in writing, at least ten days prior to the New Exercise Date, that the Exercise Date for his or her option has been changed to the New Exercise Date and that his or her option will be exercised automatically on the New Exercise Date, unless prior to such date he or she has withdrawn from the Offering Period as provided in paragraph 10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">For purposes of this paragraph, an option granted under the Plan shall be deemed to be assumed if, following the sale of assets, merger or other reorganization, the option confers the right to purchase, for each share of Common Stock subject to the option immediately prior to the sale of assets, merger or other reorganization, the consideration (whether stock, cash or other securities or property) received in the sale of assets, merger or other reorganization by holders of Common Stock for each share of Common Stock held on the effective date of such transaction (and if such holders were offered a choice of consideration, the type of consideration chosen by the holders of a majority of the outstanding shares of Common Stock)&#59; provided, however, that if such consideration received in such transaction was not solely common stock of the successor corporation or its parent (as defined in Section 424(e) of the Code), the Board may, with the consent of the successor corporation, provide for the consideration to be received upon exercise of the option to be solely common stock of the successor corporation or its parent equal in fair market value to the per share consideration received by holders of Common Stock in the sale of assets, merger or other reorganization.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">                        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Board may, if it so determines in the exercise of its sole discretion, also make provision for adjusting the Reserves, as well as the price per share of Common Stock covered by each outstanding option, in the event that the Company effects one or more reorganizations, recapitalizations, rights offerings or other increases or reductions of shares of its outstanding Common Stock, and in the event of the Company being consolidated with or merged into any other corporation.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">            </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">19.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Amendment or Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">                        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Board may at any time terminate or amend the Plan.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Except as provided in paragraph 18, no such termination may affect options previously granted, nor may an amendment make any change in any option theretofore granted which adversely affects the rights of any participant provided that an Offering Period may be terminated by the Board on an Exercise Date or by the Board&#8217;s setting a new Exercise Date with respect to an Offering Period then in progress if the Board determines that termination of the Offering Period is in the best interests of the Company and the stockholders or if continuation of the Offering Period would cause the Company to incur adverse accounting charges in the generally-accepted accounting rules applicable to the Plan.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">In addition, to the extent necessary to comply with Section 423 of the Code (or any successor rule or provision or any applicable law or regulation), the Company shall obtain stockholder approval in such a manner and to such a degree as so required.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">                        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Without stockholder consent and without regard to whether any participant rights may be considered to have been adversely affected, the Board shall be entitled to change the Offering Periods, limit the frequency and&#47;or number of changes in the amount withheld during an Offering Period, establish the exchange ratio applicable to amounts withheld in a currency other than U.S. dollars, permit payroll withholding in excess of the amount designated by a participant in order to adjust for delays or mistakes in the Company&#8217;s processing of properly completed withholding elections, establish reasonable waiting and adjustment periods and&#47;or accounting and crediting procedures to ensure that amounts applied toward the purchase of Common Stock for each participant properly correspond with amounts withheld from the participant&#8217;s Compensation, and establish such other limitations or procedures as the Board determines in its sole discretion advisable that are consistent with the Plan.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">            </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">20.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">All notices or other communications by a participant to the Company under or in connection with the Plan shall be deemed to have been duly given when received in the form specified by the Company at the location, or by the person, designated by the Company for the receipt thereof.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">            </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">21.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Conditions Upon Issuance of Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Shares shall not be issued with respect to an option unless the exercise of such option and the issuance and delivery of such shares pursuant thereto shall comply with all applicable provisions of law, domestic or foreign, including, without limitation, the Securities Act of 1933, as amended, the Securities Exchange Act of 1934, as amended, the rules and regulations promulgated thereunder, and the requirements of any stock exchange upon which the shares may then be listed, and shall be further subject to the approval of counsel for the Company with respect to such compliance.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">            </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">As a condition to the exercise of an option, the Company may require the person exercising such option to represent and warrant at the time of any such exercise that the shares are being purchased only for investment and without any present intention to sell or distribute such shares if, in the opinion of counsel for the Company, such a representation is required by any of the aforementioned applicable provisions of law.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">            </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">22.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Information Regarding Disqualifying Dispositions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">By electing to participate in the Plan, each participant agrees to provide any information about any transfer of shares of Common Stock acquired under the Plan that occurs within two years after the first business day of the Offering Period in which such shares were acquired as may be requested by the Company or any Subsidiaries in order to assist it in complying with the tax laws.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">            </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">23.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Right to Terminate Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Nothing in the Plan or in any agreement entered into pursuant to the Plan shall confer upon any Employee the right to continue in the employment of the Company or any Subsidiary, or affect any right which the Company or any Subsidiary may have to terminate the employment of such Employee.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">            </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">24.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Rights as a Stockholder</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Neither the granting of an option nor a deduction from payroll shall constitute an Employee the owner of shares covered by an option.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">No Employee shall have any right as a stockholder unless and until an option has been exercised, and the shares underlying the option have been registered in the Company&#8217;s share register.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">            </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">25.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Term of Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Plan became effective</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">upon its approval by the Company&#8217;s stockholders in December 2012 and shall continue in effect until November 30, 2032</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:112%;position:relative;top:-3.85pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> unless sooner terminated under paragraph 19.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">            </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">26.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Applicable Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">This Plan shall be governed in accordance with the laws of Delaware, applied without giving effect to any conflict-of-law principles.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> The amendment to extend the term of the Plan to November 30, 2032 will not be effective until stockholder approval is obtained.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>exhibit311-certificationof.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i7a5fff34f4b54185b878138a4d1dcba0_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SARBANES-OXLEY SECTION 302(a) CERTIFICATION</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Paul J. Diaz, certify that&#58;</font></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:37.5pt">I have reviewed this quarterly report on Form 10-Q of Myriad Genetics, Inc.&#59;</font></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:37.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:37.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:37.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:90pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:37.24pt">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:90pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:36.67pt">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:90pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:37.24pt">evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:90pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:36.67pt">disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:37.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:90pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:37.24pt">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:90pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:36.67pt">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:61.695%"><tr><td style="width:1.0%"></td><td style="width:5.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:54.113%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.815%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; November 4, 2021</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Paul J. Diaz</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Paul J. Diaz</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>exhibit312-certificationof.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i42b7d506f21c48d2981bd95d715b32c1_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SARBANES-OXLEY SECTION 302(a) CERTIFICATION</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, R. Bryan Riggsbee, certify that&#58;</font></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:37.5pt">I have reviewed this quarterly report on Form 10-Q of Myriad Genetics, Inc.&#59;</font></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:37.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:37.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:37.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:90pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:37.24pt">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:90pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:36.67pt">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:90pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:37.24pt">evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:90pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:36.67pt">disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:37.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:90pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:37.24pt">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:90pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:36.67pt">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:68.421%"><tr><td style="width:1.0%"></td><td style="width:5.096%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:58.515%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.089%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; November 4, 2021</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; R. Bryan Riggsbee</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R. Bryan Riggsbee</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial and Accounting Officer)</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>exhibit321-certificationpu.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i3ece7253d89646ce8dfcbf5d5e51f641_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code)</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Myriad Genetics, Inc., a Delaware corporation (the &#8220;Company&#8221;), does hereby certify, to such officer&#8217;s knowledge, that&#58;</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Quarterly Report on Form 10-Q for the quarter ended September&#160;30, 2021 (the &#8220;Form 10-Q&#8221;) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.432%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:43.929%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.432%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:43.930%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; November 4, 2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; November 4, 2021</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58;</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Paul J. Diaz</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58;</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; R. Bryan Riggsbee</font></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Paul J. Diaz</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R. Bryan Riggsbee</font></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal Executive Officer</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal Financial and Accounting Officer</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>mygn-20210930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:902b74c1-bcf1-4420-82df-87d4ebd2f6e9,g:dcd0bc70-dec4-4a37-a022-ac912887efc6-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:mygn="http://www.myriad.com/20210930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.myriad.com/20210930">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mygn-20210930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mygn-20210930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mygn-20210930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mygn-20210930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.myriad.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://www.myriad.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>1001002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://www.myriad.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperations" roleURI="http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations">
        <link:definition>1003004 - Statement - Condensed Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofComprehensiveIncomeLoss" roleURI="http://www.myriad.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss">
        <link:definition>1004005 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofStockholdersEquity" roleURI="http://www.myriad.com/role/CondensedConsolidatedStatementsofStockholdersEquity">
        <link:definition>1005006 - Statement - Condensed Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlows" roleURI="http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows">
        <link:definition>1006007 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentation" roleURI="http://www.myriad.com/role/BasisofPresentation">
        <link:definition>2101101 - Disclosure - Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationPolicies" roleURI="http://www.myriad.com/role/BasisofPresentationPolicies">
        <link:definition>2202201 - Disclosure - Basis of Presentation (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Revenue" roleURI="http://www.myriad.com/role/Revenue">
        <link:definition>2103102 - Disclosure - Revenue</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueTables" roleURI="http://www.myriad.com/role/RevenueTables">
        <link:definition>2304301 - Disclosure - Revenue (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueTotalRevenuebyProductandbyUSversusRestofWorldDetails" roleURI="http://www.myriad.com/role/RevenueTotalRevenuebyProductandbyUSversusRestofWorldDetails">
        <link:definition>2405401 - Disclosure - Revenue - Total Revenue by Product and by US versus Rest of World (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueReconciliationofDeferredRevenueBalancesDetails" roleURI="http://www.myriad.com/role/RevenueReconciliationofDeferredRevenueBalancesDetails">
        <link:definition>2406402 - Disclosure - Revenue - Reconciliation of Deferred Revenue Balances (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueNarrativeDetails" roleURI="http://www.myriad.com/role/RevenueNarrativeDetails">
        <link:definition>2407403 - Disclosure - Revenue - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableInvestmentSecurities" roleURI="http://www.myriad.com/role/MarketableInvestmentSecurities">
        <link:definition>2108103 - Disclosure - Marketable Investment Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableInvestmentSecuritiesTables" roleURI="http://www.myriad.com/role/MarketableInvestmentSecuritiesTables">
        <link:definition>2309302 - Disclosure - Marketable Investment Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails" roleURI="http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails">
        <link:definition>2410404 - Disclosure - Marketable Investment Securities - Fair Value for Available-for-Sale Securities by Major Security Type and Class of Security (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails" roleURI="http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails">
        <link:definition>2411405 - Disclosure - Marketable Investment Securities - Cash, Cash Equivalents, and Maturities of Debt Securities Classified as Available-For-Sale Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableInvestmentSecuritiesNarrativeDetails" roleURI="http://www.myriad.com/role/MarketableInvestmentSecuritiesNarrativeDetails">
        <link:definition>2412406 - Disclosure - Marketable Investment Securities - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.myriad.com/role/FairValueMeasurements">
        <link:definition>2113104 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.myriad.com/role/FairValueMeasurementsTables">
        <link:definition>2314303 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsNarrativeDetails" roleURI="http://www.myriad.com/role/FairValueMeasurementsNarrativeDetails">
        <link:definition>2415407 - Disclosure - Fair Value Measurements - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails" roleURI="http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails">
        <link:definition>2416408 - Disclosure - Fair Value Measurements - Fair Value of Financial Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsChangeinFairValueofContingentConsiderationDetails" roleURI="http://www.myriad.com/role/FairValueMeasurementsChangeinFairValueofContingentConsiderationDetails">
        <link:definition>2417409 - Disclosure - Fair Value Measurements - Change in Fair Value of Contingent Consideration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipmentNet" roleURI="http://www.myriad.com/role/PropertyPlantandEquipmentNet">
        <link:definition>2118105 - Disclosure - Property, Plant and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipmentNetTables" roleURI="http://www.myriad.com/role/PropertyPlantandEquipmentNetTables">
        <link:definition>2319304 - Disclosure - Property, Plant and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipmentNetBalancesDetails" roleURI="http://www.myriad.com/role/PropertyPlantandEquipmentNetBalancesDetails">
        <link:definition>2420410 - Disclosure - Property, Plant and Equipment, Net - Balances (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipmentNetDepreciationExpenseDetails" roleURI="http://www.myriad.com/role/PropertyPlantandEquipmentNetDepreciationExpenseDetails">
        <link:definition>2421411 - Disclosure - Property, Plant and Equipment, Net - Depreciation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssets" roleURI="http://www.myriad.com/role/GoodwillandIntangibleAssets">
        <link:definition>2122106 - Disclosure - Goodwill and Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsTables" roleURI="http://www.myriad.com/role/GoodwillandIntangibleAssetsTables">
        <link:definition>2323305 - Disclosure - Goodwill and Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsCarryingAmountofGoodwillDetails" roleURI="http://www.myriad.com/role/GoodwillandIntangibleAssetsCarryingAmountofGoodwillDetails">
        <link:definition>2424412 - Disclosure - Goodwill and Intangible Assets - Carrying Amount of Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsNarrativeDetails" roleURI="http://www.myriad.com/role/GoodwillandIntangibleAssetsNarrativeDetails">
        <link:definition>2425413 - Disclosure - Goodwill and Intangible Assets - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsIntangibleAssetsDetails" roleURI="http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails">
        <link:definition>2426414 - Disclosure - Goodwill and Intangible Assets - Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsIntangibleAssetsDetails_1" roleURI="http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails_1">
        <link:definition>2426414 - Disclosure - Goodwill and Intangible Assets - Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsAmortizationonIntangibleAssetsDetails" roleURI="http://www.myriad.com/role/GoodwillandIntangibleAssetsAmortizationonIntangibleAssetsDetails">
        <link:definition>2427415 - Disclosure - Goodwill and Intangible Assets - Amortization on Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedLiabilities" roleURI="http://www.myriad.com/role/AccruedLiabilities">
        <link:definition>2128107 - Disclosure - Accrued Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedLiabilitiesTables" roleURI="http://www.myriad.com/role/AccruedLiabilitiesTables">
        <link:definition>2329306 - Disclosure - Accrued Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedLiabilitiesDetails" roleURI="http://www.myriad.com/role/AccruedLiabilitiesDetails">
        <link:definition>2430416 - Disclosure - Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebt" roleURI="http://www.myriad.com/role/LongTermDebt">
        <link:definition>2131108 - Disclosure - Long-Term Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtNarrativeDetails" roleURI="http://www.myriad.com/role/LongTermDebtNarrativeDetails">
        <link:definition>2432417 - Disclosure - Long-Term Debt - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherLongTermLiabilities" roleURI="http://www.myriad.com/role/OtherLongTermLiabilities">
        <link:definition>2133109 - Disclosure - Other Long-Term Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherLongTermLiabilitiesTables" roleURI="http://www.myriad.com/role/OtherLongTermLiabilitiesTables">
        <link:definition>2334307 - Disclosure - Other Long-Term Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherLongTermLiabilitiesDetails" roleURI="http://www.myriad.com/role/OtherLongTermLiabilitiesDetails">
        <link:definition>2435418 - Disclosure - Other Long-Term Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PreferredandCommonStockholdersEquity" roleURI="http://www.myriad.com/role/PreferredandCommonStockholdersEquity">
        <link:definition>2136110 - Disclosure - Preferred and Common Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PreferredandCommonStockholdersEquityTables" roleURI="http://www.myriad.com/role/PreferredandCommonStockholdersEquityTables">
        <link:definition>2337308 - Disclosure - Preferred and Common Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PreferredandCommonStockholdersEquityNarrativeDetails" roleURI="http://www.myriad.com/role/PreferredandCommonStockholdersEquityNarrativeDetails">
        <link:definition>2438419 - Disclosure - Preferred and Common Stockholders' Equity - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PreferredandCommonStockholdersEquityCommonSharesIssuedandOutstandingDetails" roleURI="http://www.myriad.com/role/PreferredandCommonStockholdersEquityCommonSharesIssuedandOutstandingDetails">
        <link:definition>2439420 - Disclosure - Preferred and Common Stockholders' Equity - Common Shares Issued and Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PreferredandCommonStockholdersEquityReconciliationofDenominatorsofBasicandDilutedEarningsPerShareComputationsDetails" roleURI="http://www.myriad.com/role/PreferredandCommonStockholdersEquityReconciliationofDenominatorsofBasicandDilutedEarningsPerShareComputationsDetails">
        <link:definition>2440421 - Disclosure - Preferred and Common Stockholders' Equity - Reconciliation of Denominators of Basic and Diluted Earnings Per Share Computations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PreferredandCommonStockholdersEquityPotentiallyDilutiveCommonSharesExcludedfromEPSComputationDetails" roleURI="http://www.myriad.com/role/PreferredandCommonStockholdersEquityPotentiallyDilutiveCommonSharesExcludedfromEPSComputationDetails">
        <link:definition>2441422 - Disclosure - Preferred and Common Stockholders' Equity - Potentially Dilutive Common Shares Excluded from EPS Computation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.myriad.com/role/StockBasedCompensation">
        <link:definition>2142111 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.myriad.com/role/StockBasedCompensationTables">
        <link:definition>2343309 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationNarrativeDetails" roleURI="http://www.myriad.com/role/StockBasedCompensationNarrativeDetails">
        <link:definition>2444423 - Disclosure - Stock-Based Compensation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationStockOptionActivityDetails" roleURI="http://www.myriad.com/role/StockBasedCompensationStockOptionActivityDetails">
        <link:definition>2445424 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationRSUActivityDetails" roleURI="http://www.myriad.com/role/StockBasedCompensationRSUActivityDetails">
        <link:definition>2446425 - Disclosure - Stock-Based Compensation - RSU Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationStockBasedCompensationExpenseDetails" roleURI="http://www.myriad.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails">
        <link:definition>2447426 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.myriad.com/role/IncomeTaxes">
        <link:definition>2148112 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails" roleURI="http://www.myriad.com/role/IncomeTaxesDetails">
        <link:definition>2449427 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.myriad.com/role/CommitmentsandContingencies">
        <link:definition>2150113 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesDetails" roleURI="http://www.myriad.com/role/CommitmentsandContingenciesDetails">
        <link:definition>2451428 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentandRelatedInformation" roleURI="http://www.myriad.com/role/SegmentandRelatedInformation">
        <link:definition>2152114 - Disclosure - Segment and Related Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentandRelatedInformationTables" roleURI="http://www.myriad.com/role/SegmentandRelatedInformationTables">
        <link:definition>2353310 - Disclosure - Segment and Related Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentandRelatedInformationNarrativeDetails" roleURI="http://www.myriad.com/role/SegmentandRelatedInformationNarrativeDetails">
        <link:definition>2454429 - Disclosure - Segment and Related Information - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentandRelatedInformationSegmentRevenueandOperatingIncomeLossDetails" roleURI="http://www.myriad.com/role/SegmentandRelatedInformationSegmentRevenueandOperatingIncomeLossDetails">
        <link:definition>2455430 - Disclosure - Segment and Related Information - Segment Revenue and Operating Income (Loss) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentandRelatedInformationTotalOperatingLossforReportableSegmentsDetails" roleURI="http://www.myriad.com/role/SegmentandRelatedInformationTotalOperatingLossforReportableSegmentsDetails">
        <link:definition>2456431 - Disclosure - Segment and Related Information - Total Operating Loss for Reportable Segments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalCashFlowInformation" roleURI="http://www.myriad.com/role/SupplementalCashFlowInformation">
        <link:definition>2157115 - Disclosure - Supplemental Cash Flow Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalCashFlowInformationTables" roleURI="http://www.myriad.com/role/SupplementalCashFlowInformationTables">
        <link:definition>2358311 - Disclosure - Supplemental Cash Flow Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalCashFlowInformationDetails" roleURI="http://www.myriad.com/role/SupplementalCashFlowInformationDetails">
        <link:definition>2459432 - Disclosure - Supplemental Cash Flow Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Divestitures" roleURI="http://www.myriad.com/role/Divestitures">
        <link:definition>2160116 - Disclosure - Divestitures</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DivestituresTables" roleURI="http://www.myriad.com/role/DivestituresTables">
        <link:definition>2361312 - Disclosure - Divestitures (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DivestituresNarrativeDetails" roleURI="http://www.myriad.com/role/DivestituresNarrativeDetails">
        <link:definition>2462433 - Disclosure - Divestitures - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DivestituresOtherIncomeDetails" roleURI="http://www.myriad.com/role/DivestituresOtherIncomeDetails">
        <link:definition>2463434 - Disclosure - Divestitures - Other Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.myriad.com/role/SubsequentEvents">
        <link:definition>2164117 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="mygn_DisposalGroupNotDiscontinuedOperationGainLossOnInventory" abstract="false" name="DisposalGroupNotDiscontinuedOperationGainLossOnInventory" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mygn_NetChangeInCashAndCashEquivalentsClassifiedAsHeldForSale" abstract="false" name="NetChangeInCashAndCashEquivalentsClassifiedAsHeldForSale" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mygn_ContractWithCustomerLiabilityPrepayments" abstract="false" name="ContractWithCustomerLiabilityPrepayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mygn_MolecularDiagnosticTumorProfilingMember" abstract="true" name="MolecularDiagnosticTumorProfilingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mygn_CostOfPharmaceuticalAndClinicalServicesMember" abstract="true" name="CostOfPharmaceuticalAndClinicalServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mygn_EighthShareRepurchaseProgramMember" abstract="true" name="EighthShareRepurchaseProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mygn_ChangeInFairValueOfContingentConsideration" abstract="false" name="ChangeInFairValueOfContingentConsideration" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mygn_MyriadAutoimmuneAssetsMember" abstract="true" name="MyriadAutoimmuneAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mygn_ScheduleOfIntangibleAssetsTable" abstract="true" name="ScheduleOfIntangibleAssetsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="mygn_MedicareMember" abstract="true" name="MedicareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mygn_InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax" abstract="false" name="InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mygn_IntangibleAssetsLineItems" abstract="true" name="IntangibleAssetsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mygn_GainLossOnDispositionOfAssetsNetOfTransactionFees" abstract="false" name="GainLossOnDispositionOfAssetsNetOfTransactionFees" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mygn_ContractWithCustomerAssetAdjustmentToRevenueForExpandedCoveragePreviouslyConstrained" abstract="false" name="ContractWithCustomerAssetAdjustmentToRevenueForExpandedCoveragePreviouslyConstrained" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mygn_DebtInstrumentLIBORFloorPercentage" abstract="false" name="DebtInstrumentLIBORFloorPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="mygn_EmployeeStockPurchasePlanTwentyTwelveMember" abstract="true" name="EmployeeStockPurchasePlanTwentyTwelveMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mygn_BusinessCombinationContingentConsiderationLiabilityMeasurementInputTerm" abstract="false" name="BusinessCombinationContingentConsiderationLiabilityMeasurementInputTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="mygn_NonCashInterestExpense" abstract="false" name="NonCashInterestExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mygn_MolecularDiagnosticAutoimmuneMember" abstract="true" name="MolecularDiagnosticAutoimmuneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mygn_AmendmentToCreditAgreementMember" abstract="true" name="AmendmentToCreditAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mygn_PharmaceuticalAndClinicalServicesMember" abstract="true" name="PharmaceuticalAndClinicalServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mygn_ContractWithCustomerLiabilityDivestitures" abstract="false" name="ContractWithCustomerLiabilityDivestitures" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mygn_CostOfMolecularDiagnosticTestingMember" abstract="true" name="CostOfMolecularDiagnosticTestingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mygn_IncreaseDecreaseInEarningsLossPerShare" abstract="false" name="IncreaseDecreaseInEarningsLossPerShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="mygn_MolecularDiagnosticPrenatalTestingMember" abstract="true" name="MolecularDiagnosticPrenatalTestingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mygn_OtherAssetsDebtDiscount" abstract="false" name="OtherAssetsDebtDiscount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mygn_ImpairmentOfGoodwillAndLongLivedAssetsHeldForUse" abstract="false" name="ImpairmentOfGoodwillAndLongLivedAssetsHeldForUse" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mygn_ReclassificationFromAccumulatedOtherComprehensiveLossDeconsolidationOfSubsidiary" abstract="false" name="ReclassificationFromAccumulatedOtherComprehensiveLossDeconsolidationOfSubsidiary" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mygn_IncreaseDecreaseInUnrecognizedTaxBenefits" abstract="false" name="IncreaseDecreaseInUnrecognizedTaxBenefits" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mygn_DisposalGroupNotDiscontinuedOperationGainLossOther" abstract="false" name="DisposalGroupNotDiscontinuedOperationGainLossOther" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mygn_OptionsGrantedAfterDecemberFiveTwentyTwelveMember" abstract="true" name="OptionsGrantedAfterDecemberFiveTwentyTwelveMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mygn_OptionsGrantedPriorToDecemberFiveTwentyTwelveMember" abstract="true" name="OptionsGrantedPriorToDecemberFiveTwentyTwelveMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mygn_CARESActOf2020MedicarePaymentAmount" abstract="false" name="CARESActOf2020MedicarePaymentAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mygn_PerformanceObligationEstimatedTransactionPriceMember" abstract="true" name="PerformanceObligationEstimatedTransactionPriceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mygn_MolecularDiagnosticOtherTestingMember" abstract="true" name="MolecularDiagnosticOtherTestingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mygn_DebtCovenantUnrestrictedCashAndCashEquivalentsThresholdForBorrowingRestrictionMinimum" abstract="false" name="DebtCovenantUnrestrictedCashAndCashEquivalentsThresholdForBorrowingRestrictionMinimum" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mygn_InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax" abstract="false" name="InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mygn_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNetNoncurrent" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNetNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mygn_MyriadMyPathLLCLaboratoryMember" abstract="true" name="MyriadMyPathLLCLaboratoryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mygn_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" abstract="false" name="ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mygn_OptionsAndRestrictedStockUnitsMember" abstract="true" name="OptionsAndRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mygn_MolecularDiagnosticPharmacogenomicsMember" abstract="true" name="MolecularDiagnosticPharmacogenomicsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mygn_ContingentConsiderationMember" abstract="true" name="ContingentConsiderationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mygn_MolecularDiagnosticHereditaryCancerTestingMember" abstract="true" name="MolecularDiagnosticHereditaryCancerTestingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mygn_NonEmployeeDirectorMember" abstract="true" name="NonEmployeeDirectorMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mygn_InProcessResearchAndDevelopmentWithIndefiniteLivesMember" abstract="true" name="InProcessResearchAndDevelopmentWithIndefiniteLivesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mygn_TwoThousandSeventeenEmployeeDirectorAndConsultantEquityIncentivePlanMember" abstract="true" name="TwoThousandSeventeenEmployeeDirectorAndConsultantEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mygn_MyriadRBMIncMember" abstract="true" name="MyriadRBMIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mygn_PurchasedLicensesAndTechnologiesMember" abstract="true" name="PurchasedLicensesAndTechnologiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mygn_OperatingLeaseLiabilityEstablished" abstract="false" name="OperatingLeaseLiabilityEstablished" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mygn_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsAccumulatedAmortizationNoncurrent" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsAccumulatedAmortizationNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mygn_InvestmentsAndCashAmortizedCost" abstract="false" name="InvestmentsAndCashAmortizedCost" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mygn_DebtCovenantLiquidityCovenantMinimum" abstract="false" name="DebtCovenantLiquidityCovenantMinimum" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mygn_StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans" abstract="false" name="StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="mygn_RefundsPayableAndReserveCurrent" abstract="false" name="RefundsPayableAndReserveCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mygn_DiagnosticsMember" abstract="true" name="DiagnosticsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mygn_DisposalGroupNotDiscontinuedOperationTransactionCosts" abstract="false" name="DisposalGroupNotDiscontinuedOperationTransactionCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mygn_MolecularDiagnosticTestingMember" abstract="true" name="MolecularDiagnosticTestingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>mygn-20210930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:902b74c1-bcf1-4420-82df-87d4ebd2f6e9,g:dcd0bc70-dec4-4a37-a022-ac912887efc6-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.myriad.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="mygn-20210930.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.myriad.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d1203619-1d50-4ec2-8e09-2c525e4e373f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_e59bbcec-3611-46a8-b948-b286f5c28116" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_d1203619-1d50-4ec2-8e09-2c525e4e373f" xlink:to="loc_us-gaap_CommonStockValue_e59bbcec-3611-46a8-b948-b286f5c28116" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_1405c41f-e65f-4527-8760-be51f909f4cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_d1203619-1d50-4ec2-8e09-2c525e4e373f" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_1405c41f-e65f-4527-8760-be51f909f4cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_1b524c2a-da86-43e5-b5e9-f5ecd83178c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_d1203619-1d50-4ec2-8e09-2c525e4e373f" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_1b524c2a-da86-43e5-b5e9-f5ecd83178c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_01bebdd7-70d9-4739-a9be-855762982df4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_d1203619-1d50-4ec2-8e09-2c525e4e373f" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_01bebdd7-70d9-4739-a9be-855762982df4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d4b1eb82-4129-485d-932c-5557cf13ddf7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e32922cb-0a1d-4003-b443-98a68e9fe7d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d4b1eb82-4129-485d-932c-5557cf13ddf7" xlink:to="loc_us-gaap_StockholdersEquity_e32922cb-0a1d-4003-b443-98a68e9fe7d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_70d4b4b9-6101-43da-8a98-628367b02edd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d4b1eb82-4129-485d-932c-5557cf13ddf7" xlink:to="loc_us-gaap_MinorityInterest_70d4b4b9-6101-43da-8a98-628367b02edd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_76f3d4c6-f857-4482-ae59-4b264f961eb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_df6e52dc-21b7-4fc1-85df-a766debfe3aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_76f3d4c6-f857-4482-ae59-4b264f961eb8" xlink:to="loc_us-gaap_AccountsPayableCurrent_df6e52dc-21b7-4fc1-85df-a766debfe3aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_3c79a46a-06d9-4a5f-a0bd-5a3e7b3d1d3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_76f3d4c6-f857-4482-ae59-4b264f961eb8" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_3c79a46a-06d9-4a5f-a0bd-5a3e7b3d1d3a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_18fc3a79-52e4-4eb2-889d-0d6826b75eba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_76f3d4c6-f857-4482-ae59-4b264f961eb8" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_18fc3a79-52e4-4eb2-889d-0d6826b75eba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_780d3b9a-9eb6-45e2-b3c1-0845280f1989" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_76f3d4c6-f857-4482-ae59-4b264f961eb8" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_780d3b9a-9eb6-45e2-b3c1-0845280f1989" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_d503ff00-7984-4b28-a811-e81ea07d4840" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_88d22e6b-b943-4fd2-8030-94637c5ba95c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d503ff00-7984-4b28-a811-e81ea07d4840" xlink:to="loc_us-gaap_Liabilities_88d22e6b-b943-4fd2-8030-94637c5ba95c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_6bb88d22-4580-4b93-8c51-fee3d249d427" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d503ff00-7984-4b28-a811-e81ea07d4840" xlink:to="loc_us-gaap_CommitmentsAndContingencies_6bb88d22-4580-4b93-8c51-fee3d249d427" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_70771e41-41e7-45b5-9820-082a60eea4a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d503ff00-7984-4b28-a811-e81ea07d4840" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_70771e41-41e7-45b5-9820-082a60eea4a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_b19290ec-b2eb-49a7-9fcc-c7f24df590a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_d236a1ec-2cf7-4adc-a9f2-6e661091e7f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b19290ec-b2eb-49a7-9fcc-c7f24df590a9" xlink:to="loc_us-gaap_AssetsCurrent_d236a1ec-2cf7-4adc-a9f2-6e661091e7f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_393c8411-d0cd-4303-9936-58d128f4616a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b19290ec-b2eb-49a7-9fcc-c7f24df590a9" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_393c8411-d0cd-4303-9936-58d128f4616a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_6c70a91d-e6e5-4b96-989a-80c10fb84a85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b19290ec-b2eb-49a7-9fcc-c7f24df590a9" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_6c70a91d-e6e5-4b96-989a-80c10fb84a85" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_29596426-0677-4807-98dd-c1805f776dd5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b19290ec-b2eb-49a7-9fcc-c7f24df590a9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_29596426-0677-4807-98dd-c1805f776dd5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_165a03f3-2b1e-4068-bfa8-aa60db811d11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b19290ec-b2eb-49a7-9fcc-c7f24df590a9" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_165a03f3-2b1e-4068-bfa8-aa60db811d11" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_4cfa400d-426b-4b98-bbbe-caa88b27e331" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b19290ec-b2eb-49a7-9fcc-c7f24df590a9" xlink:to="loc_us-gaap_Goodwill_4cfa400d-426b-4b98-bbbe-caa88b27e331" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_5c3101bc-babc-42a2-8ea7-8c86c86d4d19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b19290ec-b2eb-49a7-9fcc-c7f24df590a9" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_5c3101bc-babc-42a2-8ea7-8c86c86d4d19" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_f357b59b-4ee7-4de8-bcc6-031b8f1dcc00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_05bca892-5722-4edf-a441-a7fc837e6a47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f357b59b-4ee7-4de8-bcc6-031b8f1dcc00" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_05bca892-5722-4edf-a441-a7fc837e6a47" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_3944391a-5234-4f63-8770-aec174d3eab0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f357b59b-4ee7-4de8-bcc6-031b8f1dcc00" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_3944391a-5234-4f63-8770-aec174d3eab0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_7bc3d5ea-afd7-47f2-b601-64bf7e45fc73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f357b59b-4ee7-4de8-bcc6-031b8f1dcc00" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_7bc3d5ea-afd7-47f2-b601-64bf7e45fc73" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_4debc69d-7cc2-4f13-91ed-d8485ee30b8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f357b59b-4ee7-4de8-bcc6-031b8f1dcc00" xlink:to="loc_us-gaap_InventoryNet_4debc69d-7cc2-4f13-91ed-d8485ee30b8d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidTaxes_36b19610-bffc-47fb-9a0c-a6af1eb3fc5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidTaxes"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f357b59b-4ee7-4de8-bcc6-031b8f1dcc00" xlink:to="loc_us-gaap_PrepaidTaxes_36b19610-bffc-47fb-9a0c-a6af1eb3fc5a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_68580b24-2257-4ba0-af6c-a0c54ff4cf22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f357b59b-4ee7-4de8-bcc6-031b8f1dcc00" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_68580b24-2257-4ba0-af6c-a0c54ff4cf22" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_a7bab4b1-3932-4dd6-b148-143db7284eeb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_68bbb223-906b-4d97-b0ef-236d9490e7a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a7bab4b1-3932-4dd6-b148-143db7284eeb" xlink:to="loc_us-gaap_LiabilitiesCurrent_68bbb223-906b-4d97-b0ef-236d9490e7a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_0c861658-bc3c-4d81-b8be-64ee7e418728" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a7bab4b1-3932-4dd6-b148-143db7284eeb" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_0c861658-bc3c-4d81-b8be-64ee7e418728" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_a31aa3d5-125a-412e-93e5-889ce72e10b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a7bab4b1-3932-4dd6-b148-143db7284eeb" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_a31aa3d5-125a-412e-93e5-889ce72e10b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_a9743c1e-f524-450e-a305-351449d5f8a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a7bab4b1-3932-4dd6-b148-143db7284eeb" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_a9743c1e-f524-450e-a305-351449d5f8a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_141eae3c-53a2-4219-8b79-0e86f310fd5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a7bab4b1-3932-4dd6-b148-143db7284eeb" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_141eae3c-53a2-4219-8b79-0e86f310fd5b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_92e5da84-3f17-42db-aad1-79d5c710fa79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a7bab4b1-3932-4dd6-b148-143db7284eeb" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_92e5da84-3f17-42db-aad1-79d5c710fa79" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="mygn-20210930.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:calculationLink xlink:role="http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_8f64a1fa-4b00-4bd7-8bda-1101edeecd49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_789bd5f7-e395-456e-a084-48a29b7ccd6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_8f64a1fa-4b00-4bd7-8bda-1101edeecd49" xlink:to="loc_us-gaap_InvestmentIncomeInterest_789bd5f7-e395-456e-a084-48a29b7ccd6b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_f59a3038-1709-4da3-aa30-91ca831197d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_8f64a1fa-4b00-4bd7-8bda-1101edeecd49" xlink:to="loc_us-gaap_InterestExpense_f59a3038-1709-4da3-aa30-91ca831197d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_c703bb3b-2abc-442e-97ca-f32606f4b083" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_8f64a1fa-4b00-4bd7-8bda-1101edeecd49" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_c703bb3b-2abc-442e-97ca-f32606f4b083" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_29f1dfe5-b847-416f-b9a5-3fc484830318" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_19832b9d-e855-452e-b8fc-f67772d32d45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_29f1dfe5-b847-416f-b9a5-3fc484830318" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_19832b9d-e855-452e-b8fc-f67772d32d45" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_1101ff19-f7ff-4732-8832-8a30c1a12025" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_29f1dfe5-b847-416f-b9a5-3fc484830318" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_1101ff19-f7ff-4732-8832-8a30c1a12025" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_9c4ae453-6f28-4a6e-97f3-05dca299c3c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_9bb6bad0-b629-4e84-913a-276cf03b96c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_9c4ae453-6f28-4a6e-97f3-05dca299c3c9" xlink:to="loc_us-gaap_OperatingIncomeLoss_9bb6bad0-b629-4e84-913a-276cf03b96c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_2e24eb2d-18e1-467f-af4f-d807663dbf5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_9c4ae453-6f28-4a6e-97f3-05dca299c3c9" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_2e24eb2d-18e1-467f-af4f-d807663dbf5a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_ecc0aa00-bb9d-4a6d-bad6-79d85547e42b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_796f2815-0259-4c66-8b17-b3d8a6bbbec7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_ecc0aa00-bb9d-4a6d-bad6-79d85547e42b" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_796f2815-0259-4c66-8b17-b3d8a6bbbec7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_a8792e7b-2987-4a05-b730-47ca07729ed1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_ecc0aa00-bb9d-4a6d-bad6-79d85547e42b" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_a8792e7b-2987-4a05-b730-47ca07729ed1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_d6f64382-760c-49d3-96f3-70a896cf6802" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_ecc0aa00-bb9d-4a6d-bad6-79d85547e42b" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_d6f64382-760c-49d3-96f3-70a896cf6802" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_d8651975-235c-4e28-8dbc-070f9b7f808c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_ecc0aa00-bb9d-4a6d-bad6-79d85547e42b" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_d8651975-235c-4e28-8dbc-070f9b7f808c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_c65575c1-08c0-4670-b944-ea84f2f2cb7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_ecc0aa00-bb9d-4a6d-bad6-79d85547e42b" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_c65575c1-08c0-4670-b944-ea84f2f2cb7a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_253e7727-1037-409a-b622-89cd73c0e9c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_c4295f04-92fb-453f-bc9b-b1fb264d5df0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_253e7727-1037-409a-b622-89cd73c0e9c9" xlink:to="loc_us-gaap_ProfitLoss_c4295f04-92fb-453f-bc9b-b1fb264d5df0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_3fb7501b-7274-42f5-8fa3-9c9aa7b26034" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_253e7727-1037-409a-b622-89cd73c0e9c9" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_3fb7501b-7274-42f5-8fa3-9c9aa7b26034" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_999d6a24-83e8-40fc-aa8f-11e37856c25c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_bd0c4e17-11bd-480a-95d2-8845cbcdf38c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_999d6a24-83e8-40fc-aa8f-11e37856c25c" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_bd0c4e17-11bd-480a-95d2-8845cbcdf38c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_cccecc34-17a9-44c0-936b-89babe67a268" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_999d6a24-83e8-40fc-aa8f-11e37856c25c" xlink:to="loc_us-gaap_CostsAndExpenses_cccecc34-17a9-44c0-936b-89babe67a268" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss" xlink:type="simple" xlink:href="mygn-20210930.xsd#CondensedConsolidatedStatementsofComprehensiveIncomeLoss"/>
  <link:calculationLink xlink:role="http://www.myriad.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_c19507e1-77d2-40a4-b2af-71296eb2f4c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_7d1fc12e-e81e-4524-b583-6a4b363a21a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_c19507e1-77d2-40a4-b2af-71296eb2f4c1" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_7d1fc12e-e81e-4524-b583-6a4b363a21a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_c1e237bc-d059-42c7-8c49-821f054ea6d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_2d86a389-d191-44f6-b3c6-88277f38065f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_c1e237bc-d059-42c7-8c49-821f054ea6d2" xlink:to="loc_us-gaap_NetIncomeLoss_2d86a389-d191-44f6-b3c6-88277f38065f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_0af93e5e-242f-40b4-81b0-20723741c127" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_c1e237bc-d059-42c7-8c49-821f054ea6d2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_0af93e5e-242f-40b4-81b0-20723741c127" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_9a3362a9-8264-490f-90c9-e9fd9af03592" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_c1e237bc-d059-42c7-8c49-821f054ea6d2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_9a3362a9-8264-490f-90c9-e9fd9af03592" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="mygn-20210930.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_db3ddfcf-8b13-40c5-b624-54b2fa8ee5e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_1e17fb4b-5716-4a8b-9cec-f43a66b443a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_db3ddfcf-8b13-40c5-b624-54b2fa8ee5e8" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_1e17fb4b-5716-4a8b-9cec-f43a66b443a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_d55a6e91-4881-41ba-918d-de8f01b9b7d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_db3ddfcf-8b13-40c5-b624-54b2fa8ee5e8" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_d55a6e91-4881-41ba-918d-de8f01b9b7d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_df0e30d1-edb0-4a3c-80e5-9ef330210c52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_db3ddfcf-8b13-40c5-b624-54b2fa8ee5e8" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_df0e30d1-edb0-4a3c-80e5-9ef330210c52" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_3c668e54-34ca-401b-933a-a6f5818be234" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_db3ddfcf-8b13-40c5-b624-54b2fa8ee5e8" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_3c668e54-34ca-401b-933a-a6f5818be234" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit_9f6e8398-c3c6-41b1-9c56-5ab7d850bd1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_db3ddfcf-8b13-40c5-b624-54b2fa8ee5e8" xlink:to="loc_us-gaap_RepaymentsOfLinesOfCredit_9f6e8398-c3c6-41b1-9c56-5ab7d850bd1c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ac89eb09-5a84-4202-b1c7-e45e114e6252" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_56764fa4-e068-4bbb-9848-6edba81d8171" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ac89eb09-5a84-4202-b1c7-e45e114e6252" xlink:to="loc_us-gaap_NetIncomeLoss_56764fa4-e068-4bbb-9848-6edba81d8171" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_698ff5dc-67c6-41fd-b0f8-0221246a0537" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ac89eb09-5a84-4202-b1c7-e45e114e6252" xlink:to="loc_us-gaap_DepreciationAndAmortization_698ff5dc-67c6-41fd-b0f8-0221246a0537" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_NonCashInterestExpense_da0611c6-6c71-4868-bb99-e2650d3d8a0b" xlink:href="mygn-20210930.xsd#mygn_NonCashInterestExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ac89eb09-5a84-4202-b1c7-e45e114e6252" xlink:to="loc_mygn_NonCashInterestExpense_da0611c6-6c71-4868-bb99-e2650d3d8a0b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_254a5747-d23b-488a-a7d9-8674e23cdb43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ac89eb09-5a84-4202-b1c7-e45e114e6252" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_254a5747-d23b-488a-a7d9-8674e23cdb43" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_5814ccbb-77a1-4cb6-adbf-db58eee96ddf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ac89eb09-5a84-4202-b1c7-e45e114e6252" xlink:to="loc_us-gaap_ShareBasedCompensation_5814ccbb-77a1-4cb6-adbf-db58eee96ddf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_649a4e27-be0a-4750-a0c0-18de7b7f3789" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ac89eb09-5a84-4202-b1c7-e45e114e6252" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_649a4e27-be0a-4750-a0c0-18de7b7f3789" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_IncreaseDecreaseInUnrecognizedTaxBenefits_6a62b714-2fac-4a4b-8d4a-c5601aee03c8" xlink:href="mygn-20210930.xsd#mygn_IncreaseDecreaseInUnrecognizedTaxBenefits"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ac89eb09-5a84-4202-b1c7-e45e114e6252" xlink:to="loc_mygn_IncreaseDecreaseInUnrecognizedTaxBenefits_6a62b714-2fac-4a4b-8d4a-c5601aee03c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_ChangeInFairValueOfContingentConsideration_34eb45d9-8f07-4aa2-a939-8b421fc6d230" xlink:href="mygn-20210930.xsd#mygn_ChangeInFairValueOfContingentConsideration"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ac89eb09-5a84-4202-b1c7-e45e114e6252" xlink:to="loc_mygn_ChangeInFairValueOfContingentConsideration_34eb45d9-8f07-4aa2-a939-8b421fc6d230" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_7d934a1b-af8a-40d4-98b6-c74a5be8dcb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWriteDown"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ac89eb09-5a84-4202-b1c7-e45e114e6252" xlink:to="loc_us-gaap_InventoryWriteDown_7d934a1b-af8a-40d4-98b6-c74a5be8dcb1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_ImpairmentOfGoodwillAndLongLivedAssetsHeldForUse_4e5fc63f-17dc-409a-acb5-464402aa0f06" xlink:href="mygn-20210930.xsd#mygn_ImpairmentOfGoodwillAndLongLivedAssetsHeldForUse"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ac89eb09-5a84-4202-b1c7-e45e114e6252" xlink:to="loc_mygn_ImpairmentOfGoodwillAndLongLivedAssetsHeldForUse_4e5fc63f-17dc-409a-acb5-464402aa0f06" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_a55e63f1-5dba-4f37-b7fc-23373920c267" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ac89eb09-5a84-4202-b1c7-e45e114e6252" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_a55e63f1-5dba-4f37-b7fc-23373920c267" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpensesOther_34581ea1-5cd2-43d4-8784-063203d8f39c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ac89eb09-5a84-4202-b1c7-e45e114e6252" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpensesOther_34581ea1-5cd2-43d4-8784-063203d8f39c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_7ee75c75-a737-42c4-8600-e3a0187b200b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ac89eb09-5a84-4202-b1c7-e45e114e6252" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_7ee75c75-a737-42c4-8600-e3a0187b200b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_5d5427e6-9871-425a-a9f0-46b1590c467d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ac89eb09-5a84-4202-b1c7-e45e114e6252" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_5d5427e6-9871-425a-a9f0-46b1590c467d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidTaxes_46214e6d-c681-45ca-8c26-9fa3b314b3f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidTaxes"/>
    <link:calculationArc order="15" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ac89eb09-5a84-4202-b1c7-e45e114e6252" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidTaxes_46214e6d-c681-45ca-8c26-9fa3b314b3f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_58152a7b-c368-4f80-818e-81959cd152b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:calculationArc order="16" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ac89eb09-5a84-4202-b1c7-e45e114e6252" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_58152a7b-c368-4f80-818e-81959cd152b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_65927ab6-1a4a-4acf-91d9-3979a2a7237f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="17" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ac89eb09-5a84-4202-b1c7-e45e114e6252" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_65927ab6-1a4a-4acf-91d9-3979a2a7237f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_8fbcab48-7049-42ea-b079-3430af90e62f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="18" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ac89eb09-5a84-4202-b1c7-e45e114e6252" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_8fbcab48-7049-42ea-b079-3430af90e62f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_a189dacf-11f5-461c-86df-3e909219fdaf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="19" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ac89eb09-5a84-4202-b1c7-e45e114e6252" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_a189dacf-11f5-461c-86df-3e909219fdaf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ef70b955-4632-4663-9d2a-187ab7ed4399" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_aa8d8787-2a13-4403-bb03-c53c2274bea4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ef70b955-4632-4663-9d2a-187ab7ed4399" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_aa8d8787-2a13-4403-bb03-c53c2274bea4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets_e0d8ba7b-7811-4fdf-96f7-2c9aa6104fc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ef70b955-4632-4663-9d2a-187ab7ed4399" xlink:to="loc_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets_e0d8ba7b-7811-4fdf-96f7-2c9aa6104fc3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_ed797f02-3605-486b-b66c-03c0c49416f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ef70b955-4632-4663-9d2a-187ab7ed4399" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_ed797f02-3605-486b-b66c-03c0c49416f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_a74733d9-af68-422f-864b-bff13c26773f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ef70b955-4632-4663-9d2a-187ab7ed4399" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_a74733d9-af68-422f-864b-bff13c26773f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_bfd10f1c-92f3-475c-af79-f5b698177892" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8f8d757b-9021-442a-9954-1cacd69ae6b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_bfd10f1c-92f3-475c-af79-f5b698177892" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8f8d757b-9021-442a-9954-1cacd69ae6b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_be467e59-0d37-47e6-94a1-f79ab4fa76a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_bfd10f1c-92f3-475c-af79-f5b698177892" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_be467e59-0d37-47e6-94a1-f79ab4fa76a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8153b1e4-7077-4786-8da1-428c79c72532" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_bfd10f1c-92f3-475c-af79-f5b698177892" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8153b1e4-7077-4786-8da1-428c79c72532" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_965cab9c-8882-43a6-a633-e3ef5834558e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_bfd10f1c-92f3-475c-af79-f5b698177892" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_965cab9c-8882-43a6-a633-e3ef5834558e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_NetChangeInCashAndCashEquivalentsClassifiedAsHeldForSale_a839322c-f5fe-4c30-a9d3-c801f6523135" xlink:href="mygn-20210930.xsd#mygn_NetChangeInCashAndCashEquivalentsClassifiedAsHeldForSale"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_bfd10f1c-92f3-475c-af79-f5b698177892" xlink:to="loc_mygn_NetChangeInCashAndCashEquivalentsClassifiedAsHeldForSale_a839322c-f5fe-4c30-a9d3-c801f6523135" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails" xlink:type="simple" xlink:href="mygn-20210930.xsd#MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails"/>
  <link:calculationLink xlink:role="http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_82b00db6-b282-4ae3-9326-f76122753211" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_3d7462bb-f049-42b3-9cb5-d2da935caa2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_82b00db6-b282-4ae3-9326-f76122753211" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_3d7462bb-f049-42b3-9cb5-d2da935caa2e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_88d7cd74-93be-4b00-93fd-228fdc5c7509" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_82b00db6-b282-4ae3-9326-f76122753211" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_88d7cd74-93be-4b00-93fd-228fdc5c7509" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_160e11b7-1387-45fa-ba72-63fdb864c1cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_82b00db6-b282-4ae3-9326-f76122753211" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_160e11b7-1387-45fa-ba72-63fdb864c1cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_InvestmentsAndCashAmortizedCost_6fbb8a77-0493-4382-ace7-700a88f16beb" xlink:href="mygn-20210930.xsd#mygn_InvestmentsAndCashAmortizedCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax_6d3fb585-632d-49ea-90cc-ae98a48ec408" xlink:href="mygn-20210930.xsd#mygn_InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mygn_InvestmentsAndCashAmortizedCost_6fbb8a77-0493-4382-ace7-700a88f16beb" xlink:to="loc_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax_6d3fb585-632d-49ea-90cc-ae98a48ec408" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax_416d777b-61c1-4eae-bc94-c744c07977ea" xlink:href="mygn-20210930.xsd#mygn_InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mygn_InvestmentsAndCashAmortizedCost_6fbb8a77-0493-4382-ace7-700a88f16beb" xlink:to="loc_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax_416d777b-61c1-4eae-bc94-c744c07977ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAndCash_f6978bb8-9459-4a42-affd-8fd1b0721f3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsAndCash"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mygn_InvestmentsAndCashAmortizedCost_6fbb8a77-0493-4382-ace7-700a88f16beb" xlink:to="loc_us-gaap_InvestmentsAndCash_f6978bb8-9459-4a42-affd-8fd1b0721f3a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails" xlink:type="simple" xlink:href="mygn-20210930.xsd#MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mygn_InvestmentsAndCashAmortizedCost_3c0dcfe0-398f-441e-a552-328833829641" xlink:href="mygn-20210930.xsd#mygn_InvestmentsAndCashAmortizedCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_98760e75-f35e-4793-9390-c126ca21e1e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mygn_InvestmentsAndCashAmortizedCost_3c0dcfe0-398f-441e-a552-328833829641" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_98760e75-f35e-4793-9390-c126ca21e1e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_65dfe9f6-6a3c-4bd7-b10d-1fa911713b47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mygn_InvestmentsAndCashAmortizedCost_3c0dcfe0-398f-441e-a552-328833829641" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_65dfe9f6-6a3c-4bd7-b10d-1fa911713b47" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_48f2d78d-00f4-47a3-afde-c1e3fd188f80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mygn_InvestmentsAndCashAmortizedCost_3c0dcfe0-398f-441e-a552-328833829641" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_48f2d78d-00f4-47a3-afde-c1e3fd188f80" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_a294cd71-effd-4829-b59f-8a4df8e76593" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mygn_InvestmentsAndCashAmortizedCost_3c0dcfe0-398f-441e-a552-328833829641" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_a294cd71-effd-4829-b59f-8a4df8e76593" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAndCash_3444a463-5a0b-4894-81e5-2fb8568c8680" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsAndCash"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a8b31daa-ab28-4449-9d82-7ff02c24ada7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InvestmentsAndCash_3444a463-5a0b-4894-81e5-2fb8568c8680" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a8b31daa-ab28-4449-9d82-7ff02c24ada7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_f67eebc1-27a8-4f56-bfa0-ba14ae366b04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InvestmentsAndCash_3444a463-5a0b-4894-81e5-2fb8568c8680" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_f67eebc1-27a8-4f56-bfa0-ba14ae366b04" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_9f2d5a66-cea7-42df-b0b0-7c015ee5a1f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InvestmentsAndCash_3444a463-5a0b-4894-81e5-2fb8568c8680" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_9f2d5a66-cea7-42df-b0b0-7c015ee5a1f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_82627818-a230-4e37-add0-ae319ada3428" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InvestmentsAndCash_3444a463-5a0b-4894-81e5-2fb8568c8680" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_82627818-a230-4e37-add0-ae319ada3428" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="mygn-20210930.xsd#FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetAssetLiability_bd6c6220-e354-4e07-ac15-3719ca552b03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueNetAssetLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_6d4f0537-28ce-4c25-984f-965b989eeb30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FairValueNetAssetLiability_bd6c6220-e354-4e07-ac15-3719ca552b03" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_6d4f0537-28ce-4c25-984f-965b989eeb30" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_ac627722-aa85-4b8b-9c24-b91c1c396dcf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FairValueNetAssetLiability_bd6c6220-e354-4e07-ac15-3719ca552b03" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_ac627722-aa85-4b8b-9c24-b91c1c396dcf" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/PropertyPlantandEquipmentNetBalancesDetails" xlink:type="simple" xlink:href="mygn-20210930.xsd#PropertyPlantandEquipmentNetBalancesDetails"/>
  <link:calculationLink xlink:role="http://www.myriad.com/role/PropertyPlantandEquipmentNetBalancesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_9710753a-4733-43d6-84ea-462272a3b5c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_5b824cd4-5e97-4f7e-a940-410aa131c78b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_9710753a-4733-43d6-84ea-462272a3b5c7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_5b824cd4-5e97-4f7e-a940-410aa131c78b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_89bc2e0e-16f4-4ef2-80b7-ee5a43a9535c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_9710753a-4733-43d6-84ea-462272a3b5c7" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_89bc2e0e-16f4-4ef2-80b7-ee5a43a9535c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails" xlink:type="simple" xlink:href="mygn-20210930.xsd#GoodwillandIntangibleAssetsIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_a6d25dc1-5cb8-416f-bd0b-76ab0be3f0bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d415e379-dcac-449f-970d-e7af10220359" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_a6d25dc1-5cb8-416f-bd0b-76ab0be3f0bb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d415e379-dcac-449f-970d-e7af10220359" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_adadb142-50c2-4175-9488-4f1ed897249a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_a6d25dc1-5cb8-416f-bd0b-76ab0be3f0bb" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_adadb142-50c2-4175-9488-4f1ed897249a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_3cd4e786-90f6-400d-9393-266b2071e214" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_dd4365d3-772c-4869-9674-59287e2fc052" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_3cd4e786-90f6-400d-9393-266b2071e214" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_dd4365d3-772c-4869-9674-59287e2fc052" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_8b478bba-0047-48a3-90b0-9cccc4dad8c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_3cd4e786-90f6-400d-9393-266b2071e214" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_8b478bba-0047-48a3-90b0-9cccc4dad8c9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails_1" xlink:type="simple" xlink:href="mygn-20210930.xsd#GoodwillandIntangibleAssetsIntangibleAssetsDetails_1"/>
  <link:calculationLink xlink:role="http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_38dbb94d-dfe1-42f4-bc09-d39cfc9db64b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_c4784ed8-35d9-463d-af18-2fb82c8a4b8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_38dbb94d-dfe1-42f4-bc09-d39cfc9db64b" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_c4784ed8-35d9-463d-af18-2fb82c8a4b8c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_60f2e324-0d29-4f80-8461-3a2506aa8d50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_38dbb94d-dfe1-42f4-bc09-d39cfc9db64b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_60f2e324-0d29-4f80-8461-3a2506aa8d50" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/AccruedLiabilitiesDetails" xlink:type="simple" xlink:href="mygn-20210930.xsd#AccruedLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.myriad.com/role/AccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_74b8b4da-c0ab-46b3-8b71-39aa8dd79741" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_9f2003a6-c2b7-4b4d-add5-e364512931b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_74b8b4da-c0ab-46b3-8b71-39aa8dd79741" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_9f2003a6-c2b7-4b4d-add5-e364512931b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveCurrent_40676880-b029-4392-90dd-e7f2326df202" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationReserveCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_74b8b4da-c0ab-46b3-8b71-39aa8dd79741" xlink:to="loc_us-gaap_LitigationReserveCurrent_40676880-b029-4392-90dd-e7f2326df202" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_e2e5dcb3-4deb-430d-aea5-e9bbded85136" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_74b8b4da-c0ab-46b3-8b71-39aa8dd79741" xlink:to="loc_us-gaap_TaxesPayableCurrent_e2e5dcb3-4deb-430d-aea5-e9bbded85136" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_RefundsPayableAndReserveCurrent_6d663a18-7147-4e3c-bb61-517088bf9026" xlink:href="mygn-20210930.xsd#mygn_RefundsPayableAndReserveCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_74b8b4da-c0ab-46b3-8b71-39aa8dd79741" xlink:to="loc_mygn_RefundsPayableAndReserveCurrent_6d663a18-7147-4e3c-bb61-517088bf9026" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_6a6e0e58-be56-4150-9f74-3c8074a7cf5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_74b8b4da-c0ab-46b3-8b71-39aa8dd79741" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_6a6e0e58-be56-4150-9f74-3c8074a7cf5f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_1e266d37-1c2e-4ff5-bf89-c5a9ef5c001a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_74b8b4da-c0ab-46b3-8b71-39aa8dd79741" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_1e266d37-1c2e-4ff5-bf89-c5a9ef5c001a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RecordedUnconditionalPurchaseObligation_3881da40-7aa4-4085-91a2-aa282b896855" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RecordedUnconditionalPurchaseObligation"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_74b8b4da-c0ab-46b3-8b71-39aa8dd79741" xlink:to="loc_us-gaap_RecordedUnconditionalPurchaseObligation_3881da40-7aa4-4085-91a2-aa282b896855" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_cf78336c-3333-4f6b-a112-b820a5889ef6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_74b8b4da-c0ab-46b3-8b71-39aa8dd79741" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_cf78336c-3333-4f6b-a112-b820a5889ef6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/OtherLongTermLiabilitiesDetails" xlink:type="simple" xlink:href="mygn-20210930.xsd#OtherLongTermLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.myriad.com/role/OtherLongTermLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_6075f3b2-27e7-46b6-ba98-fe514703d7e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_6472d32c-e317-49f1-8bac-32b9e7d60cba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_6075f3b2-27e7-46b6-ba98-fe514703d7e3" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_6472d32c-e317-49f1-8bac-32b9e7d60cba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherSundryLiabilitiesNoncurrent_eed224f4-1491-4aff-8fd9-d0abfda59ffb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherSundryLiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_6075f3b2-27e7-46b6-ba98-fe514703d7e3" xlink:to="loc_us-gaap_OtherSundryLiabilitiesNoncurrent_eed224f4-1491-4aff-8fd9-d0abfda59ffb" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/PreferredandCommonStockholdersEquityReconciliationofDenominatorsofBasicandDilutedEarningsPerShareComputationsDetails" xlink:type="simple" xlink:href="mygn-20210930.xsd#PreferredandCommonStockholdersEquityReconciliationofDenominatorsofBasicandDilutedEarningsPerShareComputationsDetails"/>
  <link:calculationLink xlink:role="http://www.myriad.com/role/PreferredandCommonStockholdersEquityReconciliationofDenominatorsofBasicandDilutedEarningsPerShareComputationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8d188ae1-08d5-408f-9812-993abe32a473" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_a1023b31-e793-44c4-93af-5c5773215d23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8d188ae1-08d5-408f-9812-993abe32a473" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_a1023b31-e793-44c4-93af-5c5773215d23" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_7a698f90-cd6e-47f0-9b4d-40c3ff861fd7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8d188ae1-08d5-408f-9812-993abe32a473" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_7a698f90-cd6e-47f0-9b4d-40c3ff861fd7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/SegmentandRelatedInformationTotalOperatingLossforReportableSegmentsDetails" xlink:type="simple" xlink:href="mygn-20210930.xsd#SegmentandRelatedInformationTotalOperatingLossforReportableSegmentsDetails"/>
  <link:calculationLink xlink:role="http://www.myriad.com/role/SegmentandRelatedInformationTotalOperatingLossforReportableSegmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_45880f1d-9a4a-48b9-b6e5-8340de87ce83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_e2b0a12d-7311-43d1-b516-330bb7661359" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_45880f1d-9a4a-48b9-b6e5-8340de87ce83" xlink:to="loc_us-gaap_OperatingIncomeLoss_e2b0a12d-7311-43d1-b516-330bb7661359" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_6f63100a-49ac-43e9-b36a-b9de8cab9192" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_45880f1d-9a4a-48b9-b6e5-8340de87ce83" xlink:to="loc_us-gaap_InvestmentIncomeInterest_6f63100a-49ac-43e9-b36a-b9de8cab9192" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_2c5bd7b0-a55e-49a2-b139-671cae0bbd3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_45880f1d-9a4a-48b9-b6e5-8340de87ce83" xlink:to="loc_us-gaap_InterestExpense_2c5bd7b0-a55e-49a2-b139-671cae0bbd3d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_f2d85dbf-baf0-487b-92ba-3fc00e9d3e2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_45880f1d-9a4a-48b9-b6e5-8340de87ce83" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_f2d85dbf-baf0-487b-92ba-3fc00e9d3e2a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/DivestituresOtherIncomeDetails" xlink:type="simple" xlink:href="mygn-20210930.xsd#DivestituresOtherIncomeDetails"/>
  <link:calculationLink xlink:role="http://www.myriad.com/role/DivestituresOtherIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_bceee26f-80e4-45a5-9a6d-2c5ba30dd7ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_cb5bea5f-7550-4ce1-b64c-cf444090a187" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_bceee26f-80e4-45a5-9a6d-2c5ba30dd7ce" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_cb5bea5f-7550-4ce1-b64c-cf444090a187" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_DisposalGroupNotDiscontinuedOperationGainLossOnInventory_96d0dcac-2e3a-4428-9dfb-648f27ff44ed" xlink:href="mygn-20210930.xsd#mygn_DisposalGroupNotDiscontinuedOperationGainLossOnInventory"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_bceee26f-80e4-45a5-9a6d-2c5ba30dd7ce" xlink:to="loc_mygn_DisposalGroupNotDiscontinuedOperationGainLossOnInventory_96d0dcac-2e3a-4428-9dfb-648f27ff44ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_DisposalGroupNotDiscontinuedOperationGainLossOther_d4d8c562-8427-484d-b870-c88c05dd6d57" xlink:href="mygn-20210930.xsd#mygn_DisposalGroupNotDiscontinuedOperationGainLossOther"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_bceee26f-80e4-45a5-9a6d-2c5ba30dd7ce" xlink:to="loc_mygn_DisposalGroupNotDiscontinuedOperationGainLossOther_d4d8c562-8427-484d-b870-c88c05dd6d57" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>mygn-20210930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:902b74c1-bcf1-4420-82df-87d4ebd2f6e9,g:dcd0bc70-dec4-4a37-a022-ac912887efc6-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="mygn-20210930.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:definitionLink xlink:role="http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended" id="i58ee530c10cc4d5d8a8b5d6dae0597e1_CondensedConsolidatedStatementsofOperations">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_23011d84-d800-44ec-b413-65a37ccb4905" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_fe57c1bb-f2c0-4167-8e3c-ae9d32466c14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_23011d84-d800-44ec-b413-65a37ccb4905" xlink:to="loc_us-gaap_RevenuesAbstract_fe57c1bb-f2c0-4167-8e3c-ae9d32466c14" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2dd416c1-0984-4c30-9ec2-76e77dc905ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_fe57c1bb-f2c0-4167-8e3c-ae9d32466c14" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2dd416c1-0984-4c30-9ec2-76e77dc905ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpensesAbstract_f0d983c2-647b-46e5-81f2-ce4e2b0fc029" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingCostsAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_23011d84-d800-44ec-b413-65a37ccb4905" xlink:to="loc_us-gaap_OperatingCostsAndExpensesAbstract_f0d983c2-647b-46e5-81f2-ce4e2b0fc029" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_708bd73b-3b99-4c21-a3d7-c67cbc2aa3a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_f0d983c2-647b-46e5-81f2-ce4e2b0fc029" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_708bd73b-3b99-4c21-a3d7-c67cbc2aa3a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_e57910f3-492f-430f-bc08-8b02bf308ace" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_f0d983c2-647b-46e5-81f2-ce4e2b0fc029" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_e57910f3-492f-430f-bc08-8b02bf308ace" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_b4ad3058-4fdd-44b6-b602-df6823abad8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_f0d983c2-647b-46e5-81f2-ce4e2b0fc029" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_b4ad3058-4fdd-44b6-b602-df6823abad8e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_c5cc1342-88dc-49ab-9abd-4034c7e2f3b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_f0d983c2-647b-46e5-81f2-ce4e2b0fc029" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_c5cc1342-88dc-49ab-9abd-4034c7e2f3b8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_f2eab170-cd97-434d-9069-5eec9db3f7ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_f0d983c2-647b-46e5-81f2-ce4e2b0fc029" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_f2eab170-cd97-434d-9069-5eec9db3f7ea" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_4526101f-fb21-4f6f-a788-fad459a20294" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_f0d983c2-647b-46e5-81f2-ce4e2b0fc029" xlink:to="loc_us-gaap_CostsAndExpenses_4526101f-fb21-4f6f-a788-fad459a20294" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_65e74bf7-54da-44b7-8aa1-4b91d1f1cf21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_23011d84-d800-44ec-b413-65a37ccb4905" xlink:to="loc_us-gaap_OperatingIncomeLoss_65e74bf7-54da-44b7-8aa1-4b91d1f1cf21" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_812b425f-d9d0-482c-b3c5-7221f4070577" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_23011d84-d800-44ec-b413-65a37ccb4905" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_812b425f-d9d0-482c-b3c5-7221f4070577" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_3bba6a49-a6da-4a0b-826f-b1f5c49a69ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_812b425f-d9d0-482c-b3c5-7221f4070577" xlink:to="loc_us-gaap_InvestmentIncomeInterest_3bba6a49-a6da-4a0b-826f-b1f5c49a69ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_3bb7e439-3f8d-4724-a23b-8f9087b1a70f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_812b425f-d9d0-482c-b3c5-7221f4070577" xlink:to="loc_us-gaap_InterestExpense_3bb7e439-3f8d-4724-a23b-8f9087b1a70f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_0be09068-77ed-4575-a7db-eb0ca852cecf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_812b425f-d9d0-482c-b3c5-7221f4070577" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_0be09068-77ed-4575-a7db-eb0ca852cecf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_50f0108a-6f68-4640-a651-86990cf6eabb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_812b425f-d9d0-482c-b3c5-7221f4070577" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_50f0108a-6f68-4640-a651-86990cf6eabb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c52a18dd-3da8-449a-b05b-9a1e908f884c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_23011d84-d800-44ec-b413-65a37ccb4905" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c52a18dd-3da8-449a-b05b-9a1e908f884c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_828873a8-e57d-485f-9139-68e69c0ddc5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_23011d84-d800-44ec-b413-65a37ccb4905" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_828873a8-e57d-485f-9139-68e69c0ddc5c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_ffd69428-48e7-4827-9175-f0341d8cf347" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_23011d84-d800-44ec-b413-65a37ccb4905" xlink:to="loc_us-gaap_ProfitLoss_ffd69428-48e7-4827-9175-f0341d8cf347" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_5cb82024-c5d4-493c-bc3b-3a9b4a70b8e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_23011d84-d800-44ec-b413-65a37ccb4905" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_5cb82024-c5d4-493c-bc3b-3a9b4a70b8e8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b2682513-4293-4e11-8073-357241adee5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_23011d84-d800-44ec-b413-65a37ccb4905" xlink:to="loc_us-gaap_NetIncomeLoss_b2682513-4293-4e11-8073-357241adee5c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_39334061-8e7f-41be-92f5-9bf7e2714f58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_23011d84-d800-44ec-b413-65a37ccb4905" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_39334061-8e7f-41be-92f5-9bf7e2714f58" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_f46ca6c2-5aa5-40c9-82f3-a1af2ad8698d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_39334061-8e7f-41be-92f5-9bf7e2714f58" xlink:to="loc_us-gaap_EarningsPerShareBasic_f46ca6c2-5aa5-40c9-82f3-a1af2ad8698d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_c7ba0e80-0079-49b4-9547-73b0b72402f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_39334061-8e7f-41be-92f5-9bf7e2714f58" xlink:to="loc_us-gaap_EarningsPerShareDiluted_c7ba0e80-0079-49b4-9547-73b0b72402f1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_1b2ee9cc-5799-4af2-8412-35d3dd4ceffe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_23011d84-d800-44ec-b413-65a37ccb4905" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_1b2ee9cc-5799-4af2-8412-35d3dd4ceffe" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_a3f36810-f3ab-4b24-80c5-48bbd216b15a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_1b2ee9cc-5799-4af2-8412-35d3dd4ceffe" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_a3f36810-f3ab-4b24-80c5-48bbd216b15a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6ed96005-b85e-445d-b64f-3879dd454c0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_1b2ee9cc-5799-4af2-8412-35d3dd4ceffe" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6ed96005-b85e-445d-b64f-3879dd454c0d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_0b3ab670-e046-4c72-9649-2a5080404ff4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_23011d84-d800-44ec-b413-65a37ccb4905" xlink:to="loc_us-gaap_StatementTable_0b3ab670-e046-4c72-9649-2a5080404ff4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_86646e96-e32f-4819-a414-6d45899fd43d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_0b3ab670-e046-4c72-9649-2a5080404ff4" xlink:to="loc_srt_ProductOrServiceAxis_86646e96-e32f-4819-a414-6d45899fd43d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_86646e96-e32f-4819-a414-6d45899fd43d_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_86646e96-e32f-4819-a414-6d45899fd43d" xlink:to="loc_srt_ProductsAndServicesDomain_86646e96-e32f-4819-a414-6d45899fd43d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_958e10e3-10d8-44c7-9638-af3ecfbfa3c5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_86646e96-e32f-4819-a414-6d45899fd43d" xlink:to="loc_srt_ProductsAndServicesDomain_958e10e3-10d8-44c7-9638-af3ecfbfa3c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MolecularDiagnosticTestingMember_8ce65b9f-97ad-49dc-b968-1a7977316606" xlink:href="mygn-20210930.xsd#mygn_MolecularDiagnosticTestingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_958e10e3-10d8-44c7-9638-af3ecfbfa3c5" xlink:to="loc_mygn_MolecularDiagnosticTestingMember_8ce65b9f-97ad-49dc-b968-1a7977316606" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_PharmaceuticalAndClinicalServicesMember_b83087cc-67fa-42f7-b156-146a7badd55b" xlink:href="mygn-20210930.xsd#mygn_PharmaceuticalAndClinicalServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_958e10e3-10d8-44c7-9638-af3ecfbfa3c5" xlink:to="loc_mygn_PharmaceuticalAndClinicalServicesMember_b83087cc-67fa-42f7-b156-146a7badd55b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.myriad.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="mygn-20210930.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.myriad.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended" id="i3f5611ef6c5f4312b98f9a99dbbf40a5_CondensedConsolidatedStatementsofStockholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_82138a41-ee20-4193-b9fb-86b128ec801a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_165f2c44-9cb0-4049-9186-25c290686ae9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_82138a41-ee20-4193-b9fb-86b128ec801a" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_165f2c44-9cb0-4049-9186-25c290686ae9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_ce80bc4e-2ba5-4d03-9ba1-cb092528567a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_82138a41-ee20-4193-b9fb-86b128ec801a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_ce80bc4e-2ba5-4d03-9ba1-cb092528567a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_9f66e066-ba50-4f44-bf10-aee8e04f7a1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_82138a41-ee20-4193-b9fb-86b128ec801a" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_9f66e066-ba50-4f44-bf10-aee8e04f7a1e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestPeriodIncreaseDecrease_19d4beb1-ee78-449a-b7e8-401f16ff45c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestPeriodIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_82138a41-ee20-4193-b9fb-86b128ec801a" xlink:to="loc_us-gaap_MinorityInterestPeriodIncreaseDecrease_19d4beb1-ee78-449a-b7e8-401f16ff45c4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0ae3d893-e269-460b-bcee-d135c8d4990e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_82138a41-ee20-4193-b9fb-86b128ec801a" xlink:to="loc_us-gaap_NetIncomeLoss_0ae3d893-e269-460b-bcee-d135c8d4990e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_ReclassificationFromAccumulatedOtherComprehensiveLossDeconsolidationOfSubsidiary_d4a43c81-15fd-4076-9c98-9b9ce997cafa" xlink:href="mygn-20210930.xsd#mygn_ReclassificationFromAccumulatedOtherComprehensiveLossDeconsolidationOfSubsidiary"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_82138a41-ee20-4193-b9fb-86b128ec801a" xlink:to="loc_mygn_ReclassificationFromAccumulatedOtherComprehensiveLossDeconsolidationOfSubsidiary_d4a43c81-15fd-4076-9c98-9b9ce997cafa" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_726e1634-1466-49b2-886e-004bb3eee485" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_82138a41-ee20-4193-b9fb-86b128ec801a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_726e1634-1466-49b2-886e-004bb3eee485" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5c0d08aa-ed7e-4c4b-99fc-ea8bb022b361" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_9c46c0f2-e781-4d0d-94e5-a74f832da30d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_82138a41-ee20-4193-b9fb-86b128ec801a" xlink:to="loc_us-gaap_StatementTable_9c46c0f2-e781-4d0d-94e5-a74f832da30d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_c00686a9-0a4a-455b-8f23-1850ee9c58c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_9c46c0f2-e781-4d0d-94e5-a74f832da30d" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_c00686a9-0a4a-455b-8f23-1850ee9c58c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_c00686a9-0a4a-455b-8f23-1850ee9c58c3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c00686a9-0a4a-455b-8f23-1850ee9c58c3" xlink:to="loc_us-gaap_EquityComponentDomain_c00686a9-0a4a-455b-8f23-1850ee9c58c3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_75eaecda-bf7d-44f1-944a-fc934ead12d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c00686a9-0a4a-455b-8f23-1850ee9c58c3" xlink:to="loc_us-gaap_EquityComponentDomain_75eaecda-bf7d-44f1-944a-fc934ead12d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_aab72022-7357-4756-b99f-b2375d61cb21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_75eaecda-bf7d-44f1-944a-fc934ead12d7" xlink:to="loc_us-gaap_CommonStockMember_aab72022-7357-4756-b99f-b2375d61cb21" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_c9dd078c-f6f1-46d7-8e77-495f239da16b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_75eaecda-bf7d-44f1-944a-fc934ead12d7" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_c9dd078c-f6f1-46d7-8e77-495f239da16b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0223b0d0-2c35-436a-acf0-fbe51d4b6715" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_75eaecda-bf7d-44f1-944a-fc934ead12d7" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0223b0d0-2c35-436a-acf0-fbe51d4b6715" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_3287d829-f584-4f5d-ad6d-d83e4af41cbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_75eaecda-bf7d-44f1-944a-fc934ead12d7" xlink:to="loc_us-gaap_RetainedEarningsMember_3287d829-f584-4f5d-ad6d-d83e4af41cbc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_752026a3-a6b7-4d06-ab00-6d04a03e4728" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_75eaecda-bf7d-44f1-944a-fc934ead12d7" xlink:to="loc_us-gaap_NoncontrollingInterestMember_752026a3-a6b7-4d06-ab00-6d04a03e4728" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.myriad.com/role/RevenueTotalRevenuebyProductandbyUSversusRestofWorldDetails" xlink:type="simple" xlink:href="mygn-20210930.xsd#RevenueTotalRevenuebyProductandbyUSversusRestofWorldDetails"/>
  <link:definitionLink xlink:role="http://www.myriad.com/role/RevenueTotalRevenuebyProductandbyUSversusRestofWorldDetails" xlink:type="extended" id="i589d383c6547494cbde36913fae3078f_RevenueTotalRevenuebyProductandbyUSversusRestofWorldDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_db51c4f0-0b9e-41b4-bb01-8dc16323b9e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1e593fc0-9f0d-46b7-bfb8-efd747262051" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_db51c4f0-0b9e-41b4-bb01-8dc16323b9e3" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1e593fc0-9f0d-46b7-bfb8-efd747262051" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_15aee584-dd4a-4058-9a88-9c46eb522de2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_db51c4f0-0b9e-41b4-bb01-8dc16323b9e3" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_15aee584-dd4a-4058-9a88-9c46eb522de2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_5b103955-7859-40aa-bfc3-7874f3046136" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_15aee584-dd4a-4058-9a88-9c46eb522de2" xlink:to="loc_srt_ProductOrServiceAxis_5b103955-7859-40aa-bfc3-7874f3046136" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_5b103955-7859-40aa-bfc3-7874f3046136_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_5b103955-7859-40aa-bfc3-7874f3046136" xlink:to="loc_srt_ProductsAndServicesDomain_5b103955-7859-40aa-bfc3-7874f3046136_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f57355b9-43b6-40c7-abeb-db4021ebf0f1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_5b103955-7859-40aa-bfc3-7874f3046136" xlink:to="loc_srt_ProductsAndServicesDomain_f57355b9-43b6-40c7-abeb-db4021ebf0f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MolecularDiagnosticTestingMember_8e3859fb-0491-4aed-8c3c-5f77bd602cb8" xlink:href="mygn-20210930.xsd#mygn_MolecularDiagnosticTestingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f57355b9-43b6-40c7-abeb-db4021ebf0f1" xlink:to="loc_mygn_MolecularDiagnosticTestingMember_8e3859fb-0491-4aed-8c3c-5f77bd602cb8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MolecularDiagnosticHereditaryCancerTestingMember_f44813d6-5489-4132-b222-bf14081ccb35" xlink:href="mygn-20210930.xsd#mygn_MolecularDiagnosticHereditaryCancerTestingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_MolecularDiagnosticTestingMember_8e3859fb-0491-4aed-8c3c-5f77bd602cb8" xlink:to="loc_mygn_MolecularDiagnosticHereditaryCancerTestingMember_f44813d6-5489-4132-b222-bf14081ccb35" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MolecularDiagnosticTumorProfilingMember_19484a6c-67f8-4adb-9a8d-e3aebc0b3cac" xlink:href="mygn-20210930.xsd#mygn_MolecularDiagnosticTumorProfilingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_MolecularDiagnosticTestingMember_8e3859fb-0491-4aed-8c3c-5f77bd602cb8" xlink:to="loc_mygn_MolecularDiagnosticTumorProfilingMember_19484a6c-67f8-4adb-9a8d-e3aebc0b3cac" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MolecularDiagnosticPrenatalTestingMember_36477bd5-0a68-4a80-ab5f-e17a7f316800" xlink:href="mygn-20210930.xsd#mygn_MolecularDiagnosticPrenatalTestingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_MolecularDiagnosticTestingMember_8e3859fb-0491-4aed-8c3c-5f77bd602cb8" xlink:to="loc_mygn_MolecularDiagnosticPrenatalTestingMember_36477bd5-0a68-4a80-ab5f-e17a7f316800" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MolecularDiagnosticPharmacogenomicsMember_95926d2b-28d8-4728-aa8f-d5c88a8ba98f" xlink:href="mygn-20210930.xsd#mygn_MolecularDiagnosticPharmacogenomicsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_MolecularDiagnosticTestingMember_8e3859fb-0491-4aed-8c3c-5f77bd602cb8" xlink:to="loc_mygn_MolecularDiagnosticPharmacogenomicsMember_95926d2b-28d8-4728-aa8f-d5c88a8ba98f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MolecularDiagnosticAutoimmuneMember_20d940ec-39e5-4f02-9c8b-05f9b1d5afc4" xlink:href="mygn-20210930.xsd#mygn_MolecularDiagnosticAutoimmuneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_MolecularDiagnosticTestingMember_8e3859fb-0491-4aed-8c3c-5f77bd602cb8" xlink:to="loc_mygn_MolecularDiagnosticAutoimmuneMember_20d940ec-39e5-4f02-9c8b-05f9b1d5afc4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MolecularDiagnosticOtherTestingMember_2ae503ad-f294-4a58-b83a-65fe0c6f48b7" xlink:href="mygn-20210930.xsd#mygn_MolecularDiagnosticOtherTestingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_MolecularDiagnosticTestingMember_8e3859fb-0491-4aed-8c3c-5f77bd602cb8" xlink:to="loc_mygn_MolecularDiagnosticOtherTestingMember_2ae503ad-f294-4a58-b83a-65fe0c6f48b7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_PharmaceuticalAndClinicalServicesMember_cf00197b-9433-4750-b3bc-5b0f5a448b23" xlink:href="mygn-20210930.xsd#mygn_PharmaceuticalAndClinicalServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f57355b9-43b6-40c7-abeb-db4021ebf0f1" xlink:to="loc_mygn_PharmaceuticalAndClinicalServicesMember_cf00197b-9433-4750-b3bc-5b0f5a448b23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_aeab64b6-a0b2-435e-a51e-6d629f2daf63" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_15aee584-dd4a-4058-9a88-9c46eb522de2" xlink:to="loc_srt_StatementGeographicalAxis_aeab64b6-a0b2-435e-a51e-6d629f2daf63" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_aeab64b6-a0b2-435e-a51e-6d629f2daf63_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_aeab64b6-a0b2-435e-a51e-6d629f2daf63" xlink:to="loc_srt_SegmentGeographicalDomain_aeab64b6-a0b2-435e-a51e-6d629f2daf63_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_af3f86bb-daec-4ae8-9326-ae17d3ab7c7d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_aeab64b6-a0b2-435e-a51e-6d629f2daf63" xlink:to="loc_srt_SegmentGeographicalDomain_af3f86bb-daec-4ae8-9326-ae17d3ab7c7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_791beba0-2150-4804-9d7a-f6ed75fa3f05" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_af3f86bb-daec-4ae8-9326-ae17d3ab7c7d" xlink:to="loc_country_US_791beba0-2150-4804-9d7a-f6ed75fa3f05" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_4cb0f8a6-2c72-4ae0-9d19-5d8d41a82a1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_af3f86bb-daec-4ae8-9326-ae17d3ab7c7d" xlink:to="loc_us-gaap_NonUsMember_4cb0f8a6-2c72-4ae0-9d19-5d8d41a82a1d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.myriad.com/role/RevenueNarrativeDetails" xlink:type="simple" xlink:href="mygn-20210930.xsd#RevenueNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.myriad.com/role/RevenueNarrativeDetails" xlink:type="extended" id="id5f35c5ca0ed4503b79b5075e3e63d7a_RevenueNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_aec6ea91-74d0-481c-8006-3e3325c64c93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_IncreaseDecreaseInEarningsLossPerShare_b0ace844-d0b2-45c2-a82c-a933b89ad735" xlink:href="mygn-20210930.xsd#mygn_IncreaseDecreaseInEarningsLossPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_aec6ea91-74d0-481c-8006-3e3325c64c93" xlink:to="loc_mygn_IncreaseDecreaseInEarningsLossPerShare_b0ace844-d0b2-45c2-a82c-a933b89ad735" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_24630dbc-8b83-4779-a533-58ec32a0028a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_aec6ea91-74d0-481c-8006-3e3325c64c93" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_24630dbc-8b83-4779-a533-58ec32a0028a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_7023e05e-82f8-4ecf-a4df-edc642b071fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_aec6ea91-74d0-481c-8006-3e3325c64c93" xlink:to="loc_us-gaap_ConcentrationRiskTable_7023e05e-82f8-4ecf-a4df-edc642b071fd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_c9a8eac5-c7f6-49d7-aac5-49910ca8315d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_7023e05e-82f8-4ecf-a4df-edc642b071fd" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_c9a8eac5-c7f6-49d7-aac5-49910ca8315d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_c9a8eac5-c7f6-49d7-aac5-49910ca8315d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_c9a8eac5-c7f6-49d7-aac5-49910ca8315d" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_c9a8eac5-c7f6-49d7-aac5-49910ca8315d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_e15b5032-9e13-4c86-b356-0d531826201b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_c9a8eac5-c7f6-49d7-aac5-49910ca8315d" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_e15b5032-9e13-4c86-b356-0d531826201b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_090ee1c7-7d2e-4694-b37a-0f28d1bb3826" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_e15b5032-9e13-4c86-b356-0d531826201b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_090ee1c7-7d2e-4694-b37a-0f28d1bb3826" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_90764a96-6758-4601-aa6b-e28710cbb022" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_7023e05e-82f8-4ecf-a4df-edc642b071fd" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_90764a96-6758-4601-aa6b-e28710cbb022" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_90764a96-6758-4601-aa6b-e28710cbb022_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_90764a96-6758-4601-aa6b-e28710cbb022" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_90764a96-6758-4601-aa6b-e28710cbb022_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_160b1b1a-b964-4e6a-8f33-f87627302ecf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_90764a96-6758-4601-aa6b-e28710cbb022" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_160b1b1a-b964-4e6a-8f33-f87627302ecf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_fb710db2-0cf0-4c27-ba37-010dd4681493" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_160b1b1a-b964-4e6a-8f33-f87627302ecf" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_fb710db2-0cf0-4c27-ba37-010dd4681493" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_a0d5f692-34df-4f90-ad15-85ecd207795c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_7023e05e-82f8-4ecf-a4df-edc642b071fd" xlink:to="loc_srt_MajorCustomersAxis_a0d5f692-34df-4f90-ad15-85ecd207795c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_a0d5f692-34df-4f90-ad15-85ecd207795c_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_a0d5f692-34df-4f90-ad15-85ecd207795c" xlink:to="loc_srt_NameOfMajorCustomerDomain_a0d5f692-34df-4f90-ad15-85ecd207795c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_0be4ef0d-c4e2-4022-adb5-cf48c4b6eabe" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_a0d5f692-34df-4f90-ad15-85ecd207795c" xlink:to="loc_srt_NameOfMajorCustomerDomain_0be4ef0d-c4e2-4022-adb5-cf48c4b6eabe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MedicareMember_2282a688-43d1-41b5-8b3f-5c89b5dc1655" xlink:href="mygn-20210930.xsd#mygn_MedicareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_0be4ef0d-c4e2-4022-adb5-cf48c4b6eabe" xlink:to="loc_mygn_MedicareMember_2282a688-43d1-41b5-8b3f-5c89b5dc1655" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_943a67ed-d12b-4c64-a93b-34240ee398c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_7023e05e-82f8-4ecf-a4df-edc642b071fd" xlink:to="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_943a67ed-d12b-4c64-a93b-34240ee398c0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_943a67ed-d12b-4c64-a93b-34240ee398c0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_943a67ed-d12b-4c64-a93b-34240ee398c0" xlink:to="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_943a67ed-d12b-4c64-a93b-34240ee398c0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_edccdd50-79b2-489b-91b6-1448c8ed86f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_943a67ed-d12b-4c64-a93b-34240ee398c0" xlink:to="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_edccdd50-79b2-489b-91b6-1448c8ed86f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_PerformanceObligationEstimatedTransactionPriceMember_2f2664e7-9218-42a4-82bb-afe7fad69455" xlink:href="mygn-20210930.xsd#mygn_PerformanceObligationEstimatedTransactionPriceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_edccdd50-79b2-489b-91b6-1448c8ed86f2" xlink:to="loc_mygn_PerformanceObligationEstimatedTransactionPriceMember_2f2664e7-9218-42a4-82bb-afe7fad69455" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails" xlink:type="simple" xlink:href="mygn-20210930.xsd#MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails"/>
  <link:definitionLink xlink:role="http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails" xlink:type="extended" id="i51693c2fc633419f898fb5033cf6a64f_MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_bef13417-a312-441e-89a0-63d6afe80fc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_6266c37f-46d2-45b2-86ea-c52da5b94465" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_bef13417-a312-441e-89a0-63d6afe80fc3" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_6266c37f-46d2-45b2-86ea-c52da5b94465" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5fd89c46-268e-426c-8f3b-3148273be68a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_6266c37f-46d2-45b2-86ea-c52da5b94465" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5fd89c46-268e-426c-8f3b-3148273be68a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_7a6286a9-594a-4274-b70b-4dd4b0e3e012" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_6266c37f-46d2-45b2-86ea-c52da5b94465" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_7a6286a9-594a-4274-b70b-4dd4b0e3e012" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_939e7017-6dfe-4c7e-b368-2aa43e7f2da9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_bef13417-a312-441e-89a0-63d6afe80fc3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAbstract_939e7017-6dfe-4c7e-b368-2aa43e7f2da9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_186945e0-407e-4a13-bbf8-f97b57d2bdaf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_939e7017-6dfe-4c7e-b368-2aa43e7f2da9" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_186945e0-407e-4a13-bbf8-f97b57d2bdaf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_223f4a16-8f8e-47a3-aaea-790ba9c65dd6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_939e7017-6dfe-4c7e-b368-2aa43e7f2da9" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_223f4a16-8f8e-47a3-aaea-790ba9c65dd6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_a98ec301-ed2e-49ce-b421-991f682ed7cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_939e7017-6dfe-4c7e-b368-2aa43e7f2da9" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_a98ec301-ed2e-49ce-b421-991f682ed7cf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5c435a2a-273b-49c4-8d2c-ffc889917260" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_939e7017-6dfe-4c7e-b368-2aa43e7f2da9" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5c435a2a-273b-49c4-8d2c-ffc889917260" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAndCashAbstract_e155df54-602a-44b0-9773-98477f4661ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsAndCashAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_bef13417-a312-441e-89a0-63d6afe80fc3" xlink:to="loc_us-gaap_InvestmentsAndCashAbstract_e155df54-602a-44b0-9773-98477f4661ba" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_InvestmentsAndCashAmortizedCost_56cdbdf8-0064-4167-895b-5b35035f1187" xlink:href="mygn-20210930.xsd#mygn_InvestmentsAndCashAmortizedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentsAndCashAbstract_e155df54-602a-44b0-9773-98477f4661ba" xlink:to="loc_mygn_InvestmentsAndCashAmortizedCost_56cdbdf8-0064-4167-895b-5b35035f1187" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax_0c787203-7597-4cbd-8f2c-3e7fed70becf" xlink:href="mygn-20210930.xsd#mygn_InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentsAndCashAbstract_e155df54-602a-44b0-9773-98477f4661ba" xlink:to="loc_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax_0c787203-7597-4cbd-8f2c-3e7fed70becf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax_76cc7e46-806b-4c3c-8568-ebc14078a2bc" xlink:href="mygn-20210930.xsd#mygn_InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentsAndCashAbstract_e155df54-602a-44b0-9773-98477f4661ba" xlink:to="loc_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax_76cc7e46-806b-4c3c-8568-ebc14078a2bc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAndCash_d97a7b2e-e11d-4ea2-ab77-162f788d30af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsAndCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentsAndCashAbstract_e155df54-602a-44b0-9773-98477f4661ba" xlink:to="loc_us-gaap_InvestmentsAndCash_d97a7b2e-e11d-4ea2-ab77-162f788d30af" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_0a60e763-dabc-4dc2-ba20-5bcb8418de69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_bef13417-a312-441e-89a0-63d6afe80fc3" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_0a60e763-dabc-4dc2-ba20-5bcb8418de69" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_c4e4ea0e-4ea7-4b24-b94e-c7a544d238aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_0a60e763-dabc-4dc2-ba20-5bcb8418de69" xlink:to="loc_us-gaap_InvestmentTypeAxis_c4e4ea0e-4ea7-4b24-b94e-c7a544d238aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_c4e4ea0e-4ea7-4b24-b94e-c7a544d238aa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_c4e4ea0e-4ea7-4b24-b94e-c7a544d238aa" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_c4e4ea0e-4ea7-4b24-b94e-c7a544d238aa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_de065aaa-976f-41d5-9a5f-b7cb081f5f5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_c4e4ea0e-4ea7-4b24-b94e-c7a544d238aa" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_de065aaa-976f-41d5-9a5f-b7cb081f5f5c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_a5062932-8d0b-46de-8333-3cc5815b6106" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_de065aaa-976f-41d5-9a5f-b7cb081f5f5c" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_a5062932-8d0b-46de-8333-3cc5815b6106" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_8a2677c4-c723-4b1b-92d4-54abdeff797d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MunicipalBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_de065aaa-976f-41d5-9a5f-b7cb081f5f5c" xlink:to="loc_us-gaap_MunicipalBondsMember_8a2677c4-c723-4b1b-92d4-54abdeff797d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_84fa3749-6397-4dae-867f-c6260a906fad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_de065aaa-976f-41d5-9a5f-b7cb081f5f5c" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_84fa3749-6397-4dae-867f-c6260a906fad" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_af5ff66a-f651-44e0-9fd8-c81099c5395b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_de065aaa-976f-41d5-9a5f-b7cb081f5f5c" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_af5ff66a-f651-44e0-9fd8-c81099c5395b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_f927dd32-4404-4f16-b690-16f0d85c29c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_0a60e763-dabc-4dc2-ba20-5bcb8418de69" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_f927dd32-4404-4f16-b690-16f0d85c29c4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_f927dd32-4404-4f16-b690-16f0d85c29c4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_f927dd32-4404-4f16-b690-16f0d85c29c4" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_f927dd32-4404-4f16-b690-16f0d85c29c4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_52216536-169d-43df-b2d5-3481b7bc8475" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_f927dd32-4404-4f16-b690-16f0d85c29c4" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_52216536-169d-43df-b2d5-3481b7bc8475" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember_d44005a8-e931-4c26-97a2-3bd45e171993" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_52216536-169d-43df-b2d5-3481b7bc8475" xlink:to="loc_us-gaap_CashMember_d44005a8-e931-4c26-97a2-3bd45e171993" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsMember_07019a3b-3fa1-4039-924b-2a532f6b2de9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_52216536-169d-43df-b2d5-3481b7bc8475" xlink:to="loc_us-gaap_CashEquivalentsMember_07019a3b-3fa1-4039-924b-2a532f6b2de9" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails" xlink:type="simple" xlink:href="mygn-20210930.xsd#MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails" xlink:type="extended" id="i901db80f423141d6875774c9e1b00ff0_MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b65adb86-e235-4c7a-ada0-246e2f6ccc0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisRollingMaturityAbstract_1d4f4a1d-a694-4b14-b3e5-6a514cd9a954" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisRollingMaturityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b65adb86-e235-4c7a-ada0-246e2f6ccc0a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisRollingMaturityAbstract_1d4f4a1d-a694-4b14-b3e5-6a514cd9a954" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_78a1cb96-41e6-468c-b89a-d4ee9b05ef37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisRollingMaturityAbstract_1d4f4a1d-a694-4b14-b3e5-6a514cd9a954" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_78a1cb96-41e6-468c-b89a-d4ee9b05ef37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_f96a5899-8392-40e3-a2ad-918390be15f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisRollingMaturityAbstract_1d4f4a1d-a694-4b14-b3e5-6a514cd9a954" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_f96a5899-8392-40e3-a2ad-918390be15f5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_6fa47fcd-6e23-48cb-8892-6c6d77c44a80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisRollingMaturityAbstract_1d4f4a1d-a694-4b14-b3e5-6a514cd9a954" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_6fa47fcd-6e23-48cb-8892-6c6d77c44a80" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_02e9dad3-8b74-4bc7-81c7-deb80b97fe6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisRollingMaturityAbstract_1d4f4a1d-a694-4b14-b3e5-6a514cd9a954" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_02e9dad3-8b74-4bc7-81c7-deb80b97fe6e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_InvestmentsAndCashAmortizedCost_01e8607c-7cdb-47d9-b4b3-c92bea83b9e3" xlink:href="mygn-20210930.xsd#mygn_InvestmentsAndCashAmortizedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisRollingMaturityAbstract_1d4f4a1d-a694-4b14-b3e5-6a514cd9a954" xlink:to="loc_mygn_InvestmentsAndCashAmortizedCost_01e8607c-7cdb-47d9-b4b3-c92bea83b9e3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueRollingMaturityAbstract_43ab38ee-3008-4222-9430-a23d9ac6368e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueRollingMaturityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b65adb86-e235-4c7a-ada0-246e2f6ccc0a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueRollingMaturityAbstract_43ab38ee-3008-4222-9430-a23d9ac6368e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_33bd3500-6098-4470-9e03-0687d68cde20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueRollingMaturityAbstract_43ab38ee-3008-4222-9430-a23d9ac6368e" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_33bd3500-6098-4470-9e03-0687d68cde20" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_7b6b2123-9683-4273-af28-d5be294278d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueRollingMaturityAbstract_43ab38ee-3008-4222-9430-a23d9ac6368e" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_7b6b2123-9683-4273-af28-d5be294278d9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_a4bc29bf-5072-483d-809c-6ee2ec3dc026" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueRollingMaturityAbstract_43ab38ee-3008-4222-9430-a23d9ac6368e" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_a4bc29bf-5072-483d-809c-6ee2ec3dc026" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_4c2d2365-a2aa-47d2-b981-a44fe1e02328" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueRollingMaturityAbstract_43ab38ee-3008-4222-9430-a23d9ac6368e" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_4c2d2365-a2aa-47d2-b981-a44fe1e02328" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAndCash_8d6f4ceb-0ac8-4543-ad49-a15bec9b4182" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsAndCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueRollingMaturityAbstract_43ab38ee-3008-4222-9430-a23d9ac6368e" xlink:to="loc_us-gaap_InvestmentsAndCash_8d6f4ceb-0ac8-4543-ad49-a15bec9b4182" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_d8a98037-ee6c-42da-a680-152ff7775228" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b65adb86-e235-4c7a-ada0-246e2f6ccc0a" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_d8a98037-ee6c-42da-a680-152ff7775228" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_475506e0-2029-4e97-b275-e7eeee591dcb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_d8a98037-ee6c-42da-a680-152ff7775228" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_475506e0-2029-4e97-b275-e7eeee591dcb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_475506e0-2029-4e97-b275-e7eeee591dcb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_475506e0-2029-4e97-b275-e7eeee591dcb" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_475506e0-2029-4e97-b275-e7eeee591dcb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_cd5177de-8895-49df-824c-ac217afcaccf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_475506e0-2029-4e97-b275-e7eeee591dcb" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_cd5177de-8895-49df-824c-ac217afcaccf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember_0fee7b4c-2065-4434-8604-4ccf20a3becb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_cd5177de-8895-49df-824c-ac217afcaccf" xlink:to="loc_us-gaap_CashMember_0fee7b4c-2065-4434-8604-4ccf20a3becb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsMember_6ae7631c-ec67-4841-ade2-b5bfea964bbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_cd5177de-8895-49df-824c-ac217afcaccf" xlink:to="loc_us-gaap_CashEquivalentsMember_6ae7631c-ec67-4841-ade2-b5bfea964bbc" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.myriad.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="mygn-20210930.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.myriad.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended" id="i80e3aefc35914fe9ba61d637792ea7cd_FairValueMeasurementsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_60402a61-7507-423a-8584-f192aaf41567" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_BusinessCombinationContingentConsiderationLiabilityMeasurementInputTerm_088d0713-5fb4-4199-b166-4c151767fc57" xlink:href="mygn-20210930.xsd#mygn_BusinessCombinationContingentConsiderationLiabilityMeasurementInputTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_60402a61-7507-423a-8584-f192aaf41567" xlink:to="loc_mygn_BusinessCombinationContingentConsiderationLiabilityMeasurementInputTerm_088d0713-5fb4-4199-b166-4c151767fc57" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_b708f7fc-5a64-4692-b0fe-8ed2893854b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_60402a61-7507-423a-8584-f192aaf41567" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_b708f7fc-5a64-4692-b0fe-8ed2893854b8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_199c23d1-f4c0-44a4-b7a9-24210510d215" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_b708f7fc-5a64-4692-b0fe-8ed2893854b8" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_199c23d1-f4c0-44a4-b7a9-24210510d215" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_199c23d1-f4c0-44a4-b7a9-24210510d215_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_199c23d1-f4c0-44a4-b7a9-24210510d215" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_199c23d1-f4c0-44a4-b7a9-24210510d215_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_92907ed3-0862-455a-9d47-22255d8aff78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_199c23d1-f4c0-44a4-b7a9-24210510d215" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_92907ed3-0862-455a-9d47-22255d8aff78" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_a0214fd2-5ba0-4053-8e8b-235efa6f8447" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_92907ed3-0862-455a-9d47-22255d8aff78" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_a0214fd2-5ba0-4053-8e8b-235efa6f8447" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_3349aaf5-2b5f-46d3-9da0-4a41f8a9d176" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_b708f7fc-5a64-4692-b0fe-8ed2893854b8" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_3349aaf5-2b5f-46d3-9da0-4a41f8a9d176" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_3349aaf5-2b5f-46d3-9da0-4a41f8a9d176_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_3349aaf5-2b5f-46d3-9da0-4a41f8a9d176" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_3349aaf5-2b5f-46d3-9da0-4a41f8a9d176_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_12954967-e472-4ac0-b3d3-a7995fb6b607" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_3349aaf5-2b5f-46d3-9da0-4a41f8a9d176" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_12954967-e472-4ac0-b3d3-a7995fb6b607" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_6a597428-9e64-4734-a7a4-b8b1508c188f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_12954967-e472-4ac0-b3d3-a7995fb6b607" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_6a597428-9e64-4734-a7a4-b8b1508c188f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="mygn-20210930.xsd#FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails" xlink:type="extended" id="i304949fe23c84a32903d76b94649dbc9_FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_eb6e5fb6-5678-4b17-9bfd-23ee0d0569d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_43ef8a69-e3b1-4c49-9cef-761d8945534e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_eb6e5fb6-5678-4b17-9bfd-23ee0d0569d6" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_43ef8a69-e3b1-4c49-9cef-761d8945534e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_62dde53a-e39a-43c6-aa09-ea1fc49e7f3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_eb6e5fb6-5678-4b17-9bfd-23ee0d0569d6" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_62dde53a-e39a-43c6-aa09-ea1fc49e7f3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetAssetLiability_440a9125-7770-4c91-988d-e2bc92f59cdf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueNetAssetLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_eb6e5fb6-5678-4b17-9bfd-23ee0d0569d6" xlink:to="loc_us-gaap_FairValueNetAssetLiability_440a9125-7770-4c91-988d-e2bc92f59cdf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fb3409ff-1f77-4288-908b-77efb42e7511" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_eb6e5fb6-5678-4b17-9bfd-23ee0d0569d6" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fb3409ff-1f77-4288-908b-77efb42e7511" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_55fee45b-8761-49e3-b173-bac3c5d3175e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fb3409ff-1f77-4288-908b-77efb42e7511" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_55fee45b-8761-49e3-b173-bac3c5d3175e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_55fee45b-8761-49e3-b173-bac3c5d3175e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_55fee45b-8761-49e3-b173-bac3c5d3175e" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_55fee45b-8761-49e3-b173-bac3c5d3175e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_035aa192-1d36-4840-8355-d027ecec8406" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_55fee45b-8761-49e3-b173-bac3c5d3175e" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_035aa192-1d36-4840-8355-d027ecec8406" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_f7c5594e-d2a8-4cc0-99e7-d05d1d75d714" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_035aa192-1d36-4840-8355-d027ecec8406" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_f7c5594e-d2a8-4cc0-99e7-d05d1d75d714" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_57c013ec-9b39-488d-8a6f-5df34e81e698" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_035aa192-1d36-4840-8355-d027ecec8406" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_57c013ec-9b39-488d-8a6f-5df34e81e698" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_82cf4d33-726b-4755-ba74-da702d706eea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_035aa192-1d36-4840-8355-d027ecec8406" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_82cf4d33-726b-4755-ba74-da702d706eea" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_970e421a-8e57-49d5-a892-38912c826f70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fb3409ff-1f77-4288-908b-77efb42e7511" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_970e421a-8e57-49d5-a892-38912c826f70" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_970e421a-8e57-49d5-a892-38912c826f70_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_970e421a-8e57-49d5-a892-38912c826f70" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_970e421a-8e57-49d5-a892-38912c826f70_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_843e9af0-873b-472f-9ae2-905c886a3e29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_970e421a-8e57-49d5-a892-38912c826f70" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_843e9af0-873b-472f-9ae2-905c886a3e29" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_ContingentConsiderationMember_0dc3ed4f-1744-441f-9368-8ed259bc3ba7" xlink:href="mygn-20210930.xsd#mygn_ContingentConsiderationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_843e9af0-873b-472f-9ae2-905c886a3e29" xlink:to="loc_mygn_ContingentConsiderationMember_0dc3ed4f-1744-441f-9368-8ed259bc3ba7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_5a8aa3b4-5c96-45a8-b3bb-4e1b00f867bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fb3409ff-1f77-4288-908b-77efb42e7511" xlink:to="loc_us-gaap_InvestmentTypeAxis_5a8aa3b4-5c96-45a8-b3bb-4e1b00f867bf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_5a8aa3b4-5c96-45a8-b3bb-4e1b00f867bf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_5a8aa3b4-5c96-45a8-b3bb-4e1b00f867bf" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_5a8aa3b4-5c96-45a8-b3bb-4e1b00f867bf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_25ebdb10-c5e9-4a1c-8f7a-6a91c7da7f14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_5a8aa3b4-5c96-45a8-b3bb-4e1b00f867bf" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_25ebdb10-c5e9-4a1c-8f7a-6a91c7da7f14" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_2be243c1-5328-417e-9c2b-ad46f85f185e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_25ebdb10-c5e9-4a1c-8f7a-6a91c7da7f14" xlink:to="loc_us-gaap_MoneyMarketFundsMember_2be243c1-5328-417e-9c2b-ad46f85f185e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_d98c3c02-75e2-415a-8dc5-dc03b6b44d5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_25ebdb10-c5e9-4a1c-8f7a-6a91c7da7f14" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_d98c3c02-75e2-415a-8dc5-dc03b6b44d5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_de213df2-40e1-4f6d-bc0d-43f92a9f0a88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MunicipalBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_25ebdb10-c5e9-4a1c-8f7a-6a91c7da7f14" xlink:to="loc_us-gaap_MunicipalBondsMember_de213df2-40e1-4f6d-bc0d-43f92a9f0a88" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_ace50fc5-e665-44d3-96e0-0789d1edd541" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_25ebdb10-c5e9-4a1c-8f7a-6a91c7da7f14" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_ace50fc5-e665-44d3-96e0-0789d1edd541" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_6542aa0f-462a-4285-a81a-57249b3b5682" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_25ebdb10-c5e9-4a1c-8f7a-6a91c7da7f14" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_6542aa0f-462a-4285-a81a-57249b3b5682" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.myriad.com/role/PropertyPlantandEquipmentNetBalancesDetails" xlink:type="simple" xlink:href="mygn-20210930.xsd#PropertyPlantandEquipmentNetBalancesDetails"/>
  <link:definitionLink xlink:role="http://www.myriad.com/role/PropertyPlantandEquipmentNetBalancesDetails" xlink:type="extended" id="i3e1fb67c34324ece9c49554c93572ea7_PropertyPlantandEquipmentNetBalancesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d4e1bd17-d74c-4b1a-b574-b6c15785fcb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_29d19b49-e27d-41cd-b792-5d4022c2fea1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d4e1bd17-d74c-4b1a-b574-b6c15785fcb8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_29d19b49-e27d-41cd-b792-5d4022c2fea1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_f14acd98-cb7f-4deb-8c71-c18280ab9859" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d4e1bd17-d74c-4b1a-b574-b6c15785fcb8" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_f14acd98-cb7f-4deb-8c71-c18280ab9859" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_d2f799c0-4dde-4f6c-9080-ab18c4abee2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d4e1bd17-d74c-4b1a-b574-b6c15785fcb8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_d2f799c0-4dde-4f6c-9080-ab18c4abee2e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6c3fccc0-7708-4f02-a0fb-f26a1d30d694" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d4e1bd17-d74c-4b1a-b574-b6c15785fcb8" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6c3fccc0-7708-4f02-a0fb-f26a1d30d694" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a485130e-d343-4c53-80e0-40f8a9fcbf3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6c3fccc0-7708-4f02-a0fb-f26a1d30d694" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a485130e-d343-4c53-80e0-40f8a9fcbf3b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a485130e-d343-4c53-80e0-40f8a9fcbf3b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a485130e-d343-4c53-80e0-40f8a9fcbf3b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a485130e-d343-4c53-80e0-40f8a9fcbf3b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0b64b434-d12f-4b75-aa62-0c5d1657a4cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a485130e-d343-4c53-80e0-40f8a9fcbf3b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0b64b434-d12f-4b75-aa62-0c5d1657a4cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_ff2657dd-4574-4f1c-af4e-ed9b0cf38b54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0b64b434-d12f-4b75-aa62-0c5d1657a4cf" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_ff2657dd-4574-4f1c-af4e-ed9b0cf38b54" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_048fd5a6-5259-4833-804f-d6ae508df73a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0b64b434-d12f-4b75-aa62-0c5d1657a4cf" xlink:to="loc_us-gaap_EquipmentMember_048fd5a6-5259-4833-804f-d6ae508df73a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.myriad.com/role/GoodwillandIntangibleAssetsCarryingAmountofGoodwillDetails" xlink:type="simple" xlink:href="mygn-20210930.xsd#GoodwillandIntangibleAssetsCarryingAmountofGoodwillDetails"/>
  <link:definitionLink xlink:role="http://www.myriad.com/role/GoodwillandIntangibleAssetsCarryingAmountofGoodwillDetails" xlink:type="extended" id="id7c955a917f24c5f9b624f11ea4441d4_GoodwillandIntangibleAssetsCarryingAmountofGoodwillDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_e77bbd42-0cf5-4048-9916-b7e8ccce1f96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_5841b246-4404-47e1-8991-abe5857018a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_e77bbd42-0cf5-4048-9916-b7e8ccce1f96" xlink:to="loc_us-gaap_GoodwillRollForward_5841b246-4404-47e1-8991-abe5857018a0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_ab925496-fca0-4894-a011-24da8048c1bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_5841b246-4404-47e1-8991-abe5857018a0" xlink:to="loc_us-gaap_Goodwill_ab925496-fca0-4894-a011-24da8048c1bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_680b2448-a2b1-492a-b921-9617dd8774d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_5841b246-4404-47e1-8991-abe5857018a0" xlink:to="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_680b2448-a2b1-492a-b921-9617dd8774d9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_86906573-afb8-4452-aac1-3052c30d3eac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_5841b246-4404-47e1-8991-abe5857018a0" xlink:to="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_86906573-afb8-4452-aac1-3052c30d3eac" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_4d324e90-f681-4501-961c-436e994d14a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_cfcd960f-077a-4ed1-ae68-b901a97d4b43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_e77bbd42-0cf5-4048-9916-b7e8ccce1f96" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_cfcd960f-077a-4ed1-ae68-b901a97d4b43" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_b8533a94-2a07-4591-9ecf-17b970bfece7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_cfcd960f-077a-4ed1-ae68-b901a97d4b43" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_b8533a94-2a07-4591-9ecf-17b970bfece7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_b8533a94-2a07-4591-9ecf-17b970bfece7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_b8533a94-2a07-4591-9ecf-17b970bfece7" xlink:to="loc_us-gaap_SegmentDomain_b8533a94-2a07-4591-9ecf-17b970bfece7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_62b74431-b3f4-4b52-a179-94b1cbaf3569" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_b8533a94-2a07-4591-9ecf-17b970bfece7" xlink:to="loc_us-gaap_SegmentDomain_62b74431-b3f4-4b52-a179-94b1cbaf3569" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_DiagnosticsMember_ea9e78ae-b254-4d4d-a9ea-230e286b9f39" xlink:href="mygn-20210930.xsd#mygn_DiagnosticsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_62b74431-b3f4-4b52-a179-94b1cbaf3569" xlink:to="loc_mygn_DiagnosticsMember_ea9e78ae-b254-4d4d-a9ea-230e286b9f39" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_7ee01814-c74c-4020-8fd8-4d8c5bfa4170" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_62b74431-b3f4-4b52-a179-94b1cbaf3569" xlink:to="loc_us-gaap_AllOtherSegmentsMember_7ee01814-c74c-4020-8fd8-4d8c5bfa4170" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.myriad.com/role/GoodwillandIntangibleAssetsNarrativeDetails" xlink:type="simple" xlink:href="mygn-20210930.xsd#GoodwillandIntangibleAssetsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.myriad.com/role/GoodwillandIntangibleAssetsNarrativeDetails" xlink:type="extended" id="i8cd641cb6a8f4f2085943fdae4effca7_GoodwillandIntangibleAssetsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_mygn_IntangibleAssetsLineItems_bd88245f-afd5-4737-bdc3-3e570530643d" xlink:href="mygn-20210930.xsd#mygn_IntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_05e3e905-df2d-45f4-a1f0-6c8b2b58ee1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_IntangibleAssetsLineItems_bd88245f-afd5-4737-bdc3-3e570530643d" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_05e3e905-df2d-45f4-a1f0-6c8b2b58ee1b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNetNoncurrent_71a31f02-7bf1-4a7f-8adf-21b8722b9cb0" xlink:href="mygn-20210930.xsd#mygn_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNetNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_IntangibleAssetsLineItems_bd88245f-afd5-4737-bdc3-3e570530643d" xlink:to="loc_mygn_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNetNoncurrent_71a31f02-7bf1-4a7f-8adf-21b8722b9cb0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsAccumulatedAmortizationNoncurrent_9ca1e75b-2dd6-40cd-b006-f3e862a32c19" xlink:href="mygn-20210930.xsd#mygn_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsAccumulatedAmortizationNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_IntangibleAssetsLineItems_bd88245f-afd5-4737-bdc3-3e570530643d" xlink:to="loc_mygn_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsAccumulatedAmortizationNoncurrent_9ca1e75b-2dd6-40cd-b006-f3e862a32c19" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_ScheduleOfIntangibleAssetsTable_ffc1ac08-0951-4783-a290-ebe1f50cfa31" xlink:href="mygn-20210930.xsd#mygn_ScheduleOfIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_mygn_IntangibleAssetsLineItems_bd88245f-afd5-4737-bdc3-3e570530643d" xlink:to="loc_mygn_ScheduleOfIntangibleAssetsTable_ffc1ac08-0951-4783-a290-ebe1f50cfa31" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_16786fd0-d9d9-4477-9d0e-78128535dddb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mygn_ScheduleOfIntangibleAssetsTable_ffc1ac08-0951-4783-a290-ebe1f50cfa31" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_16786fd0-d9d9-4477-9d0e-78128535dddb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_16786fd0-d9d9-4477-9d0e-78128535dddb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_16786fd0-d9d9-4477-9d0e-78128535dddb" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_16786fd0-d9d9-4477-9d0e-78128535dddb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_637023de-6e88-42b9-a71e-883537166c10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_16786fd0-d9d9-4477-9d0e-78128535dddb" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_637023de-6e88-42b9-a71e-883537166c10" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_InProcessResearchAndDevelopmentWithIndefiniteLivesMember_a77afa33-f389-4267-bbca-77a76148b0b5" xlink:href="mygn-20210930.xsd#mygn_InProcessResearchAndDevelopmentWithIndefiniteLivesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_637023de-6e88-42b9-a71e-883537166c10" xlink:to="loc_mygn_InProcessResearchAndDevelopmentWithIndefiniteLivesMember_a77afa33-f389-4267-bbca-77a76148b0b5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_806f8531-1e38-4f08-89c4-4c3683714978" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mygn_ScheduleOfIntangibleAssetsTable_ffc1ac08-0951-4783-a290-ebe1f50cfa31" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_806f8531-1e38-4f08-89c4-4c3683714978" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_806f8531-1e38-4f08-89c4-4c3683714978_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_806f8531-1e38-4f08-89c4-4c3683714978" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_806f8531-1e38-4f08-89c4-4c3683714978_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ad7b779b-6ae8-4615-ada9-f80bebccf61b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_806f8531-1e38-4f08-89c4-4c3683714978" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ad7b779b-6ae8-4615-ada9-f80bebccf61b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_PurchasedLicensesAndTechnologiesMember_826b59ed-f34c-4ada-bb0c-84867c9f9e0c" xlink:href="mygn-20210930.xsd#mygn_PurchasedLicensesAndTechnologiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ad7b779b-6ae8-4615-ada9-f80bebccf61b" xlink:to="loc_mygn_PurchasedLicensesAndTechnologiesMember_826b59ed-f34c-4ada-bb0c-84867c9f9e0c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_f890d165-3eab-417f-bbb8-f3367fa56895" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ad7b779b-6ae8-4615-ada9-f80bebccf61b" xlink:to="loc_us-gaap_CustomerRelationshipsMember_f890d165-3eab-417f-bbb8-f3367fa56895" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember_a55b96f1-ce83-4409-83a2-d7173c7895eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TrademarksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ad7b779b-6ae8-4615-ada9-f80bebccf61b" xlink:to="loc_us-gaap_TrademarksMember_a55b96f1-ce83-4409-83a2-d7173c7895eb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_abf86bb8-d107-4ac0-baab-7a4404451776" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mygn_ScheduleOfIntangibleAssetsTable_ffc1ac08-0951-4783-a290-ebe1f50cfa31" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_abf86bb8-d107-4ac0-baab-7a4404451776" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_abf86bb8-d107-4ac0-baab-7a4404451776_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_abf86bb8-d107-4ac0-baab-7a4404451776" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_abf86bb8-d107-4ac0-baab-7a4404451776_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_413358e8-979d-4c0a-838c-9c6d16b7c6d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_abf86bb8-d107-4ac0-baab-7a4404451776" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_413358e8-979d-4c0a-838c-9c6d16b7c6d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_ba36c3e6-534d-4420-9f53-55b6d4693d88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_413358e8-979d-4c0a-838c-9c6d16b7c6d1" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_ba36c3e6-534d-4420-9f53-55b6d4693d88" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_060e9d22-fc80-4399-a03f-5dec3a9319b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mygn_ScheduleOfIntangibleAssetsTable_ffc1ac08-0951-4783-a290-ebe1f50cfa31" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_060e9d22-fc80-4399-a03f-5dec3a9319b4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_060e9d22-fc80-4399-a03f-5dec3a9319b4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_060e9d22-fc80-4399-a03f-5dec3a9319b4" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_060e9d22-fc80-4399-a03f-5dec3a9319b4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_04fbb1e8-4c28-495a-9baa-17b3ffff5e8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_060e9d22-fc80-4399-a03f-5dec3a9319b4" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_04fbb1e8-4c28-495a-9baa-17b3ffff5e8d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MyriadRBMIncMember_2aa2d2b1-44c7-43ab-bbc5-2c1b04ab2255" xlink:href="mygn-20210930.xsd#mygn_MyriadRBMIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_04fbb1e8-4c28-495a-9baa-17b3ffff5e8d" xlink:to="loc_mygn_MyriadRBMIncMember_2aa2d2b1-44c7-43ab-bbc5-2c1b04ab2255" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails" xlink:type="simple" xlink:href="mygn-20210930.xsd#GoodwillandIntangibleAssetsIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails" xlink:type="extended" id="ifbacb35fbfb14cd3934038cfa352d068_GoodwillandIntangibleAssetsIntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_mygn_IntangibleAssetsLineItems_c3a9db27-fd3c-4500-90c0-fe26bdb2cefc" xlink:href="mygn-20210930.xsd#mygn_IntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_78a1981f-1241-41a6-8ae6-3e0492b5707f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_IntangibleAssetsLineItems_c3a9db27-fd3c-4500-90c0-fe26bdb2cefc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_78a1981f-1241-41a6-8ae6-3e0492b5707f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_9fd92f21-2b1a-481a-8779-3cf421c856cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_IntangibleAssetsLineItems_c3a9db27-fd3c-4500-90c0-fe26bdb2cefc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_9fd92f21-2b1a-481a-8779-3cf421c856cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_06699ef4-212c-4718-b4af-a14178f4d62a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_IntangibleAssetsLineItems_c3a9db27-fd3c-4500-90c0-fe26bdb2cefc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_06699ef4-212c-4718-b4af-a14178f4d62a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_d7c4548e-b1b9-44bc-a0cf-14ffe6c5d191" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_IntangibleAssetsLineItems_c3a9db27-fd3c-4500-90c0-fe26bdb2cefc" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_d7c4548e-b1b9-44bc-a0cf-14ffe6c5d191" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_88894065-90d1-4cf3-ab4e-79cde6f34c79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_IntangibleAssetsLineItems_c3a9db27-fd3c-4500-90c0-fe26bdb2cefc" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_88894065-90d1-4cf3-ab4e-79cde6f34c79" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_493707a6-ae7b-46f2-a24a-90b011c72501" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_IntangibleAssetsLineItems_c3a9db27-fd3c-4500-90c0-fe26bdb2cefc" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_493707a6-ae7b-46f2-a24a-90b011c72501" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_ScheduleOfIntangibleAssetsTable_c7332959-1b9f-465e-8168-1e15b928cc26" xlink:href="mygn-20210930.xsd#mygn_ScheduleOfIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_mygn_IntangibleAssetsLineItems_c3a9db27-fd3c-4500-90c0-fe26bdb2cefc" xlink:to="loc_mygn_ScheduleOfIntangibleAssetsTable_c7332959-1b9f-465e-8168-1e15b928cc26" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_d4438c33-c93c-4165-91ae-d61b8083a58a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mygn_ScheduleOfIntangibleAssetsTable_c7332959-1b9f-465e-8168-1e15b928cc26" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_d4438c33-c93c-4165-91ae-d61b8083a58a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_d4438c33-c93c-4165-91ae-d61b8083a58a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_d4438c33-c93c-4165-91ae-d61b8083a58a" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_d4438c33-c93c-4165-91ae-d61b8083a58a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_47affbe1-48ec-4501-b598-0e3dccfd8703" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_d4438c33-c93c-4165-91ae-d61b8083a58a" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_47affbe1-48ec-4501-b598-0e3dccfd8703" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_InProcessResearchAndDevelopmentWithIndefiniteLivesMember_9e9ffb91-d342-47de-b265-f78aac27d174" xlink:href="mygn-20210930.xsd#mygn_InProcessResearchAndDevelopmentWithIndefiniteLivesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_47affbe1-48ec-4501-b598-0e3dccfd8703" xlink:to="loc_mygn_InProcessResearchAndDevelopmentWithIndefiniteLivesMember_9e9ffb91-d342-47de-b265-f78aac27d174" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d69beeaf-ee5d-46a6-9fc6-38a5e260a527" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mygn_ScheduleOfIntangibleAssetsTable_c7332959-1b9f-465e-8168-1e15b928cc26" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d69beeaf-ee5d-46a6-9fc6-38a5e260a527" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d69beeaf-ee5d-46a6-9fc6-38a5e260a527_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d69beeaf-ee5d-46a6-9fc6-38a5e260a527" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d69beeaf-ee5d-46a6-9fc6-38a5e260a527_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_89debada-523d-43a1-b5fb-53be0f6d8c7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d69beeaf-ee5d-46a6-9fc6-38a5e260a527" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_89debada-523d-43a1-b5fb-53be0f6d8c7e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_PurchasedLicensesAndTechnologiesMember_d23825e4-ecbc-4fcb-b15a-17f770eb05e4" xlink:href="mygn-20210930.xsd#mygn_PurchasedLicensesAndTechnologiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_89debada-523d-43a1-b5fb-53be0f6d8c7e" xlink:to="loc_mygn_PurchasedLicensesAndTechnologiesMember_d23825e4-ecbc-4fcb-b15a-17f770eb05e4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_0ebca22c-ca6f-4767-ac6f-eab05adaaf7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_89debada-523d-43a1-b5fb-53be0f6d8c7e" xlink:to="loc_us-gaap_CustomerRelationshipsMember_0ebca22c-ca6f-4767-ac6f-eab05adaaf7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember_9963946c-bcf4-4601-bb7b-7bd1c4afa8f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TrademarksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_89debada-523d-43a1-b5fb-53be0f6d8c7e" xlink:to="loc_us-gaap_TrademarksMember_9963946c-bcf4-4601-bb7b-7bd1c4afa8f1" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.myriad.com/role/LongTermDebtNarrativeDetails" xlink:type="simple" xlink:href="mygn-20210930.xsd#LongTermDebtNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.myriad.com/role/LongTermDebtNarrativeDetails" xlink:type="extended" id="i50f3cdc759184a9aabac7fae52958e76_LongTermDebtNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_b0e79038-16d4-4d07-88d6-4448aab5958e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_2f72ea54-1ddc-4987-a40e-76f5b11959c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b0e79038-16d4-4d07-88d6-4448aab5958e" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_2f72ea54-1ddc-4987-a40e-76f5b11959c2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_eb397960-d0bf-4758-8f1d-5332df7ab142" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b0e79038-16d4-4d07-88d6-4448aab5958e" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_eb397960-d0bf-4758-8f1d-5332df7ab142" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_e1a61f74-d11c-44ac-8380-39caf5cc9f8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b0e79038-16d4-4d07-88d6-4448aab5958e" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_e1a61f74-d11c-44ac-8380-39caf5cc9f8d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_4e3316fb-d278-4e9f-8ed3-916ae871ce26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b0e79038-16d4-4d07-88d6-4448aab5958e" xlink:to="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_4e3316fb-d278-4e9f-8ed3-916ae871ce26" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_DebtInstrumentLIBORFloorPercentage_10905ae1-d384-43f7-bbf2-49549096ca27" xlink:href="mygn-20210930.xsd#mygn_DebtInstrumentLIBORFloorPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b0e79038-16d4-4d07-88d6-4448aab5958e" xlink:to="loc_mygn_DebtInstrumentLIBORFloorPercentage_10905ae1-d384-43f7-bbf2-49549096ca27" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_DebtCovenantLiquidityCovenantMinimum_08ee8562-4fa4-4754-a081-4f0debd9dcc6" xlink:href="mygn-20210930.xsd#mygn_DebtCovenantLiquidityCovenantMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b0e79038-16d4-4d07-88d6-4448aab5958e" xlink:to="loc_mygn_DebtCovenantLiquidityCovenantMinimum_08ee8562-4fa4-4754-a081-4f0debd9dcc6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_DebtCovenantUnrestrictedCashAndCashEquivalentsThresholdForBorrowingRestrictionMinimum_bbd76050-2462-4684-b458-3cdb9d1b1615" xlink:href="mygn-20210930.xsd#mygn_DebtCovenantUnrestrictedCashAndCashEquivalentsThresholdForBorrowingRestrictionMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b0e79038-16d4-4d07-88d6-4448aab5958e" xlink:to="loc_mygn_DebtCovenantUnrestrictedCashAndCashEquivalentsThresholdForBorrowingRestrictionMinimum_bbd76050-2462-4684-b458-3cdb9d1b1615" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit_e93fe384-cab1-4a46-a0e1-41e929e40b8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b0e79038-16d4-4d07-88d6-4448aab5958e" xlink:to="loc_us-gaap_RepaymentsOfLinesOfCredit_e93fe384-cab1-4a46-a0e1-41e929e40b8e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_9dc1ab79-0edc-4e03-a6f4-4da93fd15fc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b0e79038-16d4-4d07-88d6-4448aab5958e" xlink:to="loc_us-gaap_LongTermDebt_9dc1ab79-0edc-4e03-a6f4-4da93fd15fc8" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_OtherAssetsDebtDiscount_4d9853ca-d65b-42ef-a399-7559181a25dd" xlink:href="mygn-20210930.xsd#mygn_OtherAssetsDebtDiscount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b0e79038-16d4-4d07-88d6-4448aab5958e" xlink:to="loc_mygn_OtherAssetsDebtDiscount_4d9853ca-d65b-42ef-a399-7559181a25dd" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent_6494d1c2-a194-452d-9da2-f05ef18c24cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b0e79038-16d4-4d07-88d6-4448aab5958e" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent_6494d1c2-a194-452d-9da2-f05ef18c24cc" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_593125b5-4856-4f6b-9e83-b7a5d60f18d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b0e79038-16d4-4d07-88d6-4448aab5958e" xlink:to="loc_us-gaap_DebtInstrumentTable_593125b5-4856-4f6b-9e83-b7a5d60f18d6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_04b0981f-9e63-473d-9955-e62f5121eab8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_593125b5-4856-4f6b-9e83-b7a5d60f18d6" xlink:to="loc_us-gaap_CreditFacilityAxis_04b0981f-9e63-473d-9955-e62f5121eab8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_04b0981f-9e63-473d-9955-e62f5121eab8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_04b0981f-9e63-473d-9955-e62f5121eab8" xlink:to="loc_us-gaap_CreditFacilityDomain_04b0981f-9e63-473d-9955-e62f5121eab8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_b4de29bb-2306-4218-bc76-9c15238b437d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_04b0981f-9e63-473d-9955-e62f5121eab8" xlink:to="loc_us-gaap_CreditFacilityDomain_b4de29bb-2306-4218-bc76-9c15238b437d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_fadb4cb1-4daa-430e-83b6-60af6d7d349d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_b4de29bb-2306-4218-bc76-9c15238b437d" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_fadb4cb1-4daa-430e-83b6-60af6d7d349d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_a65f317d-d547-4b1f-932e-9f5a40eb5d54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_593125b5-4856-4f6b-9e83-b7a5d60f18d6" xlink:to="loc_us-gaap_DebtInstrumentAxis_a65f317d-d547-4b1f-932e-9f5a40eb5d54" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a65f317d-d547-4b1f-932e-9f5a40eb5d54_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_a65f317d-d547-4b1f-932e-9f5a40eb5d54" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a65f317d-d547-4b1f-932e-9f5a40eb5d54_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b19205c5-5668-4950-87b3-2f09d9e4f71c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_a65f317d-d547-4b1f-932e-9f5a40eb5d54" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b19205c5-5668-4950-87b3-2f09d9e4f71c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_AmendmentToCreditAgreementMember_070cb828-8d7c-4ad5-a4ef-3cd7f2f733ff" xlink:href="mygn-20210930.xsd#mygn_AmendmentToCreditAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b19205c5-5668-4950-87b3-2f09d9e4f71c" xlink:to="loc_mygn_AmendmentToCreditAgreementMember_070cb828-8d7c-4ad5-a4ef-3cd7f2f733ff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_95126c9b-7f67-4713-90a7-b8b2df062847" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_593125b5-4856-4f6b-9e83-b7a5d60f18d6" xlink:to="loc_us-gaap_VariableRateAxis_95126c9b-7f67-4713-90a7-b8b2df062847" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_95126c9b-7f67-4713-90a7-b8b2df062847_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_95126c9b-7f67-4713-90a7-b8b2df062847" xlink:to="loc_us-gaap_VariableRateDomain_95126c9b-7f67-4713-90a7-b8b2df062847_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_8a1bdbc0-5968-4cac-922e-7d3cd5497177" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_95126c9b-7f67-4713-90a7-b8b2df062847" xlink:to="loc_us-gaap_VariableRateDomain_8a1bdbc0-5968-4cac-922e-7d3cd5497177" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_02bc179b-851c-4828-bf49-375715fc0443" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_8a1bdbc0-5968-4cac-922e-7d3cd5497177" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_02bc179b-851c-4828-bf49-375715fc0443" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_715f28da-2b27-428b-8288-dcf5aaba8f5d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_593125b5-4856-4f6b-9e83-b7a5d60f18d6" xlink:to="loc_srt_StatementScenarioAxis_715f28da-2b27-428b-8288-dcf5aaba8f5d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_715f28da-2b27-428b-8288-dcf5aaba8f5d_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_715f28da-2b27-428b-8288-dcf5aaba8f5d" xlink:to="loc_srt_ScenarioUnspecifiedDomain_715f28da-2b27-428b-8288-dcf5aaba8f5d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_70540618-14b7-4461-a4cf-e1c15d5a6796" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_715f28da-2b27-428b-8288-dcf5aaba8f5d" xlink:to="loc_srt_ScenarioUnspecifiedDomain_70540618-14b7-4461-a4cf-e1c15d5a6796" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_0355c490-4c54-41c0-9ce5-ab6cb41927f1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_70540618-14b7-4461-a4cf-e1c15d5a6796" xlink:to="loc_srt_ScenarioForecastMember_0355c490-4c54-41c0-9ce5-ab6cb41927f1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_476f8831-9db5-4add-9fa7-5eb4bee9d8f0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_593125b5-4856-4f6b-9e83-b7a5d60f18d6" xlink:to="loc_srt_RangeAxis_476f8831-9db5-4add-9fa7-5eb4bee9d8f0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_476f8831-9db5-4add-9fa7-5eb4bee9d8f0_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_476f8831-9db5-4add-9fa7-5eb4bee9d8f0" xlink:to="loc_srt_RangeMember_476f8831-9db5-4add-9fa7-5eb4bee9d8f0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d2ba7166-7fe2-4901-abaf-6d9e607d0734" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_476f8831-9db5-4add-9fa7-5eb4bee9d8f0" xlink:to="loc_srt_RangeMember_d2ba7166-7fe2-4901-abaf-6d9e607d0734" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_3ef45a5d-b08d-4634-be48-b60d97f4d4bc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d2ba7166-7fe2-4901-abaf-6d9e607d0734" xlink:to="loc_srt_MinimumMember_3ef45a5d-b08d-4634-be48-b60d97f4d4bc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_7c63bf99-aafd-4f25-a655-7baa23f2968f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d2ba7166-7fe2-4901-abaf-6d9e607d0734" xlink:to="loc_srt_MaximumMember_7c63bf99-aafd-4f25-a655-7baa23f2968f" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.myriad.com/role/PreferredandCommonStockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="mygn-20210930.xsd#PreferredandCommonStockholdersEquityNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.myriad.com/role/PreferredandCommonStockholdersEquityNarrativeDetails" xlink:type="extended" id="i74a2a4562a3946a2ad46101d22484e1b_PreferredandCommonStockholdersEquityNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_6b2a4bee-f57b-4e20-a7ab-0a300d77c4f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_fb3768d3-fc4b-40a9-bb3c-347e46f43b56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6b2a4bee-f57b-4e20-a7ab-0a300d77c4f8" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_fb3768d3-fc4b-40a9-bb3c-347e46f43b56" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_7a1bb9a9-de2b-4dfa-a857-ef004cc557e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6b2a4bee-f57b-4e20-a7ab-0a300d77c4f8" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_7a1bb9a9-de2b-4dfa-a857-ef004cc557e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_80cfca8c-f9ad-41d7-8c6c-a7a41ec54cd6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6b2a4bee-f57b-4e20-a7ab-0a300d77c4f8" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_80cfca8c-f9ad-41d7-8c6c-a7a41ec54cd6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_c783890c-93f8-4472-ac44-23316a174dda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6b2a4bee-f57b-4e20-a7ab-0a300d77c4f8" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_c783890c-93f8-4472-ac44-23316a174dda" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_1ee96ea4-3e16-4413-8540-da4f257f356e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6b2a4bee-f57b-4e20-a7ab-0a300d77c4f8" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_1ee96ea4-3e16-4413-8540-da4f257f356e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_0ef63e0b-db0a-47c3-b39a-1378268f45b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6b2a4bee-f57b-4e20-a7ab-0a300d77c4f8" xlink:to="loc_us-gaap_CommonStockSharesIssued_0ef63e0b-db0a-47c3-b39a-1378268f45b3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_c5fd74c8-94a7-4802-837e-d01a9c51d42c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6b2a4bee-f57b-4e20-a7ab-0a300d77c4f8" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_c5fd74c8-94a7-4802-837e-d01a9c51d42c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_0d013e3e-c96c-48f0-ac8a-2b97a1f1f7bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6b2a4bee-f57b-4e20-a7ab-0a300d77c4f8" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_0d013e3e-c96c-48f0-ac8a-2b97a1f1f7bb" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_b4f62ab3-5456-4cfe-9b79-327cac45ec85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6b2a4bee-f57b-4e20-a7ab-0a300d77c4f8" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_b4f62ab3-5456-4cfe-9b79-327cac45ec85" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_48356c51-3831-4654-a9e3-c37765aff471" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6b2a4bee-f57b-4e20-a7ab-0a300d77c4f8" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_48356c51-3831-4654-a9e3-c37765aff471" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_d23f583c-18a7-4b4b-bd2c-c5504bbd2690" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_6b2a4bee-f57b-4e20-a7ab-0a300d77c4f8" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_d23f583c-18a7-4b4b-bd2c-c5504bbd2690" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_0bee9935-a32d-483a-9c4f-0e9e2a712953" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d23f583c-18a7-4b4b-bd2c-c5504bbd2690" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_0bee9935-a32d-483a-9c4f-0e9e2a712953" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_0bee9935-a32d-483a-9c4f-0e9e2a712953_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_0bee9935-a32d-483a-9c4f-0e9e2a712953" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_0bee9935-a32d-483a-9c4f-0e9e2a712953_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_7fbdfcbf-e87c-4e23-a210-29665e1c1f12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_0bee9935-a32d-483a-9c4f-0e9e2a712953" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_7fbdfcbf-e87c-4e23-a210-29665e1c1f12" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_EighthShareRepurchaseProgramMember_78f1f535-c145-4a0a-a9f9-7db89205fe42" xlink:href="mygn-20210930.xsd#mygn_EighthShareRepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_7fbdfcbf-e87c-4e23-a210-29665e1c1f12" xlink:to="loc_mygn_EighthShareRepurchaseProgramMember_78f1f535-c145-4a0a-a9f9-7db89205fe42" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.myriad.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="mygn-20210930.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.myriad.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended" id="i7094555193b34fd08925e3613d7ca78b_StockBasedCompensationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5664f498-5375-426c-aca0-05c5b83415e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_a2aa1b20-8299-4363-ab27-83283f994aeb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5664f498-5375-426c-aca0-05c5b83415e1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_a2aa1b20-8299-4363-ab27-83283f994aeb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_9547c168-6bc5-4e53-83a7-bdc058ee7330" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5664f498-5375-426c-aca0-05c5b83415e1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_9547c168-6bc5-4e53-83a7-bdc058ee7330" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_ecd54ecb-e208-4ba1-a368-7b9524e71d6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5664f498-5375-426c-aca0-05c5b83415e1" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_ecd54ecb-e208-4ba1-a368-7b9524e71d6f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_345132a0-0fd1-4b18-8336-aef47ffb4c0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5664f498-5375-426c-aca0-05c5b83415e1" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_345132a0-0fd1-4b18-8336-aef47ffb4c0c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_e912cbfa-be48-43e7-8831-164ed00f9f10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5664f498-5375-426c-aca0-05c5b83415e1" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_e912cbfa-be48-43e7-8831-164ed00f9f10" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_72cba667-82b0-42aa-a416-4eb7eb38cc05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5664f498-5375-426c-aca0-05c5b83415e1" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_72cba667-82b0-42aa-a416-4eb7eb38cc05" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_65bec041-7b9b-437a-accd-2ee22912da8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5664f498-5375-426c-aca0-05c5b83415e1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_65bec041-7b9b-437a-accd-2ee22912da8c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_de8ffae7-ccba-4751-8d53-f688dc95aa74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5664f498-5375-426c-aca0-05c5b83415e1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_de8ffae7-ccba-4751-8d53-f688dc95aa74" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_9a57bf52-52e4-4280-b659-fae035178583" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5664f498-5375-426c-aca0-05c5b83415e1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_9a57bf52-52e4-4280-b659-fae035178583" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_bc03244d-0324-4be5-9c7c-ef66ac77d176" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5664f498-5375-426c-aca0-05c5b83415e1" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_bc03244d-0324-4be5-9c7c-ef66ac77d176" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f2dd203e-ee3a-4496-91e7-3e84f3547ad9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5664f498-5375-426c-aca0-05c5b83415e1" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f2dd203e-ee3a-4496-91e7-3e84f3547ad9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_641dff79-1d09-46f4-a93c-45f0cd96c25b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f2dd203e-ee3a-4496-91e7-3e84f3547ad9" xlink:to="loc_us-gaap_PlanNameAxis_641dff79-1d09-46f4-a93c-45f0cd96c25b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_641dff79-1d09-46f4-a93c-45f0cd96c25b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_641dff79-1d09-46f4-a93c-45f0cd96c25b" xlink:to="loc_us-gaap_PlanNameDomain_641dff79-1d09-46f4-a93c-45f0cd96c25b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_4d120a57-b9a8-4d22-941e-fad406dfbada" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_641dff79-1d09-46f4-a93c-45f0cd96c25b" xlink:to="loc_us-gaap_PlanNameDomain_4d120a57-b9a8-4d22-941e-fad406dfbada" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_TwoThousandSeventeenEmployeeDirectorAndConsultantEquityIncentivePlanMember_d77912e5-360a-4fe9-b857-479d7fdd39af" xlink:href="mygn-20210930.xsd#mygn_TwoThousandSeventeenEmployeeDirectorAndConsultantEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_4d120a57-b9a8-4d22-941e-fad406dfbada" xlink:to="loc_mygn_TwoThousandSeventeenEmployeeDirectorAndConsultantEquityIncentivePlanMember_d77912e5-360a-4fe9-b857-479d7fdd39af" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_EmployeeStockPurchasePlanTwentyTwelveMember_779c3b54-6c52-4ad2-b4f7-55ad24383616" xlink:href="mygn-20210930.xsd#mygn_EmployeeStockPurchasePlanTwentyTwelveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_4d120a57-b9a8-4d22-941e-fad406dfbada" xlink:to="loc_mygn_EmployeeStockPurchasePlanTwentyTwelveMember_779c3b54-6c52-4ad2-b4f7-55ad24383616" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_7f80f9d1-e186-401e-8bfa-318dafe484c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f2dd203e-ee3a-4496-91e7-3e84f3547ad9" xlink:to="loc_us-gaap_AwardTypeAxis_7f80f9d1-e186-401e-8bfa-318dafe484c4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7f80f9d1-e186-401e-8bfa-318dafe484c4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_7f80f9d1-e186-401e-8bfa-318dafe484c4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7f80f9d1-e186-401e-8bfa-318dafe484c4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c8f76aa6-4373-452a-91f2-f3823393af49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_7f80f9d1-e186-401e-8bfa-318dafe484c4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c8f76aa6-4373-452a-91f2-f3823393af49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_OptionsAndRestrictedStockUnitsMember_1fb762e1-ca75-47b4-83c3-bf45b955fb58" xlink:href="mygn-20210930.xsd#mygn_OptionsAndRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c8f76aa6-4373-452a-91f2-f3823393af49" xlink:to="loc_mygn_OptionsAndRestrictedStockUnitsMember_1fb762e1-ca75-47b4-83c3-bf45b955fb58" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_92a1d975-2c27-48e6-9447-dec8e60396aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_OptionsAndRestrictedStockUnitsMember_1fb762e1-ca75-47b4-83c3-bf45b955fb58" xlink:to="loc_us-gaap_EmployeeStockOptionMember_92a1d975-2c27-48e6-9447-dec8e60396aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_ec768f64-945b-4b17-8be9-d63719a1f706" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_OptionsAndRestrictedStockUnitsMember_1fb762e1-ca75-47b4-83c3-bf45b955fb58" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_ec768f64-945b-4b17-8be9-d63719a1f706" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateAxis_780c9585-2895-42e1-a780-7eb0cf99f2bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardDateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f2dd203e-ee3a-4496-91e7-3e84f3547ad9" xlink:to="loc_us-gaap_AwardDateAxis_780c9585-2895-42e1-a780-7eb0cf99f2bb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateDomain_780c9585-2895-42e1-a780-7eb0cf99f2bb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardDateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardDateAxis_780c9585-2895-42e1-a780-7eb0cf99f2bb" xlink:to="loc_us-gaap_AwardDateDomain_780c9585-2895-42e1-a780-7eb0cf99f2bb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateDomain_b2bd2cea-f391-462a-a97c-68a644d9c72c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardDateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardDateAxis_780c9585-2895-42e1-a780-7eb0cf99f2bb" xlink:to="loc_us-gaap_AwardDateDomain_b2bd2cea-f391-462a-a97c-68a644d9c72c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_OptionsGrantedAfterDecemberFiveTwentyTwelveMember_be5fc5c5-df81-49a9-be3b-a72b5b2be091" xlink:href="mygn-20210930.xsd#mygn_OptionsGrantedAfterDecemberFiveTwentyTwelveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AwardDateDomain_b2bd2cea-f391-462a-a97c-68a644d9c72c" xlink:to="loc_mygn_OptionsGrantedAfterDecemberFiveTwentyTwelveMember_be5fc5c5-df81-49a9-be3b-a72b5b2be091" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_OptionsGrantedPriorToDecemberFiveTwentyTwelveMember_1bc41959-a9dd-4d6c-89ee-9209d223833d" xlink:href="mygn-20210930.xsd#mygn_OptionsGrantedPriorToDecemberFiveTwentyTwelveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AwardDateDomain_b2bd2cea-f391-462a-a97c-68a644d9c72c" xlink:to="loc_mygn_OptionsGrantedPriorToDecemberFiveTwentyTwelveMember_1bc41959-a9dd-4d6c-89ee-9209d223833d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_7d0cb281-2900-4a9b-bcc3-0a9edbf97fd3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f2dd203e-ee3a-4496-91e7-3e84f3547ad9" xlink:to="loc_srt_TitleOfIndividualAxis_7d0cb281-2900-4a9b-bcc3-0a9edbf97fd3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_7d0cb281-2900-4a9b-bcc3-0a9edbf97fd3_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_7d0cb281-2900-4a9b-bcc3-0a9edbf97fd3" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_7d0cb281-2900-4a9b-bcc3-0a9edbf97fd3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_37f8fd4f-05dd-4e6f-877f-f9e29354a57c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_7d0cb281-2900-4a9b-bcc3-0a9edbf97fd3" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_37f8fd4f-05dd-4e6f-877f-f9e29354a57c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_NonEmployeeDirectorMember_c71ca8b0-c1db-41a6-b572-10512020c9a6" xlink:href="mygn-20210930.xsd#mygn_NonEmployeeDirectorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_37f8fd4f-05dd-4e6f-877f-f9e29354a57c" xlink:to="loc_mygn_NonEmployeeDirectorMember_c71ca8b0-c1db-41a6-b572-10512020c9a6" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.myriad.com/role/StockBasedCompensationRSUActivityDetails" xlink:type="simple" xlink:href="mygn-20210930.xsd#StockBasedCompensationRSUActivityDetails"/>
  <link:definitionLink xlink:role="http://www.myriad.com/role/StockBasedCompensationRSUActivityDetails" xlink:type="extended" id="i3bc4d3d5b6864a69bcec5a9780f92f97_StockBasedCompensationRSUActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4f7cab73-0611-44ca-ac5b-10751591540c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1e6eca4b-6d01-4355-8110-a50cc866e1ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4f7cab73-0611-44ca-ac5b-10751591540c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1e6eca4b-6d01-4355-8110-a50cc866e1ff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_852b2213-7005-4ddc-b918-91450d00bb29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1e6eca4b-6d01-4355-8110-a50cc866e1ff" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_852b2213-7005-4ddc-b918-91450d00bb29" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_ad3b7e57-8717-4d50-be25-4f03a7eae8c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1e6eca4b-6d01-4355-8110-a50cc866e1ff" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_ad3b7e57-8717-4d50-be25-4f03a7eae8c9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_6af89b31-2764-441e-a421-56fe105df6a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1e6eca4b-6d01-4355-8110-a50cc866e1ff" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_6af89b31-2764-441e-a421-56fe105df6a0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_9cdd7200-32a4-4e2a-b44c-8eff4b36d29a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1e6eca4b-6d01-4355-8110-a50cc866e1ff" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_9cdd7200-32a4-4e2a-b44c-8eff4b36d29a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_e2022426-0e72-4caa-8528-44554b24c63b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_be9f2ced-b42c-4468-8136-16798fe8f3f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4f7cab73-0611-44ca-ac5b-10751591540c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_be9f2ced-b42c-4468-8136-16798fe8f3f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_fe720568-9074-43b3-abe4-34bf53632c27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_be9f2ced-b42c-4468-8136-16798fe8f3f6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_fe720568-9074-43b3-abe4-34bf53632c27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a2d69fce-1fd8-42d4-9c8f-3665c421354c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_be9f2ced-b42c-4468-8136-16798fe8f3f6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a2d69fce-1fd8-42d4-9c8f-3665c421354c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_7e7a2d3d-41dd-4c22-b123-24a99f0d6f07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_be9f2ced-b42c-4468-8136-16798fe8f3f6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_7e7a2d3d-41dd-4c22-b123-24a99f0d6f07" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_6bc4787b-b1d9-4bd8-9827-8869ceae15e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_be9f2ced-b42c-4468-8136-16798fe8f3f6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_6bc4787b-b1d9-4bd8-9827-8869ceae15e1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6f5ce908-b566-408b-9550-afe7ead54d8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6c6ecf36-2ff6-42a7-8811-ec915b5222da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4f7cab73-0611-44ca-ac5b-10751591540c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6c6ecf36-2ff6-42a7-8811-ec915b5222da" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_bc10e7bf-85ae-486e-8927-5a30ac01eede" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6c6ecf36-2ff6-42a7-8811-ec915b5222da" xlink:to="loc_us-gaap_AwardTypeAxis_bc10e7bf-85ae-486e-8927-5a30ac01eede" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bc10e7bf-85ae-486e-8927-5a30ac01eede_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_bc10e7bf-85ae-486e-8927-5a30ac01eede" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bc10e7bf-85ae-486e-8927-5a30ac01eede_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a7cb1661-a05e-4a41-8ac7-c13c07616683" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_bc10e7bf-85ae-486e-8927-5a30ac01eede" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a7cb1661-a05e-4a41-8ac7-c13c07616683" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_0fca42a1-e53f-4ca2-ac51-47df075c8b86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a7cb1661-a05e-4a41-8ac7-c13c07616683" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_0fca42a1-e53f-4ca2-ac51-47df075c8b86" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.myriad.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="mygn-20210930.xsd#StockBasedCompensationStockBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.myriad.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="extended" id="i865b46a65db34620ba6f1de26de8be2d_StockBasedCompensationStockBasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2cb647a9-66d8-4c44-89e8-e3647bdd115e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_4f93e292-5c94-4476-8617-aca87143a39f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2cb647a9-66d8-4c44-89e8-e3647bdd115e" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_4f93e292-5c94-4476-8617-aca87143a39f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_16e4e42e-b30c-4fd1-ae46-957bc189ffef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2cb647a9-66d8-4c44-89e8-e3647bdd115e" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_16e4e42e-b30c-4fd1-ae46-957bc189ffef" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_a2ae73c4-0216-4f93-be22-e4b3462bfe7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_16e4e42e-b30c-4fd1-ae46-957bc189ffef" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_a2ae73c4-0216-4f93-be22-e4b3462bfe7c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_a2ae73c4-0216-4f93-be22-e4b3462bfe7c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_a2ae73c4-0216-4f93-be22-e4b3462bfe7c" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_a2ae73c4-0216-4f93-be22-e4b3462bfe7c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_f85703e1-9e8c-4e88-816e-bd5d6a2ac803" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_a2ae73c4-0216-4f93-be22-e4b3462bfe7c" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_f85703e1-9e8c-4e88-816e-bd5d6a2ac803" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_CostOfMolecularDiagnosticTestingMember_27c268d2-251a-4a9c-8824-50f5ddbf0d9f" xlink:href="mygn-20210930.xsd#mygn_CostOfMolecularDiagnosticTestingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_f85703e1-9e8c-4e88-816e-bd5d6a2ac803" xlink:to="loc_mygn_CostOfMolecularDiagnosticTestingMember_27c268d2-251a-4a9c-8824-50f5ddbf0d9f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_CostOfPharmaceuticalAndClinicalServicesMember_ef0cc2a7-0bc3-4971-bce4-cb81f7888eb0" xlink:href="mygn-20210930.xsd#mygn_CostOfPharmaceuticalAndClinicalServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_f85703e1-9e8c-4e88-816e-bd5d6a2ac803" xlink:to="loc_mygn_CostOfPharmaceuticalAndClinicalServicesMember_ef0cc2a7-0bc3-4971-bce4-cb81f7888eb0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_e92f9223-1c23-4c43-9f01-41ca4e2dafaf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_f85703e1-9e8c-4e88-816e-bd5d6a2ac803" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_e92f9223-1c23-4c43-9f01-41ca4e2dafaf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_6c6a490a-010d-441b-abba-7a6bec6fcf12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_f85703e1-9e8c-4e88-816e-bd5d6a2ac803" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_6c6a490a-010d-441b-abba-7a6bec6fcf12" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.myriad.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="mygn-20210930.xsd#IncomeTaxesDetails"/>
  <link:definitionLink xlink:role="http://www.myriad.com/role/IncomeTaxesDetails" xlink:type="extended" id="i72f8a842dbc04643b48c5e7df3c0bafd_IncomeTaxesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_8e26a3fa-67f2-4cc4-b936-0ad1fbfe396b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_de1030f3-3376-405f-916b-9ed2b4adc7d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_8e26a3fa-67f2-4cc4-b936-0ad1fbfe396b" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_de1030f3-3376-405f-916b-9ed2b4adc7d6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_d312c6ef-76d6-46ce-aae3-c1e59a24c309" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_8e26a3fa-67f2-4cc4-b936-0ad1fbfe396b" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_d312c6ef-76d6-46ce-aae3-c1e59a24c309" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationYearUnderExamination_d5d5331e-4a93-45c9-927b-68a343dbd67d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExaminationYearUnderExamination"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_8e26a3fa-67f2-4cc4-b936-0ad1fbfe396b" xlink:to="loc_us-gaap_IncomeTaxExaminationYearUnderExamination_d5d5331e-4a93-45c9-927b-68a343dbd67d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_08c95d39-e683-472d-8eb1-276f7b8a0dab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_8e26a3fa-67f2-4cc4-b936-0ad1fbfe396b" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_08c95d39-e683-472d-8eb1-276f7b8a0dab" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_966d70ba-4168-42c8-9fe7-413ab9713501" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_08c95d39-e683-472d-8eb1-276f7b8a0dab" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_966d70ba-4168-42c8-9fe7-413ab9713501" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_966d70ba-4168-42c8-9fe7-413ab9713501_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_966d70ba-4168-42c8-9fe7-413ab9713501" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_966d70ba-4168-42c8-9fe7-413ab9713501_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_e6e8f135-f6d0-4346-ad9c-1664cad2d465" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_966d70ba-4168-42c8-9fe7-413ab9713501" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_e6e8f135-f6d0-4346-ad9c-1664cad2d465" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_bd218102-145e-4b3a-ac3e-a5cf2f0a6025" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_e6e8f135-f6d0-4346-ad9c-1664cad2d465" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_bd218102-145e-4b3a-ac3e-a5cf2f0a6025" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_d669c1af-6411-4249-9289-820dc978d308" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_e6e8f135-f6d0-4346-ad9c-1664cad2d465" xlink:to="loc_us-gaap_ForeignCountryMember_d669c1af-6411-4249-9289-820dc978d308" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis_3d4e7546-3fe5-414f-97f5-9735e52f4365" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_08c95d39-e683-472d-8eb1-276f7b8a0dab" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameAxis_3d4e7546-3fe5-414f-97f5-9735e52f4365" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_3d4e7546-3fe5-414f-97f5-9735e52f4365_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_3d4e7546-3fe5-414f-97f5-9735e52f4365" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_3d4e7546-3fe5-414f-97f5-9735e52f4365_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_95cdd758-5aba-4326-a079-a7318c7d504a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_3d4e7546-3fe5-414f-97f5-9735e52f4365" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_95cdd758-5aba-4326-a079-a7318c7d504a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CaliforniaFranchiseTaxBoardMember_00c7e2d2-2a19-4999-a1a8-c2b6fae0b873" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CaliforniaFranchiseTaxBoardMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_95cdd758-5aba-4326-a079-a7318c7d504a" xlink:to="loc_us-gaap_CaliforniaFranchiseTaxBoardMember_00c7e2d2-2a19-4999-a1a8-c2b6fae0b873" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewJerseyDivisionOfTaxationMember_e8874152-f756-4fde-ad72-2ab52468b510" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewJerseyDivisionOfTaxationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_95cdd758-5aba-4326-a079-a7318c7d504a" xlink:to="loc_us-gaap_NewJerseyDivisionOfTaxationMember_e8874152-f756-4fde-ad72-2ab52468b510" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalMinistryOfFinanceGermanyMember_715c104f-442b-46a6-90da-a9c500f3df7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FederalMinistryOfFinanceGermanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_95cdd758-5aba-4326-a079-a7318c7d504a" xlink:to="loc_us-gaap_FederalMinistryOfFinanceGermanyMember_715c104f-442b-46a6-90da-a9c500f3df7a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SwissFederalTaxAdministrationFTAMember_e18ecf17-c7bf-48a3-9acf-4b796df08a4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SwissFederalTaxAdministrationFTAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_95cdd758-5aba-4326-a079-a7318c7d504a" xlink:to="loc_us-gaap_SwissFederalTaxAdministrationFTAMember_e18ecf17-c7bf-48a3-9acf-4b796df08a4a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis_3732ae2d-959d-4685-870a-b0bb6f1d3430" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_08c95d39-e683-472d-8eb1-276f7b8a0dab" xlink:to="loc_us-gaap_TaxPeriodAxis_3732ae2d-959d-4685-870a-b0bb6f1d3430" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_3732ae2d-959d-4685-870a-b0bb6f1d3430_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxPeriodAxis_3732ae2d-959d-4685-870a-b0bb6f1d3430" xlink:to="loc_us-gaap_TaxPeriodDomain_3732ae2d-959d-4685-870a-b0bb6f1d3430_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_d19042f0-f4fe-49f1-9286-c2bfff381155" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxPeriodAxis_3732ae2d-959d-4685-870a-b0bb6f1d3430" xlink:to="loc_us-gaap_TaxPeriodDomain_d19042f0-f4fe-49f1-9286-c2bfff381155" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarliestTaxYearMember_fbfc5233-9cb5-486d-84d5-476d09906976" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarliestTaxYearMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_d19042f0-f4fe-49f1-9286-c2bfff381155" xlink:to="loc_us-gaap_EarliestTaxYearMember_fbfc5233-9cb5-486d-84d5-476d09906976" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LatestTaxYearMember_7eaf327e-8a7e-41ba-bcc8-445ca712d338" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LatestTaxYearMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_d19042f0-f4fe-49f1-9286-c2bfff381155" xlink:to="loc_us-gaap_LatestTaxYearMember_7eaf327e-8a7e-41ba-bcc8-445ca712d338" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.myriad.com/role/SegmentandRelatedInformationSegmentRevenueandOperatingIncomeLossDetails" xlink:type="simple" xlink:href="mygn-20210930.xsd#SegmentandRelatedInformationSegmentRevenueandOperatingIncomeLossDetails"/>
  <link:definitionLink xlink:role="http://www.myriad.com/role/SegmentandRelatedInformationSegmentRevenueandOperatingIncomeLossDetails" xlink:type="extended" id="i7c52934bebc84063b9463a8d64bd595b_SegmentandRelatedInformationSegmentRevenueandOperatingIncomeLossDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_0da40328-6ba8-4fbd-b8be-185e542300a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b912f535-642d-49de-9b2e-8d76be8e98e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_0da40328-6ba8-4fbd-b8be-185e542300a8" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b912f535-642d-49de-9b2e-8d76be8e98e4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_d03c6968-397c-4519-b0c2-b1b1018dc3e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_0da40328-6ba8-4fbd-b8be-185e542300a8" xlink:to="loc_us-gaap_DepreciationAndAmortization_d03c6968-397c-4519-b0c2-b1b1018dc3e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_a4a1fe2c-acb6-48fe-b595-fc4a5223857a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_0da40328-6ba8-4fbd-b8be-185e542300a8" xlink:to="loc_us-gaap_OperatingIncomeLoss_a4a1fe2c-acb6-48fe-b595-fc4a5223857a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_87b37da3-b3ba-48c2-9b4f-4296d42086db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_0da40328-6ba8-4fbd-b8be-185e542300a8" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_87b37da3-b3ba-48c2-9b4f-4296d42086db" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_d1f6ed16-630b-4d8f-b5e2-f55b9703dd12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_87b37da3-b3ba-48c2-9b4f-4296d42086db" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_d1f6ed16-630b-4d8f-b5e2-f55b9703dd12" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_d1f6ed16-630b-4d8f-b5e2-f55b9703dd12_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_d1f6ed16-630b-4d8f-b5e2-f55b9703dd12" xlink:to="loc_us-gaap_SegmentDomain_d1f6ed16-630b-4d8f-b5e2-f55b9703dd12_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_90802b7e-f24b-4cfc-9aef-89e9199bed74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_d1f6ed16-630b-4d8f-b5e2-f55b9703dd12" xlink:to="loc_us-gaap_SegmentDomain_90802b7e-f24b-4cfc-9aef-89e9199bed74" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_DiagnosticsMember_8c9f533f-0715-41bd-8a1d-d62bf3b896f2" xlink:href="mygn-20210930.xsd#mygn_DiagnosticsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_90802b7e-f24b-4cfc-9aef-89e9199bed74" xlink:to="loc_mygn_DiagnosticsMember_8c9f533f-0715-41bd-8a1d-d62bf3b896f2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_5d406354-320e-442f-99bd-b510aaf29fc6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_90802b7e-f24b-4cfc-9aef-89e9199bed74" xlink:to="loc_us-gaap_AllOtherSegmentsMember_5d406354-320e-442f-99bd-b510aaf29fc6" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.myriad.com/role/DivestituresNarrativeDetails" xlink:type="simple" xlink:href="mygn-20210930.xsd#DivestituresNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.myriad.com/role/DivestituresNarrativeDetails" xlink:type="extended" id="i7f9657c82ce845b398ab8af187936199_DivestituresNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_e1bc947b-864d-472f-9e06-05d355417156" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_02aa4314-af2e-4c34-b418-4ed86859ac52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_e1bc947b-864d-472f-9e06-05d355417156" xlink:to="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_02aa4314-af2e-4c34-b418-4ed86859ac52" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries_cc3cc024-252f-4974-8b8f-eafce6462ac2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_e1bc947b-864d-472f-9e06-05d355417156" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries_cc3cc024-252f-4974-8b8f-eafce6462ac2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_GainLossOnDispositionOfAssetsNetOfTransactionFees_a7a31237-0f1e-4e4f-b6c0-62b6fe98d866" xlink:href="mygn-20210930.xsd#mygn_GainLossOnDispositionOfAssetsNetOfTransactionFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_e1bc947b-864d-472f-9e06-05d355417156" xlink:to="loc_mygn_GainLossOnDispositionOfAssetsNetOfTransactionFees_a7a31237-0f1e-4e4f-b6c0-62b6fe98d866" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_5e4a70c8-cde5-468e-8fb9-dd94f7da05c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_e1bc947b-864d-472f-9e06-05d355417156" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_5e4a70c8-cde5-468e-8fb9-dd94f7da05c4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_DisposalGroupNotDiscontinuedOperationTransactionCosts_284efff4-25bd-4120-9488-3e6066844ad0" xlink:href="mygn-20210930.xsd#mygn_DisposalGroupNotDiscontinuedOperationTransactionCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_e1bc947b-864d-472f-9e06-05d355417156" xlink:to="loc_mygn_DisposalGroupNotDiscontinuedOperationTransactionCosts_284efff4-25bd-4120-9488-3e6066844ad0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFirmPurchaseCommitmentLoss_4c306bcf-9f1e-4a1e-9792-fe3aef038ebf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFirmPurchaseCommitmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_e1bc947b-864d-472f-9e06-05d355417156" xlink:to="loc_us-gaap_InventoryFirmPurchaseCommitmentLoss_4c306bcf-9f1e-4a1e-9792-fe3aef038ebf" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_c8ef1154-481e-42ae-bcc4-07dcda7ad12c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWriteDown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_e1bc947b-864d-472f-9e06-05d355417156" xlink:to="loc_us-gaap_InventoryWriteDown_c8ef1154-481e-42ae-bcc4-07dcda7ad12c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_a7f840ec-368b-4347-be7b-98d8ec56485d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_e1bc947b-864d-472f-9e06-05d355417156" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_a7f840ec-368b-4347-be7b-98d8ec56485d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_ad89394d-a9bb-48ca-9ef7-04aac459bbee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_a7f840ec-368b-4347-be7b-98d8ec56485d" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_ad89394d-a9bb-48ca-9ef7-04aac459bbee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_ad89394d-a9bb-48ca-9ef7-04aac459bbee_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_ad89394d-a9bb-48ca-9ef7-04aac459bbee" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_ad89394d-a9bb-48ca-9ef7-04aac459bbee_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_1e519fe9-db99-4702-9fdf-b25858704e78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_ad89394d-a9bb-48ca-9ef7-04aac459bbee" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_1e519fe9-db99-4702-9fdf-b25858704e78" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_59a4a60b-2ac9-4677-af76-8cc480f1cc2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_1e519fe9-db99-4702-9fdf-b25858704e78" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_59a4a60b-2ac9-4677-af76-8cc480f1cc2c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_e7877f20-04d4-408f-9bc9-b13875940445" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_a7f840ec-368b-4347-be7b-98d8ec56485d" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_e7877f20-04d4-408f-9bc9-b13875940445" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_e7877f20-04d4-408f-9bc9-b13875940445_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_e7877f20-04d4-408f-9bc9-b13875940445" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_e7877f20-04d4-408f-9bc9-b13875940445_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_8aca7c22-d500-4b34-acf3-1f7832509efe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_e7877f20-04d4-408f-9bc9-b13875940445" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_8aca7c22-d500-4b34-acf3-1f7832509efe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MyriadMyPathLLCLaboratoryMember_6af11b85-513b-4498-84d5-9e170950636a" xlink:href="mygn-20210930.xsd#mygn_MyriadMyPathLLCLaboratoryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_8aca7c22-d500-4b34-acf3-1f7832509efe" xlink:to="loc_mygn_MyriadMyPathLLCLaboratoryMember_6af11b85-513b-4498-84d5-9e170950636a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MyriadRBMIncMember_d97750aa-93e4-44a4-b3b4-41e9112b529c" xlink:href="mygn-20210930.xsd#mygn_MyriadRBMIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_8aca7c22-d500-4b34-acf3-1f7832509efe" xlink:to="loc_mygn_MyriadRBMIncMember_d97750aa-93e4-44a4-b3b4-41e9112b529c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MyriadAutoimmuneAssetsMember_62afd424-7bd4-4c1a-8c0d-3e7b0e786589" xlink:href="mygn-20210930.xsd#mygn_MyriadAutoimmuneAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_8aca7c22-d500-4b34-acf3-1f7832509efe" xlink:to="loc_mygn_MyriadAutoimmuneAssetsMember_62afd424-7bd4-4c1a-8c0d-3e7b0e786589" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.myriad.com/role/DivestituresOtherIncomeDetails" xlink:type="simple" xlink:href="mygn-20210930.xsd#DivestituresOtherIncomeDetails"/>
  <link:definitionLink xlink:role="http://www.myriad.com/role/DivestituresOtherIncomeDetails" xlink:type="extended" id="i39547b4e1a9f49cc92cf93aedc73c7d0_DivestituresOtherIncomeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_8c80b7e3-36a7-4e0b-8c2d-1d9a7f9bdd49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_ebdff558-2461-4472-85d8-d2b8405932c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_8c80b7e3-36a7-4e0b-8c2d-1d9a7f9bdd49" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_ebdff558-2461-4472-85d8-d2b8405932c5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_DisposalGroupNotDiscontinuedOperationGainLossOnInventory_7a607ea4-e830-424d-bf70-4c7980b35cf1" xlink:href="mygn-20210930.xsd#mygn_DisposalGroupNotDiscontinuedOperationGainLossOnInventory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_8c80b7e3-36a7-4e0b-8c2d-1d9a7f9bdd49" xlink:to="loc_mygn_DisposalGroupNotDiscontinuedOperationGainLossOnInventory_7a607ea4-e830-424d-bf70-4c7980b35cf1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_DisposalGroupNotDiscontinuedOperationGainLossOther_8596999d-6df7-4607-93f8-8779cdaca53e" xlink:href="mygn-20210930.xsd#mygn_DisposalGroupNotDiscontinuedOperationGainLossOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_8c80b7e3-36a7-4e0b-8c2d-1d9a7f9bdd49" xlink:to="loc_mygn_DisposalGroupNotDiscontinuedOperationGainLossOther_8596999d-6df7-4607-93f8-8779cdaca53e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_1b2c7ff9-054a-481f-8f05-1d318f491b5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_8c80b7e3-36a7-4e0b-8c2d-1d9a7f9bdd49" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_1b2c7ff9-054a-481f-8f05-1d318f491b5f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_6b497a09-f761-473d-b75f-013d209fb230" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_8c80b7e3-36a7-4e0b-8c2d-1d9a7f9bdd49" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_6b497a09-f761-473d-b75f-013d209fb230" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_a802a8f2-c0c2-40f3-9c98-75cc51b26b0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_6b497a09-f761-473d-b75f-013d209fb230" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_a802a8f2-c0c2-40f3-9c98-75cc51b26b0e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_a802a8f2-c0c2-40f3-9c98-75cc51b26b0e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_a802a8f2-c0c2-40f3-9c98-75cc51b26b0e" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_a802a8f2-c0c2-40f3-9c98-75cc51b26b0e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_43a1b417-289e-4d57-a9a0-7017bbbca65e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_a802a8f2-c0c2-40f3-9c98-75cc51b26b0e" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_43a1b417-289e-4d57-a9a0-7017bbbca65e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MyriadRBMIncMember_db73c596-511e-4903-816f-3d7372ce5449" xlink:href="mygn-20210930.xsd#mygn_MyriadRBMIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_43a1b417-289e-4d57-a9a0-7017bbbca65e" xlink:to="loc_mygn_MyriadRBMIncMember_db73c596-511e-4903-816f-3d7372ce5449" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MyriadMyPathLLCLaboratoryMember_90d2915a-0ab0-4547-bff4-e3f4a1229bf3" xlink:href="mygn-20210930.xsd#mygn_MyriadMyPathLLCLaboratoryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_43a1b417-289e-4d57-a9a0-7017bbbca65e" xlink:to="loc_mygn_MyriadMyPathLLCLaboratoryMember_90d2915a-0ab0-4547-bff4-e3f4a1229bf3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MyriadAutoimmuneAssetsMember_547a85cf-570b-48be-995a-a43c751d8416" xlink:href="mygn-20210930.xsd#mygn_MyriadAutoimmuneAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_43a1b417-289e-4d57-a9a0-7017bbbca65e" xlink:to="loc_mygn_MyriadAutoimmuneAssetsMember_547a85cf-570b-48be-995a-a43c751d8416" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_dae0cc56-93aa-46c5-9ef8-8e59528c6c00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_6b497a09-f761-473d-b75f-013d209fb230" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_dae0cc56-93aa-46c5-9ef8-8e59528c6c00" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_dae0cc56-93aa-46c5-9ef8-8e59528c6c00_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_dae0cc56-93aa-46c5-9ef8-8e59528c6c00" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_dae0cc56-93aa-46c5-9ef8-8e59528c6c00_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_85605f1a-605b-470b-a8fa-ac4efe015ea4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_dae0cc56-93aa-46c5-9ef8-8e59528c6c00" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_85605f1a-605b-470b-a8fa-ac4efe015ea4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_7865fe6a-1077-4a69-8fc7-4152b2183d0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_85605f1a-605b-470b-a8fa-ac4efe015ea4" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_7865fe6a-1077-4a69-8fc7-4152b2183d0a" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>mygn-20210930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:902b74c1-bcf1-4420-82df-87d4ebd2f6e9,g:dcd0bc70-dec4-4a37-a022-ac912887efc6-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_d3e584a7-e150-496b-8126-56579259298b_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale, Due after five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_783c2623-52d1-4267-b53a-537469195d87_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share repurchase program, authorized amount</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_5d82c39b-bd42-4b2d-b8a9-f63d2a3637e5_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2a93ac8d-ad81-47bc-9dba-97fea4cc971a_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs vested (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_b873b625-8347-44fd-be10-fbd001dfb138_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5ba48365-7920-4da2-985d-56db2286c36d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_e1953f10-f9fe-4f21-82fd-3bd514479e22_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) attributable to Myriad Genetics, Inc. stockholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_43eec913-a6ef-459b-93f9-67bafa9d0e1d_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) attributable to Myriad Genetics, Inc. stockholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_6f34d82e-51d8-4d2d-ab3e-374b14603eba_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_35111c1b-d6c4-42a6-9941-514d6c07751f_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_94bc086e-1ed3-4e2e-9679-189c094e0e59_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_260f4b19-1f6e-475a-87ba-ec4f080683af_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock outstanding (shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_aedb7bae-4705-4627-9c6b-f94af83571ee_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee compensation and benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_c157ee94-9564-4ff3-a43c-a7534e9ebd1d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_6e8f8cc2-b52c-4465-82a3-ee8be08619fc_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_1bee9b58-34cf-4f19-99b9-acd397dd227c_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_3e2ddd67-6810-4b5d-8c5b-f2a155dc4f50_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_d2678ab6-6b4a-421c-8a5a-3ef3118f4093_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs canceled (dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_6e2cb205-1ddc-4261-ac99-68511338992a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum number of shares per participant per offering period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Shares Per Employee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_e8762644-c4cc-4a6c-86df-77fbe1d778f4_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_dd9fcc2a-39c0-4c80-a71b-bf7a0c7e17a5_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Deferred Revenue Balances</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_e9286c19-1468-4eca-bf81-351bc4d10a0f_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of contingent consideration recognized at acquisition</link:label>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for Contingent Consideration Liability, Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:to="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_ca5dd55e-dd50-4909-8fec-d70bd6426232_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_7ee20ee7-d337-4b85-bf8c-b94dc6c2e8fa_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_87b63f6a-fcea-4936-a5d6-29c6e4a09347_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ac941989-d406-4ab8-bd54-24300fe4a284_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_36f360a8-5a2f-4f05-97ac-11b820bc205c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2bf6c3c1-8c4e-42f3-bca4-a5abe90fb937_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares available for grant</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_12487a56-7768-488d-b383-0141292aaad1_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8cc8cfff-4ca5-496f-a9de-99873baee8c0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of change in fair value of contingent consideration</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_20af3d0d-15c6-4f98-903c-c30b1ed35d9c_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based payment expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_cd446328-5b6b-41d2-a7c4-fc78c00570d8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value recognized in the income statement</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_5dd33cb2-1119-485a-80dc-fb70b354e0a2_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options canceled or expired (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_774d2864-3357-41b1-8759-25094a2a643e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on sale of businesses and assets</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_label_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDispositionOfAssets1" xlink:to="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_8b976200-c5d4-4e75-a5ac-9c78fe38b7bd_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Divestitures</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_8576072e-3908-4207-97e2-f2f5bad68425_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_CostOfPharmaceuticalAndClinicalServicesMember_c031dee3-cd56-4803-bc1d-425e08bca91a_terseLabel_en-US" xlink:label="lab_mygn_CostOfPharmaceuticalAndClinicalServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of pharmaceutical and clinical services</link:label>
    <link:label id="lab_mygn_CostOfPharmaceuticalAndClinicalServicesMember_label_en-US" xlink:label="lab_mygn_CostOfPharmaceuticalAndClinicalServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost Of Pharmaceutical And Clinical Services [Member]</link:label>
    <link:label id="lab_mygn_CostOfPharmaceuticalAndClinicalServicesMember_documentation_en-US" xlink:label="lab_mygn_CostOfPharmaceuticalAndClinicalServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Primary financial statement caption in which the reported facts about the cost of pharmaceutical and clinical services expense have been included.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_CostOfPharmaceuticalAndClinicalServicesMember" xlink:href="mygn-20210930.xsd#mygn_CostOfPharmaceuticalAndClinicalServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_CostOfPharmaceuticalAndClinicalServicesMember" xlink:to="lab_mygn_CostOfPharmaceuticalAndClinicalServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_411886c7-35f9-4be5-bf44-dd3fc3a9d3e9_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_6b1d30f9-5f62-4758-9399-dde588f3fb69_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_efbc28ab-bc92-4bea-8fa2-330a5e4d9e69_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share repurchase program, remaining repurchase authorization</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Remaining Authorized Repurchase Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_bd6cec7b-bb46-4497-b51e-0f75120b0025_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti-dilutive options and RSUs excluded from EPS computation</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_98dc2406-853b-455e-9f29-b684952f6c90_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_2cfca13a-6c74-467b-be34-77ae3bb3b387_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidTaxes_d4c4eba9-e724-4c7e-a94d-9642c237598a_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid taxes</link:label>
    <link:label id="lab_us-gaap_PrepaidTaxes_label_en-US" xlink:label="lab_us-gaap_PrepaidTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidTaxes" xlink:to="lab_us-gaap_PrepaidTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_MyriadMyPathLLCLaboratoryMember_8846428c-535d-4b23-8f9c-be21cf9abaaa_terseLabel_en-US" xlink:label="lab_mygn_MyriadMyPathLLCLaboratoryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Myriad myPath LLC laboratory</link:label>
    <link:label id="lab_mygn_MyriadMyPathLLCLaboratoryMember_label_en-US" xlink:label="lab_mygn_MyriadMyPathLLCLaboratoryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Myriad My Path LLC Laboratory [Member]</link:label>
    <link:label id="lab_mygn_MyriadMyPathLLCLaboratoryMember_documentation_en-US" xlink:label="lab_mygn_MyriadMyPathLLCLaboratoryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Myriad My Path LLC Laboratory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MyriadMyPathLLCLaboratoryMember" xlink:href="mygn-20210930.xsd#mygn_MyriadMyPathLLCLaboratoryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_MyriadMyPathLLCLaboratoryMember" xlink:to="lab_mygn_MyriadMyPathLLCLaboratoryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_919e6f7e-7457-4377-9d6d-b2311243ae77_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs granted (dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MunicipalBondsMember_7b6b226d-8221-4f70-aad1-02279ac4b0a1_terseLabel_en-US" xlink:label="lab_us-gaap_MunicipalBondsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Municipal bonds</link:label>
    <link:label id="lab_us-gaap_MunicipalBondsMember_label_en-US" xlink:label="lab_us-gaap_MunicipalBondsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Municipal Bonds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MunicipalBondsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MunicipalBondsMember" xlink:to="lab_us-gaap_MunicipalBondsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_d533464a-ff07-4c4c-aae9-577ecad872c5_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_458f8ae9-0038-489e-a4a9-3fafee905ba9_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) on available-for-sale debt securities, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_55823538-88a8-4a4a-b24f-f96c0ff81eb6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameAxis_a645f894-2e61-49d6-99b4-e4324298126f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_839a4be8-7617-4138-af07-3589bb633d2f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Non-amortizable Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2175a001-5323-4b4c-95c5-0a126d55e41e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_9de5d81b-fc17-4422-9bc3-e233996817b5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain" xlink:to="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_cd0993b8-0d84-47e9-9da3-98de1a89ecf4_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_388d7fcc-dc4e-4906-94f7-f47dd9d27e43_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_90dfe75a-513e-46c0-8e92-66a7dab4a54e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value for Available-for-Sale Securities by Major Security Type and Class of Security</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetImpairment_9fcd0e06-a8f4-4b92-a73b-ea70b765bf85_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and long-lived asset impairment charges</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetImpairment_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Asset Impairment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_8d4935a5-cfc6-4e52-b7fb-3d03b24f2614_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable at end of period (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_OperatingLeaseLiabilityEstablished_cfcfdc74-b2ae-43ed-8920-dae76c58e692_terseLabel_en-US" xlink:label="lab_mygn_OperatingLeaseLiabilityEstablished" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_mygn_OperatingLeaseLiabilityEstablished_label_en-US" xlink:label="lab_mygn_OperatingLeaseLiabilityEstablished" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Liability Established</link:label>
    <link:label id="lab_mygn_OperatingLeaseLiabilityEstablished_documentation_en-US" xlink:label="lab_mygn_OperatingLeaseLiabilityEstablished" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Liability Established</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_OperatingLeaseLiabilityEstablished" xlink:href="mygn-20210930.xsd#mygn_OperatingLeaseLiabilityEstablished"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_OperatingLeaseLiabilityEstablished" xlink:to="lab_mygn_OperatingLeaseLiabilityEstablished" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_0639a7d7-6f3a-4d75-9a48-c8ddc2d2be37_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue increase (decrease) due to changes in estimated transaction price due to contractual adjustments</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, Cumulative Catch-up Adjustment to Revenue, Change in Estimate of Transaction Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:to="lab_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_9354ddef-3c92-48c1-9b73-af12e17cd28b_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash, Cash Equivalents, and Maturities of Debt Securities Classified as Available-For-Sale Securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_b5b08829-38a9-40a9-8d60-762b02e3fc32_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs granted (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashEquivalentsMember_3bb17fac-7900-4cbc-adce-eb2af14d5818_terseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsMember" xlink:to="lab_us-gaap_CashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_5a308df9-3b6e-422e-bd1f-9cbc8e1e95dd_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_f8ca3fc7-6322-4a4a-b966-6a8280558356_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk (percent)</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_ContractWithCustomerLiabilityDivestitures_57afd536-0ea0-4b21-a29d-6e994aec88c5_negatedTerseLabel_en-US" xlink:label="lab_mygn_ContractWithCustomerLiabilityDivestitures" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Divestitures</link:label>
    <link:label id="lab_mygn_ContractWithCustomerLiabilityDivestitures_label_en-US" xlink:label="lab_mygn_ContractWithCustomerLiabilityDivestitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Divestitures</link:label>
    <link:label id="lab_mygn_ContractWithCustomerLiabilityDivestitures_documentation_en-US" xlink:label="lab_mygn_ContractWithCustomerLiabilityDivestitures" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Divestitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_ContractWithCustomerLiabilityDivestitures" xlink:href="mygn-20210930.xsd#mygn_ContractWithCustomerLiabilityDivestitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_ContractWithCustomerLiabilityDivestitures" xlink:to="lab_mygn_ContractWithCustomerLiabilityDivestitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_a2f05815-fbc2-41c7-83e8-0a9fa801b730_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from common stock issued under stock-based compensation plans</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d8576cfc-1ec8-4259-b7ef-0d0f51473be4_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding, beginning (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_282ec04d-2e57-4dee-b1a7-cf5064358e4b_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding, ending (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_7ca8622a-70ff-4838-92b8-ea1d0e9b3d51_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_OptionsGrantedAfterDecemberFiveTwentyTwelveMember_4a26312c-3d92-4fa7-8469-af23ef99a995_terseLabel_en-US" xlink:label="lab_mygn_OptionsGrantedAfterDecemberFiveTwentyTwelveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards granted after December 5, 2012</link:label>
    <link:label id="lab_mygn_OptionsGrantedAfterDecemberFiveTwentyTwelveMember_label_en-US" xlink:label="lab_mygn_OptionsGrantedAfterDecemberFiveTwentyTwelveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options Granted After December Five Twenty Twelve [Member]</link:label>
    <link:label id="lab_mygn_OptionsGrantedAfterDecemberFiveTwentyTwelveMember_documentation_en-US" xlink:label="lab_mygn_OptionsGrantedAfterDecemberFiveTwentyTwelveMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted after December 5, 2012.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_OptionsGrantedAfterDecemberFiveTwentyTwelveMember" xlink:href="mygn-20210930.xsd#mygn_OptionsGrantedAfterDecemberFiveTwentyTwelveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_OptionsGrantedAfterDecemberFiveTwentyTwelveMember" xlink:to="lab_mygn_OptionsGrantedAfterDecemberFiveTwentyTwelveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_6c6c282e-ca31-49a0-9314-2be47559217c_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_8b83ee58-dd5a-477e-8319-ae4f4f307365_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_8ecab64f-5993-4489-adb1-4abdc741bbd7_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale:</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesDisclosureAbstract_fb280f72-38f5-4d77-87e1-7a59b9811653_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:to="lab_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_31a27611-2919-460e-8e77-4cc3490fd5e2_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_PerformanceObligationEstimatedTransactionPriceMember_676b040f-09df-4f6d-b682-01e0a1b18668_terseLabel_en-US" xlink:label="lab_mygn_PerformanceObligationEstimatedTransactionPriceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance obligation estimate</link:label>
    <link:label id="lab_mygn_PerformanceObligationEstimatedTransactionPriceMember_label_en-US" xlink:label="lab_mygn_PerformanceObligationEstimatedTransactionPriceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Obligation Estimated Transaction Price [Member]</link:label>
    <link:label id="lab_mygn_PerformanceObligationEstimatedTransactionPriceMember_documentation_en-US" xlink:label="lab_mygn_PerformanceObligationEstimatedTransactionPriceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Obligation Estimated Transaction Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_PerformanceObligationEstimatedTransactionPriceMember" xlink:href="mygn-20210930.xsd#mygn_PerformanceObligationEstimatedTransactionPriceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_PerformanceObligationEstimatedTransactionPriceMember" xlink:to="lab_mygn_PerformanceObligationEstimatedTransactionPriceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_70d3103c-175e-4e0c-9dd5-cbb2f53ed4db_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_bb761593-561a-4c7f-95d4-9b51d65cded6_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_8d355bbd-ea65-4bf6-b9b9-33f66b0d6498_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_842a7ea6-8ca3-45cf-9118-443009d16017_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Translation adjustments recognized in other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Other Comprehensive Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_cd82f9f9-3fda-4627-82c7-74450c03879c_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_f484fd6e-350b-4e31-b909-71b191edc4fc_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_35d2384c-c374-428a-b059-3e20053f7213_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_cc558cc6-859d-42d4-9584-af661530edcf_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Long-Term Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxPeriodDomain_ab54fcec-16af-498f-93f2-964effb788fb_terseLabel_en-US" xlink:label="lab_us-gaap_TaxPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxPeriodDomain_label_en-US" xlink:label="lab_us-gaap_TaxPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodDomain" xlink:to="lab_us-gaap_TaxPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_6ef53260-ecb4-4370-a406-3f1530a5d693_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2363402a-9a54-4407-bab5-e7a89b37daf8_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Expense [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_396cca8b-8636-4514-824c-a14e94393e16_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_d6f2f1cc-24b7-44c4-af52-262e54f178d8_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_GainLossOnDispositionOfAssetsNetOfTransactionFees_86226b13-8e4b-470c-8a31-c2e3e31e5680_terseLabel_en-US" xlink:label="lab_mygn_GainLossOnDispositionOfAssetsNetOfTransactionFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net gain on sale of assets adjusted for transaction fees</link:label>
    <link:label id="lab_mygn_GainLossOnDispositionOfAssetsNetOfTransactionFees_label_en-US" xlink:label="lab_mygn_GainLossOnDispositionOfAssetsNetOfTransactionFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) On Disposition of Assets, Net Of Transaction Fees</link:label>
    <link:label id="lab_mygn_GainLossOnDispositionOfAssetsNetOfTransactionFees_documentation_en-US" xlink:label="lab_mygn_GainLossOnDispositionOfAssetsNetOfTransactionFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) On Disposition of Assets, Net Of Transaction Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_GainLossOnDispositionOfAssetsNetOfTransactionFees" xlink:href="mygn-20210930.xsd#mygn_GainLossOnDispositionOfAssetsNetOfTransactionFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_GainLossOnDispositionOfAssetsNetOfTransactionFees" xlink:to="lab_mygn_GainLossOnDispositionOfAssetsNetOfTransactionFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_a2fa8d56-a0e6-4adf-92eb-113632bdde57_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_e5f62aa2-1556-4ffb-bbed-6ee1f80ef2b9_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal agency issues</link:label>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_label_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury and Government [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasuryAndGovernmentMember" xlink:to="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets_31c48243-7ae1-4efa-bdbc-53044524bb70_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of businesses and assets</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sales of Business, Affiliate and Productive Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" xlink:to="lab_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_fce3c08d-2e76-4b29-8349-6c5cc5aa6413_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LatestTaxYearMember_f33275e4-4a29-446d-8c88-77bd7692991d_terseLabel_en-US" xlink:label="lab_us-gaap_LatestTaxYearMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Latest tax year</link:label>
    <link:label id="lab_us-gaap_LatestTaxYearMember_label_en-US" xlink:label="lab_us-gaap_LatestTaxYearMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Latest Tax Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LatestTaxYearMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LatestTaxYearMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LatestTaxYearMember" xlink:to="lab_us-gaap_LatestTaxYearMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_cfb9c87d-3661-4b4e-b87c-f626eaea8b47_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs outstanding, beginning (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_98a82376-7854-4083-81ac-1a78ffeb9dcb_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs outstanding, ending (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_0418f8b9-4101-45d9-a600-10bb35f85e5d_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_aabe189b-6f15-493f-a877-d881780ab138_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_8a371236-1177-4145-98f2-10206d919277_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_ec8a58bb-bb35-49f1-90b7-758d5ca9b6c6_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale, Due after one year through five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_03e9ac43-21ea-48f5-ae55-7cdb2494863e_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Total Revenue by Product and by U.S versus Rest of World</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4d19e177-b732-43da-b11f-ffe9c32d1f71_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs, Number of shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_AmendmentToCreditAgreementMember_2c1f3e8e-19c9-4667-91a1-f149a7858b1e_terseLabel_en-US" xlink:label="lab_mygn_AmendmentToCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended facility</link:label>
    <link:label id="lab_mygn_AmendmentToCreditAgreementMember_label_en-US" xlink:label="lab_mygn_AmendmentToCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment To Credit Agreement [Member]</link:label>
    <link:label id="lab_mygn_AmendmentToCreditAgreementMember_documentation_en-US" xlink:label="lab_mygn_AmendmentToCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment to Credit Agreement [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_AmendmentToCreditAgreementMember" xlink:href="mygn-20210930.xsd#mygn_AmendmentToCreditAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_AmendmentToCreditAgreementMember" xlink:to="lab_mygn_AmendmentToCreditAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_3f9c5ce1-4a0a-4cc7-90b1-d21239df7fb5_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_ede9a936-6259-4079-9e1d-c30ee03bf670_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares authorized</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FederalMinistryOfFinanceGermanyMember_06a8289e-e2f3-4fd8-bddd-271b5815e52c_terseLabel_en-US" xlink:label="lab_us-gaap_FederalMinistryOfFinanceGermanyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Germany</link:label>
    <link:label id="lab_us-gaap_FederalMinistryOfFinanceGermanyMember_label_en-US" xlink:label="lab_us-gaap_FederalMinistryOfFinanceGermanyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Ministry of Finance, Germany [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalMinistryOfFinanceGermanyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FederalMinistryOfFinanceGermanyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FederalMinistryOfFinanceGermanyMember" xlink:to="lab_us-gaap_FederalMinistryOfFinanceGermanyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax_bf0875e1-8fa7-4045-9ead-1812577393f5_negatedTerseLabel_en-US" xlink:label="lab_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total, Gross unrealized holding losses</link:label>
    <link:label id="lab_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments And Cash, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:label id="lab_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax_documentation_en-US" xlink:label="lab_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments And Cash, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="mygn-20210930.xsd#mygn_InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_62bc9b97-5480-4884-9582-826d5baa32e7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_e8ef1def-e8ee-4528-a7ed-dcec6348e599_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_2f2d43ff-0f05-4330-b993-016a76ff53f8_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_d1cec3b6-44e4-44e7-8d92-b88beb0ce9fa_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding balances</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_9192ee2e-41d4-448e-8b09-5a70f617ca77_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_078ae171-8666-4a33-b889-e08c0a029071_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c2eb7739-4874-4dfe-96c4-fb801ec7f764_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_c499755a-ce65-4107-a2a2-867795d04ec7_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_53a48166-0ae5-4f93-b850-cdaf14c1dabd_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares outstanding:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_0588465d-173c-4488-8b95-ca9c7a017c36_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_MyriadAutoimmuneAssetsMember_e4ad1228-349b-4519-a405-2f829b9acf1f_terseLabel_en-US" xlink:label="lab_mygn_MyriadAutoimmuneAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Select operating assets and intellectual property of Myriad Autoimmune business unit</link:label>
    <link:label id="lab_mygn_MyriadAutoimmuneAssetsMember_2aaf7192-4031-430e-ab3e-a9746b08209a_verboseLabel_en-US" xlink:label="lab_mygn_MyriadAutoimmuneAssetsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Myriad Autoimmune assets</link:label>
    <link:label id="lab_mygn_MyriadAutoimmuneAssetsMember_label_en-US" xlink:label="lab_mygn_MyriadAutoimmuneAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Myriad Autoimmune Assets [Member]</link:label>
    <link:label id="lab_mygn_MyriadAutoimmuneAssetsMember_documentation_en-US" xlink:label="lab_mygn_MyriadAutoimmuneAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Myriad Autoimmune Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MyriadAutoimmuneAssetsMember" xlink:href="mygn-20210930.xsd#mygn_MyriadAutoimmuneAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_MyriadAutoimmuneAssetsMember" xlink:to="lab_mygn_MyriadAutoimmuneAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_CostOfMolecularDiagnosticTestingMember_559814cc-26d1-458f-9df1-0806605e9391_terseLabel_en-US" xlink:label="lab_mygn_CostOfMolecularDiagnosticTestingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of molecular diagnostic testing</link:label>
    <link:label id="lab_mygn_CostOfMolecularDiagnosticTestingMember_label_en-US" xlink:label="lab_mygn_CostOfMolecularDiagnosticTestingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost Of Molecular Diagnostic Testing [Member]</link:label>
    <link:label id="lab_mygn_CostOfMolecularDiagnosticTestingMember_documentation_en-US" xlink:label="lab_mygn_CostOfMolecularDiagnosticTestingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Primary financial statement caption in which the reported facts about the cost of molecular diagnostic testing expense have been included.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_CostOfMolecularDiagnosticTestingMember" xlink:href="mygn-20210930.xsd#mygn_CostOfMolecularDiagnosticTestingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_CostOfMolecularDiagnosticTestingMember" xlink:to="lab_mygn_CostOfMolecularDiagnosticTestingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_2976504b-6116-428e-88fd-9759cf5027d2_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_cfda3655-3109-48a8-aa61-a7e9672108fb_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accrued liabilities</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_8025ded2-50d7-40c0-8334-9a7da91078fe_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_747cd636-67f3-4859-8a44-9476b9d0dc18_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenues</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_3a65fa7c-10b4-47cd-8e65-a53627ddeb11_periodStartLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenues - beginning balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_50defe25-44de-4b6e-9229-f6b6cc9ecf1f_periodEndLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenues - ending balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_3bdd4d8f-abe6-4306-9335-3527c331331a_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_16899aba-9929-4f52-ab7a-604da650b879_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercised (dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_056fba0d-cf88-4363-95ce-17964fe168ec_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US government securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Agencies Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowElementsAbstract_b76a9b7a-bb30-4d91-b0c0-a3ee11bfe80e_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Elements [Abstract]</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowElementsAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Elements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_df45019d-e3ad-46d0-9650-aaac8896f4fb_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue and Concentration Risk [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems" xlink:to="lab_us-gaap_ConcentrationRiskLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_600fea2d-9039-457b-b081-a2fdc4ce56a7_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_1b1a6e36-2ca3-4688-a905-7fce168f9835_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_3bbdd057-704d-402c-810d-21b820c23835_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyTable" xlink:to="lab_us-gaap_IncomeTaxContingencyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_19eacdf9-6992-4b4d-84e1-1580b24cede8_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_d216262b-a3dd-4b29-9a4c-b0c270c69d4d_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_b6bd0382-dce0-4a82-90ea-b491ce737027_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_1ab5660b-a5df-481b-a6cf-c539441cd014_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in the fair value of contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_4abb5abb-dbec-472f-8cdb-46f38104ca34_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable investment securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesCurrent" xlink:to="lab_us-gaap_MarketableSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1e32240d-a8df-400a-a8f0-e6bebdefb0a9_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of foreign exchange rates on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_d11f2ac8-db4e-4438-a761-ff9940ef6481_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial and Nonfinancial Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_301aabb1-faeb-486a-a236-0e6e87355e73_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general, and administrative expense</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_40b3b4fd-49db-40aa-beab-003fc33d4024_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options canceled or expired (dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_1631d14b-aab9-4e54-96f4-1ef03e06cdfd_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_81900fe9-5667-4ac9-8607-7a7dc2bde818_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock authorized (shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_3fecc436-6018-4a5f-b254-a09c5b7659dc_terseLabel_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassifications</link:label>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_label_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification, Comparability Adjustment [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfProductiveAssets_6715a3ee-d9a8-47d2-8953-0b62d222e323_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of assets</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfProductiveAssets_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Productive Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:to="lab_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_82efbadc-cd85-417e-b50f-6f9470d04f30_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_cadd7179-0543-4c88-9935-32ca97a96efd_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_3a7edece-300a-4d52-b5a5-81ae4e53ea73_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale, Gross unrealized holding gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_MyriadRBMIncMember_c665fc26-348b-40ff-8506-9281a378b755_terseLabel_en-US" xlink:label="lab_mygn_MyriadRBMIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Myriad RBM, Inc.</link:label>
    <link:label id="lab_mygn_MyriadRBMIncMember_label_en-US" xlink:label="lab_mygn_MyriadRBMIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Myriad RBM, Inc [Member]</link:label>
    <link:label id="lab_mygn_MyriadRBMIncMember_documentation_en-US" xlink:label="lab_mygn_MyriadRBMIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Myriad RBM, Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MyriadRBMIncMember" xlink:href="mygn-20210930.xsd#mygn_MyriadRBMIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_MyriadRBMIncMember" xlink:to="lab_mygn_MyriadRBMIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueNetAssetLiability_6e2ec2c5-f3a4-46b8-8aa5-c999be13d608_totalLabel_en-US" xlink:label="lab_us-gaap_FairValueNetAssetLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_FairValueNetAssetLiability_label_en-US" xlink:label="lab_us-gaap_FairValueNetAssetLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Net Asset (Liability)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetAssetLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueNetAssetLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueNetAssetLiability" xlink:to="lab_us-gaap_FairValueNetAssetLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_63f7f6d3-56f9-4209-8f83-fbd090d929a7_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_046642e9-25d2-4d1d-9cbc-2e5d8059f1be_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock_99ff841c-ab0d-44a6-b339-9bab36b1f832_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information</link:label>
    <link:label id="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Supplemental Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowSupplementalDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:to="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized_56b8ea2d-e319-4837-a5d9-c056cdf41af6_negatedLabel_en-US" xlink:label="lab_mygn_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue recognized</link:label>
    <link:label id="lab_mygn_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized_label_en-US" xlink:label="lab_mygn_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Including New Contract, Revenue Recognized</link:label>
    <link:label id="lab_mygn_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized_documentation_en-US" xlink:label="lab_mygn_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Including New Contract, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" xlink:href="mygn-20210930.xsd#mygn_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" xlink:to="lab_mygn_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_e88b0913-c4a6-4805-8c44-b77bfb0a90c7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIncomeTaxRefunds_29a26c9b-aaac-490f-af27-f6c3e38b0555_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIncomeTaxRefunds" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash received for income tax receivables</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIncomeTaxRefunds_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIncomeTaxRefunds" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Income Tax Refunds</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIncomeTaxRefunds" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIncomeTaxRefunds"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIncomeTaxRefunds" xlink:to="lab_us-gaap_ProceedsFromIncomeTaxRefunds" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_8349b6a6-1b3c-4ccf-abb2-5c86482000e3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable at end of period (dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_141d477e-7037-4c2b-91b8-40c2786e2890_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_5b2d58ee-1731-4f8e-bd54-56d88312d2eb_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_91f1be47-e95d-4192-b70b-604053e3d2dd_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_f7e81fdc-78a6-4b35-8c9b-545780ed274c_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, 79.7 million and 75.4 million shares outstanding at September&#160;30, 2021 and December 31, 2020, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_1e118868-d9ed-48a8-97dc-03ce12ce9432_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_ed0f3117-293d-4771-86c9-ca6bc2f7e84e_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other income (expense), net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_4e35f032-ec9d-47bb-bb0d-5641a48d2dd9_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average period for recognition of stock-based compensation expense (in years)</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e0c2fd3a-e362-488f-9c02-f703eef69f66_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs outstanding, beginning (dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1f83c1bb-a871-45d3-9d61-51d14d3db952_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs outstanding, ending (dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_659c2eed-0903-4f49-9e56-d0ebb99c2757_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer concentration</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_d25cbd3d-3764-4a2f-946e-d574f856adfe_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_5de20b21-05e1-4936-854c-f452406c4265_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_MolecularDiagnosticPharmacogenomicsMember_6ea08c0b-2099-48f1-b308-3faa1035343b_terseLabel_en-US" xlink:label="lab_mygn_MolecularDiagnosticPharmacogenomicsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molecular Diagnostic - Pharmacogenomics</link:label>
    <link:label id="lab_mygn_MolecularDiagnosticPharmacogenomicsMember_label_en-US" xlink:label="lab_mygn_MolecularDiagnosticPharmacogenomicsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molecular Diagnostic Pharmacogenomics [Member]</link:label>
    <link:label id="lab_mygn_MolecularDiagnosticPharmacogenomicsMember_documentation_en-US" xlink:label="lab_mygn_MolecularDiagnosticPharmacogenomicsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molecular Diagnostic Pharmacogenomics</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MolecularDiagnosticPharmacogenomicsMember" xlink:href="mygn-20210930.xsd#mygn_MolecularDiagnosticPharmacogenomicsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_MolecularDiagnosticPharmacogenomicsMember" xlink:to="lab_mygn_MolecularDiagnosticPharmacogenomicsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_1dcf06d9-3b1c-4b8c-aef4-6388830d0ef6_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_RefundsPayableAndReserveCurrent_63269ed4-818f-452c-82e5-2752e0c73659_terseLabel_en-US" xlink:label="lab_mygn_RefundsPayableAndReserveCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Refunds payable and reserves</link:label>
    <link:label id="lab_mygn_RefundsPayableAndReserveCurrent_label_en-US" xlink:label="lab_mygn_RefundsPayableAndReserveCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Refunds Payable And Reserve, Current</link:label>
    <link:label id="lab_mygn_RefundsPayableAndReserveCurrent_documentation_en-US" xlink:label="lab_mygn_RefundsPayableAndReserveCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Refunds Payable And Reserve, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_RefundsPayableAndReserveCurrent" xlink:href="mygn-20210930.xsd#mygn_RefundsPayableAndReserveCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_RefundsPayableAndReserveCurrent" xlink:to="lab_mygn_RefundsPayableAndReserveCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWriteDown_58ed15e8-4fd4-4793-bc3a-6c98b2da0d01_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on inventory</link:label>
    <link:label id="lab_us-gaap_InventoryWriteDown_label_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Write-down</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWriteDown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWriteDown" xlink:to="lab_us-gaap_InventoryWriteDown" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_MedicareMember_d1ff889f-983c-4bfe-ad88-c7795a648d0c_terseLabel_en-US" xlink:label="lab_mygn_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare</link:label>
    <link:label id="lab_mygn_MedicareMember_label_en-US" xlink:label="lab_mygn_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare [Member]</link:label>
    <link:label id="lab_mygn_MedicareMember_documentation_en-US" xlink:label="lab_mygn_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MedicareMember" xlink:href="mygn-20210930.xsd#mygn_MedicareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_MedicareMember" xlink:to="lab_mygn_MedicareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_ImpairmentOfGoodwillAndLongLivedAssetsHeldForUse_51f2c0af-462e-4af7-adff-76bff71f8681_verboseLabel_en-US" xlink:label="lab_mygn_ImpairmentOfGoodwillAndLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of goodwill and long-lived assets</link:label>
    <link:label id="lab_mygn_ImpairmentOfGoodwillAndLongLivedAssetsHeldForUse_label_en-US" xlink:label="lab_mygn_ImpairmentOfGoodwillAndLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment Of Goodwill And Long-Lived Assets Held For Use</link:label>
    <link:label id="lab_mygn_ImpairmentOfGoodwillAndLongLivedAssetsHeldForUse_documentation_en-US" xlink:label="lab_mygn_ImpairmentOfGoodwillAndLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment Of Goodwill And Long-Lived Assets Held For Use</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_ImpairmentOfGoodwillAndLongLivedAssetsHeldForUse" xlink:href="mygn-20210930.xsd#mygn_ImpairmentOfGoodwillAndLongLivedAssetsHeldForUse"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_ImpairmentOfGoodwillAndLongLivedAssetsHeldForUse" xlink:to="lab_mygn_ImpairmentOfGoodwillAndLongLivedAssetsHeldForUse" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_10769b9b-4312-4487-a25b-07f3437b51e1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fees associated with refinancing of revolving credit facility</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentMaturityDate_f876a841-3a36-411c-b9d4-721e1120497e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentMaturityDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity date</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentMaturityDate_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentMaturityDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Maturity Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentMaturityDate" xlink:to="lab_us-gaap_DebtInstrumentMaturityDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_01ac0137-f64a-4a6f-bd0a-7296fc6eda57_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents:</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidTaxes_1791ed90-c2de-422d-8e49-1a3349ff42c1_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidTaxes" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid taxes</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidTaxes_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidTaxes" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_b09931c0-d060-42f0-a327-8483352d4db4_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis" xlink:to="lab_us-gaap_DisposalGroupClassificationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueRollingMaturityAbstract_f46bb71c-fe67-4966-8215-7f77f46a8e77_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueRollingMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated fair value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueRollingMaturityAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueRollingMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Fair Value, Rolling Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueRollingMaturityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueRollingMaturityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueRollingMaturityAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueRollingMaturityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_81f9ae1e-b5ca-40ca-902c-d0f1a9ff45d6_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_e5b5137e-4910-4bb5-8592-faf2ecd8df17_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Investment Securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillLineItems_ef5f5ed7-7d78-4ccb-bdbf-1eab9bdc6f65_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:label id="lab_us-gaap_GoodwillLineItems_label_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillLineItems" xlink:to="lab_us-gaap_GoodwillLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_9dd249b8-2693-4d61-8600-68a9228caa1c_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total costs and expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_9b0ecc8e-ac79-4895-a460-aa6085a59050_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_7e1e6d05-e9b0-41df-ab9c-9f9f42a22fb7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems" xlink:to="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewJerseyDivisionOfTaxationMember_76a9073b-24d8-488a-993b-7591c78a6c6d_terseLabel_en-US" xlink:label="lab_us-gaap_NewJerseyDivisionOfTaxationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Jersey</link:label>
    <link:label id="lab_us-gaap_NewJerseyDivisionOfTaxationMember_label_en-US" xlink:label="lab_us-gaap_NewJerseyDivisionOfTaxationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Jersey Division of Taxation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewJerseyDivisionOfTaxationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewJerseyDivisionOfTaxationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewJerseyDivisionOfTaxationMember" xlink:to="lab_us-gaap_NewJerseyDivisionOfTaxationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_df4714b5-580b-4007-8ea7-734c97c354e3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_c9b90485-e085-41ec-b238-76e82acfec57_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital expenditures</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Productive Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireProductiveAssets" xlink:to="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5d19c30c-8617-4102-aba5-2dd232a98508_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_NetChangeInCashAndCashEquivalentsClassifiedAsHeldForSale_8cfe1354-c2b7-4c51-907e-4c5002b5b189_terseLabel_en-US" xlink:label="lab_mygn_NetChangeInCashAndCashEquivalentsClassifiedAsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in cash and cash equivalents classified as held for sale</link:label>
    <link:label id="lab_mygn_NetChangeInCashAndCashEquivalentsClassifiedAsHeldForSale_label_en-US" xlink:label="lab_mygn_NetChangeInCashAndCashEquivalentsClassifiedAsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Change In Cash And Cash Equivalents Classified As Held For Sale</link:label>
    <link:label id="lab_mygn_NetChangeInCashAndCashEquivalentsClassifiedAsHeldForSale_documentation_en-US" xlink:label="lab_mygn_NetChangeInCashAndCashEquivalentsClassifiedAsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Change In Cash And Cash Equivalents Classified As Held For Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_NetChangeInCashAndCashEquivalentsClassifiedAsHeldForSale" xlink:href="mygn-20210930.xsd#mygn_NetChangeInCashAndCashEquivalentsClassifiedAsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_NetChangeInCashAndCashEquivalentsClassifiedAsHeldForSale" xlink:to="lab_mygn_NetChangeInCashAndCashEquivalentsClassifiedAsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_69472eaa-f674-470b-a8c7-8984b06a9a57_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general, and administrative expense</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_8cdf881f-6ac4-43b2-bf5c-4139af8ed6aa_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_34dfc0c6-c5aa-4a20-b94b-15fcfeb814e6_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ec28de31-b088-4022-9de6-26e32e7c6a77_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_81b3a65d-3c59-445f-b3ea-3ab885dc93ba_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_DisposalGroupNotDiscontinuedOperationGainLossOnInventory_90f131ac-dd73-4b54-b4da-dd1f7405008c_terseLabel_en-US" xlink:label="lab_mygn_DisposalGroupNotDiscontinuedOperationGainLossOnInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) on inventory</link:label>
    <link:label id="lab_mygn_DisposalGroupNotDiscontinuedOperationGainLossOnInventory_label_en-US" xlink:label="lab_mygn_DisposalGroupNotDiscontinuedOperationGainLossOnInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Not Discontinued Operation, Gain (Loss) On Inventory</link:label>
    <link:label id="lab_mygn_DisposalGroupNotDiscontinuedOperationGainLossOnInventory_documentation_en-US" xlink:label="lab_mygn_DisposalGroupNotDiscontinuedOperationGainLossOnInventory" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Not Discontinued Operation, Gain (Loss) On Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_DisposalGroupNotDiscontinuedOperationGainLossOnInventory" xlink:href="mygn-20210930.xsd#mygn_DisposalGroupNotDiscontinuedOperationGainLossOnInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_DisposalGroupNotDiscontinuedOperationGainLossOnInventory" xlink:to="lab_mygn_DisposalGroupNotDiscontinuedOperationGainLossOnInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_af41072f-4cbc-4c69-beee-0ba11aab27f5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_89dac198-9973-4c20-a609-658741c16fc8_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_cb785a8b-614b-4665-b01d-54e0c976676d_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_6dfe23f4-c8a8-4fb4-9a11-dc4c868df39f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_5803cb1c-8f99-4525-b4ac-931231570556_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingCostsAndExpensesAbstract_f476a85d-2c4e-4791-87ea-84d345bc6a64_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingCostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingCostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingCostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingCostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="lab_us-gaap_OperatingCostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_692c07c4-871a-487c-85ce-ecb2548fdc9c_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_97405706-9ef4-4689-a088-7e323a8b3a96_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_c350cb0f-f7ca-4d3c-b450-890542286965_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_CARESActOf2020MedicarePaymentAmount_2cd34895-0a42-4500-aa8f-e9283d42232b_terseLabel_en-US" xlink:label="lab_mygn_CARESActOf2020MedicarePaymentAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advance Medicare payments to provide relief from economic impacts of COVID-19</link:label>
    <link:label id="lab_mygn_CARESActOf2020MedicarePaymentAmount_label_en-US" xlink:label="lab_mygn_CARESActOf2020MedicarePaymentAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CARES Act Of 2020 Medicare Payment Amount</link:label>
    <link:label id="lab_mygn_CARESActOf2020MedicarePaymentAmount_documentation_en-US" xlink:label="lab_mygn_CARESActOf2020MedicarePaymentAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CARES Act of 2020 Medicare payment amount.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_CARESActOf2020MedicarePaymentAmount" xlink:href="mygn-20210930.xsd#mygn_CARESActOf2020MedicarePaymentAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_CARESActOf2020MedicarePaymentAmount" xlink:to="lab_mygn_CARESActOf2020MedicarePaymentAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_1e7e5f91-2ec7-499a-81e6-0e3e52d3b126_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment and Related Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_6827cfd9-7f9e-466b-8ed2-e053706ee530_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_b9008da7-215f-4463-b74e-0d924b0444fd_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment operating income (loss)</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_e3ba8910-ca94-424e-9570-4fef85bd3a9b_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating loss for reportable segments</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b607d046-6e8b-4dd3-bdaf-ccea59ac73c2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_39aae1c9-8110-425c-8414-627c8c1c3cb5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_a5a22a1e-6405-47fe-bd30-7f037bb6606c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current maturities of operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_f07c540e-cbf2-444f-9525-bde16e027b54_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale, Due after one year through five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0e0304c7-014a-4e40-9ba0-1e0b7f0967cc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale, Gross unrealized holding losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d7f42a47-3efd-47ab-a710-5a4129aa7d8e_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares issued and outstanding</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateTypeDomain_25e62424-3068-4ff1-80b1-90dd0ff95d02_terseLabel_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Accounting Estimate, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateTypeDomain_label_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Accounting Estimate, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:to="lab_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_b6eac6c5-8a73-4002-8d07-9cb37bf61257_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_ba452438-2bd8-4ad9-8b33-102cf0d19a79_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_8ffd7784-8ce6-492f-867f-9678765e9b62_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_53ca4f67-486d-4501-882f-eaddbcb4e127_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_9e470e24-9519-49f6-85a8-040b11fcdc35_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_887a96fe-d16c-42a6-98ce-ad19f1c79fc6_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, Amortized cost</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_98ed6ac3-88a4-4628-b535-1ace0cff7392_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_563a75ef-ada2-45d2-90cc-9d58bfcdf826_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_01c71706-8979-4b30-abc5-c91d826afebe_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_3e256b95-d6a6-4ba8-b185-2af36cf328c9_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable investment securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_18693933-d698-4ad5-a7c5-049e734e83dc_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restricted Stock Unit Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_c4eb43b5-40df-457a-b03b-885a85a16a2a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid during the period for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid" xlink:to="lab_us-gaap_IncomeTaxesPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsAndCashAbstract_2ab506ab-670d-47bb-b1df-5322a0453388_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsAndCashAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total:</link:label>
    <link:label id="lab_us-gaap_InvestmentsAndCashAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsAndCashAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments and Cash [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAndCashAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsAndCashAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsAndCashAbstract" xlink:to="lab_us-gaap_InvestmentsAndCashAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_MolecularDiagnosticPrenatalTestingMember_571e3b56-6286-40c7-a88c-6b5fb7e04f5c_terseLabel_en-US" xlink:label="lab_mygn_MolecularDiagnosticPrenatalTestingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molecular diagnostic - Prenatal</link:label>
    <link:label id="lab_mygn_MolecularDiagnosticPrenatalTestingMember_label_en-US" xlink:label="lab_mygn_MolecularDiagnosticPrenatalTestingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molecular Diagnostic Prenatal Testing [Member]</link:label>
    <link:label id="lab_mygn_MolecularDiagnosticPrenatalTestingMember_documentation_en-US" xlink:label="lab_mygn_MolecularDiagnosticPrenatalTestingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molecular diagnostic Prenatal testing.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MolecularDiagnosticPrenatalTestingMember" xlink:href="mygn-20210930.xsd#mygn_MolecularDiagnosticPrenatalTestingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_MolecularDiagnosticPrenatalTestingMember" xlink:to="lab_mygn_MolecularDiagnosticPrenatalTestingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_cb3948b8-fae6-4653-b025-5c9e68a9acdf_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_ba766d68-1d94-4090-b582-ef6eedfb734e_totalLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Other Income</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_92342d4c-e6c9-4add-b782-862bde7d4f60_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares repurchased</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased and Retired During Period, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:to="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_a6d8b0bf-a62a-4af8-b637-81eb7593157b_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis" xlink:to="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock_a173126c-fdb5-46f8-ac8c-214feabb5bff_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Long-Term Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_95220ab2-8bc0-414e-9736-0c48ed53b0bc_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_66dc7d53-b0fc-4cf6-9f65-a505829bcf6b_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_5ecfcf57-fcae-4963-94a8-1f1fac414a40_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_7321cf4f-a01a-409b-8970-4bcc7ae9d16b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_fcf16c4a-acde-4eea-a8cc-0d0987d44db8_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_57ccc21d-4a58-48a5-aaa7-bd7d298d1c04_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted (dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_de63e156-f303-4bfb-8329-a7792dbf5629_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_ca9bc24d-b97f-4971-b8e0-f897e0e734bf_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_ec52de73-c775-44fb-bff9-be726ee61862_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Myriad Genetics, Inc. stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_3d0ec80c-9a7c-4ab1-9f13-1435845fb944_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_8e6e295e-64fb-4fdc-a53f-5918d6bc2629_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning common stock issued</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_f4ba60e6-d3a0-45fc-9f5b-b2a01171eb01_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued at end of period</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_00a4a481-4ae6-490d-8b1c-14b125700026_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of contingent consideration</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_IncreaseDecreaseInUnrecognizedTaxBenefits_2dee31cf-a189-442d-88fc-dfb32d71f79d_terseLabel_en-US" xlink:label="lab_mygn_IncreaseDecreaseInUnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits</link:label>
    <link:label id="lab_mygn_IncreaseDecreaseInUnrecognizedTaxBenefits_label_en-US" xlink:label="lab_mygn_IncreaseDecreaseInUnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Unrecognized Tax Benefits</link:label>
    <link:label id="lab_mygn_IncreaseDecreaseInUnrecognizedTaxBenefits_documentation_en-US" xlink:label="lab_mygn_IncreaseDecreaseInUnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in unrecognized tax benefits.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_IncreaseDecreaseInUnrecognizedTaxBenefits" xlink:href="mygn-20210930.xsd#mygn_IncreaseDecreaseInUnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_IncreaseDecreaseInUnrecognizedTaxBenefits" xlink:to="lab_mygn_IncreaseDecreaseInUnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_ContractWithCustomerAssetAdjustmentToRevenueForExpandedCoveragePreviouslyConstrained_fd0bc1ad-30fa-4dc4-8972-07b76e7475ab_terseLabel_en-US" xlink:label="lab_mygn_ContractWithCustomerAssetAdjustmentToRevenueForExpandedCoveragePreviouslyConstrained" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue recognized due to expanded local coverage determination for which revenue was previously constrained</link:label>
    <link:label id="lab_mygn_ContractWithCustomerAssetAdjustmentToRevenueForExpandedCoveragePreviouslyConstrained_label_en-US" xlink:label="lab_mygn_ContractWithCustomerAssetAdjustmentToRevenueForExpandedCoveragePreviouslyConstrained" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Asset, Adjustment To Revenue For Expanded Coverage, Previously Constrained</link:label>
    <link:label id="lab_mygn_ContractWithCustomerAssetAdjustmentToRevenueForExpandedCoveragePreviouslyConstrained_documentation_en-US" xlink:label="lab_mygn_ContractWithCustomerAssetAdjustmentToRevenueForExpandedCoveragePreviouslyConstrained" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Asset, Adjustment To Revenue For Expanded Coverage, Previously Constrained</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_ContractWithCustomerAssetAdjustmentToRevenueForExpandedCoveragePreviouslyConstrained" xlink:href="mygn-20210930.xsd#mygn_ContractWithCustomerAssetAdjustmentToRevenueForExpandedCoveragePreviouslyConstrained"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_ContractWithCustomerAssetAdjustmentToRevenueForExpandedCoveragePreviouslyConstrained" xlink:to="lab_mygn_ContractWithCustomerAssetAdjustmentToRevenueForExpandedCoveragePreviouslyConstrained" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_0a38f0ce-df7d-42d3-9100-10d84bd2cc5e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Supplemental Cash Flow Information</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_d4d664c1-e0b2-487c-ae57-7f9e0320f246_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputExpectedTermMember_23201d3b-b194-4736-bfd6-6b41708876ef_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement input, expected term</link:label>
    <link:label id="lab_us-gaap_MeasurementInputExpectedTermMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Expected Term [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedTermMember" xlink:to="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_NonEmployeeDirectorMember_ab197992-041c-4e2d-9685-687bbbb397cf_terseLabel_en-US" xlink:label="lab_mygn_NonEmployeeDirectorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-employee director</link:label>
    <link:label id="lab_mygn_NonEmployeeDirectorMember_label_en-US" xlink:label="lab_mygn_NonEmployeeDirectorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Employee Director [Member]</link:label>
    <link:label id="lab_mygn_NonEmployeeDirectorMember_documentation_en-US" xlink:label="lab_mygn_NonEmployeeDirectorMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non employee director.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_NonEmployeeDirectorMember" xlink:href="mygn-20210930.xsd#mygn_NonEmployeeDirectorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_NonEmployeeDirectorMember" xlink:to="lab_mygn_NonEmployeeDirectorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_MolecularDiagnosticTumorProfilingMember_2fc87531-3afb-41e2-be29-f2842c1345c8_terseLabel_en-US" xlink:label="lab_mygn_MolecularDiagnosticTumorProfilingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molecular diagnostic - Tumor Profiling</link:label>
    <link:label id="lab_mygn_MolecularDiagnosticTumorProfilingMember_label_en-US" xlink:label="lab_mygn_MolecularDiagnosticTumorProfilingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molecular Diagnostic Tumor Profiling [Member]</link:label>
    <link:label id="lab_mygn_MolecularDiagnosticTumorProfilingMember_documentation_en-US" xlink:label="lab_mygn_MolecularDiagnosticTumorProfilingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molecular Diagnostic Tumor Profiling</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MolecularDiagnosticTumorProfilingMember" xlink:href="mygn-20210930.xsd#mygn_MolecularDiagnosticTumorProfilingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_MolecularDiagnosticTumorProfilingMember" xlink:to="lab_mygn_MolecularDiagnosticTumorProfilingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_fc7e202b-156f-4fae-bc73-57fe7bcfc654_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_bcfa0894-eae4-4421-9587-a460406b3328_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) on divestiture</link:label>
    <link:label id="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_label_en-US" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:to="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameDomain_415545db-0c77-448f-9bfb-6712da04126a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_f5bf0e38-36ac-4023-bb4b-25daf7348a43_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_fda1a51e-3014-49ff-bc2d-32985a9f74c5_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_ad0e60e1-ac5a-4a82-bb79-e59b8e63d3a6_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations and Disposal Groups [Abstract]</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations and Disposal Groups [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_PurchasedLicensesAndTechnologiesMember_d73bef66-b6ac-4d21-8492-8f95dba80c30_terseLabel_en-US" xlink:label="lab_mygn_PurchasedLicensesAndTechnologiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchased licenses and technologies</link:label>
    <link:label id="lab_mygn_PurchasedLicensesAndTechnologiesMember_label_en-US" xlink:label="lab_mygn_PurchasedLicensesAndTechnologiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchased Licenses And Technologies [Member]</link:label>
    <link:label id="lab_mygn_PurchasedLicensesAndTechnologiesMember_documentation_en-US" xlink:label="lab_mygn_PurchasedLicensesAndTechnologiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchased licenses and technologies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_PurchasedLicensesAndTechnologiesMember" xlink:href="mygn-20210930.xsd#mygn_PurchasedLicensesAndTechnologiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_PurchasedLicensesAndTechnologiesMember" xlink:to="lab_mygn_PurchasedLicensesAndTechnologiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax_7029916c-bca0-4b67-be88-67c74f8c8eac_terseLabel_en-US" xlink:label="lab_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total, Gross unrealized holding gains</link:label>
    <link:label id="lab_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments And Cash, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:label id="lab_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax_documentation_en-US" xlink:label="lab_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments And Cash, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="mygn-20210930.xsd#mygn_InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_03b89cf3-5458-4db9-a5d5-a328be353c79_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_d9b37e68-c933-40ae-a13c-1384e92692e8_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_1bb7abe7-0d00-4119-a8a0-fc9b6122f4a5_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award expiration period (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_950357cc-c2b2-42b6-9121-cddf3af158cf_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_743ec83c-5bf2-48e4-bfb7-a5c3c33b7a36_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Undrawn fee (percent)</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Unused Capacity, Commitment Fee Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:to="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_a7207e95-dcde-44cc-885a-e165d622c470_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_54426416-2f9e-4015-a993-75f91b4581a6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis" xlink:to="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_b8036c5b-81e5-480c-9ef7-ea92b1fb081a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_68480232-8dfd-4efb-ab23-8a11718957ed_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_574e9db3-8811-4494-9dc6-00af1d3eb4c9_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable" xlink:to="lab_us-gaap_ConcentrationRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_464c2047-af7d-4b0d-920a-6a0412c216dc_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Fair Value of Contingent Consideration</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLinesOfCredit_4fcf5f6a-6b32-45f1-9d8f-82bf55eb5fde_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLinesOfCredit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of revolving credit facility</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLinesOfCredit_83e53d0d-6620-41fe-a038-d0d07d6d9bea_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal repayment</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLinesOfCredit" xlink:to="lab_us-gaap_RepaymentsOfLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_DiagnosticsMember_d9ba9dca-435c-4081-a9e0-d98ff5b5d962_terseLabel_en-US" xlink:label="lab_mygn_DiagnosticsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diagnostics</link:label>
    <link:label id="lab_mygn_DiagnosticsMember_label_en-US" xlink:label="lab_mygn_DiagnosticsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diagnostics [Member]</link:label>
    <link:label id="lab_mygn_DiagnosticsMember_documentation_en-US" xlink:label="lab_mygn_DiagnosticsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diagnostics.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_DiagnosticsMember" xlink:href="mygn-20210930.xsd#mygn_DiagnosticsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_DiagnosticsMember" xlink:to="lab_mygn_DiagnosticsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_17ef88bb-22a4-4957-958c-bf1659d09f45_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-amortizable</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent_54664b26-eb22-4606-bd9d-d0e97c0ab6fa_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized debt discount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_486325f0-fc79-43fd-a8aa-d4e693f1d385_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_af1fde81-1350-43c0-80d0-082447a24a96_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_fd121e92-348b-4910-9dcf-68dc00695ee8_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_254507d1-5f1a-415e-a699-2d11137fec51_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_24e43638-75ad-4e10-8240-384700343194_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_f3e54bed-cb80-44f6-be30-39c2da07c346_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_MolecularDiagnosticAutoimmuneMember_50c0b22c-750e-4a65-afa2-08d9af3627d8_terseLabel_en-US" xlink:label="lab_mygn_MolecularDiagnosticAutoimmuneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molecular Diagnostic - Autoimmune</link:label>
    <link:label id="lab_mygn_MolecularDiagnosticAutoimmuneMember_label_en-US" xlink:label="lab_mygn_MolecularDiagnosticAutoimmuneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molecular Diagnostic Autoimmune [Member]</link:label>
    <link:label id="lab_mygn_MolecularDiagnosticAutoimmuneMember_documentation_en-US" xlink:label="lab_mygn_MolecularDiagnosticAutoimmuneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molecular Diagnostic Autoimmune</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MolecularDiagnosticAutoimmuneMember" xlink:href="mygn-20210930.xsd#mygn_MolecularDiagnosticAutoimmuneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_MolecularDiagnosticAutoimmuneMember" xlink:to="lab_mygn_MolecularDiagnosticAutoimmuneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_68ce6c6d-16bb-440f-8cbe-269fb147a126_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_2470173a-6d49-4711-a7fb-421908989ae6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_057bfa51-b888-4585-a85a-47b3e2f81025_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_IncreaseDecreaseInEarningsLossPerShare_a88414d4-16f9-46c5-88b4-19d2836d5606_terseLabel_en-US" xlink:label="lab_mygn_IncreaseDecreaseInEarningsLossPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in earnings per share (dollars per share)</link:label>
    <link:label id="lab_mygn_IncreaseDecreaseInEarningsLossPerShare_label_en-US" xlink:label="lab_mygn_IncreaseDecreaseInEarningsLossPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase Decrease In Earnings Loss Per Share</link:label>
    <link:label id="lab_mygn_IncreaseDecreaseInEarningsLossPerShare_documentation_en-US" xlink:label="lab_mygn_IncreaseDecreaseInEarningsLossPerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase decrease in earnings (loss) per share.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_IncreaseDecreaseInEarningsLossPerShare" xlink:href="mygn-20210930.xsd#mygn_IncreaseDecreaseInEarningsLossPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_IncreaseDecreaseInEarningsLossPerShare" xlink:to="lab_mygn_IncreaseDecreaseInEarningsLossPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_9b090964-c08e-4079-863a-f542340fe53e_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_EighthShareRepurchaseProgramMember_31cbead8-feba-43fb-8e6c-48f14b30d871_terseLabel_en-US" xlink:label="lab_mygn_EighthShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eighth Share Repurchase Program</link:label>
    <link:label id="lab_mygn_EighthShareRepurchaseProgramMember_label_en-US" xlink:label="lab_mygn_EighthShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eighth Share Repurchase Program [Member]</link:label>
    <link:label id="lab_mygn_EighthShareRepurchaseProgramMember_documentation_en-US" xlink:label="lab_mygn_EighthShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eighth share repurchase program.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_EighthShareRepurchaseProgramMember" xlink:href="mygn-20210930.xsd#mygn_EighthShareRepurchaseProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_EighthShareRepurchaseProgramMember" xlink:to="lab_mygn_EighthShareRepurchaseProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_a29ac10d-59b7-488e-9d06-9ff555f10479_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_56ceef36-587f-4163-bed0-37178380f24f_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_05ee9e4a-f273-4274-8aea-e60bdd48a5ac_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs canceled (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_562acf26-7d56-4a6e-a4fb-b5149b8eba4d_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_b905a1d3-0da7-43e5-b49a-ae06070e59e5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Revenue and Operating Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_d61e162d-183f-44b0-a5ed-ce72c9a7db41_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_195ea5b1-66d5-4a79-9dad-489585e3188b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsAccumulatedAmortizationNoncurrent_0526b5ad-bdaa-4733-b041-d2389185eccb_terseLabel_en-US" xlink:label="lab_mygn_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsAccumulatedAmortizationNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated amortization on intangible assets included in sale</link:label>
    <link:label id="lab_mygn_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsAccumulatedAmortizationNoncurrent_label_en-US" xlink:label="lab_mygn_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsAccumulatedAmortizationNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Intangible Assets, Accumulated Amortization, Noncurrent</link:label>
    <link:label id="lab_mygn_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsAccumulatedAmortizationNoncurrent_documentation_en-US" xlink:label="lab_mygn_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsAccumulatedAmortizationNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount classified as accumulated amortization of intangible assets attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsAccumulatedAmortizationNoncurrent" xlink:href="mygn-20210930.xsd#mygn_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsAccumulatedAmortizationNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsAccumulatedAmortizationNoncurrent" xlink:to="lab_mygn_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsAccumulatedAmortizationNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_DebtCovenantLiquidityCovenantMinimum_4c0ac2a3-88b8-4475-8741-e45d4a3c1d46_terseLabel_en-US" xlink:label="lab_mygn_DebtCovenantLiquidityCovenantMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum liquidity covenant</link:label>
    <link:label id="lab_mygn_DebtCovenantLiquidityCovenantMinimum_label_en-US" xlink:label="lab_mygn_DebtCovenantLiquidityCovenantMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Covenant, Liquidity Covenant Minimum</link:label>
    <link:label id="lab_mygn_DebtCovenantLiquidityCovenantMinimum_documentation_en-US" xlink:label="lab_mygn_DebtCovenantLiquidityCovenantMinimum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Covenant, Liquidity Covenant Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_DebtCovenantLiquidityCovenantMinimum" xlink:href="mygn-20210930.xsd#mygn_DebtCovenantLiquidityCovenantMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_DebtCovenantLiquidityCovenantMinimum" xlink:to="lab_mygn_DebtCovenantLiquidityCovenantMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_b79a7b73-b5f1-46a6-9c15-cda1ba36684c_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2bb18303-26cd-4350-aa28-54873cabcdb4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_fff4ecfb-a37a-4f5f-bbe6-c14fbd4442bb_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_8e6c937e-342d-4753-9992-476255ee0b54_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_88bc5da8-c68a-4941-b9bb-b2a5b14ea5a6_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized stock-based compensation expense related to stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_d99b5579-fb14-4027-8ab2-794169cec7ac_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_e6b4aa35-a8a9-4f31-a366-2bc6ad72791d_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_ChangeInFairValueOfContingentConsideration_49acd8d5-f143-462e-9f45-6f07f879365c_terseLabel_en-US" xlink:label="lab_mygn_ChangeInFairValueOfContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of contingent consideration</link:label>
    <link:label id="lab_mygn_ChangeInFairValueOfContingentConsideration_label_en-US" xlink:label="lab_mygn_ChangeInFairValueOfContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Fair Value Of Contingent Consideration</link:label>
    <link:label id="lab_mygn_ChangeInFairValueOfContingentConsideration_documentation_en-US" xlink:label="lab_mygn_ChangeInFairValueOfContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of contingent consideration.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_ChangeInFairValueOfContingentConsideration" xlink:href="mygn-20210930.xsd#mygn_ChangeInFairValueOfContingentConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_ChangeInFairValueOfContingentConsideration" xlink:to="lab_mygn_ChangeInFairValueOfContingentConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_5d8464d2-ada5-4e98-8332-4d479ab3e784_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_b87cdb2e-b5a7-4d33-b35b-ff98def2da41_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_008f05d0-0771-412e-bc70-22b1b59ccd20_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Denominators of Basic and Diluted Earnings Per Share Computations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Weighted Average Number of Shares [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_8e3ab7ec-84da-4fe8-84e3-32f7bd2b4155_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_634c2b77-ea8e-45f2-970f-6edc348733a5_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_ContractWithCustomerLiabilityPrepayments_7c9d429f-c7ac-4b38-af33-73c06b1a9dff_terseLabel_en-US" xlink:label="lab_mygn_ContractWithCustomerLiabilityPrepayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayments</link:label>
    <link:label id="lab_mygn_ContractWithCustomerLiabilityPrepayments_label_en-US" xlink:label="lab_mygn_ContractWithCustomerLiabilityPrepayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Prepayments</link:label>
    <link:label id="lab_mygn_ContractWithCustomerLiabilityPrepayments_documentation_en-US" xlink:label="lab_mygn_ContractWithCustomerLiabilityPrepayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with customer, liability, prepayments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_ContractWithCustomerLiabilityPrepayments" xlink:href="mygn-20210930.xsd#mygn_ContractWithCustomerLiabilityPrepayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_ContractWithCustomerLiabilityPrepayments" xlink:to="lab_mygn_ContractWithCustomerLiabilityPrepayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_79a11d74-4694-4e99-a8a7-8e1b2ada24b4_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized stock-based compensation expense related to RSUs</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_660ae817-b836-4c2b-9295-0942723fb2ee_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisRollingMaturityAbstract_4e22570a-7b39-487e-806b-2c873a8949e9_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisRollingMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisRollingMaturityAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisRollingMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost, Rolling Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisRollingMaturityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisRollingMaturityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisRollingMaturityAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisRollingMaturityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_5f7337b2-f3bc-4a06-a6eb-ffd1a5f3e9f9_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in foreign currency translation adjustment, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_2b23ed88-d1e7-4e27-8f4f-45da4ffa15dc_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_a16372d6-b6cd-427e-9aad-8d311ec83e05_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term marketable investment securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesNoncurrent" xlink:to="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_c7f9fa70-1969-4619-8f5d-47f0e48df013_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_703957a8-a26c-484d-9d23-5f0da14bef0e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_b00632cc-5ca9-4abb-aee9-7fc33ce0cc18_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenues</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_290d34dd-18b7-40e5-bcfa-14cc3991ac4f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Weighted average exercise price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_2547e077-4a09-4335-9e9d-b008ed7eb197_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under stock-based compensation plans, net of shares exchanged for withholding tax</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b83b8ffa-9629-4796-b315-7e1c9c5c33dd_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale, Estimated fair value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_InProcessResearchAndDevelopmentWithIndefiniteLivesMember_26a2f980-b212-4541-a47e-078cb2ec5a71_terseLabel_en-US" xlink:label="lab_mygn_InProcessResearchAndDevelopmentWithIndefiniteLivesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In-process research and development</link:label>
    <link:label id="lab_mygn_InProcessResearchAndDevelopmentWithIndefiniteLivesMember_label_en-US" xlink:label="lab_mygn_InProcessResearchAndDevelopmentWithIndefiniteLivesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research And Development With Indefinite Lives [Member]</link:label>
    <link:label id="lab_mygn_InProcessResearchAndDevelopmentWithIndefiniteLivesMember_documentation_en-US" xlink:label="lab_mygn_InProcessResearchAndDevelopmentWithIndefiniteLivesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In process research and development with indefinite lives.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_InProcessResearchAndDevelopmentWithIndefiniteLivesMember" xlink:href="mygn-20210930.xsd#mygn_InProcessResearchAndDevelopmentWithIndefiniteLivesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_InProcessResearchAndDevelopmentWithIndefiniteLivesMember" xlink:to="lab_mygn_InProcessResearchAndDevelopmentWithIndefiniteLivesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFirmPurchaseCommitmentLoss_45cf62b9-9252-43e7-905a-289bd1b8075b_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFirmPurchaseCommitmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on non-cancelable purchase commitment</link:label>
    <link:label id="lab_us-gaap_InventoryFirmPurchaseCommitmentLoss_label_en-US" xlink:label="lab_us-gaap_InventoryFirmPurchaseCommitmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Firm Purchase Commitment, Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFirmPurchaseCommitmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFirmPurchaseCommitmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFirmPurchaseCommitmentLoss" xlink:to="lab_us-gaap_InventoryFirmPurchaseCommitmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_b5581ebb-4199-4ddf-b12d-22d65cb8e428_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Carrying Amount, total</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_5e97ac35-99e0-46c2-83fb-11d7a95db425_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_7d2bd9ec-65a4-457d-a96e-210c1862663e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxPeriodAxis_86eb7150-ed72-46ef-adc5-5f82e08f75d9_terseLabel_en-US" xlink:label="lab_us-gaap_TaxPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxPeriodAxis_label_en-US" xlink:label="lab_us-gaap_TaxPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodAxis" xlink:to="lab_us-gaap_TaxPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_MolecularDiagnosticOtherTestingMember_769c0917-ca35-4748-b8a7-ec3853925eb2_terseLabel_en-US" xlink:label="lab_mygn_MolecularDiagnosticOtherTestingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molecular diagnostic - Other</link:label>
    <link:label id="lab_mygn_MolecularDiagnosticOtherTestingMember_label_en-US" xlink:label="lab_mygn_MolecularDiagnosticOtherTestingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molecular Diagnostic Other Testing [Member]</link:label>
    <link:label id="lab_mygn_MolecularDiagnosticOtherTestingMember_documentation_en-US" xlink:label="lab_mygn_MolecularDiagnosticOtherTestingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molecular diagnostic other testing.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MolecularDiagnosticOtherTestingMember" xlink:href="mygn-20210930.xsd#mygn_MolecularDiagnosticOtherTestingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_MolecularDiagnosticOtherTestingMember" xlink:to="lab_mygn_MolecularDiagnosticOtherTestingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_16684e35-4372-4a98-a3e2-e47f4aa81a91_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) before income tax</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_4325f07c-4497-43ba-a0af-df7fde5d87a5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_DisposalGroupNotDiscontinuedOperationGainLossOther_b9f9951e-4195-4390-a180-11dab7376a0a_terseLabel_en-US" xlink:label="lab_mygn_DisposalGroupNotDiscontinuedOperationGainLossOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_mygn_DisposalGroupNotDiscontinuedOperationGainLossOther_label_en-US" xlink:label="lab_mygn_DisposalGroupNotDiscontinuedOperationGainLossOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Not Discontinued Operation, Gain (Loss) Other</link:label>
    <link:label id="lab_mygn_DisposalGroupNotDiscontinuedOperationGainLossOther_documentation_en-US" xlink:label="lab_mygn_DisposalGroupNotDiscontinuedOperationGainLossOther" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Not Discontinued Operation, Gain (Loss) Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_DisposalGroupNotDiscontinuedOperationGainLossOther" xlink:href="mygn-20210930.xsd#mygn_DisposalGroupNotDiscontinuedOperationGainLossOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_DisposalGroupNotDiscontinuedOperationGainLossOther" xlink:to="lab_mygn_DisposalGroupNotDiscontinuedOperationGainLossOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d3670d36-07b6-4bfe-a760-a509dcd751e2_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_799712f1-5afc-4309-82e7-e3cac49706fe_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_92798a43-e402-47a8-8fe5-cbe1c22197ea_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale, Amortized cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_b2e54a26-f4d4-4f29-9868-6bd8a0f2e49f_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_IntangibleAssetsLineItems_0ac1f59a-3053-4d43-b34e-e1c4e88f3ee9_terseLabel_en-US" xlink:label="lab_mygn_IntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets [Line Items]</link:label>
    <link:label id="lab_mygn_IntangibleAssetsLineItems_label_en-US" xlink:label="lab_mygn_IntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets [Line Items]</link:label>
    <link:label id="lab_mygn_IntangibleAssetsLineItems_documentation_en-US" xlink:label="lab_mygn_IntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_IntangibleAssetsLineItems" xlink:href="mygn-20210930.xsd#mygn_IntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_IntangibleAssetsLineItems" xlink:to="lab_mygn_IntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_EmployeeStockPurchasePlanTwentyTwelveMember_018a0700-9493-479c-9337-fcf133efb57c_terseLabel_en-US" xlink:label="lab_mygn_EmployeeStockPurchasePlanTwentyTwelveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2012 Purchase Plan</link:label>
    <link:label id="lab_mygn_EmployeeStockPurchasePlanTwentyTwelveMember_label_en-US" xlink:label="lab_mygn_EmployeeStockPurchasePlanTwentyTwelveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan Twenty Twelve [Member]</link:label>
    <link:label id="lab_mygn_EmployeeStockPurchasePlanTwentyTwelveMember_documentation_en-US" xlink:label="lab_mygn_EmployeeStockPurchasePlanTwentyTwelveMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan Twenty Twelve [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_EmployeeStockPurchasePlanTwentyTwelveMember" xlink:href="mygn-20210930.xsd#mygn_EmployeeStockPurchasePlanTwentyTwelveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_EmployeeStockPurchasePlanTwentyTwelveMember" xlink:to="lab_mygn_EmployeeStockPurchasePlanTwentyTwelveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_9501759d-7841-4e70-81ab-475bd7e3e5d7_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_fe26adef-6ed7-4e52-ac74-e22573931103_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_f9a4009b-ebce-4ddd-b2c2-5c6a3c53ca38_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_d4e8168b-2764-49f4-a814-684bafd4f366_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_03164e0d-e4bb-4d67-8b39-c1eae0b062f6_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_312a9d7c-73e8-4a84-b0ca-3878043bd5ff_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Divestitures</link:label>
    <link:label id="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_label_en-US" xlink:label="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Written off Related to Sale of Business Unit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:to="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_TwoThousandSeventeenEmployeeDirectorAndConsultantEquityIncentivePlanMember_6990dc49-dea0-4638-9ac5-c07d58a0d503_terseLabel_en-US" xlink:label="lab_mygn_TwoThousandSeventeenEmployeeDirectorAndConsultantEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 Plan</link:label>
    <link:label id="lab_mygn_TwoThousandSeventeenEmployeeDirectorAndConsultantEquityIncentivePlanMember_label_en-US" xlink:label="lab_mygn_TwoThousandSeventeenEmployeeDirectorAndConsultantEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Seventeen Employee Director And Consultant Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_mygn_TwoThousandSeventeenEmployeeDirectorAndConsultantEquityIncentivePlanMember_documentation_en-US" xlink:label="lab_mygn_TwoThousandSeventeenEmployeeDirectorAndConsultantEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Seventeen Employee Director And Consultant Equity Incentive Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_TwoThousandSeventeenEmployeeDirectorAndConsultantEquityIncentivePlanMember" xlink:href="mygn-20210930.xsd#mygn_TwoThousandSeventeenEmployeeDirectorAndConsultantEquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_TwoThousandSeventeenEmployeeDirectorAndConsultantEquityIncentivePlanMember" xlink:to="lab_mygn_TwoThousandSeventeenEmployeeDirectorAndConsultantEquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_12cd01b0-c37c-462b-9d39-32c2497014a2_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposed of by sale</link:label>
    <link:label id="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_label_en-US" xlink:label="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:to="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExaminationYearUnderExamination_f36575e9-7202-44b9-b4b9-d997ec41afae_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationYearUnderExamination" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax year being audited in income tax examination</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExaminationYearUnderExamination_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationYearUnderExamination" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Examination, Year under Examination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationYearUnderExamination" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExaminationYearUnderExamination"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationYearUnderExamination" xlink:to="lab_us-gaap_IncomeTaxExaminationYearUnderExamination" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_59f506b7-3331-4a12-827e-2d8e90b774e2_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_ec82fa45-b6c7-4b93-a721-46fef734937a_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_1f030708-c5e9-493b-8015-59bb7528207e_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock authorized (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_ebc43f7f-82d0-4168-b9ef-6d6bedf8abf0_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_3aa1d6f9-a2bb-4d39-97c7-5c398e0308ec_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_59178bd1-be9d-4105-a18a-41202365f053_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestPeriodIncreaseDecrease_7b16e3ba-2d7d-447a-b5c2-cbaecbd42e76_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-controlling interest</link:label>
    <link:label id="lab_us-gaap_MinorityInterestPeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_MinorityInterestPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestPeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestPeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestPeriodIncreaseDecrease" xlink:to="lab_us-gaap_MinorityInterestPeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_ContingentConsiderationMember_fe1350ca-4dfe-4209-9ae6-000d55cf5bb9_terseLabel_en-US" xlink:label="lab_mygn_ContingentConsiderationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_mygn_ContingentConsiderationMember_label_en-US" xlink:label="lab_mygn_ContingentConsiderationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration [Member]</link:label>
    <link:label id="lab_mygn_ContingentConsiderationMember_documentation_en-US" xlink:label="lab_mygn_ContingentConsiderationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_ContingentConsiderationMember" xlink:href="mygn-20210930.xsd#mygn_ContingentConsiderationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_ContingentConsiderationMember" xlink:to="lab_mygn_ContingentConsiderationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_07c79110-9888-4ad9-913f-3f51a6bd634c_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-controlling interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_ebb90661-b4d5-4e98-b63d-b840697235a9_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_67c6961a-3c07-48c9-bbdd-e45881dbd177_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_InvestmentsAndCashAmortizedCost_2d39b9b2-7e73-4df8-93ab-ceec6b4f4d83_totalLabel_en-US" xlink:label="lab_mygn_InvestmentsAndCashAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total, Amortized cost</link:label>
    <link:label id="lab_mygn_InvestmentsAndCashAmortizedCost_label_en-US" xlink:label="lab_mygn_InvestmentsAndCashAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments And Cash, Amortized Cost</link:label>
    <link:label id="lab_mygn_InvestmentsAndCashAmortizedCost_documentation_en-US" xlink:label="lab_mygn_InvestmentsAndCashAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments And Cash, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_InvestmentsAndCashAmortizedCost" xlink:href="mygn-20210930.xsd#mygn_InvestmentsAndCashAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_InvestmentsAndCashAmortizedCost" xlink:to="lab_mygn_InvestmentsAndCashAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_04d5c05e-d0ac-4ed9-beb6-715081ca9c59_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization" xlink:to="lab_us-gaap_DepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_c026bc01-777a-4b96-a0a7-27ed87acd119_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to non-controlling interest</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0b3348ff-c2ef-40f3-8a66-e5514c9616ba_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_936208dd-6ce1-49b2-9ff7-2cc6583f9a72_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving credit facility</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashMember_f3f5e908-9bbd-43e7-a1cf-bdf9f86694e5_terseLabel_en-US" xlink:label="lab_us-gaap_CashMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_us-gaap_CashMember_label_en-US" xlink:label="lab_us-gaap_CashMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashMember" xlink:to="lab_us-gaap_CashMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_c59bb2ce-9750-4f99-95aa-6251c4178c60_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllOtherSegmentsMember_c54b1a52-14a0-4cd7-82ab-5f24894f9be6_terseLabel_en-US" xlink:label="lab_us-gaap_AllOtherSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_AllOtherSegmentsMember_label_en-US" xlink:label="lab_us-gaap_AllOtherSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Segments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllOtherSegmentsMember" xlink:to="lab_us-gaap_AllOtherSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d8968dba-4f85-49d7-b1cb-b00cf1ad9ba1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_7d3d0e6a-3656-442b-b235-12e686ae0dc2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_53b34328-a1a7-4eb2-bd7c-18a153df5914_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis_aa42393c-1cc4-435b-b93d-36a38fb83024_terseLabel_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Accounting Estimate by Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Accounting Estimate by Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:to="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_b711023b-3250-49a5-bc9a-df24e310b1a7_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. [Member]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_ab43544e-d5ed-4869-b8f3-e92bd74f2ce3_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_26ffd02e-4d97-4535-ae12-ad4ba9e13c74_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares outstanding used to compute basic EPS</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_ebd85c4d-e147-49c3-857e-d301017fcbc1_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_d9e092ec-618d-41e6-9d56-50597cb781c3_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_4ea0626f-5f2c-49d0-9d4b-bb92339dfd87_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_90beee8c-725d-4df2-aad5-7f8cc7f57e44_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash lease expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Amortization Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_a3606b10-07c6-416d-ae48-33518ae2eb1d_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of dilutive shares</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number Diluted Shares Outstanding Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_BusinessCombinationContingentConsiderationLiabilityMeasurementInputTerm_7b6a3ebd-fbed-4981-b8a8-41adefa3761d_terseLabel_en-US" xlink:label="lab_mygn_BusinessCombinationContingentConsiderationLiabilityMeasurementInputTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement period for earn out liability</link:label>
    <link:label id="lab_mygn_BusinessCombinationContingentConsiderationLiabilityMeasurementInputTerm_label_en-US" xlink:label="lab_mygn_BusinessCombinationContingentConsiderationLiabilityMeasurementInputTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Measurement Input, Term</link:label>
    <link:label id="lab_mygn_BusinessCombinationContingentConsiderationLiabilityMeasurementInputTerm_documentation_en-US" xlink:label="lab_mygn_BusinessCombinationContingentConsiderationLiabilityMeasurementInputTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Measurement Input, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_BusinessCombinationContingentConsiderationLiabilityMeasurementInputTerm" xlink:href="mygn-20210930.xsd#mygn_BusinessCombinationContingentConsiderationLiabilityMeasurementInputTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_BusinessCombinationContingentConsiderationLiabilityMeasurementInputTerm" xlink:to="lab_mygn_BusinessCombinationContingentConsiderationLiabilityMeasurementInputTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedContractCostGross_c68c1482-5f47-4bad-9947-3e98ac12dc6c_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized costs incurred to obtain or fulfill contract</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostGross_label_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedContractCostGross" xlink:to="lab_us-gaap_CapitalizedContractCostGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonUsMember_16b9e0e9-0b2e-4297-a241-a72ffbc7e9bc_terseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RoW</link:label>
    <link:label id="lab_us-gaap_NonUsMember_label_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember" xlink:to="lab_us-gaap_NonUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_548bc10f-012e-4e79-a313-048c0aa0a2b6_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_bf096cd2-dec5-4300-9d19-78b1edd7db73_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Recorded Amortization Expense for Intangible Assets</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived Intangible Assets Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_b75fd209-8290-42fd-87a6-3acc45de7b87_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income (loss) attributable to Myriad Genetics, Inc. stockholders</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_74d814ce-84d5-4e83-ab08-d9a6f140b792_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangibles, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_4e9dbd54-0429-4074-b055-17e0b80b0f8e_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net, total</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_3215c9d3-4f8c-4000-9706-260460e5211b_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_fea83dbe-9786-4b7e-a977-b683aa3371ea_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term deferred taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_e1192de5-80de-47c3-a9b7-6aa23c1adab3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service period for award vesting (in years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_5dfccd78-0d1d-4ca9-9166-27f6ccd74038_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate bonds and notes</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_e3a3ce76-017b-439c-b317-706dd2578c07_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_PharmaceuticalAndClinicalServicesMember_a52a4091-0329-4d79-82e7-6f017f61d70e_terseLabel_en-US" xlink:label="lab_mygn_PharmaceuticalAndClinicalServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical and clinical services</link:label>
    <link:label id="lab_mygn_PharmaceuticalAndClinicalServicesMember_label_en-US" xlink:label="lab_mygn_PharmaceuticalAndClinicalServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical And Clinical Services [Member]</link:label>
    <link:label id="lab_mygn_PharmaceuticalAndClinicalServicesMember_documentation_en-US" xlink:label="lab_mygn_PharmaceuticalAndClinicalServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical and clinical services.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_PharmaceuticalAndClinicalServicesMember" xlink:href="mygn-20210930.xsd#mygn_PharmaceuticalAndClinicalServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_PharmaceuticalAndClinicalServicesMember" xlink:to="lab_mygn_PharmaceuticalAndClinicalServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_DebtCovenantUnrestrictedCashAndCashEquivalentsThresholdForBorrowingRestrictionMinimum_dd67352a-d2b1-4db1-9839-1647ff11faed_terseLabel_en-US" xlink:label="lab_mygn_DebtCovenantUnrestrictedCashAndCashEquivalentsThresholdForBorrowingRestrictionMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum unrestricted cash and cash equivalents threshold per covenant</link:label>
    <link:label id="lab_mygn_DebtCovenantUnrestrictedCashAndCashEquivalentsThresholdForBorrowingRestrictionMinimum_label_en-US" xlink:label="lab_mygn_DebtCovenantUnrestrictedCashAndCashEquivalentsThresholdForBorrowingRestrictionMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Covenant, Unrestricted Cash And Cash Equivalents Threshold For Borrowing Restriction, Minimum</link:label>
    <link:label id="lab_mygn_DebtCovenantUnrestrictedCashAndCashEquivalentsThresholdForBorrowingRestrictionMinimum_documentation_en-US" xlink:label="lab_mygn_DebtCovenantUnrestrictedCashAndCashEquivalentsThresholdForBorrowingRestrictionMinimum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Covenant, Unrestricted Cash And Cash Equivalents Threshold For Borrowing Restriction, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_DebtCovenantUnrestrictedCashAndCashEquivalentsThresholdForBorrowingRestrictionMinimum" xlink:href="mygn-20210930.xsd#mygn_DebtCovenantUnrestrictedCashAndCashEquivalentsThresholdForBorrowingRestrictionMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_DebtCovenantUnrestrictedCashAndCashEquivalentsThresholdForBorrowingRestrictionMinimum" xlink:to="lab_mygn_DebtCovenantUnrestrictedCashAndCashEquivalentsThresholdForBorrowingRestrictionMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_77db937b-09c7-475c-bf4a-5101e2d2f1a1_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_633533ce-23b2-4cae-9bb5-2d4f82b29265_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_NonCashInterestExpense_16fb7217-08d0-4b53-8c30-299a536512de_terseLabel_en-US" xlink:label="lab_mygn_NonCashInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest expense</link:label>
    <link:label id="lab_mygn_NonCashInterestExpense_label_en-US" xlink:label="lab_mygn_NonCashInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Cash Interest Expense</link:label>
    <link:label id="lab_mygn_NonCashInterestExpense_documentation_en-US" xlink:label="lab_mygn_NonCashInterestExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non cash interest expense.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_NonCashInterestExpense" xlink:href="mygn-20210930.xsd#mygn_NonCashInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_NonCashInterestExpense" xlink:to="lab_mygn_NonCashInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCountryMember_6f1723f0-acd2-44be-bc00-4a4b7e2dcc67_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_ForeignCountryMember_label_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCountryMember" xlink:to="lab_us-gaap_ForeignCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationReserveCurrent_012a9c56-83da-4620-9b16-6a9790074f15_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationReserveCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal accrual</link:label>
    <link:label id="lab_us-gaap_LitigationReserveCurrent_877c2f07-6fae-4b58-b5da-9942bca1feaf_verboseLabel_en-US" xlink:label="lab_us-gaap_LitigationReserveCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential settlement accrual</link:label>
    <link:label id="lab_us-gaap_LitigationReserveCurrent_label_en-US" xlink:label="lab_us-gaap_LitigationReserveCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Litigation Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationReserveCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationReserveCurrent" xlink:to="lab_us-gaap_LitigationReserveCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ca611d31-88c9-4688-b73c-6dfd4bd1b75d_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_4eaab77d-dede-49b0-9d1b-f07fffe0986c_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_5fb67400-b641-479a-9fdb-7235b4cca1bd_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued royalties</link:label>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Royalties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedRoyaltiesCurrent" xlink:to="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_c3f04e80-dff6-4812-bb14-d96e8f636ddf_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_9de81533-666e-4f96-9bde-94aa6b423055_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock outstanding (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_ef56755c-026f-426e-a68f-26e068c18f91_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning common stock outstanding</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_23abe41e-970a-4427-9ead-356f8ddba72d_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock outstanding at end of period</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_58b3bc65-40fd-41de-afaf-9c9d23d2be4e_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale, Due after five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_86ee4c38-23c6-4b4e-8917-5abe61e18d4f_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of revenue</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_1257508e-f1fa-4e00-815a-b5d1bfc5a495_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherSundryLiabilitiesNoncurrent_c391101b-b94b-4633-a216-31e16c90ce27_terseLabel_en-US" xlink:label="lab_us-gaap_OtherSundryLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherSundryLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherSundryLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Sundry Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherSundryLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherSundryLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherSundryLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherSundryLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_c430554e-0c96-4c0e-a6ea-c003af8ad983_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInContractWithCustomerLiabilityAbstract_ce21952f-2ea8-4f49-a305-8b11f74529fa_terseLabel_en-US" xlink:label="lab_us-gaap_ChangeInContractWithCustomerLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Deferred Revenue</link:label>
    <link:label id="lab_us-gaap_ChangeInContractWithCustomerLiabilityAbstract_label_en-US" xlink:label="lab_us-gaap_ChangeInContractWithCustomerLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Contract with Customer, Liability [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInContractWithCustomerLiabilityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInContractWithCustomerLiabilityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInContractWithCustomerLiabilityAbstract" xlink:to="lab_us-gaap_ChangeInContractWithCustomerLiabilityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries_b834fac4-e475-444d-9583-94ddbf1876d7_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of business</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Divestiture of Interest in Consolidated Subsidiaries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries" xlink:to="lab_us-gaap_ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_152656ba-61cb-4f67-9eb1-ca49b85ab079_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Number of shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_OptionsAndRestrictedStockUnitsMember_59f879b1-22ce-4de2-a7bd-a66d32fcc4c8_terseLabel_en-US" xlink:label="lab_mygn_OptionsAndRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options and RSUs</link:label>
    <link:label id="lab_mygn_OptionsAndRestrictedStockUnitsMember_label_en-US" xlink:label="lab_mygn_OptionsAndRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options And Restricted Stock Units [Member]</link:label>
    <link:label id="lab_mygn_OptionsAndRestrictedStockUnitsMember_documentation_en-US" xlink:label="lab_mygn_OptionsAndRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options and Restricted Stock Units.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_OptionsAndRestrictedStockUnitsMember" xlink:href="mygn-20210930.xsd#mygn_OptionsAndRestrictedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_OptionsAndRestrictedStockUnitsMember" xlink:to="lab_mygn_OptionsAndRestrictedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardDateDomain_8f8a0dba-9292-40c5-947f-26feaa96c830_terseLabel_en-US" xlink:label="lab_us-gaap_AwardDateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Date [Domain]</link:label>
    <link:label id="lab_us-gaap_AwardDateDomain_label_en-US" xlink:label="lab_us-gaap_AwardDateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Date [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardDateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardDateDomain" xlink:to="lab_us-gaap_AwardDateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_50fdaf5f-a3b7-4055-bae2-68dee0c52b14_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Divestitures [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_b03c8529-2ba5-4d7e-a214-7bac8327d42f_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Property, Plant and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_36337e4e-c1b0-4175-ae77-2ed2940b3fc4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_182d7b89-de17-4202-a44d-8be98fc95bfc_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain" xlink:to="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_72ecb0e5-6b63-4463-bc00-7d1b995b620d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of additional shares authorized</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_53420cbb-907b-4a3d-9c5e-a3f3aeafa6ad_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer relationships</link:label>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_label_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Relationships [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerRelationshipsMember" xlink:to="lab_us-gaap_CustomerRelationshipsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_2ce5980a-b6cb-4c84-b0bc-04dfa64c3ee4_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale, Due within one year</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_befc3bfb-4a56-4cec-b33a-c940584dc793_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant, and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_bd740244-82c7-4aa1-ae14-6b64c600957c_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_3bd56fb7-3e21-4f67-ae03-bf5b7c9691cf_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_a27f0c5a-6eac-43eb-b52c-6ddb1087a0ef_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_a2f4e4df-5aae-47a2-bf6d-c721a0ca4e80_totalLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsAndCash_88095bb6-f36d-4762-a76a-ec3be90d4b2f_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsAndCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total, Estimated fair value</link:label>
    <link:label id="lab_us-gaap_InvestmentsAndCash_19b2f0f6-71fb-47e6-82e8-392836496719_totalLabel_en-US" xlink:label="lab_us-gaap_InvestmentsAndCash" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total, Estimated fair value</link:label>
    <link:label id="lab_us-gaap_InvestmentsAndCash_label_en-US" xlink:label="lab_us-gaap_InvestmentsAndCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments and Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAndCash" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsAndCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsAndCash" xlink:to="lab_us-gaap_InvestmentsAndCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_c67beb2e-3d30-453e-b240-968353509091_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_78044cb9-e704-4e10-8b8d-42b8ef658684_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_7344488e-b961-4469-a8bb-144aca9544c7_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_e8f55f55-e204-4b04-afb1-4bf560a54507_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_9863a267-48c9-4006-9a45-bd6e5cc19ea0_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_90553a45-3e05-47c6-9a8c-39a8e75c4563_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquipmentMember_bd84dfd6-1d30-4898-b800-1b854fe307e3_terseLabel_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment</link:label>
    <link:label id="lab_us-gaap_EquipmentMember_label_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember" xlink:to="lab_us-gaap_EquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TrademarksMember_069f0c86-3607-4a43-8f69-e9cfaceda4b7_terseLabel_en-US" xlink:label="lab_us-gaap_TrademarksMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks</link:label>
    <link:label id="lab_us-gaap_TrademarksMember_label_en-US" xlink:label="lab_us-gaap_TrademarksMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TrademarksMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TrademarksMember" xlink:to="lab_us-gaap_TrademarksMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_DebtInstrumentLIBORFloorPercentage_9e50e956-1094-4e5b-a75a-f760b60de2a1_terseLabel_en-US" xlink:label="lab_mygn_DebtInstrumentLIBORFloorPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIBOR floor (percent)</link:label>
    <link:label id="lab_mygn_DebtInstrumentLIBORFloorPercentage_label_en-US" xlink:label="lab_mygn_DebtInstrumentLIBORFloorPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, LIBOR Floor, Percentage</link:label>
    <link:label id="lab_mygn_DebtInstrumentLIBORFloorPercentage_documentation_en-US" xlink:label="lab_mygn_DebtInstrumentLIBORFloorPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, LIBOR Floor, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_DebtInstrumentLIBORFloorPercentage" xlink:href="mygn-20210930.xsd#mygn_DebtInstrumentLIBORFloorPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_DebtInstrumentLIBORFloorPercentage" xlink:to="lab_mygn_DebtInstrumentLIBORFloorPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7116ae6c-652b-4a82-b2b1-0b49d7f6d26d_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding, beginning (dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_867444e4-fee8-4a3a-9055-725e6e441cc9_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding, ending (dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_7f522d3c-6703-49a5-bfe9-c32adc0bc5fe_verboseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_e199ffdd-8f07-458f-967b-2e325aba6aab_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities, available-for-sale, in unrealized loss position</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_9d8b09cd-6b86-491f-b0fa-150263797889_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_74f54247-b56d-49c0-beb4-2cb70dee8134_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable" xlink:to="lab_us-gaap_ScheduleOfGoodwillTable" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNetNoncurrent_0dd35b63-703d-4dbb-8254-bf6082e2689f_terseLabel_en-US" xlink:label="lab_mygn_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNetNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net decrease in intangible assets due to sale</link:label>
    <link:label id="lab_mygn_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNetNoncurrent_label_en-US" xlink:label="lab_mygn_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNetNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Intangible Assets, Net, Noncurrent</link:label>
    <link:label id="lab_mygn_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNetNoncurrent_documentation_en-US" xlink:label="lab_mygn_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNetNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount classified as intangible assets, net of accumulated amortization, attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNetNoncurrent" xlink:href="mygn-20210930.xsd#mygn_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNetNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNetNoncurrent" xlink:to="lab_mygn_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNetNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_285ecb88-9c18-4a7e-b8db-5b21588143dd_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_MolecularDiagnosticHereditaryCancerTestingMember_e861ca7f-a885-401e-b2f9-665b6986b57c_terseLabel_en-US" xlink:label="lab_mygn_MolecularDiagnosticHereditaryCancerTestingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molecular diagnostic - Hereditary Cancer</link:label>
    <link:label id="lab_mygn_MolecularDiagnosticHereditaryCancerTestingMember_label_en-US" xlink:label="lab_mygn_MolecularDiagnosticHereditaryCancerTestingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molecular Diagnostic Hereditary Cancer Testing [Member]</link:label>
    <link:label id="lab_mygn_MolecularDiagnosticHereditaryCancerTestingMember_documentation_en-US" xlink:label="lab_mygn_MolecularDiagnosticHereditaryCancerTestingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molecular diagnostic hereditary cancer testing.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MolecularDiagnosticHereditaryCancerTestingMember" xlink:href="mygn-20210930.xsd#mygn_MolecularDiagnosticHereditaryCancerTestingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_MolecularDiagnosticHereditaryCancerTestingMember" xlink:to="lab_mygn_MolecularDiagnosticHereditaryCancerTestingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_6bfabe98-9144-46c9-8510-18abb362ecb5_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) per share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_08f0f1ca-265f-4e25-964e-2645f906e7ac_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs, Weighted average grant date fair value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_ed1fb973-def1-460a-9fd2-1b9b33c01e86_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SwissFederalTaxAdministrationFTAMember_c02c6a17-a22a-408f-a3f7-4abe9241c638_terseLabel_en-US" xlink:label="lab_us-gaap_SwissFederalTaxAdministrationFTAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Switzerland</link:label>
    <link:label id="lab_us-gaap_SwissFederalTaxAdministrationFTAMember_label_en-US" xlink:label="lab_us-gaap_SwissFederalTaxAdministrationFTAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Swiss Federal Tax Administration (FTA) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SwissFederalTaxAdministrationFTAMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SwissFederalTaxAdministrationFTAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SwissFederalTaxAdministrationFTAMember" xlink:to="lab_us-gaap_SwissFederalTaxAdministrationFTAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_16b98e1f-4f6a-4441-8bc9-35973456f9b9_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Approximate tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_236e36b3-d732-4f7f-8b14-468e8a46271d_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_0bcbe3a9-b759-45ef-9812-8a73f9ea4f22_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_e5958af3-a299-403e-8de6-023ea7866ba1_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from maturities and sales of marketable investment securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_2948f96c-23b1-482f-b1a1-742c25c1cb99_terseLabel_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_89f063d6-bb0d-4fed-8b46-8fbabdda5753_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at beginning of the period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4fca1579-137e-432a-affa-2510d9c679a1_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at end of the period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_e3feadaa-a930-46d1-80f2-b3510c82f464_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_8cf623d2-62b5-4077-882e-d33892abc6cf_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S.</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_16c702d7-8162-40fe-9211-22d3791a7e23_terseLabel_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued taxes payable</link:label>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_label_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxesPayableCurrent" xlink:to="lab_us-gaap_TaxesPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_c87f451e-6928-4dfe-a4ac-2ce2678c82fd_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_685ddaad-cce4-4286-8efb-2e4a187a29bd_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_026f33e7-1d34-4237-889a-8f45646250b4_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Carrying Amount, amortizable</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_85a6ea16-46ed-438b-8c82-f502316bd88e_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares available for issuance under the Plan</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardDateAxis_2bf81e1e-299f-408d-937d-354e7d4504c8_terseLabel_en-US" xlink:label="lab_us-gaap_AwardDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Date [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardDateAxis_label_en-US" xlink:label="lab_us-gaap_AwardDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardDateAxis" xlink:to="lab_us-gaap_AwardDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_2d3062f3-08e4-4bda-9159-ca9fc99b11eb_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_4381470a-70f1-4e28-8211-714cc68d4e35_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Amortizable Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_3f2fd372-13dd-4ff8-acc5-d32ce763d64b_terseLabel_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIBOR</link:label>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_label_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">London Interbank Offered Rate (LIBOR) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:to="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_1f3ef46c-3e37-49c1-b20e-bf5be513b96a_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_52becacc-47c8-43e9-99b7-c7299549e7c8_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain" xlink:to="lab_us-gaap_DisposalGroupClassificationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_44cb37ed-7e1a-4a6b-9d88-752c8157aaeb_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, Estimated fair value</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_b2e64c72-d120-4218-bdf5-3204caeba15c_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_57827aa5-5033-4804-92c8-88cb562f841a_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercised (shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_21679732-e847-4723-9223-f253f292c776_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_aa7c5c66-b6d5-4aef-b4b2-8f90e9f72eb2_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares outstanding and dilutive securities used to compute diluted EPS</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_d254187b-ef8b-4ee4-9667-45666e971733_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets included in sale</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Intangible Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarliestTaxYearMember_269957c6-3d77-4ab1-9796-b4a709c503f9_terseLabel_en-US" xlink:label="lab_us-gaap_EarliestTaxYearMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earliest tax year</link:label>
    <link:label id="lab_us-gaap_EarliestTaxYearMember_label_en-US" xlink:label="lab_us-gaap_EarliestTaxYearMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earliest Tax Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarliestTaxYearMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarliestTaxYearMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarliestTaxYearMember" xlink:to="lab_us-gaap_EarliestTaxYearMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_4667f22c-554a-46b1-b507-4f648c12c422_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_1ede190a-22ff-4991-a364-2f3c2219f8a7_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_038857a0-e5e1-42e0-8373-0fd350032a89_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidExpensesOther_67a7215b-3761-4671-bbba-2590499a6a84_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidExpensesOther_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expenses, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_5c9c6474-f4dc-4daa-9cae-325072b5af88_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis spread on rate (percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_7a62e21c-1eec-4f70-a3cc-b3910ebea3ad_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred and Common Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_ea2115fe-2316-4cc8-a66e-2235b37956f1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Amounts Recognized in Other Income</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:to="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_21faa9c0-97b2-4e64-baa2-ecce35e429f8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Potential Dilutive Common Shares</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_64888c3c-8311-4c2f-aeea-780ec9f1e751_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_44252caa-603e-4857-a00c-f8dbfe9438f4_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_9cae8279-3b61-406e-8a45-02c676b9c2ac_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_201d66f2-994f-41b7-bda4-e8da7ec740ff_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_cd8271b3-2c8b-4cf8-8211-cadf7eee3118_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_7f906f70-fc32-4abf-95c4-79350c529173_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f07ab04d-9aa2-482f-883b-5e8c31d61f4b_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_b3713458-8a94-46f3-9a96-352b77eea4e2_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5c994a74-58ed-4e53-8d90-915c49a0de71_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_22385beb-18bb-4d79-a9af-8e0b48fd71b8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs vested (dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_15b87a05-add7-4adb-80af-6fe5019ead46_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_6befffa5-e0d2-4e75-bb37-d9ca2743d018_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of tax withheld for common stock issued under stock-based compensation plans</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_a8183a70-1e93-439e-987c-8969a6cd2f7a_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Establishment of operating lease right-of-use assets and lease liabilities</link:label>
    <link:label id="lab_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Operating Activities, Lessee [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowOperatingActivitiesLesseeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:to="lab_us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_OptionsGrantedPriorToDecemberFiveTwentyTwelveMember_88185ea0-456f-4548-98d1-8c5e8e5c74c6_terseLabel_en-US" xlink:label="lab_mygn_OptionsGrantedPriorToDecemberFiveTwentyTwelveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards granted prior to December 5, 2012</link:label>
    <link:label id="lab_mygn_OptionsGrantedPriorToDecemberFiveTwentyTwelveMember_label_en-US" xlink:label="lab_mygn_OptionsGrantedPriorToDecemberFiveTwentyTwelveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options Granted Prior To December Five Twenty Twelve [Member]</link:label>
    <link:label id="lab_mygn_OptionsGrantedPriorToDecemberFiveTwentyTwelveMember_documentation_en-US" xlink:label="lab_mygn_OptionsGrantedPriorToDecemberFiveTwentyTwelveMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted prior to December 5, 2012.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_OptionsGrantedPriorToDecemberFiveTwentyTwelveMember" xlink:href="mygn-20210930.xsd#mygn_OptionsGrantedPriorToDecemberFiveTwentyTwelveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_OptionsGrantedPriorToDecemberFiveTwentyTwelveMember" xlink:to="lab_mygn_OptionsGrantedPriorToDecemberFiveTwentyTwelveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_86faeb7d-f94d-481f-a66c-c976f049d97a_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum aggregate principal commitment</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_9dd41013-54b9-4cb9-90c7-5817e6e9a980_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Translation adjustments</link:label>
    <link:label id="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Foreign Currency Translation Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:to="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_5a609559-12c4-410b-8b3e-924b8049b95a_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_6e9e420e-a3f4-45be-87a0-082436e70531_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_b23aa90d-ac78-4184-bfb0-bd7dec3fb581_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_ScheduleOfIntangibleAssetsTable_2371ba31-b09d-40c3-a6e0-28a177faf088_terseLabel_en-US" xlink:label="lab_mygn_ScheduleOfIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Intangible Assets [Table]</link:label>
    <link:label id="lab_mygn_ScheduleOfIntangibleAssetsTable_label_en-US" xlink:label="lab_mygn_ScheduleOfIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Intangible Assets [Table]</link:label>
    <link:label id="lab_mygn_ScheduleOfIntangibleAssetsTable_documentation_en-US" xlink:label="lab_mygn_ScheduleOfIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_ScheduleOfIntangibleAssetsTable" xlink:href="mygn-20210930.xsd#mygn_ScheduleOfIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_ScheduleOfIntangibleAssetsTable" xlink:to="lab_mygn_ScheduleOfIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CaliforniaFranchiseTaxBoardMember_369af8fc-3e28-4e43-bec3-68876a493455_terseLabel_en-US" xlink:label="lab_us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">California</link:label>
    <link:label id="lab_us-gaap_CaliforniaFranchiseTaxBoardMember_label_en-US" xlink:label="lab_us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">California Franchise Tax Board [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CaliforniaFranchiseTaxBoardMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:to="lab_us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_71ccb82e-0fca-41fc-86d7-a633ab901694_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_fe6cea39-a84f-41b5-84fc-09624286866e_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_6ee452fa-db37-4b54-ba56-b3ef2c7338de_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value of Financial Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_93fa3f29-d6bd-48c2-b504-6c1c05cce058_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_d6b8c384-66ea-4c8a-b2e3-f2f6ec28a1d4_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_DisposalGroupNotDiscontinuedOperationTransactionCosts_4404ed3a-d5bb-4f2d-8ec7-cd18d7d6d8e3_terseLabel_en-US" xlink:label="lab_mygn_DisposalGroupNotDiscontinuedOperationTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction costs</link:label>
    <link:label id="lab_mygn_DisposalGroupNotDiscontinuedOperationTransactionCosts_label_en-US" xlink:label="lab_mygn_DisposalGroupNotDiscontinuedOperationTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Not Discontinued Operation, Transaction Costs</link:label>
    <link:label id="lab_mygn_DisposalGroupNotDiscontinuedOperationTransactionCosts_documentation_en-US" xlink:label="lab_mygn_DisposalGroupNotDiscontinuedOperationTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Not Discontinued Operation, Transaction Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_DisposalGroupNotDiscontinuedOperationTransactionCosts" xlink:href="mygn-20210930.xsd#mygn_DisposalGroupNotDiscontinuedOperationTransactionCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_DisposalGroupNotDiscontinuedOperationTransactionCosts" xlink:to="lab_mygn_DisposalGroupNotDiscontinuedOperationTransactionCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_f60f4098-eb11-452e-83f2-bdd1505a5c4e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_c2c9db71-6b9c-4f11-b70c-d3b087e63f34_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_fa4e02bf-04eb-429c-82e1-b6f36f40c326_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_61702b72-797e-44dd-92b1-5caed1b625b7_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net, amortizable</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_050864fe-c81c-46f7-9e94-ea45411e3aeb_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_ce46b915-f109-4b39-a821-b9f87c39e315_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_abf67a2a-e5ca-4958-ba46-4f022efeb4d8_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_OtherAssetsDebtDiscount_bb2df877-80bc-4417-8936-fcd857d4ed44_terseLabel_en-US" xlink:label="lab_mygn_OtherAssetsDebtDiscount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt discount reclassified to other assets</link:label>
    <link:label id="lab_mygn_OtherAssetsDebtDiscount_label_en-US" xlink:label="lab_mygn_OtherAssetsDebtDiscount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Debt Discount</link:label>
    <link:label id="lab_mygn_OtherAssetsDebtDiscount_documentation_en-US" xlink:label="lab_mygn_OtherAssetsDebtDiscount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Debt Discount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_OtherAssetsDebtDiscount" xlink:href="mygn-20210930.xsd#mygn_OtherAssetsDebtDiscount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_OtherAssetsDebtDiscount" xlink:to="lab_mygn_OtherAssetsDebtDiscount" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_ReclassificationFromAccumulatedOtherComprehensiveLossDeconsolidationOfSubsidiary_b900e1b9-31c2-4afa-a893-31d7f1228737_terseLabel_en-US" xlink:label="lab_mygn_ReclassificationFromAccumulatedOtherComprehensiveLossDeconsolidationOfSubsidiary" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of accumulated other comprehensive loss upon the deconsolidation of a subsidiary</link:label>
    <link:label id="lab_mygn_ReclassificationFromAccumulatedOtherComprehensiveLossDeconsolidationOfSubsidiary_label_en-US" xlink:label="lab_mygn_ReclassificationFromAccumulatedOtherComprehensiveLossDeconsolidationOfSubsidiary" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification From Accumulated Other Comprehensive Loss, Deconsolidation Of Subsidiary</link:label>
    <link:label id="lab_mygn_ReclassificationFromAccumulatedOtherComprehensiveLossDeconsolidationOfSubsidiary_documentation_en-US" xlink:label="lab_mygn_ReclassificationFromAccumulatedOtherComprehensiveLossDeconsolidationOfSubsidiary" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification From Accumulated Other Comprehensive Loss, Deconsolidation Of Subsidiary</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_ReclassificationFromAccumulatedOtherComprehensiveLossDeconsolidationOfSubsidiary" xlink:href="mygn-20210930.xsd#mygn_ReclassificationFromAccumulatedOtherComprehensiveLossDeconsolidationOfSubsidiary"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_ReclassificationFromAccumulatedOtherComprehensiveLossDeconsolidationOfSubsidiary" xlink:to="lab_mygn_ReclassificationFromAccumulatedOtherComprehensiveLossDeconsolidationOfSubsidiary" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RecordedUnconditionalPurchaseObligation_c5836b6c-5c4d-4ba9-9ef0-0ece62bbbf9c_terseLabel_en-US" xlink:label="lab_us-gaap_RecordedUnconditionalPurchaseObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase commitment</link:label>
    <link:label id="lab_us-gaap_RecordedUnconditionalPurchaseObligation_label_en-US" xlink:label="lab_us-gaap_RecordedUnconditionalPurchaseObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recorded Unconditional Purchase Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RecordedUnconditionalPurchaseObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RecordedUnconditionalPurchaseObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RecordedUnconditionalPurchaseObligation" xlink:to="lab_us-gaap_RecordedUnconditionalPurchaseObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_022c8a75-7766-404f-8444-ebd2cbcf56ab_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-controlling interest</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans_feed2829-4182-40bb-ad30-a8364e7f7c54_terseLabel_en-US" xlink:label="lab_mygn_StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued upon exercise of options, vesting of restricted stock units, and purchases under employee stock purchase plan</link:label>
    <link:label id="lab_mygn_StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_mygn_StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Share-Based Payment Arrangement And Employee Stock Purchase Plans</link:label>
    <link:label id="lab_mygn_StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans_documentation_en-US" xlink:label="lab_mygn_StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Share-Based Payment Arrangement And Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans" xlink:href="mygn-20210930.xsd#mygn_StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans" xlink:to="lab_mygn_StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_b00f2eb7-92a6-44c1-9df4-862d7bcda64e_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_03bb27b0-9c02-42a3-a9f4-b4749425f8d6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Changes in Carrying Amount of Goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_55a868b2-04f7-4cda-9e4f-595170418478_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_16f09479-3258-4786-be8a-553f39812606_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale, Due within one year</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_44a8f094-4b29-45cf-9cf2-a40a0f098e36_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_a80442a0-cfd6-41f5-8228-2d1983419bcc_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock_fe0ce902-ca9f-4a89-92e9-7f2aef1f8ef2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Common Shares Issued and Outstanding</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Common Stock Outstanding Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_MolecularDiagnosticTestingMember_ff691306-f204-45c8-b24e-2112c468b8e0_terseLabel_en-US" xlink:label="lab_mygn_MolecularDiagnosticTestingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molecular diagnostic testing</link:label>
    <link:label id="lab_mygn_MolecularDiagnosticTestingMember_label_en-US" xlink:label="lab_mygn_MolecularDiagnosticTestingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molecular Diagnostic Testing [Member]</link:label>
    <link:label id="lab_mygn_MolecularDiagnosticTestingMember_documentation_en-US" xlink:label="lab_mygn_MolecularDiagnosticTestingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molecular diagnostic testing.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MolecularDiagnosticTestingMember" xlink:href="mygn-20210930.xsd#mygn_MolecularDiagnosticTestingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_MolecularDiagnosticTestingMember" xlink:to="lab_mygn_MolecularDiagnosticTestingMember" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>mygn-20210930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:902b74c1-bcf1-4420-82df-87d4ebd2f6e9,g:dcd0bc70-dec4-4a37-a022-ac912887efc6-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.myriad.com/role/Cover" xlink:type="simple" xlink:href="mygn-20210930.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_fd6e2bfa-910a-4b44-b4bf-702b5e1438a4" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_ce228845-f88f-4335-bdbe-f41467639322" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fd6e2bfa-910a-4b44-b4bf-702b5e1438a4" xlink:to="loc_dei_DocumentType_ce228845-f88f-4335-bdbe-f41467639322" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_799db6b6-4652-474b-9238-1f1b98a819c9" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fd6e2bfa-910a-4b44-b4bf-702b5e1438a4" xlink:to="loc_dei_DocumentQuarterlyReport_799db6b6-4652-474b-9238-1f1b98a819c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_33449cc5-788a-4b41-94a4-a355d7ced91a" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fd6e2bfa-910a-4b44-b4bf-702b5e1438a4" xlink:to="loc_dei_DocumentPeriodEndDate_33449cc5-788a-4b41-94a4-a355d7ced91a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_f82e6c52-8755-48e9-b5b5-fc5afd2daa9d" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fd6e2bfa-910a-4b44-b4bf-702b5e1438a4" xlink:to="loc_dei_DocumentTransitionReport_f82e6c52-8755-48e9-b5b5-fc5afd2daa9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_2399f24e-4f91-4553-9866-75425d741033" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fd6e2bfa-910a-4b44-b4bf-702b5e1438a4" xlink:to="loc_dei_EntityFileNumber_2399f24e-4f91-4553-9866-75425d741033" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_9dab6225-4523-4942-89fe-aafe1ff0cdb3" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fd6e2bfa-910a-4b44-b4bf-702b5e1438a4" xlink:to="loc_dei_EntityRegistrantName_9dab6225-4523-4942-89fe-aafe1ff0cdb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_f889865b-3e0c-46d9-bef3-28704d42617f" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fd6e2bfa-910a-4b44-b4bf-702b5e1438a4" xlink:to="loc_dei_EntityCentralIndexKey_f889865b-3e0c-46d9-bef3-28704d42617f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_b4bacc5c-a528-4a8a-b821-02316b49aa36" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fd6e2bfa-910a-4b44-b4bf-702b5e1438a4" xlink:to="loc_dei_CurrentFiscalYearEndDate_b4bacc5c-a528-4a8a-b821-02316b49aa36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_ab52fd8b-1dc3-48be-8afe-5b9d86b7081e" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fd6e2bfa-910a-4b44-b4bf-702b5e1438a4" xlink:to="loc_dei_DocumentFiscalYearFocus_ab52fd8b-1dc3-48be-8afe-5b9d86b7081e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_a365fdad-4dc3-4d69-922e-4ce85add1f81" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fd6e2bfa-910a-4b44-b4bf-702b5e1438a4" xlink:to="loc_dei_DocumentFiscalPeriodFocus_a365fdad-4dc3-4d69-922e-4ce85add1f81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_ce17fa7f-9a92-4cd3-b08c-d60ce2cd4e1a" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fd6e2bfa-910a-4b44-b4bf-702b5e1438a4" xlink:to="loc_dei_AmendmentFlag_ce17fa7f-9a92-4cd3-b08c-d60ce2cd4e1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_9dc63384-aeb0-489b-a638-b653d3851026" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fd6e2bfa-910a-4b44-b4bf-702b5e1438a4" xlink:to="loc_dei_EntityIncorporationStateCountryCode_9dc63384-aeb0-489b-a638-b653d3851026" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_6a334b14-ed01-414a-8431-6b4e3b32a25e" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fd6e2bfa-910a-4b44-b4bf-702b5e1438a4" xlink:to="loc_dei_EntityTaxIdentificationNumber_6a334b14-ed01-414a-8431-6b4e3b32a25e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_e3bedb72-a6ac-4633-bed8-051828a66a40" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fd6e2bfa-910a-4b44-b4bf-702b5e1438a4" xlink:to="loc_dei_EntityAddressAddressLine1_e3bedb72-a6ac-4633-bed8-051828a66a40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_15bc8f03-e574-4788-9824-36fa81c0e349" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fd6e2bfa-910a-4b44-b4bf-702b5e1438a4" xlink:to="loc_dei_EntityAddressCityOrTown_15bc8f03-e574-4788-9824-36fa81c0e349" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_fa89d98c-f3c2-44da-9172-d8b913fa560a" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fd6e2bfa-910a-4b44-b4bf-702b5e1438a4" xlink:to="loc_dei_EntityAddressStateOrProvince_fa89d98c-f3c2-44da-9172-d8b913fa560a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_63c35349-cf0c-4e71-ae33-1129ede931e2" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fd6e2bfa-910a-4b44-b4bf-702b5e1438a4" xlink:to="loc_dei_EntityAddressPostalZipCode_63c35349-cf0c-4e71-ae33-1129ede931e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_6d053d9a-253a-4e9c-83f8-f0357b65b017" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fd6e2bfa-910a-4b44-b4bf-702b5e1438a4" xlink:to="loc_dei_CityAreaCode_6d053d9a-253a-4e9c-83f8-f0357b65b017" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_1828bfa0-831b-4142-a5e2-66b5de660c46" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fd6e2bfa-910a-4b44-b4bf-702b5e1438a4" xlink:to="loc_dei_LocalPhoneNumber_1828bfa0-831b-4142-a5e2-66b5de660c46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_483e080f-a494-475c-8f29-821ce9611613" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fd6e2bfa-910a-4b44-b4bf-702b5e1438a4" xlink:to="loc_dei_Security12bTitle_483e080f-a494-475c-8f29-821ce9611613" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_13d62288-8eb9-41e4-a0d6-b70e56ff335c" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fd6e2bfa-910a-4b44-b4bf-702b5e1438a4" xlink:to="loc_dei_TradingSymbol_13d62288-8eb9-41e4-a0d6-b70e56ff335c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_1e8ffadd-0a31-45c6-918b-f74477450b5a" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fd6e2bfa-910a-4b44-b4bf-702b5e1438a4" xlink:to="loc_dei_SecurityExchangeName_1e8ffadd-0a31-45c6-918b-f74477450b5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_3b8623ec-9568-4d9f-bbea-09d348461586" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fd6e2bfa-910a-4b44-b4bf-702b5e1438a4" xlink:to="loc_dei_EntityCurrentReportingStatus_3b8623ec-9568-4d9f-bbea-09d348461586" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_0ec790c5-513f-47d9-a4fc-78df47bb731d" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fd6e2bfa-910a-4b44-b4bf-702b5e1438a4" xlink:to="loc_dei_EntityInteractiveDataCurrent_0ec790c5-513f-47d9-a4fc-78df47bb731d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_0eb3bbe5-96c0-420b-aa3a-c942a00f0735" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fd6e2bfa-910a-4b44-b4bf-702b5e1438a4" xlink:to="loc_dei_EntityFilerCategory_0eb3bbe5-96c0-420b-aa3a-c942a00f0735" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_d2eebe6a-887e-4faa-bd27-b84f5bb704d5" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fd6e2bfa-910a-4b44-b4bf-702b5e1438a4" xlink:to="loc_dei_EntitySmallBusiness_d2eebe6a-887e-4faa-bd27-b84f5bb704d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_01930043-7d1b-4936-ae11-c4c2e67e8a1d" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fd6e2bfa-910a-4b44-b4bf-702b5e1438a4" xlink:to="loc_dei_EntityEmergingGrowthCompany_01930043-7d1b-4936-ae11-c4c2e67e8a1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_cc96b307-3c5d-4edc-84f6-059b9b98b19e" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fd6e2bfa-910a-4b44-b4bf-702b5e1438a4" xlink:to="loc_dei_EntityShellCompany_cc96b307-3c5d-4edc-84f6-059b9b98b19e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_19ae082c-5a7c-4ebc-88b7-b24e27a022a7" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fd6e2bfa-910a-4b44-b4bf-702b5e1438a4" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_19ae082c-5a7c-4ebc-88b7-b24e27a022a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="mygn-20210930.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_7a488107-e5de-4217-b146-26b9e4e1deea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_6a8c71e9-4373-46ee-a8f8-0055e5959071" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_7a488107-e5de-4217-b146-26b9e4e1deea" xlink:to="loc_us-gaap_AssetsAbstract_6a8c71e9-4373-46ee-a8f8-0055e5959071" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_4d844769-8b29-4f5c-930d-007e3f34e71b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6a8c71e9-4373-46ee-a8f8-0055e5959071" xlink:to="loc_us-gaap_AssetsCurrentAbstract_4d844769-8b29-4f5c-930d-007e3f34e71b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6b48f7c0-8d85-46fb-ac5d-ab46dd62b9a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4d844769-8b29-4f5c-930d-007e3f34e71b" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6b48f7c0-8d85-46fb-ac5d-ab46dd62b9a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_b77386ab-92cf-407b-a1e7-89e60baeddd7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4d844769-8b29-4f5c-930d-007e3f34e71b" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_b77386ab-92cf-407b-a1e7-89e60baeddd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_40d4e97a-f2a0-4a82-95b4-17442cecd3e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4d844769-8b29-4f5c-930d-007e3f34e71b" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_40d4e97a-f2a0-4a82-95b4-17442cecd3e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_d7ca10fd-6e55-40af-ac53-920ab8c3973d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4d844769-8b29-4f5c-930d-007e3f34e71b" xlink:to="loc_us-gaap_InventoryNet_d7ca10fd-6e55-40af-ac53-920ab8c3973d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidTaxes_30e090ad-0061-4255-a76a-e5b0194b58d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidTaxes"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4d844769-8b29-4f5c-930d-007e3f34e71b" xlink:to="loc_us-gaap_PrepaidTaxes_30e090ad-0061-4255-a76a-e5b0194b58d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_aa0871e4-e539-4a85-b073-056311790244" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4d844769-8b29-4f5c-930d-007e3f34e71b" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_aa0871e4-e539-4a85-b073-056311790244" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_df0b4514-072f-4e83-af90-90dec788cf95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4d844769-8b29-4f5c-930d-007e3f34e71b" xlink:to="loc_us-gaap_AssetsCurrent_df0b4514-072f-4e83-af90-90dec788cf95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_13c85ffd-f5ba-4246-8f36-5495b9ed0895" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6a8c71e9-4373-46ee-a8f8-0055e5959071" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_13c85ffd-f5ba-4246-8f36-5495b9ed0895" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_f4a2f43d-64b4-40e0-9d6c-f152bf0bb03b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6a8c71e9-4373-46ee-a8f8-0055e5959071" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_f4a2f43d-64b4-40e0-9d6c-f152bf0bb03b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_baead262-dea7-42b1-926a-59cbbe8a60a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6a8c71e9-4373-46ee-a8f8-0055e5959071" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_baead262-dea7-42b1-926a-59cbbe8a60a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_6618abbb-45b5-4a77-a3bb-0f8345a0454b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6a8c71e9-4373-46ee-a8f8-0055e5959071" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_6618abbb-45b5-4a77-a3bb-0f8345a0454b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_9de74dbd-edb0-4e07-b01f-2e480aa13aba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6a8c71e9-4373-46ee-a8f8-0055e5959071" xlink:to="loc_us-gaap_Goodwill_9de74dbd-edb0-4e07-b01f-2e480aa13aba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_10e4c0f6-0655-4178-b703-1ef7f367732c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6a8c71e9-4373-46ee-a8f8-0055e5959071" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_10e4c0f6-0655-4178-b703-1ef7f367732c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_f5f007a4-2510-42f4-ae2e-808b408534f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6a8c71e9-4373-46ee-a8f8-0055e5959071" xlink:to="loc_us-gaap_Assets_f5f007a4-2510-42f4-ae2e-808b408534f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_89075dd7-fe1e-4db4-b4d1-46ae8a5437e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_7a488107-e5de-4217-b146-26b9e4e1deea" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_89075dd7-fe1e-4db4-b4d1-46ae8a5437e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_407d9a5a-c47a-4bcf-9a2d-1054ac1dd76b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_89075dd7-fe1e-4db4-b4d1-46ae8a5437e5" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_407d9a5a-c47a-4bcf-9a2d-1054ac1dd76b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_a2a762a5-c7a3-48ff-a0ae-de18a85f8c1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_407d9a5a-c47a-4bcf-9a2d-1054ac1dd76b" xlink:to="loc_us-gaap_AccountsPayableCurrent_a2a762a5-c7a3-48ff-a0ae-de18a85f8c1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_a29d4809-d1df-42a1-b466-f7352a5d0545" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_407d9a5a-c47a-4bcf-9a2d-1054ac1dd76b" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_a29d4809-d1df-42a1-b466-f7352a5d0545" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_5f9c608d-cd3a-473b-86c8-15fadaa9f737" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_407d9a5a-c47a-4bcf-9a2d-1054ac1dd76b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_5f9c608d-cd3a-473b-86c8-15fadaa9f737" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_94f5f871-ecfb-43f1-9f65-e253f3c187d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_407d9a5a-c47a-4bcf-9a2d-1054ac1dd76b" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_94f5f871-ecfb-43f1-9f65-e253f3c187d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_d63869ef-5204-4768-b9c1-f12942e74a0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_407d9a5a-c47a-4bcf-9a2d-1054ac1dd76b" xlink:to="loc_us-gaap_LiabilitiesCurrent_d63869ef-5204-4768-b9c1-f12942e74a0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_c19bf747-42c4-4365-91a3-b44ae6122069" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_89075dd7-fe1e-4db4-b4d1-46ae8a5437e5" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_c19bf747-42c4-4365-91a3-b44ae6122069" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_bc06a9b0-c374-41a0-ae64-8d708e37cb3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_89075dd7-fe1e-4db4-b4d1-46ae8a5437e5" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_bc06a9b0-c374-41a0-ae64-8d708e37cb3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_dc4c4da7-950c-444c-9d0a-5345e5625f9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_89075dd7-fe1e-4db4-b4d1-46ae8a5437e5" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_dc4c4da7-950c-444c-9d0a-5345e5625f9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_217d03ab-7f9e-4f8c-8189-a71c1da0f0e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_89075dd7-fe1e-4db4-b4d1-46ae8a5437e5" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_217d03ab-7f9e-4f8c-8189-a71c1da0f0e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_8228b403-b7fe-44e1-b430-44c3b91a942d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_89075dd7-fe1e-4db4-b4d1-46ae8a5437e5" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_8228b403-b7fe-44e1-b430-44c3b91a942d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_0621635b-1459-439d-aae3-9eb7ffcb022b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_89075dd7-fe1e-4db4-b4d1-46ae8a5437e5" xlink:to="loc_us-gaap_Liabilities_0621635b-1459-439d-aae3-9eb7ffcb022b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_da11b958-ae54-41d7-9d4b-1cfd0c599c31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_89075dd7-fe1e-4db4-b4d1-46ae8a5437e5" xlink:to="loc_us-gaap_CommitmentsAndContingencies_da11b958-ae54-41d7-9d4b-1cfd0c599c31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_fb443da6-3536-4ead-8d4c-1c55a2b7c94d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_89075dd7-fe1e-4db4-b4d1-46ae8a5437e5" xlink:to="loc_us-gaap_StockholdersEquityAbstract_fb443da6-3536-4ead-8d4c-1c55a2b7c94d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_e4ac88b0-5781-4d91-bc6b-3a7f36d30516" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_fb443da6-3536-4ead-8d4c-1c55a2b7c94d" xlink:to="loc_us-gaap_CommonStockValue_e4ac88b0-5781-4d91-bc6b-3a7f36d30516" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_14ca4c29-4a0f-4f11-a95b-216770a046bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_fb443da6-3536-4ead-8d4c-1c55a2b7c94d" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_14ca4c29-4a0f-4f11-a95b-216770a046bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_c991e0b2-212e-41b2-afd4-896f70e2fc57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_fb443da6-3536-4ead-8d4c-1c55a2b7c94d" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_c991e0b2-212e-41b2-afd4-896f70e2fc57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d53b7e8e-d72c-4376-802d-98611221ec7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_fb443da6-3536-4ead-8d4c-1c55a2b7c94d" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d53b7e8e-d72c-4376-802d-98611221ec7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_fdf33e2b-8349-4042-bdf4-1314db4b421a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_fb443da6-3536-4ead-8d4c-1c55a2b7c94d" xlink:to="loc_us-gaap_StockholdersEquity_fdf33e2b-8349-4042-bdf4-1314db4b421a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_fa6c9c1b-afbd-487e-aafa-2333f73ceb75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_fb443da6-3536-4ead-8d4c-1c55a2b7c94d" xlink:to="loc_us-gaap_MinorityInterest_fa6c9c1b-afbd-487e-aafa-2333f73ceb75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d944636a-290f-4d77-b77c-d61744b8a04a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_fb443da6-3536-4ead-8d4c-1c55a2b7c94d" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d944636a-290f-4d77-b77c-d61744b8a04a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_2f58766b-bbb4-477a-adb9-43be59949f42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_89075dd7-fe1e-4db4-b4d1-46ae8a5437e5" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_2f58766b-bbb4-477a-adb9-43be59949f42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="mygn-20210930.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_6d8c3981-5167-48a1-8152-bc0a0df10643" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_ce9214be-cc3f-4a0d-8dd5-6471f8e8fe9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_6d8c3981-5167-48a1-8152-bc0a0df10643" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_ce9214be-cc3f-4a0d-8dd5-6471f8e8fe9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="mygn-20210930.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_e4826946-ec8d-4ddc-9ac8-f03666b2a90e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_0b3ab670-e046-4c72-9649-2a5080404ff4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e4826946-ec8d-4ddc-9ac8-f03666b2a90e" xlink:to="loc_us-gaap_StatementTable_0b3ab670-e046-4c72-9649-2a5080404ff4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_86646e96-e32f-4819-a414-6d45899fd43d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_0b3ab670-e046-4c72-9649-2a5080404ff4" xlink:to="loc_srt_ProductOrServiceAxis_86646e96-e32f-4819-a414-6d45899fd43d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_958e10e3-10d8-44c7-9638-af3ecfbfa3c5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_86646e96-e32f-4819-a414-6d45899fd43d" xlink:to="loc_srt_ProductsAndServicesDomain_958e10e3-10d8-44c7-9638-af3ecfbfa3c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MolecularDiagnosticTestingMember_8ce65b9f-97ad-49dc-b968-1a7977316606" xlink:href="mygn-20210930.xsd#mygn_MolecularDiagnosticTestingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_958e10e3-10d8-44c7-9638-af3ecfbfa3c5" xlink:to="loc_mygn_MolecularDiagnosticTestingMember_8ce65b9f-97ad-49dc-b968-1a7977316606" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_PharmaceuticalAndClinicalServicesMember_b83087cc-67fa-42f7-b156-146a7badd55b" xlink:href="mygn-20210930.xsd#mygn_PharmaceuticalAndClinicalServicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_958e10e3-10d8-44c7-9638-af3ecfbfa3c5" xlink:to="loc_mygn_PharmaceuticalAndClinicalServicesMember_b83087cc-67fa-42f7-b156-146a7badd55b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_23011d84-d800-44ec-b413-65a37ccb4905" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_0b3ab670-e046-4c72-9649-2a5080404ff4" xlink:to="loc_us-gaap_StatementLineItems_23011d84-d800-44ec-b413-65a37ccb4905" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_fe57c1bb-f2c0-4167-8e3c-ae9d32466c14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_23011d84-d800-44ec-b413-65a37ccb4905" xlink:to="loc_us-gaap_RevenuesAbstract_fe57c1bb-f2c0-4167-8e3c-ae9d32466c14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2dd416c1-0984-4c30-9ec2-76e77dc905ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_fe57c1bb-f2c0-4167-8e3c-ae9d32466c14" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2dd416c1-0984-4c30-9ec2-76e77dc905ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpensesAbstract_f0d983c2-647b-46e5-81f2-ce4e2b0fc029" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingCostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_23011d84-d800-44ec-b413-65a37ccb4905" xlink:to="loc_us-gaap_OperatingCostsAndExpensesAbstract_f0d983c2-647b-46e5-81f2-ce4e2b0fc029" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_708bd73b-3b99-4c21-a3d7-c67cbc2aa3a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_f0d983c2-647b-46e5-81f2-ce4e2b0fc029" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_708bd73b-3b99-4c21-a3d7-c67cbc2aa3a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_e57910f3-492f-430f-bc08-8b02bf308ace" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_f0d983c2-647b-46e5-81f2-ce4e2b0fc029" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_e57910f3-492f-430f-bc08-8b02bf308ace" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_b4ad3058-4fdd-44b6-b602-df6823abad8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_f0d983c2-647b-46e5-81f2-ce4e2b0fc029" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_b4ad3058-4fdd-44b6-b602-df6823abad8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_c5cc1342-88dc-49ab-9abd-4034c7e2f3b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_f0d983c2-647b-46e5-81f2-ce4e2b0fc029" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_c5cc1342-88dc-49ab-9abd-4034c7e2f3b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_f2eab170-cd97-434d-9069-5eec9db3f7ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_f0d983c2-647b-46e5-81f2-ce4e2b0fc029" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_f2eab170-cd97-434d-9069-5eec9db3f7ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_4526101f-fb21-4f6f-a788-fad459a20294" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_f0d983c2-647b-46e5-81f2-ce4e2b0fc029" xlink:to="loc_us-gaap_CostsAndExpenses_4526101f-fb21-4f6f-a788-fad459a20294" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_65e74bf7-54da-44b7-8aa1-4b91d1f1cf21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_23011d84-d800-44ec-b413-65a37ccb4905" xlink:to="loc_us-gaap_OperatingIncomeLoss_65e74bf7-54da-44b7-8aa1-4b91d1f1cf21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_812b425f-d9d0-482c-b3c5-7221f4070577" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_23011d84-d800-44ec-b413-65a37ccb4905" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_812b425f-d9d0-482c-b3c5-7221f4070577" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_3bba6a49-a6da-4a0b-826f-b1f5c49a69ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_812b425f-d9d0-482c-b3c5-7221f4070577" xlink:to="loc_us-gaap_InvestmentIncomeInterest_3bba6a49-a6da-4a0b-826f-b1f5c49a69ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_3bb7e439-3f8d-4724-a23b-8f9087b1a70f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_812b425f-d9d0-482c-b3c5-7221f4070577" xlink:to="loc_us-gaap_InterestExpense_3bb7e439-3f8d-4724-a23b-8f9087b1a70f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_0be09068-77ed-4575-a7db-eb0ca852cecf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_812b425f-d9d0-482c-b3c5-7221f4070577" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_0be09068-77ed-4575-a7db-eb0ca852cecf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_50f0108a-6f68-4640-a651-86990cf6eabb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_812b425f-d9d0-482c-b3c5-7221f4070577" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_50f0108a-6f68-4640-a651-86990cf6eabb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c52a18dd-3da8-449a-b05b-9a1e908f884c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_23011d84-d800-44ec-b413-65a37ccb4905" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c52a18dd-3da8-449a-b05b-9a1e908f884c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_828873a8-e57d-485f-9139-68e69c0ddc5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_23011d84-d800-44ec-b413-65a37ccb4905" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_828873a8-e57d-485f-9139-68e69c0ddc5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_ffd69428-48e7-4827-9175-f0341d8cf347" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_23011d84-d800-44ec-b413-65a37ccb4905" xlink:to="loc_us-gaap_ProfitLoss_ffd69428-48e7-4827-9175-f0341d8cf347" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_5cb82024-c5d4-493c-bc3b-3a9b4a70b8e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_23011d84-d800-44ec-b413-65a37ccb4905" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_5cb82024-c5d4-493c-bc3b-3a9b4a70b8e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b2682513-4293-4e11-8073-357241adee5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_23011d84-d800-44ec-b413-65a37ccb4905" xlink:to="loc_us-gaap_NetIncomeLoss_b2682513-4293-4e11-8073-357241adee5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_39334061-8e7f-41be-92f5-9bf7e2714f58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_23011d84-d800-44ec-b413-65a37ccb4905" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_39334061-8e7f-41be-92f5-9bf7e2714f58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_f46ca6c2-5aa5-40c9-82f3-a1af2ad8698d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_39334061-8e7f-41be-92f5-9bf7e2714f58" xlink:to="loc_us-gaap_EarningsPerShareBasic_f46ca6c2-5aa5-40c9-82f3-a1af2ad8698d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_c7ba0e80-0079-49b4-9547-73b0b72402f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_39334061-8e7f-41be-92f5-9bf7e2714f58" xlink:to="loc_us-gaap_EarningsPerShareDiluted_c7ba0e80-0079-49b4-9547-73b0b72402f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_1b2ee9cc-5799-4af2-8412-35d3dd4ceffe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_23011d84-d800-44ec-b413-65a37ccb4905" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_1b2ee9cc-5799-4af2-8412-35d3dd4ceffe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_a3f36810-f3ab-4b24-80c5-48bbd216b15a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_1b2ee9cc-5799-4af2-8412-35d3dd4ceffe" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_a3f36810-f3ab-4b24-80c5-48bbd216b15a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6ed96005-b85e-445d-b64f-3879dd454c0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_1b2ee9cc-5799-4af2-8412-35d3dd4ceffe" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6ed96005-b85e-445d-b64f-3879dd454c0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss" xlink:type="simple" xlink:href="mygn-20210930.xsd#CondensedConsolidatedStatementsofComprehensiveIncomeLoss"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_b337d30e-dc75-42fb-a098-aa0b6f2606af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8d290693-dad4-4bc3-b157-b937ef33cf57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_b337d30e-dc75-42fb-a098-aa0b6f2606af" xlink:to="loc_us-gaap_NetIncomeLoss_8d290693-dad4-4bc3-b157-b937ef33cf57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_2a782db1-f7c7-4500-bbd9-ca56e4b0d75d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_b337d30e-dc75-42fb-a098-aa0b6f2606af" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_2a782db1-f7c7-4500-bbd9-ca56e4b0d75d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_3373c93f-fc5c-4f48-88f6-ad7713bff991" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_b337d30e-dc75-42fb-a098-aa0b6f2606af" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_3373c93f-fc5c-4f48-88f6-ad7713bff991" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_2b733015-9c8b-4c27-9f69-d4a92df4daed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_b337d30e-dc75-42fb-a098-aa0b6f2606af" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_2b733015-9c8b-4c27-9f69-d4a92df4daed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_7c818f93-a99a-4680-95ba-bb343b9d40d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_b337d30e-dc75-42fb-a098-aa0b6f2606af" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_7c818f93-a99a-4680-95ba-bb343b9d40d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="mygn-20210930.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_3b94d4b3-408d-4b8b-823f-fd3151045dd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_9c46c0f2-e781-4d0d-94e5-a74f832da30d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_3b94d4b3-408d-4b8b-823f-fd3151045dd2" xlink:to="loc_us-gaap_StatementTable_9c46c0f2-e781-4d0d-94e5-a74f832da30d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_c00686a9-0a4a-455b-8f23-1850ee9c58c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_9c46c0f2-e781-4d0d-94e5-a74f832da30d" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_c00686a9-0a4a-455b-8f23-1850ee9c58c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_75eaecda-bf7d-44f1-944a-fc934ead12d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c00686a9-0a4a-455b-8f23-1850ee9c58c3" xlink:to="loc_us-gaap_EquityComponentDomain_75eaecda-bf7d-44f1-944a-fc934ead12d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_aab72022-7357-4756-b99f-b2375d61cb21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_75eaecda-bf7d-44f1-944a-fc934ead12d7" xlink:to="loc_us-gaap_CommonStockMember_aab72022-7357-4756-b99f-b2375d61cb21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_c9dd078c-f6f1-46d7-8e77-495f239da16b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_75eaecda-bf7d-44f1-944a-fc934ead12d7" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_c9dd078c-f6f1-46d7-8e77-495f239da16b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0223b0d0-2c35-436a-acf0-fbe51d4b6715" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_75eaecda-bf7d-44f1-944a-fc934ead12d7" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0223b0d0-2c35-436a-acf0-fbe51d4b6715" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_3287d829-f584-4f5d-ad6d-d83e4af41cbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_75eaecda-bf7d-44f1-944a-fc934ead12d7" xlink:to="loc_us-gaap_RetainedEarningsMember_3287d829-f584-4f5d-ad6d-d83e4af41cbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_752026a3-a6b7-4d06-ab00-6d04a03e4728" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_75eaecda-bf7d-44f1-944a-fc934ead12d7" xlink:to="loc_us-gaap_NoncontrollingInterestMember_752026a3-a6b7-4d06-ab00-6d04a03e4728" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_82138a41-ee20-4193-b9fb-86b128ec801a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_9c46c0f2-e781-4d0d-94e5-a74f832da30d" xlink:to="loc_us-gaap_StatementLineItems_82138a41-ee20-4193-b9fb-86b128ec801a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_165f2c44-9cb0-4049-9186-25c290686ae9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_82138a41-ee20-4193-b9fb-86b128ec801a" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_165f2c44-9cb0-4049-9186-25c290686ae9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_ce80bc4e-2ba5-4d03-9ba1-cb092528567a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_82138a41-ee20-4193-b9fb-86b128ec801a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_ce80bc4e-2ba5-4d03-9ba1-cb092528567a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_9f66e066-ba50-4f44-bf10-aee8e04f7a1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_82138a41-ee20-4193-b9fb-86b128ec801a" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_9f66e066-ba50-4f44-bf10-aee8e04f7a1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestPeriodIncreaseDecrease_19d4beb1-ee78-449a-b7e8-401f16ff45c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestPeriodIncreaseDecrease"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_82138a41-ee20-4193-b9fb-86b128ec801a" xlink:to="loc_us-gaap_MinorityInterestPeriodIncreaseDecrease_19d4beb1-ee78-449a-b7e8-401f16ff45c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0ae3d893-e269-460b-bcee-d135c8d4990e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_82138a41-ee20-4193-b9fb-86b128ec801a" xlink:to="loc_us-gaap_NetIncomeLoss_0ae3d893-e269-460b-bcee-d135c8d4990e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_ReclassificationFromAccumulatedOtherComprehensiveLossDeconsolidationOfSubsidiary_d4a43c81-15fd-4076-9c98-9b9ce997cafa" xlink:href="mygn-20210930.xsd#mygn_ReclassificationFromAccumulatedOtherComprehensiveLossDeconsolidationOfSubsidiary"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_82138a41-ee20-4193-b9fb-86b128ec801a" xlink:to="loc_mygn_ReclassificationFromAccumulatedOtherComprehensiveLossDeconsolidationOfSubsidiary_d4a43c81-15fd-4076-9c98-9b9ce997cafa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_726e1634-1466-49b2-886e-004bb3eee485" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_82138a41-ee20-4193-b9fb-86b128ec801a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_726e1634-1466-49b2-886e-004bb3eee485" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5c0d08aa-ed7e-4c4b-99fc-ea8bb022b361" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_82138a41-ee20-4193-b9fb-86b128ec801a" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5c0d08aa-ed7e-4c4b-99fc-ea8bb022b361" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="mygn-20210930.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_e0c6e4f7-92c1-4a51-b8ab-bcd9ce46179a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_931a4f52-b36b-4bb0-89b3-c0085105719c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e0c6e4f7-92c1-4a51-b8ab-bcd9ce46179a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_931a4f52-b36b-4bb0-89b3-c0085105719c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f92bb921-1fd4-44bb-9cc1-04994e72bebb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_931a4f52-b36b-4bb0-89b3-c0085105719c" xlink:to="loc_us-gaap_NetIncomeLoss_f92bb921-1fd4-44bb-9cc1-04994e72bebb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2f1ce610-0629-45de-9ae0-2a3610b1bdc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_931a4f52-b36b-4bb0-89b3-c0085105719c" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2f1ce610-0629-45de-9ae0-2a3610b1bdc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_8eb0f205-66fc-440b-b609-11cc35335a85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2f1ce610-0629-45de-9ae0-2a3610b1bdc9" xlink:to="loc_us-gaap_DepreciationAndAmortization_8eb0f205-66fc-440b-b609-11cc35335a85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_NonCashInterestExpense_f24686f2-ab27-402f-a5cf-139bed8fa576" xlink:href="mygn-20210930.xsd#mygn_NonCashInterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2f1ce610-0629-45de-9ae0-2a3610b1bdc9" xlink:to="loc_mygn_NonCashInterestExpense_f24686f2-ab27-402f-a5cf-139bed8fa576" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_b00721d4-4a28-4f88-8ce7-ff435033734a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2f1ce610-0629-45de-9ae0-2a3610b1bdc9" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_b00721d4-4a28-4f88-8ce7-ff435033734a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_55d442e3-d612-4ae1-8bf1-12c40ecf2913" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2f1ce610-0629-45de-9ae0-2a3610b1bdc9" xlink:to="loc_us-gaap_ShareBasedCompensation_55d442e3-d612-4ae1-8bf1-12c40ecf2913" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_e957b27a-cbf9-43dd-9c13-e1e96e1551b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2f1ce610-0629-45de-9ae0-2a3610b1bdc9" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_e957b27a-cbf9-43dd-9c13-e1e96e1551b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_IncreaseDecreaseInUnrecognizedTaxBenefits_8534e584-2b70-4414-8a67-f44b16009f8e" xlink:href="mygn-20210930.xsd#mygn_IncreaseDecreaseInUnrecognizedTaxBenefits"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2f1ce610-0629-45de-9ae0-2a3610b1bdc9" xlink:to="loc_mygn_IncreaseDecreaseInUnrecognizedTaxBenefits_8534e584-2b70-4414-8a67-f44b16009f8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_ChangeInFairValueOfContingentConsideration_fea9fdbc-0b91-4b98-b70c-37ed72fcb96d" xlink:href="mygn-20210930.xsd#mygn_ChangeInFairValueOfContingentConsideration"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2f1ce610-0629-45de-9ae0-2a3610b1bdc9" xlink:to="loc_mygn_ChangeInFairValueOfContingentConsideration_fea9fdbc-0b91-4b98-b70c-37ed72fcb96d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_af4be557-b4ba-4d2f-8441-60a3af6ddf9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWriteDown"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2f1ce610-0629-45de-9ae0-2a3610b1bdc9" xlink:to="loc_us-gaap_InventoryWriteDown_af4be557-b4ba-4d2f-8441-60a3af6ddf9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_ImpairmentOfGoodwillAndLongLivedAssetsHeldForUse_fbbecfe9-1b64-4bb0-991f-d484f31701bd" xlink:href="mygn-20210930.xsd#mygn_ImpairmentOfGoodwillAndLongLivedAssetsHeldForUse"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2f1ce610-0629-45de-9ae0-2a3610b1bdc9" xlink:to="loc_mygn_ImpairmentOfGoodwillAndLongLivedAssetsHeldForUse_fbbecfe9-1b64-4bb0-991f-d484f31701bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_f7f91cb4-81bd-4663-a005-09417c1debbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2f1ce610-0629-45de-9ae0-2a3610b1bdc9" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_f7f91cb4-81bd-4663-a005-09417c1debbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8aca2dd7-0e0e-4fe6-863d-3cff2a522eca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2f1ce610-0629-45de-9ae0-2a3610b1bdc9" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8aca2dd7-0e0e-4fe6-863d-3cff2a522eca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpensesOther_849998d3-8e0d-412a-a021-02f296909d36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8aca2dd7-0e0e-4fe6-863d-3cff2a522eca" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpensesOther_849998d3-8e0d-412a-a021-02f296909d36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_50e69e75-cdb3-45ef-9ca1-b1152e0e67a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8aca2dd7-0e0e-4fe6-863d-3cff2a522eca" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_50e69e75-cdb3-45ef-9ca1-b1152e0e67a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_08f973ac-2b2f-40b4-b51c-ceaa08d49c3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8aca2dd7-0e0e-4fe6-863d-3cff2a522eca" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_08f973ac-2b2f-40b4-b51c-ceaa08d49c3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidTaxes_6ffa7a85-f432-4e69-b646-7a8e4ff40158" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidTaxes"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8aca2dd7-0e0e-4fe6-863d-3cff2a522eca" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidTaxes_6ffa7a85-f432-4e69-b646-7a8e4ff40158" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_9dfe2b3a-c071-4324-abb8-3bc6d69685e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8aca2dd7-0e0e-4fe6-863d-3cff2a522eca" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_9dfe2b3a-c071-4324-abb8-3bc6d69685e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_deedc57a-b852-411e-8e26-41a5bc96a119" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8aca2dd7-0e0e-4fe6-863d-3cff2a522eca" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_deedc57a-b852-411e-8e26-41a5bc96a119" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_3ff3df45-11db-4d2d-b5bf-1519091e5c8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8aca2dd7-0e0e-4fe6-863d-3cff2a522eca" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_3ff3df45-11db-4d2d-b5bf-1519091e5c8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_ca8486cc-3fce-412f-89e3-395bc0f75c5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8aca2dd7-0e0e-4fe6-863d-3cff2a522eca" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_ca8486cc-3fce-412f-89e3-395bc0f75c5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_faa80996-8d23-44fc-bcca-3cd5b2916655" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_931a4f52-b36b-4bb0-89b3-c0085105719c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_faa80996-8d23-44fc-bcca-3cd5b2916655" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_78110722-dea8-4dd5-a44c-91fefc9c3bc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e0c6e4f7-92c1-4a51-b8ab-bcd9ce46179a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_78110722-dea8-4dd5-a44c-91fefc9c3bc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_11f4db88-c1e2-4ff7-b057-575754d8af10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_78110722-dea8-4dd5-a44c-91fefc9c3bc3" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_11f4db88-c1e2-4ff7-b057-575754d8af10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets_d430d037-b8a4-4caa-8eaf-029be4641255" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_78110722-dea8-4dd5-a44c-91fefc9c3bc3" xlink:to="loc_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets_d430d037-b8a4-4caa-8eaf-029be4641255" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_f430628f-226f-4ece-aa35-335c62ec5c4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_78110722-dea8-4dd5-a44c-91fefc9c3bc3" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_f430628f-226f-4ece-aa35-335c62ec5c4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_08caa39d-7dd0-4258-824e-4eb4f0f36632" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_78110722-dea8-4dd5-a44c-91fefc9c3bc3" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_08caa39d-7dd0-4258-824e-4eb4f0f36632" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_358e4f0a-c529-4751-8213-fe02ff758c26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_78110722-dea8-4dd5-a44c-91fefc9c3bc3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_358e4f0a-c529-4751-8213-fe02ff758c26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0fb73b79-c947-4bba-a702-2057828a271c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e0c6e4f7-92c1-4a51-b8ab-bcd9ce46179a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0fb73b79-c947-4bba-a702-2057828a271c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_c330153f-972e-44cb-9930-0c88aa8e7b8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0fb73b79-c947-4bba-a702-2057828a271c" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_c330153f-972e-44cb-9930-0c88aa8e7b8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_589e7561-db40-418e-b633-1b00ed23ecb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0fb73b79-c947-4bba-a702-2057828a271c" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_589e7561-db40-418e-b633-1b00ed23ecb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_8064f4d0-60e4-4882-8dc4-0d0d34f5440c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0fb73b79-c947-4bba-a702-2057828a271c" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_8064f4d0-60e4-4882-8dc4-0d0d34f5440c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_f88f72f3-6ca9-41c5-b53b-62edb8c589b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0fb73b79-c947-4bba-a702-2057828a271c" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_f88f72f3-6ca9-41c5-b53b-62edb8c589b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit_ec313e08-9959-4631-b358-1602ae8c4fd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0fb73b79-c947-4bba-a702-2057828a271c" xlink:to="loc_us-gaap_RepaymentsOfLinesOfCredit_ec313e08-9959-4631-b358-1602ae8c4fd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_19b7c78b-1b98-492c-a310-38e7a4a21f0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0fb73b79-c947-4bba-a702-2057828a271c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_19b7c78b-1b98-492c-a310-38e7a4a21f0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8622747b-7404-46b9-9bd1-c9bad8840fb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e0c6e4f7-92c1-4a51-b8ab-bcd9ce46179a" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8622747b-7404-46b9-9bd1-c9bad8840fb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_NetChangeInCashAndCashEquivalentsClassifiedAsHeldForSale_19f6347b-6cbe-4c6d-a686-82509062c7ed" xlink:href="mygn-20210930.xsd#mygn_NetChangeInCashAndCashEquivalentsClassifiedAsHeldForSale"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e0c6e4f7-92c1-4a51-b8ab-bcd9ce46179a" xlink:to="loc_mygn_NetChangeInCashAndCashEquivalentsClassifiedAsHeldForSale_19f6347b-6cbe-4c6d-a686-82509062c7ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_908c6fae-44f5-45c0-9314-f7a45b3872ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e0c6e4f7-92c1-4a51-b8ab-bcd9ce46179a" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_908c6fae-44f5-45c0-9314-f7a45b3872ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_46db4eb8-2401-4ff2-8969-6f253c19c3a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e0c6e4f7-92c1-4a51-b8ab-bcd9ce46179a" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_46db4eb8-2401-4ff2-8969-6f253c19c3a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_58a8acc5-20b7-47d9-ba4a-135d007c0a7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e0c6e4f7-92c1-4a51-b8ab-bcd9ce46179a" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_58a8acc5-20b7-47d9-ba4a-135d007c0a7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/BasisofPresentation" xlink:type="simple" xlink:href="mygn-20210930.xsd#BasisofPresentation"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/BasisofPresentation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_46020641-3b24-46ac-8caf-8b648a886f2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_6f6f30a5-7f90-4745-9c7c-5613c7360570" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_46020641-3b24-46ac-8caf-8b648a886f2b" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_6f6f30a5-7f90-4745-9c7c-5613c7360570" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/BasisofPresentationPolicies" xlink:type="simple" xlink:href="mygn-20210930.xsd#BasisofPresentationPolicies"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/BasisofPresentationPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_423ae33e-9186-4cf5-8f0b-7b96f2d7ffaf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_9b63a9f8-9b74-4d9a-a3b4-27388f3b8e44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_423ae33e-9186-4cf5-8f0b-7b96f2d7ffaf" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_9b63a9f8-9b74-4d9a-a3b4-27388f3b8e44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_d1b68f96-8585-4e01-bfb0-4bbc0eb1edb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_423ae33e-9186-4cf5-8f0b-7b96f2d7ffaf" xlink:to="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_d1b68f96-8585-4e01-bfb0-4bbc0eb1edb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_44fa1e01-ad74-43c8-a42a-ff158360bb0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_423ae33e-9186-4cf5-8f0b-7b96f2d7ffaf" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_44fa1e01-ad74-43c8-a42a-ff158360bb0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/Revenue" xlink:type="simple" xlink:href="mygn-20210930.xsd#Revenue"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/Revenue" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_e1d351f9-7ce6-4349-904d-4654aedccd70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_7877edf3-1c6f-4ed9-9680-87b0e7e8b083" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_e1d351f9-7ce6-4349-904d-4654aedccd70" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_7877edf3-1c6f-4ed9-9680-87b0e7e8b083" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/RevenueTables" xlink:type="simple" xlink:href="mygn-20210930.xsd#RevenueTables"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/RevenueTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_4c9694da-613e-4cb2-a837-42f5c39870f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_42fa2f06-2499-4e43-bd1b-d1b16a19f50d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_4c9694da-613e-4cb2-a837-42f5c39870f8" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_42fa2f06-2499-4e43-bd1b-d1b16a19f50d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_a9cc045e-ee93-417a-b24c-db29d14971ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_4c9694da-613e-4cb2-a837-42f5c39870f8" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_a9cc045e-ee93-417a-b24c-db29d14971ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/RevenueTotalRevenuebyProductandbyUSversusRestofWorldDetails" xlink:type="simple" xlink:href="mygn-20210930.xsd#RevenueTotalRevenuebyProductandbyUSversusRestofWorldDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/RevenueTotalRevenuebyProductandbyUSversusRestofWorldDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_6db080cb-7cd7-4d8a-9c6a-b2bcb832fe2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_15aee584-dd4a-4058-9a88-9c46eb522de2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_6db080cb-7cd7-4d8a-9c6a-b2bcb832fe2b" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_15aee584-dd4a-4058-9a88-9c46eb522de2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_5b103955-7859-40aa-bfc3-7874f3046136" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_15aee584-dd4a-4058-9a88-9c46eb522de2" xlink:to="loc_srt_ProductOrServiceAxis_5b103955-7859-40aa-bfc3-7874f3046136" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f57355b9-43b6-40c7-abeb-db4021ebf0f1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_5b103955-7859-40aa-bfc3-7874f3046136" xlink:to="loc_srt_ProductsAndServicesDomain_f57355b9-43b6-40c7-abeb-db4021ebf0f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MolecularDiagnosticTestingMember_8e3859fb-0491-4aed-8c3c-5f77bd602cb8" xlink:href="mygn-20210930.xsd#mygn_MolecularDiagnosticTestingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f57355b9-43b6-40c7-abeb-db4021ebf0f1" xlink:to="loc_mygn_MolecularDiagnosticTestingMember_8e3859fb-0491-4aed-8c3c-5f77bd602cb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MolecularDiagnosticHereditaryCancerTestingMember_f44813d6-5489-4132-b222-bf14081ccb35" xlink:href="mygn-20210930.xsd#mygn_MolecularDiagnosticHereditaryCancerTestingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_MolecularDiagnosticTestingMember_8e3859fb-0491-4aed-8c3c-5f77bd602cb8" xlink:to="loc_mygn_MolecularDiagnosticHereditaryCancerTestingMember_f44813d6-5489-4132-b222-bf14081ccb35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MolecularDiagnosticTumorProfilingMember_19484a6c-67f8-4adb-9a8d-e3aebc0b3cac" xlink:href="mygn-20210930.xsd#mygn_MolecularDiagnosticTumorProfilingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_MolecularDiagnosticTestingMember_8e3859fb-0491-4aed-8c3c-5f77bd602cb8" xlink:to="loc_mygn_MolecularDiagnosticTumorProfilingMember_19484a6c-67f8-4adb-9a8d-e3aebc0b3cac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MolecularDiagnosticPrenatalTestingMember_36477bd5-0a68-4a80-ab5f-e17a7f316800" xlink:href="mygn-20210930.xsd#mygn_MolecularDiagnosticPrenatalTestingMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_MolecularDiagnosticTestingMember_8e3859fb-0491-4aed-8c3c-5f77bd602cb8" xlink:to="loc_mygn_MolecularDiagnosticPrenatalTestingMember_36477bd5-0a68-4a80-ab5f-e17a7f316800" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MolecularDiagnosticPharmacogenomicsMember_95926d2b-28d8-4728-aa8f-d5c88a8ba98f" xlink:href="mygn-20210930.xsd#mygn_MolecularDiagnosticPharmacogenomicsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_MolecularDiagnosticTestingMember_8e3859fb-0491-4aed-8c3c-5f77bd602cb8" xlink:to="loc_mygn_MolecularDiagnosticPharmacogenomicsMember_95926d2b-28d8-4728-aa8f-d5c88a8ba98f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MolecularDiagnosticAutoimmuneMember_20d940ec-39e5-4f02-9c8b-05f9b1d5afc4" xlink:href="mygn-20210930.xsd#mygn_MolecularDiagnosticAutoimmuneMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_MolecularDiagnosticTestingMember_8e3859fb-0491-4aed-8c3c-5f77bd602cb8" xlink:to="loc_mygn_MolecularDiagnosticAutoimmuneMember_20d940ec-39e5-4f02-9c8b-05f9b1d5afc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MolecularDiagnosticOtherTestingMember_2ae503ad-f294-4a58-b83a-65fe0c6f48b7" xlink:href="mygn-20210930.xsd#mygn_MolecularDiagnosticOtherTestingMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_MolecularDiagnosticTestingMember_8e3859fb-0491-4aed-8c3c-5f77bd602cb8" xlink:to="loc_mygn_MolecularDiagnosticOtherTestingMember_2ae503ad-f294-4a58-b83a-65fe0c6f48b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_PharmaceuticalAndClinicalServicesMember_cf00197b-9433-4750-b3bc-5b0f5a448b23" xlink:href="mygn-20210930.xsd#mygn_PharmaceuticalAndClinicalServicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f57355b9-43b6-40c7-abeb-db4021ebf0f1" xlink:to="loc_mygn_PharmaceuticalAndClinicalServicesMember_cf00197b-9433-4750-b3bc-5b0f5a448b23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_aeab64b6-a0b2-435e-a51e-6d629f2daf63" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_15aee584-dd4a-4058-9a88-9c46eb522de2" xlink:to="loc_srt_StatementGeographicalAxis_aeab64b6-a0b2-435e-a51e-6d629f2daf63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_af3f86bb-daec-4ae8-9326-ae17d3ab7c7d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_aeab64b6-a0b2-435e-a51e-6d629f2daf63" xlink:to="loc_srt_SegmentGeographicalDomain_af3f86bb-daec-4ae8-9326-ae17d3ab7c7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_791beba0-2150-4804-9d7a-f6ed75fa3f05" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_af3f86bb-daec-4ae8-9326-ae17d3ab7c7d" xlink:to="loc_country_US_791beba0-2150-4804-9d7a-f6ed75fa3f05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_4cb0f8a6-2c72-4ae0-9d19-5d8d41a82a1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_af3f86bb-daec-4ae8-9326-ae17d3ab7c7d" xlink:to="loc_us-gaap_NonUsMember_4cb0f8a6-2c72-4ae0-9d19-5d8d41a82a1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_db51c4f0-0b9e-41b4-bb01-8dc16323b9e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_15aee584-dd4a-4058-9a88-9c46eb522de2" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_db51c4f0-0b9e-41b4-bb01-8dc16323b9e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1e593fc0-9f0d-46b7-bfb8-efd747262051" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_db51c4f0-0b9e-41b4-bb01-8dc16323b9e3" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1e593fc0-9f0d-46b7-bfb8-efd747262051" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/RevenueReconciliationofDeferredRevenueBalancesDetails" xlink:type="simple" xlink:href="mygn-20210930.xsd#RevenueReconciliationofDeferredRevenueBalancesDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/RevenueReconciliationofDeferredRevenueBalancesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_1eb6f718-4b75-43bc-b70c-f0714d87ffa3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInContractWithCustomerLiabilityAbstract_3957c2cb-6272-4228-8787-ffb290d70a30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInContractWithCustomerLiabilityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_1eb6f718-4b75-43bc-b70c-f0714d87ffa3" xlink:to="loc_us-gaap_ChangeInContractWithCustomerLiabilityAbstract_3957c2cb-6272-4228-8787-ffb290d70a30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_6a5e89cb-d4ed-469c-b42f-13ce6018543e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInContractWithCustomerLiabilityAbstract_3957c2cb-6272-4228-8787-ffb290d70a30" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_6a5e89cb-d4ed-469c-b42f-13ce6018543e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized_ed848ede-5e54-427c-bfb0-d09ebee8d60c" xlink:href="mygn-20210930.xsd#mygn_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInContractWithCustomerLiabilityAbstract_3957c2cb-6272-4228-8787-ffb290d70a30" xlink:to="loc_mygn_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized_ed848ede-5e54-427c-bfb0-d09ebee8d60c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_ContractWithCustomerLiabilityPrepayments_b298c71b-2578-4a39-9fe5-0563785de9d9" xlink:href="mygn-20210930.xsd#mygn_ContractWithCustomerLiabilityPrepayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInContractWithCustomerLiabilityAbstract_3957c2cb-6272-4228-8787-ffb290d70a30" xlink:to="loc_mygn_ContractWithCustomerLiabilityPrepayments_b298c71b-2578-4a39-9fe5-0563785de9d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_ContractWithCustomerLiabilityDivestitures_cb1f71d1-a194-48e8-baa6-723e9cfe2e5b" xlink:href="mygn-20210930.xsd#mygn_ContractWithCustomerLiabilityDivestitures"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInContractWithCustomerLiabilityAbstract_3957c2cb-6272-4228-8787-ffb290d70a30" xlink:to="loc_mygn_ContractWithCustomerLiabilityDivestitures_cb1f71d1-a194-48e8-baa6-723e9cfe2e5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_fd04e0d2-dd1b-433f-b72e-859f2b7f5ebd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInContractWithCustomerLiabilityAbstract_3957c2cb-6272-4228-8787-ffb290d70a30" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_fd04e0d2-dd1b-433f-b72e-859f2b7f5ebd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/RevenueNarrativeDetails" xlink:type="simple" xlink:href="mygn-20210930.xsd#RevenueNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/RevenueNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_4b9397cb-fd54-4523-9222-f5bd293d9d0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_CARESActOf2020MedicarePaymentAmount_774923a7-6380-48b4-9ebf-3b6602a8cc06" xlink:href="mygn-20210930.xsd#mygn_CARESActOf2020MedicarePaymentAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_4b9397cb-fd54-4523-9222-f5bd293d9d0e" xlink:to="loc_mygn_CARESActOf2020MedicarePaymentAmount_774923a7-6380-48b4-9ebf-3b6602a8cc06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_54877c4c-65c0-45de-aa39-5ff608390c05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_4b9397cb-fd54-4523-9222-f5bd293d9d0e" xlink:to="loc_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_54877c4c-65c0-45de-aa39-5ff608390c05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_ContractWithCustomerAssetAdjustmentToRevenueForExpandedCoveragePreviouslyConstrained_ca941064-ac84-47d2-9117-95d3cab511e5" xlink:href="mygn-20210930.xsd#mygn_ContractWithCustomerAssetAdjustmentToRevenueForExpandedCoveragePreviouslyConstrained"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_4b9397cb-fd54-4523-9222-f5bd293d9d0e" xlink:to="loc_mygn_ContractWithCustomerAssetAdjustmentToRevenueForExpandedCoveragePreviouslyConstrained_ca941064-ac84-47d2-9117-95d3cab511e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostGross_9bec17d9-0aef-4667-a915-88d0897a20bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_4b9397cb-fd54-4523-9222-f5bd293d9d0e" xlink:to="loc_us-gaap_CapitalizedContractCostGross_9bec17d9-0aef-4667-a915-88d0897a20bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_7023e05e-82f8-4ecf-a4df-edc642b071fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_4b9397cb-fd54-4523-9222-f5bd293d9d0e" xlink:to="loc_us-gaap_ConcentrationRiskTable_7023e05e-82f8-4ecf-a4df-edc642b071fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_c9a8eac5-c7f6-49d7-aac5-49910ca8315d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_7023e05e-82f8-4ecf-a4df-edc642b071fd" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_c9a8eac5-c7f6-49d7-aac5-49910ca8315d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_e15b5032-9e13-4c86-b356-0d531826201b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_c9a8eac5-c7f6-49d7-aac5-49910ca8315d" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_e15b5032-9e13-4c86-b356-0d531826201b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_090ee1c7-7d2e-4694-b37a-0f28d1bb3826" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_e15b5032-9e13-4c86-b356-0d531826201b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_090ee1c7-7d2e-4694-b37a-0f28d1bb3826" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_90764a96-6758-4601-aa6b-e28710cbb022" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_7023e05e-82f8-4ecf-a4df-edc642b071fd" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_90764a96-6758-4601-aa6b-e28710cbb022" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_160b1b1a-b964-4e6a-8f33-f87627302ecf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_90764a96-6758-4601-aa6b-e28710cbb022" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_160b1b1a-b964-4e6a-8f33-f87627302ecf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_fb710db2-0cf0-4c27-ba37-010dd4681493" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_160b1b1a-b964-4e6a-8f33-f87627302ecf" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_fb710db2-0cf0-4c27-ba37-010dd4681493" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_a0d5f692-34df-4f90-ad15-85ecd207795c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_7023e05e-82f8-4ecf-a4df-edc642b071fd" xlink:to="loc_srt_MajorCustomersAxis_a0d5f692-34df-4f90-ad15-85ecd207795c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_0be4ef0d-c4e2-4022-adb5-cf48c4b6eabe" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_a0d5f692-34df-4f90-ad15-85ecd207795c" xlink:to="loc_srt_NameOfMajorCustomerDomain_0be4ef0d-c4e2-4022-adb5-cf48c4b6eabe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MedicareMember_2282a688-43d1-41b5-8b3f-5c89b5dc1655" xlink:href="mygn-20210930.xsd#mygn_MedicareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_0be4ef0d-c4e2-4022-adb5-cf48c4b6eabe" xlink:to="loc_mygn_MedicareMember_2282a688-43d1-41b5-8b3f-5c89b5dc1655" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_943a67ed-d12b-4c64-a93b-34240ee398c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_7023e05e-82f8-4ecf-a4df-edc642b071fd" xlink:to="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_943a67ed-d12b-4c64-a93b-34240ee398c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_edccdd50-79b2-489b-91b6-1448c8ed86f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_943a67ed-d12b-4c64-a93b-34240ee398c0" xlink:to="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_edccdd50-79b2-489b-91b6-1448c8ed86f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_PerformanceObligationEstimatedTransactionPriceMember_2f2664e7-9218-42a4-82bb-afe7fad69455" xlink:href="mygn-20210930.xsd#mygn_PerformanceObligationEstimatedTransactionPriceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_edccdd50-79b2-489b-91b6-1448c8ed86f2" xlink:to="loc_mygn_PerformanceObligationEstimatedTransactionPriceMember_2f2664e7-9218-42a4-82bb-afe7fad69455" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_aec6ea91-74d0-481c-8006-3e3325c64c93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_7023e05e-82f8-4ecf-a4df-edc642b071fd" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_aec6ea91-74d0-481c-8006-3e3325c64c93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_IncreaseDecreaseInEarningsLossPerShare_b0ace844-d0b2-45c2-a82c-a933b89ad735" xlink:href="mygn-20210930.xsd#mygn_IncreaseDecreaseInEarningsLossPerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_aec6ea91-74d0-481c-8006-3e3325c64c93" xlink:to="loc_mygn_IncreaseDecreaseInEarningsLossPerShare_b0ace844-d0b2-45c2-a82c-a933b89ad735" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_24630dbc-8b83-4779-a533-58ec32a0028a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_aec6ea91-74d0-481c-8006-3e3325c64c93" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_24630dbc-8b83-4779-a533-58ec32a0028a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/MarketableInvestmentSecurities" xlink:type="simple" xlink:href="mygn-20210930.xsd#MarketableInvestmentSecurities"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/MarketableInvestmentSecurities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_c6e28dd0-5854-4b50-b521-897cd87a8692" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_87874474-a2c6-4067-9640-96df6f83ca57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_c6e28dd0-5854-4b50-b521-897cd87a8692" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_87874474-a2c6-4067-9640-96df6f83ca57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/MarketableInvestmentSecuritiesTables" xlink:type="simple" xlink:href="mygn-20210930.xsd#MarketableInvestmentSecuritiesTables"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/MarketableInvestmentSecuritiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_68e0c8f8-6fc6-4850-a365-cd7ede29f0b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_f295c87c-b3d2-47ad-8e1c-279a33298ab8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_68e0c8f8-6fc6-4850-a365-cd7ede29f0b1" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_f295c87c-b3d2-47ad-8e1c-279a33298ab8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_9d900085-b9a2-46de-b691-ddd00d81719a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_68e0c8f8-6fc6-4850-a365-cd7ede29f0b1" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_9d900085-b9a2-46de-b691-ddd00d81719a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails" xlink:type="simple" xlink:href="mygn-20210930.xsd#MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_1e1f8a85-5e22-451d-9f60-2f31c58d2368" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_0a60e763-dabc-4dc2-ba20-5bcb8418de69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_1e1f8a85-5e22-451d-9f60-2f31c58d2368" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_0a60e763-dabc-4dc2-ba20-5bcb8418de69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_c4e4ea0e-4ea7-4b24-b94e-c7a544d238aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_0a60e763-dabc-4dc2-ba20-5bcb8418de69" xlink:to="loc_us-gaap_InvestmentTypeAxis_c4e4ea0e-4ea7-4b24-b94e-c7a544d238aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_de065aaa-976f-41d5-9a5f-b7cb081f5f5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_c4e4ea0e-4ea7-4b24-b94e-c7a544d238aa" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_de065aaa-976f-41d5-9a5f-b7cb081f5f5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_a5062932-8d0b-46de-8333-3cc5815b6106" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_de065aaa-976f-41d5-9a5f-b7cb081f5f5c" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_a5062932-8d0b-46de-8333-3cc5815b6106" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_8a2677c4-c723-4b1b-92d4-54abdeff797d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MunicipalBondsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_de065aaa-976f-41d5-9a5f-b7cb081f5f5c" xlink:to="loc_us-gaap_MunicipalBondsMember_8a2677c4-c723-4b1b-92d4-54abdeff797d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_84fa3749-6397-4dae-867f-c6260a906fad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_de065aaa-976f-41d5-9a5f-b7cb081f5f5c" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_84fa3749-6397-4dae-867f-c6260a906fad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_af5ff66a-f651-44e0-9fd8-c81099c5395b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_de065aaa-976f-41d5-9a5f-b7cb081f5f5c" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_af5ff66a-f651-44e0-9fd8-c81099c5395b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_f927dd32-4404-4f16-b690-16f0d85c29c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_0a60e763-dabc-4dc2-ba20-5bcb8418de69" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_f927dd32-4404-4f16-b690-16f0d85c29c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_52216536-169d-43df-b2d5-3481b7bc8475" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_f927dd32-4404-4f16-b690-16f0d85c29c4" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_52216536-169d-43df-b2d5-3481b7bc8475" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember_d44005a8-e931-4c26-97a2-3bd45e171993" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_52216536-169d-43df-b2d5-3481b7bc8475" xlink:to="loc_us-gaap_CashMember_d44005a8-e931-4c26-97a2-3bd45e171993" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsMember_07019a3b-3fa1-4039-924b-2a532f6b2de9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_52216536-169d-43df-b2d5-3481b7bc8475" xlink:to="loc_us-gaap_CashEquivalentsMember_07019a3b-3fa1-4039-924b-2a532f6b2de9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_bef13417-a312-441e-89a0-63d6afe80fc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_0a60e763-dabc-4dc2-ba20-5bcb8418de69" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_bef13417-a312-441e-89a0-63d6afe80fc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_6266c37f-46d2-45b2-86ea-c52da5b94465" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_bef13417-a312-441e-89a0-63d6afe80fc3" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_6266c37f-46d2-45b2-86ea-c52da5b94465" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5fd89c46-268e-426c-8f3b-3148273be68a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_6266c37f-46d2-45b2-86ea-c52da5b94465" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5fd89c46-268e-426c-8f3b-3148273be68a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_7a6286a9-594a-4274-b70b-4dd4b0e3e012" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_6266c37f-46d2-45b2-86ea-c52da5b94465" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_7a6286a9-594a-4274-b70b-4dd4b0e3e012" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_939e7017-6dfe-4c7e-b368-2aa43e7f2da9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_bef13417-a312-441e-89a0-63d6afe80fc3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAbstract_939e7017-6dfe-4c7e-b368-2aa43e7f2da9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_186945e0-407e-4a13-bbf8-f97b57d2bdaf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_939e7017-6dfe-4c7e-b368-2aa43e7f2da9" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_186945e0-407e-4a13-bbf8-f97b57d2bdaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_223f4a16-8f8e-47a3-aaea-790ba9c65dd6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_939e7017-6dfe-4c7e-b368-2aa43e7f2da9" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_223f4a16-8f8e-47a3-aaea-790ba9c65dd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_a98ec301-ed2e-49ce-b421-991f682ed7cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_939e7017-6dfe-4c7e-b368-2aa43e7f2da9" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_a98ec301-ed2e-49ce-b421-991f682ed7cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5c435a2a-273b-49c4-8d2c-ffc889917260" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_939e7017-6dfe-4c7e-b368-2aa43e7f2da9" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5c435a2a-273b-49c4-8d2c-ffc889917260" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAndCashAbstract_e155df54-602a-44b0-9773-98477f4661ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsAndCashAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_bef13417-a312-441e-89a0-63d6afe80fc3" xlink:to="loc_us-gaap_InvestmentsAndCashAbstract_e155df54-602a-44b0-9773-98477f4661ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_InvestmentsAndCashAmortizedCost_56cdbdf8-0064-4167-895b-5b35035f1187" xlink:href="mygn-20210930.xsd#mygn_InvestmentsAndCashAmortizedCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAndCashAbstract_e155df54-602a-44b0-9773-98477f4661ba" xlink:to="loc_mygn_InvestmentsAndCashAmortizedCost_56cdbdf8-0064-4167-895b-5b35035f1187" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax_0c787203-7597-4cbd-8f2c-3e7fed70becf" xlink:href="mygn-20210930.xsd#mygn_InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAndCashAbstract_e155df54-602a-44b0-9773-98477f4661ba" xlink:to="loc_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax_0c787203-7597-4cbd-8f2c-3e7fed70becf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax_76cc7e46-806b-4c3c-8568-ebc14078a2bc" xlink:href="mygn-20210930.xsd#mygn_InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAndCashAbstract_e155df54-602a-44b0-9773-98477f4661ba" xlink:to="loc_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax_76cc7e46-806b-4c3c-8568-ebc14078a2bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAndCash_d97a7b2e-e11d-4ea2-ab77-162f788d30af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsAndCash"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAndCashAbstract_e155df54-602a-44b0-9773-98477f4661ba" xlink:to="loc_us-gaap_InvestmentsAndCash_d97a7b2e-e11d-4ea2-ab77-162f788d30af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails" xlink:type="simple" xlink:href="mygn-20210930.xsd#MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_8d05e407-c6e7-4588-ad99-5862a97e5dc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_d8a98037-ee6c-42da-a680-152ff7775228" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_8d05e407-c6e7-4588-ad99-5862a97e5dc9" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_d8a98037-ee6c-42da-a680-152ff7775228" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_475506e0-2029-4e97-b275-e7eeee591dcb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_d8a98037-ee6c-42da-a680-152ff7775228" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_475506e0-2029-4e97-b275-e7eeee591dcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_cd5177de-8895-49df-824c-ac217afcaccf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_475506e0-2029-4e97-b275-e7eeee591dcb" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_cd5177de-8895-49df-824c-ac217afcaccf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember_0fee7b4c-2065-4434-8604-4ccf20a3becb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_cd5177de-8895-49df-824c-ac217afcaccf" xlink:to="loc_us-gaap_CashMember_0fee7b4c-2065-4434-8604-4ccf20a3becb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsMember_6ae7631c-ec67-4841-ade2-b5bfea964bbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_cd5177de-8895-49df-824c-ac217afcaccf" xlink:to="loc_us-gaap_CashEquivalentsMember_6ae7631c-ec67-4841-ade2-b5bfea964bbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b65adb86-e235-4c7a-ada0-246e2f6ccc0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_d8a98037-ee6c-42da-a680-152ff7775228" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b65adb86-e235-4c7a-ada0-246e2f6ccc0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisRollingMaturityAbstract_1d4f4a1d-a694-4b14-b3e5-6a514cd9a954" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisRollingMaturityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b65adb86-e235-4c7a-ada0-246e2f6ccc0a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisRollingMaturityAbstract_1d4f4a1d-a694-4b14-b3e5-6a514cd9a954" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_78a1cb96-41e6-468c-b89a-d4ee9b05ef37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisRollingMaturityAbstract_1d4f4a1d-a694-4b14-b3e5-6a514cd9a954" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_78a1cb96-41e6-468c-b89a-d4ee9b05ef37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_f96a5899-8392-40e3-a2ad-918390be15f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisRollingMaturityAbstract_1d4f4a1d-a694-4b14-b3e5-6a514cd9a954" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_f96a5899-8392-40e3-a2ad-918390be15f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_6fa47fcd-6e23-48cb-8892-6c6d77c44a80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisRollingMaturityAbstract_1d4f4a1d-a694-4b14-b3e5-6a514cd9a954" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_6fa47fcd-6e23-48cb-8892-6c6d77c44a80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_02e9dad3-8b74-4bc7-81c7-deb80b97fe6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisRollingMaturityAbstract_1d4f4a1d-a694-4b14-b3e5-6a514cd9a954" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_02e9dad3-8b74-4bc7-81c7-deb80b97fe6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_InvestmentsAndCashAmortizedCost_01e8607c-7cdb-47d9-b4b3-c92bea83b9e3" xlink:href="mygn-20210930.xsd#mygn_InvestmentsAndCashAmortizedCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisRollingMaturityAbstract_1d4f4a1d-a694-4b14-b3e5-6a514cd9a954" xlink:to="loc_mygn_InvestmentsAndCashAmortizedCost_01e8607c-7cdb-47d9-b4b3-c92bea83b9e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueRollingMaturityAbstract_43ab38ee-3008-4222-9430-a23d9ac6368e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueRollingMaturityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b65adb86-e235-4c7a-ada0-246e2f6ccc0a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueRollingMaturityAbstract_43ab38ee-3008-4222-9430-a23d9ac6368e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_33bd3500-6098-4470-9e03-0687d68cde20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueRollingMaturityAbstract_43ab38ee-3008-4222-9430-a23d9ac6368e" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_33bd3500-6098-4470-9e03-0687d68cde20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_7b6b2123-9683-4273-af28-d5be294278d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueRollingMaturityAbstract_43ab38ee-3008-4222-9430-a23d9ac6368e" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_7b6b2123-9683-4273-af28-d5be294278d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_a4bc29bf-5072-483d-809c-6ee2ec3dc026" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueRollingMaturityAbstract_43ab38ee-3008-4222-9430-a23d9ac6368e" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_a4bc29bf-5072-483d-809c-6ee2ec3dc026" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_4c2d2365-a2aa-47d2-b981-a44fe1e02328" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueRollingMaturityAbstract_43ab38ee-3008-4222-9430-a23d9ac6368e" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_4c2d2365-a2aa-47d2-b981-a44fe1e02328" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAndCash_8d6f4ceb-0ac8-4543-ad49-a15bec9b4182" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsAndCash"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueRollingMaturityAbstract_43ab38ee-3008-4222-9430-a23d9ac6368e" xlink:to="loc_us-gaap_InvestmentsAndCash_8d6f4ceb-0ac8-4543-ad49-a15bec9b4182" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/MarketableInvestmentSecuritiesNarrativeDetails" xlink:type="simple" xlink:href="mygn-20210930.xsd#MarketableInvestmentSecuritiesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/MarketableInvestmentSecuritiesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_88b08ad9-b6de-41e4-999a-da08f6a47d57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_d1ebcf87-300a-4ca3-8176-258fdab53bd8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_88b08ad9-b6de-41e4-999a-da08f6a47d57" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_d1ebcf87-300a-4ca3-8176-258fdab53bd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="mygn-20210930.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_e00a97ab-ac3d-4749-9aa8-46641bc1c854" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_fb90eb18-3923-4287-89b2-46fba6f65e13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_e00a97ab-ac3d-4749-9aa8-46641bc1c854" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_fb90eb18-3923-4287-89b2-46fba6f65e13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="mygn-20210930.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_d7414498-5c99-42c2-92f6-bfb31874c748" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_64006e20-4e4f-49a7-8068-c5c3ee9cf584" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_d7414498-5c99-42c2-92f6-bfb31874c748" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_64006e20-4e4f-49a7-8068-c5c3ee9cf584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_be017436-be3f-48a2-97c8-5656f5481d0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_d7414498-5c99-42c2-92f6-bfb31874c748" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_be017436-be3f-48a2-97c8-5656f5481d0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="mygn-20210930.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_97080799-d56e-40ea-af6c-ae71de3c7afa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_b708f7fc-5a64-4692-b0fe-8ed2893854b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_97080799-d56e-40ea-af6c-ae71de3c7afa" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_b708f7fc-5a64-4692-b0fe-8ed2893854b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_199c23d1-f4c0-44a4-b7a9-24210510d215" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_b708f7fc-5a64-4692-b0fe-8ed2893854b8" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_199c23d1-f4c0-44a4-b7a9-24210510d215" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_92907ed3-0862-455a-9d47-22255d8aff78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_199c23d1-f4c0-44a4-b7a9-24210510d215" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_92907ed3-0862-455a-9d47-22255d8aff78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_a0214fd2-5ba0-4053-8e8b-235efa6f8447" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_92907ed3-0862-455a-9d47-22255d8aff78" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_a0214fd2-5ba0-4053-8e8b-235efa6f8447" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_3349aaf5-2b5f-46d3-9da0-4a41f8a9d176" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_b708f7fc-5a64-4692-b0fe-8ed2893854b8" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_3349aaf5-2b5f-46d3-9da0-4a41f8a9d176" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_12954967-e472-4ac0-b3d3-a7995fb6b607" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_3349aaf5-2b5f-46d3-9da0-4a41f8a9d176" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_12954967-e472-4ac0-b3d3-a7995fb6b607" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_6a597428-9e64-4734-a7a4-b8b1508c188f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_12954967-e472-4ac0-b3d3-a7995fb6b607" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_6a597428-9e64-4734-a7a4-b8b1508c188f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_60402a61-7507-423a-8584-f192aaf41567" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_b708f7fc-5a64-4692-b0fe-8ed2893854b8" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_60402a61-7507-423a-8584-f192aaf41567" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_BusinessCombinationContingentConsiderationLiabilityMeasurementInputTerm_088d0713-5fb4-4199-b166-4c151767fc57" xlink:href="mygn-20210930.xsd#mygn_BusinessCombinationContingentConsiderationLiabilityMeasurementInputTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_60402a61-7507-423a-8584-f192aaf41567" xlink:to="loc_mygn_BusinessCombinationContingentConsiderationLiabilityMeasurementInputTerm_088d0713-5fb4-4199-b166-4c151767fc57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="mygn-20210930.xsd#FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_8ffe8a02-9800-4e74-bc16-ba814dad3dd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fb3409ff-1f77-4288-908b-77efb42e7511" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_8ffe8a02-9800-4e74-bc16-ba814dad3dd4" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fb3409ff-1f77-4288-908b-77efb42e7511" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_55fee45b-8761-49e3-b173-bac3c5d3175e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fb3409ff-1f77-4288-908b-77efb42e7511" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_55fee45b-8761-49e3-b173-bac3c5d3175e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_035aa192-1d36-4840-8355-d027ecec8406" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_55fee45b-8761-49e3-b173-bac3c5d3175e" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_035aa192-1d36-4840-8355-d027ecec8406" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_f7c5594e-d2a8-4cc0-99e7-d05d1d75d714" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_035aa192-1d36-4840-8355-d027ecec8406" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_f7c5594e-d2a8-4cc0-99e7-d05d1d75d714" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_57c013ec-9b39-488d-8a6f-5df34e81e698" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_035aa192-1d36-4840-8355-d027ecec8406" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_57c013ec-9b39-488d-8a6f-5df34e81e698" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_82cf4d33-726b-4755-ba74-da702d706eea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_035aa192-1d36-4840-8355-d027ecec8406" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_82cf4d33-726b-4755-ba74-da702d706eea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_970e421a-8e57-49d5-a892-38912c826f70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fb3409ff-1f77-4288-908b-77efb42e7511" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_970e421a-8e57-49d5-a892-38912c826f70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_843e9af0-873b-472f-9ae2-905c886a3e29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_970e421a-8e57-49d5-a892-38912c826f70" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_843e9af0-873b-472f-9ae2-905c886a3e29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_ContingentConsiderationMember_0dc3ed4f-1744-441f-9368-8ed259bc3ba7" xlink:href="mygn-20210930.xsd#mygn_ContingentConsiderationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_843e9af0-873b-472f-9ae2-905c886a3e29" xlink:to="loc_mygn_ContingentConsiderationMember_0dc3ed4f-1744-441f-9368-8ed259bc3ba7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_5a8aa3b4-5c96-45a8-b3bb-4e1b00f867bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fb3409ff-1f77-4288-908b-77efb42e7511" xlink:to="loc_us-gaap_InvestmentTypeAxis_5a8aa3b4-5c96-45a8-b3bb-4e1b00f867bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_25ebdb10-c5e9-4a1c-8f7a-6a91c7da7f14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_5a8aa3b4-5c96-45a8-b3bb-4e1b00f867bf" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_25ebdb10-c5e9-4a1c-8f7a-6a91c7da7f14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_2be243c1-5328-417e-9c2b-ad46f85f185e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_25ebdb10-c5e9-4a1c-8f7a-6a91c7da7f14" xlink:to="loc_us-gaap_MoneyMarketFundsMember_2be243c1-5328-417e-9c2b-ad46f85f185e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_d98c3c02-75e2-415a-8dc5-dc03b6b44d5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_25ebdb10-c5e9-4a1c-8f7a-6a91c7da7f14" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_d98c3c02-75e2-415a-8dc5-dc03b6b44d5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_de213df2-40e1-4f6d-bc0d-43f92a9f0a88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MunicipalBondsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_25ebdb10-c5e9-4a1c-8f7a-6a91c7da7f14" xlink:to="loc_us-gaap_MunicipalBondsMember_de213df2-40e1-4f6d-bc0d-43f92a9f0a88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_ace50fc5-e665-44d3-96e0-0789d1edd541" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_25ebdb10-c5e9-4a1c-8f7a-6a91c7da7f14" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_ace50fc5-e665-44d3-96e0-0789d1edd541" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_6542aa0f-462a-4285-a81a-57249b3b5682" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_25ebdb10-c5e9-4a1c-8f7a-6a91c7da7f14" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_6542aa0f-462a-4285-a81a-57249b3b5682" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_eb6e5fb6-5678-4b17-9bfd-23ee0d0569d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fb3409ff-1f77-4288-908b-77efb42e7511" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_eb6e5fb6-5678-4b17-9bfd-23ee0d0569d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_43ef8a69-e3b1-4c49-9cef-761d8945534e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_eb6e5fb6-5678-4b17-9bfd-23ee0d0569d6" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_43ef8a69-e3b1-4c49-9cef-761d8945534e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_62dde53a-e39a-43c6-aa09-ea1fc49e7f3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_eb6e5fb6-5678-4b17-9bfd-23ee0d0569d6" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_62dde53a-e39a-43c6-aa09-ea1fc49e7f3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetAssetLiability_440a9125-7770-4c91-988d-e2bc92f59cdf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueNetAssetLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_eb6e5fb6-5678-4b17-9bfd-23ee0d0569d6" xlink:to="loc_us-gaap_FairValueNetAssetLiability_440a9125-7770-4c91-988d-e2bc92f59cdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/FairValueMeasurementsChangeinFairValueofContingentConsiderationDetails" xlink:type="simple" xlink:href="mygn-20210930.xsd#FairValueMeasurementsChangeinFairValueofContingentConsiderationDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/FairValueMeasurementsChangeinFairValueofContingentConsiderationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_e8331d00-f485-4b41-8096-5a2903b1ba80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_20961baa-4ebc-4d34-92c3-d818a1e8553e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_e8331d00-f485-4b41-8096-5a2903b1ba80" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_20961baa-4ebc-4d34-92c3-d818a1e8553e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_bfb7076b-8416-40e6-9dcc-b678a60c5874" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_20961baa-4ebc-4d34-92c3-d818a1e8553e" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_bfb7076b-8416-40e6-9dcc-b678a60c5874" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_13a1973c-303c-40cc-8a87-bbdd857a6bb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_20961baa-4ebc-4d34-92c3-d818a1e8553e" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_13a1973c-303c-40cc-8a87-bbdd857a6bb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_661678dc-b027-4c1e-9710-24983449a4e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_20961baa-4ebc-4d34-92c3-d818a1e8553e" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_661678dc-b027-4c1e-9710-24983449a4e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_71551b43-148f-4199-bf3c-b1921290741c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_20961baa-4ebc-4d34-92c3-d818a1e8553e" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_71551b43-148f-4199-bf3c-b1921290741c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_9c9450eb-4363-4561-8e9f-816d98817b20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_20961baa-4ebc-4d34-92c3-d818a1e8553e" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_9c9450eb-4363-4561-8e9f-816d98817b20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/PropertyPlantandEquipmentNet" xlink:type="simple" xlink:href="mygn-20210930.xsd#PropertyPlantandEquipmentNet"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/PropertyPlantandEquipmentNet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_6851c00b-85c0-462c-85f8-e4126ec6739a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_56783778-4539-4e88-b952-0ac66146f600" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_6851c00b-85c0-462c-85f8-e4126ec6739a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_56783778-4539-4e88-b952-0ac66146f600" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/PropertyPlantandEquipmentNetTables" xlink:type="simple" xlink:href="mygn-20210930.xsd#PropertyPlantandEquipmentNetTables"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/PropertyPlantandEquipmentNetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_003f7e9a-8c33-4fd7-adb1-1398251408fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_5efa1491-f9cc-4706-a86e-f8bfdc33c55c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_003f7e9a-8c33-4fd7-adb1-1398251408fe" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_5efa1491-f9cc-4706-a86e-f8bfdc33c55c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/PropertyPlantandEquipmentNetBalancesDetails" xlink:type="simple" xlink:href="mygn-20210930.xsd#PropertyPlantandEquipmentNetBalancesDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/PropertyPlantandEquipmentNetBalancesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_ab3f6521-6605-4b2b-84a3-b6b84d855173" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6c3fccc0-7708-4f02-a0fb-f26a1d30d694" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_ab3f6521-6605-4b2b-84a3-b6b84d855173" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6c3fccc0-7708-4f02-a0fb-f26a1d30d694" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a485130e-d343-4c53-80e0-40f8a9fcbf3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6c3fccc0-7708-4f02-a0fb-f26a1d30d694" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a485130e-d343-4c53-80e0-40f8a9fcbf3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0b64b434-d12f-4b75-aa62-0c5d1657a4cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a485130e-d343-4c53-80e0-40f8a9fcbf3b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0b64b434-d12f-4b75-aa62-0c5d1657a4cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_ff2657dd-4574-4f1c-af4e-ed9b0cf38b54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0b64b434-d12f-4b75-aa62-0c5d1657a4cf" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_ff2657dd-4574-4f1c-af4e-ed9b0cf38b54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_048fd5a6-5259-4833-804f-d6ae508df73a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0b64b434-d12f-4b75-aa62-0c5d1657a4cf" xlink:to="loc_us-gaap_EquipmentMember_048fd5a6-5259-4833-804f-d6ae508df73a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d4e1bd17-d74c-4b1a-b574-b6c15785fcb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6c3fccc0-7708-4f02-a0fb-f26a1d30d694" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d4e1bd17-d74c-4b1a-b574-b6c15785fcb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_29d19b49-e27d-41cd-b792-5d4022c2fea1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d4e1bd17-d74c-4b1a-b574-b6c15785fcb8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_29d19b49-e27d-41cd-b792-5d4022c2fea1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_f14acd98-cb7f-4deb-8c71-c18280ab9859" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d4e1bd17-d74c-4b1a-b574-b6c15785fcb8" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_f14acd98-cb7f-4deb-8c71-c18280ab9859" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_d2f799c0-4dde-4f6c-9080-ab18c4abee2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d4e1bd17-d74c-4b1a-b574-b6c15785fcb8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_d2f799c0-4dde-4f6c-9080-ab18c4abee2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/PropertyPlantandEquipmentNetDepreciationExpenseDetails" xlink:type="simple" xlink:href="mygn-20210930.xsd#PropertyPlantandEquipmentNetDepreciationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/PropertyPlantandEquipmentNetDepreciationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_3e8a2620-0422-4c64-b792-bee11c6cca9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_7a876be2-4cab-4865-92ea-7dbd74d64e64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_3e8a2620-0422-4c64-b792-bee11c6cca9f" xlink:to="loc_us-gaap_Depreciation_7a876be2-4cab-4865-92ea-7dbd74d64e64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/GoodwillandIntangibleAssets" xlink:type="simple" xlink:href="mygn-20210930.xsd#GoodwillandIntangibleAssets"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/GoodwillandIntangibleAssets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3d163007-28d3-4687-a280-95d4cbd247e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_a1fb24da-4120-43fe-a901-4af6ad6c4826" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3d163007-28d3-4687-a280-95d4cbd247e1" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_a1fb24da-4120-43fe-a901-4af6ad6c4826" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/GoodwillandIntangibleAssetsTables" xlink:type="simple" xlink:href="mygn-20210930.xsd#GoodwillandIntangibleAssetsTables"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/GoodwillandIntangibleAssetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4716d221-085f-46bb-bacb-9278d9d19b65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_90efa518-3ec1-47f4-83ab-2ab7cbb11852" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4716d221-085f-46bb-bacb-9278d9d19b65" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_90efa518-3ec1-47f4-83ab-2ab7cbb11852" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_dc5d3e7b-66ed-442f-85b8-42623aff2c65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4716d221-085f-46bb-bacb-9278d9d19b65" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_dc5d3e7b-66ed-442f-85b8-42623aff2c65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_58ef6f99-9acb-4755-8524-b2b7ff689ddf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4716d221-085f-46bb-bacb-9278d9d19b65" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_58ef6f99-9acb-4755-8524-b2b7ff689ddf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_ade2ee54-d7f7-4ec0-8cce-2cb179faed65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4716d221-085f-46bb-bacb-9278d9d19b65" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_ade2ee54-d7f7-4ec0-8cce-2cb179faed65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/GoodwillandIntangibleAssetsCarryingAmountofGoodwillDetails" xlink:type="simple" xlink:href="mygn-20210930.xsd#GoodwillandIntangibleAssetsCarryingAmountofGoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/GoodwillandIntangibleAssetsCarryingAmountofGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_cde0cdca-25c8-4c06-8a0b-9ee91d48fdfb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_cfcd960f-077a-4ed1-ae68-b901a97d4b43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_cde0cdca-25c8-4c06-8a0b-9ee91d48fdfb" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_cfcd960f-077a-4ed1-ae68-b901a97d4b43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_b8533a94-2a07-4591-9ecf-17b970bfece7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_cfcd960f-077a-4ed1-ae68-b901a97d4b43" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_b8533a94-2a07-4591-9ecf-17b970bfece7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_62b74431-b3f4-4b52-a179-94b1cbaf3569" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_b8533a94-2a07-4591-9ecf-17b970bfece7" xlink:to="loc_us-gaap_SegmentDomain_62b74431-b3f4-4b52-a179-94b1cbaf3569" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_DiagnosticsMember_ea9e78ae-b254-4d4d-a9ea-230e286b9f39" xlink:href="mygn-20210930.xsd#mygn_DiagnosticsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_62b74431-b3f4-4b52-a179-94b1cbaf3569" xlink:to="loc_mygn_DiagnosticsMember_ea9e78ae-b254-4d4d-a9ea-230e286b9f39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_7ee01814-c74c-4020-8fd8-4d8c5bfa4170" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_62b74431-b3f4-4b52-a179-94b1cbaf3569" xlink:to="loc_us-gaap_AllOtherSegmentsMember_7ee01814-c74c-4020-8fd8-4d8c5bfa4170" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_e77bbd42-0cf5-4048-9916-b7e8ccce1f96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_cfcd960f-077a-4ed1-ae68-b901a97d4b43" xlink:to="loc_us-gaap_GoodwillLineItems_e77bbd42-0cf5-4048-9916-b7e8ccce1f96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_5841b246-4404-47e1-8991-abe5857018a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_e77bbd42-0cf5-4048-9916-b7e8ccce1f96" xlink:to="loc_us-gaap_GoodwillRollForward_5841b246-4404-47e1-8991-abe5857018a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_ab925496-fca0-4894-a011-24da8048c1bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_5841b246-4404-47e1-8991-abe5857018a0" xlink:to="loc_us-gaap_Goodwill_ab925496-fca0-4894-a011-24da8048c1bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_680b2448-a2b1-492a-b921-9617dd8774d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_5841b246-4404-47e1-8991-abe5857018a0" xlink:to="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_680b2448-a2b1-492a-b921-9617dd8774d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_86906573-afb8-4452-aac1-3052c30d3eac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_5841b246-4404-47e1-8991-abe5857018a0" xlink:to="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_86906573-afb8-4452-aac1-3052c30d3eac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_4d324e90-f681-4501-961c-436e994d14a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_5841b246-4404-47e1-8991-abe5857018a0" xlink:to="loc_us-gaap_Goodwill_4d324e90-f681-4501-961c-436e994d14a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/GoodwillandIntangibleAssetsNarrativeDetails" xlink:type="simple" xlink:href="mygn-20210930.xsd#GoodwillandIntangibleAssetsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/GoodwillandIntangibleAssetsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b9f738f9-a124-413d-94d0-ff98306dd8e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_ScheduleOfIntangibleAssetsTable_ffc1ac08-0951-4783-a290-ebe1f50cfa31" xlink:href="mygn-20210930.xsd#mygn_ScheduleOfIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b9f738f9-a124-413d-94d0-ff98306dd8e5" xlink:to="loc_mygn_ScheduleOfIntangibleAssetsTable_ffc1ac08-0951-4783-a290-ebe1f50cfa31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_16786fd0-d9d9-4477-9d0e-78128535dddb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_ScheduleOfIntangibleAssetsTable_ffc1ac08-0951-4783-a290-ebe1f50cfa31" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_16786fd0-d9d9-4477-9d0e-78128535dddb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_637023de-6e88-42b9-a71e-883537166c10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_16786fd0-d9d9-4477-9d0e-78128535dddb" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_637023de-6e88-42b9-a71e-883537166c10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_InProcessResearchAndDevelopmentWithIndefiniteLivesMember_a77afa33-f389-4267-bbca-77a76148b0b5" xlink:href="mygn-20210930.xsd#mygn_InProcessResearchAndDevelopmentWithIndefiniteLivesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_637023de-6e88-42b9-a71e-883537166c10" xlink:to="loc_mygn_InProcessResearchAndDevelopmentWithIndefiniteLivesMember_a77afa33-f389-4267-bbca-77a76148b0b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_806f8531-1e38-4f08-89c4-4c3683714978" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_ScheduleOfIntangibleAssetsTable_ffc1ac08-0951-4783-a290-ebe1f50cfa31" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_806f8531-1e38-4f08-89c4-4c3683714978" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ad7b779b-6ae8-4615-ada9-f80bebccf61b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_806f8531-1e38-4f08-89c4-4c3683714978" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ad7b779b-6ae8-4615-ada9-f80bebccf61b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_PurchasedLicensesAndTechnologiesMember_826b59ed-f34c-4ada-bb0c-84867c9f9e0c" xlink:href="mygn-20210930.xsd#mygn_PurchasedLicensesAndTechnologiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ad7b779b-6ae8-4615-ada9-f80bebccf61b" xlink:to="loc_mygn_PurchasedLicensesAndTechnologiesMember_826b59ed-f34c-4ada-bb0c-84867c9f9e0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_f890d165-3eab-417f-bbb8-f3367fa56895" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ad7b779b-6ae8-4615-ada9-f80bebccf61b" xlink:to="loc_us-gaap_CustomerRelationshipsMember_f890d165-3eab-417f-bbb8-f3367fa56895" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember_a55b96f1-ce83-4409-83a2-d7173c7895eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TrademarksMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ad7b779b-6ae8-4615-ada9-f80bebccf61b" xlink:to="loc_us-gaap_TrademarksMember_a55b96f1-ce83-4409-83a2-d7173c7895eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_abf86bb8-d107-4ac0-baab-7a4404451776" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_ScheduleOfIntangibleAssetsTable_ffc1ac08-0951-4783-a290-ebe1f50cfa31" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_abf86bb8-d107-4ac0-baab-7a4404451776" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_413358e8-979d-4c0a-838c-9c6d16b7c6d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_abf86bb8-d107-4ac0-baab-7a4404451776" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_413358e8-979d-4c0a-838c-9c6d16b7c6d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_ba36c3e6-534d-4420-9f53-55b6d4693d88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_413358e8-979d-4c0a-838c-9c6d16b7c6d1" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_ba36c3e6-534d-4420-9f53-55b6d4693d88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_060e9d22-fc80-4399-a03f-5dec3a9319b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_ScheduleOfIntangibleAssetsTable_ffc1ac08-0951-4783-a290-ebe1f50cfa31" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_060e9d22-fc80-4399-a03f-5dec3a9319b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_04fbb1e8-4c28-495a-9baa-17b3ffff5e8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_060e9d22-fc80-4399-a03f-5dec3a9319b4" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_04fbb1e8-4c28-495a-9baa-17b3ffff5e8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MyriadRBMIncMember_2aa2d2b1-44c7-43ab-bbc5-2c1b04ab2255" xlink:href="mygn-20210930.xsd#mygn_MyriadRBMIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_04fbb1e8-4c28-495a-9baa-17b3ffff5e8d" xlink:to="loc_mygn_MyriadRBMIncMember_2aa2d2b1-44c7-43ab-bbc5-2c1b04ab2255" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_IntangibleAssetsLineItems_bd88245f-afd5-4737-bdc3-3e570530643d" xlink:href="mygn-20210930.xsd#mygn_IntangibleAssetsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_ScheduleOfIntangibleAssetsTable_ffc1ac08-0951-4783-a290-ebe1f50cfa31" xlink:to="loc_mygn_IntangibleAssetsLineItems_bd88245f-afd5-4737-bdc3-3e570530643d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_05e3e905-df2d-45f4-a1f0-6c8b2b58ee1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_IntangibleAssetsLineItems_bd88245f-afd5-4737-bdc3-3e570530643d" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_05e3e905-df2d-45f4-a1f0-6c8b2b58ee1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNetNoncurrent_71a31f02-7bf1-4a7f-8adf-21b8722b9cb0" xlink:href="mygn-20210930.xsd#mygn_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNetNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_IntangibleAssetsLineItems_bd88245f-afd5-4737-bdc3-3e570530643d" xlink:to="loc_mygn_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNetNoncurrent_71a31f02-7bf1-4a7f-8adf-21b8722b9cb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsAccumulatedAmortizationNoncurrent_9ca1e75b-2dd6-40cd-b006-f3e862a32c19" xlink:href="mygn-20210930.xsd#mygn_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsAccumulatedAmortizationNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_IntangibleAssetsLineItems_bd88245f-afd5-4737-bdc3-3e570530643d" xlink:to="loc_mygn_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsAccumulatedAmortizationNoncurrent_9ca1e75b-2dd6-40cd-b006-f3e862a32c19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails" xlink:type="simple" xlink:href="mygn-20210930.xsd#GoodwillandIntangibleAssetsIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0c695c01-bf1c-4d18-8ca0-9d1fd402d753" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_ScheduleOfIntangibleAssetsTable_c7332959-1b9f-465e-8168-1e15b928cc26" xlink:href="mygn-20210930.xsd#mygn_ScheduleOfIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0c695c01-bf1c-4d18-8ca0-9d1fd402d753" xlink:to="loc_mygn_ScheduleOfIntangibleAssetsTable_c7332959-1b9f-465e-8168-1e15b928cc26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_d4438c33-c93c-4165-91ae-d61b8083a58a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_ScheduleOfIntangibleAssetsTable_c7332959-1b9f-465e-8168-1e15b928cc26" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_d4438c33-c93c-4165-91ae-d61b8083a58a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_47affbe1-48ec-4501-b598-0e3dccfd8703" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_d4438c33-c93c-4165-91ae-d61b8083a58a" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_47affbe1-48ec-4501-b598-0e3dccfd8703" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_InProcessResearchAndDevelopmentWithIndefiniteLivesMember_9e9ffb91-d342-47de-b265-f78aac27d174" xlink:href="mygn-20210930.xsd#mygn_InProcessResearchAndDevelopmentWithIndefiniteLivesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_47affbe1-48ec-4501-b598-0e3dccfd8703" xlink:to="loc_mygn_InProcessResearchAndDevelopmentWithIndefiniteLivesMember_9e9ffb91-d342-47de-b265-f78aac27d174" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d69beeaf-ee5d-46a6-9fc6-38a5e260a527" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_ScheduleOfIntangibleAssetsTable_c7332959-1b9f-465e-8168-1e15b928cc26" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d69beeaf-ee5d-46a6-9fc6-38a5e260a527" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_89debada-523d-43a1-b5fb-53be0f6d8c7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d69beeaf-ee5d-46a6-9fc6-38a5e260a527" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_89debada-523d-43a1-b5fb-53be0f6d8c7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_PurchasedLicensesAndTechnologiesMember_d23825e4-ecbc-4fcb-b15a-17f770eb05e4" xlink:href="mygn-20210930.xsd#mygn_PurchasedLicensesAndTechnologiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_89debada-523d-43a1-b5fb-53be0f6d8c7e" xlink:to="loc_mygn_PurchasedLicensesAndTechnologiesMember_d23825e4-ecbc-4fcb-b15a-17f770eb05e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_0ebca22c-ca6f-4767-ac6f-eab05adaaf7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_89debada-523d-43a1-b5fb-53be0f6d8c7e" xlink:to="loc_us-gaap_CustomerRelationshipsMember_0ebca22c-ca6f-4767-ac6f-eab05adaaf7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember_9963946c-bcf4-4601-bb7b-7bd1c4afa8f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TrademarksMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_89debada-523d-43a1-b5fb-53be0f6d8c7e" xlink:to="loc_us-gaap_TrademarksMember_9963946c-bcf4-4601-bb7b-7bd1c4afa8f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_IntangibleAssetsLineItems_c3a9db27-fd3c-4500-90c0-fe26bdb2cefc" xlink:href="mygn-20210930.xsd#mygn_IntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_ScheduleOfIntangibleAssetsTable_c7332959-1b9f-465e-8168-1e15b928cc26" xlink:to="loc_mygn_IntangibleAssetsLineItems_c3a9db27-fd3c-4500-90c0-fe26bdb2cefc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_78a1981f-1241-41a6-8ae6-3e0492b5707f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_IntangibleAssetsLineItems_c3a9db27-fd3c-4500-90c0-fe26bdb2cefc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_78a1981f-1241-41a6-8ae6-3e0492b5707f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_9fd92f21-2b1a-481a-8779-3cf421c856cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_IntangibleAssetsLineItems_c3a9db27-fd3c-4500-90c0-fe26bdb2cefc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_9fd92f21-2b1a-481a-8779-3cf421c856cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_06699ef4-212c-4718-b4af-a14178f4d62a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_IntangibleAssetsLineItems_c3a9db27-fd3c-4500-90c0-fe26bdb2cefc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_06699ef4-212c-4718-b4af-a14178f4d62a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_d7c4548e-b1b9-44bc-a0cf-14ffe6c5d191" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_IntangibleAssetsLineItems_c3a9db27-fd3c-4500-90c0-fe26bdb2cefc" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_d7c4548e-b1b9-44bc-a0cf-14ffe6c5d191" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_88894065-90d1-4cf3-ab4e-79cde6f34c79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_IntangibleAssetsLineItems_c3a9db27-fd3c-4500-90c0-fe26bdb2cefc" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_88894065-90d1-4cf3-ab4e-79cde6f34c79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_493707a6-ae7b-46f2-a24a-90b011c72501" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_IntangibleAssetsLineItems_c3a9db27-fd3c-4500-90c0-fe26bdb2cefc" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_493707a6-ae7b-46f2-a24a-90b011c72501" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails_1" xlink:type="simple" xlink:href="mygn-20210930.xsd#GoodwillandIntangibleAssetsIntangibleAssetsDetails_1"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.myriad.com/role/GoodwillandIntangibleAssetsAmortizationonIntangibleAssetsDetails" xlink:type="simple" xlink:href="mygn-20210930.xsd#GoodwillandIntangibleAssetsAmortizationonIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/GoodwillandIntangibleAssetsAmortizationonIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1effbc0c-2e5e-48bb-bcc3-dfcbf1bc9f00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_11ced65e-0bbf-4c99-8183-ea688372c090" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1effbc0c-2e5e-48bb-bcc3-dfcbf1bc9f00" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_11ced65e-0bbf-4c99-8183-ea688372c090" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/AccruedLiabilities" xlink:type="simple" xlink:href="mygn-20210930.xsd#AccruedLiabilities"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/AccruedLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_2e50a801-5391-4f81-974c-e6e8486c99f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_24c20656-8dc0-4c4d-861d-c44ed815dba0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_2e50a801-5391-4f81-974c-e6e8486c99f9" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_24c20656-8dc0-4c4d-861d-c44ed815dba0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/AccruedLiabilitiesTables" xlink:type="simple" xlink:href="mygn-20210930.xsd#AccruedLiabilitiesTables"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/AccruedLiabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_bf6e078f-0d8a-4842-bd11-4a22f56b011a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_5c6f5be3-4c6e-469c-bf4a-fb30f67b2763" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_bf6e078f-0d8a-4842-bd11-4a22f56b011a" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_5c6f5be3-4c6e-469c-bf4a-fb30f67b2763" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/AccruedLiabilitiesDetails" xlink:type="simple" xlink:href="mygn-20210930.xsd#AccruedLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/AccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_d347e36a-18de-4adf-a159-fd90578fdb9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_92faa31b-1892-4b40-9b65-5097ed5eef1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_d347e36a-18de-4adf-a159-fd90578fdb9e" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_92faa31b-1892-4b40-9b65-5097ed5eef1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveCurrent_34cf6884-0976-4876-a8af-455f7564c974" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationReserveCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_d347e36a-18de-4adf-a159-fd90578fdb9e" xlink:to="loc_us-gaap_LitigationReserveCurrent_34cf6884-0976-4876-a8af-455f7564c974" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_1c4678b1-36f2-444f-8b5b-7ec291077601" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_d347e36a-18de-4adf-a159-fd90578fdb9e" xlink:to="loc_us-gaap_TaxesPayableCurrent_1c4678b1-36f2-444f-8b5b-7ec291077601" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_RefundsPayableAndReserveCurrent_92306e0d-19db-4d2c-b394-6ba2d14ffaa9" xlink:href="mygn-20210930.xsd#mygn_RefundsPayableAndReserveCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_d347e36a-18de-4adf-a159-fd90578fdb9e" xlink:to="loc_mygn_RefundsPayableAndReserveCurrent_92306e0d-19db-4d2c-b394-6ba2d14ffaa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_8f5da59a-4e9b-4697-b221-5331e38fc513" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_d347e36a-18de-4adf-a159-fd90578fdb9e" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_8f5da59a-4e9b-4697-b221-5331e38fc513" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_22abbd32-01d9-4524-85ab-d572f0497be7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_d347e36a-18de-4adf-a159-fd90578fdb9e" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_22abbd32-01d9-4524-85ab-d572f0497be7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RecordedUnconditionalPurchaseObligation_a8a35414-17d2-44b5-8de8-7d8fc05dd011" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RecordedUnconditionalPurchaseObligation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_d347e36a-18de-4adf-a159-fd90578fdb9e" xlink:to="loc_us-gaap_RecordedUnconditionalPurchaseObligation_a8a35414-17d2-44b5-8de8-7d8fc05dd011" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_0a346143-646d-4eca-b6c7-5b5474726acb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_d347e36a-18de-4adf-a159-fd90578fdb9e" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_0a346143-646d-4eca-b6c7-5b5474726acb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_86f91f18-bf3b-439c-af03-c7e241b0395a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_d347e36a-18de-4adf-a159-fd90578fdb9e" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_86f91f18-bf3b-439c-af03-c7e241b0395a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/LongTermDebt" xlink:type="simple" xlink:href="mygn-20210930.xsd#LongTermDebt"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/LongTermDebt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_9cecb2e0-2ba5-4b47-963f-62567b84e1b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_687bed8f-73cd-444d-9bd2-dedac85566d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_9cecb2e0-2ba5-4b47-963f-62567b84e1b1" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_687bed8f-73cd-444d-9bd2-dedac85566d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/LongTermDebtNarrativeDetails" xlink:type="simple" xlink:href="mygn-20210930.xsd#LongTermDebtNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/LongTermDebtNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_941ccb0f-e980-4854-bdcc-d11e63773a7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_593125b5-4856-4f6b-9e83-b7a5d60f18d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_941ccb0f-e980-4854-bdcc-d11e63773a7e" xlink:to="loc_us-gaap_DebtInstrumentTable_593125b5-4856-4f6b-9e83-b7a5d60f18d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_04b0981f-9e63-473d-9955-e62f5121eab8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_593125b5-4856-4f6b-9e83-b7a5d60f18d6" xlink:to="loc_us-gaap_CreditFacilityAxis_04b0981f-9e63-473d-9955-e62f5121eab8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_b4de29bb-2306-4218-bc76-9c15238b437d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_04b0981f-9e63-473d-9955-e62f5121eab8" xlink:to="loc_us-gaap_CreditFacilityDomain_b4de29bb-2306-4218-bc76-9c15238b437d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_fadb4cb1-4daa-430e-83b6-60af6d7d349d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_b4de29bb-2306-4218-bc76-9c15238b437d" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_fadb4cb1-4daa-430e-83b6-60af6d7d349d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_a65f317d-d547-4b1f-932e-9f5a40eb5d54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_593125b5-4856-4f6b-9e83-b7a5d60f18d6" xlink:to="loc_us-gaap_DebtInstrumentAxis_a65f317d-d547-4b1f-932e-9f5a40eb5d54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b19205c5-5668-4950-87b3-2f09d9e4f71c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_a65f317d-d547-4b1f-932e-9f5a40eb5d54" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b19205c5-5668-4950-87b3-2f09d9e4f71c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_AmendmentToCreditAgreementMember_070cb828-8d7c-4ad5-a4ef-3cd7f2f733ff" xlink:href="mygn-20210930.xsd#mygn_AmendmentToCreditAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b19205c5-5668-4950-87b3-2f09d9e4f71c" xlink:to="loc_mygn_AmendmentToCreditAgreementMember_070cb828-8d7c-4ad5-a4ef-3cd7f2f733ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_95126c9b-7f67-4713-90a7-b8b2df062847" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_593125b5-4856-4f6b-9e83-b7a5d60f18d6" xlink:to="loc_us-gaap_VariableRateAxis_95126c9b-7f67-4713-90a7-b8b2df062847" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_8a1bdbc0-5968-4cac-922e-7d3cd5497177" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_95126c9b-7f67-4713-90a7-b8b2df062847" xlink:to="loc_us-gaap_VariableRateDomain_8a1bdbc0-5968-4cac-922e-7d3cd5497177" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_02bc179b-851c-4828-bf49-375715fc0443" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_8a1bdbc0-5968-4cac-922e-7d3cd5497177" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_02bc179b-851c-4828-bf49-375715fc0443" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_715f28da-2b27-428b-8288-dcf5aaba8f5d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_593125b5-4856-4f6b-9e83-b7a5d60f18d6" xlink:to="loc_srt_StatementScenarioAxis_715f28da-2b27-428b-8288-dcf5aaba8f5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_70540618-14b7-4461-a4cf-e1c15d5a6796" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_715f28da-2b27-428b-8288-dcf5aaba8f5d" xlink:to="loc_srt_ScenarioUnspecifiedDomain_70540618-14b7-4461-a4cf-e1c15d5a6796" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_0355c490-4c54-41c0-9ce5-ab6cb41927f1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_70540618-14b7-4461-a4cf-e1c15d5a6796" xlink:to="loc_srt_ScenarioForecastMember_0355c490-4c54-41c0-9ce5-ab6cb41927f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_476f8831-9db5-4add-9fa7-5eb4bee9d8f0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_593125b5-4856-4f6b-9e83-b7a5d60f18d6" xlink:to="loc_srt_RangeAxis_476f8831-9db5-4add-9fa7-5eb4bee9d8f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d2ba7166-7fe2-4901-abaf-6d9e607d0734" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_476f8831-9db5-4add-9fa7-5eb4bee9d8f0" xlink:to="loc_srt_RangeMember_d2ba7166-7fe2-4901-abaf-6d9e607d0734" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_3ef45a5d-b08d-4634-be48-b60d97f4d4bc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d2ba7166-7fe2-4901-abaf-6d9e607d0734" xlink:to="loc_srt_MinimumMember_3ef45a5d-b08d-4634-be48-b60d97f4d4bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_7c63bf99-aafd-4f25-a655-7baa23f2968f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d2ba7166-7fe2-4901-abaf-6d9e607d0734" xlink:to="loc_srt_MaximumMember_7c63bf99-aafd-4f25-a655-7baa23f2968f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_b0e79038-16d4-4d07-88d6-4448aab5958e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_593125b5-4856-4f6b-9e83-b7a5d60f18d6" xlink:to="loc_us-gaap_DebtInstrumentLineItems_b0e79038-16d4-4d07-88d6-4448aab5958e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_2f72ea54-1ddc-4987-a40e-76f5b11959c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b0e79038-16d4-4d07-88d6-4448aab5958e" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_2f72ea54-1ddc-4987-a40e-76f5b11959c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_eb397960-d0bf-4758-8f1d-5332df7ab142" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b0e79038-16d4-4d07-88d6-4448aab5958e" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_eb397960-d0bf-4758-8f1d-5332df7ab142" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_e1a61f74-d11c-44ac-8380-39caf5cc9f8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b0e79038-16d4-4d07-88d6-4448aab5958e" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_e1a61f74-d11c-44ac-8380-39caf5cc9f8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_4e3316fb-d278-4e9f-8ed3-916ae871ce26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b0e79038-16d4-4d07-88d6-4448aab5958e" xlink:to="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_4e3316fb-d278-4e9f-8ed3-916ae871ce26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_DebtInstrumentLIBORFloorPercentage_10905ae1-d384-43f7-bbf2-49549096ca27" xlink:href="mygn-20210930.xsd#mygn_DebtInstrumentLIBORFloorPercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b0e79038-16d4-4d07-88d6-4448aab5958e" xlink:to="loc_mygn_DebtInstrumentLIBORFloorPercentage_10905ae1-d384-43f7-bbf2-49549096ca27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_DebtCovenantLiquidityCovenantMinimum_08ee8562-4fa4-4754-a081-4f0debd9dcc6" xlink:href="mygn-20210930.xsd#mygn_DebtCovenantLiquidityCovenantMinimum"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b0e79038-16d4-4d07-88d6-4448aab5958e" xlink:to="loc_mygn_DebtCovenantLiquidityCovenantMinimum_08ee8562-4fa4-4754-a081-4f0debd9dcc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_DebtCovenantUnrestrictedCashAndCashEquivalentsThresholdForBorrowingRestrictionMinimum_bbd76050-2462-4684-b458-3cdb9d1b1615" xlink:href="mygn-20210930.xsd#mygn_DebtCovenantUnrestrictedCashAndCashEquivalentsThresholdForBorrowingRestrictionMinimum"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b0e79038-16d4-4d07-88d6-4448aab5958e" xlink:to="loc_mygn_DebtCovenantUnrestrictedCashAndCashEquivalentsThresholdForBorrowingRestrictionMinimum_bbd76050-2462-4684-b458-3cdb9d1b1615" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit_e93fe384-cab1-4a46-a0e1-41e929e40b8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b0e79038-16d4-4d07-88d6-4448aab5958e" xlink:to="loc_us-gaap_RepaymentsOfLinesOfCredit_e93fe384-cab1-4a46-a0e1-41e929e40b8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_9dc1ab79-0edc-4e03-a6f4-4da93fd15fc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b0e79038-16d4-4d07-88d6-4448aab5958e" xlink:to="loc_us-gaap_LongTermDebt_9dc1ab79-0edc-4e03-a6f4-4da93fd15fc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_OtherAssetsDebtDiscount_4d9853ca-d65b-42ef-a399-7559181a25dd" xlink:href="mygn-20210930.xsd#mygn_OtherAssetsDebtDiscount"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b0e79038-16d4-4d07-88d6-4448aab5958e" xlink:to="loc_mygn_OtherAssetsDebtDiscount_4d9853ca-d65b-42ef-a399-7559181a25dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent_6494d1c2-a194-452d-9da2-f05ef18c24cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b0e79038-16d4-4d07-88d6-4448aab5958e" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent_6494d1c2-a194-452d-9da2-f05ef18c24cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/OtherLongTermLiabilities" xlink:type="simple" xlink:href="mygn-20210930.xsd#OtherLongTermLiabilities"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/OtherLongTermLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_14b6c7eb-243a-4c82-9d5e-277958d74e76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureTextBlock_677719d7-1d4f-43f1-a316-66106c12673a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_14b6c7eb-243a-4c82-9d5e-277958d74e76" xlink:to="loc_us-gaap_OtherLiabilitiesDisclosureTextBlock_677719d7-1d4f-43f1-a316-66106c12673a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/OtherLongTermLiabilitiesTables" xlink:type="simple" xlink:href="mygn-20210930.xsd#OtherLongTermLiabilitiesTables"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/OtherLongTermLiabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_5b21240c-ddad-4f48-a646-3a932b36f584" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_37786d1b-16d6-4f3e-bc20-314ce322124e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_5b21240c-ddad-4f48-a646-3a932b36f584" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_37786d1b-16d6-4f3e-bc20-314ce322124e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/OtherLongTermLiabilitiesDetails" xlink:type="simple" xlink:href="mygn-20210930.xsd#OtherLongTermLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/OtherLongTermLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_29548566-dcf3-4f2e-ad83-afc4b5c1ba51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_09d7cf8e-233b-4cc2-b7dc-68137d8a10d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_29548566-dcf3-4f2e-ad83-afc4b5c1ba51" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_09d7cf8e-233b-4cc2-b7dc-68137d8a10d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherSundryLiabilitiesNoncurrent_1dd5cf31-0eee-48c2-9a42-fbcca38ac10a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherSundryLiabilitiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_29548566-dcf3-4f2e-ad83-afc4b5c1ba51" xlink:to="loc_us-gaap_OtherSundryLiabilitiesNoncurrent_1dd5cf31-0eee-48c2-9a42-fbcca38ac10a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_a716dbe3-f321-4d98-ab39-94f7ec8d2dfa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_29548566-dcf3-4f2e-ad83-afc4b5c1ba51" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_a716dbe3-f321-4d98-ab39-94f7ec8d2dfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/PreferredandCommonStockholdersEquity" xlink:type="simple" xlink:href="mygn-20210930.xsd#PreferredandCommonStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/PreferredandCommonStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_36fc3bec-4340-40e5-8a75-0a53f8b5583e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_6e7d40a0-2c87-4dd8-a44a-9a35a5529418" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_36fc3bec-4340-40e5-8a75-0a53f8b5583e" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_6e7d40a0-2c87-4dd8-a44a-9a35a5529418" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/PreferredandCommonStockholdersEquityTables" xlink:type="simple" xlink:href="mygn-20210930.xsd#PreferredandCommonStockholdersEquityTables"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/PreferredandCommonStockholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_847dcd3b-c391-4e80-8ded-2f11c04440de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock_67aa3011-1b30-4fdc-ad34-6aae809e3990" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_847dcd3b-c391-4e80-8ded-2f11c04440de" xlink:to="loc_us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock_67aa3011-1b30-4fdc-ad34-6aae809e3990" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_75e969aa-60d8-4b72-b37f-1fdf7fc18d53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_847dcd3b-c391-4e80-8ded-2f11c04440de" xlink:to="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_75e969aa-60d8-4b72-b37f-1fdf7fc18d53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_4d92e777-bf48-4323-ae56-f4e5bbc7d20c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_847dcd3b-c391-4e80-8ded-2f11c04440de" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_4d92e777-bf48-4323-ae56-f4e5bbc7d20c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/PreferredandCommonStockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="mygn-20210930.xsd#PreferredandCommonStockholdersEquityNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/PreferredandCommonStockholdersEquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_b852aa2d-5480-4cec-a036-52ea16efdcb6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_d23f583c-18a7-4b4b-bd2c-c5504bbd2690" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_b852aa2d-5480-4cec-a036-52ea16efdcb6" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_d23f583c-18a7-4b4b-bd2c-c5504bbd2690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_0bee9935-a32d-483a-9c4f-0e9e2a712953" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d23f583c-18a7-4b4b-bd2c-c5504bbd2690" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_0bee9935-a32d-483a-9c4f-0e9e2a712953" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_7fbdfcbf-e87c-4e23-a210-29665e1c1f12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_0bee9935-a32d-483a-9c4f-0e9e2a712953" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_7fbdfcbf-e87c-4e23-a210-29665e1c1f12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_EighthShareRepurchaseProgramMember_78f1f535-c145-4a0a-a9f9-7db89205fe42" xlink:href="mygn-20210930.xsd#mygn_EighthShareRepurchaseProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_7fbdfcbf-e87c-4e23-a210-29665e1c1f12" xlink:to="loc_mygn_EighthShareRepurchaseProgramMember_78f1f535-c145-4a0a-a9f9-7db89205fe42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_6b2a4bee-f57b-4e20-a7ab-0a300d77c4f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d23f583c-18a7-4b4b-bd2c-c5504bbd2690" xlink:to="loc_us-gaap_ClassOfStockLineItems_6b2a4bee-f57b-4e20-a7ab-0a300d77c4f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_fb3768d3-fc4b-40a9-bb3c-347e46f43b56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6b2a4bee-f57b-4e20-a7ab-0a300d77c4f8" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_fb3768d3-fc4b-40a9-bb3c-347e46f43b56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_7a1bb9a9-de2b-4dfa-a857-ef004cc557e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6b2a4bee-f57b-4e20-a7ab-0a300d77c4f8" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_7a1bb9a9-de2b-4dfa-a857-ef004cc557e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_80cfca8c-f9ad-41d7-8c6c-a7a41ec54cd6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6b2a4bee-f57b-4e20-a7ab-0a300d77c4f8" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_80cfca8c-f9ad-41d7-8c6c-a7a41ec54cd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_c783890c-93f8-4472-ac44-23316a174dda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6b2a4bee-f57b-4e20-a7ab-0a300d77c4f8" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_c783890c-93f8-4472-ac44-23316a174dda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_1ee96ea4-3e16-4413-8540-da4f257f356e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6b2a4bee-f57b-4e20-a7ab-0a300d77c4f8" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_1ee96ea4-3e16-4413-8540-da4f257f356e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_0ef63e0b-db0a-47c3-b39a-1378268f45b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6b2a4bee-f57b-4e20-a7ab-0a300d77c4f8" xlink:to="loc_us-gaap_CommonStockSharesIssued_0ef63e0b-db0a-47c3-b39a-1378268f45b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_c5fd74c8-94a7-4802-837e-d01a9c51d42c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6b2a4bee-f57b-4e20-a7ab-0a300d77c4f8" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_c5fd74c8-94a7-4802-837e-d01a9c51d42c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_0d013e3e-c96c-48f0-ac8a-2b97a1f1f7bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6b2a4bee-f57b-4e20-a7ab-0a300d77c4f8" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_0d013e3e-c96c-48f0-ac8a-2b97a1f1f7bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_b4f62ab3-5456-4cfe-9b79-327cac45ec85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6b2a4bee-f57b-4e20-a7ab-0a300d77c4f8" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_b4f62ab3-5456-4cfe-9b79-327cac45ec85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_48356c51-3831-4654-a9e3-c37765aff471" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6b2a4bee-f57b-4e20-a7ab-0a300d77c4f8" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_48356c51-3831-4654-a9e3-c37765aff471" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/PreferredandCommonStockholdersEquityCommonSharesIssuedandOutstandingDetails" xlink:type="simple" xlink:href="mygn-20210930.xsd#PreferredandCommonStockholdersEquityCommonSharesIssuedandOutstandingDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/PreferredandCommonStockholdersEquityCommonSharesIssuedandOutstandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_1e2f22a3-527c-4d6c-8f61-ed69776f907a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c124e684-1215-4558-bf8c-5e8d4a754096" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_1e2f22a3-527c-4d6c-8f61-ed69776f907a" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c124e684-1215-4558-bf8c-5e8d4a754096" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_85a57129-b6c4-4164-aaf7-96a4f15831cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c124e684-1215-4558-bf8c-5e8d4a754096" xlink:to="loc_us-gaap_CommonStockSharesIssued_85a57129-b6c4-4164-aaf7-96a4f15831cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_1ea75548-e98d-4b9c-a1eb-495aed8c95cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c124e684-1215-4558-bf8c-5e8d4a754096" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_1ea75548-e98d-4b9c-a1eb-495aed8c95cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans_f5942b80-d006-43e1-a998-e715aad7e39c" xlink:href="mygn-20210930.xsd#mygn_StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c124e684-1215-4558-bf8c-5e8d4a754096" xlink:to="loc_mygn_StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans_f5942b80-d006-43e1-a998-e715aad7e39c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_c1b598d6-f171-4c92-ae23-bc940b72579f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c124e684-1215-4558-bf8c-5e8d4a754096" xlink:to="loc_us-gaap_CommonStockSharesIssued_c1b598d6-f171-4c92-ae23-bc940b72579f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_13de3ce7-d15f-4b18-bbea-c13f088e9688" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c124e684-1215-4558-bf8c-5e8d4a754096" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_13de3ce7-d15f-4b18-bbea-c13f088e9688" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/PreferredandCommonStockholdersEquityReconciliationofDenominatorsofBasicandDilutedEarningsPerShareComputationsDetails" xlink:type="simple" xlink:href="mygn-20210930.xsd#PreferredandCommonStockholdersEquityReconciliationofDenominatorsofBasicandDilutedEarningsPerShareComputationsDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/PreferredandCommonStockholdersEquityReconciliationofDenominatorsofBasicandDilutedEarningsPerShareComputationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_76296c2c-1880-43c9-bef3-e0bf00baf802" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_5452984b-b996-4298-af12-f0ddbc683b82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_76296c2c-1880-43c9-bef3-e0bf00baf802" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_5452984b-b996-4298-af12-f0ddbc683b82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_107f3a26-f1af-442a-a0d6-f4d53bb845c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_76296c2c-1880-43c9-bef3-e0bf00baf802" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_107f3a26-f1af-442a-a0d6-f4d53bb845c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_59fcb913-e23d-4535-aebd-3f6b63adc3b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_76296c2c-1880-43c9-bef3-e0bf00baf802" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_59fcb913-e23d-4535-aebd-3f6b63adc3b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/PreferredandCommonStockholdersEquityPotentiallyDilutiveCommonSharesExcludedfromEPSComputationDetails" xlink:type="simple" xlink:href="mygn-20210930.xsd#PreferredandCommonStockholdersEquityPotentiallyDilutiveCommonSharesExcludedfromEPSComputationDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/PreferredandCommonStockholdersEquityPotentiallyDilutiveCommonSharesExcludedfromEPSComputationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_1df0a442-b888-4800-8797-25a0530162c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_17d10563-5093-436c-94cb-46ab5c9d517e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_1df0a442-b888-4800-8797-25a0530162c9" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_17d10563-5093-436c-94cb-46ab5c9d517e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="mygn-20210930.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0b7bff26-5463-48ed-93f8-745d0ef9f114" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_358d2abf-7108-4e72-adc1-d0e867df7383" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0b7bff26-5463-48ed-93f8-745d0ef9f114" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_358d2abf-7108-4e72-adc1-d0e867df7383" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="mygn-20210930.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c1b943aa-7703-45ef-ab8e-e6e2a78155ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_d3ce10ce-ca74-4a76-a07d-5ec64052ea9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c1b943aa-7703-45ef-ab8e-e6e2a78155ef" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_d3ce10ce-ca74-4a76-a07d-5ec64052ea9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_5dcee957-d2e5-4d84-9fa8-dba023a0e9b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c1b943aa-7703-45ef-ab8e-e6e2a78155ef" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_5dcee957-d2e5-4d84-9fa8-dba023a0e9b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_711bef2c-857b-4dee-bd82-4ebf391c0df7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c1b943aa-7703-45ef-ab8e-e6e2a78155ef" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_711bef2c-857b-4dee-bd82-4ebf391c0df7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="mygn-20210930.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6978ef58-747a-4c92-89f0-bf4831e212f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f2dd203e-ee3a-4496-91e7-3e84f3547ad9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6978ef58-747a-4c92-89f0-bf4831e212f8" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f2dd203e-ee3a-4496-91e7-3e84f3547ad9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_641dff79-1d09-46f4-a93c-45f0cd96c25b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f2dd203e-ee3a-4496-91e7-3e84f3547ad9" xlink:to="loc_us-gaap_PlanNameAxis_641dff79-1d09-46f4-a93c-45f0cd96c25b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_4d120a57-b9a8-4d22-941e-fad406dfbada" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_641dff79-1d09-46f4-a93c-45f0cd96c25b" xlink:to="loc_us-gaap_PlanNameDomain_4d120a57-b9a8-4d22-941e-fad406dfbada" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_TwoThousandSeventeenEmployeeDirectorAndConsultantEquityIncentivePlanMember_d77912e5-360a-4fe9-b857-479d7fdd39af" xlink:href="mygn-20210930.xsd#mygn_TwoThousandSeventeenEmployeeDirectorAndConsultantEquityIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_4d120a57-b9a8-4d22-941e-fad406dfbada" xlink:to="loc_mygn_TwoThousandSeventeenEmployeeDirectorAndConsultantEquityIncentivePlanMember_d77912e5-360a-4fe9-b857-479d7fdd39af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_EmployeeStockPurchasePlanTwentyTwelveMember_779c3b54-6c52-4ad2-b4f7-55ad24383616" xlink:href="mygn-20210930.xsd#mygn_EmployeeStockPurchasePlanTwentyTwelveMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_4d120a57-b9a8-4d22-941e-fad406dfbada" xlink:to="loc_mygn_EmployeeStockPurchasePlanTwentyTwelveMember_779c3b54-6c52-4ad2-b4f7-55ad24383616" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_7f80f9d1-e186-401e-8bfa-318dafe484c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f2dd203e-ee3a-4496-91e7-3e84f3547ad9" xlink:to="loc_us-gaap_AwardTypeAxis_7f80f9d1-e186-401e-8bfa-318dafe484c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c8f76aa6-4373-452a-91f2-f3823393af49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_7f80f9d1-e186-401e-8bfa-318dafe484c4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c8f76aa6-4373-452a-91f2-f3823393af49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_OptionsAndRestrictedStockUnitsMember_1fb762e1-ca75-47b4-83c3-bf45b955fb58" xlink:href="mygn-20210930.xsd#mygn_OptionsAndRestrictedStockUnitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c8f76aa6-4373-452a-91f2-f3823393af49" xlink:to="loc_mygn_OptionsAndRestrictedStockUnitsMember_1fb762e1-ca75-47b4-83c3-bf45b955fb58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_92a1d975-2c27-48e6-9447-dec8e60396aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_OptionsAndRestrictedStockUnitsMember_1fb762e1-ca75-47b4-83c3-bf45b955fb58" xlink:to="loc_us-gaap_EmployeeStockOptionMember_92a1d975-2c27-48e6-9447-dec8e60396aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_ec768f64-945b-4b17-8be9-d63719a1f706" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_OptionsAndRestrictedStockUnitsMember_1fb762e1-ca75-47b4-83c3-bf45b955fb58" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_ec768f64-945b-4b17-8be9-d63719a1f706" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateAxis_780c9585-2895-42e1-a780-7eb0cf99f2bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardDateAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f2dd203e-ee3a-4496-91e7-3e84f3547ad9" xlink:to="loc_us-gaap_AwardDateAxis_780c9585-2895-42e1-a780-7eb0cf99f2bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateDomain_b2bd2cea-f391-462a-a97c-68a644d9c72c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardDateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardDateAxis_780c9585-2895-42e1-a780-7eb0cf99f2bb" xlink:to="loc_us-gaap_AwardDateDomain_b2bd2cea-f391-462a-a97c-68a644d9c72c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_OptionsGrantedAfterDecemberFiveTwentyTwelveMember_be5fc5c5-df81-49a9-be3b-a72b5b2be091" xlink:href="mygn-20210930.xsd#mygn_OptionsGrantedAfterDecemberFiveTwentyTwelveMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardDateDomain_b2bd2cea-f391-462a-a97c-68a644d9c72c" xlink:to="loc_mygn_OptionsGrantedAfterDecemberFiveTwentyTwelveMember_be5fc5c5-df81-49a9-be3b-a72b5b2be091" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_OptionsGrantedPriorToDecemberFiveTwentyTwelveMember_1bc41959-a9dd-4d6c-89ee-9209d223833d" xlink:href="mygn-20210930.xsd#mygn_OptionsGrantedPriorToDecemberFiveTwentyTwelveMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardDateDomain_b2bd2cea-f391-462a-a97c-68a644d9c72c" xlink:to="loc_mygn_OptionsGrantedPriorToDecemberFiveTwentyTwelveMember_1bc41959-a9dd-4d6c-89ee-9209d223833d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_7d0cb281-2900-4a9b-bcc3-0a9edbf97fd3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f2dd203e-ee3a-4496-91e7-3e84f3547ad9" xlink:to="loc_srt_TitleOfIndividualAxis_7d0cb281-2900-4a9b-bcc3-0a9edbf97fd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_37f8fd4f-05dd-4e6f-877f-f9e29354a57c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_7d0cb281-2900-4a9b-bcc3-0a9edbf97fd3" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_37f8fd4f-05dd-4e6f-877f-f9e29354a57c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_NonEmployeeDirectorMember_c71ca8b0-c1db-41a6-b572-10512020c9a6" xlink:href="mygn-20210930.xsd#mygn_NonEmployeeDirectorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_37f8fd4f-05dd-4e6f-877f-f9e29354a57c" xlink:to="loc_mygn_NonEmployeeDirectorMember_c71ca8b0-c1db-41a6-b572-10512020c9a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5664f498-5375-426c-aca0-05c5b83415e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f2dd203e-ee3a-4496-91e7-3e84f3547ad9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5664f498-5375-426c-aca0-05c5b83415e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_a2aa1b20-8299-4363-ab27-83283f994aeb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5664f498-5375-426c-aca0-05c5b83415e1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_a2aa1b20-8299-4363-ab27-83283f994aeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_9547c168-6bc5-4e53-83a7-bdc058ee7330" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5664f498-5375-426c-aca0-05c5b83415e1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_9547c168-6bc5-4e53-83a7-bdc058ee7330" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_ecd54ecb-e208-4ba1-a368-7b9524e71d6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5664f498-5375-426c-aca0-05c5b83415e1" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_ecd54ecb-e208-4ba1-a368-7b9524e71d6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_345132a0-0fd1-4b18-8336-aef47ffb4c0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5664f498-5375-426c-aca0-05c5b83415e1" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_345132a0-0fd1-4b18-8336-aef47ffb4c0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_e912cbfa-be48-43e7-8831-164ed00f9f10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5664f498-5375-426c-aca0-05c5b83415e1" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_e912cbfa-be48-43e7-8831-164ed00f9f10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_72cba667-82b0-42aa-a416-4eb7eb38cc05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5664f498-5375-426c-aca0-05c5b83415e1" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_72cba667-82b0-42aa-a416-4eb7eb38cc05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_65bec041-7b9b-437a-accd-2ee22912da8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5664f498-5375-426c-aca0-05c5b83415e1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_65bec041-7b9b-437a-accd-2ee22912da8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_de8ffae7-ccba-4751-8d53-f688dc95aa74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5664f498-5375-426c-aca0-05c5b83415e1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_de8ffae7-ccba-4751-8d53-f688dc95aa74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_9a57bf52-52e4-4280-b659-fae035178583" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5664f498-5375-426c-aca0-05c5b83415e1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_9a57bf52-52e4-4280-b659-fae035178583" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_bc03244d-0324-4be5-9c7c-ef66ac77d176" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5664f498-5375-426c-aca0-05c5b83415e1" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_bc03244d-0324-4be5-9c7c-ef66ac77d176" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="simple" xlink:href="mygn-20210930.xsd#StockBasedCompensationStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7b133a3e-7b0f-4458-8e62-ac68738c0358" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_bf2b0134-3348-470d-b152-efd86688589a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7b133a3e-7b0f-4458-8e62-ac68738c0358" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_bf2b0134-3348-470d-b152-efd86688589a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8694a383-e3fa-4346-a2a9-9748cf354be5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_bf2b0134-3348-470d-b152-efd86688589a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8694a383-e3fa-4346-a2a9-9748cf354be5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_310b6fea-c077-4c82-969b-1f9dacf10ef7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_bf2b0134-3348-470d-b152-efd86688589a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_310b6fea-c077-4c82-969b-1f9dacf10ef7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_64b8ec93-ea8c-482b-8b25-db3d0a8edb5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_bf2b0134-3348-470d-b152-efd86688589a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_64b8ec93-ea8c-482b-8b25-db3d0a8edb5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_8332ec55-ed40-4c34-b32b-62fdaf55b422" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_bf2b0134-3348-470d-b152-efd86688589a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_8332ec55-ed40-4c34-b32b-62fdaf55b422" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_137b1062-3c48-483b-bb5e-7b1114d65aea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_bf2b0134-3348-470d-b152-efd86688589a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_137b1062-3c48-483b-bb5e-7b1114d65aea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_83c80452-f5c0-4385-b5bd-66fe3311af5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7b133a3e-7b0f-4458-8e62-ac68738c0358" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_83c80452-f5c0-4385-b5bd-66fe3311af5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_eeb60aa6-3620-4e22-98df-3683267a4a04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7b133a3e-7b0f-4458-8e62-ac68738c0358" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_eeb60aa6-3620-4e22-98df-3683267a4a04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5e7723a9-c964-4cba-b468-8e73503e5c95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_eeb60aa6-3620-4e22-98df-3683267a4a04" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5e7723a9-c964-4cba-b468-8e73503e5c95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_dde6e741-86bf-4f75-9655-12e96f310595" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_eeb60aa6-3620-4e22-98df-3683267a4a04" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_dde6e741-86bf-4f75-9655-12e96f310595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_b19f8afc-3b5a-49eb-9115-375023bacc54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_eeb60aa6-3620-4e22-98df-3683267a4a04" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_b19f8afc-3b5a-49eb-9115-375023bacc54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_1360165a-899d-4f53-b11f-17758156b89c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_eeb60aa6-3620-4e22-98df-3683267a4a04" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_1360165a-899d-4f53-b11f-17758156b89c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b514e235-4b06-4baa-a799-84563ad87b1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_eeb60aa6-3620-4e22-98df-3683267a4a04" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b514e235-4b06-4baa-a799-84563ad87b1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_a3a3b184-0e85-4802-b61a-ee010707e62e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7b133a3e-7b0f-4458-8e62-ac68738c0358" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_a3a3b184-0e85-4802-b61a-ee010707e62e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/StockBasedCompensationRSUActivityDetails" xlink:type="simple" xlink:href="mygn-20210930.xsd#StockBasedCompensationRSUActivityDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/StockBasedCompensationRSUActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ea72c2de-bb43-476e-95e3-76fa62cf8b73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6c6ecf36-2ff6-42a7-8811-ec915b5222da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ea72c2de-bb43-476e-95e3-76fa62cf8b73" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6c6ecf36-2ff6-42a7-8811-ec915b5222da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_bc10e7bf-85ae-486e-8927-5a30ac01eede" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6c6ecf36-2ff6-42a7-8811-ec915b5222da" xlink:to="loc_us-gaap_AwardTypeAxis_bc10e7bf-85ae-486e-8927-5a30ac01eede" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a7cb1661-a05e-4a41-8ac7-c13c07616683" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_bc10e7bf-85ae-486e-8927-5a30ac01eede" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a7cb1661-a05e-4a41-8ac7-c13c07616683" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_0fca42a1-e53f-4ca2-ac51-47df075c8b86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a7cb1661-a05e-4a41-8ac7-c13c07616683" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_0fca42a1-e53f-4ca2-ac51-47df075c8b86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4f7cab73-0611-44ca-ac5b-10751591540c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6c6ecf36-2ff6-42a7-8811-ec915b5222da" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4f7cab73-0611-44ca-ac5b-10751591540c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1e6eca4b-6d01-4355-8110-a50cc866e1ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4f7cab73-0611-44ca-ac5b-10751591540c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1e6eca4b-6d01-4355-8110-a50cc866e1ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_852b2213-7005-4ddc-b918-91450d00bb29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1e6eca4b-6d01-4355-8110-a50cc866e1ff" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_852b2213-7005-4ddc-b918-91450d00bb29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_ad3b7e57-8717-4d50-be25-4f03a7eae8c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1e6eca4b-6d01-4355-8110-a50cc866e1ff" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_ad3b7e57-8717-4d50-be25-4f03a7eae8c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_6af89b31-2764-441e-a421-56fe105df6a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1e6eca4b-6d01-4355-8110-a50cc866e1ff" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_6af89b31-2764-441e-a421-56fe105df6a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_9cdd7200-32a4-4e2a-b44c-8eff4b36d29a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1e6eca4b-6d01-4355-8110-a50cc866e1ff" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_9cdd7200-32a4-4e2a-b44c-8eff4b36d29a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_e2022426-0e72-4caa-8528-44554b24c63b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1e6eca4b-6d01-4355-8110-a50cc866e1ff" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_e2022426-0e72-4caa-8528-44554b24c63b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_be9f2ced-b42c-4468-8136-16798fe8f3f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4f7cab73-0611-44ca-ac5b-10751591540c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_be9f2ced-b42c-4468-8136-16798fe8f3f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_fe720568-9074-43b3-abe4-34bf53632c27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_be9f2ced-b42c-4468-8136-16798fe8f3f6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_fe720568-9074-43b3-abe4-34bf53632c27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a2d69fce-1fd8-42d4-9c8f-3665c421354c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_be9f2ced-b42c-4468-8136-16798fe8f3f6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a2d69fce-1fd8-42d4-9c8f-3665c421354c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_7e7a2d3d-41dd-4c22-b123-24a99f0d6f07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_be9f2ced-b42c-4468-8136-16798fe8f3f6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_7e7a2d3d-41dd-4c22-b123-24a99f0d6f07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_6bc4787b-b1d9-4bd8-9827-8869ceae15e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_be9f2ced-b42c-4468-8136-16798fe8f3f6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_6bc4787b-b1d9-4bd8-9827-8869ceae15e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6f5ce908-b566-408b-9550-afe7ead54d8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_be9f2ced-b42c-4468-8136-16798fe8f3f6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6f5ce908-b566-408b-9550-afe7ead54d8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="mygn-20210930.xsd#StockBasedCompensationStockBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_91e33869-e4f0-44a2-8785-9468148714cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_16e4e42e-b30c-4fd1-ae46-957bc189ffef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_91e33869-e4f0-44a2-8785-9468148714cf" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_16e4e42e-b30c-4fd1-ae46-957bc189ffef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_a2ae73c4-0216-4f93-be22-e4b3462bfe7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_16e4e42e-b30c-4fd1-ae46-957bc189ffef" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_a2ae73c4-0216-4f93-be22-e4b3462bfe7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_f85703e1-9e8c-4e88-816e-bd5d6a2ac803" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_a2ae73c4-0216-4f93-be22-e4b3462bfe7c" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_f85703e1-9e8c-4e88-816e-bd5d6a2ac803" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_CostOfMolecularDiagnosticTestingMember_27c268d2-251a-4a9c-8824-50f5ddbf0d9f" xlink:href="mygn-20210930.xsd#mygn_CostOfMolecularDiagnosticTestingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_f85703e1-9e8c-4e88-816e-bd5d6a2ac803" xlink:to="loc_mygn_CostOfMolecularDiagnosticTestingMember_27c268d2-251a-4a9c-8824-50f5ddbf0d9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_CostOfPharmaceuticalAndClinicalServicesMember_ef0cc2a7-0bc3-4971-bce4-cb81f7888eb0" xlink:href="mygn-20210930.xsd#mygn_CostOfPharmaceuticalAndClinicalServicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_f85703e1-9e8c-4e88-816e-bd5d6a2ac803" xlink:to="loc_mygn_CostOfPharmaceuticalAndClinicalServicesMember_ef0cc2a7-0bc3-4971-bce4-cb81f7888eb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_e92f9223-1c23-4c43-9f01-41ca4e2dafaf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_f85703e1-9e8c-4e88-816e-bd5d6a2ac803" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_e92f9223-1c23-4c43-9f01-41ca4e2dafaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_6c6a490a-010d-441b-abba-7a6bec6fcf12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_f85703e1-9e8c-4e88-816e-bd5d6a2ac803" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_6c6a490a-010d-441b-abba-7a6bec6fcf12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2cb647a9-66d8-4c44-89e8-e3647bdd115e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_16e4e42e-b30c-4fd1-ae46-957bc189ffef" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2cb647a9-66d8-4c44-89e8-e3647bdd115e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_4f93e292-5c94-4476-8617-aca87143a39f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2cb647a9-66d8-4c44-89e8-e3647bdd115e" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_4f93e292-5c94-4476-8617-aca87143a39f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/IncomeTaxes" xlink:type="simple" xlink:href="mygn-20210930.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_55843922-a66d-43de-9a9e-8fc294d04db4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_a0fb81fc-0f3b-4a75-8515-e2198a41e75b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_55843922-a66d-43de-9a9e-8fc294d04db4" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_a0fb81fc-0f3b-4a75-8515-e2198a41e75b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="mygn-20210930.xsd#IncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_f48d4147-c01d-410f-b86d-8cbaf4890d9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_08c95d39-e683-472d-8eb1-276f7b8a0dab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f48d4147-c01d-410f-b86d-8cbaf4890d9f" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_08c95d39-e683-472d-8eb1-276f7b8a0dab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_966d70ba-4168-42c8-9fe7-413ab9713501" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_08c95d39-e683-472d-8eb1-276f7b8a0dab" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_966d70ba-4168-42c8-9fe7-413ab9713501" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_e6e8f135-f6d0-4346-ad9c-1664cad2d465" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_966d70ba-4168-42c8-9fe7-413ab9713501" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_e6e8f135-f6d0-4346-ad9c-1664cad2d465" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_bd218102-145e-4b3a-ac3e-a5cf2f0a6025" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_e6e8f135-f6d0-4346-ad9c-1664cad2d465" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_bd218102-145e-4b3a-ac3e-a5cf2f0a6025" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_d669c1af-6411-4249-9289-820dc978d308" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCountryMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_e6e8f135-f6d0-4346-ad9c-1664cad2d465" xlink:to="loc_us-gaap_ForeignCountryMember_d669c1af-6411-4249-9289-820dc978d308" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis_3d4e7546-3fe5-414f-97f5-9735e52f4365" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_08c95d39-e683-472d-8eb1-276f7b8a0dab" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameAxis_3d4e7546-3fe5-414f-97f5-9735e52f4365" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_95cdd758-5aba-4326-a079-a7318c7d504a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_3d4e7546-3fe5-414f-97f5-9735e52f4365" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_95cdd758-5aba-4326-a079-a7318c7d504a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CaliforniaFranchiseTaxBoardMember_00c7e2d2-2a19-4999-a1a8-c2b6fae0b873" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CaliforniaFranchiseTaxBoardMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_95cdd758-5aba-4326-a079-a7318c7d504a" xlink:to="loc_us-gaap_CaliforniaFranchiseTaxBoardMember_00c7e2d2-2a19-4999-a1a8-c2b6fae0b873" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewJerseyDivisionOfTaxationMember_e8874152-f756-4fde-ad72-2ab52468b510" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewJerseyDivisionOfTaxationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_95cdd758-5aba-4326-a079-a7318c7d504a" xlink:to="loc_us-gaap_NewJerseyDivisionOfTaxationMember_e8874152-f756-4fde-ad72-2ab52468b510" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalMinistryOfFinanceGermanyMember_715c104f-442b-46a6-90da-a9c500f3df7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FederalMinistryOfFinanceGermanyMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_95cdd758-5aba-4326-a079-a7318c7d504a" xlink:to="loc_us-gaap_FederalMinistryOfFinanceGermanyMember_715c104f-442b-46a6-90da-a9c500f3df7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SwissFederalTaxAdministrationFTAMember_e18ecf17-c7bf-48a3-9acf-4b796df08a4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SwissFederalTaxAdministrationFTAMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_95cdd758-5aba-4326-a079-a7318c7d504a" xlink:to="loc_us-gaap_SwissFederalTaxAdministrationFTAMember_e18ecf17-c7bf-48a3-9acf-4b796df08a4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis_3732ae2d-959d-4685-870a-b0bb6f1d3430" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_08c95d39-e683-472d-8eb1-276f7b8a0dab" xlink:to="loc_us-gaap_TaxPeriodAxis_3732ae2d-959d-4685-870a-b0bb6f1d3430" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_d19042f0-f4fe-49f1-9286-c2bfff381155" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodAxis_3732ae2d-959d-4685-870a-b0bb6f1d3430" xlink:to="loc_us-gaap_TaxPeriodDomain_d19042f0-f4fe-49f1-9286-c2bfff381155" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarliestTaxYearMember_fbfc5233-9cb5-486d-84d5-476d09906976" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarliestTaxYearMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_d19042f0-f4fe-49f1-9286-c2bfff381155" xlink:to="loc_us-gaap_EarliestTaxYearMember_fbfc5233-9cb5-486d-84d5-476d09906976" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LatestTaxYearMember_7eaf327e-8a7e-41ba-bcc8-445ca712d338" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LatestTaxYearMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_d19042f0-f4fe-49f1-9286-c2bfff381155" xlink:to="loc_us-gaap_LatestTaxYearMember_7eaf327e-8a7e-41ba-bcc8-445ca712d338" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_8e26a3fa-67f2-4cc4-b936-0ad1fbfe396b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_08c95d39-e683-472d-8eb1-276f7b8a0dab" xlink:to="loc_us-gaap_IncomeTaxContingencyLineItems_8e26a3fa-67f2-4cc4-b936-0ad1fbfe396b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_de1030f3-3376-405f-916b-9ed2b4adc7d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_8e26a3fa-67f2-4cc4-b936-0ad1fbfe396b" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_de1030f3-3376-405f-916b-9ed2b4adc7d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_d312c6ef-76d6-46ce-aae3-c1e59a24c309" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_8e26a3fa-67f2-4cc4-b936-0ad1fbfe396b" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_d312c6ef-76d6-46ce-aae3-c1e59a24c309" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationYearUnderExamination_d5d5331e-4a93-45c9-927b-68a343dbd67d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExaminationYearUnderExamination"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_8e26a3fa-67f2-4cc4-b936-0ad1fbfe396b" xlink:to="loc_us-gaap_IncomeTaxExaminationYearUnderExamination_d5d5331e-4a93-45c9-927b-68a343dbd67d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="mygn-20210930.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_165c2fa0-9571-4b7e-a304-0d4779c1107f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_40cd79b9-4063-4f17-adfb-e630b6738a4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_165c2fa0-9571-4b7e-a304-0d4779c1107f" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_40cd79b9-4063-4f17-adfb-e630b6738a4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="mygn-20210930.xsd#CommitmentsandContingenciesDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f94bdb6f-d41a-4972-94e0-35a08f046099" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveCurrent_71386632-cf26-499d-bd45-f4f9b33c7d97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationReserveCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f94bdb6f-d41a-4972-94e0-35a08f046099" xlink:to="loc_us-gaap_LitigationReserveCurrent_71386632-cf26-499d-bd45-f4f9b33c7d97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/SegmentandRelatedInformation" xlink:type="simple" xlink:href="mygn-20210930.xsd#SegmentandRelatedInformation"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/SegmentandRelatedInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_96d0eedd-9472-45ff-89ed-0ac85da3140c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_b31a8a95-4be7-4b2a-8c87-9404f7f27182" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_96d0eedd-9472-45ff-89ed-0ac85da3140c" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_b31a8a95-4be7-4b2a-8c87-9404f7f27182" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/SegmentandRelatedInformationTables" xlink:type="simple" xlink:href="mygn-20210930.xsd#SegmentandRelatedInformationTables"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/SegmentandRelatedInformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_820100e2-fde1-40b1-a2f2-71bd327240fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_a6311a69-8764-43d0-b259-d654fcbd7ba8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_820100e2-fde1-40b1-a2f2-71bd327240fb" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_a6311a69-8764-43d0-b259-d654fcbd7ba8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/SegmentandRelatedInformationNarrativeDetails" xlink:type="simple" xlink:href="mygn-20210930.xsd#SegmentandRelatedInformationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/SegmentandRelatedInformationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_1876253e-df45-4426-9b62-3a82204735e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_9bf480bf-26aa-4be0-b158-bddf32deab93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_1876253e-df45-4426-9b62-3a82204735e8" xlink:to="loc_us-gaap_NumberOfReportableSegments_9bf480bf-26aa-4be0-b158-bddf32deab93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/SegmentandRelatedInformationSegmentRevenueandOperatingIncomeLossDetails" xlink:type="simple" xlink:href="mygn-20210930.xsd#SegmentandRelatedInformationSegmentRevenueandOperatingIncomeLossDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/SegmentandRelatedInformationSegmentRevenueandOperatingIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_5a6c5e09-66eb-4bc6-8f58-35e9b13d5ba7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_87b37da3-b3ba-48c2-9b4f-4296d42086db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_5a6c5e09-66eb-4bc6-8f58-35e9b13d5ba7" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_87b37da3-b3ba-48c2-9b4f-4296d42086db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_d1f6ed16-630b-4d8f-b5e2-f55b9703dd12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_87b37da3-b3ba-48c2-9b4f-4296d42086db" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_d1f6ed16-630b-4d8f-b5e2-f55b9703dd12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_90802b7e-f24b-4cfc-9aef-89e9199bed74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_d1f6ed16-630b-4d8f-b5e2-f55b9703dd12" xlink:to="loc_us-gaap_SegmentDomain_90802b7e-f24b-4cfc-9aef-89e9199bed74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_DiagnosticsMember_8c9f533f-0715-41bd-8a1d-d62bf3b896f2" xlink:href="mygn-20210930.xsd#mygn_DiagnosticsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_90802b7e-f24b-4cfc-9aef-89e9199bed74" xlink:to="loc_mygn_DiagnosticsMember_8c9f533f-0715-41bd-8a1d-d62bf3b896f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_5d406354-320e-442f-99bd-b510aaf29fc6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_90802b7e-f24b-4cfc-9aef-89e9199bed74" xlink:to="loc_us-gaap_AllOtherSegmentsMember_5d406354-320e-442f-99bd-b510aaf29fc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_0da40328-6ba8-4fbd-b8be-185e542300a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_87b37da3-b3ba-48c2-9b4f-4296d42086db" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_0da40328-6ba8-4fbd-b8be-185e542300a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b912f535-642d-49de-9b2e-8d76be8e98e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_0da40328-6ba8-4fbd-b8be-185e542300a8" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b912f535-642d-49de-9b2e-8d76be8e98e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_d03c6968-397c-4519-b0c2-b1b1018dc3e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_0da40328-6ba8-4fbd-b8be-185e542300a8" xlink:to="loc_us-gaap_DepreciationAndAmortization_d03c6968-397c-4519-b0c2-b1b1018dc3e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_a4a1fe2c-acb6-48fe-b595-fc4a5223857a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_0da40328-6ba8-4fbd-b8be-185e542300a8" xlink:to="loc_us-gaap_OperatingIncomeLoss_a4a1fe2c-acb6-48fe-b595-fc4a5223857a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/SegmentandRelatedInformationTotalOperatingLossforReportableSegmentsDetails" xlink:type="simple" xlink:href="mygn-20210930.xsd#SegmentandRelatedInformationTotalOperatingLossforReportableSegmentsDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/SegmentandRelatedInformationTotalOperatingLossforReportableSegmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_7de2bbda-5645-4d57-baa8-d47e7567ab47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_4c28b5a1-d638-44e9-8d7b-f1c5f9bbb6d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_7de2bbda-5645-4d57-baa8-d47e7567ab47" xlink:to="loc_us-gaap_OperatingIncomeLoss_4c28b5a1-d638-44e9-8d7b-f1c5f9bbb6d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_93e1cfab-a2fd-49b9-8bed-d20526340df6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_7de2bbda-5645-4d57-baa8-d47e7567ab47" xlink:to="loc_us-gaap_InvestmentIncomeInterest_93e1cfab-a2fd-49b9-8bed-d20526340df6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_60e9d0d3-b626-452d-bcf3-d4264aabbbe1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_7de2bbda-5645-4d57-baa8-d47e7567ab47" xlink:to="loc_us-gaap_InterestExpense_60e9d0d3-b626-452d-bcf3-d4264aabbbe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_9fefadf1-06ff-4a69-b337-46b9fa5e3cca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_7de2bbda-5645-4d57-baa8-d47e7567ab47" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_9fefadf1-06ff-4a69-b337-46b9fa5e3cca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_867c500d-e11b-4c98-9c72-e1d0688cff45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_7de2bbda-5645-4d57-baa8-d47e7567ab47" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_867c500d-e11b-4c98-9c72-e1d0688cff45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_796cd480-8911-4975-9635-4140787316af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_7de2bbda-5645-4d57-baa8-d47e7567ab47" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_796cd480-8911-4975-9635-4140787316af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_4a002e8e-4a2b-4987-845d-dd727728f71d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_7de2bbda-5645-4d57-baa8-d47e7567ab47" xlink:to="loc_us-gaap_ProfitLoss_4a002e8e-4a2b-4987-845d-dd727728f71d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_5c6af431-54ad-408b-ae2e-3383b3fd7ffa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_7de2bbda-5645-4d57-baa8-d47e7567ab47" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_5c6af431-54ad-408b-ae2e-3383b3fd7ffa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_979f4262-2d76-4d1e-986e-e0bdedaac613" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_7de2bbda-5645-4d57-baa8-d47e7567ab47" xlink:to="loc_us-gaap_NetIncomeLoss_979f4262-2d76-4d1e-986e-e0bdedaac613" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/SupplementalCashFlowInformation" xlink:type="simple" xlink:href="mygn-20210930.xsd#SupplementalCashFlowInformation"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/SupplementalCashFlowInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_10d157c8-7720-4c43-b61c-2121f65ade41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowSupplementalDisclosuresTextBlock_9500e232-bdf4-45fd-8288-c5f9b7f87c68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowSupplementalDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_10d157c8-7720-4c43-b61c-2121f65ade41" xlink:to="loc_us-gaap_CashFlowSupplementalDisclosuresTextBlock_9500e232-bdf4-45fd-8288-c5f9b7f87c68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/SupplementalCashFlowInformationTables" xlink:type="simple" xlink:href="mygn-20210930.xsd#SupplementalCashFlowInformationTables"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/SupplementalCashFlowInformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_b8ecf6e4-cb66-4805-9b20-2ce087141ff9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_55adbe2a-c204-467b-8d3d-22c4aa7df803" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_b8ecf6e4-cb66-4805-9b20-2ce087141ff9" xlink:to="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_55adbe2a-c204-467b-8d3d-22c4aa7df803" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/SupplementalCashFlowInformationDetails" xlink:type="simple" xlink:href="mygn-20210930.xsd#SupplementalCashFlowInformationDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/SupplementalCashFlowInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_718fcdc0-1a9f-4392-94b7-b74e737698e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_27bd92b4-9ae0-4f31-9e4d-19a5ff5f3f96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_718fcdc0-1a9f-4392-94b7-b74e737698e4" xlink:to="loc_us-gaap_IncomeTaxesPaid_27bd92b4-9ae0-4f31-9e4d-19a5ff5f3f96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_7727e747-df06-4682-b9db-e79d6909d612" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_718fcdc0-1a9f-4392-94b7-b74e737698e4" xlink:to="loc_us-gaap_InterestPaidNet_7727e747-df06-4682-b9db-e79d6909d612" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIncomeTaxRefunds_eb2439fe-ffeb-46e6-924a-2c9439f4e9c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIncomeTaxRefunds"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_718fcdc0-1a9f-4392-94b7-b74e737698e4" xlink:to="loc_us-gaap_ProceedsFromIncomeTaxRefunds_eb2439fe-ffeb-46e6-924a-2c9439f4e9c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_6423cb51-887b-44c7-a08e-5b0e699055cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowOperatingActivitiesLesseeAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_718fcdc0-1a9f-4392-94b7-b74e737698e4" xlink:to="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_6423cb51-887b-44c7-a08e-5b0e699055cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_0bacdf1e-3a76-4898-82cf-76355f72d172" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_6423cb51-887b-44c7-a08e-5b0e699055cc" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_0bacdf1e-3a76-4898-82cf-76355f72d172" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_OperatingLeaseLiabilityEstablished_b9b57cea-31a9-49de-82d0-2a35a381e1d5" xlink:href="mygn-20210930.xsd#mygn_OperatingLeaseLiabilityEstablished"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_6423cb51-887b-44c7-a08e-5b0e699055cc" xlink:to="loc_mygn_OperatingLeaseLiabilityEstablished_b9b57cea-31a9-49de-82d0-2a35a381e1d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/Divestitures" xlink:type="simple" xlink:href="mygn-20210930.xsd#Divestitures"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/Divestitures" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_c43906c8-06e3-4719-aa51-f2a0d0349e86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_ed97419b-31e0-46d1-95d9-c81495ccf003" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_c43906c8-06e3-4719-aa51-f2a0d0349e86" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_ed97419b-31e0-46d1-95d9-c81495ccf003" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/DivestituresTables" xlink:type="simple" xlink:href="mygn-20210930.xsd#DivestituresTables"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/DivestituresTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_4c29830a-faaf-4a45-8830-a78622e91727" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_45a70e3e-424a-4a63-837c-0f2f05ff4474" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_4c29830a-faaf-4a45-8830-a78622e91727" xlink:to="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_45a70e3e-424a-4a63-837c-0f2f05ff4474" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/DivestituresNarrativeDetails" xlink:type="simple" xlink:href="mygn-20210930.xsd#DivestituresNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/DivestituresNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_db6722df-fb6f-4c4c-966f-6d1fa6c774e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_a7f840ec-368b-4347-be7b-98d8ec56485d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_db6722df-fb6f-4c4c-966f-6d1fa6c774e1" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_a7f840ec-368b-4347-be7b-98d8ec56485d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_ad89394d-a9bb-48ca-9ef7-04aac459bbee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_a7f840ec-368b-4347-be7b-98d8ec56485d" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_ad89394d-a9bb-48ca-9ef7-04aac459bbee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_1e519fe9-db99-4702-9fdf-b25858704e78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_ad89394d-a9bb-48ca-9ef7-04aac459bbee" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_1e519fe9-db99-4702-9fdf-b25858704e78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_59a4a60b-2ac9-4677-af76-8cc480f1cc2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_1e519fe9-db99-4702-9fdf-b25858704e78" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_59a4a60b-2ac9-4677-af76-8cc480f1cc2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_e7877f20-04d4-408f-9bc9-b13875940445" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_a7f840ec-368b-4347-be7b-98d8ec56485d" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_e7877f20-04d4-408f-9bc9-b13875940445" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_8aca7c22-d500-4b34-acf3-1f7832509efe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_e7877f20-04d4-408f-9bc9-b13875940445" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_8aca7c22-d500-4b34-acf3-1f7832509efe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MyriadMyPathLLCLaboratoryMember_6af11b85-513b-4498-84d5-9e170950636a" xlink:href="mygn-20210930.xsd#mygn_MyriadMyPathLLCLaboratoryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_8aca7c22-d500-4b34-acf3-1f7832509efe" xlink:to="loc_mygn_MyriadMyPathLLCLaboratoryMember_6af11b85-513b-4498-84d5-9e170950636a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MyriadRBMIncMember_d97750aa-93e4-44a4-b3b4-41e9112b529c" xlink:href="mygn-20210930.xsd#mygn_MyriadRBMIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_8aca7c22-d500-4b34-acf3-1f7832509efe" xlink:to="loc_mygn_MyriadRBMIncMember_d97750aa-93e4-44a4-b3b4-41e9112b529c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MyriadAutoimmuneAssetsMember_62afd424-7bd4-4c1a-8c0d-3e7b0e786589" xlink:href="mygn-20210930.xsd#mygn_MyriadAutoimmuneAssetsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_8aca7c22-d500-4b34-acf3-1f7832509efe" xlink:to="loc_mygn_MyriadAutoimmuneAssetsMember_62afd424-7bd4-4c1a-8c0d-3e7b0e786589" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_e1bc947b-864d-472f-9e06-05d355417156" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_a7f840ec-368b-4347-be7b-98d8ec56485d" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_e1bc947b-864d-472f-9e06-05d355417156" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_02aa4314-af2e-4c34-b418-4ed86859ac52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_e1bc947b-864d-472f-9e06-05d355417156" xlink:to="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_02aa4314-af2e-4c34-b418-4ed86859ac52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries_cc3cc024-252f-4974-8b8f-eafce6462ac2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_e1bc947b-864d-472f-9e06-05d355417156" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries_cc3cc024-252f-4974-8b8f-eafce6462ac2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_GainLossOnDispositionOfAssetsNetOfTransactionFees_a7a31237-0f1e-4e4f-b6c0-62b6fe98d866" xlink:href="mygn-20210930.xsd#mygn_GainLossOnDispositionOfAssetsNetOfTransactionFees"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_e1bc947b-864d-472f-9e06-05d355417156" xlink:to="loc_mygn_GainLossOnDispositionOfAssetsNetOfTransactionFees_a7a31237-0f1e-4e4f-b6c0-62b6fe98d866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_5e4a70c8-cde5-468e-8fb9-dd94f7da05c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_e1bc947b-864d-472f-9e06-05d355417156" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_5e4a70c8-cde5-468e-8fb9-dd94f7da05c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_DisposalGroupNotDiscontinuedOperationTransactionCosts_284efff4-25bd-4120-9488-3e6066844ad0" xlink:href="mygn-20210930.xsd#mygn_DisposalGroupNotDiscontinuedOperationTransactionCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_e1bc947b-864d-472f-9e06-05d355417156" xlink:to="loc_mygn_DisposalGroupNotDiscontinuedOperationTransactionCosts_284efff4-25bd-4120-9488-3e6066844ad0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFirmPurchaseCommitmentLoss_4c306bcf-9f1e-4a1e-9792-fe3aef038ebf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFirmPurchaseCommitmentLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_e1bc947b-864d-472f-9e06-05d355417156" xlink:to="loc_us-gaap_InventoryFirmPurchaseCommitmentLoss_4c306bcf-9f1e-4a1e-9792-fe3aef038ebf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_c8ef1154-481e-42ae-bcc4-07dcda7ad12c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWriteDown"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_e1bc947b-864d-472f-9e06-05d355417156" xlink:to="loc_us-gaap_InventoryWriteDown_c8ef1154-481e-42ae-bcc4-07dcda7ad12c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/DivestituresOtherIncomeDetails" xlink:type="simple" xlink:href="mygn-20210930.xsd#DivestituresOtherIncomeDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/DivestituresOtherIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_56267b74-3297-4ef4-b27d-15f31cd26bb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_6b497a09-f761-473d-b75f-013d209fb230" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_56267b74-3297-4ef4-b27d-15f31cd26bb1" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_6b497a09-f761-473d-b75f-013d209fb230" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_a802a8f2-c0c2-40f3-9c98-75cc51b26b0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_6b497a09-f761-473d-b75f-013d209fb230" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_a802a8f2-c0c2-40f3-9c98-75cc51b26b0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_43a1b417-289e-4d57-a9a0-7017bbbca65e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_a802a8f2-c0c2-40f3-9c98-75cc51b26b0e" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_43a1b417-289e-4d57-a9a0-7017bbbca65e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MyriadRBMIncMember_db73c596-511e-4903-816f-3d7372ce5449" xlink:href="mygn-20210930.xsd#mygn_MyriadRBMIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_43a1b417-289e-4d57-a9a0-7017bbbca65e" xlink:to="loc_mygn_MyriadRBMIncMember_db73c596-511e-4903-816f-3d7372ce5449" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MyriadMyPathLLCLaboratoryMember_90d2915a-0ab0-4547-bff4-e3f4a1229bf3" xlink:href="mygn-20210930.xsd#mygn_MyriadMyPathLLCLaboratoryMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_43a1b417-289e-4d57-a9a0-7017bbbca65e" xlink:to="loc_mygn_MyriadMyPathLLCLaboratoryMember_90d2915a-0ab0-4547-bff4-e3f4a1229bf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MyriadAutoimmuneAssetsMember_547a85cf-570b-48be-995a-a43c751d8416" xlink:href="mygn-20210930.xsd#mygn_MyriadAutoimmuneAssetsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_43a1b417-289e-4d57-a9a0-7017bbbca65e" xlink:to="loc_mygn_MyriadAutoimmuneAssetsMember_547a85cf-570b-48be-995a-a43c751d8416" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_dae0cc56-93aa-46c5-9ef8-8e59528c6c00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_6b497a09-f761-473d-b75f-013d209fb230" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_dae0cc56-93aa-46c5-9ef8-8e59528c6c00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_85605f1a-605b-470b-a8fa-ac4efe015ea4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_dae0cc56-93aa-46c5-9ef8-8e59528c6c00" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_85605f1a-605b-470b-a8fa-ac4efe015ea4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_7865fe6a-1077-4a69-8fc7-4152b2183d0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_85605f1a-605b-470b-a8fa-ac4efe015ea4" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_7865fe6a-1077-4a69-8fc7-4152b2183d0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_8c80b7e3-36a7-4e0b-8c2d-1d9a7f9bdd49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_6b497a09-f761-473d-b75f-013d209fb230" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_8c80b7e3-36a7-4e0b-8c2d-1d9a7f9bdd49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_ebdff558-2461-4472-85d8-d2b8405932c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_8c80b7e3-36a7-4e0b-8c2d-1d9a7f9bdd49" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_ebdff558-2461-4472-85d8-d2b8405932c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_DisposalGroupNotDiscontinuedOperationGainLossOnInventory_7a607ea4-e830-424d-bf70-4c7980b35cf1" xlink:href="mygn-20210930.xsd#mygn_DisposalGroupNotDiscontinuedOperationGainLossOnInventory"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_8c80b7e3-36a7-4e0b-8c2d-1d9a7f9bdd49" xlink:to="loc_mygn_DisposalGroupNotDiscontinuedOperationGainLossOnInventory_7a607ea4-e830-424d-bf70-4c7980b35cf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_DisposalGroupNotDiscontinuedOperationGainLossOther_8596999d-6df7-4607-93f8-8779cdaca53e" xlink:href="mygn-20210930.xsd#mygn_DisposalGroupNotDiscontinuedOperationGainLossOther"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_8c80b7e3-36a7-4e0b-8c2d-1d9a7f9bdd49" xlink:to="loc_mygn_DisposalGroupNotDiscontinuedOperationGainLossOther_8596999d-6df7-4607-93f8-8779cdaca53e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_1b2c7ff9-054a-481f-8f05-1d318f491b5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_8c80b7e3-36a7-4e0b-8c2d-1d9a7f9bdd49" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_1b2c7ff9-054a-481f-8f05-1d318f491b5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/SubsequentEvents" xlink:type="simple" xlink:href="mygn-20210930.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_26c18305-5dd7-4d6c-8b11-8654b7111136" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_f6aa4199-885c-46da-8f9f-4c35a219a581" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_26c18305-5dd7-4d6c-8b11-8654b7111136" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_f6aa4199-885c-46da-8f9f-4c35a219a581" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>mygn-20210930_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2021"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:mygn="http://www.myriad.com/20210930"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="mygn-20210930.xsd" xlink:type="simple"/>
    <context id="i526dd58342b2430ab657188009969982_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i686dc3f8181f43699bf8c3b5a9751e8c_I20211027">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
        </entity>
        <period>
            <instant>2021-10-27</instant>
        </period>
    </context>
    <context id="i7bca861d20d64642b8c0cb91a290112d_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i21cc3685be5d4e2e8f00283addc53a8f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifbc28960af99464087c70e2155273621_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticTestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="icc0e2c6320b64071a6e19bf0ded7e102_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticTestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ie8a469542115473daa7666e3dceae657_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticTestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie51b08f1c1f44da4bb023303aa0fb7d9_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticTestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i79cd3eef56ae4f639da562ce851a382e_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:PharmaceuticalAndClinicalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie94a660aba69415a910d7f90711081eb_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:PharmaceuticalAndClinicalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i695f1ac67bde49628842e3563e17c85e_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:PharmaceuticalAndClinicalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib855c77efb97481b968697136ef35610_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:PharmaceuticalAndClinicalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic2c3e03438af4889ac973627c642f5ec_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic932914e17ea4777879ab952bc47a286_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if653f84940094fdc88956b69c3739df5_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9fd2bfc03de94eb4a23ff40a2dfd6fe7_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6735c278f56c4d2286aba604c5af25f6_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id8fe9a482f344283b898248f34c5db4d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic698543044ba4469ba8751bae898951c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3c851333c120429494592618fb0e4572_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ic26cca04ca2b4dd694bd9641fa5123c4_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ie993214cd1d8450aa22158093bdba0b6_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i8808683eb1f94ae4a2c56f558c2c44d0_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ic487f8b588f74b249c58ff8b2e14f2f2_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i749ef50c3e724e34a1c233ae09ec290a_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i838807b0749e445cb7c40c97e6854df5_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ia60976ab8abc463ebc9edd0688cead34_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ia1c450cd54f5427891132bfd983e0317_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ie2b71276d33f4f37af748f45b0cac148_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i71bfb9a9cbab40e4b2ee82f3c9d4e30b_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ib2ef1fdcdaaa463faa4cb4a9e259428b_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i61643ef3fddf427bab68f34f288ffdbe_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i273996af01934354b9835c65bd479b9e_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ief2d705cf1e84ddebcf24754f7a3b890_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="idd849afda7b942948aa9c83f57ffaeac_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="if5fc7e59c62b42ad92216ba6836b6eb8_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i1bce2263b540455893f4d80b0de511c9_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i8acfa22e3dc144acaa3254b56b5c801f_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ibc4b5cd85a7a4e8291ff3e4c80dc8756_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ic976e79981cb4e17a90b071ed83778dd_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ia9f2038ca2c74e13bf97f356d8a0ef8e_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i809ae31b44854c4eab5bc730c4471cb7_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7055540d7cfb415fafe2dac25f373950_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic19852c9069943c28e1fa3345a711650_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i691c4f02f3464e09bb1a483b5726a5c3_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i26e03ce4366849f4ad19d964861a49f7_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ib871f90b68b641f89b0eabe7f24ebcf9_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i5237cb26929043d6b2c706d0a5a289d6_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i9be196750c9340469be5f26a4d4e5835_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i0c6bac27ede64afeb4dbc13729f58578_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ifd82562daef9481db9764cfedc560e47_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i602bb4299a7f49a78984421bea48e2d2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6f1113acaf4c4991a6389007d99fd17f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic00338bab29748f28e289324358531f0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icc25381d7b004bd686b31d1d7f06dc8a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0fd66a47efdc463d8b56854a06ea9eb0_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ie59a85cd0de74256a4070826a06ab2ee_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i03600303e63e4b17b220e55c943b073d_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i1f2d8d71b25549ff846e9b42b31323ef_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i740bb39577154e0a943a066cee5730d4_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i14c8904c520e416b9c51933b8b024cd1_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i9fa028178e4d40088533a95f689bc888_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i9644cd21559142acbc76c26cfab92eb6_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ie6b465bbce9349f88227b2188438b68d_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i24dac68960214b9f993eaa8df10274b2_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i8032c809a65c47bda9a36a0b5229bfef_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i9af20bf23942493aad5860b2c2e56978_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie2a868eedf484113abf4a011ceff8fd4_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib07b6c87c8e242108fbc9023fce23cc9_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ia74c427781b6435fa165763f7d2b6818_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i03c0a03785d94bfa95d4de1d0a89a121_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i4438d624363b4476a68d74da26614067_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i3a1959e9612e44579e775f75a541e4a8_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i4b38d81b9f4e4aa8b1b021b9bb1b0958_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ie0450de8f0b54d7591325d511dad90ca_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i171029b6cf5d41df9d00d9688277e104_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i70b7a4c941544cd7894d1e4defd87c79_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i53e5c42e5a894d47b34f9f9504d85a50_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id7bead8553aa40e19e389e9e36a5a52f_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic89788fb0cac4113ab3e5d22b824bee3_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="if5489fa2beb84874846c50045cb4a8fe_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i12b5bd71050148fe920686b278365e75_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i1926bf39b52c48a4957fc9a924a82cf7_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="icffee6692ce64627b1016dc94b08f0f0_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ida000af1413e4fddbdffb1f6b6d73047_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticHereditaryCancerTestingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia65390d217d44664a03c7762eb80226c_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticHereditaryCancerTestingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="idb939ee30c9346759fabe2cbfd1ebf71_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticHereditaryCancerTestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib782ea6f17aa43faaa46806bd14f5af2_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticHereditaryCancerTestingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7942c920d42c4be98d7627dea2b75aab_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticHereditaryCancerTestingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7d4b33a6e9cf4ff695a151252fa5202d_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticHereditaryCancerTestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i9987b934bd0a407b89b3de550f71f1eb_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticTumorProfilingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i120342914ab84d57803cdba7e390e6e0_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticTumorProfilingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ifacd49fb220e4e6688cac0490136867d_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticTumorProfilingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="idc7756538c044225a9ce5c1d9d342449_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticTumorProfilingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i3bbf9b3b2d1b4c0c904cdd117771580a_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticTumorProfilingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="icc9ac75befb64b00b1cbd10949fa3e69_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticTumorProfilingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5f8b38682e3a4c6586f56116a4e54db9_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticPrenatalTestingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6b8709823fb647138c0501d0018d62cc_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticPrenatalTestingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iac13adff54494e56be97dcfc0308c7f5_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticPrenatalTestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie36dcf4cd4e14f4890cf021f262a8b82_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticPrenatalTestingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia94b623d77a449e49aa7fce28c810d9c_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticPrenatalTestingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i4acdbc594a6a4b88a090b04e5ef69aec_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticPrenatalTestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia5e3a39bcef84311a38d3c37cbbee981_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticPharmacogenomicsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1e84513d519942359ce079c27c934ab7_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticPharmacogenomicsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7f4d0d8a569142149d4db9527cbf6122_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticPharmacogenomicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i632d974bc19746629c875de8d85005de_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticPharmacogenomicsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia8ffaf88f5554b8a8bfb8d0f7aaef001_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticPharmacogenomicsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7e91c91b1c9a4945acdfe9e7245038ed_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticPharmacogenomicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7376ab53741d440ba61c388e5c932c1b_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticAutoimmuneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3c33023861bc44e592a2a61939a657a6_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticAutoimmuneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1ce0af94533d4d0cb17bfae079adab31_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticAutoimmuneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic1e715fa83dc47248899710d4f312340_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticAutoimmuneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i3d9d935b97a14723b2ce8cd0fdd3685b_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticAutoimmuneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia5880f6561e344b698bf53ef48281f5f_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticAutoimmuneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i8511c5f276ed4618bd7d3abcdfd81278_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticOtherTestingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7cd8b28b3de341ab88d9b759b56cb960_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticOtherTestingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i2269a2a3c55f4f48b394d629ae9ece31_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticOtherTestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic301e05aafb54177bf154d4e00dca137_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticOtherTestingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ie0c4bdb320014fe28dabebe98a245d34_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticOtherTestingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5428af14384f4775a235df5d1a72c351_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticOtherTestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i978447da133848e09d69b6941e3c3e12_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticTestingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9e833f5a117c4014b693ba5dbcd17f05_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticTestingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9f6b592da0d94089824ddd9eeaec60ca_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticTestingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i628878e014504ba3927b3541bbfee9d6_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticTestingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i2777203c45e44986ad24f2e01bb5cd2c_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:PharmaceuticalAndClinicalServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4bb010a87eb34230a4d879b7f8b5d7f3_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:PharmaceuticalAndClinicalServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if4850f75cb284b14b1e3b920fd17fee3_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:PharmaceuticalAndClinicalServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if98b526cb9c84315b8808c1225488499_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:PharmaceuticalAndClinicalServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i34864de2cd5e41bd98ef24a86d7f39a1_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5e6310ec543143dc8a87a1867afc2439_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3b754f9a3006470cb13ba2789a352d5e_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7eb57d5345554df7a7ffeb66aa7ef9d6_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i48501743237742c6975110396e917242_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticHereditaryCancerTestingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7824951a746645c39acedbdd215f57f5_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticHereditaryCancerTestingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ifcc2e81b5a204336b461cdc53955b3cd_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticHereditaryCancerTestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic7c83e62f13142e3bf47bdf15510f328_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticHereditaryCancerTestingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i18e0522d4e264244b4b7ff08c869a121_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticHereditaryCancerTestingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iee003a09d07f4dbf86ab56c0275a5909_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticHereditaryCancerTestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i9e5e62422b964677bbf81111118a8530_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticTumorProfilingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i2dd22965d073433da620ee6bb158d276_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticTumorProfilingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7fe0144d6efa41859c2eba711e85303a_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticTumorProfilingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i55af35cd863d4959bf0125bc9cb46d23_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticTumorProfilingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5c2131fe4d3c47358dd98a5d078c009b_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticTumorProfilingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic91ecdd5628742b5828be3bf25416996_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticTumorProfilingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ifae9cf930088446e9ad24962231957ba_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticPrenatalTestingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8ee8c5ff36994621b42226a17e561d2e_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticPrenatalTestingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8c200a9b3e0d4ac49242d25105281dcd_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticPrenatalTestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib8fb168011b74d318bab8b56b11dbda3_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticPrenatalTestingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic992acb15b7b4eb7a73e11782d653862_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticPrenatalTestingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i4efd4f48f7f647819d1ee5f36d044d08_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticPrenatalTestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i1fc1f94f6c144040a6a027fe642d8327_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticPharmacogenomicsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4e578e3ded2b44bfb1c2e543c14336fe_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticPharmacogenomicsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ibf03794b4694454c96339d25e089fd86_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticPharmacogenomicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4790f46fe81f43b7a34b7d4e7be6b08d_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticPharmacogenomicsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i3d82cbad6d4f4ad4b4867f492374ddbc_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticPharmacogenomicsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i227a5837ccdc40d09a3935542fa8f306_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticPharmacogenomicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i1643deb3ad9f45619ca4221f05389dc7_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticAutoimmuneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia0485078c2524525b58fcac4538292d8_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticAutoimmuneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1413cd2d66404ae0b0033e4828c87987_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticAutoimmuneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0ad30cfcd30642859241e76dc224b27e_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticAutoimmuneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia022822da300492793546d0fe4c7b26b_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticAutoimmuneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i2b38c623286c42b898b7e8154ca4672e_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticAutoimmuneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5c5bea7f5b774599827c2380d64fab41_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticOtherTestingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic2e771554aba45edaeb4d3458b0c1d77_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticOtherTestingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8c5c05f89d074455a96647a1c66e3797_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticOtherTestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie293ea67e0dc4e379586937a664f26a6_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticOtherTestingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i96fe192a524c4c7780b693b19a1ee594_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticOtherTestingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i85e565a842f34303958c7c5dbc22906f_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticOtherTestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i2150fb2a47cc41a8a8afed1f431f9875_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticTestingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ieeda1d918cdc4e4c8c9a40ede0b9980e_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticTestingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i54646e3f899541a2892e6c43188dd3ca_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticTestingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i4765fcb411c541578d82bf58e0edcd57_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticTestingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ie9ffcf60567a49298db6b5581ef8dbec_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:PharmaceuticalAndClinicalServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i67ed4f8f16804e2d91b367cc0ad882e6_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:PharmaceuticalAndClinicalServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i822cef9d3a1148dfa0df42a55879158a_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:PharmaceuticalAndClinicalServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id2561e4e6a72407fa6fcb4dda8635c44_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:PharmaceuticalAndClinicalServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ifb886d225660433bb8c479ba4c1cf8ce_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iaab7b12e36bb4e709ac9d2fd74a39b5e_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia7eb822f2ce54831a5e78a74b2e44672_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i2bc09983c7244893bff666d06f800fa8_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia7d2894297e4420e8cad6a4c76510fc1_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ic929fbb9734546f8ba6190d002b58254_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">mygn:PerformanceObligationEstimatedTransactionPriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i437a8c83f80c43f5bb7969a1427d84af_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">mygn:PerformanceObligationEstimatedTransactionPriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib2b1d515b0df442caf3a61b77cd756eb_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mygn:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4c9ecd2a8793414a828047a9bf1593e4_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mygn:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ide0992200fac419ab9eb95a8229f286b_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mygn:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i9463c7d008224ba994869b57828ab6a2_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mygn:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ie18df879613d4bb19a671fecd56a73ef_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i55b41215c9044cb8bdb7a95355f2cee3_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i20c433933c2b4c689e241c3fd658ffa4_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i474e395867254271927d4271ff603665_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i0f849fd49ae643249e914d79d76dcb81_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i50d5d52f5abe44ae90e97be189c0c2c0_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i89beb1b281b84d588eff0b2c4a0c5dfb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i784e7cc69b2447578da174c05c94a660_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ide2c0b04a05e4f40b02f2431e83b3536_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1e3de8ef1a9243968a201ad829b59152_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id5e0328e3e08484f88ad3cfbf16c738f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i47594399039d468c97b0901e9244c85e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1f71ce0e78ae4d43bdf7b1af72891a7e_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib44dd41f27d8480d8f588e0a3bf99cba_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i3d975988e4a74a9dbe6e71a5b5546389_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i4996139414984f65bb79f0d63ac3f655_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="id012a77974384595bcd158dfde0ea68e_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i22cef9e6ab314518ab6c3a7c7d612f84_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ia4d9dbc5ea804408a5936ee65bfc03fe_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i0dd65111dedb44d595f99ccb1991e8fe_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ib78f55a38b1d452e8216debd6bd284c8_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ia1e3572a358f489bacc6b0b33b2e63d5_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i4b6dea85317046bc87a3e54a0f0f3ffc_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i7ec450647a3c4906981f1552178b524d_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i69d2dc8810554913bdaf6702c8068256_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i83b400ca04df4b53901e5ccced571202_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="iba04c9e73cfd46ad82a9eea96b7282e2_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i20eb373912734049b280784af93920ce_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ibdc5dad50ef14763bc23b7f645b991d5_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i53fc983dd40d4345b5662806620d7a69_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mygn:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i92c674fcb51e4f128ed0956b57defa1a_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mygn:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i36f381783c3a43ca93842d8b7723cb09_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mygn:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i476783a7d7a846aca1e3115c994a7824_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mygn:ContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ifb3432fef1734dcf938bc72ecde8321c_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i0ba8c79bbcbe4cfdae12d33bf2783cb3_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="if8c6a3bacee84320baf1e19f8abf5951_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ic9870ea197d5485389a0710db39dac7e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idac1b2ac3b4c4ea287843c55138d31fe_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iefe8366531d2402295ef25ebb060e068_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if070826acb484e4b88cfbb934f2510a0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6e8d32c49f294155b6e1ca65383d3960_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9c5647e0218944d0aa8af898642f148e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibf68d852a72c4154b30db158bdb79561_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0330620427f647ed9cc3899d676e3b70_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1213355c05b74525b0feb4f71cee0825_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8a792264bad64b069150fc3385ef30ea_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i02209a0a76af4ebdbef9df556c34a6d8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia5d2a4f35b5e4114a4bdedc325290a90_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i591bb847d18a4e38a3b89e766c088008_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ieb2b2109f1474e9d98f51788f0de8c5e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idc1c646e04584219aac582f20b8676ad_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i707c13e32e584ee3a2051a60c642c899_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i81a717b368544963b5d0268a420c7e31_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mygn:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if110d6f8bc9445f19d915e3c19311eb2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mygn:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i353263ed75ed4422b659d68ccbb565d7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mygn:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6f239555bbeb4f1085317b6f3100affb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mygn:ContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i41e4b0464a314ee7a5506f2010385fab_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2460434fcbba45b1b2398bd2547de226_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3f3a1bdca0f24500a339d8a108a0211f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i94b157c71c86440fa7ba1b5891dd3e43_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ifc0bbee828074f62b3cdac04425562c8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i80977ee86e3c41ebb192c62d6bfce59a_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i9ebba697932d49ea8da9c7220efb9033_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i38ac573972c0484c9db1cb89e06de15a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mygn:DiagnosticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibde16baaa28343bd960624b1aaf1ae77_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i90324a4d56084a4391c5819f5c839f86_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mygn:DiagnosticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iee82af509aa24703b7bb72450fba9e9f_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6edc95151d8a4e0d834e3ba92ab2a90b_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mygn:DiagnosticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i579d27c0f10940d8a1ceface7d29c915_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i7b032b60a10145f682547141173ac516_I20210701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">mygn:PurchasedLicensesAndTechnologiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mygn:MyriadRBMIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-01</instant>
        </period>
    </context>
    <context id="id4c41467e09242c3a31f5150b7bc13fe_I20210701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mygn:MyriadRBMIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">mygn:InProcessResearchAndDevelopmentWithIndefiniteLivesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-01</instant>
        </period>
    </context>
    <context id="i2e1dbd573f0047b298ea8f3eb9afc6cf_I20210701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mygn:MyriadRBMIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-01</instant>
        </period>
    </context>
    <context id="i5951f47f63a2499780fd5e72af21ade5_I20210701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mygn:MyriadRBMIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-01</instant>
        </period>
    </context>
    <context id="i5a2255bae3b5469a85c3193359dabe47_I20210701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mygn:MyriadRBMIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-01</instant>
        </period>
    </context>
    <context id="ie644acbcb7a046da9f6a9073e27ef84f_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">mygn:PurchasedLicensesAndTechnologiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ia5b94635b0ee49179e69f248a30a5218_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">mygn:PurchasedLicensesAndTechnologiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2b16ee9a891f452fbef45868672b00d6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0cc0c3bdd23f47d483982f371199a356_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id685e06a6fe54277a65c4a43bf1ca98b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">mygn:InProcessResearchAndDevelopmentWithIndefiniteLivesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia36cf797382046e0a337c61433dfd1b6_D20180731-20180731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mygn:AmendmentToCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-31</startDate>
            <endDate>2018-07-31</endDate>
        </period>
    </context>
    <context id="i20dcb26940bd445f93184c60d07dab71_I20161223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-23</instant>
        </period>
    </context>
    <context id="if69f7cf080614d7fa0f9398ec3a0d790_I20180731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mygn:AmendmentToCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-07-31</instant>
        </period>
    </context>
    <context id="i2d7436f51ca44c63b220baabb793f869_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mygn:AmendmentToCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic14444ddb59c4b859b297e3eb63f800d_I20210221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mygn:AmendmentToCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-21</instant>
        </period>
    </context>
    <context id="i12f34ee4c63b4e07a09ead597eb2afb8_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mygn:AmendmentToCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="id22d71fd31db4689a2b97ef092347fe3_D20200401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mygn:AmendmentToCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i1cd2ac076ee74bdaaad3ecd73d94eee1_D20200401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mygn:AmendmentToCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i4847f17e28e147c0a68edabf5abcea78_D20220701-20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mygn:AmendmentToCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-01</endDate>
        </period>
    </context>
    <context id="i7adf104e7dc740cbb75258256d3d3de0_D20220701-20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mygn:AmendmentToCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-01</endDate>
        </period>
    </context>
    <context id="i7b9e6a1375a94b0e869e4e993a658963_D20220701-20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mygn:AmendmentToCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-01</endDate>
        </period>
    </context>
    <context id="i417e2a66751b4095bd0c48dc41dd4530_D20220701-20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mygn:AmendmentToCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-01</endDate>
        </period>
    </context>
    <context id="ib42c463d1fe74078a52b79074501653e_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i408d12bd10e24b0daf055d6dce17ee34_D20210731-20210731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mygn:AmendmentToCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-31</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="idb96586e8d014be6a63ed5c14054d982_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mygn:AmendmentToCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3269c20860fd42e5b0cecdb3249f343d_I20160630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">mygn:EighthShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-06-30</instant>
        </period>
    </context>
    <context id="i52adcde188a640e99ba9a44e311c8d73_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mygn:TwoThousandSeventeenEmployeeDirectorAndConsultantEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ief9e8a3ae25b43aeb183d65978160f05_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i69bf2abe7da64ff79bc46cba39640e19_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">mygn:NonEmployeeDirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mygn:OptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i92c8275b0ba847e78c2cd5b91dd57e8c_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i965028ac5b28491f8ce013eceafc3791_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">mygn:OptionsGrantedAfterDecemberFiveTwentyTwelveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8d8d18090245443bb8fcbbabba18bd99_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">mygn:OptionsGrantedPriorToDecemberFiveTwentyTwelveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4801dc9ebc814bf4a4e7c0b3d186670f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i82ee8762af6f49b6830a17198018205b_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i8bcfc26140eb424887a7993eb83c6035_I20121231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mygn:EmployeeStockPurchasePlanTwentyTwelveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2012-12-31</instant>
        </period>
    </context>
    <context id="ib0ff30ba23574507a2d7f464c815dfac_D20210923-20210923">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mygn:EmployeeStockPurchasePlanTwentyTwelveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-23</startDate>
            <endDate>2021-09-23</endDate>
        </period>
    </context>
    <context id="i2c1a3b837ee04e2c812eb8cbc112adaf_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mygn:EmployeeStockPurchasePlanTwentyTwelveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ie53d91b4b6c74e609ea917eadc9521fb_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">mygn:CostOfMolecularDiagnosticTestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib0b0e187d88d4a79a51af53f0c258395_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">mygn:CostOfMolecularDiagnosticTestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i15b426ffab40406b9ce00055e4e71cc7_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">mygn:CostOfMolecularDiagnosticTestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i10453dc072584904908a86492c478db1_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">mygn:CostOfMolecularDiagnosticTestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ib8134e30745e401f875787e150c90a29_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">mygn:CostOfPharmaceuticalAndClinicalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0a4213b0025742348a551e459281952a_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">mygn:CostOfPharmaceuticalAndClinicalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i96d4380fb0a44bda931ad908ae56cd15_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">mygn:CostOfPharmaceuticalAndClinicalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if45947be73124386a5d96c5f812ce163_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">mygn:CostOfPharmaceuticalAndClinicalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7b57125252b04e19a0ab135ecb14306e_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i74a661b5521240d6b08faf29ed4cca5f_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic1e22d907e804cb3a166674ed56d1159_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iaa209599dfc04850bdd9bb0c340449ec_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i4fba22e0d9a14b43ae418e9b7737a767_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8738e02b8c234e90be4290e058314e09_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i4b061eccb63f4b98914dd480e34a8f10_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib580291452e04f9790478ef2b24b14d7_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if31d376449604749a8d84a4ea233ed1b_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CaliforniaFranchiseTaxBoardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:EarliestTaxYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4b90c2422e9e4d78837a3d9edef5f3aa_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CaliforniaFranchiseTaxBoardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:LatestTaxYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7c84552a53104c5d863802c21e95e8d4_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:NewJerseyDivisionOfTaxationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:EarliestTaxYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="idab04f47fe4d4dfa8e8043a6d25016fd_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:NewJerseyDivisionOfTaxationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:LatestTaxYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1d977692ef0d4d53a4a9b42cabf5e593_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:FederalMinistryOfFinanceGermanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:EarliestTaxYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iaf68da87f99f4445b6e3aaf98ff69a2a_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:FederalMinistryOfFinanceGermanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:LatestTaxYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib988f9d7160144ba85f9202205918ecc_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:SwissFederalTaxAdministrationFTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:EarliestTaxYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i84120dcedb01422a848d3618dbae3f74_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:SwissFederalTaxAdministrationFTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:LatestTaxYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ife30149d9d1d4b99ac1339407e85293d_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mygn:DiagnosticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iacd3d37549084b26b52a7a2565dbb4ab_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i19766b831a824fe78592ac40be72d491_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mygn:DiagnosticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i91eb354042484b21815c154fc961e6c4_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id9a30e30fb7d46af9ad9962658bc3126_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mygn:DiagnosticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7eb09159cfc64597873d8167aa298bfe_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5b97fc75f0ec45e0bd58df1dad474b32_D20210528-20210528">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mygn:MyriadMyPathLLCLaboratoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-28</startDate>
            <endDate>2021-05-28</endDate>
        </period>
    </context>
    <context id="ie5db1cb383af4d9091b44997a3e2b23f_D20210701-20210701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mygn:MyriadRBMIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-07-01</endDate>
        </period>
    </context>
    <context id="i6b8313a324f94c6caad8b75523488f35_D20210913-20210913">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mygn:MyriadAutoimmuneAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-13</startDate>
            <endDate>2021-09-13</endDate>
        </period>
    </context>
    <context id="ib8b44ab869f44ebd9da9cf10c35e35c4_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mygn:MyriadRBMIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iae9bd564d0e24269a0860f286b76a8c8_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mygn:MyriadRBMIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic7ad8f15a58548759fdb4e238c847c6b_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mygn:MyriadMyPathLLCLaboratoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1b39e1079fcf498da2478fc0bfa35a9c_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mygn:MyriadMyPathLLCLaboratoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id8db12274a5e41019919e2f3e84a1cfd_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id6f9bab1ac3d4f769be2cf49d2c11dc1_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if410392a6c864eb4bcc542e0317057f6_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mygn:MyriadAutoimmuneAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia7f3ca65537e48c2a6d04c65e5799212_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mygn:MyriadAutoimmuneAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="security">
        <measure>mygn:security</measure>
    </unit>
    <unit id="segment">
        <measure>mygn:segment</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180L2ZyYWc6Y2FkZjRhNjFjOTVhNDJjZWEyM2JlMWRlMmExNTU0ZWMvdGFibGU6ODdjYTk4Mjg5MmRmNDM3N2EwNWQyMzc3ZWYxYzgyZjkvdGFibGVyYW5nZTo4N2NhOTgyODkyZGY0Mzc3YTA1ZDIzNzdlZjFjODJmOV8xLTEtMS0xLTE4MTY0_96278c5c-fda7-4208-b1e1-694116496589">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180L2ZyYWc6Y2FkZjRhNjFjOTVhNDJjZWEyM2JlMWRlMmExNTU0ZWMvdGFibGU6ODdjYTk4Mjg5MmRmNDM3N2EwNWQyMzc3ZWYxYzgyZjkvdGFibGVyYW5nZTo4N2NhOTgyODkyZGY0Mzc3YTA1ZDIzNzdlZjFjODJmOV8yLTEtMS0xLTE4MTY0_5e3f64d3-85c2-48a1-bc9e-1f84c72a57c0">0000899923</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180L2ZyYWc6Y2FkZjRhNjFjOTVhNDJjZWEyM2JlMWRlMmExNTU0ZWMvdGFibGU6ODdjYTk4Mjg5MmRmNDM3N2EwNWQyMzc3ZWYxYzgyZjkvdGFibGVyYW5nZTo4N2NhOTgyODkyZGY0Mzc3YTA1ZDIzNzdlZjFjODJmOV8zLTEtMS0xLTE4MTY0_c6838d1b-cdce-4ebf-84ea-ab9c3499873c">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180L2ZyYWc6Y2FkZjRhNjFjOTVhNDJjZWEyM2JlMWRlMmExNTU0ZWMvdGFibGU6ODdjYTk4Mjg5MmRmNDM3N2EwNWQyMzc3ZWYxYzgyZjkvdGFibGVyYW5nZTo4N2NhOTgyODkyZGY0Mzc3YTA1ZDIzNzdlZjFjODJmOV80LTEtMS0xLTE4MTY0_7e19b56c-c569-4da6-98ff-4cf142fc6939">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180L2ZyYWc6Y2FkZjRhNjFjOTVhNDJjZWEyM2JlMWRlMmExNTU0ZWMvdGFibGU6ODdjYTk4Mjg5MmRmNDM3N2EwNWQyMzc3ZWYxYzgyZjkvdGFibGVyYW5nZTo4N2NhOTgyODkyZGY0Mzc3YTA1ZDIzNzdlZjFjODJmOV81LTEtMS0xLTE4MTY0_b3d8c391-fccf-45c8-9059-79908618a32b">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentType
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xL2ZyYWc6M2JjM2JkYzFkYmFiNDdiN2E1YTZlN2IxODA1MmRmNGUvdGV4dHJlZ2lvbjozYmMzYmRjMWRiYWI0N2I3YTVhNmU3YjE4MDUyZGY0ZV8yMzc4_df59c0de-d8e5-489c-a81e-ca23d0a6274b">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xL2ZyYWc6M2JjM2JkYzFkYmFiNDdiN2E1YTZlN2IxODA1MmRmNGUvdGFibGU6MTQ5OTA1MzI4MDU5NDA0ODg2NzFkZjhlZmVmZmJjYmEvdGFibGVyYW5nZToxNDk5MDUzMjgwNTk0MDQ4ODY3MWRmOGVmZWZmYmNiYV8wLTAtMS0xLTE4MTY0_3cce996b-2566-44b6-8ecb-b0337b926e41">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xL2ZyYWc6M2JjM2JkYzFkYmFiNDdiN2E1YTZlN2IxODA1MmRmNGUvdGV4dHJlZ2lvbjozYmMzYmRjMWRiYWI0N2I3YTVhNmU3YjE4MDUyZGY0ZV8yMTc_d13b264b-5231-4b45-9a55-a3041259b707">2021-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xL2ZyYWc6M2JjM2JkYzFkYmFiNDdiN2E1YTZlN2IxODA1MmRmNGUvdGFibGU6ZTVjY2UyZTU0YmQ3NGRhYmJlM2FlNDc3YzlhZjYwMGQvdGFibGVyYW5nZTplNWNjZTJlNTRiZDc0ZGFiYmUzYWU0NzdjOWFmNjAwZF8wLTAtMS0xLTE4MTY0_92709980-3639-43b5-8654-43ec6f871755">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xL2ZyYWc6M2JjM2JkYzFkYmFiNDdiN2E1YTZlN2IxODA1MmRmNGUvdGV4dHJlZ2lvbjozYmMzYmRjMWRiYWI0N2I3YTVhNmU3YjE4MDUyZGY0ZV8yMzc0_be0df4d4-f1dd-43df-af86-d50a83f98524">0-26642</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xL2ZyYWc6M2JjM2JkYzFkYmFiNDdiN2E1YTZlN2IxODA1MmRmNGUvdGV4dHJlZ2lvbjozYmMzYmRjMWRiYWI0N2I3YTVhNmU3YjE4MDUyZGY0ZV8yMzcx_378f5bdd-ee5e-4d85-931e-c206debf5382">MYRIAD GENETICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xL2ZyYWc6M2JjM2JkYzFkYmFiNDdiN2E1YTZlN2IxODA1MmRmNGUvdGV4dHJlZ2lvbjozYmMzYmRjMWRiYWI0N2I3YTVhNmU3YjE4MDUyZGY0ZV8yMzc5_939d683c-5f49-4c0c-a8f2-7946cc552209">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityAddressAddressLine1
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xL2ZyYWc6M2JjM2JkYzFkYmFiNDdiN2E1YTZlN2IxODA1MmRmNGUvdGV4dHJlZ2lvbjozYmMzYmRjMWRiYWI0N2I3YTVhNmU3YjE4MDUyZGY0ZV8yMzgw_bdfb9bf4-92f4-4da5-8d73-1dfd98a36e34">320 Wakara Way</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xL2ZyYWc6M2JjM2JkYzFkYmFiNDdiN2E1YTZlN2IxODA1MmRmNGUvdGV4dHJlZ2lvbjozYmMzYmRjMWRiYWI0N2I3YTVhNmU3YjE4MDUyZGY0ZV8yMzc1_f1b8ea0a-7921-415e-b413-2bdd9d53615e">Salt Lake City</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xL2ZyYWc6M2JjM2JkYzFkYmFiNDdiN2E1YTZlN2IxODA1MmRmNGUvdGV4dHJlZ2lvbjozYmMzYmRjMWRiYWI0N2I3YTVhNmU3YjE4MDUyZGY0ZV8yMzc3_c6484499-5fdd-482d-a1e2-c2dfdef032d3">UT</dei:EntityAddressStateOrProvince>
    <dei:EntityTaxIdentificationNumber
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xL2ZyYWc6M2JjM2JkYzFkYmFiNDdiN2E1YTZlN2IxODA1MmRmNGUvdGV4dHJlZ2lvbjozYmMzYmRjMWRiYWI0N2I3YTVhNmU3YjE4MDUyZGY0ZV8yMzgx_379496e6-c769-4113-8441-de9bd0b6315b">87-0494517</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressPostalZipCode
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xL2ZyYWc6M2JjM2JkYzFkYmFiNDdiN2E1YTZlN2IxODA1MmRmNGUvdGV4dHJlZ2lvbjozYmMzYmRjMWRiYWI0N2I3YTVhNmU3YjE4MDUyZGY0ZV8yMzcy_e8e64dad-78d2-407b-9cc6-67977ae88486">84108</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xL2ZyYWc6M2JjM2JkYzFkYmFiNDdiN2E1YTZlN2IxODA1MmRmNGUvdGV4dHJlZ2lvbjozYmMzYmRjMWRiYWI0N2I3YTVhNmU3YjE4MDUyZGY0ZV8yMzcz_204381ca-142f-467a-8c52-fdd24d7f0433">801</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xL2ZyYWc6M2JjM2JkYzFkYmFiNDdiN2E1YTZlN2IxODA1MmRmNGUvdGV4dHJlZ2lvbjozYmMzYmRjMWRiYWI0N2I3YTVhNmU3YjE4MDUyZGY0ZV8yMzgy_36a3ebc0-4610-446c-81d3-8c68bc4dac43">584-3600</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xL2ZyYWc6M2JjM2JkYzFkYmFiNDdiN2E1YTZlN2IxODA1MmRmNGUvdGFibGU6MjhhMDlkNmU4NTEyNGEyYTkwMWYzZWJjYWJjZGJhOGUvdGFibGVyYW5nZToyOGEwOWQ2ZTg1MTI0YTJhOTAxZjNlYmNhYmNkYmE4ZV8xLTAtMS0xLTE4MTY0_eae810e8-4d00-4f7c-8e4b-e91ab8fd6829">Common Stock, $0.01 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xL2ZyYWc6M2JjM2JkYzFkYmFiNDdiN2E1YTZlN2IxODA1MmRmNGUvdGFibGU6MjhhMDlkNmU4NTEyNGEyYTkwMWYzZWJjYWJjZGJhOGUvdGFibGVyYW5nZToyOGEwOWQ2ZTg1MTI0YTJhOTAxZjNlYmNhYmNkYmE4ZV8xLTItMS0xLTE4MTY0_71e8e639-3c30-4a35-a28d-8685140b994f">MYGN</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xL2ZyYWc6M2JjM2JkYzFkYmFiNDdiN2E1YTZlN2IxODA1MmRmNGUvdGFibGU6MjhhMDlkNmU4NTEyNGEyYTkwMWYzZWJjYWJjZGJhOGUvdGFibGVyYW5nZToyOGEwOWQ2ZTg1MTI0YTJhOTAxZjNlYmNhYmNkYmE4ZV8xLTQtMS0xLTE4MTY0_a79a4891-85eb-479c-bb6c-7e741b673226">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xL2ZyYWc6M2JjM2JkYzFkYmFiNDdiN2E1YTZlN2IxODA1MmRmNGUvdGV4dHJlZ2lvbjozYmMzYmRjMWRiYWI0N2I3YTVhNmU3YjE4MDUyZGY0ZV8yMzgz_288171b3-d88c-4bdf-a03b-c18a11d47303">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xL2ZyYWc6M2JjM2JkYzFkYmFiNDdiN2E1YTZlN2IxODA1MmRmNGUvdGV4dHJlZ2lvbjozYmMzYmRjMWRiYWI0N2I3YTVhNmU3YjE4MDUyZGY0ZV8yMzg0_00f6a8df-1029-4377-913e-76243ffbc09b">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xL2ZyYWc6M2JjM2JkYzFkYmFiNDdiN2E1YTZlN2IxODA1MmRmNGUvdGFibGU6NDNjM2I3MmRmNGZmNGViOWEwZWRiNWY1MWM0MjY5MTQvdGFibGVyYW5nZTo0M2MzYjcyZGY0ZmY0ZWI5YTBlZGI1ZjUxYzQyNjkxNF8wLTAtMS0xLTE4MTY0_5327c66a-2611-4ab4-9771-dd301c42ea91">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xL2ZyYWc6M2JjM2JkYzFkYmFiNDdiN2E1YTZlN2IxODA1MmRmNGUvdGFibGU6NDNjM2I3MmRmNGZmNGViOWEwZWRiNWY1MWM0MjY5MTQvdGFibGVyYW5nZTo0M2MzYjcyZGY0ZmY0ZWI5YTBlZGI1ZjUxYzQyNjkxNF8xLTQtMS0xLTE4MTY0_31e16f29-7d97-483d-a7ef-b4fd97d6b160">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xL2ZyYWc6M2JjM2JkYzFkYmFiNDdiN2E1YTZlN2IxODA1MmRmNGUvdGFibGU6NDNjM2I3MmRmNGZmNGViOWEwZWRiNWY1MWM0MjY5MTQvdGFibGVyYW5nZTo0M2MzYjcyZGY0ZmY0ZWI5YTBlZGI1ZjUxYzQyNjkxNF8yLTQtMS0xLTE4MTY0_dd979d46-acae-4182-8346-e1e68cb5603f">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xL2ZyYWc6M2JjM2JkYzFkYmFiNDdiN2E1YTZlN2IxODA1MmRmNGUvdGV4dHJlZ2lvbjozYmMzYmRjMWRiYWI0N2I3YTVhNmU3YjE4MDUyZGY0ZV8yNzQ4Nzc5MDcxODMw_03eac384-5cd5-49ba-b5e2-13fd8ea5fb49">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i686dc3f8181f43699bf8c3b5a9751e8c_I20211027"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xL2ZyYWc6M2JjM2JkYzFkYmFiNDdiN2E1YTZlN2IxODA1MmRmNGUvdGV4dHJlZ2lvbjozYmMzYmRjMWRiYWI0N2I3YTVhNmU3YjE4MDUyZGY0ZV8yMzE4_0df2f291-940e-4d16-a32e-0beeb968c6f0"
      unitRef="shares">79854649</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfNC0xLTEtMS0xODE2NA_d3d7f6e9-d736-42ef-8048-7e38d3f69e94"
      unitRef="usd">295200000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfNC0zLTEtMS0xODE2NA_21573806-7b6c-44e9-ac7e-56f72e96ff19"
      unitRef="usd">117000000.0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfNS0xLTEtMS0xODE2NA_5b3a3db6-b61f-4623-b7c2-c22be3f55253"
      unitRef="usd">70900000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfNS0zLTEtMS0xODE2NA_4f043a99-f955-47a7-b22b-3863244c5654"
      unitRef="usd">33700000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfNi0xLTEtMS0xODE2NA_4a7b0e15-0993-48bb-ac81-8e9e8ba33a6f"
      unitRef="usd">93600000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfNi0zLTEtMS0xODE2NA_c24fcc0a-1bf7-45e2-95b2-009c6323a063"
      unitRef="usd">89500000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfNy0xLTEtMS0xODE2NA_41d21a86-b4a8-48b7-8308-231ae38db79c"
      unitRef="usd">18600000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfNy0zLTEtMS0xODE2NA_7448e780-4de2-4c52-a4b8-a192717adc92"
      unitRef="usd">27100000</us-gaap:InventoryNet>
    <us-gaap:PrepaidTaxes
      contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfOS0xLTEtMS0xODE2NA_8c763535-a362-49bb-b195-e3abcf893861"
      unitRef="usd">400000</us-gaap:PrepaidTaxes>
    <us-gaap:PrepaidTaxes
      contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfOS0zLTEtMS0xODE2NA_72c0e6b4-4866-4104-8774-1baa09a32a7a"
      unitRef="usd">108400000</us-gaap:PrepaidTaxes>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfMTAtMS0xLTEtMTgxNjQ_92347ac0-ff42-4505-810e-724a9895b08f"
      unitRef="usd">20200000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfMTAtMy0xLTEtMTgxNjQ_587d7ea3-afcb-4bf2-a197-6dc336fa731e"
      unitRef="usd">13700000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfMTEtMS0xLTEtMTgxNjQ_cd77b91b-cb50-484a-8539-97e107039695"
      unitRef="usd">498900000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfMTEtMy0xLTEtMTgxNjQ_3785fe2e-c71a-4363-ab5f-a08934c20493"
      unitRef="usd">389400000</us-gaap:AssetsCurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfMTItMS0xLTEtMTgxNjQ_c65816e1-524e-464e-be56-18b0f2e7b89d"
      unitRef="usd">83600000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfMTItMy0xLTEtMTgxNjQ_c86ff5ac-e4be-47d3-bb2d-bca4fb5bc62f"
      unitRef="usd">59700000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfMTMtMS0xLTEtMTgxNjQ_d0652cc8-ff0a-4db5-b4ed-17431dda5252"
      unitRef="usd">47500000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfMTMtMy0xLTEtMTgxNjQ_ef6c4831-2da6-4b41-aac8-855039e6cad5"
      unitRef="usd">21000000.0</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfMTQtMS0xLTEtMTgxNjQ_cf38ef2f-dbf5-48ee-8514-4dba41d6b7f9"
      unitRef="usd">43400000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfMTQtMy0xLTEtMTgxNjQ_00f16b00-4065-4fc7-9db5-3e5a41100649"
      unitRef="usd">40700000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfMTUtMS0xLTEtMTgxNjQ_bae631dc-8661-4478-9de6-f4598fe07a2d"
      unitRef="usd">414800000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfMTUtMy0xLTEtMTgxNjQ_aa55c803-e276-42ee-be10-eb014c31616e"
      unitRef="usd">576500000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfMTYtMS0xLTEtMTgxNjQ_ec36e420-f857-40bd-9451-fab3a7adf079"
      unitRef="usd">239700000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfMTYtMy0xLTEtMTgxNjQ_b5f99a3f-0889-4f2f-a252-e33252c8759c"
      unitRef="usd">329200000</us-gaap:Goodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfMTctMS0xLTEtMTgxNjQ_1dbe64bd-70bb-4b25-a83d-c6052c39050f"
      unitRef="usd">8000000.0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfMTctMy0xLTEtMTgxNjQ_37663049-b2b3-4c93-9800-a4946aa9a0f8"
      unitRef="usd">2300000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfMTgtMS0xLTEtMTgxNjQ_0de1e99f-d3a7-45c7-91e2-e785cebcd278"
      unitRef="usd">1335900000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfMTgtMy0xLTEtMTgxNjQ_b5e140c9-b49d-4ca1-9c92-2ddc97bf1e96"
      unitRef="usd">1418800000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfMjEtMS0xLTEtMTgxNjQ_da2aadaf-5a9a-4f05-98f0-0c2ef69e4cb8"
      unitRef="usd">15700000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfMjEtMy0xLTEtMTgxNjQ_72b93a4c-d644-4435-96b2-33d758997067"
      unitRef="usd">20500000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfMjItMS0xLTEtMTgxNjQ_9144c901-e75e-47b6-9b7f-6ff3db3036a4"
      unitRef="usd">163200000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfMjItMy0xLTEtMTgxNjQ_6f8b5cfd-04a4-4013-8009-b2fbfb6cf3e4"
      unitRef="usd">79100000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfMjMtMS0xLTEtMTgxNjQ_6a5b4c7a-ee82-47d6-b5c2-84183ba442f0"
      unitRef="usd">12800000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfMjMtMy0xLTEtMTgxNjQ_cccf1ccf-c040-4156-9425-53cb71d91390"
      unitRef="usd">13600000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfMjQtMS0xLTEtMTgxNjQ_ba53f249-0912-4a4e-a141-3116579a75a7"
      unitRef="usd">11500000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfMjQtMy0xLTEtMTgxNjQ_a0b7f4e3-7bb0-4b5a-9755-db1854326f92"
      unitRef="usd">32700000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfMjctMS0xLTEtMTgxNjQ_d18c0e13-681e-4801-b005-de785e9eb686"
      unitRef="usd">203200000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfMjctMy0xLTEtMTgxNjQ_14364af2-b40d-44c5-9d9f-49062f51918e"
      unitRef="usd">145900000</us-gaap:LiabilitiesCurrent>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfMjgtMS0xLTEtMTgxNjQ_7ea33e76-dd34-4831-b708-408835168d35"
      unitRef="usd">32000000.0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfMjgtMy0xLTEtMTgxNjQ_95dd40fb-76cc-4730-b862-5189c9c0e44f"
      unitRef="usd">30500000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfMjktMS0xLTEtMTgxNjQ_5efbc52d-4c39-4f01-997b-7bd2d41a7eca"
      unitRef="usd">40700000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfMjktMy0xLTEtMTgxNjQ_930e1ded-4b1f-4699-83d4-8fa66914c923"
      unitRef="usd">71300000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfMzAtMS0xLTEtMTgxNjQ_4504c41c-b88a-4cd3-8566-3fe26d12eb66"
      unitRef="usd">80700000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfMzAtMy0xLTEtMTgxNjQ_e2fb8299-49e8-4266-b697-0b07fc55720d"
      unitRef="usd">50600000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfMzEtMS0xLTEtMTgxNjQ_5e3815d0-9e5e-4fe9-8060-73db2d8bade6"
      unitRef="usd">0</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfMzEtMy0xLTEtMTgxNjQ_da3e3f4a-10a4-4a0b-b717-a68c154b3652"
      unitRef="usd">224800000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfMzItMS0xLTEtMTgxNjQ_5b5c868c-685f-4360-8db0-3944859114e9"
      unitRef="usd">10800000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfMzItMy0xLTEtMTgxNjQ_a1e9ba7b-7d7c-4ec0-bb49-2cf366658b8e"
      unitRef="usd">14700000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfMzMtMS0xLTEtMTgxNjQ_36c677aa-02f4-4112-ab44-cfa729fd69e5"
      unitRef="usd">367400000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfMzMtMy0xLTEtMTgxNjQ_984aac74-7e6a-4ba0-ba9f-3d6581b5a272"
      unitRef="usd">537800000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfMzQtMS0xLTEtMTgxNjQ_17e0d001-89f8-4a3c-94c2-0aa26dc1e688"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfMzQtMy0xLTEtMTgxNjQ_a2cf8ff8-1c82-4db1-b386-3823e111ff6d"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfMzYtMC0xLTEtMTgxNjQvdGV4dHJlZ2lvbjpjYjIyMDIzYWUzY2Q0MDIxYTQ2MGNjNzI2NTU1Mzc4NV8xOA_0e86a9f9-11b7-4000-82c5-e04f1b9ad688"
      unitRef="shares">79700000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfMzYtMC0xLTEtMTgxNjQvdGV4dHJlZ2lvbjpjYjIyMDIzYWUzY2Q0MDIxYTQ2MGNjNzI2NTU1Mzc4NV8yNQ_de819335-b25f-4e23-97f6-9414b8c7633b"
      unitRef="shares">75400000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfMzYtMS0xLTEtMTgxNjQ_360751c8-8f1c-4da7-a264-f11fa8fa619b"
      unitRef="usd">800000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfMzYtMy0xLTEtMTgxNjQ_0a41cede-4b1e-4c0a-8a64-b11a319323dc"
      unitRef="usd">800000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfMzctMS0xLTEtMTgxNjQ_3ccd035c-d9a9-4dfd-8acf-3d181e8dc9fc"
      unitRef="usd">1218800000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfMzctMy0xLTEtMTgxNjQ_fab12ea7-02bd-408b-a3d4-b79375e2ddee"
      unitRef="usd">1109500000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfMzgtMS0xLTEtMTgxNjQ_79826020-cd6f-4c1c-b288-796c14ed0457"
      unitRef="usd">-4400000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfMzgtMy0xLTEtMTgxNjQ_42e4f0db-371a-4c0a-943e-bd4514a18c12"
      unitRef="usd">-2300000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfMzktMS0xLTEtMTgxNjQ_eeef7933-91b8-41a9-87d6-cf68de73b0fa"
      unitRef="usd">-246600000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfMzktMy0xLTEtMTgxNjQ_98f7af64-5015-4ee2-9950-fb68ea49b127"
      unitRef="usd">-227000000.0</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfNDAtMS0xLTEtMTgxNjQ_517291a5-4271-49a3-a12a-b09db42f6ba1"
      unitRef="usd">968600000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfNDAtMy0xLTEtMTgxNjQ_432997ca-c7e9-48a6-b457-1b718527dda0"
      unitRef="usd">881000000.0</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfNDEtMS0xLTEtMTgxNjQ_46480876-9514-4054-b383-0c542bfab0b4"
      unitRef="usd">-100000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfNDEtMy0xLTEtMTgxNjQ_a84e6d85-fed6-4742-8891-70e76e619625"
      unitRef="usd">0</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfNDItMS0xLTEtMTgxNjQ_f985232f-e58b-4d80-948a-9eba40a3022c"
      unitRef="usd">968500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfNDItMy0xLTEtMTgxNjQ_e7c851b7-96f7-4bdc-85b0-1ff1fedf12a5"
      unitRef="usd">881000000.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfNDMtMS0xLTEtMTgxNjQ_dd4bbd0f-839a-4e34-9a99-f0d1baaeb21b"
      unitRef="usd">1335900000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xNi9mcmFnOjc5ZDU0MTJiMTgwYjRkY2ZiNjQxOGI2YzViNjVkYjNjL3RhYmxlOjFiYWUxZjVhZWJkYzQ0OWVhZDQ5ZTk2ZGE2OTZhYmI2L3RhYmxlcmFuZ2U6MWJhZTFmNWFlYmRjNDQ5ZWFkNDllOTZkYTY5NmFiYjZfNDMtMy0xLTEtMTgxNjQ_c41958ef-d01c-47d7-a11d-9272cd7c4ea8"
      unitRef="usd">1418800000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifbc28960af99464087c70e2155273621_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMy0xLTEtMS0xODE2NA_4795704e-aa44-4b57-a8c9-3127cb849d4f"
      unitRef="usd">167300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icc0e2c6320b64071a6e19bf0ded7e102_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMy0zLTEtMS0xODE2NA_c298afdb-2442-4fb7-91e5-fa879f4bb31f"
      unitRef="usd">135700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie8a469542115473daa7666e3dceae657_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMy01LTEtMS0xODE2NA_dbe912c3-93ed-4d1a-a3df-ce54061ee4c8"
      unitRef="usd">505600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie51b08f1c1f44da4bb023303aa0fb7d9_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMy03LTEtMS0xODE2NA_2acf78a7-1ca4-4578-9ecc-c89d283daa10"
      unitRef="usd">369500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i79cd3eef56ae4f639da562ce851a382e_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfNC0xLTEtMS0xODE2NA_47219182-7810-483b-a86e-a8728299174c"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie94a660aba69415a910d7f90711081eb_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfNC0zLTEtMS0xODE2NA_f5cdbf58-edf8-46e1-b3f8-e3efb13e3ab0"
      unitRef="usd">9500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i695f1ac67bde49628842e3563e17c85e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfNC01LTEtMS0xODE2NA_7ce9a299-53da-457e-bb39-0d4aa074bd9b"
      unitRef="usd">24200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib855c77efb97481b968697136ef35610_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfNC03LTEtMS0xODE2NA_55a8e536-acc5-42ab-899e-d9d0e8d0d07a"
      unitRef="usd">32900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfNS0xLTEtMS0xODE2NA_160cbe9c-fa52-4bcc-9baa-56e1c24c254e"
      unitRef="usd">167300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic2c3e03438af4889ac973627c642f5ec_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfNS0zLTEtMS0xODE2NA_d5b35215-d8eb-44d3-8c65-8a9d96fe3763"
      unitRef="usd">145200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfNS01LTEtMS0xODE2NA_c941c349-327d-4dca-bd1a-5099bb33fbab"
      unitRef="usd">529800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfNS03LTEtMS0xODE2NA_536a7551-dee3-48dd-a3aa-bdae86640650"
      unitRef="usd">402400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ifbc28960af99464087c70e2155273621_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfNy0xLTEtMS0xODE2NA_1b7e1c4a-50f2-4196-ad1e-6b13df3054d4"
      unitRef="usd">47800000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="icc0e2c6320b64071a6e19bf0ded7e102_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfNy0zLTEtMS0xODE2NA_14ecc94d-b222-416f-97d1-238710f3586a"
      unitRef="usd">39900000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ie8a469542115473daa7666e3dceae657_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfNy01LTEtMS0xODE2NA_8bd3b69a-b612-4b10-bff5-8ed727ccb1b9"
      unitRef="usd">139900000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ie51b08f1c1f44da4bb023303aa0fb7d9_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfNy03LTEtMS0xODE2NA_c0c48be0-5537-48a2-bd06-c9f2ba0c47bc"
      unitRef="usd">115200000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i79cd3eef56ae4f639da562ce851a382e_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfOC0xLTEtMS0xODE2NA_a3b19587-163a-4b97-a9f3-98b03de70d9a"
      unitRef="usd">0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ie94a660aba69415a910d7f90711081eb_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfOC0zLTEtMS0xODE2NA_0a143a34-33d5-4ad3-a15f-3a38d52ead9f"
      unitRef="usd">4300000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i695f1ac67bde49628842e3563e17c85e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfOC01LTEtMS0xODE2NA_3b5380f6-00a4-47f7-be85-9f8e30c6f202"
      unitRef="usd">11900000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ib855c77efb97481b968697136ef35610_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfOC03LTEtMS0xODE2NA_32e8f46b-7fd4-40b6-8b0e-155306913532"
      unitRef="usd">15800000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfOS0xLTEtMS0xODE2NA_da070723-cbe2-4cb2-9def-e258e62fd1dc"
      unitRef="usd">18800000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ic2c3e03438af4889ac973627c642f5ec_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfOS0zLTEtMS0xODE2NA_40c9e451-130a-4183-877c-b506aeb5a10a"
      unitRef="usd">17600000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfOS01LTEtMS0xODE2NA_524833f4-70a5-4517-ace6-f2f04c05e4cd"
      unitRef="usd">61400000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfOS03LTEtMS0xODE2NA_3523e7f5-4a35-46f3-9171-48c3e52a0a3f"
      unitRef="usd">54700000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMTAtMS0xLTEtMTgxNjQ_4fe9c70b-3596-4548-975c-5f141aa97d93"
      unitRef="usd">180200000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ic2c3e03438af4889ac973627c642f5ec_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMTAtMy0xLTEtMTgxNjQ_dd8ad2ee-7b56-4a8e-b7d3-ec124f15e57b"
      unitRef="usd">124100000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMTAtNS0xLTEtMTgxNjQ_cbb8ad65-61b1-40d7-a1d0-bb64d9fa15aa"
      unitRef="usd">460500000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMTAtNy0xLTEtMTgxNjQ_c8d65ca6-a4e3-425c-b2ba-6310def39bb1"
      unitRef="usd">364400000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMTEtMS0xLTEtMTgxNjQ_17e71853-7b89-4f4b-b1ce-ff5e180050d1"
      unitRef="usd">400000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="ic2c3e03438af4889ac973627c642f5ec_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMTEtMy0xLTEtMTgxNjQ_80765321-c202-4448-a619-54fa253abdee"
      unitRef="usd">-1100000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMTEtNS0xLTEtMTgxNjQ_8f1fb03f-0c47-4a43-9dd6-1fa4809dd95c"
      unitRef="usd">1700000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMTEtNy0xLTEtMTgxNjQ_915455f1-df41-4afd-be1c-7c7c16980dbc"
      unitRef="usd">-4500000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:GoodwillAndIntangibleAssetImpairment
      contextRef="ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMTItMS0xLTEtMTgxNjQ_94348c9e-4a87-41d8-9726-177e07b5dcc3"
      unitRef="usd">0</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:GoodwillAndIntangibleAssetImpairment
      contextRef="ic2c3e03438af4889ac973627c642f5ec_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMTItMy0xLTEtMTgxNjQ_0158d351-7423-40a0-a90c-5a808da2c819"
      unitRef="usd">0</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:GoodwillAndIntangibleAssetImpairment
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMTItNS0xLTEtMTgxNjQ_2f8e4b93-dd9d-486f-8d51-355b9440e02e"
      unitRef="usd">1800000</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:GoodwillAndIntangibleAssetImpairment
      contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMTItNy0xLTEtMTgxNjQ_1620edd7-03ad-4fea-a5ab-c51cb677a283"
      unitRef="usd">98400000</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:CostsAndExpenses
      contextRef="ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMTMtMS0xLTEtMTgxNjQ_d9555c38-528c-40b6-a91f-b69aa544786f"
      unitRef="usd">247200000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="ic2c3e03438af4889ac973627c642f5ec_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMTMtMy0xLTEtMTgxNjQ_64f53080-e1ab-4b58-8b6b-e5412e747b19"
      unitRef="usd">184800000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMTMtNS0xLTEtMTgxNjQ_13c9673b-ffc6-439d-bcba-56d26405f64d"
      unitRef="usd">677200000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMTMtNy0xLTEtMTgxNjQ_48e10758-5b79-4241-b3e6-95f98a8a2063"
      unitRef="usd">644000000.0</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMTQtMS0xLTEtMTgxNjQ_34c83d2b-c054-4e14-8fdc-72dfd0273dfd"
      unitRef="usd">-79900000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ic2c3e03438af4889ac973627c642f5ec_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMTQtMy0xLTEtMTgxNjQ_169f8039-7d00-44bc-9126-cf445d772fbe"
      unitRef="usd">-39600000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMTQtNS0xLTEtMTgxNjQ_cf3cc77c-c831-4783-8c6b-4b1a5eac8959"
      unitRef="usd">-147400000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMTQtNy0xLTEtMTgxNjQ_ad483248-f1d4-405b-aca9-0b8854786b96"
      unitRef="usd">-241600000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMTYtMS0xLTEtMTgxNjQ_d66f1dde-c963-4da9-8c86-b80bf3bd299b"
      unitRef="usd">200000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="ic2c3e03438af4889ac973627c642f5ec_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMTYtMy0xLTEtMTgxNjQ_89c9b2cc-e3a5-4b28-ad22-828ddccf9c75"
      unitRef="usd">400000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMTYtNS0xLTEtMTgxNjQ_8f941836-837b-4454-a1f9-ae4d004cee65"
      unitRef="usd">600000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMTYtNy0xLTEtMTgxNjQ_a3522544-7534-435a-807d-f2de3a743ec7"
      unitRef="usd">1700000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMTctMS0xLTEtMTgxNjQ_5fbdb68b-1deb-4a8e-ae3c-d95fe508db09"
      unitRef="usd">1100000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ic2c3e03438af4889ac973627c642f5ec_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMTctMy0xLTEtMTgxNjQ_161ce08f-5759-4f0d-95ed-10fa639e5236"
      unitRef="usd">2900000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMTctNS0xLTEtMTgxNjQ_19bae33b-07fa-4683-86f5-3cc3094c13c3"
      unitRef="usd">6100000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMTctNy0xLTEtMTgxNjQ_d685b969-5c5d-43da-936d-60c600f67a95"
      unitRef="usd">8300000</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMTgtMS0xLTEtMTgxNjQ_fc26f893-7078-4eaf-96d2-9e44a4a64c22"
      unitRef="usd">120600000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ic2c3e03438af4889ac973627c642f5ec_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMTgtMy0xLTEtMTgxNjQ_999cc151-d702-401f-b4c3-9ea063679592"
      unitRef="usd">-1600000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMTgtNS0xLTEtMTgxNjQ_6de3ee92-9c71-480c-87c5-0aef02c4ceaf"
      unitRef="usd">139300000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMTgtNy0xLTEtMTgxNjQ_a05cccad-30fa-40c3-9060-21ba30226d3a"
      unitRef="usd">14900000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMTktMS0xLTEtMTgxNjQ_2f96b92a-c4cd-424d-a978-1b65ee321b5e"
      unitRef="usd">119700000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ic2c3e03438af4889ac973627c642f5ec_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMTktMy0xLTEtMTgxNjQ_09b1e35e-ab75-43dc-ae99-356d1ae3a13d"
      unitRef="usd">-4100000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMTktNS0xLTEtMTgxNjQ_b53e916b-f654-4428-9adf-97c886011938"
      unitRef="usd">133800000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMTktNy0xLTEtMTgxNjQ_c0d8bf87-647a-403b-ac0d-2f826a087f79"
      unitRef="usd">8300000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMjAtMS0xLTEtMTgxNjQ_cc3f2039-cf30-4010-9c5d-ad0374b595eb"
      unitRef="usd">39800000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ic2c3e03438af4889ac973627c642f5ec_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMjAtMy0xLTEtMTgxNjQ_d48d2b2a-0716-4764-91ea-3d0ed7221ecb"
      unitRef="usd">-43700000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMjAtNS0xLTEtMTgxNjQ_92c052c5-5c3c-4745-8844-313193b606f7"
      unitRef="usd">-13600000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMjAtNy0xLTEtMTgxNjQ_39db9493-0e1b-452c-9577-f2ee5fd6c763"
      unitRef="usd">-233300000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMjEtMS0xLTEtMTgxNjQ_56ad8eb3-6175-40af-ad1c-52446cce1d79"
      unitRef="usd">15200000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ic2c3e03438af4889ac973627c642f5ec_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMjEtMy0xLTEtMTgxNjQ_9e148a86-9a9c-40e8-b8f4-15259ca011eb"
      unitRef="usd">-28500000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMjEtNS0xLTEtMTgxNjQ_fb2144d5-b28f-4212-8d7b-6a375f875dc5"
      unitRef="usd">6000000.0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMjEtNy0xLTEtMTgxNjQ_229c7a36-1986-4293-8cf9-37c6bd88793b"
      unitRef="usd">-47400000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMjItMS0xLTEtMTgxNjQ_d69d3624-96b0-4720-ae62-9d826fd145b1"
      unitRef="usd">24600000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ic2c3e03438af4889ac973627c642f5ec_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMjItMy0xLTEtMTgxNjQ_eff902e2-0c51-434c-8fc9-75e1f87f3173"
      unitRef="usd">-15200000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMjItNS0xLTEtMTgxNjQ_60308322-614c-426b-a4e3-c45615614b76"
      unitRef="usd">-19600000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMjItNy0xLTEtMTgxNjQ_939280dd-772c-495c-a2be-a2f00bf7edcc"
      unitRef="usd">-185900000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMjMtMS0xLTEtMTgxNjQ_d352147b-0aa3-4ef4-8bca-0d27a208f385"
      unitRef="usd">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="ic2c3e03438af4889ac973627c642f5ec_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMjMtMy0xLTEtMTgxNjQ_6a55236f-2490-4c2a-bf15-1dd3da01f542"
      unitRef="usd">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMjMtNS0xLTEtMTgxNjQ_8fb83360-4745-403f-a162-c89c8bd4e8c9"
      unitRef="usd">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMjMtNy0xLTEtMTgxNjQ_e976ca03-feda-4586-879c-9238935dd349"
      unitRef="usd">-100000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMjQtMS0xLTEtMTgxNjQ_df2b0bb6-822a-4101-9045-fe01978adbcb"
      unitRef="usd">24600000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic2c3e03438af4889ac973627c642f5ec_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMjQtMy0xLTEtMTgxNjQ_b153b368-ca44-454d-8ee3-53f824969636"
      unitRef="usd">-15200000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMjQtNS0xLTEtMTgxNjQ_b03736f6-45b4-48bd-a863-d700108d10ce"
      unitRef="usd">-19600000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMjQtNy0xLTEtMTgxNjQ_01f21dd6-48ce-4000-b6d9-c8ea236bdeab"
      unitRef="usd">-185800000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMjYtMS0xLTEtMTgxNjQ_50a9a26e-9573-42cd-a861-8799f789bc41"
      unitRef="usdPerShare">0.31</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ic2c3e03438af4889ac973627c642f5ec_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMjYtMy0xLTEtMTgxNjQ_c634d5ca-92d8-4eda-9616-e7935d0ed38c"
      unitRef="usdPerShare">-0.20</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMjYtNS0xLTEtMTgxNjQ_2910ba48-1533-45a2-9c9d-b02783f28144"
      unitRef="usdPerShare">-0.25</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMjYtNy0xLTEtMTgxNjQ_e1a7c20a-1917-4c63-9a45-8cb593c99f4b"
      unitRef="usdPerShare">-2.49</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMjctMS0xLTEtMjE4ODA_209f2c76-07a7-4efa-b96d-dc76081f1610"
      unitRef="usdPerShare">0.30</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ic2c3e03438af4889ac973627c642f5ec_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMjctMy0xLTEtMjE4ODA_d5924d25-beb3-47b2-92ce-bdcda9414935"
      unitRef="usdPerShare">-0.20</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMjctNS0xLTEtMjE4ODA_bdcf2018-b6e8-4fb0-9aec-00e2aa0daa46"
      unitRef="usdPerShare">-0.25</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMjctNy0xLTEtMjE4ODA_a61aed65-e4bc-4b8f-9674-b71cba3b331d"
      unitRef="usdPerShare">-2.49</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMjgtMS0xLTEtMTgxNjQ_a839bcee-936f-4da2-90a7-4ef06eb92f24"
      unitRef="shares">78800000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ic2c3e03438af4889ac973627c642f5ec_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMjgtMy0xLTEtMTgxNjQ_ca57c2b0-7659-4968-a30e-f079b005c5ed"
      unitRef="shares">74700000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMjgtNS0xLTEtMTgxNjQ_c25a4093-f22d-4252-980e-2f5091b35d75"
      unitRef="shares">77300000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMjgtNy0xLTEtMTgxNjQ_df558b05-2795-4af0-918c-1747adf389c1"
      unitRef="shares">74600000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMzAtMS0xLTEtMjE4ODI_0c8e7e01-606d-4602-9b86-76f5f588ed17"
      unitRef="shares">81500000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ic2c3e03438af4889ac973627c642f5ec_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMzAtMy0xLTEtMjE4ODI_313ea036-ce0e-4367-a1ff-4eeb11b01890"
      unitRef="shares">74700000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMzAtNS0xLTEtMjE4ODI_a5575434-e859-44fb-b629-dbcc493119bf"
      unitRef="shares">77300000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18xOS9mcmFnOjE3YzZlZWJkNWI5MjQ1OGJiZjFlNTkzZTE5ZjM5MzdkL3RhYmxlOmVkNTk1MzBkMzk3NDQyYWViY2Y0ZTVjYTNjZmI5YzZjL3RhYmxlcmFuZ2U6ZWQ1OTUzMGQzOTc0NDJhZWJjZjRlNWNhM2NmYjljNmNfMzAtNy0xLTEtMjE4ODI_ef1438e0-341d-43a0-9af5-96b63527f652"
      unitRef="shares">74600000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yMi9mcmFnOjc1NDM0MThjZWZjZDRmYjZiYjMzZmRlY2UzMDdmMzIxL3RhYmxlOmU4ZTFhMzg1YzI4NTQyNmRiMGMyNjM1ZjYyMTM2M2ZiL3RhYmxlcmFuZ2U6ZThlMWEzODVjMjg1NDI2ZGIwYzI2MzVmNjIxMzYzZmJfMi0xLTEtMS0xODE2NA_ddeca0ea-ec8b-4f5f-906b-086244fc866a"
      unitRef="usd">24600000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic2c3e03438af4889ac973627c642f5ec_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yMi9mcmFnOjc1NDM0MThjZWZjZDRmYjZiYjMzZmRlY2UzMDdmMzIxL3RhYmxlOmU4ZTFhMzg1YzI4NTQyNmRiMGMyNjM1ZjYyMTM2M2ZiL3RhYmxlcmFuZ2U6ZThlMWEzODVjMjg1NDI2ZGIwYzI2MzVmNjIxMzYzZmJfMi0zLTEtMS0xODE2NA_ec9b41dc-21b2-4499-a77f-5f0f05d8bf03"
      unitRef="usd">-15200000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yMi9mcmFnOjc1NDM0MThjZWZjZDRmYjZiYjMzZmRlY2UzMDdmMzIxL3RhYmxlOmU4ZTFhMzg1YzI4NTQyNmRiMGMyNjM1ZjYyMTM2M2ZiL3RhYmxlcmFuZ2U6ZThlMWEzODVjMjg1NDI2ZGIwYzI2MzVmNjIxMzYzZmJfMi01LTEtMS0xODE2NA_4b2380f7-faf6-4817-9f6c-2fd25cfa391d"
      unitRef="usd">-19600000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yMi9mcmFnOjc1NDM0MThjZWZjZDRmYjZiYjMzZmRlY2UzMDdmMzIxL3RhYmxlOmU4ZTFhMzg1YzI4NTQyNmRiMGMyNjM1ZjYyMTM2M2ZiL3RhYmxlcmFuZ2U6ZThlMWEzODVjMjg1NDI2ZGIwYzI2MzVmNjIxMzYzZmJfMi03LTEtMS0xODE2NA_b3e0d203-6254-4233-ae82-9debeea383fb"
      unitRef="usd">-185800000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yMi9mcmFnOjc1NDM0MThjZWZjZDRmYjZiYjMzZmRlY2UzMDdmMzIxL3RhYmxlOmU4ZTFhMzg1YzI4NTQyNmRiMGMyNjM1ZjYyMTM2M2ZiL3RhYmxlcmFuZ2U6ZThlMWEzODVjMjg1NDI2ZGIwYzI2MzVmNjIxMzYzZmJfMy0xLTEtMS0xODE2NA_95f87e5e-8f7b-4120-b3f0-56715e5dfd24"
      unitRef="usd">-200000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ic2c3e03438af4889ac973627c642f5ec_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yMi9mcmFnOjc1NDM0MThjZWZjZDRmYjZiYjMzZmRlY2UzMDdmMzIxL3RhYmxlOmU4ZTFhMzg1YzI4NTQyNmRiMGMyNjM1ZjYyMTM2M2ZiL3RhYmxlcmFuZ2U6ZThlMWEzODVjMjg1NDI2ZGIwYzI2MzVmNjIxMzYzZmJfMy0zLTEtMS0xODE2NA_8b0acd45-7f84-45c9-bab6-abd1e048327a"
      unitRef="usd">-200000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yMi9mcmFnOjc1NDM0MThjZWZjZDRmYjZiYjMzZmRlY2UzMDdmMzIxL3RhYmxlOmU4ZTFhMzg1YzI4NTQyNmRiMGMyNjM1ZjYyMTM2M2ZiL3RhYmxlcmFuZ2U6ZThlMWEzODVjMjg1NDI2ZGIwYzI2MzVmNjIxMzYzZmJfMy01LTEtMS0xODE2NA_d782a635-ace3-4540-a8a0-35918993e29f"
      unitRef="usd">-500000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yMi9mcmFnOjc1NDM0MThjZWZjZDRmYjZiYjMzZmRlY2UzMDdmMzIxL3RhYmxlOmU4ZTFhMzg1YzI4NTQyNmRiMGMyNjM1ZjYyMTM2M2ZiL3RhYmxlcmFuZ2U6ZThlMWEzODVjMjg1NDI2ZGIwYzI2MzVmNjIxMzYzZmJfMy03LTEtMS0xODE2NA_00330840-9a10-4914-9891-6267f9ef9e33"
      unitRef="usd">500000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yMi9mcmFnOjc1NDM0MThjZWZjZDRmYjZiYjMzZmRlY2UzMDdmMzIxL3RhYmxlOmU4ZTFhMzg1YzI4NTQyNmRiMGMyNjM1ZjYyMTM2M2ZiL3RhYmxlcmFuZ2U6ZThlMWEzODVjMjg1NDI2ZGIwYzI2MzVmNjIxMzYzZmJfNC0xLTEtMS0xODE2NA_586d838c-87bc-4138-a9da-0a2efff6f00a"
      unitRef="usd">-200000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="ic2c3e03438af4889ac973627c642f5ec_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yMi9mcmFnOjc1NDM0MThjZWZjZDRmYjZiYjMzZmRlY2UzMDdmMzIxL3RhYmxlOmU4ZTFhMzg1YzI4NTQyNmRiMGMyNjM1ZjYyMTM2M2ZiL3RhYmxlcmFuZ2U6ZThlMWEzODVjMjg1NDI2ZGIwYzI2MzVmNjIxMzYzZmJfNC0zLTEtMS0xODE2NA_f816f39d-2c2d-41e4-8448-e575c8e7a930"
      unitRef="usd">1800000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yMi9mcmFnOjc1NDM0MThjZWZjZDRmYjZiYjMzZmRlY2UzMDdmMzIxL3RhYmxlOmU4ZTFhMzg1YzI4NTQyNmRiMGMyNjM1ZjYyMTM2M2ZiL3RhYmxlcmFuZ2U6ZThlMWEzODVjMjg1NDI2ZGIwYzI2MzVmNjIxMzYzZmJfNC01LTEtMS0xODE2NA_bbcc27fa-9367-4a33-9803-b68a20ea3bb5"
      unitRef="usd">-1600000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yMi9mcmFnOjc1NDM0MThjZWZjZDRmYjZiYjMzZmRlY2UzMDdmMzIxL3RhYmxlOmU4ZTFhMzg1YzI4NTQyNmRiMGMyNjM1ZjYyMTM2M2ZiL3RhYmxlcmFuZ2U6ZThlMWEzODVjMjg1NDI2ZGIwYzI2MzVmNjIxMzYzZmJfNC03LTEtMS0xODE2NA_c7bba50a-949f-4b2b-8438-47da93e1e05e"
      unitRef="usd">1100000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yMi9mcmFnOjc1NDM0MThjZWZjZDRmYjZiYjMzZmRlY2UzMDdmMzIxL3RhYmxlOmU4ZTFhMzg1YzI4NTQyNmRiMGMyNjM1ZjYyMTM2M2ZiL3RhYmxlcmFuZ2U6ZThlMWEzODVjMjg1NDI2ZGIwYzI2MzVmNjIxMzYzZmJfNS0xLTEtMS0xODE2NA_bbcc669b-92f8-45e9-ba40-21d23b367416"
      unitRef="usd">24200000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic2c3e03438af4889ac973627c642f5ec_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yMi9mcmFnOjc1NDM0MThjZWZjZDRmYjZiYjMzZmRlY2UzMDdmMzIxL3RhYmxlOmU4ZTFhMzg1YzI4NTQyNmRiMGMyNjM1ZjYyMTM2M2ZiL3RhYmxlcmFuZ2U6ZThlMWEzODVjMjg1NDI2ZGIwYzI2MzVmNjIxMzYzZmJfNS0zLTEtMS0xODE2NA_2e515e9c-ba30-4239-b991-a9694ef8afce"
      unitRef="usd">-13600000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yMi9mcmFnOjc1NDM0MThjZWZjZDRmYjZiYjMzZmRlY2UzMDdmMzIxL3RhYmxlOmU4ZTFhMzg1YzI4NTQyNmRiMGMyNjM1ZjYyMTM2M2ZiL3RhYmxlcmFuZ2U6ZThlMWEzODVjMjg1NDI2ZGIwYzI2MzVmNjIxMzYzZmJfNS01LTEtMS0xODE2NA_13895aa2-9870-42fe-84e7-22b9e2519628"
      unitRef="usd">-21700000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yMi9mcmFnOjc1NDM0MThjZWZjZDRmYjZiYjMzZmRlY2UzMDdmMzIxL3RhYmxlOmU4ZTFhMzg1YzI4NTQyNmRiMGMyNjM1ZjYyMTM2M2ZiL3RhYmxlcmFuZ2U6ZThlMWEzODVjMjg1NDI2ZGIwYzI2MzVmNjIxMzYzZmJfNS03LTEtMS0xODE2NA_a791aeb8-100a-4463-a37d-fe70c31b7b22"
      unitRef="usd">-184200000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yMi9mcmFnOjc1NDM0MThjZWZjZDRmYjZiYjMzZmRlY2UzMDdmMzIxL3RhYmxlOmU4ZTFhMzg1YzI4NTQyNmRiMGMyNjM1ZjYyMTM2M2ZiL3RhYmxlcmFuZ2U6ZThlMWEzODVjMjg1NDI2ZGIwYzI2MzVmNjIxMzYzZmJfNy0xLTEtMS0xODE2NA_c2330e81-e7c9-4bc8-8d33-24132b04f14c"
      unitRef="usd">24200000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ic2c3e03438af4889ac973627c642f5ec_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yMi9mcmFnOjc1NDM0MThjZWZjZDRmYjZiYjMzZmRlY2UzMDdmMzIxL3RhYmxlOmU4ZTFhMzg1YzI4NTQyNmRiMGMyNjM1ZjYyMTM2M2ZiL3RhYmxlcmFuZ2U6ZThlMWEzODVjMjg1NDI2ZGIwYzI2MzVmNjIxMzYzZmJfNy0zLTEtMS0xODE2NA_8e747f41-71b1-40a3-b4e0-2558f032dbb1"
      unitRef="usd">-13600000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yMi9mcmFnOjc1NDM0MThjZWZjZDRmYjZiYjMzZmRlY2UzMDdmMzIxL3RhYmxlOmU4ZTFhMzg1YzI4NTQyNmRiMGMyNjM1ZjYyMTM2M2ZiL3RhYmxlcmFuZ2U6ZThlMWEzODVjMjg1NDI2ZGIwYzI2MzVmNjIxMzYzZmJfNy01LTEtMS0xODE2NA_aa41579b-df68-4fd8-b019-f87df1e2f5ad"
      unitRef="usd">-21700000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yMi9mcmFnOjc1NDM0MThjZWZjZDRmYjZiYjMzZmRlY2UzMDdmMzIxL3RhYmxlOmU4ZTFhMzg1YzI4NTQyNmRiMGMyNjM1ZjYyMTM2M2ZiL3RhYmxlcmFuZ2U6ZThlMWEzODVjMjg1NDI2ZGIwYzI2MzVmNjIxMzYzZmJfNy03LTEtMS0xODE2NA_2c8b779b-ef11-4d92-b5da-0cb32b181786"
      unitRef="usd">-184200000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic932914e17ea4777879ab952bc47a286_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMS0xLTEtMS0xODE2NA_46bce2d1-6ff1-4f83-b4e6-8a9c4f30b8c1"
      unitRef="usd">700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if653f84940094fdc88956b69c3739df5_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMS0zLTEtMS0xODE2NA_e33df6f4-04bf-4600-923c-f9eb641fedbf"
      unitRef="usd">1085100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9fd2bfc03de94eb4a23ff40a2dfd6fe7_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMS01LTEtMS0xODE2NA_eeba45dd-9d86-4835-ac5b-90dd64ddb27f"
      unitRef="usd">-5300000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6735c278f56c4d2286aba604c5af25f6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMS03LTEtMS0xODE2NA_54c22fc4-1f32-4e07-b132-20031751ff5e"
      unitRef="usd">-3300000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id8fe9a482f344283b898248f34c5db4d_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMS05LTEtMS0xODE2NA_1dec9e82-9ed3-4815-ad56-15f94f68881c"
      unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic698543044ba4469ba8751bae898951c_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMS0xMy0xLTEtMTgxNjQ_f608570b-b1c5-4b40-b50b-58aa15614900"
      unitRef="usd">1077300000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i3c851333c120429494592618fb0e4572_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMi0zLTEtMS0xODE2NA_77ea950f-8b63-4e08-995c-51ddd6dd7c06"
      unitRef="usd">200000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ic26cca04ca2b4dd694bd9641fa5123c4_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMi0xMy0xLTEtMTgxNjQ_331622e9-d6f2-433c-9af2-51f3b3eca853"
      unitRef="usd">200000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i3c851333c120429494592618fb0e4572_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMy0zLTEtMS0xODE2NA_63ec7a72-9d88-4899-afc9-2de183e298e7"
      unitRef="usd">7500000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ic26cca04ca2b4dd694bd9641fa5123c4_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMy0xMy0xLTEtMTgxNjQ_0ced49a2-c54d-4d92-9f64-085575a248e7"
      unitRef="usd">7500000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:MinorityInterestPeriodIncreaseDecrease
      contextRef="ie993214cd1d8450aa22158093bdba0b6_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfNC05LTEtMS0xODE2NA_266c7464-56ba-4399-b052-7f3fca357c3e"
      unitRef="usd">-100000</us-gaap:MinorityInterestPeriodIncreaseDecrease>
    <us-gaap:MinorityInterestPeriodIncreaseDecrease
      contextRef="ic26cca04ca2b4dd694bd9641fa5123c4_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfNC0xMy0xLTEtMTgxNjQ_db3e0194-f86d-4daf-9743-e22e092397ba"
      unitRef="usd">-100000</us-gaap:MinorityInterestPeriodIncreaseDecrease>
    <us-gaap:NetIncomeLoss
      contextRef="i8808683eb1f94ae4a2c56f558c2c44d0_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfNS03LTEtMS0xODE2NA_26a8f081-b84f-47d8-8b37-63336b582edb"
      unitRef="usd">-115200000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic26cca04ca2b4dd694bd9641fa5123c4_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfNS0xMy0xLTEtMTgxNjQ_3f613c8f-50a7-4105-9ba6-d0b2c8c468ec"
      unitRef="usd">-115200000</us-gaap:NetIncomeLoss>
    <mygn:ReclassificationFromAccumulatedOtherComprehensiveLossDeconsolidationOfSubsidiary
      contextRef="ic487f8b588f74b249c58ff8b2e14f2f2_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfNi01LTEtMS0xODE2NA_7b21a6eb-6c6a-457f-9cc5-591428551fdd"
      unitRef="usd">100000</mygn:ReclassificationFromAccumulatedOtherComprehensiveLossDeconsolidationOfSubsidiary>
    <mygn:ReclassificationFromAccumulatedOtherComprehensiveLossDeconsolidationOfSubsidiary
      contextRef="ic26cca04ca2b4dd694bd9641fa5123c4_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfNi0xMy0xLTEtMTgxNjQ_dbeafcbb-3b7a-46fe-b66a-36dfa02d6d64"
      unitRef="usd">100000</mygn:ReclassificationFromAccumulatedOtherComprehensiveLossDeconsolidationOfSubsidiary>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ic487f8b588f74b249c58ff8b2e14f2f2_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfNy01LTEtMS0xODE2NA_0fcf254b-f47a-4d3d-9d6d-01be34dc50a9"
      unitRef="usd">-2600000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ic26cca04ca2b4dd694bd9641fa5123c4_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfNy0xMy0xLTEtMTgxNjQ_dc0ce079-cb92-4b11-8a0e-e3c6bb61d5a4"
      unitRef="usd">-2600000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i749ef50c3e724e34a1c233ae09ec290a_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfOC0xLTEtMS0xODE2NA_0c329c17-bc0c-4600-a430-2af096033748"
      unitRef="usd">700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i838807b0749e445cb7c40c97e6854df5_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfOC0zLTEtMS0xODE2NA_66bfcf7b-0010-4e86-96fc-14d2e1ffc708"
      unitRef="usd">1092800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia60976ab8abc463ebc9edd0688cead34_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfOC01LTEtMS0xODE2NA_1577a740-0878-41b5-b595-6f97022f74fe"
      unitRef="usd">-7800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia1c450cd54f5427891132bfd983e0317_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfOC03LTEtMS0xODE2NA_1451116c-3a46-4046-95fc-eb3cc62765ca"
      unitRef="usd">-118500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie2b71276d33f4f37af748f45b0cac148_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfOC05LTEtMS0xODE2NA_bb230958-dbe1-4ff4-834d-eee2e3096b6f"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i71bfb9a9cbab40e4b2ee82f3c9d4e30b_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfOC0xMy0xLTEtMTgxNjQ_cc30e54a-b16b-4250-9834-5b69a507cdb5"
      unitRef="usd">967200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ib2ef1fdcdaaa463faa4cb4a9e259428b_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfOS0zLTEtMS0xODE2NA_152a3160-6cad-4d27-a8b1-bdf75611324a"
      unitRef="usd">1900000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i61643ef3fddf427bab68f34f288ffdbe_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfOS0xMy0xLTEtMTgxNjQ_2c0417f6-bc83-4d84-98c0-c0cd89d97f74"
      unitRef="usd">1900000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ib2ef1fdcdaaa463faa4cb4a9e259428b_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMTAtMy0xLTEtMTgxNjQ_cdc34687-4139-4d23-8700-f9224710f116"
      unitRef="usd">1900000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i61643ef3fddf427bab68f34f288ffdbe_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMTAtMTMtMS0xLTE4MTY0_c55ce39f-8620-4559-8877-9dcc9aa353f6"
      unitRef="usd">1900000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="i273996af01934354b9835c65bd479b9e_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMTEtNy0xLTEtMTgxNjQ_455d51a8-707d-4f01-b1bb-d7ada527a5a1"
      unitRef="usd">-55400000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i61643ef3fddf427bab68f34f288ffdbe_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMTEtMTMtMS0xLTE4MTY0_2f16eead-dc25-4244-ab06-8e397e554fb8"
      unitRef="usd">-55400000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ief2d705cf1e84ddebcf24754f7a3b890_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMTItNS0xLTEtMTgxNjQ_97dcd716-7acc-4e67-9f2c-658322903a6b"
      unitRef="usd">2600000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i61643ef3fddf427bab68f34f288ffdbe_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMTItMTMtMS0xLTE4MTY0_b741316e-c49a-4a34-b937-50e62cfc5d60"
      unitRef="usd">2600000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idd849afda7b942948aa9c83f57ffaeac_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMTMtMS0xLTEtMTgxNjQ_978c36cb-6c8b-4ab1-9d5c-d5d2105ecd55"
      unitRef="usd">700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if5fc7e59c62b42ad92216ba6836b6eb8_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMTMtMy0xLTEtMTgxNjQ_fb15d273-6d52-4775-913d-7e574d09e258"
      unitRef="usd">1096600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1bce2263b540455893f4d80b0de511c9_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMTMtNS0xLTEtMTgxNjQ_f493e15b-4e21-46e9-8052-d018cbe60a45"
      unitRef="usd">-5200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8acfa22e3dc144acaa3254b56b5c801f_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMTMtNy0xLTEtMTgxNjQ_ecf0ae08-c80c-4e4a-9984-2599741988e3"
      unitRef="usd">-173900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibc4b5cd85a7a4e8291ff3e4c80dc8756_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMTMtOS0xLTEtMTgxNjQ_3a85b9bf-b66c-4fca-bad1-3e6c190a9fb8"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic976e79981cb4e17a90b071ed83778dd_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMTMtMTMtMS0xLTE4MTY0_6e7bca12-eba9-4a25-9060-65105c8f3b4a"
      unitRef="usd">918200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ia9f2038ca2c74e13bf97f356d8a0ef8e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMTQtMS0xLTEtMTk0MDY_f8fd0988-7cb8-421c-8409-e3255d7f4d75"
      unitRef="usd">100000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i809ae31b44854c4eab5bc730c4471cb7_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMTQtMy0xLTEtMTk0MDY_f1c4a37e-9bdb-4e25-a42d-5301a5826406"
      unitRef="usd">-3800000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ic2c3e03438af4889ac973627c642f5ec_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMTQtMTMtMS0xLTE5NDg5_4edb8c31-b4fb-4755-83f5-a7472d0c83a4"
      unitRef="usd">-3700000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i809ae31b44854c4eab5bc730c4471cb7_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMTUtMy0xLTEtMTk0MDY_6a9c7a60-5265-44c8-9b53-c3a676647f6d"
      unitRef="usd">8400000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ic2c3e03438af4889ac973627c642f5ec_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMTUtMTMtMS0xLTE5NDg5_eb6c18e1-9bf3-4b45-962b-e935eee48d91"
      unitRef="usd">8400000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="i7055540d7cfb415fafe2dac25f373950_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMTYtNy0xLTEtMTk0MDY_282f3cdb-b661-453a-a6c4-b39139b14911"
      unitRef="usd">-15200000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic2c3e03438af4889ac973627c642f5ec_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMTYtMTMtMS0xLTE5NDg5_3ce8d88e-99c4-4062-8f21-e0a7dcb0c84b"
      unitRef="usd">-15200000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ic19852c9069943c28e1fa3345a711650_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMTctNS0xLTEtMTk0MDY_83bee0a2-0204-4aef-80bf-19476c68ed45"
      unitRef="usd">1600000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ic2c3e03438af4889ac973627c642f5ec_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMTctMTMtMS0xLTE5NDg5_13b3ff4f-2180-49ee-bc45-a68ffe56a11b"
      unitRef="usd">1600000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i691c4f02f3464e09bb1a483b5726a5c3_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMTgtMS0xLTEtMTk0MjI_b500e02a-4850-49dd-803d-c69eb37b462c"
      unitRef="usd">800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i26e03ce4366849f4ad19d964861a49f7_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMTgtMy0xLTEtMTk0MjI_61b3083b-828b-49d4-ab9c-3ce3040407e9"
      unitRef="usd">1101200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib871f90b68b641f89b0eabe7f24ebcf9_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMTgtNS0xLTEtMTk0MjI_c1dbcd4b-8121-44cf-bb6c-a57110f86aa2"
      unitRef="usd">-3600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5237cb26929043d6b2c706d0a5a289d6_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMTgtNy0xLTEtMTk0MjI_0338fabc-25b4-4af8-a31f-6849cf298cf3"
      unitRef="usd">-189100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9be196750c9340469be5f26a4d4e5835_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMTgtOS0xLTEtMTk0NjE_ddcde6ef-c8c1-4341-9e5f-fc54534a1e9f"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0c6bac27ede64afeb4dbc13729f58578_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMTgtMTMtMS0xLTE5NDg5_61a496d1-134e-4bc9-911c-a7516d19c5ba"
      unitRef="usd">909300000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifd82562daef9481db9764cfedc560e47_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMTUtMS0xLTEtMTgxNjQ_bcabf902-7b4a-4ec3-b8ce-9e04d280d351"
      unitRef="usd">800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i602bb4299a7f49a78984421bea48e2d2_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMTUtMy0xLTEtMTgxNjQ_d82b8765-75dc-4bbf-9d45-39056cb50cf6"
      unitRef="usd">1109500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6f1113acaf4c4991a6389007d99fd17f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMTUtNS0xLTEtMTgxNjQ_fa79e8f1-1a6d-45e0-9d3c-300a7915a603"
      unitRef="usd">-2300000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic00338bab29748f28e289324358531f0_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMTUtNy0xLTEtMTgxNjQ_13802261-2cca-4b7d-ab31-564a7cceeda0"
      unitRef="usd">-227000000.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icc25381d7b004bd686b31d1d7f06dc8a_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMTUtOS0xLTEtMTgxNjQ_8fc54182-419c-4822-9418-a09d9942c9f4"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMTUtMTMtMS0xLTE4MTY0_cc36c861-7a56-4815-b7c2-6fe3913595cd"
      unitRef="usd">881000000.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i0fd66a47efdc463d8b56854a06ea9eb0_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMTYtMy0xLTEtMTgxNjQ_6300dd0e-474f-4247-a12c-987098ce1bb4"
      unitRef="usd">26000000.0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ie59a85cd0de74256a4070826a06ab2ee_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMTYtMTMtMS0xLTE4MTY0_0e0451bf-32b9-45e4-8a63-d13d81e508c3"
      unitRef="usd">26000000.0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i0fd66a47efdc463d8b56854a06ea9eb0_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMTctMy0xLTEtMTgxNjQ_b0685d9c-516b-45fb-b500-aef3c0468f33"
      unitRef="usd">9000000.0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ie59a85cd0de74256a4070826a06ab2ee_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMTctMTMtMS0xLTE4MTY0_81b6daa4-21ed-4984-bc8f-b4a59b896ea3"
      unitRef="usd">9000000.0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="i03600303e63e4b17b220e55c943b073d_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMTgtNy0xLTEtMTgxNjQ_958a8d04-2936-4abc-8fd0-cb2780e6cfb0"
      unitRef="usd">-39500000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie59a85cd0de74256a4070826a06ab2ee_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMTgtMTMtMS0xLTE4MTY0_8acfddc6-b2ca-4c1e-8eeb-3b967466612c"
      unitRef="usd">-39500000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i1f2d8d71b25549ff846e9b42b31323ef_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMTktNS0xLTEtMTgxNjQ_7c27bb94-2997-44dc-a47e-6901006486b2"
      unitRef="usd">-1300000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ie59a85cd0de74256a4070826a06ab2ee_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMTktMTMtMS0xLTE4MTY0_d6f50997-5663-4b60-9c04-6a6120b968ec"
      unitRef="usd">-1300000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i740bb39577154e0a943a066cee5730d4_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMjAtMS0xLTEtMTgxNjQ_8ede0b15-88a7-402e-bf1e-b265a34f107f"
      unitRef="usd">800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i14c8904c520e416b9c51933b8b024cd1_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMjAtMy0xLTEtMTgxNjQ_2bfb5c6a-29d8-45de-ad23-c2f846e37c20"
      unitRef="usd">1144500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9fa028178e4d40088533a95f689bc888_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMjAtNS0xLTEtMTgxNjQ_9e9ae347-4e03-44ad-975d-0e5599e8c651"
      unitRef="usd">-3600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9644cd21559142acbc76c26cfab92eb6_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMjAtNy0xLTEtMTgxNjQ_6398c026-6da9-4ada-ab44-db23eee78e63"
      unitRef="usd">-266500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie6b465bbce9349f88227b2188438b68d_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMjAtOS0xLTEtMTgxNjQ_f3178ec4-9a18-4be8-acd2-80f3aed20de1"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i24dac68960214b9f993eaa8df10274b2_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMjAtMTMtMS0xLTE4MTY0_60c4696c-b50e-4f5c-9cc2-ba859ac5f96a"
      unitRef="usd">875200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i8032c809a65c47bda9a36a0b5229bfef_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMjEtMy0xLTEtMTgxNjQ_6c224715-c397-49a7-a2d7-972e9a3d6229"
      unitRef="usd">23500000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i9af20bf23942493aad5860b2c2e56978_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMjEtMTMtMS0xLTE4MTY0_3cb5d6c6-3441-4da5-a286-4a4d4739a36b"
      unitRef="usd">23500000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i8032c809a65c47bda9a36a0b5229bfef_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMjItMy0xLTEtMTgxNjQ_dbcfb3ea-4ad9-4d1a-95f9-119c57e037c8"
      unitRef="usd">8900000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i9af20bf23942493aad5860b2c2e56978_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMjItMTMtMS0xLTE4MTY0_0c03fe92-48b0-4ff8-8c44-d86be62f147e"
      unitRef="usd">8900000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:MinorityInterestPeriodIncreaseDecrease
      contextRef="ie2a868eedf484113abf4a011ceff8fd4_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMjMtOS0xLTEtMTgxNjQ_0a445784-3abf-432a-a328-2bf396fce6a0"
      unitRef="usd">-100000</us-gaap:MinorityInterestPeriodIncreaseDecrease>
    <us-gaap:MinorityInterestPeriodIncreaseDecrease
      contextRef="i9af20bf23942493aad5860b2c2e56978_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMjMtMTMtMS0xLTE4MTY0_52e4afea-1887-4b67-944b-027de297b8ef"
      unitRef="usd">-100000</us-gaap:MinorityInterestPeriodIncreaseDecrease>
    <us-gaap:NetIncomeLoss
      contextRef="ib07b6c87c8e242108fbc9023fce23cc9_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMjQtNy0xLTEtMTgxNjQ_d40c672d-26c1-470e-9a97-95f1f7afa4fc"
      unitRef="usd">-4700000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9af20bf23942493aad5860b2c2e56978_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMjQtMTMtMS0xLTE4MTY0_865378fe-9dd7-4555-9ef9-20edeef7df0c"
      unitRef="usd">-4700000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ia74c427781b6435fa165763f7d2b6818_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMjUtNS0xLTEtMTgxNjQ_064114da-6daa-4c5c-8917-2c518dd4b836"
      unitRef="usd">-400000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i9af20bf23942493aad5860b2c2e56978_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMjUtMTMtMS0xLTE4MTY0_3cc8e4ef-3d55-413f-81ef-cf0320c294c7"
      unitRef="usd">-400000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i03c0a03785d94bfa95d4de1d0a89a121_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMjYtMS0xLTEtMTgxNjQ_71bfd4aa-cbe5-4590-b514-82c95b29fe39"
      unitRef="usd">800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4438d624363b4476a68d74da26614067_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMjYtMy0xLTEtMTgxNjQ_3985a827-0d58-4ad8-a1d5-b50c5aae593e"
      unitRef="usd">1176900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3a1959e9612e44579e775f75a541e4a8_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMjYtNS0xLTEtMTgxNjQ_3c804431-0bd5-4384-8d04-9bd593de110c"
      unitRef="usd">-4000000.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4b38d81b9f4e4aa8b1b021b9bb1b0958_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMjYtNy0xLTEtMTgxNjQ_44ead5fe-d83e-4208-a650-2c2404b620a1"
      unitRef="usd">-271200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie0450de8f0b54d7591325d511dad90ca_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMjYtOS0xLTEtMTgxNjQ_166dd98c-fe57-424f-a920-b0c56c3efcd2"
      unitRef="usd">-100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i171029b6cf5d41df9d00d9688277e104_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMjYtMTMtMS0xLTE4MTY0_4b414959-14bc-4087-8a62-72fb2b0b0ab4"
      unitRef="usd">902400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i70b7a4c941544cd7894d1e4defd87c79_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMzItMy0xLTEtMTk1MzY_50de8eeb-aa10-402c-b7ac-40bbbfaacc1d"
      unitRef="usd">31900000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMzItMTMtMS0xLTE5NTg4_9c6d4308-4f52-430f-a1f8-52ccd36ca74b"
      unitRef="usd">31900000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i70b7a4c941544cd7894d1e4defd87c79_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMzMtMy0xLTEtMTk1MzY_07861e56-3d91-4138-ba1e-ba6074f563f6"
      unitRef="usd">10000000.0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMzMtMTMtMS0xLTE5NTg4_42fef40c-d9ef-4fae-8f45-02ce63fb2c3a"
      unitRef="usd">10000000.0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="i53e5c42e5a894d47b34f9f9504d85a50_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMzQtNy0xLTEtMTk1NjI_9d42e0a5-a4cf-40cc-b2b4-a7ff8fa44010"
      unitRef="usd">24600000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMzQtMTMtMS0xLTE5NTg4_0e2635ae-808c-4ec3-a124-21dd41a945c9"
      unitRef="usd">24600000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="id7bead8553aa40e19e389e9e36a5a52f_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMzUtNS0xLTEtMTk1MzY_6dc815dc-42ef-4233-8427-14d5a587f690"
      unitRef="usd">-400000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMzUtMTMtMS0xLTE5NTg4_c5a13f8a-56c1-4aa1-8577-0efc596bdf9a"
      unitRef="usd">-400000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic89788fb0cac4113ab3e5d22b824bee3_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMzYtMS0xLTEtMTk1MDc_cac39b42-29fa-4236-906e-45eab4b4b689"
      unitRef="usd">800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if5489fa2beb84874846c50045cb4a8fe_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMzYtMy0xLTEtMTk1MDc_ba34b5bc-c234-4fb1-9cd4-095da6534ed9"
      unitRef="usd">1218800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i12b5bd71050148fe920686b278365e75_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMzYtNS0xLTEtMTk1MDc_08ad2ff1-4b5d-45ce-95a5-08b19c63fde1"
      unitRef="usd">-4400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1926bf39b52c48a4957fc9a924a82cf7_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMzYtNy0xLTEtMTk1MDc_695bbce1-b112-480b-91d6-a1bd3671ca43"
      unitRef="usd">-246600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icffee6692ce64627b1016dc94b08f0f0_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMzYtOS0xLTEtMTk1MDc_7753349a-85a5-41fe-b3a3-e3900941698b"
      unitRef="usd">-100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yNS9mcmFnOjA3OTZlNjExMzIwZDRkZDViYjllMjU5ZjFlYjMwYjJlL3RhYmxlOmVkNThhMzU3NzZhNDRhNzA4OTRjMzk0OWE0YTE0YjM3L3RhYmxlcmFuZ2U6ZWQ1OGEzNTc3NmE0NGE3MDg5NGMzOTQ5YTRhMTRiMzdfMzYtMTMtMS0xLTE5NTg4_5337fe91-0746-40af-8376-5ef10fef85a2"
      unitRef="usd">968500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfMy0xLTEtMS0xODE2NA_0e7ee652-2c61-4b36-99d3-89bb5755ddd8"
      unitRef="usd">-19600000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfMy0zLTEtMS0xODE2NA_1d22cd64-a4e9-49eb-ae70-663b9a7ae0a6"
      unitRef="usd">-185800000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfNS0xLTEtMS0xODE2NA_4b84a5ea-7764-48e8-80d8-6046e4e8b031"
      unitRef="usd">49500000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfNS0zLTEtMS0xODE2NA_378ee569-4f35-447e-9b1e-c30d3974b575"
      unitRef="usd">53300000</us-gaap:DepreciationAndAmortization>
    <mygn:NonCashInterestExpense
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfNi0xLTEtMS0xODE2NA_479f543e-685d-4bf3-b6fe-c3b11969b0c7"
      unitRef="usd">1300000</mygn:NonCashInterestExpense>
    <mygn:NonCashInterestExpense
      contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfNi0zLTEtMS0xODE2NA_df80881d-fe2a-49a7-9f1b-583b848120ad"
      unitRef="usd">400000</mygn:NonCashInterestExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfNy0xLTEtMS0xODE2NA_51f9e695-eafb-4a7c-9abd-8e78e25cfd6a"
      unitRef="usd">9800000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfNy0zLTEtMS0xODE2NA_5f2b9ec7-693f-4760-97a0-f59dd509e4ea"
      unitRef="usd">9600000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:ShareBasedCompensation
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfOC0xLTEtMS0xODE2NA_5cea998f-f9e3-4f06-abd8-adf39ce8830b"
      unitRef="usd">27900000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfOC0zLTEtMS0xODE2NA_15bf3bc2-0d02-46a5-8c3a-c2f2a72bd25e"
      unitRef="usd">17800000</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfOS0xLTEtMS0xODE2NA_62640085-90b4-437f-861a-9acf00468364"
      unitRef="usd">27800000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfOS0zLTEtMS0xODE2NA_bbc90e7e-8805-4383-9feb-fe2b94e5ffcb"
      unitRef="usd">600000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <mygn:IncreaseDecreaseInUnrecognizedTaxBenefits
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfMTAtMS0xLTEtMTgxNjQ_24285b8c-6078-477e-b945-556dd0f2c372"
      unitRef="usd">1500000</mygn:IncreaseDecreaseInUnrecognizedTaxBenefits>
    <mygn:IncreaseDecreaseInUnrecognizedTaxBenefits
      contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfMTAtMy0xLTEtMTgxNjQ_c8d7bc1d-26d5-47ab-b46e-b4ee97d213fa"
      unitRef="usd">14900000</mygn:IncreaseDecreaseInUnrecognizedTaxBenefits>
    <mygn:ChangeInFairValueOfContingentConsideration
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfMTEtMS0xLTEtMTgxNjQ_8407add2-6003-4c60-acd4-c7d61a071cc9"
      unitRef="usd">1700000</mygn:ChangeInFairValueOfContingentConsideration>
    <mygn:ChangeInFairValueOfContingentConsideration
      contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfMTEtMy0xLTEtMTgxNjQ_cd57fcbc-09bc-4155-b314-47c9f35c51ce"
      unitRef="usd">-4500000</mygn:ChangeInFairValueOfContingentConsideration>
    <us-gaap:InventoryWriteDown
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfMTItMS0xLTEtMTgxNjQ_b5dd97c1-d174-4618-af0f-5c4e479844a2"
      unitRef="usd">6500000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfMTItMy0xLTEtMTgxNjQ_385fa59f-fe08-4a0e-a1f6-091f60aef673"
      unitRef="usd">0</us-gaap:InventoryWriteDown>
    <mygn:ImpairmentOfGoodwillAndLongLivedAssetsHeldForUse
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfMTMtMS0xLTEtMTgxNjQ_d326da25-7ea1-4378-9d42-bc105196a294"
      unitRef="usd">1800000</mygn:ImpairmentOfGoodwillAndLongLivedAssetsHeldForUse>
    <mygn:ImpairmentOfGoodwillAndLongLivedAssetsHeldForUse
      contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfMTMtMy0xLTEtMTgxNjQ_fbf9f217-e2c9-4765-b252-94b0da093025"
      unitRef="usd">98400000</mygn:ImpairmentOfGoodwillAndLongLivedAssetsHeldForUse>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfMTQtMS0xLTEtMTgxNjQ_ee994d75-610d-4807-9c74-f0553dbba739"
      unitRef="usd">162000000.0</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfMTQtMy0xLTEtMTgxNjQ_09366d74-2eee-4999-afb7-186a4fbd0d77"
      unitRef="usd">1000000.0</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:IncreaseDecreaseInPrepaidExpensesOther
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfMTctMS0xLTEtMTgxNjQ_bf62ae9d-91e8-4a79-99ca-1ee2fa62ebb9"
      unitRef="usd">6700000</us-gaap:IncreaseDecreaseInPrepaidExpensesOther>
    <us-gaap:IncreaseDecreaseInPrepaidExpensesOther
      contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfMTctMy0xLTEtMTgxNjQ_1c6546d4-63db-4442-8a36-0d55b52e88b3"
      unitRef="usd">-5400000</us-gaap:IncreaseDecreaseInPrepaidExpensesOther>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfMTgtMS0xLTEtMTgxNjQ_b388b8a9-5996-41d1-9b02-317d8e2d4563"
      unitRef="usd">11600000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfMTgtMy0xLTEtMTgxNjQ_a10ac906-f900-4d83-9446-95686fbbbab5"
      unitRef="usd">-33300000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfMjAtMS0xLTEtMTgxNjQ_72168cff-f264-4d33-8ec3-ca7aa4b24c17"
      unitRef="usd">1600000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfMjAtMy0xLTEtMTgxNjQ_c58a0d14-6b01-4e4e-827a-14629122e452"
      unitRef="usd">-1700000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidTaxes
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfMjEtMS0xLTEtMTgxNjQ_c2d49c34-039b-48a6-827b-b24c747d7f17"
      unitRef="usd">-108000000.0</us-gaap:IncreaseDecreaseInPrepaidTaxes>
    <us-gaap:IncreaseDecreaseInPrepaidTaxes
      contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfMjEtMy0xLTEtMTgxNjQ_df56b492-ee05-43cd-85f3-dcb9fde4ec0a"
      unitRef="usd">83200000</us-gaap:IncreaseDecreaseInPrepaidTaxes>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfMjItMS0xLTEtMTgxNjQ_758b6259-97b0-4c7b-bb8b-a48744d0014c"
      unitRef="usd">3600000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfMjItMy0xLTEtMTgxNjQ_a14dfbee-8f78-4b80-ba30-9372d6688081"
      unitRef="usd">1200000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfMjMtMS0xLTEtMTgxNjQ_6d70744e-a966-4c94-8e28-7b612f2c9b48"
      unitRef="usd">-4800000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfMjMtMy0xLTEtMTgxNjQ_523ea073-fa80-42cf-a05a-f1cd568cc304"
      unitRef="usd">-2600000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfMjQtMS0xLTEtMTgxNjQ_631f51fe-14cd-435a-b1fd-eb0894224da4"
      unitRef="usd">78200000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfMjQtMy0xLTEtMTgxNjQ_4378e2d5-6bd8-48db-bb3f-0f4d5e521e69"
      unitRef="usd">3100000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfMjUtMS0xLTEtMTgxNjQ_8015b350-3a69-463b-98e9-a3aaa82668e1"
      unitRef="usd">-20400000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfMjUtMy0xLTEtMTgxNjQ_c6fff754-4b75-4352-9c24-27bf107388f9"
      unitRef="usd">28500000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfMjYtMS0xLTEtMTgxNjQ_e8d62e3e-f7b7-4002-b1be-81c220816aeb"
      unitRef="usd">28100000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfMjYtMy0xLTEtMTgxNjQ_de43012c-399b-47be-9ad3-8cdddefb52ab"
      unitRef="usd">-12500000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfMjgtMS0xLTEtMTgxNjQ_f5979e48-3d89-4934-8be8-fc1449181070"
      unitRef="usd">14600000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfMjgtMy0xLTEtMTgxNjQ_30d97ae4-6ceb-4589-bbdc-e8afbd35b411"
      unitRef="usd">6800000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfMjktMS0xLTEtMTgxNjQ_976369dd-c22d-41ec-a01c-5e7a450a4f08"
      unitRef="usd">379100000</us-gaap:ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets>
    <us-gaap:ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets
      contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfMjktMy0xLTEtMTgxNjQ_8e614be5-3d38-43b4-bfce-9dd8008cfba6"
      unitRef="usd">21300000</us-gaap:ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfMzEtMS0xLTEtMTgxNjQ_9d8dda34-a791-4def-8cb4-df0e3d34c237"
      unitRef="usd">101000000.0</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfMzEtMy0xLTEtMTgxNjQ_dc93aa47-4440-4b22-8a88-fb2a5a71c736"
      unitRef="usd">15800000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfMzItMS0xLTEtMTgxNjQ_d027cc56-5f1b-497c-9a2a-d20d04d5480d"
      unitRef="usd">36800000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfMzItMy0xLTEtMTgxNjQ_61889fd3-fad5-4377-88a4-cd417e725732"
      unitRef="usd">51900000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfMzMtMS0xLTEtMTgxNjQ_e06127db-7389-41d2-84fd-a2e12fd9fc14"
      unitRef="usd">300300000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfMzMtMy0xLTEtMTgxNjQ_bea699e2-cb86-4162-9a7f-6e3666bf5286"
      unitRef="usd">50600000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfMzUtMS0xLTEtMTgxNjQ_895c3d53-521e-48c5-9439-a6912f1500a1"
      unitRef="usd">90000000.0</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfMzUtMy0xLTEtMTgxNjQ_a287ca7a-1314-45d7-b684-f88aad795c61"
      unitRef="usd">2200000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfMzYtMS0xLTEtMTgxNjQ_a5980f0d-c760-4e64-b5f5-c5eb7d8c382c"
      unitRef="usd">8600000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfMzYtMy0xLTEtMTgxNjQ_db450f0b-ad9e-4197-8dea-f77ef1ac3456"
      unitRef="usd">3900000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfMzctMS0xLTEtMTgxNjQ_c85e82ec-482f-458d-a917-a6bd118bc4f5"
      unitRef="usd">3300000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfMzctMy0xLTEtMTgxNjQ_119da050-e31b-458c-a621-6efce96f1c23"
      unitRef="usd">100000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfMzgtMS0xLTEtMTgxNjQ_02e81b17-1799-49da-85ce-28124b7f0a78"
      unitRef="usd">1200000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfMzgtMy0xLTEtMTgxNjQ_d68f0b48-66d6-43df-a07f-99457400db68"
      unitRef="usd">1000000.0</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:RepaymentsOfLinesOfCredit
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfMzktMS0xLTEtMTgxNjQ_18c633d1-635e-4a58-97a4-1aca11e2c3ce"
      unitRef="usd">226400000</us-gaap:RepaymentsOfLinesOfCredit>
    <us-gaap:RepaymentsOfLinesOfCredit
      contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfMzktMy0xLTEtMTgxNjQ_2b00f2f2-bb6f-403b-9dda-7835f093b1f9"
      unitRef="usd">0</us-gaap:RepaymentsOfLinesOfCredit>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfNDAtMS0xLTEtMTgxNjQ_a2c54904-7be0-4250-a7ae-41a9fb03a82a"
      unitRef="usd">-149500000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfNDAtMy0xLTEtMTgxNjQ_810ca2d6-9b1e-457f-a93c-cd1621bcd3ae"
      unitRef="usd">-2800000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfNDEtMS0xLTEtMTgxNjQ_5a713626-126f-4b78-869f-d9099e8bc825"
      unitRef="usd">-700000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfNDEtMy0xLTEtMTgxNjQ_b4613069-3f5d-41ae-8892-7de4e789387e"
      unitRef="usd">300000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <mygn:NetChangeInCashAndCashEquivalentsClassifiedAsHeldForSale
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfNDItMS0xLTEtMTgxNjQ_35f1c52d-5283-47c7-8831-65bb5125fd69"
      unitRef="usd">0</mygn:NetChangeInCashAndCashEquivalentsClassifiedAsHeldForSale>
    <mygn:NetChangeInCashAndCashEquivalentsClassifiedAsHeldForSale
      contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfNDItMy0xLTEtMTgxNjQ_394535c9-2483-49bf-8ba1-a7060faece8e"
      unitRef="usd">1500000</mygn:NetChangeInCashAndCashEquivalentsClassifiedAsHeldForSale>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfNDMtMS0xLTEtMTgxNjQ_d75e6426-fbf1-40e4-8652-285f78bdb166"
      unitRef="usd">178200000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfNDMtMy0xLTEtMTgxNjQ_84cd9319-f827-4f44-a411-e1bdb3ce5c2f"
      unitRef="usd">37100000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfNDQtMS0xLTEtMTgxNjQ_06a4bb4f-196e-43e0-812c-69fc8ed560be"
      unitRef="usd">117000000.0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ic698543044ba4469ba8751bae898951c_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfNDQtMy0xLTEtMTgxNjQ_6c571cee-c2b9-4cb6-9e1e-9890f3511c86"
      unitRef="usd">81200000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfNDUtMS0xLTEtMTgxNjQ_e92d3411-fc60-4502-955f-215ada627b89"
      unitRef="usd">295200000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i0c6bac27ede64afeb4dbc13729f58578_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18yOC9mcmFnOjM4YjcyOWQ0ODRhZTRhZGViYTJkYmQ3NDUzMzk4YWI5L3RhYmxlOmY2NGRjZDA2M2I1ZDRkYjc4NzRjNGI3ODQwZGVlMTBjL3RhYmxlcmFuZ2U6ZjY0ZGNkMDYzYjVkNGRiNzg3NGM0Yjc4NDBkZWUxMGNfNDUtMy0xLTEtMTgxNjQ_5a7b8861-47fb-461f-bbee-571544c78ccd"
      unitRef="usd">118300000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNC9mcmFnOmIyNjgwNTlkNzdlZDQ4YjZhOWZlMGRmYzJlM2Q1N2ZkL3RleHRyZWdpb246YjI2ODA1OWQ3N2VkNDhiNmE5ZmUwZGZjMmUzZDU3ZmRfNTAzNA_30ed1fa6-26a9-4f4a-8af6-b8998a4d0529">BASIS OF PRESENTATION&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Myriad Genetics, Inc. and its subsidiaries (collectively, the &#x201c;Company&#x201d; or &#x201c;Myriad&#x201d;) discover and commercialize genetic tests that determine the risk of developing disease, assess the risk of disease progression, and guide treatment decisions across medical specialties where critical genetic insights can significantly improve patient care and lower healthcare costs. The Company's mission and purpose is to advance health and well-being for all, empower individuals with vital genetic insights and enable healthcare providers to better detect, treat and prevent disease. The Company generates revenue by performing molecular diagnostic tests and, prior to the sale of Myriad RBM, Inc. on July 1, 2021 as described in Note 16, by providing pharmaceutical services to the pharmaceutical and biotechnology industries and medical research institutions utilizing its multiplexed immunoassay technology. The Company&#x2019;s corporate headquarters are located in Salt Lake City, Utah.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying Condensed Consolidated Financial Statements for the Company have been prepared in accordance with U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;) for interim financial information and pursuant to the applicable rules and regulations of the Securities and Exchange Commission (&#x201c;SEC&#x201d;).&#160;All intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, the accompanying financial statements contain all adjustments (consisting of normal and recurring accruals) necessary to present fairly all financial statements in accordance with GAAP. The Condensed Consolidated Financial Statements herein should be read in conjunction with the Company&#x2019;s audited Consolidated Financial Statements and notes thereto included in the Company&#x2019;s Transition Report on Form 10-K for the transition period ended December&#160;31, 2020 (the &#x201c;Transition Report on Form 10-K&#x201d;). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenue and expenses during the reporting period. Operating results for the three and nine months ended September&#160;30, 2021 may not necessarily be indicative of results to be expected for any other interim period or for the full year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has historically experienced seasonality in its testing business. The volume of testing is negatively impacted by the summer season, which is generally reflected in the quarter ending June 30 and the quarter ending September 30. The quarter ending December 31 is generally strong as the Company sees an increase in volumes from patients who have met their annual insurance deductible. Conversely, the quarter ending March 31 is typically negatively impacted by the annual reset of patient deductibles.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Due to the COVID-19 global pandemic, including variants of COVID-19 (&#x201c;COVID-19&#x201d;), seasonality may not follow the same pattern as in prior years. Volumes and results of operations were impacted negatively in calendar year 2020 by COVID-19. As such, the Company&#x2019;s year over year results may not be comparable. Management continues to monitor the impact of COVID-19 on the Company&#x2019;s financial condition, liquidity, operations, suppliers, industry, and workforce. Given the variants of COVID-19 that have surfaced around the world, the Company is not able to fully estimate the effects of COVID-19 on results of operations, financial condition, or liquidity for future periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reclassifications&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain prior period amounts have been reclassified to conform with the current period presentation. The reclassifications have no impact on the total assets, total liabilities, stockholders&#x2019; equity, cash flows from operations, or net income (loss) for the period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recently Adopted Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (&#x201c;ASU 2019-12&#x201d;). ASU 2019-12 is a new accounting standard to simplify accounting for income taxes and remove, modify, and add to the disclosure requirements of income taxes. The standard is effective for fiscal years beginning after December 15, 2020, with early adoption permitted. This guidance was adopted&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; with no material impact to t&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;he Company's Condensed Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNC9mcmFnOmIyNjgwNTlkNzdlZDQ4YjZhOWZlMGRmYzJlM2Q1N2ZkL3RleHRyZWdpb246YjI2ODA1OWQ3N2VkNDhiNmE5ZmUwZGZjMmUzZDU3ZmRfNTAzOA_6c845d23-3c3e-449d-88c6-b37abb20d937">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying Condensed Consolidated Financial Statements for the Company have been prepared in accordance with U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;) for interim financial information and pursuant to the applicable rules and regulations of the Securities and Exchange Commission (&#x201c;SEC&#x201d;).&#160;All intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, the accompanying financial statements contain all adjustments (consisting of normal and recurring accruals) necessary to present fairly all financial statements in accordance with GAAP. The Condensed Consolidated Financial Statements herein should be read in conjunction with the Company&#x2019;s audited Consolidated Financial Statements and notes thereto included in the Company&#x2019;s Transition Report on Form 10-K for the transition period ended December&#160;31, 2020 (the &#x201c;Transition Report on Form 10-K&#x201d;). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenue and expenses during the reporting period. Operating results for the three and nine months ended September&#160;30, 2021 may not necessarily be indicative of results to be expected for any other interim period or for the full year.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNC9mcmFnOmIyNjgwNTlkNzdlZDQ4YjZhOWZlMGRmYzJlM2Q1N2ZkL3RleHRyZWdpb246YjI2ODA1OWQ3N2VkNDhiNmE5ZmUwZGZjMmUzZDU3ZmRfNTAzNg_46da4dd2-8ff1-49df-a567-38547708e07d">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reclassifications&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain prior period amounts have been reclassified to conform with the current period presentation. The reclassifications have no impact on the total assets, total liabilities, stockholders&#x2019; equity, cash flows from operations, or net income (loss) for the period.&lt;/span&gt;&lt;/div&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNC9mcmFnOmIyNjgwNTlkNzdlZDQ4YjZhOWZlMGRmYzJlM2Q1N2ZkL3RleHRyZWdpb246YjI2ODA1OWQ3N2VkNDhiNmE5ZmUwZGZjMmUzZDU3ZmRfNTA0MA_b7db37b0-b428-449a-a09b-58ddc6219806">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recently Adopted Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (&#x201c;ASU 2019-12&#x201d;). ASU 2019-12 is a new accounting standard to simplify accounting for income taxes and remove, modify, and add to the disclosure requirements of income taxes. The standard is effective for fiscal years beginning after December 15, 2020, with early adoption permitted. This guidance was adopted&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; with no material impact to t&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;he Company's Condensed Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RleHRyZWdpb246NTI5NjY0NzZiODk1NGMzMTkwYzQ4Y2FkYWZkMzM5NTlfNzQ0OQ_46fe1876-63ff-4203-ba71-1d4cadb75b84">REVENUE&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Myriad generates revenue by performing molecular diagnostic testing, and prior to the sale of Myriad RBM, Inc. on July 1, 2021, pharmaceutical services. Molecular diagnostic revenues consists of the following categories (products): Hereditary Cancer (myRisk, BRACAnalysis, BRACAnalysis CDx), Tumor Profiling (myChoice CDx, Prolaris, and EndoPredict), Prenatal (Foresight and Prequel), Pharmacogenomics (GeneSight), Autoimmune (Vectra), and Other. The Company previously provided pharmaceutical services and clinical services prior to the sale of Myriad RBM, Inc. and Privatklinik Dr. Robert Schindlbeck GmbH &amp;amp; Co. KG (the &#x201c;Clinic&#x201d;), respectively. Prior to the sale of the Myriad myPath, LLC laboratory in May 2021 and select assets of the Myriad Autoimmune (Vectra) business unit in September 2021, the associated revenue was included within Molecular diagnostic revenues. See Note 16 for a discussion of these divestitures. Revenue is recorded at the estimated amount of consideration to be received. The Company has determined that the communication of test results or the completion of pharmaceutical and clinical services indicates transfer of control for revenue recognition purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents detail regarding the composition of the Company&#x2019;s total revenue by category and by U.S. versus rest of world (&#x201c;RoW&#x201d;):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.200%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="36" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;RoW&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;RoW&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Molecular diagnostic revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Hereditary Cancer&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;68.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;79.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;72.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;80.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Tumor Profiling&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;21.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;32.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prenatal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;23.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;23.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pharmacogenomics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Autoimmune&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total molecular diagnostic revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;144.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;22.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;167.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;124.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;135.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pharmaceutical and clinical services revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;144.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;22.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;167.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;134.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;145.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="36" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Nine months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;RoW&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;RoW&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Molecular diagnostic revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Hereditary Cancer&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;207.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;34.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;241.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;188.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;205.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Tumor Profiling&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;63.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;94.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;33.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;41.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prenatal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;76.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;76.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;53.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;53.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pharmacogenomics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;64.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;64.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;40.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;40.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Autoimmune&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;28.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;28.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;26.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;26.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total molecular diagnostic revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;439.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;65.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;505.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;344.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;25.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;369.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pharmaceutical and clinical services revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;29.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;32.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;464.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;65.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;529.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;373.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;29.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;402.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;The Company performs its obligation under a contract with a customer by processing diagnostic tests and communicating the test results to customers, in exchange for consideration from the customer. The Company has the right to bill its customers upon the completion of performance obligations and thus does not record contract assets. Occasionally, customers make payments prior to the Company&#x2019;s performance of its contractual obligations. When this occurs, the Company records a contract liability as deferred revenue. Included within the Company's deferred revenues are advance Medicare payments. During the fiscal year ended June 30, 2020, the Company received approximately $29.7 million in advance Medicare payments to provide relief from the economic impacts of COVID-19 on the Company. The advanced Medicare payments began being applied against services performed in April 2021 and will continue until the funds previously received are fully earned. A reconciliation of the beginning and ending balances of deferred revenues is shown in the table below:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.000%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.626%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Nine months ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred revenues - beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;32.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue recognized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(30.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(8.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepayments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;37.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Divestitures&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred revenues - ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;32.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with ASC Topic 606, Revenue from Contracts with Customers, the Company has elected not to disclose the aggregate amount of the transaction price allocated to remaining performance obligations for its contracts that are one year or less, as the revenue is expected to be recognized within the next year. Furthermore, the Company has elected not to disclose the aggregate amount of the transaction price allocated to remaining performance obligations for its agreements wherein the Company&#x2019;s right to payment is in an amount that directly corresponds with the value of the Company&#x2019;s performance to date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In determining the transaction price, the Company includes an estimate of the expected amount of consideration as revenue. The Company applies this method consistently for similar contracts when estimating the effect of any uncertainty on an amount of variable consideration to which it will be entitled. An estimate of transaction price does not include any estimated amount of variable consideration that is constrained. In addition, the Company considers all the information (historical, current, and forecast) that is reasonably available to identify possible consideration amounts. The Company considers the probability of the variable consideration for each possible scenario. The Company also has significant experience with historical discount patterns and uses this experience to estimate transaction prices. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The estimate of revenue is affected by assumptions in payor behavior such as changes in payor mix, payor collections, current customer contractual requirements, and experience with collections from third-party payors. When assessing the total consideration for insurance carriers and patients, revenues are further constrained for estimated refunds. The Company reserves certain amounts in Accrued liabilities in the Company&#x2019;s Condensed Consolidated Balance Sheets in anticipation of requests for refunds of payments made previously by insurance carriers, which are accounted for as reductions in revenues in the Condensed Consolidated Statements of Operations and Comprehensive Income (Loss).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Cash collections for certain diagnostic tests delivered may differ from rates originally estimated, primarily driven by changes in the estimated transaction price due to contractual adjustments, obtaining updated information from payors and patients that was unknown at the time the performance obligation was met, and settlements with third party payors. During the three and nine months ended September 30, 2021, the Company recognized $7.6 million and $16.6 million in revenue, respectively, which resulted in a $0.07 impact and $0.16 impact to earnings per share, respectively, for tests in which the performance obligation of delivering the tests results was met in prior periods. The changes were primarily driven by changes in the estimated transaction price. Additionally, during the three months ended March 31, 2021, the Company recognized $6.8 million of revenue due to expanded coverage for Prolaris, for which revenue was fully constrained in a prior period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company applies the practical expedient related to costs to obtain or fulfill a contract since the amortization period for such costs will be one year or less. Accordingly, no costs incurred to obtain or fulfill a contract have been capitalized. The Company also applies the practical expedient for not adjusting revenue recognized for the effects of the time value of money. This practical expedient has been elected because the Company collects very little cash from customers under payment terms and the vast majority of payment terms have a payback period of less than one year. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable. Substantially all of the Company&#x2019;s accounts receivable are with companies in the healthcare industry, U.S. and state governmental agencies that make payments on the customer's behalf, and individuals. The Company does not believe that receivables due from U.S. and state governmental agencies, such as Medicare, represent a credit risk since the related healthcare programs are funded by the U.S. and state governments. The Company only has one payor, Medicare, that represents greater than 10% of its revenues. Revenues received from Medicare represented approximately 17% of total revenue for each of the three and nine months ended September&#160;30, 2021, and 16% and 15% of total revenue for the three and nine months ended September&#160;30, 2020, respectively. Concentrations of credit risk are mitigated due to the number of the Company&#x2019;s customers as well as their dispersion across many geographic regions. No payor accounted for more than 10% of accounts receivable at September&#160;30, 2021 or December&#160;31, 2020. The Company does not require collateral from its customers.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RleHRyZWdpb246NTI5NjY0NzZiODk1NGMzMTkwYzQ4Y2FkYWZkMzM5NTlfNzQ0OA_729d5c30-ac55-4a89-bec9-b2fee1f907ed">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents detail regarding the composition of the Company&#x2019;s total revenue by category and by U.S. versus rest of world (&#x201c;RoW&#x201d;):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.200%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="36" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;RoW&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;RoW&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Molecular diagnostic revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Hereditary Cancer&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;68.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;79.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;72.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;80.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Tumor Profiling&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;21.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;32.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prenatal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;23.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;23.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pharmacogenomics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Autoimmune&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total molecular diagnostic revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;144.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;22.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;167.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;124.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;135.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pharmaceutical and clinical services revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;144.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;22.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;167.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;134.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;145.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="36" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Nine months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;RoW&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;RoW&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Molecular diagnostic revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Hereditary Cancer&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;207.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;34.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;241.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;188.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;205.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Tumor Profiling&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;63.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;94.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;33.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;41.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prenatal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;76.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;76.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;53.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;53.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pharmacogenomics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;64.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;64.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;40.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;40.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Autoimmune&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;28.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;28.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;26.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;26.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total molecular diagnostic revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;439.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;65.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;505.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;344.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;25.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;369.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pharmaceutical and clinical services revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;29.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;32.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;464.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;65.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;529.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;373.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;29.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;402.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ida000af1413e4fddbdffb1f6b6d73047_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfNC0xLTEtMS0xODE2NA_9f14b430-6e53-4125-a14b-5f4efa1c020d"
      unitRef="usd">68200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia65390d217d44664a03c7762eb80226c_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfNC0zLTEtMS0xODE2NA_e0c0c251-8980-40bd-9d74-2a322b2fc645"
      unitRef="usd">11200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idb939ee30c9346759fabe2cbfd1ebf71_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfNC01LTEtMS0xODE2NA_9bcc4e01-c18d-4bbf-8e27-5119ffbd1255"
      unitRef="usd">79400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib782ea6f17aa43faaa46806bd14f5af2_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfNC03LTEtMS0xODE2NA_84e32431-b87f-4e9c-b851-adf93b28ef29"
      unitRef="usd">72000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7942c920d42c4be98d7627dea2b75aab_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfNC05LTEtMS0xODE2NA_4d819305-c390-443f-abb8-01b8ad2251f8"
      unitRef="usd">8500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7d4b33a6e9cf4ff695a151252fa5202d_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfNC0xMS0xLTEtMTgxNjQ_54c3d5f3-3928-4bf5-bbca-7baae9e89429"
      unitRef="usd">80500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9987b934bd0a407b89b3de550f71f1eb_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfNS0xLTEtMS0xODE2NA_35cab7af-42a4-42f7-8690-6096d01fa97f"
      unitRef="usd">21400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i120342914ab84d57803cdba7e390e6e0_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfNS0zLTEtMS0xODE2NA_3ad695af-1b84-4e9d-88d8-aeaca8c8b743"
      unitRef="usd">11500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifacd49fb220e4e6688cac0490136867d_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfNS01LTEtMS0xODE2NA_45ad5cc2-41d8-494f-886b-d66a2cc83c43"
      unitRef="usd">32900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idc7756538c044225a9ce5c1d9d342449_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfNS03LTEtMS0xODE2NA_ab0c5339-60a3-4b87-b556-14002303f6f9"
      unitRef="usd">14400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3bbf9b3b2d1b4c0c904cdd117771580a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfNS05LTEtMS0xODE2NA_1566cc2d-7757-4eed-b6d7-ce443b7513b5"
      unitRef="usd">2600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icc9ac75befb64b00b1cbd10949fa3e69_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfNS0xMS0xLTEtMTgxNjQ_d771c5d0-a533-4922-9e2e-64c932e5f243"
      unitRef="usd">17000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5f8b38682e3a4c6586f56116a4e54db9_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfNi0xLTEtMS0xODE2NA_bf9b2383-fd93-4eb0-b282-9a5c2307c058"
      unitRef="usd">23500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6b8709823fb647138c0501d0018d62cc_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfNi0zLTEtMS0xODE2NA_5bf0109d-f057-4444-aa41-110e5e8557cf"
      unitRef="usd">100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iac13adff54494e56be97dcfc0308c7f5_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfNi01LTEtMS0xODE2NA_57cce671-77dd-4695-9ad9-7b8ef291aacc"
      unitRef="usd">23600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie36dcf4cd4e14f4890cf021f262a8b82_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfNi03LTEtMS0xODE2NA_13b2f713-8a1f-4b14-9766-4d8ae4d6a2d6"
      unitRef="usd">16500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia94b623d77a449e49aa7fce28c810d9c_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfNi05LTEtMS0xODE2NA_853f94ad-5bd8-493f-a065-cebb426a67b9"
      unitRef="usd">100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4acdbc594a6a4b88a090b04e5ef69aec_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfNi0xMS0xLTEtMTgxNjQ_8aab277c-1d9f-4e69-bd50-6588fd5b62da"
      unitRef="usd">16600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia5e3a39bcef84311a38d3c37cbbee981_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfNy0xLTEtMS0xODE2NA_7c83914e-96aa-488a-8eb8-866993d7d2d0"
      unitRef="usd">24100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1e84513d519942359ce079c27c934ab7_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfNy0zLTEtMS0xODE2NA_f301e87f-98c2-4dbc-8d4b-66cda388fdd4"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7f4d0d8a569142149d4db9527cbf6122_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfNy01LTEtMS0xODE2NA_7403457a-4ef2-43b2-883b-4bfefd0d7269"
      unitRef="usd">24100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i632d974bc19746629c875de8d85005de_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfNy03LTEtMS0xODE2NA_9ace4159-a844-4ba2-b9a1-4a38d8f7df1d"
      unitRef="usd">11900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia8ffaf88f5554b8a8bfb8d0f7aaef001_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfNy05LTEtMS0xODE2NA_6d53b2b3-c2b5-4b93-8a18-56fe453a92dd"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7e91c91b1c9a4945acdfe9e7245038ed_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfNy0xMS0xLTEtMTgxNjQ_5e5562d5-6d25-4fb1-b71a-a6fb3b13cffc"
      unitRef="usd">11900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7376ab53741d440ba61c388e5c932c1b_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfOC0xLTEtMS0xODE2NA_5ae21dd6-0506-45ba-a0c6-8c1f9fccb4a4"
      unitRef="usd">7300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3c33023861bc44e592a2a61939a657a6_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfOC0zLTEtMS0xODE2NA_d9a3f513-e290-472a-92a0-78531a4f0fd8"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1ce0af94533d4d0cb17bfae079adab31_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfOC01LTEtMS0xODE2NA_5a36a74d-baf1-48c3-9b5d-11bc1010b015"
      unitRef="usd">7300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic1e715fa83dc47248899710d4f312340_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfOC03LTEtMS0xODE2NA_0b17728f-7375-49f9-a2b4-3506f33f63b5"
      unitRef="usd">9100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3d9d935b97a14723b2ce8cd0fdd3685b_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfOC05LTEtMS0xODE2NA_3945ea1a-9595-419c-a9cf-511093bc49fd"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia5880f6561e344b698bf53ef48281f5f_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfOC0xMS0xLTEtMTgxNjQ_be318eb6-f8e7-453d-a2e8-ca3603acffa4"
      unitRef="usd">9100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8511c5f276ed4618bd7d3abcdfd81278_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfOS0xLTEtMS0xODE2NA_aafad47b-8035-4fff-b40a-5ef909c96919"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7cd8b28b3de341ab88d9b759b56cb960_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfOS0zLTEtMS0xODE2NA_e5534fa8-3d39-4f58-bc35-83b5f3316bbb"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2269a2a3c55f4f48b394d629ae9ece31_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfOS01LTEtMS0xODE2NA_b91c8c0a-c606-4093-b089-fbce6a584f9a"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic301e05aafb54177bf154d4e00dca137_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfOS03LTEtMS0xODE2NA_61b5e572-0b44-4f13-a9fa-944bbb5940f9"
      unitRef="usd">600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie0c4bdb320014fe28dabebe98a245d34_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfOS05LTEtMS0xODE2NA_9080e700-0b7f-44c6-a702-729246c3bac5"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5428af14384f4775a235df5d1a72c351_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfOS0xMS0xLTEtMTgxNjQ_a8a6fe70-9e50-4d23-9170-e2955a7adb6b"
      unitRef="usd">600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i978447da133848e09d69b6941e3c3e12_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMTAtMS0xLTEtMTgxNjQ_a92ef01c-02ff-464f-92d0-a0e502c9e9da"
      unitRef="usd">144500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9e833f5a117c4014b693ba5dbcd17f05_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMTAtMy0xLTEtMTgxNjQ_e2f57387-13c2-44c7-b4ca-9b215b98396d"
      unitRef="usd">22800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifbc28960af99464087c70e2155273621_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMTAtNS0xLTEtMTgxNjQ_6375e7b5-82b7-42ca-83b0-dedab871ef16"
      unitRef="usd">167300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9f6b592da0d94089824ddd9eeaec60ca_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMTAtNy0xLTEtMTgxNjQ_7b146de5-5f65-4967-9335-b2963653a6f7"
      unitRef="usd">124500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i628878e014504ba3927b3541bbfee9d6_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMTAtOS0xLTEtMTgxNjQ_15274a78-cee9-4cff-956c-a57c25219e8b"
      unitRef="usd">11200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icc0e2c6320b64071a6e19bf0ded7e102_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMTAtMTEtMS0xLTE4MTY0_a60fd831-7628-4420-897c-45dc5107401a"
      unitRef="usd">135700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2777203c45e44986ad24f2e01bb5cd2c_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMTEtMS0xLTEtMTgxNjQ_daff5cbd-bdfd-492f-a11d-fa42817d8178"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4bb010a87eb34230a4d879b7f8b5d7f3_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMTEtMy0xLTEtMTgxNjQ_65b9a2f1-0b90-405e-a66e-cc63b9d774cc"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i79cd3eef56ae4f639da562ce851a382e_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMTEtNS0xLTEtMTgxNjQ_b28ca841-d00c-4a67-aca1-c6e85b4b5c2c"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if4850f75cb284b14b1e3b920fd17fee3_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMTEtNy0xLTEtMTgxNjQ_de8cd57f-44a5-4bea-ae7a-f565b5295578"
      unitRef="usd">9500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if98b526cb9c84315b8808c1225488499_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMTEtOS0xLTEtMTgxNjQ_d82d922b-17cb-4577-b63f-1365c3a6be89"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie94a660aba69415a910d7f90711081eb_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMTEtMTEtMS0xLTE4MTY0_175d15dd-4e52-42f5-99ae-23bd7896e494"
      unitRef="usd">9500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i34864de2cd5e41bd98ef24a86d7f39a1_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMTItMS0xLTEtMTgxNjQ_8a499631-b134-4256-8d33-dc52afb9ad5c"
      unitRef="usd">144500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5e6310ec543143dc8a87a1867afc2439_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMTItMy0xLTEtMTgxNjQ_fb94d02d-8522-4289-9154-2a58ddaf0133"
      unitRef="usd">22800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMTItNS0xLTEtMTgxNjQ_ede47b7e-7e13-4686-b525-47916f3e1205"
      unitRef="usd">167300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3b754f9a3006470cb13ba2789a352d5e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMTItNy0xLTEtMTgxNjQ_d78d2728-2df2-4d04-8486-36bdce2c0498"
      unitRef="usd">134000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7eb57d5345554df7a7ffeb66aa7ef9d6_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMTItOS0xLTEtMTgxNjQ_bf2f70e8-871e-4f39-959e-f6a218dc4cf5"
      unitRef="usd">11200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic2c3e03438af4889ac973627c642f5ec_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMTItMTEtMS0xLTE4MTY0_e39c6ed6-4402-4294-ba6a-6dc473922676"
      unitRef="usd">145200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i48501743237742c6975110396e917242_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMTgtMS0xLTEtMTgxNjQ_b3067a9b-5fc5-436d-8761-d08d163571e4"
      unitRef="usd">207100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7824951a746645c39acedbdd215f57f5_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMTgtMy0xLTEtMTgxNjQ_8544fa12-c2d6-434b-a75f-e1d58f2d1ee8"
      unitRef="usd">34400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifcc2e81b5a204336b461cdc53955b3cd_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMTgtNS0xLTEtMTgxNjQ_19918e53-80db-42a0-a5b9-e6bb20ec31b6"
      unitRef="usd">241500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic7c83e62f13142e3bf47bdf15510f328_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMTgtNy0xLTEtMTgxNjQ_a3c8d36f-f039-42d2-a877-3d1a12f73e3d"
      unitRef="usd">188200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i18e0522d4e264244b4b7ff08c869a121_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMTgtOS0xLTEtMTgxNjQ_ba915b16-66ae-4609-8f20-89279dae774e"
      unitRef="usd">17400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iee003a09d07f4dbf86ab56c0275a5909_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMTgtMTEtMS0xLTE4MTY0_f195ddb2-523a-46ae-a819-f85359e0dc79"
      unitRef="usd">205600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9e5e62422b964677bbf81111118a8530_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMTktMS0xLTEtMTgxNjQ_fff77a54-d2af-4264-961f-8c925859f19c"
      unitRef="usd">63900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2dd22965d073433da620ee6bb158d276_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMTktMy0xLTEtMTgxNjQ_0b5c6f38-ef7e-4dd8-8c01-70998a93c759"
      unitRef="usd">30500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7fe0144d6efa41859c2eba711e85303a_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMTktNS0xLTEtMTgxNjQ_429d2c2a-2f54-450f-a620-dafa68df35e1"
      unitRef="usd">94400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i55af35cd863d4959bf0125bc9cb46d23_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMTktNy0xLTEtMTgxNjQ_58b8f320-6901-4d92-bf18-22fc23e4295a"
      unitRef="usd">33700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5c2131fe4d3c47358dd98a5d078c009b_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMTktOS0xLTEtMTgxNjQ_6f20a80e-be5e-4d0e-8481-92aa56c5ec4d"
      unitRef="usd">7500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic91ecdd5628742b5828be3bf25416996_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMTktMTEtMS0xLTE4MTY0_55cac39a-ca2f-4b36-b68c-6231c842d15a"
      unitRef="usd">41200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifae9cf930088446e9ad24962231957ba_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMjAtMS0xLTEtMTgxNjQ_35749316-95ea-44b7-a04a-da29c9af8339"
      unitRef="usd">76300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8ee8c5ff36994621b42226a17e561d2e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMjAtMy0xLTEtMTgxNjQ_df35cb93-fdd4-46c6-a842-ee7f27cd520e"
      unitRef="usd">400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8c200a9b3e0d4ac49242d25105281dcd_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMjAtNS0xLTEtMTgxNjQ_1e4323f3-ae2c-4b43-8d4b-f0d8aeedf68a"
      unitRef="usd">76700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib8fb168011b74d318bab8b56b11dbda3_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMjAtNy0xLTEtMTgxNjQ_185e88d1-2285-4759-8806-f1087517ae4e"
      unitRef="usd">53200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic992acb15b7b4eb7a73e11782d653862_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMjAtOS0xLTEtMTgxNjQ_24682cb3-0454-4f0d-8ff7-b4225b0c9c4e"
      unitRef="usd">300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4efd4f48f7f647819d1ee5f36d044d08_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMjAtMTEtMS0xLTE4MTY0_54fb717a-ab22-4573-bdcd-2954b3eb396a"
      unitRef="usd">53500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1fc1f94f6c144040a6a027fe642d8327_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMjEtMS0xLTEtMTgxNjQ_4b24c094-1621-4dad-a61f-8b67fcc95248"
      unitRef="usd">64300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4e578e3ded2b44bfb1c2e543c14336fe_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMjEtMy0xLTEtMTgxNjQ_2b1ce6aa-82db-470d-94e1-3383cb01b6a4"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibf03794b4694454c96339d25e089fd86_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMjEtNS0xLTEtMTgxNjQ_85ac93bb-5eec-40f4-ab80-8136cfb1a451"
      unitRef="usd">64300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4790f46fe81f43b7a34b7d4e7be6b08d_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMjEtNy0xLTEtMTgxNjQ_af59036d-1bec-4f99-8265-acb4aead0ddd"
      unitRef="usd">40800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3d82cbad6d4f4ad4b4867f492374ddbc_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMjEtOS0xLTEtMTgxNjQ_dfbcfe02-2fdf-4d88-8b51-e37a6a204569"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i227a5837ccdc40d09a3935542fa8f306_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMjEtMTEtMS0xLTE4MTY0_07f180f3-d57b-48ec-b503-194f7aed3f53"
      unitRef="usd">40800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1643deb3ad9f45619ca4221f05389dc7_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMjItMS0xLTEtMTgxNjQ_d88b49e0-1670-449e-b392-6f2eb3b1aad1"
      unitRef="usd">28200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia0485078c2524525b58fcac4538292d8_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMjItMy0xLTEtMTgxNjQ_7e02eae0-fdc3-4ca0-a1a5-78bd3d36ec6f"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1413cd2d66404ae0b0033e4828c87987_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMjItNS0xLTEtMTgxNjQ_2b56c375-c577-4957-a252-a1ebd80c6b07"
      unitRef="usd">28200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0ad30cfcd30642859241e76dc224b27e_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMjItNy0xLTEtMTgxNjQ_d4fd8e12-4a18-4587-93c7-5913695c2532"
      unitRef="usd">26800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia022822da300492793546d0fe4c7b26b_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMjItOS0xLTEtMTgxNjQ_1d276388-9e81-4dc0-a1f0-19ad134b38ab"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2b38c623286c42b898b7e8154ca4672e_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMjItMTEtMS0xLTE4MTY0_e5d32232-9a45-4640-9a9d-591f012483f3"
      unitRef="usd">26800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5c5bea7f5b774599827c2380d64fab41_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMjMtMS0xLTEtMTgxNjQ_68f133c6-a315-4cb5-a237-2a1b0108e972"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic2e771554aba45edaeb4d3458b0c1d77_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMjMtMy0xLTEtMTgxNjQ_2fa7202e-5194-42e9-a8a5-889bb8222abb"
      unitRef="usd">500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8c5c05f89d074455a96647a1c66e3797_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMjMtNS0xLTEtMTgxNjQ_b20e2ab1-0416-40a4-92d7-82c7bd8e7881"
      unitRef="usd">500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie293ea67e0dc4e379586937a664f26a6_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMjMtNy0xLTEtMTgxNjQ_eb6987ff-7315-403d-a60d-13a2ec78d4f4"
      unitRef="usd">1600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i96fe192a524c4c7780b693b19a1ee594_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMjMtOS0xLTEtMTgxNjQ_d530a1e4-394d-4fdc-95c3-a95888222e73"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i85e565a842f34303958c7c5dbc22906f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMjMtMTEtMS0xLTE4MTY0_612b34e5-db3e-4fd4-88ca-338d127f927d"
      unitRef="usd">1600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2150fb2a47cc41a8a8afed1f431f9875_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMjQtMS0xLTEtMTgxNjQ_88d29cc3-fa49-4789-9c3a-7bb464b674c9"
      unitRef="usd">439800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ieeda1d918cdc4e4c8c9a40ede0b9980e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMjQtMy0xLTEtMTgxNjQ_c50f7c7e-4c65-493d-9743-cc896845ea5c"
      unitRef="usd">65800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie8a469542115473daa7666e3dceae657_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMjQtNS0xLTEtMTgxNjQ_8c3509aa-c805-4bfe-b7a6-6bdc79897284"
      unitRef="usd">505600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i54646e3f899541a2892e6c43188dd3ca_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMjQtNy0xLTEtMTgxNjQ_5221f789-d71c-4872-9f97-7e1155197071"
      unitRef="usd">344300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4765fcb411c541578d82bf58e0edcd57_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMjQtOS0xLTEtMTgxNjQ_5275a55c-fb08-4fbc-a49a-c2de762f2574"
      unitRef="usd">25200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie51b08f1c1f44da4bb023303aa0fb7d9_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMjQtMTEtMS0xLTE4MTY0_d32af0ab-1af7-4778-a981-ae4683061531"
      unitRef="usd">369500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie9ffcf60567a49298db6b5581ef8dbec_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMjUtMS0xLTEtMTgxNjQ_ebae0cd6-b764-44d6-87d3-4710e1944316"
      unitRef="usd">24200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i67ed4f8f16804e2d91b367cc0ad882e6_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMjUtMy0xLTEtMTgxNjQ_fb86dd16-1c86-4383-ba81-43566478963c"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i695f1ac67bde49628842e3563e17c85e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMjUtNS0xLTEtMTgxNjQ_c5dc7632-5eb4-47d6-ae1c-82ad0c81aa8b"
      unitRef="usd">24200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i822cef9d3a1148dfa0df42a55879158a_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMjUtNy0xLTEtMTgxNjQ_3cf83f4f-4071-4088-ba4f-91ebe6ae7ef7"
      unitRef="usd">29000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id2561e4e6a72407fa6fcb4dda8635c44_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMjUtOS0xLTEtMTgxNjQ_52df8475-7703-47f1-b7d3-474caab93d9e"
      unitRef="usd">3900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib855c77efb97481b968697136ef35610_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMjUtMTEtMS0xLTE4MTY0_aa22029b-f75f-4611-a9fa-e3fdf8ab5681"
      unitRef="usd">32900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifb886d225660433bb8c479ba4c1cf8ce_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMjYtMS0xLTEtMTgxNjQ_de240585-4eaf-4bf7-8fee-758dc435ad30"
      unitRef="usd">464000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaab7b12e36bb4e709ac9d2fd74a39b5e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMjYtMy0xLTEtMTgxNjQ_4c2cbe67-59d8-486e-8119-792aabc1ee1b"
      unitRef="usd">65800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMjYtNS0xLTEtMTgxNjQ_b7dd923b-14ad-4d13-bb2c-b3373ea9be77"
      unitRef="usd">529800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia7eb822f2ce54831a5e78a74b2e44672_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMjYtNy0xLTEtMTgxNjQ_a2721c52-a4d7-49f9-a580-6fe0c4db898e"
      unitRef="usd">373300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2bc09983c7244893bff666d06f800fa8_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMjYtOS0xLTEtMTgxNjQ_de045c6b-0aee-46c8-816c-4e4c7d6ba511"
      unitRef="usd">29100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjVhYjA5MjIwNjRjYTQ5M2ZhMzEwNTNlNTIzNGNmODcxL3RhYmxlcmFuZ2U6NWFiMDkyMjA2NGNhNDkzZmEzMTA1M2U1MjM0Y2Y4NzFfMjYtMTEtMS0xLTE4MTY0_3d63dd4b-f3c1-4b2b-b6aa-b9d1de6870d3"
      unitRef="usd">402400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <mygn:CARESActOf2020MedicarePaymentAmount
      contextRef="ia7d2894297e4420e8cad6a4c76510fc1_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RleHRyZWdpb246NTI5NjY0NzZiODk1NGMzMTkwYzQ4Y2FkYWZkMzM5NTlfMTg3Mw_121a244a-b74f-4c2b-acf8-260b66add9e4"
      unitRef="usd">29700000</mygn:CARESActOf2020MedicarePaymentAmount>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RleHRyZWdpb246NTI5NjY0NzZiODk1NGMzMTkwYzQ4Y2FkYWZkMzM5NTlfNzQ1Mg_99ed8b56-ea05-4c79-a4f5-7f82a83f7ae0">A reconciliation of the beginning and ending balances of deferred revenues is shown in the table below:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.000%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.626%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Nine months ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred revenues - beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;32.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue recognized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(30.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(8.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepayments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;37.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Divestitures&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred revenues - ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;32.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjZiODFjNGQ2OTBkODQ4NTdhZmQ2MjE4YTRlZGNkMTNjL3RhYmxlcmFuZ2U6NmI4MWM0ZDY5MGQ4NDg1N2FmZDYyMThhNGVkY2QxM2NfMi0xLTEtMS0xODE2NA_b78cd921-af7c-4445-9211-ce58c14a6069"
      unitRef="usd">32700000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ic698543044ba4469ba8751bae898951c_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjZiODFjNGQ2OTBkODQ4NTdhZmQ2MjE4YTRlZGNkMTNjL3RhYmxlcmFuZ2U6NmI4MWM0ZDY5MGQ4NDg1N2FmZDYyMThhNGVkY2QxM2NfMi0zLTEtMS0xODE2NA_082beb86-703c-4162-9b96-431c40e07145"
      unitRef="usd">3600000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <mygn:ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjZiODFjNGQ2OTBkODQ4NTdhZmQ2MjE4YTRlZGNkMTNjL3RhYmxlcmFuZ2U6NmI4MWM0ZDY5MGQ4NDg1N2FmZDYyMThhNGVkY2QxM2NfMy0xLTEtMS0xODE2NA_33f36152-02ad-474a-a20b-85cc52e3a8c6"
      unitRef="usd">30300000</mygn:ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized>
    <mygn:ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized
      contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjZiODFjNGQ2OTBkODQ4NTdhZmQ2MjE4YTRlZGNkMTNjL3RhYmxlcmFuZ2U6NmI4MWM0ZDY5MGQ4NDg1N2FmZDYyMThhNGVkY2QxM2NfMy0zLTEtMS0xODE2NA_b706ce54-5e57-4a12-b02d-8b7f97ea8fe8"
      unitRef="usd">8400000</mygn:ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized>
    <mygn:ContractWithCustomerLiabilityPrepayments
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjZiODFjNGQ2OTBkODQ4NTdhZmQ2MjE4YTRlZGNkMTNjL3RhYmxlcmFuZ2U6NmI4MWM0ZDY5MGQ4NDg1N2FmZDYyMThhNGVkY2QxM2NfNC0xLTEtMS0xODE2NA_4a3f08c1-99b9-4a4f-bfa9-8d828e42f381"
      unitRef="usd">10100000</mygn:ContractWithCustomerLiabilityPrepayments>
    <mygn:ContractWithCustomerLiabilityPrepayments
      contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjZiODFjNGQ2OTBkODQ4NTdhZmQ2MjE4YTRlZGNkMTNjL3RhYmxlcmFuZ2U6NmI4MWM0ZDY5MGQ4NDg1N2FmZDYyMThhNGVkY2QxM2NfNC0zLTEtMS0xODE2NA_fca94103-d6da-46ab-9e1e-a45bc15e9dcc"
      unitRef="usd">37100000</mygn:ContractWithCustomerLiabilityPrepayments>
    <mygn:ContractWithCustomerLiabilityDivestitures
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjZiODFjNGQ2OTBkODQ4NTdhZmQ2MjE4YTRlZGNkMTNjL3RhYmxlcmFuZ2U6NmI4MWM0ZDY5MGQ4NDg1N2FmZDYyMThhNGVkY2QxM2NfNS0xLTEtMS0yODc4Mw_17b8982e-67b8-4445-822f-d09ddcb5ec97"
      unitRef="usd">1000000.0</mygn:ContractWithCustomerLiabilityDivestitures>
    <mygn:ContractWithCustomerLiabilityDivestitures
      contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjZiODFjNGQ2OTBkODQ4NTdhZmQ2MjE4YTRlZGNkMTNjL3RhYmxlcmFuZ2U6NmI4MWM0ZDY5MGQ4NDg1N2FmZDYyMThhNGVkY2QxM2NfNS00LTEtMS0yODc4OA_10638e9e-cfef-4368-901f-d7dfb177fffc"
      unitRef="usd">0</mygn:ContractWithCustomerLiabilityDivestitures>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjZiODFjNGQ2OTBkODQ4NTdhZmQ2MjE4YTRlZGNkMTNjL3RhYmxlcmFuZ2U6NmI4MWM0ZDY5MGQ4NDg1N2FmZDYyMThhNGVkY2QxM2NfNi0xLTEtMS0xODE2NA_a0a365b0-7acb-4e74-a46f-7a71971aa6b5"
      unitRef="usd">11500000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i0c6bac27ede64afeb4dbc13729f58578_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RhYmxlOjZiODFjNGQ2OTBkODQ4NTdhZmQ2MjE4YTRlZGNkMTNjL3RhYmxlcmFuZ2U6NmI4MWM0ZDY5MGQ4NDg1N2FmZDYyMThhNGVkY2QxM2NfNi0zLTEtMS0xODE2NA_eb68f228-7387-4c4d-81e3-55a7df85f126"
      unitRef="usd">32300000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice
      contextRef="ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RleHRyZWdpb246NTI5NjY0NzZiODk1NGMzMTkwYzQ4Y2FkYWZkMzM5NTlfNTE0MQ_8ff564d8-6007-4b40-8658-cb478aede2a6"
      unitRef="usd">7600000</us-gaap:ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice>
    <us-gaap:ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RleHRyZWdpb246NTI5NjY0NzZiODk1NGMzMTkwYzQ4Y2FkYWZkMzM5NTlfNTE0OA_8898541d-aebc-44c7-9790-4813b9f8adb2"
      unitRef="usd">16600000</us-gaap:ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice>
    <mygn:IncreaseDecreaseInEarningsLossPerShare
      contextRef="ic929fbb9734546f8ba6190d002b58254_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RleHRyZWdpb246NTI5NjY0NzZiODk1NGMzMTkwYzQ4Y2FkYWZkMzM5NTlfNTE5Nw_81e612dd-22af-4c03-8cf8-7a2b25557bb8"
      unitRef="usdPerShare">0.07</mygn:IncreaseDecreaseInEarningsLossPerShare>
    <mygn:IncreaseDecreaseInEarningsLossPerShare
      contextRef="i437a8c83f80c43f5bb7969a1427d84af_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RleHRyZWdpb246NTI5NjY0NzZiODk1NGMzMTkwYzQ4Y2FkYWZkMzM5NTlfMTA5OTUxMTYzNjk3Ng_9e2f43f3-a56f-4b76-9084-2db6b6ba845b"
      unitRef="usdPerShare">0.16</mygn:IncreaseDecreaseInEarningsLossPerShare>
    <mygn:ContractWithCustomerAssetAdjustmentToRevenueForExpandedCoveragePreviouslyConstrained
      contextRef="ie59a85cd0de74256a4070826a06ab2ee_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RleHRyZWdpb246NTI5NjY0NzZiODk1NGMzMTkwYzQ4Y2FkYWZkMzM5NTlfNTUxMg_bd8c42e9-6bec-48c2-85b6-fc7fa92cc7e1"
      unitRef="usd">6800000</mygn:ContractWithCustomerAssetAdjustmentToRevenueForExpandedCoveragePreviouslyConstrained>
    <us-gaap:CapitalizedContractCostGross
      contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RleHRyZWdpb246NTI5NjY0NzZiODk1NGMzMTkwYzQ4Y2FkYWZkMzM5NTlfNTgwMg_7ebbab95-0a43-46ec-8dc4-c0de60b065e0"
      unitRef="usd">0</us-gaap:CapitalizedContractCostGross>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ib2b1d515b0df442caf3a61b77cd756eb_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RleHRyZWdpb246NTI5NjY0NzZiODk1NGMzMTkwYzQ4Y2FkYWZkMzM5NTlfNjk3Ng_7c7f98e7-b85f-49f1-83ae-f9b21da1276f"
      unitRef="number">0.17</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i4c9ecd2a8793414a828047a9bf1593e4_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RleHRyZWdpb246NTI5NjY0NzZiODk1NGMzMTkwYzQ4Y2FkYWZkMzM5NTlfNjk3Ng_d3d7424a-fb12-4890-9c21-d804bc8f9c1d"
      unitRef="number">0.17</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ide0992200fac419ab9eb95a8229f286b_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RleHRyZWdpb246NTI5NjY0NzZiODk1NGMzMTkwYzQ4Y2FkYWZkMzM5NTlfNzA0OQ_700b09d5-05ec-4524-80c4-365cf3395e12"
      unitRef="number">0.16</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i9463c7d008224ba994869b57828ab6a2_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN18zNy9mcmFnOjUyOTY2NDc2Yjg5NTRjMzE5MGM0OGNhZGFmZDMzOTU5L3RleHRyZWdpb246NTI5NjY0NzZiODk1NGMzMTkwYzQ4Y2FkYWZkMzM5NTlfNzA1Ng_c595ef2b-c449-4d1c-b08b-e492216aa292"
      unitRef="number">0.15</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RleHRyZWdpb246MzAwZWUxYzI4MGM4NGY0Y2IzNGRiZTNmY2YxODkyYmJfNjE5_fbbb98e8-149b-40e8-ade0-a084edf7e0d4">MARKETABLE INVESTMENT SECURITIES&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amortized cost, gross unrealized holding gains, gross unrealized holding losses, and fair value for available-for-sale securities by major security type and class of security at September&#160;30, 2021 and December&#160;31, 2020 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amortized&lt;br/&gt;cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;holding&lt;br/&gt;gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;holding&lt;br/&gt;losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Estimated&lt;br/&gt;fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;208.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;208.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;86.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;86.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;295.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;295.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Available-for-sale:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate bonds and notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;90.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;90.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;19.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;19.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Federal agency issues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;US government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;413.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;413.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amortized&lt;br/&gt;cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;holding&lt;br/&gt;gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;holding&lt;br/&gt;losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Estimated&lt;br/&gt;fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December 31, 2020:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;47.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;47.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;69.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;69.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;117.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;117.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Available-for-sale:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate bonds and notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;28.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;29.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Federal agency issues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;US government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;170.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;171.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash, cash equivalents, and maturities of debt securities classified as available-for-sale securities were as follows at September&#160;30, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amortized&lt;br/&gt;cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Estimated&lt;br/&gt;fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Available-for-sale:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Due within one year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;70.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;70.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Due after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;47.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;47.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Due after five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;413.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;413.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no debt securities classified as available-for-sale in a gross unrealized loss position as of September&#160;30, 2021 or December 31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additional information relating to fair value of marketable investment securities can be found in Note 4.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RleHRyZWdpb246MzAwZWUxYzI4MGM4NGY0Y2IzNGRiZTNmY2YxODkyYmJfNjIw_95c730fe-5407-41cb-bb64-0d6d6f701452">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amortized cost, gross unrealized holding gains, gross unrealized holding losses, and fair value for available-for-sale securities by major security type and class of security at September&#160;30, 2021 and December&#160;31, 2020 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amortized&lt;br/&gt;cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;holding&lt;br/&gt;gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;holding&lt;br/&gt;losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Estimated&lt;br/&gt;fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;208.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;208.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;86.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;86.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;295.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;295.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Available-for-sale:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate bonds and notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;90.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;90.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;19.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;19.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Federal agency issues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;US government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;413.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;413.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amortized&lt;br/&gt;cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;holding&lt;br/&gt;gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;holding&lt;br/&gt;losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Estimated&lt;br/&gt;fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December 31, 2020:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;47.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;47.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;69.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;69.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;117.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;117.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Available-for-sale:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate bonds and notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;28.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;29.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Federal agency issues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;US government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;170.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;171.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ie18df879613d4bb19a671fecd56a73ef_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOmE0OTgwYTMzNmQzMDQ0NmY5NTAwMGY2YjJmNzhjMDNmL3RhYmxlcmFuZ2U6YTQ5ODBhMzM2ZDMwNDQ2Zjk1MDAwZjZiMmY3OGMwM2ZfMy0xLTEtMS0xODE2NA_3f7f9de5-1099-4b3d-a7be-7cffb070a4e4"
      unitRef="usd">208800000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ie18df879613d4bb19a671fecd56a73ef_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOmE0OTgwYTMzNmQzMDQ0NmY5NTAwMGY2YjJmNzhjMDNmL3RhYmxlcmFuZ2U6YTQ5ODBhMzM2ZDMwNDQ2Zjk1MDAwZjZiMmY3OGMwM2ZfMy03LTEtMS0xODE2NA_0a708567-2168-4b73-aaad-2b13616e5e7a"
      unitRef="usd">208800000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i55b41215c9044cb8bdb7a95355f2cee3_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOmE0OTgwYTMzNmQzMDQ0NmY5NTAwMGY2YjJmNzhjMDNmL3RhYmxlcmFuZ2U6YTQ5ODBhMzM2ZDMwNDQ2Zjk1MDAwZjZiMmY3OGMwM2ZfNC0xLTEtMS0xODE2NA_66b3d514-b77d-4557-9e3d-8837caaf7316"
      unitRef="usd">86400000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i55b41215c9044cb8bdb7a95355f2cee3_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOmE0OTgwYTMzNmQzMDQ0NmY5NTAwMGY2YjJmNzhjMDNmL3RhYmxlcmFuZ2U6YTQ5ODBhMzM2ZDMwNDQ2Zjk1MDAwZjZiMmY3OGMwM2ZfNC03LTEtMS0xODE2NA_583cd608-70cb-4b02-ac31-f6736fd6a545"
      unitRef="usd">86400000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOmE0OTgwYTMzNmQzMDQ0NmY5NTAwMGY2YjJmNzhjMDNmL3RhYmxlcmFuZ2U6YTQ5ODBhMzM2ZDMwNDQ2Zjk1MDAwZjZiMmY3OGMwM2ZfNS0xLTEtMS0xODE2NA_cbc39476-46bd-43f7-ac77-eb8992d3c7c9"
      unitRef="usd">295200000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOmE0OTgwYTMzNmQzMDQ0NmY5NTAwMGY2YjJmNzhjMDNmL3RhYmxlcmFuZ2U6YTQ5ODBhMzM2ZDMwNDQ2Zjk1MDAwZjZiMmY3OGMwM2ZfNS03LTEtMS0xODE2NA_d8bb1e62-1f1b-4393-bd76-048e22d54a2c"
      unitRef="usd">295200000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i20c433933c2b4c689e241c3fd658ffa4_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOmE0OTgwYTMzNmQzMDQ0NmY5NTAwMGY2YjJmNzhjMDNmL3RhYmxlcmFuZ2U6YTQ5ODBhMzM2ZDMwNDQ2Zjk1MDAwZjZiMmY3OGMwM2ZfNy0xLTEtMS0xODE2NA_2b5d8a62-3c07-41b0-b3dd-f89f4f102bd6"
      unitRef="usd">90700000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i20c433933c2b4c689e241c3fd658ffa4_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOmE0OTgwYTMzNmQzMDQ0NmY5NTAwMGY2YjJmNzhjMDNmL3RhYmxlcmFuZ2U6YTQ5ODBhMzM2ZDMwNDQ2Zjk1MDAwZjZiMmY3OGMwM2ZfNy0zLTEtMS0xODE2NA_3f72e529-512c-4156-a2a5-85faa98c7d6c"
      unitRef="usd">200000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i20c433933c2b4c689e241c3fd658ffa4_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOmE0OTgwYTMzNmQzMDQ0NmY5NTAwMGY2YjJmNzhjMDNmL3RhYmxlcmFuZ2U6YTQ5ODBhMzM2ZDMwNDQ2Zjk1MDAwZjZiMmY3OGMwM2ZfNy01LTEtMS0xODE2NA_c622c4dc-195c-457b-95e0-16bee1243c3d"
      unitRef="usd">100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i20c433933c2b4c689e241c3fd658ffa4_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOmE0OTgwYTMzNmQzMDQ0NmY5NTAwMGY2YjJmNzhjMDNmL3RhYmxlcmFuZ2U6YTQ5ODBhMzM2ZDMwNDQ2Zjk1MDAwZjZiMmY3OGMwM2ZfNy03LTEtMS0xODE2NA_aa3bcafc-6427-4f68-9f32-52cef32b92c3"
      unitRef="usd">90800000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i474e395867254271927d4271ff603665_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOmE0OTgwYTMzNmQzMDQ0NmY5NTAwMGY2YjJmNzhjMDNmL3RhYmxlcmFuZ2U6YTQ5ODBhMzM2ZDMwNDQ2Zjk1MDAwZjZiMmY3OGMwM2ZfOC0xLTEtMS0xODE2NA_a5b89fa9-a5cb-4776-a72e-da33fe6d3016"
      unitRef="usd">19400000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i474e395867254271927d4271ff603665_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOmE0OTgwYTMzNmQzMDQ0NmY5NTAwMGY2YjJmNzhjMDNmL3RhYmxlcmFuZ2U6YTQ5ODBhMzM2ZDMwNDQ2Zjk1MDAwZjZiMmY3OGMwM2ZfOC0zLTEtMS0xODE2NA_e0d7968d-aded-4105-9c08-2aa7706c23b3"
      unitRef="usd">100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i474e395867254271927d4271ff603665_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOmE0OTgwYTMzNmQzMDQ0NmY5NTAwMGY2YjJmNzhjMDNmL3RhYmxlcmFuZ2U6YTQ5ODBhMzM2ZDMwNDQ2Zjk1MDAwZjZiMmY3OGMwM2ZfOC01LTEtMS0xODE2NA_c84fa9b0-1c47-468c-9c56-f0bbab6a115f"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i474e395867254271927d4271ff603665_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOmE0OTgwYTMzNmQzMDQ0NmY5NTAwMGY2YjJmNzhjMDNmL3RhYmxlcmFuZ2U6YTQ5ODBhMzM2ZDMwNDQ2Zjk1MDAwZjZiMmY3OGMwM2ZfOC03LTEtMS0xODE2NA_f8848f68-4bda-405e-87d1-e70d5ac05f72"
      unitRef="usd">19500000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i0f849fd49ae643249e914d79d76dcb81_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOmE0OTgwYTMzNmQzMDQ0NmY5NTAwMGY2YjJmNzhjMDNmL3RhYmxlcmFuZ2U6YTQ5ODBhMzM2ZDMwNDQ2Zjk1MDAwZjZiMmY3OGMwM2ZfOS0xLTEtMS0xODE2NA_c5a472e4-a6d3-4087-9b3e-5164b6b11bbd"
      unitRef="usd">2600000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i0f849fd49ae643249e914d79d76dcb81_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOmE0OTgwYTMzNmQzMDQ0NmY5NTAwMGY2YjJmNzhjMDNmL3RhYmxlcmFuZ2U6YTQ5ODBhMzM2ZDMwNDQ2Zjk1MDAwZjZiMmY3OGMwM2ZfOS0zLTEtMS0xODE2NA_67da37bc-804c-4b3d-b6c9-31c3da88bdbc"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i0f849fd49ae643249e914d79d76dcb81_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOmE0OTgwYTMzNmQzMDQ0NmY5NTAwMGY2YjJmNzhjMDNmL3RhYmxlcmFuZ2U6YTQ5ODBhMzM2ZDMwNDQ2Zjk1MDAwZjZiMmY3OGMwM2ZfOS01LTEtMS0xODE2NA_1ed792d1-2b81-4d03-87a5-d3a9c445be2d"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0f849fd49ae643249e914d79d76dcb81_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOmE0OTgwYTMzNmQzMDQ0NmY5NTAwMGY2YjJmNzhjMDNmL3RhYmxlcmFuZ2U6YTQ5ODBhMzM2ZDMwNDQ2Zjk1MDAwZjZiMmY3OGMwM2ZfOS03LTEtMS0xODE2NA_ffd36d3e-ca15-4808-bcae-1cfd7ec15f47"
      unitRef="usd">2600000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i50d5d52f5abe44ae90e97be189c0c2c0_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOmE0OTgwYTMzNmQzMDQ0NmY5NTAwMGY2YjJmNzhjMDNmL3RhYmxlcmFuZ2U6YTQ5ODBhMzM2ZDMwNDQ2Zjk1MDAwZjZiMmY3OGMwM2ZfMTAtMS0xLTEtMTgxNjQ_daf9e16c-fe1d-420f-901c-34e4b701ccaa"
      unitRef="usd">5500000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i50d5d52f5abe44ae90e97be189c0c2c0_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOmE0OTgwYTMzNmQzMDQ0NmY5NTAwMGY2YjJmNzhjMDNmL3RhYmxlcmFuZ2U6YTQ5ODBhMzM2ZDMwNDQ2Zjk1MDAwZjZiMmY3OGMwM2ZfMTAtMy0xLTEtMTgxNjQ_bc8b6256-cbb1-4df3-bae1-731015e5cee2"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i50d5d52f5abe44ae90e97be189c0c2c0_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOmE0OTgwYTMzNmQzMDQ0NmY5NTAwMGY2YjJmNzhjMDNmL3RhYmxlcmFuZ2U6YTQ5ODBhMzM2ZDMwNDQ2Zjk1MDAwZjZiMmY3OGMwM2ZfMTAtNS0xLTEtMTgxNjQ_72e5140d-2860-49d6-a122-fb85143ef4d4"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i50d5d52f5abe44ae90e97be189c0c2c0_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOmE0OTgwYTMzNmQzMDQ0NmY5NTAwMGY2YjJmNzhjMDNmL3RhYmxlcmFuZ2U6YTQ5ODBhMzM2ZDMwNDQ2Zjk1MDAwZjZiMmY3OGMwM2ZfMTAtNy0xLTEtMTgxNjQ_a0fd4575-3362-4539-9576-2add2b4b4dd1"
      unitRef="usd">5500000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <mygn:InvestmentsAndCashAmortizedCost
      contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOmE0OTgwYTMzNmQzMDQ0NmY5NTAwMGY2YjJmNzhjMDNmL3RhYmxlcmFuZ2U6YTQ5ODBhMzM2ZDMwNDQ2Zjk1MDAwZjZiMmY3OGMwM2ZfMTEtMS0xLTEtMTgxNjQ_bb582ca8-437f-4aee-a243-e83700e5df5e"
      unitRef="usd">413400000</mygn:InvestmentsAndCashAmortizedCost>
    <mygn:InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOmE0OTgwYTMzNmQzMDQ0NmY5NTAwMGY2YjJmNzhjMDNmL3RhYmxlcmFuZ2U6YTQ5ODBhMzM2ZDMwNDQ2Zjk1MDAwZjZiMmY3OGMwM2ZfMTEtMy0xLTEtMTgxNjQ_a95ac3c4-5ebb-483d-8801-e312f7522d05"
      unitRef="usd">300000</mygn:InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax>
    <mygn:InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOmE0OTgwYTMzNmQzMDQ0NmY5NTAwMGY2YjJmNzhjMDNmL3RhYmxlcmFuZ2U6YTQ5ODBhMzM2ZDMwNDQ2Zjk1MDAwZjZiMmY3OGMwM2ZfMTEtNS0xLTEtMTgxNjQ_42e3614c-8a51-4286-b921-c7dc18ca007b"
      unitRef="usd">100000</mygn:InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:InvestmentsAndCash
      contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOmE0OTgwYTMzNmQzMDQ0NmY5NTAwMGY2YjJmNzhjMDNmL3RhYmxlcmFuZ2U6YTQ5ODBhMzM2ZDMwNDQ2Zjk1MDAwZjZiMmY3OGMwM2ZfMTEtNy0xLTEtMTgxNjQ_8dedef1d-ef9f-456b-979c-ea05fce50b21"
      unitRef="usd">413600000</us-gaap:InvestmentsAndCash>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i89beb1b281b84d588eff0b2c4a0c5dfb_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOjI2MzAxNzUxOThhNzRhODNiMGIzNmM0NWVmZGU0ZWQ3L3RhYmxlcmFuZ2U6MjYzMDE3NTE5OGE3NGE4M2IwYjM2YzQ1ZWZkZTRlZDdfMy0xLTEtMS0xODE2NA_99d0b38a-f8cb-45b9-9617-3d8f8bf34774"
      unitRef="usd">47900000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i89beb1b281b84d588eff0b2c4a0c5dfb_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOjI2MzAxNzUxOThhNzRhODNiMGIzNmM0NWVmZGU0ZWQ3L3RhYmxlcmFuZ2U6MjYzMDE3NTE5OGE3NGE4M2IwYjM2YzQ1ZWZkZTRlZDdfMy03LTEtMS0xODE2NA_308f0890-8ce9-489b-85e9-bd5c9b07a78b"
      unitRef="usd">47900000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i784e7cc69b2447578da174c05c94a660_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOjI2MzAxNzUxOThhNzRhODNiMGIzNmM0NWVmZGU0ZWQ3L3RhYmxlcmFuZ2U6MjYzMDE3NTE5OGE3NGE4M2IwYjM2YzQ1ZWZkZTRlZDdfNC0xLTEtMS0xODE2NA_5fbc2477-27dc-41b8-ab4d-d1030ac624ee"
      unitRef="usd">69100000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i784e7cc69b2447578da174c05c94a660_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOjI2MzAxNzUxOThhNzRhODNiMGIzNmM0NWVmZGU0ZWQ3L3RhYmxlcmFuZ2U6MjYzMDE3NTE5OGE3NGE4M2IwYjM2YzQ1ZWZkZTRlZDdfNC03LTEtMS0xODE2NA_509cc2ec-5690-408f-a55e-f42e2d1c79de"
      unitRef="usd">69100000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOjI2MzAxNzUxOThhNzRhODNiMGIzNmM0NWVmZGU0ZWQ3L3RhYmxlcmFuZ2U6MjYzMDE3NTE5OGE3NGE4M2IwYjM2YzQ1ZWZkZTRlZDdfNS0xLTEtMS0xODE2NA_eb49b5bf-e955-4d57-90e4-88cc1761eca2"
      unitRef="usd">117000000.0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOjI2MzAxNzUxOThhNzRhODNiMGIzNmM0NWVmZGU0ZWQ3L3RhYmxlcmFuZ2U6MjYzMDE3NTE5OGE3NGE4M2IwYjM2YzQ1ZWZkZTRlZDdfNS03LTEtMS0xODE2NA_ce837d40-aec4-4298-a734-f4247bb19c1e"
      unitRef="usd">117000000.0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ide2c0b04a05e4f40b02f2431e83b3536_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOjI2MzAxNzUxOThhNzRhODNiMGIzNmM0NWVmZGU0ZWQ3L3RhYmxlcmFuZ2U6MjYzMDE3NTE5OGE3NGE4M2IwYjM2YzQ1ZWZkZTRlZDdfNy0xLTEtMS0xODE2NA_ccc6a795-9c67-4ab6-ab2a-106ed50b92d7"
      unitRef="usd">28800000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ide2c0b04a05e4f40b02f2431e83b3536_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOjI2MzAxNzUxOThhNzRhODNiMGIzNmM0NWVmZGU0ZWQ3L3RhYmxlcmFuZ2U6MjYzMDE3NTE5OGE3NGE4M2IwYjM2YzQ1ZWZkZTRlZDdfNy0zLTEtMS0xODE2NA_e0796bf1-991d-4909-8638-b4eb1ff6dd78"
      unitRef="usd">500000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ide2c0b04a05e4f40b02f2431e83b3536_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOjI2MzAxNzUxOThhNzRhODNiMGIzNmM0NWVmZGU0ZWQ3L3RhYmxlcmFuZ2U6MjYzMDE3NTE5OGE3NGE4M2IwYjM2YzQ1ZWZkZTRlZDdfNy01LTEtMS0xODE2NA_275c2a49-78d8-4f4e-8992-367b38ecf57f"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ide2c0b04a05e4f40b02f2431e83b3536_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOjI2MzAxNzUxOThhNzRhODNiMGIzNmM0NWVmZGU0ZWQ3L3RhYmxlcmFuZ2U6MjYzMDE3NTE5OGE3NGE4M2IwYjM2YzQ1ZWZkZTRlZDdfNy03LTEtMS0xODE2NA_073e4053-7715-4b5e-9dae-137146d3ea1a"
      unitRef="usd">29300000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i1e3de8ef1a9243968a201ad829b59152_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOjI2MzAxNzUxOThhNzRhODNiMGIzNmM0NWVmZGU0ZWQ3L3RhYmxlcmFuZ2U6MjYzMDE3NTE5OGE3NGE4M2IwYjM2YzQ1ZWZkZTRlZDdfOC0xLTEtMS0xODE2NA_d51ede9e-7596-44e3-8c4c-a6c98adbd6ca"
      unitRef="usd">9400000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i1e3de8ef1a9243968a201ad829b59152_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOjI2MzAxNzUxOThhNzRhODNiMGIzNmM0NWVmZGU0ZWQ3L3RhYmxlcmFuZ2U6MjYzMDE3NTE5OGE3NGE4M2IwYjM2YzQ1ZWZkZTRlZDdfOC0zLTEtMS0xODE2NA_1a76eaa8-72a4-49d6-81df-0c203a861703"
      unitRef="usd">200000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i1e3de8ef1a9243968a201ad829b59152_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOjI2MzAxNzUxOThhNzRhODNiMGIzNmM0NWVmZGU0ZWQ3L3RhYmxlcmFuZ2U6MjYzMDE3NTE5OGE3NGE4M2IwYjM2YzQ1ZWZkZTRlZDdfOC01LTEtMS0xODE2NA_c24b2294-a797-4371-8fee-65a11fb39d87"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1e3de8ef1a9243968a201ad829b59152_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOjI2MzAxNzUxOThhNzRhODNiMGIzNmM0NWVmZGU0ZWQ3L3RhYmxlcmFuZ2U6MjYzMDE3NTE5OGE3NGE4M2IwYjM2YzQ1ZWZkZTRlZDdfOC03LTEtMS0xODE2NA_e7168083-477c-4827-b16e-2cc9955f00f1"
      unitRef="usd">9600000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="id5e0328e3e08484f88ad3cfbf16c738f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOjI2MzAxNzUxOThhNzRhODNiMGIzNmM0NWVmZGU0ZWQ3L3RhYmxlcmFuZ2U6MjYzMDE3NTE5OGE3NGE4M2IwYjM2YzQ1ZWZkZTRlZDdfOS0xLTEtMS0xODE2NA_3ee606ee-17d9-4441-898f-466fc1212855"
      unitRef="usd">4000000.0</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="id5e0328e3e08484f88ad3cfbf16c738f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOjI2MzAxNzUxOThhNzRhODNiMGIzNmM0NWVmZGU0ZWQ3L3RhYmxlcmFuZ2U6MjYzMDE3NTE5OGE3NGE4M2IwYjM2YzQ1ZWZkZTRlZDdfOS0zLTEtMS0xODE2NA_e594c28c-b49f-4f2d-af62-559a65624d93"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="id5e0328e3e08484f88ad3cfbf16c738f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOjI2MzAxNzUxOThhNzRhODNiMGIzNmM0NWVmZGU0ZWQ3L3RhYmxlcmFuZ2U6MjYzMDE3NTE5OGE3NGE4M2IwYjM2YzQ1ZWZkZTRlZDdfOS01LTEtMS0xODE2NA_c15b76a6-cc4f-4437-ba90-cb6fa4208a59"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id5e0328e3e08484f88ad3cfbf16c738f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOjI2MzAxNzUxOThhNzRhODNiMGIzNmM0NWVmZGU0ZWQ3L3RhYmxlcmFuZ2U6MjYzMDE3NTE5OGE3NGE4M2IwYjM2YzQ1ZWZkZTRlZDdfOS03LTEtMS0xODE2NA_795c33ab-17b8-44a6-bdb0-3fdb99b153ef"
      unitRef="usd">4000000.0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i47594399039d468c97b0901e9244c85e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOjI2MzAxNzUxOThhNzRhODNiMGIzNmM0NWVmZGU0ZWQ3L3RhYmxlcmFuZ2U6MjYzMDE3NTE5OGE3NGE4M2IwYjM2YzQ1ZWZkZTRlZDdfMTAtMS0xLTEtMTgxNjQ_25da06eb-8195-4c26-8e28-b0e5ff178099"
      unitRef="usd">11700000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i47594399039d468c97b0901e9244c85e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOjI2MzAxNzUxOThhNzRhODNiMGIzNmM0NWVmZGU0ZWQ3L3RhYmxlcmFuZ2U6MjYzMDE3NTE5OGE3NGE4M2IwYjM2YzQ1ZWZkZTRlZDdfMTAtMy0xLTEtMTgxNjQ_a89a2f8e-b6bb-4d17-8c0a-101427d926a8"
      unitRef="usd">100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i47594399039d468c97b0901e9244c85e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOjI2MzAxNzUxOThhNzRhODNiMGIzNmM0NWVmZGU0ZWQ3L3RhYmxlcmFuZ2U6MjYzMDE3NTE5OGE3NGE4M2IwYjM2YzQ1ZWZkZTRlZDdfMTAtNS0xLTEtMTgxNjQ_430e5d15-3cb8-4148-8734-f236c9e9674a"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i47594399039d468c97b0901e9244c85e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOjI2MzAxNzUxOThhNzRhODNiMGIzNmM0NWVmZGU0ZWQ3L3RhYmxlcmFuZ2U6MjYzMDE3NTE5OGE3NGE4M2IwYjM2YzQ1ZWZkZTRlZDdfMTAtNy0xLTEtMTgxNjQ_d89fc6b3-46c9-4582-8b3f-f551f87be2e7"
      unitRef="usd">11800000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <mygn:InvestmentsAndCashAmortizedCost
      contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOjI2MzAxNzUxOThhNzRhODNiMGIzNmM0NWVmZGU0ZWQ3L3RhYmxlcmFuZ2U6MjYzMDE3NTE5OGE3NGE4M2IwYjM2YzQ1ZWZkZTRlZDdfMTEtMS0xLTEtMTgxNjQ_51cae036-6b65-4f13-8fbf-fd4bf3f9ea76"
      unitRef="usd">170900000</mygn:InvestmentsAndCashAmortizedCost>
    <mygn:InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOjI2MzAxNzUxOThhNzRhODNiMGIzNmM0NWVmZGU0ZWQ3L3RhYmxlcmFuZ2U6MjYzMDE3NTE5OGE3NGE4M2IwYjM2YzQ1ZWZkZTRlZDdfMTEtMy0xLTEtMTgxNjQ_c0d9f5a4-9333-4ad6-bea6-e128e13e9f20"
      unitRef="usd">800000</mygn:InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax>
    <mygn:InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOjI2MzAxNzUxOThhNzRhODNiMGIzNmM0NWVmZGU0ZWQ3L3RhYmxlcmFuZ2U6MjYzMDE3NTE5OGE3NGE4M2IwYjM2YzQ1ZWZkZTRlZDdfMTEtNS0xLTEtMTgxNjQ_8d82a80b-9618-43d0-987b-6a9e8c258ccf"
      unitRef="usd">0</mygn:InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:InvestmentsAndCash
      contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOjI2MzAxNzUxOThhNzRhODNiMGIzNmM0NWVmZGU0ZWQ3L3RhYmxlcmFuZ2U6MjYzMDE3NTE5OGE3NGE4M2IwYjM2YzQ1ZWZkZTRlZDdfMTEtNy0xLTEtMTgxNjQ_2c2a6f89-8a4e-4419-a5b7-610fd53aa2fc"
      unitRef="usd">171700000</us-gaap:InvestmentsAndCash>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RleHRyZWdpb246MzAwZWUxYzI4MGM4NGY0Y2IzNGRiZTNmY2YxODkyYmJfNjE4_4b09e02a-347a-4174-b5ee-37ad7e53061b">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash, cash equivalents, and maturities of debt securities classified as available-for-sale securities were as follows at September&#160;30, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amortized&lt;br/&gt;cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Estimated&lt;br/&gt;fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Available-for-sale:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Due within one year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;70.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;70.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Due after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;47.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;47.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Due after five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;413.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;413.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ie18df879613d4bb19a671fecd56a73ef_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOjVhMTA0NzA3ZWViYzQxNDFhOGQ0NjAxMzU2N2YyNTYzL3RhYmxlcmFuZ2U6NWExMDQ3MDdlZWJjNDE0MWE4ZDQ2MDEzNTY3ZjI1NjNfMS0xLTEtMS0xODE2NA_2f3bd2ad-3005-4ba3-9042-ecc1ffa67937"
      unitRef="usd">208800000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ie18df879613d4bb19a671fecd56a73ef_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOjVhMTA0NzA3ZWViYzQxNDFhOGQ0NjAxMzU2N2YyNTYzL3RhYmxlcmFuZ2U6NWExMDQ3MDdlZWJjNDE0MWE4ZDQ2MDEzNTY3ZjI1NjNfMS0zLTEtMS0xODE2NA_a21777a6-c3f0-4c4b-8e3e-382e11223910"
      unitRef="usd">208800000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i55b41215c9044cb8bdb7a95355f2cee3_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOjVhMTA0NzA3ZWViYzQxNDFhOGQ0NjAxMzU2N2YyNTYzL3RhYmxlcmFuZ2U6NWExMDQ3MDdlZWJjNDE0MWE4ZDQ2MDEzNTY3ZjI1NjNfMi0xLTEtMS0xODE2NA_90bfdae0-2840-4674-8f36-32c193c7fa28"
      unitRef="usd">86400000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i55b41215c9044cb8bdb7a95355f2cee3_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOjVhMTA0NzA3ZWViYzQxNDFhOGQ0NjAxMzU2N2YyNTYzL3RhYmxlcmFuZ2U6NWExMDQ3MDdlZWJjNDE0MWE4ZDQ2MDEzNTY3ZjI1NjNfMi0zLTEtMS0xODE2NA_afd637b0-1a8a-4f9a-a116-c059f4336af2"
      unitRef="usd">86400000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
      contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOjVhMTA0NzA3ZWViYzQxNDFhOGQ0NjAxMzU2N2YyNTYzL3RhYmxlcmFuZ2U6NWExMDQ3MDdlZWJjNDE0MWE4ZDQ2MDEzNTY3ZjI1NjNfNC0xLTEtMS0xODE2NA_8759220a-123c-444d-9e61-4ad00eb793c4"
      unitRef="usd">70700000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOjVhMTA0NzA3ZWViYzQxNDFhOGQ0NjAxMzU2N2YyNTYzL3RhYmxlcmFuZ2U6NWExMDQ3MDdlZWJjNDE0MWE4ZDQ2MDEzNTY3ZjI1NjNfNC0zLTEtMS0xODE2NA_a4271e95-a81d-4a01-91c1-336dac5ddde0"
      unitRef="usd">70900000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
      contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOjVhMTA0NzA3ZWViYzQxNDFhOGQ0NjAxMzU2N2YyNTYzL3RhYmxlcmFuZ2U6NWExMDQ3MDdlZWJjNDE0MWE4ZDQ2MDEzNTY3ZjI1NjNfNS0xLTEtMS0xODE2NA_096563b1-45c0-49fa-8296-216b0dd3853d"
      unitRef="usd">47500000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOjVhMTA0NzA3ZWViYzQxNDFhOGQ0NjAxMzU2N2YyNTYzL3RhYmxlcmFuZ2U6NWExMDQ3MDdlZWJjNDE0MWE4ZDQ2MDEzNTY3ZjI1NjNfNS0zLTEtMS0xODE2NA_661cd566-65e9-4999-af21-809b4bce6cc9"
      unitRef="usd">47500000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost
      contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOjVhMTA0NzA3ZWViYzQxNDFhOGQ0NjAxMzU2N2YyNTYzL3RhYmxlcmFuZ2U6NWExMDQ3MDdlZWJjNDE0MWE4ZDQ2MDEzNTY3ZjI1NjNfNi0xLTEtMS0xODE2NA_a0502219-05c5-4691-ba31-76ad1d3c3c6e"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue
      contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOjVhMTA0NzA3ZWViYzQxNDFhOGQ0NjAxMzU2N2YyNTYzL3RhYmxlcmFuZ2U6NWExMDQ3MDdlZWJjNDE0MWE4ZDQ2MDEzNTY3ZjI1NjNfNi0zLTEtMS0xODE2NA_963468ba-a6d4-4738-ab2b-6de8eb2bc9e0"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue>
    <mygn:InvestmentsAndCashAmortizedCost
      contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOjVhMTA0NzA3ZWViYzQxNDFhOGQ0NjAxMzU2N2YyNTYzL3RhYmxlcmFuZ2U6NWExMDQ3MDdlZWJjNDE0MWE4ZDQ2MDEzNTY3ZjI1NjNfNy0xLTEtMS0xODE2NA_cad9bc20-102c-492a-b881-ea5e14b35da6"
      unitRef="usd">413400000</mygn:InvestmentsAndCashAmortizedCost>
    <us-gaap:InvestmentsAndCash
      contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RhYmxlOjVhMTA0NzA3ZWViYzQxNDFhOGQ0NjAxMzU2N2YyNTYzL3RhYmxlcmFuZ2U6NWExMDQ3MDdlZWJjNDE0MWE4ZDQ2MDEzNTY3ZjI1NjNfNy0zLTEtMS0xODE2NA_764b9c06-5b56-42e5-b7dc-9da047681ded"
      unitRef="usd">413600000</us-gaap:InvestmentsAndCash>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RleHRyZWdpb246MzAwZWUxYzI4MGM4NGY0Y2IzNGRiZTNmY2YxODkyYmJfMzky_532f1975-53fb-47fe-b310-e7a0d5d795a5"
      unitRef="security">0</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180MC9mcmFnOjMwMGVlMWMyODBjODRmNGNiMzRkYmUzZmNmMTg5MmJiL3RleHRyZWdpb246MzAwZWUxYzI4MGM4NGY0Y2IzNGRiZTNmY2YxODkyYmJfMzky_cf3f16a1-53ee-4872-81b4-155a37e94fc5"
      unitRef="security">0</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RleHRyZWdpb246MzQ4MWIzZWU0NWZjNDRiYTk0OThkMGEzNzJhMGYwM2NfNDczOA_8c8e62b8-d29b-4608-b972-f1160981df73">FAIR VALUE MEASUREMENTS&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the Company&#x2019;s financial instruments reflects the amounts that the Company estimates it will receive in connection with the sale of an asset or pay in connection with the transfer of a liability in an orderly transaction between market participants at the measurement date (exit price). The fair value hierarchy prioritizes the use of inputs used in valuation techniques into the following three levels:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1&#x2014;quoted prices in active markets for identical assets and liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2&#x2014;observable inputs other than quoted prices in active markets for identical assets and liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&#160;&#160;Some of the Company&#x2019;s marketable securities primarily utilize broker quotes in a non-active market for valuation of these securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 3&#x2014;unobservable inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All of the Company&#x2019;s financial instruments are valued using quoted prices in active markets or based on other observable inputs.&#160;&#160;For Level 2 securities, the Company uses a third party pricing service which provides documentation on an ongoing basis that includes, among other things, pricing information with respect to reference data, methodology, inputs summarized by asset class, pricing application and corroborative information. For Level 3 contingent consideration, the Company reassesses the fair value of expected contingent consideration and the corresponding liability each reporting period using the Monte Carlo Method, which is consistent with the initial measurement of the expected earn out liability.&#160;This fair value measurement is considered a Level 3 measurement because the Company estimates projections during the expected measurement period of approximately 13.8 years, utilizing various potential pay-out scenarios.&#160;&#160;Probabilities were applied to each potential scenario and the resulting values were discounted using a rate that considers weighted average cost of capital as well as a specific risk premium associated with the riskiness of the earn-out itself, the related projections, and the overall business.&#160;The contingent earn-out liabilities are classified as components of Accrued liabilities and Other long-term liabilities in the Company&#x2019;s Condensed Consolidated Balance Sheets.&#160;&#160;Changes to contingent consideration liabilities are reflected in Change in the fair value of contingent consideration in the Company&#x2019;s Condensed Consolidated Statements of Operations. Changes to the unobservable inputs could have a material impact on the Company&#x2019;s financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the fair value of the financial assets and liabilities that the Company re-measures on a regular basis:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Money market funds (a)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;86.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;86.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate bonds and notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;90.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;90.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;19.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;19.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Federal agency issues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;US government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(8.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(8.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;86.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;118.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(8.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;196.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:27.13pt"&gt;Money market funds are primarily comprised of exchange traded funds and accrued interest.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Money market funds (a)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;69.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;69.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate bonds and notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;29.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;29.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Federal agency issues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;US government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(10.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(10.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;69.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;54.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(10.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;112.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:27.13pt"&gt;Money market funds are primarily comprised of exchange traded funds and accrued interest.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The following table reconciles the change in the fair value of the contingent consideration during the periods presented:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Balance December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payment of contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Change in fair value recognized in the income statement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Translation adjustments recognized in other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Ending balance September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <mygn:BusinessCombinationContingentConsiderationLiabilityMeasurementInputTerm
      contextRef="i1f71ce0e78ae4d43bdf7b1af72891a7e_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RleHRyZWdpb246MzQ4MWIzZWU0NWZjNDRiYTk0OThkMGEzNzJhMGYwM2NfMTg3MQ_31701f1b-7273-47be-92ff-b5bf5536c102">P13Y9M18D</mygn:BusinessCombinationContingentConsiderationLiabilityMeasurementInputTerm>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RleHRyZWdpb246MzQ4MWIzZWU0NWZjNDRiYTk0OThkMGEzNzJhMGYwM2NfNDczNw_94a0ae38-4c72-47d2-8414-48c3fb11599f">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the fair value of the financial assets and liabilities that the Company re-measures on a regular basis:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Money market funds (a)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;86.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;86.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate bonds and notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;90.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;90.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;19.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;19.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Federal agency issues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;US government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(8.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(8.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;86.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;118.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(8.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;196.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:27.13pt"&gt;Money market funds are primarily comprised of exchange traded funds and accrued interest.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Money market funds (a)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;69.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;69.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate bonds and notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;29.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;29.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Federal agency issues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;US government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(10.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(10.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;69.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;54.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(10.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;112.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:27.13pt"&gt;Money market funds are primarily comprised of exchange traded funds and accrued interest.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ib44dd41f27d8480d8f588e0a3bf99cba_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RhYmxlOjhjN2UwODE2YWQxYjQ5MjVhNzRmYWI1YzIzZjA5Mzc5L3RhYmxlcmFuZ2U6OGM3ZTA4MTZhZDFiNDkyNWE3NGZhYjVjMjNmMDkzNzlfMi0xLTEtMS0xODE2NA_d6c6429a-2a5e-49d1-ac6d-ec2a1524d008"
      unitRef="usd">86400000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i3d975988e4a74a9dbe6e71a5b5546389_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RhYmxlOjhjN2UwODE2YWQxYjQ5MjVhNzRmYWI1YzIzZjA5Mzc5L3RhYmxlcmFuZ2U6OGM3ZTA4MTZhZDFiNDkyNWE3NGZhYjVjMjNmMDkzNzlfMi0zLTEtMS0xODE2NA_5902e50a-964a-472c-af24-bf4be423c8cf"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i4996139414984f65bb79f0d63ac3f655_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RhYmxlOjhjN2UwODE2YWQxYjQ5MjVhNzRmYWI1YzIzZjA5Mzc5L3RhYmxlcmFuZ2U6OGM3ZTA4MTZhZDFiNDkyNWE3NGZhYjVjMjNmMDkzNzlfMi01LTEtMS0xODE2NA_cda3921d-8a97-4390-8ae3-fc4528dd4428"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="id012a77974384595bcd158dfde0ea68e_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RhYmxlOjhjN2UwODE2YWQxYjQ5MjVhNzRmYWI1YzIzZjA5Mzc5L3RhYmxlcmFuZ2U6OGM3ZTA4MTZhZDFiNDkyNWE3NGZhYjVjMjNmMDkzNzlfMi03LTEtMS0xODE2NA_4d25fc4f-083f-4514-ac70-e6401884241f"
      unitRef="usd">86400000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i22cef9e6ab314518ab6c3a7c7d612f84_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RhYmxlOjhjN2UwODE2YWQxYjQ5MjVhNzRmYWI1YzIzZjA5Mzc5L3RhYmxlcmFuZ2U6OGM3ZTA4MTZhZDFiNDkyNWE3NGZhYjVjMjNmMDkzNzlfMy0xLTEtMS0xODE2NA_ced838b1-d6d3-460e-bbf7-dd369e5194c2"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ia4d9dbc5ea804408a5936ee65bfc03fe_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RhYmxlOjhjN2UwODE2YWQxYjQ5MjVhNzRmYWI1YzIzZjA5Mzc5L3RhYmxlcmFuZ2U6OGM3ZTA4MTZhZDFiNDkyNWE3NGZhYjVjMjNmMDkzNzlfMy0zLTEtMS0xODE2NA_b6f37167-761b-4c63-a340-cfd4eb98f2b8"
      unitRef="usd">90800000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i0dd65111dedb44d595f99ccb1991e8fe_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RhYmxlOjhjN2UwODE2YWQxYjQ5MjVhNzRmYWI1YzIzZjA5Mzc5L3RhYmxlcmFuZ2U6OGM3ZTA4MTZhZDFiNDkyNWE3NGZhYjVjMjNmMDkzNzlfMy01LTEtMS0xODE2NA_c30cce71-5614-4831-806d-5b5372fd42dd"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i20c433933c2b4c689e241c3fd658ffa4_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RhYmxlOjhjN2UwODE2YWQxYjQ5MjVhNzRmYWI1YzIzZjA5Mzc5L3RhYmxlcmFuZ2U6OGM3ZTA4MTZhZDFiNDkyNWE3NGZhYjVjMjNmMDkzNzlfMy03LTEtMS0xODE2NA_b9c4a480-5b4b-4164-9698-364f18bd367d"
      unitRef="usd">90800000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ib78f55a38b1d452e8216debd6bd284c8_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RhYmxlOjhjN2UwODE2YWQxYjQ5MjVhNzRmYWI1YzIzZjA5Mzc5L3RhYmxlcmFuZ2U6OGM3ZTA4MTZhZDFiNDkyNWE3NGZhYjVjMjNmMDkzNzlfNC0xLTEtMS0xODE2NA_79d8439e-79a3-47bd-b2f4-5bf535c7716a"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ia1e3572a358f489bacc6b0b33b2e63d5_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RhYmxlOjhjN2UwODE2YWQxYjQ5MjVhNzRmYWI1YzIzZjA5Mzc5L3RhYmxlcmFuZ2U6OGM3ZTA4MTZhZDFiNDkyNWE3NGZhYjVjMjNmMDkzNzlfNC0zLTEtMS0xODE2NA_41333d78-7e60-4d49-9b1f-a846d8966557"
      unitRef="usd">19500000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i4b6dea85317046bc87a3e54a0f0f3ffc_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RhYmxlOjhjN2UwODE2YWQxYjQ5MjVhNzRmYWI1YzIzZjA5Mzc5L3RhYmxlcmFuZ2U6OGM3ZTA4MTZhZDFiNDkyNWE3NGZhYjVjMjNmMDkzNzlfNC01LTEtMS0xODE2NA_0521ad94-a985-489b-ade8-f09fed4783bb"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i474e395867254271927d4271ff603665_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RhYmxlOjhjN2UwODE2YWQxYjQ5MjVhNzRmYWI1YzIzZjA5Mzc5L3RhYmxlcmFuZ2U6OGM3ZTA4MTZhZDFiNDkyNWE3NGZhYjVjMjNmMDkzNzlfNC03LTEtMS0xODE2NA_62c57c16-3f1c-4d1e-8456-181bb964bf3f"
      unitRef="usd">19500000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i7ec450647a3c4906981f1552178b524d_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RhYmxlOjhjN2UwODE2YWQxYjQ5MjVhNzRmYWI1YzIzZjA5Mzc5L3RhYmxlcmFuZ2U6OGM3ZTA4MTZhZDFiNDkyNWE3NGZhYjVjMjNmMDkzNzlfNS0xLTEtMS0xODE2NA_9de9cf32-f42f-45e9-a26e-9d044c4c489b"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i69d2dc8810554913bdaf6702c8068256_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RhYmxlOjhjN2UwODE2YWQxYjQ5MjVhNzRmYWI1YzIzZjA5Mzc5L3RhYmxlcmFuZ2U6OGM3ZTA4MTZhZDFiNDkyNWE3NGZhYjVjMjNmMDkzNzlfNS0zLTEtMS0xODE2NA_5b9ee4f5-7a17-47d9-8a57-60bf111ae4b7"
      unitRef="usd">2600000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i83b400ca04df4b53901e5ccced571202_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RhYmxlOjhjN2UwODE2YWQxYjQ5MjVhNzRmYWI1YzIzZjA5Mzc5L3RhYmxlcmFuZ2U6OGM3ZTA4MTZhZDFiNDkyNWE3NGZhYjVjMjNmMDkzNzlfNS01LTEtMS0xODE2NA_bc7ece10-fe4a-4657-a242-a65d6e94d704"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i0f849fd49ae643249e914d79d76dcb81_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RhYmxlOjhjN2UwODE2YWQxYjQ5MjVhNzRmYWI1YzIzZjA5Mzc5L3RhYmxlcmFuZ2U6OGM3ZTA4MTZhZDFiNDkyNWE3NGZhYjVjMjNmMDkzNzlfNS03LTEtMS0xODE2NA_04136bdb-6a17-4d6d-a464-6f70b1987843"
      unitRef="usd">2600000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iba04c9e73cfd46ad82a9eea96b7282e2_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RhYmxlOjhjN2UwODE2YWQxYjQ5MjVhNzRmYWI1YzIzZjA5Mzc5L3RhYmxlcmFuZ2U6OGM3ZTA4MTZhZDFiNDkyNWE3NGZhYjVjMjNmMDkzNzlfNi0xLTEtMS0xODE2NA_1c22e8ac-3848-4446-b71e-9477173aa74c"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i20eb373912734049b280784af93920ce_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RhYmxlOjhjN2UwODE2YWQxYjQ5MjVhNzRmYWI1YzIzZjA5Mzc5L3RhYmxlcmFuZ2U6OGM3ZTA4MTZhZDFiNDkyNWE3NGZhYjVjMjNmMDkzNzlfNi0zLTEtMS0xODE2NA_9780c0dc-f1bc-4121-9535-b1e1b43a02f4"
      unitRef="usd">5500000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ibdc5dad50ef14763bc23b7f645b991d5_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RhYmxlOjhjN2UwODE2YWQxYjQ5MjVhNzRmYWI1YzIzZjA5Mzc5L3RhYmxlcmFuZ2U6OGM3ZTA4MTZhZDFiNDkyNWE3NGZhYjVjMjNmMDkzNzlfNi01LTEtMS0xODE2NA_3e0b9718-1536-4896-ba97-ee29a06d3b74"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i50d5d52f5abe44ae90e97be189c0c2c0_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RhYmxlOjhjN2UwODE2YWQxYjQ5MjVhNzRmYWI1YzIzZjA5Mzc5L3RhYmxlcmFuZ2U6OGM3ZTA4MTZhZDFiNDkyNWE3NGZhYjVjMjNmMDkzNzlfNi03LTEtMS0xODE2NA_70d55362-7e98-4875-9484-d72a0cb76091"
      unitRef="usd">5500000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i53fc983dd40d4345b5662806620d7a69_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RhYmxlOjhjN2UwODE2YWQxYjQ5MjVhNzRmYWI1YzIzZjA5Mzc5L3RhYmxlcmFuZ2U6OGM3ZTA4MTZhZDFiNDkyNWE3NGZhYjVjMjNmMDkzNzlfNy0xLTEtMS0xODE2NA_d4cacec6-866c-4d14-9f82-d717d237bea2"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i92c674fcb51e4f128ed0956b57defa1a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RhYmxlOjhjN2UwODE2YWQxYjQ5MjVhNzRmYWI1YzIzZjA5Mzc5L3RhYmxlcmFuZ2U6OGM3ZTA4MTZhZDFiNDkyNWE3NGZhYjVjMjNmMDkzNzlfNy0zLTEtMS0xODE2NA_99b96c22-4498-4e86-8165-d18ab8e06557"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i36f381783c3a43ca93842d8b7723cb09_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RhYmxlOjhjN2UwODE2YWQxYjQ5MjVhNzRmYWI1YzIzZjA5Mzc5L3RhYmxlcmFuZ2U6OGM3ZTA4MTZhZDFiNDkyNWE3NGZhYjVjMjNmMDkzNzlfNy01LTEtMS0xODE2NA_6cdf2d4c-9d99-4b80-959d-05f79824417a"
      unitRef="usd">8800000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i476783a7d7a846aca1e3115c994a7824_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RhYmxlOjhjN2UwODE2YWQxYjQ5MjVhNzRmYWI1YzIzZjA5Mzc5L3RhYmxlcmFuZ2U6OGM3ZTA4MTZhZDFiNDkyNWE3NGZhYjVjMjNmMDkzNzlfNy03LTEtMS0xODE2NA_5bdfecf6-1cec-43ca-959b-285d34e49226"
      unitRef="usd">8800000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:FairValueNetAssetLiability
      contextRef="ifb3432fef1734dcf938bc72ecde8321c_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RhYmxlOjhjN2UwODE2YWQxYjQ5MjVhNzRmYWI1YzIzZjA5Mzc5L3RhYmxlcmFuZ2U6OGM3ZTA4MTZhZDFiNDkyNWE3NGZhYjVjMjNmMDkzNzlfOC0xLTEtMS0xODE2NA_f540a6af-a090-47d8-95ec-64c9394a884e"
      unitRef="usd">86400000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="i0ba8c79bbcbe4cfdae12d33bf2783cb3_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RhYmxlOjhjN2UwODE2YWQxYjQ5MjVhNzRmYWI1YzIzZjA5Mzc5L3RhYmxlcmFuZ2U6OGM3ZTA4MTZhZDFiNDkyNWE3NGZhYjVjMjNmMDkzNzlfOC0zLTEtMS0xODE2NA_d13eb491-fa15-4a2d-b1d7-759b837cfe91"
      unitRef="usd">118400000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="if8c6a3bacee84320baf1e19f8abf5951_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RhYmxlOjhjN2UwODE2YWQxYjQ5MjVhNzRmYWI1YzIzZjA5Mzc5L3RhYmxlcmFuZ2U6OGM3ZTA4MTZhZDFiNDkyNWE3NGZhYjVjMjNmMDkzNzlfOC01LTEtMS0xODE2NA_edd2ce24-ad62-4d8e-8709-ae0a67307a31"
      unitRef="usd">-8800000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RhYmxlOjhjN2UwODE2YWQxYjQ5MjVhNzRmYWI1YzIzZjA5Mzc5L3RhYmxlcmFuZ2U6OGM3ZTA4MTZhZDFiNDkyNWE3NGZhYjVjMjNmMDkzNzlfOC03LTEtMS0xODE2NA_c8a7919e-af10-415a-a3ac-2ec354a7e4d4"
      unitRef="usd">196000000.0</us-gaap:FairValueNetAssetLiability>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ic9870ea197d5485389a0710db39dac7e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RhYmxlOjc3OWViZTkxOGQwMTQ5YmJiY2FkOTZiNDc1OTMwYjI3L3RhYmxlcmFuZ2U6Nzc5ZWJlOTE4ZDAxNDliYmJjYWQ5NmI0NzU5MzBiMjdfMi0xLTEtMS0xODE2NA_dbb0e8f2-ba6b-4190-b7c0-6a37ebb6ee7b"
      unitRef="usd">69100000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="idac1b2ac3b4c4ea287843c55138d31fe_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RhYmxlOjc3OWViZTkxOGQwMTQ5YmJiY2FkOTZiNDc1OTMwYjI3L3RhYmxlcmFuZ2U6Nzc5ZWJlOTE4ZDAxNDliYmJjYWQ5NmI0NzU5MzBiMjdfMi0zLTEtMS0xODE2NA_46a41442-bceb-42ff-8d56-89c4ec50935e"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iefe8366531d2402295ef25ebb060e068_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RhYmxlOjc3OWViZTkxOGQwMTQ5YmJiY2FkOTZiNDc1OTMwYjI3L3RhYmxlcmFuZ2U6Nzc5ZWJlOTE4ZDAxNDliYmJjYWQ5NmI0NzU5MzBiMjdfMi01LTEtMS0xODE2NA_da01dee5-06f3-4edd-aa0e-b4d0363e3e3f"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="if070826acb484e4b88cfbb934f2510a0_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RhYmxlOjc3OWViZTkxOGQwMTQ5YmJiY2FkOTZiNDc1OTMwYjI3L3RhYmxlcmFuZ2U6Nzc5ZWJlOTE4ZDAxNDliYmJjYWQ5NmI0NzU5MzBiMjdfMi03LTEtMS0xODE2NA_b24a5764-9677-459e-b280-777eca9f603c"
      unitRef="usd">69100000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i6e8d32c49f294155b6e1ca65383d3960_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RhYmxlOjc3OWViZTkxOGQwMTQ5YmJiY2FkOTZiNDc1OTMwYjI3L3RhYmxlcmFuZ2U6Nzc5ZWJlOTE4ZDAxNDliYmJjYWQ5NmI0NzU5MzBiMjdfMy0xLTEtMS0xODE2NA_a40030bc-389c-4450-af54-a57f1cb4efe4"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i9c5647e0218944d0aa8af898642f148e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RhYmxlOjc3OWViZTkxOGQwMTQ5YmJiY2FkOTZiNDc1OTMwYjI3L3RhYmxlcmFuZ2U6Nzc5ZWJlOTE4ZDAxNDliYmJjYWQ5NmI0NzU5MzBiMjdfMy0zLTEtMS0xODE2NA_9e21d5cb-ebe6-43ea-a24a-0ec2025f4900"
      unitRef="usd">29300000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ibf68d852a72c4154b30db158bdb79561_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RhYmxlOjc3OWViZTkxOGQwMTQ5YmJiY2FkOTZiNDc1OTMwYjI3L3RhYmxlcmFuZ2U6Nzc5ZWJlOTE4ZDAxNDliYmJjYWQ5NmI0NzU5MzBiMjdfMy01LTEtMS0xODE2NA_bb26450b-ffe4-4010-af3b-e6fb58ba5332"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ide2c0b04a05e4f40b02f2431e83b3536_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RhYmxlOjc3OWViZTkxOGQwMTQ5YmJiY2FkOTZiNDc1OTMwYjI3L3RhYmxlcmFuZ2U6Nzc5ZWJlOTE4ZDAxNDliYmJjYWQ5NmI0NzU5MzBiMjdfMy03LTEtMS0xODE2NA_a8089b00-c7fc-4bdb-b3f2-f8b4c708617d"
      unitRef="usd">29300000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i0330620427f647ed9cc3899d676e3b70_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RhYmxlOjc3OWViZTkxOGQwMTQ5YmJiY2FkOTZiNDc1OTMwYjI3L3RhYmxlcmFuZ2U6Nzc5ZWJlOTE4ZDAxNDliYmJjYWQ5NmI0NzU5MzBiMjdfNC0xLTEtMS0xODE2NA_1520e52d-db3c-4b25-b72f-abc95c7dcf83"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i1213355c05b74525b0feb4f71cee0825_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RhYmxlOjc3OWViZTkxOGQwMTQ5YmJiY2FkOTZiNDc1OTMwYjI3L3RhYmxlcmFuZ2U6Nzc5ZWJlOTE4ZDAxNDliYmJjYWQ5NmI0NzU5MzBiMjdfNC0zLTEtMS0xODE2NA_f6019149-326b-4d50-8b4c-35f5aa3109f5"
      unitRef="usd">9600000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i8a792264bad64b069150fc3385ef30ea_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RhYmxlOjc3OWViZTkxOGQwMTQ5YmJiY2FkOTZiNDc1OTMwYjI3L3RhYmxlcmFuZ2U6Nzc5ZWJlOTE4ZDAxNDliYmJjYWQ5NmI0NzU5MzBiMjdfNC01LTEtMS0xODE2NA_726b132e-63f5-47d8-8481-acf748f250b8"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i1e3de8ef1a9243968a201ad829b59152_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RhYmxlOjc3OWViZTkxOGQwMTQ5YmJiY2FkOTZiNDc1OTMwYjI3L3RhYmxlcmFuZ2U6Nzc5ZWJlOTE4ZDAxNDliYmJjYWQ5NmI0NzU5MzBiMjdfNC03LTEtMS0xODE2NA_4966d761-66a9-4fc5-b074-e79ce656ecca"
      unitRef="usd">9600000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i02209a0a76af4ebdbef9df556c34a6d8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RhYmxlOjc3OWViZTkxOGQwMTQ5YmJiY2FkOTZiNDc1OTMwYjI3L3RhYmxlcmFuZ2U6Nzc5ZWJlOTE4ZDAxNDliYmJjYWQ5NmI0NzU5MzBiMjdfNS0xLTEtMS0xODE2NA_a63b1f2f-6351-4676-b426-1ca36c86f14f"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ia5d2a4f35b5e4114a4bdedc325290a90_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RhYmxlOjc3OWViZTkxOGQwMTQ5YmJiY2FkOTZiNDc1OTMwYjI3L3RhYmxlcmFuZ2U6Nzc5ZWJlOTE4ZDAxNDliYmJjYWQ5NmI0NzU5MzBiMjdfNS0zLTEtMS0xODE2NA_9a760cf9-efbb-4cdb-964b-32c83ece4171"
      unitRef="usd">4000000.0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i591bb847d18a4e38a3b89e766c088008_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RhYmxlOjc3OWViZTkxOGQwMTQ5YmJiY2FkOTZiNDc1OTMwYjI3L3RhYmxlcmFuZ2U6Nzc5ZWJlOTE4ZDAxNDliYmJjYWQ5NmI0NzU5MzBiMjdfNS01LTEtMS0xODE2NA_45fc67d7-e4b1-44ce-832a-461033a57bd3"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="id5e0328e3e08484f88ad3cfbf16c738f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RhYmxlOjc3OWViZTkxOGQwMTQ5YmJiY2FkOTZiNDc1OTMwYjI3L3RhYmxlcmFuZ2U6Nzc5ZWJlOTE4ZDAxNDliYmJjYWQ5NmI0NzU5MzBiMjdfNS03LTEtMS0xODE2NA_6db52d82-35d1-4960-90a6-cb6b534319c5"
      unitRef="usd">4000000.0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ieb2b2109f1474e9d98f51788f0de8c5e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RhYmxlOjc3OWViZTkxOGQwMTQ5YmJiY2FkOTZiNDc1OTMwYjI3L3RhYmxlcmFuZ2U6Nzc5ZWJlOTE4ZDAxNDliYmJjYWQ5NmI0NzU5MzBiMjdfNi0xLTEtMS0xODE2NA_6ef4edbb-26e6-4288-9edc-ac00a44e2587"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="idc1c646e04584219aac582f20b8676ad_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RhYmxlOjc3OWViZTkxOGQwMTQ5YmJiY2FkOTZiNDc1OTMwYjI3L3RhYmxlcmFuZ2U6Nzc5ZWJlOTE4ZDAxNDliYmJjYWQ5NmI0NzU5MzBiMjdfNi0zLTEtMS0xODE2NA_90e6bde0-8456-4d81-aaf6-d66528ba95cd"
      unitRef="usd">11800000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i707c13e32e584ee3a2051a60c642c899_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RhYmxlOjc3OWViZTkxOGQwMTQ5YmJiY2FkOTZiNDc1OTMwYjI3L3RhYmxlcmFuZ2U6Nzc5ZWJlOTE4ZDAxNDliYmJjYWQ5NmI0NzU5MzBiMjdfNi01LTEtMS0xODE2NA_4f5e1811-92c7-44ca-8c2f-74d83f3b2b52"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i47594399039d468c97b0901e9244c85e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RhYmxlOjc3OWViZTkxOGQwMTQ5YmJiY2FkOTZiNDc1OTMwYjI3L3RhYmxlcmFuZ2U6Nzc5ZWJlOTE4ZDAxNDliYmJjYWQ5NmI0NzU5MzBiMjdfNi03LTEtMS0xODE2NA_05b0bccd-6668-47af-96dc-6656ddf3f464"
      unitRef="usd">11800000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i81a717b368544963b5d0268a420c7e31_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RhYmxlOjc3OWViZTkxOGQwMTQ5YmJiY2FkOTZiNDc1OTMwYjI3L3RhYmxlcmFuZ2U6Nzc5ZWJlOTE4ZDAxNDliYmJjYWQ5NmI0NzU5MzBiMjdfNy0xLTEtMS0xODE2NA_4491f5dc-cd68-4e29-81d1-63529206a74f"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="if110d6f8bc9445f19d915e3c19311eb2_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RhYmxlOjc3OWViZTkxOGQwMTQ5YmJiY2FkOTZiNDc1OTMwYjI3L3RhYmxlcmFuZ2U6Nzc5ZWJlOTE4ZDAxNDliYmJjYWQ5NmI0NzU5MzBiMjdfNy0zLTEtMS0xODE2NA_37cdf108-45aa-47c9-8000-fb3398ee6ab6"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i353263ed75ed4422b659d68ccbb565d7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RhYmxlOjc3OWViZTkxOGQwMTQ5YmJiY2FkOTZiNDc1OTMwYjI3L3RhYmxlcmFuZ2U6Nzc5ZWJlOTE4ZDAxNDliYmJjYWQ5NmI0NzU5MzBiMjdfNy01LTEtMS0xODE2NA_e66108f6-3abe-4f65-af14-03c3b14eb4e9"
      unitRef="usd">10900000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i6f239555bbeb4f1085317b6f3100affb_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RhYmxlOjc3OWViZTkxOGQwMTQ5YmJiY2FkOTZiNDc1OTMwYjI3L3RhYmxlcmFuZ2U6Nzc5ZWJlOTE4ZDAxNDliYmJjYWQ5NmI0NzU5MzBiMjdfNy03LTEtMS0xODE2NA_74fb1e12-a975-4660-95f8-56edf9da2c00"
      unitRef="usd">10900000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:FairValueNetAssetLiability
      contextRef="i41e4b0464a314ee7a5506f2010385fab_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RhYmxlOjc3OWViZTkxOGQwMTQ5YmJiY2FkOTZiNDc1OTMwYjI3L3RhYmxlcmFuZ2U6Nzc5ZWJlOTE4ZDAxNDliYmJjYWQ5NmI0NzU5MzBiMjdfOC0xLTEtMS0xODE2NA_3ecbe33f-22de-4097-855a-3066dd848017"
      unitRef="usd">69100000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="i2460434fcbba45b1b2398bd2547de226_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RhYmxlOjc3OWViZTkxOGQwMTQ5YmJiY2FkOTZiNDc1OTMwYjI3L3RhYmxlcmFuZ2U6Nzc5ZWJlOTE4ZDAxNDliYmJjYWQ5NmI0NzU5MzBiMjdfOC0zLTEtMS0xODE2NA_843a4b69-fa0b-4000-9634-8a812c824c37"
      unitRef="usd">54700000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="i3f3a1bdca0f24500a339d8a108a0211f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RhYmxlOjc3OWViZTkxOGQwMTQ5YmJiY2FkOTZiNDc1OTMwYjI3L3RhYmxlcmFuZ2U6Nzc5ZWJlOTE4ZDAxNDliYmJjYWQ5NmI0NzU5MzBiMjdfOC01LTEtMS0xODE2NA_ee82d577-1939-4fab-8aad-a1f792498389"
      unitRef="usd">-10900000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RhYmxlOjc3OWViZTkxOGQwMTQ5YmJiY2FkOTZiNDc1OTMwYjI3L3RhYmxlcmFuZ2U6Nzc5ZWJlOTE4ZDAxNDliYmJjYWQ5NmI0NzU5MzBiMjdfOC03LTEtMS0xODE2NA_745e53bf-4431-4f24-921d-ea1e5df174e0"
      unitRef="usd">112900000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RleHRyZWdpb246MzQ4MWIzZWU0NWZjNDRiYTk0OThkMGEzNzJhMGYwM2NfNDczNg_2a7c9cf9-f56b-4044-9144-4849fb647afb">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The following table reconciles the change in the fair value of the contingent consideration during the periods presented:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Balance December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payment of contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Change in fair value recognized in the income statement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Translation adjustments recognized in other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Ending balance September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RhYmxlOmMxZjQzNjIzYjFkNjQwNWZhYzA3NGVlZmVmYjliMmQxL3RhYmxlcmFuZ2U6YzFmNDM2MjNiMWQ2NDA1ZmFjMDc0ZWVmZWZiOWIyZDFfMS0xLTEtMS0xODE2NA_54813767-8878-4119-8274-f56470ad34f6"
      unitRef="usd">10900000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RhYmxlOmMxZjQzNjIzYjFkNjQwNWZhYzA3NGVlZmVmYjliMmQxL3RhYmxlcmFuZ2U6YzFmNDM2MjNiMWQ2NDA1ZmFjMDc0ZWVmZWZiOWIyZDFfMi0xLTEtMS0xODE2NA_04a3205a-4c39-482f-8a19-c3bb51582113"
      unitRef="usd">3300000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RhYmxlOmMxZjQzNjIzYjFkNjQwNWZhYzA3NGVlZmVmYjliMmQxL3RhYmxlcmFuZ2U6YzFmNDM2MjNiMWQ2NDA1ZmFjMDc0ZWVmZWZiOWIyZDFfMy0xLTEtMS0xODE2NA_076a0166-ef93-49e7-bf15-ee7eae492838"
      unitRef="usd">-1700000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RhYmxlOmMxZjQzNjIzYjFkNjQwNWZhYzA3NGVlZmVmYjliMmQxL3RhYmxlcmFuZ2U6YzFmNDM2MjNiMWQ2NDA1ZmFjMDc0ZWVmZWZiOWIyZDFfNC0xLTEtMS0xODE2NA_a74937c0-8007-47b4-af81-4669ab214f87"
      unitRef="usd">500000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180My9mcmFnOjM0ODFiM2VlNDVmYzQ0YmE5NDk4ZDBhMzcyYTBmMDNjL3RhYmxlOmMxZjQzNjIzYjFkNjQwNWZhYzA3NGVlZmVmYjliMmQxL3RhYmxlcmFuZ2U6YzFmNDM2MjNiMWQ2NDA1ZmFjMDc0ZWVmZWZiOWIyZDFfNS0xLTEtMS0xODE2NA_9884ec9f-3236-4efe-9094-a9c85d18aac2"
      unitRef="usd">8800000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180Ni9mcmFnOmVjMGQzZWIyYTkwZjQzYzlhZjIxZTE5MzRhZjgwNzRlL3RleHRyZWdpb246ZWMwZDNlYjJhOTBmNDNjOWFmMjFlMTkzNGFmODA3NGVfNDU_e33c6453-7016-4a33-89ef-ea44e0339c6c">PROPERTY, PLANT AND EQUIPMENT, NET&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.226%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.511%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.513%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;September 30,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;38.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;35.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;110.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;117.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;148.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;153.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(105.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(112.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;43.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;40.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The change in equipment from December 31, 2020 to September 30, 2021 was primarily due to the sales of Myriad RBM, Inc. and select assets of the Myriad Autoimmune business. See Note 16 for additional information on these divestitures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.215%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three months ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Nine months ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180Ni9mcmFnOmVjMGQzZWIyYTkwZjQzYzlhZjIxZTE5MzRhZjgwNzRlL3RleHRyZWdpb246ZWMwZDNlYjJhOTBmNDNjOWFmMjFlMTkzNGFmODA3NGVfNDY_1a3847c8-7aff-4936-99d6-026bd25b3f0a">&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.226%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.511%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.513%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;September 30,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;38.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;35.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;110.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;117.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;148.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;153.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(105.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(112.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;43.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;40.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The change in equipment from December 31, 2020 to September 30, 2021 was primarily due to the sales of Myriad RBM, Inc. and select assets of the Myriad Autoimmune business. See Note 16 for additional information on these divestitures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.215%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three months ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Nine months ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i94b157c71c86440fa7ba1b5891dd3e43_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180Ni9mcmFnOmVjMGQzZWIyYTkwZjQzYzlhZjIxZTE5MzRhZjgwNzRlL3RhYmxlOmJjYzFkYzM5NDU3NjQ3ZTVhM2EyYzAxMjUwZTEwOTYzL3RhYmxlcmFuZ2U6YmNjMWRjMzk0NTc2NDdlNWEzYTJjMDEyNTBlMTA5NjNfMS0xLTEtMS0xODE2NA_4f17e341-411b-4d96-9c01-0559749ab01c"
      unitRef="usd">38100000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ifc0bbee828074f62b3cdac04425562c8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180Ni9mcmFnOmVjMGQzZWIyYTkwZjQzYzlhZjIxZTE5MzRhZjgwNzRlL3RhYmxlOmJjYzFkYzM5NDU3NjQ3ZTVhM2EyYzAxMjUwZTEwOTYzL3RhYmxlcmFuZ2U6YmNjMWRjMzk0NTc2NDdlNWEzYTJjMDEyNTBlMTA5NjNfMS0zLTEtMS0xODE2NA_a7019201-bbda-4781-9a2b-9d3d38da7993"
      unitRef="usd">35700000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i80977ee86e3c41ebb192c62d6bfce59a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180Ni9mcmFnOmVjMGQzZWIyYTkwZjQzYzlhZjIxZTE5MzRhZjgwNzRlL3RhYmxlOmJjYzFkYzM5NDU3NjQ3ZTVhM2EyYzAxMjUwZTEwOTYzL3RhYmxlcmFuZ2U6YmNjMWRjMzk0NTc2NDdlNWEzYTJjMDEyNTBlMTA5NjNfMi0xLTEtMS0xODE2NA_e79be712-9976-4fbb-8dd3-e62d0da413d7"
      unitRef="usd">110300000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i9ebba697932d49ea8da9c7220efb9033_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180Ni9mcmFnOmVjMGQzZWIyYTkwZjQzYzlhZjIxZTE5MzRhZjgwNzRlL3RhYmxlOmJjYzFkYzM5NDU3NjQ3ZTVhM2EyYzAxMjUwZTEwOTYzL3RhYmxlcmFuZ2U6YmNjMWRjMzk0NTc2NDdlNWEzYTJjMDEyNTBlMTA5NjNfMi0zLTEtMS0xODE2NA_e09d1acf-4ad8-48bb-93bb-5371c272e8aa"
      unitRef="usd">117900000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180Ni9mcmFnOmVjMGQzZWIyYTkwZjQzYzlhZjIxZTE5MzRhZjgwNzRlL3RhYmxlOmJjYzFkYzM5NDU3NjQ3ZTVhM2EyYzAxMjUwZTEwOTYzL3RhYmxlcmFuZ2U6YmNjMWRjMzk0NTc2NDdlNWEzYTJjMDEyNTBlMTA5NjNfMy0xLTEtMS0xODE2NA_de42e315-9c59-46c9-a89a-16dce3da2bf2"
      unitRef="usd">148400000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180Ni9mcmFnOmVjMGQzZWIyYTkwZjQzYzlhZjIxZTE5MzRhZjgwNzRlL3RhYmxlOmJjYzFkYzM5NDU3NjQ3ZTVhM2EyYzAxMjUwZTEwOTYzL3RhYmxlcmFuZ2U6YmNjMWRjMzk0NTc2NDdlNWEzYTJjMDEyNTBlMTA5NjNfMy0zLTEtMS0xODE2NA_d64d8bbd-315f-41d9-b7d3-d4d45379290f"
      unitRef="usd">153600000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180Ni9mcmFnOmVjMGQzZWIyYTkwZjQzYzlhZjIxZTE5MzRhZjgwNzRlL3RhYmxlOmJjYzFkYzM5NDU3NjQ3ZTVhM2EyYzAxMjUwZTEwOTYzL3RhYmxlcmFuZ2U6YmNjMWRjMzk0NTc2NDdlNWEzYTJjMDEyNTBlMTA5NjNfNC0xLTEtMS0xODE2NA_d19361de-ab9d-4f00-9859-d9a04465fea7"
      unitRef="usd">105000000.0</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180Ni9mcmFnOmVjMGQzZWIyYTkwZjQzYzlhZjIxZTE5MzRhZjgwNzRlL3RhYmxlOmJjYzFkYzM5NDU3NjQ3ZTVhM2EyYzAxMjUwZTEwOTYzL3RhYmxlcmFuZ2U6YmNjMWRjMzk0NTc2NDdlNWEzYTJjMDEyNTBlMTA5NjNfNC0zLTEtMS0xODE2NA_31ccc27a-4650-48c0-b8b4-68cc5ff7b8e9"
      unitRef="usd">112900000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180Ni9mcmFnOmVjMGQzZWIyYTkwZjQzYzlhZjIxZTE5MzRhZjgwNzRlL3RhYmxlOmJjYzFkYzM5NDU3NjQ3ZTVhM2EyYzAxMjUwZTEwOTYzL3RhYmxlcmFuZ2U6YmNjMWRjMzk0NTc2NDdlNWEzYTJjMDEyNTBlMTA5NjNfNS0xLTEtMS0xODE2NA_3c1c6290-b280-47e5-b163-38cfa87f029e"
      unitRef="usd">43400000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180Ni9mcmFnOmVjMGQzZWIyYTkwZjQzYzlhZjIxZTE5MzRhZjgwNzRlL3RhYmxlOmJjYzFkYzM5NDU3NjQ3ZTVhM2EyYzAxMjUwZTEwOTYzL3RhYmxlcmFuZ2U6YmNjMWRjMzk0NTc2NDdlNWEzYTJjMDEyNTBlMTA5NjNfNS0zLTEtMS0xODE2NA_30d8a46e-5bc1-4c0d-af21-53366601947a"
      unitRef="usd">40700000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180Ni9mcmFnOmVjMGQzZWIyYTkwZjQzYzlhZjIxZTE5MzRhZjgwNzRlL3RhYmxlOmExNmNmNzJhZGIzNTQ2YjQ5MGFjZDM4YTVhMzZlNzA1L3RhYmxlcmFuZ2U6YTE2Y2Y3MmFkYjM1NDZiNDkwYWNkMzhhNWEzNmU3MDVfMi0xLTEtMS0xODE2NA_e9e2a9ea-31b6-44c5-9cd4-b51564574d64"
      unitRef="usd">2600000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="ic2c3e03438af4889ac973627c642f5ec_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180Ni9mcmFnOmVjMGQzZWIyYTkwZjQzYzlhZjIxZTE5MzRhZjgwNzRlL3RhYmxlOmExNmNmNzJhZGIzNTQ2YjQ5MGFjZDM4YTVhMzZlNzA1L3RhYmxlcmFuZ2U6YTE2Y2Y3MmFkYjM1NDZiNDkwYWNkMzhhNWEzNmU3MDVfMi0zLTEtMS0xODE2NA_6fc5808c-42b0-45ad-8aa2-6e825f36876e"
      unitRef="usd">2400000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180Ni9mcmFnOmVjMGQzZWIyYTkwZjQzYzlhZjIxZTE5MzRhZjgwNzRlL3RhYmxlOmExNmNmNzJhZGIzNTQ2YjQ5MGFjZDM4YTVhMzZlNzA1L3RhYmxlcmFuZ2U6YTE2Y2Y3MmFkYjM1NDZiNDkwYWNkMzhhNWEzNmU3MDVfMi01LTEtMS0xODE2NA_307668c4-9b33-47aa-9dba-00068346f9ae"
      unitRef="usd">8900000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180Ni9mcmFnOmVjMGQzZWIyYTkwZjQzYzlhZjIxZTE5MzRhZjgwNzRlL3RhYmxlOmExNmNmNzJhZGIzNTQ2YjQ5MGFjZDM4YTVhMzZlNzA1L3RhYmxlcmFuZ2U6YTE2Y2Y3MmFkYjM1NDZiNDkwYWNkMzhhNWEzNmU3MDVfMi03LTEtMS0xODE2NA_aabb2e33-fdfd-47ee-9b2d-06d563c147b0"
      unitRef="usd">7500000</us-gaap:Depreciation>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180OS9mcmFnOjhjMzIzNjRiN2RmMDQyNTNiMTQzYmE5ZmQ4MzJhYTFhL3RleHRyZWdpb246OGMzMjM2NGI3ZGYwNDI1M2IxNDNiYTlmZDgzMmFhMWFfOTIy_0e4a21db-8617-480c-b729-7dc8b91bca0d">GOODWILL AND INTANGIBLE ASSETS&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the changes in the carrying amount of goodwill for the nine months ended September&#160;30, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.321%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.759%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.636%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.716%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Diagnostic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;272.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;329.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Divestitures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(56.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(88.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;During the quarter ended September 30, 2021, the Company completed the sale of Myriad RBM, Inc. and select operating assets and intellectual property, including the Vectra&#xae; test, from the Myriad Autoimmune business unit. See Note 16 for additional information on these divestitures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets have primarily consisted of amortizable assets of purchased licenses and technologies, customer relationships, and trade names as well as non-amortizable intangible assets of in-process technologies and research and development.&#160;As of September 30, 2021, the Company's intangible assets consist of only purchased licenses and technologies due to the completion of the sales of Myriad RBM, Inc. and select operating assets and intellectual property, including the Vectra&#xae; test, from the Myriad Autoimmune business unit. In connection with these sales, the Company sold $199.1 million in purchased licenses and technologies, $4.8 million in-process research and development intangible assets, $4.7 million in customer relationships, and $3.0 million in trademarks, resulting in an aggregate decrease of intangible assets of $120.0 million, net of $91.6 million in accumulated amortization. See Note 16 for additional information on these divestitures.  The following summarizes the amounts reported as intangible assets:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At September 30, 2021:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Purchased licenses and technologies&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;617.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(202.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;414.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total amortized intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;617.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(202.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;414.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;617.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(202.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;414.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December 31, 2020:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Purchased licenses and technologies&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;818.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(248.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;570.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(4.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total amortized intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;825.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(254.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;571.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In-process research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total unamortized intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;830.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(254.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;576.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded amortization expense during the respective periods for these intangible assets as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three months ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Nine months ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;40.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;45.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180OS9mcmFnOjhjMzIzNjRiN2RmMDQyNTNiMTQzYmE5ZmQ4MzJhYTFhL3RleHRyZWdpb246OGMzMjM2NGI3ZGYwNDI1M2IxNDNiYTlmZDgzMmFhMWFfOTIz_f7c7623e-beb4-4b63-8cb9-1fdbbc429454">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the changes in the carrying amount of goodwill for the nine months ended September&#160;30, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.321%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.759%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.636%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.716%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Diagnostic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;272.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;329.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Divestitures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(56.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(88.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="i38ac573972c0484c9db1cb89e06de15a_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180OS9mcmFnOjhjMzIzNjRiN2RmMDQyNTNiMTQzYmE5ZmQ4MzJhYTFhL3RhYmxlOjYzZTdhYmJlOGEzMTQ3Mjc5NTk3NDg3MmMxY2MzYTAyL3RhYmxlcmFuZ2U6NjNlN2FiYmU4YTMxNDcyNzk1OTc0ODcyYzFjYzNhMDJfMS0xLTEtMS0xODE2NA_2ea5bdfd-8bea-4e05-85a8-e8537022c706"
      unitRef="usd">272300000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ibde16baaa28343bd960624b1aaf1ae77_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180OS9mcmFnOjhjMzIzNjRiN2RmMDQyNTNiMTQzYmE5ZmQ4MzJhYTFhL3RhYmxlOjYzZTdhYmJlOGEzMTQ3Mjc5NTk3NDg3MmMxY2MzYTAyL3RhYmxlcmFuZ2U6NjNlN2FiYmU4YTMxNDcyNzk1OTc0ODcyYzFjYzNhMDJfMS0zLTEtMS0xODE2NA_52b022a4-be6b-497b-a6a8-de5718fec801"
      unitRef="usd">56900000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180OS9mcmFnOjhjMzIzNjRiN2RmMDQyNTNiMTQzYmE5ZmQ4MzJhYTFhL3RhYmxlOjYzZTdhYmJlOGEzMTQ3Mjc5NTk3NDg3MmMxY2MzYTAyL3RhYmxlcmFuZ2U6NjNlN2FiYmU4YTMxNDcyNzk1OTc0ODcyYzFjYzNhMDJfMS01LTEtMS0xODE2NA_e54fffbf-a7ea-4557-ab7e-293e58b4dc89"
      unitRef="usd">329200000</us-gaap:Goodwill>
    <us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit
      contextRef="i90324a4d56084a4391c5819f5c839f86_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180OS9mcmFnOjhjMzIzNjRiN2RmMDQyNTNiMTQzYmE5ZmQ4MzJhYTFhL3RhYmxlOjYzZTdhYmJlOGEzMTQ3Mjc5NTk3NDg3MmMxY2MzYTAyL3RhYmxlcmFuZ2U6NjNlN2FiYmU4YTMxNDcyNzk1OTc0ODcyYzFjYzNhMDJfMi0xLTEtMS0xODE2NA_41b78cc1-8ac7-4130-9735-141fc5a231ad"
      unitRef="usd">31600000</us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit>
    <us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit
      contextRef="iee82af509aa24703b7bb72450fba9e9f_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180OS9mcmFnOjhjMzIzNjRiN2RmMDQyNTNiMTQzYmE5ZmQ4MzJhYTFhL3RhYmxlOjYzZTdhYmJlOGEzMTQ3Mjc5NTk3NDg3MmMxY2MzYTAyL3RhYmxlcmFuZ2U6NjNlN2FiYmU4YTMxNDcyNzk1OTc0ODcyYzFjYzNhMDJfMi0zLTEtMS0xODE2NA_152b89f6-7b79-407e-9a5f-450f5674937a"
      unitRef="usd">56900000</us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit>
    <us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180OS9mcmFnOjhjMzIzNjRiN2RmMDQyNTNiMTQzYmE5ZmQ4MzJhYTFhL3RhYmxlOjYzZTdhYmJlOGEzMTQ3Mjc5NTk3NDg3MmMxY2MzYTAyL3RhYmxlcmFuZ2U6NjNlN2FiYmU4YTMxNDcyNzk1OTc0ODcyYzFjYzNhMDJfMi01LTEtMS0xODE2NA_d4b15feb-59d3-46b0-b990-c225a8c33f53"
      unitRef="usd">88500000</us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i90324a4d56084a4391c5819f5c839f86_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180OS9mcmFnOjhjMzIzNjRiN2RmMDQyNTNiMTQzYmE5ZmQ4MzJhYTFhL3RhYmxlOjYzZTdhYmJlOGEzMTQ3Mjc5NTk3NDg3MmMxY2MzYTAyL3RhYmxlcmFuZ2U6NjNlN2FiYmU4YTMxNDcyNzk1OTc0ODcyYzFjYzNhMDJfMy0xLTEtMS0xODE2NA_0f049354-526a-4a75-8924-868c579ea697"
      unitRef="usd">-1000000.0</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="iee82af509aa24703b7bb72450fba9e9f_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180OS9mcmFnOjhjMzIzNjRiN2RmMDQyNTNiMTQzYmE5ZmQ4MzJhYTFhL3RhYmxlOjYzZTdhYmJlOGEzMTQ3Mjc5NTk3NDg3MmMxY2MzYTAyL3RhYmxlcmFuZ2U6NjNlN2FiYmU4YTMxNDcyNzk1OTc0ODcyYzFjYzNhMDJfMy0zLTEtMS0xODE2NA_6630deba-191a-4809-8cfe-7111155a5077"
      unitRef="usd">0</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180OS9mcmFnOjhjMzIzNjRiN2RmMDQyNTNiMTQzYmE5ZmQ4MzJhYTFhL3RhYmxlOjYzZTdhYmJlOGEzMTQ3Mjc5NTk3NDg3MmMxY2MzYTAyL3RhYmxlcmFuZ2U6NjNlN2FiYmU4YTMxNDcyNzk1OTc0ODcyYzFjYzNhMDJfMy01LTEtMS0xODE2NA_e9a62ca3-b59b-429c-822a-1f30f3704af6"
      unitRef="usd">-1000000.0</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:Goodwill
      contextRef="i6edc95151d8a4e0d834e3ba92ab2a90b_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180OS9mcmFnOjhjMzIzNjRiN2RmMDQyNTNiMTQzYmE5ZmQ4MzJhYTFhL3RhYmxlOjYzZTdhYmJlOGEzMTQ3Mjc5NTk3NDg3MmMxY2MzYTAyL3RhYmxlcmFuZ2U6NjNlN2FiYmU4YTMxNDcyNzk1OTc0ODcyYzFjYzNhMDJfNC0xLTEtMS0xODE2NA_79e66cc5-0377-40fb-898d-a7da913fc921"
      unitRef="usd">239700000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i579d27c0f10940d8a1ceface7d29c915_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180OS9mcmFnOjhjMzIzNjRiN2RmMDQyNTNiMTQzYmE5ZmQ4MzJhYTFhL3RhYmxlOjYzZTdhYmJlOGEzMTQ3Mjc5NTk3NDg3MmMxY2MzYTAyL3RhYmxlcmFuZ2U6NjNlN2FiYmU4YTMxNDcyNzk1OTc0ODcyYzFjYzNhMDJfNC0zLTEtMS0xODE2NA_557eb7f0-0249-4c19-98a3-e1c6bc6c2f8b"
      unitRef="usd">0</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180OS9mcmFnOjhjMzIzNjRiN2RmMDQyNTNiMTQzYmE5ZmQ4MzJhYTFhL3RhYmxlOjYzZTdhYmJlOGEzMTQ3Mjc5NTk3NDg3MmMxY2MzYTAyL3RhYmxlcmFuZ2U6NjNlN2FiYmU4YTMxNDcyNzk1OTc0ODcyYzFjYzNhMDJfNC01LTEtMS0xODE2NA_2421b65b-45ca-4a82-ac8e-a8926b36f647"
      unitRef="usd">239700000</us-gaap:Goodwill>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent
      contextRef="i7b032b60a10145f682547141173ac516_I20210701"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180OS9mcmFnOjhjMzIzNjRiN2RmMDQyNTNiMTQzYmE5ZmQ4MzJhYTFhL3RleHRyZWdpb246OGMzMjM2NGI3ZGYwNDI1M2IxNDNiYTlmZDgzMmFhMWFfMTA5OTUxMTYzMDc0MQ_ae5f046f-113d-48ea-8e73-4d79dc2ad99b"
      unitRef="usd">199100000</us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent
      contextRef="id4c41467e09242c3a31f5150b7bc13fe_I20210701"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180OS9mcmFnOjhjMzIzNjRiN2RmMDQyNTNiMTQzYmE5ZmQ4MzJhYTFhL3RleHRyZWdpb246OGMzMjM2NGI3ZGYwNDI1M2IxNDNiYTlmZDgzMmFhMWFfMTA5OTUxMTYzMDY5NA_71f4b702-79f5-451e-a893-86d1e80e38a9"
      unitRef="usd">4800000</us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent
      contextRef="i2e1dbd573f0047b298ea8f3eb9afc6cf_I20210701"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180OS9mcmFnOjhjMzIzNjRiN2RmMDQyNTNiMTQzYmE5ZmQ4MzJhYTFhL3RleHRyZWdpb246OGMzMjM2NGI3ZGYwNDI1M2IxNDNiYTlmZDgzMmFhMWFfMTA5OTUxMTYzMDcyNA_2f2a7fd6-17d7-4c4d-b76b-7fb82434948e"
      unitRef="usd">4700000</us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent
      contextRef="i5951f47f63a2499780fd5e72af21ade5_I20210701"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180OS9mcmFnOjhjMzIzNjRiN2RmMDQyNTNiMTQzYmE5ZmQ4MzJhYTFhL3RleHRyZWdpb246OGMzMjM2NGI3ZGYwNDI1M2IxNDNiYTlmZDgzMmFhMWFfMTA5OTUxMTYzMDcwOQ_ce6cc8cb-41b7-41c7-a4fd-8c6286259b51"
      unitRef="usd">3000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent>
    <mygn:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNetNoncurrent
      contextRef="i5a2255bae3b5469a85c3193359dabe47_I20210701"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180OS9mcmFnOjhjMzIzNjRiN2RmMDQyNTNiMTQzYmE5ZmQ4MzJhYTFhL3RleHRyZWdpb246OGMzMjM2NGI3ZGYwNDI1M2IxNDNiYTlmZDgzMmFhMWFfMTA5OTUxMTYzMDY3OQ_857b5bbc-0111-49a7-9ccb-b5f3e92ebf1e"
      unitRef="usd">120000000</mygn:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNetNoncurrent>
    <mygn:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsAccumulatedAmortizationNoncurrent
      contextRef="i5a2255bae3b5469a85c3193359dabe47_I20210701"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180OS9mcmFnOjhjMzIzNjRiN2RmMDQyNTNiMTQzYmE5ZmQ4MzJhYTFhL3RleHRyZWdpb246OGMzMjM2NGI3ZGYwNDI1M2IxNDNiYTlmZDgzMmFhMWFfMTA5OTUxMTYzMDY2Nw_3880ea18-baee-486f-8228-706c03687fac"
      unitRef="usd">91600000</mygn:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsAccumulatedAmortizationNoncurrent>
    <us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180OS9mcmFnOjhjMzIzNjRiN2RmMDQyNTNiMTQzYmE5ZmQ4MzJhYTFhL3RleHRyZWdpb246OGMzMjM2NGI3ZGYwNDI1M2IxNDNiYTlmZDgzMmFhMWFfOTI0_9235072f-e002-43be-8d4a-17836dadcd4b">The following summarizes the amounts reported as intangible assets:&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At September 30, 2021:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Purchased licenses and technologies&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;617.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(202.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;414.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total amortized intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;617.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(202.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;414.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;617.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(202.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;414.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December 31, 2020:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Purchased licenses and technologies&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;818.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(248.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;570.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(4.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total amortized intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;825.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(254.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;571.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In-process research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total unamortized intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;830.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(254.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;576.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180OS9mcmFnOjhjMzIzNjRiN2RmMDQyNTNiMTQzYmE5ZmQ4MzJhYTFhL3RleHRyZWdpb246OGMzMjM2NGI3ZGYwNDI1M2IxNDNiYTlmZDgzMmFhMWFfOTI0_b9169103-876c-4c60-9ec9-547f481e1cf7">The following summarizes the amounts reported as intangible assets:&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At September 30, 2021:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Purchased licenses and technologies&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;617.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(202.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;414.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total amortized intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;617.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(202.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;414.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;617.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(202.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;414.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December 31, 2020:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Purchased licenses and technologies&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;818.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(248.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;570.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(4.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total amortized intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;825.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(254.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;571.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In-process research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total unamortized intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;830.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(254.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;576.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ie644acbcb7a046da9f6a9073e27ef84f_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180OS9mcmFnOjhjMzIzNjRiN2RmMDQyNTNiMTQzYmE5ZmQ4MzJhYTFhL3RhYmxlOmMxNjg1ZDJiNmFjNjQ2MWRhYjIzMDgwYjAzNmYxY2E5L3RhYmxlcmFuZ2U6YzE2ODVkMmI2YWM2NDYxZGFiMjMwODBiMDM2ZjFjYTlfMi0xLTEtMS0xODE2NA_130e7fdb-e054-4961-b10a-5c1beed12b6d"
      unitRef="usd">617400000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ie644acbcb7a046da9f6a9073e27ef84f_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180OS9mcmFnOjhjMzIzNjRiN2RmMDQyNTNiMTQzYmE5ZmQ4MzJhYTFhL3RhYmxlOmMxNjg1ZDJiNmFjNjQ2MWRhYjIzMDgwYjAzNmYxY2E5L3RhYmxlcmFuZ2U6YzE2ODVkMmI2YWM2NDYxZGFiMjMwODBiMDM2ZjFjYTlfMi0zLTEtMS0xODE2NA_5603dde6-82ca-47db-a828-a24739007ac7"
      unitRef="usd">202600000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ie644acbcb7a046da9f6a9073e27ef84f_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180OS9mcmFnOjhjMzIzNjRiN2RmMDQyNTNiMTQzYmE5ZmQ4MzJhYTFhL3RhYmxlOmMxNjg1ZDJiNmFjNjQ2MWRhYjIzMDgwYjAzNmYxY2E5L3RhYmxlcmFuZ2U6YzE2ODVkMmI2YWM2NDYxZGFiMjMwODBiMDM2ZjFjYTlfMi01LTEtMS0xODE2NA_6dcee605-fe22-4c5d-b367-4076c6bc439a"
      unitRef="usd">414800000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180OS9mcmFnOjhjMzIzNjRiN2RmMDQyNTNiMTQzYmE5ZmQ4MzJhYTFhL3RhYmxlOmMxNjg1ZDJiNmFjNjQ2MWRhYjIzMDgwYjAzNmYxY2E5L3RhYmxlcmFuZ2U6YzE2ODVkMmI2YWM2NDYxZGFiMjMwODBiMDM2ZjFjYTlfNS0xLTEtMS0xODE2NA_04bc6b3e-3e29-449b-9a73-313cdd93929f"
      unitRef="usd">617400000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180OS9mcmFnOjhjMzIzNjRiN2RmMDQyNTNiMTQzYmE5ZmQ4MzJhYTFhL3RhYmxlOmMxNjg1ZDJiNmFjNjQ2MWRhYjIzMDgwYjAzNmYxY2E5L3RhYmxlcmFuZ2U6YzE2ODVkMmI2YWM2NDYxZGFiMjMwODBiMDM2ZjFjYTlfNS0zLTEtMS0xODE2NA_269974da-5082-4369-ae51-eca86f8fce62"
      unitRef="usd">202600000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180OS9mcmFnOjhjMzIzNjRiN2RmMDQyNTNiMTQzYmE5ZmQ4MzJhYTFhL3RhYmxlOmMxNjg1ZDJiNmFjNjQ2MWRhYjIzMDgwYjAzNmYxY2E5L3RhYmxlcmFuZ2U6YzE2ODVkMmI2YWM2NDYxZGFiMjMwODBiMDM2ZjFjYTlfNS01LTEtMS0xODE2NA_9802d9c6-2407-45a4-b86e-a66ee04846df"
      unitRef="usd">414800000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180OS9mcmFnOjhjMzIzNjRiN2RmMDQyNTNiMTQzYmE5ZmQ4MzJhYTFhL3RhYmxlOmMxNjg1ZDJiNmFjNjQ2MWRhYjIzMDgwYjAzNmYxY2E5L3RhYmxlcmFuZ2U6YzE2ODVkMmI2YWM2NDYxZGFiMjMwODBiMDM2ZjFjYTlfOS0xLTEtMS0xODE2NA_7f3edea7-f9ca-4c71-a99d-1b81188db931"
      unitRef="usd">617400000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180OS9mcmFnOjhjMzIzNjRiN2RmMDQyNTNiMTQzYmE5ZmQ4MzJhYTFhL3RhYmxlOmMxNjg1ZDJiNmFjNjQ2MWRhYjIzMDgwYjAzNmYxY2E5L3RhYmxlcmFuZ2U6YzE2ODVkMmI2YWM2NDYxZGFiMjMwODBiMDM2ZjFjYTlfOS0zLTEtMS0xODE2NA_93477223-ac5e-4484-b7d8-bcf8561429c6"
      unitRef="usd">202600000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180OS9mcmFnOjhjMzIzNjRiN2RmMDQyNTNiMTQzYmE5ZmQ4MzJhYTFhL3RhYmxlOmMxNjg1ZDJiNmFjNjQ2MWRhYjIzMDgwYjAzNmYxY2E5L3RhYmxlcmFuZ2U6YzE2ODVkMmI2YWM2NDYxZGFiMjMwODBiMDM2ZjFjYTlfOS01LTEtMS0xODE2NA_a6585ddd-e3eb-4211-b462-af893ee75ee7"
      unitRef="usd">414800000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ia5b94635b0ee49179e69f248a30a5218_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180OS9mcmFnOjhjMzIzNjRiN2RmMDQyNTNiMTQzYmE5ZmQ4MzJhYTFhL3RhYmxlOmMzMzg4YWQ3YmRmNTRkNjE5ODg4ZGU3YzE1Zjk1Nzg4L3RhYmxlcmFuZ2U6YzMzODhhZDdiZGY1NGQ2MTk4ODhkZTdjMTVmOTU3ODhfMi0xLTEtMS0xODE2NA_41cb013f-819a-4d21-9ae9-b6bd843f6b18"
      unitRef="usd">818200000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ia5b94635b0ee49179e69f248a30a5218_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180OS9mcmFnOjhjMzIzNjRiN2RmMDQyNTNiMTQzYmE5ZmQ4MzJhYTFhL3RhYmxlOmMzMzg4YWQ3YmRmNTRkNjE5ODg4ZGU3YzE1Zjk1Nzg4L3RhYmxlcmFuZ2U6YzMzODhhZDdiZGY1NGQ2MTk4ODhkZTdjMTVmOTU3ODhfMi0zLTEtMS0xODE2NA_832c63f5-d4ef-4547-9e46-043dd0aa2d56"
      unitRef="usd">248200000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ia5b94635b0ee49179e69f248a30a5218_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180OS9mcmFnOjhjMzIzNjRiN2RmMDQyNTNiMTQzYmE5ZmQ4MzJhYTFhL3RhYmxlOmMzMzg4YWQ3YmRmNTRkNjE5ODg4ZGU3YzE1Zjk1Nzg4L3RhYmxlcmFuZ2U6YzMzODhhZDdiZGY1NGQ2MTk4ODhkZTdjMTVmOTU3ODhfMi01LTEtMS0xODE2NA_fdbf1655-b859-472e-a7fd-a81d7a6f3ebd"
      unitRef="usd">570000000.0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i2b16ee9a891f452fbef45868672b00d6_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180OS9mcmFnOjhjMzIzNjRiN2RmMDQyNTNiMTQzYmE5ZmQ4MzJhYTFhL3RhYmxlOmMzMzg4YWQ3YmRmNTRkNjE5ODg4ZGU3YzE1Zjk1Nzg4L3RhYmxlcmFuZ2U6YzMzODhhZDdiZGY1NGQ2MTk4ODhkZTdjMTVmOTU3ODhfMy0xLTEtMS0xODE2NA_07634651-cdc5-49a1-a715-a3a9435fd93a"
      unitRef="usd">4700000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i2b16ee9a891f452fbef45868672b00d6_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180OS9mcmFnOjhjMzIzNjRiN2RmMDQyNTNiMTQzYmE5ZmQ4MzJhYTFhL3RhYmxlOmMzMzg4YWQ3YmRmNTRkNjE5ODg4ZGU3YzE1Zjk1Nzg4L3RhYmxlcmFuZ2U6YzMzODhhZDdiZGY1NGQ2MTk4ODhkZTdjMTVmOTU3ODhfMy0zLTEtMS0xODE2NA_723e6e80-ba5d-49eb-abb8-370561d09ea6"
      unitRef="usd">4500000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i2b16ee9a891f452fbef45868672b00d6_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180OS9mcmFnOjhjMzIzNjRiN2RmMDQyNTNiMTQzYmE5ZmQ4MzJhYTFhL3RhYmxlOmMzMzg4YWQ3YmRmNTRkNjE5ODg4ZGU3YzE1Zjk1Nzg4L3RhYmxlcmFuZ2U6YzMzODhhZDdiZGY1NGQ2MTk4ODhkZTdjMTVmOTU3ODhfMy01LTEtMS0xODE2NA_89af134b-171c-4843-8897-f8b6a7299c24"
      unitRef="usd">200000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i0cc0c3bdd23f47d483982f371199a356_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180OS9mcmFnOjhjMzIzNjRiN2RmMDQyNTNiMTQzYmE5ZmQ4MzJhYTFhL3RhYmxlOmMzMzg4YWQ3YmRmNTRkNjE5ODg4ZGU3YzE1Zjk1Nzg4L3RhYmxlcmFuZ2U6YzMzODhhZDdiZGY1NGQ2MTk4ODhkZTdjMTVmOTU3ODhfNC0xLTEtMS0xODE2NA_c1bfe3ee-fbcb-41f5-b223-f870fa3535da"
      unitRef="usd">3000000.0</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i0cc0c3bdd23f47d483982f371199a356_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180OS9mcmFnOjhjMzIzNjRiN2RmMDQyNTNiMTQzYmE5ZmQ4MzJhYTFhL3RhYmxlOmMzMzg4YWQ3YmRmNTRkNjE5ODg4ZGU3YzE1Zjk1Nzg4L3RhYmxlcmFuZ2U6YzMzODhhZDdiZGY1NGQ2MTk4ODhkZTdjMTVmOTU3ODhfNC0zLTEtMS0xODE2NA_42a28c22-9c61-454d-a7b1-8f4aec0c54b8"
      unitRef="usd">1500000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i0cc0c3bdd23f47d483982f371199a356_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180OS9mcmFnOjhjMzIzNjRiN2RmMDQyNTNiMTQzYmE5ZmQ4MzJhYTFhL3RhYmxlOmMzMzg4YWQ3YmRmNTRkNjE5ODg4ZGU3YzE1Zjk1Nzg4L3RhYmxlcmFuZ2U6YzMzODhhZDdiZGY1NGQ2MTk4ODhkZTdjMTVmOTU3ODhfNC01LTEtMS0xODE2NA_fdac76ca-1fc9-45f0-b1c4-312cbb1cd00f"
      unitRef="usd">1500000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180OS9mcmFnOjhjMzIzNjRiN2RmMDQyNTNiMTQzYmE5ZmQ4MzJhYTFhL3RhYmxlOmMzMzg4YWQ3YmRmNTRkNjE5ODg4ZGU3YzE1Zjk1Nzg4L3RhYmxlcmFuZ2U6YzMzODhhZDdiZGY1NGQ2MTk4ODhkZTdjMTVmOTU3ODhfNS0xLTEtMS0xODE2NA_fa8cbb6c-c99a-436d-9a82-0cb7df3534f9"
      unitRef="usd">825900000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180OS9mcmFnOjhjMzIzNjRiN2RmMDQyNTNiMTQzYmE5ZmQ4MzJhYTFhL3RhYmxlOmMzMzg4YWQ3YmRmNTRkNjE5ODg4ZGU3YzE1Zjk1Nzg4L3RhYmxlcmFuZ2U6YzMzODhhZDdiZGY1NGQ2MTk4ODhkZTdjMTVmOTU3ODhfNS0zLTEtMS0xODE2NA_fb4aa941-6fc4-40d5-945c-b1d85a3e777e"
      unitRef="usd">254200000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180OS9mcmFnOjhjMzIzNjRiN2RmMDQyNTNiMTQzYmE5ZmQ4MzJhYTFhL3RhYmxlOmMzMzg4YWQ3YmRmNTRkNjE5ODg4ZGU3YzE1Zjk1Nzg4L3RhYmxlcmFuZ2U6YzMzODhhZDdiZGY1NGQ2MTk4ODhkZTdjMTVmOTU3ODhfNS01LTEtMS0xODE2NA_1f9fabee-bb4f-4507-b8fc-82789bf76bdf"
      unitRef="usd">571700000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="id685e06a6fe54277a65c4a43bf1ca98b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180OS9mcmFnOjhjMzIzNjRiN2RmMDQyNTNiMTQzYmE5ZmQ4MzJhYTFhL3RhYmxlOmMzMzg4YWQ3YmRmNTRkNjE5ODg4ZGU3YzE1Zjk1Nzg4L3RhYmxlcmFuZ2U6YzMzODhhZDdiZGY1NGQ2MTk4ODhkZTdjMTVmOTU3ODhfNi0xLTEtMS0xODE2NA_0fb8f3a0-1069-4462-8b31-652e2c2d817b"
      unitRef="usd">4800000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="id685e06a6fe54277a65c4a43bf1ca98b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180OS9mcmFnOjhjMzIzNjRiN2RmMDQyNTNiMTQzYmE5ZmQ4MzJhYTFhL3RhYmxlOmMzMzg4YWQ3YmRmNTRkNjE5ODg4ZGU3YzE1Zjk1Nzg4L3RhYmxlcmFuZ2U6YzMzODhhZDdiZGY1NGQ2MTk4ODhkZTdjMTVmOTU3ODhfNi01LTEtMS0xODE2NA_b613a390-b7f5-47e5-95a3-5d791d8833d0"
      unitRef="usd">4800000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180OS9mcmFnOjhjMzIzNjRiN2RmMDQyNTNiMTQzYmE5ZmQ4MzJhYTFhL3RhYmxlOmMzMzg4YWQ3YmRmNTRkNjE5ODg4ZGU3YzE1Zjk1Nzg4L3RhYmxlcmFuZ2U6YzMzODhhZDdiZGY1NGQ2MTk4ODhkZTdjMTVmOTU3ODhfNy0xLTEtMS0xODE2NA_644bdd70-f085-4990-9552-719a4e963402"
      unitRef="usd">4800000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180OS9mcmFnOjhjMzIzNjRiN2RmMDQyNTNiMTQzYmE5ZmQ4MzJhYTFhL3RhYmxlOmMzMzg4YWQ3YmRmNTRkNjE5ODg4ZGU3YzE1Zjk1Nzg4L3RhYmxlcmFuZ2U6YzMzODhhZDdiZGY1NGQ2MTk4ODhkZTdjMTVmOTU3ODhfNy01LTEtMS0xODE2NA_0366a48f-890b-4809-bbdf-6343e2d7207b"
      unitRef="usd">4800000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180OS9mcmFnOjhjMzIzNjRiN2RmMDQyNTNiMTQzYmE5ZmQ4MzJhYTFhL3RhYmxlOmMzMzg4YWQ3YmRmNTRkNjE5ODg4ZGU3YzE1Zjk1Nzg4L3RhYmxlcmFuZ2U6YzMzODhhZDdiZGY1NGQ2MTk4ODhkZTdjMTVmOTU3ODhfOC0xLTEtMS0xODE2NA_beb79bb2-7463-4936-a8c5-1ae6d66dcc87"
      unitRef="usd">830700000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180OS9mcmFnOjhjMzIzNjRiN2RmMDQyNTNiMTQzYmE5ZmQ4MzJhYTFhL3RhYmxlOmMzMzg4YWQ3YmRmNTRkNjE5ODg4ZGU3YzE1Zjk1Nzg4L3RhYmxlcmFuZ2U6YzMzODhhZDdiZGY1NGQ2MTk4ODhkZTdjMTVmOTU3ODhfOC0zLTEtMS0xODE2NA_672b98f8-d19b-4e75-a6a0-bc8b1f83bdcd"
      unitRef="usd">254200000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180OS9mcmFnOjhjMzIzNjRiN2RmMDQyNTNiMTQzYmE5ZmQ4MzJhYTFhL3RhYmxlOmMzMzg4YWQ3YmRmNTRkNjE5ODg4ZGU3YzE1Zjk1Nzg4L3RhYmxlcmFuZ2U6YzMzODhhZDdiZGY1NGQ2MTk4ODhkZTdjMTVmOTU3ODhfOC01LTEtMS0xODE2NA_da155d0d-a32a-4ba4-b495-9f71e41a388a"
      unitRef="usd">576500000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180OS9mcmFnOjhjMzIzNjRiN2RmMDQyNTNiMTQzYmE5ZmQ4MzJhYTFhL3RleHRyZWdpb246OGMzMjM2NGI3ZGYwNDI1M2IxNDNiYTlmZDgzMmFhMWFfOTIx_a02e6c4b-a772-4586-a9e6-124d078824b2">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded amortization expense during the respective periods for these intangible assets as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three months ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Nine months ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;40.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;45.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180OS9mcmFnOjhjMzIzNjRiN2RmMDQyNTNiMTQzYmE5ZmQ4MzJhYTFhL3RhYmxlOjVlMWU3MzJmMmZiMzQ1M2M5YmY5OWNkZWUyMjdiODBiL3RhYmxlcmFuZ2U6NWUxZTczMmYyZmIzNDUzYzliZjk5Y2RlZTIyN2I4MGJfMi0xLTEtMS0xODE2NA_dda9224b-9761-49f0-9b19-342da92c2f14"
      unitRef="usd">11600000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ic2c3e03438af4889ac973627c642f5ec_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180OS9mcmFnOjhjMzIzNjRiN2RmMDQyNTNiMTQzYmE5ZmQ4MzJhYTFhL3RhYmxlOjVlMWU3MzJmMmZiMzQ1M2M5YmY5OWNkZWUyMjdiODBiL3RhYmxlcmFuZ2U6NWUxZTczMmYyZmIzNDUzYzliZjk5Y2RlZTIyN2I4MGJfMi0zLTEtMS0xODE2NA_2e26baf8-77c0-49fa-8ea3-3c5ccefab803"
      unitRef="usd">15300000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180OS9mcmFnOjhjMzIzNjRiN2RmMDQyNTNiMTQzYmE5ZmQ4MzJhYTFhL3RhYmxlOjVlMWU3MzJmMmZiMzQ1M2M5YmY5OWNkZWUyMjdiODBiL3RhYmxlcmFuZ2U6NWUxZTczMmYyZmIzNDUzYzliZjk5Y2RlZTIyN2I4MGJfMi01LTEtMS0xODE2NA_69716194-b561-498b-ac71-502ffe7c7417"
      unitRef="usd">40600000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN180OS9mcmFnOjhjMzIzNjRiN2RmMDQyNTNiMTQzYmE5ZmQ4MzJhYTFhL3RhYmxlOjVlMWU3MzJmMmZiMzQ1M2M5YmY5OWNkZWUyMjdiODBiL3RhYmxlcmFuZ2U6NWUxZTczMmYyZmIzNDUzYzliZjk5Y2RlZTIyN2I4MGJfMi03LTEtMS0xODE2NA_7c0a8317-66e6-49a2-85fe-5852d6bdcf37"
      unitRef="usd">45800000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN181Mi9mcmFnOmMzZDM1ZjAyNGY3ZDRiZjFiMDEwMDJhZTkxYjAyZTc2L3RleHRyZWdpb246YzNkMzVmMDI0ZjdkNGJmMWIwMTAwMmFlOTFiMDJlNzZfMjY_75264d21-e240-43b1-9057-eb7646b23574">ACCRUED LIABILITIES&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.226%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.511%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.513%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;September 30,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Employee compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;54.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;48.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Legal accrual&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;48.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued taxes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Refunds payable and reserves&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Short-term contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Purchase commitment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;21.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;163.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;79.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the quarter ended September 30, 2021, the Company accrued $48.0&#160;million for a potential settlement of the qui tam lawsuit against Crescendo Bioscience, Inc. and the Company. Refer to Note 13&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for additional information&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN181Mi9mcmFnOmMzZDM1ZjAyNGY3ZDRiZjFiMDEwMDJhZTkxYjAyZTc2L3RleHRyZWdpb246YzNkMzVmMDI0ZjdkNGJmMWIwMTAwMmFlOTFiMDJlNzZfMjc_343b996f-ba51-465f-a2ac-fe4440ad1a6b">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.226%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.511%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.513%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;September 30,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Employee compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;54.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;48.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Legal accrual&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;48.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued taxes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Refunds payable and reserves&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Short-term contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Purchase commitment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;21.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;163.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;79.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN181Mi9mcmFnOmMzZDM1ZjAyNGY3ZDRiZjFiMDEwMDJhZTkxYjAyZTc2L3RhYmxlOmQ4YmFjODI0OTJiMDRmYzhhZjJjMGIzMGQ0NGEyMTZkL3RhYmxlcmFuZ2U6ZDhiYWM4MjQ5MmIwNGZjOGFmMmMwYjMwZDQ0YTIxNmRfMS0xLTEtMS0xODE2NA_0b470fb1-10d0-4354-85cf-8c965eebc9c8"
      unitRef="usd">54000000.0</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN181Mi9mcmFnOmMzZDM1ZjAyNGY3ZDRiZjFiMDEwMDJhZTkxYjAyZTc2L3RhYmxlOmQ4YmFjODI0OTJiMDRmYzhhZjJjMGIzMGQ0NGEyMTZkL3RhYmxlcmFuZ2U6ZDhiYWM4MjQ5MmIwNGZjOGFmMmMwYjMwZDQ0YTIxNmRfMS0zLTEtMS0xODE2NA_ee862c87-513b-4833-b3af-8011c8c4af7e"
      unitRef="usd">48900000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:LitigationReserveCurrent
      contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN181Mi9mcmFnOmMzZDM1ZjAyNGY3ZDRiZjFiMDEwMDJhZTkxYjAyZTc2L3RhYmxlOmQ4YmFjODI0OTJiMDRmYzhhZjJjMGIzMGQ0NGEyMTZkL3RhYmxlcmFuZ2U6ZDhiYWM4MjQ5MmIwNGZjOGFmMmMwYjMwZDQ0YTIxNmRfMi0xLTEtMS0yNTU1MA_3ccd6ba4-9093-4c60-86d7-894431d64c19"
      unitRef="usd">48000000.0</us-gaap:LitigationReserveCurrent>
    <us-gaap:LitigationReserveCurrent
      contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN181Mi9mcmFnOmMzZDM1ZjAyNGY3ZDRiZjFiMDEwMDJhZTkxYjAyZTc2L3RhYmxlOmQ4YmFjODI0OTJiMDRmYzhhZjJjMGIzMGQ0NGEyMTZkL3RhYmxlcmFuZ2U6ZDhiYWM4MjQ5MmIwNGZjOGFmMmMwYjMwZDQ0YTIxNmRfMi0zLTEtMS0yNTU1MA_01ba34f9-f081-4e67-831b-c97f78c25c9a"
      unitRef="usd">0</us-gaap:LitigationReserveCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN181Mi9mcmFnOmMzZDM1ZjAyNGY3ZDRiZjFiMDEwMDJhZTkxYjAyZTc2L3RhYmxlOmQ4YmFjODI0OTJiMDRmYzhhZjJjMGIzMGQ0NGEyMTZkL3RhYmxlcmFuZ2U6ZDhiYWM4MjQ5MmIwNGZjOGFmMmMwYjMwZDQ0YTIxNmRfMi0xLTEtMS0xODE2NA_6e023031-6313-4115-9b38-c042d93ca6ef"
      unitRef="usd">17300000</us-gaap:TaxesPayableCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN181Mi9mcmFnOmMzZDM1ZjAyNGY3ZDRiZjFiMDEwMDJhZTkxYjAyZTc2L3RhYmxlOmQ4YmFjODI0OTJiMDRmYzhhZjJjMGIzMGQ0NGEyMTZkL3RhYmxlcmFuZ2U6ZDhiYWM4MjQ5MmIwNGZjOGFmMmMwYjMwZDQ0YTIxNmRfMi0zLTEtMS0xODE2NA_dc31326d-6ae6-4dbf-ae0e-2290644e110c"
      unitRef="usd">4300000</us-gaap:TaxesPayableCurrent>
    <mygn:RefundsPayableAndReserveCurrent
      contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN181Mi9mcmFnOmMzZDM1ZjAyNGY3ZDRiZjFiMDEwMDJhZTkxYjAyZTc2L3RhYmxlOmQ4YmFjODI0OTJiMDRmYzhhZjJjMGIzMGQ0NGEyMTZkL3RhYmxlcmFuZ2U6ZDhiYWM4MjQ5MmIwNGZjOGFmMmMwYjMwZDQ0YTIxNmRfMy0xLTEtMS0xODE2NA_bc20e1ad-4860-4f9d-a9c5-d83383b88344"
      unitRef="usd">8900000</mygn:RefundsPayableAndReserveCurrent>
    <mygn:RefundsPayableAndReserveCurrent
      contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN181Mi9mcmFnOmMzZDM1ZjAyNGY3ZDRiZjFiMDEwMDJhZTkxYjAyZTc2L3RhYmxlOmQ4YmFjODI0OTJiMDRmYzhhZjJjMGIzMGQ0NGEyMTZkL3RhYmxlcmFuZ2U6ZDhiYWM4MjQ5MmIwNGZjOGFmMmMwYjMwZDQ0YTIxNmRfMy0zLTEtMS0xODE2NA_e611b426-4d59-4286-a453-48bdf10c8624"
      unitRef="usd">9300000</mygn:RefundsPayableAndReserveCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN181Mi9mcmFnOmMzZDM1ZjAyNGY3ZDRiZjFiMDEwMDJhZTkxYjAyZTc2L3RhYmxlOmQ4YmFjODI0OTJiMDRmYzhhZjJjMGIzMGQ0NGEyMTZkL3RhYmxlcmFuZ2U6ZDhiYWM4MjQ5MmIwNGZjOGFmMmMwYjMwZDQ0YTIxNmRfNC0xLTEtMS0xODE2NA_b6061cac-8d39-4d36-8361-fa08a81c7987"
      unitRef="usd">3300000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN181Mi9mcmFnOmMzZDM1ZjAyNGY3ZDRiZjFiMDEwMDJhZTkxYjAyZTc2L3RhYmxlOmQ4YmFjODI0OTJiMDRmYzhhZjJjMGIzMGQ0NGEyMTZkL3RhYmxlcmFuZ2U6ZDhiYWM4MjQ5MmIwNGZjOGFmMmMwYjMwZDQ0YTIxNmRfNC0zLTEtMS0xODE2NA_f7a68627-0434-4b24-badf-44205c694780"
      unitRef="usd">3400000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN181Mi9mcmFnOmMzZDM1ZjAyNGY3ZDRiZjFiMDEwMDJhZTkxYjAyZTc2L3RhYmxlOmQ4YmFjODI0OTJiMDRmYzhhZjJjMGIzMGQ0NGEyMTZkL3RhYmxlcmFuZ2U6ZDhiYWM4MjQ5MmIwNGZjOGFmMmMwYjMwZDQ0YTIxNmRfNS0xLTEtMS0xODE2NA_22c2e5c3-7e51-4069-8b75-4549f1af09cd"
      unitRef="usd">5000000.0</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN181Mi9mcmFnOmMzZDM1ZjAyNGY3ZDRiZjFiMDEwMDJhZTkxYjAyZTc2L3RhYmxlOmQ4YmFjODI0OTJiMDRmYzhhZjJjMGIzMGQ0NGEyMTZkL3RhYmxlcmFuZ2U6ZDhiYWM4MjQ5MmIwNGZjOGFmMmMwYjMwZDQ0YTIxNmRfNS0zLTEtMS0xODE2NA_18a189b4-10a3-468d-880d-70b293827d59"
      unitRef="usd">3800000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:RecordedUnconditionalPurchaseObligation
      contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN181Mi9mcmFnOmMzZDM1ZjAyNGY3ZDRiZjFiMDEwMDJhZTkxYjAyZTc2L3RhYmxlOmQ4YmFjODI0OTJiMDRmYzhhZjJjMGIzMGQ0NGEyMTZkL3RhYmxlcmFuZ2U6ZDhiYWM4MjQ5MmIwNGZjOGFmMmMwYjMwZDQ0YTIxNmRfNi0xLTEtMS0xODE2NA_70dd4c2c-f5a5-44db-b0c5-fb63bbbb4d5f"
      unitRef="usd">5200000</us-gaap:RecordedUnconditionalPurchaseObligation>
    <us-gaap:RecordedUnconditionalPurchaseObligation
      contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN181Mi9mcmFnOmMzZDM1ZjAyNGY3ZDRiZjFiMDEwMDJhZTkxYjAyZTc2L3RhYmxlOmQ4YmFjODI0OTJiMDRmYzhhZjJjMGIzMGQ0NGEyMTZkL3RhYmxlcmFuZ2U6ZDhiYWM4MjQ5MmIwNGZjOGFmMmMwYjMwZDQ0YTIxNmRfNi0zLTEtMS0xODE2NA_8d1d0ce5-d8cb-459f-9e6d-ec497ef90edf"
      unitRef="usd">0</us-gaap:RecordedUnconditionalPurchaseObligation>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN181Mi9mcmFnOmMzZDM1ZjAyNGY3ZDRiZjFiMDEwMDJhZTkxYjAyZTc2L3RhYmxlOmQ4YmFjODI0OTJiMDRmYzhhZjJjMGIzMGQ0NGEyMTZkL3RhYmxlcmFuZ2U6ZDhiYWM4MjQ5MmIwNGZjOGFmMmMwYjMwZDQ0YTIxNmRfNy0xLTEtMS0xODE2NA_b294ab41-0626-487f-b2ab-0590ecf7129e"
      unitRef="usd">21500000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN181Mi9mcmFnOmMzZDM1ZjAyNGY3ZDRiZjFiMDEwMDJhZTkxYjAyZTc2L3RhYmxlOmQ4YmFjODI0OTJiMDRmYzhhZjJjMGIzMGQ0NGEyMTZkL3RhYmxlcmFuZ2U6ZDhiYWM4MjQ5MmIwNGZjOGFmMmMwYjMwZDQ0YTIxNmRfNy0zLTEtMS0xODE2NA_88363572-6ba3-4fc0-9a60-f1f9981c785e"
      unitRef="usd">9400000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN181Mi9mcmFnOmMzZDM1ZjAyNGY3ZDRiZjFiMDEwMDJhZTkxYjAyZTc2L3RhYmxlOmQ4YmFjODI0OTJiMDRmYzhhZjJjMGIzMGQ0NGEyMTZkL3RhYmxlcmFuZ2U6ZDhiYWM4MjQ5MmIwNGZjOGFmMmMwYjMwZDQ0YTIxNmRfOC0xLTEtMS0xODE2NA_6f34a809-82df-47d7-aeea-a5e8877fe92c"
      unitRef="usd">163200000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN181Mi9mcmFnOmMzZDM1ZjAyNGY3ZDRiZjFiMDEwMDJhZTkxYjAyZTc2L3RhYmxlOmQ4YmFjODI0OTJiMDRmYzhhZjJjMGIzMGQ0NGEyMTZkL3RhYmxlcmFuZ2U6ZDhiYWM4MjQ5MmIwNGZjOGFmMmMwYjMwZDQ0YTIxNmRfOC0zLTEtMS0xODE2NA_3fedf5ee-41db-41a2-8c40-cb5fbe5feb91"
      unitRef="usd">79100000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LitigationReserveCurrent
      contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN181Mi9mcmFnOmMzZDM1ZjAyNGY3ZDRiZjFiMDEwMDJhZTkxYjAyZTc2L3RleHRyZWdpb246YzNkMzVmMDI0ZjdkNGJmMWIwMTAwMmFlOTFiMDJlNzZfMjc0ODc3OTA3MTQ5Ng_9146fb18-cae6-4e44-9621-9d50683e77fb"
      unitRef="usd">48000000</us-gaap:LitigationReserveCurrent>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN181NS9mcmFnOmZhM2YyZmVmNzZjNjQ3MjRhNGMyNjVjYTE0MDU4MmFiL3RleHRyZWdpb246ZmEzZjJmZWY3NmM2NDcyNGE0YzI2NWNhMTQwNTgyYWJfNTMxNQ_456321e1-64f5-4e52-b357-216a3baa5a65">LONG-TERM DEBT&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 23, 2016, the Company entered into a senior secured revolving credit facility (the &#x201c;Facility&#x201d;) by and among Myriad, as borrower, and the lenders from time to time party thereto. On July 31, 2018, the Company entered into Amendment No. 1 which effected an &#x201c;amend and extend&#x201d; transaction with respect to the Facility by which the maturity date thereof was extended to July 31, 2023 and the maximum aggregate principal commitment was increased from $300.0 million to $350.0 million.&#160;On May 1, 2020, the Company entered into Amendment No. 2, which waived the Company&#x2019;s compliance with certain financial covenants, amended compliance with certain operating covenants, and modified the interest rate and other terms during a modification period from March 31, 2020 through June 30, 2021 (the &#x201c;Modification Period&#x201d;). On February 22, 2021, the Company entered into Amendment No. 3 (the &#x201c;Amended Facility&#x201d;), which, among other things, decreased the maximum aggregate principal commitment from $350.0&#160;million to $300.0&#160;million, with a further reduction in the maximum aggregate principal commitment from $300.0&#160;million to $250.0&#160;million by September 30, 2021 (if not previously reduced to such amount in connection with certain specified asset sales), waived the Company&#x2019;s compliance with certain financial covenants through the quarter ending March 31, 2022, extended the Modification Period for an additional year, through June 30, 2022, and revised certain negative covenants in connection with the extension. The amendments were accounted for as modifications pursuant to guidance in ASC 470-50, Debt.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Amended Facility contains customary loan terms, interest rates, representations and warranties, affirmative and negative covenants, in each case, subject to customary limitations, exceptions and exclusions. The Amended Facility also contains certain customary events of default. Amendment No. 2 modified the Facility to increase the interest rate to be fixed at a spread of LIBOR plus 350 basis points on drawn balance and the undrawn fee was increased to 50 basis points during the Modification Period. At the end of the Modification Period, interest rates return to the previous pricing based on a spread of LIBOR plus 150-250 basis points on drawn balances and an undrawn fee ranging from 25 to 45 basis points, in each case, based on the Company's leverage ratio. The LIBOR floor was also increased to 1.0% during the Modification Period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Covenants in the Amended Facility impose operating and financial restrictions on the Company. These restrictions may prohibit or place limitations on, among other things, the Company&#x2019;s ability to incur additional indebtedness, create certain types of liens, and complete mergers, consolidations, or change in control transactions. The Amended Facility may also prohibit or place limitations on the Company&#x2019;s ability to sell assets, pay dividends or provide other distributions to stockholders. Beginning with the quarter ended June 30, 2022, the Company must maintain specified leverage and interest ratios measured as of the end of each quarter as a financial covenant in the Amended Facility. Amendment No. 2 modified the Amended Facility's compliance with the leverage covenant and the interest coverage ratio covenant, which were waived through March 31, 2021.  Amendment No. 2 also revised certain negative covenants of the Amended Facility during the Modification Period. Amendment No. 3 waived compliance with the leverage ratio and the interest coverage ratio covenants through the quarter ending March 31, 2022 and also lowered the minimum liquidity covenant, which was added by Amendment No. 2, to $150.0&#160;million, and made it applicable through such quarter. Amendment No. 3 restricted the Company from borrowing under the Amended Facility if unrestricted cash and cash equivalents exceed $150.0&#160;million, unless such borrowings are in connection with acquisitions. The Company was in compliance with all applicable financial covenants at September&#160;30, 2021. &lt;/span&gt;&lt;/div&gt;During the nine months ended September 30, 2021, the Company made principal repayments totaling $226.4&#160;million on the Amended Facility, including a voluntary principal payment on July 30, 2021 of $106.4&#160;million to pay off the remaining outstanding balances on the Amended Facility. As a result, the Company had no outstanding balances under the Amended Facility as of September 30, 2021. During the transition period ended December 31, 2020, the Company did not make any principal repayments. The $1.8&#160;million long-term debt discount associated with the Amended Facility is recorded to Other assets in the Condensed Consolidated Balance Sheet. The Company's maximum aggregate principal commitment on its Amended Facility is $250.0&#160;million as of September 30, 2021.As of December 31, 2020, the Company had a long-term debt balance of $224.8&#160;million, net of a $1.9&#160;million long-term debt discount.</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="ia36cf797382046e0a337c61433dfd1b6_D20180731-20180731"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN181NS9mcmFnOmZhM2YyZmVmNzZjNjQ3MjRhNGMyNjVjYTE0MDU4MmFiL3RleHRyZWdpb246ZmEzZjJmZWY3NmM2NDcyNGE0YzI2NWNhMTQwNTgyYWJfMzk4_29eac453-5c1c-4933-819d-55c6bc592586">2023-07-31</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i20dcb26940bd445f93184c60d07dab71_I20161223"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN181NS9mcmFnOmZhM2YyZmVmNzZjNjQ3MjRhNGMyNjVjYTE0MDU4MmFiL3RleHRyZWdpb246ZmEzZjJmZWY3NmM2NDcyNGE0YzI2NWNhMTQwNTgyYWJfNDY3_24998b78-78eb-4fa5-82cc-760d5b26b266"
      unitRef="usd">300000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="if69f7cf080614d7fa0f9398ec3a0d790_I20180731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN181NS9mcmFnOmZhM2YyZmVmNzZjNjQ3MjRhNGMyNjVjYTE0MDU4MmFiL3RleHRyZWdpb246ZmEzZjJmZWY3NmM2NDcyNGE0YzI2NWNhMTQwNTgyYWJfNDcz_ae31ac02-5c9b-4384-a039-d5d6ef06c4bb"
      unitRef="usd">350000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i2d7436f51ca44c63b220baabb793f869_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN181NS9mcmFnOmZhM2YyZmVmNzZjNjQ3MjRhNGMyNjVjYTE0MDU4MmFiL3RleHRyZWdpb246ZmEzZjJmZWY3NmM2NDcyNGE0YzI2NWNhMTQwNTgyYWJfOTgx_7b5ead9f-7351-45ce-b1f5-364a62a0602e"
      unitRef="usd">350000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="ic14444ddb59c4b859b297e3eb63f800d_I20210221"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN181NS9mcmFnOmZhM2YyZmVmNzZjNjQ3MjRhNGMyNjVjYTE0MDU4MmFiL3RleHRyZWdpb246ZmEzZjJmZWY3NmM2NDcyNGE0YzI2NWNhMTQwNTgyYWJfOTg3_763d71f5-2925-47fe-8fcd-a116ca7b6aed"
      unitRef="usd">300000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="ic14444ddb59c4b859b297e3eb63f800d_I20210221"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN181NS9mcmFnOmZhM2YyZmVmNzZjNjQ3MjRhNGMyNjVjYTE0MDU4MmFiL3RleHRyZWdpb246ZmEzZjJmZWY3NmM2NDcyNGE0YzI2NWNhMTQwNTgyYWJfMTA2Nw_53ff763a-5438-4c22-856b-3116423c8e7f"
      unitRef="usd">300000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i12f34ee4c63b4e07a09ead597eb2afb8_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN181NS9mcmFnOmZhM2YyZmVmNzZjNjQ3MjRhNGMyNjVjYTE0MDU4MmFiL3RleHRyZWdpb246ZmEzZjJmZWY3NmM2NDcyNGE0YzI2NWNhMTQwNTgyYWJfMTA3Mw_550a4f16-d976-42a0-abdd-0845c7a7b5bb"
      unitRef="usd">250000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="id22d71fd31db4689a2b97ef092347fe3_D20200401-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN181NS9mcmFnOmZhM2YyZmVmNzZjNjQ3MjRhNGMyNjVjYTE0MDU4MmFiL3RleHRyZWdpb246ZmEzZjJmZWY3NmM2NDcyNGE0YzI2NWNhMTQwNTgyYWJfMjAxNw_d32fc680-836d-4302-804a-ba8b0ba39a96"
      unitRef="number">0.0350</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage
      contextRef="i1cd2ac076ee74bdaaad3ecd73d94eee1_D20200401-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN181NS9mcmFnOmZhM2YyZmVmNzZjNjQ3MjRhNGMyNjVjYTE0MDU4MmFiL3RleHRyZWdpb246ZmEzZjJmZWY3NmM2NDcyNGE0YzI2NWNhMTQwNTgyYWJfMjA4Nw_28d7a2b1-396f-4cc7-9345-40319fbac525"
      unitRef="number">0.0050</us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i4847f17e28e147c0a68edabf5abcea78_D20220701-20220701"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN181NS9mcmFnOmZhM2YyZmVmNzZjNjQ3MjRhNGMyNjVjYTE0MDU4MmFiL3RleHRyZWdpb246ZmEzZjJmZWY3NmM2NDcyNGE0YzI2NWNhMTQwNTgyYWJfMjI1Mg_671bba5a-381a-48d8-b448-6e85867864bc"
      unitRef="number">0.0150</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i7adf104e7dc740cbb75258256d3d3de0_D20220701-20220701"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN181NS9mcmFnOmZhM2YyZmVmNzZjNjQ3MjRhNGMyNjVjYTE0MDU4MmFiL3RleHRyZWdpb246ZmEzZjJmZWY3NmM2NDcyNGE0YzI2NWNhMTQwNTgyYWJfMjI1NQ_669836a4-747b-46db-ac55-954b8429dcd2"
      unitRef="number">0.0250</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage
      contextRef="i7b9e6a1375a94b0e869e4e993a658963_D20220701-20220701"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN181NS9mcmFnOmZhM2YyZmVmNzZjNjQ3MjRhNGMyNjVjYTE0MDU4MmFiL3RleHRyZWdpb246ZmEzZjJmZWY3NmM2NDcyNGE0YzI2NWNhMTQwNTgyYWJfMjMyMQ_a84df2e2-8047-4470-a263-059320c3fc52"
      unitRef="number">0.0025</us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage>
    <us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage
      contextRef="i417e2a66751b4095bd0c48dc41dd4530_D20220701-20220701"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN181NS9mcmFnOmZhM2YyZmVmNzZjNjQ3MjRhNGMyNjVjYTE0MDU4MmFiL3RleHRyZWdpb246ZmEzZjJmZWY3NmM2NDcyNGE0YzI2NWNhMTQwNTgyYWJfMjMyNw_89489045-6d0e-4c55-8685-cebfcaab8d8b"
      unitRef="number">0.0045</us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage>
    <mygn:DebtInstrumentLIBORFloorPercentage
      contextRef="i1cd2ac076ee74bdaaad3ecd73d94eee1_D20200401-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN181NS9mcmFnOmZhM2YyZmVmNzZjNjQ3MjRhNGMyNjVjYTE0MDU4MmFiL3RleHRyZWdpb246ZmEzZjJmZWY3NmM2NDcyNGE0YzI2NWNhMTQwNTgyYWJfMjQzNQ_82e6fb2a-f3d8-4346-b119-135f76cdd0c2"
      unitRef="number">0.010</mygn:DebtInstrumentLIBORFloorPercentage>
    <mygn:DebtCovenantLiquidityCovenantMinimum
      contextRef="ic14444ddb59c4b859b297e3eb63f800d_I20210221"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN181NS9mcmFnOmZhM2YyZmVmNzZjNjQ3MjRhNGMyNjVjYTE0MDU4MmFiL3RleHRyZWdpb246ZmEzZjJmZWY3NmM2NDcyNGE0YzI2NWNhMTQwNTgyYWJfMjc0ODc3OTA3OTIyOA_16411760-4680-4424-af77-25d87865b99e"
      unitRef="usd">150000000</mygn:DebtCovenantLiquidityCovenantMinimum>
    <mygn:DebtCovenantUnrestrictedCashAndCashEquivalentsThresholdForBorrowingRestrictionMinimum
      contextRef="ic14444ddb59c4b859b297e3eb63f800d_I20210221"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN181NS9mcmFnOmZhM2YyZmVmNzZjNjQ3MjRhNGMyNjVjYTE0MDU4MmFiL3RleHRyZWdpb246ZmEzZjJmZWY3NmM2NDcyNGE0YzI2NWNhMTQwNTgyYWJfNDA3OQ_1556a8c9-256f-4d5a-9c6e-5f6355ff6e9a"
      unitRef="usd">150000000</mygn:DebtCovenantUnrestrictedCashAndCashEquivalentsThresholdForBorrowingRestrictionMinimum>
    <us-gaap:RepaymentsOfLinesOfCredit
      contextRef="ib42c463d1fe74078a52b79074501653e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN181NS9mcmFnOmZhM2YyZmVmNzZjNjQ3MjRhNGMyNjVjYTE0MDU4MmFiL3RleHRyZWdpb246ZmEzZjJmZWY3NmM2NDcyNGE0YzI2NWNhMTQwNTgyYWJfMTY0OTI2NzQ0OTcwNw_3b017803-da7c-4c43-a85e-c5cd09389861"
      unitRef="usd">226400000</us-gaap:RepaymentsOfLinesOfCredit>
    <us-gaap:RepaymentsOfLinesOfCredit
      contextRef="i408d12bd10e24b0daf055d6dce17ee34_D20210731-20210731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN181NS9mcmFnOmZhM2YyZmVmNzZjNjQ3MjRhNGMyNjVjYTE0MDU4MmFiL3RleHRyZWdpb246ZmEzZjJmZWY3NmM2NDcyNGE0YzI2NWNhMTQwNTgyYWJfMTA5OTUxMTYzNTY5NQ_18a631ef-b708-4a4e-a2ee-ba9d0ce60b70"
      unitRef="usd">106400000</us-gaap:RepaymentsOfLinesOfCredit>
    <us-gaap:LongTermDebt
      contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN181NS9mcmFnOmZhM2YyZmVmNzZjNjQ3MjRhNGMyNjVjYTE0MDU4MmFiL3RleHRyZWdpb246ZmEzZjJmZWY3NmM2NDcyNGE0YzI2NWNhMTQwNTgyYWJfMjc0ODc3OTA3NzM4OQ_9f91928a-8970-4d3a-8e70-2a424b20780d"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:RepaymentsOfLinesOfCredit
      contextRef="idb96586e8d014be6a63ed5c14054d982_D20200701-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN181NS9mcmFnOmZhM2YyZmVmNzZjNjQ3MjRhNGMyNjVjYTE0MDU4MmFiL3RleHRyZWdpb246ZmEzZjJmZWY3NmM2NDcyNGE0YzI2NWNhMTQwNTgyYWJfNDQwOQ_4a949f13-e656-413a-8c4e-a8e5a8bc57c4"
      unitRef="usd">0</us-gaap:RepaymentsOfLinesOfCredit>
    <mygn:OtherAssetsDebtDiscount
      contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN181NS9mcmFnOmZhM2YyZmVmNzZjNjQ3MjRhNGMyNjVjYTE0MDU4MmFiL3RleHRyZWdpb246ZmEzZjJmZWY3NmM2NDcyNGE0YzI2NWNhMTQwNTgyYWJfMTY0OTI2NzQ0OTYwNg_66f953cf-3048-4c8e-bae6-6c4645254fd0"
      unitRef="usd">1800000</mygn:OtherAssetsDebtDiscount>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i12f34ee4c63b4e07a09ead597eb2afb8_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN181NS9mcmFnOmZhM2YyZmVmNzZjNjQ3MjRhNGMyNjVjYTE0MDU4MmFiL3RleHRyZWdpb246ZmEzZjJmZWY3NmM2NDcyNGE0YzI2NWNhMTQwNTgyYWJfMTY0OTI2NzQ0OTIwMQ_550a4f16-d976-42a0-abdd-0845c7a7b5bb"
      unitRef="usd">250000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LongTermDebt
      contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN181NS9mcmFnOmZhM2YyZmVmNzZjNjQ3MjRhNGMyNjVjYTE0MDU4MmFiL3RleHRyZWdpb246ZmEzZjJmZWY3NmM2NDcyNGE0YzI2NWNhMTQwNTgyYWJfMTY0OTI2NzQ1MDA1OA_9372d04d-4ea1-48f7-b6ca-94f33fb3e788"
      unitRef="usd">224800000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentUnamortizedDiscountNoncurrent
      contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN181NS9mcmFnOmZhM2YyZmVmNzZjNjQ3MjRhNGMyNjVjYTE0MDU4MmFiL3RleHRyZWdpb246ZmEzZjJmZWY3NmM2NDcyNGE0YzI2NWNhMTQwNTgyYWJfMTY0OTI2NzQ1MDA3Ng_f51da8bc-687d-4451-a2ca-c76f0c98fb98"
      unitRef="usd">1900000</us-gaap:DebtInstrumentUnamortizedDiscountNoncurrent>
    <us-gaap:OtherLiabilitiesDisclosureTextBlock
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN181OC9mcmFnOjU4N2EyMGJiYjM5OTRjMzk4OGNlNjA0ZGFkYjc1ZTA1L3RleHRyZWdpb246NTg3YTIwYmJiMzk5NGMzOTg4Y2U2MDRkYWRiNzVlMDVfMzE2_a9a46ba4-ffd7-406d-820a-d24884b4e5a1">OTHER LONG-TERM LIABILITIES&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.046%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.037%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;September 30,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;The Company's balance of other long-term liabilities as of September&#160;30, 2021 and December&#160;31, 2020 primarily consists of the Company&#x2019;s portion of social security taxes that have been deferred under the Coronavirus Aid, Relief, and Economic Security Act (&#x201c;CARES Act&#x201d;) that do not have to be remitted until December 2022.</us-gaap:OtherLiabilitiesDisclosureTextBlock>
    <us-gaap:OtherNoncurrentLiabilitiesTableTextBlock
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN181OC9mcmFnOjU4N2EyMGJiYjM5OTRjMzk4OGNlNjA0ZGFkYjc1ZTA1L3RleHRyZWdpb246NTg3YTIwYmJiMzk5NGMzOTg4Y2U2MDRkYWRiNzVlMDVfMzE3_aaf69452-cb82-4f54-b49b-bcbc45f7fb8c">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.046%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.037%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;September 30,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:OtherNoncurrentLiabilitiesTableTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN181OC9mcmFnOjU4N2EyMGJiYjM5OTRjMzk4OGNlNjA0ZGFkYjc1ZTA1L3RhYmxlOjkzZGI3NDY1NWM1ODRjNzRiMWEzZDQzODRjNzNhNDlkL3RhYmxlcmFuZ2U6OTNkYjc0NjU1YzU4NGM3NGIxYTNkNDM4NGM3M2E0OWRfMS0xLTEtMS0xODE2NA_7c886de2-f5d5-4312-b154-07edbeb55905"
      unitRef="usd">5500000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN181OC9mcmFnOjU4N2EyMGJiYjM5OTRjMzk4OGNlNjA0ZGFkYjc1ZTA1L3RhYmxlOjkzZGI3NDY1NWM1ODRjNzRiMWEzZDQzODRjNzNhNDlkL3RhYmxlcmFuZ2U6OTNkYjc0NjU1YzU4NGM3NGIxYTNkNDM4NGM3M2E0OWRfMS0zLTEtMS0xODE2NA_056287bf-f737-408e-af23-9743b1a7faad"
      unitRef="usd">7400000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:OtherSundryLiabilitiesNoncurrent
      contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN181OC9mcmFnOjU4N2EyMGJiYjM5OTRjMzk4OGNlNjA0ZGFkYjc1ZTA1L3RhYmxlOjkzZGI3NDY1NWM1ODRjNzRiMWEzZDQzODRjNzNhNDlkL3RhYmxlcmFuZ2U6OTNkYjc0NjU1YzU4NGM3NGIxYTNkNDM4NGM3M2E0OWRfMi0xLTEtMS0xODE2NA_1a37d5c9-5c91-49ae-bc7d-38147eb74783"
      unitRef="usd">5300000</us-gaap:OtherSundryLiabilitiesNoncurrent>
    <us-gaap:OtherSundryLiabilitiesNoncurrent
      contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN181OC9mcmFnOjU4N2EyMGJiYjM5OTRjMzk4OGNlNjA0ZGFkYjc1ZTA1L3RhYmxlOjkzZGI3NDY1NWM1ODRjNzRiMWEzZDQzODRjNzNhNDlkL3RhYmxlcmFuZ2U6OTNkYjc0NjU1YzU4NGM3NGIxYTNkNDM4NGM3M2E0OWRfMi0zLTEtMS0xODE2NA_05b2564c-ec0c-47f2-a2fa-e390e7300c60"
      unitRef="usd">7300000</us-gaap:OtherSundryLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN181OC9mcmFnOjU4N2EyMGJiYjM5OTRjMzk4OGNlNjA0ZGFkYjc1ZTA1L3RhYmxlOjkzZGI3NDY1NWM1ODRjNzRiMWEzZDQzODRjNzNhNDlkL3RhYmxlcmFuZ2U6OTNkYjc0NjU1YzU4NGM3NGIxYTNkNDM4NGM3M2E0OWRfMy0xLTEtMS0xODE2NA_657f013e-caaa-4cd2-a984-ddf9f530dc86"
      unitRef="usd">10800000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN181OC9mcmFnOjU4N2EyMGJiYjM5OTRjMzk4OGNlNjA0ZGFkYjc1ZTA1L3RhYmxlOjkzZGI3NDY1NWM1ODRjNzRiMWEzZDQzODRjNzNhNDlkL3RhYmxlcmFuZ2U6OTNkYjc0NjU1YzU4NGM3NGIxYTNkNDM4NGM3M2E0OWRfMy0zLTEtMS0xODE2NA_981faddd-40d6-47d0-a469-e41260e60bdb"
      unitRef="usd">14700000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182MS9mcmFnOjdhYzhiYmE4ZTc4YzRiMzZhNGQ2YjUwOTAyZmU2Y2UwL3RleHRyZWdpb246N2FjOGJiYThlNzhjNGIzNmE0ZDZiNTA5MDJmZTZjZTBfMTkwMQ_41588e59-598a-4bc5-946c-43af42fb2570">PREFERRED AND COMMON STOCKHOLDERS' EQUITY&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is authorized to issue up to 5.0 million shares of preferred stock, par value $0.01 per share. There were no preferred shares outstanding at September&#160;30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is authorized to issue up to 150.0 million shares of common stock, par value $0.01 per share. There were 79.7 million shares issued and outstanding at September&#160;30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Common shares issued and outstanding&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.046%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.599%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine months ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning common stock issued and outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;75.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;74.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Common stock issued upon exercise of options, vesting of restricted stock units, and purchases under employee stock purchase plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Common stock issued and outstanding at end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;79.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;75.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic earnings per share is computed based on the weighted-average number of shares of common stock outstanding.&#160;&#160;Diluted earnings per share is computed based on the weighted-average number of shares of common stock, including the dilutive effect of common stock equivalents, outstanding.&#160;&#160;In periods when the Company has a net loss, stock awards are excluded from the calculation of diluted net loss per share as their inclusion would have an antidilutive effect.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a reconciliation of the denominators of the basic and diluted earnings per share (&#x201c;EPS&#x201d;) computations:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three months ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Nine months ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted-average shares outstanding used to compute basic EPS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;78.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;74.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;77.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;74.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effect of dilutive shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted-average shares outstanding and dilutive securities used to compute diluted EPS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;81.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;74.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;77.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;74.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain outstanding options and restricted stock units (&#x201c;RSUs&#x201d;) were excluded from the computation of diluted earnings per share because the effect would have been anti-dilutive. These potential dilutive common shares, which may be dilutive to future diluted earnings per share, are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.444%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.377%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.377%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.444%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.377%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.444%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.521%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.521%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three months ended &lt;br/&gt;September 30, &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Nine months ended&lt;br/&gt;&#160;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Anti-dilutive options and RSUs excluded from EPS computation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock Repurchase Program&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the Company&#x2019;s Board of Directors authorized a share repurchase program of $200.0 million of the Company&#x2019;s outstanding common stock from time to time or on an accelerated basis through open market transactions or privately negotiated transactions as determined by the Company's management. The amount and timing of stock repurchases under the program will depend on business and market conditions, stock price, trading restrictions, acquisition activity and other factors.&#160;&#160;As of September&#160;30, 2021, the Company is authorized to repurchase up to $110.7 million of shares under this authorization. No shares were repurchased during the nine months ended September 30, 2021 or 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182MS9mcmFnOjdhYzhiYmE4ZTc4YzRiMzZhNGQ2YjUwOTAyZmU2Y2UwL3RleHRyZWdpb246N2FjOGJiYThlNzhjNGIzNmE0ZDZiNTA5MDJmZTZjZTBfODg_7994c361-8f29-4c13-b887-c2bbbaf43747"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182MS9mcmFnOjdhYzhiYmE4ZTc4YzRiMzZhNGQ2YjUwOTAyZmU2Y2UwL3RleHRyZWdpb246N2FjOGJiYThlNzhjNGIzNmE0ZDZiNTA5MDJmZTZjZTBfMTI4_defd723a-955f-4e51-a22b-cefca95ad39c"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182MS9mcmFnOjdhYzhiYmE4ZTc4YzRiMzZhNGQ2YjUwOTAyZmU2Y2UwL3RleHRyZWdpb246N2FjOGJiYThlNzhjNGIzNmE0ZDZiNTA5MDJmZTZjZTBfMTUz_34805646-3622-4628-bcec-b4ef91cfa94d"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182MS9mcmFnOjdhYzhiYmE4ZTc4YzRiMzZhNGQ2YjUwOTAyZmU2Y2UwL3RleHRyZWdpb246N2FjOGJiYThlNzhjNGIzNmE0ZDZiNTA5MDJmZTZjZTBfMjMz_fccc63de-d574-4d20-ad85-f1b2cd0d71d8"
      unitRef="shares">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182MS9mcmFnOjdhYzhiYmE4ZTc4YzRiMzZhNGQ2YjUwOTAyZmU2Y2UwL3RleHRyZWdpb246N2FjOGJiYThlNzhjNGIzNmE0ZDZiNTA5MDJmZTZjZTBfMjcw_8bce615f-7c41-437f-b5d1-f97495890e75"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182MS9mcmFnOjdhYzhiYmE4ZTc4YzRiMzZhNGQ2YjUwOTAyZmU2Y2UwL3RleHRyZWdpb246N2FjOGJiYThlNzhjNGIzNmE0ZDZiNTA5MDJmZTZjZTBfMjk1_d65d0031-9a43-4de6-9550-e2ced5204802"
      unitRef="shares">79700000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182MS9mcmFnOjdhYzhiYmE4ZTc4YzRiMzZhNGQ2YjUwOTAyZmU2Y2UwL3RleHRyZWdpb246N2FjOGJiYThlNzhjNGIzNmE0ZDZiNTA5MDJmZTZjZTBfMjk1_eb288948-8c6a-403e-bbeb-7f42a85a6661"
      unitRef="shares">79700000</us-gaap:CommonStockSharesIssued>
    <us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182MS9mcmFnOjdhYzhiYmE4ZTc4YzRiMzZhNGQ2YjUwOTAyZmU2Y2UwL3RleHRyZWdpb246N2FjOGJiYThlNzhjNGIzNmE0ZDZiNTA5MDJmZTZjZTBfMTkwMg_9b6b63c3-9a0c-4425-82a7-57e9bca6a22f">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Common shares issued and outstanding&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.046%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.599%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine months ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning common stock issued and outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;75.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;74.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Common stock issued upon exercise of options, vesting of restricted stock units, and purchases under employee stock purchase plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Common stock issued and outstanding at end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;79.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;75.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182MS9mcmFnOjdhYzhiYmE4ZTc4YzRiMzZhNGQ2YjUwOTAyZmU2Y2UwL3RhYmxlOmI1ZGExZDFkMGI1MDRjMzQ4MjIzZTQwNDIwOWFiZjg5L3RhYmxlcmFuZ2U6YjVkYTFkMWQwYjUwNGMzNDgyMjNlNDA0MjA5YWJmODlfMi0xLTEtMS0xODE2NA_6a664d13-7669-4b13-82be-7d2a99a29e3c"
      unitRef="shares">75400000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182MS9mcmFnOjdhYzhiYmE4ZTc4YzRiMzZhNGQ2YjUwOTAyZmU2Y2UwL3RhYmxlOmI1ZGExZDFkMGI1MDRjMzQ4MjIzZTQwNDIwOWFiZjg5L3RhYmxlcmFuZ2U6YjVkYTFkMWQwYjUwNGMzNDgyMjNlNDA0MjA5YWJmODlfMi0xLTEtMS0xODE2NA_cb306fa2-cb7f-4dca-aad9-816040064b45"
      unitRef="shares">75400000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="ic698543044ba4469ba8751bae898951c_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182MS9mcmFnOjdhYzhiYmE4ZTc4YzRiMzZhNGQ2YjUwOTAyZmU2Y2UwL3RhYmxlOmI1ZGExZDFkMGI1MDRjMzQ4MjIzZTQwNDIwOWFiZjg5L3RhYmxlcmFuZ2U6YjVkYTFkMWQwYjUwNGMzNDgyMjNlNDA0MjA5YWJmODlfMi0zLTEtMS0xODE2NA_580b3118-a445-4ce7-8f67-b55f1339ff98"
      unitRef="shares">74500000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ic698543044ba4469ba8751bae898951c_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182MS9mcmFnOjdhYzhiYmE4ZTc4YzRiMzZhNGQ2YjUwOTAyZmU2Y2UwL3RhYmxlOmI1ZGExZDFkMGI1MDRjMzQ4MjIzZTQwNDIwOWFiZjg5L3RhYmxlcmFuZ2U6YjVkYTFkMWQwYjUwNGMzNDgyMjNlNDA0MjA5YWJmODlfMi0zLTEtMS0xODE2NA_c2b840e2-7f97-4512-88bd-cb23a4104016"
      unitRef="shares">74500000</us-gaap:CommonStockSharesOutstanding>
    <mygn:StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182MS9mcmFnOjdhYzhiYmE4ZTc4YzRiMzZhNGQ2YjUwOTAyZmU2Y2UwL3RhYmxlOmI1ZGExZDFkMGI1MDRjMzQ4MjIzZTQwNDIwOWFiZjg5L3RhYmxlcmFuZ2U6YjVkYTFkMWQwYjUwNGMzNDgyMjNlNDA0MjA5YWJmODlfMy0xLTEtMS0xODE2NA_305f3ddb-cf87-4585-8dcf-d030b15b4695"
      unitRef="shares">4300000</mygn:StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans>
    <mygn:StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans
      contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182MS9mcmFnOjdhYzhiYmE4ZTc4YzRiMzZhNGQ2YjUwOTAyZmU2Y2UwL3RhYmxlOmI1ZGExZDFkMGI1MDRjMzQ4MjIzZTQwNDIwOWFiZjg5L3RhYmxlcmFuZ2U6YjVkYTFkMWQwYjUwNGMzNDgyMjNlNDA0MjA5YWJmODlfMy0zLTEtMS0xODE2NA_75e4b2e7-e6f3-4246-aee8-3f28fb6fa361"
      unitRef="shares">700000</mygn:StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182MS9mcmFnOjdhYzhiYmE4ZTc4YzRiMzZhNGQ2YjUwOTAyZmU2Y2UwL3RhYmxlOmI1ZGExZDFkMGI1MDRjMzQ4MjIzZTQwNDIwOWFiZjg5L3RhYmxlcmFuZ2U6YjVkYTFkMWQwYjUwNGMzNDgyMjNlNDA0MjA5YWJmODlfNS0xLTEtMS0xODE2NA_030a0066-d22e-4edc-9bfb-008b08551623"
      unitRef="shares">79700000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182MS9mcmFnOjdhYzhiYmE4ZTc4YzRiMzZhNGQ2YjUwOTAyZmU2Y2UwL3RhYmxlOmI1ZGExZDFkMGI1MDRjMzQ4MjIzZTQwNDIwOWFiZjg5L3RhYmxlcmFuZ2U6YjVkYTFkMWQwYjUwNGMzNDgyMjNlNDA0MjA5YWJmODlfNS0xLTEtMS0xODE2NA_fc9e32d1-3fb4-4e3d-97e0-719d278656a5"
      unitRef="shares">79700000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i0c6bac27ede64afeb4dbc13729f58578_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182MS9mcmFnOjdhYzhiYmE4ZTc4YzRiMzZhNGQ2YjUwOTAyZmU2Y2UwL3RhYmxlOmI1ZGExZDFkMGI1MDRjMzQ4MjIzZTQwNDIwOWFiZjg5L3RhYmxlcmFuZ2U6YjVkYTFkMWQwYjUwNGMzNDgyMjNlNDA0MjA5YWJmODlfNS0zLTEtMS0xODE2NA_07065ded-7d72-4e63-87f2-534629aa2bbd"
      unitRef="shares">75200000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i0c6bac27ede64afeb4dbc13729f58578_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182MS9mcmFnOjdhYzhiYmE4ZTc4YzRiMzZhNGQ2YjUwOTAyZmU2Y2UwL3RhYmxlOmI1ZGExZDFkMGI1MDRjMzQ4MjIzZTQwNDIwOWFiZjg5L3RhYmxlcmFuZ2U6YjVkYTFkMWQwYjUwNGMzNDgyMjNlNDA0MjA5YWJmODlfNS0zLTEtMS0xODE2NA_5c35dc36-47da-4e4c-aea5-084fd4d29730"
      unitRef="shares">75200000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182MS9mcmFnOjdhYzhiYmE4ZTc4YzRiMzZhNGQ2YjUwOTAyZmU2Y2UwL3RleHRyZWdpb246N2FjOGJiYThlNzhjNGIzNmE0ZDZiNTA5MDJmZTZjZTBfMTkwMw_c2a549ce-62d0-4ebb-af53-6387fe6a0243">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a reconciliation of the denominators of the basic and diluted earnings per share (&#x201c;EPS&#x201d;) computations:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three months ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Nine months ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted-average shares outstanding used to compute basic EPS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;78.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;74.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;77.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;74.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effect of dilutive shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted-average shares outstanding and dilutive securities used to compute diluted EPS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;81.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;74.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;77.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;74.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182MS9mcmFnOjdhYzhiYmE4ZTc4YzRiMzZhNGQ2YjUwOTAyZmU2Y2UwL3RhYmxlOmI3NTEzZWUxMzNhYjQ1OGM5YzcwMjQ1M2MzZWM2OTI3L3RhYmxlcmFuZ2U6Yjc1MTNlZTEzM2FiNDU4YzljNzAyNDUzYzNlYzY5MjdfMy0xLTEtMS0xODE2NA_ea1464cd-d62a-46c8-952b-e96e110220c3"
      unitRef="shares">78800000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ic2c3e03438af4889ac973627c642f5ec_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182MS9mcmFnOjdhYzhiYmE4ZTc4YzRiMzZhNGQ2YjUwOTAyZmU2Y2UwL3RhYmxlOmI3NTEzZWUxMzNhYjQ1OGM5YzcwMjQ1M2MzZWM2OTI3L3RhYmxlcmFuZ2U6Yjc1MTNlZTEzM2FiNDU4YzljNzAyNDUzYzNlYzY5MjdfMy0zLTEtMS0xODE2NA_07199ddf-e1f9-49ae-92a0-9303efb1d253"
      unitRef="shares">74700000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182MS9mcmFnOjdhYzhiYmE4ZTc4YzRiMzZhNGQ2YjUwOTAyZmU2Y2UwL3RhYmxlOmI3NTEzZWUxMzNhYjQ1OGM5YzcwMjQ1M2MzZWM2OTI3L3RhYmxlcmFuZ2U6Yjc1MTNlZTEzM2FiNDU4YzljNzAyNDUzYzNlYzY5MjdfMy01LTEtMS0xODE2NA_149de4d1-5f07-4333-9d03-3cfff95d74d4"
      unitRef="shares">77300000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182MS9mcmFnOjdhYzhiYmE4ZTc4YzRiMzZhNGQ2YjUwOTAyZmU2Y2UwL3RhYmxlOmI3NTEzZWUxMzNhYjQ1OGM5YzcwMjQ1M2MzZWM2OTI3L3RhYmxlcmFuZ2U6Yjc1MTNlZTEzM2FiNDU4YzljNzAyNDUzYzNlYzY5MjdfMy03LTEtMS0xODE2NA_799335a3-31ce-43f7-93a6-d87df558a3d7"
      unitRef="shares">74600000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182MS9mcmFnOjdhYzhiYmE4ZTc4YzRiMzZhNGQ2YjUwOTAyZmU2Y2UwL3RhYmxlOmI3NTEzZWUxMzNhYjQ1OGM5YzcwMjQ1M2MzZWM2OTI3L3RhYmxlcmFuZ2U6Yjc1MTNlZTEzM2FiNDU4YzljNzAyNDUzYzNlYzY5MjdfNC0xLTEtMS0xODE2NA_68108580-6c0f-4ef3-8612-36d8030aad0c"
      unitRef="shares">2700000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="ic2c3e03438af4889ac973627c642f5ec_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182MS9mcmFnOjdhYzhiYmE4ZTc4YzRiMzZhNGQ2YjUwOTAyZmU2Y2UwL3RhYmxlOmI3NTEzZWUxMzNhYjQ1OGM5YzcwMjQ1M2MzZWM2OTI3L3RhYmxlcmFuZ2U6Yjc1MTNlZTEzM2FiNDU4YzljNzAyNDUzYzNlYzY5MjdfNC0zLTEtMS0xODE2NA_79e85d6c-9021-42a7-b1bc-6579e3e4ab8b"
      unitRef="shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182MS9mcmFnOjdhYzhiYmE4ZTc4YzRiMzZhNGQ2YjUwOTAyZmU2Y2UwL3RhYmxlOmI3NTEzZWUxMzNhYjQ1OGM5YzcwMjQ1M2MzZWM2OTI3L3RhYmxlcmFuZ2U6Yjc1MTNlZTEzM2FiNDU4YzljNzAyNDUzYzNlYzY5MjdfNC01LTEtMS0xODE2NA_04130df7-5980-4140-8bad-6009b528cfe2"
      unitRef="shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182MS9mcmFnOjdhYzhiYmE4ZTc4YzRiMzZhNGQ2YjUwOTAyZmU2Y2UwL3RhYmxlOmI3NTEzZWUxMzNhYjQ1OGM5YzcwMjQ1M2MzZWM2OTI3L3RhYmxlcmFuZ2U6Yjc1MTNlZTEzM2FiNDU4YzljNzAyNDUzYzNlYzY5MjdfNC03LTEtMS0xODE2NA_512adfde-29ab-4b99-9023-f8584c01d036"
      unitRef="shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182MS9mcmFnOjdhYzhiYmE4ZTc4YzRiMzZhNGQ2YjUwOTAyZmU2Y2UwL3RhYmxlOmI3NTEzZWUxMzNhYjQ1OGM5YzcwMjQ1M2MzZWM2OTI3L3RhYmxlcmFuZ2U6Yjc1MTNlZTEzM2FiNDU4YzljNzAyNDUzYzNlYzY5MjdfNS0xLTEtMS0xODE2NA_157165af-0604-4a03-9099-8f6312d3711a"
      unitRef="shares">81500000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ic2c3e03438af4889ac973627c642f5ec_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182MS9mcmFnOjdhYzhiYmE4ZTc4YzRiMzZhNGQ2YjUwOTAyZmU2Y2UwL3RhYmxlOmI3NTEzZWUxMzNhYjQ1OGM5YzcwMjQ1M2MzZWM2OTI3L3RhYmxlcmFuZ2U6Yjc1MTNlZTEzM2FiNDU4YzljNzAyNDUzYzNlYzY5MjdfNS0zLTEtMS0xODE2NA_794a6de6-5d33-4aab-aba1-e3e74edd1d9e"
      unitRef="shares">74700000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182MS9mcmFnOjdhYzhiYmE4ZTc4YzRiMzZhNGQ2YjUwOTAyZmU2Y2UwL3RhYmxlOmI3NTEzZWUxMzNhYjQ1OGM5YzcwMjQ1M2MzZWM2OTI3L3RhYmxlcmFuZ2U6Yjc1MTNlZTEzM2FiNDU4YzljNzAyNDUzYzNlYzY5MjdfNS01LTEtMS0xODE2NA_5b095305-04b4-4a6e-8f8a-5bec095273a4"
      unitRef="shares">77300000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182MS9mcmFnOjdhYzhiYmE4ZTc4YzRiMzZhNGQ2YjUwOTAyZmU2Y2UwL3RhYmxlOmI3NTEzZWUxMzNhYjQ1OGM5YzcwMjQ1M2MzZWM2OTI3L3RhYmxlcmFuZ2U6Yjc1MTNlZTEzM2FiNDU4YzljNzAyNDUzYzNlYzY5MjdfNS03LTEtMS0xODE2NA_f21a4694-c69c-4ecb-9bb2-fe4b39a672ce"
      unitRef="shares">74600000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182MS9mcmFnOjdhYzhiYmE4ZTc4YzRiMzZhNGQ2YjUwOTAyZmU2Y2UwL3RleHRyZWdpb246N2FjOGJiYThlNzhjNGIzNmE0ZDZiNTA5MDJmZTZjZTBfMTkwNA_4a92bb59-a1e7-44a7-afb0-5ca2e42446bf">These potential dilutive common shares, which may be dilutive to future diluted earnings per share, are as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.444%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.377%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.377%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.444%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.377%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.444%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.521%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.521%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three months ended &lt;br/&gt;September 30, &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Nine months ended&lt;br/&gt;&#160;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Anti-dilutive options and RSUs excluded from EPS computation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182MS9mcmFnOjdhYzhiYmE4ZTc4YzRiMzZhNGQ2YjUwOTAyZmU2Y2UwL3RhYmxlOjhmZjdmM2ZkOWY0YzQyMzhhODc0NTg0MTY5OTFmMzVlL3RhYmxlcmFuZ2U6OGZmN2YzZmQ5ZjRjNDIzOGE4NzQ1ODQxNjk5MWYzNWVfMi0xLTEtMS0yNjk2Mg_36abfcdb-705c-4e45-beba-16def1652e11"
      unitRef="shares">100000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ic2c3e03438af4889ac973627c642f5ec_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182MS9mcmFnOjdhYzhiYmE4ZTc4YzRiMzZhNGQ2YjUwOTAyZmU2Y2UwL3RhYmxlOjhmZjdmM2ZkOWY0YzQyMzhhODc0NTg0MTY5OTFmMzVlL3RhYmxlcmFuZ2U6OGZmN2YzZmQ5ZjRjNDIzOGE4NzQ1ODQxNjk5MWYzNWVfMi0zLTEtMS0yNjkxOA_e25323ca-f4e1-4d6e-923e-be72d3cacbc4"
      unitRef="shares">7300000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182MS9mcmFnOjdhYzhiYmE4ZTc4YzRiMzZhNGQ2YjUwOTAyZmU2Y2UwL3RhYmxlOjhmZjdmM2ZkOWY0YzQyMzhhODc0NTg0MTY5OTFmMzVlL3RhYmxlcmFuZ2U6OGZmN2YzZmQ5ZjRjNDIzOGE4NzQ1ODQxNjk5MWYzNWVfMi0xLTEtMS0xODE2NA_5d2fdcd9-e1a2-46f3-b956-4b28adda2fe9"
      unitRef="shares">4900000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182MS9mcmFnOjdhYzhiYmE4ZTc4YzRiMzZhNGQ2YjUwOTAyZmU2Y2UwL3RhYmxlOjhmZjdmM2ZkOWY0YzQyMzhhODc0NTg0MTY5OTFmMzVlL3RhYmxlcmFuZ2U6OGZmN2YzZmQ5ZjRjNDIzOGE4NzQ1ODQxNjk5MWYzNWVfMi0zLTEtMS0xODE2NA_60d960fc-50b4-4fbf-8280-f4294d1766ff"
      unitRef="shares">7300000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="i3269c20860fd42e5b0cecdb3249f343d_I20160630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182MS9mcmFnOjdhYzhiYmE4ZTc4YzRiMzZhNGQ2YjUwOTAyZmU2Y2UwL3RleHRyZWdpb246N2FjOGJiYThlNzhjNGIzNmE0ZDZiNTA5MDJmZTZjZTBfMTM3MQ_de38bc08-f1e5-4216-b44b-7d2c1476ef17"
      unitRef="usd">200000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
      contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182MS9mcmFnOjdhYzhiYmE4ZTc4YzRiMzZhNGQ2YjUwOTAyZmU2Y2UwL3RleHRyZWdpb246N2FjOGJiYThlNzhjNGIzNmE0ZDZiNTA5MDJmZTZjZTBfMTgxNA_35684bc5-6451-42e8-a626-b21d94427d89"
      unitRef="usd">110700000</us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182MS9mcmFnOjdhYzhiYmE4ZTc4YzRiMzZhNGQ2YjUwOTAyZmU2Y2UwL3RleHRyZWdpb246N2FjOGJiYThlNzhjNGIzNmE0ZDZiNTA5MDJmZTZjZTBfMTg1Mw_9e4e719e-c176-43f6-b0e4-00ec38c62b1f"
      unitRef="shares">0</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182MS9mcmFnOjdhYzhiYmE4ZTc4YzRiMzZhNGQ2YjUwOTAyZmU2Y2UwL3RleHRyZWdpb246N2FjOGJiYThlNzhjNGIzNmE0ZDZiNTA5MDJmZTZjZTBfMTg1Mw_c446205e-d2e3-49ab-888f-209c42608bcc"
      unitRef="shares">0</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182NC9mcmFnOjA2NTZiZmUyZmE0ZDQwN2JiYjYwOTZhMDdiNGZmMjQyL3RleHRyZWdpb246MDY1NmJmZTJmYTRkNDA3YmJiNjA5NmEwN2I0ZmYyNDJfMzE4NQ_03f6cb3d-1c7c-491c-a7e5-695f23dbf6c0">STOCK-BASED COMPENSATION&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 30, 2017, the Company&#x2019;s stockholders approved the adoption of the 2017 Employee, Director and Consultant Equity Incentive Plan (as amended, the &#x201c;2017 Plan&#x201d;). The 2017 Plan allows the Company, under the direction of the Compensation and Human Capital Committee of the Board of Directors, to make grants of restricted and unrestricted stock awards to employees, consultants, and directors. Stockholders have approved amendments to the 2017 Plan increasing the shares available to grant.  As of September&#160;30, 2021, the Company has 3.6&#160;million shares of common stock available for grant under the 2017 Plan.  If an RSU awarded under the 2017 Plan is cancelled or forfeited without the issuance of shares of common stock, the unissued or reacquired shares that were subject to the RSU will again be available for issuance pursuant to the 2017 Plan. To the extent that awards outstanding under the Company's prior equity plans expire or are cancelled without delivery of shares of common stock, they also will be available for issuance pursuant to the 2017 Plan. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The number of shares, terms, and vesting periods are generally determined by the Company&#x2019;s Board of Directors or a committee thereof on an award-by-award basis. RSUs granted to employees generally vest ratably over four years either on the anniversary of the date on which the RSUs were granted or during the month in which such anniversary dates occur. The number of RSUs awarded to certain employees may be increased or reduced based on certain additional performance metrics. Options and RSUs granted to non-employee directors vest in full upon completion of one year of service on the anniversary following the date of the grant. Options generally vest ratably over service periods of four years.&#160;Options granted after December 5, 2012 expire eight years from the date of grant, and options granted prior to that date generally expire ten years from the date of grant. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the stock option activity under the Company&#x2019;s equity plans and inducement awards, for the nine months ended September&#160;30, 2021 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(number of shares in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number&lt;br/&gt;of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options outstanding at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;23.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options canceled or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;25.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options outstanding at September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options exercisable at September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;23.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2021, there was $2.6 million of total unrecognized stock-based compensation expense related to stock options that will be recognized over a weighted-average period of 2.3 years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the RSU activity under the Company&#x2019;s equity plans and inducement awards, including RSU awards with performance metrics, for the nine months ended September&#160;30, 2021 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(number of shares in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number&lt;br/&gt;of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Grant Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;RSUs outstanding at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;RSUs granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;29.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;RSUs vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;RSUs canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;RSUs outstanding at September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;23.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2021, there was $68.2 million of total unrecognized stock-based compensation expense related to RSUs that will be recognized over a &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;weighted-average period of&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; 2.6 years.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also has an Employee Stock Purchase Plan that was approved by stockholders in 2012 (the &#x201c;2012 Purchase Plan&#x201d;), under which 2.0 million shares of common stock have been authorized.&#160;&#160;On September 23, 2021, the Board of Directors of the Company approved an amended and restated 2012 Employee Stock Purchase Plan, which authorizes an additional 2.0&#160;million shares of common stock and extends the term of the 2012 Purchase Plan to November 30, 2032, subject in each case to obtaining stockholder approval. The amended and restated 2012 Employee Stock Purchase Plan also amended certain provisions of the 2012 Purchase Plan effective upon approval by the Board of Directors, including expanding the definition of "offering period" to provide that the Board of Directors may determine the period in accordance with the terms of the plan, and capping the number of shares that may be purchased by any participant during an offering period at 5,000 shares. Shares are issued under the 2012 Purchase Plan twice yearly at the end of each offering period.&#160;&#160;As of September&#160;30, 2021, approximately 0.1 million shares of common stock are available for issuance under the 2012 Purchase Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock-Based Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense recognized and included in the Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) was allocated as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three months ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Nine months ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of molecular diagnostic testing&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of pharmaceutical and clinical services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general, and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;23.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;27.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i52adcde188a640e99ba9a44e311c8d73_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182NC9mcmFnOjA2NTZiZmUyZmE0ZDQwN2JiYjYwOTZhMDdiNGZmMjQyL3RleHRyZWdpb246MDY1NmJmZTJmYTRkNDA3YmJiNjA5NmEwN2I0ZmYyNDJfNTM2_b6c076b8-5649-41b1-ad14-7424fe1dda1d"
      unitRef="shares">3600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ief9e8a3ae25b43aeb183d65978160f05_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182NC9mcmFnOjA2NTZiZmUyZmE0ZDQwN2JiYjYwOTZhMDdiNGZmMjQyL3RleHRyZWdpb246MDY1NmJmZTJmYTRkNDA3YmJiNjA5NmEwN2I0ZmYyNDJfMTI3Mg_8217558d-cfe5-4ed0-97d9-29170073ac10">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i69bf2abe7da64ff79bc46cba39640e19_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182NC9mcmFnOjA2NTZiZmUyZmE0ZDQwN2JiYjYwOTZhMDdiNGZmMjQyL3RleHRyZWdpb246MDY1NmJmZTJmYTRkNDA3YmJiNjA5NmEwN2I0ZmYyNDJfMTYxMQ_9cb7ec49-fda8-4a52-bdf7-308fd9eb49b8">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i92c8275b0ba847e78c2cd5b91dd57e8c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182NC9mcmFnOjA2NTZiZmUyZmE0ZDQwN2JiYjYwOTZhMDdiNGZmMjQyL3RleHRyZWdpb246MDY1NmJmZTJmYTRkNDA3YmJiNjA5NmEwN2I0ZmYyNDJfMTczMg_0cc61b3e-0bfa-46c6-93fc-0f2b67e9a211">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i965028ac5b28491f8ce013eceafc3791_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182NC9mcmFnOjA2NTZiZmUyZmE0ZDQwN2JiYjYwOTZhMDdiNGZmMjQyL3RleHRyZWdpb246MDY1NmJmZTJmYTRkNDA3YmJiNjA5NmEwN2I0ZmYyNDJfMTc4Mg_d5fa16cb-1d68-4c31-9568-b6b0f84cfc9c">P8Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i8d8d18090245443bb8fcbbabba18bd99_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182NC9mcmFnOjA2NTZiZmUyZmE0ZDQwN2JiYjYwOTZhMDdiNGZmMjQyL3RleHRyZWdpb246MDY1NmJmZTJmYTRkNDA3YmJiNjA5NmEwN2I0ZmYyNDJfMTg2NQ_ecd14376-ef91-4d3b-abb3-b33bf7286d4b">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182NC9mcmFnOjA2NTZiZmUyZmE0ZDQwN2JiYjYwOTZhMDdiNGZmMjQyL3RleHRyZWdpb246MDY1NmJmZTJmYTRkNDA3YmJiNjA5NmEwN2I0ZmYyNDJfMzE4Mw_93a84a01-d64d-44cb-854e-3f4de4bc2927">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the stock option activity under the Company&#x2019;s equity plans and inducement awards, for the nine months ended September&#160;30, 2021 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(number of shares in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number&lt;br/&gt;of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options outstanding at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;23.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options canceled or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;25.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options outstanding at September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options exercisable at September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;23.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182NC9mcmFnOjA2NTZiZmUyZmE0ZDQwN2JiYjYwOTZhMDdiNGZmMjQyL3RhYmxlOjQyOGMzZjlmMzI0YzQ2N2NhMjhlNzk2MmNmMGViNjVkL3RhYmxlcmFuZ2U6NDI4YzNmOWYzMjRjNDY3Y2EyOGU3OTYyY2YwZWI2NWRfMS0xLTEtMS0xODE2NA_dd4e4997-0885-4d6b-896a-5e09d500774d"
      unitRef="shares">5200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i21cc3685be5d4e2e8f00283addc53a8f_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182NC9mcmFnOjA2NTZiZmUyZmE0ZDQwN2JiYjYwOTZhMDdiNGZmMjQyL3RhYmxlOjQyOGMzZjlmMzI0YzQ2N2NhMjhlNzk2MmNmMGViNjVkL3RhYmxlcmFuZ2U6NDI4YzNmOWYzMjRjNDY3Y2EyOGU3OTYyY2YwZWI2NWRfMS0zLTEtMS0xODE2NA_cda0044a-c972-4f8b-951d-07d7a1f4d4b8"
      unitRef="usdPerShare">23.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182NC9mcmFnOjA2NTZiZmUyZmE0ZDQwN2JiYjYwOTZhMDdiNGZmMjQyL3RhYmxlOjQyOGMzZjlmMzI0YzQ2N2NhMjhlNzk2MmNmMGViNjVkL3RhYmxlcmFuZ2U6NDI4YzNmOWYzMjRjNDY3Y2EyOGU3OTYyY2YwZWI2NWRfMi0xLTEtMS0xODE2NA_12e57be3-c35b-4409-9fcf-97372181cd7c"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182NC9mcmFnOjA2NTZiZmUyZmE0ZDQwN2JiYjYwOTZhMDdiNGZmMjQyL3RhYmxlOjQyOGMzZjlmMzI0YzQ2N2NhMjhlNzk2MmNmMGViNjVkL3RhYmxlcmFuZ2U6NDI4YzNmOWYzMjRjNDY3Y2EyOGU3OTYyY2YwZWI2NWRfMi0zLTEtMS0xODE2NA_fb53e611-afe6-43bb-b3d5-0a4ff2602134"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182NC9mcmFnOjA2NTZiZmUyZmE0ZDQwN2JiYjYwOTZhMDdiNGZmMjQyL3RhYmxlOjQyOGMzZjlmMzI0YzQ2N2NhMjhlNzk2MmNmMGViNjVkL3RhYmxlcmFuZ2U6NDI4YzNmOWYzMjRjNDY3Y2EyOGU3OTYyY2YwZWI2NWRfNC0xLTEtMS0xODE2NA_9895cbdd-1e37-4ea8-8a1e-264ac31ea18c"
      unitRef="shares">3600000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182NC9mcmFnOjA2NTZiZmUyZmE0ZDQwN2JiYjYwOTZhMDdiNGZmMjQyL3RhYmxlOjQyOGMzZjlmMzI0YzQ2N2NhMjhlNzk2MmNmMGViNjVkL3RhYmxlcmFuZ2U6NDI4YzNmOWYzMjRjNDY3Y2EyOGU3OTYyY2YwZWI2NWRfNC0zLTEtMS0xODE2NA_6c0301e1-5b49-46a1-9cc6-26c8c6dd1456"
      unitRef="usdPerShare">24.26</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182NC9mcmFnOjA2NTZiZmUyZmE0ZDQwN2JiYjYwOTZhMDdiNGZmMjQyL3RhYmxlOjQyOGMzZjlmMzI0YzQ2N2NhMjhlNzk2MmNmMGViNjVkL3RhYmxlcmFuZ2U6NDI4YzNmOWYzMjRjNDY3Y2EyOGU3OTYyY2YwZWI2NWRfNS0xLTEtMS0xODE2NA_dd42736a-17a4-42ab-83a2-12e61d1adfe0"
      unitRef="shares">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182NC9mcmFnOjA2NTZiZmUyZmE0ZDQwN2JiYjYwOTZhMDdiNGZmMjQyL3RhYmxlOjQyOGMzZjlmMzI0YzQ2N2NhMjhlNzk2MmNmMGViNjVkL3RhYmxlcmFuZ2U6NDI4YzNmOWYzMjRjNDY3Y2EyOGU3OTYyY2YwZWI2NWRfNS0zLTEtMS0xODE2NA_a78ac584-2938-4b40-90c6-f697e879aa96"
      unitRef="usdPerShare">25.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182NC9mcmFnOjA2NTZiZmUyZmE0ZDQwN2JiYjYwOTZhMDdiNGZmMjQyL3RhYmxlOjQyOGMzZjlmMzI0YzQ2N2NhMjhlNzk2MmNmMGViNjVkL3RhYmxlcmFuZ2U6NDI4YzNmOWYzMjRjNDY3Y2EyOGU3OTYyY2YwZWI2NWRfNi0xLTEtMS0xODE2NA_bbd346c2-7f6c-46be-ac63-7805d200afa6"
      unitRef="shares">1500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182NC9mcmFnOjA2NTZiZmUyZmE0ZDQwN2JiYjYwOTZhMDdiNGZmMjQyL3RhYmxlOjQyOGMzZjlmMzI0YzQ2N2NhMjhlNzk2MmNmMGViNjVkL3RhYmxlcmFuZ2U6NDI4YzNmOWYzMjRjNDY3Y2EyOGU3OTYyY2YwZWI2NWRfNi0zLTEtMS0xODE2NA_baaf66e5-9b4c-4ebc-9bd2-13f9af4710e7"
      unitRef="usdPerShare">20.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182NC9mcmFnOjA2NTZiZmUyZmE0ZDQwN2JiYjYwOTZhMDdiNGZmMjQyL3RhYmxlOjQyOGMzZjlmMzI0YzQ2N2NhMjhlNzk2MmNmMGViNjVkL3RhYmxlcmFuZ2U6NDI4YzNmOWYzMjRjNDY3Y2EyOGU3OTYyY2YwZWI2NWRfNy0xLTEtMS0xODE2NA_028ce7e8-e3ef-4eb0-a261-ecbc9c715e0f"
      unitRef="shares">1100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182NC9mcmFnOjA2NTZiZmUyZmE0ZDQwN2JiYjYwOTZhMDdiNGZmMjQyL3RhYmxlOjQyOGMzZjlmMzI0YzQ2N2NhMjhlNzk2MmNmMGViNjVkL3RhYmxlcmFuZ2U6NDI4YzNmOWYzMjRjNDY3Y2EyOGU3OTYyY2YwZWI2NWRfNy0zLTEtMS0xODE2NA_8c4d525e-f295-4390-b0cb-df661288f9c8"
      unitRef="usdPerShare">23.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182NC9mcmFnOjA2NTZiZmUyZmE0ZDQwN2JiYjYwOTZhMDdiNGZmMjQyL3RleHRyZWdpb246MDY1NmJmZTJmYTRkNDA3YmJiNjA5NmEwN2I0ZmYyNDJfMjA2OA_a838efeb-ba0d-430b-8e1f-a7b257528495"
      unitRef="usd">2600000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i92c8275b0ba847e78c2cd5b91dd57e8c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182NC9mcmFnOjA2NTZiZmUyZmE0ZDQwN2JiYjYwOTZhMDdiNGZmMjQyL3RleHRyZWdpb246MDY1NmJmZTJmYTRkNDA3YmJiNjA5NmEwN2I0ZmYyNDJfMjIwOQ_c1d8d2eb-b594-483f-beb8-262b0ba01307">P2Y3M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182NC9mcmFnOjA2NTZiZmUyZmE0ZDQwN2JiYjYwOTZhMDdiNGZmMjQyL3RleHRyZWdpb246MDY1NmJmZTJmYTRkNDA3YmJiNjA5NmEwN2I0ZmYyNDJfMzE4Mg_853fa1db-57b5-4ff9-b5c4-a77fb83d1f40">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the RSU activity under the Company&#x2019;s equity plans and inducement awards, including RSU awards with performance metrics, for the nine months ended September&#160;30, 2021 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(number of shares in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number&lt;br/&gt;of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Grant Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;RSUs outstanding at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;RSUs granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;29.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;RSUs vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;RSUs canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;RSUs outstanding at September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;23.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i4801dc9ebc814bf4a4e7c0b3d186670f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182NC9mcmFnOjA2NTZiZmUyZmE0ZDQwN2JiYjYwOTZhMDdiNGZmMjQyL3RhYmxlOmE1Y2Q3N2Q2ODdmNTRlNDlhOTA3MmVhY2Q0NTY4ZmRkL3RhYmxlcmFuZ2U6YTVjZDc3ZDY4N2Y1NGU0OWE5MDcyZWFjZDQ1NjhmZGRfMS0xLTEtMS0xODE2NA_1e9993e5-147c-4ba2-847b-1a2748e95689"
      unitRef="shares">3200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i4801dc9ebc814bf4a4e7c0b3d186670f_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182NC9mcmFnOjA2NTZiZmUyZmE0ZDQwN2JiYjYwOTZhMDdiNGZmMjQyL3RhYmxlOmE1Y2Q3N2Q2ODdmNTRlNDlhOTA3MmVhY2Q0NTY4ZmRkL3RhYmxlcmFuZ2U6YTVjZDc3ZDY4N2Y1NGU0OWE5MDcyZWFjZDQ1NjhmZGRfMS0zLTEtMS0xODE2NA_42026c93-1e3a-4993-9681-6bf36a0ee07f"
      unitRef="usdPerShare">20.56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ief9e8a3ae25b43aeb183d65978160f05_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182NC9mcmFnOjA2NTZiZmUyZmE0ZDQwN2JiYjYwOTZhMDdiNGZmMjQyL3RhYmxlOmE1Y2Q3N2Q2ODdmNTRlNDlhOTA3MmVhY2Q0NTY4ZmRkL3RhYmxlcmFuZ2U6YTVjZDc3ZDY4N2Y1NGU0OWE5MDcyZWFjZDQ1NjhmZGRfMi0xLTEtMS0xODE2NA_8d60ff2f-a541-4bb3-a32b-3db626d70728"
      unitRef="shares">1700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ief9e8a3ae25b43aeb183d65978160f05_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182NC9mcmFnOjA2NTZiZmUyZmE0ZDQwN2JiYjYwOTZhMDdiNGZmMjQyL3RhYmxlOmE1Y2Q3N2Q2ODdmNTRlNDlhOTA3MmVhY2Q0NTY4ZmRkL3RhYmxlcmFuZ2U6YTVjZDc3ZDY4N2Y1NGU0OWE5MDcyZWFjZDQ1NjhmZGRfMi0zLTEtMS0xODE2NA_370f522a-480b-4123-aa74-3ec836739cff"
      unitRef="usdPerShare">29.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="ief9e8a3ae25b43aeb183d65978160f05_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182NC9mcmFnOjA2NTZiZmUyZmE0ZDQwN2JiYjYwOTZhMDdiNGZmMjQyL3RhYmxlOmE1Y2Q3N2Q2ODdmNTRlNDlhOTA3MmVhY2Q0NTY4ZmRkL3RhYmxlcmFuZ2U6YTVjZDc3ZDY4N2Y1NGU0OWE5MDcyZWFjZDQ1NjhmZGRfNC0xLTEtMS0xODE2NA_6d674fb9-ae2f-4a3d-9bb4-df6b2e915208"
      unitRef="shares">800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="ief9e8a3ae25b43aeb183d65978160f05_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182NC9mcmFnOjA2NTZiZmUyZmE0ZDQwN2JiYjYwOTZhMDdiNGZmMjQyL3RhYmxlOmE1Y2Q3N2Q2ODdmNTRlNDlhOTA3MmVhY2Q0NTY4ZmRkL3RhYmxlcmFuZ2U6YTVjZDc3ZDY4N2Y1NGU0OWE5MDcyZWFjZDQ1NjhmZGRfNC0zLTEtMS0xODE2NA_6832e15d-0e70-48a2-b842-ae979bc71ebe"
      unitRef="usdPerShare">24.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="ief9e8a3ae25b43aeb183d65978160f05_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182NC9mcmFnOjA2NTZiZmUyZmE0ZDQwN2JiYjYwOTZhMDdiNGZmMjQyL3RhYmxlOmE1Y2Q3N2Q2ODdmNTRlNDlhOTA3MmVhY2Q0NTY4ZmRkL3RhYmxlcmFuZ2U6YTVjZDc3ZDY4N2Y1NGU0OWE5MDcyZWFjZDQ1NjhmZGRfNS0xLTEtMS0xODE2NA_1d3d765f-2480-40c2-95b1-96f110458d22"
      unitRef="shares">700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="ief9e8a3ae25b43aeb183d65978160f05_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182NC9mcmFnOjA2NTZiZmUyZmE0ZDQwN2JiYjYwOTZhMDdiNGZmMjQyL3RhYmxlOmE1Y2Q3N2Q2ODdmNTRlNDlhOTA3MmVhY2Q0NTY4ZmRkL3RhYmxlcmFuZ2U6YTVjZDc3ZDY4N2Y1NGU0OWE5MDcyZWFjZDQ1NjhmZGRfNS0zLTEtMS0xODE2NA_4c035a61-8c9c-4aac-86e0-646f3f1051b0"
      unitRef="usdPerShare">24.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i82ee8762af6f49b6830a17198018205b_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182NC9mcmFnOjA2NTZiZmUyZmE0ZDQwN2JiYjYwOTZhMDdiNGZmMjQyL3RhYmxlOmE1Y2Q3N2Q2ODdmNTRlNDlhOTA3MmVhY2Q0NTY4ZmRkL3RhYmxlcmFuZ2U6YTVjZDc3ZDY4N2Y1NGU0OWE5MDcyZWFjZDQ1NjhmZGRfNi0xLTEtMS0xODE2NA_ea2522f5-9ee5-4e31-bb99-3e29d73f9c35"
      unitRef="shares">3400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i82ee8762af6f49b6830a17198018205b_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182NC9mcmFnOjA2NTZiZmUyZmE0ZDQwN2JiYjYwOTZhMDdiNGZmMjQyL3RhYmxlOmE1Y2Q3N2Q2ODdmNTRlNDlhOTA3MmVhY2Q0NTY4ZmRkL3RhYmxlcmFuZ2U6YTVjZDc3ZDY4N2Y1NGU0OWE5MDcyZWFjZDQ1NjhmZGRfNi0zLTEtMS0xODE2NA_d0071ffe-85e7-4be4-9918-a4fb8f43afc0"
      unitRef="usdPerShare">23.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="i82ee8762af6f49b6830a17198018205b_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182NC9mcmFnOjA2NTZiZmUyZmE0ZDQwN2JiYjYwOTZhMDdiNGZmMjQyL3RleHRyZWdpb246MDY1NmJmZTJmYTRkNDA3YmJiNjA5NmEwN2I0ZmYyNDJfMjQzNA_089e8fd8-3607-4562-85a4-e149fd914f41"
      unitRef="usd">68200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ief9e8a3ae25b43aeb183d65978160f05_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182NC9mcmFnOjA2NTZiZmUyZmE0ZDQwN2JiYjYwOTZhMDdiNGZmMjQyL3RleHRyZWdpb246MDY1NmJmZTJmYTRkNDA3YmJiNjA5NmEwN2I0ZmYyNDJfMjU2Ng_353a5e18-6c51-4227-948b-3bafdf4361da">P2Y7M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i8bcfc26140eb424887a7993eb83c6035_I20121231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182NC9mcmFnOjA2NTZiZmUyZmE0ZDQwN2JiYjYwOTZhMDdiNGZmMjQyL3RleHRyZWdpb246MDY1NmJmZTJmYTRkNDA3YmJiNjA5NmEwN2I0ZmYyNDJfMjczNQ_4418e70a-ada6-4617-bec8-9b79f966a5f0"
      unitRef="shares">2000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="ib0ff30ba23574507a2d7f464c815dfac_D20210923-20210923"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182NC9mcmFnOjA2NTZiZmUyZmE0ZDQwN2JiYjYwOTZhMDdiNGZmMjQyL3RleHRyZWdpb246MDY1NmJmZTJmYTRkNDA3YmJiNjA5NmEwN2I0ZmYyNDJfMjc0ODc3OTA3NDgzNQ_e38f8624-ca08-4ecc-82b6-0d1e1da0a9a9"
      unitRef="shares">2000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee
      contextRef="ib0ff30ba23574507a2d7f464c815dfac_D20210923-20210923"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182NC9mcmFnOjA2NTZiZmUyZmE0ZDQwN2JiYjYwOTZhMDdiNGZmMjQyL3RleHRyZWdpb246MDY1NmJmZTJmYTRkNDA3YmJiNjA5NmEwN2I0ZmYyNDJfMjc0ODc3OTA3NDgyOA_32687a6d-8b3e-40c0-8782-b3985b15d0e8"
      unitRef="shares">5000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i2c1a3b837ee04e2c812eb8cbc112adaf_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182NC9mcmFnOjA2NTZiZmUyZmE0ZDQwN2JiYjYwOTZhMDdiNGZmMjQyL3RleHRyZWdpb246MDY1NmJmZTJmYTRkNDA3YmJiNjA5NmEwN2I0ZmYyNDJfMjkwNQ_773e8728-dc30-490a-9f91-e0463090f8d7"
      unitRef="shares">100000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182NC9mcmFnOjA2NTZiZmUyZmE0ZDQwN2JiYjYwOTZhMDdiNGZmMjQyL3RleHRyZWdpb246MDY1NmJmZTJmYTRkNDA3YmJiNjA5NmEwN2I0ZmYyNDJfMzE4NA_9236fd89-510d-4d39-be5d-bd880f5a00b3">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense recognized and included in the Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) was allocated as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three months ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Nine months ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of molecular diagnostic testing&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of pharmaceutical and clinical services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general, and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;23.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;27.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie53d91b4b6c74e609ea917eadc9521fb_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182NC9mcmFnOjA2NTZiZmUyZmE0ZDQwN2JiYjYwOTZhMDdiNGZmMjQyL3RhYmxlOmRmODRkMTkwMTYyMzRmNWU5MGUwYWJlNmE0MTQ0YzI2L3RhYmxlcmFuZ2U6ZGY4NGQxOTAxNjIzNGY1ZTkwZTBhYmU2YTQxNDRjMjZfMi0xLTEtMS0xODE2NA_978a674e-3307-4573-ba20-61f039d6b8b4"
      unitRef="usd">400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib0b0e187d88d4a79a51af53f0c258395_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182NC9mcmFnOjA2NTZiZmUyZmE0ZDQwN2JiYjYwOTZhMDdiNGZmMjQyL3RhYmxlOmRmODRkMTkwMTYyMzRmNWU5MGUwYWJlNmE0MTQ0YzI2L3RhYmxlcmFuZ2U6ZGY4NGQxOTAxNjIzNGY1ZTkwZTBhYmU2YTQxNDRjMjZfMi0zLTEtMS0xODE2NA_868b15fd-3f8b-4429-abe2-dfd18b1ef92b"
      unitRef="usd">300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i15b426ffab40406b9ce00055e4e71cc7_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182NC9mcmFnOjA2NTZiZmUyZmE0ZDQwN2JiYjYwOTZhMDdiNGZmMjQyL3RhYmxlOmRmODRkMTkwMTYyMzRmNWU5MGUwYWJlNmE0MTQ0YzI2L3RhYmxlcmFuZ2U6ZGY4NGQxOTAxNjIzNGY1ZTkwZTBhYmU2YTQxNDRjMjZfMi01LTEtMS0xODE2NA_87cfd5cd-8324-45ce-94ad-d23c77a91dec"
      unitRef="usd">1100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i10453dc072584904908a86492c478db1_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182NC9mcmFnOjA2NTZiZmUyZmE0ZDQwN2JiYjYwOTZhMDdiNGZmMjQyL3RhYmxlOmRmODRkMTkwMTYyMzRmNWU5MGUwYWJlNmE0MTQ0YzI2L3RhYmxlcmFuZ2U6ZGY4NGQxOTAxNjIzNGY1ZTkwZTBhYmU2YTQxNDRjMjZfMi03LTEtMS0xODE2NA_9b3219b4-b62f-4572-abbd-769e9b1d22eb"
      unitRef="usd">1000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib8134e30745e401f875787e150c90a29_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182NC9mcmFnOjA2NTZiZmUyZmE0ZDQwN2JiYjYwOTZhMDdiNGZmMjQyL3RhYmxlOmRmODRkMTkwMTYyMzRmNWU5MGUwYWJlNmE0MTQ0YzI2L3RhYmxlcmFuZ2U6ZGY4NGQxOTAxNjIzNGY1ZTkwZTBhYmU2YTQxNDRjMjZfMy0xLTEtMS0xODE2NA_cad2593a-86c3-487e-b98b-c97068504fa6"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0a4213b0025742348a551e459281952a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182NC9mcmFnOjA2NTZiZmUyZmE0ZDQwN2JiYjYwOTZhMDdiNGZmMjQyL3RhYmxlOmRmODRkMTkwMTYyMzRmNWU5MGUwYWJlNmE0MTQ0YzI2L3RhYmxlcmFuZ2U6ZGY4NGQxOTAxNjIzNGY1ZTkwZTBhYmU2YTQxNDRjMjZfMy0zLTEtMS0xODE2NA_3bf95fcd-cd19-4d9f-bb7d-599e4b7322f2"
      unitRef="usd">100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i96d4380fb0a44bda931ad908ae56cd15_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182NC9mcmFnOjA2NTZiZmUyZmE0ZDQwN2JiYjYwOTZhMDdiNGZmMjQyL3RhYmxlOmRmODRkMTkwMTYyMzRmNWU5MGUwYWJlNmE0MTQ0YzI2L3RhYmxlcmFuZ2U6ZGY4NGQxOTAxNjIzNGY1ZTkwZTBhYmU2YTQxNDRjMjZfMy01LTEtMS0xODE2NA_9e61a76b-6847-437a-80d3-4c1ba30dd1c2"
      unitRef="usd">100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if45947be73124386a5d96c5f812ce163_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182NC9mcmFnOjA2NTZiZmUyZmE0ZDQwN2JiYjYwOTZhMDdiNGZmMjQyL3RhYmxlOmRmODRkMTkwMTYyMzRmNWU5MGUwYWJlNmE0MTQ0YzI2L3RhYmxlcmFuZ2U6ZGY4NGQxOTAxNjIzNGY1ZTkwZTBhYmU2YTQxNDRjMjZfMy03LTEtMS0xODE2NA_a0fedae0-eb79-45aa-adc7-61e04d849a8e"
      unitRef="usd">300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7b57125252b04e19a0ab135ecb14306e_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182NC9mcmFnOjA2NTZiZmUyZmE0ZDQwN2JiYjYwOTZhMDdiNGZmMjQyL3RhYmxlOmRmODRkMTkwMTYyMzRmNWU5MGUwYWJlNmE0MTQ0YzI2L3RhYmxlcmFuZ2U6ZGY4NGQxOTAxNjIzNGY1ZTkwZTBhYmU2YTQxNDRjMjZfNC0xLTEtMS0xODE2NA_2e6287c2-38a2-4be7-860b-8762bf9fbdf3"
      unitRef="usd">800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i74a661b5521240d6b08faf29ed4cca5f_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182NC9mcmFnOjA2NTZiZmUyZmE0ZDQwN2JiYjYwOTZhMDdiNGZmMjQyL3RhYmxlOmRmODRkMTkwMTYyMzRmNWU5MGUwYWJlNmE0MTQ0YzI2L3RhYmxlcmFuZ2U6ZGY4NGQxOTAxNjIzNGY1ZTkwZTBhYmU2YTQxNDRjMjZfNC0zLTEtMS0xODE2NA_aae8fb1b-5fa6-4804-b328-407386885d20"
      unitRef="usd">1300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic1e22d907e804cb3a166674ed56d1159_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182NC9mcmFnOjA2NTZiZmUyZmE0ZDQwN2JiYjYwOTZhMDdiNGZmMjQyL3RhYmxlOmRmODRkMTkwMTYyMzRmNWU5MGUwYWJlNmE0MTQ0YzI2L3RhYmxlcmFuZ2U6ZGY4NGQxOTAxNjIzNGY1ZTkwZTBhYmU2YTQxNDRjMjZfNC01LTEtMS0xODE2NA_33749454-d032-4ca6-895e-7e186855d05a"
      unitRef="usd">3300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iaa209599dfc04850bdd9bb0c340449ec_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182NC9mcmFnOjA2NTZiZmUyZmE0ZDQwN2JiYjYwOTZhMDdiNGZmMjQyL3RhYmxlOmRmODRkMTkwMTYyMzRmNWU5MGUwYWJlNmE0MTQ0YzI2L3RhYmxlcmFuZ2U6ZGY4NGQxOTAxNjIzNGY1ZTkwZTBhYmU2YTQxNDRjMjZfNC03LTEtMS0xODE2NA_a9ac4fe5-6b3b-4a54-b350-7a3f94eee300"
      unitRef="usd">3600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4fba22e0d9a14b43ae418e9b7737a767_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182NC9mcmFnOjA2NTZiZmUyZmE0ZDQwN2JiYjYwOTZhMDdiNGZmMjQyL3RhYmxlOmRmODRkMTkwMTYyMzRmNWU5MGUwYWJlNmE0MTQ0YzI2L3RhYmxlcmFuZ2U6ZGY4NGQxOTAxNjIzNGY1ZTkwZTBhYmU2YTQxNDRjMjZfNS0xLTEtMS0xODE2NA_f6aa6b7c-82e7-4d4d-be99-e5357ff88816"
      unitRef="usd">8800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i8738e02b8c234e90be4290e058314e09_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182NC9mcmFnOjA2NTZiZmUyZmE0ZDQwN2JiYjYwOTZhMDdiNGZmMjQyL3RhYmxlOmRmODRkMTkwMTYyMzRmNWU5MGUwYWJlNmE0MTQ0YzI2L3RhYmxlcmFuZ2U6ZGY4NGQxOTAxNjIzNGY1ZTkwZTBhYmU2YTQxNDRjMjZfNS0zLTEtMS0xODE2NA_c3a18af6-a658-49e7-944d-80e27d079b2e"
      unitRef="usd">6700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4b061eccb63f4b98914dd480e34a8f10_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182NC9mcmFnOjA2NTZiZmUyZmE0ZDQwN2JiYjYwOTZhMDdiNGZmMjQyL3RhYmxlOmRmODRkMTkwMTYyMzRmNWU5MGUwYWJlNmE0MTQ0YzI2L3RhYmxlcmFuZ2U6ZGY4NGQxOTAxNjIzNGY1ZTkwZTBhYmU2YTQxNDRjMjZfNS01LTEtMS0xODE2NA_b462d707-5a9d-4fda-a3ab-e732b6557f88"
      unitRef="usd">23400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib580291452e04f9790478ef2b24b14d7_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182NC9mcmFnOjA2NTZiZmUyZmE0ZDQwN2JiYjYwOTZhMDdiNGZmMjQyL3RhYmxlOmRmODRkMTkwMTYyMzRmNWU5MGUwYWJlNmE0MTQ0YzI2L3RhYmxlcmFuZ2U6ZGY4NGQxOTAxNjIzNGY1ZTkwZTBhYmU2YTQxNDRjMjZfNS03LTEtMS0xODE2NA_1f153604-b44a-4b6f-8b9d-8bfb62f9f27d"
      unitRef="usd">12900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182NC9mcmFnOjA2NTZiZmUyZmE0ZDQwN2JiYjYwOTZhMDdiNGZmMjQyL3RhYmxlOmRmODRkMTkwMTYyMzRmNWU5MGUwYWJlNmE0MTQ0YzI2L3RhYmxlcmFuZ2U6ZGY4NGQxOTAxNjIzNGY1ZTkwZTBhYmU2YTQxNDRjMjZfNi0xLTEtMS0xODE2NA_bd603638-1a51-476e-8fed-72f771fa6a13"
      unitRef="usd">10000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic2c3e03438af4889ac973627c642f5ec_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182NC9mcmFnOjA2NTZiZmUyZmE0ZDQwN2JiYjYwOTZhMDdiNGZmMjQyL3RhYmxlOmRmODRkMTkwMTYyMzRmNWU5MGUwYWJlNmE0MTQ0YzI2L3RhYmxlcmFuZ2U6ZGY4NGQxOTAxNjIzNGY1ZTkwZTBhYmU2YTQxNDRjMjZfNi0zLTEtMS0xODE2NA_23ab6d21-74f2-47a8-923d-a8d5cd995701"
      unitRef="usd">8400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182NC9mcmFnOjA2NTZiZmUyZmE0ZDQwN2JiYjYwOTZhMDdiNGZmMjQyL3RhYmxlOmRmODRkMTkwMTYyMzRmNWU5MGUwYWJlNmE0MTQ0YzI2L3RhYmxlcmFuZ2U6ZGY4NGQxOTAxNjIzNGY1ZTkwZTBhYmU2YTQxNDRjMjZfNi01LTEtMS0xODE2NA_4f068073-d89f-4f6a-a968-a7f21395f22d"
      unitRef="usd">27900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182NC9mcmFnOjA2NTZiZmUyZmE0ZDQwN2JiYjYwOTZhMDdiNGZmMjQyL3RhYmxlOmRmODRkMTkwMTYyMzRmNWU5MGUwYWJlNmE0MTQ0YzI2L3RhYmxlcmFuZ2U6ZGY4NGQxOTAxNjIzNGY1ZTkwZTBhYmU2YTQxNDRjMjZfNi03LTEtMS0xODE2NA_07e54dca-1479-4084-b954-8a5521cdfa57"
      unitRef="usd">17800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182Ny9mcmFnOjUyY2IyYmViNTUwYTQzODU4NDk3M2U2MmY4NTAwN2Q3L3RleHRyZWdpb246NTJjYjJiZWI1NTBhNDM4NTg0OTczZTYyZjg1MDA3ZDdfMTkyMg_cb49989f-28a5-4597-b319-650d069369f0">INCOME TAXES In order to determine the Company&#x2019;s quarterly provision for income taxes, the Company used an estimated annual effective tax rate that is based on expected annual income and statutory tax rates in the various jurisdictions in which the Company operates.&#160;Certain significant or unusual items are separately recognized in the quarter during which they occur and can be a source of variability in the effective tax rate from quarter to quarter.&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income tax expense for the three months ended September&#160;30, 2021 was $15.2 million, or approximately 38.2% of pre-tax income compared to an income tax benefit of $28.5 million, or approximately 65.2% of pre-tax loss, for the three months ended September&#160;30, 2020.&#160;Income tax expense for the nine months ended September&#160;30, 2021 was $6.0 million, or approximately (44.1)% of pre-tax loss compared to an income tax benefit of $47.4 million, or approximately 20.3% of pre-tax loss, for the nine months ended September&#160;30, 2020.&#160;&#160;&#160;Income tax expense for the three and nine months ended September&#160;30, 2021 is based on the Company&#x2019;s estimated annualized effective tax rate for the fiscal year ending December 31, 2021, adjusted for discrete items recognized during the respective periods.&#160;&#160;For the three and nine months ended September&#160;30, 2021, the Company&#x2019;s recognized effective tax rate differs from the U.S. federal statutory rate primarily due to disallowed executive compensation expenses, disallowed meals and entertainment expenses, stock compensation expenses, benefit recorded as a result of the CARES Act, asset impairment expenses, release of a valuation allowance, and differences between the book and tax basis of assets divested.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company files U.S., foreign and state income tax returns in jurisdictions with various statutes of limitations.&#160;&#160;The Company is currently under audit by the State of California for the fiscal years ended June 30, 2017-2018, the State of New Jersey for the fiscal years ended June 30, 2013-2017; Germany for the fiscal years ended June 30, 2013-2015; and Switzerland for the fiscal years ended June 30, 2015-2016. Annual and interim tax provisions include amounts considered necessary to pay assessments that may result from examination of prior year tax returns; however, the amount ultimately paid upon resolution of issues may differ materially from the amount accrued.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182Ny9mcmFnOjUyY2IyYmViNTUwYTQzODU4NDk3M2U2MmY4NTAwN2Q3L3RleHRyZWdpb246NTJjYjJiZWI1NTBhNDM4NTg0OTczZTYyZjg1MDA3ZDdfNTEz_e836bcd3-807d-4b54-a509-624c0b229238"
      unitRef="usd">15200000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182Ny9mcmFnOjUyY2IyYmViNTUwYTQzODU4NDk3M2U2MmY4NTAwN2Q3L3RleHRyZWdpb246NTJjYjJiZWI1NTBhNDM4NTg0OTczZTYyZjg1MDA3ZDdfNTM0_d9a3997c-a09e-414d-b4c0-23c3647becd5"
      unitRef="number">0.382</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ic2c3e03438af4889ac973627c642f5ec_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182Ny9mcmFnOjUyY2IyYmViNTUwYTQzODU4NDk3M2U2MmY4NTAwN2Q3L3RleHRyZWdpb246NTJjYjJiZWI1NTBhNDM4NTg0OTczZTYyZjg1MDA3ZDdfNTkw_d339a33a-6267-401c-b98f-9d7dd7f3528b"
      unitRef="usd">-28500000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="ic2c3e03438af4889ac973627c642f5ec_D20200701-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182Ny9mcmFnOjUyY2IyYmViNTUwYTQzODU4NDk3M2U2MmY4NTAwN2Q3L3RleHRyZWdpb246NTJjYjJiZWI1NTBhNDM4NTg0OTczZTYyZjg1MDA3ZDdfNjEx_adfb89a3-0059-44c9-9f01-66ab5a789c44"
      unitRef="number">0.652</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182Ny9mcmFnOjUyY2IyYmViNTUwYTQzODU4NDk3M2U2MmY4NTAwN2Q3L3RleHRyZWdpb246NTJjYjJiZWI1NTBhNDM4NTg0OTczZTYyZjg1MDA3ZDdfMTA5OTUxMTYyOTk2Ng_edaed20a-2b00-47b9-a6c2-87d4869987bb"
      unitRef="usd">6000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182Ny9mcmFnOjUyY2IyYmViNTUwYTQzODU4NDk3M2U2MmY4NTAwN2Q3L3RleHRyZWdpb246NTJjYjJiZWI1NTBhNDM4NTg0OTczZTYyZjg1MDA3ZDdfMTA5OTUxMTYyOTk3MA_077490a5-bed8-492b-91d1-e80fe0e843f4"
      unitRef="number">-0.441</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182Ny9mcmFnOjUyY2IyYmViNTUwYTQzODU4NDk3M2U2MmY4NTAwN2Q3L3RleHRyZWdpb246NTJjYjJiZWI1NTBhNDM4NTg0OTczZTYyZjg1MDA3ZDdfMTA5OTUxMTYyOTk3NA_92145c67-c164-4d8f-870d-3088dfcc32a2"
      unitRef="usd">-47400000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182Ny9mcmFnOjUyY2IyYmViNTUwYTQzODU4NDk3M2U2MmY4NTAwN2Q3L3RleHRyZWdpb246NTJjYjJiZWI1NTBhNDM4NTg0OTczZTYyZjg1MDA3ZDdfMTA5OTUxMTYyOTk3OA_76ef24f9-3b02-4b8a-8a7b-37f78ea46945"
      unitRef="number">0.203</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:IncomeTaxExaminationYearUnderExamination
      contextRef="if31d376449604749a8d84a4ea233ed1b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182Ny9mcmFnOjUyY2IyYmViNTUwYTQzODU4NDk3M2U2MmY4NTAwN2Q3L3RleHRyZWdpb246NTJjYjJiZWI1NTBhNDM4NTg0OTczZTYyZjg1MDA3ZDdfMTQzMg_1aaaeb24-9bc9-477b-8ba0-01f25a93efd5">2017</us-gaap:IncomeTaxExaminationYearUnderExamination>
    <us-gaap:IncomeTaxExaminationYearUnderExamination
      contextRef="i4b90c2422e9e4d78837a3d9edef5f3aa_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182Ny9mcmFnOjUyY2IyYmViNTUwYTQzODU4NDk3M2U2MmY4NTAwN2Q3L3RleHRyZWdpb246NTJjYjJiZWI1NTBhNDM4NTg0OTczZTYyZjg1MDA3ZDdfMTQzNQ_9275bf03-bb3f-42e3-abad-e5fc472c9c6e">2018</us-gaap:IncomeTaxExaminationYearUnderExamination>
    <us-gaap:IncomeTaxExaminationYearUnderExamination
      contextRef="i7c84552a53104c5d863802c21e95e8d4_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182Ny9mcmFnOjUyY2IyYmViNTUwYTQzODU4NDk3M2U2MmY4NTAwN2Q3L3RleHRyZWdpb246NTJjYjJiZWI1NTBhNDM4NTg0OTczZTYyZjg1MDA3ZDdfMTQ5Mw_bbc8f1f5-2973-4568-ab67-20623480113f">2013</us-gaap:IncomeTaxExaminationYearUnderExamination>
    <us-gaap:IncomeTaxExaminationYearUnderExamination
      contextRef="idab04f47fe4d4dfa8e8043a6d25016fd_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182Ny9mcmFnOjUyY2IyYmViNTUwYTQzODU4NDk3M2U2MmY4NTAwN2Q3L3RleHRyZWdpb246NTJjYjJiZWI1NTBhNDM4NTg0OTczZTYyZjg1MDA3ZDdfMTQ5Ng_41688401-8eb6-4f7e-a5f9-ed6029f5dd19">2017</us-gaap:IncomeTaxExaminationYearUnderExamination>
    <us-gaap:IncomeTaxExaminationYearUnderExamination
      contextRef="i1d977692ef0d4d53a4a9b42cabf5e593_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182Ny9mcmFnOjUyY2IyYmViNTUwYTQzODU4NDk3M2U2MmY4NTAwN2Q3L3RleHRyZWdpb246NTJjYjJiZWI1NTBhNDM4NTg0OTczZTYyZjg1MDA3ZDdfMTkyMA_d0f33cc3-9be5-4053-aea1-9e7ce4177a29">2013</us-gaap:IncomeTaxExaminationYearUnderExamination>
    <us-gaap:IncomeTaxExaminationYearUnderExamination
      contextRef="iaf68da87f99f4445b6e3aaf98ff69a2a_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182Ny9mcmFnOjUyY2IyYmViNTUwYTQzODU4NDk3M2U2MmY4NTAwN2Q3L3RleHRyZWdpb246NTJjYjJiZWI1NTBhNDM4NTg0OTczZTYyZjg1MDA3ZDdfMTkyMQ_d6126fb0-d0d0-4818-b3f2-2969671c51a2">2015</us-gaap:IncomeTaxExaminationYearUnderExamination>
    <us-gaap:IncomeTaxExaminationYearUnderExamination
      contextRef="ib988f9d7160144ba85f9202205918ecc_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182Ny9mcmFnOjUyY2IyYmViNTUwYTQzODU4NDk3M2U2MmY4NTAwN2Q3L3RleHRyZWdpb246NTJjYjJiZWI1NTBhNDM4NTg0OTczZTYyZjg1MDA3ZDdfMTY1NA_278b81fb-6222-4a58-ac6a-3fe1310944f3">2015</us-gaap:IncomeTaxExaminationYearUnderExamination>
    <us-gaap:IncomeTaxExaminationYearUnderExamination
      contextRef="i84120dcedb01422a848d3618dbae3f74_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN182Ny9mcmFnOjUyY2IyYmViNTUwYTQzODU4NDk3M2U2MmY4NTAwN2Q3L3RleHRyZWdpb246NTJjYjJiZWI1NTBhNDM4NTg0OTczZTYyZjg1MDA3ZDdfMTY1Nw_5837c4b0-5e7c-4729-82d2-dfdc9d9937d0">2016</us-gaap:IncomeTaxExaminationYearUnderExamination>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183MC9mcmFnOjU2MWU4NTAyZDVmMjQ0MTc5YWVkYmRlY2YwNzBmMWI2L3RleHRyZWdpb246NTYxZTg1MDJkNWYyNDQxNzlhZWRiZGVjZjA3MGYxYjZfNjgw_84534649-13d8-4c35-8b32-0e6a2b551590">COMMITMENTS AND CONTINGENCIES&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to various claims and legal proceedings covering matters that arise in the ordinary course of its business activities, including the matters described below. Estimates for resolution of legal and other contingencies are accrued when losses are probable and reasonably estimable in accordance with ASC 450, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contingencies&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Qui Tam Lawsuit&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the Company's wholly owned subsidiary, Crescendo Bioscience, Inc. (&#x201c;CBI&#x201d;), received a subpoena from the Office of Inspector General of the Department of Health and Human Services requesting that CBI produce documents relating to entities that received payment from CBI for the collection and processing of blood specimens for testing, including a named unrelated company, healthcare providers and other third party entities. The Office of Inspector General subsequently requested additional documentation in December 2017. CBI provided to the Office of Inspector General the documents requested. On January 30, 2020, the United States District Court for the Northern District of California unsealed a qui tam complaint, filed on April 16, 2016 against CBI and the Company, alleging violations of the Federal and California False Claims Acts and the California Insurance Fraud Prevention Act.  On January 22, 2020, after a multi-year investigation into CBI&#x2019;s and the Company&#x2019;s alleged conduct, the United States declined to intervene. On January 27, 2020, the State of California likewise filed its notice of declination. The Company was not aware of the complaint until after it was unsealed. On May 23, 2020, the court denied CBI and the Company&#x2019;s motion to dismiss. The Company has accrued $48.0 million for a potential settlement of this qui tam lawsuit against CBI and the Company, which is included in accrued liabilities in the Company's Condensed Consolidated Balance Sheet. If no settlement is reached, the Company intends to continue to vigorously defend this case, but it cannot predict with any degree of certainty the ultimate resolution of this matter or determine whether, or to what extent, any loss with respect to this matter may exceed the amount that it has accrued.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Purported Securities Class Action&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 27, 2019, a purported class action complaint was filed in the United States District Court for the District of Utah, against the Company, its former President and Chief Executive Officer, Mark C. Capone, and its Chief Financial Officer, R. Bryan Riggsbee (&#x201c;Defendants&#x201d;). On February 21, 2020, the plaintiff filed an amended class action complaint, which added the Company&#x2019;s former Executive Vice President of Clinical Development, Bryan M. Dechairo, as an additional Defendant. This action, captioned &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;In re Myriad Genetics, Inc. Securities Litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (No. 2:19-cv-00707-DBB), is premised upon allegations that the Defendants made false and misleading statements regarding the Company's business, operations, and acquisitions.  The lead plaintiff seeks the payment of damages allegedly sustained by it and the purported class by reason of the allegations set forth in the amended complaint, plus interest, and legal and other costs and fees.  On March 16, 2021, the United States District Court for the District of Utah denied the Company&#x2019;s motion to dismiss. The Company intends to vigorously defend against this action. Due to the nature of this matter and inherent uncertainties, it is not possible to provide an evaluation of the likelihood of an unfavorable outcome or an estimate of the amount or range of potential loss, if any.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stockholder Derivative Actions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 9, 2021, a stockholder derivative complaint was filed in the Delaware Court of Chancery against the Company's former President and Chief Executive Officer, Mark C. Capone, its Chief Financial Officer, R. Bryan Riggsbee, its former Executive Vice President of Clinical Development, Bryan M. Dechairo, and certain of its current and former directors, Lawrence C. Best, Walter Gilbert, John T. Henderson, Heiner Dreismann, Dennis Langer, Lee N. Newcomer, S. Louise Phanstiel, and Colleen F. Reitan (collectively, the "Individual Defendants"), and the Company, as nominal defendant. The complaint is premised upon similar allegations as set forth in the securities class action, including that the Individual Defendants made false and misleading statements regarding the Company's business and operations. The plaintiff, Donna Hickock, asserts breach of fiduciary duty and unjust enrichment claims against the Individual Defendants and seeks, on behalf of the Company, damages allegedly sustained by the Company as a result of the alleged breaches, or disgorgement or restitution, from each of the Individual Defendants, plus interest. Plaintiff Hickock also seeks legal and other costs and fees relating to this action. The Company intends to vigorously defend against this action. Due to the nature of this matter and inherent uncertainties, it is not possible to provide an evaluation of the likelihood of an unfavorable outcome or an estimate of the amount or range of potential loss, if any.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 17, 2021, a second stockholder derivative complaint was filed in the United States District Court for the District of Delaware against the Individual Defendants, and the Company, as nominal defendant. The action is premised upon similar allegations as set forth in the securities class action and Hickock stockholder derivative action. The plaintiff, Karen Marcey, asserts that the Individual Defendants violated U.S. securities laws and breached their fiduciary duties, and also asserts unjust enrichment, waste of corporate assets and insider trading claims against all or some of the Individual Defendants. Plaintiff Marcey seeks, on behalf of the Company, damages allegedly sustained by the Company as a result of the alleged violations and restitution from the Individual Defendants, plus interest and, on behalf of herself, legal and other costs and fees relating to this action. The Company intends to vigorously defend against this action. Due to the nature of this matter and inherent uncertainties, it is not possible to provide an evaluation of the likelihood of an unfavorable outcome or an estimate of the amount or range of potential loss, if any.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On July 27, 2020, a lawsuit was filed against the Company in the Superior Court of Suffolk County, Massachusetts, by Heide Abelli and Victor Pricolo. The plaintiffs claim negligence, breach of contract and associated torts in connection with an alleged error in testing performed by the Company in 2004.  The plaintiffs seek damages allegedly sustained by them by reason of the allegations set forth in their complaint, together with interest and costs. The Company intends to vigorously defend against this action. Due to the nature of this matter and inherent uncertainties, it is not possible to provide an evaluation of the likelihood of an unfavorable outcome or an estimate of the amount or range of potential loss, if any.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;As of September&#160;30, 2021, the management of the Company believes any reasonably possible liability that may result from the resolution of any other matters will not have a material adverse effect on the Company&#x2019;s consolidated financial position, operating results, or cash flows. However, it is possible that the ultimate resolution of other matters, if unfavorable, may be material to the results of operations or financial condition for a particular period.&lt;/span&gt;&lt;/div&gt;From time to time, the Company receives recoupment requests from third-party payors for alleged overpayments. The Company disagrees with the contentions of the pending requests or has recorded an estimated reserve for the alleged overpayments.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LitigationReserveCurrent
      contextRef="i7bca861d20d64642b8c0cb91a290112d_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183MC9mcmFnOjU2MWU4NTAyZDVmMjQ0MTc5YWVkYmRlY2YwNzBmMWI2L3RleHRyZWdpb246NTYxZTg1MDJkNWYyNDQxNzlhZWRiZGVjZjA3MGYxYjZfMTA0NDUzNjA0NzI2Nzc_45952624-4a94-4ef0-91a1-1d38bbc6ae1b"
      unitRef="usd">48000000</us-gaap:LitigationReserveCurrent>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RleHRyZWdpb246NjU2MTNmZDlhOGFkNGVkNDhiMzM4ZGZiYTBiZDMwMGRfMTAwNg_f7b92bdb-624b-4fb2-8719-95062e86c9f3">SEGMENT AND RELATED INFORMATIONThe Company&#x2019;s business is aligned with how the chief operating decision maker reviews performance and makes decisions in managing the Company.&#160;The business units have been aggregated into two reportable segments: (i)&#160;diagnostics and (ii) other. The diagnostics segment provides testing and collaborative development of testing that is designed to determine the risk of developing disease, assess the risk of disease progression, and guide treatment decisions across medical specialties where critical genetic insights can significantly improve patient care and lower healthcare costs. The other segment provides testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients, and includes corporate services such as finance, human resources, legal and information technology.&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Segment revenue and operating income (loss) were as follows during the periods presented:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Diagnostics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Three months ended September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;167.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Segment operating loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(21.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(58.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(79.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Three months ended September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;130.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;145.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Segment operating loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(39.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(39.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Nine months ended September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;496.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;529.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;49.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Segment operating income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;26.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(173.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(147.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Nine months ended September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;362.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;40.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;402.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;50.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;53.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Segment operating loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(127.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(113.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(241.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three months ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Nine months ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total operating loss for reportable segments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(79.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(39.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(147.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(241.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unallocated amounts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(6.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(8.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;120.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;139.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income (loss) from operations before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;39.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(43.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(13.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(233.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income tax expense (benefit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(28.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(47.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(15.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(19.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(185.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net loss attributable to non-controlling interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net income (loss) attributable to Myriad Genetics, Inc. stockholders&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(15.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(19.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(185.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RleHRyZWdpb246NjU2MTNmZDlhOGFkNGVkNDhiMzM4ZGZiYTBiZDMwMGRfMjI1_d08c929c-0c1b-4eb8-b6a1-240c6ca0b6fd"
      unitRef="segment">2</us-gaap:NumberOfReportableSegments>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RleHRyZWdpb246NjU2MTNmZDlhOGFkNGVkNDhiMzM4ZGZiYTBiZDMwMGRfMTAwNw_fe846d08-8889-4ab5-8c2c-d0626c21e056">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Segment revenue and operating income (loss) were as follows during the periods presented:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Diagnostics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Three months ended September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;167.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Segment operating loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(21.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(58.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(79.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Three months ended September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;130.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;145.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Segment operating loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(39.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(39.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Nine months ended September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;496.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;529.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;49.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Segment operating income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;26.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(173.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(147.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Nine months ended September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;362.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;40.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;402.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;50.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;53.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Segment operating loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(127.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(113.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(241.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three months ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Nine months ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total operating loss for reportable segments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(79.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(39.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(147.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(241.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unallocated amounts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(6.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(8.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;120.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;139.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income (loss) from operations before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;39.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(43.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(13.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(233.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income tax expense (benefit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(28.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(47.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(15.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(19.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(185.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net loss attributable to non-controlling interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net income (loss) attributable to Myriad Genetics, Inc. stockholders&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(15.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(19.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(185.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ife30149d9d1d4b99ac1339407e85293d_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOmE1ZDg5N2ZkYTQwMDRhODk4OGVhNmVlYjVkODIyYTNhL3RhYmxlcmFuZ2U6YTVkODk3ZmRhNDAwNGE4OTg4ZWE2ZWViNWQ4MjJhM2FfMi0xLTEtMS0xODE2NA_41a34b1e-e887-4b27-92ab-b1882332f352"
      unitRef="usd">161700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iacd3d37549084b26b52a7a2565dbb4ab_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOmE1ZDg5N2ZkYTQwMDRhODk4OGVhNmVlYjVkODIyYTNhL3RhYmxlcmFuZ2U6YTVkODk3ZmRhNDAwNGE4OTg4ZWE2ZWViNWQ4MjJhM2FfMi0zLTEtMS0xODE2NA_c2b0007b-75d8-4d02-8cd5-a2f43f0f78f5"
      unitRef="usd">5600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOmE1ZDg5N2ZkYTQwMDRhODk4OGVhNmVlYjVkODIyYTNhL3RhYmxlcmFuZ2U6YTVkODk3ZmRhNDAwNGE4OTg4ZWE2ZWViNWQ4MjJhM2FfMi01LTEtMS0xODE2NA_e7110459-1cbc-405d-b097-5b4dcb36b528"
      unitRef="usd">167300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:DepreciationAndAmortization
      contextRef="ife30149d9d1d4b99ac1339407e85293d_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOmE1ZDg5N2ZkYTQwMDRhODk4OGVhNmVlYjVkODIyYTNhL3RhYmxlcmFuZ2U6YTVkODk3ZmRhNDAwNGE4OTg4ZWE2ZWViNWQ4MjJhM2FfMy0xLTEtMS0xODE2NA_e798a030-6c3e-48bf-8baa-5f01f6941c61"
      unitRef="usd">13100000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="iacd3d37549084b26b52a7a2565dbb4ab_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOmE1ZDg5N2ZkYTQwMDRhODk4OGVhNmVlYjVkODIyYTNhL3RhYmxlcmFuZ2U6YTVkODk3ZmRhNDAwNGE4OTg4ZWE2ZWViNWQ4MjJhM2FfMy0zLTEtMS0xODE2NA_ed2f0173-ae89-495a-b217-8539f63c1da9"
      unitRef="usd">1100000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOmE1ZDg5N2ZkYTQwMDRhODk4OGVhNmVlYjVkODIyYTNhL3RhYmxlcmFuZ2U6YTVkODk3ZmRhNDAwNGE4OTg4ZWE2ZWViNWQ4MjJhM2FfMy01LTEtMS0xODE2NA_79acb9c2-393e-4e7e-af00-c575a96ecb2a"
      unitRef="usd">14200000</us-gaap:DepreciationAndAmortization>
    <us-gaap:OperatingIncomeLoss
      contextRef="ife30149d9d1d4b99ac1339407e85293d_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOmE1ZDg5N2ZkYTQwMDRhODk4OGVhNmVlYjVkODIyYTNhL3RhYmxlcmFuZ2U6YTVkODk3ZmRhNDAwNGE4OTg4ZWE2ZWViNWQ4MjJhM2FfNC0xLTEtMS0xODE2NA_03f28a1f-a010-4d90-a342-6a693d8b9544"
      unitRef="usd">-21700000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="iacd3d37549084b26b52a7a2565dbb4ab_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOmE1ZDg5N2ZkYTQwMDRhODk4OGVhNmVlYjVkODIyYTNhL3RhYmxlcmFuZ2U6YTVkODk3ZmRhNDAwNGE4OTg4ZWE2ZWViNWQ4MjJhM2FfNC0zLTEtMS0xODE2NA_350d3d0e-bb14-4013-9df4-b7b4bc0aa8cb"
      unitRef="usd">-58200000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOmE1ZDg5N2ZkYTQwMDRhODk4OGVhNmVlYjVkODIyYTNhL3RhYmxlcmFuZ2U6YTVkODk3ZmRhNDAwNGE4OTg4ZWE2ZWViNWQ4MjJhM2FfNC01LTEtMS0xODE2NA_da298951-ec7d-4cb6-92e3-5fe0f1ee7aa5"
      unitRef="usd">-79900000</us-gaap:OperatingIncomeLoss>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i19766b831a824fe78592ac40be72d491_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOmE1ZDg5N2ZkYTQwMDRhODk4OGVhNmVlYjVkODIyYTNhL3RhYmxlcmFuZ2U6YTVkODk3ZmRhNDAwNGE4OTg4ZWE2ZWViNWQ4MjJhM2FfNy0xLTEtMS0xODE2NA_a16dbb58-cf47-477d-8b7d-77d4de21899f"
      unitRef="usd">130500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i91eb354042484b21815c154fc961e6c4_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOmE1ZDg5N2ZkYTQwMDRhODk4OGVhNmVlYjVkODIyYTNhL3RhYmxlcmFuZ2U6YTVkODk3ZmRhNDAwNGE4OTg4ZWE2ZWViNWQ4MjJhM2FfNy0zLTEtMS0xODE2NA_149d6297-f999-4400-acfa-06e258581827"
      unitRef="usd">14700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic2c3e03438af4889ac973627c642f5ec_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOmE1ZDg5N2ZkYTQwMDRhODk4OGVhNmVlYjVkODIyYTNhL3RhYmxlcmFuZ2U6YTVkODk3ZmRhNDAwNGE4OTg4ZWE2ZWViNWQ4MjJhM2FfNy01LTEtMS0xODE2NA_c557a8eb-edc0-4731-b205-e0ccdb1cd11a"
      unitRef="usd">145200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:DepreciationAndAmortization
      contextRef="i19766b831a824fe78592ac40be72d491_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOmE1ZDg5N2ZkYTQwMDRhODk4OGVhNmVlYjVkODIyYTNhL3RhYmxlcmFuZ2U6YTVkODk3ZmRhNDAwNGE4OTg4ZWE2ZWViNWQ4MjJhM2FfOC0xLTEtMS0xODE2NA_8aa3e1cb-483f-4c68-8874-0c6f1addc0d4"
      unitRef="usd">16700000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i91eb354042484b21815c154fc961e6c4_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOmE1ZDg5N2ZkYTQwMDRhODk4OGVhNmVlYjVkODIyYTNhL3RhYmxlcmFuZ2U6YTVkODk3ZmRhNDAwNGE4OTg4ZWE2ZWViNWQ4MjJhM2FfOC0zLTEtMS0xODE2NA_f5199307-41d0-42f9-8dfc-0042473702ad"
      unitRef="usd">1000000.0</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="ic2c3e03438af4889ac973627c642f5ec_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOmE1ZDg5N2ZkYTQwMDRhODk4OGVhNmVlYjVkODIyYTNhL3RhYmxlcmFuZ2U6YTVkODk3ZmRhNDAwNGE4OTg4ZWE2ZWViNWQ4MjJhM2FfOC01LTEtMS0xODE2NA_152659c6-ced0-474b-8620-fd7ad8eb56e2"
      unitRef="usd">17700000</us-gaap:DepreciationAndAmortization>
    <us-gaap:OperatingIncomeLoss
      contextRef="i19766b831a824fe78592ac40be72d491_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOmE1ZDg5N2ZkYTQwMDRhODk4OGVhNmVlYjVkODIyYTNhL3RhYmxlcmFuZ2U6YTVkODk3ZmRhNDAwNGE4OTg4ZWE2ZWViNWQ4MjJhM2FfOS0xLTEtMS0xODE2NA_33b81287-944b-4f50-adab-bbbd8c1aaf82"
      unitRef="usd">-300000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i91eb354042484b21815c154fc961e6c4_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOmE1ZDg5N2ZkYTQwMDRhODk4OGVhNmVlYjVkODIyYTNhL3RhYmxlcmFuZ2U6YTVkODk3ZmRhNDAwNGE4OTg4ZWE2ZWViNWQ4MjJhM2FfOS0zLTEtMS0xODE2NA_dc206077-3527-4a59-8381-6933467a3f14"
      unitRef="usd">-39300000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ic2c3e03438af4889ac973627c642f5ec_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOmE1ZDg5N2ZkYTQwMDRhODk4OGVhNmVlYjVkODIyYTNhL3RhYmxlcmFuZ2U6YTVkODk3ZmRhNDAwNGE4OTg4ZWE2ZWViNWQ4MjJhM2FfOS01LTEtMS0xODE2NA_f74f661e-546e-4f6d-a16a-c723cd7919e9"
      unitRef="usd">-39600000</us-gaap:OperatingIncomeLoss>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i90324a4d56084a4391c5819f5c839f86_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOmE1ZDg5N2ZkYTQwMDRhODk4OGVhNmVlYjVkODIyYTNhL3RhYmxlcmFuZ2U6YTVkODk3ZmRhNDAwNGE4OTg4ZWE2ZWViNWQ4MjJhM2FfMTItMS0xLTEtMTgxNjQ_47d6a13c-61b0-40aa-a3e8-3ccdc6a1093a"
      unitRef="usd">496600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iee82af509aa24703b7bb72450fba9e9f_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOmE1ZDg5N2ZkYTQwMDRhODk4OGVhNmVlYjVkODIyYTNhL3RhYmxlcmFuZ2U6YTVkODk3ZmRhNDAwNGE4OTg4ZWE2ZWViNWQ4MjJhM2FfMTItMy0xLTEtMTgxNjQ_f9fe54d2-33b2-4190-93ff-99ebed74d846"
      unitRef="usd">33200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOmE1ZDg5N2ZkYTQwMDRhODk4OGVhNmVlYjVkODIyYTNhL3RhYmxlcmFuZ2U6YTVkODk3ZmRhNDAwNGE4OTg4ZWE2ZWViNWQ4MjJhM2FfMTItNS0xLTEtMTgxNjQ_98126f6f-6449-4b55-99b8-12480836dbc2"
      unitRef="usd">529800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:DepreciationAndAmortization
      contextRef="i90324a4d56084a4391c5819f5c839f86_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOmE1ZDg5N2ZkYTQwMDRhODk4OGVhNmVlYjVkODIyYTNhL3RhYmxlcmFuZ2U6YTVkODk3ZmRhNDAwNGE4OTg4ZWE2ZWViNWQ4MjJhM2FfMTMtMS0xLTEtMTgxNjQ_6f080d66-8a69-4840-aa81-7439192d4d71"
      unitRef="usd">45800000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="iee82af509aa24703b7bb72450fba9e9f_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOmE1ZDg5N2ZkYTQwMDRhODk4OGVhNmVlYjVkODIyYTNhL3RhYmxlcmFuZ2U6YTVkODk3ZmRhNDAwNGE4OTg4ZWE2ZWViNWQ4MjJhM2FfMTMtMy0xLTEtMTgxNjQ_793bf913-43fc-4a34-97d9-d26fe4c4dd4f"
      unitRef="usd">3700000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOmE1ZDg5N2ZkYTQwMDRhODk4OGVhNmVlYjVkODIyYTNhL3RhYmxlcmFuZ2U6YTVkODk3ZmRhNDAwNGE4OTg4ZWE2ZWViNWQ4MjJhM2FfMTMtNS0xLTEtMTgxNjQ_9068a788-82a7-443a-8b99-e8624a10ce20"
      unitRef="usd">49500000</us-gaap:DepreciationAndAmortization>
    <us-gaap:OperatingIncomeLoss
      contextRef="i90324a4d56084a4391c5819f5c839f86_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOmE1ZDg5N2ZkYTQwMDRhODk4OGVhNmVlYjVkODIyYTNhL3RhYmxlcmFuZ2U6YTVkODk3ZmRhNDAwNGE4OTg4ZWE2ZWViNWQ4MjJhM2FfMTQtMS0xLTEtMTgxNjQ_498cf74d-f1e6-43c4-b70b-ebc71d25d38c"
      unitRef="usd">26300000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="iee82af509aa24703b7bb72450fba9e9f_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOmE1ZDg5N2ZkYTQwMDRhODk4OGVhNmVlYjVkODIyYTNhL3RhYmxlcmFuZ2U6YTVkODk3ZmRhNDAwNGE4OTg4ZWE2ZWViNWQ4MjJhM2FfMTQtMy0xLTEtMTgxNjQ_6cf7aedb-b72f-48a4-ada2-402fba5a9e3b"
      unitRef="usd">-173700000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOmE1ZDg5N2ZkYTQwMDRhODk4OGVhNmVlYjVkODIyYTNhL3RhYmxlcmFuZ2U6YTVkODk3ZmRhNDAwNGE4OTg4ZWE2ZWViNWQ4MjJhM2FfMTQtNS0xLTEtMTgxNjQ_5f47702c-bcb7-4875-8d80-95e416fc2e36"
      unitRef="usd">-147400000</us-gaap:OperatingIncomeLoss>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id9a30e30fb7d46af9ad9962658bc3126_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOmE1ZDg5N2ZkYTQwMDRhODk4OGVhNmVlYjVkODIyYTNhL3RhYmxlcmFuZ2U6YTVkODk3ZmRhNDAwNGE4OTg4ZWE2ZWViNWQ4MjJhM2FfMTctMS0xLTEtMTgxNjQ_008ddab9-c727-4ef1-a1eb-1e9c7bc79c94"
      unitRef="usd">362000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7eb09159cfc64597873d8167aa298bfe_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOmE1ZDg5N2ZkYTQwMDRhODk4OGVhNmVlYjVkODIyYTNhL3RhYmxlcmFuZ2U6YTVkODk3ZmRhNDAwNGE4OTg4ZWE2ZWViNWQ4MjJhM2FfMTctMy0xLTEtMTgxNjQ_5c30e5cb-de8d-4a8e-a344-d0e24ad96f2f"
      unitRef="usd">40400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOmE1ZDg5N2ZkYTQwMDRhODk4OGVhNmVlYjVkODIyYTNhL3RhYmxlcmFuZ2U6YTVkODk3ZmRhNDAwNGE4OTg4ZWE2ZWViNWQ4MjJhM2FfMTctNS0xLTEtMTgxNjQ_d7134769-6e21-46a4-ad92-2dec5fe930af"
      unitRef="usd">402400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:DepreciationAndAmortization
      contextRef="id9a30e30fb7d46af9ad9962658bc3126_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOmE1ZDg5N2ZkYTQwMDRhODk4OGVhNmVlYjVkODIyYTNhL3RhYmxlcmFuZ2U6YTVkODk3ZmRhNDAwNGE4OTg4ZWE2ZWViNWQ4MjJhM2FfMTgtMS0xLTEtMTgxNjQ_4f0077da-c124-404f-a4f6-30403bab1762"
      unitRef="usd">50200000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i7eb09159cfc64597873d8167aa298bfe_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOmE1ZDg5N2ZkYTQwMDRhODk4OGVhNmVlYjVkODIyYTNhL3RhYmxlcmFuZ2U6YTVkODk3ZmRhNDAwNGE4OTg4ZWE2ZWViNWQ4MjJhM2FfMTgtMy0xLTEtMTgxNjQ_1f185ad8-c43e-44a4-b817-0de38ad709dd"
      unitRef="usd">3100000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOmE1ZDg5N2ZkYTQwMDRhODk4OGVhNmVlYjVkODIyYTNhL3RhYmxlcmFuZ2U6YTVkODk3ZmRhNDAwNGE4OTg4ZWE2ZWViNWQ4MjJhM2FfMTgtNS0xLTEtMTgxNjQ_c70b946a-1665-4a19-ae7b-18b888bf2a2e"
      unitRef="usd">53300000</us-gaap:DepreciationAndAmortization>
    <us-gaap:OperatingIncomeLoss
      contextRef="id9a30e30fb7d46af9ad9962658bc3126_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOmE1ZDg5N2ZkYTQwMDRhODk4OGVhNmVlYjVkODIyYTNhL3RhYmxlcmFuZ2U6YTVkODk3ZmRhNDAwNGE4OTg4ZWE2ZWViNWQ4MjJhM2FfMTktMS0xLTEtMTgxNjQ_c6be4b75-8e0c-4681-a1bc-c7498dbfa8ee"
      unitRef="usd">-127700000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i7eb09159cfc64597873d8167aa298bfe_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOmE1ZDg5N2ZkYTQwMDRhODk4OGVhNmVlYjVkODIyYTNhL3RhYmxlcmFuZ2U6YTVkODk3ZmRhNDAwNGE4OTg4ZWE2ZWViNWQ4MjJhM2FfMTktMy0xLTEtMTgxNjQ_574ade42-72bd-4e9e-9d0d-7c9b17d609b8"
      unitRef="usd">-113900000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOmE1ZDg5N2ZkYTQwMDRhODk4OGVhNmVlYjVkODIyYTNhL3RhYmxlcmFuZ2U6YTVkODk3ZmRhNDAwNGE4OTg4ZWE2ZWViNWQ4MjJhM2FfMTktNS0xLTEtMTgxNjQ_c292d038-a582-4588-9c3b-6c01a608e1dd"
      unitRef="usd">-241600000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOjkxMmU2Yjk5ODk2ZTRiMmNiMjBjMzU2ODY5ODVjODQ1L3RhYmxlcmFuZ2U6OTEyZTZiOTk4OTZlNGIyY2IyMGMzNTY4Njk4NWM4NDVfMi0xLTEtMS0xODE2NA_f677ec4b-a3a0-48b4-aab1-78ea55a4f82f"
      unitRef="usd">-79900000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ic2c3e03438af4889ac973627c642f5ec_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOjkxMmU2Yjk5ODk2ZTRiMmNiMjBjMzU2ODY5ODVjODQ1L3RhYmxlcmFuZ2U6OTEyZTZiOTk4OTZlNGIyY2IyMGMzNTY4Njk4NWM4NDVfMi0zLTEtMS0xODE2NA_62a9dd87-0b4f-48f4-aca6-c62c24d4efc2"
      unitRef="usd">-39600000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOjkxMmU2Yjk5ODk2ZTRiMmNiMjBjMzU2ODY5ODVjODQ1L3RhYmxlcmFuZ2U6OTEyZTZiOTk4OTZlNGIyY2IyMGMzNTY4Njk4NWM4NDVfMi01LTEtMS0xODE2NA_e674346e-9a75-4003-a4e8-78c25635e925"
      unitRef="usd">-147400000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOjkxMmU2Yjk5ODk2ZTRiMmNiMjBjMzU2ODY5ODVjODQ1L3RhYmxlcmFuZ2U6OTEyZTZiOTk4OTZlNGIyY2IyMGMzNTY4Njk4NWM4NDVfMi03LTEtMS0xODE2NA_8677b484-6fcf-4b2d-9d44-55c428e89821"
      unitRef="usd">-241600000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOjkxMmU2Yjk5ODk2ZTRiMmNiMjBjMzU2ODY5ODVjODQ1L3RhYmxlcmFuZ2U6OTEyZTZiOTk4OTZlNGIyY2IyMGMzNTY4Njk4NWM4NDVfNC0xLTEtMS0xODE2NA_01c1212b-59d7-40c7-ae36-47558eaf9d44"
      unitRef="usd">200000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="ic2c3e03438af4889ac973627c642f5ec_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOjkxMmU2Yjk5ODk2ZTRiMmNiMjBjMzU2ODY5ODVjODQ1L3RhYmxlcmFuZ2U6OTEyZTZiOTk4OTZlNGIyY2IyMGMzNTY4Njk4NWM4NDVfNC0zLTEtMS0xODE2NA_03cc7f4d-0f45-40fd-905a-8f874496ab48"
      unitRef="usd">400000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOjkxMmU2Yjk5ODk2ZTRiMmNiMjBjMzU2ODY5ODVjODQ1L3RhYmxlcmFuZ2U6OTEyZTZiOTk4OTZlNGIyY2IyMGMzNTY4Njk4NWM4NDVfNC01LTEtMS0xODE2NA_8fa376f5-0759-4e07-b678-63a3fa2d8db5"
      unitRef="usd">600000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOjkxMmU2Yjk5ODk2ZTRiMmNiMjBjMzU2ODY5ODVjODQ1L3RhYmxlcmFuZ2U6OTEyZTZiOTk4OTZlNGIyY2IyMGMzNTY4Njk4NWM4NDVfNC03LTEtMS0xODE2NA_66613e7d-ff25-4f81-a1b5-3a3ac667505c"
      unitRef="usd">1700000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOjkxMmU2Yjk5ODk2ZTRiMmNiMjBjMzU2ODY5ODVjODQ1L3RhYmxlcmFuZ2U6OTEyZTZiOTk4OTZlNGIyY2IyMGMzNTY4Njk4NWM4NDVfNS0xLTEtMS0xODE2NA_28906cf1-f9b1-460e-8a74-4ffb96153933"
      unitRef="usd">1100000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ic2c3e03438af4889ac973627c642f5ec_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOjkxMmU2Yjk5ODk2ZTRiMmNiMjBjMzU2ODY5ODVjODQ1L3RhYmxlcmFuZ2U6OTEyZTZiOTk4OTZlNGIyY2IyMGMzNTY4Njk4NWM4NDVfNS0zLTEtMS0xODE2NA_33bddd4b-4303-41f1-8a99-f09b7283d91d"
      unitRef="usd">2900000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOjkxMmU2Yjk5ODk2ZTRiMmNiMjBjMzU2ODY5ODVjODQ1L3RhYmxlcmFuZ2U6OTEyZTZiOTk4OTZlNGIyY2IyMGMzNTY4Njk4NWM4NDVfNS01LTEtMS0xODE2NA_113385a1-dec4-4edd-a4e3-8ddbb599e097"
      unitRef="usd">6100000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOjkxMmU2Yjk5ODk2ZTRiMmNiMjBjMzU2ODY5ODVjODQ1L3RhYmxlcmFuZ2U6OTEyZTZiOTk4OTZlNGIyY2IyMGMzNTY4Njk4NWM4NDVfNS03LTEtMS0xODE2NA_17cd26ef-1617-41ee-b4d8-f4f9857a1482"
      unitRef="usd">8300000</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOjkxMmU2Yjk5ODk2ZTRiMmNiMjBjMzU2ODY5ODVjODQ1L3RhYmxlcmFuZ2U6OTEyZTZiOTk4OTZlNGIyY2IyMGMzNTY4Njk4NWM4NDVfNi0xLTEtMS0xODE2NA_73033eba-09e9-4ef2-8948-dfa9328685a6"
      unitRef="usd">120600000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ic2c3e03438af4889ac973627c642f5ec_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOjkxMmU2Yjk5ODk2ZTRiMmNiMjBjMzU2ODY5ODVjODQ1L3RhYmxlcmFuZ2U6OTEyZTZiOTk4OTZlNGIyY2IyMGMzNTY4Njk4NWM4NDVfNi0zLTEtMS0xODE2NA_afc57210-d6b4-44e9-8b52-21c5c4c27ef8"
      unitRef="usd">-1600000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOjkxMmU2Yjk5ODk2ZTRiMmNiMjBjMzU2ODY5ODVjODQ1L3RhYmxlcmFuZ2U6OTEyZTZiOTk4OTZlNGIyY2IyMGMzNTY4Njk4NWM4NDVfNi01LTEtMS0xODE2NA_46783b4d-8384-452b-93bb-9ed672ba7387"
      unitRef="usd">139300000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOjkxMmU2Yjk5ODk2ZTRiMmNiMjBjMzU2ODY5ODVjODQ1L3RhYmxlcmFuZ2U6OTEyZTZiOTk4OTZlNGIyY2IyMGMzNTY4Njk4NWM4NDVfNi03LTEtMS0xODE2NA_e5704da7-2ad9-4dea-817b-c5e73f304b10"
      unitRef="usd">14900000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOjkxMmU2Yjk5ODk2ZTRiMmNiMjBjMzU2ODY5ODVjODQ1L3RhYmxlcmFuZ2U6OTEyZTZiOTk4OTZlNGIyY2IyMGMzNTY4Njk4NWM4NDVfNy0xLTEtMS0xODE2NA_30dad95f-a5cd-4c7e-be84-73ba2ad27aeb"
      unitRef="usd">39800000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ic2c3e03438af4889ac973627c642f5ec_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOjkxMmU2Yjk5ODk2ZTRiMmNiMjBjMzU2ODY5ODVjODQ1L3RhYmxlcmFuZ2U6OTEyZTZiOTk4OTZlNGIyY2IyMGMzNTY4Njk4NWM4NDVfNy0zLTEtMS0xODE2NA_b01637de-26c5-4ddf-89fa-a426e2550b00"
      unitRef="usd">-43700000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOjkxMmU2Yjk5ODk2ZTRiMmNiMjBjMzU2ODY5ODVjODQ1L3RhYmxlcmFuZ2U6OTEyZTZiOTk4OTZlNGIyY2IyMGMzNTY4Njk4NWM4NDVfNy01LTEtMS0xODE2NA_ce31874b-928d-44bc-91b5-dc5146c583a6"
      unitRef="usd">-13600000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOjkxMmU2Yjk5ODk2ZTRiMmNiMjBjMzU2ODY5ODVjODQ1L3RhYmxlcmFuZ2U6OTEyZTZiOTk4OTZlNGIyY2IyMGMzNTY4Njk4NWM4NDVfNy03LTEtMS0xODE2NA_cd790509-eb23-4028-a31e-bf4970267baf"
      unitRef="usd">-233300000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOjkxMmU2Yjk5ODk2ZTRiMmNiMjBjMzU2ODY5ODVjODQ1L3RhYmxlcmFuZ2U6OTEyZTZiOTk4OTZlNGIyY2IyMGMzNTY4Njk4NWM4NDVfOC0xLTEtMS0xODE2NA_c527eac9-9483-44df-a8f0-b3e1843f2874"
      unitRef="usd">15200000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ic2c3e03438af4889ac973627c642f5ec_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOjkxMmU2Yjk5ODk2ZTRiMmNiMjBjMzU2ODY5ODVjODQ1L3RhYmxlcmFuZ2U6OTEyZTZiOTk4OTZlNGIyY2IyMGMzNTY4Njk4NWM4NDVfOC0zLTEtMS0xODE2NA_9bcf4b77-8baf-43dd-a6d9-2c80f47db642"
      unitRef="usd">-28500000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOjkxMmU2Yjk5ODk2ZTRiMmNiMjBjMzU2ODY5ODVjODQ1L3RhYmxlcmFuZ2U6OTEyZTZiOTk4OTZlNGIyY2IyMGMzNTY4Njk4NWM4NDVfOC01LTEtMS0xODE2NA_0a0c1b67-9ba4-4f65-aa1e-73ce96e86b2c"
      unitRef="usd">6000000.0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOjkxMmU2Yjk5ODk2ZTRiMmNiMjBjMzU2ODY5ODVjODQ1L3RhYmxlcmFuZ2U6OTEyZTZiOTk4OTZlNGIyY2IyMGMzNTY4Njk4NWM4NDVfOC03LTEtMS0xODE2NA_cf16bb03-8a7d-4712-80d6-2a12ef3f0f68"
      unitRef="usd">-47400000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOjkxMmU2Yjk5ODk2ZTRiMmNiMjBjMzU2ODY5ODVjODQ1L3RhYmxlcmFuZ2U6OTEyZTZiOTk4OTZlNGIyY2IyMGMzNTY4Njk4NWM4NDVfOS0xLTEtMS0xODE2NA_f65f489c-d69c-42c2-8ca7-3bede2cb2276"
      unitRef="usd">24600000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ic2c3e03438af4889ac973627c642f5ec_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOjkxMmU2Yjk5ODk2ZTRiMmNiMjBjMzU2ODY5ODVjODQ1L3RhYmxlcmFuZ2U6OTEyZTZiOTk4OTZlNGIyY2IyMGMzNTY4Njk4NWM4NDVfOS0zLTEtMS0xODE2NA_a4074eaa-a36a-4948-9e4b-13bf1f1fe36d"
      unitRef="usd">-15200000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOjkxMmU2Yjk5ODk2ZTRiMmNiMjBjMzU2ODY5ODVjODQ1L3RhYmxlcmFuZ2U6OTEyZTZiOTk4OTZlNGIyY2IyMGMzNTY4Njk4NWM4NDVfOS01LTEtMS0xODE2NA_3382ebf6-9cd0-403f-9327-36c5a3248b84"
      unitRef="usd">-19600000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOjkxMmU2Yjk5ODk2ZTRiMmNiMjBjMzU2ODY5ODVjODQ1L3RhYmxlcmFuZ2U6OTEyZTZiOTk4OTZlNGIyY2IyMGMzNTY4Njk4NWM4NDVfOS03LTEtMS0xODE2NA_8e31fe3e-28ca-430b-9259-0bed23e87f5b"
      unitRef="usd">-185900000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOjkxMmU2Yjk5ODk2ZTRiMmNiMjBjMzU2ODY5ODVjODQ1L3RhYmxlcmFuZ2U6OTEyZTZiOTk4OTZlNGIyY2IyMGMzNTY4Njk4NWM4NDVfMTAtMS0xLTEtMTgxNjQ_e9ab0712-2096-4643-bfd9-7a2be8f2d0cd"
      unitRef="usd">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="ic2c3e03438af4889ac973627c642f5ec_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOjkxMmU2Yjk5ODk2ZTRiMmNiMjBjMzU2ODY5ODVjODQ1L3RhYmxlcmFuZ2U6OTEyZTZiOTk4OTZlNGIyY2IyMGMzNTY4Njk4NWM4NDVfMTAtMy0xLTEtMTgxNjQ_d65bd003-64c8-4187-9513-33422a0ba014"
      unitRef="usd">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOjkxMmU2Yjk5ODk2ZTRiMmNiMjBjMzU2ODY5ODVjODQ1L3RhYmxlcmFuZ2U6OTEyZTZiOTk4OTZlNGIyY2IyMGMzNTY4Njk4NWM4NDVfMTAtNS0xLTEtMTgxNjQ_ccc07d2f-729d-48ee-9f4b-4f233debfbaa"
      unitRef="usd">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOjkxMmU2Yjk5ODk2ZTRiMmNiMjBjMzU2ODY5ODVjODQ1L3RhYmxlcmFuZ2U6OTEyZTZiOTk4OTZlNGIyY2IyMGMzNTY4Njk4NWM4NDVfMTAtNy0xLTEtMTgxNjQ_cec41c9a-d422-46df-bb0c-11132f299934"
      unitRef="usd">-100000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOjkxMmU2Yjk5ODk2ZTRiMmNiMjBjMzU2ODY5ODVjODQ1L3RhYmxlcmFuZ2U6OTEyZTZiOTk4OTZlNGIyY2IyMGMzNTY4Njk4NWM4NDVfMTEtMS0xLTEtMTgxNjQ_350a6d28-298a-44f1-9158-5a6123e1b468"
      unitRef="usd">24600000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic2c3e03438af4889ac973627c642f5ec_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOjkxMmU2Yjk5ODk2ZTRiMmNiMjBjMzU2ODY5ODVjODQ1L3RhYmxlcmFuZ2U6OTEyZTZiOTk4OTZlNGIyY2IyMGMzNTY4Njk4NWM4NDVfMTEtMy0xLTEtMTgxNjQ_cd9597f5-1969-4da2-a71d-ac65cf1567cc"
      unitRef="usd">-15200000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOjkxMmU2Yjk5ODk2ZTRiMmNiMjBjMzU2ODY5ODVjODQ1L3RhYmxlcmFuZ2U6OTEyZTZiOTk4OTZlNGIyY2IyMGMzNTY4Njk4NWM4NDVfMTEtNS0xLTEtMTgxNjQ_21d78e16-ee98-4cbd-8d0e-85f93334f89e"
      unitRef="usd">-19600000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183My9mcmFnOjY1NjEzZmQ5YThhZDRlZDQ4YjMzOGRmYmEwYmQzMDBkL3RhYmxlOjkxMmU2Yjk5ODk2ZTRiMmNiMjBjMzU2ODY5ODVjODQ1L3RhYmxlcmFuZ2U6OTEyZTZiOTk4OTZlNGIyY2IyMGMzNTY4Njk4NWM4NDVfMTEtNy0xLTEtMTgxNjQ_ea6c4dbc-e823-4675-8498-9aaa6a5739a6"
      unitRef="usd">-185800000</us-gaap:NetIncomeLoss>
    <us-gaap:CashFlowSupplementalDisclosuresTextBlock
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183Ni9mcmFnOjI0N2ExOTlmOTk2OTQ4ODhiMDI4ZGUwM2MwZTY1MTJhL3RleHRyZWdpb246MjQ3YTE5OWY5OTY5NDg4OGIwMjhkZTAzYzBlNjUxMmFfNDI_053280f5-f29c-4514-b85a-027e5bd02496">SUPPLEMENTAL CASH FLOW INFORMATION&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.046%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.599%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Nine months ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash paid during the period for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash paid for interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash received for income tax receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Establishment of operating lease right-of-use assets and lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;40.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;46.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:CashFlowSupplementalDisclosuresTextBlock>
    <us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183Ni9mcmFnOjI0N2ExOTlmOTk2OTQ4ODhiMDI4ZGUwM2MwZTY1MTJhL3RleHRyZWdpb246MjQ3YTE5OWY5OTY5NDg4OGIwMjhkZTAzYzBlNjUxMmFfNDE_bfad6fc6-e84a-45e0-a346-b90fffc84aae">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.046%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.599%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Nine months ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash paid during the period for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash paid for interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash received for income tax receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Establishment of operating lease right-of-use assets and lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;40.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;46.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock>
    <us-gaap:IncomeTaxesPaid
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183Ni9mcmFnOjI0N2ExOTlmOTk2OTQ4ODhiMDI4ZGUwM2MwZTY1MTJhL3RhYmxlOjljNDc2YTMxODNhNTRjNjBhMjUzYzZlZDM1ZDA2NzY3L3RhYmxlcmFuZ2U6OWM0NzZhMzE4M2E1NGM2MGEyNTNjNmVkMzVkMDY3NjdfMi0xLTEtMS0xODE2NA_6abee198-ff36-4185-b341-a60edab772e4"
      unitRef="usd">2400000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183Ni9mcmFnOjI0N2ExOTlmOTk2OTQ4ODhiMDI4ZGUwM2MwZTY1MTJhL3RhYmxlOjljNDc2YTMxODNhNTRjNjBhMjUzYzZlZDM1ZDA2NzY3L3RhYmxlcmFuZ2U6OWM0NzZhMzE4M2E1NGM2MGEyNTNjNmVkMzVkMDY3NjdfMi0zLTEtMS0xODE2NA_d40c12db-a6f8-47ee-a7da-57dd8dd2aef0"
      unitRef="usd">2300000</us-gaap:IncomeTaxesPaid>
    <us-gaap:InterestPaidNet
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183Ni9mcmFnOjI0N2ExOTlmOTk2OTQ4ODhiMDI4ZGUwM2MwZTY1MTJhL3RhYmxlOjljNDc2YTMxODNhNTRjNjBhMjUzYzZlZDM1ZDA2NzY3L3RhYmxlcmFuZ2U6OWM0NzZhMzE4M2E1NGM2MGEyNTNjNmVkMzVkMDY3NjdfMy0xLTEtMS0xODE2NA_0936ea89-3670-4979-b37c-0d94a4783ea6"
      unitRef="usd">2100000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183Ni9mcmFnOjI0N2ExOTlmOTk2OTQ4ODhiMDI4ZGUwM2MwZTY1MTJhL3RhYmxlOjljNDc2YTMxODNhNTRjNjBhMjUzYzZlZDM1ZDA2NzY3L3RhYmxlcmFuZ2U6OWM0NzZhMzE4M2E1NGM2MGEyNTNjNmVkMzVkMDY3NjdfMy0zLTEtMS0xODE2NA_24a68675-6429-40d0-9a4b-5072ad6dd07f"
      unitRef="usd">6900000</us-gaap:InterestPaidNet>
    <us-gaap:ProceedsFromIncomeTaxRefunds
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183Ni9mcmFnOjI0N2ExOTlmOTk2OTQ4ODhiMDI4ZGUwM2MwZTY1MTJhL3RhYmxlOjljNDc2YTMxODNhNTRjNjBhMjUzYzZlZDM1ZDA2NzY3L3RhYmxlcmFuZ2U6OWM0NzZhMzE4M2E1NGM2MGEyNTNjNmVkMzVkMDY3NjdfNC0xLTEtMS0xODE2NA_7d717181-888a-44e4-b4ee-97c94243dce6"
      unitRef="usd">89900000</us-gaap:ProceedsFromIncomeTaxRefunds>
    <us-gaap:ProceedsFromIncomeTaxRefunds
      contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183Ni9mcmFnOjI0N2ExOTlmOTk2OTQ4ODhiMDI4ZGUwM2MwZTY1MTJhL3RhYmxlOjljNDc2YTMxODNhNTRjNjBhMjUzYzZlZDM1ZDA2NzY3L3RhYmxlcmFuZ2U6OWM0NzZhMzE4M2E1NGM2MGEyNTNjNmVkMzVkMDY3NjdfNC0zLTEtMS0xODE2NA_958110da-b5ce-4935-aa56-fb3849c566fe"
      unitRef="usd">0</us-gaap:ProceedsFromIncomeTaxRefunds>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183Ni9mcmFnOjI0N2ExOTlmOTk2OTQ4ODhiMDI4ZGUwM2MwZTY1MTJhL3RhYmxlOjljNDc2YTMxODNhNTRjNjBhMjUzYzZlZDM1ZDA2NzY3L3RhYmxlcmFuZ2U6OWM0NzZhMzE4M2E1NGM2MGEyNTNjNmVkMzVkMDY3NjdfNy0xLTEtMS0xODE2NA_e193d7e4-364f-4862-a0d5-0305e689e08a"
      unitRef="usd">40500000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183Ni9mcmFnOjI0N2ExOTlmOTk2OTQ4ODhiMDI4ZGUwM2MwZTY1MTJhL3RhYmxlOjljNDc2YTMxODNhNTRjNjBhMjUzYzZlZDM1ZDA2NzY3L3RhYmxlcmFuZ2U6OWM0NzZhMzE4M2E1NGM2MGEyNTNjNmVkMzVkMDY3NjdfNy0zLTEtMS0xODE2NA_c4bde549-5efa-4053-add6-643711ad3f6d"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <mygn:OperatingLeaseLiabilityEstablished
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183Ni9mcmFnOjI0N2ExOTlmOTk2OTQ4ODhiMDI4ZGUwM2MwZTY1MTJhL3RhYmxlOjljNDc2YTMxODNhNTRjNjBhMjUzYzZlZDM1ZDA2NzY3L3RhYmxlcmFuZ2U6OWM0NzZhMzE4M2E1NGM2MGEyNTNjNmVkMzVkMDY3NjdfOC0xLTEtMS0xODE2NA_35845e97-70f2-4a8c-9f9b-88ee6775cf7c"
      unitRef="usd">46800000</mygn:OperatingLeaseLiabilityEstablished>
    <mygn:OperatingLeaseLiabilityEstablished
      contextRef="i56d8d419460447f1b88d128613dfe0b4_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183Ni9mcmFnOjI0N2ExOTlmOTk2OTQ4ODhiMDI4ZGUwM2MwZTY1MTJhL3RhYmxlOjljNDc2YTMxODNhNTRjNjBhMjUzYzZlZDM1ZDA2NzY3L3RhYmxlcmFuZ2U6OWM0NzZhMzE4M2E1NGM2MGEyNTNjNmVkMzVkMDY3NjdfOC0zLTEtMS0xODE2NA_75f81e3c-aa4d-474f-b1da-5d9462738d29"
      unitRef="usd">0</mygn:OperatingLeaseLiabilityEstablished>
    <us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183OS9mcmFnOmNjZjdkY2MyMTZlOTRmNGRiMGI2NmRkYjBjNjIzMGFlL3RleHRyZWdpb246Y2NmN2RjYzIxNmU5NGY0ZGIwYjY2ZGRiMGM2MjMwYWVfMjUwNA_90a2b169-c1ac-47eb-8ccb-c900704ed7f2">DIVESTITURES&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 28, 2021, the Company completed its sale of the Myriad myPath, LLC laboratory to Castle Biosciences, Inc. for cash consideration of $32.5 million. The transaction was accounted for as a sale of assets and the Company recognized a gain of $31.2 million, net of transaction costs of $1.3 million, in Other income (expense) on the Company&#x2019;s Condensed Consolidated Statements of Operations related to the sale. Prior to the sale, Myriad myPath operations were included in the Company&#x2019;s diagnostics reporting segment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 1, 2021, the Company completed its sale of Myriad RBM, Inc., a wholly owned subsidiary of the Company, to IQVIA RDS, Inc. for cash consideration of $197.0 million. The transaction was accounted for as a sale of a business and the Company recognized a gain of $121.0 million, net of transaction costs of $4.8 million, in Other income (expense) on the Company's Condensed Consolidated Statements of Operations. Prior to the sale, Myriad RBM, Inc. operations were included in the Company&#x2019;s other reporting segment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 13, 2021, the Company completed its sale of select operating assets and intellectual property, including the Vectra&#xae; test, from the Myriad Autoimmune business unit to Laboratory Corporation of America Holdings for cash consideration of $150.0 million. The transaction was accounted for as a sale of a business and the Company recognized a loss of $0.6 million, net of transaction costs of $4.4 million, in Other income (expense) on the Company's Condensed Consolidated Statements of Operations. Prior to the sale, the Myriad Autoimmune business operations were included in the Company&#x2019;s diagnostics reporting segment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The operating results of these businesses do not qualify for reporting as discontinued operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Inventory&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the divestiture transactions, the Company recognized losses of $5.2 million and $6.5 million for a non-cancelable inventory purchase commitment and inventory, respectively, during the nine months ended September 30, 2021, as the Company will no longer have use for the goods. Both of these losses are included in Other income (expense) in the Company's Condensed Consolidated Statements of Operations for the nine months ended September 30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table details the amounts recognized in Other income for the three and nine months ended September 30, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.514%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.516%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three months ended September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Nine months ended&lt;br/&gt;&#160;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gain on sale of Myriad RBM, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;121.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;121.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gain on sale of Myriad myPath, LLC laboratory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;31.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gain (loss) on inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(11.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Loss on sale of Myriad Autoimmune assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total Other Income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;120.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;139.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>
    <us-gaap:ProceedsFromSaleOfProductiveAssets
      contextRef="i5b97fc75f0ec45e0bd58df1dad474b32_D20210528-20210528"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183OS9mcmFnOmNjZjdkY2MyMTZlOTRmNGRiMGI2NmRkYjBjNjIzMGFlL3RleHRyZWdpb246Y2NmN2RjYzIxNmU5NGY0ZGIwYjY2ZGRiMGM2MjMwYWVfMzYw_e4dc6c95-922b-4c7e-b0af-a93a78328e7a"
      unitRef="usd">32500000</us-gaap:ProceedsFromSaleOfProductiveAssets>
    <mygn:GainLossOnDispositionOfAssetsNetOfTransactionFees
      contextRef="i5b97fc75f0ec45e0bd58df1dad474b32_D20210528-20210528"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183OS9mcmFnOmNjZjdkY2MyMTZlOTRmNGRiMGI2NmRkYjBjNjIzMGFlL3RleHRyZWdpb246Y2NmN2RjYzIxNmU5NGY0ZGIwYjY2ZGRiMGM2MjMwYWVfNDU5_4d5d051f-e948-48a1-864c-dcf00fdb699b"
      unitRef="usd">31200000</mygn:GainLossOnDispositionOfAssetsNetOfTransactionFees>
    <mygn:DisposalGroupNotDiscontinuedOperationTransactionCosts
      contextRef="i5b97fc75f0ec45e0bd58df1dad474b32_D20210528-20210528"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183OS9mcmFnOmNjZjdkY2MyMTZlOTRmNGRiMGI2NmRkYjBjNjIzMGFlL3RleHRyZWdpb246Y2NmN2RjYzIxNmU5NGY0ZGIwYjY2ZGRiMGM2MjMwYWVfMTA5OTUxMTYzNTc5Nw_296ef2e3-1bea-49b9-9425-3f4120254cac"
      unitRef="usd">1300000</mygn:DisposalGroupNotDiscontinuedOperationTransactionCosts>
    <us-gaap:ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries
      contextRef="ie5db1cb383af4d9091b44997a3e2b23f_D20210701-20210701"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183OS9mcmFnOmNjZjdkY2MyMTZlOTRmNGRiMGI2NmRkYjBjNjIzMGFlL3RleHRyZWdpb246Y2NmN2RjYzIxNmU5NGY0ZGIwYjY2ZGRiMGM2MjMwYWVfMTA5OTUxMTYzNDQ3NA_bc9d43a5-1180-4991-a435-4c8c6f272f0f"
      unitRef="usd">197000000</us-gaap:ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries>
    <us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
      contextRef="ie5db1cb383af4d9091b44997a3e2b23f_D20210701-20210701"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183OS9mcmFnOmNjZjdkY2MyMTZlOTRmNGRiMGI2NmRkYjBjNjIzMGFlL3RleHRyZWdpb246Y2NmN2RjYzIxNmU5NGY0ZGIwYjY2ZGRiMGM2MjMwYWVfMTY0OTI2NzQ0ODI1MQ_5dac1006-b708-44f6-8de0-43bb8d2f73be"
      unitRef="usd">121000000</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal>
    <mygn:DisposalGroupNotDiscontinuedOperationTransactionCosts
      contextRef="ie5db1cb383af4d9091b44997a3e2b23f_D20210701-20210701"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183OS9mcmFnOmNjZjdkY2MyMTZlOTRmNGRiMGI2NmRkYjBjNjIzMGFlL3RleHRyZWdpb246Y2NmN2RjYzIxNmU5NGY0ZGIwYjY2ZGRiMGM2MjMwYWVfMTA5OTUxMTYzNDUxNA_88908281-7204-4d0c-8a62-6a63c88c0199"
      unitRef="usd">4800000</mygn:DisposalGroupNotDiscontinuedOperationTransactionCosts>
    <us-gaap:ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries
      contextRef="i6b8313a324f94c6caad8b75523488f35_D20210913-20210913"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183OS9mcmFnOmNjZjdkY2MyMTZlOTRmNGRiMGI2NmRkYjBjNjIzMGFlL3RleHRyZWdpb246Y2NmN2RjYzIxNmU5NGY0ZGIwYjY2ZGRiMGM2MjMwYWVfMTY0OTI2NzQ0NTE5OA_99e90258-77de-40a3-93f4-35ff9b549fd0"
      unitRef="usd">150000000</us-gaap:ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries>
    <us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
      contextRef="i6b8313a324f94c6caad8b75523488f35_D20210913-20210913"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183OS9mcmFnOmNjZjdkY2MyMTZlOTRmNGRiMGI2NmRkYjBjNjIzMGFlL3RleHRyZWdpb246Y2NmN2RjYzIxNmU5NGY0ZGIwYjY2ZGRiMGM2MjMwYWVfMTY0OTI2NzQ0ODMyMw_69f8cf6f-2a53-46ea-b402-70e7c072febe"
      unitRef="usd">-600000</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal>
    <mygn:DisposalGroupNotDiscontinuedOperationTransactionCosts
      contextRef="i6b8313a324f94c6caad8b75523488f35_D20210913-20210913"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183OS9mcmFnOmNjZjdkY2MyMTZlOTRmNGRiMGI2NmRkYjBjNjIzMGFlL3RleHRyZWdpb246Y2NmN2RjYzIxNmU5NGY0ZGIwYjY2ZGRiMGM2MjMwYWVfMTA5OTUxMTYzNDU1NQ_a34ee1a6-2c18-4b79-a332-0650dae50b87"
      unitRef="usd">4400000</mygn:DisposalGroupNotDiscontinuedOperationTransactionCosts>
    <us-gaap:InventoryFirmPurchaseCommitmentLoss
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183OS9mcmFnOmNjZjdkY2MyMTZlOTRmNGRiMGI2NmRkYjBjNjIzMGFlL3RleHRyZWdpb246Y2NmN2RjYzIxNmU5NGY0ZGIwYjY2ZGRiMGM2MjMwYWVfMTY0OTI2NzQ0ODE3MQ_506b289b-5869-41fe-b96a-6340508c677b"
      unitRef="usd">5200000</us-gaap:InventoryFirmPurchaseCommitmentLoss>
    <us-gaap:InventoryWriteDown
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183OS9mcmFnOmNjZjdkY2MyMTZlOTRmNGRiMGI2NmRkYjBjNjIzMGFlL3RleHRyZWdpb246Y2NmN2RjYzIxNmU5NGY0ZGIwYjY2ZGRiMGM2MjMwYWVfMTY0OTI2NzQ0ODE3OQ_7be5c0c0-881f-42f4-a195-314249073ed7"
      unitRef="usd">6500000</us-gaap:InventoryWriteDown>
    <us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183OS9mcmFnOmNjZjdkY2MyMTZlOTRmNGRiMGI2NmRkYjBjNjIzMGFlL3RleHRyZWdpb246Y2NmN2RjYzIxNmU5NGY0ZGIwYjY2ZGRiMGM2MjMwYWVfMjc0ODc3OTA3ODEzMQ_a0325e83-cef5-487d-b91c-64aeb693fdea">&lt;div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table details the amounts recognized in Other income for the three and nine months ended September 30, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.514%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.516%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three months ended September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Nine months ended&lt;br/&gt;&#160;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gain on sale of Myriad RBM, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;121.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;121.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gain on sale of Myriad myPath, LLC laboratory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;31.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gain (loss) on inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(11.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Loss on sale of Myriad Autoimmune assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total Other Income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;120.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;139.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock>
    <us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
      contextRef="ib8b44ab869f44ebd9da9cf10c35e35c4_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183OS9mcmFnOmNjZjdkY2MyMTZlOTRmNGRiMGI2NmRkYjBjNjIzMGFlL3RhYmxlOjBkMTg0NmYwYmNlNjQ4YTI4NjgxYzlmYWU3YmVmZmY4L3RhYmxlcmFuZ2U6MGQxODQ2ZjBiY2U2NDhhMjg2ODFjOWZhZTdiZWZmZjhfMS0xLTEtMS0yODYxNw_31149cbc-6d4d-4d93-b12e-ee1d5ea734a7"
      unitRef="usd">121000000.0</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal>
    <us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
      contextRef="iae9bd564d0e24269a0860f286b76a8c8_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183OS9mcmFnOmNjZjdkY2MyMTZlOTRmNGRiMGI2NmRkYjBjNjIzMGFlL3RhYmxlOjBkMTg0NmYwYmNlNjQ4YTI4NjgxYzlmYWU3YmVmZmY4L3RhYmxlcmFuZ2U6MGQxODQ2ZjBiY2U2NDhhMjg2ODFjOWZhZTdiZWZmZjhfMS0zLTEtMS0yODYxNw_860fa99a-7e01-4f72-b720-48810585e0c2"
      unitRef="usd">121000000.0</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal>
    <us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
      contextRef="ic7ad8f15a58548759fdb4e238c847c6b_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183OS9mcmFnOmNjZjdkY2MyMTZlOTRmNGRiMGI2NmRkYjBjNjIzMGFlL3RhYmxlOjBkMTg0NmYwYmNlNjQ4YTI4NjgxYzlmYWU3YmVmZmY4L3RhYmxlcmFuZ2U6MGQxODQ2ZjBiY2U2NDhhMjg2ODFjOWZhZTdiZWZmZjhfMi0xLTEtMS0yODYxNw_7cde60bc-2224-4cb8-9c16-261dea7e9c04"
      unitRef="usd">0</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal>
    <us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
      contextRef="i1b39e1079fcf498da2478fc0bfa35a9c_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183OS9mcmFnOmNjZjdkY2MyMTZlOTRmNGRiMGI2NmRkYjBjNjIzMGFlL3RhYmxlOjBkMTg0NmYwYmNlNjQ4YTI4NjgxYzlmYWU3YmVmZmY4L3RhYmxlcmFuZ2U6MGQxODQ2ZjBiY2U2NDhhMjg2ODFjOWZhZTdiZWZmZjhfMi0zLTEtMS0yODYxNw_3c64ac9c-845c-4f61-b5b7-6c78e8ac2f6a"
      unitRef="usd">31200000</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal>
    <mygn:DisposalGroupNotDiscontinuedOperationGainLossOnInventory
      contextRef="id8db12274a5e41019919e2f3e84a1cfd_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183OS9mcmFnOmNjZjdkY2MyMTZlOTRmNGRiMGI2NmRkYjBjNjIzMGFlL3RhYmxlOjBkMTg0NmYwYmNlNjQ4YTI4NjgxYzlmYWU3YmVmZmY4L3RhYmxlcmFuZ2U6MGQxODQ2ZjBiY2U2NDhhMjg2ODFjOWZhZTdiZWZmZjhfMy0xLTEtMS0yODYyNg_aee6f48e-5127-4551-8f42-b8e24f935367"
      unitRef="usd">800000</mygn:DisposalGroupNotDiscontinuedOperationGainLossOnInventory>
    <mygn:DisposalGroupNotDiscontinuedOperationGainLossOnInventory
      contextRef="id6f9bab1ac3d4f769be2cf49d2c11dc1_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183OS9mcmFnOmNjZjdkY2MyMTZlOTRmNGRiMGI2NmRkYjBjNjIzMGFlL3RhYmxlOjBkMTg0NmYwYmNlNjQ4YTI4NjgxYzlmYWU3YmVmZmY4L3RhYmxlcmFuZ2U6MGQxODQ2ZjBiY2U2NDhhMjg2ODFjOWZhZTdiZWZmZjhfMy0zLTEtMS0yODYzMw_bad9d53d-7ee7-41af-9169-45b59b7af314"
      unitRef="usd">-11700000</mygn:DisposalGroupNotDiscontinuedOperationGainLossOnInventory>
    <us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
      contextRef="if410392a6c864eb4bcc542e0317057f6_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183OS9mcmFnOmNjZjdkY2MyMTZlOTRmNGRiMGI2NmRkYjBjNjIzMGFlL3RhYmxlOjBkMTg0NmYwYmNlNjQ4YTI4NjgxYzlmYWU3YmVmZmY4L3RhYmxlcmFuZ2U6MGQxODQ2ZjBiY2U2NDhhMjg2ODFjOWZhZTdiZWZmZjhfNC0xLTEtMS0yODY0MQ_d1ba30cd-16c1-406c-8a43-3f06e79f5737"
      unitRef="usd">-600000</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal>
    <us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
      contextRef="ia7f3ca65537e48c2a6d04c65e5799212_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183OS9mcmFnOmNjZjdkY2MyMTZlOTRmNGRiMGI2NmRkYjBjNjIzMGFlL3RhYmxlOjBkMTg0NmYwYmNlNjQ4YTI4NjgxYzlmYWU3YmVmZmY4L3RhYmxlcmFuZ2U6MGQxODQ2ZjBiY2U2NDhhMjg2ODFjOWZhZTdiZWZmZjhfNC0zLTEtMS0yODY0MQ_1fbf6de4-355e-4520-b103-05042e876e67"
      unitRef="usd">-600000</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal>
    <mygn:DisposalGroupNotDiscontinuedOperationGainLossOther
      contextRef="id8db12274a5e41019919e2f3e84a1cfd_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183OS9mcmFnOmNjZjdkY2MyMTZlOTRmNGRiMGI2NmRkYjBjNjIzMGFlL3RhYmxlOjBkMTg0NmYwYmNlNjQ4YTI4NjgxYzlmYWU3YmVmZmY4L3RhYmxlcmFuZ2U6MGQxODQ2ZjBiY2U2NDhhMjg2ODFjOWZhZTdiZWZmZjhfNS0xLTEtMS0yODY0MQ_633c861f-392f-4e10-b52a-b4ec887d250f"
      unitRef="usd">-600000</mygn:DisposalGroupNotDiscontinuedOperationGainLossOther>
    <mygn:DisposalGroupNotDiscontinuedOperationGainLossOther
      contextRef="id6f9bab1ac3d4f769be2cf49d2c11dc1_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183OS9mcmFnOmNjZjdkY2MyMTZlOTRmNGRiMGI2NmRkYjBjNjIzMGFlL3RhYmxlOjBkMTg0NmYwYmNlNjQ4YTI4NjgxYzlmYWU3YmVmZmY4L3RhYmxlcmFuZ2U6MGQxODQ2ZjBiY2U2NDhhMjg2ODFjOWZhZTdiZWZmZjhfNS0zLTEtMS0yODY0MQ_24379092-f7cf-416f-95d7-db7bc77207a4"
      unitRef="usd">-600000</mygn:DisposalGroupNotDiscontinuedOperationGainLossOther>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183OS9mcmFnOmNjZjdkY2MyMTZlOTRmNGRiMGI2NmRkYjBjNjIzMGFlL3RhYmxlOjBkMTg0NmYwYmNlNjQ4YTI4NjgxYzlmYWU3YmVmZmY4L3RhYmxlcmFuZ2U6MGQxODQ2ZjBiY2U2NDhhMjg2ODFjOWZhZTdiZWZmZjhfNi0xLTEtMS0zNDQwOA_d7df76c3-9adb-4877-aed7-5c2dee24c6af"
      unitRef="usd">120600000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN183OS9mcmFnOmNjZjdkY2MyMTZlOTRmNGRiMGI2NmRkYjBjNjIzMGFlL3RhYmxlOjBkMTg0NmYwYmNlNjQ4YTI4NjgxYzlmYWU3YmVmZmY4L3RhYmxlcmFuZ2U6MGQxODQ2ZjBiY2U2NDhhMjg2ODFjOWZhZTdiZWZmZjhfNi00LTEtMS0zMDQyNg_78652503-b480-410d-962d-470d5d231a9c"
      unitRef="usd">139300000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="i526dd58342b2430ab657188009969982_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU4MTRhNzE5NjI5MzQ3OTI5MDFjYjIzMzAzNjFiYjE3L3NlYzo1ODE0YTcxOTYyOTM0NzkyOTAxY2IyMzMwMzYxYmIxN184Mi9mcmFnOmMwN2Q2YmYxOGIzMDRhOWY4YTVjNGYyODM2OTc4NGUxL3RleHRyZWdpb246YzA3ZDZiZjE4YjMwNGE5ZjhhNWM0ZjI4MzY5Nzg0ZTFfODM2_db5684d2-5a2f-4775-822e-2464ac7cede5">SUBSEQUENT EVENTSThe Company evaluated subsequent events from the balance sheet date through the date the financial statements were issued. Based upon this review, the Company did not identify any subsequent events that would have required adjustment or disclosure in the financial statements.</us-gaap:SubsequentEventsTextBlock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139657724674344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Oct. 27, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">0-26642<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">MYRIAD GENETICS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000899923<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">87-0494517<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">320 Wakara Way<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Salt Lake City<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">UT<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">84108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">801<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">584-3600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.01 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MYGN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79,854,649<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139657731100456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 295.2<span></span>
</td>
<td class="nump">$ 117.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable investment securities</a></td>
<td class="nump">70.9<span></span>
</td>
<td class="nump">33.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Trade accounts receivable</a></td>
<td class="nump">93.6<span></span>
</td>
<td class="nump">89.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">18.6<span></span>
</td>
<td class="nump">27.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidTaxes', window );">Prepaid taxes</a></td>
<td class="nump">0.4<span></span>
</td>
<td class="nump">108.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">20.2<span></span>
</td>
<td class="nump">13.7<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">498.9<span></span>
</td>
<td class="nump">389.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">83.6<span></span>
</td>
<td class="nump">59.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Long-term marketable investment securities</a></td>
<td class="nump">47.5<span></span>
</td>
<td class="nump">21.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant, and equipment, net</a></td>
<td class="nump">43.4<span></span>
</td>
<td class="nump">40.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangibles, net</a></td>
<td class="nump">414.8<span></span>
</td>
<td class="nump">576.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">239.7<span></span>
</td>
<td class="nump">329.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">8.0<span></span>
</td>
<td class="nump">2.3<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">1,335.9<span></span>
</td>
<td class="nump">1,418.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">15.7<span></span>
</td>
<td class="nump">20.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">163.2<span></span>
</td>
<td class="nump">79.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current maturities of operating lease liabilities</a></td>
<td class="nump">12.8<span></span>
</td>
<td class="nump">13.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenues</a></td>
<td class="nump">11.5<span></span>
</td>
<td class="nump">32.7<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">203.2<span></span>
</td>
<td class="nump">145.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">32.0<span></span>
</td>
<td class="nump">30.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Long-term deferred taxes</a></td>
<td class="nump">40.7<span></span>
</td>
<td class="nump">71.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Noncurrent operating lease liabilities</a></td>
<td class="nump">80.7<span></span>
</td>
<td class="nump">50.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">224.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">10.8<span></span>
</td>
<td class="nump">14.7<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">367.4<span></span>
</td>
<td class="nump">537.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, 79.7 million and 75.4 million shares outstanding at September&#160;30, 2021 and December 31, 2020, respectively</a></td>
<td class="nump">0.8<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">1,218.8<span></span>
</td>
<td class="nump">1,109.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(4.4)<span></span>
</td>
<td class="num">(2.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(246.6)<span></span>
</td>
<td class="num">(227.0)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Myriad Genetics, Inc. stockholders&#8217; equity</a></td>
<td class="nump">968.6<span></span>
</td>
<td class="nump">881.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Non-controlling interest</a></td>
<td class="num">(0.1)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total stockholders' equity</a></td>
<td class="nump">968.5<span></span>
</td>
<td class="nump">881.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 1,335.9<span></span>
</td>
<td class="nump">$ 1,418.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6787-107765<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123349782&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139657726887256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - shares<br> shares in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">79.7<span></span>
</td>
<td class="nump">75.4<span></span>
</td>
<td class="nump">75.2<span></span>
</td>
<td class="nump">74.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139657727010440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 167.3<span></span>
</td>
<td class="nump">$ 145.2<span></span>
</td>
<td class="nump">$ 529.8<span></span>
</td>
<td class="nump">$ 402.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">18.8<span></span>
</td>
<td class="nump">17.6<span></span>
</td>
<td class="nump">61.4<span></span>
</td>
<td class="nump">54.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general, and administrative expense</a></td>
<td class="nump">180.2<span></span>
</td>
<td class="nump">124.1<span></span>
</td>
<td class="nump">460.5<span></span>
</td>
<td class="nump">364.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in the fair value of contingent consideration</a></td>
<td class="nump">0.4<span></span>
</td>
<td class="num">(1.1)<span></span>
</td>
<td class="nump">1.7<span></span>
</td>
<td class="num">(4.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetImpairment', window );">Goodwill and long-lived asset impairment charges</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
<td class="nump">98.4<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total costs and expenses</a></td>
<td class="nump">247.2<span></span>
</td>
<td class="nump">184.8<span></span>
</td>
<td class="nump">677.2<span></span>
</td>
<td class="nump">644.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(79.9)<span></span>
</td>
<td class="num">(39.6)<span></span>
</td>
<td class="num">(147.4)<span></span>
</td>
<td class="num">(241.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
<td class="nump">1.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(1.1)<span></span>
</td>
<td class="num">(2.9)<span></span>
</td>
<td class="num">(6.1)<span></span>
</td>
<td class="num">(8.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other</a></td>
<td class="nump">120.6<span></span>
</td>
<td class="num">(1.6)<span></span>
</td>
<td class="nump">139.3<span></span>
</td>
<td class="nump">14.9<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense), net</a></td>
<td class="nump">119.7<span></span>
</td>
<td class="num">(4.1)<span></span>
</td>
<td class="nump">133.8<span></span>
</td>
<td class="nump">8.3<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income (loss) before income tax</a></td>
<td class="nump">39.8<span></span>
</td>
<td class="num">(43.7)<span></span>
</td>
<td class="num">(13.6)<span></span>
</td>
<td class="num">(233.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense (benefit)</a></td>
<td class="nump">15.2<span></span>
</td>
<td class="num">(28.5)<span></span>
</td>
<td class="nump">6.0<span></span>
</td>
<td class="num">(47.4)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">24.6<span></span>
</td>
<td class="num">(15.2)<span></span>
</td>
<td class="num">(19.6)<span></span>
</td>
<td class="num">(185.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to non-controlling interest</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) attributable to Myriad Genetics, Inc. stockholders</a></td>
<td class="nump">$ 24.6<span></span>
</td>
<td class="num">$ (15.2)<span></span>
</td>
<td class="num">$ (19.6)<span></span>
</td>
<td class="num">$ (185.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Net income (loss) per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="nump">$ 0.31<span></span>
</td>
<td class="num">$ (0.20)<span></span>
</td>
<td class="num">$ (0.25)<span></span>
</td>
<td class="num">$ (2.49)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="nump">$ 0.30<span></span>
</td>
<td class="num">$ (0.20)<span></span>
</td>
<td class="num">$ (0.25)<span></span>
</td>
<td class="num">$ (2.49)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract', window );"><strong>Weighted average shares outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (shares)</a></td>
<td class="nump">78.8<span></span>
</td>
<td class="nump">74.7<span></span>
</td>
<td class="nump">77.3<span></span>
</td>
<td class="nump">74.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (shares)</a></td>
<td class="nump">81.5<span></span>
</td>
<td class="nump">74.7<span></span>
</td>
<td class="nump">77.3<span></span>
</td>
<td class="nump">74.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mygn_MolecularDiagnosticTestingMember', window );">Molecular diagnostic testing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 167.3<span></span>
</td>
<td class="nump">$ 135.7<span></span>
</td>
<td class="nump">$ 505.6<span></span>
</td>
<td class="nump">$ 369.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of revenue</a></td>
<td class="nump">47.8<span></span>
</td>
<td class="nump">39.9<span></span>
</td>
<td class="nump">139.9<span></span>
</td>
<td class="nump">115.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mygn_PharmaceuticalAndClinicalServicesMember', window );">Pharmaceutical and clinical services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">9.5<span></span>
</td>
<td class="nump">24.2<span></span>
</td>
<td class="nump">32.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of revenue</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 4.3<span></span>
</td>
<td class="nump">$ 11.9<span></span>
</td>
<td class="nump">$ 15.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingCostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingCostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mygn_MolecularDiagnosticTestingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mygn_MolecularDiagnosticTestingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mygn_PharmaceuticalAndClinicalServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mygn_PharmaceuticalAndClinicalServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139657726999736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Income (Loss) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) attributable to Myriad Genetics, Inc. stockholders</a></td>
<td class="nump">$ 24.6<span></span>
</td>
<td class="num">$ (15.2)<span></span>
</td>
<td class="num">$ (19.6)<span></span>
</td>
<td class="num">$ (185.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on available-for-sale debt securities, net of tax</a></td>
<td class="num">(0.2)<span></span>
</td>
<td class="num">(0.2)<span></span>
</td>
<td class="num">(0.5)<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Change in foreign currency translation adjustment, net of tax</a></td>
<td class="num">(0.2)<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
<td class="num">(1.6)<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive income (loss)</a></td>
<td class="nump">24.2<span></span>
</td>
<td class="num">(13.6)<span></span>
</td>
<td class="num">(21.7)<span></span>
</td>
<td class="num">(184.2)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income (loss) attributable to Myriad Genetics, Inc. stockholders</a></td>
<td class="nump">$ 24.2<span></span>
</td>
<td class="num">$ (13.6)<span></span>
</td>
<td class="num">$ (21.7)<span></span>
</td>
<td class="num">$ (184.2)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139657815849944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders' Equity - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common stock</div></th>
<th class="th"><div>Additional paid-in capital</div></th>
<th class="th"><div>Accumulated other comprehensive loss</div></th>
<th class="th"><div>Accumulated deficit</div></th>
<th class="th"><div>Non-controlling interest</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="nump">$ 1,077.3<span></span>
</td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="nump">$ 1,085.1<span></span>
</td>
<td class="num">$ (5.3)<span></span>
</td>
<td class="num">$ (3.3)<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock under stock-based compensation plans, net of shares exchanged for withholding tax</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based payment expense</a></td>
<td class="nump">7.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestPeriodIncreaseDecrease', window );">Non-controlling interest</a></td>
<td class="num">(0.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(115.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(115.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_ReclassificationFromAccumulatedOtherComprehensiveLossDeconsolidationOfSubsidiary', window );">Reclassification out of accumulated other comprehensive loss upon the deconsolidation of a subsidiary</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(2.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Mar. 31, 2020</a></td>
<td class="nump">967.2<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
<td class="nump">1,092.8<span></span>
</td>
<td class="num">(7.8)<span></span>
</td>
<td class="num">(118.5)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="nump">1,077.3<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
<td class="nump">1,085.1<span></span>
</td>
<td class="num">(5.3)<span></span>
</td>
<td class="num">(3.3)<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(185.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Sep. 30, 2020</a></td>
<td class="nump">909.3<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
<td class="nump">1,101.2<span></span>
</td>
<td class="num">(3.6)<span></span>
</td>
<td class="num">(189.1)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Mar. 31, 2020</a></td>
<td class="nump">967.2<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
<td class="nump">1,092.8<span></span>
</td>
<td class="num">(7.8)<span></span>
</td>
<td class="num">(118.5)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock under stock-based compensation plans, net of shares exchanged for withholding tax</a></td>
<td class="nump">1.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based payment expense</a></td>
<td class="nump">1.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(55.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(55.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">2.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Jun. 30, 2020</a></td>
<td class="nump">918.2<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
<td class="nump">1,096.6<span></span>
</td>
<td class="num">(5.2)<span></span>
</td>
<td class="num">(173.9)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock under stock-based compensation plans, net of shares exchanged for withholding tax</a></td>
<td class="num">(3.7)<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="num">(3.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based payment expense</a></td>
<td class="nump">8.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(15.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">1.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Sep. 30, 2020</a></td>
<td class="nump">909.3<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
<td class="nump">1,101.2<span></span>
</td>
<td class="num">(3.6)<span></span>
</td>
<td class="num">(189.1)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">881.0<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
<td class="nump">1,109.5<span></span>
</td>
<td class="num">(2.3)<span></span>
</td>
<td class="num">(227.0)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock under stock-based compensation plans, net of shares exchanged for withholding tax</a></td>
<td class="nump">26.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based payment expense</a></td>
<td class="nump">9.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(39.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(39.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(1.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Mar. 31, 2021</a></td>
<td class="nump">875.2<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
<td class="nump">1,144.5<span></span>
</td>
<td class="num">(3.6)<span></span>
</td>
<td class="num">(266.5)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">881.0<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
<td class="nump">1,109.5<span></span>
</td>
<td class="num">(2.3)<span></span>
</td>
<td class="num">(227.0)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(19.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Sep. 30, 2021</a></td>
<td class="nump">968.5<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
<td class="nump">1,218.8<span></span>
</td>
<td class="num">(4.4)<span></span>
</td>
<td class="num">(246.6)<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Mar. 31, 2021</a></td>
<td class="nump">875.2<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
<td class="nump">1,144.5<span></span>
</td>
<td class="num">(3.6)<span></span>
</td>
<td class="num">(266.5)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock under stock-based compensation plans, net of shares exchanged for withholding tax</a></td>
<td class="nump">23.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based payment expense</a></td>
<td class="nump">8.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestPeriodIncreaseDecrease', window );">Non-controlling interest</a></td>
<td class="num">(0.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(4.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(0.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Jun. 30, 2021</a></td>
<td class="nump">902.4<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
<td class="nump">1,176.9<span></span>
</td>
<td class="num">(4.0)<span></span>
</td>
<td class="num">(271.2)<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock under stock-based compensation plans, net of shares exchanged for withholding tax</a></td>
<td class="nump">31.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based payment expense</a></td>
<td class="nump">10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">24.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(0.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Sep. 30, 2021</a></td>
<td class="nump">$ 968.5<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="nump">$ 1,218.8<span></span>
</td>
<td class="num">$ (4.4)<span></span>
</td>
<td class="num">$ (246.6)<span></span>
</td>
<td class="num">$ (0.1)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_ReclassificationFromAccumulatedOtherComprehensiveLossDeconsolidationOfSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reclassification From Accumulated Other Comprehensive Loss, Deconsolidation Of Subsidiary</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_ReclassificationFromAccumulatedOtherComprehensiveLossDeconsolidationOfSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net Increase or Decrease in balance of noncontrolling interest in the subsidiary during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139657727079896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) attributable to Myriad Genetics, Inc. stockholders</a></td>
<td class="num">$ (19.6)<span></span>
</td>
<td class="num">$ (185.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">49.5<span></span>
</td>
<td class="nump">53.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_NonCashInterestExpense', window );">Non-cash interest expense</a></td>
<td class="nump">1.3<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Non-cash lease expense</a></td>
<td class="nump">9.8<span></span>
</td>
<td class="nump">9.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">27.9<span></span>
</td>
<td class="nump">17.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes', window );">Deferred income taxes</a></td>
<td class="num">(27.8)<span></span>
</td>
<td class="num">(0.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_IncreaseDecreaseInUnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">1.5<span></span>
</td>
<td class="nump">14.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_ChangeInFairValueOfContingentConsideration', window );">Change in fair value of contingent consideration</a></td>
<td class="nump">1.7<span></span>
</td>
<td class="num">(4.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Loss on inventory</a></td>
<td class="nump">6.5<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_ImpairmentOfGoodwillAndLongLivedAssetsHeldForUse', window );">Impairment of goodwill and long-lived assets</a></td>
<td class="nump">1.8<span></span>
</td>
<td class="nump">98.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Gain on sale of businesses and assets</a></td>
<td class="num">(162.0)<span></span>
</td>
<td class="num">(1.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpensesOther', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(6.7)<span></span>
</td>
<td class="nump">5.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Trade accounts receivable</a></td>
<td class="num">(11.6)<span></span>
</td>
<td class="nump">33.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(1.6)<span></span>
</td>
<td class="nump">1.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidTaxes', window );">Prepaid taxes</a></td>
<td class="nump">108.0<span></span>
</td>
<td class="num">(83.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other assets</a></td>
<td class="num">(3.6)<span></span>
</td>
<td class="num">(1.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(4.8)<span></span>
</td>
<td class="num">(2.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued liabilities</a></td>
<td class="nump">78.2<span></span>
</td>
<td class="nump">3.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenues</a></td>
<td class="num">(20.4)<span></span>
</td>
<td class="nump">28.5<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by (used in) operating activities</a></td>
<td class="nump">28.1<span></span>
</td>
<td class="num">(12.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Capital expenditures</a></td>
<td class="num">(14.6)<span></span>
</td>
<td class="num">(6.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets', window );">Proceeds from sale of businesses and assets</a></td>
<td class="nump">379.1<span></span>
</td>
<td class="nump">21.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of marketable investment securities</a></td>
<td class="num">(101.0)<span></span>
</td>
<td class="num">(15.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds from maturities and sales of marketable investment securities</a></td>
<td class="nump">36.8<span></span>
</td>
<td class="nump">51.9<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="nump">300.3<span></span>
</td>
<td class="nump">50.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Proceeds from common stock issued under stock-based compensation plans</a></td>
<td class="nump">90.0<span></span>
</td>
<td class="nump">2.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Payment of tax withheld for common stock issued under stock-based compensation plans</a></td>
<td class="num">(8.6)<span></span>
</td>
<td class="num">(3.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities', window );">Payment of contingent consideration recognized at acquisition</a></td>
<td class="num">(3.3)<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Fees associated with refinancing of revolving credit facility</a></td>
<td class="num">(1.2)<span></span>
</td>
<td class="num">(1.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLinesOfCredit', window );">Repayment of revolving credit facility</a></td>
<td class="num">(226.4)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="num">(149.5)<span></span>
</td>
<td class="num">(2.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of foreign exchange rates on cash and cash equivalents</a></td>
<td class="num">(0.7)<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_NetChangeInCashAndCashEquivalentsClassifiedAsHeldForSale', window );">Change in cash and cash equivalents classified as held for sale</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash and cash equivalents</a></td>
<td class="nump">178.2<span></span>
</td>
<td class="nump">37.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of the period</a></td>
<td class="nump">117.0<span></span>
</td>
<td class="nump">81.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of the period</a></td>
<td class="nump">$ 295.2<span></span>
</td>
<td class="nump">$ 118.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_ChangeInFairValueOfContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of contingent consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_ChangeInFairValueOfContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_ImpairmentOfGoodwillAndLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Impairment Of Goodwill And Long-Lived Assets Held For Use</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_ImpairmentOfGoodwillAndLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_IncreaseDecreaseInUnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_IncreaseDecreaseInUnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_NetChangeInCashAndCashEquivalentsClassifiedAsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net Change In Cash And Cash Equivalents Classified As Held For Sale</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_NetChangeInCashAndCashEquivalentsClassifiedAsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_NonCashInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non cash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_NonCashInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123371682&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpensesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of consideration paid in advance for other costs that provide economic benefits in future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpensesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of consideration paid in advance for income and other taxes that provide economic benefits in future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4542-108314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123362884&amp;loc=d3e9212-128498<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123362884&amp;loc=d3e9215-128498<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123385561&amp;loc=d3e9135-128495<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate cash proceeds received from a combination of transactions in which noncurrent assets are sold, which may include the sale of a business, an investment in an affiliate (including an equity method investee), property, plant and equipment and intangible assets. Excludes sales of trading, available-for-sale, and held-to-maturity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139657721970792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Basis of Presentation</a></td>
<td class="text">BASIS OF PRESENTATION<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Myriad Genetics, Inc. and its subsidiaries (collectively, the &#8220;Company&#8221; or &#8220;Myriad&#8221;) discover and commercialize genetic tests that determine the risk of developing disease, assess the risk of disease progression, and guide treatment decisions across medical specialties where critical genetic insights can significantly improve patient care and lower healthcare costs. The Company's mission and purpose is to advance health and well-being for all, empower individuals with vital genetic insights and enable healthcare providers to better detect, treat and prevent disease. The Company generates revenue by performing molecular diagnostic tests and, prior to the sale of Myriad RBM, Inc. on July 1, 2021 as described in Note 16, by providing pharmaceutical services to the pharmaceutical and biotechnology industries and medical research institutions utilizing its multiplexed immunoassay technology. The Company&#8217;s corporate headquarters are located in Salt Lake City, Utah.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying Condensed Consolidated Financial Statements for the Company have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) for interim financial information and pursuant to the applicable rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;).&#160;All intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, the accompanying financial statements contain all adjustments (consisting of normal and recurring accruals) necessary to present fairly all financial statements in accordance with GAAP. The Condensed Consolidated Financial Statements herein should be read in conjunction with the Company&#8217;s audited Consolidated Financial Statements and notes thereto included in the Company&#8217;s Transition Report on Form 10-K for the transition period ended December&#160;31, 2020 (the &#8220;Transition Report on Form 10-K&#8221;). </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenue and expenses during the reporting period. Operating results for the three and nine months ended September&#160;30, 2021 may not necessarily be indicative of results to be expected for any other interim period or for the full year.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has historically experienced seasonality in its testing business. The volume of testing is negatively impacted by the summer season, which is generally reflected in the quarter ending June 30 and the quarter ending September 30. The quarter ending December 31 is generally strong as the Company sees an increase in volumes from patients who have met their annual insurance deductible. Conversely, the quarter ending March 31 is typically negatively impacted by the annual reset of patient deductibles.  </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the COVID-19 global pandemic, including variants of COVID-19 (&#8220;COVID-19&#8221;), seasonality may not follow the same pattern as in prior years. Volumes and results of operations were impacted negatively in calendar year 2020 by COVID-19. As such, the Company&#8217;s year over year results may not be comparable. Management continues to monitor the impact of COVID-19 on the Company&#8217;s financial condition, liquidity, operations, suppliers, industry, and workforce. Given the variants of COVID-19 that have surfaced around the world, the Company is not able to fully estimate the effects of COVID-19 on results of operations, financial condition, or liquidity for future periods.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reclassifications</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior period amounts have been reclassified to conform with the current period presentation. The reclassifications have no impact on the total assets, total liabilities, stockholders&#8217; equity, cash flows from operations, or net income (loss) for the period.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Adopted Standards</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (&#8220;ASU 2019-12&#8221;). ASU 2019-12 is a new accounting standard to simplify accounting for income taxes and remove, modify, and add to the disclosure requirements of income taxes. The standard is effective for fiscal years beginning after December 15, 2020, with early adoption permitted. This guidance was adopted</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> with no material impact to t</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he Company's Condensed Consolidated Financial Statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139657722115976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue</a></td>
<td class="text">REVENUE<div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Myriad generates revenue by performing molecular diagnostic testing, and prior to the sale of Myriad RBM, Inc. on July 1, 2021, pharmaceutical services. Molecular diagnostic revenues consists of the following categories (products): Hereditary Cancer (myRisk, BRACAnalysis, BRACAnalysis CDx), Tumor Profiling (myChoice CDx, Prolaris, and EndoPredict), Prenatal (Foresight and Prequel), Pharmacogenomics (GeneSight), Autoimmune (Vectra), and Other. The Company previously provided pharmaceutical services and clinical services prior to the sale of Myriad RBM, Inc. and Privatklinik Dr. Robert Schindlbeck GmbH &amp; Co. KG (the &#8220;Clinic&#8221;), respectively. Prior to the sale of the Myriad myPath, LLC laboratory in May 2021 and select assets of the Myriad Autoimmune (Vectra) business unit in September 2021, the associated revenue was included within Molecular diagnostic revenues. See Note 16 for a discussion of these divestitures. Revenue is recorded at the estimated amount of consideration to be received. The Company has determined that the communication of test results or the completion of pharmaceutical and clinical services indicates transfer of control for revenue recognition purposes.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents detail regarding the composition of the Company&#8217;s total revenue by category and by U.S. versus rest of world (&#8220;RoW&#8221;):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.200%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.624%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.624%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.624%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.624%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.624%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.630%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="36" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">RoW</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">RoW</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molecular diagnostic revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hereditary Cancer</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tumor Profiling</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prenatal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmacogenomics</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Autoimmune</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total molecular diagnostic revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">144.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">167.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">124.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">135.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical and clinical services revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">144.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">167.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">134.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">145.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="36" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">RoW</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">RoW</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molecular diagnostic revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hereditary Cancer</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">207.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">241.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">188.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">205.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tumor Profiling</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prenatal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmacogenomics</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Autoimmune</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total molecular diagnostic revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">439.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">505.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">344.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">369.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical and clinical services revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">464.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">529.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">373.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">402.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The Company performs its obligation under a contract with a customer by processing diagnostic tests and communicating the test results to customers, in exchange for consideration from the customer. The Company has the right to bill its customers upon the completion of performance obligations and thus does not record contract assets. Occasionally, customers make payments prior to the Company&#8217;s performance of its contractual obligations. When this occurs, the Company records a contract liability as deferred revenue. Included within the Company's deferred revenues are advance Medicare payments. During the fiscal year ended June 30, 2020, the Company received approximately $29.7 million in advance Medicare payments to provide relief from the economic impacts of COVID-19 on the Company. The advanced Medicare payments began being applied against services performed in April 2021 and will continue until the funds previously received are fully earned. A reconciliation of the beginning and ending balances of deferred revenues is shown in the table below:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.000%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.624%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.626%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine months ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenues - beginning balance</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue recognized</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(30.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepayments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Divestitures</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenues - ending balance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with ASC Topic 606, Revenue from Contracts with Customers, the Company has elected not to disclose the aggregate amount of the transaction price allocated to remaining performance obligations for its contracts that are one year or less, as the revenue is expected to be recognized within the next year. Furthermore, the Company has elected not to disclose the aggregate amount of the transaction price allocated to remaining performance obligations for its agreements wherein the Company&#8217;s right to payment is in an amount that directly corresponds with the value of the Company&#8217;s performance to date. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In determining the transaction price, the Company includes an estimate of the expected amount of consideration as revenue. The Company applies this method consistently for similar contracts when estimating the effect of any uncertainty on an amount of variable consideration to which it will be entitled. An estimate of transaction price does not include any estimated amount of variable consideration that is constrained. In addition, the Company considers all the information (historical, current, and forecast) that is reasonably available to identify possible consideration amounts. The Company considers the probability of the variable consideration for each possible scenario. The Company also has significant experience with historical discount patterns and uses this experience to estimate transaction prices. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The estimate of revenue is affected by assumptions in payor behavior such as changes in payor mix, payor collections, current customer contractual requirements, and experience with collections from third-party payors. When assessing the total consideration for insurance carriers and patients, revenues are further constrained for estimated refunds. The Company reserves certain amounts in Accrued liabilities in the Company&#8217;s Condensed Consolidated Balance Sheets in anticipation of requests for refunds of payments made previously by insurance carriers, which are accounted for as reductions in revenues in the Condensed Consolidated Statements of Operations and Comprehensive Income (Loss).</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cash collections for certain diagnostic tests delivered may differ from rates originally estimated, primarily driven by changes in the estimated transaction price due to contractual adjustments, obtaining updated information from payors and patients that was unknown at the time the performance obligation was met, and settlements with third party payors. During the three and nine months ended September 30, 2021, the Company recognized $7.6 million and $16.6 million in revenue, respectively, which resulted in a $0.07 impact and $0.16 impact to earnings per share, respectively, for tests in which the performance obligation of delivering the tests results was met in prior periods. The changes were primarily driven by changes in the estimated transaction price. Additionally, during the three months ended March 31, 2021, the Company recognized $6.8 million of revenue due to expanded coverage for Prolaris, for which revenue was fully constrained in a prior period. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies the practical expedient related to costs to obtain or fulfill a contract since the amortization period for such costs will be one year or less. Accordingly, no costs incurred to obtain or fulfill a contract have been capitalized. The Company also applies the practical expedient for not adjusting revenue recognized for the effects of the time value of money. This practical expedient has been elected because the Company collects very little cash from customers under payment terms and the vast majority of payment terms have a payback period of less than one year. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable. Substantially all of the Company&#8217;s accounts receivable are with companies in the healthcare industry, U.S. and state governmental agencies that make payments on the customer's behalf, and individuals. The Company does not believe that receivables due from U.S. and state governmental agencies, such as Medicare, represent a credit risk since the related healthcare programs are funded by the U.S. and state governments. The Company only has one payor, Medicare, that represents greater than 10% of its revenues. Revenues received from Medicare represented approximately 17% of total revenue for each of the three and nine months ended September&#160;30, 2021, and 16% and 15% of total revenue for the three and nine months ended September&#160;30, 2020, respectively. Concentrations of credit risk are mitigated due to the number of the Company&#8217;s customers as well as their dispersion across many geographic regions. No payor accounted for more than 10% of accounts receivable at September&#160;30, 2021 or December&#160;31, 2020. The Company does not require collateral from its customers.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139657724226728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Investment Securities<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Marketable Investment Securities</a></td>
<td class="text">MARKETABLE INVESTMENT SECURITIES<div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortized cost, gross unrealized holding gains, gross unrealized holding losses, and fair value for available-for-sale securities by major security type and class of security at September&#160;30, 2021 and December&#160;31, 2020 were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized<br/>cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>unrealized<br/>holding<br/>gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>unrealized<br/>holding<br/>losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated<br/>fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">208.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">208.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">295.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">295.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-sale:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate bonds and notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Municipal bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal agency issues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">US government securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">413.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.1)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">413.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized<br/>cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>unrealized<br/>holding<br/>gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>unrealized<br/>holding<br/>losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated<br/>fair value</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2020:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47.9&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47.9&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total cash and cash equivalents</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">117.0&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">117.0&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-sale:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate bonds and notes</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28.8&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.5&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29.3&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Municipal bonds</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal agency issues</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.0&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.0&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">US government securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">170.9&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.8&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">171.7&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents, and maturities of debt securities classified as available-for-sale securities were as follows at September&#160;30, 2021:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized<br/>cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated<br/>fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due within one year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due after one year through five years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due after five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">413.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">413.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no debt securities classified as available-for-sale in a gross unrealized loss position as of September&#160;30, 2021 or December 31, 2020.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional information relating to fair value of marketable investment securities can be found in Note 4.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2176304<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph (b)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139657721846872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">FAIR VALUE MEASUREMENTS<div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Company&#8217;s financial instruments reflects the amounts that the Company estimates it will receive in connection with the sale of an asset or pay in connection with the transfer of a liability in an orderly transaction between market participants at the measurement date (exit price). The fair value hierarchy prioritizes the use of inputs used in valuation techniques into the following three levels:</span></div><div style="margin-top:9pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1&#8212;quoted prices in active markets for identical assets and liabilities.</span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2&#8212;observable inputs other than quoted prices in active markets for identical assets and liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&#160;&#160;Some of the Company&#8217;s marketable securities primarily utilize broker quotes in a non-active market for valuation of these securities.</span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3&#8212;unobservable inputs.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the Company&#8217;s financial instruments are valued using quoted prices in active markets or based on other observable inputs.&#160;&#160;For Level 2 securities, the Company uses a third party pricing service which provides documentation on an ongoing basis that includes, among other things, pricing information with respect to reference data, methodology, inputs summarized by asset class, pricing application and corroborative information. For Level 3 contingent consideration, the Company reassesses the fair value of expected contingent consideration and the corresponding liability each reporting period using the Monte Carlo Method, which is consistent with the initial measurement of the expected earn out liability.&#160;This fair value measurement is considered a Level 3 measurement because the Company estimates projections during the expected measurement period of approximately 13.8 years, utilizing various potential pay-out scenarios.&#160;&#160;Probabilities were applied to each potential scenario and the resulting values were discounted using a rate that considers weighted average cost of capital as well as a specific risk premium associated with the riskiness of the earn-out itself, the related projections, and the overall business.&#160;The contingent earn-out liabilities are classified as components of Accrued liabilities and Other long-term liabilities in the Company&#8217;s Condensed Consolidated Balance Sheets.&#160;&#160;Changes to contingent consideration liabilities are reflected in Change in the fair value of contingent consideration in the Company&#8217;s Condensed Consolidated Statements of Operations. Changes to the unobservable inputs could have a material impact on the Company&#8217;s financial statements.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the fair value of the financial assets and liabilities that the Company re-measures on a regular basis:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September 30, 2021</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds (a)</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate bonds and notes</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90.8&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90.8&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Municipal bonds</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal agency issues</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.6&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.6&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">US government securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8.8)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8.8)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86.4&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">118.4&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8.8)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">196.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:27.13pt">Money market funds are primarily comprised of exchange traded funds and accrued interest.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2020</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds (a)</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate bonds and notes</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29.3&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29.3&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Municipal bonds</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal agency issues</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.0&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.0&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">US government securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10.9)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10.9)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69.1&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54.7&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10.9)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112.9&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:27.13pt">Money market funds are primarily comprised of exchange traded funds and accrued interest.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following table reconciles the change in the fair value of the contingent consideration during the periods presented:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.596%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance December 31, 2020</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.9&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payment of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in fair value recognized in the income statement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Translation adjustments recognized in other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ending balance September 30, 2021</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139657721968136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property, Plant and Equipment, Net</a></td>
<td class="text">PROPERTY, PLANT AND EQUIPMENT, NET<div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.226%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.511%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.513%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold improvements</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38.1&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35.7&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equipment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">110.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">117.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment, gross</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">148.4&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">153.6&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less accumulated depreciation</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(105.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(112.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment, net</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43.4&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40.7&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in equipment from December 31, 2020 to September 30, 2021 was primarily due to the sales of Myriad RBM, Inc. and select assets of the Myriad Autoimmune business. See Note 16 for additional information on these divestitures.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.215%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine months ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.6&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.4&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.9&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.5&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139657722171336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill and Intangible Assets</a></td>
<td class="text">GOODWILL AND INTANGIBLE ASSETS<div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the carrying amount of goodwill for the nine months ended September&#160;30, 2021:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.321%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.759%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.636%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.716%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Diagnostic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">329.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Divestitures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Translation adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the quarter ended September 30, 2021, the Company completed the sale of Myriad RBM, Inc. and select operating assets and intellectual property, including the Vectra&#174; test, from the Myriad Autoimmune business unit. See Note 16 for additional information on these divestitures.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets have primarily consisted of amortizable assets of purchased licenses and technologies, customer relationships, and trade names as well as non-amortizable intangible assets of in-process technologies and research and development.&#160;As of September 30, 2021, the Company's intangible assets consist of only purchased licenses and technologies due to the completion of the sales of Myriad RBM, Inc. and select operating assets and intellectual property, including the Vectra&#174; test, from the Myriad Autoimmune business unit. In connection with these sales, the Company sold $199.1 million in purchased licenses and technologies, $4.8 million in-process research and development intangible assets, $4.7 million in customer relationships, and $3.0 million in trademarks, resulting in an aggregate decrease of intangible assets of $120.0 million, net of $91.6 million in accumulated amortization. See Note 16 for additional information on these divestitures.  The following summarizes the amounts reported as intangible assets:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.350%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September 30, 2021:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchased licenses and technologies</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">617.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(202.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">414.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total amortized intangible assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">617.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(202.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">414.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total intangible assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">617.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(202.6)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">414.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.350%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2020:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchased licenses and technologies</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">818.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(248.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">570.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customer relationships</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.7&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4.5)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.2&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trademarks</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total amortized intangible assets</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">825.9&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(254.2)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">571.7&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In-process research and development</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total unamortized intangible assets</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.8&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.8&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total intangible assets</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">830.7&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(254.2)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">576.5&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded amortization expense during the respective periods for these intangible assets as follows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.603%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine months ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of intangible assets</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.6&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15.3&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40.6&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45.8&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139657723570360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilities<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Liabilities</a></td>
<td class="text">ACCRUED LIABILITIES<div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.226%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.511%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.513%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee compensation and benefits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legal accrual</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued taxes payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refunds payable and reserves</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued royalties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchase commitment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total accrued liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">163.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the quarter ended September 30, 2021, the Company accrued $48.0&#160;million for a potential settlement of the qui tam lawsuit against Crescendo Bioscience, Inc. and the Company. Refer to Note 13</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional information</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139657723546632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Long-Term Debt</a></td>
<td class="text">LONG-TERM DEBT<div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 23, 2016, the Company entered into a senior secured revolving credit facility (the &#8220;Facility&#8221;) by and among Myriad, as borrower, and the lenders from time to time party thereto. On July 31, 2018, the Company entered into Amendment No. 1 which effected an &#8220;amend and extend&#8221; transaction with respect to the Facility by which the maturity date thereof was extended to July 31, 2023 and the maximum aggregate principal commitment was increased from $300.0 million to $350.0 million.&#160;On May 1, 2020, the Company entered into Amendment No. 2, which waived the Company&#8217;s compliance with certain financial covenants, amended compliance with certain operating covenants, and modified the interest rate and other terms during a modification period from March 31, 2020 through June 30, 2021 (the &#8220;Modification Period&#8221;). On February 22, 2021, the Company entered into Amendment No. 3 (the &#8220;Amended Facility&#8221;), which, among other things, decreased the maximum aggregate principal commitment from $350.0&#160;million to $300.0&#160;million, with a further reduction in the maximum aggregate principal commitment from $300.0&#160;million to $250.0&#160;million by September 30, 2021 (if not previously reduced to such amount in connection with certain specified asset sales), waived the Company&#8217;s compliance with certain financial covenants through the quarter ending March 31, 2022, extended the Modification Period for an additional year, through June 30, 2022, and revised certain negative covenants in connection with the extension. The amendments were accounted for as modifications pursuant to guidance in ASC 470-50, Debt.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended Facility contains customary loan terms, interest rates, representations and warranties, affirmative and negative covenants, in each case, subject to customary limitations, exceptions and exclusions. The Amended Facility also contains certain customary events of default. Amendment No. 2 modified the Facility to increase the interest rate to be fixed at a spread of LIBOR plus 350 basis points on drawn balance and the undrawn fee was increased to 50 basis points during the Modification Period. At the end of the Modification Period, interest rates return to the previous pricing based on a spread of LIBOR plus 150-250 basis points on drawn balances and an undrawn fee ranging from 25 to 45 basis points, in each case, based on the Company's leverage ratio. The LIBOR floor was also increased to 1.0% during the Modification Period. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Covenants in the Amended Facility impose operating and financial restrictions on the Company. These restrictions may prohibit or place limitations on, among other things, the Company&#8217;s ability to incur additional indebtedness, create certain types of liens, and complete mergers, consolidations, or change in control transactions. The Amended Facility may also prohibit or place limitations on the Company&#8217;s ability to sell assets, pay dividends or provide other distributions to stockholders. Beginning with the quarter ended June 30, 2022, the Company must maintain specified leverage and interest ratios measured as of the end of each quarter as a financial covenant in the Amended Facility. Amendment No. 2 modified the Amended Facility's compliance with the leverage covenant and the interest coverage ratio covenant, which were waived through March 31, 2021.  Amendment No. 2 also revised certain negative covenants of the Amended Facility during the Modification Period. Amendment No. 3 waived compliance with the leverage ratio and the interest coverage ratio covenants through the quarter ending March 31, 2022 and also lowered the minimum liquidity covenant, which was added by Amendment No. 2, to $150.0&#160;million, and made it applicable through such quarter. Amendment No. 3 restricted the Company from borrowing under the Amended Facility if unrestricted cash and cash equivalents exceed $150.0&#160;million, unless such borrowings are in connection with acquisitions. The Company was in compliance with all applicable financial covenants at September&#160;30, 2021. </span></div>During the nine months ended September 30, 2021, the Company made principal repayments totaling $226.4&#160;million on the Amended Facility, including a voluntary principal payment on July 30, 2021 of $106.4&#160;million to pay off the remaining outstanding balances on the Amended Facility. As a result, the Company had no outstanding balances under the Amended Facility as of September 30, 2021. During the transition period ended December 31, 2020, the Company did not make any principal repayments. The $1.8&#160;million long-term debt discount associated with the Amended Facility is recorded to Other assets in the Condensed Consolidated Balance Sheet. The Company's maximum aggregate principal commitment on its Amended Facility is $250.0&#160;million as of September 30, 2021.As of December 31, 2020, the Company had a long-term debt balance of $224.8&#160;million, net of a $1.9&#160;million long-term debt discount.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139657721964088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Long-Term Liabilities<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureTextBlock', window );">Other Long-Term Liabilities</a></td>
<td class="text">OTHER LONG-TERM LIABILITIES<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.046%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.037%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other long-term liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table>The Company's balance of other long-term liabilities as of September&#160;30, 2021 and December&#160;31, 2020 primarily consists of the Company&#8217;s portion of social security taxes that have been deferred under the Coronavirus Aid, Relief, and Economic Security Act (&#8220;CARES Act&#8221;) that do not have to be remitted until December 2022.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139657722209800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Preferred and Common Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Preferred and Common Stockholders' Equity</a></td>
<td class="text">PREFERRED AND COMMON STOCKHOLDERS' EQUITY<div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is authorized to issue up to 5.0 million shares of preferred stock, par value $0.01 per share. There were no preferred shares outstanding at September&#160;30, 2021.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is authorized to issue up to 150.0 million shares of common stock, par value $0.01 per share. There were 79.7 million shares issued and outstanding at September&#160;30, 2021.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Common shares issued and outstanding</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.046%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.599%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning common stock issued and outstanding</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75.4&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74.5&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stock issued upon exercise of options, vesting of restricted stock units, and purchases under employee stock purchase plan</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stock issued and outstanding at end of period</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings per share is computed based on the weighted-average number of shares of common stock outstanding.&#160;&#160;Diluted earnings per share is computed based on the weighted-average number of shares of common stock, including the dilutive effect of common stock equivalents, outstanding.&#160;&#160;In periods when the Company has a net loss, stock awards are excluded from the calculation of diluted net loss per share as their inclusion would have an antidilutive effect.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a reconciliation of the denominators of the basic and diluted earnings per share (&#8220;EPS&#8221;) computations:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.603%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine months ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Denominator:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average shares outstanding used to compute basic EPS</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effect of dilutive shares</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.7&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average shares outstanding and dilutive securities used to compute diluted EPS</span></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81.5&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74.7&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77.3&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74.6&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain outstanding options and restricted stock units (&#8220;RSUs&#8221;) were excluded from the computation of diluted earnings per share because the effect would have been anti-dilutive. These potential dilutive common shares, which may be dilutive to future diluted earnings per share, are as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.444%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.377%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.377%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.444%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.377%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.444%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.521%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.521%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.446%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended <br/>September 30, </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine months ended<br/>&#160;September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Anti-dilutive options and RSUs excluded from EPS computation</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.1&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.3&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.9&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.3&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Repurchase Program</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Company&#8217;s Board of Directors authorized a share repurchase program of $200.0 million of the Company&#8217;s outstanding common stock from time to time or on an accelerated basis through open market transactions or privately negotiated transactions as determined by the Company's management. The amount and timing of stock repurchases under the program will depend on business and market conditions, stock price, trading restrictions, acquisition activity and other factors.&#160;&#160;As of September&#160;30, 2021, the Company is authorized to repurchase up to $110.7 million of shares under this authorization. No shares were repurchased during the nine months ended September 30, 2021 or 2020.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139657722094072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">STOCK-BASED COMPENSATION<div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 30, 2017, the Company&#8217;s stockholders approved the adoption of the 2017 Employee, Director and Consultant Equity Incentive Plan (as amended, the &#8220;2017 Plan&#8221;). The 2017 Plan allows the Company, under the direction of the Compensation and Human Capital Committee of the Board of Directors, to make grants of restricted and unrestricted stock awards to employees, consultants, and directors. Stockholders have approved amendments to the 2017 Plan increasing the shares available to grant.  As of September&#160;30, 2021, the Company has 3.6&#160;million shares of common stock available for grant under the 2017 Plan.  If an RSU awarded under the 2017 Plan is cancelled or forfeited without the issuance of shares of common stock, the unissued or reacquired shares that were subject to the RSU will again be available for issuance pursuant to the 2017 Plan. To the extent that awards outstanding under the Company's prior equity plans expire or are cancelled without delivery of shares of common stock, they also will be available for issuance pursuant to the 2017 Plan. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of shares, terms, and vesting periods are generally determined by the Company&#8217;s Board of Directors or a committee thereof on an award-by-award basis. RSUs granted to employees generally vest ratably over four years either on the anniversary of the date on which the RSUs were granted or during the month in which such anniversary dates occur. The number of RSUs awarded to certain employees may be increased or reduced based on certain additional performance metrics. Options and RSUs granted to non-employee directors vest in full upon completion of one year of service on the anniversary following the date of the grant. Options generally vest ratably over service periods of four years.&#160;Options granted after December 5, 2012 expire eight years from the date of grant, and options granted prior to that date generally expire ten years from the date of grant. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the stock option activity under the Company&#8217;s equity plans and inducement awards, for the nine months ended September&#160;30, 2021 is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(number of shares in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number<br/>of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>Average<br/>Exercise<br/>Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.2&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23.24&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options exercised</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24.26&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options canceled or expired</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.1)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25.03&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options outstanding at September 30, 2021</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20.57&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options exercisable at September 30, 2021</span></td><td colspan="2" style="background-color:#cff0fc;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.1&#160;</span></td><td style="background-color:#cff0fc;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23.20&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021, there was $2.6 million of total unrecognized stock-based compensation expense related to stock options that will be recognized over a weighted-average period of 2.3 years. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Units</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the RSU activity under the Company&#8217;s equity plans and inducement awards, including RSU awards with performance metrics, for the nine months ended September&#160;30, 2021 is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(number of shares in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number<br/>of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>Average<br/>Grant Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.2&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20.56&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29.95&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs vested</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs canceled</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.7)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24.63&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs outstanding at September 30, 2021</span></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.4&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23.91&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021, there was $68.2 million of total unrecognized stock-based compensation expense related to RSUs that will be recognized over a </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">weighted-average period of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 2.6 years.&#160;</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also has an Employee Stock Purchase Plan that was approved by stockholders in 2012 (the &#8220;2012 Purchase Plan&#8221;), under which 2.0 million shares of common stock have been authorized.&#160;&#160;On September 23, 2021, the Board of Directors of the Company approved an amended and restated 2012 Employee Stock Purchase Plan, which authorizes an additional 2.0&#160;million shares of common stock and extends the term of the 2012 Purchase Plan to November 30, 2032, subject in each case to obtaining stockholder approval. The amended and restated 2012 Employee Stock Purchase Plan also amended certain provisions of the 2012 Purchase Plan effective upon approval by the Board of Directors, including expanding the definition of "offering period" to provide that the Board of Directors may determine the period in accordance with the terms of the plan, and capping the number of shares that may be purchased by any participant during an offering period at 5,000 shares. Shares are issued under the 2012 Purchase Plan twice yearly at the end of each offering period.&#160;&#160;As of September&#160;30, 2021, approximately 0.1 million shares of common stock are available for issuance under the 2012 Purchase Plan.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-Based Compensation Expense</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense recognized and included in the Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) was allocated as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.603%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine months ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of molecular diagnostic testing</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.4&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.3&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.1&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.0&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of pharmaceutical and clinical services</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.8&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.3&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.3&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.6&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general, and administrative expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total stock-based compensation expense</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.0&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.4&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27.9&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17.8&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139657724139560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">INCOME TAXES In order to determine the Company&#8217;s quarterly provision for income taxes, the Company used an estimated annual effective tax rate that is based on expected annual income and statutory tax rates in the various jurisdictions in which the Company operates.&#160;Certain significant or unusual items are separately recognized in the quarter during which they occur and can be a source of variability in the effective tax rate from quarter to quarter.<div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax expense for the three months ended September&#160;30, 2021 was $15.2 million, or approximately 38.2% of pre-tax income compared to an income tax benefit of $28.5 million, or approximately 65.2% of pre-tax loss, for the three months ended September&#160;30, 2020.&#160;Income tax expense for the nine months ended September&#160;30, 2021 was $6.0 million, or approximately (44.1)% of pre-tax loss compared to an income tax benefit of $47.4 million, or approximately 20.3% of pre-tax loss, for the nine months ended September&#160;30, 2020.&#160;&#160;&#160;Income tax expense for the three and nine months ended September&#160;30, 2021 is based on the Company&#8217;s estimated annualized effective tax rate for the fiscal year ending December 31, 2021, adjusted for discrete items recognized during the respective periods.&#160;&#160;For the three and nine months ended September&#160;30, 2021, the Company&#8217;s recognized effective tax rate differs from the U.S. federal statutory rate primarily due to disallowed executive compensation expenses, disallowed meals and entertainment expenses, stock compensation expenses, benefit recorded as a result of the CARES Act, asset impairment expenses, release of a valuation allowance, and differences between the book and tax basis of assets divested.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company files U.S., foreign and state income tax returns in jurisdictions with various statutes of limitations.&#160;&#160;The Company is currently under audit by the State of California for the fiscal years ended June 30, 2017-2018, the State of New Jersey for the fiscal years ended June 30, 2013-2017; Germany for the fiscal years ended June 30, 2013-2015; and Switzerland for the fiscal years ended June 30, 2015-2016. Annual and interim tax provisions include amounts considered necessary to pay assessments that may result from examination of prior year tax returns; however, the amount ultimately paid upon resolution of issues may differ materially from the amount accrued.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139657721934328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">COMMITMENTS AND CONTINGENCIES<div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to various claims and legal proceedings covering matters that arise in the ordinary course of its business activities, including the matters described below. Estimates for resolution of legal and other contingencies are accrued when losses are probable and reasonably estimable in accordance with ASC 450, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Qui Tam Lawsuit</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Company's wholly owned subsidiary, Crescendo Bioscience, Inc. (&#8220;CBI&#8221;), received a subpoena from the Office of Inspector General of the Department of Health and Human Services requesting that CBI produce documents relating to entities that received payment from CBI for the collection and processing of blood specimens for testing, including a named unrelated company, healthcare providers and other third party entities. The Office of Inspector General subsequently requested additional documentation in December 2017. CBI provided to the Office of Inspector General the documents requested. On January 30, 2020, the United States District Court for the Northern District of California unsealed a qui tam complaint, filed on April 16, 2016 against CBI and the Company, alleging violations of the Federal and California False Claims Acts and the California Insurance Fraud Prevention Act.  On January 22, 2020, after a multi-year investigation into CBI&#8217;s and the Company&#8217;s alleged conduct, the United States declined to intervene. On January 27, 2020, the State of California likewise filed its notice of declination. The Company was not aware of the complaint until after it was unsealed. On May 23, 2020, the court denied CBI and the Company&#8217;s motion to dismiss. The Company has accrued $48.0 million for a potential settlement of this qui tam lawsuit against CBI and the Company, which is included in accrued liabilities in the Company's Condensed Consolidated Balance Sheet. If no settlement is reached, the Company intends to continue to vigorously defend this case, but it cannot predict with any degree of certainty the ultimate resolution of this matter or determine whether, or to what extent, any loss with respect to this matter may exceed the amount that it has accrued.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Purported Securities Class Action</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 27, 2019, a purported class action complaint was filed in the United States District Court for the District of Utah, against the Company, its former President and Chief Executive Officer, Mark C. Capone, and its Chief Financial Officer, R. Bryan Riggsbee (&#8220;Defendants&#8221;). On February 21, 2020, the plaintiff filed an amended class action complaint, which added the Company&#8217;s former Executive Vice President of Clinical Development, Bryan M. Dechairo, as an additional Defendant. This action, captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Myriad Genetics, Inc. Securities Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (No. 2:19-cv-00707-DBB), is premised upon allegations that the Defendants made false and misleading statements regarding the Company's business, operations, and acquisitions.  The lead plaintiff seeks the payment of damages allegedly sustained by it and the purported class by reason of the allegations set forth in the amended complaint, plus interest, and legal and other costs and fees.  On March 16, 2021, the United States District Court for the District of Utah denied the Company&#8217;s motion to dismiss. The Company intends to vigorously defend against this action. Due to the nature of this matter and inherent uncertainties, it is not possible to provide an evaluation of the likelihood of an unfavorable outcome or an estimate of the amount or range of potential loss, if any.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stockholder Derivative Actions</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 9, 2021, a stockholder derivative complaint was filed in the Delaware Court of Chancery against the Company's former President and Chief Executive Officer, Mark C. Capone, its Chief Financial Officer, R. Bryan Riggsbee, its former Executive Vice President of Clinical Development, Bryan M. Dechairo, and certain of its current and former directors, Lawrence C. Best, Walter Gilbert, John T. Henderson, Heiner Dreismann, Dennis Langer, Lee N. Newcomer, S. Louise Phanstiel, and Colleen F. Reitan (collectively, the "Individual Defendants"), and the Company, as nominal defendant. The complaint is premised upon similar allegations as set forth in the securities class action, including that the Individual Defendants made false and misleading statements regarding the Company's business and operations. The plaintiff, Donna Hickock, asserts breach of fiduciary duty and unjust enrichment claims against the Individual Defendants and seeks, on behalf of the Company, damages allegedly sustained by the Company as a result of the alleged breaches, or disgorgement or restitution, from each of the Individual Defendants, plus interest. Plaintiff Hickock also seeks legal and other costs and fees relating to this action. The Company intends to vigorously defend against this action. Due to the nature of this matter and inherent uncertainties, it is not possible to provide an evaluation of the likelihood of an unfavorable outcome or an estimate of the amount or range of potential loss, if any.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 17, 2021, a second stockholder derivative complaint was filed in the United States District Court for the District of Delaware against the Individual Defendants, and the Company, as nominal defendant. The action is premised upon similar allegations as set forth in the securities class action and Hickock stockholder derivative action. The plaintiff, Karen Marcey, asserts that the Individual Defendants violated U.S. securities laws and breached their fiduciary duties, and also asserts unjust enrichment, waste of corporate assets and insider trading claims against all or some of the Individual Defendants. Plaintiff Marcey seeks, on behalf of the Company, damages allegedly sustained by the Company as a result of the alleged violations and restitution from the Individual Defendants, plus interest and, on behalf of herself, legal and other costs and fees relating to this action. The Company intends to vigorously defend against this action. Due to the nature of this matter and inherent uncertainties, it is not possible to provide an evaluation of the likelihood of an unfavorable outcome or an estimate of the amount or range of potential loss, if any.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Matters</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On July 27, 2020, a lawsuit was filed against the Company in the Superior Court of Suffolk County, Massachusetts, by Heide Abelli and Victor Pricolo. The plaintiffs claim negligence, breach of contract and associated torts in connection with an alleged error in testing performed by the Company in 2004.  The plaintiffs seek damages allegedly sustained by them by reason of the allegations set forth in their complaint, together with interest and costs. The Company intends to vigorously defend against this action. Due to the nature of this matter and inherent uncertainties, it is not possible to provide an evaluation of the likelihood of an unfavorable outcome or an estimate of the amount or range of potential loss, if any.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of September&#160;30, 2021, the management of the Company believes any reasonably possible liability that may result from the resolution of any other matters will not have a material adverse effect on the Company&#8217;s consolidated financial position, operating results, or cash flows. However, it is possible that the ultimate resolution of other matters, if unfavorable, may be material to the results of operations or financial condition for a particular period.</span></div>From time to time, the Company receives recoupment requests from third-party payors for alleged overpayments. The Company disagrees with the contentions of the pending requests or has recorded an estimated reserve for the alleged overpayments.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139657723519960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment and Related Information<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment and Related Information</a></td>
<td class="text">SEGMENT AND RELATED INFORMATIONThe Company&#8217;s business is aligned with how the chief operating decision maker reviews performance and makes decisions in managing the Company.&#160;The business units have been aggregated into two reportable segments: (i)&#160;diagnostics and (ii) other. The diagnostics segment provides testing and collaborative development of testing that is designed to determine the risk of developing disease, assess the risk of disease progression, and guide treatment decisions across medical specialties where critical genetic insights can significantly improve patient care and lower healthcare costs. The other segment provides testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients, and includes corporate services such as finance, human resources, legal and information technology.<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Segment revenue and operating income (loss) were as follows during the periods presented:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.350%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Diagnostics</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Three months ended September 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">167.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Segment operating loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(21.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(58.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(79.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Three months ended September 30, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">130.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">145.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Segment operating loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(39.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(39.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nine months ended September 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">529.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Segment operating income (loss)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(173.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(147.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nine months ended September 30, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">362.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">402.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Segment operating loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(127.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(113.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(241.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;padding-left:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.603%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine months ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total operating loss for reportable segments</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(79.9)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(39.6)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(147.4)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(241.6)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unallocated amounts:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.2&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.4&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.6&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.7&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">120.6&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1.6)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">139.3&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14.9&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income (loss) from operations before income taxes</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(43.7)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(13.6)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(233.3)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax expense (benefit)</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15.2&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(28.5)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.0&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(47.4)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income (loss)</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(15.2)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(19.6)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(185.9)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss attributable to non-controlling interest</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.1)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income (loss) attributable to Myriad Genetics, Inc. stockholders</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24.6&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(15.2)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(19.6)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(185.8)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI http://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139657723470600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Cash Flow Information<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental Cash Flow Elements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowSupplementalDisclosuresTextBlock', window );">Supplemental Cash Flow Information</a></td>
<td class="text">SUPPLEMENTAL CASH FLOW INFORMATION<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.046%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.599%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine months ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid during the period for income taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash received for income tax receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Establishment of operating lease right-of-use assets and lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease right-of-use assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowSupplementalDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -URI http://asc.fasb.org/topic&amp;trid=2134446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowSupplementalDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139657722155624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Divestitures<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock', window );">Divestitures</a></td>
<td class="text">DIVESTITURES<div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 28, 2021, the Company completed its sale of the Myriad myPath, LLC laboratory to Castle Biosciences, Inc. for cash consideration of $32.5 million. The transaction was accounted for as a sale of assets and the Company recognized a gain of $31.2 million, net of transaction costs of $1.3 million, in Other income (expense) on the Company&#8217;s Condensed Consolidated Statements of Operations related to the sale. Prior to the sale, Myriad myPath operations were included in the Company&#8217;s diagnostics reporting segment.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 1, 2021, the Company completed its sale of Myriad RBM, Inc., a wholly owned subsidiary of the Company, to IQVIA RDS, Inc. for cash consideration of $197.0 million. The transaction was accounted for as a sale of a business and the Company recognized a gain of $121.0 million, net of transaction costs of $4.8 million, in Other income (expense) on the Company's Condensed Consolidated Statements of Operations. Prior to the sale, Myriad RBM, Inc. operations were included in the Company&#8217;s other reporting segment.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 13, 2021, the Company completed its sale of select operating assets and intellectual property, including the Vectra&#174; test, from the Myriad Autoimmune business unit to Laboratory Corporation of America Holdings for cash consideration of $150.0 million. The transaction was accounted for as a sale of a business and the Company recognized a loss of $0.6 million, net of transaction costs of $4.4 million, in Other income (expense) on the Company's Condensed Consolidated Statements of Operations. Prior to the sale, the Myriad Autoimmune business operations were included in the Company&#8217;s diagnostics reporting segment.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The operating results of these businesses do not qualify for reporting as discontinued operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inventory</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the divestiture transactions, the Company recognized losses of $5.2 million and $6.5 million for a non-cancelable inventory purchase commitment and inventory, respectively, during the nine months ended September 30, 2021, as the Company will no longer have use for the goods. Both of these losses are included in Other income (expense) in the Company's Condensed Consolidated Statements of Operations for the nine months ended September 30, 2021.</span></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table details the amounts recognized in Other income for the three and nine months ended September 30, 2021:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.502%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.514%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.516%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine months ended<br/>&#160;September 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain on sale of Myriad RBM, Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">121.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">121.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain on sale of Myriad myPath, LLC laboratory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain (loss) on inventory</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(11.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss on sale of Myriad Autoimmune assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Other Income</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">120.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">139.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=2122178<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139657722144552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">SUBSEQUENT EVENTSThe Company evaluated subsequent events from the balance sheet date through the date the financial statements were issued. Based upon this review, the Company did not identify any subsequent events that would have required adjustment or disclosure in the financial statements.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139657723574808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying Condensed Consolidated Financial Statements for the Company have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) for interim financial information and pursuant to the applicable rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;).&#160;All intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, the accompanying financial statements contain all adjustments (consisting of normal and recurring accruals) necessary to present fairly all financial statements in accordance with GAAP. The Condensed Consolidated Financial Statements herein should be read in conjunction with the Company&#8217;s audited Consolidated Financial Statements and notes thereto included in the Company&#8217;s Transition Report on Form 10-K for the transition period ended December&#160;31, 2020 (the &#8220;Transition Report on Form 10-K&#8221;). </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenue and expenses during the reporting period. Operating results for the three and nine months ended September&#160;30, 2021 may not necessarily be indicative of results to be expected for any other interim period or for the full year.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassifications</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reclassifications</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior period amounts have been reclassified to conform with the current period presentation. The reclassifications have no impact on the total assets, total liabilities, stockholders&#8217; equity, cash flows from operations, or net income (loss) for the period.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Adopted Standards</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (&#8220;ASU 2019-12&#8221;). ASU 2019-12 is a new accounting standard to simplify accounting for income taxes and remove, modify, and add to the disclosure requirements of income taxes. The standard is effective for fiscal years beginning after December 15, 2020, with early adoption permitted. This guidance was adopted</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> with no material impact to t</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he Company's Condensed Consolidated Financial Statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429488&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139657723519960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Total Revenue by Product and by U.S versus Rest of World</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents detail regarding the composition of the Company&#8217;s total revenue by category and by U.S. versus rest of world (&#8220;RoW&#8221;):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.200%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.624%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.624%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.624%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.624%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.624%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.630%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="36" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">RoW</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">RoW</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molecular diagnostic revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hereditary Cancer</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tumor Profiling</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prenatal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmacogenomics</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Autoimmune</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total molecular diagnostic revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">144.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">167.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">124.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">135.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical and clinical services revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">144.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">167.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">134.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">145.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="36" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">RoW</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">RoW</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molecular diagnostic revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hereditary Cancer</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">207.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">241.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">188.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">205.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tumor Profiling</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prenatal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmacogenomics</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Autoimmune</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total molecular diagnostic revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">439.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">505.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">344.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">369.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical and clinical services revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">464.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">529.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">373.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">402.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Reconciliation of Deferred Revenue Balances</a></td>
<td class="text">A reconciliation of the beginning and ending balances of deferred revenues is shown in the table below:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.000%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.624%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.626%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine months ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenues - beginning balance</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue recognized</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(30.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepayments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Divestitures</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenues - ending balance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139657807797848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Investment Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Schedule of Fair Value for Available-for-Sale Securities by Major Security Type and Class of Security</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortized cost, gross unrealized holding gains, gross unrealized holding losses, and fair value for available-for-sale securities by major security type and class of security at September&#160;30, 2021 and December&#160;31, 2020 were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized<br/>cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>unrealized<br/>holding<br/>gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>unrealized<br/>holding<br/>losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated<br/>fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">208.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">208.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">295.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">295.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-sale:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate bonds and notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Municipal bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal agency issues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">US government securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">413.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.1)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">413.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized<br/>cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>unrealized<br/>holding<br/>gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>unrealized<br/>holding<br/>losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated<br/>fair value</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2020:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47.9&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47.9&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total cash and cash equivalents</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">117.0&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">117.0&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-sale:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate bonds and notes</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28.8&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.5&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29.3&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Municipal bonds</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal agency issues</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.0&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.0&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">US government securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">170.9&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.8&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">171.7&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Schedule of Cash, Cash Equivalents, and Maturities of Debt Securities Classified as Available-For-Sale Securities</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents, and maturities of debt securities classified as available-for-sale securities were as follows at September&#160;30, 2021:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized<br/>cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated<br/>fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due within one year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due after one year through five years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due after five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">413.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">413.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139657721863240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Schedule of Fair Value of Financial Assets and Liabilities</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the fair value of the financial assets and liabilities that the Company re-measures on a regular basis:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September 30, 2021</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds (a)</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate bonds and notes</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90.8&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90.8&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Municipal bonds</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal agency issues</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.6&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.6&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">US government securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8.8)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8.8)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86.4&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">118.4&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8.8)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">196.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:27.13pt">Money market funds are primarily comprised of exchange traded funds and accrued interest.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2020</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds (a)</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate bonds and notes</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29.3&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29.3&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Municipal bonds</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal agency issues</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.0&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.0&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">US government securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10.9)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10.9)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69.1&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54.7&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10.9)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112.9&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:27.13pt">Money market funds are primarily comprised of exchange traded funds and accrued interest.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Change in Fair Value of Contingent Consideration</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following table reconciles the change in the fair value of the contingent consideration during the periods presented:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.596%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance December 31, 2020</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.9&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payment of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in fair value recognized in the income statement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Translation adjustments recognized in other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ending balance September 30, 2021</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19279-110258<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2C<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=SL7498348-110258<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139657723869992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property, Plant and Equipment, Net</a></td>
<td class="text"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.226%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.511%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.513%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold improvements</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38.1&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35.7&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equipment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">110.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">117.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment, gross</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">148.4&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">153.6&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less accumulated depreciation</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(105.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(112.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment, net</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43.4&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40.7&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in equipment from December 31, 2020 to September 30, 2021 was primarily due to the sales of Myriad RBM, Inc. and select assets of the Myriad Autoimmune business. See Note 16 for additional information on these divestitures.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.215%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine months ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.6&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.4&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.9&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.5&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139657727106648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Schedule of Changes in Carrying Amount of Goodwill</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the carrying amount of goodwill for the nine months ended September&#160;30, 2021:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.321%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.759%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.636%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.716%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Diagnostic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">329.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Divestitures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Translation adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Amortizable Intangible Assets</a></td>
<td class="text">The following summarizes the amounts reported as intangible assets:<div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.350%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September 30, 2021:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchased licenses and technologies</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">617.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(202.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">414.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total amortized intangible assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">617.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(202.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">414.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total intangible assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">617.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(202.6)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">414.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.350%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2020:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchased licenses and technologies</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">818.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(248.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">570.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customer relationships</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.7&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4.5)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.2&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trademarks</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total amortized intangible assets</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">825.9&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(254.2)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">571.7&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In-process research and development</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total unamortized intangible assets</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.8&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.8&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total intangible assets</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">830.7&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(254.2)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">576.5&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Non-amortizable Intangible Assets</a></td>
<td class="text">The following summarizes the amounts reported as intangible assets:<div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.350%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September 30, 2021:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchased licenses and technologies</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">617.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(202.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">414.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total amortized intangible assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">617.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(202.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">414.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total intangible assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">617.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(202.6)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">414.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.350%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2020:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchased licenses and technologies</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">818.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(248.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">570.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customer relationships</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.7&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4.5)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.2&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trademarks</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total amortized intangible assets</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">825.9&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(254.2)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">571.7&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In-process research and development</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total unamortized intangible assets</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.8&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.8&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total intangible assets</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">830.7&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(254.2)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">576.5&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock', window );">Schedule of Recorded Amortization Expense for Intangible Assets</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded amortization expense during the respective periods for these intangible assets as follows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.603%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine months ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of intangible assets</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.6&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15.3&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40.6&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45.8&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b),(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139657724218760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Liabilities</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.226%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.511%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.513%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee compensation and benefits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legal accrual</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued taxes payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refunds payable and reserves</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued royalties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchase commitment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total accrued liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">163.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139657723498792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Long-Term Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock', window );">Schedule of Other Long-Term Liabilities</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.046%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.037%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other long-term liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of other noncurrent liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139657722086824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Preferred and Common Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock', window );">Summary of Common Shares Issued and Outstanding</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Common shares issued and outstanding</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.046%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.599%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning common stock issued and outstanding</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75.4&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74.5&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stock issued upon exercise of options, vesting of restricted stock units, and purchases under employee stock purchase plan</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stock issued and outstanding at end of period</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock', window );">Reconciliation of Denominators of Basic and Diluted Earnings Per Share Computations</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a reconciliation of the denominators of the basic and diluted earnings per share (&#8220;EPS&#8221;) computations:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.603%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine months ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Denominator:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average shares outstanding used to compute basic EPS</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effect of dilutive shares</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.7&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average shares outstanding and dilutive securities used to compute diluted EPS</span></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81.5&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74.7&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77.3&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74.6&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Potential Dilutive Common Shares</a></td>
<td class="text">These potential dilutive common shares, which may be dilutive to future diluted earnings per share, are as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.444%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.377%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.377%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.444%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.377%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.444%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.521%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.521%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.446%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended <br/>September 30, </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine months ended<br/>&#160;September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Anti-dilutive options and RSUs excluded from EPS computation</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.1&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.3&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.9&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.3&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139657724226728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activity</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the stock option activity under the Company&#8217;s equity plans and inducement awards, for the nine months ended September&#160;30, 2021 is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(number of shares in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number<br/>of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>Average<br/>Exercise<br/>Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.2&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23.24&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options exercised</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24.26&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options canceled or expired</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.1)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25.03&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options outstanding at September 30, 2021</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20.57&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options exercisable at September 30, 2021</span></td><td colspan="2" style="background-color:#cff0fc;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.1&#160;</span></td><td style="background-color:#cff0fc;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23.20&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of Restricted Stock Unit Activity</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the RSU activity under the Company&#8217;s equity plans and inducement awards, including RSU awards with performance metrics, for the nine months ended September&#160;30, 2021 is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(number of shares in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number<br/>of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>Average<br/>Grant Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.2&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20.56&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29.95&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs vested</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs canceled</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.7)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24.63&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs outstanding at September 30, 2021</span></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.4&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23.91&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-Based Compensation Expense</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense recognized and included in the Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) was allocated as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.603%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine months ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of molecular diagnostic testing</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.4&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.3&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.1&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.0&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of pharmaceutical and clinical services</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.8&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.3&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.3&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.6&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general, and administrative expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total stock-based compensation expense</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.0&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.4&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27.9&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17.8&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139657724194168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment and Related Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Segment Revenue and Operating Income (Loss)</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Segment revenue and operating income (loss) were as follows during the periods presented:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.350%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Diagnostics</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Three months ended September 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">167.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Segment operating loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(21.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(58.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(79.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Three months ended September 30, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">130.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">145.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Segment operating loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(39.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(39.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nine months ended September 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">529.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Segment operating income (loss)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(173.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(147.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nine months ended September 30, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">362.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">402.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Segment operating loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(127.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(113.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(241.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;padding-left:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.603%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine months ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total operating loss for reportable segments</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(79.9)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(39.6)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(147.4)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(241.6)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unallocated amounts:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.2&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.4&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.6&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.7&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">120.6&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1.6)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">139.3&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14.9&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income (loss) from operations before income taxes</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(43.7)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(13.6)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(233.3)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax expense (benefit)</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15.2&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(28.5)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.0&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(47.4)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income (loss)</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(15.2)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(19.6)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(185.9)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss attributable to non-controlling interest</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.1)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income (loss) attributable to Myriad Genetics, Inc. stockholders</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24.6&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(15.2)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(19.6)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(185.8)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139657722145400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Cash Flow Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental Cash Flow Elements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock', window );">Schedule of Supplemental Cash Flow Information</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.046%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.599%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine months ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid during the period for income taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash received for income tax receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Establishment of operating lease right-of-use assets and lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease right-of-use assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of supplemental cash flow information for the periods presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139657722066904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Divestitures (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock', window );">Schedule of Amounts Recognized in Other Income</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table details the amounts recognized in Other income for the three and nine months ended September 30, 2021:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.502%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.514%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.516%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine months ended<br/>&#160;September 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain on sale of Myriad RBM, Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">121.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">121.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain on sale of Myriad myPath, LLC laboratory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain (loss) on inventory</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(11.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss on sale of Myriad Autoimmune assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Other Income</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">120.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">139.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=SL51724579-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1474-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5D<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721677-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721659-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721665-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721671-107760<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721663-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139657731384472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Total Revenue by Product and by US versus Rest of World (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 167.3<span></span>
</td>
<td class="nump">$ 145.2<span></span>
</td>
<td class="nump">$ 529.8<span></span>
</td>
<td class="nump">$ 402.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">144.5<span></span>
</td>
<td class="nump">134.0<span></span>
</td>
<td class="nump">464.0<span></span>
</td>
<td class="nump">373.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">RoW</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">22.8<span></span>
</td>
<td class="nump">11.2<span></span>
</td>
<td class="nump">65.8<span></span>
</td>
<td class="nump">29.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mygn_MolecularDiagnosticTestingMember', window );">Molecular diagnostic testing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">167.3<span></span>
</td>
<td class="nump">135.7<span></span>
</td>
<td class="nump">505.6<span></span>
</td>
<td class="nump">369.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mygn_MolecularDiagnosticTestingMember', window );">Molecular diagnostic testing | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">144.5<span></span>
</td>
<td class="nump">124.5<span></span>
</td>
<td class="nump">439.8<span></span>
</td>
<td class="nump">344.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mygn_MolecularDiagnosticTestingMember', window );">Molecular diagnostic testing | RoW</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">22.8<span></span>
</td>
<td class="nump">11.2<span></span>
</td>
<td class="nump">65.8<span></span>
</td>
<td class="nump">25.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mygn_MolecularDiagnosticHereditaryCancerTestingMember', window );">Molecular diagnostic - Hereditary Cancer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">79.4<span></span>
</td>
<td class="nump">80.5<span></span>
</td>
<td class="nump">241.5<span></span>
</td>
<td class="nump">205.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mygn_MolecularDiagnosticHereditaryCancerTestingMember', window );">Molecular diagnostic - Hereditary Cancer | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">68.2<span></span>
</td>
<td class="nump">72.0<span></span>
</td>
<td class="nump">207.1<span></span>
</td>
<td class="nump">188.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mygn_MolecularDiagnosticHereditaryCancerTestingMember', window );">Molecular diagnostic - Hereditary Cancer | RoW</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">11.2<span></span>
</td>
<td class="nump">8.5<span></span>
</td>
<td class="nump">34.4<span></span>
</td>
<td class="nump">17.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mygn_MolecularDiagnosticTumorProfilingMember', window );">Molecular diagnostic - Tumor Profiling</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">32.9<span></span>
</td>
<td class="nump">17.0<span></span>
</td>
<td class="nump">94.4<span></span>
</td>
<td class="nump">41.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mygn_MolecularDiagnosticTumorProfilingMember', window );">Molecular diagnostic - Tumor Profiling | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">21.4<span></span>
</td>
<td class="nump">14.4<span></span>
</td>
<td class="nump">63.9<span></span>
</td>
<td class="nump">33.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mygn_MolecularDiagnosticTumorProfilingMember', window );">Molecular diagnostic - Tumor Profiling | RoW</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">11.5<span></span>
</td>
<td class="nump">2.6<span></span>
</td>
<td class="nump">30.5<span></span>
</td>
<td class="nump">7.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mygn_MolecularDiagnosticPrenatalTestingMember', window );">Molecular diagnostic - Prenatal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">23.6<span></span>
</td>
<td class="nump">16.6<span></span>
</td>
<td class="nump">76.7<span></span>
</td>
<td class="nump">53.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mygn_MolecularDiagnosticPrenatalTestingMember', window );">Molecular diagnostic - Prenatal | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">23.5<span></span>
</td>
<td class="nump">16.5<span></span>
</td>
<td class="nump">76.3<span></span>
</td>
<td class="nump">53.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mygn_MolecularDiagnosticPrenatalTestingMember', window );">Molecular diagnostic - Prenatal | RoW</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mygn_MolecularDiagnosticPharmacogenomicsMember', window );">Molecular Diagnostic - Pharmacogenomics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">24.1<span></span>
</td>
<td class="nump">11.9<span></span>
</td>
<td class="nump">64.3<span></span>
</td>
<td class="nump">40.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mygn_MolecularDiagnosticPharmacogenomicsMember', window );">Molecular Diagnostic - Pharmacogenomics | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">24.1<span></span>
</td>
<td class="nump">11.9<span></span>
</td>
<td class="nump">64.3<span></span>
</td>
<td class="nump">40.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mygn_MolecularDiagnosticPharmacogenomicsMember', window );">Molecular Diagnostic - Pharmacogenomics | RoW</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mygn_MolecularDiagnosticAutoimmuneMember', window );">Molecular Diagnostic - Autoimmune</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">7.3<span></span>
</td>
<td class="nump">9.1<span></span>
</td>
<td class="nump">28.2<span></span>
</td>
<td class="nump">26.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mygn_MolecularDiagnosticAutoimmuneMember', window );">Molecular Diagnostic - Autoimmune | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">7.3<span></span>
</td>
<td class="nump">9.1<span></span>
</td>
<td class="nump">28.2<span></span>
</td>
<td class="nump">26.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mygn_MolecularDiagnosticAutoimmuneMember', window );">Molecular Diagnostic - Autoimmune | RoW</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mygn_MolecularDiagnosticOtherTestingMember', window );">Molecular diagnostic - Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">1.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mygn_MolecularDiagnosticOtherTestingMember', window );">Molecular diagnostic - Other | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">1.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mygn_MolecularDiagnosticOtherTestingMember', window );">Molecular diagnostic - Other | RoW</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mygn_PharmaceuticalAndClinicalServicesMember', window );">Pharmaceutical and clinical services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">9.5<span></span>
</td>
<td class="nump">24.2<span></span>
</td>
<td class="nump">32.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mygn_PharmaceuticalAndClinicalServicesMember', window );">Pharmaceutical and clinical services | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">9.5<span></span>
</td>
<td class="nump">24.2<span></span>
</td>
<td class="nump">29.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mygn_PharmaceuticalAndClinicalServicesMember', window );">Pharmaceutical and clinical services | RoW</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 3.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mygn_MolecularDiagnosticTestingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mygn_MolecularDiagnosticTestingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mygn_MolecularDiagnosticHereditaryCancerTestingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mygn_MolecularDiagnosticHereditaryCancerTestingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mygn_MolecularDiagnosticTumorProfilingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mygn_MolecularDiagnosticTumorProfilingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mygn_MolecularDiagnosticPrenatalTestingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mygn_MolecularDiagnosticPrenatalTestingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mygn_MolecularDiagnosticPharmacogenomicsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mygn_MolecularDiagnosticPharmacogenomicsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mygn_MolecularDiagnosticAutoimmuneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mygn_MolecularDiagnosticAutoimmuneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mygn_MolecularDiagnosticOtherTestingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mygn_MolecularDiagnosticOtherTestingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mygn_PharmaceuticalAndClinicalServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mygn_PharmaceuticalAndClinicalServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139657724908600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Reconciliation of Deferred Revenue Balances (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInContractWithCustomerLiabilityAbstract', window );"><strong>Reconciliation of Deferred Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenues - beginning balance</a></td>
<td class="nump">$ 32.7<span></span>
</td>
<td class="nump">$ 3.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized', window );">Revenue recognized</a></td>
<td class="num">(30.3)<span></span>
</td>
<td class="num">(8.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_ContractWithCustomerLiabilityPrepayments', window );">Prepayments</a></td>
<td class="nump">10.1<span></span>
</td>
<td class="nump">37.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_ContractWithCustomerLiabilityDivestitures', window );">Divestitures</a></td>
<td class="num">(1.0)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenues - ending balance</a></td>
<td class="nump">$ 11.5<span></span>
</td>
<td class="nump">$ 32.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_ContractWithCustomerLiabilityDivestitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Liability, Divestitures</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_ContractWithCustomerLiabilityDivestitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Liability, Including New Contract, Revenue Recognized</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_ContractWithCustomerLiabilityPrepayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract with customer, liability, prepayments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_ContractWithCustomerLiabilityPrepayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInContractWithCustomerLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInContractWithCustomerLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139657807728296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_CARESActOf2020MedicarePaymentAmount', window );">Advance Medicare payments to provide relief from economic impacts of COVID-19</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,700,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice', window );">Revenue increase (decrease) due to changes in estimated transaction price due to contractual adjustments</a></td>
<td class="nump">$ 7,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_ContractWithCustomerAssetAdjustmentToRevenueForExpandedCoveragePreviouslyConstrained', window );">Revenue recognized due to expanded local coverage determination for which revenue was previously constrained</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostGross', window );">Capitalized costs incurred to obtain or fulfill contract</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingEstimateByTypeAxis=mygn_PerformanceObligationEstimatedTransactionPriceMember', window );">Performance obligation estimate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Revenue and Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_IncreaseDecreaseInEarningsLossPerShare', window );">Change in earnings per share (dollars per share)</a></td>
<td class="nump">$ 0.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember', window );">Revenues | Customer concentration | Medicare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Revenue and Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (percent)</a></td>
<td class="nump">17.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_CARESActOf2020MedicarePaymentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>CARES Act of 2020 Medicare payment amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_CARESActOf2020MedicarePaymentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_ContractWithCustomerAssetAdjustmentToRevenueForExpandedCoveragePreviouslyConstrained">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Asset, Adjustment To Revenue For Expanded Coverage, Previously Constrained</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_ContractWithCustomerAssetAdjustmentToRevenueForExpandedCoveragePreviouslyConstrained</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_IncreaseDecreaseInEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in earnings (loss) per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_IncreaseDecreaseInEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123353750&amp;loc=SL49131252-203054<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in estimate of transaction price which increases (decreases) right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time. Includes, but is not limited to, change in assessment of whether estimate of variable consideration is constrained.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingEstimateByTypeAxis=mygn_PerformanceObligationEstimatedTransactionPriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingEstimateByTypeAxis=mygn_PerformanceObligationEstimatedTransactionPriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=mygn_MedicareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=mygn_MedicareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139657724772216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Investment Securities - Fair Value for Available-for-Sale Securities by Major Security Type and Class of Security (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract', window );"><strong>Cash and cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, Amortized cost</a></td>
<td class="nump">$ 295.2<span></span>
</td>
<td class="nump">$ 117.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents, Estimated fair value</a></td>
<td class="nump">295.2<span></span>
</td>
<td class="nump">117.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsAndCashAbstract', window );"><strong>Total:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_InvestmentsAndCashAmortizedCost', window );">Total, Amortized cost</a></td>
<td class="nump">413.4<span></span>
</td>
<td class="nump">170.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax', window );">Total, Gross unrealized holding gains</a></td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax', window );">Total, Gross unrealized holding losses</a></td>
<td class="num">(0.1)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsAndCash', window );">Total, Estimated fair value</a></td>
<td class="nump">413.6<span></span>
</td>
<td class="nump">171.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashMember', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract', window );"><strong>Cash and cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, Amortized cost</a></td>
<td class="nump">208.8<span></span>
</td>
<td class="nump">47.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents, Estimated fair value</a></td>
<td class="nump">208.8<span></span>
</td>
<td class="nump">47.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashEquivalentsMember', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract', window );"><strong>Cash and cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, Amortized cost</a></td>
<td class="nump">86.4<span></span>
</td>
<td class="nump">69.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents, Estimated fair value</a></td>
<td class="nump">86.4<span></span>
</td>
<td class="nump">69.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate bonds and notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Available-for-sale:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Available-for-sale, Amortized cost</a></td>
<td class="nump">90.7<span></span>
</td>
<td class="nump">28.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale, Gross unrealized holding gains</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale, Gross unrealized holding losses</a></td>
<td class="num">(0.1)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale, Estimated fair value</a></td>
<td class="nump">90.8<span></span>
</td>
<td class="nump">29.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MunicipalBondsMember', window );">Municipal bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Available-for-sale:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Available-for-sale, Amortized cost</a></td>
<td class="nump">19.4<span></span>
</td>
<td class="nump">9.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale, Gross unrealized holding gains</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale, Gross unrealized holding losses</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale, Estimated fair value</a></td>
<td class="nump">19.5<span></span>
</td>
<td class="nump">9.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasuryAndGovernmentMember', window );">Federal agency issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Available-for-sale:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Available-for-sale, Amortized cost</a></td>
<td class="nump">2.6<span></span>
</td>
<td class="nump">4.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale, Gross unrealized holding gains</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale, Gross unrealized holding losses</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale, Estimated fair value</a></td>
<td class="nump">2.6<span></span>
</td>
<td class="nump">4.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">US government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Available-for-sale:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Available-for-sale, Amortized cost</a></td>
<td class="nump">5.5<span></span>
</td>
<td class="nump">11.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale, Gross unrealized holding gains</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale, Gross unrealized holding losses</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale, Estimated fair value</a></td>
<td class="nump">$ 5.5<span></span>
</td>
<td class="nump">$ 11.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investments And Cash, Accumulated Gross Unrealized Gain, before Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investments And Cash, Accumulated Gross Unrealized Loss, before Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_InvestmentsAndCashAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investments And Cash, Amortized Cost</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_InvestmentsAndCashAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAndCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of investments and unrestricted cash as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAndCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAndCashAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAndCashAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MunicipalBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MunicipalBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139657724773768">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Investment Securities - Cash, Cash Equivalents, and Maturities of Debt Securities Classified as Available-For-Sale Securities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisRollingMaturityAbstract', window );"><strong>Amortized cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 295.2<span></span>
</td>
<td class="nump">$ 117.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost', window );">Available-for-sale, Due within one year</a></td>
<td class="nump">70.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost', window );">Available-for-sale, Due after one year through five years</a></td>
<td class="nump">47.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost', window );">Available-for-sale, Due after five years</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_InvestmentsAndCashAmortizedCost', window );">Total, Amortized cost</a></td>
<td class="nump">413.4<span></span>
</td>
<td class="nump">170.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueRollingMaturityAbstract', window );"><strong>Estimated fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">295.2<span></span>
</td>
<td class="nump">117.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Available-for-sale, Due within one year</a></td>
<td class="nump">70.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Available-for-sale, Due after one year through five years</a></td>
<td class="nump">47.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue', window );">Available-for-sale, Due after five years</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsAndCash', window );">Total, Estimated fair value</a></td>
<td class="nump">413.6<span></span>
</td>
<td class="nump">171.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashMember', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisRollingMaturityAbstract', window );"><strong>Amortized cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">208.8<span></span>
</td>
<td class="nump">47.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueRollingMaturityAbstract', window );"><strong>Estimated fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">208.8<span></span>
</td>
<td class="nump">47.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashEquivalentsMember', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisRollingMaturityAbstract', window );"><strong>Amortized cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">86.4<span></span>
</td>
<td class="nump">69.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueRollingMaturityAbstract', window );"><strong>Estimated fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 86.4<span></span>
</td>
<td class="nump">$ 69.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_InvestmentsAndCashAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investments And Cash, Amortized Cost</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_InvestmentsAndCashAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=SL120269850-112803<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=SL120269850-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueRollingMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueRollingMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisRollingMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisRollingMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAndCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of investments and unrestricted cash as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAndCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139657723700872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Investment Securities - Narrative (Details) - security<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions', window );">Debt securities, available-for-sale, in unrealized loss position</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139657723696344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Measurement input, expected term</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_BusinessCombinationContingentConsiderationLiabilityMeasurementInputTerm', window );">Measurement period for earn out liability</a></td>
<td class="text">13 years 9 months 18 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_BusinessCombinationContingentConsiderationLiabilityMeasurementInputTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Contingent Consideration, Liability, Measurement Input, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_BusinessCombinationContingentConsiderationLiabilityMeasurementInputTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139657725520424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Fair Value of Financial Assets and Liabilities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Total</a></td>
<td class="nump">$ 196.0<span></span>
</td>
<td class="nump">$ 112.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">86.4<span></span>
</td>
<td class="nump">69.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate bonds and notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">90.8<span></span>
</td>
<td class="nump">29.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MunicipalBondsMember', window );">Municipal bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">19.5<span></span>
</td>
<td class="nump">9.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasuryAndGovernmentMember', window );">Federal agency issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">2.6<span></span>
</td>
<td class="nump">4.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">US government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">5.5<span></span>
</td>
<td class="nump">11.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=mygn_ContingentConsiderationMember', window );">Contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Financial liabilities</a></td>
<td class="num">(8.8)<span></span>
</td>
<td class="num">(10.9)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Total</a></td>
<td class="nump">86.4<span></span>
</td>
<td class="nump">69.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">86.4<span></span>
</td>
<td class="nump">69.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Corporate bonds and notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Municipal bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Federal agency issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | US government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Financial liabilities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Total</a></td>
<td class="nump">118.4<span></span>
</td>
<td class="nump">54.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Corporate bonds and notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">90.8<span></span>
</td>
<td class="nump">29.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Municipal bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">19.5<span></span>
</td>
<td class="nump">9.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Federal agency issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">2.6<span></span>
</td>
<td class="nump">4.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | US government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">5.5<span></span>
</td>
<td class="nump">11.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Financial liabilities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Total</a></td>
<td class="num">(8.8)<span></span>
</td>
<td class="num">(10.9)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Corporate bonds and notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Municipal bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Federal agency issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | US government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Financial liabilities</a></td>
<td class="num">$ (8.8)<span></span>
</td>
<td class="num">$ (10.9)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetAssetLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of asset after deduction of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetAssetLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MunicipalBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MunicipalBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=mygn_ContingentConsiderationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=mygn_ContingentConsiderationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139657725612744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Change in Fair Value of Contingent Consideration (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Reconciliation of change in fair value of contingent consideration</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="nump">$ 10.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Payment of contingent consideration</a></td>
<td class="num">(3.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value recognized in the income statement</a></td>
<td class="nump">1.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome', window );">Translation adjustments recognized in other comprehensive loss</a></td>
<td class="num">(0.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
<td class="nump">$ 8.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in other comprehensive income (OCI) from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139657726733272">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property, Plant and Equipment, Net - Balances (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 148.4<span></span>
</td>
<td class="nump">$ 153.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation</a></td>
<td class="num">(105.0)<span></span>
</td>
<td class="num">(112.9)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">43.4<span></span>
</td>
<td class="nump">40.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">38.1<span></span>
</td>
<td class="nump">35.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 110.3<span></span>
</td>
<td class="nump">$ 117.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139657727241096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment, Net - Depreciation Expense (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 2.6<span></span>
</td>
<td class="nump">$ 2.4<span></span>
</td>
<td class="nump">$ 8.9<span></span>
</td>
<td class="nump">$ 7.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139657808269816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Carrying Amount of Goodwill (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="nump">$ 329.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit', window );">Divestitures</a></td>
<td class="num">(88.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Translation adjustments</a></td>
<td class="num">(1.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="nump">239.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mygn_DiagnosticsMember', window );">Diagnostics</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="nump">272.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit', window );">Divestitures</a></td>
<td class="num">(31.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Translation adjustments</a></td>
<td class="num">(1.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="nump">239.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="nump">56.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit', window );">Divestitures</a></td>
<td class="num">(56.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Translation adjustments</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillForeignCurrencyTranslationGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of divestiture of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mygn_DiagnosticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mygn_DiagnosticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139657731137496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Narrative (Details) - Disposed of by sale - Myriad RBM, Inc.<br> $ in Millions</strong></div></th>
<th class="th">
<div>Jul. 01, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_IntangibleAssetsLineItems', window );"><strong>Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNetNoncurrent', window );">Net decrease in intangible assets due to sale</a></td>
<td class="nump">$ 120.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsAccumulatedAmortizationNoncurrent', window );">Accumulated amortization on intangible assets included in sale</a></td>
<td class="nump">91.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=mygn_PurchasedLicensesAndTechnologiesMember', window );">Purchased licenses and technologies</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_IntangibleAssetsLineItems', window );"><strong>Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent', window );">Intangible assets included in sale</a></td>
<td class="nump">199.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer relationships</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_IntangibleAssetsLineItems', window );"><strong>Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent', window );">Intangible assets included in sale</a></td>
<td class="nump">4.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember', window );">Trademarks</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_IntangibleAssetsLineItems', window );"><strong>Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent', window );">Intangible assets included in sale</a></td>
<td class="nump">3.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=mygn_InProcessResearchAndDevelopmentWithIndefiniteLivesMember', window );">In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_IntangibleAssetsLineItems', window );"><strong>Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent', window );">Intangible assets included in sale</a></td>
<td class="nump">$ 4.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsAccumulatedAmortizationNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as accumulated amortization of intangible assets attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsAccumulatedAmortizationNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNetNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as intangible assets, net of accumulated amortization, attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNetNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_IntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_IntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as intangible assets, excluding goodwill, attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2510-110228<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mygn_MyriadRBMIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mygn_MyriadRBMIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=mygn_PurchasedLicensesAndTechnologiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=mygn_PurchasedLicensesAndTechnologiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=mygn_InProcessResearchAndDevelopmentWithIndefiniteLivesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=mygn_InProcessResearchAndDevelopmentWithIndefiniteLivesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139657726200760">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Intangible Assets (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_IntangibleAssetsLineItems', window );"><strong>Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount, amortizable</a></td>
<td class="nump">$ 617.4<span></span>
</td>
<td class="nump">$ 825.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(202.6)<span></span>
</td>
<td class="num">(254.2)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net, amortizable</a></td>
<td class="nump">414.8<span></span>
</td>
<td class="nump">571.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Non-amortizable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Gross Carrying Amount, total</a></td>
<td class="nump">617.4<span></span>
</td>
<td class="nump">830.7<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Net, total</a></td>
<td class="nump">414.8<span></span>
</td>
<td class="nump">576.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=mygn_PurchasedLicensesAndTechnologiesMember', window );">Purchased licenses and technologies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_IntangibleAssetsLineItems', window );"><strong>Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount, amortizable</a></td>
<td class="nump">617.4<span></span>
</td>
<td class="nump">818.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(202.6)<span></span>
</td>
<td class="num">(248.2)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net, amortizable</a></td>
<td class="nump">$ 414.8<span></span>
</td>
<td class="nump">570.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_IntangibleAssetsLineItems', window );"><strong>Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount, amortizable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4.5)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net, amortizable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember', window );">Trademarks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_IntangibleAssetsLineItems', window );"><strong>Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount, amortizable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.5)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net, amortizable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=mygn_InProcessResearchAndDevelopmentWithIndefiniteLivesMember', window );">In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_IntangibleAssetsLineItems', window );"><strong>Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Non-amortizable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_IntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_IntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=mygn_PurchasedLicensesAndTechnologiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=mygn_PurchasedLicensesAndTechnologiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=mygn_InProcessResearchAndDevelopmentWithIndefiniteLivesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=mygn_InProcessResearchAndDevelopmentWithIndefiniteLivesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139657731088600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Amortization on Intangible Assets (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">$ 11.6<span></span>
</td>
<td class="nump">$ 15.3<span></span>
</td>
<td class="nump">$ 40.6<span></span>
</td>
<td class="nump">$ 45.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139657722170616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Liabilities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employee compensation and benefits</a></td>
<td class="nump">$ 54.0<span></span>
</td>
<td class="nump">$ 48.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationReserveCurrent', window );">Legal accrual</a></td>
<td class="nump">48.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Accrued taxes payable</a></td>
<td class="nump">17.3<span></span>
</td>
<td class="nump">4.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_RefundsPayableAndReserveCurrent', window );">Refunds payable and reserves</a></td>
<td class="nump">8.9<span></span>
</td>
<td class="nump">9.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Short-term contingent consideration</a></td>
<td class="nump">3.3<span></span>
</td>
<td class="nump">3.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrent', window );">Accrued royalties</a></td>
<td class="nump">5.0<span></span>
</td>
<td class="nump">3.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RecordedUnconditionalPurchaseObligation', window );">Purchase commitment</a></td>
<td class="nump">5.2<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued liabilities</a></td>
<td class="nump">21.5<span></span>
</td>
<td class="nump">9.4<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued liabilities</a></td>
<td class="nump">$ 163.2<span></span>
</td>
<td class="nump">$ 79.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_RefundsPayableAndReserveCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Refunds Payable And Reserve, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_RefundsPayableAndReserveCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationReserveCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of reserve for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid within one year of the date of the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 55<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=116646759&amp;loc=d3e15243-108350<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationReserveCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RecordedUnconditionalPurchaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the recorded obligation to transfer funds in the future for fixed or minimum amounts or quantities of goods or services at fixed or minimum prices (for example, as in take-or-pay contracts or throughput contracts).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25383-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RecordedUnconditionalPurchaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139657725687032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">27 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 01, 2022</div></th>
<th class="th"><div>Jul. 31, 2021</div></th>
<th class="th"><div>Jul. 31, 2018</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Feb. 21, 2021</div></th>
<th class="th"><div>Dec. 23, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLinesOfCredit', window );">Principal repayment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 226,400,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Outstanding balances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 224,800,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_OtherAssetsDebtDiscount', window );">Debt discount reclassified to other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent', window );">Unamortized debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum aggregate principal commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLinesOfCredit', window );">Principal repayment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 226,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving credit facility | Amended facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum aggregate principal commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
<td class="nump">$ 250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_DebtCovenantLiquidityCovenantMinimum', window );">Minimum liquidity covenant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_DebtCovenantUnrestrictedCashAndCashEquivalentsThresholdForBorrowingRestrictionMinimum', window );">Minimum unrestricted cash and cash equivalents threshold per covenant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLinesOfCredit', window );">Principal repayment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 106,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving credit facility | Amended facility | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage', window );">Undrawn fee (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_DebtInstrumentLIBORFloorPercentage', window );">LIBOR floor (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving credit facility | Amended facility | Forecast | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage', window );">Undrawn fee (percent)</a></td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving credit facility | Amended facility | Forecast | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage', window );">Undrawn fee (percent)</a></td>
<td class="nump">0.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving credit facility | Amended facility | LIBOR | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on rate (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving credit facility | Amended facility | LIBOR | Forecast | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on rate (percent)</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving credit facility | Amended facility | LIBOR | Forecast | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on rate (percent)</a></td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_DebtCovenantLiquidityCovenantMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Covenant, Liquidity Covenant Minimum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_DebtCovenantLiquidityCovenantMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_DebtCovenantUnrestrictedCashAndCashEquivalentsThresholdForBorrowingRestrictionMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Covenant, Unrestricted Cash And Cash Equivalents Threshold For Borrowing Restriction, Minimum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_DebtCovenantUnrestrictedCashAndCashEquivalentsThresholdForBorrowingRestrictionMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_DebtInstrumentLIBORFloorPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, LIBOR Floor, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_DebtInstrumentLIBORFloorPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_OtherAssetsDebtDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Assets, Debt Discount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_OtherAssetsDebtDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of debt discount to be amortized after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mygn_AmendmentToCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mygn_AmendmentToCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139657723648152">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Long-Term Liabilities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration</a></td>
<td class="nump">$ 5.5<span></span>
</td>
<td class="nump">$ 7.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherSundryLiabilitiesNoncurrent', window );">Other</a></td>
<td class="nump">5.3<span></span>
</td>
<td class="nump">7.3<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Total other long-term liabilities</a></td>
<td class="nump">$ 10.8<span></span>
</td>
<td class="nump">$ 14.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSundryLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are expected to be paid after one year (or the normal operating cycle, if longer), from the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSundryLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139657831659960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Preferred and Common Stockholders' Equity - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock authorized (shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock outstanding (shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock authorized (shares)</a></td>
<td class="nump">150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock issued (shares)</a></td>
<td class="nump">79,700,000<span></span>
</td>
<td class="nump">75,200,000<span></span>
</td>
<td class="nump">75,400,000<span></span>
</td>
<td class="nump">74,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock outstanding (shares)</a></td>
<td class="nump">79,700,000<span></span>
</td>
<td class="nump">75,200,000<span></span>
</td>
<td class="nump">75,400,000<span></span>
</td>
<td class="nump">74,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1', window );">Share repurchase program, remaining repurchase authorization</a></td>
<td class="nump">$ 110,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Shares repurchased</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=mygn_EighthShareRepurchaseProgramMember', window );">Eighth Share Repurchase Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Share repurchase program, authorized amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount remaining of a stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased and retired during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=mygn_EighthShareRepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=mygn_EighthShareRepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139657721951720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Preferred and Common Stockholders' Equity - Common Shares Issued and Outstanding (Details) - shares<br> shares in Millions</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Common shares issued and outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Beginning common stock issued</a></td>
<td class="nump">75.4<span></span>
</td>
<td class="nump">74.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning common stock outstanding</a></td>
<td class="nump">75.4<span></span>
</td>
<td class="nump">74.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans', window );">Common stock issued upon exercise of options, vesting of restricted stock units, and purchases under employee stock purchase plan</a></td>
<td class="nump">4.3<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock issued at end of period</a></td>
<td class="nump">79.7<span></span>
</td>
<td class="nump">75.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock outstanding at end of period</a></td>
<td class="nump">79.7<span></span>
</td>
<td class="nump">75.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Share-Based Payment Arrangement And Employee Stock Purchase Plans</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139657722001576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Preferred and Common Stockholders' Equity - Reconciliation of Denominators of Basic and Diluted Earnings Per Share Computations (Details) - shares<br> shares in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares outstanding used to compute basic EPS</a></td>
<td class="nump">78.8<span></span>
</td>
<td class="nump">74.7<span></span>
</td>
<td class="nump">77.3<span></span>
</td>
<td class="nump">74.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Effect of dilutive shares</a></td>
<td class="nump">2.7<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares outstanding and dilutive securities used to compute diluted EPS</a></td>
<td class="nump">81.5<span></span>
</td>
<td class="nump">74.7<span></span>
</td>
<td class="nump">77.3<span></span>
</td>
<td class="nump">74.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139657725394984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Preferred and Common Stockholders' Equity - Potentially Dilutive Common Shares Excluded from EPS Computation (Details) - shares<br> shares in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive options and RSUs excluded from EPS computation</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">7.3<span></span>
</td>
<td class="nump">4.9<span></span>
</td>
<td class="nump">7.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139657724290072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 23, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2012</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized stock-based compensation expense related to stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=mygn_OptionsAndRestrictedStockUnitsMember', window );">Options and RSUs | Non-employee director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Service period for award vesting (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Service period for award vesting (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period for recognition of stock-based compensation expense (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options | Awards granted after December 5, 2012</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Award expiration period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options | Awards granted prior to December 5, 2012</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Award expiration period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Service period for award vesting (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized stock-based compensation expense related to RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 68.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period for recognition of stock-based compensation expense (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mygn_TwoThousandSeventeenEmployeeDirectorAndConsultantEquityIncentivePlanMember', window );">2017 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mygn_EmployeeStockPurchasePlanTwentyTwelveMember', window );">2012 Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of additional shares authorized</a></td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee', window );">Maximum number of shares per participant per offering period</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares available for issuance under the Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The highest quantity of shares an employee can purchase under the plan per period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=mygn_OptionsAndRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=mygn_OptionsAndRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=mygn_NonEmployeeDirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=mygn_NonEmployeeDirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=mygn_OptionsGrantedAfterDecemberFiveTwentyTwelveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=mygn_OptionsGrantedAfterDecemberFiveTwentyTwelveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=mygn_OptionsGrantedPriorToDecemberFiveTwentyTwelveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=mygn_OptionsGrantedPriorToDecemberFiveTwentyTwelveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mygn_TwoThousandSeventeenEmployeeDirectorAndConsultantEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mygn_TwoThousandSeventeenEmployeeDirectorAndConsultantEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mygn_EmployeeStockPurchasePlanTwentyTwelveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mygn_EmployeeStockPurchasePlanTwentyTwelveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139657727098280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Stock Option Activity (Details)<br> shares in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Options, Number of shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, beginning (shares) | shares</a></td>
<td class="nump">5.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Options granted (shares) | shares</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised (shares) | shares</a></td>
<td class="num">(3.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Options canceled or expired (shares) | shares</a></td>
<td class="num">(0.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, ending (shares) | shares</a></td>
<td class="nump">1.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable at end of period (shares) | shares</a></td>
<td class="nump">1.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Options, Weighted average exercise price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding, beginning (dollars per share) | $ / shares</a></td>
<td class="nump">$ 23.24<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options granted (dollars per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Options exercised (dollars per share) | $ / shares</a></td>
<td class="nump">24.26<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Options canceled or expired (dollars per share) | $ / shares</a></td>
<td class="nump">25.03<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding, ending (dollars per share) | $ / shares</a></td>
<td class="nump">20.57<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options exercisable at end of period (dollars per share) | $ / shares</a></td>
<td class="nump">$ 23.20<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139657726999736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - RSU Activity (Details) - RSUs<br> shares in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>RSUs, Number of shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">RSUs outstanding, beginning (shares) | shares</a></td>
<td class="nump">3.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">RSUs granted (shares) | shares</a></td>
<td class="nump">1.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">RSUs vested (shares) | shares</a></td>
<td class="num">(0.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">RSUs canceled (shares) | shares</a></td>
<td class="num">(0.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">RSUs outstanding, ending (shares) | shares</a></td>
<td class="nump">3.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>RSUs, Weighted average grant date fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">RSUs outstanding, beginning (dollars per share) | $ / shares</a></td>
<td class="nump">$ 20.56<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">RSUs granted (dollars per share) | $ / shares</a></td>
<td class="nump">29.95<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">RSUs vested (dollars per share) | $ / shares</a></td>
<td class="nump">24.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">RSUs canceled (dollars per share) | $ / shares</a></td>
<td class="nump">24.63<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">RSUs outstanding, ending (dollars per share) | $ / shares</a></td>
<td class="nump">$ 23.91<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139657808522552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Stock-Based Compensation Expense (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Compensation Expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 10.0<span></span>
</td>
<td class="nump">$ 8.4<span></span>
</td>
<td class="nump">$ 27.9<span></span>
</td>
<td class="nump">$ 17.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=mygn_CostOfMolecularDiagnosticTestingMember', window );">Cost of molecular diagnostic testing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Compensation Expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">0.4<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=mygn_CostOfPharmaceuticalAndClinicalServicesMember', window );">Cost of pharmaceutical and clinical services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Compensation Expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Compensation Expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">0.8<span></span>
</td>
<td class="nump">1.3<span></span>
</td>
<td class="nump">3.3<span></span>
</td>
<td class="nump">3.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general, and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Compensation Expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 8.8<span></span>
</td>
<td class="nump">$ 6.7<span></span>
</td>
<td class="nump">$ 23.4<span></span>
</td>
<td class="nump">$ 12.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=mygn_CostOfMolecularDiagnosticTestingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=mygn_CostOfMolecularDiagnosticTestingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=mygn_CostOfPharmaceuticalAndClinicalServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=mygn_CostOfPharmaceuticalAndClinicalServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139657807621576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense (benefit)</a></td>
<td class="nump">$ 15.2<span></span>
</td>
<td class="num">$ (28.5)<span></span>
</td>
<td class="nump">$ 6.0<span></span>
</td>
<td class="num">$ (47.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Approximate tax rate</a></td>
<td class="nump">38.20%<span></span>
</td>
<td class="nump">65.20%<span></span>
</td>
<td class="num">(44.10%)<span></span>
</td>
<td class="nump">20.30%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | California | Earliest tax year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationYearUnderExamination', window );">Tax year being audited in income tax examination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | California | Latest tax year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationYearUnderExamination', window );">Tax year being audited in income tax examination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | New Jersey | Earliest tax year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationYearUnderExamination', window );">Tax year being audited in income tax examination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2013<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | New Jersey | Latest tax year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationYearUnderExamination', window );">Tax year being audited in income tax examination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign | Germany | Earliest tax year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationYearUnderExamination', window );">Tax year being audited in income tax examination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2013<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign | Germany | Latest tax year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationYearUnderExamination', window );">Tax year being audited in income tax examination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign | Switzerland | Earliest tax year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationYearUnderExamination', window );">Tax year being audited in income tax examination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign | Switzerland | Latest tax year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationYearUnderExamination', window );">Tax year being audited in income tax examination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationYearUnderExamination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax year being audited in the income tax examination, in YYYY format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationYearUnderExamination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:gYearListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_CaliforniaFranchiseTaxBoardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_CaliforniaFranchiseTaxBoardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=us-gaap_EarliestTaxYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=us-gaap_EarliestTaxYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=us-gaap_LatestTaxYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=us-gaap_LatestTaxYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_NewJerseyDivisionOfTaxationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_NewJerseyDivisionOfTaxationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_FederalMinistryOfFinanceGermanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_FederalMinistryOfFinanceGermanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_SwissFederalTaxAdministrationFTAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_SwissFederalTaxAdministrationFTAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139657723326648">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationReserveCurrent', window );">Potential settlement accrual</a></td>
<td class="nump">$ 48.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationReserveCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of reserve for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid within one year of the date of the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 55<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=116646759&amp;loc=d3e15243-108350<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationReserveCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139657724224376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment and Related Information - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2021 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments</a></td>
<td class="nump">2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139657828924888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment and Related Information - Segment Revenue and Operating Income (Loss) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 167.3<span></span>
</td>
<td class="nump">$ 145.2<span></span>
</td>
<td class="nump">$ 529.8<span></span>
</td>
<td class="nump">$ 402.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">14.2<span></span>
</td>
<td class="nump">17.7<span></span>
</td>
<td class="nump">49.5<span></span>
</td>
<td class="nump">53.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Segment operating income (loss)</a></td>
<td class="num">(79.9)<span></span>
</td>
<td class="num">(39.6)<span></span>
</td>
<td class="num">(147.4)<span></span>
</td>
<td class="num">(241.6)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mygn_DiagnosticsMember', window );">Diagnostics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">161.7<span></span>
</td>
<td class="nump">130.5<span></span>
</td>
<td class="nump">496.6<span></span>
</td>
<td class="nump">362.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">13.1<span></span>
</td>
<td class="nump">16.7<span></span>
</td>
<td class="nump">45.8<span></span>
</td>
<td class="nump">50.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Segment operating income (loss)</a></td>
<td class="num">(21.7)<span></span>
</td>
<td class="num">(0.3)<span></span>
</td>
<td class="nump">26.3<span></span>
</td>
<td class="num">(127.7)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">5.6<span></span>
</td>
<td class="nump">14.7<span></span>
</td>
<td class="nump">33.2<span></span>
</td>
<td class="nump">40.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">1.1<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
<td class="nump">3.7<span></span>
</td>
<td class="nump">3.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Segment operating income (loss)</a></td>
<td class="num">$ (58.2)<span></span>
</td>
<td class="num">$ (39.3)<span></span>
</td>
<td class="num">$ (173.7)<span></span>
</td>
<td class="num">$ (113.9)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mygn_DiagnosticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mygn_DiagnosticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139657726163560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment and Related Information - Total Operating Loss for Reportable Segments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="6">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Total operating loss for reportable segments</a></td>
<td class="num">$ (79.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (39.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (147.4)<span></span>
</td>
<td class="num">$ (241.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
<td class="nump">1.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(1.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6.1)<span></span>
</td>
<td class="num">(8.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other</a></td>
<td class="nump">120.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">139.3<span></span>
</td>
<td class="nump">14.9<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income (loss) before income tax</a></td>
<td class="nump">39.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(43.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13.6)<span></span>
</td>
<td class="num">(233.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense (benefit)</a></td>
<td class="nump">15.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(28.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.0<span></span>
</td>
<td class="num">(47.4)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">24.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19.6)<span></span>
</td>
<td class="num">(185.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to non-controlling interest</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) attributable to Myriad Genetics, Inc. stockholders</a></td>
<td class="nump">$ 24.6<span></span>
</td>
<td class="num">$ (4.7)<span></span>
</td>
<td class="num">$ (39.5)<span></span>
</td>
<td class="num">$ (15.2)<span></span>
</td>
<td class="num">$ (55.4)<span></span>
</td>
<td class="num">$ (115.2)<span></span>
</td>
<td class="num">$ (19.6)<span></span>
</td>
<td class="num">$ (185.8)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139657722015768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Cash Flow Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental Cash Flow Elements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash paid during the period for income taxes</a></td>
<td class="nump">$ 2.4<span></span>
</td>
<td class="nump">$ 2.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">2.1<span></span>
</td>
<td class="nump">6.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIncomeTaxRefunds', window );">Cash received for income tax receivables</a></td>
<td class="nump">89.9<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowOperatingActivitiesLesseeAbstract', window );"><strong>Establishment of operating lease right-of-use assets and lease liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease right-of-use assets</a></td>
<td class="nump">40.5<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_OperatingLeaseLiabilityEstablished', window );">Operating lease liabilities</a></td>
<td class="nump">$ 46.8<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_OperatingLeaseLiabilityEstablished">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease Liability Established</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_OperatingLeaseLiabilityEstablished</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowOperatingActivitiesLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowOperatingActivitiesLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIncomeTaxRefunds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash received during the period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIncomeTaxRefunds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139657725599192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Divestitures - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 13, 2021</div></th>
<th class="th"><div>Jul. 01, 2021</div></th>
<th class="th"><div>May 28, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Divestitures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFirmPurchaseCommitmentLoss', window );">Loss on non-cancelable purchase commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Loss on inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.5<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember', window );">Disposed of by sale | Myriad myPath LLC laboratory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Divestitures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfProductiveAssets', window );">Proceeds from sale of assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_GainLossOnDispositionOfAssetsNetOfTransactionFees', window );">Net gain on sale of assets adjusted for transaction fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal', window );">Gain (loss) on divestiture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">31.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_DisposalGroupNotDiscontinuedOperationTransactionCosts', window );">Transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember', window );">Disposed of by sale | Myriad RBM, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Divestitures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries', window );">Proceeds from sale of business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 197.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal', window );">Gain (loss) on divestiture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">121.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">121.0<span></span>
</td>
<td class="nump">121.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_DisposalGroupNotDiscontinuedOperationTransactionCosts', window );">Transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember', window );">Disposed of by sale | Select operating assets and intellectual property of Myriad Autoimmune business unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Divestitures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries', window );">Proceeds from sale of business</a></td>
<td class="nump">$ 150.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal', window );">Gain (loss) on divestiture</a></td>
<td class="num">(0.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.6)<span></span>
</td>
<td class="num">$ (0.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_DisposalGroupNotDiscontinuedOperationTransactionCosts', window );">Transaction costs</a></td>
<td class="nump">$ 4.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_DisposalGroupNotDiscontinuedOperationTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Not Discontinued Operation, Transaction Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_DisposalGroupNotDiscontinuedOperationTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_GainLossOnDispositionOfAssetsNetOfTransactionFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) On Disposition of Assets, Net Of Transaction Fees</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_GainLossOnDispositionOfAssetsNetOfTransactionFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2443-110228<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFirmPurchaseCommitmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss recognized on firm purchase commitment for inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4578-108314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFirmPurchaseCommitmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4542-108314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the deconsolidation of a previously consolidated subsidiary or the sale of investment in consolidated subsidiaries (generally greater than 50 percent).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mygn_MyriadMyPathLLCLaboratoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mygn_MyriadMyPathLLCLaboratoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mygn_MyriadRBMIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mygn_MyriadRBMIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mygn_MyriadAutoimmuneAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mygn_MyriadAutoimmuneAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139657807600712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Divestitures - Other Income (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 13, 2021</div></th>
<th class="th"><div>Jul. 01, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Divestitures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Total Other Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120.6<span></span>
</td>
<td class="num">$ (1.6)<span></span>
</td>
<td class="nump">$ 139.3<span></span>
</td>
<td class="nump">$ 14.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember', window );">Disposed of by sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Divestitures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_DisposalGroupNotDiscontinuedOperationGainLossOnInventory', window );">Gain (loss) on inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_DisposalGroupNotDiscontinuedOperationGainLossOther', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mygn_MyriadRBMIncMember', window );">Myriad RBM, Inc. | Disposed of by sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Divestitures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal', window );">Gain (loss) on divestiture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 121.0<span></span>
</td>
<td class="nump">121.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">121.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mygn_MyriadMyPathLLCLaboratoryMember', window );">Myriad myPath LLC laboratory | Disposed of by sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Divestitures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal', window );">Gain (loss) on divestiture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mygn_MyriadAutoimmuneAssetsMember', window );">Myriad Autoimmune assets | Disposed of by sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Divestitures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal', window );">Gain (loss) on divestiture</a></td>
<td class="num">$ (0.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_DisposalGroupNotDiscontinuedOperationGainLossOnInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Not Discontinued Operation, Gain (Loss) On Inventory</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_DisposalGroupNotDiscontinuedOperationGainLossOnInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_DisposalGroupNotDiscontinuedOperationGainLossOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Not Discontinued Operation, Gain (Loss) Other</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_DisposalGroupNotDiscontinuedOperationGainLossOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2443-110228<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mygn_MyriadRBMIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mygn_MyriadRBMIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mygn_MyriadMyPathLLCLaboratoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mygn_MyriadMyPathLLCLaboratoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mygn_MyriadAutoimmuneAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mygn_MyriadAutoimmuneAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>83
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M_@I:I! _4F[XFL,:$J@EH4[;#2BTR8&Q10Z'%25#>9AT#BE^=O1+BU.^M%E
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MWM8P$"HQ\(':_\JTO]&RJ'ZH64FM959=;CD#\<8 OE]+J0\WYK>?YK>^J_\
M4$L#!!0    ( ): 9%-IRQ7(30(  ,\%   8    >&PO=V]R:W-H965T<R]S
M:&5E=#,N>&ULC91-C]HP$(;_BI53*VUQ/J#LKD*DY6/5'E9"B]H>JAY,,A +
MQTYMLVS_?<=.B((45G# 'GN>US.>C-.3T@=3 ECR7@EI9D%I;?U(J<E+J)@9
MJ1HD[NR4KIA%4^^IJ36PPD.5H'$8?J45XS+(4K^VUEFJCE9P"6M-S+&JF/XW
M!Z%.LR *S@NO?%]:MT"SM&9[V(#]4:\U6K13*7@%TG EB8;=+'B*'E>)\_<.
M/SF<3&].7"9;I0[.^%[,@M %! )RZQ08#F^P "&<$(;QM]4,NB,=V)^?U9]]
M[IC+EAE8*/&+%[:<!?<!*6#'CL*^JM,W:/.9.+U<">/_R:GU#0.2'XU550MC
M!!67S<C>VWOH ='X"A"W0'PKD+1 <BLP;H'QK<"D!7SJM,G=7]R269:E6IV(
M=MZHYB;^]CV-]\6E^TXV5N,N1\YF"R4+K#H4!&=&"5XPB\:<"29S(!LG;,BG
M-=,@;0F6YTQ\)E^(*7'%G <NR0L7 BMO4FHQ+"=.\S:$>1-"?"6$#=0CDH1W
M) [C: !??(PO(4<\\G@X@"]O/WT(7]U\>O1PB5,L15>/N*M'[/62:^%8O'_L
M0TO4CCQSB57@3)"U,MPWUN^GK;$:V^O/!X<EW6&)/VQ\M?A5A9KXD>6'NW,M
M\3$QELF"R_U0+1O%>Z_H'J&W;/HPFJ;TK5^Q :?):!SV?M$EL1PDXDNGU8#3
M>#3IG)H[H+UF<$_="]-[+@T1L$,L'$VQ@73S?#2&5;7OCZVRV&U^6N*+"]HY
MX/Y.*7LV7,MU;WCV'U!+ P04    " "7@&13QQZ>$C$'  "O(   &    'AL
M+W=O<FMS:&5E=',O<VAE970T+GAM;*U:VW+;-A#]%8PF#\F,11$ J8O']DPL
MJ6T>W'CLIGF&24CBA")4 K*3O^_R8I(BEK#:Q \1*1TLL >+W0,@5R\J_Z9W
M4AKR?9]F^GJT,^9P.9GH:"?W0GOJ(#/X9:/RO3#PFF\G^I!+$9>-]NF$^?YT
MLA=)-KJY*K^[SV^NU-&D22;O<Z*/^[W(?]S*5+U<C^CH]8N'9+LSQ1>3FZN#
MV,I':;X<[G-XFS16XF0O,YVHC.1R<SWZ2"_7?%8T*!%_)_)%=YY)X<J34M^*
MET_Q]<@O1B13&9G"A("/9[F4:5I8@G'\4QL=-7T6#;O/K]9_*YT'9YZ$EDN5
M?DUBL[L>S4<DEAMQ3,V#>OE#U@Z%A;U(I;K\E[S46']$HJ,V:E\WAA'LDZSZ
M%-]K(CH-P [>@-4-6+]!,-" UPWXN3T$=8/@W!["ND'I^J3RO21N)8RXN<K5
M"\D+-%@K'DKVR]; 5Y(5@?)H<O@U@7;F9JFR&*9=Q@2>M$J36!AX>33P ?%@
M-%$;\OD@<U',JR9C\N5Q1=Z_^T#T3N12DR0C=TF:%C]>D'?=UZN)@0$6W4RB
M>C"WU6#8P& XN5.9V6FRAD'%2/N5N_W"T7X"Q#3LL%=V;IG3X*,\>(3[%X3Y
MC"+C69[?W,?<^;G>U_^[]Q,R>!,JO+3'!^P]R&>9':6^=-@*&EM!:2L8L/67
M,B*%1%-:Q *E:CXMFQ?)[OF&3F<>OYH\=^E'4$'HL5/4RD:%;.'-3U%K&Q7X
MS L:U(F?8>-GZ.1LJ30L(9'%1'X_%.O,R=ZTL3IULO<@M11YM"L-QT!BJ@[%
M8GWM!".TLCCO4C7O<[!$0#-OVJ/3!DUIAZ>*31L4!MX,)W/6N#USNOT(Y23)
MMA=D*S-(2.E%Z;^((2TFVA09ZEFZ*)@A%/C]:%DB*!9XM$>"C0JFOA?V6+!1
M?!H,Q=2\H6'NI&&Y$]E6%IG6["39B"0GSR(]RB)31Y#_@*(B%N!1)W&=N#$Z
MYM;@_/XT+FW,F%I<V"#:F>J*"<10T*'KA(A%0\3"2<3O2L4O4&S*,$A5MAVG
M$ $0$5J#PDKV!Z"F7!81E*JM1 M2U4/8):%'P9N(U0+QOY]=;,QB[@5^YX_B
M9%"_K>3^&3DULC(.6H=]:SPLF%EK 8'1>=!W;H7 IC/+VKJ&=:F<!@.+@78$
M#'6Z78N3; LAH'%GJ1U\LX6WP-FO/4?:\(65"S$8!2+[Z1##L8!V[)UZSUKO
MF;/ ?(8<D$,NB-1>DO?UE']P%1G:UGO*G<Q^RHP$B6=J\RBU'$DB5A1AH*#/
M) ::]FFT072HJM!6BU"W&&G\=-2.VH0[$RXQ%/,6?5<1U+1O:XVAYA[WS\D9
MK3RAH7OQ%.&#^ALB9=":D"4"&U-[E2#&8#'QOL<(+.BP=^IC*Y:H6RU5>5&A
M"^6"9-*@_B-2B"[Z96V)P,:V6,",<6[5" 1V[H2W$HJZ-=2GFH B5WX@3W*C
M<OG*BA'?42H0%6/)YR6"&@>\3]@*@U%N+W0$QH R/N!_JYVH6SQ]:EQ]7>WD
M_1/(R4UB/J#.(^+&VF$L$=28S?MR<%7#3@I@WW%,*,V&)"-MI1)U:Z4_I6F"
MOYQ[U%E;I8#TM=:\C1K;G*Q0F%5!URAL'@XM>];*(>:60X7'A:=$&),G3T<C
MGE*8>$4RE8T+G9RK<CL!M%3I'V.$V9*EKP_?AJS>AJR9+:'&OC>PW%DKCIA;
M'%G3;K%Q]R-/1$Q^AS5@DDA?$%@A'M%&1=]V*H7] RJIZFZG[DA!4%BDH# [
M4E 81,I\@*160S&WAK)) DE9G6^YA!1KA11S"ZE;H9.(O(<=6PPQ)W+==H"N
MP]K<XD0+\;[80%!C2WRM!E#]G2H&8UXPM I;;<7<VFJ5I,?B0/$_.!]@SO=]
MMT&8[SC*\AV!.7QOQ15S'_Y\+4^IBPWI,VQ18,M>'YFJH]$&=FB0?)SQU2H<
MYE8X=7Q5YG%2;6DQLX]_,%1@E7 ,91W-K7%;X:+[-T!P*V:86\PTP>7RW%82
M<]JOS$L$A7F.H!#/45MG>=[*&.:6,7<JE=$15A.)$['-8,\/ 6"@B$%,N4*J
MU0ML\=.'O;RMQ?R<HPG'<6_=_JWS7@S&0VN>$%CHAU9!06!\NA@ZE>)MT>7T
M%Q[Z\K9.<>8^^ .[Q2&?BT=FGTO.K'6.H$#1][>I"(K:L#4&.RGRI]YV;AO<
M1?,>UO1>1/((H2VJ,[X(,.6+EOES$O6/MDX[:DL4#WX^U-NDS]T[ZK=#/7Q3
M4G)[([RP-A,(""18_\P-07$V)*YY6W'X]%>&>)O1N3NCGQ/BE869B[^9?9?3
MSR4K!$2I'=T(RI:<D\X%[%[FV_+F6Y-('3-37; UWS:WZQ_+.^7>][?T<DF1
M[U?T<EW=G;?FJZO\.Y%ODTR35&Z@*]^;P83GU>UX]6+4H;S^?5+&J'WYN),"
MA'T!@-\W2IG7EZ*#YO\HW/P+4$L#!!0    ( )> 9%,A=5>^=0,  #X+   8
M    >&PO=V]R:W-H965T<R]S:&5E=#4N>&ULK59;C]HX%/XK5M2'5BKDPBT=
M =(,S.Y6ZE2CHME]J/;!) ?BCF.SMH&9_?5[G(0T!$-1MR^)+]^Y?3X^/N.]
M5,\Z S#D)>="3[S,F,V-[^LD@YSJKMR P)V55#DU.%5K7V\4T+00RKD?!<'0
MSRD3WG1<K#VJZ5AN#6<"'A71VSRGZO4.N-Q/O- [+'QAZ\S8!7\ZWM U+, \
M;1X5SOQ:2\IR$)I)012L)MYM>',?6WP!^)/!7C?&Q$:RE/+93CZF$R^P#@&'
MQ%@-%'\[F 'G5A&Z\4^ETZM-6L'F^*#]MR)VC&5)-<PD_XNE)IMXL4=26-$M
M-U_D_@^HXAE8?8GDNOB2?84-/))LM9%Y)8P>Y$R4?_I2\= 00#UN@:@2B-H"
M_3,"O4J@=ZV%?B70O];"H!(H0O?+V OBYM30Z5C)/5$6C=KLH&"_D$:^F+!Y
MLC *=QG*F>E,BA1/'5*"(RTY2ZG!R<+@#]/!:")7N)5C$F8V.W9 /HI$YD#>
M?I):OR,=\K28D[=OWI$WA GRP#C'!-!CWZ!WUH:?5)[<E9Y$9SSID0<I3*;)
M/7J4.N3GE^4_7)#WD96:FNA S5UT4>$"-EW2"]Z3*(A"AS^SZ\4#5SC_S_K]
M3UL_(J-7YTFOT-<[I^^0$&?SX>OM4AN%%__O"^;ZM;E^8:Y_QMQGK)"LRC->
MY!DU1K'EUM E!V(D>7A5C*;D=Q!@6*+?6S>Z!.]+\IQ)GH)RIF!I=5A8M25T
M-XWZW>'8WS7/]134"0?=Z!@U=Z$^M'7=NU#QH!O7L"-Z!C4]@XOT/ E\$SC[
M%V_J&M^" T>V\.XHXY:C#KXA'4V1K!26AFA(MHH9!L@4,F9/T= 7%T6EY;CI
M<= .?G8-:.X$#5H$G8*:F"-VAC4[PXOLS#(JUF"K$7* +X7 0JH4B.258((*
MS6GY1J7?L+[:G/X1)<-K*#D%A8UC+AEQ* I/4L:E*'0S,JH9&5UFY.C"'ETL
M5[RC$P_PEK3C/05UPEX[F+D#%87=42MDEZZX:?(HZKB..O[9J']1.8E=Y:1-
MU"G(190#Y2#*I<M!E-]H"')0ZZ(3TR216V'*FE^OULW>;='CM-;OPIM9Z%B?
M8W-8]G+?U9>=Y0-5:R8TX;!"4T%WA!=<E=U:.3%R4[0C2VFPN2F&&3:XH"P
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M]JGTIBL^8\]Z6L7@050(3JMZ1+I3A52LY[3J"3]R,N0T"O[*V:?2C2JJ8L]
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M*TDED)_?Y+EXO*@>"#T\Q'SQ'U!+ P04    " "7@&13M&BM8ML'   S(
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MN$)=]'W^";W[[3WZ#?$2W?$\A]U0%WT-8,R4_72_\,=Z8>Q9>(+N1*G7"MT
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M#]/Z_KJ9IKY.OZ,2MD:AG"UA2HA9,+RL;ZCK%RTVU27O0F@MBNIQS2C0I1&
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M9)9H]*_+PR G$[_:,*BR0\5HU(YH+ARTL: 8HE3[G@=&6)6<1M*]J[L!CF9
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MPV=BA8@8O=EUO7-@#=E[>##SR$#T8'[>OR0 2@3@;G@K"-EVRFC(2H?KZ5;
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MS%2;)LT>]SBF%[,)L]6441C-YV1(9\@U2#9,J+9DK^:W'E]! VCS814#$T)
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M-%46 =_G$O5<7ZR :C<?? =02P,$%     @ EX!D4YWBMLW?!P  _!0  !D
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M]M/>9?RBM2&/WP5ON5W@Y0:OT'.P#K+71SWL(^%;6[SPI@K?MV;&>U.&TZ5
MZE@BP/.Y02&F"U+0?O"\^!M02P,$%     @ EX!D4\9\;X]  P  ^ 8  !D
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M80E9G2;0#$>C(-P<)'Q*[06.9B\8UIBV&7TN@4_SXF4,ZHI? ERS&W3JM!Z
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ML4"[)LL7<)X;X[L%"^B_)E[_%U!+ P04    " "7@&13UK99;V0"   ;!0
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M.?P>_OP7Z,GXPW@R&5_ Z=4%G%]?7EY?P?3S]?DO'Z]_O1A/I@3]VY=/G_^
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MI9P?4=G0VSL8MYG0.K'&C&@?FS:(#A\]7\*C=:#'Q+@TTDDNZ@U^C9.9X?Z
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M7@],==FK/IPN_ 5KIAU=U_QK2O=C-+R!_I]KZCWU!RMH;]PG_P!02P,$%
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M7"@)S-,&K,^T=O&%#FC_S^'JOU!+ P04    " "7@&13.5O)=UD%  "(#0
M&0   'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6R=5]MNVT80_96!FA8MH%!W
MVXTO@.TDK0,D#:*D+5#T846.I$W(769W:4GY^IY94K2<*HJ3%XF7/6<N>V9V
M>+:R[H-?,@=:%[GQYYUE".637L^G2RZ43VS)!F_FUA4JX-8M>KYTK+((*O+>
ML-\_ZA5*F\[%67SVVEV<V2KDVO!K1[XJ"N4V5YS;U7EGT-D^>*,7RR />A=G
MI5KPE,.[\K7#7:]ER73!QFMKR/'\O',Y>'(UEO5QP9^:5W[GFB22F;4?Y.8F
M.^_TQ2'..0W"H/!WR]><YT($-SXVG)W6I !WK[?LSV/LB&6F/%_;_"^=A>5Y
MYZ1#&<]5E8<W=O4[-_%,A"^UN8^_M*K7CD8=2BL?;-& X4&A3?VOUDT>=@ G
M_2\ A@U@&/VN#44OGZJ@+LZ<79&3U6"3BQAJ1,,Y;613IL'AK08N7-R8U!9,
M;]6:_5DO@%&>]](&?56CAU] _THOK0E+3\],QME]? ^>M.X,M^Y<#0\23KE,
M:-3OTK _'!S@&[7AC2+?Z*OAT5/MT]SZRC']<SGSP4$0_QXP,6Y-C*.)\7=F
M\"OH5]=_O'Q&;R__?C:E&T/69>PH6"@KL,.&,X4ET[4M2F4V/_UP,AP<GWKZ
M6"F']_F&2F=O=2P15"CIVID@SG1WD51YSD@98A\TQ!QO3*5RXOF<8VD(BAQ>
M :<":1_EGA&H>5UBS1VF,:-,1CZH4 7K-BW<XW4T?:N<MI6G]Y73/M.Q#./+
MU5*GRWO>H<E$:$+7[ )Z"7F],'JN4V4"DD*5J7RT'+CPI+")GDLE&.3 <6JQ
M^A,<;$PW^:$,ILWBSB LI6GEHN>@IAF"(&\KES+9>?18S72NPV;+M"<]<V>+
MU@*VJKE,Z*;-?LR8\1PW16C"TC%345<+2[40M(Y@9N#8"IY6RM.CP209HM3S
M'.GJ2NRJQ":OXZXAV-%),OQ1G$43?BRFFLU()94.O/ (D=TI 4$:GNL@F$?#
MDV1R@/QH\ADY*@9"^I8H^@?S8$31#TK#4=(_X.C/XW$R^.5_KCXP"^/C9'R
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M8$_$9>.6X![*#I4U+OH>*>XYPTG3-U2%EB&1)F?&[N,Q@:+;FO%Z&=?W>"8
MI_PP7T^%0P9\'V0Y[@"U!21*.1IZH!0H!O6;@LV$56I5B)./,(<FBL3F\.:Y
M=-?B")0OE]:H,2\F*7'#*3(6G00@WFUX.Q&';H,JC%EHX><(;=L"'#,T)$I
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MD"OK>":Q34 8:,SBS6DRZL(8R9:F)(GAA![WU9.8&PJ1R TR)=CL&H,(FBT
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M<FMS:&5E=',O<VAE970R,2YX;6RM5]MNXS80_17"#0H'2&5+\G4W"9!LLML
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M(A[%T1C/833R7^,H%6>$N"BK<#""@:QX+_PG#,1I%(N8_P91TA+>DF1RHIO
M[;[H#B=1@L=X&DWW?PA<_PFXM!\-^3GP&./!$!'?0#?"TCCJBWB,EY?0]:,4
MJ-+IYC':%U?<P_]!N,%TY"5+4V""?LDTFKR!#? G(@6LP12TOL?VM#R2$5+1
MC<>I%S(>C*/!#Z%\HF Z2J %T/:C@7\D>+Z.<M@'(<[Q, 6 EQ2,DW' A7)
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MKS@_ 9X78'ZN<=2M/SA ^\/J^%]02P,$%     @ EX!D4QU#'&6Y @  " 8
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M:G>-=3YGCB]6PI1?V%6^4<>#N#!69368%&1<5BM[KNMP .@&KP#"&A"6NJM
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M+A3P?FDM[8-PP/"PSG\ 4$L#!!0    ( )> 9%,7,CJ)\04  .@.   9
M>&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;*576V_;-A3^*X0'; G@^I9+;TD
M)VNW8B@:Q.GV,.R!EHXLMA2IDE0<[]?O.Z0LN9CCM=B+K<NYG^]\1[Q86_?9
MET1!/%;:^,M!&4+]:CSV64F5]"-;D\&;PKI*!MRZU=C7CF0>E2H]GDTFY^-*
M*C.XNHC/;MW5A6V"5H9NG?!-54FWN29MUY>#Z6#[X$ZMRL /QE<7M5S1@L+'
M^M;A;MQ9R55%QBMKA*/B<C"?OKH^9_DH\+NBM=^Y%IS)TMK/?/,NOQQ,."#2
ME 6V(/'W0#>D-1M"&%]:FX/.)2ON7F^MOXVY(Y>E]'1C]1\J#^7EX,5 Y%3(
M1H<[N_Z5VGS.V%YFM8^_8MW*3@8B:WRP5:N,""IETK]\;.OP+0JS5F$6XTZ.
M8I0_RR"O+IQ="\?2L,87,=6HC>"4X:8L@L-;!;UP=2V]\L(6XM:1)Q-DK-71
MK=4J4^2/+\8!7EAVG+46KY/%V1,67XKWUH32BS<FI_QK_3&BZT*<;4.\GATT
MN*!Z)$XF0S&;S*8'[)UT*9]$>R=/V/O@5M*HOV.F0W%CC4>R>4I<FOSK2J R
M;Y61)E-2BP4>$A 9O/ASOO3! 5-_'8CHM(OH-$9T^CU-V%?YPV;N2P+*,UO5
MTFR467%N.>:'\ITL<;,W(<RW"#!PD]1%*1](+(F,P+#7TD%/F6C>Y= FX#24
MXN-H,1(K,N2DUAM^336[8+G&! ZB=@K.:DU>'/WXPXO9;/+ZE_G\-EY.7Q]'
MQ\H$<JH211>9,HEPMDVI&^<;:8((-H8IZQH(E4M-PC5LFX4<K1H==6(U66Y!
M6>-44*W$F\>LE&85TZR4C]2RC6KQYF8;U$C,M4Y1M>7<9I3,H//&RRQYZBM%
M6F%$8XU1JVP762/QSL2 ;*U,"ZQ*&O >EW^8<MKM75\*WS<))H/D-B ZF7\"
M/:3G1^Q+^5AO&#9<.MV6!/D[?@[KKI':'PM#&7D/"N9BU@ERHI#*<0=A>:_K
M/<WG-H[$?03-MP.M)$<PYDO;Z!QU$[Q+VGI]:DPBZVA_!X[<F.GSUZA^DZOP
M37XX>V,#&A_8)5(%#G63I^;LLWW/7571_QW5U@6!*^9^,9T\^ZV;D-"+U4"M
MS04QTXF?4=9J24Z<3"-73<01B[?H.FR\!QZ7,TU<1T!/]0,%XR%18=/W ]7\
MTBCT= ==W.9*?B9!0 AFJIT%Z;&)ZX3A4,H@9%%@5\8<70R1![E*J$<8D*>V
MKEK)I=+]6.7*9]KZAOU"DF$*R+'KIY22&V[?=E+W93F$OE@3H]T_&9>C!S(-
M11_T6#,.O<B;"/I>)U)1;-=(?,"%C$\0,-9WSWZA=)0L&9"KJ-(F2_U=,+6E
M!K?+"%7=,,:ZB5*8("!:F1S<Q)\;*;[D UW .XXPXPS8)1.+97AV#-@B"N^V
M(14-TM^0=*,#F^:LVS1G!U?$'64:+5%%C ^=W[=EOM.$N"$760E,CYC;#+8-
MZMG1=8K('L5HX=O/.C,58Z:U4.\LPS07[E^NHW6#T<8D9W&D8A=M8/J+T!NV
M=SOH&P)A-OM<6IV3\^WX"YZ;L!F*3/I2%/A8!2J<K4#8E$81>DC/X$,91&(K
M$D> O#_N&M6BZT"7SKLNG?]7B;D.\WZ)WCIK<)VEL=C7M/]G420!P'>>V[C!
MP:0FER[WO+@Z:IM-IB_3LGH[7UP+;- &LO/%Q_CFV70VA'@LSKU\Y(U_CWV7
MB>>GD^-78H$N:55LMH.Y$PW7\&O%EC9W3.\LY_XA0A 235GO?G+X-G9&F6^=
M[KY/GQS16XC>TJ:L[ ,-,?,YQ(>)(O-\^\'14]R68E/A,."[IA)0NP 0'456
M92Y@MP7,R#3/'F.Q4L;$Y5Q@_/LR3\_2!AFFX8 PKV;N3+MU0/IH$CN#AU6C
MVJT,EI1M_Z*B8>)G8N$OJC0BG([HE]]/_GN6]UYPCW=.'Q6Y53QC\;<*JIT.
M(MW3[A@W3Z>77CR= =]+AXIXH:F ZF3T'%3DTKDJW01;Q[/,T@:<C.)EB<\'
M<BR ]X7%QF]OV$%WN+WZ!U!+ P04    " "7@&13PM"36N8$   ##   &0
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M\=,MNG1IZ #VUUJ[7J +AKY_^2]02P,$%     @ EX!D4V"'2_)5!   Z0L
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MN2;+ HV")DR0)57JB8D-692R%L;.=@[NR_U!&Y;(Y[JB&<P\9*H&]0#>_+X
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MP PS.!A.=Z'O2^UHBL*VI6<+C7>@^XW6;F?X!--#6/P%4$L#!!0    ( )>
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M<4,IMB"; JZPDA8+.&_:8G/6O!NYJM!,%H&E:.P3Y!WR:8LL7D&>PX5J[-;
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M_$/J#M^I2\?C#MVMZ*BF,FJE<N4*"BBLI\+MODYXWB;BN 8>'T9$&FP+57
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MR(.T!N;Y1@C]-+!'Q?I? ^O_ %!+ P04    " "7@&13K;QEX'L"  #<!@
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MKH*R"69])27N GMUVY<Z^PM02P,$%     @ EX!D4UN>6@&7 P  3PT  !D
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M*-5YXM?SS.)W'<ZA]%$27J XC*,/*-A3NM]W_"=5OA+K/VGQ[](A+]#73;$
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M76FU7.\>3GWP)@.Q-HFI;6#OO[^QDPTAA BUVN6!V,[WS7CF<^SQ^"#DLTH
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M":U%FC^N@,8@LP7F_4((_3S( E37::,?4$L#!!0    ( )> 9%/V6%+_$ (
M (8$   9    >&PO=V]R:W-H965T<R]S:&5E=#8U+GAM;)U4WV^;,!#^5RS4
MAU;:8@+I#U4$J26:MH=*4:-N#],>'+@$J\9F]A&Z_WYG0U&F-=6T%_#9]WW?
M?>>#K#?VV=4 R%X:I=TRJA';6\Y=64,CW,RTH.ED9VPCD$*[YZZU(*H :A1/
MXOB*-T+J*,_"WMKFF>E020UKRUS7-,+^N@=E^F4TCUXW'N6^1K_!\ZP5>]@
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M*Z\15+\=D#D*:RW<"Q06^*>RVZX=(NU/'>?;$]5:QLM=L3EI0;C@_1".7U+
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MNC[G)EH4ME4LA,;&8X<I?AJ - ZXOA)";R<F0/VQ,?T'4$L#!!0    ( )>
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M"^Y1ZDNT$SS,Y@-3(U)25><7R^%%MUVGLNQG'$8%AU$KAR^P?^]A#]8M/V>
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M[*R6#12/TZ/"EBLX>*27!SC?4J$#X/F.<_4\T*>/XL0\^Q]02P,$%     @
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M"E81A"1*_M%K6H@< -:. )P4X%0%N"G K0JHI8!:54 ]!=2K KP4X%4%-%)
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MBL>3LW>RD&P9'_TF3*J#9'RY4-\KF&L#M3]C3+XM]&DR^P+J_@502P,$%
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M #1@2!0UY^#>>12NSZEP\^O/Y!=02P,$%     @ EX!D4Y>*NQS     $P(
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M2VZC0!2%X:U8+""X[HND%6?4DTRC;  YY8=B&T312K+[MIR!?5 />A)Q1JA
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MK_^35(_G<_/U\I?E]\[)3;C@7-]6E*>_4$L#!!0    ( )> 9%/ART;(_0$
M #TI   3    6T-O;G1E;G1?5'EP97-=+GAM;,W:34[#,! %X*M4V:+&]6\!
M43; %EAP 9-,VZA);-D&RNUQ4D "004J$F_3J+4];^*1OE7/[IX]Q<FV:_NX
M*-8I^5/&8K6FSL;2>>KSRM*%SJ;\-:R8M]7&KHB)V<RPRO6)^C1-0XWB_.R2
MEO:A39.K;?XY-JY?%(':6$PN=AN'K$5AO6^;RJ:\SA[[^E/*]#6AS"?'/7'=
M^'B4-Q3LRX1AY?N UW,WCQ1"4]/DUH9T;;N\BVU;%M-S2['<7^*+'MURV514
MN^JART?*Z /9.JZ)4M>6NZ)'^Y-3OF':??*#\\<R^P+SSMO@?,P3"_3[N+>1
M#*>G/A>BD)K]K_B>F$L?_'XT3+NF^H?9^7J?7-B,\XAL?!Q^QQ]G_%[_EWT(
MD#XD2!\*I \-TH<!Z6,.TL<Q2!\G('WP&4HC**)R%%(YBJD<!56.HBI'896C
MN,I18.4HL@H4606*K )%5H$BJT"15:#(*E!D%2BR"A19!8JL$D56B2*K1)%5
MHL@J4625*+)*%%DEBJP215:)(JM"D56AR*I09%4HLBH4616*K I%5H4BJT*1
M5:'(JE%DU2BR:A19-8JL&D56C2*K1I%5H\BJ4635*+(:%%D-BJP&15:#(JM!
MD=6@R&I09#4HLAH460V*K',46>?_*>N]<YL_CA^?96>;_BV?C?^:/'\!4$L!
M A0#%     @ EH!D4P=!36*!    L0   !               ( !     &1O
M8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " "6@&13HKI\3NX    K @  $0
M            @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " "6
M@&13F5R<(Q &  "<)P  $P              @ ', 0  >&PO=&AE;64O=&AE
M;64Q+GAM;%!+ 0(4 Q0    ( ): 9%-;PHNI+@4  %05   8
M  " @0T(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " "6
M@&13FXV$<KT&  #W&P  &               @(%Q#0  >&PO=V]R:W-H965T
M<R]S:&5E=#(N>&UL4$L! A0#%     @ EH!D4VG+%<A- @  SP4  !@
M         ("!9!0  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0
M   ( )> 9%/''IX2,0<  *\@   8              " @><6  !X;"]W;W)K
M<VAE971S+W-H965T-"YX;6Q02P$"% ,4    " "7@&13(757OG4#   ^"P
M&               @(%.'@  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L!
M A0#%     @ EX!D4T@&ZI^-!P  T"P  !@              ("!^2$  'AL
M+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( )> 9%.T:*UBVP<
M #,@   8              " @;PI  !X;"]W;W)K<VAE971S+W-H965T-RYX
M;6Q02P$"% ,4    " "7@&13&ZH?OW,)  ""%@  &               @('-
M,0  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ EX!D4T62
M37)@#@  Z"8  !@              ("!=CL  'AL+W=O<FMS:&5E=',O<VAE
M970Y+GAM;%!+ 0(4 Q0    ( )> 9%,%7I6U800  *<+   9
M  " @0Q*  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @
MEX!D4YWBMLW?!P  _!0  !D              ("!I$X  'AL+W=O<FMS:&5E
M=',O<VAE970Q,2YX;6Q02P$"% ,4    " "7@&13QGQOCT #  #X!@  &0
M            @(&Z5@  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4
M Q0    ( )> 9%-:Z#:;@P4  (X.   9              " @3%:  !X;"]W
M;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ EX!D4Z$DL?(V P
MJ 8  !D              ("!ZU\  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX
M;6Q02P$"% ,4    " "7@&139"D$>F0'  !9%   &0              @(%8
M8P  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( )> 9%/6
MMEEO9 (  !L%   9              " @?-J  !X;"]W;W)K<VAE971S+W-H
M965T,38N>&UL4$L! A0#%     @ EX!D4Q[%"2/>!0  ?0\  !D
M     ("!CFT  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( )> 9%,=0QQEN0(   @&   9              "
M@1:4  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ EX!D
M4^>@3TI#!0  #P\  !D              ("!!I<  'AL+W=O<FMS:&5E=',O
M<VAE970R,RYX;6Q02P$"% ,4    " "7@&13 UF3.&T"  !D!0  &0
M        @(& G   >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0
M   ( )> 9%,7,CJ)\04  .@.   9              " @22?  !X;"]W;W)K
M<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @ EX!D4\+0DUKF!    PP
M !D              ("!3*4  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q0
M2P$"% ,4    " "7@&138(=+\E4$  #I"P  &0              @(%IJ@
M>&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( )> 9%/Q!'!_
M/@0  !P+   9              " @?6N  !X;"]W;W)K<VAE971S+W-H965T
M,C@N>&UL4$L! A0#%     @ EX!D4YOT=<PO P  Z@8  !D
M ("!:K,  'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    " "7
M@&13JW &+5\$  !B#@  &0              @('0M@  >&PO=V]R:W-H965T
M<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( )> 9%.\2I;8R (  -P%   9
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M970S-2YX;6Q02P$"% ,4    " "7@&13LMMI$J@"  #Z!0  &0
M    @(%,S@  >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    (
M )> 9%/!V^-7[0(  $H&   9              " @2O1  !X;"]W;W)K<VAE
M971S+W-H965T,S<N>&UL4$L! A0#%     @ EX!D4Q[,G+3&!P  R3,  !D
M             ("!3]0  'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"
M% ,4    " "7@&13@[^BP;H"  "Y!P  &0              @(%,W   >&PO
M=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( )> 9%/^'XG[+@0
M -0-   9              " @3W?  !X;"]W;W)K<VAE971S+W-H965T-# N
M>&UL4$L! A0#%     @ EX!D4^OQ*_P]!0  ?AL  !D              ("!
MHN,  'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"% ,4    " "7@&13
M1^[)<L8#  ""#P  &0              @($6Z0  >&PO=V]R:W-H965T<R]S
M:&5E=#0R+GAM;%!+ 0(4 Q0    ( )> 9%.^7&E5)0(  *H$   9
M      " @1/M  !X;"]W;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%
M  @ EX!D4T_=QFI3 @  *@4  !D              ("!;^\  'AL+W=O<FMS
M:&5E=',O<VAE970T-"YX;6Q02P$"% ,4    " "7@&13T"_H)F0&  #6,
M&0              @('Y\0  >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+
M 0(4 Q0    ( )> 9%."Q3A7O@(   ('   9              " @93X  !X
M;"]W;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @ EX!D4_#:A*B]
M @  X0@  !D              ("!B?L  'AL+W=O<FMS:&5E=',O<VAE970T
M-RYX;6Q02P$"% ,4    " "7@&13XCS*;7("  "V!@  &0
M@(%]_@  >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    ( )>
M9%,@_4GE%P,   @+   9              " @28! 0!X;"]W;W)K<VAE971S
M+W-H965T-#DN>&UL4$L! A0#%     @ EX!D4^WC@GX6 P   PH  !D
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M=#4T+GAM;%!+ 0(4 Q0    ( )> 9%-(\3;:5 (  +4%   9
M  " @2 7 0!X;"]W;W)K<VAE971S+W-H965T-34N>&UL4$L! A0#%     @
MEX!D4UN>6@&7 P  3PT  !D              ("!JQD! 'AL+W=O<FMS:&5E
M=',O<VAE970U-BYX;6Q02P$"% ,4    " "7@&13T&!BJ/("  "4"   &0
M            @(%Y'0$ >&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;%!+ 0(4
M Q0    ( )> 9%,A]L)8' ,  $0)   9              " @:(@ 0!X;"]W
M;W)K<VAE971S+W-H965T-3@N>&UL4$L! A0#%     @ EX!D4]J<\^": @
M_@8  !D              ("!]2,! 'AL+W=O<FMS:&5E=',O<VAE970U.2YX
M;6Q02P$"% ,4    " "7@&13,-"H<%L$   -$P  &0              @('&
M)@$ >&PO=V]R:W-H965T<R]S:&5E=#8P+GAM;%!+ 0(4 Q0    ( )> 9%/8
M:SY3/@,  ,(+   9              " @5@K 0!X;"]W;W)K<VAE971S+W-H
M965T-C$N>&UL4$L! A0#%     @ EX!D4[:@QZX/ P  .@H  !D
M     ("!S2X! 'AL+W=O<FMS:&5E=',O<VAE970V,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( )> 9%/@!D$M]@,  .X/   9              "
M@9D^ 0!X;"]W;W)K<VAE971S+W-H965T-C<N>&UL4$L! A0#%     @ EX!D
M4^P*8Q9M!   "!$  !D              ("!QD(! 'AL+W=O<FMS:&5E=',O
M<VAE970V."YX;6Q02P$"% ,4    " "7@&13V^PVM/@"  !X"   &0
M        @(%J1P$ >&PO=V]R:W-H965T<R]S:&5E=#8Y+GAM;%!+ 0(4 Q0
M   ( )> 9%,J!,TQ P0  #T/   9              " @9E* 0!X;"]W;W)K
M<VAE971S+W-H965T-S N>&UL4$L! A0#%     @ EX!D4R AD%-0 P  #0T
M !D              ("!TTX! 'AL+W=O<FMS:&5E=',O<VAE970W,2YX;6Q0
M2P$"% ,4    " "7@&13!P).EAH#   *$@  #0              @ %:4@$
M>&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( )> 9%.7BKL<P    !,"   +
M          "  9]5 0!?<F5L<R\N<F5L<U!+ 0(4 Q0    ( )> 9%.PO?7!
M2@4   HO   /              "  8A6 0!X;"]W;W)K8F]O:RYX;6Q02P$"
M% ,4    " "7@&13L 4 O38"   <*@  &@              @ '_6P$ >&PO
M7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " "7@&13X<M&R/T!
M   ]*0  $P              @ %M7@$ 6T-O;G1E;G1?5'EP97-=+GAM;%!+
4!08     3P!/ * 5  ";8 $    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>336</ContextCount>
  <ElementCount>361</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>70</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="mygn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="mygn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="mygn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="mygn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Condensed Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations</Role>
      <ShortName>Condensed Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="mygn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Income (Loss)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="mygn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Condensed Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/CondensedConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="mygn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="mygn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/BasisofPresentation</Role>
      <ShortName>Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="mygn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/Revenue</Role>
      <ShortName>Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="mygn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2108103 - Disclosure - Marketable Investment Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/MarketableInvestmentSecurities</Role>
      <ShortName>Marketable Investment Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="mygn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2113104 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="mygn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2118105 - Disclosure - Property, Plant and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/PropertyPlantandEquipmentNet</Role>
      <ShortName>Property, Plant and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="mygn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2122106 - Disclosure - Goodwill and Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/GoodwillandIntangibleAssets</Role>
      <ShortName>Goodwill and Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="mygn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2128107 - Disclosure - Accrued Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/AccruedLiabilities</Role>
      <ShortName>Accrued Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="mygn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2131108 - Disclosure - Long-Term Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/LongTermDebt</Role>
      <ShortName>Long-Term Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="mygn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2133109 - Disclosure - Other Long-Term Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/OtherLongTermLiabilities</Role>
      <ShortName>Other Long-Term Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="mygn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2136110 - Disclosure - Preferred and Common Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/PreferredandCommonStockholdersEquity</Role>
      <ShortName>Preferred and Common Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="mygn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2142111 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="mygn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2148112 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="mygn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2150113 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="mygn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2152114 - Disclosure - Segment and Related Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/SegmentandRelatedInformation</Role>
      <ShortName>Segment and Related Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="mygn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2157115 - Disclosure - Supplemental Cash Flow Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/SupplementalCashFlowInformation</Role>
      <ShortName>Supplemental Cash Flow Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="mygn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2160116 - Disclosure - Divestitures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/Divestitures</Role>
      <ShortName>Divestitures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="mygn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2164117 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="mygn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - Basis of Presentation (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/BasisofPresentationPolicies</Role>
      <ShortName>Basis of Presentation (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="mygn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2304301 - Disclosure - Revenue (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/RevenueTables</Role>
      <ShortName>Revenue (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.myriad.com/role/Revenue</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="mygn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2309302 - Disclosure - Marketable Investment Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/MarketableInvestmentSecuritiesTables</Role>
      <ShortName>Marketable Investment Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.myriad.com/role/MarketableInvestmentSecurities</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="mygn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2314303 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.myriad.com/role/FairValueMeasurements</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="mygn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2319304 - Disclosure - Property, Plant and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/PropertyPlantandEquipmentNetTables</Role>
      <ShortName>Property, Plant and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.myriad.com/role/PropertyPlantandEquipmentNet</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="mygn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2323305 - Disclosure - Goodwill and Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/GoodwillandIntangibleAssetsTables</Role>
      <ShortName>Goodwill and Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.myriad.com/role/GoodwillandIntangibleAssets</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="mygn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2329306 - Disclosure - Accrued Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/AccruedLiabilitiesTables</Role>
      <ShortName>Accrued Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.myriad.com/role/AccruedLiabilities</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="mygn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2334307 - Disclosure - Other Long-Term Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/OtherLongTermLiabilitiesTables</Role>
      <ShortName>Other Long-Term Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.myriad.com/role/OtherLongTermLiabilities</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="mygn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2337308 - Disclosure - Preferred and Common Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/PreferredandCommonStockholdersEquityTables</Role>
      <ShortName>Preferred and Common Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.myriad.com/role/PreferredandCommonStockholdersEquity</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="mygn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2343309 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.myriad.com/role/StockBasedCompensation</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="mygn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2353310 - Disclosure - Segment and Related Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/SegmentandRelatedInformationTables</Role>
      <ShortName>Segment and Related Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.myriad.com/role/SegmentandRelatedInformation</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="mygn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2358311 - Disclosure - Supplemental Cash Flow Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/SupplementalCashFlowInformationTables</Role>
      <ShortName>Supplemental Cash Flow Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.myriad.com/role/SupplementalCashFlowInformation</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="mygn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2361312 - Disclosure - Divestitures (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/DivestituresTables</Role>
      <ShortName>Divestitures (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.myriad.com/role/Divestitures</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="mygn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2405401 - Disclosure - Revenue - Total Revenue by Product and by US versus Rest of World (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/RevenueTotalRevenuebyProductandbyUSversusRestofWorldDetails</Role>
      <ShortName>Revenue - Total Revenue by Product and by US versus Rest of World (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="mygn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Revenue - Reconciliation of Deferred Revenue Balances (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/RevenueReconciliationofDeferredRevenueBalancesDetails</Role>
      <ShortName>Revenue - Reconciliation of Deferred Revenue Balances (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="mygn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Revenue - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/RevenueNarrativeDetails</Role>
      <ShortName>Revenue - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="mygn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2410404 - Disclosure - Marketable Investment Securities - Fair Value for Available-for-Sale Securities by Major Security Type and Class of Security (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails</Role>
      <ShortName>Marketable Investment Securities - Fair Value for Available-for-Sale Securities by Major Security Type and Class of Security (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="mygn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2411405 - Disclosure - Marketable Investment Securities - Cash, Cash Equivalents, and Maturities of Debt Securities Classified as Available-For-Sale Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails</Role>
      <ShortName>Marketable Investment Securities - Cash, Cash Equivalents, and Maturities of Debt Securities Classified as Available-For-Sale Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="mygn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2412406 - Disclosure - Marketable Investment Securities - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/MarketableInvestmentSecuritiesNarrativeDetails</Role>
      <ShortName>Marketable Investment Securities - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="mygn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2415407 - Disclosure - Fair Value Measurements - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/FairValueMeasurementsNarrativeDetails</Role>
      <ShortName>Fair Value Measurements - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="mygn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2416408 - Disclosure - Fair Value Measurements - Fair Value of Financial Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails</Role>
      <ShortName>Fair Value Measurements - Fair Value of Financial Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="mygn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2417409 - Disclosure - Fair Value Measurements - Change in Fair Value of Contingent Consideration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/FairValueMeasurementsChangeinFairValueofContingentConsiderationDetails</Role>
      <ShortName>Fair Value Measurements - Change in Fair Value of Contingent Consideration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="mygn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2420410 - Disclosure - Property, Plant and Equipment, Net - Balances (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/PropertyPlantandEquipmentNetBalancesDetails</Role>
      <ShortName>Property, Plant and Equipment, Net - Balances (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="mygn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2421411 - Disclosure - Property, Plant and Equipment, Net - Depreciation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/PropertyPlantandEquipmentNetDepreciationExpenseDetails</Role>
      <ShortName>Property, Plant and Equipment, Net - Depreciation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="mygn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2424412 - Disclosure - Goodwill and Intangible Assets - Carrying Amount of Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/GoodwillandIntangibleAssetsCarryingAmountofGoodwillDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Carrying Amount of Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="mygn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2425413 - Disclosure - Goodwill and Intangible Assets - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/GoodwillandIntangibleAssetsNarrativeDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="mygn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2426414 - Disclosure - Goodwill and Intangible Assets - Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="mygn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2427415 - Disclosure - Goodwill and Intangible Assets - Amortization on Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/GoodwillandIntangibleAssetsAmortizationonIntangibleAssetsDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Amortization on Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="mygn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2430416 - Disclosure - Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/AccruedLiabilitiesDetails</Role>
      <ShortName>Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.myriad.com/role/AccruedLiabilitiesTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="mygn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2432417 - Disclosure - Long-Term Debt - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/LongTermDebtNarrativeDetails</Role>
      <ShortName>Long-Term Debt - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="mygn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2435418 - Disclosure - Other Long-Term Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/OtherLongTermLiabilitiesDetails</Role>
      <ShortName>Other Long-Term Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.myriad.com/role/OtherLongTermLiabilitiesTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="mygn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2438419 - Disclosure - Preferred and Common Stockholders' Equity - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/PreferredandCommonStockholdersEquityNarrativeDetails</Role>
      <ShortName>Preferred and Common Stockholders' Equity - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="mygn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2439420 - Disclosure - Preferred and Common Stockholders' Equity - Common Shares Issued and Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/PreferredandCommonStockholdersEquityCommonSharesIssuedandOutstandingDetails</Role>
      <ShortName>Preferred and Common Stockholders' Equity - Common Shares Issued and Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="mygn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2440421 - Disclosure - Preferred and Common Stockholders' Equity - Reconciliation of Denominators of Basic and Diluted Earnings Per Share Computations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/PreferredandCommonStockholdersEquityReconciliationofDenominatorsofBasicandDilutedEarningsPerShareComputationsDetails</Role>
      <ShortName>Preferred and Common Stockholders' Equity - Reconciliation of Denominators of Basic and Diluted Earnings Per Share Computations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="mygn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2441422 - Disclosure - Preferred and Common Stockholders' Equity - Potentially Dilutive Common Shares Excluded from EPS Computation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/PreferredandCommonStockholdersEquityPotentiallyDilutiveCommonSharesExcludedfromEPSComputationDetails</Role>
      <ShortName>Preferred and Common Stockholders' Equity - Potentially Dilutive Common Shares Excluded from EPS Computation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="mygn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2444423 - Disclosure - Stock-Based Compensation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/StockBasedCompensationNarrativeDetails</Role>
      <ShortName>Stock-Based Compensation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="mygn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2445424 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/StockBasedCompensationStockOptionActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="mygn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2446425 - Disclosure - Stock-Based Compensation - RSU Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/StockBasedCompensationRSUActivityDetails</Role>
      <ShortName>Stock-Based Compensation - RSU Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="mygn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2447426 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Compensation - Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="mygn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2449427 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.myriad.com/role/IncomeTaxes</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="mygn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2451428 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.myriad.com/role/CommitmentsandContingencies</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="mygn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2454429 - Disclosure - Segment and Related Information - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/SegmentandRelatedInformationNarrativeDetails</Role>
      <ShortName>Segment and Related Information - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="mygn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2455430 - Disclosure - Segment and Related Information - Segment Revenue and Operating Income (Loss) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/SegmentandRelatedInformationSegmentRevenueandOperatingIncomeLossDetails</Role>
      <ShortName>Segment and Related Information - Segment Revenue and Operating Income (Loss) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="mygn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>2456431 - Disclosure - Segment and Related Information - Total Operating Loss for Reportable Segments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/SegmentandRelatedInformationTotalOperatingLossforReportableSegmentsDetails</Role>
      <ShortName>Segment and Related Information - Total Operating Loss for Reportable Segments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="mygn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>2459432 - Disclosure - Supplemental Cash Flow Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/SupplementalCashFlowInformationDetails</Role>
      <ShortName>Supplemental Cash Flow Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.myriad.com/role/SupplementalCashFlowInformationTables</ParentRole>
      <Position>69</Position>
    </Report>
    <Report instance="mygn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>2462433 - Disclosure - Divestitures - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/DivestituresNarrativeDetails</Role>
      <ShortName>Divestitures - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="mygn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>2463434 - Disclosure - Divestitures - Other Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/DivestituresOtherIncomeDetails</Role>
      <ShortName>Divestitures - Other Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="mygn-20210930.htm">mygn-20210930.htm</File>
    <File>exhibit101-amendedandresta.htm</File>
    <File>exhibit311-certificationof.htm</File>
    <File>exhibit312-certificationof.htm</File>
    <File>exhibit321-certificationpu.htm</File>
    <File>mygn-20210930.xsd</File>
    <File>mygn-20210930_cal.xml</File>
    <File>mygn-20210930_def.xml</File>
    <File>mygn-20210930_lab.xml</File>
    <File>mygn-20210930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/srt/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2021</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>88
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "mygn-20210930.htm": {
   "axisCustom": 0,
   "axisStandard": 32,
   "contextCount": 336,
   "dts": {
    "calculationLink": {
     "local": [
      "mygn-20210930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "mygn-20210930_def.xml"
     ]
    },
    "inline": {
     "local": [
      "mygn-20210930.htm"
     ]
    },
    "labelLink": {
     "local": [
      "mygn-20210930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "mygn-20210930_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "mygn-20210930.xsd"
     ],
     "remote": [
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 512,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021": 5,
    "total": 5
   },
   "keyCustom": 29,
   "keyStandard": 332,
   "memberCustom": 27,
   "memberStandard": 43,
   "nsprefix": "mygn",
   "nsuri": "http://www.myriad.com/20210930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "i526dd58342b2430ab657188009969982_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://www.myriad.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "i526dd58342b2430ab657188009969982_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "i526dd58342b2430ab657188009969982_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2108103 - Disclosure - Marketable Investment Securities",
     "role": "http://www.myriad.com/role/MarketableInvestmentSecurities",
     "shortName": "Marketable Investment Securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "i526dd58342b2430ab657188009969982_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "i526dd58342b2430ab657188009969982_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2113104 - Disclosure - Fair Value Measurements",
     "role": "http://www.myriad.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "i526dd58342b2430ab657188009969982_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "i526dd58342b2430ab657188009969982_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2118105 - Disclosure - Property, Plant and Equipment, Net",
     "role": "http://www.myriad.com/role/PropertyPlantandEquipmentNet",
     "shortName": "Property, Plant and Equipment, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "i526dd58342b2430ab657188009969982_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "i526dd58342b2430ab657188009969982_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2122106 - Disclosure - Goodwill and Intangible Assets",
     "role": "http://www.myriad.com/role/GoodwillandIntangibleAssets",
     "shortName": "Goodwill and Intangible Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "i526dd58342b2430ab657188009969982_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "i526dd58342b2430ab657188009969982_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2128107 - Disclosure - Accrued Liabilities",
     "role": "http://www.myriad.com/role/AccruedLiabilities",
     "shortName": "Accrued Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "i526dd58342b2430ab657188009969982_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "i526dd58342b2430ab657188009969982_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2131108 - Disclosure - Long-Term Debt",
     "role": "http://www.myriad.com/role/LongTermDebt",
     "shortName": "Long-Term Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "i526dd58342b2430ab657188009969982_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "i526dd58342b2430ab657188009969982_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2133109 - Disclosure - Other Long-Term Liabilities",
     "role": "http://www.myriad.com/role/OtherLongTermLiabilities",
     "shortName": "Other Long-Term Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "i526dd58342b2430ab657188009969982_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "i526dd58342b2430ab657188009969982_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2136110 - Disclosure - Preferred and Common Stockholders' Equity",
     "role": "http://www.myriad.com/role/PreferredandCommonStockholdersEquity",
     "shortName": "Preferred and Common Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "i526dd58342b2430ab657188009969982_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "i526dd58342b2430ab657188009969982_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2142111 - Disclosure - Stock-Based Compensation",
     "role": "http://www.myriad.com/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "i526dd58342b2430ab657188009969982_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "i526dd58342b2430ab657188009969982_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2148112 - Disclosure - Income Taxes",
     "role": "http://www.myriad.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "i526dd58342b2430ab657188009969982_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "i7bca861d20d64642b8c0cb91a290112d_I20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Condensed Consolidated Balance Sheets",
     "role": "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "i7bca861d20d64642b8c0cb91a290112d_I20210930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "i526dd58342b2430ab657188009969982_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2150113 - Disclosure - Commitments and Contingencies",
     "role": "http://www.myriad.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "i526dd58342b2430ab657188009969982_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "i526dd58342b2430ab657188009969982_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2152114 - Disclosure - Segment and Related Information",
     "role": "http://www.myriad.com/role/SegmentandRelatedInformation",
     "shortName": "Segment and Related Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "i526dd58342b2430ab657188009969982_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "i526dd58342b2430ab657188009969982_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2157115 - Disclosure - Supplemental Cash Flow Information",
     "role": "http://www.myriad.com/role/SupplementalCashFlowInformation",
     "shortName": "Supplemental Cash Flow Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "i526dd58342b2430ab657188009969982_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "i526dd58342b2430ab657188009969982_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2160116 - Disclosure - Divestitures",
     "role": "http://www.myriad.com/role/Divestitures",
     "shortName": "Divestitures",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "i526dd58342b2430ab657188009969982_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "i526dd58342b2430ab657188009969982_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2164117 - Disclosure - Subsequent Events",
     "role": "http://www.myriad.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "i526dd58342b2430ab657188009969982_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "i526dd58342b2430ab657188009969982_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2202201 - Disclosure - Basis of Presentation (Policies)",
     "role": "http://www.myriad.com/role/BasisofPresentationPolicies",
     "shortName": "Basis of Presentation (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "i526dd58342b2430ab657188009969982_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "i526dd58342b2430ab657188009969982_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2304301 - Disclosure - Revenue (Tables)",
     "role": "http://www.myriad.com/role/RevenueTables",
     "shortName": "Revenue (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "i526dd58342b2430ab657188009969982_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "i526dd58342b2430ab657188009969982_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2309302 - Disclosure - Marketable Investment Securities (Tables)",
     "role": "http://www.myriad.com/role/MarketableInvestmentSecuritiesTables",
     "shortName": "Marketable Investment Securities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "i526dd58342b2430ab657188009969982_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "i526dd58342b2430ab657188009969982_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2314303 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.myriad.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "i526dd58342b2430ab657188009969982_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "i526dd58342b2430ab657188009969982_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2319304 - Disclosure - Property, Plant and Equipment, Net (Tables)",
     "role": "http://www.myriad.com/role/PropertyPlantandEquipmentNetTables",
     "shortName": "Property, Plant and Equipment, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "i526dd58342b2430ab657188009969982_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "i7bca861d20d64642b8c0cb91a290112d_I20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.myriad.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "i526dd58342b2430ab657188009969982_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2323305 - Disclosure - Goodwill and Intangible Assets (Tables)",
     "role": "http://www.myriad.com/role/GoodwillandIntangibleAssetsTables",
     "shortName": "Goodwill and Intangible Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "i526dd58342b2430ab657188009969982_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "i526dd58342b2430ab657188009969982_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2329306 - Disclosure - Accrued Liabilities (Tables)",
     "role": "http://www.myriad.com/role/AccruedLiabilitiesTables",
     "shortName": "Accrued Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "i526dd58342b2430ab657188009969982_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "i526dd58342b2430ab657188009969982_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherNoncurrentLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2334307 - Disclosure - Other Long-Term Liabilities (Tables)",
     "role": "http://www.myriad.com/role/OtherLongTermLiabilitiesTables",
     "shortName": "Other Long-Term Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "i526dd58342b2430ab657188009969982_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherNoncurrentLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "i526dd58342b2430ab657188009969982_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2337308 - Disclosure - Preferred and Common Stockholders' Equity (Tables)",
     "role": "http://www.myriad.com/role/PreferredandCommonStockholdersEquityTables",
     "shortName": "Preferred and Common Stockholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "i526dd58342b2430ab657188009969982_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "i526dd58342b2430ab657188009969982_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2343309 - Disclosure - Stock-Based Compensation (Tables)",
     "role": "http://www.myriad.com/role/StockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "i526dd58342b2430ab657188009969982_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "i526dd58342b2430ab657188009969982_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2353310 - Disclosure - Segment and Related Information (Tables)",
     "role": "http://www.myriad.com/role/SegmentandRelatedInformationTables",
     "shortName": "Segment and Related Information (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "i526dd58342b2430ab657188009969982_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "i526dd58342b2430ab657188009969982_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2358311 - Disclosure - Supplemental Cash Flow Information (Tables)",
     "role": "http://www.myriad.com/role/SupplementalCashFlowInformationTables",
     "shortName": "Supplemental Cash Flow Information (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "i526dd58342b2430ab657188009969982_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "i526dd58342b2430ab657188009969982_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2361312 - Disclosure - Divestitures (Tables)",
     "role": "http://www.myriad.com/role/DivestituresTables",
     "shortName": "Divestitures (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "i526dd58342b2430ab657188009969982_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405401 - Disclosure - Revenue - Total Revenue by Product and by US versus Rest of World (Details)",
     "role": "http://www.myriad.com/role/RevenueTotalRevenuebyProductandbyUSversusRestofWorldDetails",
     "shortName": "Revenue - Total Revenue by Product and by US versus Rest of World (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "i34864de2cd5e41bd98ef24a86d7f39a1_D20210701-20210930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "i21cc3685be5d4e2e8f00283addc53a8f_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiabilityCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Revenue - Reconciliation of Deferred Revenue Balances (Details)",
     "role": "http://www.myriad.com/role/RevenueReconciliationofDeferredRevenueBalancesDetails",
     "shortName": "Revenue - Reconciliation of Deferred Revenue Balances (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "ic698543044ba4469ba8751bae898951c_I20191231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiabilityCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Condensed Consolidated Statements of Operations",
     "role": "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations",
     "shortName": "Condensed Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "ia7d2894297e4420e8cad6a4c76510fc1_D20190701-20200630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "mygn:CARESActOf2020MedicarePaymentAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - Revenue - Narrative (Details)",
     "role": "http://www.myriad.com/role/RevenueNarrativeDetails",
     "shortName": "Revenue - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "ia7d2894297e4420e8cad6a4c76510fc1_D20190701-20200630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "mygn:CARESActOf2020MedicarePaymentAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "i7bca861d20d64642b8c0cb91a290112d_I20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410404 - Disclosure - Marketable Investment Securities - Fair Value for Available-for-Sale Securities by Major Security Type and Class of Security (Details)",
     "role": "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails",
     "shortName": "Marketable Investment Securities - Fair Value for Available-for-Sale Securities by Major Security Type and Class of Security (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "i7bca861d20d64642b8c0cb91a290112d_I20210930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "mygn:InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "i7bca861d20d64642b8c0cb91a290112d_I20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411405 - Disclosure - Marketable Investment Securities - Cash, Cash Equivalents, and Maturities of Debt Securities Classified as Available-For-Sale Securities (Details)",
     "role": "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails",
     "shortName": "Marketable Investment Securities - Cash, Cash Equivalents, and Maturities of Debt Securities Classified as Available-For-Sale Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "i7bca861d20d64642b8c0cb91a290112d_I20210930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "i7bca861d20d64642b8c0cb91a290112d_I20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "security",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412406 - Disclosure - Marketable Investment Securities - Narrative (Details)",
     "role": "http://www.myriad.com/role/MarketableInvestmentSecuritiesNarrativeDetails",
     "shortName": "Marketable Investment Securities - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "i7bca861d20d64642b8c0cb91a290112d_I20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "security",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "i1f71ce0e78ae4d43bdf7b1af72891a7e_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mygn:BusinessCombinationContingentConsiderationLiabilityMeasurementInputTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415407 - Disclosure - Fair Value Measurements - Narrative (Details)",
     "role": "http://www.myriad.com/role/FairValueMeasurementsNarrativeDetails",
     "shortName": "Fair Value Measurements - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "i1f71ce0e78ae4d43bdf7b1af72891a7e_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mygn:BusinessCombinationContingentConsiderationLiabilityMeasurementInputTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "i7bca861d20d64642b8c0cb91a290112d_I20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueNetAssetLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416408 - Disclosure - Fair Value Measurements - Fair Value of Financial Assets and Liabilities (Details)",
     "role": "http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails",
     "shortName": "Fair Value Measurements - Fair Value of Financial Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "i7bca861d20d64642b8c0cb91a290112d_I20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueNetAssetLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "i21cc3685be5d4e2e8f00283addc53a8f_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417409 - Disclosure - Fair Value Measurements - Change in Fair Value of Contingent Consideration (Details)",
     "role": "http://www.myriad.com/role/FairValueMeasurementsChangeinFairValueofContingentConsiderationDetails",
     "shortName": "Fair Value Measurements - Change in Fair Value of Contingent Consideration (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "i21cc3685be5d4e2e8f00283addc53a8f_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "i7bca861d20d64642b8c0cb91a290112d_I20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420410 - Disclosure - Property, Plant and Equipment, Net - Balances (Details)",
     "role": "http://www.myriad.com/role/PropertyPlantandEquipmentNetBalancesDetails",
     "shortName": "Property, Plant and Equipment, Net - Balances (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "i7bca861d20d64642b8c0cb91a290112d_I20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421411 - Disclosure - Property, Plant and Equipment, Net - Depreciation Expense (Details)",
     "role": "http://www.myriad.com/role/PropertyPlantandEquipmentNetDepreciationExpenseDetails",
     "shortName": "Property, Plant and Equipment, Net - Depreciation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "i21cc3685be5d4e2e8f00283addc53a8f_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424412 - Disclosure - Goodwill and Intangible Assets - Carrying Amount of Goodwill (Details)",
     "role": "http://www.myriad.com/role/GoodwillandIntangibleAssetsCarryingAmountofGoodwillDetails",
     "shortName": "Goodwill and Intangible Assets - Carrying Amount of Goodwill (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "i526dd58342b2430ab657188009969982_D20210101-20210930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss)",
     "role": "http://www.myriad.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss",
     "shortName": "Condensed Consolidated Statements of Comprehensive Income (Loss)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "i5a2255bae3b5469a85c3193359dabe47_I20210701",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "mygn:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNetNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425413 - Disclosure - Goodwill and Intangible Assets - Narrative (Details)",
     "role": "http://www.myriad.com/role/GoodwillandIntangibleAssetsNarrativeDetails",
     "shortName": "Goodwill and Intangible Assets - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "i5a2255bae3b5469a85c3193359dabe47_I20210701",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "mygn:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNetNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "i7bca861d20d64642b8c0cb91a290112d_I20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426414 - Disclosure - Goodwill and Intangible Assets - Intangible Assets (Details)",
     "role": "http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails",
     "shortName": "Goodwill and Intangible Assets - Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "i7bca861d20d64642b8c0cb91a290112d_I20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427415 - Disclosure - Goodwill and Intangible Assets - Amortization on Intangible Assets (Details)",
     "role": "http://www.myriad.com/role/GoodwillandIntangibleAssetsAmortizationonIntangibleAssetsDetails",
     "shortName": "Goodwill and Intangible Assets - Amortization on Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "i7bca861d20d64642b8c0cb91a290112d_I20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430416 - Disclosure - Accrued Liabilities (Details)",
     "role": "http://www.myriad.com/role/AccruedLiabilitiesDetails",
     "shortName": "Accrued Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "i7bca861d20d64642b8c0cb91a290112d_I20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "i526dd58342b2430ab657188009969982_D20210101-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RepaymentsOfLinesOfCredit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432417 - Disclosure - Long-Term Debt - Narrative (Details)",
     "role": "http://www.myriad.com/role/LongTermDebtNarrativeDetails",
     "shortName": "Long-Term Debt - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "i21cc3685be5d4e2e8f00283addc53a8f_I20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:OtherNoncurrentLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "i7bca861d20d64642b8c0cb91a290112d_I20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435418 - Disclosure - Other Long-Term Liabilities (Details)",
     "role": "http://www.myriad.com/role/OtherLongTermLiabilitiesDetails",
     "shortName": "Other Long-Term Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:OtherNoncurrentLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "i7bca861d20d64642b8c0cb91a290112d_I20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "i7bca861d20d64642b8c0cb91a290112d_I20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438419 - Disclosure - Preferred and Common Stockholders' Equity - Narrative (Details)",
     "role": "http://www.myriad.com/role/PreferredandCommonStockholdersEquityNarrativeDetails",
     "shortName": "Preferred and Common Stockholders' Equity - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "i7bca861d20d64642b8c0cb91a290112d_I20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockSharesOutstanding",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "i21cc3685be5d4e2e8f00283addc53a8f_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2439420 - Disclosure - Preferred and Common Stockholders' Equity - Common Shares Issued and Outstanding (Details)",
     "role": "http://www.myriad.com/role/PreferredandCommonStockholdersEquityCommonSharesIssuedandOutstandingDetails",
     "shortName": "Preferred and Common Stockholders' Equity - Common Shares Issued and Outstanding (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "i526dd58342b2430ab657188009969982_D20210101-20210930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "mygn:StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2440421 - Disclosure - Preferred and Common Stockholders' Equity - Reconciliation of Denominators of Basic and Diluted Earnings Per Share Computations (Details)",
     "role": "http://www.myriad.com/role/PreferredandCommonStockholdersEquityReconciliationofDenominatorsofBasicandDilutedEarningsPerShareComputationsDetails",
     "shortName": "Preferred and Common Stockholders' Equity - Reconciliation of Denominators of Basic and Diluted Earnings Per Share Computations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2441422 - Disclosure - Preferred and Common Stockholders' Equity - Potentially Dilutive Common Shares Excluded from EPS Computation (Details)",
     "role": "http://www.myriad.com/role/PreferredandCommonStockholdersEquityPotentiallyDilutiveCommonSharesExcludedfromEPSComputationDetails",
     "shortName": "Preferred and Common Stockholders' Equity - Potentially Dilutive Common Shares Excluded from EPS Computation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "ic698543044ba4469ba8751bae898951c_I20191231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Condensed Consolidated Statements of Stockholders' Equity",
     "role": "http://www.myriad.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
     "shortName": "Condensed Consolidated Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "ic26cca04ca2b4dd694bd9641fa5123c4_D20200101-20200331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "i7bca861d20d64642b8c0cb91a290112d_I20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2444423 - Disclosure - Stock-Based Compensation - Narrative (Details)",
     "role": "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails",
     "shortName": "Stock-Based Compensation - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "i7bca861d20d64642b8c0cb91a290112d_I20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "i21cc3685be5d4e2e8f00283addc53a8f_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2445424 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details)",
     "role": "http://www.myriad.com/role/StockBasedCompensationStockOptionActivityDetails",
     "shortName": "Stock-Based Compensation - Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "i21cc3685be5d4e2e8f00283addc53a8f_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "i4801dc9ebc814bf4a4e7c0b3d186670f_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2446425 - Disclosure - Stock-Based Compensation - RSU Activity (Details)",
     "role": "http://www.myriad.com/role/StockBasedCompensationRSUActivityDetails",
     "shortName": "Stock-Based Compensation - RSU Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "i4801dc9ebc814bf4a4e7c0b3d186670f_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2447426 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Details)",
     "role": "http://www.myriad.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails",
     "shortName": "Stock-Based Compensation - Stock-Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2449427 - Disclosure - Income Taxes (Details)",
     "role": "http://www.myriad.com/role/IncomeTaxesDetails",
     "shortName": "Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930",
      "decimals": "3",
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "i7bca861d20d64642b8c0cb91a290112d_I20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LitigationReserveCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2451428 - Disclosure - Commitments and Contingencies (Details)",
     "role": "http://www.myriad.com/role/CommitmentsandContingenciesDetails",
     "shortName": "Commitments and Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "i526dd58342b2430ab657188009969982_D20210101-20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfReportableSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2454429 - Disclosure - Segment and Related Information - Narrative (Details)",
     "role": "http://www.myriad.com/role/SegmentandRelatedInformationNarrativeDetails",
     "shortName": "Segment and Related Information - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "i526dd58342b2430ab657188009969982_D20210101-20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfReportableSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2455430 - Disclosure - Segment and Related Information - Segment Revenue and Operating Income (Loss) (Details)",
     "role": "http://www.myriad.com/role/SegmentandRelatedInformationSegmentRevenueandOperatingIncomeLossDetails",
     "shortName": "Segment and Related Information - Segment Revenue and Operating Income (Loss) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "ife30149d9d1d4b99ac1339407e85293d_D20210701-20210930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2456431 - Disclosure - Segment and Related Information - Total Operating Loss for Reportable Segments (Details)",
     "role": "http://www.myriad.com/role/SegmentandRelatedInformationTotalOperatingLossforReportableSegmentsDetails",
     "shortName": "Segment and Related Information - Total Operating Loss for Reportable Segments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "i526dd58342b2430ab657188009969982_D20210101-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxesPaid",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2459432 - Disclosure - Supplemental Cash Flow Information (Details)",
     "role": "http://www.myriad.com/role/SupplementalCashFlowInformationDetails",
     "shortName": "Supplemental Cash Flow Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "i526dd58342b2430ab657188009969982_D20210101-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxesPaid",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "i526dd58342b2430ab657188009969982_D20210101-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - Condensed Consolidated Statements of Cash Flows",
     "role": "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "i526dd58342b2430ab657188009969982_D20210101-20210930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "mygn:NonCashInterestExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "i526dd58342b2430ab657188009969982_D20210101-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryFirmPurchaseCommitmentLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2462433 - Disclosure - Divestitures - Narrative (Details)",
     "role": "http://www.myriad.com/role/DivestituresNarrativeDetails",
     "shortName": "Divestitures - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "i526dd58342b2430ab657188009969982_D20210101-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryFirmPurchaseCommitmentLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "ibf6082e0f2b74de9bf1e18972ad27207_D20210701-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherNonoperatingIncomeExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2463434 - Disclosure - Divestitures - Other Income (Details)",
     "role": "http://www.myriad.com/role/DivestituresOtherIncomeDetails",
     "shortName": "Divestitures - Other Income (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "id8db12274a5e41019919e2f3e84a1cfd_D20210701-20210930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "mygn:DisposalGroupNotDiscontinuedOperationGainLossOnInventory",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "i526dd58342b2430ab657188009969982_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Basis of Presentation",
     "role": "http://www.myriad.com/role/BasisofPresentation",
     "shortName": "Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "i526dd58342b2430ab657188009969982_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "i526dd58342b2430ab657188009969982_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - Revenue",
     "role": "http://www.myriad.com/role/Revenue",
     "shortName": "Revenue",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20210930.htm",
      "contextRef": "i526dd58342b2430ab657188009969982_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 70,
   "tag": {
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "U.S."
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.myriad.com/role/RevenueTotalRevenuebyProductandbyUSversusRestofWorldDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r629"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r630"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r631"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "verboseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r631"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r631"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r633"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r631"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r631"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r631"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r631"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r627"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r628"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "mygn_AmendmentToCreditAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to Credit Agreement [Member].",
        "label": "Amendment To Credit Agreement [Member]",
        "terseLabel": "Amended facility"
       }
      }
     },
     "localname": "AmendmentToCreditAgreementMember",
     "nsuri": "http://www.myriad.com/20210930",
     "presentation": [
      "http://www.myriad.com/role/LongTermDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mygn_BusinessCombinationContingentConsiderationLiabilityMeasurementInputTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Contingent Consideration, Liability, Measurement Input, Term",
        "label": "Business Combination, Contingent Consideration, Liability, Measurement Input, Term",
        "terseLabel": "Measurement period for earn out liability"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInputTerm",
     "nsuri": "http://www.myriad.com/20210930",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "mygn_CARESActOf2020MedicarePaymentAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CARES Act of 2020 Medicare payment amount.",
        "label": "CARES Act Of 2020 Medicare Payment Amount",
        "terseLabel": "Advance Medicare payments to provide relief from economic impacts of COVID-19"
       }
      }
     },
     "localname": "CARESActOf2020MedicarePaymentAmount",
     "nsuri": "http://www.myriad.com/20210930",
     "presentation": [
      "http://www.myriad.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mygn_ChangeInFairValueOfContingentConsideration": {
     "auth_ref": [],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in fair value of contingent consideration.",
        "label": "Change In Fair Value Of Contingent Consideration",
        "terseLabel": "Change in fair value of contingent consideration"
       }
      }
     },
     "localname": "ChangeInFairValueOfContingentConsideration",
     "nsuri": "http://www.myriad.com/20210930",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mygn_ContingentConsiderationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent consideration.",
        "label": "Contingent Consideration [Member]",
        "terseLabel": "Contingent consideration"
       }
      }
     },
     "localname": "ContingentConsiderationMember",
     "nsuri": "http://www.myriad.com/20210930",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mygn_ContractWithCustomerAssetAdjustmentToRevenueForExpandedCoveragePreviouslyConstrained": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer, Asset, Adjustment To Revenue For Expanded Coverage, Previously Constrained",
        "label": "Contract With Customer, Asset, Adjustment To Revenue For Expanded Coverage, Previously Constrained",
        "terseLabel": "Revenue recognized due to expanded local coverage determination for which revenue was previously constrained"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAdjustmentToRevenueForExpandedCoveragePreviouslyConstrained",
     "nsuri": "http://www.myriad.com/20210930",
     "presentation": [
      "http://www.myriad.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mygn_ContractWithCustomerLiabilityDivestitures": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer, Liability, Divestitures",
        "label": "Contract With Customer, Liability, Divestitures",
        "negatedTerseLabel": "Divestitures"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityDivestitures",
     "nsuri": "http://www.myriad.com/20210930",
     "presentation": [
      "http://www.myriad.com/role/RevenueReconciliationofDeferredRevenueBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mygn_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer, Liability, Including New Contract, Revenue Recognized",
        "label": "Contract With Customer, Liability, Including New Contract, Revenue Recognized",
        "negatedLabel": "Revenue recognized"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized",
     "nsuri": "http://www.myriad.com/20210930",
     "presentation": [
      "http://www.myriad.com/role/RevenueReconciliationofDeferredRevenueBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mygn_ContractWithCustomerLiabilityPrepayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract with customer, liability, prepayments.",
        "label": "Contract With Customer, Liability, Prepayments",
        "terseLabel": "Prepayments"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityPrepayments",
     "nsuri": "http://www.myriad.com/20210930",
     "presentation": [
      "http://www.myriad.com/role/RevenueReconciliationofDeferredRevenueBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mygn_CostOfMolecularDiagnosticTestingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about the cost of molecular diagnostic testing expense have been included.",
        "label": "Cost Of Molecular Diagnostic Testing [Member]",
        "terseLabel": "Cost of molecular diagnostic testing"
       }
      }
     },
     "localname": "CostOfMolecularDiagnosticTestingMember",
     "nsuri": "http://www.myriad.com/20210930",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mygn_CostOfPharmaceuticalAndClinicalServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about the cost of pharmaceutical and clinical services expense have been included.",
        "label": "Cost Of Pharmaceutical And Clinical Services [Member]",
        "terseLabel": "Cost of pharmaceutical and clinical services"
       }
      }
     },
     "localname": "CostOfPharmaceuticalAndClinicalServicesMember",
     "nsuri": "http://www.myriad.com/20210930",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mygn_DebtCovenantLiquidityCovenantMinimum": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Covenant, Liquidity Covenant Minimum",
        "label": "Debt Covenant, Liquidity Covenant Minimum",
        "terseLabel": "Minimum liquidity covenant"
       }
      }
     },
     "localname": "DebtCovenantLiquidityCovenantMinimum",
     "nsuri": "http://www.myriad.com/20210930",
     "presentation": [
      "http://www.myriad.com/role/LongTermDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mygn_DebtCovenantUnrestrictedCashAndCashEquivalentsThresholdForBorrowingRestrictionMinimum": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Covenant, Unrestricted Cash And Cash Equivalents Threshold For Borrowing Restriction, Minimum",
        "label": "Debt Covenant, Unrestricted Cash And Cash Equivalents Threshold For Borrowing Restriction, Minimum",
        "terseLabel": "Minimum unrestricted cash and cash equivalents threshold per covenant"
       }
      }
     },
     "localname": "DebtCovenantUnrestrictedCashAndCashEquivalentsThresholdForBorrowingRestrictionMinimum",
     "nsuri": "http://www.myriad.com/20210930",
     "presentation": [
      "http://www.myriad.com/role/LongTermDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mygn_DebtInstrumentLIBORFloorPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, LIBOR Floor, Percentage",
        "label": "Debt Instrument, LIBOR Floor, Percentage",
        "terseLabel": "LIBOR floor (percent)"
       }
      }
     },
     "localname": "DebtInstrumentLIBORFloorPercentage",
     "nsuri": "http://www.myriad.com/20210930",
     "presentation": [
      "http://www.myriad.com/role/LongTermDebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mygn_DiagnosticsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Diagnostics.",
        "label": "Diagnostics [Member]",
        "terseLabel": "Diagnostics"
       }
      }
     },
     "localname": "DiagnosticsMember",
     "nsuri": "http://www.myriad.com/20210930",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsCarryingAmountofGoodwillDetails",
      "http://www.myriad.com/role/SegmentandRelatedInformationSegmentRevenueandOperatingIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mygn_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsAccumulatedAmortizationNoncurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as accumulated amortization of intangible assets attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Intangible Assets, Accumulated Amortization, Noncurrent",
        "terseLabel": "Accumulated amortization on intangible assets included in sale"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsAccumulatedAmortizationNoncurrent",
     "nsuri": "http://www.myriad.com/20210930",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mygn_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNetNoncurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as intangible assets, net of accumulated amortization, attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Intangible Assets, Net, Noncurrent",
        "terseLabel": "Net decrease in intangible assets due to sale"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNetNoncurrent",
     "nsuri": "http://www.myriad.com/20210930",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mygn_DisposalGroupNotDiscontinuedOperationGainLossOnInventory": {
     "auth_ref": [],
     "calculation": {
      "http://www.myriad.com/role/DivestituresOtherIncomeDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Not Discontinued Operation, Gain (Loss) On Inventory",
        "label": "Disposal Group, Not Discontinued Operation, Gain (Loss) On Inventory",
        "terseLabel": "Gain (loss) on inventory"
       }
      }
     },
     "localname": "DisposalGroupNotDiscontinuedOperationGainLossOnInventory",
     "nsuri": "http://www.myriad.com/20210930",
     "presentation": [
      "http://www.myriad.com/role/DivestituresOtherIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mygn_DisposalGroupNotDiscontinuedOperationGainLossOther": {
     "auth_ref": [],
     "calculation": {
      "http://www.myriad.com/role/DivestituresOtherIncomeDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Not Discontinued Operation, Gain (Loss) Other",
        "label": "Disposal Group, Not Discontinued Operation, Gain (Loss) Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DisposalGroupNotDiscontinuedOperationGainLossOther",
     "nsuri": "http://www.myriad.com/20210930",
     "presentation": [
      "http://www.myriad.com/role/DivestituresOtherIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mygn_DisposalGroupNotDiscontinuedOperationTransactionCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Not Discontinued Operation, Transaction Costs",
        "label": "Disposal Group, Not Discontinued Operation, Transaction Costs",
        "terseLabel": "Transaction costs"
       }
      }
     },
     "localname": "DisposalGroupNotDiscontinuedOperationTransactionCosts",
     "nsuri": "http://www.myriad.com/20210930",
     "presentation": [
      "http://www.myriad.com/role/DivestituresNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mygn_EighthShareRepurchaseProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Eighth share repurchase program.",
        "label": "Eighth Share Repurchase Program [Member]",
        "terseLabel": "Eighth Share Repurchase Program"
       }
      }
     },
     "localname": "EighthShareRepurchaseProgramMember",
     "nsuri": "http://www.myriad.com/20210930",
     "presentation": [
      "http://www.myriad.com/role/PreferredandCommonStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mygn_EmployeeStockPurchasePlanTwentyTwelveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Stock Purchase Plan Twenty Twelve [Member]",
        "label": "Employee Stock Purchase Plan Twenty Twelve [Member]",
        "terseLabel": "2012 Purchase Plan"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanTwentyTwelveMember",
     "nsuri": "http://www.myriad.com/20210930",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mygn_GainLossOnDispositionOfAssetsNetOfTransactionFees": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (Loss) On Disposition of Assets, Net Of Transaction Fees",
        "label": "Gain (Loss) On Disposition of Assets, Net Of Transaction Fees",
        "terseLabel": "Net gain on sale of assets adjusted for transaction fees"
       }
      }
     },
     "localname": "GainLossOnDispositionOfAssetsNetOfTransactionFees",
     "nsuri": "http://www.myriad.com/20210930",
     "presentation": [
      "http://www.myriad.com/role/DivestituresNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mygn_ImpairmentOfGoodwillAndLongLivedAssetsHeldForUse": {
     "auth_ref": [],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Impairment Of Goodwill And Long-Lived Assets Held For Use",
        "label": "Impairment Of Goodwill And Long-Lived Assets Held For Use",
        "verboseLabel": "Impairment of goodwill and long-lived assets"
       }
      }
     },
     "localname": "ImpairmentOfGoodwillAndLongLivedAssetsHeldForUse",
     "nsuri": "http://www.myriad.com/20210930",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mygn_InProcessResearchAndDevelopmentWithIndefiniteLivesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In process research and development with indefinite lives.",
        "label": "In Process Research And Development With Indefinite Lives [Member]",
        "terseLabel": "In-process research and development"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentWithIndefiniteLivesMember",
     "nsuri": "http://www.myriad.com/20210930",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails",
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mygn_IncreaseDecreaseInEarningsLossPerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease in earnings (loss) per share.",
        "label": "Increase Decrease In Earnings Loss Per Share",
        "terseLabel": "Change in earnings per share (dollars per share)"
       }
      }
     },
     "localname": "IncreaseDecreaseInEarningsLossPerShare",
     "nsuri": "http://www.myriad.com/20210930",
     "presentation": [
      "http://www.myriad.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "mygn_IncreaseDecreaseInUnrecognizedTaxBenefits": {
     "auth_ref": [],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) in unrecognized tax benefits.",
        "label": "Increase (Decrease) In Unrecognized Tax Benefits",
        "terseLabel": "Unrecognized tax benefits"
       }
      }
     },
     "localname": "IncreaseDecreaseInUnrecognizedTaxBenefits",
     "nsuri": "http://www.myriad.com/20210930",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mygn_IntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intangible assets.",
        "label": "Intangible Assets [Line Items]",
        "terseLabel": "Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "IntangibleAssetsLineItems",
     "nsuri": "http://www.myriad.com/20210930",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails",
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mygn_InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails": {
       "order": 1.0,
       "parentTag": "mygn_InvestmentsAndCashAmortizedCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments And Cash, Accumulated Gross Unrealized Gain, before Tax",
        "label": "Investments And Cash, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Total, Gross unrealized holding gains"
       }
      }
     },
     "localname": "InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://www.myriad.com/20210930",
     "presentation": [
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mygn_InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails": {
       "order": 2.0,
       "parentTag": "mygn_InvestmentsAndCashAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments And Cash, Accumulated Gross Unrealized Loss, before Tax",
        "label": "Investments And Cash, Accumulated Gross Unrealized Loss, before Tax",
        "negatedTerseLabel": "Total, Gross unrealized holding losses"
       }
      }
     },
     "localname": "InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://www.myriad.com/20210930",
     "presentation": [
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mygn_InvestmentsAndCashAmortizedCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments And Cash, Amortized Cost",
        "label": "Investments And Cash, Amortized Cost",
        "totalLabel": "Total, Amortized cost"
       }
      }
     },
     "localname": "InvestmentsAndCashAmortizedCost",
     "nsuri": "http://www.myriad.com/20210930",
     "presentation": [
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails",
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mygn_MedicareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medicare",
        "label": "Medicare [Member]",
        "terseLabel": "Medicare"
       }
      }
     },
     "localname": "MedicareMember",
     "nsuri": "http://www.myriad.com/20210930",
     "presentation": [
      "http://www.myriad.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mygn_MolecularDiagnosticAutoimmuneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Molecular Diagnostic Autoimmune",
        "label": "Molecular Diagnostic Autoimmune [Member]",
        "terseLabel": "Molecular Diagnostic - Autoimmune"
       }
      }
     },
     "localname": "MolecularDiagnosticAutoimmuneMember",
     "nsuri": "http://www.myriad.com/20210930",
     "presentation": [
      "http://www.myriad.com/role/RevenueTotalRevenuebyProductandbyUSversusRestofWorldDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mygn_MolecularDiagnosticHereditaryCancerTestingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Molecular diagnostic hereditary cancer testing.",
        "label": "Molecular Diagnostic Hereditary Cancer Testing [Member]",
        "terseLabel": "Molecular diagnostic - Hereditary Cancer"
       }
      }
     },
     "localname": "MolecularDiagnosticHereditaryCancerTestingMember",
     "nsuri": "http://www.myriad.com/20210930",
     "presentation": [
      "http://www.myriad.com/role/RevenueTotalRevenuebyProductandbyUSversusRestofWorldDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mygn_MolecularDiagnosticOtherTestingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Molecular diagnostic other testing.",
        "label": "Molecular Diagnostic Other Testing [Member]",
        "terseLabel": "Molecular diagnostic - Other"
       }
      }
     },
     "localname": "MolecularDiagnosticOtherTestingMember",
     "nsuri": "http://www.myriad.com/20210930",
     "presentation": [
      "http://www.myriad.com/role/RevenueTotalRevenuebyProductandbyUSversusRestofWorldDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mygn_MolecularDiagnosticPharmacogenomicsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Molecular Diagnostic Pharmacogenomics",
        "label": "Molecular Diagnostic Pharmacogenomics [Member]",
        "terseLabel": "Molecular Diagnostic - Pharmacogenomics"
       }
      }
     },
     "localname": "MolecularDiagnosticPharmacogenomicsMember",
     "nsuri": "http://www.myriad.com/20210930",
     "presentation": [
      "http://www.myriad.com/role/RevenueTotalRevenuebyProductandbyUSversusRestofWorldDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mygn_MolecularDiagnosticPrenatalTestingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Molecular diagnostic Prenatal testing.",
        "label": "Molecular Diagnostic Prenatal Testing [Member]",
        "terseLabel": "Molecular diagnostic - Prenatal"
       }
      }
     },
     "localname": "MolecularDiagnosticPrenatalTestingMember",
     "nsuri": "http://www.myriad.com/20210930",
     "presentation": [
      "http://www.myriad.com/role/RevenueTotalRevenuebyProductandbyUSversusRestofWorldDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mygn_MolecularDiagnosticTestingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Molecular diagnostic testing.",
        "label": "Molecular Diagnostic Testing [Member]",
        "terseLabel": "Molecular diagnostic testing"
       }
      }
     },
     "localname": "MolecularDiagnosticTestingMember",
     "nsuri": "http://www.myriad.com/20210930",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.myriad.com/role/RevenueTotalRevenuebyProductandbyUSversusRestofWorldDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mygn_MolecularDiagnosticTumorProfilingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Molecular Diagnostic Tumor Profiling",
        "label": "Molecular Diagnostic Tumor Profiling [Member]",
        "terseLabel": "Molecular diagnostic - Tumor Profiling"
       }
      }
     },
     "localname": "MolecularDiagnosticTumorProfilingMember",
     "nsuri": "http://www.myriad.com/20210930",
     "presentation": [
      "http://www.myriad.com/role/RevenueTotalRevenuebyProductandbyUSversusRestofWorldDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mygn_MyriadAutoimmuneAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Myriad Autoimmune Assets",
        "label": "Myriad Autoimmune Assets [Member]",
        "terseLabel": "Select operating assets and intellectual property of Myriad Autoimmune business unit",
        "verboseLabel": "Myriad Autoimmune assets"
       }
      }
     },
     "localname": "MyriadAutoimmuneAssetsMember",
     "nsuri": "http://www.myriad.com/20210930",
     "presentation": [
      "http://www.myriad.com/role/DivestituresNarrativeDetails",
      "http://www.myriad.com/role/DivestituresOtherIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mygn_MyriadMyPathLLCLaboratoryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Myriad My Path LLC Laboratory",
        "label": "Myriad My Path LLC Laboratory [Member]",
        "terseLabel": "Myriad myPath LLC laboratory"
       }
      }
     },
     "localname": "MyriadMyPathLLCLaboratoryMember",
     "nsuri": "http://www.myriad.com/20210930",
     "presentation": [
      "http://www.myriad.com/role/DivestituresNarrativeDetails",
      "http://www.myriad.com/role/DivestituresOtherIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mygn_MyriadRBMIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Myriad RBM, Inc",
        "label": "Myriad RBM, Inc [Member]",
        "terseLabel": "Myriad RBM, Inc."
       }
      }
     },
     "localname": "MyriadRBMIncMember",
     "nsuri": "http://www.myriad.com/20210930",
     "presentation": [
      "http://www.myriad.com/role/DivestituresNarrativeDetails",
      "http://www.myriad.com/role/DivestituresOtherIncomeDetails",
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mygn_NetChangeInCashAndCashEquivalentsClassifiedAsHeldForSale": {
     "auth_ref": [],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net Change In Cash And Cash Equivalents Classified As Held For Sale",
        "label": "Net Change In Cash And Cash Equivalents Classified As Held For Sale",
        "terseLabel": "Change in cash and cash equivalents classified as held for sale"
       }
      }
     },
     "localname": "NetChangeInCashAndCashEquivalentsClassifiedAsHeldForSale",
     "nsuri": "http://www.myriad.com/20210930",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mygn_NonCashInterestExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non cash interest expense.",
        "label": "Non Cash Interest Expense",
        "terseLabel": "Non-cash interest expense"
       }
      }
     },
     "localname": "NonCashInterestExpense",
     "nsuri": "http://www.myriad.com/20210930",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mygn_NonEmployeeDirectorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non employee director.",
        "label": "Non Employee Director [Member]",
        "terseLabel": "Non-employee director"
       }
      }
     },
     "localname": "NonEmployeeDirectorMember",
     "nsuri": "http://www.myriad.com/20210930",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mygn_OperatingLeaseLiabilityEstablished": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease Liability Established",
        "label": "Operating Lease Liability Established",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityEstablished",
     "nsuri": "http://www.myriad.com/20210930",
     "presentation": [
      "http://www.myriad.com/role/SupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mygn_OptionsAndRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Options and Restricted Stock Units.",
        "label": "Options And Restricted Stock Units [Member]",
        "terseLabel": "Options and RSUs"
       }
      }
     },
     "localname": "OptionsAndRestrictedStockUnitsMember",
     "nsuri": "http://www.myriad.com/20210930",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mygn_OptionsGrantedAfterDecemberFiveTwentyTwelveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Options granted after December 5, 2012.",
        "label": "Options Granted After December Five Twenty Twelve [Member]",
        "terseLabel": "Awards granted after December 5, 2012"
       }
      }
     },
     "localname": "OptionsGrantedAfterDecemberFiveTwentyTwelveMember",
     "nsuri": "http://www.myriad.com/20210930",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mygn_OptionsGrantedPriorToDecemberFiveTwentyTwelveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Options granted prior to December 5, 2012.",
        "label": "Options Granted Prior To December Five Twenty Twelve [Member]",
        "terseLabel": "Awards granted prior to December 5, 2012"
       }
      }
     },
     "localname": "OptionsGrantedPriorToDecemberFiveTwentyTwelveMember",
     "nsuri": "http://www.myriad.com/20210930",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mygn_OtherAssetsDebtDiscount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Assets, Debt Discount",
        "label": "Other Assets, Debt Discount",
        "terseLabel": "Debt discount reclassified to other assets"
       }
      }
     },
     "localname": "OtherAssetsDebtDiscount",
     "nsuri": "http://www.myriad.com/20210930",
     "presentation": [
      "http://www.myriad.com/role/LongTermDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mygn_PerformanceObligationEstimatedTransactionPriceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performance Obligation Estimated Transaction Price",
        "label": "Performance Obligation Estimated Transaction Price [Member]",
        "terseLabel": "Performance obligation estimate"
       }
      }
     },
     "localname": "PerformanceObligationEstimatedTransactionPriceMember",
     "nsuri": "http://www.myriad.com/20210930",
     "presentation": [
      "http://www.myriad.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mygn_PharmaceuticalAndClinicalServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pharmaceutical and clinical services.",
        "label": "Pharmaceutical And Clinical Services [Member]",
        "terseLabel": "Pharmaceutical and clinical services"
       }
      }
     },
     "localname": "PharmaceuticalAndClinicalServicesMember",
     "nsuri": "http://www.myriad.com/20210930",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.myriad.com/role/RevenueTotalRevenuebyProductandbyUSversusRestofWorldDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mygn_PurchasedLicensesAndTechnologiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchased licenses and technologies.",
        "label": "Purchased Licenses And Technologies [Member]",
        "terseLabel": "Purchased licenses and technologies"
       }
      }
     },
     "localname": "PurchasedLicensesAndTechnologiesMember",
     "nsuri": "http://www.myriad.com/20210930",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails",
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mygn_ReclassificationFromAccumulatedOtherComprehensiveLossDeconsolidationOfSubsidiary": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reclassification From Accumulated Other Comprehensive Loss, Deconsolidation Of Subsidiary",
        "label": "Reclassification From Accumulated Other Comprehensive Loss, Deconsolidation Of Subsidiary",
        "terseLabel": "Reclassification out of accumulated other comprehensive loss upon the deconsolidation of a subsidiary"
       }
      }
     },
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveLossDeconsolidationOfSubsidiary",
     "nsuri": "http://www.myriad.com/20210930",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mygn_RefundsPayableAndReserveCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.myriad.com/role/AccruedLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Refunds Payable And Reserve, Current",
        "label": "Refunds Payable And Reserve, Current",
        "terseLabel": "Refunds payable and reserves"
       }
      }
     },
     "localname": "RefundsPayableAndReserveCurrent",
     "nsuri": "http://www.myriad.com/20210930",
     "presentation": [
      "http://www.myriad.com/role/AccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mygn_ScheduleOfIntangibleAssetsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Intangible Assets [Table]",
        "label": "Schedule Of Intangible Assets [Table]",
        "terseLabel": "Schedule Of Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfIntangibleAssetsTable",
     "nsuri": "http://www.myriad.com/20210930",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails",
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mygn_StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, Share-Based Payment Arrangement And Employee Stock Purchase Plans",
        "label": "Stock Issued During Period, Shares, Share-Based Payment Arrangement And Employee Stock Purchase Plans",
        "terseLabel": "Common stock issued upon exercise of options, vesting of restricted stock units, and purchases under employee stock purchase plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans",
     "nsuri": "http://www.myriad.com/20210930",
     "presentation": [
      "http://www.myriad.com/role/PreferredandCommonStockholdersEquityCommonSharesIssuedandOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "mygn_TwoThousandSeventeenEmployeeDirectorAndConsultantEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand Seventeen Employee Director And Consultant Equity Incentive Plan",
        "label": "Two Thousand Seventeen Employee Director And Consultant Equity Incentive Plan [Member]",
        "terseLabel": "2017 Plan"
       }
      }
     },
     "localname": "TwoThousandSeventeenEmployeeDirectorAndConsultantEquityIncentivePlanMember",
     "nsuri": "http://www.myriad.com/20210930",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r202",
      "r363",
      "r368",
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r292",
      "r328",
      "r384",
      "r387",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r580",
      "r584",
      "r624",
      "r625"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/LongTermDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r292",
      "r328",
      "r384",
      "r387",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r580",
      "r584",
      "r624",
      "r625"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/LongTermDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r202",
      "r363",
      "r368",
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r198",
      "r363",
      "r366",
      "r532",
      "r579",
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.myriad.com/role/RevenueTotalRevenuebyProductandbyUSversusRestofWorldDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r198",
      "r363",
      "r366",
      "r532",
      "r579",
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.myriad.com/role/RevenueTotalRevenuebyProductandbyUSversusRestofWorldDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r292",
      "r328",
      "r374",
      "r384",
      "r387",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r580",
      "r584",
      "r624",
      "r625"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/LongTermDebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r292",
      "r328",
      "r374",
      "r384",
      "r387",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r580",
      "r584",
      "r624",
      "r625"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/LongTermDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r141",
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/LongTermDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r141",
      "r146",
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/LongTermDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r199",
      "r200",
      "r363",
      "r367",
      "r582",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/RevenueTotalRevenuebyProductandbyUSversusRestofWorldDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r199",
      "r200",
      "r363",
      "r367",
      "r582",
      "r609",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "U.S. [Member]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/RevenueTotalRevenuebyProductandbyUSversusRestofWorldDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r141",
      "r146",
      "r275",
      "r385",
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/LongTermDebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r204",
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r55"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued Liabilities"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/AccruedLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r54",
      "r516"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r22",
      "r40",
      "r205",
      "r206"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Trade accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.myriad.com/role/AccruedLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued liabilities",
        "totalLabel": "Total accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/AccruedLiabilitiesDetails",
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedRoyaltiesCurrent": {
     "auth_ref": [
      "r28",
      "r29",
      "r60"
     ],
     "calculation": {
      "http://www.myriad.com/role/AccruedLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Royalties, Current",
        "terseLabel": "Accrued royalties"
       }
      }
     },
     "localname": "AccruedRoyaltiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/AccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r52",
      "r258"
     ],
     "calculation": {
      "http://www.myriad.com/role/PropertyPlantandEquipmentNetBalancesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/PropertyPlantandEquipmentNetBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r43",
      "r76",
      "r77",
      "r78",
      "r566",
      "r589",
      "r590"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r75",
      "r78",
      "r85",
      "r86",
      "r87",
      "r133",
      "r134",
      "r135",
      "r468",
      "r585",
      "r586",
      "r634"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r133",
      "r134",
      "r135",
      "r418",
      "r419",
      "r420",
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r388",
      "r390",
      "r423",
      "r424"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based payment expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash provided by (used in) operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllOtherSegmentsMember": {
     "auth_ref": [
      "r167",
      "r185",
      "r186",
      "r187",
      "r188",
      "r190"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating segments classified as other. Excludes intersegment elimination and reconciling items.",
        "label": "Other Segments [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "AllOtherSegmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsCarryingAmountofGoodwillDetails",
      "http://www.myriad.com/role/SegmentandRelatedInformationSegmentRevenueandOperatingIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r390",
      "r414",
      "r422"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "verboseLabel": "Total stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r118",
      "r242",
      "r249"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization of intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsAmortizationonIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r154"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Anti-dilutive options and RSUs excluded from EPS computation"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/PreferredandCommonStockholdersEquityPotentiallyDilutiveCommonSharesExcludedfromEPSComputationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r128",
      "r180",
      "r187",
      "r194",
      "r226",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r462",
      "r469",
      "r495",
      "r514",
      "r516",
      "r538",
      "r563"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r25",
      "r27",
      "r72",
      "r128",
      "r226",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r462",
      "r469",
      "r495",
      "r514",
      "r516"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r478"
     ],
     "calculation": {
      "http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FairValueNetAssetLiability",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Financial assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r212"
     ],
     "calculation": {
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Available-for-sale, Gross unrealized holding gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r213"
     ],
     "calculation": {
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedTerseLabel": "Available-for-sale, Gross unrealized holding losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r210",
      "r228"
     ],
     "calculation": {
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Available-for-sale, Amortized cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale [Abstract]",
        "terseLabel": "Available-for-sale:"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost": {
     "auth_ref": [
      "r218"
     ],
     "calculation": {
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails": {
       "order": 4.0,
       "parentTag": "mygn_InvestmentsAndCashAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10",
        "terseLabel": "Available-for-sale, Due after five years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue": {
     "auth_ref": [
      "r214",
      "r218",
      "r558"
     ],
     "calculation": {
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_InvestmentsAndCash",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10",
        "terseLabel": "Available-for-sale, Due after five years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost": {
     "auth_ref": [
      "r217"
     ],
     "calculation": {
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "mygn_InvestmentsAndCashAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "terseLabel": "Available-for-sale, Due after one year through five years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "auth_ref": [
      "r214",
      "r217",
      "r557"
     ],
     "calculation": {
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InvestmentsAndCash",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "terseLabel": "Available-for-sale, Due after one year through five years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueRollingMaturityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale, Maturity, Fair Value, Rolling Maturity [Abstract]",
        "terseLabel": "Estimated fair value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesFairValueRollingMaturityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisRollingMaturityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost, Rolling Maturity [Abstract]",
        "terseLabel": "Amortized cost"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisRollingMaturityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": {
     "auth_ref": [
      "r216"
     ],
     "calculation": {
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "mygn_InvestmentsAndCashAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Available-for-sale, Due within one year"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r214",
      "r216",
      "r556"
     ],
     "calculation": {
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InvestmentsAndCash",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Available-for-sale, Due within one year"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r208",
      "r211",
      "r228",
      "r544"
     ],
     "calculation": {
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Available-for-sale, Estimated fair value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardDateAxis": {
     "auth_ref": [
      "r392",
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by date or year award under share-based payment arrangement is granted.",
        "label": "Award Date [Axis]",
        "terseLabel": "Award Date [Axis]"
       }
      }
     },
     "localname": "AwardDateAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardDateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date or year award under share-based payment arrangement is granted.",
        "label": "Award Date [Domain]",
        "terseLabel": "Award Date [Domain]"
       }
      }
     },
     "localname": "AwardDateDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r392",
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.myriad.com/role/StockBasedCompensationRSUActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/BasisofPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "auth_ref": [
      "r117",
      "r454"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "terseLabel": "Change in the fair value of contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": {
     "auth_ref": [
      "r452",
      "r453"
     ],
     "calculation": {
      "http://www.myriad.com/role/AccruedLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Current",
        "terseLabel": "Short-term contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/AccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": {
     "auth_ref": [
      "r452",
      "r453"
     ],
     "calculation": {
      "http://www.myriad.com/role/OtherLongTermLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherLiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Noncurrent",
        "terseLabel": "Contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/OtherLongTermLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CaliforniaFranchiseTaxBoardMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government of the state of California.",
        "label": "California Franchise Tax Board [Member]",
        "terseLabel": "California"
       }
      }
     },
     "localname": "CaliforniaFranchiseTaxBoardMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CapitalizedContractCostGross": {
     "auth_ref": [
      "r234"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.",
        "label": "Capitalized Contract Cost, Gross",
        "terseLabel": "Capitalized costs incurred to obtain or fulfill contract"
       }
      }
     },
     "localname": "CapitalizedContractCostGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r20",
      "r49",
      "r120"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "mygn_InvestmentsAndCashAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "Cash and cash equivalents, Amortized cost"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails",
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, at Carrying Value [Abstract]",
        "terseLabel": "Cash and cash equivalents:"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails",
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InvestmentsAndCash",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash and cash equivalents, Estimated fair value",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails",
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r113",
      "r120",
      "r122"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of the period",
        "periodStartLabel": "Cash and cash equivalents at beginning of the period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r113",
      "r496"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashEquivalentsMember": {
     "auth_ref": [
      "r31"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Equivalents [Member]",
        "terseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails",
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashFlowOperatingActivitiesLesseeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Operating Activities, Lessee [Abstract]",
        "terseLabel": "Establishment of operating lease right-of-use assets and lease liabilities"
       }
      }
     },
     "localname": "CashFlowOperatingActivitiesLesseeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/SupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashFlowSupplementalDisclosuresTextBlock": {
     "auth_ref": [
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Cash Flow, Supplemental Disclosures [Text Block]",
        "terseLabel": "Supplemental Cash Flow Information"
       }
      }
     },
     "localname": "CashFlowSupplementalDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/SupplementalCashFlowInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashMember": {
     "auth_ref": [
      "r31"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits.",
        "label": "Cash [Member]",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "CashMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails",
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ChangeInAccountingEstimateByTypeAxis": {
     "auth_ref": [
      "r141",
      "r158"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of change in accounting estimate.",
        "label": "Change in Accounting Estimate by Type [Axis]",
        "terseLabel": "Change in Accounting Estimate by Type [Axis]"
       }
      }
     },
     "localname": "ChangeInAccountingEstimateByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ChangeInAccountingEstimateTypeDomain": {
     "auth_ref": [
      "r141",
      "r158"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the accounting estimate that was changed that had the effect of adjusting the carrying amount of an existing asset or liability, or that will alter the subsequent accounting for existing or future assets or liabilities.",
        "label": "Change in Accounting Estimate, Type [Domain]",
        "terseLabel": "Change in Accounting Estimate, Type [Domain]"
       }
      }
     },
     "localname": "ChangeInAccountingEstimateTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ChangeInContractWithCustomerLiabilityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Contract with Customer, Liability [Abstract]",
        "terseLabel": "Reconciliation of Deferred Revenue"
       }
      }
     },
     "localname": "ChangeInContractWithCustomerLiabilityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/RevenueReconciliationofDeferredRevenueBalancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/PreferredandCommonStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r66",
      "r274",
      "r545",
      "r571"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r270",
      "r271",
      "r273",
      "r277",
      "r611"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r68"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Shares available for issuance under the Plan"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r133",
      "r134",
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r39"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/PreferredandCommonStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r39"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock authorized (shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/PreferredandCommonStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r39"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "periodEndLabel": "Common stock issued at end of period",
        "periodStartLabel": "Beginning common stock issued",
        "terseLabel": "Common stock issued (shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/PreferredandCommonStockholdersEquityCommonSharesIssuedandOutstandingDetails",
      "http://www.myriad.com/role/PreferredandCommonStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r39",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Common stock outstanding at end of period",
        "periodStartLabel": "Beginning common stock outstanding",
        "terseLabel": "Common stock, shares outstanding",
        "verboseLabel": "Common stock outstanding (shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.myriad.com/role/PreferredandCommonStockholdersEquityCommonSharesIssuedandOutstandingDetails",
      "http://www.myriad.com/role/PreferredandCommonStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r39",
      "r516"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, 79.7 million and 75.4 million shares outstanding at September\u00a030, 2021 and December 31, 2020, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r81",
      "r83",
      "r84",
      "r92",
      "r549",
      "r575"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income (loss) attributable to Myriad Genetics, Inc. stockholders"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r81",
      "r83",
      "r91",
      "r460",
      "r473",
      "r548",
      "r574"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Comprehensive income (loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r164",
      "r165",
      "r202",
      "r492",
      "r493",
      "r610"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r164",
      "r165",
      "r202",
      "r492",
      "r493",
      "r592",
      "r610"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r164",
      "r165",
      "r202",
      "r492",
      "r493",
      "r592",
      "r610"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Concentration Risk [Line Items]",
        "terseLabel": "Revenue and Concentration Risk [Line Items]"
       }
      }
     },
     "localname": "ConcentrationRiskLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r164",
      "r165",
      "r202",
      "r492",
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentration risk (percent)"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTable": {
     "auth_ref": [
      "r162",
      "r164",
      "r165",
      "r166",
      "r492",
      "r494",
      "r610"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Concentration Risk [Table]",
        "terseLabel": "Concentration Risk [Table]"
       }
      }
     },
     "localname": "ConcentrationRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r164",
      "r165",
      "r202",
      "r492",
      "r493",
      "r610"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContingentConsiderationByTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of contingent consideration.",
        "label": "Contingent Consideration by Type [Axis]",
        "terseLabel": "Contingent Consideration by Type [Axis]"
       }
      }
     },
     "localname": "ContingentConsiderationByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ContingentConsiderationTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of contingent payment arrangement.",
        "label": "Contingent Consideration Type [Domain]",
        "terseLabel": "Contingent Consideration Type [Domain]"
       }
      }
     },
     "localname": "ContingentConsiderationTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "auth_ref": [
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.",
        "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]",
        "terseLabel": "Reconciliation of Deferred Revenue Balances"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/RevenueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice": {
     "auth_ref": [
      "r353"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in estimate of transaction price which increases (decreases) right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time. Includes, but is not limited to, change in assessment of whether estimate of variable consideration is constrained.",
        "label": "Contract with Customer, Asset, Cumulative Catch-up Adjustment to Revenue, Change in Estimate of Transaction Price",
        "terseLabel": "Revenue increase (decrease) due to changes in estimated transaction price due to contractual adjustments"
       }
      }
     },
     "localname": "ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r351",
      "r352",
      "r364"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "periodEndLabel": "Deferred revenues - ending balance",
        "periodStartLabel": "Deferred revenues - beginning balance",
        "terseLabel": "Deferred revenues"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.myriad.com/role/RevenueReconciliationofDeferredRevenueBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r375",
      "r382",
      "r591"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate bonds and notes"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails",
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r95",
      "r532"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of revenue"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r94"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total costs and expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/LongTermDebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/LongTermDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r163",
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer concentration"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerRelationshipsMember": {
     "auth_ref": [
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.",
        "label": "Customer Relationships [Member]",
        "terseLabel": "Customer relationships"
       }
      }
     },
     "localname": "CustomerRelationshipsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails",
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r124",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r306",
      "r313",
      "r314",
      "r316",
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Long-Term Debt"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/LongTermDebt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r34",
      "r35",
      "r36",
      "r127",
      "r132",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r296",
      "r302",
      "r303",
      "r304",
      "r305",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r318",
      "r319",
      "r320",
      "r321",
      "r507",
      "r539",
      "r541",
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/LongTermDebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Basis spread on rate (percent)"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/LongTermDebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/LongTermDebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "auth_ref": [
      "r63",
      "r292",
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.",
        "label": "Debt Instrument, Maturity Date",
        "terseLabel": "Maturity date"
       }
      }
     },
     "localname": "DebtInstrumentMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/LongTermDebtNarrativeDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r64",
      "r127",
      "r132",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r296",
      "r302",
      "r303",
      "r304",
      "r305",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r318",
      "r319",
      "r320",
      "r321",
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/LongTermDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r64",
      "r127",
      "r132",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r296",
      "r302",
      "r303",
      "r304",
      "r305",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r315",
      "r318",
      "r319",
      "r320",
      "r321",
      "r343",
      "r346",
      "r347",
      "r348",
      "r504",
      "r505",
      "r507",
      "r508",
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/LongTermDebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent": {
     "auth_ref": [
      "r504",
      "r508"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of debt discount to be amortized after one year or the normal operating cycle, if longer.",
        "label": "Debt Instrument, Unamortized Discount, Noncurrent",
        "terseLabel": "Unamortized debt discount"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/LongTermDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": {
     "auth_ref": [
      "r220",
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions",
        "terseLabel": "Debt securities, available-for-sale, in unrealized loss position"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r428",
      "r429"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Long-term deferred taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r118",
      "r256"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/PropertyPlantandEquipmentNetDepreciationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r118",
      "r256"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.myriad.com/role/SegmentandRelatedInformationSegmentRevenueandOperatingIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/RevenueTotalRevenuebyProductandbyUSversusRestofWorldDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r363",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/RevenueTotalRevenuebyProductandbyUSversusRestofWorldDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Schedule of Total Revenue by Product and by U.S versus Rest of World"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/RevenueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Discontinued Operations and Disposal Groups [Abstract]",
        "terseLabel": "Discontinued Operations and Disposal Groups [Abstract]"
       }
      }
     },
     "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupClassificationAxis": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by disposal group classification.",
        "label": "Disposal Group Classification [Axis]",
        "terseLabel": "Disposal Group Classification [Axis]"
       }
      }
     },
     "localname": "DisposalGroupClassificationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/DivestituresNarrativeDetails",
      "http://www.myriad.com/role/DivestituresOtherIncomeDetails",
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupClassificationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations.",
        "label": "Disposal Group Classification [Domain]",
        "terseLabel": "Disposal Group Classification [Domain]"
       }
      }
     },
     "localname": "DisposalGroupClassificationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/DivestituresNarrativeDetails",
      "http://www.myriad.com/role/DivestituresOtherIncomeDetails",
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember": {
     "auth_ref": [
      "r255",
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal group that has been sold. Excludes disposals classified as discontinued operations.",
        "label": "Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]",
        "terseLabel": "Disposed of by sale"
       }
      }
     },
     "localname": "DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/DivestituresNarrativeDetails",
      "http://www.myriad.com/role/DivestituresOtherIncomeDetails",
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent": {
     "auth_ref": [
      "r3",
      "r4",
      "r12",
      "r254",
      "r262"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as intangible assets, excluding goodwill, attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Intangible Assets, Noncurrent",
        "terseLabel": "Intangible assets included in sale"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal": {
     "auth_ref": [
      "r118",
      "r255",
      "r260"
     ],
     "calculation": {
      "http://www.myriad.com/role/DivestituresOtherIncomeDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations.",
        "label": "Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal",
        "terseLabel": "Gain (loss) on divestiture"
       }
      }
     },
     "localname": "DisposalGroupNotDiscontinuedOperationGainLossOnDisposal",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/DivestituresNarrativeDetails",
      "http://www.myriad.com/role/DivestituresOtherIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": {
     "auth_ref": [
      "r18",
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]",
        "terseLabel": "Divestitures"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/Divestitures"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": {
     "auth_ref": [
      "r383",
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of disposal group.",
        "label": "Disposal Group Name [Domain]",
        "terseLabel": "Disposal Group Name [Domain]"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/DivestituresNarrativeDetails",
      "http://www.myriad.com/role/DivestituresOtherIncomeDetails",
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarliestTaxYearMember": {
     "auth_ref": [
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Earliest identified tax year.",
        "label": "Earliest Tax Year [Member]",
        "terseLabel": "Earliest tax year"
       }
      }
     },
     "localname": "EarliestTaxYearMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r93",
      "r138",
      "r139",
      "r140",
      "r141",
      "r142",
      "r147",
      "r149",
      "r151",
      "r152",
      "r153",
      "r156",
      "r157",
      "r476",
      "r477",
      "r550",
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic and Diluted [Abstract]",
        "terseLabel": "Net income (loss) per share:"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]",
        "terseLabel": "Weighted average shares outstanding:"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r93",
      "r138",
      "r139",
      "r140",
      "r141",
      "r142",
      "r149",
      "r151",
      "r152",
      "r153",
      "r156",
      "r157",
      "r476",
      "r477",
      "r550",
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r496"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "terseLabel": "Effect of foreign exchange rates on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Approximate tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.myriad.com/role/AccruedLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Employee compensation and benefits"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/AccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-Based Compensation Expense [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted-average period for recognition of stock-based compensation expense (in years)"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r415"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized stock-based compensation expense related to RSUs"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r415"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized stock-based compensation expense related to stock options"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]",
        "terseLabel": "Equipment"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/PropertyPlantandEquipmentNetBalancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r85",
      "r86",
      "r87",
      "r133",
      "r134",
      "r135",
      "r137",
      "r143",
      "r145",
      "r159",
      "r227",
      "r342",
      "r349",
      "r418",
      "r419",
      "r420",
      "r441",
      "r442",
      "r475",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r585",
      "r586",
      "r587",
      "r634"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r478",
      "r479",
      "r480",
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "auth_ref": [
      "r478",
      "r479",
      "r480",
      "r488",
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]",
        "terseLabel": "Schedule of Fair Value of Financial Assets and Liabilities"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]"
       }
      }
     },
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "auth_ref": [
      "r478",
      "r490",
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r304",
      "r318",
      "r319",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r479",
      "r520",
      "r521",
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails",
      "http://www.myriad.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r304",
      "r375",
      "r376",
      "r381",
      "r382",
      "r479",
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r304",
      "r318",
      "r319",
      "r375",
      "r376",
      "r381",
      "r382",
      "r479",
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r304",
      "r318",
      "r319",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r479",
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails",
      "http://www.myriad.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Reconciliation of change in fair value of contingent consideration"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsChangeinFairValueofContingentConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r483",
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Change in Fair Value of Contingent Consideration"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "auth_ref": [
      "r484"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "negatedTerseLabel": "Change in fair value recognized in the income statement"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsChangeinFairValueofContingentConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome": {
     "auth_ref": [
      "r485"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in other comprehensive income (OCI) from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Other Comprehensive Income (Loss)",
        "negatedTerseLabel": "Translation adjustments recognized in other comprehensive loss"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsChangeinFairValueofContingentConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": {
     "auth_ref": [
      "r486"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements",
        "negatedTerseLabel": "Payment of contingent consideration"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsChangeinFairValueofContingentConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r483"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsChangeinFairValueofContingentConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r304",
      "r318",
      "r319",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r520",
      "r521",
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails",
      "http://www.myriad.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueNetAssetLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of asset after deduction of liability.",
        "label": "Fair Value, Net Asset (Liability)",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "FairValueNetAssetLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FederalMinistryOfFinanceGermanyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government of Germany.",
        "label": "Federal Ministry of Finance, Germany [Member]",
        "terseLabel": "Germany"
       }
      }
     },
     "localname": "FederalMinistryOfFinanceGermanyMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r248"
     ],
     "calculation": {
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      },
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.",
        "label": "Finite-lived Intangible Assets Amortization Expense [Table Text Block]",
        "terseLabel": "Schedule of Recorded Amortization Expense for Intangible Assets"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r243",
      "r245",
      "r248",
      "r251",
      "r533",
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails",
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r248",
      "r534"
     ],
     "calculation": {
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Gross Carrying Amount, amortizable"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r243",
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails",
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r248",
      "r533"
     ],
     "calculation": {
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Net, amortizable"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.",
        "label": "Foreign Tax Authority [Member]",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "ForeignCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnDispositionOfAssets1": {
     "auth_ref": [
      "r118"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.",
        "label": "Gain (Loss) on Disposition of Assets",
        "negatedTerseLabel": "Gain on sale of businesses and assets"
       }
      }
     },
     "localname": "GainLossOnDispositionOfAssets1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r235",
      "r236",
      "r516",
      "r537"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsCarryingAmountofGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetImpairment": {
     "auth_ref": [],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 5.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill.",
        "label": "Goodwill and Intangible Asset Impairment",
        "terseLabel": "Goodwill and long-lived asset impairment charges"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetImpairment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Goodwill and Intangible Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": {
     "auth_ref": [
      "r238"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Foreign Currency Translation Gain (Loss)",
        "terseLabel": "Translation adjustments"
       }
      }
     },
     "localname": "GoodwillForeignCurrencyTranslationGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsCarryingAmountofGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Goodwill [Line Items]",
        "terseLabel": "Goodwill [Line Items]"
       }
      }
     },
     "localname": "GoodwillLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsCarryingAmountofGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]",
        "terseLabel": "Goodwill [Roll Forward]"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsCarryingAmountofGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit": {
     "auth_ref": [
      "r237"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of divestiture of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Written off Related to Sale of Business Unit",
        "negatedTerseLabel": "Divestitures"
       }
      }
     },
     "localname": "GoodwillWrittenOffRelatedToSaleOfBusinessUnit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsCarryingAmountofGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r89",
      "r180",
      "r186",
      "r190",
      "r193",
      "r196",
      "r535",
      "r546",
      "r552",
      "r577"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      },
      "http://www.myriad.com/role/SegmentandRelatedInformationTotalOperatingLossforReportableSegmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Income (loss) before income tax"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.myriad.com/role/SegmentandRelatedInformationTotalOperatingLossforReportableSegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": {
     "auth_ref": [
      "r383",
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of disposal group.",
        "label": "Disposal Group Name [Axis]",
        "terseLabel": "Disposal Group Name [Axis]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/DivestituresNarrativeDetails",
      "http://www.myriad.com/role/DivestituresOtherIncomeDetails",
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]",
        "terseLabel": "Divestitures [Line Items]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/DivestituresNarrativeDetails",
      "http://www.myriad.com/role/DivestituresOtherIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": {
     "auth_ref": [
      "r4",
      "r6",
      "r7",
      "r8",
      "r9",
      "r10",
      "r11",
      "r13",
      "r15",
      "r16",
      "r17",
      "r264",
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations [Table]",
        "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/DivestituresNarrativeDetails",
      "http://www.myriad.com/role/DivestituresOtherIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r261",
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityNameAxis": {
     "auth_ref": [
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of taxing authority.",
        "label": "Income Tax Authority, Name [Axis]",
        "terseLabel": "Income Tax Authority, Name [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority, Name [Domain]",
        "terseLabel": "Income Tax Authority, Name [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxContingencyLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Tax Contingency [Line Items]",
        "terseLabel": "Income Taxes [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxContingencyLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxContingencyTable": {
     "auth_ref": [
      "r434",
      "r436",
      "r438",
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.",
        "label": "Income Tax Contingency [Table]",
        "terseLabel": "Income Tax Contingency [Table]"
       }
      }
     },
     "localname": "IncomeTaxContingencyTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r129",
      "r432",
      "r437",
      "r439",
      "r443",
      "r445",
      "r447",
      "r448",
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExaminationYearUnderExamination": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax year being audited in the income tax examination, in YYYY format.",
        "label": "Income Tax Examination, Year under Examination",
        "terseLabel": "Tax year being audited in income tax examination"
       }
      }
     },
     "localname": "IncomeTaxExaminationYearUnderExamination",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "gYearListItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r130",
      "r144",
      "r145",
      "r178",
      "r430",
      "r444",
      "r446",
      "r578"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income tax expense (benefit)"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.myriad.com/role/IncomeTaxesDetails",
      "http://www.myriad.com/role/SegmentandRelatedInformationTotalOperatingLossforReportableSegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaid": {
     "auth_ref": [
      "r115",
      "r121"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.",
        "label": "Income Taxes Paid",
        "terseLabel": "Cash paid during the period for income taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/SupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r117"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r117"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Trade accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r117"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r117",
      "r530"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 19.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenues"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": {
     "auth_ref": [
      "r117"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.",
        "label": "Increase (Decrease) in Deferred Income Taxes",
        "negatedLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r117"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "auth_ref": [
      "r117"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "negatedTerseLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpensesOther": {
     "auth_ref": [
      "r117"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) of consideration paid in advance for other costs that provide economic benefits in future periods.",
        "label": "Increase (Decrease) in Prepaid Expenses, Other",
        "negatedTerseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidExpensesOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidTaxes": {
     "auth_ref": [
      "r117"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) of consideration paid in advance for income and other taxes that provide economic benefits in future periods.",
        "label": "Increase (Decrease) in Prepaid Taxes",
        "negatedLabel": "Prepaid taxes"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidTaxes",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Common shares issued and outstanding"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/PreferredandCommonStockholdersEquityCommonSharesIssuedandOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r244",
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets [Axis]",
        "terseLabel": "Indefinite-lived Intangible Assets [Axis]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails",
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r250"
     ],
     "calculation": {
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Non-amortizable"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r244",
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.",
        "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails",
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IntangibleAssetsGrossExcludingGoodwill": {
     "auth_ref": [],
     "calculation": {
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.",
        "label": "Intangible Assets, Gross (Excluding Goodwill)",
        "terseLabel": "Gross Carrying Amount, total"
       }
      }
     },
     "localname": "IntangibleAssetsGrossExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r241",
      "r246"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangibles, net",
        "totalLabel": "Net, total"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r88",
      "r174",
      "r503",
      "r506",
      "r551"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      },
      "http://www.myriad.com/role/SegmentandRelatedInformationTotalOperatingLossforReportableSegmentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.myriad.com/role/SegmentandRelatedInformationTotalOperatingLossforReportableSegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r111",
      "r114",
      "r121"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/SupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryFirmPurchaseCommitmentLoss": {
     "auth_ref": [
      "r231"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss recognized on firm purchase commitment for inventory.",
        "label": "Inventory, Firm Purchase Commitment, Loss",
        "terseLabel": "Loss on non-cancelable purchase commitment"
       }
      }
     },
     "localname": "InventoryFirmPurchaseCommitmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/DivestituresNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r21",
      "r71",
      "r516"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWriteDown": {
     "auth_ref": [
      "r230"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.",
        "label": "Inventory Write-down",
        "terseLabel": "Loss on inventory"
       }
      }
     },
     "localname": "InventoryWriteDown",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.myriad.com/role/DivestituresNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r97",
      "r173"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      },
      "http://www.myriad.com/role/SegmentandRelatedInformationTotalOperatingLossforReportableSegmentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.myriad.com/role/SegmentandRelatedInformationTotalOperatingLossforReportableSegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails",
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investments [Domain]"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails",
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsAndCash": {
     "auth_ref": [
      "r572"
     ],
     "calculation": {
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails": {
       "order": 3.0,
       "parentTag": "mygn_InvestmentsAndCashAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of investments and unrestricted cash as of the balance sheet date.",
        "label": "Investments and Cash",
        "terseLabel": "Total, Estimated fair value",
        "totalLabel": "Total, Estimated fair value"
       }
      }
     },
     "localname": "InvestmentsAndCash",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails",
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsAndCashAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments and Cash [Abstract]",
        "terseLabel": "Total:"
       }
      }
     },
     "localname": "InvestmentsAndCashAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "terseLabel": "Schedule of Cash, Cash Equivalents, and Maturities of Debt Securities Classified as Available-For-Sale Securities"
       }
      }
     },
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]",
        "terseLabel": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r225",
      "r536",
      "r559",
      "r608",
      "r632"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for  investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "Marketable Investment Securities"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/MarketableInvestmentSecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LatestTaxYearMember": {
     "auth_ref": [
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Latest identified tax year.",
        "label": "Latest Tax Year [Member]",
        "terseLabel": "Latest tax year"
       }
      }
     },
     "localname": "LatestTaxYearMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/PropertyPlantandEquipmentNetBalancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r58",
      "r128",
      "r188",
      "r226",
      "r278",
      "r279",
      "r280",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r463",
      "r469",
      "r470",
      "r495",
      "r514",
      "r515"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r46",
      "r128",
      "r226",
      "r495",
      "r516",
      "r543",
      "r569"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r62",
      "r128",
      "r226",
      "r278",
      "r279",
      "r280",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r463",
      "r469",
      "r470",
      "r495",
      "r514",
      "r515",
      "r516"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r478"
     ],
     "calculation": {
      "http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FairValueNetAssetLiability",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure",
        "negatedTerseLabel": "Financial liabilities"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r56"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Maximum aggregate principal commitment"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/LongTermDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.",
        "label": "Line of Credit Facility, Unused Capacity, Commitment Fee Percentage",
        "terseLabel": "Undrawn fee (percent)"
       }
      }
     },
     "localname": "LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/LongTermDebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LitigationReserveCurrent": {
     "auth_ref": [
      "r66",
      "r274",
      "r276"
     ],
     "calculation": {
      "http://www.myriad.com/role/AccruedLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of reserve for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid within one year of the date of the statement of financial position.",
        "label": "Estimated Litigation Liability, Current",
        "terseLabel": "Legal accrual",
        "verboseLabel": "Potential settlement accrual"
       }
      }
     },
     "localname": "LitigationReserveCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/AccruedLiabilitiesDetails",
      "http://www.myriad.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LondonInterbankOfferedRateLIBORMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.",
        "label": "London Interbank Offered Rate (LIBOR) [Member]",
        "terseLabel": "LIBOR"
       }
      }
     },
     "localname": "LondonInterbankOfferedRateLIBORMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/LongTermDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r36",
      "r303",
      "r317",
      "r318",
      "r319",
      "r541",
      "r565"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "terseLabel": "Outstanding balances"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/LongTermDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "terseLabel": "Long-term debt"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "auth_ref": [
      "r23",
      "r59"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current.",
        "label": "Marketable Securities, Current",
        "terseLabel": "Marketable investment securities"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesNoncurrent": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as noncurrent.",
        "label": "Marketable Securities, Noncurrent",
        "terseLabel": "Long-term marketable investment securities"
       }
      }
     },
     "localname": "MarketableSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "auth_ref": [
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.",
        "label": "Measurement Input, Expected Term [Member]",
        "terseLabel": "Measurement input, expected term"
       }
      }
     },
     "localname": "MeasurementInputExpectedTermMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r70",
      "r128",
      "r226",
      "r278",
      "r282",
      "r283",
      "r284",
      "r287",
      "r288",
      "r495",
      "r542",
      "r568"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "terseLabel": "Non-controlling interest"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestPeriodIncreaseDecrease": {
     "auth_ref": [
      "r459"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net Increase or Decrease in balance of noncontrolling interest in the subsidiary during the reporting period.",
        "label": "Noncontrolling Interest, Period Increase (Decrease)",
        "terseLabel": "Non-controlling interest"
       }
      }
     },
     "localname": "MinorityInterestPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MunicipalBondsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-term debt securities issued by state, city or local governments or the agencies operated by state, city or local governments.",
        "label": "Municipal Bonds [Member]",
        "terseLabel": "Municipal bonds"
       }
      }
     },
     "localname": "MunicipalBondsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails",
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r113"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash used in financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r113"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r113",
      "r116",
      "r119"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by (used in) operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r17",
      "r79",
      "r82",
      "r87",
      "r90",
      "r119",
      "r128",
      "r136",
      "r138",
      "r139",
      "r140",
      "r141",
      "r144",
      "r145",
      "r150",
      "r180",
      "r186",
      "r190",
      "r193",
      "r196",
      "r226",
      "r278",
      "r279",
      "r280",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r477",
      "r495",
      "r547",
      "r573"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net income (loss) attributable to Myriad Genetics, Inc. stockholders",
        "totalLabel": "Net income (loss) attributable to Myriad Genetics, Inc. stockholders",
        "verboseLabel": "Net income (loss)"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss",
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.myriad.com/role/SegmentandRelatedInformationTotalOperatingLossforReportableSegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r79",
      "r82",
      "r87",
      "r144",
      "r145",
      "r465",
      "r472"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss attributable to non-controlling interest"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.myriad.com/role/SegmentandRelatedInformationTotalOperatingLossforReportableSegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/BasisofPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NewJerseyDivisionOfTaxationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government of the state of New Jersey.",
        "label": "New Jersey Division of Taxation [Member]",
        "terseLabel": "New Jersey"
       }
      }
     },
     "localname": "NewJerseyDivisionOfTaxationMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Countries excluding the United States of America (US).",
        "label": "Non-US [Member]",
        "terseLabel": "RoW"
       }
      }
     },
     "localname": "NonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/RevenueTotalRevenuebyProductandbyUSversusRestofWorldDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r133",
      "r134",
      "r135",
      "r349",
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Non-controlling interest"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r98"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income (expense), net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income (expense):"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable segments"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/SegmentandRelatedInformationNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingCostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Costs and Expenses [Abstract]",
        "terseLabel": "Costs and expenses:"
       }
      }
     },
     "localname": "OperatingCostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r180",
      "r186",
      "r190",
      "r193",
      "r196"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.myriad.com/role/SegmentandRelatedInformationTotalOperatingLossforReportableSegmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "terseLabel": "Segment operating income (loss)",
        "totalLabel": "Operating loss",
        "verboseLabel": "Total operating loss for reportable segments"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.myriad.com/role/SegmentandRelatedInformationSegmentRevenueandOperatingIncomeLossDetails",
      "http://www.myriad.com/role/SegmentandRelatedInformationTotalOperatingLossforReportableSegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r510"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current maturities of operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r510"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Noncurrent operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r509"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "auth_ref": [
      "r118"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for right-of-use asset from operating lease.",
        "label": "Operating Lease, Right-of-Use Asset, Amortization Expense",
        "terseLabel": "Non-cash lease expense"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r19",
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/BasisofPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r28",
      "r29",
      "r30",
      "r60"
     ],
     "calculation": {
      "http://www.myriad.com/role/AccruedLiabilitiesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other accrued liabilities"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/AccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Change in foreign currency translation adjustment, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r80",
      "r83",
      "r460",
      "r461",
      "r467"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Other comprehensive income (loss), net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r74",
      "r76"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Unrealized gain (loss) on available-for-sale debt securities, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Liabilities Disclosure [Abstract]",
        "terseLabel": "Other Liabilities Disclosure [Abstract]"
       }
      }
     },
     "localname": "OtherLiabilitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for other liabilities.",
        "label": "Other Liabilities Disclosure [Text Block]",
        "terseLabel": "Other Long-Term Liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/OtherLongTermLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.myriad.com/role/OtherLongTermLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities",
        "totalLabel": "Total other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.myriad.com/role/OtherLongTermLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncurrentLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of other noncurrent liabilities.",
        "label": "Other Noncurrent Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Other Long-Term Liabilities"
       }
      }
     },
     "localname": "OtherNoncurrentLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/OtherLongTermLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r99"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      },
      "http://www.myriad.com/role/DivestituresOtherIncomeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.myriad.com/role/SegmentandRelatedInformationTotalOperatingLossforReportableSegmentsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other",
        "totalLabel": "Total Other Income"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.myriad.com/role/DivestituresOtherIncomeDetails",
      "http://www.myriad.com/role/SegmentandRelatedInformationTotalOperatingLossforReportableSegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherSundryLiabilitiesNoncurrent": {
     "auth_ref": [
      "r37",
      "r540",
      "r564"
     ],
     "calculation": {
      "http://www.myriad.com/role/OtherLongTermLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherLiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are expected to be paid after one year (or the normal operating cycle, if longer), from the balance sheet date.",
        "label": "Other Sundry Liabilities, Noncurrent",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherSundryLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/OtherLongTermLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]",
        "terseLabel": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": {
     "auth_ref": [
      "r110"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.",
        "label": "Payment for Contingent Consideration Liability, Financing Activities",
        "negatedLabel": "Payment of contingent consideration recognized at acquisition"
       }
      }
     },
     "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "auth_ref": [
      "r109"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.",
        "label": "Payments of Debt Issuance Costs",
        "negatedTerseLabel": "Fees associated with refinancing of revolving credit facility"
       }
      }
     },
     "localname": "PaymentsOfDebtIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r107"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-based Payment Arrangement",
        "negatedTerseLabel": "Payment of tax withheld for common stock issued under stock-based compensation plans"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r100",
      "r104",
      "r209"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-sale",
        "negatedLabel": "Purchases of marketable investment securities"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireProductiveAssets": {
     "auth_ref": [
      "r105",
      "r455",
      "r456",
      "r457"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.",
        "label": "Payments to Acquire Productive Assets",
        "negatedLabel": "Capital expenditures"
       }
      }
     },
     "localname": "PaymentsToAcquireProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r392",
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r38",
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/PreferredandCommonStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r38"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock authorized (shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/PreferredandCommonStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r38"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock outstanding (shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/PreferredandCommonStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r25",
      "r47",
      "r48"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidTaxes": {
     "auth_ref": [
      "r24",
      "r26",
      "r232",
      "r233"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Taxes",
        "terseLabel": "Prepaid taxes"
       }
      }
     },
     "localname": "PrepaidTaxes",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.",
        "label": "Reclassification, Comparability Adjustment [Policy Text Block]",
        "terseLabel": "Reclassifications"
       }
      }
     },
     "localname": "PriorPeriodReclassificationAdjustmentDescription",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/BasisofPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries": {
     "auth_ref": [
      "r101"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the deconsolidation of a previously consolidated subsidiary or the sale of investment in consolidated subsidiaries (generally greater than 50 percent).",
        "label": "Proceeds from Divestiture of Interest in Consolidated Subsidiaries",
        "verboseLabel": "Proceeds from sale of business"
       }
      }
     },
     "localname": "ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/DivestituresNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIncomeTaxRefunds": {
     "auth_ref": [
      "r116",
      "r121"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash received during the period as refunds for the overpayment of taxes.",
        "label": "Proceeds from Income Tax Refunds",
        "terseLabel": "Cash received for income tax receivables"
       }
      }
     },
     "localname": "ProceedsFromIncomeTaxRefunds",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/SupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "auth_ref": [
      "r106",
      "r417"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.",
        "label": "Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised",
        "terseLabel": "Proceeds from common stock issued under stock-based compensation plans"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "terseLabel": "Proceeds from maturities and sales of marketable investment securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfProductiveAssets": {
     "auth_ref": [
      "r102"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.",
        "label": "Proceeds from Sale of Productive Assets",
        "terseLabel": "Proceeds from sale of assets"
       }
      }
     },
     "localname": "ProceedsFromSaleOfProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/DivestituresNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets": {
     "auth_ref": [
      "r103"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate cash proceeds received from a combination of transactions in which noncurrent assets are sold, which may include the sale of a business, an investment in an affiliate (including an equity method investee), property, plant and equipment and intangible assets. Excludes sales of trading, available-for-sale, and held-to-maturity securities.",
        "label": "Proceeds from Sales of Business, Affiliate and Productive Assets",
        "terseLabel": "Proceeds from sale of businesses and assets"
       }
      }
     },
     "localname": "ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r17",
      "r79",
      "r82",
      "r87",
      "r112",
      "r128",
      "r136",
      "r144",
      "r145",
      "r180",
      "r186",
      "r190",
      "r193",
      "r196",
      "r226",
      "r278",
      "r279",
      "r280",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r460",
      "r464",
      "r466",
      "r472",
      "r473",
      "r477",
      "r495",
      "r552"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Net income (loss)"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.myriad.com/role/SegmentandRelatedInformationTotalOperatingLossforReportableSegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]",
        "terseLabel": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r52",
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/PropertyPlantandEquipmentNetBalancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r266",
      "r612",
      "r613",
      "r614"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property, Plant and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/PropertyPlantandEquipmentNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r51",
      "r257"
     ],
     "calculation": {
      "http://www.myriad.com/role/PropertyPlantandEquipmentNetBalancesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property, plant and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/PropertyPlantandEquipmentNetBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/PropertyPlantandEquipmentNetBalancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r32",
      "r33",
      "r259",
      "r516",
      "r560",
      "r570"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.myriad.com/role/PropertyPlantandEquipmentNetBalancesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property, plant, and equipment, net",
        "totalLabel": "Property, plant and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.myriad.com/role/PropertyPlantandEquipmentNetBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r32",
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property, Plant and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/PropertyPlantandEquipmentNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r32",
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/PropertyPlantandEquipmentNetBalancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RecordedUnconditionalPurchaseObligation": {
     "auth_ref": [
      "r272"
     ],
     "calculation": {
      "http://www.myriad.com/role/AccruedLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the recorded obligation to transfer funds in the future for fixed or minimum amounts or quantities of goods or services at fixed or minimum prices (for example, as in take-or-pay contracts or throughput contracts).",
        "label": "Recorded Unconditional Purchase Obligation",
        "terseLabel": "Purchase commitment"
       }
      }
     },
     "localname": "RecordedUnconditionalPurchaseObligation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/AccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfLinesOfCredit": {
     "auth_ref": [
      "r108",
      "r127"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.",
        "label": "Repayments of Lines of Credit",
        "negatedLabel": "Repayment of revolving credit facility",
        "terseLabel": "Principal repayment"
       }
      }
     },
     "localname": "RepaymentsOfLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.myriad.com/role/LongTermDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r426",
      "r531",
      "r626"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails",
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "RSUs"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.myriad.com/role/StockBasedCompensationRSUActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r42",
      "r349",
      "r421",
      "r516",
      "r567",
      "r588",
      "r590"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r133",
      "r134",
      "r135",
      "r137",
      "r143",
      "r145",
      "r227",
      "r418",
      "r419",
      "r420",
      "r441",
      "r442",
      "r475",
      "r585",
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]",
        "terseLabel": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r171",
      "r172",
      "r185",
      "r191",
      "r192",
      "r198",
      "r199",
      "r202",
      "r362",
      "r363",
      "r532"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Total revenue",
        "verboseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.myriad.com/role/RevenueTotalRevenuebyProductandbyUSversusRestofWorldDetails",
      "http://www.myriad.com/role/SegmentandRelatedInformationSegmentRevenueandOperatingIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerMember": {
     "auth_ref": [
      "r164",
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue from Contract with Customer Benchmark [Member]",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r365",
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/Revenue"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]",
        "terseLabel": "Revolving credit facility"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/LongTermDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r511",
      "r512"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/SupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/AccruedLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r154"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Potential Dilutive Common Shares"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/PreferredandCommonStockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Schedule of Available-for-sale Securities [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails",
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.",
        "label": "Schedule of Available-for-sale Securities Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Fair Value for Available-for-Sale Securities by Major Security Type and Class of Security"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": {
     "auth_ref": [
      "r215",
      "r219",
      "r221",
      "r222",
      "r223",
      "r224",
      "r554",
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.",
        "label": "Schedule of Available-for-sale Securities [Table]",
        "terseLabel": "Schedule of Available-for-sale Securities [Table]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails",
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented.",
        "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]",
        "terseLabel": "Schedule of Supplemental Cash Flow Information"
       }
      }
     },
     "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/SupplementalCashFlowInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in common stock outstanding.",
        "label": "Schedule of Common Stock Outstanding Roll Forward [Table Text Block]",
        "terseLabel": "Summary of Common Shares Issued and Outstanding"
       }
      }
     },
     "localname": "ScheduleOfCommonStockOutstandingRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/PreferredandCommonStockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": {
     "auth_ref": [
      "r4",
      "r6",
      "r7",
      "r8",
      "r9",
      "r10",
      "r11",
      "r13",
      "r15",
      "r16",
      "r17",
      "r264",
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]",
        "terseLabel": "Schedule of Amounts Recognized in Other Income"
       }
      }
     },
     "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/DivestituresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r390",
      "r413",
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r390",
      "r413",
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r243",
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of Amortizable Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfGoodwillTable": {
     "auth_ref": [
      "r239",
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.",
        "label": "Schedule of Goodwill [Table]",
        "terseLabel": "Schedule of Goodwill [Table]"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsCarryingAmountofGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r239",
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "terseLabel": "Schedule of Changes in Carrying Amount of Goodwill"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r250",
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.",
        "label": "Schedule of Indefinite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of Non-amortizable Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r52",
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/PropertyPlantandEquipmentNetBalancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "auth_ref": [
      "r180",
      "r183",
      "r189",
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/SegmentandRelatedInformationSegmentRevenueandOperatingIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "auth_ref": [
      "r180",
      "r183",
      "r189",
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "terseLabel": "Schedule of Segment Revenue and Operating Income (Loss)"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/SegmentandRelatedInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r392",
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.myriad.com/role/StockBasedCompensationRSUActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "verboseLabel": "Schedule of Restricted Stock Unit Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r397",
      "r409",
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "verboseLabel": "Schedule of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r67",
      "r125",
      "r160",
      "r161",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r331",
      "r335",
      "r340",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/PreferredandCommonStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock": {
     "auth_ref": [
      "r155"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).",
        "label": "Schedule of Weighted Average Number of Shares [Table Text Block]",
        "terseLabel": "Reconciliation of Denominators of Basic and Diluted Earnings Per Share Computations"
       }
      }
     },
     "localname": "ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/PreferredandCommonStockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentDomain": {
     "auth_ref": [
      "r167",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r185",
      "r186",
      "r187",
      "r188",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r196",
      "r202",
      "r268",
      "r269",
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Segments [Domain]",
        "terseLabel": "Segments [Domain]"
       }
      }
     },
     "localname": "SegmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsCarryingAmountofGoodwillDetails",
      "http://www.myriad.com/role/SegmentandRelatedInformationSegmentRevenueandOperatingIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]",
        "terseLabel": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r167",
      "r169",
      "r170",
      "r180",
      "r184",
      "r190",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r201",
      "r202",
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "Segment and Related Information"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/SegmentandRelatedInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting Information [Line Items]",
        "terseLabel": "Segment Reporting Information [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/SegmentandRelatedInformationSegmentRevenueandOperatingIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general, and administrative expense"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "Selling, general, and administrative expense"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r117"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Service period for award vesting (in years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "RSUs canceled (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationRSUActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "RSUs canceled (dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationRSUActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "RSUs granted (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationRSUActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "RSUs granted (dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationRSUActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "RSUs outstanding, ending (shares)",
        "periodStartLabel": "RSUs outstanding, beginning (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationRSUActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "RSUs, Number of shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationRSUActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "RSUs outstanding, ending (dollars per share)",
        "periodStartLabel": "RSUs outstanding, beginning (dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationRSUActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "RSUs, Weighted average grant date fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationRSUActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "RSUs vested (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationRSUActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "RSUs vested (dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationRSUActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-Based Compensation [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.myriad.com/role/StockBasedCompensationRSUActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee": {
     "auth_ref": [
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The highest quantity of shares an employee can purchase under the plan per period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Shares Per Employee",
        "terseLabel": "Maximum number of shares per participant per offering period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Number of additional shares authorized"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Number of shares authorized"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Shares available for grant"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Options exercisable at end of period (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Options exercisable at end of period (dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedLabel": "Options canceled or expired (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Options canceled or expired (dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "auth_ref": [
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures",
        "terseLabel": "Options granted (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r399",
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Options outstanding, ending (shares)",
        "periodStartLabel": "Options outstanding, beginning (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Options, Number of shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Options outstanding, ending (dollars per share)",
        "periodStartLabel": "Options outstanding, beginning (dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Options, Weighted average exercise price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r389",
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.myriad.com/role/StockBasedCompensationRSUActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Options exercised (dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Options granted (dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareRepurchaseProgramAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by share repurchase program.",
        "label": "Share Repurchase Program [Axis]",
        "terseLabel": "Share Repurchase Program [Axis]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/PreferredandCommonStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareRepurchaseProgramDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the share repurchase program.",
        "label": "Share Repurchase Program [Domain]",
        "terseLabel": "Share Repurchase Program [Domain]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/PreferredandCommonStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Award expiration period (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "auth_ref": [
      "r5",
      "r167",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r185",
      "r186",
      "r187",
      "r188",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r196",
      "r202",
      "r239",
      "r263",
      "r268",
      "r269",
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business segments.",
        "label": "Segments [Axis]",
        "terseLabel": "Segments [Axis]"
       }
      }
     },
     "localname": "StatementBusinessSegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsCarryingAmountofGoodwillDetails",
      "http://www.myriad.com/role/SegmentandRelatedInformationSegmentRevenueandOperatingIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r69",
      "r85",
      "r86",
      "r87",
      "r133",
      "r134",
      "r135",
      "r137",
      "r143",
      "r145",
      "r159",
      "r227",
      "r342",
      "r349",
      "r418",
      "r419",
      "r420",
      "r441",
      "r442",
      "r475",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r585",
      "r586",
      "r587",
      "r634"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r133",
      "r134",
      "r135",
      "r159",
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r38",
      "r39",
      "r342",
      "r349",
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Options exercised (shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r38",
      "r39",
      "r349",
      "r391",
      "r410"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Issuance of common stock under stock-based compensation plans, net of shares exchanged for withholding tax"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Authorized Amount",
        "terseLabel": "Share repurchase program, authorized amount"
       }
      }
     },
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/PreferredandCommonStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount remaining of a stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount",
        "terseLabel": "Share repurchase program, remaining repurchase authorization"
       }
      }
     },
     "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/PreferredandCommonStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares": {
     "auth_ref": [
      "r38",
      "r39",
      "r342",
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased and retired during the period.",
        "label": "Stock Repurchased and Retired During Period, Shares",
        "terseLabel": "Shares repurchased"
       }
      }
     },
     "localname": "StockRepurchasedAndRetiredDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/PreferredandCommonStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r39",
      "r44",
      "r45",
      "r128",
      "r207",
      "r226",
      "r495",
      "r516"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total Myriad Genetics, Inc. stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r0",
      "r1",
      "r86",
      "r128",
      "r133",
      "r134",
      "r135",
      "r137",
      "r143",
      "r226",
      "r227",
      "r349",
      "r418",
      "r419",
      "r420",
      "r441",
      "r442",
      "r458",
      "r459",
      "r471",
      "r475",
      "r495",
      "r497",
      "r498",
      "r502",
      "r586",
      "r587",
      "r634"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r126",
      "r327",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r341",
      "r349",
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Preferred and Common Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/PreferredandCommonStockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]",
        "terseLabel": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r517",
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowElementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Elements [Abstract]",
        "terseLabel": "Supplemental Cash Flow Elements [Abstract]"
       }
      }
     },
     "localname": "SupplementalCashFlowElementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SwissFederalTaxAdministrationFTAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government of Switzerland.",
        "label": "Swiss Federal Tax Administration (FTA) [Member]",
        "terseLabel": "Switzerland"
       }
      }
     },
     "localname": "SwissFederalTaxAdministrationFTAMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxPeriodAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about the period subject to enacted tax laws.",
        "label": "Tax Period [Axis]",
        "terseLabel": "Tax Period [Axis]"
       }
      }
     },
     "localname": "TaxPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxPeriodDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identified tax period.",
        "label": "Tax Period [Domain]",
        "terseLabel": "Tax Period [Domain]"
       }
      }
     },
     "localname": "TaxPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxesPayableCurrent": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://www.myriad.com/role/AccruedLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Taxes Payable, Current",
        "terseLabel": "Accrued taxes payable"
       }
      }
     },
     "localname": "TaxesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/AccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TrademarksMember": {
     "auth_ref": [
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style.",
        "label": "Trademarks [Member]",
        "terseLabel": "Trademarks"
       }
      }
     },
     "localname": "TrademarksMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails",
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "auth_ref": [
      "r131",
      "r375",
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).",
        "label": "US Government Agencies Debt Securities [Member]",
        "terseLabel": "US government securities"
       }
      }
     },
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails",
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasuryAndGovernmentMember": {
     "auth_ref": [
      "r375",
      "r553",
      "r591"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes investments in debt securities issued by the United States Department of the Treasury, US Government Agencies and US Government-sponsored Enterprises. Such securities may include treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years), debt securities issued by the Government National Mortgage Association (Ginnie Mae) and debt securities issued by the Federal National Mortgage Association (Fannie Mae) or the Federal Home Loan Mortgage Corporation (Freddie Mac).",
        "label": "US Treasury and Government [Member]",
        "terseLabel": "Federal agency issues"
       }
      }
     },
     "localname": "USTreasuryAndGovernmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails",
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r427",
      "r435"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "terseLabel": "Unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/LongTermDebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/LongTermDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "auth_ref": [
      "r153"
     ],
     "calculation": {
      "http://www.myriad.com/role/PreferredandCommonStockholdersEquityReconciliationofDenominatorsofBasicandDilutedEarningsPerShareComputationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.",
        "label": "Weighted Average Number Diluted Shares Outstanding Adjustment",
        "terseLabel": "Effect of dilutive shares"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/PreferredandCommonStockholdersEquityReconciliationofDenominatorsofBasicandDilutedEarningsPerShareComputationsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r148",
      "r153"
     ],
     "calculation": {
      "http://www.myriad.com/role/PreferredandCommonStockholdersEquityReconciliationofDenominatorsofBasicandDilutedEarningsPerShareComputationsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted (shares)",
        "totalLabel": "Weighted-average shares outstanding and dilutive securities used to compute diluted EPS"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.myriad.com/role/PreferredandCommonStockholdersEquityReconciliationofDenominatorsofBasicandDilutedEarningsPerShareComputationsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r147",
      "r153"
     ],
     "calculation": {
      "http://www.myriad.com/role/PreferredandCommonStockholdersEquityReconciliationofDenominatorsofBasicandDilutedEarningsPerShareComputationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic (shares)",
        "verboseLabel": "Weighted-average shares outstanding used to compute basic EPS"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.myriad.com/role/PreferredandCommonStockholdersEquityReconciliationofDenominatorsofBasicandDilutedEarningsPerShareComputationsDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 6
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3151-108585"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "230",
   "URI": "http://asc.fasb.org/topic&trid=2134446"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=124437754&loc=d3e777-108305"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8657-108599"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/subtopic&trid=2122178"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8844-108599"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8981-108599"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=124429488&loc=d3e326-107755"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "http://asc.fasb.org/topic&trid=2134510"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27337-111563"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27340-111563"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27357-111563"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4542-108314"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4578-108314"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=123353750&loc=SL49131252-203054"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b),(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2510-110228"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2443-110228"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6787-107765"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25383-109308"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=116646759&loc=d3e15243-108350"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130558-203045"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130550-203045"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)-(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=124434304&loc=d3e36027-109320"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5333-128473"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "b",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e7008-128479"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123385561&loc=d3e9135-128495"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123362884&loc=d3e9212-128498"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123362884&loc=d3e9215-128498"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568447-111683"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568740-111683"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL7498348-110258"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=123371682&loc=d3e55415-109406"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "http://asc.fasb.org/subtopic&trid=2176304"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(24))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62586-112803"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(c)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/subtopic&trid=2209399"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.1,2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(20))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.2)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "http://asc.fasb.org/subtopic&trid=2324412"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20,24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r627": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r628": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r629": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r630": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r631": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r632": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1403"
  },
  "r633": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(22))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>89
<FILENAME>0000899923-21-000090-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000899923-21-000090-xbrl.zip
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M@ W)J%&%+["8R)DJ2\J_X"]*L#&\[<P[%YOTN3D#9O?<?;T=2Q,UW60XFY/
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M7-^[-+ >G1.,AL%%0#$J-9!\[?%%P@T88A5'O/K7)FHWZ%(IU%1B;&]3I'#
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M'3E9<=2PVR7PGZ;1V6%:9F \/$4($2+PH546G367\(V^'$I<C=A'V(R03JS
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ML<9E+9ON-36V;^)NH)*B,E5]O.<!]A\1."F]SW:]JBBYK"HS57#T*ECVC-(
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M;>Q\NI&[O0+!KYB,J)CEC2TO0/AO"O",C&\_52PAHK:I?#9I\ .>-)>'[_(
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MU5=+&"S)9"9Y'!968H9+G;2IA)*'@I=WH$;\PTF5K^&?>;,HOOT_4$L#!!0
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MD93)=1R7AJ*^DC;7]&7:.CRA<TAHL3%45 <X;&]#. %DP5CWY"HSL3^2_HR
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M'F;U_%D/M.E_U[X;>"0<_P0\543KDW$!O] Q*IL[Y#MQL?^Z9[?<^EUYSJ
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MPDI^5NLY;?O[T[8;Y#12;'9VRL2$"/:V(?K=Z) -.@=)-XS[1ZQ[?!1&['C
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ML]7OU0<?]+L<".UO<!>PJQ\U!*5D@S>@F65&!+ AHG=&1B1&*QB99H?2O'I
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MR$"J:/* ,I4FS2HW'OW96[)L2X@8)2:=H3@;(JEJT[)*4N;4I'TB&H_^/ I
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MH<QS,#P&P$!MZ4Z<P$>!1-(8T>NM'4%$8RTT*C-59EHZ,PGJ2!F_0Q-BL/F
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M'=K' +-.!V^0>HX&.%,ET<);<"7;0F0A.L=Y<M9M[0AF'MXYI.H Z\< ,NB
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MM%R)I)4(7I0."4W-[*MH;>,)NVQCO^+VP;B=.6$9,UY9+H&:?,PB,V7B33+
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M\-CSP],]<OC3'C]X_D8<_G3P\>CX5_$J/W-^[N[!QY .Y@O_4#H?6: @4Z*
M24_R."1H:SPF3ISVM#05FH]V+EJ0O"!>EMZ9X$O:OOMHATI[&TE[20J>-)I\
M(8,I>*V-D$X:SQ4W(8G;:2\-AJ=VG"]Q/OZN?W8*83#Q@)>_J)S8!DZ<F]S%
M>4@R(1!T"5 2 H9Q#\E$)Y&F&%S:VJ'?$BT::-10>;'R8MMX<9%,$),"<\D3
M'J+!Z- RGA(2RT(*,D5U.S'>D@!22? I2' V#RY&9U&$ ";H,N]KTNA:.# D
M!(DA.*8R"8IM_I"&5)7[*O>M,O=)Q85G2B<A/0:6K5_KK"3HA4U,I*_8PI7[
M6L1]LWER CUCR2/0Q!E@) H<S=\Q0CA5@J94NG3QRGV5^]:+^Q:@OJ!3-!8U
M2QR1:>ZTT0QU_LF+X#!4-V";&4_,MA')(C*3^8<Q\#+=-6M[04B@(AE,4FM-
M?7$#;IJYN\1DC4JEE4HO(RK2:(&<(&:3"Z5Q5F<EP]F8*=4(ZJMK<65Y]OS3
M(,;C-^>')[_^65HW"$5<5BB] '1(P(G\H]#64B$I&D(FOD6E;E O6TJV"\?,
MT^1_JQ0SWQ^-SFS?3W+._21'K#-)*NA,$MBGWX.S)3^Z) #%_F@ZU28? /W/
MHV=';VU&42>>^\E,G%  W/FK.W[[=CHDZMX3;RX7=&4:8]UMT2>I&NS[!7?]
MHFNQ;!5C9K/?JP?Z>LIW@3.2>RTHY]SG=R(S:% 8)JE.CD04BLW6&_([V1T%
MU3%<G[_VN^V=Q9<%IC\4,#^[AN5Z]BUR]G7GPFI*16L$2:"=Y,6KHL$8X4'0
M$((,07DB;YY?5 E@30F@$GR5;Y5OE>]JR'<9J=6;MV<6Z@PFO;<$O64.LXY@
MT 53,G"LH(S[N2835>E[<J5OSN&192(9BP:"3 PP:_!@;/Y.T,0=C]YJP5=*
MZ]N  H&7U[P9[^U%*>_NQ/."B7B_>;SS*]!ZKB+W/]]N%G@KPAAK*:6G="-\
M'I$V.AY\KIC\Q7;#?O_9M$QR<K*XV9/E12D^&G7'\64<?NCZ.#V*7D0_>-.?
M7&5R*M7S9Y'S9[Y/I<Q'C+**E30V#:B- 9N\ 18BU3PRHZ/:VE&+SH&OH']J
MT%=JKE*J4JI2:H6EOK*2?TICO*I.[5*=YDQWXF- 8QEX@6':+M(DB4"T$$I8
MABW4G38@%6'A[A%W\#&N%',]W/7<1N]RE5*54I52E5*5TDI+:9'RL6@,9Q1]
MH$&C(-8R1H4FAKO@+''R#BKU+75D!]W^8#C)\9WJ!E,->;_OAS$KT\_C]-^J
M(2^@(1\^FZN:8%)ZA5DC%M)90&X,."(8J,23MUPHS^/-51-WKQ-K,7Z?*!Z^
MWIS0@)E=.>$1.6'.:@Z.1T(-0M*R6,TV@5'((3(6B6'<*&=;1 H;$,X^C./.
M5WMPKIMK[P'J8HN=NE5*54I52E5*C:A96A,M-8^.)H,VHF5>R"2$]LPC!G)_
M-2N?-M.I53_G(Z=J4XMH4_.=.)BT.A%-P6E,@"IHT(XKD)QSZ81F,;BM'4K%
M(A.K*E KG=9X<^LI>GF6<*7H!U#T?(9WDI1[G4 0JP I$6"<E1"(8UY[E#KZ
M5G'T!L2(7T3?LZ-1-^7[F>!L<#8I0+>?9S%T)B,K.E^,JYB8R9VS]_D-^<4"
MID^SOB87R1?HC,[<J!NZ=GBQ,0'G!R1)M=A]NVY2JD&RE9'2(EH :I5T5O5U
M4N@8&B]TRK]@D6)BZ>X9^Z<7^:%G>?''X>#TVGR:HT*)7PP@+AK"\R]I\"B]
M_$2!57E81'GHSG6958Y1*Z,#Z:4%%"J!\5Z ,!29%H*F$!KI.U817GFX2FGM
MI51#TBVNPJXG< M.X!OBU=$F[QQPI_(1+%,$)_-AS&5(EK @@\2V'<$;$+0^
MNL4Z_]1+[KZMXE;1=[B>54KK)J7U].VOI906\L,_W *_Q0\_?]A_=LL?QO%1
M.K;G-S:G_<4.8[\VHUWHZ+^8,[Y)\HD)=)"PG/R!EV$O,@"A+G(,7A!KMG;8
MMFR'V[X"N])OE5([I50#X"L5 *\'[Z,>O/,VMR<^$F7 .\, ':6@+8D0N9?.
M21J$Q1:=O!L0,+\^$_U@]\6S_[D<B,Y(8PWHUGEVQV+/WFJ&7H"@%9J8!/$\
M*H999;;4,\YM)"9Z9H@M@SONW):RSN9X3%8^>C8W"CW+D1E/%;C,SM.QOQ8Y
M 683,3)+4:%N9!3Z0F!YXLC*O1]BPPEO;3E/<ZV)<J1P'Z+P3GDDWJ@HM<#+
M.>@W<UX=5M1R0ISKG2A=\DDY*#8&8-02C$P>* 86:4I>$3V95638MEZ5]KV5
M%RLO+L5:MY(8):W3UGF4/#IO8@A$:NVC#1QO)\8Z"[A%)#CK)*="*:N0 -%*
M U(GP DC0":C"&-)88JE"=H\ 2Y<SEVYKW)?>YY[(>ZC'K,=' 0F@4QI0REG
M+@6C>2PCLROWK03WS59?4A244NF!6Y2 )'\Q(BN T7'O)5-2>%LJ>_0-+2 K
M^U7V6V'V6Z2+%W.*9C $SA,FKFS6"71"X8BWGJ*^FT6<NN<QP,<X'%0N; ,7
MSO;Z<HYQ8H2&X"(%3 E!<PP08V0QOR*=3)\"NQMF#"\C#%QIMM+LE\$6ZI(S
MUGAG'9*(CL6H6>+>!,P =#78TF8ZG0N!>\])%&C!4>D F2"0K04$X:2Q@B@?
MG-C:,5+5R6 MPFO+QZ O.O!^-7*&'I0MUAH=HL&$OS63[P*'8#[T$DW!!VNS
M2<Y3_NH=6A.9,,BTNTP)PZN4,,E)G8CYE"??R[FH&A7,\HQDD-Z6_J!,@=6.
M@@M)"5D<9UB<*MNFH:D:E0!:3P"5X*M\JWRK?%=#OD^4Z[]F>V8!I4]2B3PF
MGD)(R)2S3NK$,3&M4PHN5J6O=4K?G+N#>8)4)0G.:YZU/HU@M"?@B0_:!*.2
MPI72^C:@)J#I,>BKV"RDMKY;&2D]I1NASO)LT?ES<+P[GG.W!\]1ZM*?E9OB
M=>"@%2&0#&.H*$F4RD;.GXKZRLU52E5*54HMD%)MA]>\[M2X-5YUI[;I3L<'
MDX!-UI_R>KPB?WHA?.0F@9:,  IA0&NEP 3OC;5<\-0ZY6D#DA'J7+>UZ!U3
MI52E5*54I=1()1)3W!AI$Z&&(Q?HC.;"2^$"*N/,7;2S.C2H<9UJ;WPXXX_*
M2E00U&I01 7 +"]PU#D(R@8KF++"TJT=(;:Q'2V0*E WD4YK6[LE4'0#!G2E
MZ"50])S9RQ*5,=H P3,!R!#!.B)!9UM812$P.=TFCMZ D/1-7>&[DRW_X+[P
M*^N[6SNO[;I):3U'S:REE!8I>TXL*")\HE%C"-'YQ%#E0T%9[K0A"_O!:U/:
MQSSO]\>'+[\TR8P*/B@J05GO :-48!+S((7FC!G"K70W-Z6MH&XUJ"OU5BG5
MX'-[)?^4P>=ZZ#[NH3MG9#N%E&<[&SP:"V@Y@C-<@2!1,I^\")*T[=3=@-CR
M]7[P__GM<*_#R8+MX/\N$7^=FY0L]NSK0LXAZ(SA%*QR!IE!;:WQFB>A4K+1
M^LL.)7<KSZD=2AZ7FC_1\C5[2'LN?9E-K5UF9D?!!.$AB, H$=$'(1KI![\0
M6IXX-++<*KWU9;RU);TDDE=1&"^90V:#88Q*9Z7FTLGH].VD5_O!MYX19X+V
MR=',?8J##((!*B7 4!X@RU]A(*5\Z+(AO'RXOKIBY=&5&#>!&!>)<U/G(V.2
M.X$$A="&)PR:.!*BH-2;VYFQ-D5N$PO.^LD3&AZIR"IA9!101@.:9#X,A&KO
MHB06LUXH;NA;MW!4O))?);_V//<BY*>M3Y:QR(.GB-9;R\NH82&=\)K05,EO
M1<AO1@6,/A$;B88LQ1(D1 O&: 0FC%%(C=:19Q50\1N*82K]5?I;8?I;I+^"
MSU3G@Q9668R:&9H2CY@Q$[Q60M[-**XMX5M&AD<SFB"W6CCC$C@I,QDF;\'9
M0(%'Z:DAUDP2)!OJ";]BG+B,,'#EV<JS7TY(-TI&E140ZAU&JJS)YK6B,6BN
ME ZA1EQ:S:=SP? L3.<M91"=-8"6"3"DM,H5E&2[(7%7>N,:JA_>%+[V2=N4
MIO"7"[JY_2.S'L((U]XRKS)+<I>,2ES(H"V)25\E#:FKI"%3^T<^,37^>BT8
M_8X</'_U9](ID&Q=@_). S+J02,Q$#D3(JB$04V"T715AF4\04[HFC' 0NXX
M8FSDU"%J@1ZC=<)YQ8E'5%EW4G>@@*_YY2H7+)4++F:X@'JT7$4P+DRB$ (L
ML@""$VJ%9A*)W-KAFS22=H-IX$%YXU6^5;Y5OE6^ZUX4LF9[9A'5SS-?AG C
MUS:AUL9ZH[ADRDMD241?5;\VJWZ?/63B,/_=GQB#TYY3<)BR[J>$@))A#E:A
M8H%XS2T6W6\^*;E]NM\&E)$T/4)@%1O$/*!)0XM; ZVEE![7HU#;X+;X[/EM
MSNT@K?'*2@*"20&(7H-Q@H/G5BHI4249MG;T#=V *NI;C?K*S55*54I52JTP
MV%=6\H]KDE?=J=VZTZS='IWT5$>:5:;$ 1T*,)(YB(:+&"/J8&C;E*<-2%UY
MT B!E6TXLW:MAJJ4JI2JE*J4&@F8*"*$0!*43PZI2#9%%JQG(G'%C2#W#YC4
M_M3WUZE>72M%F_JCF&:)^^!*]04%%-R"E1[!<4.Y<10-S2H5?5@A;@5JI=-5
M#'BOGN3;$=.N%/T0BIXS>[F/.F@=P9C,S$@D YT8A4BL"MX1K]&UB:,W("2]
MQ!$"*^N[6SNO[;I):3W'"ZVEE!8YQJG1@GE#I#'(/=.1)LLY"JLHE7>RM&HW
MXZ<[[_VUUDA3DTQS%_/1SB!+*Q_W-B;0Q"6@!I7T4L=06B/1QIK#55!7ZJU2
M6E\IU>#S$@[=IH//]=!]W$-WSLBFW/&4, &CF@":&,%Y%&"E3BD*:2EU;3MU
M-R"V?'V$P,N]7X[W#G[8>['X'(&_R\9?Y\8VBSW[NC"T--1C(BQQE!B)<8Y:
MS*JU4$Q:X?EE5YN[M6FH76T>EY_??-FZX63_3R<(B8190"T*/8>0C2*>][@T
MT7'E4#)?6C?,EVLW7!/8IOC(<@OVUI?QUI;TF,Q*J8_(I=1H$MI 33 2M<SD
M9Y*ZG?3J'('6,^+%EXPHJ>,D'VB@69FL8D(9+&T\9/ES@OG_5#1EC@ E].&-
MOE:L4KH2XR80XR+!;J<5388XJ9U$FK1Q)%H756)8ANZ:VYFQMM)N$PL>SNB%
MG@;G V86I&6. /H$SDD/5BA*2=+26E9*N>?-]O:5<E?RJ^2W%/(3C"OOF#3,
M$.1!.N85D8%889DV05;R6Q'RFU$!"><Z6>>!"5<BA4F#Y31!4?Y]8D;[5.8(
M:'-#1\-*?Y7^5IC^%F _XR(U4@GB#<]VD<P_B\2DQ8!1:"[N9A37.0(M(\.C
M:YI@OL<_0_ ARIC :Y\U08X43!8T)"]0<+0TFM38'($5X\1EQ((KSU:>_8)G
MB9=Y-9B*&899%XD.LVE&N6(F"2V4KA&75O/I7$1\XC.6@0+E& &=-V HS::U
M$C3_VGCARAP!8K;YJM#I9<#\ZD8N=[J<<.7-Y+< H_Y]R.@.%VGB\^I'KMQ'
M-I>9]9#'V(#"C>OY),_WGEVFD] %TTGJJ*3-')64@F9"LF!C,JAI<$9)]"D&
M+R2)>!E?I8S3JN*T3L7Y[5I2R73TG//6)4,8*(<6,'H.3ON8[4:"@6D2N*"-
M))6LV-BYRGN5][Y,IB/,.63&6)4P?]%&(S+JHD4=66"W\U[-*VD]*<X,)\Y'
MG--*"E B^&SVN00FH !NB)#>">*3G.:5F&U1B;$2X]H1XR*A59DHI=QZF]"C
M,=1*K@TA*AB3 E7I=F:LH=4VL>#AC&J8K#)1)PI9H@%01))9D'O@A.17J+"2
M\*T==H/KJPYHK^2W(>3G2<E <-8QHU GEG5!;3A#+K3@-)%*?BM"?C,J(.6:
M,"8I,.^S7>Q4 .LX!2'1JK+=@R69_)C:)I7^*OVM$_TMPGZ>":YI4(X0=$%J
MF3$2\L^)R."UO9M17/-*6D:&1S.:H"X))%0S0&JR/:P9 Y-_!DM,5O*1>9.P
ML;R2%>/$1\TKJ3R[F3S+J/=<:N&B"!A9MLH(89KG1_6"6_T5$[OR:0OX]%I>
M25Z/5^3/(DVOLW:IK)"94*D ISP#F6)I.BN,\&4$DJ8W:)<MI=,-:,101E3:
M_Y^]=VUJZUC:AO^*BONIYTVJ/.PY])R<7501G[;W$R"Q<5+.E]0<C6R0N"7A
M&/_ZMV=)PB"!@XPP2]+LU,:@PUJSIJ>OOKJGI[L74BEM&/HG)_TR %0HU%R<
MV_'ODQY]X5)KC Y"?&]X411Q6/IG##OI4SARO7?X6:1"G;^[HZ.BES@3WUPU
M<2E)AZU#R<UJ:[MY\ETDNS)'I1SHE&, ):+Q$FTB.*J2L\F/R_PQRL85AQ@5
MMS*'M?'LO5;RG8FK*$%IC#01T) )<-#$,1Z(-9I:$Q+S'ET)KNYN^"H$K H$
M5(BO\JWRK?)=#?D^4".&-5LS"]"^)*TSZ!#3F#1PB0R0:FJX0M[G/$^ITKX6
MTK[9B =-%"3SF0CN;4DF &*<$B0RY/$L26J"6"W>MP$G!5Y?BFB<NO/2%[23
M/A6M2!O3UV$]"R*OI90>,I10.^>VR@*%N<"#IRC@: .13'DT0-F34E"3N)1%
MH*!,%FB [-("[E7K*S97*54I52FM25+&>DO^(?WQRIW:QIUFO7?#O(K. >$L
M10+6 /'!9.+!2>N-1=;<.O*T 0D)^VG4.>X/AW=)%U@]J%J[UKY52E5*54I5
M2DLYD$2%HE10D91(X)GVG-,D9; @/-4BWH*=U9;6]UJX=AR/LM(X$RE2*BL4
M@5+"UN1(2?!<&YI4R)YN[8CK#I@_2$?KJJB;"*</M-F]>I)?!**7X$!7B+[?
M\H\3M]>%'&-0Q/-R"#2P1$Q*G@AOE0:E%"L=M]J#T1NP)=TT"6W2ZR^ZA#8N
M\$5Z_;=FSZ]BY(ZN9<QVW:2TGI'UM932(E:<91Y-U,QS*<'F;$ EZX%[P007
M*7^[%:^-D+^GW?\P5_A&!ZZ]M\4ULYH Q$!*J@A1%J5)2RM!STL?Y"44OJF:
M7?&W2FE]I53WGU?*?ZZ6]_M:WCF/.ZHL:;&Z4BE!P"M*;*! E$-?FZ+;;5)H
MD>G=@#WFR]7B]W9?/?G/M%0\NY]^XFM6LF2Q9V\U1"^ T!JH]\)*K9F$1)T%
M@>"L4/&D%C1"4Z_DMB=U:KV2[PK+[W?GBL2;%!/U3!)C'#I$E"?B,\,?7$DG
M(#.J\U**Q"^D+0^\1W*_!_;6%_'6%O08!&,I!,EI J:\#9)9(;SQE$.([&;0
MJQ7B6X^(,[OWW&<O@W*$VV@(R)B(BUR0P)LXH-"!TZ9"/,#=*\2OV$GI"HR;
M (R+..PV.\H-TR9!Q*L9(X5P5F9EK _&F)N1L19);A,*S@;*;;(N"4!*F"AZ
MZ^ BL5I&4A+.K$TFJ-(\2&RKVGJ[@M_&@I\"9'^<H4HPX"[XH%7@*F3G+4]>
M5?!;$?";JV1F3:!<$16=)8A]CC@/0*+G(J6$QDXU%2W4,K*#*OQ5^&O/<R^R
M5Z,\*.E]2%: S<9PKCUGQH P7IEX.Z>X5HAO&1C.5HC/HK#[ ,0ZAOZP3X8X
M-'K$T"Q<BIS&Q)96(7[%,/$^-H,KSE:<O5HA'J(+Z$\K1%/P-ELKDG,F9D:Y
M!L_KCDNK\71N(US1 ,JJ4(K4) )9!F)#X,0[(ZT+,EOEMG:,EMM\5>!T [+3
M6UXA?BGM0UJ'DG=*&FL-B5ABWM^:R7<!*VBHX,%0ZY0,H#TZYDXH1[WDW/I\
MD9,-T\PP)6@M%?J@IN_9?(7XP#EH)DD0)?O:.DT<CYI8S1.*,RJ4Y=8.%QO7
M>7F#(:!"?)5OE6^5[VK(]X&2_M=LS2RRQ>8RISYS88&#%<Y%:13U// DE=6F
MTKX6TK[9B(<(7D85%!$ C$!T$GF?*:51(((6A<G[U>)]&W Z8-D5XE>V_L?:
M57Y92RD]9"BA5CEME05Z.1=XB#YD+Y(KN1P6#1!SQ,IL"6,V2)VHT,%L[9AM
MNZ2 >]7ZBLU52E5*54IKDI2QWI)_2'^\<J>V<:>Y_FZ!BIPL)V \)9"S(2:4
M;%BC?%(\,]"I;>1I Q(2]OL]<BD_I].=).AL3(F\]2PK4Z54I52E5*54I;32
M4EJHZ!5W1IF48@8#C GG,SC*6,!'-SG"+3CU#>?)]KJ]_J!)]!US@S%%?MD+
M@X1L^FD:_ULI\D(4>6_NB 1U %(;($5T! 1WQ EN"/=96)5#4HZ6(BJL':6M
MUF13?+U!80F.=@6%[PD*<WZSY E<3HXP8W0I>*>)!?"$<AT3M]J;E%N$"ANP
MI5V;JJU%7+=*J4JI2JE*:2D\RU/M53 ZF,0!>93)/EC*!;)V+D*PW\ZS:L>>
M;Z=3O\W5Y(A @](\$JX"(Z!I(M997?(X6-8N.\AA:P>V=3OZ]50]W40TK3O.
M*^4)5X2^"T+/]U134FB3$9AC1(=72DELRA:EDB*ZJ3IFVB:(WH ]XMI2K;94
M6S$IU3VNE9'2(D;<:0C M3;,*Q R.Z:D5@*- O?*L#L8\=K8Y7N:_3=SE6*I
M L8@NE(LL712E8$8RS3A03(3(W@C5 ES0SO"W%6S*_Y6*;532G4C>:7<YVIY
MOZ_EO>9<=3 )4B8BHJ\-3&1B&/X9,A6<!FXAZ!:9W@W88;[<4NV_;_:?=02M
M'=5J1[6O C05@3HJM)'1@L_.R@@QL4B=L8[Q:7.AVU6VJ/4]OR\JOYWKJ*:9
MSQ'0%0H^(2A+2XF7#(CAP4K/;4["UHYJM:CQMSW^NH >@#!1<1!*> "MG#)1
M0W1<*094Z9M!KW94:STBSFS="VND,UP3BJY'*<%@B&-1EOK'03J7I!6IZ:BF
MU=(.$;:FLE@%Q@J,"_GKPC$K;;**\52.%=BDM<Q:.@DL@3,W(V-M*M0F%)R-
MDXM@*%H]1JA'[$/SAY0P4B 6_[0""3\;[X[3VE*H@M^F@A]XI(6&>9L!L<X9
MSSR"G;>^_&)E!;]5 ;\9"@B07)0YD6A$(L I4D E*>&! P6O.'5L:X=K=DW/
MBPI_%?XV!/X2!4EC,IEZ"5%+RP2743(67;0TN I_JP%_LP>$F5(Q6A-(3E(C
M_$$FSG)*/#K *HB40^1W/0JX8N!W'YN^%5 W 5 7P%.F&>76JY!E!!:SC91&
MJXSA6B=&H6ZMM!I&YS:\P0,#*RUAX ,!:C0Q3G&B>?;<4T^=AZT=2_DU6]XM
MC2-N0!9Z;9VV:LEAK2$1M>_*$JR@IEX["!:8+/WJM;$068*8<C0ZZ.D15SW-
M +.UA\;#FK[/ERN8?V X_K\:MS E3YQC%"T?#P2%6FR@]SX[%P*+6SN"W7T#
MK4+ JD! A?@JWRK?*M_5D&]MG?:=:9_/BAJ>:.9>(]FS/K/$C-7<1:XYU97V
MM9#V?8EXR/W#=_"7#2J"H*;TB><$?\O$L6R(Y"%$H8+3X%>+]VW *8#:.FU=
M"[RLI90>,I10VW^TR@+MS04>J#:*):F(B):5,V8&@8TE_*&H1J.D1%9;.XQ>
MD[=6U;[5:E_!N4JI2JE*J17>^LI*_B$=\DJ>VD:>9MUWX#EEH(%$FS+Z\"X1
MDT$2RD-"YN1Y$*YU[&D#4A)*)?AN4ZQB8\K?K6?)F"JE*J4JI2JE9? S*9(,
MP)-T):P%V@O(-EM)(1KI)%V8G]7ZPM].IBY7@/_ <![^LA%E0YTD#@)R*1H"
M\=P#<;JT27, E-&M'0[;:DE;(55'*Y*NU%[WZDG^(;WGBLYW0><Y5Y<FKH0L
M#BXU@4 *@CC&@7 6(S!G00;;.GC>@,WH>ZL!OXHANSO4@&]QL';=I+2>(?6U
ME-(BIYNC]LFA*R6%<T 3LTD8F_"G<NA>\7P+"UXKT;; ^%^N 3].$E Q&"8C
MFGU>PMQ<"&* :\(@HF2-SLK2NQ:BK9I=\;=*:>VE5#>>[Z/)Y=U]YVIY6V%Y
MY]SN(!T3V3@BF[Z8SC%BI-:$IARD53YFZUID>C=@;_ER#?C7SWX]?+;W\[-7
MBQ>"OYJ//WZ@V0K/&UDE?HD3TVJ 7P#? V*Y,=G3X (P)IP724;.O>'@4Q*3
M.B>W.^%3ZYQ\7U"_7$(>W:FGX2^4HK >..$VN^).*6*I2@1D<A[P/V664T)^
M>:KTP#LO=WG"KSYDQ=+%IF==$#5+,*A\W"=OP&@PH(*D%&3PX$Q.-R-JK4_?
M>K@]OPJWW@GPT@<2N  "V3-B0P1"K8Q.20$IVE*?GC/S72!W(8VKP-LB@*G
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M)!:$)6@SD1DS2:EC6SN6WKWC0=T0;*_.WV=0KNK\@^O\;.UC;G1IA$:88$!
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M/WS=^>'-_NZ;IR_Q_1_G=?Z6*QNV_@$?"ZF8(#(I'&_\2C-OW8))H\>DO/)
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M_PC=HFYAN<-+)GB0\O%80!. FU#4LA+*]?][AHM#T+$%FW_[8J7@9\9#G/G
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MR[ "TYH"D[; @^4TXC_@DS41W40=D^->2^=\!:;V 9.< 2:(AJ%<) GH]!-
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M15X=15[X %M@PL6<)8!%*ZQ\LCJ&'*B@)N@LJR*W3Y%GX_JHJ"$IS=#)CY&
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M7-VF^D^E]FU1\=FM 5;JKPICB$VF)/:%0NTS.O,6W78!7ACG*[5?02U?>&L
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M;W\MK*M \$!CTB08+0GJ*4VL20*)CE%@3J+GJM'(D3=6-WYIC)P;W//QA$E
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M,#STT,#UDRUMO:(;[S[9G)66R1)-*;KV05)BM;(D!FFLAP3<HVMOSCCC=IQ
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MQ*^>-9-S\MZ2:2['?Y6)&1\K6736E>S1P*FB3";'CY7 !#>G65]QG9*R0O+
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M>?,6\X:9(+154CHM@DJ4:^LEI]& ^.7C1T^B]N8=D<WB85^<,I85LDM,A6R
M.V)98F4UF#M.M3=U^?=)P#@S1I/.-D0GI<K,)<<4B,B<8 S"!9O!*HSO'L;S
M;K P,65&$<'*>[09(L(818OD((2S -H'76'\4&%\I<KT2G M(!D%24K.@U8.
MJ3W&$)16R5S6O*]XO4F\+E3[TAK1FC41/@"16:M2,$<2*J((3$*0X-#&IRMN
M.6I>5YS>-$YUYL(II4(HIXA0&)1 *UIGP2CU.8>*T_O Z;POCM9O8, X\<XH
M(G59"U;9$J4A99<\CR7#QO+@M-:FK_4":[W DU@G QFHU-(+5*I@O%(4B9<R
M*JS*_M(D^^CK!=X-P9Y1FUY #"!$)IPG-(2H,\0JY8F@6J=DI:7,7">KX?V7
M"ZS%3RN9W2B9<:FI%#*C)^>E"BR@ 6E#XDJ:!)Q?.DM,);.;(K/Y*(R5PLN@
M'8H*#4AF%*U%+22QWC(>+9=1()DIN6(JF54R>WQD=J4X51:>A10]S5PJ]'F%
M<,EZ=(0]Y8Q=L WZJ9:FOS-:6PA6@>5)&4.8$^48L@_(:#X1S[)Q7#HK[)6#
M5971*J,] $:[BGG&8BR+X %4DL#!9DJY%=C7J(2__+F.RF,WQ6.+P3P%2H1,
MI!0,>8Q+XCA+!#S#.<O,2"C!/,;/(+(EM\]J;?J'79M^(FZ;A_O8]'AJ\DZU
M:V9N5O\9AK^MGG[,J:?,'1SE.B5EA>2!2T%]T,JP<F34.>V<Y9_6D9X8Q?](
M\\$)>BXSS:PY;( OZPSI;?]].:PSQ);^X4?=T5_]0<!I^%HD\DW_X!!;@<V)
M>%>SG6H+V_5';Q"_/$PFZ\%_OS_:^9@.<"PUMDEN?'SS8^?C7W3SX\[GS?7W
MW>VM+_3MUMZ7C=>O?FS^^-?>QNOM;QM\,R.[_=C<_<2]B:X<Y<ZJI"JC$IF(
MX3_22I>#+GO^PK,.(-T?X/B/47*>703H&:[X?#@:=_/1W:M+5LK&;^U!)P]Z
MO<$WE(-.0T>=X63B\2UC_'H"D&Z_^2VC2'6^%IDJ\&F^/V<#7B<=#IN'XC4'
MV+H! NL D51*-:<7IV%P]DBI!CIMHTX3-PY/SQ^,X,7TP^^I.SKH^:,7W7[3
MR>:FWR?/FM!\63.9W[98YJ']^O=OW33>*]6;5VA3P7FZ*C-Y\^3KE>:K.772
M?F?-"J?RW*_I"COWNXL>BV:Z<OI2C[W90X6W7#Z[>>"+[AA?%B^C:E  \3T]
ME*S1@I-RM<XN5;7P=A.K'PZ/L+6-AEC;'QSVQ_=1._Q>+?<_?,_W(W1^6D;\
M9YU^*B[=K_>_NG+G&4P3*ZD<:O[8'>\M&$>CT];1Z+0M=>P -L]Z'%[@_L;W
MG<_O\/UO?FQ__O/+YN=WW]!VVMO^L28V7__=V]G'YWSN=3?VWWV?]P*W?_RY
MO[F^P3<^;W8W/K[CF^MK;&?_S\\;ZY'N?/Q[?^?C3O?MQS='.^M_YHW%A%=*
M6B:,-L1:8XEDS!'+C2RFF#34)R&S/B>:=;U]DG?C_%V%SG/SOP=%Y__Q1TU*
M +02S[,0KW5$XXRA>(2;S:[E_-T&LYU#;!]@/.XU#QE5>KL*O2WF&Z#2"TZ5
M)S*68+WEF5B/'!=%"(HIRQD3SU;%&94J+K]A[6S^N*,#91'@@7'7RV.7=\;=
M+6[Q;A^?DJ:^<+<?!_O%-?7C!@K7.W*V.#P/A,_NELY^MHAX,[SVVG?[_QZ,
M1F_ZL7>8(+WIO_+#/EY6:>Y*-+=X;HT:[2G3FD!V@D@'AH3,% $PX$$Z--<M
M6G%7WFEQ2;ZI=MIY.W6'>'.OC=CY5**1C5:?H[L!\MVP#9W#'J -]Q4Z/<1)
M->$>K FW2'5ORR2_G)WC-XV&J]1W!>H[HXR0-]()$VDYX6>(-$$2GVW)W:R=
M#YS)7#)*T155+;R[ O*K?FEJ)TQBCA_@8#P).M(FZ,BNJFY.KR@OA@V>;E#R
MIL=GN37$5=(IA>BM9HG3I*5&-6$CC<$QSQUEC+>IRFY1+]2@Y8UQ_F+0TEDK
M(;I,!!>:E!+LQ%&'Q.^B5247M(_\V:J]:DJ8V\?7#6YHF=\C47YO8X&'C0"V
MZ[Z-="G+I#?,:>Z$-*X@( 8N!!6:A?#_V?ONIK:6+=^OHN+.O#NORLWM''RG
MJ.(8[.&\(^& CPO^H3J"L *C8 R?_JW>DD!((@@$2+#/G<$@[=!AK=\*O0)1
MAURNW7Y83/1DH$SQR;5 F?S)D^/"[!,^L?XD@3+W>OO$LH"B42S#T\:>?.ZT
M3X%>SC^#A.UMML+V__;KIQF:KG)=ER6FI%8?0DSS[Y/JIR\7!\#6^WL_SS)T
M[%\TC@].=GX?[&W#>[_"[T=GM8NOC<F8DH,?U;.#+7CWR9_'NP!#-8"AW1\?
MF]63CXWJWL^+VJ>/S=VM G92;>O[863,2RX84F 4(VX90]K$A&(N,8H9,U[Z
MM:'GO!_#9B[7@1TQQDFE(_8\!&EX(,EH+(VVSOLT&8#R^>ONY^VO>_OO*I__
MVJSM539K6Y7M+]]W/E>W:WOO*K7MO6D6G0A.&F?7P2;=.8@7(ZRW2T[[A\0R
MS9772-F4$)@;$N4&LPA3F1..'$O8WC,^:<6B;A1?I_1^X3'S1MV0FV^][;&W
M?R>H6**GWKD$K P\>LV!1]<,WR+Z:);Q^Y#JG&,.@P%Z#)2/:[KGW65'5G19
MQV.81JN*WUQ$UU]@C\;C=B-4ZLW33OO7X+RX#.<JP[GN\(P8[HA07A&O)><X
M6>4L<4(;$@*+G-W7,W*CJOBIT^XNSXG> Q7&H8OCSY/]BX\_]R^J NP*5COY
MP@[V_CZNTNWS_8O-W]63[V=P[QF,XV+*Q=&LG51_?#VI7OS$M3U/:UNA4?NQ
M?;&_]^=)=6O[O+;W!RB;FS#GVJRX+)Z(BHR3')*5VW<;T#D]*.Y8"*.XL0YL
M^+4-IN>N!/%B<5F++IIUCV<\0#B6@%D"YF0M4(^=RUF_&BN>)'7,!^LQYU0(
M2?TM3>9*P'PZP)RL-F$5)@:V 3D7<LU/39"QU"$36& Z6&5,CO02"XB!6(Y
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M3\G-K[YWZAVND5:<.@RYI\Y6UMM]A@5:;D!?)C=2+988/1=&3P?[,$^\A/U
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M^UX8-&/ZKQ"#%F #=&'"\-M-8/2QW8'!M3[T.YW8\N=C6_3)UEM_+5.;E)5
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MHUR32'Q2DSL=K21,!>VI5UPG88A)'+;<6LN$)')RIZ^7E)TH)CLH&IL-M%.
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M,4F5EYPF$7V!G'B$G+A$SN=%SLF#=!JI=#9II)3'&3DMTM$RQ+SP/B;K-&:
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MPXA:O?<H?_+DE#S[&$2MCZ;R_&^?6!:\+HIE>-K8QDWO 65[W<_V/&_L9BO
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MXX]^%X;1[7YH-UV]52SZA\O-^#"^%Z,CX?,2EN:'I=J,_BD22^*M1SHP@*7
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MCP;SRL;AJ+K75.9NY;3?Z?;A\7DCCOKU4"P6O&GSVX<*5Q@)&&5V_$R<7*R
M'S,OQJ2R70!1/O*J>!@;O /T^48;QE:8%>^N6QWP=R>>YE*=<,]@M?).G=E.
M!Q:LGK^W*=6+8Z5? QME>M?R,RO1 OUXT-_? ;&[DZ%;<&P(=9"K@U=DZO+
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M+W;WCO@^_4ZK6U]_[O_X6J]=_-VH;OV=JA?;]- :RZ6S'*445&XG&Y"FV*)
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MBI56OPADS-4Z9J9!C=MNZX.M'OS<JC>*QS_IV]]5ZBW?Z(=1M_.07UK_%2M
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M<HZBBQ/3O'P]Z*/YM]X4YP*N#3X!%HKY^_RJ(6I<:P]WN017KJ-3,"0ZE3@
MUE-X6 X /(6!YUEDC^G5 HW6),0&8&_G_([U. =\[;8'4WO0I%;.29VE2ZN
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MSJ])3JF@1M_U8%C#C1KYNJU^V=KDVD>(*<5<C28VAF<P#:/19+TU7^XGR\Z
MY5"=*N3/AIA:)1/,7WC1A2OG;K(5!7^1IZ 84HBEGKP&5T[M!5PJSWRN4Y,_
M5'%X>"3K?;<7BK(V19V;T1J-G_"LP)$\>QX>932RF=(>Q?WSC<"R.:OFH]#5
M&<G.;'9,M,YRU8=0-,3-.#3U./D<Y4'QZ,$4\Z[]WCH=GE[5S\#W1QMPW?UN
MRX*CB[W-KXQ*H%4R(.U8S+$<&&FE*7+,:.%@77'4+UZ+EWA._%FU%S<:Y0PW
MX$>C571AGB@+-0]TSL&2*VR']D6C$B,0_+R["[B9VJA7-/P-#JE"^F'U 77@
MVHMM;^J)9< M58R81PJ[F@+5],X30H'*I*6XI=X68%T@X%M[E@V3<O(^1F#Y
M0#[ ('TWS"?[N9UUAHEGK#N_G8.^5(I%K:A&P3.,N %>"2R2(%@CR;#!20<U
MOX'B36PR;U?[MVVUBUI?N;98JYKSGV[?C:=@Z!8;$!7(V9A$U\9VZ4I[G.J#
MMW+V;+;;75_\MI>FW3G9T=-_SG4(<VMVRF0*VB!!<O'7P R87R(@%V!9DK 8
M.[:.=0@_W>S]'3MXRW*#F>3%@G659AX(=:?<\)WBT-F6)3?AG^(@+P/$'JB<
MLG%D<8V\[WKQ&+Z6^>5.!^X;&[_]T>WW_U$Z2<J]F.^X<)7!V5IBZU1WD.L-
M@^^IE-\JU1U\I&J&]S$%3/.G/]A'F0*)V3*K3UZ;T$KFIV>N?&'"_>->O%JP
MM2S8.!G%MXRZC>LZ/\WI>K8W3,\Z1'?^<A73!8N6+A)-MMJ[X*=AK L^\&UR
MXLOKY!TQ=:';1>C=_A9/8VVN+POZ2Y5EG]3<U/MV==<&+Z(ZYB0E^!A36I?J
M)(5)DKT V9@[[;:C'[9MKQ%:]J@#K[9\8Q#AG\[1_16L7.O8X6==L',Z'TRP
M8(CC3GK%H\0F6D-4M,$;04ERE6M+W3K%=7/D+9COV*I<;^ON\*VB@C^>[FU]
M_+:[_^U\%^ZU^^/C:?/+9['[_O/YP9?_M)MPG=W]#_C@QPZ=C@H^?'_ F^\_
M?,_C@N?ZT7Q_0 [A.H?[;^!SG^G!_H?OS:V/)[LGA_.JU1FEK80%0XP5\8>*
M(6<I1I(DS$R03CN>'<:+IC6L>TGB1:[Q$QU;5SRN ?26 .JPPY%H%;0.W"IC
M!;%)L(0]%9J9,BX4CP 4UP#Z.  ZTP%5:D=$"H@E[1#GU"#K(D4A!0+OQ&2H
MRP"ZK'S7=0'0&N%JA)M"."(<IS(EZSCF6#KC(XQ-B,BC(MZKA:N@U AW'PA'
MIA%.^12$#T@SRH$B^H@,MP$%RKQ2P/)AB>ZIE_U*(UQ-$6L ?6  Q1RL;(\5
M,$)N,/R?MEIR0SU7.CA244124\1'!5 V;6,[1HEQ'#F9*V@*18$BNH"4--$X
M$BB-+@/H@C7K5K9MQ;59@>OH%CT#R3BU/@Z+D96AQO#IXH]^&7EU?1>]M2X0
MO(CMJ@GCD6'%@<QADK022JM(!/8&6VINX?R;C I-K>\QH!^QUZT!Z_X!ZV+&
M*>AMH,(PB[3T#'%82>0,6+?>*"RUP#Q9^>)UT;N6_K[J;2P6.Q2[\2K/1:2Q
MY90PAS$5BE/&M16"1"X,U<0(:FMWU$J([DRS!Y>,2&"L^4 ,XL$DY)P*2!@3
MN5.,TD3G!X"OJM@^%X$S,G"F<7(@>=P%:QBQ(3/\*"0LYN(U8FN!NP^!F_:.
MF"B)5=(AJ;E"G"G0FCB UO3$689#('[-!*[6DXN(;0*5R)6+BA$*\BNM"$9Z
MD32A/A+):IM\)<1VVB:W.,5@(T;1*="3PN8$?*^0)!'SH+FQ.O["L<WCU)%?
MOZ"CG,!G>SGY'^SI$/^.[>Y93BL9I:<\LW+R"^"-<D(1*N!_#O-(C,76$2:B
M=X0S+&,=9_/X>#.GBPZ-DFKE*6*Y:04'?0'&-78H5W8#RIY<2&Q^%YW'*XN\
M'N<D-32,H8%;*8D3@@(5P4$ZK)--U,3 O;<BU2;[2D##M,EN;=3)$8=$RA6
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M_O97YT5LB&(:[K?M6-G-:=]^WVKU?;O;'_;BRG0.NQB!RN>+_/[!Z5^MYCZ
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M Y"Y@N'FO0S?;$=;&#5%"-R([Q_9WM@O<ZFN1DZ<EU65A'R7JO>7!XU95@
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M&86:C0MXM'H!E>%R9_:BVRM#\D90G:.1J].D*;S+Q3ERX$(54U#&$!7^U,D
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M.Q&IH>F)0I.*#ALBC$]><F&45BQH(I7-;15<BC4TK2(T33EPA ?U(KQ#(>J
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MM8RX<0893@5BB8,2I()[F^L!S\E)N]PW "1[@#/CJ.3?XO>SV.G'?S1@GTP
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M*@'&<_#+E '&S\P+LY!M=7<WS-UMJ[Q(-?@L CZ?9MB*9 R()TD(.&A"/!(
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M%J5[UVS O2&6O<^ZPJ[^3;K:0P".;*)7-!?FYUK,0%K?R!=GKN+L0.D[SXL
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M@8\,Y\4.JT!E3VBN!M)93A0%]/79\3!Z-J\U477-4&<@Q8HYU;"3.LVNVSK
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M9Q)SO\@$^*XW(0[P#EA0$,THK__]]YD,$[D)*ZY?KNY)M__PN9^=]N#T;BG
M:Q)5NZ<[M&JM0+!VLTVN;I.KV^3J-KFZ3:YNDZM[6+FZ7_Y'3&=OWF&1;TG/
M:W*T#BK;T#UKTG*;M-R&4-832G_[*3+U(I1#Q^1#3LMUV]V]#!LO:#E69#B]
MK?OF?@0 77=-+[HF 'BPP6%W7>NU!C=N87*[=_:*NZQG'+L4D/"M@(1AX9M$
M11=BT$6CINWZS2SU!!+EYEG<V26 'V%34XHI.:GT)B' :CP_HM E?31)DU;^
M)C:.TD%4^!7&3O-OER.ICNYY9-K67.#FPSFE_?3?)' SV%9FC+%][$!4[$&%
M*E44-4UT:+>\[V$49DD.4'TV-9W%T37L!3Y.2X6>7/AR:T4+)KL[%$(8EN6-
ME"!0-)4*HAN)[:&$[X%NE6[<X69GHF97,L"F<2WG'QH#$,CG_A0 3Y<"D-_O
M %K3[*9I=M,TNVD":$T K0F@-0&T)H#V9 &T)S6Z<C5P;*F!HJP&-O&UPPX;
MG'6V'@A1L[A!$V!K*.5!/)+'6T^#J!FE'#HJ'W*$[>2T[3YBB*TN>M"!1> Z
M_34SV9LPR\&&X,Y.ULSR;7!CC^HSM^&11;SJ#L&N^X:XG.?'9]9LF4".<;.>
M%V?$K3F@H]>^B&7BP78BYZV*$D_)T).ZX/#/3#FIF#J!N$DRA:-6$N<&8, "
MX'FW/:B<1W./N-A?-XZ(X>>[E9]/TLC[=C3,8X4FDJ5?<BM?XI$G>6GDK<\R
M./5%)_EX'G<E.$*LQ\2U1Q*?KP[ />^U^_G[=C1.3"-X_K\,A%P$FV]6OX-S
M6%22V&_DN&$_E\?ON%IX/^=6Y/.'\'@?A(J=?XL@RZO_X&(0+^''1/F2RPJ;
MB%]MPUU-Q*^)^#41OR;BMT-8U43\=O9*FHC?P47\ROK@"/7!:Z,/>H4^Z%7J
M@XT7^* "&ITUG8YK'\YH G\-G3Q$TTJW[2[I<OM"(X>.Q(<<\G/;)_L:\;N+
M'G18H;]U:3]-<.=@ W\O.NVS50*O08NF[.XI#O)U<S;^ POP=-S)(VE#=7.I
MFF(P#/:'L2F/BLM$,G%F8HY5@MA9-8D\14'*&Y5..'RXZB@+X<PK=:U\^/6[
MO&MNXOQC.OS%$=Z?F>+NHKB)D4JPFRMML=MQ3W7;VLV;U^Y4,=LG;/:*0=L(
MKN*%+EM[V8(/IDTHJ[9QG":4U82RFE!6$\K:(:QJ0ED[>R5-*.O@0EFL]BFM
M]LE<[0LMM:]Q8AZ4)]YU!VO2U6OOCV]B5@VE/,R@M29FM:](?- QJVZO?;8'
M_LQ;M)L?65Z!#LRBQ$*_\MSMNE:%!6YI+!1Z([UH',(A:4!3>MLXI\JZB.KJ
M %-KL.H=@$:0T6 GX3SOM$^+RH\H26[9$_ZL]W6>I9&:3K-0.L,L@;N %[-0
MI3R3R@*'J2<H0,(>V 1! Y<!-XA%!^SOI0W(I/)0"HT(F:3FADN0U_4'3NT\
ML=H'^U5\-]W#G!=O92A'*GWIY,=Y7'*JMI$V@F7C"=Y)-VCC"6X\P8TGN/$$
M[Q!6-9[@G;V2QA-\<)Y@K7:FH'8:!?W%4*N=C2OX,!U<[DG3MJSQ!#>$LEYY
MZYZU3QI7\)YB\2&[@H][[?Z^UB^\'XVD1SUW4.O!IC'[6870.VO*$)HRA&HX
MGJY3\1K<:&H1GB1VE\4Y6W94HB,[D9]YU/)+.' <<D+^WKYJ.R/I4S\UF;-T
M>@\>Q"C;3[K;E7DE26G1PN(U#XL9?.*[FL(_@[G3:Q__U'8NX'8Q,)< 3-0(
M[CF$#<1.%F8)-D-3J9PFCHBED\B9B/E-*V#F9S&&U6C[>8#P9J(\JDJ8.Y'G
MP4EQ?["R,Y2PS23*8AZ[<RUB)88J4.G<1+?DDM!*N/667CV-UK;>TG ^[K;[
M&%Z915S4\)K"<+!R$55!I[?UHH[)=(I7Q! X99:N?F7)U?-$Z-3ME\%A_^\D
M+DA]+(^&L13?CL0(-OM:!#=BGCQ[5289H)<%&"X>?^4A1Z-'.R33K@^HQX4M
MKT$[E3$^!7L2.[,79Q++T=^?_46=G+G'HN\.3KN#WG%_T!UT7&_8[?4ZO5-W
M.'3[_]M_]O-7BB/J/FM8VO.W5^+GJIO<;8[FGJSQL-TE">%&),YS=-&8N $W
M$@3F4<$DZ&E4!'\JU2EA:-XKE?%6O'J'O<''MLN1  Z_U(62O@F;T$ BKAK[
MLNKUQ9:4YU_>7SGG7MJRP9TLK6#2(*K6\!5 (L9FE@GL(+V1DM\91M$W C1M
M322P<Y0<22)QNADVEX1%6O!3(@*<<>;#YZ67$4A+<]'*_1^IZ63U YLU43Q[
MS!R&6SWF7R2VIR0P?)KIJKHDQYK?X'GG5T::]\MA0XTO (%2W*$N1(T$%!?G
MCY;/'^+Y5X=-R^<G10)0Q\L23$T:2L"@M@-O !PC($7WV,')?]W.FRLYIHF(
M^.87C;F7Q0A">LI]8Q ]C'1^#7('X*4^(I9/+2O1TJ&W/ZA0A)X"G>8*]2.N
MI,13V),-8SD6,24*X4KZN/"OA+>S(:[N4K[-EX4&!+?GME1C7FW277JG[?[I
MR<.G3W3:)X.[+;LWZ2Z[!H)FLT^TV=/.9IL]U$2BWVX7B$WJP0, 8%!/ *SI
M"U2'V$.3_]7D?]7^2AXX_VN;0/?.PV83=&U@<\\#'QK@.O?,-_2D'(UJE6_X
M:Q1(+PNP/"IOM&2$?O)Z$SQ:!84'0[!U8+[/&O<)..\9#)I-/L$FMV8Q(_J_
MRK0TM]ONGNPXN_E%QM('93R>.Q<B]&2\<;)>Q<%KFL>VU1%W.\VA>^RNF9NW
M%08_5F+EPB?O1.)ZC8?,/FY0>A=1NG/2/JT]2C<X5R><ZYVT![5'N;NJ+R8#
M>^=S^HY/-\EH;."V-&W;_>DQS.K:Z+Q?LVD4.Y_C:*1PZNS=RAJ605"3S.;!
M\?:C=U;?]Z.5WNR&2V$_40",A*WK%W<7!?;SCDYZ^W1'6TJ3VHA2]^QN*LC!
MPZUS3Q6DYFZWS[$,12J".^D>FYJ,NW?M_=.M6ZC6VZYZ+-VCOB@ <FV/')3[
M>4?=[76/';ZC?37CW>/&_7$GN/4>Q?VQL;ZQ.O??+*GEA;NDQSQMZ>GGB8BG
MPHO&,HRFRDL6ZLT.PRX[/6[W#LHN:]PG2^Z33OML?U!@/^^HN[V:N<-WM+=N
M@&[C/FG<)]N?O^BI?F .E.ZZED7[9IDU#I0E%#C=6OO88138SSMRMPZQ[O 5
M[:L?X*1QG]S)AW_8R2,T.^? 4D8Z!V9+-2Z/98&V;0KN#F/ ?E[1"W>KJ7N[
M>SW[:K1CZR&W^Z;Q>#P8\![([;'3^L97ZOHPO:4J]#XND/NU*-\]-#FY>['(
MSG2=KX_W9-^PIW<ZN&MR2NVPYP"OU^V=MMT#N=ZZKW$(K1YT/H7,:$?<ZQJ>
MHG_ DM?*H]:L=Q?RVU3!UXB.N\=W38W?&3*NC[-BWY"GU]VZM+.NR'. M_OB
MK-W?V@E2NXO=5R/_CA&90P?;V:%Z15;H1ALJ\[JU= ^NV8\R;%1M]KWO@]M^
M((!VFW).NH.[)E,\'(QJ9#(^0K.=AA@;8C1IU=V[ILWL#3$VU-)0RZ:IT_V#
MIY:]S[7"P0!-DMI# *Z>PQYO;0:\W20E%7JQ%#C<Z#G%04Q3_>WFD;4=/19H
MDX^79I]U:-):*,<T2C&8.PH^Z^%\I>&</R+@[2F<#QZ;P4,\9DEX.)=262,F
MATDJO("G-@DPVY,$L-.92!&D$\?#.5&S.!KAKZ-0!$G;66CW5,#/ @EV6[D;
M1,Q0-N$\1XZ<+V(6QS=B"V:P#[A/E9CWY'<Z.-(D$) 82YZAAI_-AE-%Q\#I
M#UX@U)3O? ;KJ2A+ (BP*YQ!A7N528K30$7JW$@$ EP&GM;#KR'L4KT0S7<S
MWYH!:_?F>@SH\ZYKX47% ?1$S>G\8A(I3SH7[[Z7CI'P>\X_!=(*#=W#;$D<
MWB7@(I9ZS59>!?;>N\=5%-/RZ%*Z[D^EDUQ'03:5.1KK$RU6MMK[P4JRA]O/
MR6GU?DQ#D$J0=.^'G>4M6#<+V.">_%1L@_$ L 2PPW$[Y9WBPD*C32S5=)C%
M"0U#PX\3^K60=&]D$.!_A34_$?Y&LV/M48)EE.(=\RD 4^HT[F[K4!Z0OC17
MNQ4+OQ-?*KYEN)!(TU@-,Y[-EB_%XT1_G<=*^,Z7M[^VG,O0:SN </_, '-<
MWD-+C^@%0L$)=X2<9Q:]6LS.'O!KW6[!WO0G:2XEP:K%R)G*.,24)^ 5'H(%
MD"R&[P&;FD3)# ?'F%V@1 'EE$[_00[C#%D+CPN$CUA[[&VU11 9..=2 XZ^
M G!/E0@ $-%HE,@4A=;SKK5J\3&-SY&13!>?_GWY[L@=: Z],&'3?+%VXP$O
M0!G!Z[N":TPVV?T);;XV$P%/W7;_K/LH0]N.CQ]C:%NWOT.KU@H$:S<[:.;6
M$>7OT-RZ;9*%=B*PU<P_:^:?U?Y*'GC^6:V.7S&$<OLDQ=&H,_*VC;0#XCR1
M66.4O,KR ]1GU7+[['6'/]@(Q=;GWW$7:V^P?2;=EB!X](2K,CW>+7.H=*8'
M"8TWE+)?E.*>;)^P7"]*.714WBSG=DM8]+>_TR=*Q^\_XCCJW=9^V-5-\[DW
MK]2H86)UM[^F<_<]F=%3G&F3T/K#F)%;I.K7$#=ZZ\:)-+CQE#5N3\] 9QM$
MQ^[3N:*F2L-61]QM<G'=NU95U;2^YD'-O0:C=Q"C3_:@R?,!H-PVU8XU-*Y>
M]-J#EWMM76VB'!R*E74\:#3IQLI:@1MG[4Z#&W>TLE9F?NOM''?;?<PHFD6)
MPD39UY2IJ*YED4B$>1[6BSH-J5.\(H: BUFZ^I6E\.93^7+.%B:W6/\[B0M@
MCN71,);BVY$8P69?B^!&S)-GK\H)7BH\6H#AXO%7'G(T>K1#,MK[THMB2GQ^
M#<J C/$IV)/8F;TXDUB._O[L+^KDS#T6?7=PVAWTCON#[J#C>L-NK]?IG;K#
MH=O_W_ZSG[]2ZAR(P OX(&;'_^V5^+GJ)FN0+XL)EIN[5V<R1H+!S.-" ["S
M:#'E$KU0/V$^*[HJ?[)S.S<M4=@RP[;-+R_GBN;IUGX,'"0T!0Z5%0&X\PD
M1J=0ZT3LI)2:JO-FDZ4MT=L+:;^X [NTPJ2?OH$'LZ0%1\0LU )VMP!8).5]
MF@-P$JN]VRA+9U2I 0LE41A*UN,PYSM6(DCT5P&JNF"!=DT)L>W:Y7I_I0**
M+937 MAWRN"^-3^;"SY$0DL'$B]](66[AKG%7V0"Y_<F!,]W@()!-*-*@_??
M9S),Y"8'JE^Z\:F[69[IMNFK@Y/'R+7MK?[HCU^U5B!8L]G3SF8;:M*-FW3C
M)MVX23?>XRMITHT/*]WXR_^(Z>S-.RPF+JEY39+90>5+GFX_/JMFZ9)-8G%#
M* _1ONYX35)>[0GET#'YD/.*3_<TK7A!R[%BV^EM74WW(XKIKILDUD0Q#S;"
M[?8:W'CX"/>NAE%*3G[?<O(;OKAMAS&[Q]EV@18K8L<AEU*DBV-7\"MLV>)7
M-W!Q=(^8O*$-?C^<T]2R_IL$8(O-8<88V(P!9A@"XX9<*E2IHDR#I%7^;""&
M!A1)BX"TL*LI_HU7X2V2((EED@6T#SF=!=%<2F<8A1F&\OS,PZ>3,@3T 1*
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M0^=_S'(%O9U>NF#4&)<=#6YA1&3_+16,..=@;0<:@Y>J5PJ%EUV2J(WBZB%
MPXOB642.Y8D4_I\9R'M@_?B5*Q&DSD=$_ O2UGY/!1(?RH[0,W-IA%X2E0[$
M5_>$?*_,:IB"]6[YN7S S5+8X_EIW^11K6<6B\K,1%S+JD*/Y0R$$?W?FQ^%
M*< $O#@CQGIFL1\N,LJ5">!8:1I(HT,@N<&].ZF8.H&X23(L8<**+B#X"R![
M4&W]R'FKH@1U!W0EEPQ4S4(-"U")KK!BN6(V%.@0CV*G N+#1004'J+\@9\H
MP$ML[:T($)><JPG85;?8E ?IEW8;O_1N[.5'3@8:_ !'<36^O2NB<=I0(./&
MJ&#C(!HB.P&+5P\YRXO^/OW[\MV1.P .#"";*F^Q[A*X3SQ&;F(X$-F\$_@V
MFKQ8H#A524*MZ][)(!4H.<!FNU9QEG#$V-1$HL&C11@[*Z-P'+&[A=25^>V[
M(K41C6'@!OP]LIBD#SH@L#1)(C1#S0%,IQEQ*+3302'DV)[>OEF1-!+T!T:H
ME<R![WW3_DI+Y+*9LR!RV:.SZ.<Q SBU9^BM](1VTI+[<";9KL)X/UEV&+QW
M0O)Q&/O0^ MS.UQ#V9<SU+$ CMDL"I<LNA1NP6,8QY)L 1#7 :R/#@H1 H]!
M =*ROLN:<2J]"7EV46-(T*P(VB0DP#).30UL*02)XHELD_P%#F<3Z(N/%G^-
M4;4#<2VGN3?[6J &@M(ER0"Q2BD)M\2N+4T</_F?:(AZ0D )$&P@1<!!0W*)
MDA>?\704R.^$*S=1_ T>BS&*SO+T6BNPV/:2]13J 0PXPPH$3>&;%C[3SW#7
MBF[A+?[GK]@-$EBS(D\=:6!6OTGN]P@K ,:S ->;@LVC4L4>1FT= 4HJJ;V]
MP--1(:3-\]<EF6'&)PD(!NIU3A\ 30\=';1?-+K&62!B<B_@XGAA^;.W'P_M
M8K,[-OASA[DC OBO/W<DF!Q$6%7WV7;*ZA<Z);2.9_)A$'U2/C[NDUV>EK?(
MG#%+F YY-RM/G.0::PXI<M%87P:1 *961!$%?)#\5K V,$8P=SB3P7RUM!"#
MW)-H&(G%K\N6WK"EDEL4.<'5+'+,%VT['Z,DYT3 ZJ^5YDRPZY%0 15]TX=C
M4NX*#Q@&=JJ)>14MKR'-FTE$9!-*1%4,R,&'V2*0)6X$I(-'7?3]:'?J"J<9
M4, X%E/M6H@"L+P1+RT/6!$<.<]/B17RODKB;*91(V*_739#:Q$L)Z5'%\-W
MLX!TXOQF^$*8Z2:3*$[%F$'KH<F/D#%\/3$W[FN_&F=QE1FP=D'/R80@PN67
M#1RTW6SP*@<6;0]@&RQ&!U0X8HQO.>A0&<[S8\%)@84HLLX-I91J](&26SDQ
M$E0F$1P3/@+"1*" U[X.PJK,!^X$^_7B".1J&*&L2R9JE+*63\[,.3D/ F2<
MBOSEN>0-(F#9(0?^T',?72/=CA#WYLX8F2;WMC7>%[HG\^UA' GT"VAG.A.$
M?4F:?-"E#H":"-_X:.:%?Q./!S!O4>_<DKY #2?@072=WDCM1EXG 7.,;^DW
MX043&+ \PIS,)Q=]M*R>(+)I$/,:&+,60[Y!9'T;>BJ>T.5IN99(QXWE#(F7
M?0WH. ^$T9+N$7M_O69(;-/>8-=K^YOV!C^HO8'!Z3 B@_F6-.K#>+(.I3$_
MJB=!K>J\RR8:Y>)MV(S@!Y69U!2N[T Q9["Z+0/5II_ P?43N$ ]+$\BLA2R
M!RN8W8<JTP<Z_&Z79W4')^WN [<4V*52Z::?P&[22,W(Q'7[^]YYHT'E T'E
M_MF#<_R'0N4Z&&P;@OG7-6ZM_>QLT.^T!X]9P?[TEE^MKZ?7:_=W]7KJ#=C^
M&I[Z [CC7IBF'W%@)$7.U\4%[M,4J(88=MQ?,T1UT^O?8VMLSU$ &WWL#PKL
MZ1V=/B69[I'^?''WB/$JR#-#T<'=90/F4 S<!P/#;E.B55WTV)"HDR'3$,,A
M$H/;=]=8?C4CA@:-#Q&-N\?N&O_2DZ-Q/7L18CI?GIJ-%<&;5;]6JE_4<\YJ
MZA:K:QEB<NKS7G_0=NVQ45RU1Y_!E%7EZQ+T<H^4JA8I+?A@@,FRNGG:9M.Y
MBI366V>/F:YJ^;PKN)#G9P.KO4NI)2/URY.856N2]75MHRXX*)6_ZF*#O!L,
M3M,:V.7"^='E=RR<YWH/[MT6S71[@*H17<^[8'L<V]#%=A9%"62YXMDJI<9R
ME]09F5K;+6LG>*H9)MR5+K:8,E9,9UMHDH?-3[A8QVZ=T>(^-$& _X5C$7*8
M0O6BNK3HH+#8.B*,XBF5_&8QPR[/"J]]1NV*HDE*Y_@ +SI76 F!-_YZ']-E
M.^U>I_?PZ9?PQ][Q#N6*/D$&ZJZ!8.UF-\N:/NAI8+\RWW[?3 -[N,S;SF%.
M ^LTT\!V]4H.-'NW\V#9NZ"%CT9U"9%V\NS=Y3:D):5X\^ #GW]__"2=+9.[
MMCW_SCI(F".<M=UMPT];0N#1XX=EBKQ;"+ETIH=)Z&T(99\(Y87;;9]L,2"L
M7D328/%A8/%Q9UV(\\DP>6M-3'=+J[,F5M7P_4YI:A6PV/W\EPX/SU@WPVK3
MFW]4_KGPR3LI&7J-Q\I3JR\.G&S/E788!?;SCKK'@W4) 8]Y28=HIQ>=U>\I
M'2I@41.L>^$"VFVO=N^09OW(YN>^WW^W?;87M[^GU^,>G[;[3W)!AV NO-?M
MW4:4^@#;P9;Q/(.1IUQ&G'BS46N&/==/7G2V0<0=5A\;"^(.M[]7-N1^7M$+
MM]UY$@(]"-,AG\R[4AXX7B"2A/M18M]+&?#H+TR8/#"KXG_^<M9UNV_NY@C=
M1>VRL2WN@ 7N]H5WNXL!^WE%(#.>QO@_!.OB-QQ>OI#"_^"6Q/T"A[N'D7=I
MAK,M*'9%#WUZ2V3?L*?7WSK;IJ[(<X"WZQZ[.WN]!V$$K31]1*JG>X]5R',%
M]!P>FE)W8-;/G5H3[J[FV]@^=\"!,W?[EGZ[BP+[>4>]D_;9T]W1(5A :P6&
MQ.E%MXF*#>6Z+GCLP5WX48;ED_O7;V#+Q,J'!]!N4_-=^F8_.(QVQ3AX',NR
M(<:&&#=5@<_N&C#<&V)LJ*6AEDU]GJ?KFNCL+K5LW%['[3YF)P]:<?-A37F'
M#IT*^BDOV3Q?3@6M<\^@=76I%*+>?"PO#;*-BY8QB9@:U;V8BZM@R;D4<6NQ
M\9 UOSJ/IUN#"=$4F&&/'$#15'R'S5EO5#3_89)9TP&HNC>/P*&QVP&JJH&2
M<)X?'QO:-1NQSA8+7\(:'E!NFNA1L[I/$X,ABV.:I,H07(0N@U+_L1)Z/-L2
M!]U.]8Q+W;LIP%Y,/+>S/$N5;@UP%:?*XM1N,WW3&N"I)W$6O8ETHC2/PL8Q
MF79/(GN3JSOZ+,RVGT4)C4Q]32V( )Q+T^YSUL>LK5.\(H; Q;)T]2M+-?)/
M1(^];M54>?[?26QV,Q-C>30$7/QV)$:PV=<BN!'SY-FK,L\!AK, P\7CKSSD
M:/1HAV3F![04<9^PUT!Q,L:G8$]B9_;B3( 9_/W97]3)F7LL^N[@M#OH'?<'
MW4'']8;=7J_3.W6'0[?_OWU@HT2A2!#P08[/BI^K;K*&<NXR+XC;8SE75?7W
M!'*.MHB]OTQ'O5*+N=Y)W[@?2XWF[-9K*\0$?.PV28%CWFE,O8%04BT"P^(1
MW-!9[C^QVL;-LAB$3<(S@RO[#"9VH\$[[;=E2V/<B7MBPGSV3@SP"$IK6QY:
M JJ\&^[VMWCXI;L@M)HAG7&[//^V&]FHD=U.\X4/>2E4S?G";6I=5;W7$^F_
MF<8[:A%9@7FX<9K-OM@P\GS*F_MPQ^Z0R!PL*-V(#9E#;RU)KNF0&4I2,I.)
M0#(R=1:<(@N'C$%C=6Y4.L&!]]QO\7MKJ\O9[F[J1[)<K$*(<!F. E)Q:D>B
M?P#N14X8 9+)0,EK((B)P#0Y?2!G@JG3 A@TL'A0AM'F,!9*2-U$3?/0%ML^
M+0<NM+#7JNP3P@"D0VK<*4$^_A+=P*>!/O/OMIP $ <0/\EF,Z $;'X+UINB
M'KO&J 3 3;,@ WP'S1*6;^4TDB#.32*@:D1?V!DV<DV*YK9)YOM@,4Z%%T>@
MGX;15'E "FJ$1S?<: Y[N)8!F&NQ2G#W.5D%401;I[P*Y G3Z!IV0P(YG#OC
M"(X2DOR#$Z:Q,G:?_O8PCL *C1UQ+50@ALPU;'/O&@Q4!&G+ -]T%28P %B9
M;4W$M6P18\CO@_:&37KAP23%+K$($;@D>%RD #]L!PQ+Q2"JX9Q_9H""E!\/
M=Y)$82B#EGX37AC+$&]1:IM6]^3U,P]01HEQ",\!T%*MV>F+YJWR&G FV S?
M('#V=D$F(I[K9_!09O^P3_C " A0 X67RN "A0\P320@@M E8B7,*^QA )!/
M5JD^)V,?-KZ=Z<[)L ^G=KSF"KFT\T4:]<_Y'$?C6$QKQV\^P;V]C41,8>9W
M*H:[C.*$$!WXP;4"DL5+SM))%,.R/@AFQ,6X.'DVPU\\[W;LEM"ZLW&4I4DJ
MB!>@] $!Q5*O[0"?0U2SUL'G[6<T=<-A25[A?Y&3(2*AQT@&1 S DT2BL-EP
M'&7C":)5J)5?NZ5S@N^"<+N&5^ \H1Q'(-*IM;/]$)S:ESC+"^!$W XW!3 6
M8[)36#<04_16,?M04YW,Q5LNCH/=NY&IL% EW #I#2+<ES,*ZH=%G^^B17E!
M+LB^:4G8M =L!3UEFJQS#@:T[?V9J433EV&2N%P$WXVQ0S;>9IL5$_[?<Z*^
M7#O@7Q;Z&W HQ&SKPBMOVW4[IAF#N7(^+]VBUOU)E;%?-JL2W9=V=26E@T4Q
MW<Z;S]@9^_*RY5S"#IUNV_D]C.58)7 MJ-80[X,3O(>3PV&O"HL&S_T[JU:?
MC>)%A3;N&^<R23+8W6?;6EM:@38 #X/DC6XJ]!_E__W9>@>)V^D]6\/)SGY
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MY5-YY8++8RD5!C=++3'L8#-FCZU,N+PM=<*$<;EOL5,:BK421TNNH;+#!01
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M:12=:FGP6#$&=K7BL5T0XRF\^3OCN.^N=MR_&D;^'/XS2:?!S_\_4$L#!!0
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M(CNL2 8S3B>G/1Q<^JGW_#T@X\]0D[1(3L"FZ>/C/2"AP<VZ)2DM6M]I3P
M 56Z:7/#%YS6;3B0"!BX)-#_]>UW25"W_4#BQL'_1O,].JG;?"#Q0[]!ZY'Z
M"9Y;OG?:NV 0$_<LO/?]X;HLNI$"5=&45\IM78TO P@VX8_57P?/?4M2_;+W
MMNP;+K&@WEWX1?Y^:]<)<5)$0_C&((SI-C592);<3%6G56CHT1"(X8=@@>]A
M\G!. HP0'F>41L)4VY5\-%#8$HHAZ/\1%$E76"0\K2Q3*^%J*;8[K#(ZOB<<
MFC>CD0\5WA9PFTSU*&)_;X*B]?.&E/_O.JHK!0HVN0//+.OXGJY8PE"/YF@P
M<,S07+.WV,1:"]CAN%;[!9M#"V=0QG^FUR'@16^8V!:H9=SU"#N0@31!>$.:
MI<19/Z/ 7=?-@/(8,??'C 4>Y>+K'[$?+;>$=@%C/=#[@\%!$Z"S@OYB*5$[
MA#/=CHC95<!>MM:-5_ST>!X,!H>-.B[PMZ2 #J%X3H0/NKW/-,(,KB)"#2Z0
M'=FVRBA\X09,Q)S"A>2"RL_RZ;;Z[\$\7<@V&\.P8J"# _+5H2$<$( F'+LT
M@#W09QK&U R%M+"^ XQLF<=M:#RA[)YBG\@X,#7R31*=DD<#9Y0WZX3>^EEQ
MZ* 9/[&(!,GO\?*>,R]V(Q)ZX^7W1UQ*C<4#%1&;_,9XX%W2B/A!36R:"- A
MZ0SVG7(D^Y84N+H>+ZU$I@5"\?+[HZ7D6B@8?9H4;?V<".^@$3Q0EX6N'_BR
M.FQR22>4<^HECY-I!]$$_IJL]< ?.*5^4O[*BD)@4V&K0JFX+H/]C7"<:'BF
M3>#,$>L!.W3DU%8)8"MFG83CEO ?T&H8=Z[#9_!$F&X\4C?F?F0<Y%7PT$<=
M1W8>G#5#:\W16K/<X9,HHDZ48L1)'[P<C_*>KPJK+D8U>E5?$9__G00QG3!^
M]@P.!PO"[T<2T'6I\?*6_!-NJAM+Y VAPT5 !$XB)7=K.<\_O59:KVP/'#E%
M7<^8^A;6TY(5M:!VUJJJ?;CJ8V6SQ2'0DO5-[RTMB1'&8++.<IXL?;1S_V]M
M J><\"].'CZ#:L-(@.IN290\QT!JG"V/.I7;V8A8 7/UUH:V:+0?6T&]_=J.
MG("O:[]8W4]J,B]3ZT_2)M<55W'C>(-V77F+B(SA7Q48_LZ6WYI*LX"S)D^]
MQ6#NT,!BNAV@KL:E6TI09W(^W R\8E)M.&J/[/RHE!ERLIRZ#D*=X%/'0!MS
MVLXHGQ^4 -+%4+-0L<U\G1DKO8O;=^3BEA%:.\]6H._533:Y\D,2NCX)SH2@
M,K"Y\<G8#^H'45N1I ?^P!D<F0.?>0*!SDJ\I>3+6"A3@YUUI*J[F)%P2OTP
M@]T%"R,?;H81KAW[7K)_Y_WV45^6WD(.G<&QN84HZ98?OK&5=16LC3ITTD;N
MU=[?Y7U 0ES-P(1B@1K\1B,SY+4<])'2D9W/?U)VGRS)4';D%<M/%C#=H2-U
M6R=V,N"C#Z&.1_F8MAJI+D93.E4W6G^JPU#K/H<#QQXT +'?[=4FG?XO*;3-
M5>MT7U\7N %K:]AJ>.MAMAT[MZIL!'-6HI6(["3DOS+FO?@!:,J[1ERF/G@Q
M%5B:X:ICH!T2AT,[/\&3<I.HK?DEH>X.%]1"G=&PFHUV,!R.1OFP18]1%P="
MC98O(&E?0@A^-L=W4=DD+5K+=[Z#O]Y_.HZ=6Z*L@!?GY)5(2\G$/&-%LW.A
M&^@TFUJJPU"/[[YCYZ8#*_'M]CR31OEOK[<%:AE?/;8'CIW+4RJQ+7#7.XP-
ML/C=_BB4@?,.YS\?9QB[>.3_2^UP##^J9YM)T>-_Z-AU0["^E15LP9^=/: ]
MG+DNCVEVNMX,X0(Z?6IS9.<7=A(FV:GZ3JN^3AI32JW/7HY'^0RS (8NIBQY
MC=;R>>7D6F<V&CBV&2(=]$XW+)P^43SN;&RX'K%!H?5((]O.KS@B>1_IY>:I
MCFJZ68JFY:#O KBXIT>B\SG8732C/%5Q[=&ZE%K?0T9V?L55LLJ@T\VQNTRA
M=4;P"A[:<7P$XT:NRVB@Z>)X7J;?6EZMBHG>L>T[=FZ(T:+40<]VSY/7V_ ]
M #:?L[#IT1E&G/0>[\ N6B1-W[^3V_XEXZX?CF&BZGI;%(SYZ?WBX2@?U!D#
MV$4O::+Y9@%A(\YZ?WKDV+F Q!S=KL>0)H D]V<$6GHM1"P+W\41'AR,)Y!O
MW0),!>H-X]@9-O?;\@ =]516PU+UD&29FNQLI@3"_,OQ(9O[(8D8%VR"9ZZX
M0'WI!W%$O:^$AZ!,<4^YU#8>)Q8K[=3=&?4?J)G6"IV!,RS8>V-NA46O_J\K
MC->RRI)34FDKK;4%U5;V:V4KOC/:$M.X9Q$TT"=!L)2JA$$AZXJ^OKI![%$/
M/Z#P]?XQH]*M&^F[:Z(W2ML9YC8TU#'*3/6LM'YO_&5:1?6Y":ADU@0[:8%2
ME]!9\;2W.6ZE4P>(&=E,":TV<0''D]_V)QGU)2<KRZKS.-3)3+0<M+F(,QKE
MI\_*,.EBZE&LVF;)AB$OO:MTG&%N;U I8%W/)HHU+N_>+?#GF0NZJ7O&1&VN
M>D3WG6%NIX@&4?G(4H*L5-(.W96*'AZ_;Q'5 FYZ- ^<86[?AP9-X+\#L:0S
MY>XV>8'A'?SU0!\ZP]R:>%6W+7K4Y=<8U,G<3^35--+)$NB#S2,[OT<Z.0A<
MDG=3R[6Z3@&=ODL<.\/<@E]6YYVT<4Q#?7GBB9 )=O)JK_GQPCH&VCZP/[#S
M^\@SW)+$.L-O!XM;=_'5@(^VT^Q#7IQ;#=*"U,E>]$BGJ Y0Q@,-\.#XZW#"
M^+S.E(6.@[X?#>W\7NZ$G80G86AE..Z@J3^+4<U'.Y>QCWN!:L+4R2D-C9X;
M3FS4X:CWAHXSS,]'56#8^5D.C?J39\E)P+ALJ3Y^%$[7'^'9&M9UA.G-8-\9
MU>[*ZQ+IN<=R<32MPN9G@':&\M;#XEGN*V6ACN#1 \7OK:*'3$BW9RLUY>G-
MY< 9Y5<6*LU%'5^_-A"LA#QO=5V-E$M'@ZYXL5#?\R9!^N6?^G%7!1-]Z'5H
MYU^CRG)<?S&HJ]&77KVU C C5OH8[&A4L,97B5<GPS"]MNLY6C->>B=Z[(QR
M,V8FT'70,5[Z>(JM'X&2#!':H-"ZO(.!G7_9*DO>43W7\60%=%JW=6"/\K/%
M629==%#9]C?+"[4<M,[H8.B,<E.7&X!T/>G+*D.^KJ'2F\;X%/#0(S1R1KE)
ML3<(J==(TKRK@R ]QF-!_XBA 5^?S8_TSE'IQPO'SK^9N&9A*1[_FTK_9>]5
MG)#%PH=X!.^HZS!DJN[R%MRA*H21D,R7T_!WT-6""1+\REF\^,8BU)V<8H^I
MM_HZ]*_$#S$EO OQT/HP8GS9L\A81)RXT6EO0@)!>U9(YA1[8U.&(1Y! 4/+
M:2_B^*G#US$/_!,@\9F'#3WM>3%/TBWU;*S..CSMN9QZ?M2S!("-G4[*P J<
M]E1)/Z+SGA5)+NK.G(70"_GR&IX@]]Y>J8Z^T4B=3WL=8N!W%GIO/D*Q_E3#
MF?@;#;SD$Q.E.FK.\!TZ\NCXXU2$RS+8T-_\:'81BPC<'$]?E5O><[H@R^0D
M_Q*5F#-HJPINH3]BE^>7/IF&#"2X3_&<\7O.)M"*<'I+YV/*LQI0#5 *,":O
MTWZCEGH1[^,O<>*Q.71,([A%=#>YGQ%(?5P*[,'=H15#/?'G(^7/ODN%OL4U
MF;2AW5_]Z2R:R7W4#W01<W=&! 6$IIS,]8TUH6Q#"U._M#H&_*[L&/#RKER#
M16L[LPQ$SN*(^?-Y'";G'57T8"U-&\!]=&?4BP, I/ LS;*&59)MH6U>=#*#
MDMR-Q_0ZAQS4"I=.#'"#.,"%/E:!U)M2;<!F_3D@D<0#9ZX;SV,Y70^"A/@>
M<DH"_U]P"2S/\6MMN"6IM!^^@V.U0OP07[2+_N1([*W]08PLK464(:TAV#KH
M-4UU'0.KD%D&_7>3Y)A,"D/C$R>A@";!_2M*RV.G!IQ:&VL7Q8&R(6?>/V-E
MS4\L6=6$J/CKZX*$'NY=?88Q90HC*GWV62R")0XTP GP]FH%G>\7UEK=XM$\
MUUC1&._?7)_?/5P%#$),<+N8Y$[+,Q83T@_TH@LEQB1"FR\"MJ14;C*^3^,L
M4._3"Y1;PK_!<\7H4(M%&X:.\UB Y0EQP>9C?/L4V)<$7*N,*O/YE>MP$4=X
MMDDI^%OC_T$N-R4R2>69S+AA6* <!L=DQWEYHEY2O+5A:SZ)7,>CM?///&D;
MK/T,+CWEFB^DNSR;<BK+Z!M83=>&UKTSI_ZORJ:U<SZ;"XM-9HTV.;1V5%;3
M($73/UC[JFDC4^HVX'T=@B8)OE6D_K\.T^,0,'I-#W+0Y#-FY!\;AT@AS5PQ
MQ(LP>I+ "%AS^C9 *]>WTD.AQVK2/\;TL 3+TO+-,\\/'5BOYPOB<[QWM_I"
M!7A7/!?N!MR,IYJ23-5_UT04]1FU-=9XH&ZR2N%*Z5><S3,3#!)A?+V/TQD$
M3= VM>?5A7B1!;Y'5)**RW.^YQ/-BM+V!;5V+,B[.)RB<=DTQ$F:)_)Z3D,Z
M\37K*#4XM-6PZJT@(OI;6HQ4K%IK'.I%=_$K!^\'CF(".0F@+ >!*[!Z\P2W
M :-6C#$;U;X'T?R);4,#AJS:H(.+LX>OCV<N#![#P7"0SF/?J\51]3FC\F#9
MA+:M3@'".[G1$B3=C0-_JMY2!T%S' ,R\YL IEN!?C->;8"_("B47JMI1%E$
MW(9V8DR(LZPA]$\<OW!2W05LBG=+/,V@!!Z%!2'3.>.<O4!S'A(BJ-DMI,#S
MN'Q^ZX.DM364K;$LA,/B=A>:WG!LJ8XVX@8(J8)8'FY9%#WD/G!&HV\L=&,.
MR5JY+]Z>@)9J4"V&WR[O232[N;FX(6/&\5S$I<D:NH:L#=Y).^NT O,;?4D+
M)DM(#ZLXO-F$EB'KM@>P9_@27.ICY2++]]"OVEQA1ML&ZRB:N%&SLFPJSP=U
MJ_:1F#-H0WM+EH*JIBVU1&UH5P$,?Z.R?X"U7V!_:1QV5?!I0^MAB$G702]]
M3EWPP?IF:@C:T)YK".:92X4 ]T$)=S&PNP3?&3#Y66WTM]=ALOF:XDQ<12=M
MSJ\-VGAZ84\S%N,Y+8\X@$24YM [DV>XB#C X$&=+PL#$)2%QN!JN%X_VY30
M!HVIP.3A_!9J:!+";)9L0PO2G0S>#22UH: XECY1=Q:R@$W]RH5%0^HVM'3]
M+CW.@*[")\CPH6:^F&GB+Q/2UL97[T@J,@E;]LN;'YO)& AM[T;$7,JK6H"[
MPT2YMBKI6IK.9:=(;GQPU9[\&(2Z46=^I9RXI2V728;ZQ,1EC%L[[V6-U%GJ
M\E]YDF4ZC<HY;GZ7/T.O="=9^?K-1XG[J-VNZDL@)JN%DSCT!-0;:Z'2.,J?
MZ46%>ZFD:ZN'6$?[%2-K0<$V#*)&2V>9N7)T7^5FW9!;6U<CFN[6:=D^'?F2
MJ'!G=$Z^_/1O4$L#!!0    ( )> 9%.NT";?HR,  +5@ 0 5    ;7EG;BTR
M,#(Q,#DS,%]C86PN>&UL[7U;<UNWDN[[_A4^F=?3,>Z7U,Z><FQGCZN<*&4[
M)S-/+%P:%G<H4D-2CC6__C1(W2Q1$B4"U+)K<I$MBN+Z&OVAT=UH-/[^[Y^/
M)L\^X7PQGDU__(Y_S[Y[AM,TR^/IQQ^_^_W#S^"^^_=__.UO?_\_ /_YT[NW
MSU[-TLD13I?/7LXQ+#$_^VN\/'SV1\;%G\_*?';T[(_9_,_QIP#PC]4OO9P=
MG\[''P^7SP03_/I/YS]X)J)5B4-,A8-2@H$3N8"S66',HACT__?C#SEE%I-E
MD#$I4$%:"$P(",ESX9S%DLSJ0R?CZ9\_U"\Q+/ 9"3==K+[]\;O#Y?+XA^?/
M__KKK^\_Q_GD^]G\XW/!F'Q^_N[OSM[^^<;[_Y*K=W/O_?/53R_>NAAO>B-]
M+'_^G[^\?9\.\2C >+I8AFFJ#UB,?UBL7GP[2V&Y&O-[<3V[]1WU.SA_&]27
M@ N0_/O/B_S=/_[V[-EZ..:S";[#\JS^^?N[-U\\\HBT$_+W:7;TO/[X^<O9
M-.-T@9G^LIA-QKDJ^:<PJ?C?'R(N%R3%ZE.7I\?XXW>+\='Q!,]?.YQC^?&[
MH]./4ZCJ9EZRBN7?MOC4YY=X4YBDD\EJ>-[2]V>?7>$UA8Z?ETB_L1ZI\V=/
M9NF+-TVJGF;S\]^<A(B3U:NCDP5\#.%X]'XY2W\>SB:9)M'K_SX9+T]'F0LF
M#?? LV:@, EPR#R(I(5&A=+*\N605;$6)-=*OR4LXDK)9X]X7L?R.4Z6B_-7
M5J,+C)_I^M]NQ[(>U\=+]W)V=#2;KC[W_X7)"8Y0^Q@3)B !:<*:X"!Z15^$
M,T4GX3@W762[CN1+R:YPYL4\/9O-:0C(GGWW["^LUN?,M*UAA7FZ0:8O)];9
M.YXO3HZ.5I\)XR4>G?]^M7--.;"<-1STM69)@EU5_R+G<94]3'X+X_QF^C(<
MCY=A<@7<B"NFD^(%T.@"2@M+AMLPB*AY\<P7E?H0_7YLV]!#?)WT:*R8=H1)
MY!O44<9\L#S$.0$ZGN,AV>3Q)WQ#7L41OITM%K_B\J!\")]'/&JAD@B0@S.@
M)&J(&CT4C2D[R:U+H@]['@9T&RK)KY1*'576C%?O<!G&4\ROPWQ*?NGB"NA7
M6,9IO!PQ'LE;S!8LRQZ4E1Z"CPA.:VN$KRZEZD*E^[%MPQ[U=;*GL6*:$>:F
MF$3ER4D-:GZ;S5=COUS.Q_%D&>($/\Q^G1'3ITL:2OK$CV^F2YSC8CG**G*,
M3H#B@K [G<%+D4 3=HI69,[%[LF->PS^]J,X0BF\$"D""SR#J@%'5$J"=\$X
M] 4I:GL2QW9H[E]WOEV?BCLJJ]G4^V4\G<U7 W F%,U[%57T8#BI5<D<P 7O
MP @GC8U,8,Y=*',=R; =PKT39B=%-:/+VW&(XPEYL[AX>3*?XY1PF"*S2@:*
MTQ:4(O$"Q3^@HC"J>%,E[D*8FU@:.,2SD^ER\5LXK7H\ES 7@UKD!()'DK D
M3LMA+A"L,1EC01E"+[]W YXA6=(=^;#!O=U5 2VCH_D)Y@T2RF1]H* >F*D^
M4J"(+;"800>)-LK,L^S&A\V0AF0KVU.B@1J:L>+@&.<T"M./;S$L\!S5Z3DF
M[DJ2P7K0 A5YYY&\<^<SL&R<,-%JC'VH<3>N(47$C?G14"'-2/*RKOTA+?\8
M+P]?GBR6%)7/;R"SCF49?0"/D4)SC0*B),O&G-+"L<*]\YT2L_>C&U(0W)@P
MS973P[EZ,<V;8G_-9"F,@?5.56$=!,<YH.,8&(4'3K'>KM9&9 TE'SF7A4 3
M:\9<TF*?:<8RR< K(VW2,7B=>@LY4!=K=U9<GPR/'?B&IO+H:+RL.]15NCHW
MR93C-%5 )L85)II_CI%@7H)+FD-!E%DHGY7HD\^Y ]1 /:WVS&BEF*$E"2VS
MEJ.BB)DC+1TZ:O!.,++L(AB&&%3@7TV2<#">7'O^/8&ZVX6.BP4N%Z/(O? ,
M$T2!$90/%GQ)"9(M0N6B/0M]/+SU\]M(<1&#"VD")V%$*C20@:+QX(L @\9P
MYFETB^PHS !S'X_0\HW@]M%#W"F@?5?'[:#\OL 5M)'T,CE%4S:SE$%))L%[
M:4"[S(4KRG"SCWCV&JPA+<(-6-!.!>VV!<+\3UQ9UO>83N8K&U\M[!E33;(D
M#\^ !G5U  Q958J6'$N<E>A4<+K/)L&=N(:T.#;@14,E-"/&;_,9L75Y^MLD
M3)>TZM>E^;AZB;\25877WBAA@!E+!LPQ$M;E#(D[IHNU)N<^M+@+U9!2&0U(
MT4P!S2A!OE:8?AP33=?B$9#7G\]<M7_.9OFO\60RXD8'<@8EB,@1%#,.8@GD
M#Y(7EB,YA9GW<;NW0;<-1?370Y'F"FE&E8NGJU2"8HS6,V%BM5WT]!@14@C.
M16%1RCYT>(C*S=>C\D<-;#L?LI:BG7'M<GW227+&(\D3Z(L2H58JD5 N.4/_
M995YG_!G(YQM%&Z_'H7O/N2-H]WS(*9(;:/V) _6@#LC$3 E6I$DCZ[PG!+K
MDZ.^(TY\1%HR+ YKVHO^J OLIS!9)<*6+\-\?DIF=%WFS71,P7D!VM9D&-8M
M::4X!%N2DQ9-4)T2E-O &UZL_!B.W,A+-M=,UZ#I8K/:*R4]#Z"%5*"*D>"L
M91 P<:NRQ!#[3(L[0 TOC&Y!D%9::%E(LBIJ>8<)B:\$C!RRBXW&F&36&""4
M3)*2Y8=H2(M&Q6)1Z9)LI[3:':B&%T>W($8S/32,G#[1LV?STQJ[D3 Q&9_!
MID0FJW )GF.&[)33B))%UZ?P\BJ*X07++33_Z'%NF#;!XS#.'\)G7(RD(<_/
M<$8!5TF5:Q%\8 F""85CE"7I/DG5JRB&%_.VT/2CQ[FUIE]_/JYG6\E3N>*I
MGTMHG'8L"@5"U/*5&&@%*H: L:15J6>]1)^#5%N &UY@W) 7S;32H^9G%"R%
M;2J2UKPDRY2S@<B5 ZYDCE8XDCONM_*E28&X<3%&(<C,LIJ2R-Y"9%A 2).]
MH@#8AJ<I$!],7<^#-']'"<]C1KP9DW^?SC'-/D['_X/5_OZ$4RSCY6+$DC/<
MZ#I9)5GA[#A$%Y$\*YK&J+@C^;JH_Q9 0XIZ6G&@Q=@W(\(K+$@\S.OCJ 3G
MBI35 0N2AT#.-G"A0ST*@^#KP53G?$(KD),1[D*(>X -*>II18R6NNA=0W\E
MCQF\53)QA*)I/5::(03)-$C-E?)9%]>I<N9>:$,*D%J1I*T^VKE&L^G'#S@_
M>H5Q>04+5QP#DCG3,I"D@GMPT7I@Z$R1G)6L.WE)&_$,*8YJYE+L/O)M]Y:N
M6JU+/%Z@SL$ID(63PRYRA! R!TN,3);P!-MQ@VDCIB%%3\W,0QL-7&/$WY]?
M'Z*W]'W#)ECOE_1U5;\\*V<6CG[Z)9H=NF'=\O&=VF)M(TRC_EBDWMGY@K!V
M&\ZBYI$K1@5>R$^(K)9]9TOS/P?@G'',B"FK/O/M5D@M$K"+59'[^F,ORX:=
MC[2L64#I-2UXAA8\5FN871 ^VI2RZ;/(W(9H2)%K&X9L2M+NK(N614VKIY]+
M5K0GCT>2Q;3,DP$-DBQ=/1S#4W"2<V]SGZ#E&I '1J_P51+A\4/?UNVX7;YD
MF8Q11A"K0@M5XR:; A0I##.%I'9]MNWNQC6D$+8/.1KJI65-;!DO:]^MD?"%
MYU*[;#E%#A$W!:(/%"B5I)QR1&/>)]EUB6%WRW?>1>QGTNGZX-<)#?2EV_$3
MEMD<+U(*N'C]>3D/1*_Q-,Q/WQ K%K><QN'>21%]!G2ZFG)23W0E03'66I&E
MR*I/@7!'H8:T,C^2B3<M\# HT' U/P-Z9B?.$J2C:G%*H3BVV%)JM[/:':!^
MH?4E\<")33WY> /0H%;WIF3:;>P;$Z$/LWU2 9668(IPH(*I:T^1P'1.Y*GZ
M)%.?\&AOQFV'5.\EQI&/T<20&413NV AN?*>RP#"FE1H^?8F]>E(O ',D(SW
M4+AY:WKXD3IL-GEO=_L$BMK:)0-W6/LMVP*AJ +9,6N,S+%TJJC9R1/?UR[C
M4(G51I\-6U$L5KT.SD L1I@2"X%"E%C]%9(M W'>U.PF^2[*HA)]DD#7D;20
M[*#4,R*K@_HX_S1.N'@_F^21]55Q7 .MMC21DS$4BW$+46873#TZDGKUV+@-
MTY!L\DZ<N-E2HXD:&O9I7B!]3"VG?X6?<#);G2,\GX/!62_04BCM73V-SLC[
MLY+B=8JG&;GJ'G.?(UIWPAJ276U*CG;*:-=Q!5>V_I_DL,_#A("]R$?CZ7BQ
MK";[TX6QSJ88)9T :U@"Y;,$8K,$RX(C/Z 8Q_JD1K?#-Z2<6%/&=%!/,^K\
M=+(83W&Q>#D[BN1#U*&Y:"&TK!M;XWSF>[R8SP.]NMK;>GE8__IF^N*H%NH?
ME%M^Y:)"@8^R,YI[JT%(3<(A^2 NQP3,LN*C+8ZY/LW"]B3@D,I-FI)WB 1I
M?LR9!NO:6>PW1\=A/*^RC)+1VNI53\'$JH_+:N,U!1B<*J*(%&V?F&4;=$.J
M:FG*N^:J:1?=XO)*@"VT1%K7+7 F:<%G/M106X#S*5N9&/I.R:0O8#3<&4E*
M>%V8 B]*!(H8"\3D(T1>:M/.K'/I<P#RMIV1)]Y#?[2V-S0$><P8]^'M5CW9
M9(E6,QZ!)%:@1-'@2B"W)/D0+"%ELL^M% ^&.JA\?#O*]%59^SKAJXE'[[,)
M0H&3Z$CLDB $5X!SE-9IDT2G[K#W)H\?$W]_PND)GB?EKC<EONC94I<G^J]6
M]H]B9DDA)[7SF&N'GP!>UTZM3ND44RZRD\/["+!#LK>[<NEFN-Y7=_VRFBDE
M<J"D FZ#!Z7(P_'21#(<D7[;V"!,GQ*%N[.:3VQ<6_-CIV%_RE+96VZ4ZU(W
M>]NS]E!$NY68C2IJ-SSKXH*^Q+UF%CE82Y9 L: @BE# <N$-1E%4ZI-EO0-4
M@Y[>MWWTXWKX9EY2/9I4^P;7DA$:(^TDF*"B-#(('OI4:3069$CK82M.;F@;
M_F2Z;]F4OJD0B:.0-B;(K.[NB%0[<BD/3O#"M,)@.A4/=R7PSBF.[$R0SD/F
MOEXE7TR]8\.0.R2L)5^(&=WG,N([4AR#G93=>7=GC/@@7;6MP=XP)O6T<YC4
ML\[_,9NLFEJ&\;3"/)A>MGQZ,1\OZ$>OZ%L:-)R/9_G"P+%0ZBE7!$&1+!FX
M2"X>CXSX8FF\%">#TV?3NY=$P]H5'0Z)!\&@[O-A5=DSFY-RI^L.$.GTPSQ,
M%Q23UD&>YM5W9X3(_SI9G[*YD,4'*8T(=42- N59 <^2!_0E^U"8U+[/ZM1'
MGF'M]PY_+NR1/4\:UX;%X<^3V5^=(MF+3]]'[+I9E%;G/W%9'_#;?/9I3)_V
MT^GOB]H_XN?Q-$Q3S6@1+SZM3Q7G6*^L3:76*DFR@DG7'+0"K2A(" [)0/9)
M)6V/L<$.5D+,J\K)-XO%"7T^'I3WAX'FX^\TVG.:1*05FDVUI*N^_%-8J>ZH
MYGU6NJ^=VA<7TWUUK\W!\:KL<L21VQ)5!&VY 15<!)\P05$R&%-O?^YT&5%7
ML8;D4G=B\X9-N('0I-VIMG"ZLC?O<%(-T(<96?N:XCY<>TRT9&R68Y2U#@9K
MF.!<O7<I!O#<9<CH"N/1QUY'91^+>%")Z'T1=A_:;<U%0G5?Q<_&<2H,)<L<
M,).+KH),X!AJ\%BDK,M\TET)^3C8#_1COR56[D'/S<WD0:G=<LYM_VK[9R23
M,0ZU JE2H*'@9+>E#!!,T8Z[2,Y\GT*'.T ]L*+P6Z+5SCIJ6'E_? 'I;:V#
M/"@OYYC'RY$O!IWT#E)-KY%YY;34:P,ZD&%UFL7,>^WOWP+I@:6 WP1AVNBG
M98G5)JDO]JRO2!V2\QB9)T"U10HI&R)/%E!IY%RA$9W6NNTQMMU%T,8:58("
MK%<8J1AI_CKEP- B$!S/CML^(=1@=Q$ZL>7N#8*'J*%AI]'C.:9Q.$M4O3BJ
MJ;3_6?NIQKM2=$Y@[&JBE@R1%0=,""Z4"4S+/CG^.T -*4V_)Y:T4M'.G*E)
MO7KBM I]O<-0#LQP3AA,LC6PJ7>A1>\!A=$LUR-X[-I!SYLIPCL^?T@9Z<YJ
M;S7*^[G>]BH;+XX>:Q6T51:RD+$&N>0*VNS!&:O(%TPYJDZ=G1Z(=$A'@_9D
M3+HJL]VQR<V)$XHF5$JT+EH;B/XI&@@Y%LA1DS.*WI"WVH58CT]Z[>N$SY[H
MTT Q+1O1S"N)7^'ZSS?3&ZVZ25JC?""B6HC(*#BUFM7;*!APE]%&6Z1UW5K*
MW _O@<UNGR0R;,VA]GIKX]G<Q'7;G0 F&!$M5T!1< (55 2750"*8AD/B$PF
MMY6SL_4CAW3UYC[\GSZZ:,.3\Q.T/X?Q?'55XJV':$=2852ZKI:%U9X#04#P
MLO;\5H*79&A-95L19?MG;L,4]PTQI9,VVE]0]\><!NO5[*_IB-PGJ0*/$(JK
M^=*L*-"G)3-9<K4BNIQBKXN\KV/9ABW^VV!+(X4T6FLN3DJON]F<G:>NMP:\
M'7_"O+Y6ZS]PDG^>S6D<1@HU,506X):B_=59Q9"B!F648B($5IC9;LEYX).W
M2LNQ;X,B_573KC_"1;7EJ_'B>+88U]$[*&MP?!2T1H+$0>=(C"9O"<AG2B"D
MM-(+EH3ID[J[&]=69.+?F+_;4%4=8Z<OK_=;K$H=:<6DR XII-.I'F.19!B=
MI0%@1@HFLRO2]]E*VP[?5G1ZZK*3_N'3SJKK2*N;-P:/+*+5R6H(MAZ[%XF0
M&<8 96#<V4B#W^MBB/O1;46IIZX9Z4^I'=76D5#G[EN566>MA$5#WEI-A]?[
MUX(OM=U,Y-JSI(SM==_S';"VHM!3UX?TI]!C%=5_C5LGF)015:8,R=0J/)T"
M.%IKP9<@H^0JTIJ\W[5MZXP@?^IBD;VM:0]754?ZG%^<<79UU]J!J[EO+8*-
MD&3=MB^.@>,.Z8O7/F7Z8>S6 '\;@%L1ZMO/,>^NO#UX2;^%T]5::[07-D0#
M/"B*"4(JX'GV(+WU@? *:?ML=-T+;2LV?2.9Z#[ZZDNC^0GFJ[<6NA)3B,J!
M9:H>=\, D5E"IF0]@,E(\#TRZ1JZK<CTC22KNVFM(Y\VM66Z*!\?!>Y\KE3G
MO-1L%T\4$.0"$CWS@ON2P[ZH=2?0K5CVS26Y^^FR=TWN^A;#+\<"BV71U]N.
M3+U\U1@)/HL %'B&:#$KZ;OU\MP28ZM3$!]F+])_GXSG2,_,)VEUX&WMK(3@
MLK/.@@BU'%LQ"3'2EZ1E$L*JB*'O68A;H3VP=O=)7,Q=:77;B8@V^FIYD][%
M,<KW85+K[L\;1;\HA69[6-8#E#? (LLN5D_8.DXQ5J')[TTA[+4]I>%,E=2G
M:.^1@+^"0N#FC-N#:IL?ZKJ8'B\^A?&D>LOU8"2AO^P24D\4C3!;;PNM<=(P
M74M;(T1C$C"96%*^7IC6Z=K'AP']&LX4=C=U#779S?#13/@E+"NLTX/R2YC_
MB:O&()=01\$J*R6%::'4X%^(0DZ/(JRE<%FWW:SLX\ ^&.I74*C<V]BU56>[
M/G<T%/7_US0O/A',U9[)8CD?IR7F^@/"_>4+5]ZY[HATTU<_:V#P^G-:%3>]
M([O^NA1,RU$LF;-"WKD71=:JR$324F!8=#3><6M=IT9#^Y5SCZ?]7''9:EH<
M?15<*:*G]UH!3R%EXP.:N-<&+/>>]GOB_GK#Y?N&TW4]2/ 4X6]$92QJ#RS7
MO=?53IH*'&@H0E0E6-.I?>MCP]\G[I_WU9-T5Q+T)NFFT^*.:QDY*K#,5GS.
M@,OU.(APR?IDA99[/3>]>T.0_R5I5Q(T(^E:Q(-R5>R#Z4X#//)&IQ!] N=<
MK9\*!H*1$E!BT4XJK1UV87,'8884/GQ%M']J6C4ZL$V3]^R,Q!FZ:YA>3L)B
M,2[C6MI\5M9< ZY1<-)+(1*-54%023((]>K#Y!@O1@O)Y36GX[8CW8]$,*3S
ME5\!;?>G[8Y-2"\C^[4+5/-.ES'^Q2&?,IM?Y*#*]1Q4//TE_(M>7+]P^H'0
M!AJ'*OBLG+_ZBIXRGCRJE>G>,>[>$/5IA[516]7K6<>::[S2:WI]>+V>3%XL
M?PJ+,3DC(C*6HX$HJK$-*($X;LAC-EP(2ZX([U/B]U"DNSI ]SPOI9.CDU63
MPG_.9XO%9>ON>C1A?7%][4,LLU5&Q AE7740Z^5D44,6.7A)ZU80?5R>)O '
MM0?9E:K7_93]:[^9Y_Y8Z/4\S25TY[)-!)^&+-+:12-)?RL9A' EIUJTSOI4
M!S2!/Z3,R5?!V\<KOQMOO]P N[(IP0U#SJ,%+NNM\[H$B,$*, 0Q.J,23WU.
M4&V+<$@ID2=E7Q,5MNI$<>ZC+<X<^"]D'YD2HPO6 EEJB@[JS?0AH07+6'"N
M<!-QNV9;]SRHM1!;KD0FRQ*UTS3"(H/R&.I]"!0!H7=!.4R*;=M>XY$0!N%+
M-*?"M0X;^U!/M_FPY>*@N,G6V@B&)PX* ];KG%4]V:\2L]Y:#,VI-+C5?3A,
M>KQVFC;D^!+NJ!AO'4D/7M4[88(BT0NY$.1 \,BLX$6&+HOT32Q#6(Z[T:61
M"IXL_;0A"1@NRE+HY[/RI>MPF6L+B[O<C4Z9J+YP>R>E]CC8.^:GMIHO,K&<
M"C*0WA50BB,$K05(X9RDV>.-XD_ILUU-=-_,&K]8O@SS^>EX^G&5)QQY9\DK
MMAJ*U!1T65\=;\\@<6%2$!SIWVYU2/?"&T+!3'-2W+@FMKFB]A0=7T[A>A9E
M/#V8XG]AF%];7G0NZ(L!4^^@4#%;B)QEX"5XSBV74?5I8+,[]J_&X]N%?7M6
M\=ZI^:(L<4ZP/QS.9R<?#W\>?UI)\&428J1<$=FZ#(P51;,K2/):,M+L0DF.
M"_E!CCTI2[<2XZOQ.?=!V/:*?QKN5N!G,GS Z081@O J9<L!JY^M:/0@:E^
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M/DL?+O6K\>)XM@B3?\YG)\>_SI:U%=IZ>F&^F%WU[L(Z^0ZFYV\?I:@C!EW
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MER[?,K#2ZAL4T5XQ&9/S3M4)SWL0[NCS>;=@\789X/USXV %[L9Z%H/31#+
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M;$>\SBQY)"34PE N$A -UA*)[B+QA@&Q5BAAF-:1U=GW.AKR;6PK=MS<V\:
M7;O_[THM;(3I]"-, 1][<39.;TI_\6:>L?NOX>SBODBKO4!OC,?97Z ?:%%)
M7*-/$J(G^+'13-I @VJYB[,;@D-T!JELVZ9OPU38G'^[Q4"SM/15$XPP$//Z
M-TNLBY+(*+1%[4AG*ETW\1=VRVH9J$)>VS-0GQQL;>#6O9;K&%;#C1=SU2)
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MCPW 3H\A^^F^0H;?G=7ZT2P7C176T4B<R)9(:3CQ44K"2[\,SXQ,J<X=)L^
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MA& @"!O157Q90^E).;^-G^.A484LQ*YV!&X3L+4*$*EDQ<T,. L8%"C&1#@
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M8Y-Y'Y/%SS["5QA? ?[*,JMP?+YP=]XWTWTRRKMZ]?[=8VKHX&'N.@YS)V2
M$*VD6@0GM? V:1F2<BH,N@*Q;R7*\DU?FLGB^3<@WM^DF*'+*JG@ENC@D;DY
M)!(L^LG,*E"2"TI]G1FB#;K]2[?F2GZ+,T/QY2<^SOXUG%V\OIK.4-.3'_^,
MHZN$[SZ;3@'_EW!X#X)C/"NAB);H#4B7@+C <8PGHP-8<!9DI5*NK<$>H(M7
MUYQZ7.%5UV05%MXW\&4"<;BHD1ZGL\NBFO]>IMQ2$;73E@AG(I&*.?0H8VE;
M'QAE-D4!=5+IGP%U@JSIR@05O/$GIO>!EYYEX)'X&#1ZBNB-!%PX2([2*\Z%
M596V;)\ <X)LV%?E-;9E;SL6KY?^U?7RAXO=)FN",,D+$D39=;3(61?*QC)W
M.DE.,<"HU!]^>["]M2"OS9W:ACJ6A/J;TMI75U-4W'2ZE&@ZWPU)+&M(3!,M
M:" RV8RC!3C)2@5GJ$BI5EGR<[ .WY2I$B>>2I_LQ#8U4FL76&Y"ZLU@ZG8(
MOPOG,-O&'9KK4:WZOKJN3@!'+>7! ,E<(JB8(W$><NF1YYAS 9*I$R[U8/@-
M&\A]V7T;%7?=&.FV5<^J(X*-#F,MD0DUK"1OX>)J/4LDE>9/(EBG\X.E84WK
MFT>//I@GNHN>F\Z45"$B/1N-YC?SK BY1*52V:U2D@A.H>0G9()BH7.D&/4^
M<Y=CG2. I_&\1'MWJ.$^=H3?#,MU3(M+N7[QDT6+DSVV>9]]WMY[M^W1/MR0
MS4XK$RV/8*4*PED?K,_,&B<TFG+P[),[[2KXRH]*3M"G"X#9O+E,FJO!C]X,
MI\6_+PA>7>,W7YJI'_TT::Z^3/$1BTVM\CN+LG](MU7_MX$-L!"=-(%8+5/)
M/T!Z =6$JB24D@PGFYIM.WH1<M^Y[]=)$P'2M.P@?O+%:<=/TM6\P4+9-)QA
M?,B]EX))@B,21VD4D@3),%*$9+55SD=5)[K9C.W@G9:.AK\/9]R.[5IAU;V+
M\,Z$\R&_PP@>U39[-WZ-ZFA&PS3O:'X5IL,T]),A3 <QBA@IEX0K5(IT1A(;
MT&4$GR-HJ;F/]2FY)>AO7&W#U9I,Z-K;_PF-4'9+/XP72ALN.DLOAM<O,/N0
M/T_\>.KGM9QO =%ZXP7CPA":2U\1D!CEZ$B)+IGTX"P./-TJ&MCZU=_8]V0L
M4M>$%7;&[RGHEV;VI&8>2N5' P72F__7WK6T-G($X7O^2T&_N^L2R#H$ G98
M<LE15+]80VR!'PG^]ZF6[(WM75D::5H:>^<B2\)HOJGZIKNJZR52@)1;$9$+
M!4*-"#FCJ3Z3L*G/P<.>@&>^;@S>'8$!(^;0/KK\.V!^]J2MFO$O5#"EUMK6
M]MB&F"L!:$( 79QP+AA#>;>VP7M=?F;@AM.;WJKL,,#Z]^M_6*#+FX??+F^N
M/M_?I"]T6\Z65U>7=^M^J;>WB]8-SL7$<E@M[,0OZ%%!+9I*%3J4V*<I\0[@
M9BYN6@W'UNRWY+.CD>^OF\N[\NORW^M%"J5*:0V8T! I*BT5TH#P.66V,+)4
MO6:XO,8R4VLKM?;3V[=,<B./Y.@@N74TEGP-1I0$VH78FIAXB(6%V*S;DJPS
MP?;L1]G]!H_;KO ],'UZO)I*YL>+VSS[FVYO+^OE\PDO.:!&%CEAC"US@5CN
ME=U#0Y2,Y2]+G_&16X"=MAQP8EQZRX4Z4*<=4@;>@/<T(FH'@%WS2+9"/$UN
MR:B*W9TT!VCE)/21Q4JLA7W_B,A[A5!L&N<*4=E@@Q>F^#Y5#">BS9;,E-.R
M9H@R>K-E_8$7V_KIH46--OGW7P/X2(:<B* H,7;G/5!MTV39* ZBRI0Z^3&'
MH#Z^QS,R"=ZB6$\-=@@"]K<65D\P2\_[J@0_LIF=-Q'8.&9S&:+4P5LTPIB>
MK0I[W]]LZVVV]2;(L-YAH6V G[5JV07V\0S)W8%/8A[L)+CTUF;0F0B]K9$!
M\ ,E\DDIR%:(UB+9 *6JH4T\U,H*MM>.X(6?FK_#!M5^)/H.T?_8:2 7J[S,
MBX?/=/?E_/SLG.+RIOW_4XLS1U7*&"Q8J7GW,AC6C2ZP2"_0"J?=J_+%#6',
M+1<ZL5W;2UO+3J(>>R3N&MN?GRY8#D^]N]%[*XC=15WX23!D6GT3OY,%I531
M*DP#-/_\MW\89>\MT#Z/^2_W=\O+JZO[Z\<LRB?B*:K9* ,^MC4O26(/2F30
M;*8*7A"=#3A T]^_R@^C\Q&$O-'&[E0NL"IO6&^P(Q4,?.<71RT9V(;X5=&
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MK$(D<"!AY NL)^1 0,I""<,$,1_%7B@9G3W+G&6#P[TI943 +T'/;@+MC,C
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MLZ9&;55^(S=5\N8FPU%D\SG-"_ D<U"=.TTFV='IW;%S :>A[(38>[Q$R0V
MKD +$6@P A5(5?DAL(ZX_S/D4G89]S])IJ63:?]-\C"[#.=X69J=M!O9)?A,
MOZ>/R\<O2[,S<Z/J(]^O,F_/96:Q##@+O CZ0G!3ALDWM66)7EY$OA^&F)"
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M> 1B)3D4B<=$C$PM_L"I\\I9D5-S6M<:@R>M,DP7@-=*.S90.0^V'3/V"^'
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M'6-'^(,4R[EL#@%/'286QTX3J]VC&>4$^003*) 70T09ADQ$" 8H]#RE:2+
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ME?1+;;B].?()_"2BGA[6* Q"B!CBD$0\@A[57IN((HE\V6O 7 <EIT;"E:;
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M1TJ38E;2N34I]JF?$VVNM!ST2]YPZM+&J9N?=.I&&4=K GVMT1F>8H]YVU=
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MBF(1Q9!Z4B_=J5"0!))!WP_C,&!"R,BIA'H'':8VWZQ-@'-C U@;L?K@*CM
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M8L!I_?97O5Y9ED6I5R?IXOX*,'F?+LR!/OBA"C-Q+:(RW@M!,,5!J)W9!)M
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MFYA I2".3%??0)-SF&"61%:%8X\\?VHD6VL(M(I70"OYDQV%'@/O-!GV ,G
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MH)>7*)901 E2.(JI4$XU_^S$3HUD*JWK]FJR:,N"N'&,)=YV5-,_B@,SS@K
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MRJ YAX.DR; 1,BUEDF%6.,7*![-L:O1UO"2X >\V$E#C"%CHM<&SMA^L6W^
M,O+6YF]<I6.#]:P=X[U*?[WN<NY;TW>[?,0;T+FIN?-VUM"A*5*B][7?]/#5
M2[_^G\$[_2\W78\;[X$&!'2(  -)0.';T/T25B@WF'7C"NN&!O5(B#=X V'F
M!]/ZSI9;SC>/F^;F^(_E8K7Z,5]*.JO_MQ3FE/*-U(/$5)F\2V22)XAC_05
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MF#&]S]7#O<BSC":HR/.J\JN!][*IJ8WW1DO:L3;N )"V@SH$/-'']];(73Q
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M774#MG[=@/V^;%R[ <:Y5^@Y!^7D5^C!D1261^Q)-SWFP) /ZC:':FL\?>?
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MP^>V HTV( .O45:S*U"/QI:"5V"C.U@/U>Z_;3T0;BD+ FS0Q>XRC49=#H.
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MP)SS4Y[T_O!Z@JAQNF6T ]50\N\ 2B]2JE7UJP^8D'8'L?0;GEWRHEA6Z&V
M(@*K[_<$>!T5<*N42)BRQ*=*! XX[)Z@:IQ>&^W -)@&.D#3F_E7HGJQ_$8L
M3+)-@;.2P6!M%,%"J495TL9@(;HDO95/Y?_V1\]-*L9IP]$.+7M+N -TO%_B
MES#-G\*?N)I(ALRS4+DVG (+8B!8$RC.B(Q[%34=Q4W0<9.*<=ISM$/'WA+N
M!QT__?FE9DC(9WMW]AF7MV0T"8$Y6PMN4$M?S:&&R"C88-I(SJUG0K7QG;<@
M;IPF'\VQ-)@^.H#8;>)S85%IKH!909X:.@FA> :>94S6N53\4_>5 X7RX_0#
M:>C.["WC_0&R. NS00#R[@O6]Z;SD[<85OBAMFA]5WXG]%>F)EPFIPL=MT7'
M0 95&7!%&M"*?#*/F;E&@'F2K!Z"JT%R0,,)OP-3\U"(^-MBGC;[HJ@@BI+D
MN2GRYA6=U."S25"X%I'V3&2R31KQ:;IZB*T&P=* XN\ 3.^7"]H;9]_>SP)9
MZ7FNF:PO-7-?@X 8,&1A!&0,EC9&Y.3_DYNG?8H173#LR:O30WRBQZGJ(>P:
M!$B#B;X#&+TA%<Q/IK0I+@1$+/ST9YJ=UZOA7Q:+_,=T-IL8PUV(,8*J31U5
ML!:"I&]9<5+IP)16;2S3-M3U$*\- JO!5=$!O*[H]AFMRC$#YMJ; YFEJ( 7
M$*@<"X'+$-O<).\$D\:AV" PV4ND'4#A1JAXX]3E#%5BM4;)U'05MZZ^F9'
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MRJ G4<C:OL_Q.IF0*S!9:>=]R6J[%KZTP V,T'=W\?$8!9V<57MH<S&@:/N
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M@S555 ?FZ1:#DRB,$YIDHX2G/Y"3:\JL!*DINN8A(S8ZT&Z1,6ZSW)8(VDG
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M]9K3>)?3#TC[=C4]P\U@C O1?,"T.)FO/V4MI8DOQB S!D@<K-:L*/)[.(.
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M 5(L)">9,X5^7 )R] :YUCRR)DC<BKQQ+[.[ ^;P*AUU-N;:8;G/4^T_MBY
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MB,XZ -\- 3[$C1$YHY:!N/%TOLAD@(X;8B[P0JRA+3(U0>#3='W_EZ;#P'!
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M.X#M$_OQ9L9[DZRZPVO(*!"U@FR+!86)@4L)0:3(K2\!<R-3>PC5X[[Y/1Z
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M.1$>.^J$RW;8KMYQGA0Y(&V>+9/>).4NWU]_D20U6".'E5Q)==>#2J:DM9#
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M4&>3()F2R)0745MFVXQU>XJR+G-5=I+^]H;W[J+H&UH/7/Z>^9*]* 0'$7D
MY>B+L]:#) TK>'+:I#8&T^ZT=IF-T@A^0XCKT(ZVK2'Y'I=GS!COD0YSP<DT
M5)8[B'200^"*6U=4-J+-?=;C='69,]((:KN*87\]-UN&\V/<4[WY>Y,6<]5[
M-=NDM')(?FVL[;_(S0VL#MI1I:!).G/?QGC?E=(1*X3: *^IJ#HX<N^U&^ZN
MRCGG%:LW>"R3(9&*A! 5@O4IHZF]0FR;7O';T3=BFGPKV TNE@[!1JK[[IJ4
MEV26DJ4:Z@1L98J (%2@)4;&>;)"LU:Z[FGJM@*:.6&@'2R2P8[7D?,JSVZM
MJ%5F);UGE-S*V^N[RJ[\?P?G\$T/X&Y:;YL\UNW>V9;S>ZQ[E!Q7CJ7$Q!((
MU$A.61VUG9*$7%(L/"9?6-LY4T<90WQ3&G>C>V>DQ^ID;P068Z&CU'MPW$G
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M_#P\G[JET#HPVZ\7^E\X^?IMB?G%3_)]O^+[BUIH^:%\_D:\OQW[LQJ]\2&
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MB* OKA#)HHVED,VH%8%".<SKPA.K=&98?.&\S="2P^@^>#C<MF^_>>^PN#%
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MDV\5LH"HB@6MZ5LEG33<;(6]'5XZ;DAI*'"UXG('9][ZV*=?7BEX6QPK/G-
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MK6RG_2#W.''CG(\#P> Q4 THD[&/Q_>S._>L&VV<+$_!10:)9_)4>3 0M17
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M(=Y6LJ?4_.U&F/"R3>3@;> >>4>SAG#;KJN/UG V<BF#1#+!69VEI!TX-((
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MW0#T&>SF;7V$J#E)46I0D9G:7R) L-Z#4]K(D)V-O,]].Z1C>@JW$*>P0UN
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MR:*QTH5&W>5WHW-<FZT=SNY<*K>3WLDIN -J6[9X:EMUU[+V93<T%J]BCJ9
M5K63C+<"O$(&4@?F"E.&^38V\E&UWKO)<O)UTQ)O@?.?^.IB7G?VF>72&2,%
MI"),S<'($+/2->[CHY3D^_@V[?(?HNB4--DNV+D3)1M"(KV6\7[&KY6'M.LW
M'1C_F);9_/O:ZMY#7SWZO"':M&Y-[T Z:O/"3_AC-J\0NVY%:3)#S)F 5(?\
MZ5)JG7@FNS\YG8/D-P:;#=P]Y7Z*#F\>\_MS[SNFH^3!!:_)&*B5'E$$<,E9
MX@%3A?P?RUVKEC%/$C=RJ\@A<'*W1\RP(NG3<GIL3Z\BT_NUDW[ZJ8WUT7VT
MM]9*3C#.& HH&<ED9Y%#$$6 Y3%+885BI5$3_59:Z:IGS>TWW.#TRU^;']XH
MCC>2\V \N-6D<ID91*$]9*-523';&-K<&.Y)<*?::Q<\/=QPN9WH3D^CO0_S
M=8>O0UKE[_+\QEKN\?6TUG><,"*T1,B%+&]5AR[[: 3(X(1@JA97--KFC?3=
M>H1T[5)4'UQ/D,V;%F<^%N58+"!,"/6XIWW!M2.G(Q<I,H;HVQ1&/$Q3IUIK
M%U3<R50?1@"GIYBNN/D3IQ=(O[*Y^:KJNEY3O)LM#HED#?7JQNIL;RZTUG0Z
MF*21U;YD& E\R8 K!#["LH]<9AU#HW&)?5AVJQ059Z.TY#1!E#5)VR5!&[OF
M\ MRLY1@SN1&YNWNQ':J&W?!T8$6W<XBZ^#2_*K5Z\N+Q62*B\6E]E]E\F9>
M#&9NH%Y+@,JN0-35.M8Z>LMDSJU:YCY&5B]#,AJ!XKY&#X-(J >XK6F_K$%A
MCHEZS5:$(N)32> #K@)&GGL?,=LVK01_(V-D. TGWONC:7OP>NS!!-?#%2[[
M0;ODBY:R +.\EI/'#"[P3#ZRB$5&YTT13UED]S^ZBV-K'QG-!F-8!WKAQ?GY
M:OS@)?@WJ]"YWH]K!5(PK(Y- 6)#AEH<&T(1OJ0V&:CWTS-R.^N#L3(@MSO
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M(.KD3M<F:_-!DL8>FCH )NYTNQ^$_>VSJ3<_J%]B6.#_^G_^?U!+ 0(4 Q0
M   ( )> 9%,#0B?Z62@  +QC 0 >              "  0    !E>&AI8FET
M,3 Q+6%M96YD961A;F1R97-T82YH=&U02P$"% ,4    " "7@&13]"J?)0T(
M  "P*   '@              @ &5*   97AH:6)I=#,Q,2UC97)T:69I8V%T
M:6]N;V8N:'1M4$L! A0#%     @ EX!D4S""9DT."   P"@  !X
M     ( !WC   &5X:&EB:70S,3(M8V5R=&EF:6-A=&EO;F]F+FAT;5!+ 0(4
M Q0    ( )> 9%/$-\0UW00  '48   >              "  2@Y  !E>&AI
M8FET,S(Q+6-E<G1I9FEC871I;VYP=2YH=&U02P$"% ,4    " "7@&13-D%5
M6]PP @"F1!L $0              @ %!/@  ;7EG;BTR,#(Q,#DS,"YH=&U0
M2P$"% ,4    " "7@&13GK6.A((2  #*Q   $0              @ %,;P(
M;7EG;BTR,#(Q,#DS,"YX<V102P$"% ,4    " "7@&13KM FWZ,C  "U8 $
M%0              @ ']@0( ;7EG;BTR,#(Q,#DS,%]C86PN>&UL4$L! A0#
M%     @ EX!D4^F4"(+<4P  6;(# !4              ( !TZ4" &UY9VXM
M,C R,3 Y,S!?9&5F+GAM;%!+ 0(4 Q0    ( )> 9%.N,5P_=?8  *\3"@ 5
M              "  >+Y @!M>6=N+3(P,C$P.3,P7VQA8BYX;6Q02P$"% ,4
M    " "7@&13E;.]>(N-  #=@P8 %0              @ &*\ , ;7EG;BTR
E,#(Q,#DS,%]P<F4N>&UL4$L%!@     *  H N@(  $A^!     $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
